PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33900847-6	2021	Furthermore, inhibiting JNK activation by a JNK-specific inhibitor, SP600125, decreased fat accumulation and lipogenic gene expression induced by HUA.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	24-27
33894297-5	2021	NF-kappaB inhibitor (BAY-11-7082), p38 inhibitor (SB203580) and JNK inhibitor (SP600125) exhibited the potential inhibition of AGEs-induced NO production.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	64-67
33900847-6	2021	Furthermore, inhibiting JNK activation by a JNK-specific inhibitor, SP600125, decreased fat accumulation and lipogenic gene expression induced by HUA.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	44-47
33900847-6	2021	Furthermore, inhibiting JNK activation by a JNK-specific inhibitor, SP600125, decreased fat accumulation and lipogenic gene expression induced by HUA.	pyrazolanthrone	68-76	CD36 molecule	Mus musculus	88-91
33900847-7	2021	Overexpression of the lipogenic enzymes fatty acid synthase and acetyl-CoA carboxylase 1 was via activation of JNK, which was blocked by the JNK inhibitor SP600125.	pyrazolanthrone	155-163	fatty acid synthase	Homo sapiens	40-59
33900847-7	2021	Overexpression of the lipogenic enzymes fatty acid synthase and acetyl-CoA carboxylase 1 was via activation of JNK, which was blocked by the JNK inhibitor SP600125.	pyrazolanthrone	155-163	acetyl-CoA carboxylase alpha	Homo sapiens	64-88
33900847-7	2021	Overexpression of the lipogenic enzymes fatty acid synthase and acetyl-CoA carboxylase 1 was via activation of JNK, which was blocked by the JNK inhibitor SP600125.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	111-114
33900847-7	2021	Overexpression of the lipogenic enzymes fatty acid synthase and acetyl-CoA carboxylase 1 was via activation of JNK, which was blocked by the JNK inhibitor SP600125.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	141-144
33662432-6	2021	In addition, a specific inhibitor of c-Jun NH (2)-terminal kinases (JNK) SP600125 and its activator anisomycin are used to elucidate its mechanisms in acute liver failure therapy.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	68-71
33895649-10	2021	Also, our results indicated that p38 (SB203580) and JNK (SP600125) inhibitor slightly inhibited 3-DSC-induced apoptosis.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	52-55
34021889-7	2021	This is supported by the findings that pharmacological inhibition of JNK with SP600125 or expression of dominant negative c-Jun markedly attenuated Cd-induced expansion of autophagosomes and abnormal expression of Atg proteins, as well as apoptosis in PC12 cells and/or primary neurons.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Rattus norvegicus	69-72
34019587-9	2021	Moreover, extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) inhibitor U0126, p38 inhibitor SB205380, JNK inhibitor SP600125 and Akt inhibitor GSK 690693 decreased IL-1beta-induced MMP-3 mRNA and protein expression.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	115-118
34019587-9	2021	Moreover, extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) inhibitor U0126, p38 inhibitor SB205380, JNK inhibitor SP600125 and Akt inhibitor GSK 690693 decreased IL-1beta-induced MMP-3 mRNA and protein expression.	pyrazolanthrone	129-137	interleukin 1 alpha	Homo sapiens	177-185
33999413-11	2022	Moreover, the inhibitors for MAP kinase, including PD98059 (ERK) and SP600125 (JNK), suppressed the CyPA-enhanced MMP-9 in U937.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	79-82
33999413-11	2022	Moreover, the inhibitors for MAP kinase, including PD98059 (ERK) and SP600125 (JNK), suppressed the CyPA-enhanced MMP-9 in U937.	pyrazolanthrone	69-77	peptidylprolyl isomerase A	Homo sapiens	100-104
33999413-11	2022	Moreover, the inhibitors for MAP kinase, including PD98059 (ERK) and SP600125 (JNK), suppressed the CyPA-enhanced MMP-9 in U937.	pyrazolanthrone	69-77	matrix metallopeptidase 9	Homo sapiens	114-119
33966040-6	2021	GANT61-induced autophagy was blocked by TAK1 siRNA and the inhibitors of TAK1 (5Z-7-oxozeaenol, 5Z), JNK (SP600125), and AMPK (Compound C, CC).	pyrazolanthrone	106-114	mitogen-activated protein kinase kinase kinase 7	Homo sapiens	40-44
33905761-9	2021	Pretreatment with SP600125, a JNK inhibitor, could significantly block the promotion effects of FB1 on OTA-induced nephrocytotoxicity and apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Sus scrofa	30-33
34025676-8	2021	MAPK inhibitors (SB203580, PD98059, and SP600125) and a TLR-3/dsRNA complex inhibitor reduced the EXs-RBC-stimulated production of inflammatory mediators in HMC-1 cells, whereas the TLR-3 agonist [poly (A:U)] elevated the production of these mediators.	pyrazolanthrone	40-48	toll like receptor 3	Homo sapiens	182-187
32180463-7	2021	And SP600125, a JNK inhibitor, attenuated compression-induced NP cell autophagy.	pyrazolanthrone	4-12	mitogen-activated protein kinase 8	Rattus norvegicus	16-19
33780908-8	2021	Furthermore, knock-down of DUSP1, as well as TORC2/3 by siRNA caused abnormal activation of JNK during db-cAMP in-duction in ESCs, accompanied by decreased IGFBP1 expression, an ESC deciduali-zation indicator, which could be fully rescued by a JNK inhibitor SP600125.	pyrazolanthrone	258-266	dual specificity phosphatase 1	Homo sapiens	27-32
33780908-8	2021	Furthermore, knock-down of DUSP1, as well as TORC2/3 by siRNA caused abnormal activation of JNK during db-cAMP in-duction in ESCs, accompanied by decreased IGFBP1 expression, an ESC deciduali-zation indicator, which could be fully rescued by a JNK inhibitor SP600125.	pyrazolanthrone	258-266	CREB regulated transcription coactivator 2	Homo sapiens	45-52
33780908-8	2021	Furthermore, knock-down of DUSP1, as well as TORC2/3 by siRNA caused abnormal activation of JNK during db-cAMP in-duction in ESCs, accompanied by decreased IGFBP1 expression, an ESC deciduali-zation indicator, which could be fully rescued by a JNK inhibitor SP600125.	pyrazolanthrone	258-266	mitogen-activated protein kinase 8	Homo sapiens	92-95
33922211-9	2021	Pretreatment of beta-cells with pharmacological inhibitors for JNK (SP600125) and AMPK (compound C), respectively, effectively abrogated the MBP-induced apoptosis-related signals.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	63-66
33692840-11	2021	The upregulation of Nrf2, MRP1 and of Nrf2, and MRP1 mRNA expression levels in CSE-stimulated cells was inhibited by pretreatment with SP600125 (a JNK pathway inhibitor).	pyrazolanthrone	135-143	NFE2 like bZIP transcription factor 2	Homo sapiens	38-42
33923917-6	2021	SP600125, a specific mitogen-activated protein kinase (MAPK) inhibitor, reduced TGF-beta1-induced pFcRn expression in IPEC-J2 cells.	pyrazolanthrone	0-8	transforming growth factor beta 1	Sus scrofa	80-89
33338591-10	2021	Finally, cells were pretreated with SP600125, an inhibitor of JNK, later the expression of JNK and Casp3 was measured.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	62-65
33338591-10	2021	Finally, cells were pretreated with SP600125, an inhibitor of JNK, later the expression of JNK and Casp3 was measured.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	91-94
33338591-10	2021	Finally, cells were pretreated with SP600125, an inhibitor of JNK, later the expression of JNK and Casp3 was measured.	pyrazolanthrone	36-44	caspase 3	Mus musculus	99-104
33338591-13	2021	Besides, TG decoction combined with SP600125 (the JNK inhibitor) more significantly inhibited GT1-7 cell apoptosis caused by TBTC.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	50-53
33338591-13	2021	Besides, TG decoction combined with SP600125 (the JNK inhibitor) more significantly inhibited GT1-7 cell apoptosis caused by TBTC.	pyrazolanthrone	36-44	solute carrier family 2 (facilitated glucose transporter), member 1	Mus musculus	94-99
33918237-6	2021	Application of inhibitors for ERK (PD98059) and JNK (SP600125) abolished the LPS-induced effect on NF-kappaB p65 phosphorylation, which indicated that ERK and JNK signaling pathways were involved in CBN-mediated inhibition of NF-kappaB activation.	pyrazolanthrone	53-61	mitogen-activated protein kinase 1	Mus musculus	151-154
33918237-6	2021	Application of inhibitors for ERK (PD98059) and JNK (SP600125) abolished the LPS-induced effect on NF-kappaB p65 phosphorylation, which indicated that ERK and JNK signaling pathways were involved in CBN-mediated inhibition of NF-kappaB activation.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Mus musculus	159-162
33918237-6	2021	Application of inhibitors for ERK (PD98059) and JNK (SP600125) abolished the LPS-induced effect on NF-kappaB p65 phosphorylation, which indicated that ERK and JNK signaling pathways were involved in CBN-mediated inhibition of NF-kappaB activation.	pyrazolanthrone	53-61	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
33859351-5	2021	Treatment with SP600125 (a JNK inhibitor) or knockdown of JNK1 restored DDIAS expression and reversed DGG-100629-induced cell death.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	27-30
33898323-3	2021	By using specific JNK inhibitor SP600125 or CRISPR/Cas9 to delete c-Jun, we found that exosomes from SP600125-treated A549 cancer cells (Exo-SP) or from c-Jun-KO-A549 cells (Exo-c-Jun-KO) dramatically inhibited tube formation of HUVECs.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Homo sapiens	18-21
33898323-3	2021	By using specific JNK inhibitor SP600125 or CRISPR/Cas9 to delete c-Jun, we found that exosomes from SP600125-treated A549 cancer cells (Exo-SP) or from c-Jun-KO-A549 cells (Exo-c-Jun-KO) dramatically inhibited tube formation of HUVECs.	pyrazolanthrone	101-109	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-71
33898323-4	2021	And the miR-494 levels in SP600125 treated or c-Jun-KO A549 cells, Exo-SP or Exo-c-Jun-KO, and HUVECs treated with Exo-SP or Exo-c-Jun-KO were significantly decreased.	pyrazolanthrone	26-34	microRNA 494	Homo sapiens	8-15
33897417-11	2021	These findings are in tandem with those obtained using SP600125, a specific JNK inhibitor.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Rattus norvegicus	76-79
33918237-6	2021	Application of inhibitors for ERK (PD98059) and JNK (SP600125) abolished the LPS-induced effect on NF-kappaB p65 phosphorylation, which indicated that ERK and JNK signaling pathways were involved in CBN-mediated inhibition of NF-kappaB activation.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Mus musculus	48-51
33692840-11	2021	The upregulation of Nrf2, MRP1 and of Nrf2, and MRP1 mRNA expression levels in CSE-stimulated cells was inhibited by pretreatment with SP600125 (a JNK pathway inhibitor).	pyrazolanthrone	135-143	NFE2 like bZIP transcription factor 2	Homo sapiens	20-24
33692840-11	2021	The upregulation of Nrf2, MRP1 and of Nrf2, and MRP1 mRNA expression levels in CSE-stimulated cells was inhibited by pretreatment with SP600125 (a JNK pathway inhibitor).	pyrazolanthrone	135-143	ATP binding cassette subfamily C member 1	Homo sapiens	26-30
33692840-11	2021	The upregulation of Nrf2, MRP1 and of Nrf2, and MRP1 mRNA expression levels in CSE-stimulated cells was inhibited by pretreatment with SP600125 (a JNK pathway inhibitor).	pyrazolanthrone	135-143	ATP binding cassette subfamily C member 1	Homo sapiens	48-52
32772776-7	2021	However, followed by the block of the JNK signaling pathway using SP600125 inhibitor, the effects of miR-128 on the proliferation, apoptosis and autophagy of porcine ASCs were significantly suppressed.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	38-41
33692840-11	2021	The upregulation of Nrf2, MRP1 and of Nrf2, and MRP1 mRNA expression levels in CSE-stimulated cells was inhibited by pretreatment with SP600125 (a JNK pathway inhibitor).	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	147-150
33859351-5	2021	Treatment with SP600125 (a JNK inhibitor) or knockdown of JNK1 restored DDIAS expression and reversed DGG-100629-induced cell death.	pyrazolanthrone	15-23	DNA damage induced apoptosis suppressor	Homo sapiens	72-77
33676788-12	2021	In addition, a JNK1/2-specific inhibitor SP600125 blocked IgE-mediated mast cell activation and cytokine release in PCA model mice.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Mus musculus	15-21
33401054-7	2021	SP600125, a specific inhibitor of JNK, also rescues a proportion of cells from the apoptotic effect of SHK.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	34-37
33790616-13	2021	When we blocked the activation of MAPK signaling by SB203580 and SP600125, the mediated effect on p-DRP1 (s616) was reduced.	pyrazolanthrone	65-73	collapsin response mediator protein 1	Mus musculus	100-104
33730072-8	2021	Moreover, treatment of SP600125 (a specific inhibitor of JNK pathway) or cotreatment of 13-cis RA and 1,25-VD3 significantly induced a decreased expression of miR-221 and an increased expression of TIMP-3 protein.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	57-60
33730072-8	2021	Moreover, treatment of SP600125 (a specific inhibitor of JNK pathway) or cotreatment of 13-cis RA and 1,25-VD3 significantly induced a decreased expression of miR-221 and an increased expression of TIMP-3 protein.	pyrazolanthrone	23-31	microRNA 221	Homo sapiens	159-166
33730072-8	2021	Moreover, treatment of SP600125 (a specific inhibitor of JNK pathway) or cotreatment of 13-cis RA and 1,25-VD3 significantly induced a decreased expression of miR-221 and an increased expression of TIMP-3 protein.	pyrazolanthrone	23-31	TIMP metallopeptidase inhibitor 3	Homo sapiens	198-204
33420899-3	2021	JS-K significantly prompted apoptosis and SB203580 (a p38 inhibitor) and SP600125 (a JNK inhibitor) prior to JS-K could partly reverse apoptosis and activation of cleaved-caspase-3 and cleaved PARP.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	85-88
33420899-3	2021	JS-K significantly prompted apoptosis and SB203580 (a p38 inhibitor) and SP600125 (a JNK inhibitor) prior to JS-K could partly reverse apoptosis and activation of cleaved-caspase-3 and cleaved PARP.	pyrazolanthrone	73-81	collagen type XI alpha 2 chain	Homo sapiens	193-197
33420899-7	2021	SB203580 and SP600125 could attenuate phosphorylation of p38 MAPK and JNK, respectively.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	70-73
33420899-8	2021	The phosphorylation in downstream substrates of p38 MAPK and JNK was also abolished by SB203580 and SP600125 in JS-K-treated cells.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	61-64
33690262-6	2021	Western blot and immunofluorescence were used to detect the expression and localization of synaptopodin under GSDMD knockdown and JNK-specific blocker SP600125.	pyrazolanthrone	151-159	mitogen-activated protein kinase 8	Mus musculus	130-133
33788717-7	2021	Both 3-MA as an autophagy inhibitor and SP600125 as a JNK inhibitor, significantly inhibited erlotinib-induced cell death.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	54-57
33621155-6	2021	In addition, we further identified the significance of JNK-BCL2-Beclin1-autophagy signaling on DUSP4-regulated PTC carcinogenesis by combining DUSP4 silencing with JNK specific inhibitor (SP600125).	pyrazolanthrone	188-196	mitogen-activated protein kinase 8	Mus musculus	55-58
33629098-6	2021	Inhibition of p-JNK (using SP600125) blocked the Ang-2 induced invasion of HTR-8/SVneo cells.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	16-19
33629098-6	2021	Inhibition of p-JNK (using SP600125) blocked the Ang-2 induced invasion of HTR-8/SVneo cells.	pyrazolanthrone	27-35	angiopoietin 2	Homo sapiens	49-54
33621155-6	2021	In addition, we further identified the significance of JNK-BCL2-Beclin1-autophagy signaling on DUSP4-regulated PTC carcinogenesis by combining DUSP4 silencing with JNK specific inhibitor (SP600125).	pyrazolanthrone	188-196	dual specificity phosphatase 4	Mus musculus	95-100
33621155-6	2021	In addition, we further identified the significance of JNK-BCL2-Beclin1-autophagy signaling on DUSP4-regulated PTC carcinogenesis by combining DUSP4 silencing with JNK specific inhibitor (SP600125).	pyrazolanthrone	188-196	mitogen-activated protein kinase 8	Mus musculus	164-167
33355370-10	2021	EMT was also reversed when cells were treated with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580).	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	55-58
33546770-2	2021	Treatment with SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can suppress the JNK signaling pathway to alleviate donor liver ischemia-reperfusion injury (IRI).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Sus scrofa	41-64
33546770-2	2021	Treatment with SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can suppress the JNK signaling pathway to alleviate donor liver ischemia-reperfusion injury (IRI).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Sus scrofa	66-69
33546770-2	2021	Treatment with SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), can suppress the JNK signaling pathway to alleviate donor liver ischemia-reperfusion injury (IRI).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Sus scrofa	89-92
33603672-13	2021	Ga and the JNK inhibitor, sp600125, markedly suppressed Px-12-induced generation of intracellular ROS and O2 -.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Rattus norvegicus	11-14
33603672-15	2021	Moreover, sp600125 inhibited Cx43 expression.	pyrazolanthrone	10-18	gap junction protein, alpha 1	Rattus norvegicus	29-33
33526844-7	2022	Pharmacological, unspecific JNK inhibition (SP600125) reduced cell growth of all cell lines but PANC-1.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	28-31
33599317-13	2022	IL-6 induction was decreased by pretreatment of cells with NF-kappaB inhibitor SN50 or p38 MAPK inhibitor SB203580, while CCL2 induction was reduced by SN50 or JNK inhibitor SP600125.	pyrazolanthrone	174-182	C-C motif chemokine ligand 2	Homo sapiens	122-126
33599317-13	2022	IL-6 induction was decreased by pretreatment of cells with NF-kappaB inhibitor SN50 or p38 MAPK inhibitor SB203580, while CCL2 induction was reduced by SN50 or JNK inhibitor SP600125.	pyrazolanthrone	174-182	mitogen-activated protein kinase 8	Homo sapiens	160-163
33396178-7	2021	Treatment with JNK inhibitor, SP600125, suppressed cadmium-induced elevation in the ratio of phosphorylation of JNK to JNK.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	15-18
33045079-11	2021	Treatment of irradiated cells with SP600125, a JNK inhibitor, augmented ROS production and impeded cell migration.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Homo sapiens	47-50
33396178-7	2021	Treatment with JNK inhibitor, SP600125, suppressed cadmium-induced elevation in the ratio of phosphorylation of JNK to JNK.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	112-115
33396178-7	2021	Treatment with JNK inhibitor, SP600125, suppressed cadmium-induced elevation in the ratio of phosphorylation of JNK to JNK.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	112-115
33520960-4	2020	It is suggested that enhancement of the p53 signaling pathway and weakening of the spindle assembly checkpoint are associated with the SP600125-induced cell cycle arrest.	pyrazolanthrone	135-143	tumor protein p53	Homo sapiens	40-43
33569416-13	2021	Moreover, treatment with the JNK pathway inhibitor SP600125 downregulated ABCG2 expression and rescued sensitivity to 5-FU in HCT116/FUR cells.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	29-32
33569416-13	2021	Moreover, treatment with the JNK pathway inhibitor SP600125 downregulated ABCG2 expression and rescued sensitivity to 5-FU in HCT116/FUR cells.	pyrazolanthrone	51-59	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	74-79
33391422-11	2021	Furthermore, NKCC1 overexpression upregulated and activated JNK, and the targeted inhibition of JNK by SP600125 abrogated the pro-metastatic effects of NKCC1.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	96-99
33840687-10	2021	SP600125, an inhibitor of SAPK/JNK, suppressed the levels of PGE2- and PGF2alpha-upregulated osteoprotegerin mRNA expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	31-34
33840687-10	2021	SP600125, an inhibitor of SAPK/JNK, suppressed the levels of PGE2- and PGF2alpha-upregulated osteoprotegerin mRNA expression.	pyrazolanthrone	0-8	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	93-108
32567086-10	2021	Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Mus musculus	32-35
32567086-10	2021	Inhibitors of MEK1/2 (PD98059), JNK (SP600125), upstream kinase of p70 S6 kinase (rapamycin) and Akt (deguelin), all increased IL-6 release.	pyrazolanthrone	37-45	interleukin 6	Mus musculus	127-131
33391422-11	2021	Furthermore, NKCC1 overexpression upregulated and activated JNK, and the targeted inhibition of JNK by SP600125 abrogated the pro-metastatic effects of NKCC1.	pyrazolanthrone	103-111	solute carrier family 12 member 2	Homo sapiens	152-157
32360175-11	2021	The application of SP600125 (10 muM) significantly suppressed the induction of IL-6 and IL-8 by GroEL-treated cells.	pyrazolanthrone	19-27	heat shock protein family D (Hsp60) member 1	Homo sapiens	96-101
33207073-7	2021	SHP-1 knockdown exacerbated LPS-induced retinal dysfunction and increased the levels of proinflammatory mediators in the retina, which was abrogated by a c-Jun N-terminal kinase (JNK) inhibitor (SP600125).	pyrazolanthrone	195-203	protein tyrosine phosphatase, non-receptor type 6	Rattus norvegicus	0-5
33207073-7	2021	SHP-1 knockdown exacerbated LPS-induced retinal dysfunction and increased the levels of proinflammatory mediators in the retina, which was abrogated by a c-Jun N-terminal kinase (JNK) inhibitor (SP600125).	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Rattus norvegicus	154-177
33207073-7	2021	SHP-1 knockdown exacerbated LPS-induced retinal dysfunction and increased the levels of proinflammatory mediators in the retina, which was abrogated by a c-Jun N-terminal kinase (JNK) inhibitor (SP600125).	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Rattus norvegicus	179-182
32360175-11	2021	The application of SP600125 (10 muM) significantly suppressed the induction of IL-6 and IL-8 by GroEL-treated cells.	pyrazolanthrone	19-27	C-X-C motif chemokine ligand 8	Homo sapiens	88-92
33075463-5	2021	Additionally, upon sensitizing and challenging the mice with TDI, we found that RAGE inhibitor (FPS-ZM1) and JNK inhibitor (SP600125) significantly reduced the TDI-induced asthma inflammation in vivo.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Mus musculus	109-112
33185864-7	2021	SP600125, an inhibitor of JNK, eradicates TNFSF15-induced GATA3 expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	26-29
33185864-7	2021	SP600125, an inhibitor of JNK, eradicates TNFSF15-induced GATA3 expression.	pyrazolanthrone	0-8	tumor necrosis factor (ligand) superfamily, member 15	Mus musculus	42-49
33185864-7	2021	SP600125, an inhibitor of JNK, eradicates TNFSF15-induced GATA3 expression.	pyrazolanthrone	0-8	GATA binding protein 3	Mus musculus	58-63
33745380-7	2021	Pharmacological inhibition of PI3K or JNK, using thalidomide, quercetin, or SP600125, attenuated the development of morphine tolerance in mice with SNL as measured by thermal paw withdrawal.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Mus musculus	38-41
33075463-6	2021	Furthermore, SP600125 also considerably restored RAGE and p-JNK expression.	pyrazolanthrone	13-21	advanced glycosylation end product-specific receptor	Mus musculus	49-53
33075463-6	2021	Furthermore, SP600125 also considerably restored RAGE and p-JNK expression.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	60-63
33318625-5	2021	Meanwhile, EM-2 induced apoptosis in a dose-dependent manner and G2/M phase arrest in Huh-7 cells, which could be partially reversed when treated with SP600125, a JNK inhibitor.	pyrazolanthrone	151-159	mitogen-activated protein kinase 8	Homo sapiens	163-166
33384558-9	2020	To validate the docking results, the pharmacological effects of dabigatran, estazolam, leucovorin, and pitavastatin on MCAO were tested in parallel with the JNK inhibitor SP600125.	pyrazolanthrone	171-179	mitogen-activated protein kinase 8	Rattus norvegicus	157-160
33381275-9	2020	Furthermore, the blue light-induced increase in production of TNF-alpha was attenuated by SP600125 or PDTC.	pyrazolanthrone	90-98	tumor necrosis factor	Homo sapiens	62-71
31312872-9	2020	The siWnt5a or JNK inhibitor SP600125 significantly augmented the inhibitory effects of alprostadil on the Wnt5a/JNK/NF-kappaB pathway.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Rattus norvegicus	15-18
31312872-9	2020	The siWnt5a or JNK inhibitor SP600125 significantly augmented the inhibitory effects of alprostadil on the Wnt5a/JNK/NF-kappaB pathway.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Rattus norvegicus	113-116
33157237-5	2020	Furthermore, inhibition of c-Jun N-terminal kinase (JNK) and extracellular regulated protein kinases (ERK) by their inhibitor SP600125 and PD98059 dramatically blocked MMP-1-enhanced ALP activity and mineralization in BMSCs.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	27-50
31832850-5	2020	Akt phosphorylation was increased in the presence of EPE, and wortmannin and SP600125 reversed the inhibitory effects of EPE on ICAM-1 and VCAM-1 expression.	pyrazolanthrone	77-85	intercellular adhesion molecule 1	Homo sapiens	128-134
31832850-5	2020	Akt phosphorylation was increased in the presence of EPE, and wortmannin and SP600125 reversed the inhibitory effects of EPE on ICAM-1 and VCAM-1 expression.	pyrazolanthrone	77-85	vascular cell adhesion molecule 1	Homo sapiens	139-145
33157237-5	2020	Furthermore, inhibition of c-Jun N-terminal kinase (JNK) and extracellular regulated protein kinases (ERK) by their inhibitor SP600125 and PD98059 dramatically blocked MMP-1-enhanced ALP activity and mineralization in BMSCs.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	52-55
33157237-5	2020	Furthermore, inhibition of c-Jun N-terminal kinase (JNK) and extracellular regulated protein kinases (ERK) by their inhibitor SP600125 and PD98059 dramatically blocked MMP-1-enhanced ALP activity and mineralization in BMSCs.	pyrazolanthrone	126-134	mitogen-activated protein kinase 1	Homo sapiens	102-105
33157237-5	2020	Furthermore, inhibition of c-Jun N-terminal kinase (JNK) and extracellular regulated protein kinases (ERK) by their inhibitor SP600125 and PD98059 dramatically blocked MMP-1-enhanced ALP activity and mineralization in BMSCs.	pyrazolanthrone	126-134	matrix metallopeptidase 1	Homo sapiens	168-173
33157237-5	2020	Furthermore, inhibition of c-Jun N-terminal kinase (JNK) and extracellular regulated protein kinases (ERK) by their inhibitor SP600125 and PD98059 dramatically blocked MMP-1-enhanced ALP activity and mineralization in BMSCs.	pyrazolanthrone	126-134	ATHS	Homo sapiens	183-186
33271769-6	2020	Furthermore, we showed that the inhibition of JNK phosphorylation contributed to white adipocyte differentiation into beige adipocytes, which was validated by the use of SP600125.	pyrazolanthrone	170-178	mitogen-activated protein kinase 8	Homo sapiens	46-49
33125089-1	2020	SP600125 is a classic inhibitor of c-Jun-N-terminal kinase (JNK) that is widely used in numerous medicinal studies, but its administration regimen has yet to be optimized.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	60-63
33125089-18	2020	administration of SP600125 produced a high plasma exposure profile, which directly determined its efficacy of blocking the JNK signalling.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	123-126
33125089-19	2020	This effect of SP600125 on the JNK pathway may provide an optimized design for future in vivo investigations.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	31-34
31994958-6	2020	Some ATP-competitive inhibitors of JNK, such as SP600125 and AS601245, are widely used in vitro; however, this type of inhibitor lacks specificity as they indiscriminately inhibit phosphorylation of all JNK substrates.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	35-38
31994958-6	2020	Some ATP-competitive inhibitors of JNK, such as SP600125 and AS601245, are widely used in vitro; however, this type of inhibitor lacks specificity as they indiscriminately inhibit phosphorylation of all JNK substrates.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	203-206
32623775-13	2020	Furthermore, inhibition of JNK pathway by SP600125, the expression of p-JNK and p-Erk were reduced.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	27-30
33173964-11	2020	In addition, the inhibitory effects of 10 ppm Ti ions on MC3T3-E1 cells was found to be reversed by the JNK inhibitor SP600125.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Mus musculus	104-107
33181025-14	2020	Chemical inhibitors of smad2/3- (SB431542) and JNK- (SP600125) signalling pathways blocked expression of long noncoding RNA (lncRNA) - lnc949.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Mus musculus	47-50
32835935-7	2020	Furthermore, SP600125, an inhibitor of JNK, reversed CoCl2-induced the increased apoptosis of MLO-Y4 cells in term of reducing the expression of caspase-3.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	39-42
33107399-6	2020	Phosphorylation of JNK and p38 were up-regulated, and pretreatment with SB203580 and SP600125 reversed the effect of IL-1alpha on DFCs.	pyrazolanthrone	85-93	interleukin 1 alpha	Rattus norvegicus	117-126
32835935-7	2020	Furthermore, SP600125, an inhibitor of JNK, reversed CoCl2-induced the increased apoptosis of MLO-Y4 cells in term of reducing the expression of caspase-3.	pyrazolanthrone	13-21	caspase 3	Mus musculus	145-154
33239866-16	2020	Subsequently, after treatment with the ROS scavenger GSH and the JNK inhibitor SP600125, the apoptosis-inducing effect triggered by acacetin was significantly attenuated.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	65-68
33184449-7	2021	We found that neither inhibition of the MEK/ERK pathway by U0126 nor inhibition of the p38 pathway by SB203580 affected H2O2-induced ASIC1a expression, whereas inhibition of the JNK pathway by SP600125 potently decreased ASIC1a expression and abolished the H2O2-mediated increase in ASIC1a expression and ASIC currents.	pyrazolanthrone	193-201	mitogen-activated protein kinase 8	Mus musculus	178-181
33281919-16	2020	JNK expression level was significantly increased in the SE (50%) group compared to the SP600125 (P < 0.01) and the NAC group (P < 0.05).	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	0-3
33281919-17	2020	Caspase-3 was downregulated in the SE (50%) group compared to the SP600125 (P < 0.01) and NAC group (P < 0.05).	pyrazolanthrone	66-74	caspase 3	Homo sapiens	0-9
33281919-18	2020	Caspase-3 activation in the SP600125 group was higher than that in the NAC group (P < 0.05).	pyrazolanthrone	28-36	caspase 3	Homo sapiens	0-9
32712458-9	2020	This was shown by the fact that pretreatment with the JNK inhibitors SP600125 or JNK-IN-8 strongly downregulated phosphorylation of c-Jun protein and markedly reduced TNF-alpha-mediated LCN2 upregulation in PC-3 cells.	pyrazolanthrone	69-77	tumor necrosis factor	Homo sapiens	167-176
32712458-9	2020	This was shown by the fact that pretreatment with the JNK inhibitors SP600125 or JNK-IN-8 strongly downregulated phosphorylation of c-Jun protein and markedly reduced TNF-alpha-mediated LCN2 upregulation in PC-3 cells.	pyrazolanthrone	69-77	lipocalin 2	Homo sapiens	186-190
32712458-9	2020	This was shown by the fact that pretreatment with the JNK inhibitors SP600125 or JNK-IN-8 strongly downregulated phosphorylation of c-Jun protein and markedly reduced TNF-alpha-mediated LCN2 upregulation in PC-3 cells.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	54-57
32712458-9	2020	This was shown by the fact that pretreatment with the JNK inhibitors SP600125 or JNK-IN-8 strongly downregulated phosphorylation of c-Jun protein and markedly reduced TNF-alpha-mediated LCN2 upregulation in PC-3 cells.	pyrazolanthrone	69-77	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	132-137
33226363-9	2020	Conversely, these adverse events caused by AngII and MS were obviously reversed by ML3404 and SP600125.	pyrazolanthrone	94-102	angiotensinogen	Homo sapiens	43-48
32956685-6	2020	SP600125(JNK inhibitor) decreased the phosphorylation of JNK while increasing the expression of SIRT1, indicating that SIRT1 and JNK can interact with each other.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	9-12
32956685-6	2020	SP600125(JNK inhibitor) decreased the phosphorylation of JNK while increasing the expression of SIRT1, indicating that SIRT1 and JNK can interact with each other.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	57-60
32956685-6	2020	SP600125(JNK inhibitor) decreased the phosphorylation of JNK while increasing the expression of SIRT1, indicating that SIRT1 and JNK can interact with each other.	pyrazolanthrone	0-8	sirtuin 1	Homo sapiens	96-101
32956685-6	2020	SP600125(JNK inhibitor) decreased the phosphorylation of JNK while increasing the expression of SIRT1, indicating that SIRT1 and JNK can interact with each other.	pyrazolanthrone	0-8	sirtuin 1	Homo sapiens	119-124
32956685-6	2020	SP600125(JNK inhibitor) decreased the phosphorylation of JNK while increasing the expression of SIRT1, indicating that SIRT1 and JNK can interact with each other.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	57-60
32810585-12	2020	Furthermore, the JNK inhibitor SP600125 relieved CRS-induced hippocampal mitochondrial dysfunction, apoptosis via the mitochondrial apoptotic pathway, and learning and memory dysfunction.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
32735910-5	2020	Inhibition of JNK signaling with SP600125 reduced cancer cell-conditioned media-induced myotube atrophy, myosin heavy chain protein turnover, and mRNA expression of cachexia-specific ubiquitin ligases Trim63 and Fbxo32.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	14-17
33137935-6	2020	Directly treating HUVECs with recombinant Wnt11 protein significantly increased CLT formation, which was abrogated by treating cells with the JNK inhibitor SP600125, as well as the PKC inhibitor Calphostin-C.	pyrazolanthrone	156-164	Wnt family member 11	Homo sapiens	42-47
33137935-6	2020	Directly treating HUVECs with recombinant Wnt11 protein significantly increased CLT formation, which was abrogated by treating cells with the JNK inhibitor SP600125, as well as the PKC inhibitor Calphostin-C.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	142-145
32735910-5	2020	Inhibition of JNK signaling with SP600125 reduced cancer cell-conditioned media-induced myotube atrophy, myosin heavy chain protein turnover, and mRNA expression of cachexia-specific ubiquitin ligases Trim63 and Fbxo32.	pyrazolanthrone	33-41	tripartite motif containing 63	Homo sapiens	201-207
32735910-5	2020	Inhibition of JNK signaling with SP600125 reduced cancer cell-conditioned media-induced myotube atrophy, myosin heavy chain protein turnover, and mRNA expression of cachexia-specific ubiquitin ligases Trim63 and Fbxo32.	pyrazolanthrone	33-41	F-box protein 32	Homo sapiens	212-218
33013353-10	2020	In this study, pretreatment of SP600125, a JNK inhibitor, reduced autophagy and enhanced STAT3 inhibition and apoptosis.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	43-46
33194716-8	2020	Moreover, NAC and JNK-specific inhibitor SP600125 attenuated the effect of Cos.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	18-21
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	148-151
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	pyrazolanthrone	134-142	TNF receptor superfamily member 10b	Homo sapiens	213-216
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	pyrazolanthrone	134-142	dynamin 1 like	Homo sapiens	232-236
32777260-8	2020	Moreover, luteolin treatment alone or in combination with TRAIL increased the phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125 (the JNK inhibitor) significantly abolished the synergistic effect on DR5 expression and Drp1 translocation, indicating that JNK signaling activation was greatly associated with the synergistic effect exerted by luteolin in NSCLC cells.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	148-151
33116501-11	2020	A decrease in cell viability, loss of the MMP and an increase in apoptosis rate induced by this synergy could be significantly attenuated by the ROS scavenger N-acetylcysteine and JNK inhibitor SP600125.	pyrazolanthrone	194-202	mitogen-activated protein kinase 8	Homo sapiens	180-183
32688140-12	2020	We treated H9c2 cells with LY317615, SP600125, and SB203580, inhibitors of PKCalpha, JNK, and P38, respectively, thereby resulting in a substantial decrease in hypertrophy, fibrosis, and apoptosis.	pyrazolanthrone	37-45	protein kinase C, alpha	Rattus norvegicus	75-83
32688140-12	2020	We treated H9c2 cells with LY317615, SP600125, and SB203580, inhibitors of PKCalpha, JNK, and P38, respectively, thereby resulting in a substantial decrease in hypertrophy, fibrosis, and apoptosis.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	85-88
32688140-12	2020	We treated H9c2 cells with LY317615, SP600125, and SB203580, inhibitors of PKCalpha, JNK, and P38, respectively, thereby resulting in a substantial decrease in hypertrophy, fibrosis, and apoptosis.	pyrazolanthrone	37-45	mitogen activated protein kinase 14	Rattus norvegicus	94-97
33019495-9	2020	Treatment with the JNK inhibitor, SP600125, also suppressed COL1A1 and ACTA2 expression, indicating that TGFBR2 and JNK mediate the anti-fibrotic effect of miR-6133-5p.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	19-22
33019495-9	2020	Treatment with the JNK inhibitor, SP600125, also suppressed COL1A1 and ACTA2 expression, indicating that TGFBR2 and JNK mediate the anti-fibrotic effect of miR-6133-5p.	pyrazolanthrone	34-42	collagen type I alpha 1 chain	Homo sapiens	60-66
33019495-9	2020	Treatment with the JNK inhibitor, SP600125, also suppressed COL1A1 and ACTA2 expression, indicating that TGFBR2 and JNK mediate the anti-fibrotic effect of miR-6133-5p.	pyrazolanthrone	34-42	actin alpha 2, smooth muscle	Homo sapiens	71-76
33019495-9	2020	Treatment with the JNK inhibitor, SP600125, also suppressed COL1A1 and ACTA2 expression, indicating that TGFBR2 and JNK mediate the anti-fibrotic effect of miR-6133-5p.	pyrazolanthrone	34-42	transforming growth factor beta receptor 2	Homo sapiens	105-111
33019495-9	2020	Treatment with the JNK inhibitor, SP600125, also suppressed COL1A1 and ACTA2 expression, indicating that TGFBR2 and JNK mediate the anti-fibrotic effect of miR-6133-5p.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	116-119
33019495-9	2020	Treatment with the JNK inhibitor, SP600125, also suppressed COL1A1 and ACTA2 expression, indicating that TGFBR2 and JNK mediate the anti-fibrotic effect of miR-6133-5p.	pyrazolanthrone	34-42	microRNA 6133	Homo sapiens	156-164
32660795-8	2020	miR-203a-3p mimics resulted in improved CoCl2-induced apoptosis of RPEs, overexpression of SOCS3 or c-Jun N-terminal kinase (JNK) inhibitor SP600125 reversed the pro-apoptotic effect of miR-203a-3p, to a certain extent.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Rattus norvegicus	100-123
32660795-8	2020	miR-203a-3p mimics resulted in improved CoCl2-induced apoptosis of RPEs, overexpression of SOCS3 or c-Jun N-terminal kinase (JNK) inhibitor SP600125 reversed the pro-apoptotic effect of miR-203a-3p, to a certain extent.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Rattus norvegicus	125-128
32998255-10	2020	Similar results were obtained by the cotreatment with OADP and the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	67-90
32998255-10	2020	Similar results were obtained by the cotreatment with OADP and the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	92-95
32985606-7	2020	Notably, all these events were reverted by N-acetyl-L-cysteine and JNK inhibitor SP600125 furnishing evidence that APE exerted its effects through the activation of ROS/JNK signaling.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	67-70
32985606-7	2020	Notably, all these events were reverted by N-acetyl-L-cysteine and JNK inhibitor SP600125 furnishing evidence that APE exerted its effects through the activation of ROS/JNK signaling.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	169-172
33061432-7	2020	The inhibitor SP600125 was applied to confirm the role of the JNK pathway in SSD efficiency.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	62-65
33061432-13	2020	The addition of SP600125 blocked the activation of SSD on the MKK4-JNK regulatory pathway and reversed the effects of SSD on proliferation inhibition and apoptosis induction in BxPC3 cells.	pyrazolanthrone	16-24	mitogen-activated protein kinase kinase 4	Homo sapiens	62-66
33061432-13	2020	The addition of SP600125 blocked the activation of SSD on the MKK4-JNK regulatory pathway and reversed the effects of SSD on proliferation inhibition and apoptosis induction in BxPC3 cells.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Homo sapiens	67-70
32982289-6	2020	SP600125 (JNK inhibitor) was in vivo and in vitro used to verify the regulatory role of the JNK signaling pathway in the anti-hepatic carcinoma mechanism of TB.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	10-13
32982289-6	2020	SP600125 (JNK inhibitor) was in vivo and in vitro used to verify the regulatory role of the JNK signaling pathway in the anti-hepatic carcinoma mechanism of TB.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	92-95
33013461-6	2020	Furthermore, inhibitors of p38 MAPK (SB203580) and JNK (SP600125) alleviated HG- and GADD45B overexpression-induced renal tubular epithelial-mesenchymal transition and apoptosis.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	51-54
33013461-6	2020	Furthermore, inhibitors of p38 MAPK (SB203580) and JNK (SP600125) alleviated HG- and GADD45B overexpression-induced renal tubular epithelial-mesenchymal transition and apoptosis.	pyrazolanthrone	56-64	growth arrest and DNA damage inducible beta	Homo sapiens	85-92
32807499-6	2020	P110alpha knockdown or treatment with SP600125, an inhibitor of JNK, also reduced the pGSK3beta Ser9 level under HG condition.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	64-67
33059700-4	2020	An in vitro study, in which mouse hippocampal neuronal HT22 cells were treated with or without a JNK-specific inhibitor (SP600125), and molecular docking analysis were used to confirm the underlying molecular mechanism and explore the related signaling pathway prior to molecular and histological analyses.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Mus musculus	97-100
33059700-9	2020	Both the molecular docking approach and the in vitro study (in which the neuronal HT22 cells were treated with or without a p-JNK-specific inhibitor (SP600125)) further verified our in vivo findings that Gly bound to the p-JNK protein and inhibited its function and the JNK-mediated apoptotic pathway in the mouse brain and HT22 cells.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	126-129
33059700-9	2020	Both the molecular docking approach and the in vitro study (in which the neuronal HT22 cells were treated with or without a p-JNK-specific inhibitor (SP600125)) further verified our in vivo findings that Gly bound to the p-JNK protein and inhibited its function and the JNK-mediated apoptotic pathway in the mouse brain and HT22 cells.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	223-226
33059700-9	2020	Both the molecular docking approach and the in vitro study (in which the neuronal HT22 cells were treated with or without a p-JNK-specific inhibitor (SP600125)) further verified our in vivo findings that Gly bound to the p-JNK protein and inhibited its function and the JNK-mediated apoptotic pathway in the mouse brain and HT22 cells.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	223-226
32624270-5	2020	To verify the implication of JNK signal pathway, JNK inhibitor SP600125 and activator Anisomycin were injected.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Mus musculus	29-32
32977663-4	2020	SP600125 (SP), a reversible adenosine triphosphate competitive pan-JNK inhibitor, was then given orally after disease onset.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	67-70
32977663-6	2020	Nine, but not three, consecutive days of SP treatment led to a significant dose-dependent decrease of mean cumulative MOG35-55 EAE severity that was associated with increased mRNA expression of interferon gamma (INF-gamma) and tumor necrosis factor alpha (TNF-alpha) in the spinal cord.	pyrazolanthrone	41-43	interferon gamma	Mus musculus	194-221
32977663-6	2020	Nine, but not three, consecutive days of SP treatment led to a significant dose-dependent decrease of mean cumulative MOG35-55 EAE severity that was associated with increased mRNA expression of interferon gamma (INF-gamma) and tumor necrosis factor alpha (TNF-alpha) in the spinal cord.	pyrazolanthrone	41-43	tumor necrosis factor	Mus musculus	227-254
32977663-6	2020	Nine, but not three, consecutive days of SP treatment led to a significant dose-dependent decrease of mean cumulative MOG35-55 EAE severity that was associated with increased mRNA expression of interferon gamma (INF-gamma) and tumor necrosis factor alpha (TNF-alpha) in the spinal cord.	pyrazolanthrone	41-43	tumor necrosis factor	Mus musculus	256-265
32895058-4	2020	In the presence of an ERK1/2,5 inhibitor PD98059 or a JNK MAP kinase inhibitor SP600125, P19 cells successfully differentiated into cardiomyocytes displaying spontaneous beatings with expression of three types of pacemaker ion channels.	pyrazolanthrone	79-87	cyclin dependent kinase inhibitor 2D	Homo sapiens	89-92
33013353-10	2020	In this study, pretreatment of SP600125, a JNK inhibitor, reduced autophagy and enhanced STAT3 inhibition and apoptosis.	pyrazolanthrone	31-39	signal transducer and activator of transcription 3	Homo sapiens	89-94
32504758-12	2020	Moreover, inhibition of c-Jun N-terminal kinase (JNK) by SP600125 also suppressed OVA-induced allergic airway inflammation and autophagy activation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Mus musculus	24-47
32502579-5	2020	RIPK3 inhibitor GSK872, RIPk3 recombinant adeno-associated virus (rAAV) and JNK-specific inhibitor SP600125 were intracerebroventricular injected before I/R.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	76-79
32856499-10	2020	Of note, all of these biochemical changes were attenuated by silencing p66Shc or inhibiting JNK with SP600125.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Rattus norvegicus	92-95
32504758-12	2020	Moreover, inhibition of c-Jun N-terminal kinase (JNK) by SP600125 also suppressed OVA-induced allergic airway inflammation and autophagy activation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Mus musculus	49-52
32504758-12	2020	Moreover, inhibition of c-Jun N-terminal kinase (JNK) by SP600125 also suppressed OVA-induced allergic airway inflammation and autophagy activation.	pyrazolanthrone	57-65	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	82-85
32504758-13	2020	Interestingly, treating TLR2-/- mice with SP600125 showed similar OVA-induced allergic airway inflammation and autophagy activation compared to that in vehicle-treated TLR2-/- mice.	pyrazolanthrone	42-50	toll-like receptor 2	Mus musculus	24-28
32504758-13	2020	Interestingly, treating TLR2-/- mice with SP600125 showed similar OVA-induced allergic airway inflammation and autophagy activation compared to that in vehicle-treated TLR2-/- mice.	pyrazolanthrone	42-50	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	66-69
32824426-9	2020	Co-inhibition of ERK and JNK signaling pathways by their specific inhibitors (PD9805 and SP600125, respectively) resulted in the suppression of mRNA and protein levels of IL-6, IL-1beta, and TNFalpha in FLS.	pyrazolanthrone	89-97	mitogen-activated protein kinase 1	Homo sapiens	17-20
32904295-13	2020	The inhibitors of both p38 MAPK and SAPK/JNK, SB203580 and SP600125, respectively, reduced the tramadol amplification of OPG release stimulated by PGF2alpha.	pyrazolanthrone	59-67	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	121-124
32717251-10	2020	Pretreatment with JNK inhibitor SP600125 significantly attenuated caspase-3 cleavage and MMP depolarization and increased Mcl-1 protein levels in AgNPs-treated ARPE-19 cells in a dose-dependent manner.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	18-21
32717251-10	2020	Pretreatment with JNK inhibitor SP600125 significantly attenuated caspase-3 cleavage and MMP depolarization and increased Mcl-1 protein levels in AgNPs-treated ARPE-19 cells in a dose-dependent manner.	pyrazolanthrone	32-40	caspase 3	Homo sapiens	66-75
32717251-10	2020	Pretreatment with JNK inhibitor SP600125 significantly attenuated caspase-3 cleavage and MMP depolarization and increased Mcl-1 protein levels in AgNPs-treated ARPE-19 cells in a dose-dependent manner.	pyrazolanthrone	32-40	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	122-127
32824426-9	2020	Co-inhibition of ERK and JNK signaling pathways by their specific inhibitors (PD9805 and SP600125, respectively) resulted in the suppression of mRNA and protein levels of IL-6, IL-1beta, and TNFalpha in FLS.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	25-28
32824426-9	2020	Co-inhibition of ERK and JNK signaling pathways by their specific inhibitors (PD9805 and SP600125, respectively) resulted in the suppression of mRNA and protein levels of IL-6, IL-1beta, and TNFalpha in FLS.	pyrazolanthrone	89-97	interleukin 6	Homo sapiens	171-175
32824426-9	2020	Co-inhibition of ERK and JNK signaling pathways by their specific inhibitors (PD9805 and SP600125, respectively) resulted in the suppression of mRNA and protein levels of IL-6, IL-1beta, and TNFalpha in FLS.	pyrazolanthrone	89-97	interleukin 1 alpha	Homo sapiens	177-185
32824426-9	2020	Co-inhibition of ERK and JNK signaling pathways by their specific inhibitors (PD9805 and SP600125, respectively) resulted in the suppression of mRNA and protein levels of IL-6, IL-1beta, and TNFalpha in FLS.	pyrazolanthrone	89-97	tumor necrosis factor	Homo sapiens	191-199
32742343-11	2020	These effects were reversed by SP600125, an inhibitor of the JNK pathway.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	61-64
32764580-6	2020	Inhibition of JNK1/2 by pretreatment with the JNK-inhibitor SP600125 antagonized cytotoxic activity of the marine compound.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	14-20
32764580-6	2020	Inhibition of JNK1/2 by pretreatment with the JNK-inhibitor SP600125 antagonized cytotoxic activity of the marine compound.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	14-17
32922532-7	2020	What is more, p38 inhibitor SB203580 and JNK inhibitor SP600125 attenuated the upregulated expression of LC3-II and cleaved-caspase-3 by the effect of Propranolol.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	41-44
32922532-7	2020	What is more, p38 inhibitor SB203580 and JNK inhibitor SP600125 attenuated the upregulated expression of LC3-II and cleaved-caspase-3 by the effect of Propranolol.	pyrazolanthrone	55-63	caspase 3	Homo sapiens	124-133
32662511-1	2020	The aim of this study is to determine whether the c-Jun N-terminal kinase (JNK) signaling is a regulator of oxidative DNA damage, germ cell apoptosis (GCA), and mitochondrial dysfunction during testicular ischemia reperfusion injury (tIRI) using the JNK inhibitor SP600125.	pyrazolanthrone	264-272	mitogen-activated protein kinase 8	Rattus norvegicus	50-73
32662511-1	2020	The aim of this study is to determine whether the c-Jun N-terminal kinase (JNK) signaling is a regulator of oxidative DNA damage, germ cell apoptosis (GCA), and mitochondrial dysfunction during testicular ischemia reperfusion injury (tIRI) using the JNK inhibitor SP600125.	pyrazolanthrone	264-272	mitogen-activated protein kinase 8	Rattus norvegicus	75-78
32662511-11	2020	Mitochondrial dysfunction was reflected by NAD+ depletion, overexpression of uncoupling protein 2, and increased level of cytochrome c. Such tIRI-induced modulations were all attenuated by SP600125 treatment prior to reperfusion.	pyrazolanthrone	189-197	uncoupling protein 2	Rattus norvegicus	77-97
32251709-9	2020	2DP induced phosphorylation of JunB; co-treatment with SP600125 blocked the 2DP-induced Bmp6 expression partially.	pyrazolanthrone	55-63	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	31-35
32251709-9	2020	2DP induced phosphorylation of JunB; co-treatment with SP600125 blocked the 2DP-induced Bmp6 expression partially.	pyrazolanthrone	55-63	bone morphogenetic protein 6	Homo sapiens	88-92
32502840-8	2020	CD induces apoptosis by enhancing phosphorylation of JNK, further exploring the combination of CD and SP600125 reduced the overexpression of phosphate JNK levels.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	53-56
32502840-8	2020	CD induces apoptosis by enhancing phosphorylation of JNK, further exploring the combination of CD and SP600125 reduced the overexpression of phosphate JNK levels.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	151-154
32621591-7	2020	We observed significant reduction in the in vitro migration and differentiation of keratinocytes when co-cultured with medium conditioned by LOXL2-silenced hAMSCs and when treated with 10 muM SP600125, a specific JNK inhibitor.	pyrazolanthrone	192-200	lysyl oxidase like 2	Homo sapiens	141-146
31705656-7	2020	JNK antagonist SP600125 partially restored synapse development and cognitive function without affecting the expression of HIPK2.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
32407896-10	2020	In addition, pre-treatment with SP600125 (3 muM; a JNK specific inhibitor) abolished estrogen-induced expression of alpha2C-AR.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	51-54
32407896-10	2020	In addition, pre-treatment with SP600125 (3 muM; a JNK specific inhibitor) abolished estrogen-induced expression of alpha2C-AR.	pyrazolanthrone	32-40	adrenoceptor alpha 2C	Homo sapiens	116-126
32407896-11	2020	Importantly, estrogen-induced activation of alpha2C-AR promoter was attenuated with SP600125.	pyrazolanthrone	84-92	adrenoceptor alpha 2C	Homo sapiens	44-54
32407896-17	2020	Indeed, estrogen potentiated alpha2C-AR-mediated cold-induced vasoconstriction, which was abolished by SP600125.	pyrazolanthrone	103-111	adrenoceptor alpha 2C	Homo sapiens	29-39
32658869-8	2020	Inhibition of JNK signaling with a small interfering RNA (siRNA) or with sp600125 down-regulated the increase of SOD2 transcription.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	14-17
32658869-8	2020	Inhibition of JNK signaling with a small interfering RNA (siRNA) or with sp600125 down-regulated the increase of SOD2 transcription.	pyrazolanthrone	73-81	superoxide dismutase 2	Homo sapiens	113-117
32850324-10	2020	Cell proliferation and migration were inhibited after the addition of the JNK inhibitor SP600125.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Homo sapiens	74-77
32884256-8	2020	Mechanistic investigation revealed that ZnONPs selectively activated the JNK pathway and thus resulted in the ferroptotic phenotypes, JNK inhibitor SP600125 could reverse lipid peroxidation upregulation and ferroptotic cell death induced by ZnONPs in PC-12 cells.	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Rattus norvegicus	73-76
32884256-8	2020	Mechanistic investigation revealed that ZnONPs selectively activated the JNK pathway and thus resulted in the ferroptotic phenotypes, JNK inhibitor SP600125 could reverse lipid peroxidation upregulation and ferroptotic cell death induced by ZnONPs in PC-12 cells.	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Rattus norvegicus	134-137
32703964-7	2020	Inhibition of MAPK8 (by SP600125) reduced EGF-mediated MMP-9/TIMP1 ratio and invasion.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	14-19
32703964-7	2020	Inhibition of MAPK8 (by SP600125) reduced EGF-mediated MMP-9/TIMP1 ratio and invasion.	pyrazolanthrone	24-32	TIMP metallopeptidase inhibitor 1	Homo sapiens	61-66
32693803-8	2020	MMP408, PD98059, SP600125 and SB203580 were used to inhibit MMP-12, ERK, JNK and p38 respectively.	pyrazolanthrone	17-25	matrix metallopeptidase 12	Mus musculus	60-66
32693803-8	2020	MMP408, PD98059, SP600125 and SB203580 were used to inhibit MMP-12, ERK, JNK and p38 respectively.	pyrazolanthrone	17-25	mitogen-activated protein kinase 1	Mus musculus	68-71
32693803-8	2020	MMP408, PD98059, SP600125 and SB203580 were used to inhibit MMP-12, ERK, JNK and p38 respectively.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Mus musculus	73-76
32693803-8	2020	MMP408, PD98059, SP600125 and SB203580 were used to inhibit MMP-12, ERK, JNK and p38 respectively.	pyrazolanthrone	17-25	mitogen-activated protein kinase 14	Mus musculus	81-84
32765280-8	2020	Cytotoxicity of the combined regimen in MDA-MB-231 cell was significantly abrogated by SP600125, a potent c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	106-129
32765280-8	2020	Cytotoxicity of the combined regimen in MDA-MB-231 cell was significantly abrogated by SP600125, a potent c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	131-134
32621591-7	2020	We observed significant reduction in the in vitro migration and differentiation of keratinocytes when co-cultured with medium conditioned by LOXL2-silenced hAMSCs and when treated with 10 muM SP600125, a specific JNK inhibitor.	pyrazolanthrone	192-200	mitogen-activated protein kinase 8	Homo sapiens	213-216
32519392-7	2020	After respectively inhibiting mtROS (Mito-TEMPO) and JNK (SP600125), HF-induced apoptosis was reversed.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Homo sapiens	53-56
32616192-4	2020	Further study showed that NLE activated the c-Jun N-terminal kinases (JNK), the upstream of c-Jun, and its inhibitor SP600125 reversed the NLE-increased PD-L1.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Homo sapiens	44-68
32616192-4	2020	Further study showed that NLE activated the c-Jun N-terminal kinases (JNK), the upstream of c-Jun, and its inhibitor SP600125 reversed the NLE-increased PD-L1.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Homo sapiens	70-73
32616192-4	2020	Further study showed that NLE activated the c-Jun N-terminal kinases (JNK), the upstream of c-Jun, and its inhibitor SP600125 reversed the NLE-increased PD-L1.	pyrazolanthrone	117-125	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-49
32616192-4	2020	Further study showed that NLE activated the c-Jun N-terminal kinases (JNK), the upstream of c-Jun, and its inhibitor SP600125 reversed the NLE-increased PD-L1.	pyrazolanthrone	117-125	CD274 molecule	Homo sapiens	153-158
31518515-10	2020	SB203580 (p38 inhibitor) or SP600125 (JNK1/2 inhibitor) could reverse BCI-induced analgesia.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	38-42
32670287-10	2020	The elevated level of phospho-c-Jun stimulated by SAG was decreased in the presence of JNK inhibitor (SP600125) (P < 0.001).	pyrazolanthrone	102-110	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
32167616-7	2020	SP600125, an inhibitor of JNK signaling, partially abolished the BOP1 overexpression-mediated increase in the migratory and invasive ability of CRC cells.	pyrazolanthrone	0-8	BOP1 ribosomal biogenesis factor	Homo sapiens	65-69
32167616-7	2020	SP600125, an inhibitor of JNK signaling, partially abolished the BOP1 overexpression-mediated increase in the migratory and invasive ability of CRC cells.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
32554486-9	2020	Inhibition of the Wnt/JNK signaling pathway by SP600125, a JNK inhibitor, contributed to proliferation induction in NSCLC cells.	pyrazolanthrone	47-55	Wnt family member 7A	Homo sapiens	18-21
32554486-9	2020	Inhibition of the Wnt/JNK signaling pathway by SP600125, a JNK inhibitor, contributed to proliferation induction in NSCLC cells.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	22-25
32554486-9	2020	Inhibition of the Wnt/JNK signaling pathway by SP600125, a JNK inhibitor, contributed to proliferation induction in NSCLC cells.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	59-62
32670287-10	2020	The elevated level of phospho-c-Jun stimulated by SAG was decreased in the presence of JNK inhibitor (SP600125) (P < 0.001).	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	87-90
32617137-3	2020	In this study, we examined the effect of chronic ischemia on the induction of oxidative stress and c-Jun N-terminal kinase-associated detrimental effects and unveiled the inhibitory effect of specific JNK inhibitor (SP600125) on JNK-mediated brain degeneration in adult mice.	pyrazolanthrone	216-224	mitogen-activated protein kinase 8	Mus musculus	201-204
32655831-7	2020	Further study revealed that JNK/Beclin1 pathway participated in the process of autophagy and JNK inhibitor SP600125 could attenuate autophagy and reduce the invasive ability of HCC cells induced by BMP4.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	28-31
32655831-7	2020	Further study revealed that JNK/Beclin1 pathway participated in the process of autophagy and JNK inhibitor SP600125 could attenuate autophagy and reduce the invasive ability of HCC cells induced by BMP4.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	93-96
32655831-7	2020	Further study revealed that JNK/Beclin1 pathway participated in the process of autophagy and JNK inhibitor SP600125 could attenuate autophagy and reduce the invasive ability of HCC cells induced by BMP4.	pyrazolanthrone	107-115	bone morphogenetic protein 4	Homo sapiens	198-202
32617137-3	2020	In this study, we examined the effect of chronic ischemia on the induction of oxidative stress and c-Jun N-terminal kinase-associated detrimental effects and unveiled the inhibitory effect of specific JNK inhibitor (SP600125) on JNK-mediated brain degeneration in adult mice.	pyrazolanthrone	216-224	mitogen-activated protein kinase 8	Mus musculus	229-232
32617137-4	2020	Our behavioral, biochemical, and immunofluorescence studies revealed that chronic ischemic injuries sustained increased levels of oxidative stress-induced active JNK for a long time, whereas SP600125 significantly reduced the elevated level of active JNK and further regulated Nrf2/HO-1 and NF-kappaB signaling, which have been confirmed in vivo.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Mus musculus	251-254
32617137-4	2020	Our behavioral, biochemical, and immunofluorescence studies revealed that chronic ischemic injuries sustained increased levels of oxidative stress-induced active JNK for a long time, whereas SP600125 significantly reduced the elevated level of active JNK and further regulated Nrf2/HO-1 and NF-kappaB signaling, which have been confirmed in vivo.	pyrazolanthrone	191-199	nuclear factor, erythroid derived 2, like 2	Mus musculus	277-281
32617137-4	2020	Our behavioral, biochemical, and immunofluorescence studies revealed that chronic ischemic injuries sustained increased levels of oxidative stress-induced active JNK for a long time, whereas SP600125 significantly reduced the elevated level of active JNK and further regulated Nrf2/HO-1 and NF-kappaB signaling, which have been confirmed in vivo.	pyrazolanthrone	191-199	heme oxygenase 1	Mus musculus	282-286
32323751-10	2020	Furthermore, THP-1-derived macrophages pretreated with SB203580 or SP600125 prior to bacterial infection exhibited a significant inhibition in intracellular S. aureus survival.	pyrazolanthrone	67-75	GLI family zinc finger 2	Homo sapiens	13-18
31857702-7	2020	After blocking docetaxel-induced JNK activation using the JNK inhibitor SP600125 or siRNA targeting JNK, the USP33 knockout-enhanced apoptosis was reversed.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	33-36
31857702-7	2020	After blocking docetaxel-induced JNK activation using the JNK inhibitor SP600125 or siRNA targeting JNK, the USP33 knockout-enhanced apoptosis was reversed.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	58-61
31857702-7	2020	After blocking docetaxel-induced JNK activation using the JNK inhibitor SP600125 or siRNA targeting JNK, the USP33 knockout-enhanced apoptosis was reversed.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	58-61
31857702-7	2020	After blocking docetaxel-induced JNK activation using the JNK inhibitor SP600125 or siRNA targeting JNK, the USP33 knockout-enhanced apoptosis was reversed.	pyrazolanthrone	72-80	ubiquitin specific peptidase 33	Homo sapiens	109-114
32521824-7	2020	JNK inhibitor, SP600125, attenuated SEMA3A-induced podocyte apoptosis, indicating that the JNK pathway would be involved in SEMA3A-induced podocyte apoptosis.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	0-3
32521824-7	2020	JNK inhibitor, SP600125, attenuated SEMA3A-induced podocyte apoptosis, indicating that the JNK pathway would be involved in SEMA3A-induced podocyte apoptosis.	pyrazolanthrone	15-23	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A	Mus musculus	36-42
32521824-7	2020	JNK inhibitor, SP600125, attenuated SEMA3A-induced podocyte apoptosis, indicating that the JNK pathway would be involved in SEMA3A-induced podocyte apoptosis.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	91-94
32521824-7	2020	JNK inhibitor, SP600125, attenuated SEMA3A-induced podocyte apoptosis, indicating that the JNK pathway would be involved in SEMA3A-induced podocyte apoptosis.	pyrazolanthrone	15-23	sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A	Mus musculus	124-130
32588690-7	2020	SP600125 treatment markedly inhibited JNK mRNA expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	38-41
32040807-12	2020	Lead molecule (AJ-292-42151532) with the highest binding free energy (dG = 106.8 Kcal/mol) showed better efficacy than the SP600125 (reference JNK3 inhibitor) during cell-free JNK3 kinase assay (IC50 = 58.17 nM) and cell-based neuroprotective assay (EC50 = 7.5 microM).	pyrazolanthrone	123-131	mitogen-activated protein kinase 10	Homo sapiens	143-147
32040807-12	2020	Lead molecule (AJ-292-42151532) with the highest binding free energy (dG = 106.8 Kcal/mol) showed better efficacy than the SP600125 (reference JNK3 inhibitor) during cell-free JNK3 kinase assay (IC50 = 58.17 nM) and cell-based neuroprotective assay (EC50 = 7.5 microM).	pyrazolanthrone	123-131	mitogen-activated protein kinase 10	Homo sapiens	176-180
32588690-8	2020	Furthermore, VEGF protein expression (50% vs. 100%) and MVD (18.27 +- 1.70 vs. 23.17 +- 4.02) were also significantly decreased by SP600125 treatment, whereas the apoptosis index was significantly higher in the treatment group (10.23 +- 1.97% vs. 4.53 +- 1.40%).	pyrazolanthrone	131-139	vascular endothelial growth factor A	Mus musculus	13-17
32437593-7	2020	In PC12 cells, pretreatment of signal inhibitors (PD98059 (MEK inhibitor), SB203580 (p38 MAPK inhibitor), and SP600125 (JNK inhibitor)) recovered Abeta25-35 -mediated cellular dysregulations to the same extent as did IOE pretreatment.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Rattus norvegicus	120-123
32160775-8	2020	Inhibiting JNK (c-jun N-terminal kinase) signaling with SP600125 significantly reduced cathepsin K expression, elastin fragmentation, and carotid artery perimeters in SS mice.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Mus musculus	11-14
32241917-4	2020	While using mitogen-activated protein kinase (MAPK) inhibitors to investigate possible effectors of downstream PKC signaling, we unexpectedly found that an inhibitor of JUN N-terminal kinase (JNK), SP600125, induces Prss14/epithin shedding, even in the absence of PMA.	pyrazolanthrone	198-206	mitogen-activated protein kinase 8	Homo sapiens	169-190
32241917-4	2020	While using mitogen-activated protein kinase (MAPK) inhibitors to investigate possible effectors of downstream PKC signaling, we unexpectedly found that an inhibitor of JUN N-terminal kinase (JNK), SP600125, induces Prss14/epithin shedding, even in the absence of PMA.	pyrazolanthrone	198-206	mitogen-activated protein kinase 8	Homo sapiens	192-195
32241917-4	2020	While using mitogen-activated protein kinase (MAPK) inhibitors to investigate possible effectors of downstream PKC signaling, we unexpectedly found that an inhibitor of JUN N-terminal kinase (JNK), SP600125, induces Prss14/epithin shedding, even in the absence of PMA.	pyrazolanthrone	198-206	ST14 transmembrane serine protease matriptase	Homo sapiens	216-222
32241917-5	2020	SP600125-induced shedding, like that stimulated by PMA, was mediated by tumor necrosis factor-alpha-converting enzyme (TACE).	pyrazolanthrone	0-8	ADAM metallopeptidase domain 17	Homo sapiens	72-117
32437347-10	2020	Interestingly, the inhibitor JNK SP600125 almost completely blocked TAU phosphorylation.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	29-32
32437347-10	2020	Interestingly, the inhibitor JNK SP600125 almost completely blocked TAU phosphorylation.	pyrazolanthrone	33-41	microtubule associated protein tau	Homo sapiens	68-71
32241917-5	2020	SP600125-induced shedding, like that stimulated by PMA, was mediated by tumor necrosis factor-alpha-converting enzyme (TACE).	pyrazolanthrone	0-8	ADAM metallopeptidase domain 17	Homo sapiens	119-123
32241917-6	2020	In contrast, a JNK activator, anisomycin, partially abolished the effects of SP600125 on Prss14/epithin shedding.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	15-18
32241917-6	2020	In contrast, a JNK activator, anisomycin, partially abolished the effects of SP600125 on Prss14/epithin shedding.	pyrazolanthrone	77-85	ST14 transmembrane serine protease matriptase	Homo sapiens	89-95
32241917-8	2020	SP600125 increased phosphorylation of PKCbetaII and TACE and induced their translocation into the plasma membrane.	pyrazolanthrone	0-8	ADAM metallopeptidase domain 17	Homo sapiens	52-56
32160775-8	2020	Inhibiting JNK (c-jun N-terminal kinase) signaling with SP600125 significantly reduced cathepsin K expression, elastin fragmentation, and carotid artery perimeters in SS mice.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Mus musculus	16-39
32160775-8	2020	Inhibiting JNK (c-jun N-terminal kinase) signaling with SP600125 significantly reduced cathepsin K expression, elastin fragmentation, and carotid artery perimeters in SS mice.	pyrazolanthrone	56-64	cathepsin K	Mus musculus	87-98
32160775-8	2020	Inhibiting JNK (c-jun N-terminal kinase) signaling with SP600125 significantly reduced cathepsin K expression, elastin fragmentation, and carotid artery perimeters in SS mice.	pyrazolanthrone	56-64	elastin	Mus musculus	111-118
32303740-2	2020	SUMMARY ANSWER: Upregulation of P2X3 in dorsal root ganglia (DRG) tissues via the activating transcription factor 3 (ATF3)/activator protein (AP)-1 pathway contributed to endometriosis-associated hyperalgesia, which could be attenuated by the chitosan oligosaccharide stearic acid (CSOSA)/liposomes (LPs)/SP600125 delivery system.	pyrazolanthrone	305-313	purinergic receptor P2X 3	Rattus norvegicus	32-36
31945188-5	2020	The JNK inhibitor SP600125 or knockdown of JNK by infection of adenovirus expression JNK siRNA, ameliorated the APAP induced liver toxicity, and inhibited the phosphorylation of Nrf2 and the down-regulation of the detoxifying enzymes by stabilizing the transcription factor.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
31945188-5	2020	The JNK inhibitor SP600125 or knockdown of JNK by infection of adenovirus expression JNK siRNA, ameliorated the APAP induced liver toxicity, and inhibited the phosphorylation of Nrf2 and the down-regulation of the detoxifying enzymes by stabilizing the transcription factor.	pyrazolanthrone	18-26	nuclear factor, erythroid derived 2, like 2	Mus musculus	178-182
32172493-8	2020	Meanwhile, Portunus trituberculatus JNK and vitellogenin (Vg) genes exhibited the same trend in the hepatopancreas and ovaries, and the expression of the SP600125 group was downregulated (P < 0.05), while the anisomycin group was upregulated (P < 0.05).	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Mus musculus	36-39
32172493-9	2020	In addition, JNK enzyme activity and vitellin (Vn) content in the ovarian tissue showed that the JNK activity of the SP600125 group decreased, while activity increased in the anisomycin group.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Mus musculus	13-16
32172493-9	2020	In addition, JNK enzyme activity and vitellin (Vn) content in the ovarian tissue showed that the JNK activity of the SP600125 group decreased, while activity increased in the anisomycin group.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Mus musculus	97-100
32303740-2	2020	SUMMARY ANSWER: Upregulation of P2X3 in dorsal root ganglia (DRG) tissues via the activating transcription factor 3 (ATF3)/activator protein (AP)-1 pathway contributed to endometriosis-associated hyperalgesia, which could be attenuated by the chitosan oligosaccharide stearic acid (CSOSA)/liposomes (LPs)/SP600125 delivery system.	pyrazolanthrone	305-313	activating transcription factor 3	Rattus norvegicus	117-121
32303740-10	2020	SP600125, an inhibitor of c-JUN N-terminal kinase, was wrapped in CSOSA/LPs delivery system and its inhibitory effects on ADP-induced upregulation of P2X3 in DRG cells and endometriosis-induced hyperalgesia in rats were tested.	pyrazolanthrone	0-8	purinergic receptor P2X 3	Rattus norvegicus	150-154
32303740-12	2020	In DRG cells, P2X3 expression levels were elevated by ADP stimulation, but dramatically inhibited by blocking ATF3 with its siRNA and SP600125.	pyrazolanthrone	134-142	purinergic receptor P2X 3	Rattus norvegicus	14-18
32303740-14	2020	In the CSOSA/LPs/SP600125 delivery system, the drug could be effectively concentrated in endometriotic lesions, and it could alleviate endometriosis-induced hyperalgesia, reduce the size of endometriotic lesions and attenuate upregulated P2X3 expression levels in endometriosis rat models.	pyrazolanthrone	17-25	purinergic receptor P2X 3	Rattus norvegicus	238-242
31729763-12	2020	Both MAPKs were upstream to p65/NF-kB inasmuch as both MAPKs" inhibitors PD98059 and SP600125 or their down-regulation by siRNA significantly blocked the TGF-beta1-induced nuclear translocation of p65/NF-kB.	pyrazolanthrone	85-93	synaptotagmin 1	Rattus norvegicus	197-200
32319589-9	2020	Furthermore, treatment with the JNK inhibitor, SP600125, distinctly increased the viability of the cells treated with neferine and TRAIL.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	32-35
32319589-9	2020	Furthermore, treatment with the JNK inhibitor, SP600125, distinctly increased the viability of the cells treated with neferine and TRAIL.	pyrazolanthrone	47-55	TNF superfamily member 10	Homo sapiens	131-136
32237051-7	2020	In vitro results showed that ROS-induced SENP3 accumulation contributed to LPS-induced TF expression, which was reduced by JNK inhibitor SP600125.	pyrazolanthrone	137-145	SUMO/sentrin specific peptidase 3	Mus musculus	41-46
32237051-7	2020	In vitro results showed that ROS-induced SENP3 accumulation contributed to LPS-induced TF expression, which was reduced by JNK inhibitor SP600125.	pyrazolanthrone	137-145	coagulation factor III	Mus musculus	87-89
32237051-7	2020	In vitro results showed that ROS-induced SENP3 accumulation contributed to LPS-induced TF expression, which was reduced by JNK inhibitor SP600125.	pyrazolanthrone	137-145	mitogen-activated protein kinase 8	Mus musculus	123-126
32237051-8	2020	Furthermore, mice injected with LPS following SP600125 (75 mg/kg) treatment showed decreased monocytes/macrophages TF production and alleviated coagulation activation, with less severe lung injury and higher survival rates.	pyrazolanthrone	46-54	coagulation factor III	Mus musculus	115-117
31729763-12	2020	Both MAPKs were upstream to p65/NF-kB inasmuch as both MAPKs" inhibitors PD98059 and SP600125 or their down-regulation by siRNA significantly blocked the TGF-beta1-induced nuclear translocation of p65/NF-kB.	pyrazolanthrone	85-93	synaptotagmin 1	Rattus norvegicus	28-31
31729763-12	2020	Both MAPKs were upstream to p65/NF-kB inasmuch as both MAPKs" inhibitors PD98059 and SP600125 or their down-regulation by siRNA significantly blocked the TGF-beta1-induced nuclear translocation of p65/NF-kB.	pyrazolanthrone	85-93	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	32-37
31729763-12	2020	Both MAPKs were upstream to p65/NF-kB inasmuch as both MAPKs" inhibitors PD98059 and SP600125 or their down-regulation by siRNA significantly blocked the TGF-beta1-induced nuclear translocation of p65/NF-kB.	pyrazolanthrone	85-93	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	201-206
31729763-12	2020	Both MAPKs were upstream to p65/NF-kB inasmuch as both MAPKs" inhibitors PD98059 and SP600125 or their down-regulation by siRNA significantly blocked the TGF-beta1-induced nuclear translocation of p65/NF-kB.	pyrazolanthrone	85-93	transforming growth factor, beta 1	Rattus norvegicus	154-163
32373311-8	2020	After pretreatment with SP600125, mRNA expression of NGAL in the LPS group was inhibited, while that of caspase-3 was increased significantly.	pyrazolanthrone	24-32	lipocalin 2	Homo sapiens	53-57
32432052-7	2020	However, VEGF expression decreased after the pre-treatment with PI3K inhibitors (LY294002 and GDC-0941), ERK1/2 inhibitor (PD098059), and p38 MAPK inhibitor (SB203580), but not JNK inhibitor (SP600125), in a dose-dependent manner.	pyrazolanthrone	192-200	vascular endothelial growth factor A	Homo sapiens	9-13
32373311-8	2020	After pretreatment with SP600125, mRNA expression of NGAL in the LPS group was inhibited, while that of caspase-3 was increased significantly.	pyrazolanthrone	24-32	caspase 3	Homo sapiens	104-113
32373311-12	2020	We also found that NGAL and caspase 3 proteins were increased significantly in LPS and SP + LPS groups, but SP600125 decreased the NGAL level by almost 35% and increased the caspase 3 level by 50% in the SP + LPS group compared with the LPS group (P < 0.05).	pyrazolanthrone	108-116	lipocalin 2	Homo sapiens	131-135
32373311-12	2020	We also found that NGAL and caspase 3 proteins were increased significantly in LPS and SP + LPS groups, but SP600125 decreased the NGAL level by almost 35% and increased the caspase 3 level by 50% in the SP + LPS group compared with the LPS group (P < 0.05).	pyrazolanthrone	108-116	caspase 3	Homo sapiens	174-183
32326963-12	2020	The plasma membrane marker CD40 was solely inhibited by SP600125 while all three inhibitors affected expression of CD86 and CD206.	pyrazolanthrone	56-64	CD40 antigen	Mus musculus	27-31
32324169-7	2020	Accordingly, genetic ablation of BNP, as well as treatment with a potentially novel neutralizing anti-BNP monoclonal antibody (19B3) or suppression of its expression via administration of JNK inhibitor SP600125 improved cardiac output, stabilized blood pressure, and improved survival in mice with polymicrobial sepsis.	pyrazolanthrone	202-210	mitogen-activated protein kinase 8	Mus musculus	188-191
32326963-10	2020	During pathway analyses in vitro, the use of specific MAPK antagonists (SP600125, SB203580, and PD98059) revealed that JNK and p38 inhibition most efficiently attenuated LPA-induced phosphorylation of proinflammatory transcription factors (STAT1 and -3, p65, and c-Jun) and secretion of IL-6 and TNFalpha.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Mus musculus	119-122
31638096-8	2020	MN9D cells were incubated with 500 nM CPA alone or in combination with 10 muM SP600125 (JNK inhibitor) for 48 hours.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	88-91
31868268-10	2020	In contrast, when DJ-1 was silenced, the death of LNCaP, LC3 transformation and LC3 puncta formation were inhibited by JNK inhibitor SP600125, leading to the promotion of proliferation.	pyrazolanthrone	133-141	Parkinsonism associated deglycase	Homo sapiens	18-22
31868268-10	2020	In contrast, when DJ-1 was silenced, the death of LNCaP, LC3 transformation and LC3 puncta formation were inhibited by JNK inhibitor SP600125, leading to the promotion of proliferation.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Homo sapiens	119-122
31868268-11	2020	However, Bcl2 inhibition (by ABT737) reversed all the effects of SP600125.	pyrazolanthrone	65-73	BCL2 apoptosis regulator	Homo sapiens	9-13
31680322-6	2020	Our data suggested that BMP9 could significantly promote gene and protein expression of runt-related transcription factor 2, alkaline phosphatase, osteopontin, and osteocalcin, and SP600125, a JNK-specific inhibitor, could effectively decrease this tendency.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Rattus norvegicus	193-196
32167139-10	2020	Furthermore, administration of a JNK inhibitor (SP600125) or the mtROS scavenger MitoQ significantly attenuated JNK activation and subsequent mitochondrial fragmentation in DsbA-L-knockdown HK-2 cells.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	33-36
32167139-10	2020	Furthermore, administration of a JNK inhibitor (SP600125) or the mtROS scavenger MitoQ significantly attenuated JNK activation and subsequent mitochondrial fragmentation in DsbA-L-knockdown HK-2 cells.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	112-115
32167139-10	2020	Furthermore, administration of a JNK inhibitor (SP600125) or the mtROS scavenger MitoQ significantly attenuated JNK activation and subsequent mitochondrial fragmentation in DsbA-L-knockdown HK-2 cells.	pyrazolanthrone	48-56	glutathione S-transferase kappa 1	Mus musculus	173-179
31638096-9	2020	Quantitative real-time polymerase chain reaction analysis of sortilin and alpha-synuclein mRNA levels in MN9D cells revealed upregulated sortilin expression in MN9D cells cultured with CPA alone, but the combination of CPA and SP600125 could inhibit this expression.	pyrazolanthrone	227-235	sortilin 1	Mus musculus	137-145
32251495-6	2020	When compared with PQ group, the cells in both SP600125+PQ group and SB203580+PQ group had significantly increased viability and level of anti-apoptotic protein Bcl-2; and had decreased apoptotic rates, decreased levels of caspase-3 and -9, and decreased level of pro-apoptotic protein Bax.	pyrazolanthrone	47-55	BCL2 apoptosis regulator	Homo sapiens	161-166
32230861-7	2020	The specific MAPK inhibitors, U0126, SP600125, and SB203580, suppressed LPS-stimulated pro-inflammatory mediators, cell migration, and NF-kappaB nuclear translocation, indicating that MAPKs may be the upstream kinase of NF-kappaB signaling.	pyrazolanthrone	37-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	135-144
32230861-7	2020	The specific MAPK inhibitors, U0126, SP600125, and SB203580, suppressed LPS-stimulated pro-inflammatory mediators, cell migration, and NF-kappaB nuclear translocation, indicating that MAPKs may be the upstream kinase of NF-kappaB signaling.	pyrazolanthrone	37-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	220-229
32258036-8	2020	The phosphorylation of NR4A1 was increased in human osteoarthritis cartilage, and p38 inhibitor SB203580, JNK inhibitor SP600125 and ERK inhibitor FR180204 could significantly inhibited IL-1beta induced NR4A1 phosphorylation.	pyrazolanthrone	120-128	nuclear receptor subfamily 4 group A member 1	Homo sapiens	23-28
32258036-8	2020	The phosphorylation of NR4A1 was increased in human osteoarthritis cartilage, and p38 inhibitor SB203580, JNK inhibitor SP600125 and ERK inhibitor FR180204 could significantly inhibited IL-1beta induced NR4A1 phosphorylation.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	106-109
32045570-9	2020	The above changes as well as GJIC and Cx43 suppression were reversed by pretreatment with a JNK inhibitor (SP600125).	pyrazolanthrone	107-115	gap junction protein, alpha 1	Rattus norvegicus	38-42
32131874-10	2020	ROS, MMP-3 expression, and IL-6 was suppressed by administering 30 muM of SP600125 (a JNK inhibitor) in MH7A cells.	pyrazolanthrone	74-82	matrix metallopeptidase 3	Homo sapiens	5-10
32131874-10	2020	ROS, MMP-3 expression, and IL-6 was suppressed by administering 30 muM of SP600125 (a JNK inhibitor) in MH7A cells.	pyrazolanthrone	74-82	interleukin 6	Homo sapiens	27-31
32131874-10	2020	ROS, MMP-3 expression, and IL-6 was suppressed by administering 30 muM of SP600125 (a JNK inhibitor) in MH7A cells.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	86-89
32131874-11	2020	Furthermore, the administration of SP600125 (30 muM) to RA-FLS suppressed MMP-3.	pyrazolanthrone	35-43	matrix metallopeptidase 3	Homo sapiens	74-79
32045570-9	2020	The above changes as well as GJIC and Cx43 suppression were reversed by pretreatment with a JNK inhibitor (SP600125).	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Rattus norvegicus	92-95
32114433-5	2020	We have also published that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses PS1 transcription by reducing p-JNK and via p53 dependent mechanism.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	87-90
32114433-5	2020	We have also published that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses PS1 transcription by reducing p-JNK and via p53 dependent mechanism.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	97-100
32114433-5	2020	We have also published that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses PS1 transcription by reducing p-JNK and via p53 dependent mechanism.	pyrazolanthrone	120-128	presenilin 1	Homo sapiens	139-142
32114433-5	2020	We have also published that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses PS1 transcription by reducing p-JNK and via p53 dependent mechanism.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	169-174
32114433-5	2020	We have also published that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses PS1 transcription by reducing p-JNK and via p53 dependent mechanism.	pyrazolanthrone	120-128	tumor protein p53	Homo sapiens	183-186
32114433-8	2020	Consequently, one of the mechanisms of inhibition of PS1 transcription by rapamycin is similar to the mechanism of repression of PS1 transcription by JNK-specific inhibitor SP600125.	pyrazolanthrone	173-181	presenilin 1	Homo sapiens	53-56
32114433-8	2020	Consequently, one of the mechanisms of inhibition of PS1 transcription by rapamycin is similar to the mechanism of repression of PS1 transcription by JNK-specific inhibitor SP600125.	pyrazolanthrone	173-181	presenilin 1	Homo sapiens	129-132
32114433-8	2020	Consequently, one of the mechanisms of inhibition of PS1 transcription by rapamycin is similar to the mechanism of repression of PS1 transcription by JNK-specific inhibitor SP600125.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	150-153
32174780-6	2020	S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125.	pyrazolanthrone	191-199	S100 calcium binding protein A8	Homo sapiens	0-6
32189173-3	2020	JNK signaling activation and inhibition in primary corneal fibroblasts were obtained by treatments with anisomycin and SP600125, respectively.	pyrazolanthrone	119-127	mitogen-activated protein kinase 8	Homo sapiens	0-3
32189173-10	2020	However, SP600125 effectively reversed the above effect induced by TGF-beta1 treatment in corneal fibroblasts, including the TGF-beta-induced autophagy progression.	pyrazolanthrone	9-17	transforming growth factor beta 1	Homo sapiens	67-76
32189173-10	2020	However, SP600125 effectively reversed the above effect induced by TGF-beta1 treatment in corneal fibroblasts, including the TGF-beta-induced autophagy progression.	pyrazolanthrone	9-17	transforming growth factor alpha	Homo sapiens	67-75
31901732-7	2020	Treatment with SP600125, a known JNK inhibitor, prevented the LPS-induced hyper-activation of JNK and alleviated depressive-like behaviors.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Rattus norvegicus	33-36
31901732-7	2020	Treatment with SP600125, a known JNK inhibitor, prevented the LPS-induced hyper-activation of JNK and alleviated depressive-like behaviors.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Rattus norvegicus	94-97
31901732-8	2020	Moreover, LPS-induced increases in the expression levels of TNF-alpha, IL-1beta and pGR-Ser246 in these brain regions were reduced when the rats were treated with SP600125.	pyrazolanthrone	163-171	tumor necrosis factor	Rattus norvegicus	60-69
31901732-8	2020	Moreover, LPS-induced increases in the expression levels of TNF-alpha, IL-1beta and pGR-Ser246 in these brain regions were reduced when the rats were treated with SP600125.	pyrazolanthrone	163-171	interleukin 1 alpha	Rattus norvegicus	71-79
31901732-8	2020	Moreover, LPS-induced increases in the expression levels of TNF-alpha, IL-1beta and pGR-Ser246 in these brain regions were reduced when the rats were treated with SP600125.	pyrazolanthrone	163-171	progesterone receptor	Rattus norvegicus	84-87
32048500-5	2020	JNK inhibitor SP600125 was used to block the phosphorylation of JNK signaling, Western blot results showed that the activation of NF-kB was blocked and expression of GM-CSF was down-regulated.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	0-3
32048500-5	2020	JNK inhibitor SP600125 was used to block the phosphorylation of JNK signaling, Western blot results showed that the activation of NF-kB was blocked and expression of GM-CSF was down-regulated.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	64-67
32048500-5	2020	JNK inhibitor SP600125 was used to block the phosphorylation of JNK signaling, Western blot results showed that the activation of NF-kB was blocked and expression of GM-CSF was down-regulated.	pyrazolanthrone	14-22	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	166-172
31758947-4	2020	In the current study, we found that pretreatment with the JNK inhibitor SP600125 (3 mg/kg) attenuates tolerance to the antinociceptive in the formalin test and to the anti-allodynic effects of Delta9-THC (6 mg/kg) in cisplatin-evoked neuropathic pain using wild-type mice.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Mus musculus	58-61
32121405-7	2020	The JNK inhibitor SP600125 abolished Ang II-induced ferritin degradation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
32121405-7	2020	The JNK inhibitor SP600125 abolished Ang II-induced ferritin degradation.	pyrazolanthrone	18-26	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	37-43
32104530-9	2020	We confirmed this phenomenon by the suppressed nuclear Nrf2 activation in cells that were treated with respective inhibitors (PD98059, SP600125, and GF109203X).	pyrazolanthrone	135-143	NFE2 like bZIP transcription factor 2	Homo sapiens	55-59
32104150-10	2020	U0126 (inhibiting p-ERK1/2) and SB202190 (inhibiting p38) decreased the contents of MCP-1, sICAM-1, and sVCAM-1, but SP600125 (inhibiting p-JNK1/2) had none of these effects.	pyrazolanthrone	117-125	mitogen-activated protein kinase 1	Homo sapiens	53-56
32174780-6	2020	S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125.	pyrazolanthrone	191-199	mitogen-activated protein kinase 14	Homo sapiens	63-66
32174780-6	2020	S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Homo sapiens	76-79
32174780-6	2020	S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125.	pyrazolanthrone	191-199	nuclear factor kappa B subunit 1	Homo sapiens	99-108
32174780-6	2020	S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125.	pyrazolanthrone	191-199	S100 calcium binding protein A9	Homo sapiens	11-17
32174780-6	2020	S100A8 and S100A9 also induce the phosphorylation of AKT, ERK, p38 MAPK and JNK, and activation of NF-kappaB, which were blocked after exposure to TLR4i, LY294002, AKTi, PD98059, SB202190 or SP600125.	pyrazolanthrone	191-199	AKT serine/threonine kinase 1	Homo sapiens	53-56
32211094-13	2020	SP600125 (a JNK inhibitor, 10 mumol/L) attenuated the si-CTRP3-mediated inhibition of proliferation and promotion of apoptosis in AC16 cardiomyocytes transfected with anti-miR-144 and stimulated with HG.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
31862514-7	2020	Furthermore, ERK inhibitor (SCH772984), JNK inhibitor (SP600125) and p38 MAPK inhibitor (SB203580) obviously up-regulated BTB-related proteins expression as well as activated Nrf2 expression at varying degrees, indicating that ROS-MAPKs-Nrf2 is involved in the signaling pathway that leads to PM2.5-induced spermatogenesis dysfunction.	pyrazolanthrone	55-63	Eph receptor B1	Rattus norvegicus	13-16
31862514-7	2020	Furthermore, ERK inhibitor (SCH772984), JNK inhibitor (SP600125) and p38 MAPK inhibitor (SB203580) obviously up-regulated BTB-related proteins expression as well as activated Nrf2 expression at varying degrees, indicating that ROS-MAPKs-Nrf2 is involved in the signaling pathway that leads to PM2.5-induced spermatogenesis dysfunction.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Rattus norvegicus	40-43
31862514-7	2020	Furthermore, ERK inhibitor (SCH772984), JNK inhibitor (SP600125) and p38 MAPK inhibitor (SB203580) obviously up-regulated BTB-related proteins expression as well as activated Nrf2 expression at varying degrees, indicating that ROS-MAPKs-Nrf2 is involved in the signaling pathway that leads to PM2.5-induced spermatogenesis dysfunction.	pyrazolanthrone	55-63	NFE2 like bZIP transcription factor 2	Rattus norvegicus	175-179
31734714-5	2020	Furthermore, GA-induced ND7/23 cell death was significantly inhibited due to co-treatment with 10 microM of the JNK inhibitor SP600125 or the p-38 MAPK inhibitor SB239063.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Mus musculus	112-115
31916113-4	2020	So far, inhibition of c-Jun N-terminal kinase (JNK) in high calcium medium has been supposed to be the only way to induce TJ formations in HaCaT cells; however, SP600125, a potent inhibitor of JNK showed cytostatic effects and clearly attenuated epidermal differentiation and stratification.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	22-45
31916113-4	2020	So far, inhibition of c-Jun N-terminal kinase (JNK) in high calcium medium has been supposed to be the only way to induce TJ formations in HaCaT cells; however, SP600125, a potent inhibitor of JNK showed cytostatic effects and clearly attenuated epidermal differentiation and stratification.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	47-50
31916113-4	2020	So far, inhibition of c-Jun N-terminal kinase (JNK) in high calcium medium has been supposed to be the only way to induce TJ formations in HaCaT cells; however, SP600125, a potent inhibitor of JNK showed cytostatic effects and clearly attenuated epidermal differentiation and stratification.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	193-196
32211094-13	2020	SP600125 (a JNK inhibitor, 10 mumol/L) attenuated the si-CTRP3-mediated inhibition of proliferation and promotion of apoptosis in AC16 cardiomyocytes transfected with anti-miR-144 and stimulated with HG.	pyrazolanthrone	0-8	C1q and TNF related 3	Homo sapiens	57-62
32211094-13	2020	SP600125 (a JNK inhibitor, 10 mumol/L) attenuated the si-CTRP3-mediated inhibition of proliferation and promotion of apoptosis in AC16 cardiomyocytes transfected with anti-miR-144 and stimulated with HG.	pyrazolanthrone	0-8	microRNA 144	Homo sapiens	172-179
31829413-8	2020	Besides that, we finally proved that the expression and activation of Ufm1 induced by LPS was regulated by JNK/ATF2 and JNK/c-Jun pathway with the use of SP600125.	pyrazolanthrone	154-162	ubiquitin-fold modifier 1	Mus musculus	70-74
31957305-7	2020	Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan).	pyrazolanthrone	213-221	nicotinamide phosphoribosyltransferase	Homo sapiens	0-8
31957305-7	2020	Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan).	pyrazolanthrone	213-221	angiotensinogen	Homo sapiens	69-83
31957305-7	2020	Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan).	pyrazolanthrone	213-221	mitogen-activated protein kinase 8	Homo sapiens	106-129
31957305-7	2020	Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan).	pyrazolanthrone	213-221	mitogen-activated protein kinase 8	Homo sapiens	198-201
31957305-7	2020	Visfatin protein expression increased in hypoxic HCAECs with earlier angiotensin II (AngII) secretion and c-Jun N-terminal kinase (JNK) phosphorylation, which could be effectively suppressed by the JNK inhibitor (SP600125), AngII antibody or AngII receptor blocker (losartan).	pyrazolanthrone	213-221	angiotensinogen	Homo sapiens	224-229
31957305-10	2020	Hypoxia, hypoxia with HBO and exogenous addition of AngII also increased promoter transcription to visfatin; SP600125 and losartan blocked this activity.	pyrazolanthrone	109-117	angiotensinogen	Homo sapiens	52-57
31957305-10	2020	Hypoxia, hypoxia with HBO and exogenous addition of AngII also increased promoter transcription to visfatin; SP600125 and losartan blocked this activity.	pyrazolanthrone	109-117	nicotinamide phosphoribosyltransferase	Homo sapiens	99-107
31870592-9	2020	Exposure of cells to the JNK-specific inhibitor SP600125 reduced the cytotoxicity effects of CD, combination of CD and SP600125 corrected overexpression of phosphorylated JNK and reduction of phosphorylated STAT3.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	25-28
31870592-9	2020	Exposure of cells to the JNK-specific inhibitor SP600125 reduced the cytotoxicity effects of CD, combination of CD and SP600125 corrected overexpression of phosphorylated JNK and reduction of phosphorylated STAT3.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	171-174
31870592-9	2020	Exposure of cells to the JNK-specific inhibitor SP600125 reduced the cytotoxicity effects of CD, combination of CD and SP600125 corrected overexpression of phosphorylated JNK and reduction of phosphorylated STAT3.	pyrazolanthrone	48-56	signal transducer and activator of transcription 3	Homo sapiens	207-212
31870592-9	2020	Exposure of cells to the JNK-specific inhibitor SP600125 reduced the cytotoxicity effects of CD, combination of CD and SP600125 corrected overexpression of phosphorylated JNK and reduction of phosphorylated STAT3.	pyrazolanthrone	119-127	mitogen-activated protein kinase 8	Homo sapiens	25-28
31870592-9	2020	Exposure of cells to the JNK-specific inhibitor SP600125 reduced the cytotoxicity effects of CD, combination of CD and SP600125 corrected overexpression of phosphorylated JNK and reduction of phosphorylated STAT3.	pyrazolanthrone	119-127	mitogen-activated protein kinase 8	Homo sapiens	171-174
31870592-9	2020	Exposure of cells to the JNK-specific inhibitor SP600125 reduced the cytotoxicity effects of CD, combination of CD and SP600125 corrected overexpression of phosphorylated JNK and reduction of phosphorylated STAT3.	pyrazolanthrone	119-127	signal transducer and activator of transcription 3	Homo sapiens	207-212
31829413-8	2020	Besides that, we finally proved that the expression and activation of Ufm1 induced by LPS was regulated by JNK/ATF2 and JNK/c-Jun pathway with the use of SP600125.	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Mus musculus	107-110
31829413-8	2020	Besides that, we finally proved that the expression and activation of Ufm1 induced by LPS was regulated by JNK/ATF2 and JNK/c-Jun pathway with the use of SP600125.	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Mus musculus	120-123
31829413-8	2020	Besides that, we finally proved that the expression and activation of Ufm1 induced by LPS was regulated by JNK/ATF2 and JNK/c-Jun pathway with the use of SP600125.	pyrazolanthrone	154-162	jun proto-oncogene	Mus musculus	124-129
32411325-9	2020	Further studies demonstrated that the levels of p-JNK and p-ERK1/2 were significantly upregulated in NCA-treated HepG2 cells, and pretreatment with JNK and ERK1/2 inhibitors, SP600125 and PD0325901, respectively, suppressed NCA-induced cell apoptosis of HepG2 cells.	pyrazolanthrone	175-183	mitogen-activated protein kinase 8	Homo sapiens	50-53
32411325-9	2020	Further studies demonstrated that the levels of p-JNK and p-ERK1/2 were significantly upregulated in NCA-treated HepG2 cells, and pretreatment with JNK and ERK1/2 inhibitors, SP600125 and PD0325901, respectively, suppressed NCA-induced cell apoptosis of HepG2 cells.	pyrazolanthrone	175-183	mitogen-activated protein kinase 3	Homo sapiens	60-66
32411325-9	2020	Further studies demonstrated that the levels of p-JNK and p-ERK1/2 were significantly upregulated in NCA-treated HepG2 cells, and pretreatment with JNK and ERK1/2 inhibitors, SP600125 and PD0325901, respectively, suppressed NCA-induced cell apoptosis of HepG2 cells.	pyrazolanthrone	175-183	mitogen-activated protein kinase 8	Homo sapiens	148-151
31256425-9	2020	TRB3 overexpression enhances the malignant transformation abilities of HBEpC such as cell proliferation, migration and colony formation, which could be reversed by U0126 and SP600125.	pyrazolanthrone	174-182	tribbles pseudokinase 3	Homo sapiens	0-4
31963305-5	2020	The role played by c-Jun N-terminal kinase (JNK) was evaluated through the use of the specific JNK inhibitor SP600125.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Homo sapiens	44-47
31963305-5	2020	The role played by c-Jun N-terminal kinase (JNK) was evaluated through the use of the specific JNK inhibitor SP600125.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Homo sapiens	95-98
31963305-7	2020	This study also demonstrated the partial relieve of EMT induction and SM by SP600125, showing the importance of the JNK pathway in these processes.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	116-119
32419816-4	2020	To verify the mechanism of mBHD, specific inhibitors of JNK (SP600125) or p38 (SB203580) were used for co-treatment with mBHD, and then the changes in NO and nitric oxide synthase (iNOS) were measured.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	56-59
32286950-11	2020	Pretreatment with the JNK inhibitor SP600125 or siRNA targeting JNK or c-Jun suppressed PR-induced autophagy.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	22-25
31081133-11	2020	Similarly, JNK pathway inhibitor SP600125 (10 muM) also inhibited cell growth and invasion and induced apoptosis.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Mus musculus	11-14
31892847-5	2020	Further research indicated the induction of apoptosis and autophagy triggered by metformin could remarkably attenuate after the treatment of ROS scavenger NAC and JNK inhibitor SP600125.	pyrazolanthrone	177-185	mitogen-activated protein kinase 8	Homo sapiens	163-166
31782346-13	2020	Furthermore, knockdown of JNK and the JNK inhibitor SP600125 prevented the decrease of the epithelial barrier function and the increase of cell migration induced by angubindin-1.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	38-41
30843033-7	2020	Furthermore, the combination treatment of OTA and signaling inhibitors (LY294002, U0126, or SP600125) exerted synergistic antiproliferative effects in TM3 and TM4 cells.	pyrazolanthrone	92-100	tropomyosin 1, alpha	Mus musculus	151-154
32294654-12	2020	Pretreatment of cells with SN50, SB203580, and SP600125 decreased the induction of CXCL1 by poly IC.	pyrazolanthrone	47-55	C-X-C motif chemokine ligand 1	Homo sapiens	83-88
31630418-8	2020	Furthermore, the phosphorylation of c-Jun was suppressed when cardiac myocytes were treated with Act1 siRNA, TRAF6 siRNA, SB203580 (p38MAPK inhibitor) or SP600125 (JNK inhibitor) in cardiac myocytes.	pyrazolanthrone	154-162	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	36-41
31630418-8	2020	Furthermore, the phosphorylation of c-Jun was suppressed when cardiac myocytes were treated with Act1 siRNA, TRAF6 siRNA, SB203580 (p38MAPK inhibitor) or SP600125 (JNK inhibitor) in cardiac myocytes.	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Homo sapiens	164-167
31906029-5	2019	Application of the c-Jun N-terminal kinase (JNK) inhibitors SP600125 (SP) and JNK inhibitor V (JNKI) significantly reduced TAX- and NOC-induced apoptosis and G2/M arrest of human colon cancer cells.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	19-42
31906029-5	2019	Application of the c-Jun N-terminal kinase (JNK) inhibitors SP600125 (SP) and JNK inhibitor V (JNKI) significantly reduced TAX- and NOC-induced apoptosis and G2/M arrest of human colon cancer cells.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	44-47
31906029-8	2019	Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI.	pyrazolanthrone	217-219	BCL2 apoptosis regulator	Homo sapiens	70-87
31906029-8	2019	Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI.	pyrazolanthrone	217-219	BCL2 apoptosis regulator	Homo sapiens	89-94
31906029-5	2019	Application of the c-Jun N-terminal kinase (JNK) inhibitors SP600125 (SP) and JNK inhibitor V (JNKI) significantly reduced TAX- and NOC-induced apoptosis and G2/M arrest of human colon cancer cells.	pyrazolanthrone	60-62	mitogen-activated protein kinase 8	Homo sapiens	19-42
31906029-5	2019	Application of the c-Jun N-terminal kinase (JNK) inhibitors SP600125 (SP) and JNK inhibitor V (JNKI) significantly reduced TAX- and NOC-induced apoptosis and G2/M arrest of human colon cancer cells.	pyrazolanthrone	60-62	mitogen-activated protein kinase 8	Homo sapiens	44-47
31906029-8	2019	Disruption of the mitochondrial membrane potential and an increase in B-cell lymphoma-2 (Bcl-2) protein phosphorylation (pBcl-2; Ser70) by TAX and NOC were prevented by adding the PERK inhibitor GSK and JNK inhibitor SP and JNKI.	pyrazolanthrone	217-219	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	180-184
31906029-6	2019	Interestingly, TAX- and NOC-induced pPERK (Tyr980) protein expression was inhibited by adding the JNK inhibitors, SP and JNKI, and application of the PERK inhibitor GSK2606414 (GSK) significantly reduced apoptosis and G2/M arrest by TAX and NOC, with decreased pPERK (Tyr980) and pJNK, phosphorylated Cdc25C, and Cyc B1 protein expressions in human colon cancer cells.	pyrazolanthrone	114-116	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	37-41
31849448-9	2019	Results: The results of our studies showed that the pretreatment with C66 and JNK inhibitor SP600125 was capable of attenuating the LPS-induced ALI by detecting pulmonary edema, pathological changes, total protein concentration, and inflammatory cell number in bronchoalveolar lavage fluid (BALF).	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Mus musculus	78-81
31905967-7	2019	In addition, LPS-stimulated binding of c-Jun to the MMP-9 promoter was confirmed by chromatin immunoprecipitation (ChIP) assay, which was blocked by pretreatment with c-Src inhibitor II, PF431396, AG1296, LY294002, Akt inhibitor VIII, p38 MAP kinase inhibitor VIII, SP600125, and tanshinone IIA.	pyrazolanthrone	266-274	matrix metallopeptidase 9	Rattus norvegicus	52-57
31905967-7	2019	In addition, LPS-stimulated binding of c-Jun to the MMP-9 promoter was confirmed by chromatin immunoprecipitation (ChIP) assay, which was blocked by pretreatment with c-Src inhibitor II, PF431396, AG1296, LY294002, Akt inhibitor VIII, p38 MAP kinase inhibitor VIII, SP600125, and tanshinone IIA.	pyrazolanthrone	266-274	SRC proto-oncogene, non-receptor tyrosine kinase	Rattus norvegicus	167-172
31521690-3	2019	The RNA and protein levels of CPEB1 expression are increased by Ox-LDL exposure, which is abrogated by c-Jun amino-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	147-155	cytoplasmic polyadenylation element binding protein 1	Homo sapiens	30-35
31521690-3	2019	The RNA and protein levels of CPEB1 expression are increased by Ox-LDL exposure, which is abrogated by c-Jun amino-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	147-155	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-108
31949876-13	2019	SP600125, a JNK inhibitor, was used for evaluating the role of JNK in neuroinflammation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	12-15
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	pyrazolanthrone	167-175	tumor necrosis factor	Mus musculus	36-45
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	pyrazolanthrone	167-175	tumor necrosis factor	Mus musculus	78-87
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	pyrazolanthrone	167-175	interleukin 6	Mus musculus	89-93
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	pyrazolanthrone	167-175	interleukin 1 beta	Mus musculus	95-103
31849448-11	2019	In vitro, LPS-induced production of TNF-alpha and IL-6 and gene expression of TNF-alpha, IL-6, IL-1beta, and COX-2 could be inhibited by the pretreatment with C66 and SP600125.	pyrazolanthrone	167-175	cytochrome c oxidase II, mitochondrial	Mus musculus	109-114
31849448-12	2019	It was found that C66 and SP600125 could inhibit LPS-induced phosphorylation of JNK both in vitro and in vivo.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Mus musculus	80-83
31654668-6	2019	In this study, by using Bone Marrow-derived macrophages (BMMs) as osteoclast precursors (OCPs), we found that RANKL-induced TRAF3 degradation was significantly suppressed by JNK inhibitor (SP600125), which was restored by overexpression of Beclin1 (key autophagic protein).	pyrazolanthrone	189-197	TNF superfamily member 11	Homo sapiens	110-115
31654668-6	2019	In this study, by using Bone Marrow-derived macrophages (BMMs) as osteoclast precursors (OCPs), we found that RANKL-induced TRAF3 degradation was significantly suppressed by JNK inhibitor (SP600125), which was restored by overexpression of Beclin1 (key autophagic protein).	pyrazolanthrone	189-197	TNF receptor associated factor 3	Homo sapiens	124-129
31654668-6	2019	In this study, by using Bone Marrow-derived macrophages (BMMs) as osteoclast precursors (OCPs), we found that RANKL-induced TRAF3 degradation was significantly suppressed by JNK inhibitor (SP600125), which was restored by overexpression of Beclin1 (key autophagic protein).	pyrazolanthrone	189-197	mitogen-activated protein kinase 8	Homo sapiens	174-177
31654668-6	2019	In this study, by using Bone Marrow-derived macrophages (BMMs) as osteoclast precursors (OCPs), we found that RANKL-induced TRAF3 degradation was significantly suppressed by JNK inhibitor (SP600125), which was restored by overexpression of Beclin1 (key autophagic protein).	pyrazolanthrone	189-197	beclin 1	Homo sapiens	240-247
31654668-7	2019	Nevertheless, TRAF3 silencing partially reversed the reduced osteoclastogenesis under SP600125 intervention.	pyrazolanthrone	86-94	TNF receptor associated factor 3	Homo sapiens	14-19
31428903-5	2019	The early response of their expression was effectively blocked by specific inhibitors of p38 MAPK (SB202190) and JNK (SP600125), but not by B18R, a soluble type-I IFN receptor.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	113-116
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	pyrazolanthrone	273-281	chemokine (C-C motif) ligand 2	Mus musculus	148-153
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	pyrazolanthrone	273-281	chemokine (C-C motif) ligand 2	Mus musculus	155-160
31148200-5	2019	Furthermore, real-time quantitative polymerase chain reaction indicated that the PI3K inhibitor LY294002 blocked the messenger RNA (mRNA) levels of MCP-1 (CCL-2), the MEK1/2 inhibitor U0126 reduced the mRNA levels of TNF-alpha and MCP-1 (CCL-2), and the JNK1/2/3 inhibitor SP600125 prevented the upregulation of inducible nitric oxide synthase mRNA in rFIP-glu-induced cells.	pyrazolanthrone	273-281	mitogen-activated protein kinase kinase 1	Mus musculus	167-173
31814803-7	2019	Conclusion: We found the expression of PAR mRNA in P815, activation of signaling pathways of nuclear factor-kappaB (NF-kappaB), and mitogen-activated protein kinases (MAPKs) including C-Jun NH2-terminal kinase (JNK), P38, and extracellular signal-regulated kinase 1/2 (ERK1/2), and the release of multiple inflammatory mediators stimulated by thrombin, as well as the inhibition of the inflammatory releases by hirudin, SCH79797, and MAPK inhibitors including SB203580, PD98059, and SP600125.	pyrazolanthrone	483-491	AFG3-like AAA ATPase 2	Mus musculus	39-42
31622021-7	2019	The molecular data indicate that the protective effects of naringenin on autophagy flux may also be regulated via the JNK pathway, as verified via the application of JNK inhibitor SP600125.	pyrazolanthrone	180-188	mitogen-activated protein kinase 8	Homo sapiens	118-121
31622021-7	2019	The molecular data indicate that the protective effects of naringenin on autophagy flux may also be regulated via the JNK pathway, as verified via the application of JNK inhibitor SP600125.	pyrazolanthrone	180-188	mitogen-activated protein kinase 8	Homo sapiens	166-169
31707034-12	2019	The efficacy of CA on A53T alpha-synuclein degradation was reversed by the autophagy inhibitor bafilomycin A1 and the JNK inhibitor SP600125.	pyrazolanthrone	132-140	synuclein, alpha	Mus musculus	27-42
31707034-12	2019	The efficacy of CA on A53T alpha-synuclein degradation was reversed by the autophagy inhibitor bafilomycin A1 and the JNK inhibitor SP600125.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Mus musculus	118-121
31815010-10	2019	The compound SP600125, an inhibitor of JNK, suppressed autophagy and 5-FU-induced cell death in PCDH17-reexpressing CRC cells.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	39-42
31815010-10	2019	The compound SP600125, an inhibitor of JNK, suppressed autophagy and 5-FU-induced cell death in PCDH17-reexpressing CRC cells.	pyrazolanthrone	13-21	protocadherin 17	Homo sapiens	96-102
31769251-8	2019	Similar effects were provoked upon treatment with the JNK inhibitor SP600125.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	54-57
31814803-4	2019	Furthermore, inhibition of thrombin inhibitor (hirudin), PAR1 inhibitor (SCH79797), and MAPK inhibitors (SB203580, PD98059, and SP600125) on the mediator section was evaluated by ELISA and Luminex liquichip.	pyrazolanthrone	128-136	mitogen-activated protein kinase 1	Mus musculus	88-92
31685029-0	2019	SP600125 enhances C-2-induced cell death by the switch from autophagy to apoptosis in bladder cancer cells.	pyrazolanthrone	0-8	complement component 2 (within H-2S)	Mus musculus	18-21
32009784-8	2019	Results: The SP600125 JNK inhibitor effectively reduced DNA damage repair to irradiated LLC cells.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	22-25
31685029-7	2019	Utilization of JNK inhibitor SP600125 or knockdown of JNK by siRNA potentiate the cytotoxicity of C-2 through down-regulation of p62 and LC3II proteins and up-regulation of active-Caspase3 proteins, enhance the cell death effect, facilitating the switch from autophagy to apoptosis.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Mus musculus	15-18
31685029-7	2019	Utilization of JNK inhibitor SP600125 or knockdown of JNK by siRNA potentiate the cytotoxicity of C-2 through down-regulation of p62 and LC3II proteins and up-regulation of active-Caspase3 proteins, enhance the cell death effect, facilitating the switch from autophagy to apoptosis.	pyrazolanthrone	29-37	complement component 2 (within H-2S)	Mus musculus	98-101
31685029-9	2019	Combined treatment with SP600125 further enhances tumor inhibition of C-2 associated with enhanced activation of caspase3 and reduction of autophagy.	pyrazolanthrone	24-32	complement component 2 (within H-2S)	Mus musculus	70-73
31685029-9	2019	Combined treatment with SP600125 further enhances tumor inhibition of C-2 associated with enhanced activation of caspase3 and reduction of autophagy.	pyrazolanthrone	24-32	caspase 3	Mus musculus	113-121
31685029-10	2019	CONCLUSIONS: It reveals a series of molecular mechanisms about SP600125 potentiate the cytotoxicity and tumor inhibition of C-2 in bladder cancer cells through promoting C-2-induced apoptosis, expecting it provides research basis and theoretical support for new drugs development.	pyrazolanthrone	63-71	complement component 2 (within H-2S)	Mus musculus	124-127
31685029-10	2019	CONCLUSIONS: It reveals a series of molecular mechanisms about SP600125 potentiate the cytotoxicity and tumor inhibition of C-2 in bladder cancer cells through promoting C-2-induced apoptosis, expecting it provides research basis and theoretical support for new drugs development.	pyrazolanthrone	63-71	complement component 2 (within H-2S)	Mus musculus	170-173
31348577-6	2019	These actions were inhibited by SP600125, a jun kinase (JNK) inhibitor.	pyrazolanthrone	32-40	mitogen-activated protein kinase 9	Homo sapiens	44-54
31385019-7	2019	Furthermore, there were significant decreases in the level of S1P-induced COL1A1 expression when the keloid fibroblasts were treated with 30 muM SP600125 or 30 muM PD98059 and that of S1P-induced COL1A1 expression when the treated with 100 nM W146 or 100 nM JTE013 (P < 0.05).	pyrazolanthrone	145-153	collagen type I alpha 1 chain	Homo sapiens	74-80
31385019-7	2019	Furthermore, there were significant decreases in the level of S1P-induced COL1A1 expression when the keloid fibroblasts were treated with 30 muM SP600125 or 30 muM PD98059 and that of S1P-induced COL1A1 expression when the treated with 100 nM W146 or 100 nM JTE013 (P < 0.05).	pyrazolanthrone	145-153	collagen type I alpha 1 chain	Homo sapiens	196-202
31348577-6	2019	These actions were inhibited by SP600125, a jun kinase (JNK) inhibitor.	pyrazolanthrone	32-40	mitogen-activated protein kinase 9	Homo sapiens	56-59
31442556-9	2019	Furthermore, a JNK inhibitor (SP600125) and ERK inhibitor (SCH772984) partially protected mice against PAF-induced death, whereas a p38 MAP-kinase inhibitor (SB203580) provided complete protection against DIC and death.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	15-18
31442556-9	2019	Furthermore, a JNK inhibitor (SP600125) and ERK inhibitor (SCH772984) partially protected mice against PAF-induced death, whereas a p38 MAP-kinase inhibitor (SB203580) provided complete protection against DIC and death.	pyrazolanthrone	30-38	patchy fur	Mus musculus	103-106
31451010-10	2019	A JNK inhibitor (SP600125) and a JNK dominant-negative mutant suppressed M.tb-induced CTGF expression.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	2-5
30941768-13	2019	SP600125 (JNK inhibitor) disposition reversed the acceerative impacts of PEG10 on cell proliferation, migration, and invasion in T24 cells.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	10-13
31451010-12	2019	Furthermore, SP600125 inhibited M.tb-induced c-Jun phosphorylation and AP-1- luciferase activity.	pyrazolanthrone	13-21	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-75
30941768-13	2019	SP600125 (JNK inhibitor) disposition reversed the acceerative impacts of PEG10 on cell proliferation, migration, and invasion in T24 cells.	pyrazolanthrone	0-8	paternally expressed 10	Homo sapiens	73-78
31396818-6	2019	SB203580 was used as inhibitor of p38MAPK pathway, while SP600125 was used as inhibitor of JNK pathway.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	91-94
31538158-8	2019	The blockade of JNK activity by SP600125 inhibited the nuclear translocation of FoxO1, and subsequently suppressed the osteogenic differentiation and antioxidant defense system of BM-MSCs.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	16-19
31538158-8	2019	The blockade of JNK activity by SP600125 inhibited the nuclear translocation of FoxO1, and subsequently suppressed the osteogenic differentiation and antioxidant defense system of BM-MSCs.	pyrazolanthrone	32-40	forkhead box O1	Homo sapiens	80-85
31301277-11	2019	The JNK inhibitor SP600125 or knockdown of JNK by siRNA markedly attenuated Rg5-induced G2/M arrest, apoptosis and autophagy.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
31807542-9	2019	However, the proliferation and migration stimulated by Ang II were partly reversed by drug inhibitors of the four pathways, namely, PD98059, SB203580, SP600125 and XMD17-109.	pyrazolanthrone	151-159	angiotensinogen	Homo sapiens	55-61
31199065-11	2019	SP600125 (JNK inhibitor) decreased mRNA expression level of TNF-alpha and IL-1beta.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	10-13
31199065-11	2019	SP600125 (JNK inhibitor) decreased mRNA expression level of TNF-alpha and IL-1beta.	pyrazolanthrone	0-8	tumor necrosis factor	Rattus norvegicus	60-69
31199065-11	2019	SP600125 (JNK inhibitor) decreased mRNA expression level of TNF-alpha and IL-1beta.	pyrazolanthrone	0-8	interleukin 1 alpha	Rattus norvegicus	74-82
31506575-7	2019	Moreover, downregulation of JNK by its specific inhibitor SP600125 significantly diminished the anticancer activity of APE indicating that ROS generation and sustained JNK activation represented the main underlying mechanism of APE-induced cell death.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Homo sapiens	28-31
31295022-5	2019	Overexpression of the key autophagy protein Beclin1 rescued autophagy deficiency and osteoclastogenesis in the presence of a JNK inhibitor (SP600125).	pyrazolanthrone	140-148	beclin 1	Homo sapiens	44-51
31295022-5	2019	Overexpression of the key autophagy protein Beclin1 rescued autophagy deficiency and osteoclastogenesis in the presence of a JNK inhibitor (SP600125).	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	125-128
31352088-9	2019	Meanwhile, the underlying relationship among miR-196a, GPX3 and JNK pathway was explored by treatment with the JNK pathway inhibitor (SP600125), or sh-GPX3.	pyrazolanthrone	134-142	glutathione peroxidase 3	Mus musculus	55-59
31352088-9	2019	Meanwhile, the underlying relationship among miR-196a, GPX3 and JNK pathway was explored by treatment with the JNK pathway inhibitor (SP600125), or sh-GPX3.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Mus musculus	64-67
31673231-10	2019	Treatment with either an ERK1/2 inhibitor U0126 or a JNK inhibitor SP600125 rescued SNU-216 from dying of bortezomib or combined treatment.	pyrazolanthrone	67-75	mitogen-activated protein kinase 8	Homo sapiens	53-56
31646600-10	2019	However, the mRNA expression levels of p38 MAPK and JNK in UTI+SP600125 group and UTI+SB203580 group were remarkably higher than the UTI group.	pyrazolanthrone	63-71	mitogen activated protein kinase 14	Rattus norvegicus	39-42
31646600-10	2019	However, the mRNA expression levels of p38 MAPK and JNK in UTI+SP600125 group and UTI+SB203580 group were remarkably higher than the UTI group.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Rattus norvegicus	52-55
31351365-5	2019	LY294002 (a PI3K inhibitor) and SP600125 (a JNK inhibitor) reduced NG-induced HO-1 expression, whereas BIRB796 (a p38 inhibitor) and PD98059 (an ERK inhibitor) had no effect.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	44-47
31351365-5	2019	LY294002 (a PI3K inhibitor) and SP600125 (a JNK inhibitor) reduced NG-induced HO-1 expression, whereas BIRB796 (a p38 inhibitor) and PD98059 (an ERK inhibitor) had no effect.	pyrazolanthrone	32-40	heme oxygenase 1	Homo sapiens	78-82
31351365-7	2019	Indeed, the results of our experiments using LY294002 and SP600125 indicated that NG may stimulate Nrf2 through PI3K/Akt and JNK pathway activation.	pyrazolanthrone	58-66	NFE2 like bZIP transcription factor 2	Homo sapiens	99-103
31620005-4	2019	Male mice were treated with APAP (150 and 175 mg kg-1), and meanwhile JNK inhibitor SP600125 was used to interfere APAP-induced liver damage.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Mus musculus	70-73
31620005-8	2019	It was observed that apoptosis was increased in APAP-induced liver injury, and SP600125 can attenuate apoptosis through the inhibition of JNK phosphorylation.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Mus musculus	138-141
31505769-6	2019	Moreover, p38-MAPK/JNK inhibitors SB203580 and SP600125 promoted ex vivo expansion of CD34+ cells.	pyrazolanthrone	47-55	mitogen-activated protein kinase 14	Homo sapiens	10-13
31505769-6	2019	Moreover, p38-MAPK/JNK inhibitors SB203580 and SP600125 promoted ex vivo expansion of CD34+ cells.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	19-22
31505769-6	2019	Moreover, p38-MAPK/JNK inhibitors SB203580 and SP600125 promoted ex vivo expansion of CD34+ cells.	pyrazolanthrone	47-55	CD34 molecule	Homo sapiens	86-90
30998268-12	2019	ANXA3 downregulation reduced Ox resistance in CRC, and treatment with the ERK inhibitor PD098059 or JNK inhibitor SP600125 contributed to this process.	pyrazolanthrone	114-122	mitogen-activated protein kinase 8	Homo sapiens	100-103
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	74-77
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	caspase 3	Homo sapiens	79-88
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	secreted phosphoprotein 1	Homo sapiens	90-101
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	secreted phosphoprotein 1	Homo sapiens	103-106
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	BCL2 associated X, apoptosis regulator	Homo sapiens	109-112
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	matrix metallopeptidase 9	Homo sapiens	118-144
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	matrix metallopeptidase 9	Homo sapiens	146-151
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	179-182
31362241-8	2019	VSMCs treated with siRNA-ANXA3 or SP600125 showed decreased expression of JNK, caspase-3, osteopontin (OPN), Bax, and matrix metalloproteinase-9 (MMP-9), as well as phosphate (p)-JNK, but increased the expression of alpha smooth muscle actin (alpha-SMA), beta-tubulin, and Bcl-2.	pyrazolanthrone	34-42	BCL2 apoptosis regulator	Homo sapiens	273-278
31226632-10	2019	Furthermore, the anti-cancer effects of BD were alleviated effectively by a specific JNK inhibitor SP600125 in NSCLC cells.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	85-88
31348969-8	2019	Transfection with siRNAs for JNK and CHOP or pretreatment with specific pharmacological inhibitor of JNK (SP600125) in beta-cells effectively prevented the Cd-induced insulin secretion dysfunction and apoptosis.	pyrazolanthrone	106-114	mitogen-activated protein kinase 8	Rattus norvegicus	101-104
31484592-8	2019	Use of SB203580 (p38 inhibitor) and SP600125 (p-JNK inhibitor) corroborated these findings.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	48-51
31351801-3	2019	MATERIALS AND METHODS: Human pancreatic cancer cell lines SW1990 was treated with Silibinin and/or JNK/SAPK inhibitor SP600125 followed by measurement of cell viability, apoptosis, autophagy, ROS and ATP, and western blotting.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	99-107
30556589-8	2019	Furthermore, CA activated the c-Jun N-terminal kinase (JNK) signaling pathway, and treatment with JNK siRNAs or inhibitor SP600125 significantly attenuated CA-mediated autophagosome accumulation and DR5-mediated cell apoptosis.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	30-53
31894675-4	2019	Cells were pre-treated with DHM or co-treated with c-Jun N-terminal kinase (JNK) pathway inhibitor SP600125, then, the levels of migration- and invasion-related proteins were tested by Western blot.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	51-74
31894675-4	2019	Cells were pre-treated with DHM or co-treated with c-Jun N-terminal kinase (JNK) pathway inhibitor SP600125, then, the levels of migration- and invasion-related proteins were tested by Western blot.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	76-79
31894675-6	2019	Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	26-29
31894675-6	2019	Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway.	pyrazolanthrone	40-48	matrix metallopeptidase 2	Homo sapiens	68-73
31894675-6	2019	Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	180-183
31894675-6	2019	Co-treatment with DHM and JNK inhibitor SP600125 further suppressed MMP-2 expression and cell invasion in MKN45 cells, suggesting that DHM inhibited MKN45 cells metastasis through JNK/MMP-2 pathway.	pyrazolanthrone	40-48	matrix metallopeptidase 2	Homo sapiens	184-189
31185235-11	2019	Allicin combined with SP600125 (JNK inhibitor) and SB202190 (p38 inhibitor) enhanced cell viability in the presence of AA, as opposed to SCH772984 (ERK inhibitor).	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Rattus norvegicus	32-35
30475650-8	2019	Treatment with compound C (AMPK inhibitor) or SP600125 (JNK inhibitor) significantly restrained the inhibition of proliferation, apoptosis, and autophagy induced with C-K in A549 and H1975 cells.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	56-59
30556589-8	2019	Furthermore, CA activated the c-Jun N-terminal kinase (JNK) signaling pathway, and treatment with JNK siRNAs or inhibitor SP600125 significantly attenuated CA-mediated autophagosome accumulation and DR5-mediated cell apoptosis.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	55-58
30556589-8	2019	Furthermore, CA activated the c-Jun N-terminal kinase (JNK) signaling pathway, and treatment with JNK siRNAs or inhibitor SP600125 significantly attenuated CA-mediated autophagosome accumulation and DR5-mediated cell apoptosis.	pyrazolanthrone	122-130	TNF receptor superfamily member 10b	Homo sapiens	199-202
31229567-4	2019	This is supported by the findings that inhibition of JNK with SP600125 or ectopic expression of dominant negative c-Jun attenuated maduramicin-induced apoptosis in C2C12 cells.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Mus musculus	53-56
30946899-7	2019	SP600125, an inhibitor of SAPK/JNK, and SB203580, an inhibitor of p38 MAP kinase, suppressed the amplification by onalespib of the PGD2-stimulated HSP27 induction.	pyrazolanthrone	0-8	prostaglandin D2 synthase (brain)	Mus musculus	131-135
30946899-7	2019	SP600125, an inhibitor of SAPK/JNK, and SB203580, an inhibitor of p38 MAP kinase, suppressed the amplification by onalespib of the PGD2-stimulated HSP27 induction.	pyrazolanthrone	0-8	heat shock protein 1	Mus musculus	147-152
31322778-6	2019	The inhibitory effect of LPS on GPR120 expression was blocked by Toll-like receptor 4 (TLR4) inhibitor TAK242 and p38 mitogen-activated protein kinase inhibitor LY222820, but not by ERK1/2 inhibitor U0126 and c-Jun N-terminal kinase inhibitor SP600125.	pyrazolanthrone	243-251	free fatty acid receptor 4	Mus musculus	32-38
31344106-4	2019	When cells were treated with inhibitors of mitogen-activated protein kinases (MAPKs), the extracellular signal-regulated kinase (ERK) inhibitor FR180240 inhibited IL-1beta-induced IL-6 mRNA expression, but not SP600125 or SKF86002, which are c-Jun N-terminal kinase (JNK) and p38 MAPK inhibitors, respectively.	pyrazolanthrone	210-218	mitogen-activated protein kinase 1	Canis lupus familiaris	78-82
31428156-6	2019	Signaling pathway repressors including AMD3100 and SP600125 associated with the migration of BM CD44+ cells were further investigated.	pyrazolanthrone	51-59	CD44 antigen	Mus musculus	96-100
31322778-6	2019	The inhibitory effect of LPS on GPR120 expression was blocked by Toll-like receptor 4 (TLR4) inhibitor TAK242 and p38 mitogen-activated protein kinase inhibitor LY222820, but not by ERK1/2 inhibitor U0126 and c-Jun N-terminal kinase inhibitor SP600125.	pyrazolanthrone	243-251	mitogen-activated protein kinase 14	Mus musculus	114-117
31233063-6	2019	SP600125, a JNK inhibitor, and N-acetylcysteine (NAC), a ROS inhibitor, attenuated Slp-induced autophagic cell death in HCT116 cells.	pyrazolanthrone	0-8	surface layer protein	Lactobacillus acidophilus NCFM	83-86
31357761-9	2019	SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P&lt; 0.05).	pyrazolanthrone	0-8	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	103-109
31456826-5	2019	SP600125 inhibited significantly IL-6 mRNA transcription in the high responder group and did not influence the transcription level in the low responder group.	pyrazolanthrone	0-8	interleukin 6	Homo sapiens	33-37
31119897-8	2019	Pharmacological inhibition of JNK by SP600125 partially abrogated PRDM5-induced cell proliferation and migration.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	30-33
31119897-8	2019	Pharmacological inhibition of JNK by SP600125 partially abrogated PRDM5-induced cell proliferation and migration.	pyrazolanthrone	37-45	PR/SET domain 5	Homo sapiens	66-71
31258709-12	2019	JNK specific inhibitor, SP600125, significantly inhibited brucine-induced cell viability enhancement compared with the brucine-treated groups without inhibitor (P&lt;0.05).	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	0-3
31217433-8	2019	JNK inhibitor SP600125 as well as DHA-mediated JNK inactivation decreased IL-1beta secretion.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	0-3
31357761-9	2019	SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P&lt; 0.05).	pyrazolanthrone	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	116-119
31357761-9	2019	SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P&lt; 0.05).	pyrazolanthrone	0-8	BCL2 apoptosis regulator	Homo sapiens	121-126
31357761-9	2019	SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P&lt; 0.05).	pyrazolanthrone	0-8	caspase 3	Homo sapiens	128-136
31357761-9	2019	SP600125 and SB203580 had inhibited oxidative stress and apoptosis induced by palmitic acid (including CYP2E1, MDA, Bax, Bcl-2, caspase3, CHOP) (P&lt; 0.05).	pyrazolanthrone	0-8	DNA damage inducible transcript 3	Homo sapiens	138-142
31212975-8	2019	Furthermore, MAPK inhibitors including an extracellular signal-regulated kinase (ERK) 1/2 inhibitor (U0126), a p38 inhibitor (SB202190) and a c-Jun N-terminal kinase (JNK) inhibitor (SP600125) decreased the expression of soluble ICAM-1 (sICAM-1), but not ICAM-1.	pyrazolanthrone	183-191	mitogen-activated protein kinase 3	Homo sapiens	42-89
31312395-13	2019	Additionally, treatment of Gal-1 mice with the MAPK JNK/p38 signalling pathway antagonists SB203580 or SP600125 reduced cancer metastasis.	pyrazolanthrone	103-111	lectin, galactose binding, soluble 1	Mus musculus	27-32
30895561-0	2019	Roles of SP600125 in expression of JNK, RANKL and OPG in cultured dental follicle cells.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Homo sapiens	35-38
30707290-7	2019	DNMT1 knockdown increased the phosphorylation of IKKalpha/beta, IkappaBalpha, and p65 in the NF-kappaB pathway and the phosphorylation of p38 and ERK in the MAPK pathway; however, only the NF-kappaB pathway inhibitor PDTC suppressed both IL-6 and IL-8 expression, whereas inhibitors of the MAPK pathway (U0126, SB2035580, and SP600125) did not.	pyrazolanthrone	326-334	DNA methyltransferase 1	Homo sapiens	0-5
30644129-9	2019	Next we used the inhibitor of JNK pathway to inhibit the activity of the JNK pathway and the results showed that co-addition of SP600125 significantly abolished the function of ZCCHC9 to promote the proliferation and invasion of cancer cells.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	30-33
30644129-9	2019	Next we used the inhibitor of JNK pathway to inhibit the activity of the JNK pathway and the results showed that co-addition of SP600125 significantly abolished the function of ZCCHC9 to promote the proliferation and invasion of cancer cells.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	73-76
30644129-9	2019	Next we used the inhibitor of JNK pathway to inhibit the activity of the JNK pathway and the results showed that co-addition of SP600125 significantly abolished the function of ZCCHC9 to promote the proliferation and invasion of cancer cells.	pyrazolanthrone	128-136	zinc finger CCHC-type containing 9	Homo sapiens	177-183
30981511-7	2019	Moreover, we found that oridonin induced CRC cell apoptosis via the c-Jun N-terminal kinase (JNK)/c-Jun pathway as oridonin activated JNK/c-Jun pathway and the JNK inhibitor SP600125 restored oridonin-induced apoptosis in CRC cells.	pyrazolanthrone	174-182	mitogen-activated protein kinase 8	Homo sapiens	68-91
30981511-7	2019	Moreover, we found that oridonin induced CRC cell apoptosis via the c-Jun N-terminal kinase (JNK)/c-Jun pathway as oridonin activated JNK/c-Jun pathway and the JNK inhibitor SP600125 restored oridonin-induced apoptosis in CRC cells.	pyrazolanthrone	174-182	mitogen-activated protein kinase 8	Homo sapiens	93-96
30981511-7	2019	Moreover, we found that oridonin induced CRC cell apoptosis via the c-Jun N-terminal kinase (JNK)/c-Jun pathway as oridonin activated JNK/c-Jun pathway and the JNK inhibitor SP600125 restored oridonin-induced apoptosis in CRC cells.	pyrazolanthrone	174-182	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	68-73
30822534-6	2019	Pre-treatment with a PI3K/AKT inhibitor (Wortmannin), ERK1/2 inhibitor (U0126), and JNK inhibitor (SP600125) induced the signaling interactions of these molecules, and oxibendazole co-treatment with each inhibitor resulted in even greater decreases in cell proliferation.	pyrazolanthrone	99-107	AKT serine/threonine kinase 1	Homo sapiens	26-29
30822534-6	2019	Pre-treatment with a PI3K/AKT inhibitor (Wortmannin), ERK1/2 inhibitor (U0126), and JNK inhibitor (SP600125) induced the signaling interactions of these molecules, and oxibendazole co-treatment with each inhibitor resulted in even greater decreases in cell proliferation.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	84-87
30909132-6	2019	Primary HNECs were treated with HNE, bafilomycin A1, and SP600125.	pyrazolanthrone	57-65	elastase, neutrophil expressed	Homo sapiens	8-11
30909132-12	2019	HNE-induced secretion of MUC5AC was suppressed in normal primary HNECs by BECN1-siRNA, Atg5-siRNA, c-Jun-siRNA, and SP600125.	pyrazolanthrone	116-124	elastase, neutrophil expressed	Homo sapiens	0-3
30909132-12	2019	HNE-induced secretion of MUC5AC was suppressed in normal primary HNECs by BECN1-siRNA, Atg5-siRNA, c-Jun-siRNA, and SP600125.	pyrazolanthrone	116-124	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	25-31
31162246-10	2019	Interestingly, reduced autophagy and collagen secretion were observed when the JNK signaling pathway was blocked using SP600125.	pyrazolanthrone	119-127	mitogen-activated protein kinase 8	Homo sapiens	79-82
31162246-11	2019	We also observed upregulation of Akt and mTOR phosphorylation in the presence of SP600125.	pyrazolanthrone	81-89	AKT serine/threonine kinase 1	Homo sapiens	33-36
31162246-11	2019	We also observed upregulation of Akt and mTOR phosphorylation in the presence of SP600125.	pyrazolanthrone	81-89	mechanistic target of rapamycin kinase	Homo sapiens	41-45
30895561-0	2019	Roles of SP600125 in expression of JNK, RANKL and OPG in cultured dental follicle cells.	pyrazolanthrone	9-17	TNF superfamily member 11	Homo sapiens	40-45
30895561-0	2019	Roles of SP600125 in expression of JNK, RANKL and OPG in cultured dental follicle cells.	pyrazolanthrone	9-17	basic transcription factor 3 pseudogene 11	Homo sapiens	50-53
30895561-6	2019	The expression of JNK protein in the SP600125 groups showed significant decline compared with that of the control group and blank control (P < 0.05).	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	18-21
30895561-7	2019	Significant decrease was noticed in the RANKL protein expression with the elevation of SP600125.	pyrazolanthrone	87-95	TNF superfamily member 11	Homo sapiens	40-45
30895561-9	2019	After SP600125 treatment, the expression of RANKL and JNK showed a trend of decrease, and the expression of OPG showed gradual increase followed by gradual decrease.	pyrazolanthrone	6-14	TNF superfamily member 11	Homo sapiens	44-49
30895561-9	2019	After SP600125 treatment, the expression of RANKL and JNK showed a trend of decrease, and the expression of OPG showed gradual increase followed by gradual decrease.	pyrazolanthrone	6-14	mitogen-activated protein kinase 8	Homo sapiens	54-57
30895561-9	2019	After SP600125 treatment, the expression of RANKL and JNK showed a trend of decrease, and the expression of OPG showed gradual increase followed by gradual decrease.	pyrazolanthrone	6-14	basic transcription factor 3 pseudogene 11	Homo sapiens	108-111
30876940-11	2019	When the JNK inhibitor SP600125 was used in combination, the apoptosis phenomenon was reversed.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	9-12
30935901-8	2019	SP600125 and SB203580, JNK and p38 inhibitors, respectively, reduced the upregulation of MUC5AC by PHMG-p in Calu-3 cells.	pyrazolanthrone	0-8	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	89-95
30944266-7	2019	Furthermore, pre-treatment with a JNK-specific inhibitor SP600125 abated daucosterol-elicited autophagy and apoptotic cell death.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	34-37
30907478-7	2019	RA-induced cell death was significantly restored by the ROS scavenger glutathione (GSH), the pharmacological inhibitor of JNK SP600125, or specific JNK knockdown by shRNA.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	122-125
30770640-8	2019	The inhibitory effect of LIG was enhanced by the p38 MAPK inhibitor SB203580 or the JNK inhibitor SP600125 and offset by the agonist anisomycin.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Rattus norvegicus	84-87
30768131-9	2019	Moreover, an inhibitor of the SAPK/JNK signaling pathway, SP600125, significantly suppressed neuronal cell death and activation of the SAPK/JNK signaling pathway induced by CuCl2 and ZnCl2 cotreatment.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Mus musculus	35-38
30768131-9	2019	Moreover, an inhibitor of the SAPK/JNK signaling pathway, SP600125, significantly suppressed neuronal cell death and activation of the SAPK/JNK signaling pathway induced by CuCl2 and ZnCl2 cotreatment.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Mus musculus	140-143
31096598-6	2019	SB203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK) prevented detrimental effects of EEP, whereas SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), exacerbated EEP-induced neuronal cell death.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	142-165
31096598-6	2019	SB203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK) prevented detrimental effects of EEP, whereas SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), exacerbated EEP-induced neuronal cell death.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	167-170
30907478-8	2019	Additionally, signal transducer and activator of transcription 3 (STAT3) activation was suppressed by RA in human osteosarcoma, and this suppression was restored by GSH, SP600125, and JNK-shRNA.	pyrazolanthrone	170-178	signal transducer and activator of transcription 3	Homo sapiens	14-64
30907478-8	2019	Additionally, signal transducer and activator of transcription 3 (STAT3) activation was suppressed by RA in human osteosarcoma, and this suppression was restored by GSH, SP600125, and JNK-shRNA.	pyrazolanthrone	170-178	signal transducer and activator of transcription 3	Homo sapiens	66-71
31105818-0	2019	Use of Saikosaponin D and JNK inhibitor SP600125, alone or in combination, inhibits malignant properties of human osteosarcoma U2 cells.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	26-29
31105818-1	2019	Saikosaponin D (Ssd) is a major active ingredient derived from the traditional Chinese medicinal herb Bupleurum falcatum, and SP600125 is a specific inhibitor of JNK that competes with adenosine triphosphate.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	162-165
31011291-12	2019	Knockdown of MIEF1 using an siRNA-mediated loss of function assay and/or inhibition of the MAPK-JNK pathway using the specific inhibitor SP600125 abolished LATS2/5-FU-mediated deleterious effects on mitochondrial performance and SW480 cell viability.	pyrazolanthrone	137-145	mitogen-activated protein kinase 8	Homo sapiens	96-99
31011291-12	2019	Knockdown of MIEF1 using an siRNA-mediated loss of function assay and/or inhibition of the MAPK-JNK pathway using the specific inhibitor SP600125 abolished LATS2/5-FU-mediated deleterious effects on mitochondrial performance and SW480 cell viability.	pyrazolanthrone	137-145	large tumor suppressor kinase 2	Homo sapiens	156-161
31019655-13	2019	Meanwhile, ROS scavenger NAC, JNK inhibitor SP600125, and p53 inhibitor PFTalpha were used to verify that autophagy-mediated upregulation of DR5 was regulated by the SNX-2112-stimulated activation of the ROS-JNK-p53 signaling pathway.	pyrazolanthrone	44-52	TNF receptor superfamily member 10b	Homo sapiens	141-144
30599064-11	2019	The c-Src and JNK inhibitors PP2 and SP600125 were able to increase the pHe, although the differences between control and CFTR-impaired cells were not fully compensated.	pyrazolanthrone	37-45	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	4-9
30599064-11	2019	The c-Src and JNK inhibitors PP2 and SP600125 were able to increase the pHe, although the differences between control and CFTR-impaired cells were not fully compensated.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	14-17
30685603-6	2019	Quercetin, rottlerin, SP600125 and U0126 attenuated TNF-alpha-stimulated c-Jun phosphorylation and AP-1-Luc activity.	pyrazolanthrone	22-30	tumor necrosis factor	Homo sapiens	52-61
30685603-6	2019	Quercetin, rottlerin, SP600125 and U0126 attenuated TNF-alpha-stimulated c-Jun phosphorylation and AP-1-Luc activity.	pyrazolanthrone	22-30	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	73-78
30685603-7	2019	Pretreatment with quercetin, rottlerin, SP600125, or Bay 11-7082 attenuated TNF-alpha-induced NF-kappaB (p65) phosphorylation, translocation and RelA/p65-Luc activity.	pyrazolanthrone	40-48	tumor necrosis factor	Homo sapiens	76-85
30685603-7	2019	Pretreatment with quercetin, rottlerin, SP600125, or Bay 11-7082 attenuated TNF-alpha-induced NF-kappaB (p65) phosphorylation, translocation and RelA/p65-Luc activity.	pyrazolanthrone	40-48	RELA proto-oncogene, NF-kB subunit	Homo sapiens	105-108
30613914-6	2019	Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	57-60
30613914-6	2019	Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression.	pyrazolanthrone	62-70	interleukin 1 beta	Homo sapiens	110-118
30613914-6	2019	Pretreatment with specific inhibitors of ERK1/2 (U0126), JNK (SP600125), and AP-1 (tanshinone IIA) attenuated IL-1beta-induced MMP-9 expression.	pyrazolanthrone	62-70	matrix metallopeptidase 9	Homo sapiens	127-132
30613914-7	2019	In addition, inhibitors of ERK1/2 (U0126) and JNK (SP600125) attenuated IL-1beta-enhanced AP-1 activity.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	46-49
30613914-7	2019	In addition, inhibitors of ERK1/2 (U0126) and JNK (SP600125) attenuated IL-1beta-enhanced AP-1 activity.	pyrazolanthrone	51-59	interleukin 1 beta	Homo sapiens	72-80
30613914-7	2019	In addition, inhibitors of ERK1/2 (U0126) and JNK (SP600125) attenuated IL-1beta-enhanced AP-1 activity.	pyrazolanthrone	51-59	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-94
30685603-7	2019	Pretreatment with quercetin, rottlerin, SP600125, or Bay 11-7082 attenuated TNF-alpha-induced NF-kappaB (p65) phosphorylation, translocation and RelA/p65-Luc activity.	pyrazolanthrone	40-48	RELA proto-oncogene, NF-kB subunit	Homo sapiens	145-149
30685603-7	2019	Pretreatment with quercetin, rottlerin, SP600125, or Bay 11-7082 attenuated TNF-alpha-induced NF-kappaB (p65) phosphorylation, translocation and RelA/p65-Luc activity.	pyrazolanthrone	40-48	RELA proto-oncogene, NF-kB subunit	Homo sapiens	150-153
30685603-8	2019	TNF-alpha significantly increased MMP-9 promoter activity and THP-1 cell adherence, and these effects were attenuated by pretreatment with quercetin, rottlerin, SP600125, U0126, tanshinone IIA or Bay 11-7082.	pyrazolanthrone	161-169	tumor necrosis factor	Homo sapiens	0-9
30685603-8	2019	TNF-alpha significantly increased MMP-9 promoter activity and THP-1 cell adherence, and these effects were attenuated by pretreatment with quercetin, rottlerin, SP600125, U0126, tanshinone IIA or Bay 11-7082.	pyrazolanthrone	161-169	matrix metallopeptidase 9	Homo sapiens	34-39
30238980-6	2019	Ephrin A1 dose-dependently increased phosphorylation of extracellular signal-regulated kinases (ERK)1/2, c-Jun N-terminal kinases (JNK), P38, protein kinase B (AKT), P70S6K, S6, and cyclin D1, and the activated proteins were suppressed by pharmacological inhibitors including wortmannin (a PI3K inhibitor), U0126 (an ERK1/2 inhibitor), and SP600125 (a JNK inhibitor).	pyrazolanthrone	340-348	ephrin A1	Bos taurus	0-9
30745529-12	2019	Besides, SP600125 (an inhibitor of Jnk) eliminated miR-223-modulated inflammatory injury in H9c2 cells.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Rattus norvegicus	35-38
30745529-12	2019	Besides, SP600125 (an inhibitor of Jnk) eliminated miR-223-modulated inflammatory injury in H9c2 cells.	pyrazolanthrone	9-17	microRNA 223	Rattus norvegicus	51-58
30610847-9	2019	Furthermore, we selected SB239063, a p38/MAPK signaling inhibitor, and SP600125, a JNK inhibitor, to identify the functions of p38/MAPK and JNK in TLR9-mediated signaling transduction.	pyrazolanthrone	71-79	toll like receptor 9	Homo sapiens	147-151
30773423-8	2019	The involvement of MAPK cascades such as p38, ERK and p38 on compound 14a induced apoptotic cell death was evidenced by the fact that the inclusion of specific inhibitors of p38, ERK1/2 and JNK MAPK (SB2035809, PD98059 and SP600125) prevented the compound 14a towards induced apoptosis.	pyrazolanthrone	223-231	mitogen-activated protein kinase 3	Homo sapiens	19-23
30948926-5	2019	Secondly, the influence of ROS content on the activity of the JNK1/Sirt1/FoxO3a signaling pathway was explored through the application of NAC, sp600125 (a JNK1 inhibitor), and nicotinamide (a Sirt1 inhibitor).	pyrazolanthrone	143-151	forkhead box O3	Rattus norvegicus	73-79
30818884-13	2019	The p38 inhibitor SB203580 and the JNK inhibitor SP600125 suppressed MMP-9 and COX-2 expression in H2O2-treated HaCaT cells.	pyrazolanthrone	49-57	matrix metallopeptidase 9	Homo sapiens	69-74
30818884-13	2019	The p38 inhibitor SB203580 and the JNK inhibitor SP600125 suppressed MMP-9 and COX-2 expression in H2O2-treated HaCaT cells.	pyrazolanthrone	49-57	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	79-84
30863177-9	2019	Moreover, forskolin enhanced the effects of SP600125, an inhibitor of c-Jun N-terminal kinase signaling on cell apoptosis promotion and tumorigenesis inhibition via Axin-induced beta-catenin signaling repression.	pyrazolanthrone	44-52	axin 1	Homo sapiens	165-169
30863177-9	2019	Moreover, forskolin enhanced the effects of SP600125, an inhibitor of c-Jun N-terminal kinase signaling on cell apoptosis promotion and tumorigenesis inhibition via Axin-induced beta-catenin signaling repression.	pyrazolanthrone	44-52	catenin beta 1	Homo sapiens	178-190
30972205-6	2019	Furthermore, SP600125 was used to inhibit the potential downstream factor JNK1, and the osteogenic differentiation ability of DPSCs was evaluated.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	74-78
30860495-6	2019	Blocking of the c-JUN N-terminal kinase (JNK) using SP600125 in combination with BYL719 showed a synergistic anti-proliferative effect in vitro, which was accompanied by AXL downregulation and potent inhibition of the mTOR pathway.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	16-39
30860495-6	2019	Blocking of the c-JUN N-terminal kinase (JNK) using SP600125 in combination with BYL719 showed a synergistic anti-proliferative effect in vitro, which was accompanied by AXL downregulation and potent inhibition of the mTOR pathway.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	41-44
30860495-6	2019	Blocking of the c-JUN N-terminal kinase (JNK) using SP600125 in combination with BYL719 showed a synergistic anti-proliferative effect in vitro, which was accompanied by AXL downregulation and potent inhibition of the mTOR pathway.	pyrazolanthrone	52-60	AXL receptor tyrosine kinase	Homo sapiens	170-173
30860495-6	2019	Blocking of the c-JUN N-terminal kinase (JNK) using SP600125 in combination with BYL719 showed a synergistic anti-proliferative effect in vitro, which was accompanied by AXL downregulation and potent inhibition of the mTOR pathway.	pyrazolanthrone	52-60	mechanistic target of rapamycin kinase	Homo sapiens	218-222
30458182-7	2019	Moreover, we also used a selective JNK inhibitor Sp600125 to further corroborate the involvement of TLR4, JNK, and FoxO1 in the anti-inflammatory action of Ang-(1-7).	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Mus musculus	35-38
30458182-7	2019	Moreover, we also used a selective JNK inhibitor Sp600125 to further corroborate the involvement of TLR4, JNK, and FoxO1 in the anti-inflammatory action of Ang-(1-7).	pyrazolanthrone	49-57	angiogenin, ribonuclease A family, member 6	Mus musculus	156-164
30664165-10	2019	Inhibition of ROCK1 by Y27632 and JNK by SP600125 attenuated MTV-induced lung injury and decreased the expression of proteins involved in non-canonical Wnt signaling, including WISP1.	pyrazolanthrone	41-49	Rho-associated coiled-coil containing protein kinase 1	Mus musculus	14-19
30664165-10	2019	Inhibition of ROCK1 by Y27632 and JNK by SP600125 attenuated MTV-induced lung injury and decreased the expression of proteins involved in non-canonical Wnt signaling, including WISP1.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Mus musculus	34-37
30664165-10	2019	Inhibition of ROCK1 by Y27632 and JNK by SP600125 attenuated MTV-induced lung injury and decreased the expression of proteins involved in non-canonical Wnt signaling, including WISP1.	pyrazolanthrone	41-49	cellular communication network factor 4	Mus musculus	177-182
30368882-7	2019	Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	18-21
30368882-7	2019	Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression.	pyrazolanthrone	42-50	BCL2 apoptosis regulator	Homo sapiens	103-108
30368882-7	2019	Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression.	pyrazolanthrone	42-50	BCL2 associated X, apoptosis regulator	Homo sapiens	150-176
30368882-7	2019	Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression.	pyrazolanthrone	42-50	BCL2 associated X, apoptosis regulator	Homo sapiens	178-181
30368882-7	2019	Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression.	pyrazolanthrone	42-50	mitogen-activated protein kinase 14	Homo sapiens	292-295
30368882-7	2019	Pretreatment with JNK-specific inhibitors SP600125 markedly upregulated the reduced B-cell lymphoma 2 (Bcl-2) content and downregulated the increased Bcl-2-associated X protein (Bax) level and thereby eventually reduced the proportions of early and late apoptotic cells induced by ACR, while p38 suppression by SB202190 only reversed the decrease in Bcl-2 expression.	pyrazolanthrone	42-50	BCL2 apoptosis regulator	Homo sapiens	150-155
30537209-9	2019	In addition, we also found that 3-MA decreased the expression of LC3A/B and Beclin1, while the JNK inhibitor SP600125 reduced the levels of phosphorylated JNK, LC3A/B and Beclin1.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Rattus norvegicus	95-98
30537209-9	2019	In addition, we also found that 3-MA decreased the expression of LC3A/B and Beclin1, while the JNK inhibitor SP600125 reduced the levels of phosphorylated JNK, LC3A/B and Beclin1.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Rattus norvegicus	155-158
30537209-9	2019	In addition, we also found that 3-MA decreased the expression of LC3A/B and Beclin1, while the JNK inhibitor SP600125 reduced the levels of phosphorylated JNK, LC3A/B and Beclin1.	pyrazolanthrone	109-117	beclin 1	Rattus norvegicus	171-178
30642982-7	2019	A JNK inhibitor, SP600125, specifically abolishes Cd-induced CFH production.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	2-5
30642982-7	2019	A JNK inhibitor, SP600125, specifically abolishes Cd-induced CFH production.	pyrazolanthrone	17-25	complement factor H	Homo sapiens	61-64
30203888-9	2019	In addition, quercetin selectively activated the c-Jun N-terminal kinase (JNK) pathway in KRAS-mutant cells, while inhibition of phospho-JNK by SP600125 blocked quercetin-induced apoptosis.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	137-140
31933857-0	2019	Protective role of JNK inhibitor SP600125 in sepsis-induced acute lung injury.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	19-22
30621754-14	2019	Meanwhile, SP600125, a JNK inhibitor, effectively reversed XAG-induced protective autophagy and enhanced cell apoptosis in XAG-treated HCC cells.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Homo sapiens	23-26
30171832-6	2019	The IL-22-induced down-regulation of Cx43 expression and decrease in GJIC can be significantly blocked by the JNK inhibitor SP600125 and by the overexpression of IL-22RA2 (which specifically binds to IL-22 and inhibits its activity), but not by the NF-kappaB inhibitor BAY11-7082, in HaCaT cells.	pyrazolanthrone	124-132	interleukin 22	Homo sapiens	4-9
30171832-6	2019	The IL-22-induced down-regulation of Cx43 expression and decrease in GJIC can be significantly blocked by the JNK inhibitor SP600125 and by the overexpression of IL-22RA2 (which specifically binds to IL-22 and inhibits its activity), but not by the NF-kappaB inhibitor BAY11-7082, in HaCaT cells.	pyrazolanthrone	124-132	gap junction protein alpha 1	Homo sapiens	37-41
30171832-6	2019	The IL-22-induced down-regulation of Cx43 expression and decrease in GJIC can be significantly blocked by the JNK inhibitor SP600125 and by the overexpression of IL-22RA2 (which specifically binds to IL-22 and inhibits its activity), but not by the NF-kappaB inhibitor BAY11-7082, in HaCaT cells.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	110-113
30171832-6	2019	The IL-22-induced down-regulation of Cx43 expression and decrease in GJIC can be significantly blocked by the JNK inhibitor SP600125 and by the overexpression of IL-22RA2 (which specifically binds to IL-22 and inhibits its activity), but not by the NF-kappaB inhibitor BAY11-7082, in HaCaT cells.	pyrazolanthrone	124-132	nuclear factor kappa B subunit 1	Homo sapiens	249-258
29873042-6	2019	Using ERK1/2 inhibitor U0126, JNK inhibitor SP600125, and p38 inhibitor SB203580, we validated the role of MAP kinase proteins in the activation of NF-kB and caspase-3.	pyrazolanthrone	44-52	nuclear factor kappa B subunit 1	Rattus norvegicus	148-153
30670978-7	2018	RVLM microinjection of apocynin or a SAPK/JNK inhibitor (SP600125), but not an ERK1/2 inhibitor (U0126) or a p38MAPK inhibitor (SB203580), decreased AT1R mRNA and mean arterial blood pressure (MABP) in SIHR.	pyrazolanthrone	57-65	angiotensin II receptor, type 1a	Rattus norvegicus	149-153
30670978-8	2018	The increase of AT1R protein expression and MABP was inhibited by intracerebroventricular infusion (ICV), for 14 days, of SP600125, but not U0126 or SB203580 in SIHR.	pyrazolanthrone	122-130	angiotensin II receptor, type 1a	Rattus norvegicus	16-20
30431076-7	2019	Furthermore, pre-treatment with the c-Jun N-terminal kinase (JNK) inhibitor, SP600125, significantly attenuated the luteolin-induced upregulation of DR5 expression, thereby suggesting that JNK activation promotes DR5 expression.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	61-64
30431076-7	2019	Furthermore, pre-treatment with the c-Jun N-terminal kinase (JNK) inhibitor, SP600125, significantly attenuated the luteolin-induced upregulation of DR5 expression, thereby suggesting that JNK activation promotes DR5 expression.	pyrazolanthrone	77-85	TNF receptor superfamily member 10b	Homo sapiens	149-152
30431076-7	2019	Furthermore, pre-treatment with the c-Jun N-terminal kinase (JNK) inhibitor, SP600125, significantly attenuated the luteolin-induced upregulation of DR5 expression, thereby suggesting that JNK activation promotes DR5 expression.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	189-192
30431076-7	2019	Furthermore, pre-treatment with the c-Jun N-terminal kinase (JNK) inhibitor, SP600125, significantly attenuated the luteolin-induced upregulation of DR5 expression, thereby suggesting that JNK activation promotes DR5 expression.	pyrazolanthrone	77-85	TNF receptor superfamily member 10b	Homo sapiens	213-216
29476447-8	2019	wt-tPA co-administered with the JNK inhibitor SP 600125 and the ET-1 antagonist BQ 123 blocked stroke-induced elevation of IL-6.	pyrazolanthrone	46-55	mitogen-activated protein kinase 8	Sus scrofa	32-35
29476447-8	2019	wt-tPA co-administered with the JNK inhibitor SP 600125 and the ET-1 antagonist BQ 123 blocked stroke-induced elevation of IL-6.	pyrazolanthrone	46-55	interleukin 6	Sus scrofa	123-127
30404567-9	2019	Additionally, CXCL5/CXCR2 axis, JNK and p38 pathway inhibitors, SB225002, SP600125 and SB203580, suppressed the growth of PTC cells overexpressing CXCL5 in nude mice, respectively.	pyrazolanthrone	74-82	mitogen-activated protein kinase 14	Mus musculus	40-43
30391746-11	2019	GF109203X, Y-27632, SP600125, ML-7 HCl and PD98059 attenuated CPI-17 phosphorylation and MLC20 phosphorylation induced by levobupivacaine.	pyrazolanthrone	20-28	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	62-68
30391746-11	2019	GF109203X, Y-27632, SP600125, ML-7 HCl and PD98059 attenuated CPI-17 phosphorylation and MLC20 phosphorylation induced by levobupivacaine.	pyrazolanthrone	20-28	myosin light chain 12B	Rattus norvegicus	89-94
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	mitogen-activated protein kinase 1	Homo sapiens	97-100
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	116-119
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	serum amyloid A1	Homo sapiens	167-171
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	mitogen-activated protein kinase 3	Homo sapiens	202-208
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	serum amyloid A1	Homo sapiens	247-251
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	matrix metallopeptidase 1	Homo sapiens	260-265
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	matrix metallopeptidase 8	Homo sapiens	267-272
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	lysyl oxidase like 1	Homo sapiens	278-283
30461130-7	2019	Furthermore, the inhibitors for NF-kappaB (JSH-23) and mitogen-activated protein kinases (MAPKs) p38 (SB203580) and JNK (SP600125) could also attenuate the effects of SAA1, while the inhibitor for MAPK ERK1/2 (PD 98059) could block the effects of SAA1 only on MMP-1, MMP-8, and LOXL1 but not on MMP-13.	pyrazolanthrone	121-129	matrix metallopeptidase 13	Homo sapiens	295-301
30404567-9	2019	Additionally, CXCL5/CXCR2 axis, JNK and p38 pathway inhibitors, SB225002, SP600125 and SB203580, suppressed the growth of PTC cells overexpressing CXCL5 in nude mice, respectively.	pyrazolanthrone	74-82	chemokine (C-X-C motif) ligand 5	Mus musculus	14-19
30404567-9	2019	Additionally, CXCL5/CXCR2 axis, JNK and p38 pathway inhibitors, SB225002, SP600125 and SB203580, suppressed the growth of PTC cells overexpressing CXCL5 in nude mice, respectively.	pyrazolanthrone	74-82	chemokine (C-X-C motif) receptor 2	Mus musculus	20-25
30384152-10	2019	Intriguingly, both resveratrol and JNK inhibitor SP600125 suppressed TNFalpha-induced IL6 and IL8 mRNA expression (P &lt; 0.05).	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	35-38
30384152-10	2019	Intriguingly, both resveratrol and JNK inhibitor SP600125 suppressed TNFalpha-induced IL6 and IL8 mRNA expression (P &lt; 0.05).	pyrazolanthrone	49-57	tumor necrosis factor	Homo sapiens	69-77
30384152-10	2019	Intriguingly, both resveratrol and JNK inhibitor SP600125 suppressed TNFalpha-induced IL6 and IL8 mRNA expression (P &lt; 0.05).	pyrazolanthrone	49-57	interleukin 6	Homo sapiens	86-89
30384152-10	2019	Intriguingly, both resveratrol and JNK inhibitor SP600125 suppressed TNFalpha-induced IL6 and IL8 mRNA expression (P &lt; 0.05).	pyrazolanthrone	49-57	C-X-C motif chemokine ligand 8	Homo sapiens	94-97
30404567-9	2019	Additionally, CXCL5/CXCR2 axis, JNK and p38 pathway inhibitors, SB225002, SP600125 and SB203580, suppressed the growth of PTC cells overexpressing CXCL5 in nude mice, respectively.	pyrazolanthrone	74-82	chemokine (C-X-C motif) ligand 5	Mus musculus	147-152
30412649-11	2019	Moreover, the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the Janus-activated kinase (JAK)2 inhibitor AG490 suppressed Ang II-induced differentiation of BM-MSCs into keratinocytes.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Rattus norvegicus	82-105
30395942-6	2019	Curcumin, tanshinone IIA, and SP600125 inhibited WT1 protein expression in a dose-dependent manner (5-15 muM) at 24 h as shown by immunoblotting.	pyrazolanthrone	30-38	WT1 transcription factor	Homo sapiens	49-52
30412649-11	2019	Moreover, the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the Janus-activated kinase (JAK)2 inhibitor AG490 suppressed Ang II-induced differentiation of BM-MSCs into keratinocytes.	pyrazolanthrone	122-130	angiotensinogen	Rattus norvegicus	196-202
30700204-10	2019	Moreover, the intrathecal administration of JNK inhibitors SP600125 reduced the expression of glial fibrillary acidic protein, while microinjection of the SP600125 decreased the mechanical allodynia of CIBP rats.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	44-47
30719147-9	2019	Moreover, JNK inhibitor (SP600125) and MEK inhibitor (U0126) treatment abolished the increase in phosphorylated MTOR and ribosomal protein S6 as well as the increase in ZO-1 and the decrease in claudin-1 in lycopene-treated COLO-16 cells.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	10-13
30719147-9	2019	Moreover, JNK inhibitor (SP600125) and MEK inhibitor (U0126) treatment abolished the increase in phosphorylated MTOR and ribosomal protein S6 as well as the increase in ZO-1 and the decrease in claudin-1 in lycopene-treated COLO-16 cells.	pyrazolanthrone	25-33	tight junction protein 1	Homo sapiens	169-173
30719147-9	2019	Moreover, JNK inhibitor (SP600125) and MEK inhibitor (U0126) treatment abolished the increase in phosphorylated MTOR and ribosomal protein S6 as well as the increase in ZO-1 and the decrease in claudin-1 in lycopene-treated COLO-16 cells.	pyrazolanthrone	25-33	claudin 1	Homo sapiens	194-203
31112061-9	2019	IL-33 induced a-SMA and collagen 1 expression was inhibited by anti-ST2 antibody and sp600125 treatment via decreased JNK/STAT3 phosphorylation in human lung fibroblast.	pyrazolanthrone	85-93	interleukin 33	Homo sapiens	0-5
31112061-9	2019	IL-33 induced a-SMA and collagen 1 expression was inhibited by anti-ST2 antibody and sp600125 treatment via decreased JNK/STAT3 phosphorylation in human lung fibroblast.	pyrazolanthrone	85-93	actin alpha 1, skeletal muscle	Homo sapiens	14-19
31112061-9	2019	IL-33 induced a-SMA and collagen 1 expression was inhibited by anti-ST2 antibody and sp600125 treatment via decreased JNK/STAT3 phosphorylation in human lung fibroblast.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Homo sapiens	118-121
31112061-9	2019	IL-33 induced a-SMA and collagen 1 expression was inhibited by anti-ST2 antibody and sp600125 treatment via decreased JNK/STAT3 phosphorylation in human lung fibroblast.	pyrazolanthrone	85-93	signal transducer and activator of transcription 3	Homo sapiens	122-127
30829205-6	2019	Autophagy response and JNK activities were inhibited by specific inhibitor, 3MA or SP600125, respectively.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	23-26
31401057-7	2019	Finally, Annexin V-PE/7-AAD analysis uncovered that treatment with NAC or SP600125 could significantly impair PFOS-induced neuronal apoptosis.	pyrazolanthrone	74-82	annexin A5	Homo sapiens	9-18
30829205-9	2019	Blocking autophagy or JNK activation with specific inhibitor, 3MA or SP600125, potentiated cell death and caspase-3 activation.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	22-25
30829205-9	2019	Blocking autophagy or JNK activation with specific inhibitor, 3MA or SP600125, potentiated cell death and caspase-3 activation.	pyrazolanthrone	69-77	caspase 3	Homo sapiens	106-115
30574018-15	2018	Furthermore, we found that the JNK inhibitor SP600125 completely diminished the mobility shift of YAP and its phosphorylation at Tyr357, the binding of YAP and p73, the transcription of Bax and p53AIP1 as well as the apoptosis induced by ABF.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
30229380-8	2019	SP600125, an inhibitor of JNK, significantly enhanced the expression of Claudin-5 and ZO-1, and decreased the disruption of BBB and enhanced the efficiency of Ang-(1-7) in glioma rats.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	26-29
30229380-8	2019	SP600125, an inhibitor of JNK, significantly enhanced the expression of Claudin-5 and ZO-1, and decreased the disruption of BBB and enhanced the efficiency of Ang-(1-7) in glioma rats.	pyrazolanthrone	0-8	claudin 5	Rattus norvegicus	72-81
30229380-8	2019	SP600125, an inhibitor of JNK, significantly enhanced the expression of Claudin-5 and ZO-1, and decreased the disruption of BBB and enhanced the efficiency of Ang-(1-7) in glioma rats.	pyrazolanthrone	0-8	tight junction protein 1	Rattus norvegicus	86-90
30587127-5	2018	SP600125, SB203580 and ammonium pyrrolidinedithiocarbamate (PDTC) were used to inhibit JNK1/2, p38MAPK and NF-kappaB signalling pathways in septic cell model, respectively.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	87-93
30572638-7	2018	In addition, PDTC (nuclear factor-kappaB, or NF-kappaB inhibitor) and SP600125 (c-Jun N-terminal kinase, or JNK inhibitor) could inhibit the apoptosis in endothelial cells caused by high glucose.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	108-111
30574018-15	2018	Furthermore, we found that the JNK inhibitor SP600125 completely diminished the mobility shift of YAP and its phosphorylation at Tyr357, the binding of YAP and p73, the transcription of Bax and p53AIP1 as well as the apoptosis induced by ABF.	pyrazolanthrone	45-53	Yes1 associated transcriptional regulator	Homo sapiens	98-101
30574018-15	2018	Furthermore, we found that the JNK inhibitor SP600125 completely diminished the mobility shift of YAP and its phosphorylation at Tyr357, the binding of YAP and p73, the transcription of Bax and p53AIP1 as well as the apoptosis induced by ABF.	pyrazolanthrone	45-53	Yes1 associated transcriptional regulator	Homo sapiens	152-155
30574018-15	2018	Furthermore, we found that the JNK inhibitor SP600125 completely diminished the mobility shift of YAP and its phosphorylation at Tyr357, the binding of YAP and p73, the transcription of Bax and p53AIP1 as well as the apoptosis induced by ABF.	pyrazolanthrone	45-53	tumor protein p73	Homo sapiens	160-163
30574018-15	2018	Furthermore, we found that the JNK inhibitor SP600125 completely diminished the mobility shift of YAP and its phosphorylation at Tyr357, the binding of YAP and p73, the transcription of Bax and p53AIP1 as well as the apoptosis induced by ABF.	pyrazolanthrone	45-53	BCL2 associated X, apoptosis regulator	Homo sapiens	186-189
30574018-15	2018	Furthermore, we found that the JNK inhibitor SP600125 completely diminished the mobility shift of YAP and its phosphorylation at Tyr357, the binding of YAP and p73, the transcription of Bax and p53AIP1 as well as the apoptosis induced by ABF.	pyrazolanthrone	45-53	tumor protein p53 regulated apoptosis inducing protein 1	Homo sapiens	194-201
30290020-8	2018	AMN-induced melanogenesis of B16F0 cells was significantly inhibited by the addition of NAC and the JNK inhibitor, SP600125 (SP).	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Mus musculus	100-103
30439377-9	2018	SB203580 and SP600125 (p38 and JNK pathway inhibitors, respectively) attenuated GABA plus piperine-induced EPO and EPO-R expression.	pyrazolanthrone	13-21	mitogen-activated protein kinase 14	Homo sapiens	23-26
30439377-9	2018	SB203580 and SP600125 (p38 and JNK pathway inhibitors, respectively) attenuated GABA plus piperine-induced EPO and EPO-R expression.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	31-34
30439377-9	2018	SB203580 and SP600125 (p38 and JNK pathway inhibitors, respectively) attenuated GABA plus piperine-induced EPO and EPO-R expression.	pyrazolanthrone	13-21	erythropoietin	Homo sapiens	107-110
30439377-9	2018	SB203580 and SP600125 (p38 and JNK pathway inhibitors, respectively) attenuated GABA plus piperine-induced EPO and EPO-R expression.	pyrazolanthrone	13-21	erythropoietin receptor	Homo sapiens	115-120
30251772-7	2018	SP600125 can alleviated V triggered p-P38MAPK (phosphor-P38), p-ERK1/2 (phosphor-ERK1/2), p-JNK (phosphor-JNK) increase on OME cells, and SB203580 and U0126 had a similar response to phosphor-P38 and p-JNK (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 1	Homo sapiens	38-41
30251772-7	2018	SP600125 can alleviated V triggered p-P38MAPK (phosphor-P38), p-ERK1/2 (phosphor-ERK1/2), p-JNK (phosphor-JNK) increase on OME cells, and SB203580 and U0126 had a similar response to phosphor-P38 and p-JNK (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 3	Homo sapiens	64-70
30251772-7	2018	SP600125 can alleviated V triggered p-P38MAPK (phosphor-P38), p-ERK1/2 (phosphor-ERK1/2), p-JNK (phosphor-JNK) increase on OME cells, and SB203580 and U0126 had a similar response to phosphor-P38 and p-JNK (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 3	Homo sapiens	81-87
30251772-7	2018	SP600125 can alleviated V triggered p-P38MAPK (phosphor-P38), p-ERK1/2 (phosphor-ERK1/2), p-JNK (phosphor-JNK) increase on OME cells, and SB203580 and U0126 had a similar response to phosphor-P38 and p-JNK (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	92-95
30251772-7	2018	SP600125 can alleviated V triggered p-P38MAPK (phosphor-P38), p-ERK1/2 (phosphor-ERK1/2), p-JNK (phosphor-JNK) increase on OME cells, and SB203580 and U0126 had a similar response to phosphor-P38 and p-JNK (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	106-109
30251772-7	2018	SP600125 can alleviated V triggered p-P38MAPK (phosphor-P38), p-ERK1/2 (phosphor-ERK1/2), p-JNK (phosphor-JNK) increase on OME cells, and SB203580 and U0126 had a similar response to phosphor-P38 and p-JNK (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 1	Homo sapiens	56-59
30251772-7	2018	SP600125 can alleviated V triggered p-P38MAPK (phosphor-P38), p-ERK1/2 (phosphor-ERK1/2), p-JNK (phosphor-JNK) increase on OME cells, and SB203580 and U0126 had a similar response to phosphor-P38 and p-JNK (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	106-109
30290020-8	2018	AMN-induced melanogenesis of B16F0 cells was significantly inhibited by the addition of NAC and the JNK inhibitor, SP600125 (SP).	pyrazolanthrone	115-117	mitogen-activated protein kinase 8	Mus musculus	100-103
30290020-9	2018	Data of Western blotting showed that increased protein levels of melanogenesis-related enzymes of tyrosinase-related protein-1 (TRP1), TRP2 and TYR were observed in AMN-treated B16F0 cells which were inhibited by the addition of NAC and SP.	pyrazolanthrone	237-239	tyrosinase-related protein 1	Mus musculus	98-126
30290020-9	2018	Data of Western blotting showed that increased protein levels of melanogenesis-related enzymes of tyrosinase-related protein-1 (TRP1), TRP2 and TYR were observed in AMN-treated B16F0 cells which were inhibited by the addition of NAC and SP.	pyrazolanthrone	237-239	tyrosinase-related protein 1	Mus musculus	128-132
30290166-8	2018	Pre-incubation with inhibitors of JNK (SP600125) and p38 (SB202190) significantly decreases the BAX/BCL2 ratio.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	34-37
30216497-7	2018	Further studies demonstrated that injection of the JAK2 antagonist AG490 or JNK antagonist SP600125 into the RN 30 min prior to the administration of rrIL-1beta could completely prevent IL-1beta-evoked tactile allodynia, while injection of the ERK antagonist PD98059, p38 MAPK antagonist SB203580, or NF-kappaB antagonist PDTC did not affect IL-1beta-evoked tactile allodynia.	pyrazolanthrone	91-99	Eph receptor B1	Rattus norvegicus	244-247
30216497-7	2018	Further studies demonstrated that injection of the JAK2 antagonist AG490 or JNK antagonist SP600125 into the RN 30 min prior to the administration of rrIL-1beta could completely prevent IL-1beta-evoked tactile allodynia, while injection of the ERK antagonist PD98059, p38 MAPK antagonist SB203580, or NF-kappaB antagonist PDTC did not affect IL-1beta-evoked tactile allodynia.	pyrazolanthrone	91-99	mitogen activated protein kinase 14	Rattus norvegicus	268-276
30216497-7	2018	Further studies demonstrated that injection of the JAK2 antagonist AG490 or JNK antagonist SP600125 into the RN 30 min prior to the administration of rrIL-1beta could completely prevent IL-1beta-evoked tactile allodynia, while injection of the ERK antagonist PD98059, p38 MAPK antagonist SB203580, or NF-kappaB antagonist PDTC did not affect IL-1beta-evoked tactile allodynia.	pyrazolanthrone	91-99	interleukin 1 alpha	Rattus norvegicus	186-194
30072581-1	2018	TGFbeta induces migration of lung cancer cells (A549, H460, and H1299), dependent on activation of c-Jun N-terminal kinase (JNK1), and is inhibited by the JNK1 inhibitor SP600125.	pyrazolanthrone	170-178	transforming growth factor beta 1	Homo sapiens	0-7
30072581-1	2018	TGFbeta induces migration of lung cancer cells (A549, H460, and H1299), dependent on activation of c-Jun N-terminal kinase (JNK1), and is inhibited by the JNK1 inhibitor SP600125.	pyrazolanthrone	170-178	mitogen-activated protein kinase 8	Homo sapiens	124-128
30072581-1	2018	TGFbeta induces migration of lung cancer cells (A549, H460, and H1299), dependent on activation of c-Jun N-terminal kinase (JNK1), and is inhibited by the JNK1 inhibitor SP600125.	pyrazolanthrone	170-178	mitogen-activated protein kinase 8	Homo sapiens	155-159
30073566-6	2018	Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2.	pyrazolanthrone	63-71	nuclear factor kappa B subunit 1	Homo sapiens	14-23
30073566-6	2018	Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	34-37
30073566-6	2018	Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2.	pyrazolanthrone	63-71	C-X-C motif chemokine ligand 1	Homo sapiens	116-121
30073566-6	2018	Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2.	pyrazolanthrone	63-71	C-C motif chemokine ligand 2	Homo sapiens	126-130
30073566-6	2018	Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2.	pyrazolanthrone	63-71	mitogen-activated protein kinase 14	Homo sapiens	178-181
30073566-6	2018	Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2.	pyrazolanthrone	63-71	C-X-C motif chemokine ligand 1	Homo sapiens	249-254
30073566-6	2018	Inhibitors of NF-kappaB, ERK, and JNK (BAY117082, PD98059, and SP600125) significantly suppressed the expression of CXCL1 and CCL2 that were induced by LPS for 3 h. However, the p38 inhibitor, SB203580, had no obvious effect on expression levels of CXCL1 and CCL2.	pyrazolanthrone	63-71	C-C motif chemokine ligand 2	Homo sapiens	259-263
30216497-7	2018	Further studies demonstrated that injection of the JAK2 antagonist AG490 or JNK antagonist SP600125 into the RN 30 min prior to the administration of rrIL-1beta could completely prevent IL-1beta-evoked tactile allodynia, while injection of the ERK antagonist PD98059, p38 MAPK antagonist SB203580, or NF-kappaB antagonist PDTC did not affect IL-1beta-evoked tactile allodynia.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Rattus norvegicus	76-79
30503674-13	2018	SP600125 and SB203580 significantly suppressed the increase in SGLT-1 12 h after MCAO.	pyrazolanthrone	0-8	solute carrier family 5 (sodium/glucose cotransporter), member 1	Mus musculus	63-69
29671254-8	2018	Inhibitors of P38MAPK and JNK, SB203580 and SP600125, respectively, weakened the upregulation of Hsp70 by co-enzyme Q10, indicating that MAPK pathways participate in the Hsp70 upregulation by co-enzyme Q10.	pyrazolanthrone	44-52	heat shock protein family A (Hsp70) member 2	Gallus gallus	97-102
29671254-8	2018	Inhibitors of P38MAPK and JNK, SB203580 and SP600125, respectively, weakened the upregulation of Hsp70 by co-enzyme Q10, indicating that MAPK pathways participate in the Hsp70 upregulation by co-enzyme Q10.	pyrazolanthrone	44-52	heat shock protein family A (Hsp70) member 2	Gallus gallus	170-175
30290166-8	2018	Pre-incubation with inhibitors of JNK (SP600125) and p38 (SB202190) significantly decreases the BAX/BCL2 ratio.	pyrazolanthrone	39-47	BCL2 associated X, apoptosis regulator	Homo sapiens	96-99
30290166-8	2018	Pre-incubation with inhibitors of JNK (SP600125) and p38 (SB202190) significantly decreases the BAX/BCL2 ratio.	pyrazolanthrone	39-47	BCL2 apoptosis regulator	Homo sapiens	100-104
30584464-6	2018	Moreover, the JNK inhibitor SP600125 significantly promoted cell proliferation and suppressed cell apoptosis of pancreatic cancer cells under high glucose conditions.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	14-17
30568466-17	2018	We found that the JNK inhibitor SP600125 significantly inhibited the growth of breast cancer cells, and consider it a potential drug for breast cancer.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	18-21
30662622-7	2018	Furthermore, H2O2-induced proliferation inhibition, apoptosis, and inflammation in HK-2 cells were ameliorated by NAC (N-acetyl cysteine, the ROS scavenger) and SP600125 (the JNK inhibitor).	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	175-178
30207732-0	2018	Synergetic and Antagonistic Molecular Effects Mediated by the Feedback Loop of p53 and JNK between Saikosaponin D and SP600125 on Lung Cancer A549 Cells.	pyrazolanthrone	118-126	tumor protein p53	Homo sapiens	79-82
30473635-7	2018	Pre-treatment with the calcitonin receptor-like receptor (CRLR) antagonist CGRP8-37 or a MAPK pathway inhibitor (PD98059, SB203580 or SP600125) completely or partially reversed the pro-proliferative and anti-apoptotic effects and the reduced p-ERK1/2, p-p38 and p-JNK expression induced by CGRP.	pyrazolanthrone	134-142	mitogen-activated protein kinase 3	Homo sapiens	89-93
30207732-0	2018	Synergetic and Antagonistic Molecular Effects Mediated by the Feedback Loop of p53 and JNK between Saikosaponin D and SP600125 on Lung Cancer A549 Cells.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	87-90
30207732-6	2018	By eliminating the Ssd-induced increase of JNK/pJNK, additional SP600125 weakened the Ssd-induced apoptotic axis of TGFalpha-JNK-p53 and simultaneously abolished Ssd-induced apoptosis; (2) Ssd inhibited proliferation by the activation of two axes, TGFbeta-p53/p21/p27/p15/p16 and TGFalpha-Rassfia-cyclin D1.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Homo sapiens	43-46
30207732-6	2018	By eliminating the Ssd-induced increase of JNK/pJNK, additional SP600125 weakened the Ssd-induced apoptotic axis of TGFalpha-JNK-p53 and simultaneously abolished Ssd-induced apoptosis; (2) Ssd inhibited proliferation by the activation of two axes, TGFbeta-p53/p21/p27/p15/p16 and TGFalpha-Rassfia-cyclin D1.	pyrazolanthrone	64-72	tumor protein p53	Homo sapiens	129-132
30207732-1	2018	We jointly analyzed the changes in cell cycle arrest and distribution, the accumulation of subphase cells, apoptosis, and proliferation in A549 cells treated with Saikosaponin D (Ssd) and JNK inhibitor SP600125 alone or in combination.	pyrazolanthrone	202-210	mitogen-activated protein kinase 8	Homo sapiens	188-191
30207732-6	2018	By eliminating the Ssd-induced increase of JNK/pJNK, additional SP600125 weakened the Ssd-induced apoptotic axis of TGFalpha-JNK-p53 and simultaneously abolished Ssd-induced apoptosis; (2) Ssd inhibited proliferation by the activation of two axes, TGFbeta-p53/p21/p27/p15/p16 and TGFalpha-Rassfia-cyclin D1.	pyrazolanthrone	64-72	tumor protein p53	Homo sapiens	256-259
30095216-9	2018	Co-treatment of JNK signaling pathway inhibitor SP600125 impaired the PTX3-promoted transcription of Nkx2.5, Mef2c, Tbx5, dHand, and alphaMHC.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	16-19
30207732-6	2018	By eliminating the Ssd-induced increase of JNK/pJNK, additional SP600125 weakened the Ssd-induced apoptotic axis of TGFalpha-JNK-p53 and simultaneously abolished Ssd-induced apoptosis; (2) Ssd inhibited proliferation by the activation of two axes, TGFbeta-p53/p21/p27/p15/p16 and TGFalpha-Rassfia-cyclin D1.	pyrazolanthrone	64-72	cyclin dependent kinase inhibitor 1A	Homo sapiens	260-263
30207732-6	2018	By eliminating the Ssd-induced increase of JNK/pJNK, additional SP600125 weakened the Ssd-induced apoptotic axis of TGFalpha-JNK-p53 and simultaneously abolished Ssd-induced apoptosis; (2) Ssd inhibited proliferation by the activation of two axes, TGFbeta-p53/p21/p27/p15/p16 and TGFalpha-Rassfia-cyclin D1.	pyrazolanthrone	64-72	interferon alpha inducible protein 27	Homo sapiens	264-267
30207732-6	2018	By eliminating the Ssd-induced increase of JNK/pJNK, additional SP600125 weakened the Ssd-induced apoptotic axis of TGFalpha-JNK-p53 and simultaneously abolished Ssd-induced apoptosis; (2) Ssd inhibited proliferation by the activation of two axes, TGFbeta-p53/p21/p27/p15/p16 and TGFalpha-Rassfia-cyclin D1.	pyrazolanthrone	64-72	cyclin dependent kinase inhibitor 2B	Homo sapiens	268-271
30207732-6	2018	By eliminating the Ssd-induced increase of JNK/pJNK, additional SP600125 weakened the Ssd-induced apoptotic axis of TGFalpha-JNK-p53 and simultaneously abolished Ssd-induced apoptosis; (2) Ssd inhibited proliferation by the activation of two axes, TGFbeta-p53/p21/p27/p15/p16 and TGFalpha-Rassfia-cyclin D1.	pyrazolanthrone	64-72	cyclin dependent kinase inhibitor 2A	Homo sapiens	272-275
30223653-8	2018	The ROS elevation induced the sustained phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125, a JNK inhibitor, nearly completely reversed sambutoxin-induced apoptosis.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Mus musculus	108-111
30153066-7	2018	Treatment of GSTP-null mice with the JNK inhibitor 1,9-pyrazoloanthrone (SP600125) significantly attenuated pyruvate-induced hepatic gluconeogenesis and significantly altered correlations between hepatic cytokine mRNAs and metabolic outcomes in GSTP-null mice.	pyrazolanthrone	51-71	glutathione S-transferase pi 1	Homo sapiens	13-17
30153066-7	2018	Treatment of GSTP-null mice with the JNK inhibitor 1,9-pyrazoloanthrone (SP600125) significantly attenuated pyruvate-induced hepatic gluconeogenesis and significantly altered correlations between hepatic cytokine mRNAs and metabolic outcomes in GSTP-null mice.	pyrazolanthrone	51-71	mitogen-activated protein kinase 8	Homo sapiens	37-40
30153066-7	2018	Treatment of GSTP-null mice with the JNK inhibitor 1,9-pyrazoloanthrone (SP600125) significantly attenuated pyruvate-induced hepatic gluconeogenesis and significantly altered correlations between hepatic cytokine mRNAs and metabolic outcomes in GSTP-null mice.	pyrazolanthrone	51-71	glutathione S-transferase pi 1	Homo sapiens	245-249
30153066-7	2018	Treatment of GSTP-null mice with the JNK inhibitor 1,9-pyrazoloanthrone (SP600125) significantly attenuated pyruvate-induced hepatic gluconeogenesis and significantly altered correlations between hepatic cytokine mRNAs and metabolic outcomes in GSTP-null mice.	pyrazolanthrone	73-81	glutathione S-transferase pi 1	Homo sapiens	13-17
30153066-7	2018	Treatment of GSTP-null mice with the JNK inhibitor 1,9-pyrazoloanthrone (SP600125) significantly attenuated pyruvate-induced hepatic gluconeogenesis and significantly altered correlations between hepatic cytokine mRNAs and metabolic outcomes in GSTP-null mice.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	37-40
30153066-7	2018	Treatment of GSTP-null mice with the JNK inhibitor 1,9-pyrazoloanthrone (SP600125) significantly attenuated pyruvate-induced hepatic gluconeogenesis and significantly altered correlations between hepatic cytokine mRNAs and metabolic outcomes in GSTP-null mice.	pyrazolanthrone	73-81	glutathione S-transferase pi 1	Homo sapiens	245-249
30095216-9	2018	Co-treatment of JNK signaling pathway inhibitor SP600125 impaired the PTX3-promoted transcription of Nkx2.5, Mef2c, Tbx5, dHand, and alphaMHC.	pyrazolanthrone	48-56	pentraxin related gene	Mus musculus	70-74
30095216-9	2018	Co-treatment of JNK signaling pathway inhibitor SP600125 impaired the PTX3-promoted transcription of Nkx2.5, Mef2c, Tbx5, dHand, and alphaMHC.	pyrazolanthrone	48-56	NK2 homeobox 5	Mus musculus	101-107
30095216-9	2018	Co-treatment of JNK signaling pathway inhibitor SP600125 impaired the PTX3-promoted transcription of Nkx2.5, Mef2c, Tbx5, dHand, and alphaMHC.	pyrazolanthrone	48-56	myocyte enhancer factor 2C	Mus musculus	109-114
30095216-9	2018	Co-treatment of JNK signaling pathway inhibitor SP600125 impaired the PTX3-promoted transcription of Nkx2.5, Mef2c, Tbx5, dHand, and alphaMHC.	pyrazolanthrone	48-56	T-box 5	Mus musculus	116-120
30268495-9	2018	In vitro, rat lung macrophages were isolated and treated with Wnt5a, Sfrp5, and/or JNK inhibitor SP600125.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Rattus norvegicus	83-86
30215691-6	2018	JNK inhibition was achieved using either (i) the JNK-specific inhibitor SP600125 or (ii) JNK-1-null mice.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Mus musculus	0-3
30215691-6	2018	JNK inhibition was achieved using either (i) the JNK-specific inhibitor SP600125 or (ii) JNK-1-null mice.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Mus musculus	49-52
30215691-11	2018	Inhibition of JNK using either SP600125 or JNK-1-null mice prevented glucose-induced beta-cell dysfunction in isolated islets and in vivo.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Mus musculus	14-17
30011072-9	2018	Furthermore, rhEREG-improved migration and chemotaxis ability in EREG-depleted-ADSCs was restricted by a specific inhibitor, SB203580, for blocking p38 MAPK signaling, PD98059 for blocking Erk1/2 signaling, or SP600125 for blocking JNK signaling in ADSCs separately.	pyrazolanthrone	210-218	epiregulin	Homo sapiens	15-19
30269025-7	2018	SP600125, a JNK inhibitor, blocked IL-1beta-induced phosphorylation of c-Jun and JunB as well as IL-1beta-induced expression and transcription of hepcidin.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
30269025-7	2018	SP600125, a JNK inhibitor, blocked IL-1beta-induced phosphorylation of c-Jun and JunB as well as IL-1beta-induced expression and transcription of hepcidin.	pyrazolanthrone	0-8	interleukin 1 beta	Homo sapiens	35-43
30269025-7	2018	SP600125, a JNK inhibitor, blocked IL-1beta-induced phosphorylation of c-Jun and JunB as well as IL-1beta-induced expression and transcription of hepcidin.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-76
30269025-7	2018	SP600125, a JNK inhibitor, blocked IL-1beta-induced phosphorylation of c-Jun and JunB as well as IL-1beta-induced expression and transcription of hepcidin.	pyrazolanthrone	0-8	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	81-85
30269025-7	2018	SP600125, a JNK inhibitor, blocked IL-1beta-induced phosphorylation of c-Jun and JunB as well as IL-1beta-induced expression and transcription of hepcidin.	pyrazolanthrone	0-8	interleukin 1 beta	Homo sapiens	97-105
30269025-7	2018	SP600125, a JNK inhibitor, blocked IL-1beta-induced phosphorylation of c-Jun and JunB as well as IL-1beta-induced expression and transcription of hepcidin.	pyrazolanthrone	0-8	hepcidin antimicrobial peptide	Homo sapiens	146-154
30274780-6	2018	Moreover, overexpression of JNK/c-Jun promoted ABCG2 expression, SFE, and growth of hypoxic SP cells and the promotion could be rescued by c-Jun inhibitor SP600125.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	28-31
30274780-6	2018	Moreover, overexpression of JNK/c-Jun promoted ABCG2 expression, SFE, and growth of hypoxic SP cells and the promotion could be rescued by c-Jun inhibitor SP600125.	pyrazolanthrone	155-163	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	32-37
30274780-6	2018	Moreover, overexpression of JNK/c-Jun promoted ABCG2 expression, SFE, and growth of hypoxic SP cells and the promotion could be rescued by c-Jun inhibitor SP600125.	pyrazolanthrone	155-163	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	47-52
30274780-6	2018	Moreover, overexpression of JNK/c-Jun promoted ABCG2 expression, SFE, and growth of hypoxic SP cells and the promotion could be rescued by c-Jun inhibitor SP600125.	pyrazolanthrone	155-163	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	139-144
30416448-7	2018	JNK inhibitor SP600125 relieved the resistin inhibitory effects on endothelial insulin Akt/eNOS signaling.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
30416448-7	2018	JNK inhibitor SP600125 relieved the resistin inhibitory effects on endothelial insulin Akt/eNOS signaling.	pyrazolanthrone	14-22	insulin	Homo sapiens	79-86
30416448-7	2018	JNK inhibitor SP600125 relieved the resistin inhibitory effects on endothelial insulin Akt/eNOS signaling.	pyrazolanthrone	14-22	AKT serine/threonine kinase 1	Homo sapiens	87-90
30359319-6	2018	The c-jun kinase (JNK) signaling pathway was investigated by pharmacological disruption of SP600125.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	4-16
30359319-6	2018	The c-jun kinase (JNK) signaling pathway was investigated by pharmacological disruption of SP600125.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	18-21
30359319-9	2018	Pre-treatment with SP600125 or N-acetylcysteine reversed the effects of high glucose on the JNK signaling pathway and autophagy-related proteins.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	92-95
29766567-7	2018	In further functional experiments, the use of JNK inhibitors (SP600125 and DN-JNK) confirmed that the pharmaceutic inhibition of JNK augmented the melatonin-mediated CCL24 suppression and migration of U2OS cells.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	46-49
30185506-7	2018	SP600125, a Jun-amino-terminal kinase (JNK) inhibitor, attenuated LPS-induced enhancement of EDN1 and ECE1 in TSC1-knockdown MEFs without a change in phospho-S6 ribosomal protein (p-S6) level.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	12-37
30185506-7	2018	SP600125, a Jun-amino-terminal kinase (JNK) inhibitor, attenuated LPS-induced enhancement of EDN1 and ECE1 in TSC1-knockdown MEFs without a change in phospho-S6 ribosomal protein (p-S6) level.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	39-42
30185506-7	2018	SP600125, a Jun-amino-terminal kinase (JNK) inhibitor, attenuated LPS-induced enhancement of EDN1 and ECE1 in TSC1-knockdown MEFs without a change in phospho-S6 ribosomal protein (p-S6) level.	pyrazolanthrone	0-8	endothelin 1	Mus musculus	93-97
30185506-7	2018	SP600125, a Jun-amino-terminal kinase (JNK) inhibitor, attenuated LPS-induced enhancement of EDN1 and ECE1 in TSC1-knockdown MEFs without a change in phospho-S6 ribosomal protein (p-S6) level.	pyrazolanthrone	0-8	endothelin converting enzyme 1	Mus musculus	102-106
30185506-7	2018	SP600125, a Jun-amino-terminal kinase (JNK) inhibitor, attenuated LPS-induced enhancement of EDN1 and ECE1 in TSC1-knockdown MEFs without a change in phospho-S6 ribosomal protein (p-S6) level.	pyrazolanthrone	0-8	TSC complex subunit 1	Mus musculus	110-114
30131400-5	2018	Inhibition of stress-responsive c-Jun N-terminal kinase (JNK) activity with SP600125 did not affect the intercellular interactions between these embryos and the epithelial cells.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	32-55
30131400-5	2018	Inhibition of stress-responsive c-Jun N-terminal kinase (JNK) activity with SP600125 did not affect the intercellular interactions between these embryos and the epithelial cells.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	57-60
29935949-9	2018	ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors significantly blocked TNF-alpha-induced and constitutive expression of MMP-8 in UM.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	19-25
29935949-9	2018	ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors significantly blocked TNF-alpha-induced and constitutive expression of MMP-8 in UM.	pyrazolanthrone	27-35	tumor necrosis factor	Homo sapiens	70-79
29935949-9	2018	ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors significantly blocked TNF-alpha-induced and constitutive expression of MMP-8 in UM.	pyrazolanthrone	27-35	matrix metallopeptidase 8	Homo sapiens	119-124
30254586-4	2018	More importantly, by using SP600125, a selective Jnk inhibitor, we showed that Hes was able to significantly attenuate the Jnk downstream expression of Irf-3 and c-Jun, thereby inactivating NF-kappaB/MAPK signaling and transcriptional factor NFATc-1, leading to suppression of osteoclast-specific genes, which resulted in impaired osteoclastogenesis and functionality.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	49-52
30136701-16	2018	Furthermore, the JNK-specific inhibitor SP600125 abolished this effect of MKP1 knockdown on Abeta-induced neurotoxicity.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
30136701-16	2018	Furthermore, the JNK-specific inhibitor SP600125 abolished this effect of MKP1 knockdown on Abeta-induced neurotoxicity.	pyrazolanthrone	40-48	dual specificity phosphatase 1	Rattus norvegicus	74-78
30237126-11	2018	The use of specific JNK1/2 inhibitor (SP600125) resulted in the suppression of curcumol-induced ROS production and mitochondrial depolarization, which in turn, contributed to the inhibition of curcumol-triggered necroptosis.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Mus musculus	20-26
30254586-4	2018	More importantly, by using SP600125, a selective Jnk inhibitor, we showed that Hes was able to significantly attenuate the Jnk downstream expression of Irf-3 and c-Jun, thereby inactivating NF-kappaB/MAPK signaling and transcriptional factor NFATc-1, leading to suppression of osteoclast-specific genes, which resulted in impaired osteoclastogenesis and functionality.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	123-126
30254586-4	2018	More importantly, by using SP600125, a selective Jnk inhibitor, we showed that Hes was able to significantly attenuate the Jnk downstream expression of Irf-3 and c-Jun, thereby inactivating NF-kappaB/MAPK signaling and transcriptional factor NFATc-1, leading to suppression of osteoclast-specific genes, which resulted in impaired osteoclastogenesis and functionality.	pyrazolanthrone	27-35	interferon regulatory factor 3	Mus musculus	152-157
30254586-4	2018	More importantly, by using SP600125, a selective Jnk inhibitor, we showed that Hes was able to significantly attenuate the Jnk downstream expression of Irf-3 and c-Jun, thereby inactivating NF-kappaB/MAPK signaling and transcriptional factor NFATc-1, leading to suppression of osteoclast-specific genes, which resulted in impaired osteoclastogenesis and functionality.	pyrazolanthrone	27-35	jun proto-oncogene	Mus musculus	162-167
30254586-4	2018	More importantly, by using SP600125, a selective Jnk inhibitor, we showed that Hes was able to significantly attenuate the Jnk downstream expression of Irf-3 and c-Jun, thereby inactivating NF-kappaB/MAPK signaling and transcriptional factor NFATc-1, leading to suppression of osteoclast-specific genes, which resulted in impaired osteoclastogenesis and functionality.	pyrazolanthrone	27-35	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	242-249
30059683-7	2018	Among the selective inhibitors of MAPKs, the JNK inhibitor (SP600125) and p38 MAPK inhibitor (SB203580) showed steady preventive effect against H2O2 or Abeta1-42-induced apoptosis.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Rattus norvegicus	45-48
30192802-8	2018	Chemical inhibition of EGFR signaling showed a consistent and pronounced chemokine production with MEK1/2 inhibitor PD98059 and JNK inhibitor SP600125, but not with inhibitors of p38, PI3K or mTOR.	pyrazolanthrone	142-150	epidermal growth factor receptor	Homo sapiens	23-27
30192802-8	2018	Chemical inhibition of EGFR signaling showed a consistent and pronounced chemokine production with MEK1/2 inhibitor PD98059 and JNK inhibitor SP600125, but not with inhibitors of p38, PI3K or mTOR.	pyrazolanthrone	142-150	mitogen-activated protein kinase 8	Homo sapiens	128-131
30012495-10	2018	In our studies, myricetin-induced increment of ALP activity was decreased by ERK (PD98059), JNK (SP600125), p38 (SB203580), and Smad 1/5/9 (LDN193189) inhibitors.	pyrazolanthrone	97-105	alkaline phosphatase, placental	Homo sapiens	47-50
29864620-7	2018	In the presence of SP600125, a specific JNK inhibitor, induction of autophagy and apoptosis with L-A03 at 15 muM were elevated, but NO generation was attenuated, indicating that JNK inactivation is essential for apoptotic cell death.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	178-181
29906232-7	2018	Moreover, to study the regulatory mechanism between PKR and Sirt1, we found that PKR promotes JNK activation to inhibit Sirt1 activity and that this effect could be reversed by the JNK inhibitor SP600125.	pyrazolanthrone	195-203	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	52-55
29906232-7	2018	Moreover, to study the regulatory mechanism between PKR and Sirt1, we found that PKR promotes JNK activation to inhibit Sirt1 activity and that this effect could be reversed by the JNK inhibitor SP600125.	pyrazolanthrone	195-203	sirtuin 1	Homo sapiens	60-65
29906232-7	2018	Moreover, to study the regulatory mechanism between PKR and Sirt1, we found that PKR promotes JNK activation to inhibit Sirt1 activity and that this effect could be reversed by the JNK inhibitor SP600125.	pyrazolanthrone	195-203	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	81-84
29906232-7	2018	Moreover, to study the regulatory mechanism between PKR and Sirt1, we found that PKR promotes JNK activation to inhibit Sirt1 activity and that this effect could be reversed by the JNK inhibitor SP600125.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Homo sapiens	94-97
29906232-7	2018	Moreover, to study the regulatory mechanism between PKR and Sirt1, we found that PKR promotes JNK activation to inhibit Sirt1 activity and that this effect could be reversed by the JNK inhibitor SP600125.	pyrazolanthrone	195-203	sirtuin 1	Homo sapiens	120-125
29906232-7	2018	Moreover, to study the regulatory mechanism between PKR and Sirt1, we found that PKR promotes JNK activation to inhibit Sirt1 activity and that this effect could be reversed by the JNK inhibitor SP600125.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Homo sapiens	181-184
29864620-7	2018	In the presence of SP600125, a specific JNK inhibitor, induction of autophagy and apoptosis with L-A03 at 15 muM were elevated, but NO generation was attenuated, indicating that JNK inactivation is essential for apoptotic cell death.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	40-43
29864620-7	2018	In the presence of SP600125, a specific JNK inhibitor, induction of autophagy and apoptosis with L-A03 at 15 muM were elevated, but NO generation was attenuated, indicating that JNK inactivation is essential for apoptotic cell death.	pyrazolanthrone	19-27	latexin	Homo sapiens	109-112
29268033-8	2018	Moreover, treatment with the JNK inhibitor SP600125 partially reversed the G2019S-Lrrk2-induced loss of dopaminergic neurons.	pyrazolanthrone	43-51	basket	Drosophila melanogaster	29-32
29968959-7	2018	Exposure of cells to the JNK-specific inhibitor SP600125 attenuated the apoptotic effects of coronarin D.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	25-28
29663365-8	2018	Moreover, inhibition of PI3K and MAPK using LY294002, U0126, or SP600125, in addition to myricetin treatment, effectively suppressed cell proliferation compared to treatment with myricetin or each inhibitor alone.	pyrazolanthrone	64-72	mitogen-activated protein kinase 1	Canis lupus familiaris	33-37
29768726-6	2018	Further study indicated that UVB-induced production of MMP-1 and IL-6 could be inhibited by PD 98059 (an inhibitor of ERK) and SP600125 (an inhibitor of JNK).	pyrazolanthrone	127-135	matrix metallopeptidase 1	Homo sapiens	55-60
29768726-6	2018	Further study indicated that UVB-induced production of MMP-1 and IL-6 could be inhibited by PD 98059 (an inhibitor of ERK) and SP600125 (an inhibitor of JNK).	pyrazolanthrone	127-135	interleukin 6	Homo sapiens	65-69
29768726-6	2018	Further study indicated that UVB-induced production of MMP-1 and IL-6 could be inhibited by PD 98059 (an inhibitor of ERK) and SP600125 (an inhibitor of JNK).	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Homo sapiens	153-156
29860115-11	2018	Additionally, p38MAPK and JNK blockers (SB239063 and SP600125, respectively) had an effect on rats same as that of PHC.	pyrazolanthrone	53-61	mitogen activated protein kinase 14	Rattus norvegicus	14-17
29860115-11	2018	Additionally, p38MAPK and JNK blockers (SB239063 and SP600125, respectively) had an effect on rats same as that of PHC.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Rattus norvegicus	26-29
28540451-9	2018	Finally, inhibition of c-Jun N-terminal protein kinase (JNK) phosphorylation using 1 muM SP600125 prevented the increase in TGF-beta1 and CTGF upregulation and release 6 h after CGRP administration.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	23-54
28540451-9	2018	Finally, inhibition of c-Jun N-terminal protein kinase (JNK) phosphorylation using 1 muM SP600125 prevented the increase in TGF-beta1 and CTGF upregulation and release 6 h after CGRP administration.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	56-59
28540451-9	2018	Finally, inhibition of c-Jun N-terminal protein kinase (JNK) phosphorylation using 1 muM SP600125 prevented the increase in TGF-beta1 and CTGF upregulation and release 6 h after CGRP administration.	pyrazolanthrone	89-97	transforming growth factor beta 1	Homo sapiens	124-133
28540451-9	2018	Finally, inhibition of c-Jun N-terminal protein kinase (JNK) phosphorylation using 1 muM SP600125 prevented the increase in TGF-beta1 and CTGF upregulation and release 6 h after CGRP administration.	pyrazolanthrone	89-97	cellular communication network factor 2	Homo sapiens	138-142
28540451-9	2018	Finally, inhibition of c-Jun N-terminal protein kinase (JNK) phosphorylation using 1 muM SP600125 prevented the increase in TGF-beta1 and CTGF upregulation and release 6 h after CGRP administration.	pyrazolanthrone	89-97	calcitonin related polypeptide alpha	Homo sapiens	178-182
29088310-4	2018	Therefore, we investigated the disease-modifying therapeutic potential of JNK-specific inhibitor (SP600125) in TBI mice.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Mus musculus	74-77
29088310-5	2018	Treating 2 different models of TBI mice with SP600125 for 7 days dramatically inhibited activated JNK, resulting in marked reductions of amyloid precursor protein (APP) expression level and in amyloid beta production and hyperphosphorylated tau and regulation of the abnormal expression of secretases.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Mus musculus	98-101
29088310-5	2018	Treating 2 different models of TBI mice with SP600125 for 7 days dramatically inhibited activated JNK, resulting in marked reductions of amyloid precursor protein (APP) expression level and in amyloid beta production and hyperphosphorylated tau and regulation of the abnormal expression of secretases.	pyrazolanthrone	45-53	amyloid beta (A4) precursor protein	Mus musculus	137-162
29088310-8	2018	Our findings strongly suggest that active JNK is critically involved in disease development after TBI and that inhibition of JNK with SP600125 is highly efficient for slowing disease progression by reducing multiple pathological features in TBI mouse brains and regulating cognitive dysfunction.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Mus musculus	125-128
29778464-8	2018	This reduced steroidogenesis was rescued by addition of the Prx mimic ebselen or JNK inhibitor SP600125.	pyrazolanthrone	95-103	periaxin	Mus musculus	60-63
29778464-8	2018	This reduced steroidogenesis was rescued by addition of the Prx mimic ebselen or JNK inhibitor SP600125.	pyrazolanthrone	95-103	mitogen-activated protein kinase 8	Mus musculus	81-84
29749481-9	2018	In addition, the inhibition of c-Jun N-terminal kinase (JNK)/p38 activity with SP600125/SB203580 decreased the expression of Gadd45a, whereas the inactivation of extracellular signal-regulated kinase with SCH772984 had no effect on the expression of Gadd45a.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	31-54
29749481-9	2018	In addition, the inhibition of c-Jun N-terminal kinase (JNK)/p38 activity with SP600125/SB203580 decreased the expression of Gadd45a, whereas the inactivation of extracellular signal-regulated kinase with SCH772984 had no effect on the expression of Gadd45a.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	56-59
29749481-9	2018	In addition, the inhibition of c-Jun N-terminal kinase (JNK)/p38 activity with SP600125/SB203580 decreased the expression of Gadd45a, whereas the inactivation of extracellular signal-regulated kinase with SCH772984 had no effect on the expression of Gadd45a.	pyrazolanthrone	79-87	mitogen-activated protein kinase 14	Homo sapiens	61-64
29749481-9	2018	In addition, the inhibition of c-Jun N-terminal kinase (JNK)/p38 activity with SP600125/SB203580 decreased the expression of Gadd45a, whereas the inactivation of extracellular signal-regulated kinase with SCH772984 had no effect on the expression of Gadd45a.	pyrazolanthrone	79-87	growth arrest and DNA damage inducible alpha	Homo sapiens	125-132
29749481-9	2018	In addition, the inhibition of c-Jun N-terminal kinase (JNK)/p38 activity with SP600125/SB203580 decreased the expression of Gadd45a, whereas the inactivation of extracellular signal-regulated kinase with SCH772984 had no effect on the expression of Gadd45a.	pyrazolanthrone	79-87	growth arrest and DNA damage inducible alpha	Homo sapiens	250-257
30073206-0	2018	BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	27-30
30073206-8	2018	Interestingly, SP600125, a JNK inhibitor, was potent in cell growth inhibition and apoptosis induction of both parental and IMT-resistant NphA2 and MR87 cells.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	27-30
30026697-6	2018	Cardioprotective and neuroprotective mechanisms of JNK inhibitors are discussed in detail including synthetic small molecule inhibitors (AS601245, SP600125, IQ-1S, and SR-3306), ion channel inhibitor GsMTx4, JNK-interacting proteins, inhibitors of mixed-lineage kinase (MLK) and MLK-interacting proteins, inhibitors of glutamate receptors, nitric oxide (NO) donors, and anesthetics.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	51-54
29772238-9	2018	Furthermore, we identified that specific inhibitors of ERK and JNK signaling pathways, FR180204 and SP600125, can suppress TGF-beta1-induced fascin1 expression.	pyrazolanthrone	100-108	mitogen-activated protein kinase 1	Homo sapiens	55-58
29772238-9	2018	Furthermore, we identified that specific inhibitors of ERK and JNK signaling pathways, FR180204 and SP600125, can suppress TGF-beta1-induced fascin1 expression.	pyrazolanthrone	100-108	transforming growth factor beta 1	Homo sapiens	123-132
29745021-7	2018	RESULTS: Fasudil, SB203580, and SP600125 effectively inhibited the HG-induced early apoptosis increase and decreased Bax mRNA expression, the Bax/Bcl-2 protein expression ratio, and cleaved caspase-3 protein levels in the cardiomyocytes; this was accompanied by upregulation of the Bcl-2 mRNA.	pyrazolanthrone	32-40	BCL2 associated X, apoptosis regulator	Rattus norvegicus	117-120
29745021-7	2018	RESULTS: Fasudil, SB203580, and SP600125 effectively inhibited the HG-induced early apoptosis increase and decreased Bax mRNA expression, the Bax/Bcl-2 protein expression ratio, and cleaved caspase-3 protein levels in the cardiomyocytes; this was accompanied by upregulation of the Bcl-2 mRNA.	pyrazolanthrone	32-40	BCL2 associated X, apoptosis regulator	Rattus norvegicus	142-145
29745021-7	2018	RESULTS: Fasudil, SB203580, and SP600125 effectively inhibited the HG-induced early apoptosis increase and decreased Bax mRNA expression, the Bax/Bcl-2 protein expression ratio, and cleaved caspase-3 protein levels in the cardiomyocytes; this was accompanied by upregulation of the Bcl-2 mRNA.	pyrazolanthrone	32-40	BCL2, apoptosis regulator	Rattus norvegicus	146-151
29745021-7	2018	RESULTS: Fasudil, SB203580, and SP600125 effectively inhibited the HG-induced early apoptosis increase and decreased Bax mRNA expression, the Bax/Bcl-2 protein expression ratio, and cleaved caspase-3 protein levels in the cardiomyocytes; this was accompanied by upregulation of the Bcl-2 mRNA.	pyrazolanthrone	32-40	BCL2, apoptosis regulator	Rattus norvegicus	282-287
29709677-6	2018	c-Jun N-terminal kinase (JNK1 [Mapk8]) activity was reduced through SP600125 to evaluate its effects on IHH signaling.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Mus musculus	25-29
29709677-6	2018	c-Jun N-terminal kinase (JNK1 [Mapk8]) activity was reduced through SP600125 to evaluate its effects on IHH signaling.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Mus musculus	31-36
29890414-7	2018	The NF-kappaB inhibitor JSH-23 and JNK-specific inhibitor SP600125 significantly decreased NO production and IL-6 release in LPS-stimulated BV2 cells, respectively.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Mus musculus	35-38
29890414-7	2018	The NF-kappaB inhibitor JSH-23 and JNK-specific inhibitor SP600125 significantly decreased NO production and IL-6 release in LPS-stimulated BV2 cells, respectively.	pyrazolanthrone	58-66	interleukin 6	Mus musculus	109-113
29923038-9	2018	SP600125 was used as c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	46-49
29729989-11	2018	JNK inhibition (by an intracerebroventricular injection of SP600125) prevented the QUIN-induced reduction in BDNF and TrkB at 7 day post-injury, suggesting a role for the QUIN-induced JNK activation on the observed decrease in BDNF levels.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
29729989-11	2018	JNK inhibition (by an intracerebroventricular injection of SP600125) prevented the QUIN-induced reduction in BDNF and TrkB at 7 day post-injury, suggesting a role for the QUIN-induced JNK activation on the observed decrease in BDNF levels.	pyrazolanthrone	59-67	brain-derived neurotrophic factor	Rattus norvegicus	109-113
29729989-11	2018	JNK inhibition (by an intracerebroventricular injection of SP600125) prevented the QUIN-induced reduction in BDNF and TrkB at 7 day post-injury, suggesting a role for the QUIN-induced JNK activation on the observed decrease in BDNF levels.	pyrazolanthrone	59-67	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	118-122
29729989-11	2018	JNK inhibition (by an intracerebroventricular injection of SP600125) prevented the QUIN-induced reduction in BDNF and TrkB at 7 day post-injury, suggesting a role for the QUIN-induced JNK activation on the observed decrease in BDNF levels.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	184-187
29729989-11	2018	JNK inhibition (by an intracerebroventricular injection of SP600125) prevented the QUIN-induced reduction in BDNF and TrkB at 7 day post-injury, suggesting a role for the QUIN-induced JNK activation on the observed decrease in BDNF levels.	pyrazolanthrone	59-67	brain-derived neurotrophic factor	Rattus norvegicus	227-231
30116631-12	2018	But the JNK inhibitor, SP600125, cannot prevent the effect of upregulating the levels of IL-6 by MG132 in the RPE culture medium.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	8-11
29973222-9	2018	In addition, Wnt5a-induced neuronal differentiation was blocked by RhoA siRNA, as well as by a specific Rho-kinase inhibitor (Y27632) or a SAPK/JNK inhibitor (SP600125).	pyrazolanthrone	159-167	Wnt family member 5A	Homo sapiens	13-18
29973222-9	2018	In addition, Wnt5a-induced neuronal differentiation was blocked by RhoA siRNA, as well as by a specific Rho-kinase inhibitor (Y27632) or a SAPK/JNK inhibitor (SP600125).	pyrazolanthrone	159-167	mitogen-activated protein kinase 8	Homo sapiens	144-147
29973222-10	2018	Furthermore, treatment with RhoA siRNA, Y27632, or SP600125 suppressed the IL-1beta-induced neuronal differentiation.	pyrazolanthrone	51-59	interleukin 1 beta	Homo sapiens	75-83
29268033-8	2018	Moreover, treatment with the JNK inhibitor SP600125 partially reversed the G2019S-Lrrk2-induced loss of dopaminergic neurons.	pyrazolanthrone	43-51	Leucine-rich repeat kinase	Drosophila melanogaster	82-87
29384220-8	2018	Blocking JNK by SP600125 or siRNA suppressed autophagy induction upon compound C treatment.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Homo sapiens	9-12
30317758-6	2018	Thirdly, JNK inhibitor SP600125 was used to block the JNK pathway, and it was evaluated whether JNK signaling pathway mediated the DR4 and DR5 levels and finally, the subcutaneous tumor model of nude mice was constructed, and enhancement effect of HNK on TRAIL was confirmed in vivo.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Mus musculus	9-12
29858032-11	2018	The JNK inhibitor SP600125 sensitized gefitinib-resistant NSCLC cells to gefitinib.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
29928452-8	2018	Furthermore, the combination of both agents enhanced expression of phosphorylated form of JNK, and the JNK inhibitor SP600125 effectively attenuated cell death induced by the combination treatment.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Homo sapiens	103-106
29955047-11	2018	Similar to our results with Flk-1, treatment of TC-PTP/KO IPKs with the JNK inhibitor SP600125 significantly increased apoptosis after UVB irradiation, confirming that the effect of TC-PTP on UVB-mediated apoptosis is regulated by Flk-1/JNK signaling.	pyrazolanthrone	86-94	kinase insert domain protein receptor	Mus musculus	28-33
29955047-11	2018	Similar to our results with Flk-1, treatment of TC-PTP/KO IPKs with the JNK inhibitor SP600125 significantly increased apoptosis after UVB irradiation, confirming that the effect of TC-PTP on UVB-mediated apoptosis is regulated by Flk-1/JNK signaling.	pyrazolanthrone	86-94	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	48-54
29955047-11	2018	Similar to our results with Flk-1, treatment of TC-PTP/KO IPKs with the JNK inhibitor SP600125 significantly increased apoptosis after UVB irradiation, confirming that the effect of TC-PTP on UVB-mediated apoptosis is regulated by Flk-1/JNK signaling.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Mus musculus	72-75
29955047-11	2018	Similar to our results with Flk-1, treatment of TC-PTP/KO IPKs with the JNK inhibitor SP600125 significantly increased apoptosis after UVB irradiation, confirming that the effect of TC-PTP on UVB-mediated apoptosis is regulated by Flk-1/JNK signaling.	pyrazolanthrone	86-94	protein tyrosine phosphatase, non-receptor type 2	Mus musculus	182-188
29955047-11	2018	Similar to our results with Flk-1, treatment of TC-PTP/KO IPKs with the JNK inhibitor SP600125 significantly increased apoptosis after UVB irradiation, confirming that the effect of TC-PTP on UVB-mediated apoptosis is regulated by Flk-1/JNK signaling.	pyrazolanthrone	86-94	kinase insert domain protein receptor	Mus musculus	231-236
29955047-11	2018	Similar to our results with Flk-1, treatment of TC-PTP/KO IPKs with the JNK inhibitor SP600125 significantly increased apoptosis after UVB irradiation, confirming that the effect of TC-PTP on UVB-mediated apoptosis is regulated by Flk-1/JNK signaling.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Mus musculus	237-240
29926065-10	2018	The inhibitors of p38 (SB202190) and JNK (SP600125) could reduce IL-6 and TNF-alpha mRNA expression that was induced by LPS.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Mus musculus	37-40
29926065-10	2018	The inhibitors of p38 (SB202190) and JNK (SP600125) could reduce IL-6 and TNF-alpha mRNA expression that was induced by LPS.	pyrazolanthrone	42-50	interleukin 6	Mus musculus	65-69
29926065-10	2018	The inhibitors of p38 (SB202190) and JNK (SP600125) could reduce IL-6 and TNF-alpha mRNA expression that was induced by LPS.	pyrazolanthrone	42-50	tumor necrosis factor	Mus musculus	74-83
30317758-11	2018	Blocking JNK pathway by SP600125, the expression of DR4 and DR5 decreased (P &lt; 0.05), Bax expression decreased and Bcl2 expression increased compared with HNK+TRAIL group.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	9-12
30317758-11	2018	Blocking JNK pathway by SP600125, the expression of DR4 and DR5 decreased (P &lt; 0.05), Bax expression decreased and Bcl2 expression increased compared with HNK+TRAIL group.	pyrazolanthrone	24-32	TNF receptor superfamily member 10a	Homo sapiens	52-55
29559303-8	2018	The JNK inhibitor SP600125 and ERK inhibitor PD98059 abolished the RPC mediated reduction effect on the infarct size and LDH activity after reperfusion.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
29559303-9	2018	In addition, RPC increased the phosphorylation of JNK, ERK1/2 and the downstream GSK-3beta, as well as the Bcl-2/Bax ratio, while, these changes were completely reversed by SP600125 and PD98059.	pyrazolanthrone	173-181	BCL2, apoptosis regulator	Rattus norvegicus	107-112
29559303-9	2018	In addition, RPC increased the phosphorylation of JNK, ERK1/2 and the downstream GSK-3beta, as well as the Bcl-2/Bax ratio, while, these changes were completely reversed by SP600125 and PD98059.	pyrazolanthrone	173-181	BCL2 associated X, apoptosis regulator	Rattus norvegicus	113-116
29805534-9	2018	sp600125, a JNK specific inhibitor, treatment inhibited the effect of Shh on fibroblast proliferation and hedgehog-signaling marker gene expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
29805534-9	2018	sp600125, a JNK specific inhibitor, treatment inhibited the effect of Shh on fibroblast proliferation and hedgehog-signaling marker gene expression.	pyrazolanthrone	0-8	sonic hedgehog signaling molecule	Homo sapiens	70-73
29805534-10	2018	Furthermore, zinc finger protein Gli1 (Gli1) overexpression partially eliminated the effect of HG and sp600125 on fibroblast proliferation, and reduced HG-induced ROS generation in fibroblasts.	pyrazolanthrone	102-110	GLI family zinc finger 1	Homo sapiens	33-37
29805534-10	2018	Furthermore, zinc finger protein Gli1 (Gli1) overexpression partially eliminated the effect of HG and sp600125 on fibroblast proliferation, and reduced HG-induced ROS generation in fibroblasts.	pyrazolanthrone	102-110	GLI family zinc finger 1	Homo sapiens	39-43
29627502-8	2018	Both JNK inhibitor (SP600125) and ROS scavenger (N-acetylcysteine, NAC) could attenuate JG-induced autophagy and apoptosis.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	5-8
29410271-7	2018	SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor) inhibited H9c2 cell apoptosis, and at the same time Prdx1 down-regulated the activation of p38 MAPK and JNK during H/R treatment.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Rattus norvegicus	39-42
29410271-7	2018	SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor) inhibited H9c2 cell apoptosis, and at the same time Prdx1 down-regulated the activation of p38 MAPK and JNK during H/R treatment.	pyrazolanthrone	29-37	peroxiredoxin 1	Rattus norvegicus	106-111
29658585-8	2018	In addition, SP600125, a SAPK/JNK inhibitor, notably reduced the amplification by onalespib of ET-1-induced HSP27.	pyrazolanthrone	13-21	endothelin 1	Mus musculus	95-99
29658585-8	2018	In addition, SP600125, a SAPK/JNK inhibitor, notably reduced the amplification by onalespib of ET-1-induced HSP27.	pyrazolanthrone	13-21	heat shock protein 1	Mus musculus	108-113
29754474-7	2018	Pre-treatment with Z-VAD-fmk, JNK inhibitor SP600125 and N-acetyl-l-cysteine (NAC), a ROS scavenger, partly improved the survival rates and restored OMT-induced cellular damage, and reduced caspase-3 cleavage.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	30-33
30025083-4	2018	SP600125 was adopted to inhibit JNK cascades.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	32-35
29804439-5	2018	VSMCs in CD137 agonist group were treated with recombinant protein of CD137L (10 mug/ml), VSMCs in JNK inhibition group were treated with JNK inhibitor SP600125 (10 mumol/L) for 30 minutes followed by recombinant protein of CD137L (10 mug/ml) and DMSO group was treated with the same amount of DMSO in JNK inhibition group for 30 minutes, then added recombinant protein of CD137L (10 mug/ml).	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Mus musculus	99-102
29754474-8	2018	SP600125 or NAC reduced OMT-induced p-JNK and NAC significantly lowered caspase-4.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	38-41
29754474-8	2018	SP600125 or NAC reduced OMT-induced p-JNK and NAC significantly lowered caspase-4.	pyrazolanthrone	0-8	caspase 4	Homo sapiens	72-81
29955247-5	2018	Interestingly, PEITC modifications of the actin cytoskeleton were abrogated by pretreatment with JNK inhibitor, SP600125.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	97-100
29804439-5	2018	VSMCs in CD137 agonist group were treated with recombinant protein of CD137L (10 mug/ml), VSMCs in JNK inhibition group were treated with JNK inhibitor SP600125 (10 mumol/L) for 30 minutes followed by recombinant protein of CD137L (10 mug/ml) and DMSO group was treated with the same amount of DMSO in JNK inhibition group for 30 minutes, then added recombinant protein of CD137L (10 mug/ml).	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Mus musculus	138-141
29804439-5	2018	VSMCs in CD137 agonist group were treated with recombinant protein of CD137L (10 mug/ml), VSMCs in JNK inhibition group were treated with JNK inhibitor SP600125 (10 mumol/L) for 30 minutes followed by recombinant protein of CD137L (10 mug/ml) and DMSO group was treated with the same amount of DMSO in JNK inhibition group for 30 minutes, then added recombinant protein of CD137L (10 mug/ml).	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Mus musculus	138-141
29844932-10	2018	SP600125, a selective JNK inhibitor, downregulated p-JNK expression in cordycepin-treated SKOV-3 cells, leading to suppression of cordycepin-induced apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	22-25
29766185-11	2018	Moreover, the NAC and JNK inhibitor SP600125 could dramatically reverse WZ35-caused MMP-2, MMP-9, and N-cadherin reduction and E-cadherin up-regulation.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	22-25
29766185-11	2018	Moreover, the NAC and JNK inhibitor SP600125 could dramatically reverse WZ35-caused MMP-2, MMP-9, and N-cadherin reduction and E-cadherin up-regulation.	pyrazolanthrone	36-44	matrix metallopeptidase 2	Homo sapiens	84-89
29766185-11	2018	Moreover, the NAC and JNK inhibitor SP600125 could dramatically reverse WZ35-caused MMP-2, MMP-9, and N-cadherin reduction and E-cadherin up-regulation.	pyrazolanthrone	36-44	matrix metallopeptidase 9	Homo sapiens	91-96
29766185-11	2018	Moreover, the NAC and JNK inhibitor SP600125 could dramatically reverse WZ35-caused MMP-2, MMP-9, and N-cadherin reduction and E-cadherin up-regulation.	pyrazolanthrone	36-44	cadherin 2	Homo sapiens	102-112
29844932-10	2018	SP600125, a selective JNK inhibitor, downregulated p-JNK expression in cordycepin-treated SKOV-3 cells, leading to suppression of cordycepin-induced apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	53-56
29770357-2	2018	Methods: The MAPK pathways (p38, ERK1/2, JNK) were inhibited by SB203580, PD98059, and SP600125 in normal human epidermal keratinocytes (NHEKs), respectively.	pyrazolanthrone	87-95	mitogen-activated protein kinase 1	Homo sapiens	28-31
29766185-11	2018	Moreover, the NAC and JNK inhibitor SP600125 could dramatically reverse WZ35-caused MMP-2, MMP-9, and N-cadherin reduction and E-cadherin up-regulation.	pyrazolanthrone	36-44	cadherin 1	Homo sapiens	127-137
29770357-2	2018	Methods: The MAPK pathways (p38, ERK1/2, JNK) were inhibited by SB203580, PD98059, and SP600125 in normal human epidermal keratinocytes (NHEKs), respectively.	pyrazolanthrone	87-95	mitogen-activated protein kinase 3	Homo sapiens	33-39
29770357-2	2018	Methods: The MAPK pathways (p38, ERK1/2, JNK) were inhibited by SB203580, PD98059, and SP600125 in normal human epidermal keratinocytes (NHEKs), respectively.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	41-44
29867470-8	2018	Furthermore, cotreatment with TEC and ERK inhibitor SCH772984 or JNK inhibitor SP600125 suppressed the overproduction of LPS-induced NO production in BV-2 cells.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Mus musculus	65-68
29738439-8	2018	Pre-treatments by inhibitors of ERK (PD0325901), JNK (SP600125), or p38 (SB201290), respectively, all could partly inhibit the CAPE effect on NDRG1 induction in NPC cells.	pyrazolanthrone	54-62	N-myc downstream regulated 1	Homo sapiens	142-147
29738439-8	2018	Pre-treatments by inhibitors of ERK (PD0325901), JNK (SP600125), or p38 (SB201290), respectively, all could partly inhibit the CAPE effect on NDRG1 induction in NPC cells.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	49-52
29512724-10	2018	SP600125, an inhibitor of JNK, maintained MCF-7 cell viability, prevented cell apoptosis and cycle arrest, and downregulated the polysaccharide-induced protein phosphorylation/expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
29501043-7	2018	Moreover, this effect was suppressed by specific JNK inhibitor SP600125.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	49-52
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	29-34
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	BCL2 apoptosis regulator	Homo sapiens	36-41
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	BCL2 like 1	Homo sapiens	46-52
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	77-82
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	sarcoglycan beta	Homo sapiens	139-142
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	BaRF1	Human gammaherpesvirus 4	143-148
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	mitogen-activated protein kinase 8	Homo sapiens	253-261
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	mitogen-activated protein kinase 1	Homo sapiens	263-266
29725459-7	2018	The expression levels of the c-Jun, Bcl-2 and Bcl-xL proteins, and levels of c-Jun protein phosphorylation were significantly decreased in SGC-BARF1 cells subsequent to treatment with SP600125, SB203580, and U0126, which were the specific inhibitors of JNK1/2/3, p38 and ERK1/2 respectively.	pyrazolanthrone	184-192	mitogen-activated protein kinase 3	Homo sapiens	271-277
29636531-6	2018	TBT-induced beta-cell cytotoxicity and apoptosis were significantly prevented by antioxidant N-acetylcysteine (NAC) and JNK inhibitor SP600125, but not ERK1/2 inhibitor PD98059 and p38 inhibitor SB203580.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Mus musculus	120-123
29385629-8	2018	After blocking AP-1 with SP600125, we detected TBG and the Th17 related cytokines (IL-6 and IL-17).	pyrazolanthrone	25-33	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	15-19
29649125-6	2018	The formation of ROS is closely related to the activation of the stress-activated kinases, JNK and p38, while SP600125 (SP, JNK inhibitor) and SB203580 (SB, p38 inhibitor) pretreatment inhibited the generation of ROS.	pyrazolanthrone	110-112	mitogen-activated protein kinase 8	Homo sapiens	124-127
29850615-7	2018	The inhibition of p-JNK by SP600125 did not attenuate TLR4 expression, but totally inhibited both A-FABP expression and the production of the proinflammatory cytokines TNF-alpha and IL-1beta in both constant and intermittent high glucose.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	20-23
29850615-7	2018	The inhibition of p-JNK by SP600125 did not attenuate TLR4 expression, but totally inhibited both A-FABP expression and the production of the proinflammatory cytokines TNF-alpha and IL-1beta in both constant and intermittent high glucose.	pyrazolanthrone	27-35	fatty acid binding protein 4	Homo sapiens	98-104
29850615-7	2018	The inhibition of p-JNK by SP600125 did not attenuate TLR4 expression, but totally inhibited both A-FABP expression and the production of the proinflammatory cytokines TNF-alpha and IL-1beta in both constant and intermittent high glucose.	pyrazolanthrone	27-35	tumor necrosis factor	Homo sapiens	168-177
29850615-7	2018	The inhibition of p-JNK by SP600125 did not attenuate TLR4 expression, but totally inhibited both A-FABP expression and the production of the proinflammatory cytokines TNF-alpha and IL-1beta in both constant and intermittent high glucose.	pyrazolanthrone	27-35	interleukin 1 beta	Homo sapiens	182-190
29636531-7	2018	Both NAC and SP600125 inhibited JNK phosphorylation and reduced cell viability in TBT-treated beta-cells.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	32-35
29409910-0	2018	SP600125 blocks the proteolysis of cytoskeletal proteins in apoptosis induced by gas signaling molecule (NO) via decreasing the activation of caspase-3 in rabbit chondrocytes.	pyrazolanthrone	0-8	caspase-3	Oryctolagus cuniculus	142-151
29409910-6	2018	Besides, SP600125 decreased significantly the protein expression of total caspase-3 and the intracellular gene expression of caspase-3, measured by Western blot analysis and PCR.	pyrazolanthrone	9-17	caspase-3	Oryctolagus cuniculus	74-83
29409910-6	2018	Besides, SP600125 decreased significantly the protein expression of total caspase-3 and the intracellular gene expression of caspase-3, measured by Western blot analysis and PCR.	pyrazolanthrone	9-17	caspase-3	Oryctolagus cuniculus	125-134
29409910-8	2018	These results suggested that JNK pathway plays a critical role in the NO-induced chondrocyte apoptosis, and SP600125 treatment blocks the dissolution of the cytoskeletal proteins via activation of caspase-3 pathways.	pyrazolanthrone	108-116	caspase-3	Oryctolagus cuniculus	197-206
29393342-11	2018	pLVX-Puro-CTHRC1 mimics the effect of IL-1beta on chondrocyte apoptosis and JNK1/2 activity, and this is reversed by SP600125 treatment.	pyrazolanthrone	117-125	interleukin 1 beta	Homo sapiens	38-46
29549247-8	2018	The inhibition of JNK pathway in GCT cell lines with two different pharmacologic inhibitors (SP600125 and AS601245) or siRNA resulted in a dose-dependent reduction in in vitro cell growth, increased apoptosis and diminished estradiol and AMH productions.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	18-21
29549247-8	2018	The inhibition of JNK pathway in GCT cell lines with two different pharmacologic inhibitors (SP600125 and AS601245) or siRNA resulted in a dose-dependent reduction in in vitro cell growth, increased apoptosis and diminished estradiol and AMH productions.	pyrazolanthrone	93-101	anti-Mullerian hormone	Homo sapiens	238-241
29393342-11	2018	pLVX-Puro-CTHRC1 mimics the effect of IL-1beta on chondrocyte apoptosis and JNK1/2 activity, and this is reversed by SP600125 treatment.	pyrazolanthrone	117-125	collagen triple helix repeat containing 1	Homo sapiens	10-16
29393342-11	2018	pLVX-Puro-CTHRC1 mimics the effect of IL-1beta on chondrocyte apoptosis and JNK1/2 activity, and this is reversed by SP600125 treatment.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Homo sapiens	76-82
29393342-12	2018	However, transfection with shRNA-CTHRC1 or treatment with SP600125 inhibited IL-1beta-induced cell apoptosis and JNK1/2 activation.	pyrazolanthrone	58-66	interleukin 1 beta	Homo sapiens	77-85
29393342-12	2018	However, transfection with shRNA-CTHRC1 or treatment with SP600125 inhibited IL-1beta-induced cell apoptosis and JNK1/2 activation.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Homo sapiens	113-119
29330470-9	2018	Simultaneously, inhibition of JNK by SP600125 abolished beta-Ecd-induced Bax downregulation in Abeta-challenged SH-SY5Y cells, whereas LY294002 failed to do so.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	30-33
28885691-5	2018	FGF2 also increased phosphorylation of AKT, P70S6K, S6, ERK1/2, JNK, and P38 in BEND cells in a dose-dependent manner, and expression of each of those transcription factors was inhibited by their respective pharmacological inhibitor including Wormannin, U0126, and SP600125.	pyrazolanthrone	265-273	fibroblast growth factor 2	Bos taurus	0-4
29330470-9	2018	Simultaneously, inhibition of JNK by SP600125 abolished beta-Ecd-induced Bax downregulation in Abeta-challenged SH-SY5Y cells, whereas LY294002 failed to do so.	pyrazolanthrone	37-45	BCL2 associated X, apoptosis regulator	Homo sapiens	73-76
29330470-9	2018	Simultaneously, inhibition of JNK by SP600125 abolished beta-Ecd-induced Bax downregulation in Abeta-challenged SH-SY5Y cells, whereas LY294002 failed to do so.	pyrazolanthrone	37-45	amyloid beta precursor protein	Homo sapiens	95-100
29355557-5	2018	In addition, the data from JNK inhibition using SP600125 showed that over-activated JNK was responsible for Akt de-phosphorylation.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
29289695-9	2018	SP600125 attenuated isoflurane-induced neuroapoptosis by inhibiting both AIF and caspase-3 pathways and reduced cognitive impairment in neonatal rats.	pyrazolanthrone	0-8	apoptosis inducing factor, mitochondria associated 1	Rattus norvegicus	73-76
29289695-9	2018	SP600125 attenuated isoflurane-induced neuroapoptosis by inhibiting both AIF and caspase-3 pathways and reduced cognitive impairment in neonatal rats.	pyrazolanthrone	0-8	caspase 3	Rattus norvegicus	81-90
29494909-10	2018	On the other hand, NF-kappaB inhibitor (PDTC) and c-Jun amino-terminal kinase (JNK) inhibitor (SP600125) significantly inhibited production of PFOS-induced TNF-alpha and IL-6.	pyrazolanthrone	95-103	tumor necrosis factor	Rattus norvegicus	156-165
29494909-10	2018	On the other hand, NF-kappaB inhibitor (PDTC) and c-Jun amino-terminal kinase (JNK) inhibitor (SP600125) significantly inhibited production of PFOS-induced TNF-alpha and IL-6.	pyrazolanthrone	95-103	interleukin 6	Rattus norvegicus	170-174
29355557-5	2018	In addition, the data from JNK inhibition using SP600125 showed that over-activated JNK was responsible for Akt de-phosphorylation.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Rattus norvegicus	84-87
29355557-5	2018	In addition, the data from JNK inhibition using SP600125 showed that over-activated JNK was responsible for Akt de-phosphorylation.	pyrazolanthrone	48-56	AKT serine/threonine kinase 1	Rattus norvegicus	108-111
29498687-7	2018	Increased expression of BMP2 mRNA and Smad1/5/8 phosphorylation was blocked by SP600125 and PD98059, but not by SB203580.	pyrazolanthrone	79-87	bone morphogenetic protein 2	Homo sapiens	24-28
29428730-7	2018	Conversely, its cytotoxicity against SCC cells was largely attenuated by co-treatment of S1P, the Akt activator SC79, and the JNK inhibitor SP600125.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	126-129
29498687-6	2018	The addition of the JNK inhibitor SP600125, ERK inhibitor PD98059, and p38 inhibitor SB203580 suppressed wedelolactone-induced alkaline-phosphatase activity, bone mineralization, and osteoblastogenesis-related marker genes including Runx2, Bglap, and Sp7.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	20-23
29498687-7	2018	Increased expression of BMP2 mRNA and Smad1/5/8 phosphorylation was blocked by SP600125 and PD98059, but not by SB203580.	pyrazolanthrone	79-87	SMAD family member 1	Homo sapiens	38-45
29498687-6	2018	The addition of the JNK inhibitor SP600125, ERK inhibitor PD98059, and p38 inhibitor SB203580 suppressed wedelolactone-induced alkaline-phosphatase activity, bone mineralization, and osteoblastogenesis-related marker genes including Runx2, Bglap, and Sp7.	pyrazolanthrone	34-42	RUNX family transcription factor 2	Homo sapiens	233-238
29499695-11	2018	Moreover, CXCL12-mediated SMAD3 phosphorylation or SMAD3-luciferase activity was inhibited by MEKK1 siRNA or SP600125.	pyrazolanthrone	109-117	C-X-C motif chemokine ligand 12	Homo sapiens	10-16
29499695-11	2018	Moreover, CXCL12-mediated SMAD3 phosphorylation or SMAD3-luciferase activity was inhibited by MEKK1 siRNA or SP600125.	pyrazolanthrone	109-117	SMAD family member 3	Homo sapiens	26-31
29499695-11	2018	Moreover, CXCL12-mediated SMAD3 phosphorylation or SMAD3-luciferase activity was inhibited by MEKK1 siRNA or SP600125.	pyrazolanthrone	109-117	SMAD family member 3	Homo sapiens	51-56
29498687-6	2018	The addition of the JNK inhibitor SP600125, ERK inhibitor PD98059, and p38 inhibitor SB203580 suppressed wedelolactone-induced alkaline-phosphatase activity, bone mineralization, and osteoblastogenesis-related marker genes including Runx2, Bglap, and Sp7.	pyrazolanthrone	34-42	bone gamma-carboxyglutamate protein	Homo sapiens	240-245
29498687-6	2018	The addition of the JNK inhibitor SP600125, ERK inhibitor PD98059, and p38 inhibitor SB203580 suppressed wedelolactone-induced alkaline-phosphatase activity, bone mineralization, and osteoblastogenesis-related marker genes including Runx2, Bglap, and Sp7.	pyrazolanthrone	34-42	Sp7 transcription factor	Homo sapiens	251-254
29268145-4	2018	XAV939 and SP600125,the inhibitors of the WNT/beta-catenin and JNK pathways, were further applied to verify the mechanism.	pyrazolanthrone	11-19	catenin beta 1	Homo sapiens	46-58
29268145-4	2018	XAV939 and SP600125,the inhibitors of the WNT/beta-catenin and JNK pathways, were further applied to verify the mechanism.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Homo sapiens	63-66
29268145-8	2018	XAV939 and SP600125 can partly offset the effect of the WNT7B-induced differentiation of HDPCs.	pyrazolanthrone	11-19	Wnt family member 7B	Homo sapiens	56-61
29247669-10	2018	SP600125, an inhibitor of c-Jun, and mithramycin, an inhibitor of Sp1, decreased the level of ABCC2.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-31
28441795-7	2018	Furthermore, LPS-stimulated production of ROS, activation of NADPH oxidase and expression of inflammatory mediators were markedly suppressed by treatment with selective inhibitor of p38MAPK (SB203580) and JNK (SP600125).	pyrazolanthrone	210-218	mitogen-activated protein kinase 8	Homo sapiens	205-208
29247669-10	2018	SP600125, an inhibitor of c-Jun, and mithramycin, an inhibitor of Sp1, decreased the level of ABCC2.	pyrazolanthrone	0-8	ATP binding cassette subfamily C member 2	Homo sapiens	94-99
29247669-11	2018	The promoter activity of ABCC2 was decreased by claudin-2 knockdown, SP600125 and mithramycin treatments, suggesting that claudin-2 is involved in the up-regulation of ABCC2 expression at the transcriptional level.	pyrazolanthrone	69-77	ATP binding cassette subfamily C member 2	Homo sapiens	25-30
29247669-11	2018	The promoter activity of ABCC2 was decreased by claudin-2 knockdown, SP600125 and mithramycin treatments, suggesting that claudin-2 is involved in the up-regulation of ABCC2 expression at the transcriptional level.	pyrazolanthrone	69-77	claudin 2	Homo sapiens	122-131
29247669-11	2018	The promoter activity of ABCC2 was decreased by claudin-2 knockdown, SP600125 and mithramycin treatments, suggesting that claudin-2 is involved in the up-regulation of ABCC2 expression at the transcriptional level.	pyrazolanthrone	69-77	ATP binding cassette subfamily C member 2	Homo sapiens	168-173
29383484-7	2018	Autophagy response and JNK activities were inhibited by specific inhibitor, 3MA or SP600125, respectively.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	23-26
28820947-6	2018	Functional assays showed that SP600125, an inhibitor of SAPK/JNK, prevented the increase in endothelin (ET)-1-induced contraction in the CSM from ethanol-treated rats.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	61-64
29383484-10	2018	Blocking autophagy or JNK activation with specific inhibitor, 3MA or SP600125, potentiated cell death and caspase-3 activation.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	22-25
29383484-10	2018	Blocking autophagy or JNK activation with specific inhibitor, 3MA or SP600125, potentiated cell death and caspase-3 activation.	pyrazolanthrone	69-77	caspase 3	Homo sapiens	106-115
29487502-4	2018	We found that the up-regulated level of Netrin-1 and its receptor DCC promoted axonal regeneration and synaptic formation; the overexpression of Netrin-1 activated the JNK1 signaling pathway; these effects were partially reduced when JNK1 signaling pathway was inhibited by SP600125 (JNK specific inhibitor).	pyrazolanthrone	274-282	netrin 1	Rattus norvegicus	40-48
29091309-9	2018	In addition, the JNK inhibitor SP600125, and the EGFR inhibitors AG1478 and PD168393, also had an inhibitory effect on EREG expression, suggesting that EGFR, activated in Caco-2/pRS26 cells, is involved in the observed EREG upregulation.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	17-20
29091309-9	2018	In addition, the JNK inhibitor SP600125, and the EGFR inhibitors AG1478 and PD168393, also had an inhibitory effect on EREG expression, suggesting that EGFR, activated in Caco-2/pRS26 cells, is involved in the observed EREG upregulation.	pyrazolanthrone	31-39	epiregulin	Homo sapiens	119-123
29091309-9	2018	In addition, the JNK inhibitor SP600125, and the EGFR inhibitors AG1478 and PD168393, also had an inhibitory effect on EREG expression, suggesting that EGFR, activated in Caco-2/pRS26 cells, is involved in the observed EREG upregulation.	pyrazolanthrone	31-39	epidermal growth factor receptor	Homo sapiens	152-156
29328382-6	2018	Furthermore, the activation of c-Jun N-terminal kinase (JNK) in cells treated with P-PostC with or without co-treatment with SP600125, an inhibitor of JNK, was also determined by western blotting.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Rattus norvegicus	31-54
29328382-6	2018	Furthermore, the activation of c-Jun N-terminal kinase (JNK) in cells treated with P-PostC with or without co-treatment with SP600125, an inhibitor of JNK, was also determined by western blotting.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Rattus norvegicus	56-59
29328382-6	2018	Furthermore, the activation of c-Jun N-terminal kinase (JNK) in cells treated with P-PostC with or without co-treatment with SP600125, an inhibitor of JNK, was also determined by western blotting.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Rattus norvegicus	151-154
29264665-4	2018	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced lipopolysaccharide-induced production of inflammatory mediators and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	20-23
29264665-4	2018	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced lipopolysaccharide-induced production of inflammatory mediators and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	153-156
29264665-4	2018	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced lipopolysaccharide-induced production of inflammatory mediators and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 14	Homo sapiens	161-164
29155130-8	2018	Pre-treatment with specific p38, ERK1/2, and JNK1/2 inhibitors (SB203580, U0126, SP600125, respectively) attenuated the inducible phosphorylation events.	pyrazolanthrone	81-89	mitogen-activated protein kinase 14	Mus musculus	28-31
29155130-8	2018	Pre-treatment with specific p38, ERK1/2, and JNK1/2 inhibitors (SB203580, U0126, SP600125, respectively) attenuated the inducible phosphorylation events.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Mus musculus	45-49
29483719-11	2018	The inhibitors of MAPK (U0126, SP600125,SB203580) and inhibitor of AKT (perifosine) could also inhibit Runx2 expression.	pyrazolanthrone	31-39	RUNX family transcription factor 2	Homo sapiens	103-108
28749049-8	2018	When hPDLSCs were treated with the inhibitors of NF-kappaB and MAPK pathways (U0126, SP600125, SB203580, and BMS345541), the effects of MTA on the differentiation of hPDLSCs were suppressed.	pyrazolanthrone	85-93	nuclear factor kappa B subunit 1	Homo sapiens	49-58
29328481-8	2018	Treating cells with insulin, SP600125 and U0126 indicated that the Akt/mTOR pathway and JNK were involved in TTF1-NP-induced autophagy.	pyrazolanthrone	29-37	transcription termination factor 1	Homo sapiens	109-113
29681986-9	2018	Additional, the effects of SP600125, an inhibitor of phospho-JNK, were similar to the results of FYCWYC.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Rattus norvegicus	61-64
29487502-4	2018	We found that the up-regulated level of Netrin-1 and its receptor DCC promoted axonal regeneration and synaptic formation; the overexpression of Netrin-1 activated the JNK1 signaling pathway; these effects were partially reduced when JNK1 signaling pathway was inhibited by SP600125 (JNK specific inhibitor).	pyrazolanthrone	274-282	DCC netrin 1 receptor	Rattus norvegicus	66-69
29487502-4	2018	We found that the up-regulated level of Netrin-1 and its receptor DCC promoted axonal regeneration and synaptic formation; the overexpression of Netrin-1 activated the JNK1 signaling pathway; these effects were partially reduced when JNK1 signaling pathway was inhibited by SP600125 (JNK specific inhibitor).	pyrazolanthrone	274-282	netrin 1	Rattus norvegicus	145-153
29487502-4	2018	We found that the up-regulated level of Netrin-1 and its receptor DCC promoted axonal regeneration and synaptic formation; the overexpression of Netrin-1 activated the JNK1 signaling pathway; these effects were partially reduced when JNK1 signaling pathway was inhibited by SP600125 (JNK specific inhibitor).	pyrazolanthrone	274-282	mitogen-activated protein kinase 8	Rattus norvegicus	168-171
29207022-12	2018	SP600125 is an ATP-competitive, efficient, selective and reversible inhibitor of JNK.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	81-84
29459829-8	2018	The JNK kinase inhibitor, SP600125, markedly inhibited PTTH-stimulated JNK phosphorylation and ecdysteroid synthesis.	pyrazolanthrone	26-34	c-Jun NH2-terminal kinase	Bombyx mori	4-7
29459829-8	2018	The JNK kinase inhibitor, SP600125, markedly inhibited PTTH-stimulated JNK phosphorylation and ecdysteroid synthesis.	pyrazolanthrone	26-34	prothoracicotropic hormone	Bombyx mori	55-59
29459829-8	2018	The JNK kinase inhibitor, SP600125, markedly inhibited PTTH-stimulated JNK phosphorylation and ecdysteroid synthesis.	pyrazolanthrone	26-34	c-Jun NH2-terminal kinase	Bombyx mori	71-74
29459829-9	2018	The kinase assay of JNK in PGs confirmed its stimulation by PTTH and inhibition by SP600125.	pyrazolanthrone	83-91	c-Jun NH2-terminal kinase	Bombyx mori	20-23
28993908-8	2018	Furthermore, inhibiting JNK activation by a JNK-specific inhibitor, SP600125, decreased DNA damage levels induced by 4-methoxy-TEMPO.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	24-27
28993908-8	2018	Furthermore, inhibiting JNK activation by a JNK-specific inhibitor, SP600125, decreased DNA damage levels induced by 4-methoxy-TEMPO.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	44-47
29183675-5	2018	Microinjection of JAK2 inhibitor AG490, ERK inhibitor PD98059 and also JNK inhibitor SP600125 into the RN significantly increased the paw withdrawal threshold (PWT) and alleviated SNI-induced mechanical allodynia.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
29291542-4	2018	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced lipopolysaccharide-caused production of inflammatory mediators, activation of the JNK and p38-MAPK, and production of reactive oxygen species in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	20-23
29291542-4	2018	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced lipopolysaccharide-caused production of inflammatory mediators, activation of the JNK and p38-MAPK, and production of reactive oxygen species in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	149-152
28369910-6	2018	Elimination of ROS with the antioxidant N-acetyl cysteine (NAC) or inhibition of JNK with the JNK inhibitor SP600125 reduced ethanol-induced autophagy and subsequent autophagy-mediated apoptosis.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Mus musculus	81-84
28369910-6	2018	Elimination of ROS with the antioxidant N-acetyl cysteine (NAC) or inhibition of JNK with the JNK inhibitor SP600125 reduced ethanol-induced autophagy and subsequent autophagy-mediated apoptosis.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Mus musculus	94-97
28885729-11	2018	These effects was reversed by knockdown of OB-Rb and/or pre-incubation with PD98059 (ERK1/2 inhibitor), SP600125 (JNK1/2 inhibitor).	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Homo sapiens	114-120
28681925-9	2018	The JNK inhibitor, SP600125 inhibited the Wnt5a-induced downregulation of bone-related gene expression in HPDLSCs.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
28681925-9	2018	The JNK inhibitor, SP600125 inhibited the Wnt5a-induced downregulation of bone-related gene expression in HPDLSCs.	pyrazolanthrone	19-27	Wnt family member 5A	Homo sapiens	42-47
28681925-10	2018	Additionally, SP600125 inhibited the Wnt5a-induced suppression of the alizarin red-positive reaction in HPDLSCs.	pyrazolanthrone	14-22	Wnt family member 5A	Homo sapiens	37-42
29273684-0	2018	SP600125 suppresses Keap1 expression and results in NRF2-mediated prevention of diabetic nephropathy.	pyrazolanthrone	0-8	kelch-like ECH-associated protein 1	Mus musculus	20-25
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	54-57
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	pyrazolanthrone	44-52	hypoxia inducible factor 1 subunit alpha	Homo sapiens	121-131
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	pyrazolanthrone	44-52	vascular endothelial growth factor A	Homo sapiens	136-140
29083089-7	2018	Furthermore, both U0126 (ErK inhibitor) and SP600125 (JNK inhibitor) significantly suppressed the enhanced production of HIF-1alpha and VEGF induced by HMGB1.	pyrazolanthrone	44-52	high mobility group box 1	Homo sapiens	152-157
29273684-7	2018	To explore the mechanism by which SP600125 activates NRF2, mouse mesangial cells (MMCs) were treated with high glucose (HG), in the presence or absence of either SP600125 or JNK siRNA.	pyrazolanthrone	34-42	nuclear factor, erythroid derived 2, like 2	Mus musculus	53-57
29273684-9	2018	SP600125 inactivated JNK, inhibited kelch-like ECH-associated protein 1 expression, preserved NRF2 protein and facilitated its nuclear translocation in the kidneys of the WT mice, the effects of which were similarly produced by either SP600125 or JNK siRNA in HG-treated MMCs.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	21-24
29273684-0	2018	SP600125 suppresses Keap1 expression and results in NRF2-mediated prevention of diabetic nephropathy.	pyrazolanthrone	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	52-56
29273684-9	2018	SP600125 inactivated JNK, inhibited kelch-like ECH-associated protein 1 expression, preserved NRF2 protein and facilitated its nuclear translocation in the kidneys of the WT mice, the effects of which were similarly produced by either SP600125 or JNK siRNA in HG-treated MMCs.	pyrazolanthrone	0-8	kelch-like ECH-associated protein 1	Mus musculus	36-71
29273684-2	2018	The JNK inhibitor SP600125 was reported to ameliorate DN.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
29273684-9	2018	SP600125 inactivated JNK, inhibited kelch-like ECH-associated protein 1 expression, preserved NRF2 protein and facilitated its nuclear translocation in the kidneys of the WT mice, the effects of which were similarly produced by either SP600125 or JNK siRNA in HG-treated MMCs.	pyrazolanthrone	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	94-98
29273684-9	2018	SP600125 inactivated JNK, inhibited kelch-like ECH-associated protein 1 expression, preserved NRF2 protein and facilitated its nuclear translocation in the kidneys of the WT mice, the effects of which were similarly produced by either SP600125 or JNK siRNA in HG-treated MMCs.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	247-250
29273684-11	2018	The present study demonstrates that NRF2 is required for SP600125"s protection against DN.	pyrazolanthrone	57-65	nuclear factor, erythroid derived 2, like 2	Mus musculus	36-40
29273684-12	2018	SP600125 activates NRF2 possibly via inhibition of JNK-induced Keap1 expression.	pyrazolanthrone	0-8	nuclear factor, erythroid derived 2, like 2	Mus musculus	19-23
29273684-12	2018	SP600125 activates NRF2 possibly via inhibition of JNK-induced Keap1 expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	51-54
29273684-4	2018	We previously reported that SP600125 activated nuclear factor erythroid 2-related factor 2 (NRF2), a governor of the cellular antioxidant defense system, in the aortas of the diabetic mice.	pyrazolanthrone	28-36	nuclear factor, erythroid derived 2, like 2	Mus musculus	92-96
29273684-12	2018	SP600125 activates NRF2 possibly via inhibition of JNK-induced Keap1 expression.	pyrazolanthrone	0-8	kelch-like ECH-associated protein 1	Mus musculus	63-68
29552311-8	2018	On the other hand, expression plasmid of SIRT1, N-acetyl cysteine or SP600125 (JNK specific inhibitor) abolished the effect of miR-29b on oxaliplatin-treated OR-SW480.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	79-82
29434974-9	2018	The addition of SP600125 to the cells incubated with DHA resulted in a significant decrease in the caspase-3 and c-Jun expression levels compared with those cells incubated with DHA alone.	pyrazolanthrone	16-24	caspase 3	Homo sapiens	99-108
29434974-9	2018	The addition of SP600125 to the cells incubated with DHA resulted in a significant decrease in the caspase-3 and c-Jun expression levels compared with those cells incubated with DHA alone.	pyrazolanthrone	16-24	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	113-118
29552311-8	2018	On the other hand, expression plasmid of SIRT1, N-acetyl cysteine or SP600125 (JNK specific inhibitor) abolished the effect of miR-29b on oxaliplatin-treated OR-SW480.	pyrazolanthrone	69-77	microRNA 29b-1	Homo sapiens	127-134
29637869-11	2018	In addition, MAPKs inhibitors (SP600125, U0126, and SB203580) reversed MAM-induced cell death and ATM/Chk2 activation.	pyrazolanthrone	31-39	ATM serine/threonine kinase	Homo sapiens	98-101
29417765-4	2018	Previous studies have relied upon the broad spectrum JNK inhibitor, SP600125, to characterize the role of JNK signaling in a number of cell lines, including the breast cancer cell line MCF-7.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	53-56
29417765-4	2018	Previous studies have relied upon the broad spectrum JNK inhibitor, SP600125, to characterize the role of JNK signaling in a number of cell lines, including the breast cancer cell line MCF-7.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	106-109
29417765-5	2018	In line with previous literature, our study has demonstrated that SP600125 treatment inhibited c-Jun and JNK phosphorylation and MCF-7 proliferation.	pyrazolanthrone	66-74	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	95-100
29417765-5	2018	In line with previous literature, our study has demonstrated that SP600125 treatment inhibited c-Jun and JNK phosphorylation and MCF-7 proliferation.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	105-108
29175444-6	2018	Further, the decreased Ces1d and Ces1e expression induced by 17beta-estradiol could be abolished by SP600125, an inhibitor of AP-1, both at mRNA and protein levels.	pyrazolanthrone	100-108	carboxylesterase 1	Homo sapiens	23-28
29175444-6	2018	Further, the decreased Ces1d and Ces1e expression induced by 17beta-estradiol could be abolished by SP600125, an inhibitor of AP-1, both at mRNA and protein levels.	pyrazolanthrone	100-108	carboxylesterase 1E	Mus musculus	33-38
29175444-6	2018	Further, the decreased Ces1d and Ces1e expression induced by 17beta-estradiol could be abolished by SP600125, an inhibitor of AP-1, both at mRNA and protein levels.	pyrazolanthrone	100-108	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	126-130
29175444-7	2018	Likewise, the increased c-Jun expression induced by 17beta-estradiol could almost be abolished by SP600125.	pyrazolanthrone	98-106	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	24-29
29373608-7	2018	IL-33 also stimulated phosphorylations of c-Jun N-terminal kinase (JNK) and c-Jun, and enhanced activator protein (AP)-1 DNA-binding activity, all of which were suppressed by SP600125, a JNK inhibitor.	pyrazolanthrone	175-183	interleukin 33	Homo sapiens	0-5
29373608-7	2018	IL-33 also stimulated phosphorylations of c-Jun N-terminal kinase (JNK) and c-Jun, and enhanced activator protein (AP)-1 DNA-binding activity, all of which were suppressed by SP600125, a JNK inhibitor.	pyrazolanthrone	175-183	mitogen-activated protein kinase 8	Homo sapiens	42-65
29373608-7	2018	IL-33 also stimulated phosphorylations of c-Jun N-terminal kinase (JNK) and c-Jun, and enhanced activator protein (AP)-1 DNA-binding activity, all of which were suppressed by SP600125, a JNK inhibitor.	pyrazolanthrone	175-183	mitogen-activated protein kinase 8	Homo sapiens	67-70
29373608-7	2018	IL-33 also stimulated phosphorylations of c-Jun N-terminal kinase (JNK) and c-Jun, and enhanced activator protein (AP)-1 DNA-binding activity, all of which were suppressed by SP600125, a JNK inhibitor.	pyrazolanthrone	175-183	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	42-47
29373608-7	2018	IL-33 also stimulated phosphorylations of c-Jun N-terminal kinase (JNK) and c-Jun, and enhanced activator protein (AP)-1 DNA-binding activity, all of which were suppressed by SP600125, a JNK inhibitor.	pyrazolanthrone	175-183	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	96-120
29373608-7	2018	IL-33 also stimulated phosphorylations of c-Jun N-terminal kinase (JNK) and c-Jun, and enhanced activator protein (AP)-1 DNA-binding activity, all of which were suppressed by SP600125, a JNK inhibitor.	pyrazolanthrone	175-183	mitogen-activated protein kinase 8	Homo sapiens	187-190
29373608-8	2018	Moreover, IL-33-induced IL-8 mRNA and secretion were also suppressed by SP600125.	pyrazolanthrone	72-80	interleukin 33	Homo sapiens	10-15
29373608-8	2018	Moreover, IL-33-induced IL-8 mRNA and secretion were also suppressed by SP600125.	pyrazolanthrone	72-80	C-X-C motif chemokine ligand 8	Homo sapiens	24-28
29212786-8	2018	Meanwhile, we found that these effects could be abolished by ER stress inhibitor 4-phenylbutyrate or JNK inhibitor SP600125 in vitro.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Mus musculus	101-104
29354064-5	2017	Our results demonstrated that the specific c-Jun N-terminal kinase (JNK) pathway inhibitor, SP600125, but neither the specific inhibitor of extracellular signaling-regulated kinase (ERK) kinase MEK1/2, U0126, nor the specific inhibitor of p38 MAPK, SB203580, significantly blocks LPS-induced oxLDL uptake, suggesting that the JNK pathway is the upstream mediator of LPS-induced oxLDL uptake/foam cell formation.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	43-66
29354064-5	2017	Our results demonstrated that the specific c-Jun N-terminal kinase (JNK) pathway inhibitor, SP600125, but neither the specific inhibitor of extracellular signaling-regulated kinase (ERK) kinase MEK1/2, U0126, nor the specific inhibitor of p38 MAPK, SB203580, significantly blocks LPS-induced oxLDL uptake, suggesting that the JNK pathway is the upstream mediator of LPS-induced oxLDL uptake/foam cell formation.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	68-71
29637869-11	2018	In addition, MAPKs inhibitors (SP600125, U0126, and SB203580) reversed MAM-induced cell death and ATM/Chk2 activation.	pyrazolanthrone	31-39	checkpoint kinase 2	Homo sapiens	102-106
30212812-10	2018	On the other hand, both SB203580 and SP600125 reduced the TRAP-stimulated secretion of PDGF-AB.	pyrazolanthrone	37-45	TRAP	Homo sapiens	58-62
30231248-7	2018	We found that PTX (inhibitor of G(alpha)i/o), LY294002 (inhibitor of PI3K) or SP600125 (inhibitor of JNK1/2) prevented up-regulation of M1 genes expression mediated by S1P/S1PR2/3 signal, and S1P-induced JNK phosphorylation was inhibited by antagonists of S1PR2/3, PTX or LY294002.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	101-107
29991018-11	2018	The enhancing effects of Ang II on EPC adhesion, migration and in vitro vasculogenesis were reversed by p38 inhibitor SB202190 and JNK inhibitor SP600125.	pyrazolanthrone	145-153	angiotensinogen	Homo sapiens	25-31
29991018-11	2018	The enhancing effects of Ang II on EPC adhesion, migration and in vitro vasculogenesis were reversed by p38 inhibitor SB202190 and JNK inhibitor SP600125.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	131-134
29486473-11	2018	JNK inhibitor SP600125 prevented PA-mediated increase of Nox4, IL-8, IL-6 and iTG.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	0-3
30231248-7	2018	We found that PTX (inhibitor of G(alpha)i/o), LY294002 (inhibitor of PI3K) or SP600125 (inhibitor of JNK1/2) prevented up-regulation of M1 genes expression mediated by S1P/S1PR2/3 signal, and S1P-induced JNK phosphorylation was inhibited by antagonists of S1PR2/3, PTX or LY294002.	pyrazolanthrone	78-86	sphingosine-1-phosphate receptor 1	Mus musculus	168-171
30231248-7	2018	We found that PTX (inhibitor of G(alpha)i/o), LY294002 (inhibitor of PI3K) or SP600125 (inhibitor of JNK1/2) prevented up-regulation of M1 genes expression mediated by S1P/S1PR2/3 signal, and S1P-induced JNK phosphorylation was inhibited by antagonists of S1PR2/3, PTX or LY294002.	pyrazolanthrone	78-86	sphingosine-1-phosphate receptor 2	Mus musculus	172-177
30231248-7	2018	We found that PTX (inhibitor of G(alpha)i/o), LY294002 (inhibitor of PI3K) or SP600125 (inhibitor of JNK1/2) prevented up-regulation of M1 genes expression mediated by S1P/S1PR2/3 signal, and S1P-induced JNK phosphorylation was inhibited by antagonists of S1PR2/3, PTX or LY294002.	pyrazolanthrone	78-86	sphingosine-1-phosphate receptor 1	Mus musculus	172-175
30231248-7	2018	We found that PTX (inhibitor of G(alpha)i/o), LY294002 (inhibitor of PI3K) or SP600125 (inhibitor of JNK1/2) prevented up-regulation of M1 genes expression mediated by S1P/S1PR2/3 signal, and S1P-induced JNK phosphorylation was inhibited by antagonists of S1PR2/3, PTX or LY294002.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	101-104
30231248-7	2018	We found that PTX (inhibitor of G(alpha)i/o), LY294002 (inhibitor of PI3K) or SP600125 (inhibitor of JNK1/2) prevented up-regulation of M1 genes expression mediated by S1P/S1PR2/3 signal, and S1P-induced JNK phosphorylation was inhibited by antagonists of S1PR2/3, PTX or LY294002.	pyrazolanthrone	78-86	sphingosine-1-phosphate receptor 2	Mus musculus	256-261
29486473-11	2018	JNK inhibitor SP600125 prevented PA-mediated increase of Nox4, IL-8, IL-6 and iTG.	pyrazolanthrone	14-22	NADPH oxidase 4	Mus musculus	57-61
29486473-11	2018	JNK inhibitor SP600125 prevented PA-mediated increase of Nox4, IL-8, IL-6 and iTG.	pyrazolanthrone	14-22	chemokine (C-X-C motif) ligand 15	Mus musculus	63-67
29486473-11	2018	JNK inhibitor SP600125 prevented PA-mediated increase of Nox4, IL-8, IL-6 and iTG.	pyrazolanthrone	14-22	interleukin 6	Mus musculus	69-73
30003858-12	2018	The combinational treatment with P38-specific inhibitor SB202190 and JUN-specific inhibitor SP600125 significantly suppressed cell growth and migration, which was further attributed to the induction of autophagy flux and inhibition of EMT processing.	pyrazolanthrone	92-100	mitogen-activated protein kinase 14	Homo sapiens	33-36
29590661-11	2018	Co-administration of a JNK inhibitor (SP600125) or p38 inhibitor (SB203580) abolished cell death and ER stress effects during PD treatment.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	23-26
29843131-4	2018	In a subgroup, we exposed cells to 360 cycles of IH with the JNK inhibitor SP600125.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	61-64
29843131-8	2018	JNK inhibitor SP600125 partially restored AKT/ GSK-3beta phosphorylation and glycogen synthesis, but did not affect other IH-induced glucose metabolic changes.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
29843131-8	2018	JNK inhibitor SP600125 partially restored AKT/ GSK-3beta phosphorylation and glycogen synthesis, but did not affect other IH-induced glucose metabolic changes.	pyrazolanthrone	14-22	AKT serine/threonine kinase 1	Homo sapiens	42-45
29843131-8	2018	JNK inhibitor SP600125 partially restored AKT/ GSK-3beta phosphorylation and glycogen synthesis, but did not affect other IH-induced glucose metabolic changes.	pyrazolanthrone	14-22	glycogen synthase kinase 3 beta	Homo sapiens	47-56
30468094-8	2018	LPS-induced transactivation of AP-1 was also inhibited by JNK inhibitor SP600125 and ERK1/2 inhibitor PD98059.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	58-61
28884507-6	2018	Interestingly, the Wnt pathway was suppressed during the ECM expansion-mediated increase in pluripotency, but was activated in an osteogenic differentiation environment, as confirmed by treatment with the XAV-939 beta-catenin inhibitor or the SP600125 c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	243-251	mitogen-activated protein kinase 8	Homo sapiens	252-291
29398016-15	2018	The allergens (Der p2 and Der p3)-induced IL-6/IL-8 expression and NCA released from Beas-2B could be downregulated by dexamethasone and transcription factor inhibitor SP600125.	pyrazolanthrone	168-176	interleukin 6	Homo sapiens	42-46
29398016-15	2018	The allergens (Der p2 and Der p3)-induced IL-6/IL-8 expression and NCA released from Beas-2B could be downregulated by dexamethasone and transcription factor inhibitor SP600125.	pyrazolanthrone	168-176	C-X-C motif chemokine ligand 8	Homo sapiens	47-51
30336480-5	2018	Relative to diluent control, incubation of the NSPs for 24 h with SP600125, an anthrapyrazolone inhibitor of JNK, resulted in increased abundance of mitochondrial superoxide radicals (p &lt; 0.05), concomitant with decreases in mitochondrial membrane potential (p &lt; 0.001), while maintaining a consistent and stable mitochondrial mass.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	109-112
28922542-12	2018	Moreover, the JNK inhibitor SP600125-protected HTB-54 cells from DPDS 6-induced cell death indicating that JNK activation is involved in DPDS 6-induced autophagy.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	14-17
28922542-12	2018	Moreover, the JNK inhibitor SP600125-protected HTB-54 cells from DPDS 6-induced cell death indicating that JNK activation is involved in DPDS 6-induced autophagy.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	107-110
29552858-4	2018	The effects of OP-D and 11,12-EET on phosphorylation of JNK/c-Jun induced by Ang II were measured by Western blot and RT-PCR with the help of JNK specific inhibitor SP600125 and CYP450 isozymes selective inhibitor 6-(2-propargyloxyphenyl) hexanoic acid (PPOH).	pyrazolanthrone	165-173	mitogen-activated protein kinase 8	Homo sapiens	56-59
28703856-7	2018	Expression of ET-1 was increased by stroke and potentiated by tPA but returned to sham levels by tPA-A296-299 and the JNK antagonist SP600125.	pyrazolanthrone	133-141	endothelin-1	Sus scrofa	14-18
28703856-7	2018	Expression of ET-1 was increased by stroke and potentiated by tPA but returned to sham levels by tPA-A296-299 and the JNK antagonist SP600125.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Sus scrofa	118-121
29221728-12	2018	The JNK pathway inhibitor SP600125 significantly increased the cell viability of SHSY-5Y cells induced by EIso.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	4-7
29387217-12	2018	The p38 inhibitor PD169316 partially blocked lapatinib-induced proliferation inhibition and apoptosis, whereas the JNK inhibitor SP600125 had no such effects.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	115-118
29221728-8	2018	SP600125, a specific inhibitor of JNK, was used to detect the role of JNK pathway in the neurotoxicity of EIso.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	34-37
29221728-8	2018	SP600125, a specific inhibitor of JNK, was used to detect the role of JNK pathway in the neurotoxicity of EIso.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	70-73
28858391-6	2018	Further study indicated that UVB-induced production of MMP-1 and IL-6 could be inhibited by PD 98059 (an ERK inhibitor) and SP600125 (A JNK inhibitor), implied that EPS inhibited UVB-induced MMP-1 and IL-6 secretion by inactivating MAPK signaling pathway.	pyrazolanthrone	124-132	matrix metallopeptidase 1	Homo sapiens	55-60
28858391-6	2018	Further study indicated that UVB-induced production of MMP-1 and IL-6 could be inhibited by PD 98059 (an ERK inhibitor) and SP600125 (A JNK inhibitor), implied that EPS inhibited UVB-induced MMP-1 and IL-6 secretion by inactivating MAPK signaling pathway.	pyrazolanthrone	124-132	interleukin 6	Homo sapiens	65-69
28858391-6	2018	Further study indicated that UVB-induced production of MMP-1 and IL-6 could be inhibited by PD 98059 (an ERK inhibitor) and SP600125 (A JNK inhibitor), implied that EPS inhibited UVB-induced MMP-1 and IL-6 secretion by inactivating MAPK signaling pathway.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	136-139
29552858-4	2018	The effects of OP-D and 11,12-EET on phosphorylation of JNK/c-Jun induced by Ang II were measured by Western blot and RT-PCR with the help of JNK specific inhibitor SP600125 and CYP450 isozymes selective inhibitor 6-(2-propargyloxyphenyl) hexanoic acid (PPOH).	pyrazolanthrone	165-173	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	60-65
29552858-4	2018	The effects of OP-D and 11,12-EET on phosphorylation of JNK/c-Jun induced by Ang II were measured by Western blot and RT-PCR with the help of JNK specific inhibitor SP600125 and CYP450 isozymes selective inhibitor 6-(2-propargyloxyphenyl) hexanoic acid (PPOH).	pyrazolanthrone	165-173	angiogenin	Homo sapiens	77-80
29552858-4	2018	The effects of OP-D and 11,12-EET on phosphorylation of JNK/c-Jun induced by Ang II were measured by Western blot and RT-PCR with the help of JNK specific inhibitor SP600125 and CYP450 isozymes selective inhibitor 6-(2-propargyloxyphenyl) hexanoic acid (PPOH).	pyrazolanthrone	165-173	mitogen-activated protein kinase 8	Homo sapiens	142-145
29552858-7	2018	The phosphorylation of JNK and c-Jun could be inhibited by the pre-treatment with SP600125, 11,12-EET and OP-D. Pre-treatment with OP-D could significantly reduce the release of LDH induced by Ang II stimulation, decrease the expression of caspase-3, and diminish the apoptosis of cells.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	23-26
29552858-7	2018	The phosphorylation of JNK and c-Jun could be inhibited by the pre-treatment with SP600125, 11,12-EET and OP-D. Pre-treatment with OP-D could significantly reduce the release of LDH induced by Ang II stimulation, decrease the expression of caspase-3, and diminish the apoptosis of cells.	pyrazolanthrone	82-90	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	31-36
29552858-7	2018	The phosphorylation of JNK and c-Jun could be inhibited by the pre-treatment with SP600125, 11,12-EET and OP-D. Pre-treatment with OP-D could significantly reduce the release of LDH induced by Ang II stimulation, decrease the expression of caspase-3, and diminish the apoptosis of cells.	pyrazolanthrone	82-90	angiogenin	Homo sapiens	193-196
29552858-7	2018	The phosphorylation of JNK and c-Jun could be inhibited by the pre-treatment with SP600125, 11,12-EET and OP-D. Pre-treatment with OP-D could significantly reduce the release of LDH induced by Ang II stimulation, decrease the expression of caspase-3, and diminish the apoptosis of cells.	pyrazolanthrone	82-90	caspase 3	Homo sapiens	240-249
29416631-7	2018	This cladoloside C2-induced apoptosis was partially blocked by specific inhibition by Fas, CerS6, and p38 siRNA transfection, and by specific inhibition of JNK by SP600125 or dominant negative-JNK transfection.	pyrazolanthrone	163-171	mitogen-activated protein kinase 8	Homo sapiens	156-159
29151904-12	2017	Of note, pretreatment with the JNK inhibitor, SP600125, decreased the rates of autophagy and apoptosis, suggesting a crucial role served by the JNK signaling pathway in the activation of autophagy by curcumol.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	31-34
28833827-14	2017	Furthermore, inhibition of JNK by its inhibitor SP600125 dramatically blocked POSTN-enhanced scratch closure, ALP activity and mineralization in PDLSCs.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	27-30
28833827-14	2017	Furthermore, inhibition of JNK by its inhibitor SP600125 dramatically blocked POSTN-enhanced scratch closure, ALP activity and mineralization in PDLSCs.	pyrazolanthrone	48-56	periostin	Homo sapiens	78-83
28833827-14	2017	Furthermore, inhibition of JNK by its inhibitor SP600125 dramatically blocked POSTN-enhanced scratch closure, ALP activity and mineralization in PDLSCs.	pyrazolanthrone	48-56	alkaline phosphatase, placental	Homo sapiens	110-113
29096379-6	2017	The JNK kinase, a MAPK family member, was identified as a putative candidate of druggable target for EM therapeutics; the inhibitory activity of eight naturally occurring compounds as well as a sophisticated kinase inhibitor SP600125 against the JNK was tested using enzymatic activity analysis.	pyrazolanthrone	225-233	mitogen-activated protein kinase 8	Homo sapiens	4-7
29096379-6	2017	The JNK kinase, a MAPK family member, was identified as a putative candidate of druggable target for EM therapeutics; the inhibitory activity of eight naturally occurring compounds as well as a sophisticated kinase inhibitor SP600125 against the JNK was tested using enzymatic activity analysis.	pyrazolanthrone	225-233	mitogen-activated protein kinase 8	Homo sapiens	246-249
29285098-7	2017	Furthermore, subsequent to inhibition of the MAPK pathway by specific inhibitors (PD98059, SB203580 and SP600125), the expression of MMP-9 was reduced, indicating that the inhibitory effect of aspirin on MMP-9 in TNF-alpha-treated RAW264.7 cells may be, at least in part, through suppression of NF-kappaB activation and the MAPK pathway.	pyrazolanthrone	104-112	matrix metallopeptidase 9	Mus musculus	133-138
29285098-7	2017	Furthermore, subsequent to inhibition of the MAPK pathway by specific inhibitors (PD98059, SB203580 and SP600125), the expression of MMP-9 was reduced, indicating that the inhibitory effect of aspirin on MMP-9 in TNF-alpha-treated RAW264.7 cells may be, at least in part, through suppression of NF-kappaB activation and the MAPK pathway.	pyrazolanthrone	104-112	matrix metallopeptidase 9	Mus musculus	204-209
28990107-3	2017	rBMSCs were treated for 7 days with or without estradiol and further treated with or without the JNK-specific inhibitor SP600125.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Rattus norvegicus	97-100
28990107-6	2017	All groups treated with SP600125 expressed low levels of TGF-beta1 and Cbfalpha1 mRNA and protein, and low p-JNK protein expression.	pyrazolanthrone	24-32	transforming growth factor, beta 1	Rattus norvegicus	57-66
28990107-6	2017	All groups treated with SP600125 expressed low levels of TGF-beta1 and Cbfalpha1 mRNA and protein, and low p-JNK protein expression.	pyrazolanthrone	24-32	RUNX family transcription factor 2	Rattus norvegicus	71-80
28990107-6	2017	All groups treated with SP600125 expressed low levels of TGF-beta1 and Cbfalpha1 mRNA and protein, and low p-JNK protein expression.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Rattus norvegicus	109-112
29250183-6	2017	Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	26-29
29250183-6	2017	Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells.	pyrazolanthrone	14-22	XIAP associated factor 1	Homo sapiens	142-174
29250183-6	2017	Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells.	pyrazolanthrone	14-22	XIAP associated factor 1	Homo sapiens	176-180
29250183-6	2017	Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells.	pyrazolanthrone	14-22	BCL2 apoptosis regulator	Homo sapiens	219-223
29250183-6	2017	Additionally, SP600125 (a JNK inhibitor) and SB203580 (a p38-MAPK inhibitor) effectively inhibited apoptosis and attenuated the expression of X-linked IAP-associated factor 1 (XAF1) and apoptotic Bcl-2 family proteins (BCL2 antagonist/killer 1 and BCL2-associated X protein) in Amp-treated colon cancer cells.	pyrazolanthrone	14-22	BCL2 apoptosis regulator	Homo sapiens	248-252
29151904-12	2017	Of note, pretreatment with the JNK inhibitor, SP600125, decreased the rates of autophagy and apoptosis, suggesting a crucial role served by the JNK signaling pathway in the activation of autophagy by curcumol.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	144-147
29157812-9	2017	Screening of MAP kinase phosphorylation showed a combined activation of IL-1alpha/AKBA on JNK, while the JNK inhibitor SP600125 abolished MMP-9 upregulation induced by IL-1alpha/AKBA.	pyrazolanthrone	119-127	matrix metallopeptidase 9	Homo sapiens	138-143
29157812-9	2017	Screening of MAP kinase phosphorylation showed a combined activation of IL-1alpha/AKBA on JNK, while the JNK inhibitor SP600125 abolished MMP-9 upregulation induced by IL-1alpha/AKBA.	pyrazolanthrone	119-127	interleukin 1 alpha	Homo sapiens	168-177
28783177-7	2017	Systemic treatment with HGF-shRNA, SP600125 or stattic also reduced generation of EGFP(Axin2)+ hepatic cell-originated CD90+ CSCs in aberrant autophagic cirrhotic livers by inactivating HGF/Met/JNK or HGF/Met/STAT3 signaling, further preventing hepatocarcinogenesis.	pyrazolanthrone	35-43	axin 2	Rattus norvegicus	87-92
28783177-7	2017	Systemic treatment with HGF-shRNA, SP600125 or stattic also reduced generation of EGFP(Axin2)+ hepatic cell-originated CD90+ CSCs in aberrant autophagic cirrhotic livers by inactivating HGF/Met/JNK or HGF/Met/STAT3 signaling, further preventing hepatocarcinogenesis.	pyrazolanthrone	35-43	Thy-1 cell surface antigen	Rattus norvegicus	119-123
29081082-7	2017	However, SP600125, a specific JNK (c-Jun N-terminal protein kinase) pathway inhibitor, could attenuate oxygen free radicals levels in CSMCs as well as the anti-apoptotic effects of 14,15-EET under OGD conditions.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Homo sapiens	30-33
29081082-7	2017	However, SP600125, a specific JNK (c-Jun N-terminal protein kinase) pathway inhibitor, could attenuate oxygen free radicals levels in CSMCs as well as the anti-apoptotic effects of 14,15-EET under OGD conditions.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Homo sapiens	35-66
29218082-5	2017	Activities of protein C (PC), protein S (PS), activated PC (APC) were evaluated in cells pre-treated with JNK inhibitor SP600125 and c-Jun silencing.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Mus musculus	106-109
28923349-4	2017	Inhibitors of c-JNK (SP600125) and p38-MAPK (SB203580) attenuated the lipoteichoic acid- or peptidoglycan-induced production of inflammatory mediators, the activation of the JNK and p38-MAPK, and the production of reactive oxygen species in keratinocytes.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	16-19
28923349-4	2017	Inhibitors of c-JNK (SP600125) and p38-MAPK (SB203580) attenuated the lipoteichoic acid- or peptidoglycan-induced production of inflammatory mediators, the activation of the JNK and p38-MAPK, and the production of reactive oxygen species in keratinocytes.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	174-177
28826721-6	2017	Targeting this newly identified AR/EPHB6/JNK signaling with JNK inhibitor (SP600125) may then block/reverse the Enz-increased CRPC cell invasion.	pyrazolanthrone	75-83	EPH receptor B6	Homo sapiens	35-40
28941802-10	2017	In addition, the IL-1beta receptor antagonist IL1RN or the JNK inhibitor SP600125, both restored the down-regulation of RPS27 induced by CFTRinh-172, implying a role of autocrine IL-1beta and JNK signaling downstream of Cl- in RPS27 modulation.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	59-62
28941802-10	2017	In addition, the IL-1beta receptor antagonist IL1RN or the JNK inhibitor SP600125, both restored the down-regulation of RPS27 induced by CFTRinh-172, implying a role of autocrine IL-1beta and JNK signaling downstream of Cl- in RPS27 modulation.	pyrazolanthrone	73-81	ribosomal protein S27	Homo sapiens	120-125
28941802-10	2017	In addition, the IL-1beta receptor antagonist IL1RN or the JNK inhibitor SP600125, both restored the down-regulation of RPS27 induced by CFTRinh-172, implying a role of autocrine IL-1beta and JNK signaling downstream of Cl- in RPS27 modulation.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	192-195
28941802-10	2017	In addition, the IL-1beta receptor antagonist IL1RN or the JNK inhibitor SP600125, both restored the down-regulation of RPS27 induced by CFTRinh-172, implying a role of autocrine IL-1beta and JNK signaling downstream of Cl- in RPS27 modulation.	pyrazolanthrone	73-81	ribosomal protein S27	Homo sapiens	227-232
28826721-6	2017	Targeting this newly identified AR/EPHB6/JNK signaling with JNK inhibitor (SP600125) may then block/reverse the Enz-increased CRPC cell invasion.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	41-44
28826721-6	2017	Targeting this newly identified AR/EPHB6/JNK signaling with JNK inhibitor (SP600125) may then block/reverse the Enz-increased CRPC cell invasion.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	60-63
28063235-9	2017	Moreover, the abundance of adiponectin-activated signaling molecules were suppressed by pharmacological inhibitors including wortmannin, U0126, SP600125, and SB203580, respectively, in pLE cells.	pyrazolanthrone	144-152	adiponectin, C1Q and collagen domain containing	Homo sapiens	27-38
28842171-4	2017	In PC-12 cells, inhibition of JNK by SP600125 (JNK inhibitor) resulted in significantly lower levels of autophagy upon colistin treatment, depending on the expression levels of Beclin1, LC3-II, p62 degradation and reduction in the number of autophagic vacuoles.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	30-33
28842171-4	2017	In PC-12 cells, inhibition of JNK by SP600125 (JNK inhibitor) resulted in significantly lower levels of autophagy upon colistin treatment, depending on the expression levels of Beclin1, LC3-II, p62 degradation and reduction in the number of autophagic vacuoles.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	47-50
28842171-4	2017	In PC-12 cells, inhibition of JNK by SP600125 (JNK inhibitor) resulted in significantly lower levels of autophagy upon colistin treatment, depending on the expression levels of Beclin1, LC3-II, p62 degradation and reduction in the number of autophagic vacuoles.	pyrazolanthrone	37-45	beclin 1	Rattus norvegicus	177-184
28842171-4	2017	In PC-12 cells, inhibition of JNK by SP600125 (JNK inhibitor) resulted in significantly lower levels of autophagy upon colistin treatment, depending on the expression levels of Beclin1, LC3-II, p62 degradation and reduction in the number of autophagic vacuoles.	pyrazolanthrone	37-45	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	194-197
28926773-2	2017	METHODS: Mice corneas were pretreated with Dectin-1 siRNA or SP600125 (the inhibitor of JNK) before A. fumigatus infection.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Mus musculus	88-91
28926773-6	2017	SP600125 treatment before infection significantly inhibited IL-1beta production compared with DMSO control both in mice corneas and THP-1 macrophages.	pyrazolanthrone	0-8	interleukin 1 beta	Mus musculus	60-68
29383102-7	2017	Elevated expression of BANCR induced JNK activation, which can be decreased by the specific JNK inhibitor SP600125.	pyrazolanthrone	106-114	BRAF-activated non-protein coding RNA	Homo sapiens	23-28
29045468-9	2017	The JNK inhibitor SP600125 strongly inhibited Bax expression.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
29045468-9	2017	The JNK inhibitor SP600125 strongly inhibited Bax expression.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Homo sapiens	46-49
29019920-11	2017	The findings from an assay searching for the inhibitor revealed that SB203580 (a specific p38 inhibitor) or SP600125 (a p-JNK inhibitor) attenuated pratol-induced cellular tyrosinase activity whereas PD98059 (an ERK inhibitor) did not.	pyrazolanthrone	108-116	tyrosinase	Mus musculus	172-182
29019920-11	2017	The findings from an assay searching for the inhibitor revealed that SB203580 (a specific p38 inhibitor) or SP600125 (a p-JNK inhibitor) attenuated pratol-induced cellular tyrosinase activity whereas PD98059 (an ERK inhibitor) did not.	pyrazolanthrone	108-116	mitogen-activated protein kinase 1	Mus musculus	212-215
29383102-7	2017	Elevated expression of BANCR induced JNK activation, which can be decreased by the specific JNK inhibitor SP600125.	pyrazolanthrone	106-114	mitogen-activated protein kinase 8	Homo sapiens	37-40
29383102-7	2017	Elevated expression of BANCR induced JNK activation, which can be decreased by the specific JNK inhibitor SP600125.	pyrazolanthrone	106-114	mitogen-activated protein kinase 8	Homo sapiens	92-95
28647646-6	2017	A c-Jun N-terminal kinase (JNK) inhibitor SP600125 was used to evaluate the involvement of JNK pathway in these effects of WNT5A.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
28647646-11	2017	Blockage of the JNK pathway by its inhibitor, SP600125, impaired these effects of WNT5A on chondrocytes.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Rattus norvegicus	16-19
28647646-11	2017	Blockage of the JNK pathway by its inhibitor, SP600125, impaired these effects of WNT5A on chondrocytes.	pyrazolanthrone	46-54	Wnt family member 5A	Rattus norvegicus	82-87
28432555-5	2017	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	20-23
29552055-3	2017	The potential of 1,9-Pyrazoloanthrone (1,9-P), a c-Jun-N-terminal Kinase (JNK-3) inhibitor which could stop or retard the rate of apoptosis of neuronal cells was also evaluated.	pyrazolanthrone	17-37	mitogen-activated protein kinase 10	Homo sapiens	74-79
29552055-3	2017	The potential of 1,9-Pyrazoloanthrone (1,9-P), a c-Jun-N-terminal Kinase (JNK-3) inhibitor which could stop or retard the rate of apoptosis of neuronal cells was also evaluated.	pyrazolanthrone	17-22	mitogen-activated protein kinase 10	Homo sapiens	74-79
28835457-9	2017	The JNK inhibitors SP600125 and AEG3482 strongly decreased intracellular IL-27p28 in F4/80+CD11b+ macrophages.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Mus musculus	4-7
28835457-9	2017	The JNK inhibitors SP600125 and AEG3482 strongly decreased intracellular IL-27p28 in F4/80+CD11b+ macrophages.	pyrazolanthrone	19-27	interleukin 27	Mus musculus	73-81
28835457-9	2017	The JNK inhibitors SP600125 and AEG3482 strongly decreased intracellular IL-27p28 in F4/80+CD11b+ macrophages.	pyrazolanthrone	19-27	adhesion G protein-coupled receptor E1	Mus musculus	85-90
28835457-9	2017	The JNK inhibitors SP600125 and AEG3482 strongly decreased intracellular IL-27p28 in F4/80+CD11b+ macrophages.	pyrazolanthrone	19-27	integrin alpha M	Mus musculus	91-96
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	mitogen-activated protein kinase 1	Homo sapiens	15-59
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	64-87
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	89-92
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	NFKB inhibitor alpha	Homo sapiens	173-186
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	mitogen-activated protein kinase 1	Homo sapiens	54-57
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	277-280
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	mitogen-activated protein kinase 1	Homo sapiens	269-272
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	277-280
29042991-7	2017	Treatment with extracellular signal-regulated kinase (ERK)- and c-Jun N-terminal kinase (JNK)-specific inhibitors U0126 and sp600125, respectively, led to the activation of IkappaB-alpha; however, the inhibitor of IkappaBalpha phosphorylation Bay11-7082 did not affect ERK and JNK activity, suggesting that ERK/JNK signaling occurs upstream of NF-kappaB in VECs.	pyrazolanthrone	124-132	nuclear factor kappa B subunit 1	Homo sapiens	344-353
28432555-5	2017	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	tumor necrosis factor	Homo sapiens	71-80
28432555-5	2017	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	nuclear factor kappa B subunit 1	Homo sapiens	138-147
28432555-5	2017	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	178-181
28432555-5	2017	Inhibitors of the c-JNK (SP600125) and p38-MAPK (SB203580) reduced the TNF-alpha-induced production of inflammatory mediators, binding of NF-kappaB to DNA, and activation of the JNK and p38-MAPK in keratinocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 14	Homo sapiens	186-189
28931802-11	2017	Inhibition of JNK with SP600125 attenuated palmitate-induced apoptosis.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	14-17
29200725-6	2017	After SP600125 (JNK inhibitor) was intrathecally injected in CFA rats, PWTs and PWLs were tested to investigate the change of ligustilide"s analgesic effect.	pyrazolanthrone	6-14	mitogen-activated protein kinase 8	Rattus norvegicus	16-19
28637660-6	2017	Furthermore, treatment with pharmacological inhibitors against ERK1/2 (PD98059), JNK (SP600125), or NF-kappaB (BAY11-7085) significantly suppressed IL-33-induced GRO-alpha gene expression and secretion from HUVECs.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	81-84
28389245-7	2017	The activation of JNK and p38 was also critical for thymol-induced apoptosis since it was abrogated by the treatment of JNK inhibitor (SP600125), and p38 inhibitor (SB203580) but not ERK inhibitor (SCH772984).	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	18-21
28389245-7	2017	The activation of JNK and p38 was also critical for thymol-induced apoptosis since it was abrogated by the treatment of JNK inhibitor (SP600125), and p38 inhibitor (SB203580) but not ERK inhibitor (SCH772984).	pyrazolanthrone	135-143	mitogen-activated protein kinase 14	Homo sapiens	26-29
28389245-7	2017	The activation of JNK and p38 was also critical for thymol-induced apoptosis since it was abrogated by the treatment of JNK inhibitor (SP600125), and p38 inhibitor (SB203580) but not ERK inhibitor (SCH772984).	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	120-123
28979136-4	2017	Interfering peptide 11R-DEP:611-628 and JNK inhibitor SP600125 were used alone or in combination to treat A549 cells, and the cell proliferation and apoptosis were assessed by flow cytometry assay; caspase 3 and cleaved caspase 3, phosphor-JNK, and total JNK were detected by Western blotting; and nuclear factor kappa B (NF-kappaB) localization was determined by immunofluorescence staining.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	40-43
28733031-6	2017	Serum and LTbetaR antibody activated the MKK4-JNK signaling pathway, and SP600125, a JNK inhibitor, blocked p100 processing.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Mus musculus	85-88
29245930-9	2017	Finally, HMNQ increased expression of JNK phosphorylation and the JNK inhibitor SP600125 rescued HMNQ-induced cell death, suggesting that the cytotoxicity of HMNQ is mediated by the JNK signaling pathway.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Homo sapiens	66-69
29245930-9	2017	Finally, HMNQ increased expression of JNK phosphorylation and the JNK inhibitor SP600125 rescued HMNQ-induced cell death, suggesting that the cytotoxicity of HMNQ is mediated by the JNK signaling pathway.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Homo sapiens	66-69
28891980-8	2017	The ROS antioxidant N-acetylcysteine (NAC), the Akt-specific activator insulin-like growth factor-1 (IGF-1) and the JNK-specific inhibitor SP600125 attenuated SH-induced autophagy.	pyrazolanthrone	139-147	mitogen-activated protein kinase 8	Homo sapiens	116-119
28637660-6	2017	Furthermore, treatment with pharmacological inhibitors against ERK1/2 (PD98059), JNK (SP600125), or NF-kappaB (BAY11-7085) significantly suppressed IL-33-induced GRO-alpha gene expression and secretion from HUVECs.	pyrazolanthrone	86-94	interleukin 33	Homo sapiens	148-153
28637660-6	2017	Furthermore, treatment with pharmacological inhibitors against ERK1/2 (PD98059), JNK (SP600125), or NF-kappaB (BAY11-7085) significantly suppressed IL-33-induced GRO-alpha gene expression and secretion from HUVECs.	pyrazolanthrone	86-94	C-X-C motif chemokine ligand 1	Homo sapiens	162-171
28803608-4	2017	Moreover, the JNK inhibitor SP600125 significantly inhibited the upregulation of NDRG1 and IDI protein levels by combination treatment of docetaxel and simvastatin.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	14-17
28803608-4	2017	Moreover, the JNK inhibitor SP600125 significantly inhibited the upregulation of NDRG1 and IDI protein levels by combination treatment of docetaxel and simvastatin.	pyrazolanthrone	28-36	N-myc downstream regulated 1	Homo sapiens	81-86
28656272-12	2017	Furthermore, M-CSF induced the phosphorylation of c-Jun N-terminal kinase (JNK) and p38; however, the level of E2 in the medium was not altered when the cells were pretreated with the JNK inhibitor SP600125 or the p38 inhibitor SB203580.	pyrazolanthrone	198-206	colony stimulating factor 1	Homo sapiens	13-18
27766421-10	2017	Furthermore, the addition of FGF7 augmented mineralization in the cells with increased expression of osteogenic markers, and this augmentation was significantly suppressed by an inhibitor specific for c-Jun N-terminal kinase (SP600125) or extracellular-signal-regulated kinase (PD98059).	pyrazolanthrone	226-234	fibroblast growth factor 7	Rattus norvegicus	29-33
28656249-8	2017	Furthermore, ROS, and activation of p38, JNK and c-Jun, were revealed to serve pro-apoptosis roles which aggravated damage to epithelial barrier integrity, as assessed by flow cytometry using Annexin V-fluorescein isothiocyanate staining and pretreatment of cells with specific inhibitors of ROS, JNK, p38 and c-Jun (BHA, SP600125, SB203580 and c-Jun peptide, respectively).	pyrazolanthrone	322-330	mitogen activated protein kinase 14	Rattus norvegicus	36-39
28962172-15	2017	Phospho-ERK, p38 and JNK were markedly increased by psoralen compared with the control group (P&lt;0.05), and the specific inhibitors of ERK (SCH772984), p38 (SB203580) and JNK (SP600125) reversed the stimulatory effects of psoralen on signal marker phosphorylation (P&lt;0.05).	pyrazolanthrone	178-186	mitogen-activated protein kinase 14	Homo sapiens	154-157
28656272-12	2017	Furthermore, M-CSF induced the phosphorylation of c-Jun N-terminal kinase (JNK) and p38; however, the level of E2 in the medium was not altered when the cells were pretreated with the JNK inhibitor SP600125 or the p38 inhibitor SB203580.	pyrazolanthrone	198-206	mitogen-activated protein kinase 8	Homo sapiens	75-78
28656272-12	2017	Furthermore, M-CSF induced the phosphorylation of c-Jun N-terminal kinase (JNK) and p38; however, the level of E2 in the medium was not altered when the cells were pretreated with the JNK inhibitor SP600125 or the p38 inhibitor SB203580.	pyrazolanthrone	198-206	mitogen-activated protein kinase 8	Homo sapiens	184-187
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	pyrazolanthrone	233-241	apolipoprotein H	Homo sapiens	19-27
28101818-6	2017	TRAIL-induced ATG expression was attenuated by JNK silencing or treatment with the JNK inhibitor SP600125, indicating the involvement of the JNK pathway.	pyrazolanthrone	97-105	TNF superfamily member 10	Homo sapiens	0-5
28101818-6	2017	TRAIL-induced ATG expression was attenuated by JNK silencing or treatment with the JNK inhibitor SP600125, indicating the involvement of the JNK pathway.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Homo sapiens	83-86
28101818-6	2017	TRAIL-induced ATG expression was attenuated by JNK silencing or treatment with the JNK inhibitor SP600125, indicating the involvement of the JNK pathway.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Homo sapiens	83-86
28842382-9	2017	MLA (100nM), PD98059 (an ERK inhibitor; 20muM), SB203580 (a p38 inhibitor; 20muM) and SP600125 (a JNK inhibitor; 20muM) also blocked cell migration and varenicline-induced downregulation of VE-cadherin expression in HUVECs.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	98-101
28677786-8	2017	Furthermore, LPS-stimulation significantly upregulated HMGB-1 secretion via the c-Jun N-terminal kinase (JNK) signaling pathway in RAW264.7 macrophages, whereas pretreatment with the JNK inhibitor SP600125 markedly downregulated LPS-induced HMGB-1 levels.	pyrazolanthrone	197-205	high mobility group box 1	Homo sapiens	55-61
28677786-8	2017	Furthermore, LPS-stimulation significantly upregulated HMGB-1 secretion via the c-Jun N-terminal kinase (JNK) signaling pathway in RAW264.7 macrophages, whereas pretreatment with the JNK inhibitor SP600125 markedly downregulated LPS-induced HMGB-1 levels.	pyrazolanthrone	197-205	mitogen-activated protein kinase 8	Homo sapiens	183-186
28713943-4	2017	Treatment with the JNK pathway inhibitor, SP600125, at a concentration of 11 microM, decreased the mRNA expression levels of mdr1 and P-gp, as determined using reverse transcription-quantitative polymerase chain reaction and western blot analyses, and similar effects were observed following exposure to ASIV.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	19-22
28713943-4	2017	Treatment with the JNK pathway inhibitor, SP600125, at a concentration of 11 microM, decreased the mRNA expression levels of mdr1 and P-gp, as determined using reverse transcription-quantitative polymerase chain reaction and western blot analyses, and similar effects were observed following exposure to ASIV.	pyrazolanthrone	42-50	ATP binding cassette subfamily B member 1	Homo sapiens	125-129
28713943-5	2017	Furthermore, electrophoretic mobility shift assays demonstrated that the DNA-binding activity of activator protein-1 (AP-1) was decreased by 0.1 mM ASIV or 11 microM SP600125.	pyrazolanthrone	166-174	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	118-122
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	pyrazolanthrone	233-241	apolipoprotein H	Homo sapiens	28-36
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	pyrazolanthrone	233-241	apolipoprotein H	Homo sapiens	28-36
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	pyrazolanthrone	233-241	mechanistic target of rapamycin kinase	Homo sapiens	92-96
28734155-8	2017	Moreover, the anti-beta2GPI/beta2GPI or APS-IgG/beta2GPI complex-induced phosphorylation of mTOR in THP-1 cells was down-regulated through inhibition of p38 (10muM, SB203580) or ERK (5muM, U0126) rather than inhibition of JNK (90nM, SP600125) or NF-kappaB (20muM, PDTC).	pyrazolanthrone	233-241	mitogen-activated protein kinase 1	Homo sapiens	153-156
28552569-8	2017	Alcohol activates JNK1 to upregulate transcription of Brf1 and Pol III genes, whereas inhibition of JNK1 by SP600125 or its siRNA significantly decreases the induction of these genes.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	100-104
28859160-11	2017	And the JNK inhibitor, SP600125 markedly blocked IGFBP2-mediated Akt activation.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	8-11
28859160-11	2017	And the JNK inhibitor, SP600125 markedly blocked IGFBP2-mediated Akt activation.	pyrazolanthrone	23-31	insulin like growth factor binding protein 2	Homo sapiens	49-55
28859160-11	2017	And the JNK inhibitor, SP600125 markedly blocked IGFBP2-mediated Akt activation.	pyrazolanthrone	23-31	AKT serine/threonine kinase 1	Homo sapiens	65-68
28838336-14	2017	Compared with As group, phosphorylation of JNK was lower in the SP600125/As group, phosphorylation of JNK in SP600125/Ms group was lower than the Ms group, and it showed no differences between the SP600125 &amp;amp; As group and the SP600125 &amp;amp; Ms group.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Rattus norvegicus	43-46
28838336-14	2017	Compared with As group, phosphorylation of JNK was lower in the SP600125/As group, phosphorylation of JNK in SP600125/Ms group was lower than the Ms group, and it showed no differences between the SP600125 &amp;amp; As group and the SP600125 &amp;amp; Ms group.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Rattus norvegicus	102-105
28838336-14	2017	Compared with As group, phosphorylation of JNK was lower in the SP600125/As group, phosphorylation of JNK in SP600125/Ms group was lower than the Ms group, and it showed no differences between the SP600125 &amp;amp; As group and the SP600125 &amp;amp; Ms group.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Rattus norvegicus	102-105
28838336-14	2017	Compared with As group, phosphorylation of JNK was lower in the SP600125/As group, phosphorylation of JNK in SP600125/Ms group was lower than the Ms group, and it showed no differences between the SP600125 &amp;amp; As group and the SP600125 &amp;amp; Ms group.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Rattus norvegicus	102-105
28947973-4	2017	Hyperbaric oxygen might plays similar roles with the JNK-specific inhibitor SP600125, inducing the increase of Sox-9 and COL2 expression.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Rattus norvegicus	53-56
28583366-8	2017	Pre-treatment with n-acetyl-l-cysteine (NAC), a ROS scavenger, enhanced PTX-mediated cell cycle arrest, apoptosis and the JNK and ERK MAPK activation, while pre-treatment with SP600125 or PD98509 attenuated PTX-mediated effects in HepG2 cells.	pyrazolanthrone	176-184	X-linked Kx blood group	Homo sapiens	40-43
28597042-7	2017	Preincubation with JNK-specific inhibitor, SP600125, significantly inhibited these genes" expression at mRNA and protein levels, enhanced chemosensitivity of lung cancer cells to cisplatin, and promoted cisplatin-induced apoptosis.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	19-22
28651835-8	2017	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed Andro-induced decrease in the expression of HIF-1alpha and VEGFA, but not MTA1 and HDAC1.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-49
28651835-8	2017	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed Andro-induced decrease in the expression of HIF-1alpha and VEGFA, but not MTA1 and HDAC1.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	51-54
28651835-8	2017	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed Andro-induced decrease in the expression of HIF-1alpha and VEGFA, but not MTA1 and HDAC1.	pyrazolanthrone	0-8	hypoxia inducible factor 1 subunit alpha	Homo sapiens	110-120
28651835-8	2017	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed Andro-induced decrease in the expression of HIF-1alpha and VEGFA, but not MTA1 and HDAC1.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Homo sapiens	125-130
28474156-0	2017	JNK Inhibitor SP600125 Attenuates Paraquat-Induced Acute Lung Injury: an In Vivo and In Vitro Study.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
28474156-13	2017	JNK inhibitor SP600125 reduced JNK phosphorylation, downregulated cleaved caspase-3 protein level, decreased AP-1 transcriptional activity and ROS level, and reduced the transcription and expression of TNF-alpha and IL-6, which improved ALI and cell apoptosis after paraquat poisoning.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
28474156-13	2017	JNK inhibitor SP600125 reduced JNK phosphorylation, downregulated cleaved caspase-3 protein level, decreased AP-1 transcriptional activity and ROS level, and reduced the transcription and expression of TNF-alpha and IL-6, which improved ALI and cell apoptosis after paraquat poisoning.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	31-34
28474156-13	2017	JNK inhibitor SP600125 reduced JNK phosphorylation, downregulated cleaved caspase-3 protein level, decreased AP-1 transcriptional activity and ROS level, and reduced the transcription and expression of TNF-alpha and IL-6, which improved ALI and cell apoptosis after paraquat poisoning.	pyrazolanthrone	14-22	tumor necrosis factor	Homo sapiens	202-211
28474156-13	2017	JNK inhibitor SP600125 reduced JNK phosphorylation, downregulated cleaved caspase-3 protein level, decreased AP-1 transcriptional activity and ROS level, and reduced the transcription and expression of TNF-alpha and IL-6, which improved ALI and cell apoptosis after paraquat poisoning.	pyrazolanthrone	14-22	interleukin 6	Homo sapiens	216-220
28505368-7	2017	Additionally, pretreatment with SP600125 or restoration of FXR expression in liver by use of recombinant adenovirus, attenuated CCl4-induced liver injury.	pyrazolanthrone	32-40	chemokine (C-C motif) ligand 4	Mus musculus	128-132
29050275-7	2017	A ROS scavenger, N-acetylcysteine (NAC) and a JNK-specific inhibitor, SP600125 attenuated AB23A-induced autophagy and apoptotic cell death.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	46-49
28720813-7	2017	The addition of SP600125 to both cell lines increased the cleavage of caspase 3 and PARP, but did not affect the G0/G1 arrest.	pyrazolanthrone	16-24	caspase 3	Homo sapiens	70-79
28720813-7	2017	The addition of SP600125 to both cell lines increased the cleavage of caspase 3 and PARP, but did not affect the G0/G1 arrest.	pyrazolanthrone	16-24	collagen type XI alpha 2 chain	Homo sapiens	84-88
28701229-10	2017	Anti-TNF-alpha could downregulate activation of JNK, and SP600125 could downregulate expression of TNF-alpha in the kidneys.	pyrazolanthrone	57-65	tumor necrosis factor	Homo sapiens	99-108
28507277-8	2017	Besides, si-JNK or JNK inhibitor SP600125 affected the activation of Notch1 signaling pathway, and prevents cell apoptosis.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
28507277-8	2017	Besides, si-JNK or JNK inhibitor SP600125 affected the activation of Notch1 signaling pathway, and prevents cell apoptosis.	pyrazolanthrone	33-41	notch receptor 1	Homo sapiens	69-75
28680052-7	2017	JNK1/2 inhibition with SP600125, or siRNA AQP5 gene silencing reduced hypertonic-induced rises in proinflammatory cytokine expression and cell death.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	0-4
28478520-3	2017	Other forty rats were assigned to SAL group, AFG group, LY group (PKCbeta inhibitor LY333531 was injected intragastrically to the rats who were under acute blood glucose fluctuation) and SP group (JNK inhibitor SP600125 was injected intraperitoneally to the rats who were under acute blood glucose fluctuation).	pyrazolanthrone	211-219	mitogen-activated protein kinase 8	Rattus norvegicus	197-200
28789411-4	2017	Notably, JNK inhibition by SP600125 also reduced cell growth.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	9-12
28505368-6	2017	Treatment of Fxr-null hepatocytes with TCA, but not T-beta-MCA, significantly increased c-Jun-N-terminal kinase (JNK) activation and Ccl2 mRNA levels, and up-regulation of Ccl2 mRNA was attenuated by co-treatment with a JNK inhibitor SP600125, indicating that TCA directly amplifies hepatocyte inflammatory signaling mainly mediated by JNK under FXR-deficiency.	pyrazolanthrone	234-242	nuclear receptor subfamily 1, group H, member 4	Mus musculus	13-16
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Mus musculus	15-18
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	interleukin 6	Mus musculus	101-105
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	aconitase 1	Mus musculus	174-178
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	solute carrier family 11 (proton-coupled divalent metal ion transporters), member 2	Mus musculus	183-187
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	solute carrier family 40 (iron-regulated transporter), member 1	Mus musculus	211-215
28672025-7	2017	Phosphorylated JNK increased significantly compared to the control after BV2 cells were treated with IL-6 for 1 h. Pretreatment with SP600125 attenuated the up-regulation of IRP1 and DMT1 and down-regulation of FPN1 (compared to IL-6-treated group).	pyrazolanthrone	133-141	interleukin 6	Mus musculus	229-233
28947973-4	2017	Hyperbaric oxygen might plays similar roles with the JNK-specific inhibitor SP600125, inducing the increase of Sox-9 and COL2 expression.	pyrazolanthrone	76-84	SRY-box transcription factor 9	Rattus norvegicus	111-116
28414098-9	2017	Both calcium chelator BAPTA-AM and JNK inhibitor SP600125 could attenuate necroptotic features, including mitochondrial ROS elevation, mitochondrial depolarization, and ATP depletion.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	35-38
28430744-13	2017	The JNK inhibitor SP600125 inhibited GEM-induced autophagy activation and increased GEM"s cytotoxicity.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
28672972-6	2017	This finding was confirmed by the use of JNK-specific inhibitor, SP600125.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	41-44
28427999-7	2017	Finally, rats were treated with ERK1/2 inhibitor U0126, p38 MAPK inhibitor SB20358, or JNK inhibitor SP600125 after rSB1 pretreatment and then subjected to OALT.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Rattus norvegicus	87-90
28414095-8	2017	Furthermore, the phosphorylation of ERK1/2 induced by the JNK inhibitor SP600125 inhibited the basal activity of Akt, which normally supported cell viability.	pyrazolanthrone	72-80	mitogen activated protein kinase 3	Rattus norvegicus	36-42
27181592-8	2017	Either attenuation of intracellular ROS with antioxidant NAC or inhibition of JNK phosphorylation with SP600125 or JNK siRNA could significantly prevent H2O2-induced parthanatos in glioma cells.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	78-81
27181592-9	2017	Additionally, inhibition of JNK with SP600125 alleviated intracellular accumulation of ROS and attenuated mitochondrial generation of superoxide.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	28-31
28498464-5	2017	Furthermore, S100A8/A9 markedly enhanced the nuclear translocation of NF-kappaB p65 and the DNA-binding activities of NF-kappaB in BV-2 microglial cells, and suppression of ERK and JNK/MAPK signaling pathways by PD98059 or SP600125 significantly inhibited NF-kappaB activity and the release of TNF-alpha and IL-6 in the S100A8/A9-treated BV-2 microglial cells.	pyrazolanthrone	223-231	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	13-19
28498464-5	2017	Furthermore, S100A8/A9 markedly enhanced the nuclear translocation of NF-kappaB p65 and the DNA-binding activities of NF-kappaB in BV-2 microglial cells, and suppression of ERK and JNK/MAPK signaling pathways by PD98059 or SP600125 significantly inhibited NF-kappaB activity and the release of TNF-alpha and IL-6 in the S100A8/A9-treated BV-2 microglial cells.	pyrazolanthrone	223-231	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	70-79
28414095-8	2017	Furthermore, the phosphorylation of ERK1/2 induced by the JNK inhibitor SP600125 inhibited the basal activity of Akt, which normally supported cell viability.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Rattus norvegicus	58-61
28414095-8	2017	Furthermore, the phosphorylation of ERK1/2 induced by the JNK inhibitor SP600125 inhibited the basal activity of Akt, which normally supported cell viability.	pyrazolanthrone	72-80	AKT serine/threonine kinase 1	Rattus norvegicus	113-116
28455228-5	2017	However, SP600125 could not only abrogated the JNK activation caused by brusatol, but also reverse the p38 activation and the decrease of Bcl-2 as SB203580 did.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Homo sapiens	47-50
28730070-8	2017	Various signal pathway inhibitors, including SP600125 (JNK inhibitor), SB203580 (p38 MAPK inhibitor) and BAY11-7082 (NF-kappaB inhibitor) significantly decreased the UVB-induced secretion of IL-6 and IL-8 secretion (P&lt;0.05).	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	55-58
28730070-8	2017	Various signal pathway inhibitors, including SP600125 (JNK inhibitor), SB203580 (p38 MAPK inhibitor) and BAY11-7082 (NF-kappaB inhibitor) significantly decreased the UVB-induced secretion of IL-6 and IL-8 secretion (P&lt;0.05).	pyrazolanthrone	45-53	interleukin 6	Homo sapiens	191-195
28455228-5	2017	However, SP600125 could not only abrogated the JNK activation caused by brusatol, but also reverse the p38 activation and the decrease of Bcl-2 as SB203580 did.	pyrazolanthrone	9-17	mitogen-activated protein kinase 14	Homo sapiens	103-106
28455228-5	2017	However, SP600125 could not only abrogated the JNK activation caused by brusatol, but also reverse the p38 activation and the decrease of Bcl-2 as SB203580 did.	pyrazolanthrone	9-17	BCL2 apoptosis regulator	Homo sapiens	138-143
28455228-6	2017	Besides, SP600125 and SB203580 also reversed the inactivation of NF-kappab and Stat3.	pyrazolanthrone	9-17	nuclear factor kappa B subunit 1	Homo sapiens	65-74
28455228-6	2017	Besides, SP600125 and SB203580 also reversed the inactivation of NF-kappab and Stat3.	pyrazolanthrone	9-17	signal transducer and activator of transcription 3	Homo sapiens	79-84
29931897-7	2017	SP600125 reduced p-JNK protein expression, and enhanced GSH-Px activity significantly.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	19-22
28449039-12	2017	In addition, apoptosis induced by the PPI was remarkably suppressed by the JNK inhibitor SP600125.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	75-78
28590410-7	2017	Furthermore, the effect of resveratrol on the levels of MITF and tyrosinase was suppressed when melanocytes were pre-treated with SP600125 (JNK inhibitor).	pyrazolanthrone	130-138	melanocyte inducing transcription factor	Homo sapiens	56-60
28590410-7	2017	Furthermore, the effect of resveratrol on the levels of MITF and tyrosinase was suppressed when melanocytes were pre-treated with SP600125 (JNK inhibitor).	pyrazolanthrone	130-138	tyrosinase	Homo sapiens	65-75
28590410-7	2017	Furthermore, the effect of resveratrol on the levels of MITF and tyrosinase was suppressed when melanocytes were pre-treated with SP600125 (JNK inhibitor).	pyrazolanthrone	130-138	mitogen-activated protein kinase 8	Homo sapiens	140-143
28111233-9	2017	Furthermore, JNK inhibitor SP600125 was shown to promote the effect of CtBP2 on insulin signaling.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	13-16
28756921-2	2017	METHODS: Cervical cancer Hela cells were cultured and treated with different dosages of juglone (10, 20, and 40 mumol/L, respectively) and c-Jun N-terminal kinase (JNK) inhibitor SP600125 (10, 20, and 40 mumol/L, respectively).	pyrazolanthrone	179-187	mitogen-activated protein kinase 8	Homo sapiens	164-167
28756921-6	2017	In cells treated with 40 mumol/L juglone and SP600125, the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 were significantly lower than those of cells treated with 40 mumol/L juglone (P &lt; 0.05), and the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 reduced more remarkably as the SP600125 dosage increased (P &lt; 0.05).	pyrazolanthrone	45-53	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
28756921-6	2017	In cells treated with 40 mumol/L juglone and SP600125, the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 were significantly lower than those of cells treated with 40 mumol/L juglone (P &lt; 0.05), and the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 reduced more remarkably as the SP600125 dosage increased (P &lt; 0.05).	pyrazolanthrone	45-53	Fas ligand	Homo sapiens	98-102
28756921-6	2017	In cells treated with 40 mumol/L juglone and SP600125, the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 were significantly lower than those of cells treated with 40 mumol/L juglone (P &lt; 0.05), and the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 reduced more remarkably as the SP600125 dosage increased (P &lt; 0.05).	pyrazolanthrone	45-53	caspase 3	Homo sapiens	107-116
28756921-6	2017	In cells treated with 40 mumol/L juglone and SP600125, the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 were significantly lower than those of cells treated with 40 mumol/L juglone (P &lt; 0.05), and the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 reduced more remarkably as the SP600125 dosage increased (P &lt; 0.05).	pyrazolanthrone	45-53	BCL2 associated X, apoptosis regulator	Homo sapiens	240-243
28756921-6	2017	In cells treated with 40 mumol/L juglone and SP600125, the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 were significantly lower than those of cells treated with 40 mumol/L juglone (P &lt; 0.05), and the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 reduced more remarkably as the SP600125 dosage increased (P &lt; 0.05).	pyrazolanthrone	45-53	Fas ligand	Homo sapiens	256-260
28756921-6	2017	In cells treated with 40 mumol/L juglone and SP600125, the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 were significantly lower than those of cells treated with 40 mumol/L juglone (P &lt; 0.05), and the protein expressions of Bax, CytC, Fas, FasL and Caspase-3 reduced more remarkably as the SP600125 dosage increased (P &lt; 0.05).	pyrazolanthrone	45-53	caspase 3	Homo sapiens	265-274
28111233-9	2017	Furthermore, JNK inhibitor SP600125 was shown to promote the effect of CtBP2 on insulin signaling.	pyrazolanthrone	27-35	C-terminal binding protein 2	Homo sapiens	71-76
28111233-9	2017	Furthermore, JNK inhibitor SP600125 was shown to promote the effect of CtBP2 on insulin signaling.	pyrazolanthrone	27-35	insulin	Homo sapiens	80-87
27775163-8	2017	Moreover, phosphorylation of AKT, ERK1/2, P38, and JNK proteins were suppressed by their inhibitors wortmannin, U0126, SB203580, and SP600125, respectively.	pyrazolanthrone	133-141	AKT serine/threonine kinase 1	Sus scrofa	29-32
27775163-8	2017	Moreover, phosphorylation of AKT, ERK1/2, P38, and JNK proteins were suppressed by their inhibitors wortmannin, U0126, SB203580, and SP600125, respectively.	pyrazolanthrone	133-141	mitogen-activated protein kinase 3	Sus scrofa	34-40
28537766-7	2017	Inhibitors of AKT (LY294002), ERK1/2 (U0126), and JNK (SP600125) arrested the G1/S transition, similar to the effect of pirfenidone.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	50-53
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	pyrazolanthrone	94-102	cyclin dependent kinase 2	Homo sapiens	18-22
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	pyrazolanthrone	94-102	cyclin dependent kinase 6	Homo sapiens	24-28
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	pyrazolanthrone	94-102	cyclin D1	Homo sapiens	30-39
28537766-9	2017	The expression of CDK2, CDK6, cyclin D1, and cyclin D3 were inhibited by LY294002, U0126, and SP600125.	pyrazolanthrone	94-102	cyclin D3	Homo sapiens	45-54
28546532-7	2017	After JNK specific inhibitor (SP600125) was added, EOCs apoptosis protein expressions were measured by Western blot analysis.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	6-9
26651837-13	2017	Blockade of JNK, an upstream effector of c-Jun by specific inhibitor SP600125 did not fully protect from ET-1 mediated activation of pro-apoptotic enzymes in primary hippocampal cells.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	12-15
26651837-13	2017	Blockade of JNK, an upstream effector of c-Jun by specific inhibitor SP600125 did not fully protect from ET-1 mediated activation of pro-apoptotic enzymes in primary hippocampal cells.	pyrazolanthrone	69-77	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	41-46
28618937-9	2017	Hypoxia-induced invasion of A549 cells was inhibited by the pharmacologic inhibitors of c-Jun N-terminal kinase (SP600125) and extracellular signal-regulated protein kinase (U0126) as well as 37-kDa laminin receptor precursor-specific siRNA or antibody.	pyrazolanthrone	113-121	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	88-93
28487977-8	2017	Application of SP600125, an inhibitor of a key regulator of cell migration c-Jun N-terminal kinase (JNK), inhibited the migration of normal cells.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	75-98
28487977-8	2017	Application of SP600125, an inhibitor of a key regulator of cell migration c-Jun N-terminal kinase (JNK), inhibited the migration of normal cells.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	100-103
28618937-3	2017	In addition, we further demonstrated that the c-Jun N-terminal kinase inhibitor SP600125 and extracellular signal-regulated protein kinase inhibitor U0126 blocked the c-Jun activity and abolished hypoxia-induced 37-kDa laminin receptor precursor expression and promoter activity in a concentration-dependent manner.	pyrazolanthrone	80-88	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	46-51
28618937-3	2017	In addition, we further demonstrated that the c-Jun N-terminal kinase inhibitor SP600125 and extracellular signal-regulated protein kinase inhibitor U0126 blocked the c-Jun activity and abolished hypoxia-induced 37-kDa laminin receptor precursor expression and promoter activity in a concentration-dependent manner.	pyrazolanthrone	80-88	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	167-172
28618937-3	2017	In addition, we further demonstrated that the c-Jun N-terminal kinase inhibitor SP600125 and extracellular signal-regulated protein kinase inhibitor U0126 blocked the c-Jun activity and abolished hypoxia-induced 37-kDa laminin receptor precursor expression and promoter activity in a concentration-dependent manner.	pyrazolanthrone	80-88	ribosomal protein SA	Homo sapiens	212-235
28618937-6	2017	The inhibition of 37-kDa laminin receptor precursor expression by SP600125 and U0126 could be rescued by c-Jun overexpression.	pyrazolanthrone	66-74	ribosomal protein SA	Homo sapiens	18-41
28618937-6	2017	The inhibition of 37-kDa laminin receptor precursor expression by SP600125 and U0126 could be rescued by c-Jun overexpression.	pyrazolanthrone	66-74	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	105-110
28535665-8	2017	Further, exposure to a JNK inhibitor (SP600125) decreased migration and invasion of EGI-1 cells.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	23-26
28546532-11	2017	Supplementation of JNK-specific inhibitor (SP600125) decreased expression of Bax and cleaved caspase 3/9, and alleviated ADMA-induced apoptosis.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	19-22
28546532-11	2017	Supplementation of JNK-specific inhibitor (SP600125) decreased expression of Bax and cleaved caspase 3/9, and alleviated ADMA-induced apoptosis.	pyrazolanthrone	43-51	BCL2 associated X, apoptosis regulator	Homo sapiens	77-80
28336411-9	2017	The JNK inhibitor SP600125 eliminated spatial memory retrieval impairment, hippocampal CA1 LTD enhancement and the decreased glutamate uptake caused by acute stress, indicating that exogenous H2S exerts these roles by inhibiting the activation of JNK signaling pathway.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
28542135-6	2017	The specific inhibitors U0126, SP600125 and SB202190 attenuated the expression of MAPKs, and regulated the expression of cleaved caspase-8, -9 and -3.	pyrazolanthrone	31-39	caspase 8	Homo sapiens	129-149
28526886-8	2017	JNK was suppressed by SP600125 or Jnk siRNA.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Mus musculus	0-3
28336411-9	2017	The JNK inhibitor SP600125 eliminated spatial memory retrieval impairment, hippocampal CA1 LTD enhancement and the decreased glutamate uptake caused by acute stress, indicating that exogenous H2S exerts these roles by inhibiting the activation of JNK signaling pathway.	pyrazolanthrone	18-26	carbonic anhydrase 1	Homo sapiens	87-90
28336411-9	2017	The JNK inhibitor SP600125 eliminated spatial memory retrieval impairment, hippocampal CA1 LTD enhancement and the decreased glutamate uptake caused by acute stress, indicating that exogenous H2S exerts these roles by inhibiting the activation of JNK signaling pathway.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	247-250
27488855-12	2017	Furthermore, pretreatment with SP600125 (an inhibitor of JNK) diminished the phosphorylation of JNK3 and c-Jun, and further inhibited the activation of caspase-3 after cerebral I/R.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
28656059-11	2017	We also defined the decreased p21 ubiquitination and differentiation ability were reversed after treatment with JNK inhibitor, SP600125 in PARK2 KO mice derived neural stem cells.	pyrazolanthrone	127-135	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	30-33
28656059-11	2017	We also defined the decreased p21 ubiquitination and differentiation ability were reversed after treatment with JNK inhibitor, SP600125 in PARK2 KO mice derived neural stem cells.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Mus musculus	112-115
28656059-11	2017	We also defined the decreased p21 ubiquitination and differentiation ability were reversed after treatment with JNK inhibitor, SP600125 in PARK2 KO mice derived neural stem cells.	pyrazolanthrone	127-135	parkin RBR E3 ubiquitin protein ligase	Mus musculus	139-144
28237815-8	2017	Administration of JNK inhibitor SP600125 significantly decreased seizure frequency in a dose-dependent manner without causing overt behavioral abnormalities.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	18-21
28188818-4	2017	JNK1/2 inhibitor, SP600125, was used to investigate the role of JNK1/2 signaling in the BALB/c mouse model of DENV-induced liver injury.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	0-6
28188818-4	2017	JNK1/2 inhibitor, SP600125, was used to investigate the role of JNK1/2 signaling in the BALB/c mouse model of DENV-induced liver injury.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	0-4
27488855-12	2017	Furthermore, pretreatment with SP600125 (an inhibitor of JNK) diminished the phosphorylation of JNK3 and c-Jun, and further inhibited the activation of caspase-3 after cerebral I/R.	pyrazolanthrone	31-39	mitogen activated protein kinase 10	Rattus norvegicus	96-100
27488855-12	2017	Furthermore, pretreatment with SP600125 (an inhibitor of JNK) diminished the phosphorylation of JNK3 and c-Jun, and further inhibited the activation of caspase-3 after cerebral I/R.	pyrazolanthrone	31-39	caspase 3	Rattus norvegicus	152-161
28238946-7	2017	Furthermore, metformin significantly suppresses the phosphorylation of AMPK and JNK, and the suppression of carboxylesterases induced by metformin is repeatedly abolished by AMPK inhibitor Compound C and JNK inhibitor SP600125.	pyrazolanthrone	218-226	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	71-75
28238946-7	2017	Furthermore, metformin significantly suppresses the phosphorylation of AMPK and JNK, and the suppression of carboxylesterases induced by metformin is repeatedly abolished by AMPK inhibitor Compound C and JNK inhibitor SP600125.	pyrazolanthrone	218-226	mitogen-activated protein kinase 8	Homo sapiens	80-83
28238946-7	2017	Furthermore, metformin significantly suppresses the phosphorylation of AMPK and JNK, and the suppression of carboxylesterases induced by metformin is repeatedly abolished by AMPK inhibitor Compound C and JNK inhibitor SP600125.	pyrazolanthrone	218-226	carboxylesterase 1D	Mus musculus	108-125
28238946-7	2017	Furthermore, metformin significantly suppresses the phosphorylation of AMPK and JNK, and the suppression of carboxylesterases induced by metformin is repeatedly abolished by AMPK inhibitor Compound C and JNK inhibitor SP600125.	pyrazolanthrone	218-226	protein kinase AMP-activated catalytic subunit alpha 1	Homo sapiens	174-178
28238946-7	2017	Furthermore, metformin significantly suppresses the phosphorylation of AMPK and JNK, and the suppression of carboxylesterases induced by metformin is repeatedly abolished by AMPK inhibitor Compound C and JNK inhibitor SP600125.	pyrazolanthrone	218-226	mitogen-activated protein kinase 8	Homo sapiens	204-207
28339087-8	2017	Notably, in LmcMF cells, both KRasV12-CM and HB-EGF activated extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK), whereas KRasV12-CM-induced migration of IMFs was suppressed following treatment with either an ERK inhibitor (FR180204) or a JNK inhibitor (SP600125).	pyrazolanthrone	281-289	heparin-binding EGF-like growth factor	Mus musculus	45-51
27645622-11	2017	Hypoxia increased, whereas the TRB3-mut plasmid, SP600125, and TNF-alpha antibody abolished the hypoxia-induced TRB3 promoter activity.	pyrazolanthrone	49-57	tribbles pseudokinase 3	Rattus norvegicus	112-116
28387244-7	2017	Cotreatment of cells with the JNK inhibitor SP600125 considerably attenuated MT-6-induced apoptosis, mitochondria membrane potential loss, DR5 upregulation, and suppression of cell viability.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	30-33
29903256-5	2017	RESULTS: The expression of TRAF2 mRNA and c-Jun mRNA in different groups of TNF-alpha neutralization antibody and JNK kinase inhibitors SP600125 groups were decreased compared with CC10, respectively the groups of 48h( 0.	pyrazolanthrone	136-144	TNF receptor associated factor 2	Homo sapiens	27-32
29903256-5	2017	RESULTS: The expression of TRAF2 mRNA and c-Jun mRNA in different groups of TNF-alpha neutralization antibody and JNK kinase inhibitors SP600125 groups were decreased compared with CC10, respectively the groups of 48h( 0.	pyrazolanthrone	136-144	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	42-47
29903256-5	2017	RESULTS: The expression of TRAF2 mRNA and c-Jun mRNA in different groups of TNF-alpha neutralization antibody and JNK kinase inhibitors SP600125 groups were decreased compared with CC10, respectively the groups of 48h( 0.	pyrazolanthrone	136-144	secretoglobin family 1A member 1	Homo sapiens	181-185
29903256-10	2017	The expression of TRAF2 mRNA in groups of TNF-alpha neutralization antibody and JNK kinase inhibitors SP600125 groups( respectively 1.	pyrazolanthrone	102-110	TNF receptor associated factor 2	Homo sapiens	18-23
28235485-6	2017	Beclin1 and LC3 II/I increased in JSRV-Env transfected NIH3T3 cells treated with mTOR inhibitor (rapamycin), ERK1/2 inhibitor (PD 98059), p38 inhibitor (SB 203580) and JNK inhibitor (SP 600125), suggesting that Akt/mTOR and MAPK pathways were responsible for JSRV-Env decreased autophagy.	pyrazolanthrone	183-192	envelope protein	Jaagsiekte sheep retrovirus	39-42
28387244-7	2017	Cotreatment of cells with the JNK inhibitor SP600125 considerably attenuated MT-6-induced apoptosis, mitochondria membrane potential loss, DR5 upregulation, and suppression of cell viability.	pyrazolanthrone	44-52	TNF receptor superfamily member 10b	Homo sapiens	139-142
28232185-6	2017	Induction of PCSK9 was selectively inhibited by TLR-4 blockade and further downstream by the SAPK/JNK-inhibitor SP600125, whereas inhibitors of ERK1/2, p38 or PI3-kinase pathways had no effect.	pyrazolanthrone	112-120	proprotein convertase subtilisin/kexin type 9	Homo sapiens	13-18
28428754-6	2017	In particular, the JNK-specific inhibitor SP600125 restored the induction of P-JNK, P-p53 (Ser15), p21, CyclinD1 and CyclinE by Pu-erh tea extract.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	19-22
28428754-6	2017	In particular, the JNK-specific inhibitor SP600125 restored the induction of P-JNK, P-p53 (Ser15), p21, CyclinD1 and CyclinE by Pu-erh tea extract.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	79-82
28428754-6	2017	In particular, the JNK-specific inhibitor SP600125 restored the induction of P-JNK, P-p53 (Ser15), p21, CyclinD1 and CyclinE by Pu-erh tea extract.	pyrazolanthrone	42-50	H3 histone pseudogene 16	Homo sapiens	99-102
28428754-6	2017	In particular, the JNK-specific inhibitor SP600125 restored the induction of P-JNK, P-p53 (Ser15), p21, CyclinD1 and CyclinE by Pu-erh tea extract.	pyrazolanthrone	42-50	cyclin D1	Homo sapiens	104-112
28393934-8	2017	JNK inhibition by the specific inhibitor SP600125 enhanced partially the cell viability.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
28178378-6	2017	Inhibition of JNK/c-jun pathway with its inhibitor SP600125 reversed the phosphorylation of c-jun and the activation of caspase-3 induced by co-treatment of HuH-7 cells with melatonin and sorafenib in a dose-dependent manner.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	14-17
28488455-7	2017	MGO treatment down-regulated Ire1alpha, a key ER stress mediator, increased JNK phosphorylation and activated mitochondrial apoptosis; down-regulated Bcl-2 expression which could be attenuated by the JNK inhibitor SP600125 and further inhibited cytochrome c leakage from mitochondria and blocked the conversion of pro caspase 3 into cleaved caspase 3, all these might contribute to the inhibition of INS-1 cell apoptosis.	pyrazolanthrone	214-222	BCL2, apoptosis regulator	Rattus norvegicus	150-155
28129433-8	2017	Furthermore, we noticed that expression of wild-type PP5 or dominant negative c-Jun, or pretreatment with JNK inhibitor SP600125 reinforced celastrol"s suppression of Cd-induced NOX2 and its regulatory proteins, and consequential ROS in neuronal cells.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Rattus norvegicus	106-109
28129433-8	2017	Furthermore, we noticed that expression of wild-type PP5 or dominant negative c-Jun, or pretreatment with JNK inhibitor SP600125 reinforced celastrol"s suppression of Cd-induced NOX2 and its regulatory proteins, and consequential ROS in neuronal cells.	pyrazolanthrone	120-128	cytochrome b-245 beta chain	Rattus norvegicus	178-182
28462010-4	2017	The activity of c-Jun N-terminal kinase (JNK) was inhibited with SP600125 or by transfection with JNK short hairpin RNA.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	16-39
28462010-4	2017	The activity of c-Jun N-terminal kinase (JNK) was inhibited with SP600125 or by transfection with JNK short hairpin RNA.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	41-44
28178378-6	2017	Inhibition of JNK/c-jun pathway with its inhibitor SP600125 reversed the phosphorylation of c-jun and the activation of caspase-3 induced by co-treatment of HuH-7 cells with melatonin and sorafenib in a dose-dependent manner.	pyrazolanthrone	51-59	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-23
28178378-6	2017	Inhibition of JNK/c-jun pathway with its inhibitor SP600125 reversed the phosphorylation of c-jun and the activation of caspase-3 induced by co-treatment of HuH-7 cells with melatonin and sorafenib in a dose-dependent manner.	pyrazolanthrone	51-59	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	92-97
28178378-6	2017	Inhibition of JNK/c-jun pathway with its inhibitor SP600125 reversed the phosphorylation of c-jun and the activation of caspase-3 induced by co-treatment of HuH-7 cells with melatonin and sorafenib in a dose-dependent manner.	pyrazolanthrone	51-59	caspase 3	Homo sapiens	120-129
28011284-6	2017	We further illustrated that either a T103A mutation or the suppression of phosphorylation of T103 by the JNK inhibitor SP600125 inhibited the efficient recruitment of Tudor-SN into SGs.	pyrazolanthrone	119-127	mitogen-activated protein kinase 8	Homo sapiens	105-108
28087840-6	2017	MAPK inhibitors (SP600125, SB20852, and U0126) suppressed PARP cleavage induced by TNF-alpha/Cholix.	pyrazolanthrone	17-25	mitogen-activated protein kinase 1	Homo sapiens	0-4
28087840-6	2017	MAPK inhibitors (SP600125, SB20852, and U0126) suppressed PARP cleavage induced by TNF-alpha/Cholix.	pyrazolanthrone	17-25	poly(ADP-ribose) polymerase 1	Homo sapiens	58-62
28087840-6	2017	MAPK inhibitors (SP600125, SB20852, and U0126) suppressed PARP cleavage induced by TNF-alpha/Cholix.	pyrazolanthrone	17-25	tumor necrosis factor	Homo sapiens	83-99
28321599-5	2017	In contrast, the specific JNK inhibitor SP600125 decreased the VPA-stimulated increase in neuronal differentiation of mouse embryonic NSCs and neurite outgrowth of NSC-derived neurons.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Mus musculus	26-29
28400700-8	2017	The p38 inhibitor (SB203580) attenuated RBP4-stimulated vascular cell adhesion molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein (MCP-1), and interleukin 6 (IL-6) production, while the JNK inhibitor (SP600125) reduced RBP4-stimulated sICAM-1, endothelial cell selectin (E-selectin), and MCP-1 production.	pyrazolanthrone	248-256	mitogen-activated protein kinase 14	Mus musculus	4-7
28400700-8	2017	The p38 inhibitor (SB203580) attenuated RBP4-stimulated vascular cell adhesion molecule 1 (VCAM-1), intracellular adhesion molecule 1 (ICAM-1), monocyte chemoattractant protein (MCP-1), and interleukin 6 (IL-6) production, while the JNK inhibitor (SP600125) reduced RBP4-stimulated sICAM-1, endothelial cell selectin (E-selectin), and MCP-1 production.	pyrazolanthrone	248-256	retinol binding protein 4, plasma	Mus musculus	40-44
28302166-4	2017	Blocking JNK activity with SP600125 inhibits HSCs activation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	9-12
28119076-7	2017	Conversely, intrathecal injection of the JNK inhibitor SP600125 prevented SNI and ddC-induced nociceptive behavior and, its inactive dose co-administrated with amitriptyline induced an antinociceptive effect.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Mus musculus	41-44
28112176-9	2017	Furthermore, SB203580 (a p38 inhibitor) or SP600125 (a JNK inhibitor) dose-dependently inhibited the viral replication in the host cells, whereas PD98059 (an ERK inhibitor) was not effective.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	55-58
28076833-7	2017	SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor) could rescue GQ-induced cell death and attenuate mitochondrial signal pathway activation.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	39-42
28011284-6	2017	We further illustrated that either a T103A mutation or the suppression of phosphorylation of T103 by the JNK inhibitor SP600125 inhibited the efficient recruitment of Tudor-SN into SGs.	pyrazolanthrone	119-127	staphylococcal nuclease and tudor domain containing 1	Homo sapiens	167-175
28012230-2	2017	In the present study, RNA interference (RNAi) and JNK inhibitor SP600125, which target MUC1 and/or JNK, were used to treat HCC cells in vitro, and the results showed that both silencing the expression of MUC1 and blocking the activity of JNK inhibited the proliferation of HCC cells.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Mus musculus	50-53
28012230-2	2017	In the present study, RNA interference (RNAi) and JNK inhibitor SP600125, which target MUC1 and/or JNK, were used to treat HCC cells in vitro, and the results showed that both silencing the expression of MUC1 and blocking the activity of JNK inhibited the proliferation of HCC cells.	pyrazolanthrone	64-72	mucin 1, transmembrane	Mus musculus	87-91
28012230-2	2017	In the present study, RNA interference (RNAi) and JNK inhibitor SP600125, which target MUC1 and/or JNK, were used to treat HCC cells in vitro, and the results showed that both silencing the expression of MUC1 and blocking the activity of JNK inhibited the proliferation of HCC cells.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Mus musculus	99-102
28012230-2	2017	In the present study, RNA interference (RNAi) and JNK inhibitor SP600125, which target MUC1 and/or JNK, were used to treat HCC cells in vitro, and the results showed that both silencing the expression of MUC1 and blocking the activity of JNK inhibited the proliferation of HCC cells.	pyrazolanthrone	64-72	mucin 1, transmembrane	Mus musculus	204-208
28012230-2	2017	In the present study, RNA interference (RNAi) and JNK inhibitor SP600125, which target MUC1 and/or JNK, were used to treat HCC cells in vitro, and the results showed that both silencing the expression of MUC1 and blocking the activity of JNK inhibited the proliferation of HCC cells.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Mus musculus	99-102
28012230-4	2017	Furthermore, the results from immunohistochemical staining assays showed that the inhibitory effects of MUC1 gene silencing and SP600125 on the proliferation of HCC cells in vivo were through the JNK/TGF-beta signaling pathway.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Mus musculus	196-199
27809352-7	2017	Moreover, the HCV core-induced up-regulation of T-bet and Tim-3 expression in M/Mphi can be abrogated by incubating the cells with SP600125 - an inhibitor for the c-Jun N-terminal kinase (JNK) signalling pathway.	pyrazolanthrone	131-139	T-box transcription factor 21	Homo sapiens	48-53
27809352-7	2017	Moreover, the HCV core-induced up-regulation of T-bet and Tim-3 expression in M/Mphi can be abrogated by incubating the cells with SP600125 - an inhibitor for the c-Jun N-terminal kinase (JNK) signalling pathway.	pyrazolanthrone	131-139	hepatitis A virus cellular receptor 2	Homo sapiens	58-63
27439062-11	2017	The JNK inhibitor SP600125 normalized sympathoexcitation and GAD1 and GABRA1 expression in PVN in CHF rats.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
28138710-13	2017	Conversely, pretreatment with the ROS scavenger N-acetylcysteine or the JNK/SAPK-specific inhibitor SP600125 prevented moscatilin-mediated reductions in cell viability.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	72-75
28138710-13	2017	Conversely, pretreatment with the ROS scavenger N-acetylcysteine or the JNK/SAPK-specific inhibitor SP600125 prevented moscatilin-mediated reductions in cell viability.	pyrazolanthrone	100-108	mitogen-activated protein kinase 9	Homo sapiens	76-80
29027433-6	2017	Combined use of JNK inhibitor SP600125 and p38 inhibitor SB203580 could decrease p21 and increase beta-Catenin protein expressions.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	16-19
29027433-6	2017	Combined use of JNK inhibitor SP600125 and p38 inhibitor SB203580 could decrease p21 and increase beta-Catenin protein expressions.	pyrazolanthrone	30-38	H3 histone pseudogene 16	Homo sapiens	81-84
29027433-6	2017	Combined use of JNK inhibitor SP600125 and p38 inhibitor SB203580 could decrease p21 and increase beta-Catenin protein expressions.	pyrazolanthrone	30-38	catenin beta 1	Homo sapiens	98-110
28099944-5	2017	Additionally, SP600125, a specific JNK inhibitor, significantly increased Foxo3a phosphorylation, which downregulated Foxo3a translocation into the nucleus, indicating that CAV1 mediates JNK regulation of Foxo3a.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	35-38
28099944-5	2017	Additionally, SP600125, a specific JNK inhibitor, significantly increased Foxo3a phosphorylation, which downregulated Foxo3a translocation into the nucleus, indicating that CAV1 mediates JNK regulation of Foxo3a.	pyrazolanthrone	14-22	forkhead box O3	Homo sapiens	74-80
28099944-5	2017	Additionally, SP600125, a specific JNK inhibitor, significantly increased Foxo3a phosphorylation, which downregulated Foxo3a translocation into the nucleus, indicating that CAV1 mediates JNK regulation of Foxo3a.	pyrazolanthrone	14-22	forkhead box O3	Homo sapiens	118-124
28099944-5	2017	Additionally, SP600125, a specific JNK inhibitor, significantly increased Foxo3a phosphorylation, which downregulated Foxo3a translocation into the nucleus, indicating that CAV1 mediates JNK regulation of Foxo3a.	pyrazolanthrone	14-22	caveolin 1	Homo sapiens	173-177
28099944-5	2017	Additionally, SP600125, a specific JNK inhibitor, significantly increased Foxo3a phosphorylation, which downregulated Foxo3a translocation into the nucleus, indicating that CAV1 mediates JNK regulation of Foxo3a.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	187-190
28099944-5	2017	Additionally, SP600125, a specific JNK inhibitor, significantly increased Foxo3a phosphorylation, which downregulated Foxo3a translocation into the nucleus, indicating that CAV1 mediates JNK regulation of Foxo3a.	pyrazolanthrone	14-22	forkhead box O3	Homo sapiens	118-124
28367093-8	2017	Moreover, the administration of the JNK-specific inhibitor SP600125 to SW620 with BEX2 overexpression abolished the effect of BEX2 on SW620 cell proliferation.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	36-39
28367093-8	2017	Moreover, the administration of the JNK-specific inhibitor SP600125 to SW620 with BEX2 overexpression abolished the effect of BEX2 on SW620 cell proliferation.	pyrazolanthrone	59-67	brain expressed X-linked 2	Homo sapiens	82-86
28367093-8	2017	Moreover, the administration of the JNK-specific inhibitor SP600125 to SW620 with BEX2 overexpression abolished the effect of BEX2 on SW620 cell proliferation.	pyrazolanthrone	59-67	brain expressed X-linked 2	Homo sapiens	126-130
28039458-6	2017	SP exerts its main effects through direct and highly significant inhibition of the ROCK pathway, known to be involved in the regulation of cell migration and beta-catenin turnover.	pyrazolanthrone	0-2	catenin beta 1	Homo sapiens	158-170
28039458-7	2017	Consistently, SP treatment resulted in a significant decrease in beta-catenin levels with respect to basal conditions in tumor but not in normal spheroids, indicating that the effect is promisingly selective on tumor cells.In conclusion, we provide the morphological and molecular characterization of thyroid normal and tumor spheroids.	pyrazolanthrone	14-16	catenin beta 1	Homo sapiens	65-77
28280414-8	2017	In addition, treatment of JNK inhibitor (SP 600125) abolished quercetin-stimulated Foxo3a activity, suggesting JNK as a possible upstream signaling in regulation of Foxo3a activity.	pyrazolanthrone	41-50	mitogen-activated protein kinase 8	Homo sapiens	26-29
28280414-8	2017	In addition, treatment of JNK inhibitor (SP 600125) abolished quercetin-stimulated Foxo3a activity, suggesting JNK as a possible upstream signaling in regulation of Foxo3a activity.	pyrazolanthrone	41-50	forkhead box O3	Homo sapiens	83-89
28280414-8	2017	In addition, treatment of JNK inhibitor (SP 600125) abolished quercetin-stimulated Foxo3a activity, suggesting JNK as a possible upstream signaling in regulation of Foxo3a activity.	pyrazolanthrone	41-50	mitogen-activated protein kinase 8	Homo sapiens	111-114
28280414-8	2017	In addition, treatment of JNK inhibitor (SP 600125) abolished quercetin-stimulated Foxo3a activity, suggesting JNK as a possible upstream signaling in regulation of Foxo3a activity.	pyrazolanthrone	41-50	forkhead box O3	Homo sapiens	165-171
27439062-11	2017	The JNK inhibitor SP600125 normalized sympathoexcitation and GAD1 and GABRA1 expression in PVN in CHF rats.	pyrazolanthrone	18-26	glutamate decarboxylase 1	Rattus norvegicus	61-65
27439062-11	2017	The JNK inhibitor SP600125 normalized sympathoexcitation and GAD1 and GABRA1 expression in PVN in CHF rats.	pyrazolanthrone	18-26	gamma-aminobutyric acid type A receptor subunit alpha 1	Rattus norvegicus	70-76
27895138-8	2017	It was also showed that both the JNK inhibitor SP600125 and the NF-kappaB inhibitor PDTC significantly attenuated thermal hyperalgesia and mechanical allodynia in CCI rats.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Rattus norvegicus	33-36
26507465-4	2017	We further showed that a Jun kinase (JNK) pathway inhibitor, SP600125, down-regulated expression of OXR1 during infection, leading to elevated H2 O2 levels in the hemolymph, resulting in lower viability of the injected bacteria inside the silkworm larvae.	pyrazolanthrone	61-69	c-Jun NH2-terminal kinase	Bombyx mori	25-35
26507465-4	2017	We further showed that a Jun kinase (JNK) pathway inhibitor, SP600125, down-regulated expression of OXR1 during infection, leading to elevated H2 O2 levels in the hemolymph, resulting in lower viability of the injected bacteria inside the silkworm larvae.	pyrazolanthrone	61-69	c-Jun NH2-terminal kinase	Bombyx mori	37-40
26507465-4	2017	We further showed that a Jun kinase (JNK) pathway inhibitor, SP600125, down-regulated expression of OXR1 during infection, leading to elevated H2 O2 levels in the hemolymph, resulting in lower viability of the injected bacteria inside the silkworm larvae.	pyrazolanthrone	61-69	oxygen resistance gene 1	Bombyx mori	100-104
26922429-8	2017	Pretreatment with PD98059, SP600125, SB431542, and SIS3, but not SB203580, significantly reduced TGF-beta1-induced Egr-1 protein expression.	pyrazolanthrone	27-35	transforming growth factor beta 1	Homo sapiens	97-106
26922429-8	2017	Pretreatment with PD98059, SP600125, SB431542, and SIS3, but not SB203580, significantly reduced TGF-beta1-induced Egr-1 protein expression.	pyrazolanthrone	27-35	early growth response 1	Homo sapiens	115-120
28039587-6	2017	These effects were attenuated by treatment of cells with either SP600125 (JNK inhibitor) or c-Jun siRNA.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Homo sapiens	74-77
27771174-7	2017	These responses were inhibited by c-Jun N-terminal kinase (JNK) inhibitor SP600125 and dexamethasone.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Mus musculus	34-57
27771174-7	2017	These responses were inhibited by c-Jun N-terminal kinase (JNK) inhibitor SP600125 and dexamethasone.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Mus musculus	59-62
28099584-10	2017	When treated with SP600125 and 131I, the non-transfected SW579 cell lines significantly inhibited JNK pathway, NF-kappaB pathway and the expression of BTG2.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	98-101
27988353-12	2017	Urantide and JNK inhibitor SP600125 abrogated migration, invasion, or MMP9/2 expression in response to UII.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	13-16
27988353-12	2017	Urantide and JNK inhibitor SP600125 abrogated migration, invasion, or MMP9/2 expression in response to UII.	pyrazolanthrone	27-35	matrix metallopeptidase 9	Homo sapiens	70-74
27988353-12	2017	Urantide and JNK inhibitor SP600125 abrogated migration, invasion, or MMP9/2 expression in response to UII.	pyrazolanthrone	27-35	urotensin 2	Homo sapiens	103-106
27988353-13	2017	UII induced actin polymerization and fascin protein expression, and could be reversed by apocynin and SP600125.	pyrazolanthrone	102-110	urotensin 2	Homo sapiens	0-3
27919822-6	2017	Furthermore, the intrathecal administration of SP600125 (JNK inhibitor) prevented the development of allodynia in CPIP-injured mice.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Mus musculus	57-60
28099584-10	2017	When treated with SP600125 and 131I, the non-transfected SW579 cell lines significantly inhibited JNK pathway, NF-kappaB pathway and the expression of BTG2.	pyrazolanthrone	18-26	nuclear factor kappa B subunit 1	Homo sapiens	111-120
28099584-10	2017	When treated with SP600125 and 131I, the non-transfected SW579 cell lines significantly inhibited JNK pathway, NF-kappaB pathway and the expression of BTG2.	pyrazolanthrone	18-26	BTG anti-proliferation factor 2	Homo sapiens	151-155
28081713-7	2017	Additionally, pretreatment with JNK inhibitor SP600125 effectively suppressed Abeta25-35 induced PC12 cell cytotoxicity.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Rattus norvegicus	32-35
28098804-7	2017	Furthermore, SP600125 and SB203580 aggravated olaquindox-induced DNA damage and S-phase arrest, suppressed the expression of GADD45a.	pyrazolanthrone	13-21	growth arrest and DNA damage inducible alpha	Homo sapiens	125-132
28395342-6	2017	In addition, FGF2 increases phosphorylation of AKT, P70S6K, S6, ERK1/2, JNK, P38, and P90RSK in a time-dependent manner, and increases in their expression was suppressed by Wortmannin (a phosphatidylinositol 3-kinase [PI3K] inhibitor), U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and SB203580 (a P38 inhibitor) based on western blot analyses.	pyrazolanthrone	265-273	fibroblast growth factor 2	Homo sapiens	13-17
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	24-27
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	144-154
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	growth differentiation factor 2	Homo sapiens	180-184
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	RUNX family transcription factor 2	Homo sapiens	267-302
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	RUNX family transcription factor 2	Homo sapiens	304-309
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	alkaline phosphatase, placental	Homo sapiens	312-332
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	alkaline phosphatase, placental	Homo sapiens	334-337
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	secreted phosphoprotein 1	Homo sapiens	340-351
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	secreted phosphoprotein 1	Homo sapiens	353-356
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	bone gamma-carboxyglutamate protein	Homo sapiens	363-374
28052093-4	2017	Our results showed that JNK inhibition by the specific inhibitor SP600125 or adenovirus expressing small interfering RNA (siRNA) targeting JNK (AdR-si-JNK) significantly decreased BMP9-induced gene and protein expression of early and late osteogenic markers, such as runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), in hPDLSCs.	pyrazolanthrone	65-73	bone gamma-carboxyglutamate protein	Homo sapiens	376-379
28849452-6	2017	In addition, we found that treatment of the cells with p38 inhibitor (SB203580) suppressed taurine-induced HO-1 expression and cytoprotection, but inhibitors of c-Jun NH2 terminal kinase (JNK) (SP600125) or extracellular signal regulated kinase (ERK) (PD98059) did not.	pyrazolanthrone	194-202	mitogen-activated protein kinase 8	Mus musculus	188-191
28101000-5	2016	Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126 (inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated expression of p-p38, p-ERK1/2, and p-JNK1/2.	pyrazolanthrone	107-115	mitogen activated protein kinase 14	Rattus norvegicus	185-188
28101000-5	2016	Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126 (inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated expression of p-p38, p-ERK1/2, and p-JNK1/2.	pyrazolanthrone	107-115	mitogen activated protein kinase 3	Rattus norvegicus	192-198
28849451-8	2017	In addition, we found reduced TauCl-induced HO-1 expression and cytoprotection following treatment of the cells with an extracellular signal-regulated kinase (ERK) inhibitor (PD98059) or a p38 inhibitor (SB203580), but not following treatment with a SP600125 as a c-Jun NH2-terminal kinase (JNK) inhibitor.	pyrazolanthrone	250-258	mitogen-activated protein kinase 1	Mus musculus	159-162
28849452-6	2017	In addition, we found that treatment of the cells with p38 inhibitor (SB203580) suppressed taurine-induced HO-1 expression and cytoprotection, but inhibitors of c-Jun NH2 terminal kinase (JNK) (SP600125) or extracellular signal regulated kinase (ERK) (PD98059) did not.	pyrazolanthrone	194-202	mitogen-activated protein kinase 8	Mus musculus	161-186
27603596-5	2017	DR5 induction was regulated by C/EBP homologous protein (CHOP) and JNK as CHOP siRNA or JNK inhibitor SP600125 considerably abolished the DR5 induction.	pyrazolanthrone	102-110	TNF receptor superfamily member 10b	Homo sapiens	0-3
27603596-5	2017	DR5 induction was regulated by C/EBP homologous protein (CHOP) and JNK as CHOP siRNA or JNK inhibitor SP600125 considerably abolished the DR5 induction.	pyrazolanthrone	102-110	DNA damage inducible transcript 3	Homo sapiens	31-55
27603596-5	2017	DR5 induction was regulated by C/EBP homologous protein (CHOP) and JNK as CHOP siRNA or JNK inhibitor SP600125 considerably abolished the DR5 induction.	pyrazolanthrone	102-110	DNA damage inducible transcript 3	Homo sapiens	57-61
27603596-5	2017	DR5 induction was regulated by C/EBP homologous protein (CHOP) and JNK as CHOP siRNA or JNK inhibitor SP600125 considerably abolished the DR5 induction.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	67-70
27603596-5	2017	DR5 induction was regulated by C/EBP homologous protein (CHOP) and JNK as CHOP siRNA or JNK inhibitor SP600125 considerably abolished the DR5 induction.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	88-91
27603596-5	2017	DR5 induction was regulated by C/EBP homologous protein (CHOP) and JNK as CHOP siRNA or JNK inhibitor SP600125 considerably abolished the DR5 induction.	pyrazolanthrone	102-110	TNF receptor superfamily member 10b	Homo sapiens	138-141
28250268-9	2017	Treatment of the cells with specific inhibitors including SB203580, SP600125, and LY294002 suppressed the luteolin-induced HO-1 expression, suggesting the involvement of p38 MAPK, JNK, and Akt in HO-1 induction.	pyrazolanthrone	68-76	mitogen activated protein kinase 14	Rattus norvegicus	170-173
28250268-9	2017	Treatment of the cells with specific inhibitors including SB203580, SP600125, and LY294002 suppressed the luteolin-induced HO-1 expression, suggesting the involvement of p38 MAPK, JNK, and Akt in HO-1 induction.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Rattus norvegicus	180-183
28250268-9	2017	Treatment of the cells with specific inhibitors including SB203580, SP600125, and LY294002 suppressed the luteolin-induced HO-1 expression, suggesting the involvement of p38 MAPK, JNK, and Akt in HO-1 induction.	pyrazolanthrone	68-76	AKT serine/threonine kinase 1	Rattus norvegicus	189-192
27774624-12	2017	TNF-alpha-induced NF-kappaB activation was also blocked by inhibitors of p38 (SB203580) or JNK (SP600125).	pyrazolanthrone	96-104	tumor necrosis factor	Homo sapiens	0-9
28966244-11	2017	Moreover, EA treatment increased phosphorylation of c-jun N-terminal kinase (JNK) and JNK inhibitor, SP600125, blocked the effect of EA on neurite outgrowth.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Mus musculus	86-89
27774624-12	2017	TNF-alpha-induced NF-kappaB activation was also blocked by inhibitors of p38 (SB203580) or JNK (SP600125).	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	91-94
29268268-6	2017	Three specific MAPK blockers, U0126, SB20358 and SP600125, were used to block ERK1/2, P38 and JNK during trans-differentiation.	pyrazolanthrone	49-57	mitogen-activated protein kinase 3	Homo sapiens	78-84
29268268-6	2017	Three specific MAPK blockers, U0126, SB20358 and SP600125, were used to block ERK1/2, P38 and JNK during trans-differentiation.	pyrazolanthrone	49-57	mitogen-activated protein kinase 1	Homo sapiens	86-89
29268268-6	2017	Three specific MAPK blockers, U0126, SB20358 and SP600125, were used to block ERK1/2, P38 and JNK during trans-differentiation.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	94-97
28968596-4	2017	RESULTS: The EGF-induced migration was suppressed by PD98059, an inhibitor of MEK1/2, as well as SB203580, an inhibitor of p38 MAP kinase, SP600125, an inhibitor of SAPK/JNK, and deguelin, an inhibitor of Akt.	pyrazolanthrone	139-147	epidermal growth factor	Homo sapiens	13-16
27702885-9	2017	Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Mus musculus	30-34
29130959-11	2017	H/R treatment increased the levels of phosphorylated c-Jun N-terminal kinases (p-JNK), which was dramatically attenuated by ginsenoside Rg1 and SP600125 (a specific JNK inhibitor).	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Rattus norvegicus	81-84
29130959-11	2017	H/R treatment increased the levels of phosphorylated c-Jun N-terminal kinases (p-JNK), which was dramatically attenuated by ginsenoside Rg1 and SP600125 (a specific JNK inhibitor).	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Rattus norvegicus	165-168
27702885-9	2017	Pharmacological inhibition of JNK1/2 activity (SP600125) is capable of reversing the hypertrophic phenotype in DUSP12 knockout (KO) mice.	pyrazolanthrone	47-55	dual specificity phosphatase 12	Mus musculus	111-117
28465707-7	2017	The downmodulation of IL-6 by P. cicadae was inhibited by the p38 inhibitor (SB203580) or JNK inhibitor (SP600125).	pyrazolanthrone	105-113	interleukin 6	Homo sapiens	22-26
28465707-7	2017	The downmodulation of IL-6 by P. cicadae was inhibited by the p38 inhibitor (SB203580) or JNK inhibitor (SP600125).	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	90-93
27959394-6	2017	The use of JNK inhibitor (SP600125) enhanced the inhibitory effects of miR-214 overexpression on osteogenic differentiation, ALP activity, and Col I, OCN and OPN gene expression in the BMSCs.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	11-14
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	19-22
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	68-71
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	68-71
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	19-22
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	68-71
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	68-71
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	19-22
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	68-71
27814615-3	2017	Phosphorylation of JNK was suppressed by pretreatment of cells with JNK-specific inhibitor (SP600125) and was up-regulated by S. miltiorrhiza; S. miltiorrhiza combined with SP600125 prevented SP600125-induced down-regulation of phospho-JNK both in normal amniotic fluid volume and in isolated oligohydramnios.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	68-71
27814615-4	2017	In isolated oligohydramnios, AQP3 expression was significantly suppressed by SP600125 in a concentration- and time-dependent mannner, while its expression was up-regulated by S. miltiorrhiza.	pyrazolanthrone	77-85	aquaporin 3 (Gill blood group)	Homo sapiens	29-33
27814615-5	2017	S. miltiorrhiza combined with SP600125 inhibited the increased expression of AQP3 relative to the S. miltiorrhiza treated group.	pyrazolanthrone	30-38	aquaporin 3 (Gill blood group)	Homo sapiens	77-81
27959394-6	2017	The use of JNK inhibitor (SP600125) enhanced the inhibitory effects of miR-214 overexpression on osteogenic differentiation, ALP activity, and Col I, OCN and OPN gene expression in the BMSCs.	pyrazolanthrone	26-34	microRNA 214	Homo sapiens	71-78
27959394-6	2017	The use of JNK inhibitor (SP600125) enhanced the inhibitory effects of miR-214 overexpression on osteogenic differentiation, ALP activity, and Col I, OCN and OPN gene expression in the BMSCs.	pyrazolanthrone	26-34	alkaline phosphatase, placental	Homo sapiens	125-128
27959394-6	2017	The use of JNK inhibitor (SP600125) enhanced the inhibitory effects of miR-214 overexpression on osteogenic differentiation, ALP activity, and Col I, OCN and OPN gene expression in the BMSCs.	pyrazolanthrone	26-34	bone gamma-carboxyglutamate protein	Homo sapiens	150-153
27959394-6	2017	The use of JNK inhibitor (SP600125) enhanced the inhibitory effects of miR-214 overexpression on osteogenic differentiation, ALP activity, and Col I, OCN and OPN gene expression in the BMSCs.	pyrazolanthrone	26-34	secreted phosphoprotein 1	Homo sapiens	158-161
27237101-12	2017	This effect is reversed by the beta (beta)-adrenoceptor antagonist propranolol, extracellular signal-regulated kinases (ERK) inhibitor U0126, and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	186-194	mitogen-activated protein kinase 8	Homo sapiens	146-169
27237101-12	2017	This effect is reversed by the beta (beta)-adrenoceptor antagonist propranolol, extracellular signal-regulated kinases (ERK) inhibitor U0126, and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	186-194	mitogen-activated protein kinase 8	Homo sapiens	171-174
27237101-14	2017	NE up-regulates LPS-induced c-Fos expression, which is counteracted by propranolol, U0126, and SP600125.	pyrazolanthrone	95-103	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
27588401-8	2016	Cotreatment with JNK inhibitor SP600125, we demonstrated that apoptosis induced by vitexin was suppressed, while the inhibition of autophagy by vitexin was reversed.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Mus musculus	17-20
27909723-8	2017	Treatment with SP600125, an inhibitor of JNK, relieved NAFLD in rats.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Rattus norvegicus	41-44
27909723-9	2017	Furthermore, SP600125 decreased the expression levels of autophagy-associated genes, including Beclin-1, microtubule-associated protein 1A/1B light chain 3, autophagy related gene (Atg)3 and Atg5, and the phosphorylation of insulin receptor (IR) beta-subunit, IR substrate-1 and protein kinase B in vivo.	pyrazolanthrone	13-21	beclin 1	Rattus norvegicus	95-155
27909723-9	2017	Furthermore, SP600125 decreased the expression levels of autophagy-associated genes, including Beclin-1, microtubule-associated protein 1A/1B light chain 3, autophagy related gene (Atg)3 and Atg5, and the phosphorylation of insulin receptor (IR) beta-subunit, IR substrate-1 and protein kinase B in vivo.	pyrazolanthrone	13-21	autophagy related 3	Rattus norvegicus	181-186
27909723-9	2017	Furthermore, SP600125 decreased the expression levels of autophagy-associated genes, including Beclin-1, microtubule-associated protein 1A/1B light chain 3, autophagy related gene (Atg)3 and Atg5, and the phosphorylation of insulin receptor (IR) beta-subunit, IR substrate-1 and protein kinase B in vivo.	pyrazolanthrone	13-21	autophagy related 5	Rattus norvegicus	191-195
28163121-8	2017	BIRB0796 and SP600125, a p38 MAP kinase inhibitor and a SAPK/JNK inhibitor, respectively, markedly reduced the amplification by EGCG of the PGE2-stimulated osteoprotegerin release.	pyrazolanthrone	13-21	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	156-171
27841083-9	2017	Administration of SP600125 protects neurons from thrombin-induced apoptosis.	pyrazolanthrone	18-26	coagulation factor II, thrombin	Homo sapiens	49-57
27912883-9	2016	However, miltirone-induced Nrf2/HO-1 expression can only be effectively blocked by JNK inhibitor SP600125.	pyrazolanthrone	97-105	NFE2 like bZIP transcription factor 2	Homo sapiens	27-31
27912883-9	2016	However, miltirone-induced Nrf2/HO-1 expression can only be effectively blocked by JNK inhibitor SP600125.	pyrazolanthrone	97-105	heme oxygenase 1	Homo sapiens	32-36
27912883-9	2016	However, miltirone-induced Nrf2/HO-1 expression can only be effectively blocked by JNK inhibitor SP600125.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Homo sapiens	83-86
27145925-5	2016	METHODS: The effect of JNK inhibitors SP600125 and JNK-IN-8 on the proliferation and survival of genetically highly representative human melanoma cell lines was studied in assays of proliferation and apoptosis.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	23-26
27936150-5	2016	SP600125, a selective JNK inhibitor, attenuated the oxidative stress-induced MGCs apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	22-25
27194217-9	2016	The role of extracellular signal-regulated kinase (ERK) 1/2 and/or ERK 5 signalling in PCB-induced ROS production was implicated through the reduction in ROS in the presence of the specific inhibitor U0126, whereas reduced ROS production after the use of SB203580 and SP600125 indicated the involvement of the p38 mitogen-activated protein kinase (MAPK) and c-Jun amino-terminal kinase (JNK) pathways, respectively.	pyrazolanthrone	268-276	pyruvate carboxylase	Homo sapiens	87-90
26822174-6	2016	Antioxidant N-acetyl-L-cysteine (NAC) and c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 inhibited PEITC-induced DR4 and DR5 expression.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	42-67
26822174-6	2016	Antioxidant N-acetyl-L-cysteine (NAC) and c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 inhibited PEITC-induced DR4 and DR5 expression.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	69-72
26822174-6	2016	Antioxidant N-acetyl-L-cysteine (NAC) and c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 inhibited PEITC-induced DR4 and DR5 expression.	pyrazolanthrone	84-92	TNF receptor superfamily member 10a	Homo sapiens	117-120
26822174-6	2016	Antioxidant N-acetyl-L-cysteine (NAC) and c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 inhibited PEITC-induced DR4 and DR5 expression.	pyrazolanthrone	84-92	TNF receptor superfamily member 10b	Homo sapiens	125-128
27884327-1	2016	BACKGROUND: The goals of this study were to validate the role of c-Jun N-terminal kinase (JNK) activation in skin flap apoptosis in a rat model of abdomen skin ischemia and/or reperfusion (IR) and to compare the protective effect of SP600125 and hydrogen-rich saline in skin IR injury.	pyrazolanthrone	233-241	mitogen-activated protein kinase 8	Rattus norvegicus	90-93
27884327-9	2016	RESULTS: Compared to the IR group and the dimethyl sulfoxide group, the SP group and the H group had larger skin flap survival area, more blood perfusion and lower levels of caspase-3 activity.	pyrazolanthrone	72-74	caspase 3	Rattus norvegicus	174-183
27884327-11	2016	Bax was significantly decreased in the SP group.	pyrazolanthrone	39-41	BCL2 associated X, apoptosis regulator	Rattus norvegicus	0-3
27884327-13	2016	CONCLUSIONS: IR-induced JNK phosphorylation was reduced by SP600125, indicating that JNK mediates the apoptosis pathways in rat skin.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
27884327-13	2016	CONCLUSIONS: IR-induced JNK phosphorylation was reduced by SP600125, indicating that JNK mediates the apoptosis pathways in rat skin.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	85-88
27884327-14	2016	In the SP and the H groups, the apoptotic factors measured showed similar expression levels, indicating that JNK inhibition during IR may be associated with H-mediated protection against skin IR apoptosis.	pyrazolanthrone	7-9	mitogen-activated protein kinase 8	Rattus norvegicus	109-112
28105176-6	2016	DHA also elevates the expression of cyclooxygenase-2 and matrix metalloproteinase-13, which is abolished by treatment with the JNK inhibitor SP600125.	pyrazolanthrone	141-149	prostaglandin-endoperoxide synthase 2	Homo sapiens	36-84
28105176-6	2016	DHA also elevates the expression of cyclooxygenase-2 and matrix metalloproteinase-13, which is abolished by treatment with the JNK inhibitor SP600125.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	127-130
28105181-6	2016	Furthermore, gemcitabine-induced apoptosis and Bim levels decreased when c-Jun phosphorylation was blocked by SP600125.	pyrazolanthrone	110-118	BCL2 like 11	Homo sapiens	47-50
28105181-6	2016	Furthermore, gemcitabine-induced apoptosis and Bim levels decreased when c-Jun phosphorylation was blocked by SP600125.	pyrazolanthrone	110-118	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	73-78
27819344-7	2016	SP600125 and PD98059, specific inhibitors of JNK kinase and ERK kinase, significantly blocked the SL4-induced G2/M phase arrest and upregulation of p21.	pyrazolanthrone	0-8	cyclin dependent kinase inhibitor 1A	Homo sapiens	148-151
27924151-1	2016	BACKGROUND: The JNK inhibitor SP600125 strongly inhibits cell proliferation in many human cancer cells by blocking mitosis progression and inducing cell death.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	16-19
27924151-8	2016	Additionally, SP600125- induced delayed apoptosis and cell death was accompanied by significant poly ADP-ribose polymerase (PARP) cleavage and caspase-3 activation in the late phase (at 72 h).	pyrazolanthrone	14-22	poly(ADP-ribose) polymerase 1	Homo sapiens	96-122
27924151-8	2016	Additionally, SP600125- induced delayed apoptosis and cell death was accompanied by significant poly ADP-ribose polymerase (PARP) cleavage and caspase-3 activation in the late phase (at 72 h).	pyrazolanthrone	14-22	poly(ADP-ribose) polymerase 1	Homo sapiens	124-128
27924151-8	2016	Additionally, SP600125- induced delayed apoptosis and cell death was accompanied by significant poly ADP-ribose polymerase (PARP) cleavage and caspase-3 activation in the late phase (at 72 h).	pyrazolanthrone	14-22	caspase 3	Homo sapiens	143-152
27484511-12	2016	Finally, the employment of NAC and MAPK inhibitors (U0126, SP600125 and SB203580) remarkably blocked the S phase arrest, apoptosis and down-regulation of P-gp induced by Z5.	pyrazolanthrone	59-67	mitogen-activated protein kinase 3	Homo sapiens	35-39
27484511-12	2016	Finally, the employment of NAC and MAPK inhibitors (U0126, SP600125 and SB203580) remarkably blocked the S phase arrest, apoptosis and down-regulation of P-gp induced by Z5.	pyrazolanthrone	59-67	phosphoglycolate phosphatase	Homo sapiens	154-158
27779694-6	2016	N-acetyl-L-cysteine is a ROS scavenger and antioxidant, and the inhibition of JNK with SP600125 prevented fentanyl-induced autophagy.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	78-81
27688298-8	2016	Pharmacological JNK antagonism with SP600125 markedly improved insulin-mediated vasodilation by sixfold (p&lt;0.001), while endothelial cells exposed to recombinant WNT5A developed insulin resistance and impaired eNOS phosphorylation (p&lt;0.05).	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	16-19
27688298-8	2016	Pharmacological JNK antagonism with SP600125 markedly improved insulin-mediated vasodilation by sixfold (p&lt;0.001), while endothelial cells exposed to recombinant WNT5A developed insulin resistance and impaired eNOS phosphorylation (p&lt;0.05).	pyrazolanthrone	36-44	insulin	Homo sapiens	63-70
27895401-3	2016	Using HER2-positve GC cell lines SNU-216 and NCI-N87, HER2 expression was silenced by RNA interference, and the activations of JNK and AKT were suppressed by SP600125 and LY294002, respectively.	pyrazolanthrone	158-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	6-10
27895401-3	2016	Using HER2-positve GC cell lines SNU-216 and NCI-N87, HER2 expression was silenced by RNA interference, and the activations of JNK and AKT were suppressed by SP600125 and LY294002, respectively.	pyrazolanthrone	158-166	erb-b2 receptor tyrosine kinase 2	Homo sapiens	54-58
27895401-3	2016	Using HER2-positve GC cell lines SNU-216 and NCI-N87, HER2 expression was silenced by RNA interference, and the activations of JNK and AKT were suppressed by SP600125 and LY294002, respectively.	pyrazolanthrone	158-166	mitogen-activated protein kinase 8	Homo sapiens	127-130
27895401-3	2016	Using HER2-positve GC cell lines SNU-216 and NCI-N87, HER2 expression was silenced by RNA interference, and the activations of JNK and AKT were suppressed by SP600125 and LY294002, respectively.	pyrazolanthrone	158-166	AKT serine/threonine kinase 1	Homo sapiens	135-138
26659566-5	2016	IS pretreatment of HUVECs significantly increased IL-1beta-induced E-selectin expression, monocyte adhesion, and the phosphorylation of mitogen-activated protein kinases (ERK, p38, and JNK) and transcription factors (NF-kappaB and AP-1), and phosphorylation was decreased by pretreatment with inhibitors of ERK1/2 (PD98059), p38 MAPK (SB202190), and JNK (SP600125).	pyrazolanthrone	355-363	interleukin 1 beta	Homo sapiens	50-58
27619643-5	2016	After CD147 stealth siRNA transfection treatment, the production of VEGF was reduced depended on the inhibition efficiency of CD147 siRNAs.The special signaling pathway inhibitors LY294002, SP600125, SB203580 and U0126 were added to cultures respectively and the results showed LY294002 dose-dependently inhibited the expression of VEGF.	pyrazolanthrone	190-198	vascular endothelial growth factor A	Homo sapiens	68-72
27629794-6	2016	Furthermore, our results indicate that death receptor expression may also be regulated by JNK activation, because pre-treatment of cells with JNK inhibitor SP600125 significantly decreases gefitinib-induced death receptor upregulation.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	90-93
27629794-6	2016	Furthermore, our results indicate that death receptor expression may also be regulated by JNK activation, because pre-treatment of cells with JNK inhibitor SP600125 significantly decreases gefitinib-induced death receptor upregulation.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	142-145
27629794-7	2016	Interestingly, SP600125 also inhibits the expression CHOP, yet CHOP has no impact on death receptor expressions.	pyrazolanthrone	15-23	DNA damage inducible transcript 3	Homo sapiens	53-57
27717822-9	2016	We also discovered that caffeine treatment significantly increased the phosphorylation of JNK and that the addition of 30 muM SP600125 (JNKi), a specific JNK inhibitor, partially attenuated caffeine-induced cell death without preventing the caffeine-dependent reduction in basal and maximal OCR.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	136-139
27306149-6	2016	The specific extracellular signal-regulated kinase inhibitor SP600125 (JNK inhibitor), EGCG (100 muM) and c-Jun N-terminal kinase (JNK) siRNA attenuated endoglin proteins following Ang II induction.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
27597132-10	2016	We also observed that pretreatment with the JNK and p38 inhibitors (SP600125 and SB203580) decreased GEN-induced cell death.	pyrazolanthrone	68-76	mitogen-activated protein kinase 14	Homo sapiens	52-55
28025994-11	2016	The JNK inhibitor, SP600125, decreased CCL2 expression and attenuated pain behavior.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
28025994-11	2016	The JNK inhibitor, SP600125, decreased CCL2 expression and attenuated pain behavior.	pyrazolanthrone	19-27	C-C motif chemokine ligand 2	Rattus norvegicus	39-43
27584055-8	2016	Thus, p38 inhibitor (SB203580) in HT22 cells and JNK inhibitor (SP600125) in BV2 microglia cells significantly suppressed HO-1 expression by DTMF.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Mus musculus	49-52
27306149-6	2016	The specific extracellular signal-regulated kinase inhibitor SP600125 (JNK inhibitor), EGCG (100 muM) and c-Jun N-terminal kinase (JNK) siRNA attenuated endoglin proteins following Ang II induction.	pyrazolanthrone	61-69	endoglin	Rattus norvegicus	153-161
27306149-6	2016	The specific extracellular signal-regulated kinase inhibitor SP600125 (JNK inhibitor), EGCG (100 muM) and c-Jun N-terminal kinase (JNK) siRNA attenuated endoglin proteins following Ang II induction.	pyrazolanthrone	61-69	angiotensinogen	Rattus norvegicus	181-187
27306149-9	2016	Finally, EGCG and the JNK inhibitor (SP600125) were found to have attenuated endoglin expression significantly in Ang II-induced CFs, as determined through confocal microscopy.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
27306149-9	2016	Finally, EGCG and the JNK inhibitor (SP600125) were found to have attenuated endoglin expression significantly in Ang II-induced CFs, as determined through confocal microscopy.	pyrazolanthrone	37-45	endoglin	Rattus norvegicus	77-85
27306149-9	2016	Finally, EGCG and the JNK inhibitor (SP600125) were found to have attenuated endoglin expression significantly in Ang II-induced CFs, as determined through confocal microscopy.	pyrazolanthrone	37-45	angiotensinogen	Rattus norvegicus	114-120
27605628-7	2016	injection of the JNK inhibitor, SP600125.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
26497035-7	2016	Moreover, thrombin-stimulated PKCalpha/betaII, PKCdelta, p38 MAPK, JNK1/2, or p65 phosphorylation was abrogated by their respective inhibitor of PPACK, GPA2A, D609, ET-18-OCH3, Go6983, Rottlerin, SB202190, SP600125, Bay11-7082, or Helenalin.	pyrazolanthrone	206-214	coagulation factor II, thrombin	Homo sapiens	10-18
26497035-7	2016	Moreover, thrombin-stimulated PKCalpha/betaII, PKCdelta, p38 MAPK, JNK1/2, or p65 phosphorylation was abrogated by their respective inhibitor of PPACK, GPA2A, D609, ET-18-OCH3, Go6983, Rottlerin, SB202190, SP600125, Bay11-7082, or Helenalin.	pyrazolanthrone	206-214	protein kinase C alpha	Homo sapiens	30-45
26497035-7	2016	Moreover, thrombin-stimulated PKCalpha/betaII, PKCdelta, p38 MAPK, JNK1/2, or p65 phosphorylation was abrogated by their respective inhibitor of PPACK, GPA2A, D609, ET-18-OCH3, Go6983, Rottlerin, SB202190, SP600125, Bay11-7082, or Helenalin.	pyrazolanthrone	206-214	mitogen-activated protein kinase 14	Homo sapiens	57-60
27763558-8	2016	In DC, LPS up-regulated AQP3 mRNA levels (p &lt; 0.05) compared to control; these effects were inhibited by CLI095, SP600125 and BAY11-7082 (p &lt; 0.05).	pyrazolanthrone	116-124	aquaporin 3	Mus musculus	24-28
27589684-7	2016	Treatment of the cells either with SP600125, an inhibitor of JNK, or with JNK siRNA, led to eradication of TNFSF15-induced GATA3 expression.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Mus musculus	61-64
27589684-7	2016	Treatment of the cells either with SP600125, an inhibitor of JNK, or with JNK siRNA, led to eradication of TNFSF15-induced GATA3 expression.	pyrazolanthrone	35-43	tumor necrosis factor (ligand) superfamily, member 15	Mus musculus	107-114
27589684-7	2016	Treatment of the cells either with SP600125, an inhibitor of JNK, or with JNK siRNA, led to eradication of TNFSF15-induced GATA3 expression.	pyrazolanthrone	35-43	GATA binding protein 3	Mus musculus	123-128
27767172-4	2016	JNK was activated by AEZS-136, and AEZS-136-induced necroptosis was blocked by the necroptosis inhibitor necrostatin-1 or the JNK inhibitor SP600125, suggesting that JNK activation is required to trigger necroptosis following dual PI3K/ERK inhibition.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	0-3
27767172-4	2016	JNK was activated by AEZS-136, and AEZS-136-induced necroptosis was blocked by the necroptosis inhibitor necrostatin-1 or the JNK inhibitor SP600125, suggesting that JNK activation is required to trigger necroptosis following dual PI3K/ERK inhibition.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	126-129
27767172-4	2016	JNK was activated by AEZS-136, and AEZS-136-induced necroptosis was blocked by the necroptosis inhibitor necrostatin-1 or the JNK inhibitor SP600125, suggesting that JNK activation is required to trigger necroptosis following dual PI3K/ERK inhibition.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	126-129
27767172-4	2016	JNK was activated by AEZS-136, and AEZS-136-induced necroptosis was blocked by the necroptosis inhibitor necrostatin-1 or the JNK inhibitor SP600125, suggesting that JNK activation is required to trigger necroptosis following dual PI3K/ERK inhibition.	pyrazolanthrone	140-148	mitogen-activated protein kinase 1	Homo sapiens	236-239
27600429-10	2016	The apoptosis-induction of isoalantolactone could be abrogated by co-treatment with SB203580 (inhibitor of p38 MAPK) or SP600125 (inhibitor of JNK).	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	143-146
27515513-8	2016	Pretreatment of chondrocytes with SB202190 (p38 inhibitor), SP600125 (JNK inhibitor) and BAY-11-7082 (NF-kappaB inhibitor) inhibit AGEs-induced apoptosis and degeneration.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	70-73
27739415-7	2016	Cd treatment also induces a decrease in proliferation and an increase in apoptosis of HRMCs, but only the decrease in HRMC proliferation was reversed by pretreatment with SP600125, an inhibitor of the JNK pathway.	pyrazolanthrone	171-179	mitogen-activated protein kinase 8	Homo sapiens	201-204
27484838-11	2016	Furthermore, inhibition of JNK by its inhibitor, SP600125, or MEK/Erk signalling by its inhibitor, PD98059, dramatically blocked IGFBP5-enhanced ALP activity and in vitro mineralization in both PDLSCs and WJCMSCs.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	27-30
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 3	Homo sapiens	40-46
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 9	Homo sapiens	59-63
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	64-67
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 3	Homo sapiens	90-96
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 9	Homo sapiens	101-105
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	106-109
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 1	Homo sapiens	151-154
27580989-10	2016	Moreover, pharmacological inhibitors of ERK1/2 (U0126) and SAPK/JNK (SP600125) suppressed ERK1/2 and SAPK/JNK activation respectively, and blockage of P38 MAPK by its inhibitor (SB203580) had a synergistic effect with curcumin.	pyrazolanthrone	69-77	mitogen-activated protein kinase 3	Homo sapiens	155-159
27562721-7	2016	As a specific inhibitor for AP-1 activation, SP600125 also significantly suppressed the basal transcriptional activity of IRAK-M, the binding activity of c-Fos/c-Jun with IRAK-M promoter, and IRAK-M protein expression.	pyrazolanthrone	45-53	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-32
27562721-7	2016	As a specific inhibitor for AP-1 activation, SP600125 also significantly suppressed the basal transcriptional activity of IRAK-M, the binding activity of c-Fos/c-Jun with IRAK-M promoter, and IRAK-M protein expression.	pyrazolanthrone	45-53	interleukin 1 receptor associated kinase 3	Homo sapiens	122-128
27562721-7	2016	As a specific inhibitor for AP-1 activation, SP600125 also significantly suppressed the basal transcriptional activity of IRAK-M, the binding activity of c-Fos/c-Jun with IRAK-M promoter, and IRAK-M protein expression.	pyrazolanthrone	45-53	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	154-159
27562721-7	2016	As a specific inhibitor for AP-1 activation, SP600125 also significantly suppressed the basal transcriptional activity of IRAK-M, the binding activity of c-Fos/c-Jun with IRAK-M promoter, and IRAK-M protein expression.	pyrazolanthrone	45-53	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	160-165
27562721-7	2016	As a specific inhibitor for AP-1 activation, SP600125 also significantly suppressed the basal transcriptional activity of IRAK-M, the binding activity of c-Fos/c-Jun with IRAK-M promoter, and IRAK-M protein expression.	pyrazolanthrone	45-53	interleukin 1 receptor associated kinase 3	Homo sapiens	171-177
27562721-7	2016	As a specific inhibitor for AP-1 activation, SP600125 also significantly suppressed the basal transcriptional activity of IRAK-M, the binding activity of c-Fos/c-Jun with IRAK-M promoter, and IRAK-M protein expression.	pyrazolanthrone	45-53	interleukin 1 receptor associated kinase 3	Homo sapiens	171-177
27484838-11	2016	Furthermore, inhibition of JNK by its inhibitor, SP600125, or MEK/Erk signalling by its inhibitor, PD98059, dramatically blocked IGFBP5-enhanced ALP activity and in vitro mineralization in both PDLSCs and WJCMSCs.	pyrazolanthrone	49-57	insulin like growth factor binding protein 5	Homo sapiens	129-135
27484838-11	2016	Furthermore, inhibition of JNK by its inhibitor, SP600125, or MEK/Erk signalling by its inhibitor, PD98059, dramatically blocked IGFBP5-enhanced ALP activity and in vitro mineralization in both PDLSCs and WJCMSCs.	pyrazolanthrone	49-57	alkaline phosphatase, placental	Homo sapiens	145-148
27698841-8	2016	Treatment with the JNK inhibitor, SP600125, abolished the upregulatory effect of SPAG9 on JunD.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	19-22
27633119-6	2016	In addition, pretreatment with N-acetyl-cysteine (NAC) and SP600125, the inhibitor of ROS and JNK, induced MKN45 cell proliferation, prevented the cell apoptosis and released the cells from cycle arrest.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	94-97
27633119-7	2016	Finally, we found that pretreatment with NAC prevented the JNK, p53, caspase-9 and -3 protein phosphorylation induced by the polysaccharide, however, pretreatment with SP600125 did not affect the generation of ROS, suggesting that ROS is upstream of JNK.	pyrazolanthrone	168-176	tumor protein p53	Homo sapiens	64-67
27698841-8	2016	Treatment with the JNK inhibitor, SP600125, abolished the upregulatory effect of SPAG9 on JunD.	pyrazolanthrone	34-42	sperm associated antigen 9	Homo sapiens	81-86
27698841-8	2016	Treatment with the JNK inhibitor, SP600125, abolished the upregulatory effect of SPAG9 on JunD.	pyrazolanthrone	34-42	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-94
27357535-6	2016	Specific inhibitors of p38 (SB203580), ERK (PD98059), and JNK (SP600125) inhibited MK1-EPS-induced HUVEC proliferation, tube formation, and cell migration, and partially attenuated MKI-EPS-induced expression of p21 and ICAM1, and STAT3 phosphorylation.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	58-61
27473919-6	2016	Furthermore, exposure of the cells to etoposide induced the phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 but not p38-MAPK, which was suppressed by the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059), respectively.	pyrazolanthrone	228-236	mitogen activated protein kinase 3	Rattus norvegicus	79-157
27473919-6	2016	Furthermore, exposure of the cells to etoposide induced the phosphorylation of c-Jun N-terminal kinase (JNK) and extracellular signal-related kinase (ERK)1/2 but not p38-MAPK, which was suppressed by the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059), respectively.	pyrazolanthrone	228-236	mitogen-activated protein kinase 8	Rattus norvegicus	104-107
27473919-7	2016	Additionally, pretreatment with both SP600125 and PD98059 effectively suppressed etoposide-induced beta-cell cytotoxicity, apoptosis, and GSK-3 protein phosphorylation; however, LiCl did not reverse JNK and ERK1/2 phosphorylation.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	199-202
27473919-7	2016	Additionally, pretreatment with both SP600125 and PD98059 effectively suppressed etoposide-induced beta-cell cytotoxicity, apoptosis, and GSK-3 protein phosphorylation; however, LiCl did not reverse JNK and ERK1/2 phosphorylation.	pyrazolanthrone	37-45	mitogen activated protein kinase 3	Rattus norvegicus	207-213
27667455-12	2016	Therefore, these data indicated that H-89 blocked the SP600125-induced polyploidization of CMK cells mainly by changing S6K1 phosphorylation state, rather than its inhibitory effect on PKA.	pyrazolanthrone	54-62	ribosomal protein S6 kinase B1	Homo sapiens	120-124
27667455-13	2016	Conclusion H-89 can block the polyploidization of SP600125-induced CMK cells by regulating S6K1 phosphorylation state.	pyrazolanthrone	50-58	ribosomal protein S6 kinase B1	Homo sapiens	91-95
27667458-2	2016	Methods Megakaryocytic leukemia cell lines (Dami, Meg-01 and HEL cells) were induced towards polyploidization by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	113-121	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	8-11
27667458-2	2016	Methods Megakaryocytic leukemia cell lines (Dami, Meg-01 and HEL cells) were induced towards polyploidization by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	125-148
27667458-2	2016	Methods Megakaryocytic leukemia cell lines (Dami, Meg-01 and HEL cells) were induced towards polyploidization by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	150-153
27667458-6	2016	Results SP600125 induced polyploidization and increased the phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) in Dami, Meg-01 and HEL cells.	pyrazolanthrone	8-16	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	130-136
27667458-6	2016	Results SP600125 induced polyploidization and increased the phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4E-BP1) in Dami, Meg-01 and HEL cells.	pyrazolanthrone	8-16	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	147-150
27667458-7	2016	However, the effect of SP600125 on polyploidization of the three cell lines was different, with the strongest effect on Dami cells and the weakest on Meg-01 cells.	pyrazolanthrone	23-31	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	150-153
27667458-8	2016	Moreover, SP600125 increased the phosphorylation of S6K1 Thr421/Ser424 and decreased the phosphorylation of Thr389 in Dami cells.	pyrazolanthrone	10-18	ribosomal protein S6 kinase B1	Homo sapiens	52-56
27667458-10	2016	Interestingly, H-89 only partially blocked the polyploidization of Dami cells, although it decreased the phosphorylation of 4E-BP1 in all SP600125-induced three cell lines.	pyrazolanthrone	138-146	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	124-130
27667458-14	2016	Conclusion SP600125-induced polyploidization of megakaryocytic leukemia cell lines is dependent on the effect of SP600125 on phosphorylation of S6K1 in cell lines at the different differentiation stages.	pyrazolanthrone	11-19	ribosomal protein S6 kinase B1	Homo sapiens	144-148
27667458-14	2016	Conclusion SP600125-induced polyploidization of megakaryocytic leukemia cell lines is dependent on the effect of SP600125 on phosphorylation of S6K1 in cell lines at the different differentiation stages.	pyrazolanthrone	113-121	ribosomal protein S6 kinase B1	Homo sapiens	144-148
27357535-6	2016	Specific inhibitors of p38 (SB203580), ERK (PD98059), and JNK (SP600125) inhibited MK1-EPS-induced HUVEC proliferation, tube formation, and cell migration, and partially attenuated MKI-EPS-induced expression of p21 and ICAM1, and STAT3 phosphorylation.	pyrazolanthrone	63-71	potassium voltage-gated channel subfamily A member 1	Homo sapiens	83-86
27261070-12	2016	Furthermore, the DHPG-induced proliferation of OCCM-30 cells was reduced by pretreatment with SB203580, SP600125, and PD98059, inhibitors of p38, JNK, and ERK1/2, respectively.	pyrazolanthrone	104-112	mitogen-activated protein kinase 14	Mus musculus	141-144
27261070-12	2016	Furthermore, the DHPG-induced proliferation of OCCM-30 cells was reduced by pretreatment with SB203580, SP600125, and PD98059, inhibitors of p38, JNK, and ERK1/2, respectively.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Mus musculus	146-149
27261070-12	2016	Furthermore, the DHPG-induced proliferation of OCCM-30 cells was reduced by pretreatment with SB203580, SP600125, and PD98059, inhibitors of p38, JNK, and ERK1/2, respectively.	pyrazolanthrone	104-112	mitogen-activated protein kinase 3	Mus musculus	155-161
26680008-6	2016	Inhibition of JNK activation by SP600125 prevents the decrease in O2 ( -) production and the mitochondrial network fragmentation observed in cells exposed to the ER stress but has no impact on the reduction of the mitochondrial membrane potential.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	14-17
27412245-9	2016	SP600125 (JNK) was applied to inhibit the mitogen-activated protein kinases (MAPK) pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	10-13
27424123-9	2016	Inhibition of ERK1/2 by PD98059, JNK by SP600125 or GSK3beta by LiCl suppressed cyclin D1 phosphorylation and downregulation by kahweol.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	33-36
27424123-9	2016	Inhibition of ERK1/2 by PD98059, JNK by SP600125 or GSK3beta by LiCl suppressed cyclin D1 phosphorylation and downregulation by kahweol.	pyrazolanthrone	40-48	cyclin D1	Homo sapiens	80-89
27459971-11	2016	STC-1-induced MMP-9 expression was suppressed by SP600125 (a JNK inhibitor) in the Hs578T cells.	pyrazolanthrone	49-57	stanniocalcin 1	Homo sapiens	0-5
27112440-6	2016	When combining GAS with the MEK inhibitor U0126 or the JNK inhibitor SP600125, we observed a synergistic effect against Abeta (1-42)-induced reduction in cell viability of NPCs.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Mus musculus	55-58
27459971-11	2016	STC-1-induced MMP-9 expression was suppressed by SP600125 (a JNK inhibitor) in the Hs578T cells.	pyrazolanthrone	49-57	matrix metallopeptidase 9	Homo sapiens	14-19
27459971-11	2016	STC-1-induced MMP-9 expression was suppressed by SP600125 (a JNK inhibitor) in the Hs578T cells.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	61-64
27602114-2	2016	The results of the migration and Matrigel invasion assays indicated that the inhibitor of JNK SP600125 could inhibit the effect of 4-HPR on EJ cells.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	90-93
27459971-12	2016	STC-1-induced cell invasiveness was also inhibited by SP600125.	pyrazolanthrone	54-62	stanniocalcin 1	Homo sapiens	0-5
27602114-2	2016	The results of the migration and Matrigel invasion assays indicated that the inhibitor of JNK SP600125 could inhibit the effect of 4-HPR on EJ cells.	pyrazolanthrone	94-102	haptoglobin-related protein	Homo sapiens	133-136
27602117-7	2016	The JNK inhibitor, SP600125, reversed DHA-induced cell death in suspended HUVECs, suggesting that the JNK pathway may mediate DHA-induced endothelial cell anoikis.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
27602117-7	2016	The JNK inhibitor, SP600125, reversed DHA-induced cell death in suspended HUVECs, suggesting that the JNK pathway may mediate DHA-induced endothelial cell anoikis.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	102-105
27656674-14	2016	SB203508 (p38MAK inhibitor), SP600125 (JNK inhibitor) and Y27632 (Rho-kinase inhibitor) reduced succinate-induced contraction in both endothelium-intact and endothelium-denuded rat aortic rings, while PD98059 (ERK1/2 inhibitor) did not affect succinate-induced contraction.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Rattus norvegicus	39-42
27618898-11	2016	SP600125, the JNK inhibitor, significantly augmented the anti-IL-6 activity of ET.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	14-17
27570977-5	2016	Furthermore, the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 MAPK was detected in Vitamin K2-treated cells and both SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38 MAPK) completely abolished the Vitamin K2-induced apoptosis and loss of mitochondria membrane potential.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	36-59
27570977-5	2016	Furthermore, the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 MAPK was detected in Vitamin K2-treated cells and both SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38 MAPK) completely abolished the Vitamin K2-induced apoptosis and loss of mitochondria membrane potential.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	61-64
27648363-8	2016	The JNK-specific inhibitor SP600125 upregulated nuclear translocation of beta-catenin, and downregulated Dickkopf-1 (Dkk1), which has been shown to be a potent inhibitor of Wnt signaling.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	4-7
27570977-5	2016	Furthermore, the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 MAPK was detected in Vitamin K2-treated cells and both SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38 MAPK) completely abolished the Vitamin K2-induced apoptosis and loss of mitochondria membrane potential.	pyrazolanthrone	129-137	mitogen-activated protein kinase 14	Homo sapiens	70-73
27570977-5	2016	Furthermore, the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 MAPK was detected in Vitamin K2-treated cells and both SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38 MAPK) completely abolished the Vitamin K2-induced apoptosis and loss of mitochondria membrane potential.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	155-158
27570977-5	2016	Furthermore, the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 MAPK was detected in Vitamin K2-treated cells and both SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38 MAPK) completely abolished the Vitamin K2-induced apoptosis and loss of mitochondria membrane potential.	pyrazolanthrone	129-137	mitogen-activated protein kinase 14	Homo sapiens	190-193
27438371-3	2016	Since JNK is known to be suppressed by beta1 integrins and mediates radiation-induced apoptosis, we tested the effect of SP600125, an inhibitor of c-Jun amino-terminal kinase (JNK) in the TRAMP model system.	pyrazolanthrone	121-129	jun proto-oncogene	Mus musculus	147-152
27438371-3	2016	Since JNK is known to be suppressed by beta1 integrins and mediates radiation-induced apoptosis, we tested the effect of SP600125, an inhibitor of c-Jun amino-terminal kinase (JNK) in the TRAMP model system.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Mus musculus	176-179
27438371-3	2016	Since JNK is known to be suppressed by beta1 integrins and mediates radiation-induced apoptosis, we tested the effect of SP600125, an inhibitor of c-Jun amino-terminal kinase (JNK) in the TRAMP model system.	pyrazolanthrone	121-129	tumor necrosis factor receptor superfamily, member 25	Mus musculus	188-193
27438371-4	2016	Our results show that SP600125 negates the effect of radiation on tumor growth in beta1pc-/- /TRAMP mice and leads to invasive adenocarcinoma.	pyrazolanthrone	22-30	tumor necrosis factor receptor superfamily, member 25	Mus musculus	94-99
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	pyrazolanthrone	298-306	mitogen-activated protein kinase 8	Homo sapiens	168-191
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	pyrazolanthrone	298-306	mitogen-activated protein kinase 8	Homo sapiens	193-196
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	pyrazolanthrone	298-300	mitogen-activated protein kinase 8	Homo sapiens	168-191
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	pyrazolanthrone	298-300	mitogen-activated protein kinase 8	Homo sapiens	193-196
27438150-0	2016	Effect of JNK inhibitor SP600125 on hair cell regeneration in zebrafish (Danio rerio) larvae.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8b	Danio rerio	10-13
27438150-4	2016	We eliminated hair cells of 5-day post-fertilization zebrafish larvae using neomycin followed by JNK inhibition with SP600125.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8b	Danio rerio	97-100
27438150-8	2016	Finally, JNK inhibition with SP600125 decreased the expression of genes related to Wnt.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8b	Danio rerio	9-12
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	285-293	Oncogene OVC (ovarian adenocarcinoma oncogene)	Homo sapiens	31-35
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	285-293	mitogen-activated protein kinase 1	Homo sapiens	101-146
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	285-293	mitogen-activated protein kinase 1	Homo sapiens	148-151
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	285-293	mitogen-activated protein kinase 14	Homo sapiens	173-209
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	285-293	mitogen-activated protein kinase 1	Homo sapiens	211-215
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	285-293	mitogen-activated protein kinase 8	Homo sapiens	245-268
27490539-6	2016	Moreover, the transcription of hST8Sia VI induced by physcion in SK-N-BE(2)-C cells was inhibited by extracellular signal-regulated protein kinase (ERK) inhibitor U0126 and p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580, but not c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	285-293	mitogen-activated protein kinase 8	Homo sapiens	270-273
27648363-8	2016	The JNK-specific inhibitor SP600125 upregulated nuclear translocation of beta-catenin, and downregulated Dickkopf-1 (Dkk1), which has been shown to be a potent inhibitor of Wnt signaling.	pyrazolanthrone	27-35	catenin beta 1	Homo sapiens	73-85
27648363-8	2016	The JNK-specific inhibitor SP600125 upregulated nuclear translocation of beta-catenin, and downregulated Dickkopf-1 (Dkk1), which has been shown to be a potent inhibitor of Wnt signaling.	pyrazolanthrone	27-35	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	105-115
27648363-8	2016	The JNK-specific inhibitor SP600125 upregulated nuclear translocation of beta-catenin, and downregulated Dickkopf-1 (Dkk1), which has been shown to be a potent inhibitor of Wnt signaling.	pyrazolanthrone	27-35	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	117-121
27556216-8	2016	Treatment of either acute or chronic hyperglycemic vessels with JNK inhibitor SP600125 or JNK-interacting protein-1 (JIP1) inhibitor BI-78D3, but not p38 inhibitor SB203580, preserved bradykinin-induced dilation in an L-NAME-sensitive manner.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Sus scrofa	64-67
27315281-9	2016	The combination treatment of PDTC and SP600125, a JNK pathway inhibitor, increased the survival of Cd-stimulated HRGECs compared with those cells treated with PDTC alone (p&lt;0.05).	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	50-53
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	pyrazolanthrone	87-95	mitogen activated protein kinase 14	Rattus norvegicus	20-23
27216154-4	2016	Electron microscopic analyses demonstrated that both oxaliplatin- and hypoxia-induced formations of autophagosomes were reduced significantly in HT29 cells treated with the JNK inhibitor SP600125.	pyrazolanthrone	187-195	mitogen-activated protein kinase 8	Homo sapiens	173-176
27314600-8	2016	However, the JNK inhibitor, SP600125, significantly inhibited LPS-induced IL-1beta production.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	13-16
27314600-8	2016	However, the JNK inhibitor, SP600125, significantly inhibited LPS-induced IL-1beta production.	pyrazolanthrone	28-36	interleukin 1 beta	Homo sapiens	74-82
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	pyrazolanthrone	87-95	Eph receptor B1	Rattus norvegicus	28-31
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	pyrazolanthrone	87-95	nitric oxide synthase 2	Rattus norvegicus	139-143
27068033-6	2016	Blockage of JAK and p38/JNK/ERK MAPKs with their specific inhibitors, AG490, SB202190, SP600125 and U0126 significantly reduced PM-induced iNOS expression and IL-1beta production.	pyrazolanthrone	87-95	interleukin 1 beta	Rattus norvegicus	159-167
27174766-6	2016	These pro-inflammatory responses were inhibited by the STAT3 blocker, AG490 and P38/JNK MAPK blockers SB202190, SP600125.	pyrazolanthrone	112-120	signal transducer and activator of transcription 3	Rattus norvegicus	55-60
27421653-11	2016	The inhibitor of SAPK/JNK (SP600125) blocked the PPI-inhibited p65 and DNMT1 protein expression.	pyrazolanthrone	27-35	RELA proto-oncogene, NF-kB subunit	Homo sapiens	63-66
27421653-11	2016	The inhibitor of SAPK/JNK (SP600125) blocked the PPI-inhibited p65 and DNMT1 protein expression.	pyrazolanthrone	27-35	DNA methyltransferase 1	Homo sapiens	71-76
27501764-5	2016	In vitro, incubation with bile significantly reduced L02 cell viability; this effect was significantly attenuated by pretreatment with SP600125 (a JNK inhibitor) and enhanced when co-incubated with taurine zinc SDs.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	147-150
27174766-6	2016	These pro-inflammatory responses were inhibited by the STAT3 blocker, AG490 and P38/JNK MAPK blockers SB202190, SP600125.	pyrazolanthrone	112-120	mitogen activated protein kinase 14	Rattus norvegicus	80-83
27174766-6	2016	These pro-inflammatory responses were inhibited by the STAT3 blocker, AG490 and P38/JNK MAPK blockers SB202190, SP600125.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Rattus norvegicus	84-87
27174766-9	2016	However, P38/JNK MAPK blockers SB202190, SP600125 also obviously attenuated STAT3 activation and transnuclear transport induced by Arsenic trioxide.	pyrazolanthrone	41-49	mitogen activated protein kinase 14	Rattus norvegicus	9-12
27174766-9	2016	However, P38/JNK MAPK blockers SB202190, SP600125 also obviously attenuated STAT3 activation and transnuclear transport induced by Arsenic trioxide.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	13-16
27174766-9	2016	However, P38/JNK MAPK blockers SB202190, SP600125 also obviously attenuated STAT3 activation and transnuclear transport induced by Arsenic trioxide.	pyrazolanthrone	41-49	signal transducer and activator of transcription 3	Rattus norvegicus	76-81
27233606-0	2016	SP600125 enhances the anti-apoptotic capacity and migration of bone marrow mesenchymal stem cells treated with tumor necrosis factor-alpha.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	111-138
27321552-6	2016	Conversely, JNK inhbitor SP600125 reversed the effect of Dieckol on PARP, p-NF-kB, alpha -SMA, and p-JNK in LX-2 cells.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	12-15
27321552-6	2016	Conversely, JNK inhbitor SP600125 reversed the effect of Dieckol on PARP, p-NF-kB, alpha -SMA, and p-JNK in LX-2 cells.	pyrazolanthrone	25-33	collagen type XI alpha 2 chain	Homo sapiens	68-72
27321552-6	2016	Conversely, JNK inhbitor SP600125 reversed the effect of Dieckol on PARP, p-NF-kB, alpha -SMA, and p-JNK in LX-2 cells.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	101-104
27233606-3	2016	This study aimed to investigate if the c-Jun N-terminal kinases (JNK)-specific inhibitor SP600125 could enhance the anti-apoptosis and migration of BMSCs treated with TNF-alpha.	pyrazolanthrone	89-97	tumor necrosis factor	Homo sapiens	167-176
27233606-6	2016	We showed that the survival capacity and migration of BMSCs was significantly inhibited by TNF-alpha, which was blocked by pretreatment with SP600125.	pyrazolanthrone	141-149	tumor necrosis factor	Homo sapiens	91-100
27233606-7	2016	In the presence of SP600125, expression of cleaved caspase-9/-3 and p53 as well as the ratio of Bax to Bcl-2 was significantly decreased compared to treatment with TNF-alpha alone.	pyrazolanthrone	19-27	caspase 9	Homo sapiens	51-60
27233606-7	2016	In the presence of SP600125, expression of cleaved caspase-9/-3 and p53 as well as the ratio of Bax to Bcl-2 was significantly decreased compared to treatment with TNF-alpha alone.	pyrazolanthrone	19-27	tumor protein p53	Homo sapiens	68-71
27233606-7	2016	In the presence of SP600125, expression of cleaved caspase-9/-3 and p53 as well as the ratio of Bax to Bcl-2 was significantly decreased compared to treatment with TNF-alpha alone.	pyrazolanthrone	19-27	BCL2 associated X, apoptosis regulator	Homo sapiens	96-99
27233606-7	2016	In the presence of SP600125, expression of cleaved caspase-9/-3 and p53 as well as the ratio of Bax to Bcl-2 was significantly decreased compared to treatment with TNF-alpha alone.	pyrazolanthrone	19-27	BCL2 apoptosis regulator	Homo sapiens	103-108
27233606-7	2016	In the presence of SP600125, expression of cleaved caspase-9/-3 and p53 as well as the ratio of Bax to Bcl-2 was significantly decreased compared to treatment with TNF-alpha alone.	pyrazolanthrone	19-27	tumor necrosis factor	Homo sapiens	164-173
27233606-8	2016	Our results therefore indicate that SP600125 improves the migration capacity of TNF-alpha-treated BMSCs and exerts a significant effect on the viability of TNF-alpha-treated BMSCs through reducing the up-regulation of p53, caspase-9/-3 and the Bcl-2 family induced by TNF-alpha.	pyrazolanthrone	36-44	tumor necrosis factor	Homo sapiens	80-89
27233606-8	2016	Our results therefore indicate that SP600125 improves the migration capacity of TNF-alpha-treated BMSCs and exerts a significant effect on the viability of TNF-alpha-treated BMSCs through reducing the up-regulation of p53, caspase-9/-3 and the Bcl-2 family induced by TNF-alpha.	pyrazolanthrone	36-44	tumor necrosis factor	Homo sapiens	156-165
27233606-8	2016	Our results therefore indicate that SP600125 improves the migration capacity of TNF-alpha-treated BMSCs and exerts a significant effect on the viability of TNF-alpha-treated BMSCs through reducing the up-regulation of p53, caspase-9/-3 and the Bcl-2 family induced by TNF-alpha.	pyrazolanthrone	36-44	tumor protein p53	Homo sapiens	218-221
27233606-8	2016	Our results therefore indicate that SP600125 improves the migration capacity of TNF-alpha-treated BMSCs and exerts a significant effect on the viability of TNF-alpha-treated BMSCs through reducing the up-regulation of p53, caspase-9/-3 and the Bcl-2 family induced by TNF-alpha.	pyrazolanthrone	36-44	caspase 9	Homo sapiens	223-235
27233606-8	2016	Our results therefore indicate that SP600125 improves the migration capacity of TNF-alpha-treated BMSCs and exerts a significant effect on the viability of TNF-alpha-treated BMSCs through reducing the up-regulation of p53, caspase-9/-3 and the Bcl-2 family induced by TNF-alpha.	pyrazolanthrone	36-44	BCL2 apoptosis regulator	Homo sapiens	244-249
27233606-8	2016	Our results therefore indicate that SP600125 improves the migration capacity of TNF-alpha-treated BMSCs and exerts a significant effect on the viability of TNF-alpha-treated BMSCs through reducing the up-regulation of p53, caspase-9/-3 and the Bcl-2 family induced by TNF-alpha.	pyrazolanthrone	36-44	tumor necrosis factor	Homo sapiens	156-165
27292614-12	2016	Moreover, co-treatment with NAC (ROS scavenger), SB203580 (p38 inhibitor), SP600125 (JNK inhibitor) or salubrinal (ER stress inhibitor) significantly attenuated TBMS1-induced apoptosis.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	85-88
27433090-8	2016	Furthermore, UII enhanced the phosphorylation of JNK (P &lt; 0.05), while the activity of JNK, insulin signaling, such as total protein of IRS-1 (P &lt; 0.001), phosphorylation of IRS-1 (P &lt; 0.001) and GSK-3beta (P &lt; 0.05), and glycogen synthesis (P &lt; 0.001) could be reversed by pretreatment with the JNK inhibitor SP600125.	pyrazolanthrone	325-333	urotensin 2	Homo sapiens	13-16
27433090-11	2016	CONCLUSION: UII induces insulin resistance, and this can be reversed by JNK inhibitor SP600125 and antioxidant/NADPH oxidase inhibitor apocynin targeting the insulin signaling pathway in HepG2 cells.	pyrazolanthrone	86-94	urotensin 2	Homo sapiens	12-15
27433090-11	2016	CONCLUSION: UII induces insulin resistance, and this can be reversed by JNK inhibitor SP600125 and antioxidant/NADPH oxidase inhibitor apocynin targeting the insulin signaling pathway in HepG2 cells.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	72-75
26581032-9	2016	A JNK inhibitor (SP600125) and p75 siRNA transfection attenuated the BDNF-induced cell apoptosis.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	2-5
27066979-4	2016	First, SPC activated JNK and STAT3, and the JNK inhibitor SP600125 or STAT3 inhibitor stattic impaired the SPC-induced expression of cardiac transcription factors and GATA4 nucleus translocation, which suggests that JNK and STAT3 participated in SPC-promoted cardiac differentiation.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Homo sapiens	44-47
27066979-4	2016	First, SPC activated JNK and STAT3, and the JNK inhibitor SP600125 or STAT3 inhibitor stattic impaired the SPC-induced expression of cardiac transcription factors and GATA4 nucleus translocation, which suggests that JNK and STAT3 participated in SPC-promoted cardiac differentiation.	pyrazolanthrone	58-66	GATA binding protein 4	Homo sapiens	167-172
27066979-4	2016	First, SPC activated JNK and STAT3, and the JNK inhibitor SP600125 or STAT3 inhibitor stattic impaired the SPC-induced expression of cardiac transcription factors and GATA4 nucleus translocation, which suggests that JNK and STAT3 participated in SPC-promoted cardiac differentiation.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Homo sapiens	44-47
27066979-5	2016	Moreover, STAT3 activation was inhibited by SP600125, whereas JNK was inhibited by beta-cyclodextrin as a lipid raft breaker, which indicates a lipid raft/JNK/STAT3 pathway involved in SPC-induced myogenic transition.	pyrazolanthrone	44-52	signal transducer and activator of transcription 3	Homo sapiens	10-15
26581032-9	2016	A JNK inhibitor (SP600125) and p75 siRNA transfection attenuated the BDNF-induced cell apoptosis.	pyrazolanthrone	17-25	brain derived neurotrophic factor	Homo sapiens	69-73
27072084-1	2016	To investigate whether the mitochondrial apoptotic pathway mediates myocardial cell injuries in rats under brain death (BD), and observe the effects and mechanisms of the c-Jun N-terminal kinase (JNK) inhibitor SP600125 on cell death in the heart.	pyrazolanthrone	211-219	mitogen-activated protein kinase 8	Rattus norvegicus	171-194
26581032-10	2016	Moreover, OBA9 cells pretreated with SP600125 or p75 siRNA showed cell proliferation by BDNF stimulation, though it was reduced by U0126 and TrkB siRNA.	pyrazolanthrone	37-45	brain derived neurotrophic factor	Homo sapiens	88-92
27072084-1	2016	To investigate whether the mitochondrial apoptotic pathway mediates myocardial cell injuries in rats under brain death (BD), and observe the effects and mechanisms of the c-Jun N-terminal kinase (JNK) inhibitor SP600125 on cell death in the heart.	pyrazolanthrone	211-219	mitogen-activated protein kinase 8	Rattus norvegicus	196-199
26581032-10	2016	Moreover, OBA9 cells pretreated with SP600125 or p75 siRNA showed cell proliferation by BDNF stimulation, though it was reduced by U0126 and TrkB siRNA.	pyrazolanthrone	37-45	neurotrophic receptor tyrosine kinase 2	Homo sapiens	141-145
27072084-8	2016	The BD + SP600125 group had decreased p-JNK expression, and reduced mitochondrial apoptosis-related gene expression.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Rattus norvegicus	40-43
27072084-10	2016	The JNK inhibitor SP600125 could protect myocardial cells under BD through the inhibition of mitochondrial apoptosis-related pathways.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
27271793-7	2016	SB203580 or co-administration of SB203580 and SP600125 decreased TNF-alpha level, which may have contributed to the inactivation of p65NF-kappaB and increase in GR expression, as confirmed by western blotting.	pyrazolanthrone	46-54	tumor necrosis factor	Rattus norvegicus	65-74
27106512-9	2016	The amentoflavone-induced increases of ALP and mineralization were significantly diminished when the JNK and p38 MAPK pathways were blocked by selected inhibitors (SP600125, SB203580) in hMSCs.	pyrazolanthrone	164-172	alkaline phosphatase, placental	Homo sapiens	39-42
27106512-9	2016	The amentoflavone-induced increases of ALP and mineralization were significantly diminished when the JNK and p38 MAPK pathways were blocked by selected inhibitors (SP600125, SB203580) in hMSCs.	pyrazolanthrone	164-172	mitogen-activated protein kinase 8	Homo sapiens	101-104
27106512-9	2016	The amentoflavone-induced increases of ALP and mineralization were significantly diminished when the JNK and p38 MAPK pathways were blocked by selected inhibitors (SP600125, SB203580) in hMSCs.	pyrazolanthrone	164-172	mitogen-activated protein kinase 14	Homo sapiens	109-112
27347203-6	2016	Inhibition of JNK1/2 was achieved by pharmacological agents (SP600125) and by small interfering RNA (siRNA) silencing, while JNK1/2 was induced by active MAPK kinase 7.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	14-20
27347203-8	2016	Inhibition of JNK1/2 with either SP600125 treatment or specific siRNA silencing resulted in decreased levels of p-Ser STAT3 and increased levels of p-Tyr STAT3 and cyclin D1 in both cell lines.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	14-18
27347203-8	2016	Inhibition of JNK1/2 with either SP600125 treatment or specific siRNA silencing resulted in decreased levels of p-Ser STAT3 and increased levels of p-Tyr STAT3 and cyclin D1 in both cell lines.	pyrazolanthrone	33-41	signal transducer and activator of transcription 3	Homo sapiens	118-123
27347203-8	2016	Inhibition of JNK1/2 with either SP600125 treatment or specific siRNA silencing resulted in decreased levels of p-Ser STAT3 and increased levels of p-Tyr STAT3 and cyclin D1 in both cell lines.	pyrazolanthrone	33-41	signal transducer and activator of transcription 3	Homo sapiens	154-159
27347203-8	2016	Inhibition of JNK1/2 with either SP600125 treatment or specific siRNA silencing resulted in decreased levels of p-Ser STAT3 and increased levels of p-Tyr STAT3 and cyclin D1 in both cell lines.	pyrazolanthrone	33-41	cyclin D1	Homo sapiens	164-173
27322250-10	2016	The specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059) effectively reversed the phosphorylation level of JNK and ERK1/2, and attenuated the apoptosis.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	13-16
27322250-10	2016	The specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059) effectively reversed the phosphorylation level of JNK and ERK1/2, and attenuated the apoptosis.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	119-122
27322250-10	2016	The specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059) effectively reversed the phosphorylation level of JNK and ERK1/2, and attenuated the apoptosis.	pyrazolanthrone	28-36	mitogen-activated protein kinase 3	Mus musculus	127-133
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	pyrazolanthrone	47-55	mitogen-activated protein kinase 14	Mus musculus	85-88
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Mus musculus	93-96
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	pyrazolanthrone	47-55	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-156
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	pyrazolanthrone	47-55	colony stimulating factor 3 (granulocyte)	Mus musculus	178-183
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	pyrazolanthrone	47-55	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	185-191
27121155-7	2016	Furthermore, we found that U0126, SB203580 and SP600125 (specific inhibitors of ERK, p38 and JNK, respectively) markedly inhibited the IKK/IkappaB/NF-kappaB-dependent release of G-CSF, GM-CSF and M-CSF.	pyrazolanthrone	47-55	colony stimulating factor 1 (macrophage)	Mus musculus	186-191
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	0-3
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	82-85
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	82-85
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	82-85
27358039-4	2016	JNK was activated by PP242, and PP242-induced autophagy was blocked by inhibiting JNK pathway with SP600125 or JNK siRNA, suggesting that JNK activation is required for the mTORC1/2 inhibitor-mediated induction of autophagy in NSCLC cells.	pyrazolanthrone	99-107	CREB regulated transcription coactivator 2	Mus musculus	173-181
27398138-3	2016	The inhibitor of JNK (SP600125) and Sal A were used in type 2 diabetic (T2D) rats, outcome measures included heart hemodynamic data, myocardial infarct size, the release of lactate dehydrogenase (LDH), SERCA2a activity, cardiomyocyte apotosis, expression levels of Bcl-2, Bax and cleaved caspase-3, and the phosphorylation status of Akt and JNK.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
27398138-5	2016	Pretreatment with the SP600125 and Sal A decreased the p-JNK levels and increased the p-Akt levels in diabetic rats with I/R, and heart hemodynamic data improved, infarct size and LDH release decreased, SERCA2a activity increased, Bax and cleaved caspase-3 expression levels decreased, and the expression of Bcl-2 and the Bcl-2/Bax ratio increased.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
27398138-5	2016	Pretreatment with the SP600125 and Sal A decreased the p-JNK levels and increased the p-Akt levels in diabetic rats with I/R, and heart hemodynamic data improved, infarct size and LDH release decreased, SERCA2a activity increased, Bax and cleaved caspase-3 expression levels decreased, and the expression of Bcl-2 and the Bcl-2/Bax ratio increased.	pyrazolanthrone	22-30	AKT serine/threonine kinase 1	Rattus norvegicus	88-91
27398138-5	2016	Pretreatment with the SP600125 and Sal A decreased the p-JNK levels and increased the p-Akt levels in diabetic rats with I/R, and heart hemodynamic data improved, infarct size and LDH release decreased, SERCA2a activity increased, Bax and cleaved caspase-3 expression levels decreased, and the expression of Bcl-2 and the Bcl-2/Bax ratio increased.	pyrazolanthrone	22-30	BCL2 associated X, apoptosis regulator	Rattus norvegicus	231-234
27398138-5	2016	Pretreatment with the SP600125 and Sal A decreased the p-JNK levels and increased the p-Akt levels in diabetic rats with I/R, and heart hemodynamic data improved, infarct size and LDH release decreased, SERCA2a activity increased, Bax and cleaved caspase-3 expression levels decreased, and the expression of Bcl-2 and the Bcl-2/Bax ratio increased.	pyrazolanthrone	22-30	BCL2, apoptosis regulator	Rattus norvegicus	308-313
27398138-5	2016	Pretreatment with the SP600125 and Sal A decreased the p-JNK levels and increased the p-Akt levels in diabetic rats with I/R, and heart hemodynamic data improved, infarct size and LDH release decreased, SERCA2a activity increased, Bax and cleaved caspase-3 expression levels decreased, and the expression of Bcl-2 and the Bcl-2/Bax ratio increased.	pyrazolanthrone	22-30	BCL2, apoptosis regulator	Rattus norvegicus	322-327
27398138-5	2016	Pretreatment with the SP600125 and Sal A decreased the p-JNK levels and increased the p-Akt levels in diabetic rats with I/R, and heart hemodynamic data improved, infarct size and LDH release decreased, SERCA2a activity increased, Bax and cleaved caspase-3 expression levels decreased, and the expression of Bcl-2 and the Bcl-2/Bax ratio increased.	pyrazolanthrone	22-30	BCL2 associated X, apoptosis regulator	Rattus norvegicus	328-331
27268017-8	2016	In vitro analysis showed that JNK inhibition by SP600125 in SNU-638 cells decreased cyclin D1 protein expression and increased FOXO1 activation.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	30-33
27268017-8	2016	In vitro analysis showed that JNK inhibition by SP600125 in SNU-638 cells decreased cyclin D1 protein expression and increased FOXO1 activation.	pyrazolanthrone	48-56	cyclin D1	Homo sapiens	84-93
27268017-8	2016	In vitro analysis showed that JNK inhibition by SP600125 in SNU-638 cells decreased cyclin D1 protein expression and increased FOXO1 activation.	pyrazolanthrone	48-56	forkhead box O1	Homo sapiens	127-132
27271793-7	2016	SB203580 or co-administration of SB203580 and SP600125 decreased TNF-alpha level, which may have contributed to the inactivation of p65NF-kappaB and increase in GR expression, as confirmed by western blotting.	pyrazolanthrone	46-54	nuclear receptor subfamily 3, group C, member 1	Rattus norvegicus	161-163
27263652-8	2016	Inhibition of JNK by SP600125 markedly decreased LC3-II and Beclin1, restored phosphorylated Bcl-2, and reduced the cytotoxicity induced by the two compounds in combination.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
27038234-7	2016	Intrathecal administration of the JNK inhibitor SP600125 inhibited N/OFQ-evoked allodynia.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	34-37
27263652-8	2016	Inhibition of JNK by SP600125 markedly decreased LC3-II and Beclin1, restored phosphorylated Bcl-2, and reduced the cytotoxicity induced by the two compounds in combination.	pyrazolanthrone	21-29	beclin 1	Homo sapiens	60-67
27263652-8	2016	Inhibition of JNK by SP600125 markedly decreased LC3-II and Beclin1, restored phosphorylated Bcl-2, and reduced the cytotoxicity induced by the two compounds in combination.	pyrazolanthrone	21-29	BCL2 apoptosis regulator	Homo sapiens	93-98
27253411-7	2016	Downregulation of JNK by its specific inhibitor SP600125 could attenuate apoptosis and autophagy induced by erianin.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	18-21
27108344-5	2016	Meanwhile, the ROS scavenger N-acetyl-L-cysteine (NAC) and the Jnk inhibitor SP600125 were found to inhibit the MPPa-PDT-induced autophagy, and NAC could also inhibit Jnk phosphorylation.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	63-66
27108344-5	2016	Meanwhile, the ROS scavenger N-acetyl-L-cysteine (NAC) and the Jnk inhibitor SP600125 were found to inhibit the MPPa-PDT-induced autophagy, and NAC could also inhibit Jnk phosphorylation.	pyrazolanthrone	77-85	X-linked Kx blood group	Homo sapiens	144-147
27108344-5	2016	Meanwhile, the ROS scavenger N-acetyl-L-cysteine (NAC) and the Jnk inhibitor SP600125 were found to inhibit the MPPa-PDT-induced autophagy, and NAC could also inhibit Jnk phosphorylation.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	167-170
27109479-10	2016	The increase in c-Jun N-terminal kinases (JNK) phosphorylation by LPS in HUVECs was markedly blocked by UTI or JNK inhibitor SP600125.	pyrazolanthrone	125-133	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-21
27109479-10	2016	The increase in c-Jun N-terminal kinases (JNK) phosphorylation by LPS in HUVECs was markedly blocked by UTI or JNK inhibitor SP600125.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Homo sapiens	42-45
27109479-10	2016	The increase in c-Jun N-terminal kinases (JNK) phosphorylation by LPS in HUVECs was markedly blocked by UTI or JNK inhibitor SP600125.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Homo sapiens	111-114
27038234-7	2016	Intrathecal administration of the JNK inhibitor SP600125 inhibited N/OFQ-evoked allodynia.	pyrazolanthrone	48-56	prepronociceptin	Mus musculus	67-72
27112839-9	2016	Accordingly, dephosphorylation of c-Jun and SP1 by the specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 prevented the increase in TGFbeta1 expression.	pyrazolanthrone	104-112	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	34-39
27112839-9	2016	Accordingly, dephosphorylation of c-Jun and SP1 by the specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 prevented the increase in TGFbeta1 expression.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Homo sapiens	64-87
27112839-9	2016	Accordingly, dephosphorylation of c-Jun and SP1 by the specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 prevented the increase in TGFbeta1 expression.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Homo sapiens	89-92
27060497-6	2016	SP600125, which is known to inhibit JNK, restored the levels of antigen-induced degranulation and phosphorylation of Syk in BMMCs sensitized with higher concentrations of a clone SPE-7 when it was added before sensitization.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	36-39
27112839-9	2016	Accordingly, dephosphorylation of c-Jun and SP1 by the specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 prevented the increase in TGFbeta1 expression.	pyrazolanthrone	104-112	transforming growth factor beta 1	Homo sapiens	139-147
27125675-10	2016	Furthermore, JNK inhibitor SP600125 and Akt (Ser473) inhibitor LY294002 enhanced the inhibition of curcumol on NF-kappaB p65 nuclear translocation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	13-16
27060497-6	2016	SP600125, which is known to inhibit JNK, restored the levels of antigen-induced degranulation and phosphorylation of Syk in BMMCs sensitized with higher concentrations of a clone SPE-7 when it was added before sensitization.	pyrazolanthrone	0-8	spleen tyrosine kinase	Mus musculus	117-120
27125675-10	2016	Furthermore, JNK inhibitor SP600125 and Akt (Ser473) inhibitor LY294002 enhanced the inhibition of curcumol on NF-kappaB p65 nuclear translocation.	pyrazolanthrone	27-35	nuclear factor kappa B subunit 1	Homo sapiens	111-120
27125675-11	2016	Finally, supplementation with SP600125, LY294002, or NF-kappaB inhibitor Ammonium pyrrolidinedithiocarbamate (PDTC) significantly enhanced the inhibitory effect of curcumol on MMP-9 expression and cell migration, invasion, and adhesion in MDA-MB-231 cells.	pyrazolanthrone	30-38	matrix metallopeptidase 9	Homo sapiens	176-181
26924229-8	2016	Under hypoxic conditions, DUSP26 expression levels were elevated together with JNK activation, and treatment with JNK inhibitor SP600125, or the DUSP26 inhibitor NSC-87877, reduced hypoxia-induced Abeta generation by diminishing vesicle trafficking of C99 to the axons.	pyrazolanthrone	128-136	dual specificity phosphatase 26	Homo sapiens	26-32
26924229-8	2016	Under hypoxic conditions, DUSP26 expression levels were elevated together with JNK activation, and treatment with JNK inhibitor SP600125, or the DUSP26 inhibitor NSC-87877, reduced hypoxia-induced Abeta generation by diminishing vesicle trafficking of C99 to the axons.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	79-82
26924229-8	2016	Under hypoxic conditions, DUSP26 expression levels were elevated together with JNK activation, and treatment with JNK inhibitor SP600125, or the DUSP26 inhibitor NSC-87877, reduced hypoxia-induced Abeta generation by diminishing vesicle trafficking of C99 to the axons.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	114-117
26924229-8	2016	Under hypoxic conditions, DUSP26 expression levels were elevated together with JNK activation, and treatment with JNK inhibitor SP600125, or the DUSP26 inhibitor NSC-87877, reduced hypoxia-induced Abeta generation by diminishing vesicle trafficking of C99 to the axons.	pyrazolanthrone	128-136	amyloid beta precursor protein	Homo sapiens	197-202
27074555-4	2016	The JNK inhibitor SP600125 and the p38MAPK inhibitor SB203580 but not the MEK1/2 inhibitor U0126 significantly attenuated carfilzomib/vorinostat-induced apoptosis, suggesting that p38MAPK and JNK activation contribute to carfilzomib and vorinostat-induced apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
26898292-5	2016	Treatment with the JNK blocker SP600125 before antiretroviral administration abolished mechanical hypersensitivity with no effect on thermal response.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Mus musculus	19-22
27229480-6	2016	Interestingly, 11 protein spots, including heterogeneous nuclear ribonucleoprotein K (hnRNP K), lamin B1 and TAR DNA-binding protein (TDP43), were significantly influenced by SP600125, but not by wortmannin.	pyrazolanthrone	175-183	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	43-84
27229480-6	2016	Interestingly, 11 protein spots, including heterogeneous nuclear ribonucleoprotein K (hnRNP K), lamin B1 and TAR DNA-binding protein (TDP43), were significantly influenced by SP600125, but not by wortmannin.	pyrazolanthrone	175-183	heterogeneous nuclear ribonucleoprotein K	Homo sapiens	86-93
27229480-6	2016	Interestingly, 11 protein spots, including heterogeneous nuclear ribonucleoprotein K (hnRNP K), lamin B1 and TAR DNA-binding protein (TDP43), were significantly influenced by SP600125, but not by wortmannin.	pyrazolanthrone	175-183	lamin B1	Homo sapiens	96-104
27229480-6	2016	Interestingly, 11 protein spots, including heterogeneous nuclear ribonucleoprotein K (hnRNP K), lamin B1 and TAR DNA-binding protein (TDP43), were significantly influenced by SP600125, but not by wortmannin.	pyrazolanthrone	175-183	TAR DNA binding protein	Homo sapiens	109-132
27229480-6	2016	Interestingly, 11 protein spots, including heterogeneous nuclear ribonucleoprotein K (hnRNP K), lamin B1 and TAR DNA-binding protein (TDP43), were significantly influenced by SP600125, but not by wortmannin.	pyrazolanthrone	175-183	TAR DNA binding protein	Homo sapiens	134-139
27035222-8	2016	ROS scavenger, N-acetyl-L-cysteine (NAC, 5 mM), was able to hinder the autophagy, apoptosis and phosphorylation of JNK, and JNK inhibitor (SP600125, 10 microM) significantly inhibited the autophagy and apoptosis, and attenuated the sensitivity of MG63 cells to AE-PDT.	pyrazolanthrone	139-147	mitogen-activated protein kinase 8	Homo sapiens	124-127
27229480-3	2016	In addition, NGF enhanced TrkA-induced morphological changes and cell death, and this effect was significantly suppressed by the JNK inhibitor SP600125, but not by the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin.	pyrazolanthrone	143-151	neurotrophic receptor tyrosine kinase 1	Homo sapiens	26-30
27229480-3	2016	In addition, NGF enhanced TrkA-induced morphological changes and cell death, and this effect was significantly suppressed by the JNK inhibitor SP600125, but not by the phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Homo sapiens	129-132
27347349-8	2016	IL-1beta and TNF-alpha could activate AP1 transcriptional activity in hFOB1.19 cells (P &lt; 0.001), but the activation was inhibited when cells were pretreated with inhibitor of JNKs, SP600125 (P &lt; 0.001).	pyrazolanthrone	185-193	interleukin 1 beta	Homo sapiens	0-8
27080425-5	2016	Intrathecal administration of a specific inhibitor of JNK phosphorylation, SP600125, given at 1 and 4h after SCI, reduced the p-JNK expression, the number of spinal apoptotic cells and many of the histological signs of spinal injury.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
27080425-5	2016	Intrathecal administration of a specific inhibitor of JNK phosphorylation, SP600125, given at 1 and 4h after SCI, reduced the p-JNK expression, the number of spinal apoptotic cells and many of the histological signs of spinal injury.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Rattus norvegicus	128-131
27347349-8	2016	IL-1beta and TNF-alpha could activate AP1 transcriptional activity in hFOB1.19 cells (P &lt; 0.001), but the activation was inhibited when cells were pretreated with inhibitor of JNKs, SP600125 (P &lt; 0.001).	pyrazolanthrone	185-193	tumor necrosis factor	Homo sapiens	13-22
27347349-8	2016	IL-1beta and TNF-alpha could activate AP1 transcriptional activity in hFOB1.19 cells (P &lt; 0.001), but the activation was inhibited when cells were pretreated with inhibitor of JNKs, SP600125 (P &lt; 0.001).	pyrazolanthrone	185-193	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	38-41
27013242-5	2016	Importantly, disruption of JNK signaling with a specific inhibitor (SP600125) or knockdown technology (Lenti-JNK-shRNAs) resulted in significantly suppressed cyst breakdown and primordial follicle formation in cultured mouse ovaries.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Mus musculus	27-30
27013242-8	2016	WNT4 expression is upregulated after SP600125 treatment.	pyrazolanthrone	37-45	wingless-type MMTV integration site family, member 4	Mus musculus	0-4
27084452-8	2016	Both a JNK inhibitor (SP600125) and a ROCK inhibitor (Y27632) reduced G12-induced JNK and c-Jun activation, and markedly inhibited G12-induced cellular invasion.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Homo sapiens	7-10
27084452-8	2016	Both a JNK inhibitor (SP600125) and a ROCK inhibitor (Y27632) reduced G12-induced JNK and c-Jun activation, and markedly inhibited G12-induced cellular invasion.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Homo sapiens	82-85
27084452-8	2016	Both a JNK inhibitor (SP600125) and a ROCK inhibitor (Y27632) reduced G12-induced JNK and c-Jun activation, and markedly inhibited G12-induced cellular invasion.	pyrazolanthrone	22-30	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-95
26985867-7	2016	In addition, using SP600125, a specific inhibitor for c-Jun N-terminal kinase (JNK) signaling, we demonstrated that JNK signaling was involved in the miR-155-mediated suppression of SRA expression.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	54-77
27164297-11	2016	Treatment of MAPK8/9/10-specific inhibitor SP600125, but not MAPK11/12/13/14-specific inhibitor SB203580, largely abolished Rabl3 knockdown-induced LC3-I/LC3-II conversion and autophagic cell death.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	13-23
27164297-11	2016	Treatment of MAPK8/9/10-specific inhibitor SP600125, but not MAPK11/12/13/14-specific inhibitor SB203580, largely abolished Rabl3 knockdown-induced LC3-I/LC3-II conversion and autophagic cell death.	pyrazolanthrone	43-51	RAB, member of RAS oncogene family like 3	Homo sapiens	124-129
27261862-3	2016	Rat models were respectively subject to subcutaneous injection of Cathepsin B siRNA and JNK inhibitor SP600125.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Rattus norvegicus	88-91
27261862-10	2016	JNK inhibitor SP600125 had no influence on the expression of Cathepsin B and Caspase-3, but effectively inhibited the expression of p-JNK.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
27261862-10	2016	JNK inhibitor SP600125 had no influence on the expression of Cathepsin B and Caspase-3, but effectively inhibited the expression of p-JNK.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Rattus norvegicus	134-137
27141946-7	2016	Treating FAK small interfering RNA (FAK siRNA) or specific inhibitor for JNK (SP600125) to iPSCs significantly reduced the phosphorylation of JNK and the expressions of Mef2c and Bcl-2.	pyrazolanthrone	78-86	PTK2 protein tyrosine kinase 2	Mus musculus	9-12
27141946-7	2016	Treating FAK small interfering RNA (FAK siRNA) or specific inhibitor for JNK (SP600125) to iPSCs significantly reduced the phosphorylation of JNK and the expressions of Mef2c and Bcl-2.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	73-76
27141946-7	2016	Treating FAK small interfering RNA (FAK siRNA) or specific inhibitor for JNK (SP600125) to iPSCs significantly reduced the phosphorylation of JNK and the expressions of Mef2c and Bcl-2.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	142-145
27141946-7	2016	Treating FAK small interfering RNA (FAK siRNA) or specific inhibitor for JNK (SP600125) to iPSCs significantly reduced the phosphorylation of JNK and the expressions of Mef2c and Bcl-2.	pyrazolanthrone	78-86	myocyte enhancer factor 2C	Mus musculus	169-174
27141946-7	2016	Treating FAK small interfering RNA (FAK siRNA) or specific inhibitor for JNK (SP600125) to iPSCs significantly reduced the phosphorylation of JNK and the expressions of Mef2c and Bcl-2.	pyrazolanthrone	78-86	B cell leukemia/lymphoma 2	Mus musculus	179-184
27017522-6	2016	Inhibition of NF-kB (BAY 11-7085), JNK (SP600125) and PI3K (LY294002) signaling pathways decreased the expression of TREM-1 (p &lt; 0.01), MMP-1 (p &lt; 0.001) and MMP-9 (p &lt; 0.01) in TNF-alpha-treated VSMCs isolated from S carotid plaques compared to AS patients.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	35-38
27017522-6	2016	Inhibition of NF-kB (BAY 11-7085), JNK (SP600125) and PI3K (LY294002) signaling pathways decreased the expression of TREM-1 (p &lt; 0.01), MMP-1 (p &lt; 0.001) and MMP-9 (p &lt; 0.01) in TNF-alpha-treated VSMCs isolated from S carotid plaques compared to AS patients.	pyrazolanthrone	40-48	triggering receptor expressed on myeloid cells 1	Homo sapiens	117-123
27133064-6	2016	After the treatment of JNK inhibitor SP600125, it obviously reversed costunolide-induced apoptosis.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	23-26
26932601-9	2016	In parallel, the application of inhibitors SP600125 and PD98059, inhibitors of the JNK and ERK signaling pathways, respectively, not only reversed such effects of Ex-4 on JNK and ERK but also resulted in lower percentages of S-phase cells and fewer numbers of Edu(+) cells.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	83-86
26932601-9	2016	In parallel, the application of inhibitors SP600125 and PD98059, inhibitors of the JNK and ERK signaling pathways, respectively, not only reversed such effects of Ex-4 on JNK and ERK but also resulted in lower percentages of S-phase cells and fewer numbers of Edu(+) cells.	pyrazolanthrone	43-51	mitogen-activated protein kinase 1	Homo sapiens	91-94
26932601-9	2016	In parallel, the application of inhibitors SP600125 and PD98059, inhibitors of the JNK and ERK signaling pathways, respectively, not only reversed such effects of Ex-4 on JNK and ERK but also resulted in lower percentages of S-phase cells and fewer numbers of Edu(+) cells.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	171-174
26932601-9	2016	In parallel, the application of inhibitors SP600125 and PD98059, inhibitors of the JNK and ERK signaling pathways, respectively, not only reversed such effects of Ex-4 on JNK and ERK but also resulted in lower percentages of S-phase cells and fewer numbers of Edu(+) cells.	pyrazolanthrone	43-51	mitogen-activated protein kinase 1	Homo sapiens	179-182
26985867-7	2016	In addition, using SP600125, a specific inhibitor for c-Jun N-terminal kinase (JNK) signaling, we demonstrated that JNK signaling was involved in the miR-155-mediated suppression of SRA expression.	pyrazolanthrone	19-27	microRNA 155	Homo sapiens	150-157
26985867-7	2016	In addition, using SP600125, a specific inhibitor for c-Jun N-terminal kinase (JNK) signaling, we demonstrated that JNK signaling was involved in the miR-155-mediated suppression of SRA expression.	pyrazolanthrone	19-27	macrophage scavenger receptor 1	Homo sapiens	182-185
26985867-7	2016	In addition, using SP600125, a specific inhibitor for c-Jun N-terminal kinase (JNK) signaling, we demonstrated that JNK signaling was involved in the miR-155-mediated suppression of SRA expression.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	79-82
26985867-7	2016	In addition, using SP600125, a specific inhibitor for c-Jun N-terminal kinase (JNK) signaling, we demonstrated that JNK signaling was involved in the miR-155-mediated suppression of SRA expression.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	116-119
27156929-7	2016	Furthermore, in vivo, both of SP600125 (JNK inhibitor) and SB203580 (p38 inhibitor) could decrease the expression of Bax and caspase-3, but increase Bcl-2 levels in HK2 cells treated with iopamidol.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	40-43
26914888-7	2016	Additionally, we showed that although TLR9 deficiency had no effect on OVA-induced phosphorylation of JNK, inhibition of JNK by specific inhibitor SP600125 significantly decreased OVA-induced expression of TLR9, suggesting that JNK is the upstream signal molecular of TLR9.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Mus musculus	121-124
26914888-7	2016	Additionally, we showed that although TLR9 deficiency had no effect on OVA-induced phosphorylation of JNK, inhibition of JNK by specific inhibitor SP600125 significantly decreased OVA-induced expression of TLR9, suggesting that JNK is the upstream signal molecular of TLR9.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Mus musculus	121-124
26914888-7	2016	Additionally, we showed that although TLR9 deficiency had no effect on OVA-induced phosphorylation of JNK, inhibition of JNK by specific inhibitor SP600125 significantly decreased OVA-induced expression of TLR9, suggesting that JNK is the upstream signal molecular of TLR9.	pyrazolanthrone	147-155	toll-like receptor 9	Mus musculus	206-210
27156929-7	2016	Furthermore, in vivo, both of SP600125 (JNK inhibitor) and SB203580 (p38 inhibitor) could decrease the expression of Bax and caspase-3, but increase Bcl-2 levels in HK2 cells treated with iopamidol.	pyrazolanthrone	30-38	BCL2 associated X, apoptosis regulator	Rattus norvegicus	117-120
26914888-9	2016	Similarly, SP600125 significantly restored the protein expression of HIOMT and the level of melatonin in OVA-challenged WT mice, while such effect was not further enhanced by TLR9 deficiency.	pyrazolanthrone	11-19	acetylserotonin O-methyltransferase	Mus musculus	69-74
27156929-7	2016	Furthermore, in vivo, both of SP600125 (JNK inhibitor) and SB203580 (p38 inhibitor) could decrease the expression of Bax and caspase-3, but increase Bcl-2 levels in HK2 cells treated with iopamidol.	pyrazolanthrone	30-38	caspase 3	Rattus norvegicus	125-134
27156929-7	2016	Furthermore, in vivo, both of SP600125 (JNK inhibitor) and SB203580 (p38 inhibitor) could decrease the expression of Bax and caspase-3, but increase Bcl-2 levels in HK2 cells treated with iopamidol.	pyrazolanthrone	30-38	BCL2, apoptosis regulator	Rattus norvegicus	149-154
26968558-8	2016	Similarly, high glucose up-regulated ACE expression in NRK-52E cells, which was blocked by the p38 MAPK inhibitor SB203580, but not the extracellular signal-regulated kinase (ERK) inhibitor FR180204 or the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	246-254	angiotensin I converting enzyme	Rattus norvegicus	37-40
26899864-9	2016	Compare to Abeta-only group, the administration of SP600125 and/or bucladesine improved spatial reference learning (P < 0.001) and memory (P < 0.01).	pyrazolanthrone	51-59	amyloid beta precursor protein	Rattus norvegicus	11-16
26986492-9	2016	Additionally, the inhibition of JNK with SP600125 repressed the apoptotic cell death induced by RCM extract, ellagic acid and quercetin, and the inhibition of JNK appeared to switch apoptosis to necrosis.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	32-35
27107990-9	2016	In addition, COMP-Ang1-mediated activation of Akt and c-Jun was suppressed by treating each of pharmacological inhibitors specific to phosphoinositide 3-kinase (PI3K) (LY294002 and Wortmannin) or MAPKs (PD98059, SB203580, and SP600125).	pyrazolanthrone	226-234	cartilage oligomeric matrix protein	Homo sapiens	13-17
27107990-9	2016	In addition, COMP-Ang1-mediated activation of Akt and c-Jun was suppressed by treating each of pharmacological inhibitors specific to phosphoinositide 3-kinase (PI3K) (LY294002 and Wortmannin) or MAPKs (PD98059, SB203580, and SP600125).	pyrazolanthrone	226-234	angiopoietin 1	Homo sapiens	18-22
27107990-9	2016	In addition, COMP-Ang1-mediated activation of Akt and c-Jun was suppressed by treating each of pharmacological inhibitors specific to phosphoinositide 3-kinase (PI3K) (LY294002 and Wortmannin) or MAPKs (PD98059, SB203580, and SP600125).	pyrazolanthrone	226-234	AKT serine/threonine kinase 1	Homo sapiens	46-49
27107990-9	2016	In addition, COMP-Ang1-mediated activation of Akt and c-Jun was suppressed by treating each of pharmacological inhibitors specific to phosphoinositide 3-kinase (PI3K) (LY294002 and Wortmannin) or MAPKs (PD98059, SB203580, and SP600125).	pyrazolanthrone	226-234	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	54-59
26899864-11	2016	In summary, it seems that the improvement of spatial memory by SP600125 and/or bucladesine in Abeta-injected rats is in relation with normalizing of autophagy to the physiologic level, possibly through neuroprotection and/or neuroplasticity.	pyrazolanthrone	63-71	amyloid beta precursor protein	Rattus norvegicus	94-99
26899864-10	2016	Compared to the Abeta-only group, the treatment with SP600125 and/or bucladesine also reduced beclin1, Atg7, Atg12, and LC3 II/I (P < 0.0001) which was similar to amount of normal rats.	pyrazolanthrone	53-61	amyloid beta precursor protein	Rattus norvegicus	16-21
26899864-10	2016	Compared to the Abeta-only group, the treatment with SP600125 and/or bucladesine also reduced beclin1, Atg7, Atg12, and LC3 II/I (P < 0.0001) which was similar to amount of normal rats.	pyrazolanthrone	53-61	beclin 1	Rattus norvegicus	94-101
26899864-10	2016	Compared to the Abeta-only group, the treatment with SP600125 and/or bucladesine also reduced beclin1, Atg7, Atg12, and LC3 II/I (P < 0.0001) which was similar to amount of normal rats.	pyrazolanthrone	53-61	autophagy related 7	Rattus norvegicus	103-107
26986870-8	2016	Inhibition of MAPKs using specific inhibitors (ERK inhibitor U0126, JNK inhibitor SP600125 and P38 inhibitor SB202190) facilitated TRAIL-mediated apoptosis and cytotoxicity.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	68-71
26899864-10	2016	Compared to the Abeta-only group, the treatment with SP600125 and/or bucladesine also reduced beclin1, Atg7, Atg12, and LC3 II/I (P < 0.0001) which was similar to amount of normal rats.	pyrazolanthrone	53-61	autophagy related 12	Rattus norvegicus	109-114
26986870-8	2016	Inhibition of MAPKs using specific inhibitors (ERK inhibitor U0126, JNK inhibitor SP600125 and P38 inhibitor SB202190) facilitated TRAIL-mediated apoptosis and cytotoxicity.	pyrazolanthrone	82-90	TNF superfamily member 10	Homo sapiens	131-136
26986870-9	2016	Additionally, SP600125 upregulated TRAL receptors as well as downregulated C-IAP2 and Mcl-1 suggesting the anti-apoptotic role of JNK.	pyrazolanthrone	14-22	baculoviral IAP repeat containing 3	Homo sapiens	75-81
26899864-10	2016	Compared to the Abeta-only group, the treatment with SP600125 and/or bucladesine also reduced beclin1, Atg7, Atg12, and LC3 II/I (P < 0.0001) which was similar to amount of normal rats.	pyrazolanthrone	53-61	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	120-128
26986870-9	2016	Additionally, SP600125 upregulated TRAL receptors as well as downregulated C-IAP2 and Mcl-1 suggesting the anti-apoptotic role of JNK.	pyrazolanthrone	14-22	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	86-91
26986870-9	2016	Additionally, SP600125 upregulated TRAL receptors as well as downregulated C-IAP2 and Mcl-1 suggesting the anti-apoptotic role of JNK.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	130-133
27008853-5	2016	Additionally, p53 knockout attenuated the apoptosis, and the apoptosis-related protein bax expression and cleaved caspase-3 activation induced by MPE in the p53 knockout C57BL/6 mice, whereas JNK inhibitor SP600125 but not ERK inhibitor U0126 inhibited MPE-induced apoptosis, supporting the conclusion that JNK/p53 might play a critical role in the tubular cell apoptosis induced by MPE and other 3-MCPD fatty acid esters.	pyrazolanthrone	206-214	mitogen-activated protein kinase 8	Mus musculus	192-195
26647389-8	2016	The use of selective MAPK inhibitors, namely PD98059, SB203580, and SP600125, blocked the effects of exendin-4 on kinase activation (ERK1/2, p38, and JNK), as well as cell proliferation and differentiation in MC3T3-E1 cells.	pyrazolanthrone	68-76	mitogen-activated protein kinase 1	Mus musculus	21-25
27008853-5	2016	Additionally, p53 knockout attenuated the apoptosis, and the apoptosis-related protein bax expression and cleaved caspase-3 activation induced by MPE in the p53 knockout C57BL/6 mice, whereas JNK inhibitor SP600125 but not ERK inhibitor U0126 inhibited MPE-induced apoptosis, supporting the conclusion that JNK/p53 might play a critical role in the tubular cell apoptosis induced by MPE and other 3-MCPD fatty acid esters.	pyrazolanthrone	206-214	transformation related protein 53, pseudogene	Mus musculus	14-17
27033605-7	2016	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the bakuchiol induced cell growth inhibitory effects.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	22-45
27033605-7	2016	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the bakuchiol induced cell growth inhibitory effects.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	47-50
27098079-10	2016	RESULTS: JNK inhibitors SP600125 and TAT-JNK-III, dose-dependently and significantly (p &lt; 0.05) protected against glutamate excitotoxicity and trophic factor withdrawal induced RGC death in culture.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Rattus norvegicus	9-12
27046040-8	2016	The TGF-alpha-induced cell migration was inhibited by SP600125, a c-Jun N-terminal kinases (JNK) inhibitor.	pyrazolanthrone	54-62	transforming growth factor alpha	Homo sapiens	4-13
27046040-8	2016	The TGF-alpha-induced cell migration was inhibited by SP600125, a c-Jun N-terminal kinases (JNK) inhibitor.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	92-95
26854718-7	2016	Moreover, pharmacological inhibition of JNK with SP600125 or knockdown of its level with SiRNA reversed mitochondrial depolarization attenuated the elevation of Bax/Bcl-2 and suppressed nuclear accumulation of AIF.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Mus musculus	40-43
30123617-10	2016	SP600125, an inhibitor of JNK, reduced rasfonin-dependent autophagic flux and apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
27045589-5	2016	We identified JNK signaling as a potential area of intervention and now show that inhibiting JNK using the pan-JNK inhibitor, SP600125, is effective in the HER2-positive, resistant JIMT-1 xenograft mammary tumor model.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	14-17
27045589-5	2016	We identified JNK signaling as a potential area of intervention and now show that inhibiting JNK using the pan-JNK inhibitor, SP600125, is effective in the HER2-positive, resistant JIMT-1 xenograft mammary tumor model.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	93-96
27045589-5	2016	We identified JNK signaling as a potential area of intervention and now show that inhibiting JNK using the pan-JNK inhibitor, SP600125, is effective in the HER2-positive, resistant JIMT-1 xenograft mammary tumor model.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	93-96
27045589-5	2016	We identified JNK signaling as a potential area of intervention and now show that inhibiting JNK using the pan-JNK inhibitor, SP600125, is effective in the HER2-positive, resistant JIMT-1 xenograft mammary tumor model.	pyrazolanthrone	126-134	erb-b2 receptor tyrosine kinase 2	Homo sapiens	156-160
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	growth differentiation factor 2	Homo sapiens	18-23
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	alkaline phosphatase, placental	Homo sapiens	32-35
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 1	Homo sapiens	118-121
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	123-146
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	148-151
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 1	Homo sapiens	158-199
26879145-9	2016	Recombinant human BMP-9-induced ALP activity was suppressed by SB203580, SP600125, and U0126, which are inhibitors of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase 1/2 (ERK1/2), respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 3	Homo sapiens	201-207
26708719-3	2016	SP600125, a JNK inhibitor, has been reported to block acetaminophen-induced liver injury.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	12-15
26708719-13	2016	Administration of SP600125 before or with acetaminophen protected Jnk(Deltahepa) and control mice from liver injury.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	66-69
26708719-16	2016	JNK inhibition with SP600125 shows off-target effects.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Mus musculus	0-3
26647389-8	2016	The use of selective MAPK inhibitors, namely PD98059, SB203580, and SP600125, blocked the effects of exendin-4 on kinase activation (ERK1/2, p38, and JNK), as well as cell proliferation and differentiation in MC3T3-E1 cells.	pyrazolanthrone	68-76	mitogen-activated protein kinase 3	Mus musculus	133-139
26647389-8	2016	The use of selective MAPK inhibitors, namely PD98059, SB203580, and SP600125, blocked the effects of exendin-4 on kinase activation (ERK1/2, p38, and JNK), as well as cell proliferation and differentiation in MC3T3-E1 cells.	pyrazolanthrone	68-76	mitogen-activated protein kinase 14	Mus musculus	141-144
26647389-8	2016	The use of selective MAPK inhibitors, namely PD98059, SB203580, and SP600125, blocked the effects of exendin-4 on kinase activation (ERK1/2, p38, and JNK), as well as cell proliferation and differentiation in MC3T3-E1 cells.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Mus musculus	150-153
26808220-10	2016	Per1 siRNA-induced mechanical hypersensitivity was attenuated with intrathecal treatment of either the JNK inhibitor SP600125 or the selective CCL2 receptor (CCR2) antagonist RS504393, indicating that these intracellular messengers are crucial in mediating the mechanical hypersensitivity following the downregulation of PER1 expression.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Mus musculus	103-106
26903295-6	2016	Inhibiting c-jun N-terminal kinase (JNK) phosphorylation activity on c-jun by SP600125, or adding a c-jun peptide, induced the nucleoplasmic translocation of GLTSCR2 from the nucleolus and enhanced protein degradation through the proteasome-polyubiquitination pathway.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	11-34
26787261-6	2016	Conversely, CHOP depletion attenuated the increase of sub-G1 population by arjunic acid, and also JNK inhibitor SP600125 blocked the cytotoxicity and upregulation of IRE1 alpha and CHOP induced by arjunic acid in A549 and H460 cells.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	98-101
26787261-6	2016	Conversely, CHOP depletion attenuated the increase of sub-G1 population by arjunic acid, and also JNK inhibitor SP600125 blocked the cytotoxicity and upregulation of IRE1 alpha and CHOP induced by arjunic acid in A549 and H460 cells.	pyrazolanthrone	112-120	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	166-176
26787261-6	2016	Conversely, CHOP depletion attenuated the increase of sub-G1 population by arjunic acid, and also JNK inhibitor SP600125 blocked the cytotoxicity and upregulation of IRE1 alpha and CHOP induced by arjunic acid in A549 and H460 cells.	pyrazolanthrone	112-120	DNA damage inducible transcript 3	Homo sapiens	181-185
26746802-5	2016	In the present study, andrographolide (10 muM) increased HO-1 protein and messenger RNA expressions, Nrf2 phosphorylation, and nuclear translocation in CECs, and these activities were disrupted by a p38 MAPK inhibitor, SB203580, but not by the extracellular signal-regulated kinase inhibitor PD98059 or c-Jun amino-terminal kinase inhibitor SP600125.	pyrazolanthrone	341-349	mitogen activated protein kinase 14	Rattus norvegicus	199-202
26903295-6	2016	Inhibiting c-jun N-terminal kinase (JNK) phosphorylation activity on c-jun by SP600125, or adding a c-jun peptide, induced the nucleoplasmic translocation of GLTSCR2 from the nucleolus and enhanced protein degradation through the proteasome-polyubiquitination pathway.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	36-39
26903295-6	2016	Inhibiting c-jun N-terminal kinase (JNK) phosphorylation activity on c-jun by SP600125, or adding a c-jun peptide, induced the nucleoplasmic translocation of GLTSCR2 from the nucleolus and enhanced protein degradation through the proteasome-polyubiquitination pathway.	pyrazolanthrone	78-86	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	11-16
26903295-6	2016	Inhibiting c-jun N-terminal kinase (JNK) phosphorylation activity on c-jun by SP600125, or adding a c-jun peptide, induced the nucleoplasmic translocation of GLTSCR2 from the nucleolus and enhanced protein degradation through the proteasome-polyubiquitination pathway.	pyrazolanthrone	78-86	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	69-74
26903295-6	2016	Inhibiting c-jun N-terminal kinase (JNK) phosphorylation activity on c-jun by SP600125, or adding a c-jun peptide, induced the nucleoplasmic translocation of GLTSCR2 from the nucleolus and enhanced protein degradation through the proteasome-polyubiquitination pathway.	pyrazolanthrone	78-86	NOP53 ribosome biogenesis factor	Homo sapiens	158-165
26985039-5	2016	Moreover, DH infusion of the JNK inhibitor SP600125 prevented G-1 from enhancing object recognition and spatial memory, but the ERK inhibitor U0126 did not.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Mus musculus	29-32
26655383-7	2016	In C2C12, alpha-LA lowers the activation of the JNK signaling pathway and increases PPARbeta mRNA and protein levels (2-fold) to the same extent as with the JNK inhibitor SP600125.	pyrazolanthrone	171-179	mitogen-activated protein kinase 8	Mus musculus	157-160
26898453-21	2016	The expression levels of p-JNK and TGF-beta1 significantly decreased when LY2157299 and SP600125 were injected simultaneously.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
26898453-21	2016	The expression levels of p-JNK and TGF-beta1 significantly decreased when LY2157299 and SP600125 were injected simultaneously.	pyrazolanthrone	88-96	transforming growth factor, beta 1	Rattus norvegicus	35-44
26898453-23	2016	Compared with the sham group, the expression of TGF-beta1 was almost unchanged by the injection of SP600125 alone, but the expression of p-JNK significantly decreased.	pyrazolanthrone	99-107	transforming growth factor, beta 1	Rattus norvegicus	48-57
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	31-34
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	pyrazolanthrone	46-54	cytochrome c, somatic	Homo sapiens	113-125
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	pyrazolanthrone	46-54	caspase 3	Homo sapiens	135-144
26985944-7	2016	Moreover, both pharmacological JNK inhibitors SP600125 and JNK siRNA dramatically blocked PTX-induced apoptosis, cytochrome c release, caspase 3, and PARP cleavage.	pyrazolanthrone	46-54	poly(ADP-ribose) polymerase 1	Homo sapiens	150-154
26849940-7	2016	While, SP600125 (one JNK inhibitor) and SB203580 (one p38 inhibitor) markedly up-regulated Bcl-2 level, down-regulated the levels of Bax, cleaved caspase-3/9, and obviously boosted Cytochrome c release induced by dioscin.	pyrazolanthrone	7-15	mitogen-activated protein kinase 8	Homo sapiens	21-24
26849940-7	2016	While, SP600125 (one JNK inhibitor) and SB203580 (one p38 inhibitor) markedly up-regulated Bcl-2 level, down-regulated the levels of Bax, cleaved caspase-3/9, and obviously boosted Cytochrome c release induced by dioscin.	pyrazolanthrone	7-15	BCL2 apoptosis regulator	Homo sapiens	91-96
26849940-7	2016	While, SP600125 (one JNK inhibitor) and SB203580 (one p38 inhibitor) markedly up-regulated Bcl-2 level, down-regulated the levels of Bax, cleaved caspase-3/9, and obviously boosted Cytochrome c release induced by dioscin.	pyrazolanthrone	7-15	BCL2 associated X, apoptosis regulator	Homo sapiens	133-136
26849940-7	2016	While, SP600125 (one JNK inhibitor) and SB203580 (one p38 inhibitor) markedly up-regulated Bcl-2 level, down-regulated the levels of Bax, cleaved caspase-3/9, and obviously boosted Cytochrome c release induced by dioscin.	pyrazolanthrone	7-15	cytochrome c, somatic	Homo sapiens	181-193
26794464-6	2016	Additionally, pre-treatments with the MAPKs inhibitors SP600125 and PD98059, inhibitors of JNK and ERK1/2 activation, respectively, but not of rolipram, a type IV phosphodiesterase inhibitor, suppressed the increase in the expression of LIMP-2 after Cer administration.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Rattus norvegicus	91-94
26794464-6	2016	Additionally, pre-treatments with the MAPKs inhibitors SP600125 and PD98059, inhibitors of JNK and ERK1/2 activation, respectively, but not of rolipram, a type IV phosphodiesterase inhibitor, suppressed the increase in the expression of LIMP-2 after Cer administration.	pyrazolanthrone	55-63	mitogen activated protein kinase 3	Rattus norvegicus	99-105
26833194-9	2016	Moreover, inhibition of Abl through ST571 treatment and its downstream effector JNK through SP600125 treatment blocked GADD45alpha upregulation and cell death triggered by curcumin.	pyrazolanthrone	92-100	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	24-27
26786718-11	2016	ICI 182780, U0126 (an ERK1/2 inhibitor) and SP600125 (a JNK inhibitor) prevented the increases in arterial relaxation and eNOS levels.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Rattus norvegicus	56-59
26895670-8	2016	Microinjection of SP600125, a JNK inhibitor, into the CN 1 day after CCI attenuated injury-induced behavioral hypersensitivity in a dose-dependent manner.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	30-33
26833194-9	2016	Moreover, inhibition of Abl through ST571 treatment and its downstream effector JNK through SP600125 treatment blocked GADD45alpha upregulation and cell death triggered by curcumin.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	80-83
26549707-4	2016	Increased phosphorylated c-Jun N-terminal kinase (JNK) protein expression was detected in AMN- but not SORA- or STI-treated SKOV-3 cells, and the JNK inhibitors, SP600125 and JNKI, showed slight but significant enhancement of AMN-induced cell death in SKOV-3 cells.	pyrazolanthrone	162-170	mitogen-activated protein kinase 8	Homo sapiens	50-53
26704630-2	2016	Recent in-vitro studies show that 1,9-pyrazoloanthrone (1,9-P) a potent JNK-3 inhibitor prevents the apoptosis of dopaminergic cells of brain.	pyrazolanthrone	34-54	mitogen activated protein kinase 10	Rattus norvegicus	72-77
26806093-7	2016	Pretreatment with specific pharmacological inhibitors (in RIN-m5F cells and isolated mouse islets) of JNK (SP600125) and AMPK (Compound C) or transfection with si-RNAs (in RIN-m5F cells) specific to JNK and AMPKalpha effectively prevented the Mo-induced apoptosis and related signals, but inhibitors of ERK1/2 and GSK3-alpha/beta (PD98059 and LiCl, respectively) did not reverse the Mo-induced effects.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Mus musculus	102-105
26704630-2	2016	Recent in-vitro studies show that 1,9-pyrazoloanthrone (1,9-P) a potent JNK-3 inhibitor prevents the apoptosis of dopaminergic cells of brain.	pyrazolanthrone	56-61	mitogen activated protein kinase 10	Rattus norvegicus	72-77
26859149-9	2016	Pretreatment with a p-JNK-specific inhibitor (SP600125) could effectively protect hESCs from NaF-induced cell death in a concentration- and time-dependent manner.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	22-25
26883396-8	2016	JNK inhibitors, SP600125, effectively inhibited the expression of p-JNK, p-c-Jun, IL-6 and TNF-alpha.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Homo sapiens	0-3
26883396-8	2016	JNK inhibitors, SP600125, effectively inhibited the expression of p-JNK, p-c-Jun, IL-6 and TNF-alpha.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Homo sapiens	68-71
26883396-8	2016	JNK inhibitors, SP600125, effectively inhibited the expression of p-JNK, p-c-Jun, IL-6 and TNF-alpha.	pyrazolanthrone	16-24	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	75-80
26883396-8	2016	JNK inhibitors, SP600125, effectively inhibited the expression of p-JNK, p-c-Jun, IL-6 and TNF-alpha.	pyrazolanthrone	16-24	interleukin 6	Homo sapiens	82-86
26883396-8	2016	JNK inhibitors, SP600125, effectively inhibited the expression of p-JNK, p-c-Jun, IL-6 and TNF-alpha.	pyrazolanthrone	16-24	tumor necrosis factor	Homo sapiens	91-100
26908192-7	2016	Moreover, arecoline (0.25 mM) activated JNK while SP600125 (a JNK inhibitor) attenuated arecoline-induced TGF-beta gene transcriptional activity.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Sus scrofa	62-65
26908192-8	2016	SP600125, but not SB431542 (a TGF-beta receptor type I kinase inhibitor), attenuated arecoline-induced fibronectin and PAI1 protein expressions.	pyrazolanthrone	0-8	fibronectin 1	Mus musculus	103-114
26908192-8	2016	SP600125, but not SB431542 (a TGF-beta receptor type I kinase inhibitor), attenuated arecoline-induced fibronectin and PAI1 protein expressions.	pyrazolanthrone	0-8	serpin family E member 1	Sus scrofa	119-123
26903805-3	2016	In this study, we used the small molecule JNK inhibitor SP600125 to examine the effect of JNK signaling abrogation on the development of hair cells in the zebrafish lateral line neuromast.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8b	Danio rerio	42-45
26903805-7	2016	We also showed that SP600125 induced cell death in developing neuromasts as measured by cleaved caspase-3 immunohistochemistry, and this was accompanied with an induction of p53 gene expression.	pyrazolanthrone	20-28	tumor protein p53	Danio rerio	174-177
26548719-9	2016	CoQ0-induced Nrf2 activation appears to be regulated by ROS-JNK-signaling cascades, as evidenced by suppressed Nrf2 activation upon treatment with pharmacological inhibitors of ROS (N-acetylcysteine) and JNK (SP600125).	pyrazolanthrone	209-217	nuclear factor, erythroid derived 2, like 2	Mus musculus	13-17
26893560-7	2016	CdTe QDs further promoted an increased C/EBP homologous protein expression, phosphorylation of c-JUN NH2-terminal kinase, and cleavage of ER-resident caspase-4, while the specific inhibitor (SP600125, Z-LEVD-fmk, or salubrinal) significantly attenuated QDs-triggered apoptosis, indicating that all three ER stress-mediated apoptosis pathways were activated and the direct participation of ER in the CdTe QDs-caused apoptotic cell death in HUVECs.	pyrazolanthrone	191-199	caspase 4	Homo sapiens	150-159
26559961-2	2016	In this study, we found that replication of H5N1 influenza virus was influenced by the JNK inhibitor SP600125.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Homo sapiens	87-90
26838746-6	2016	Inhibition of JNK activation by intrathecal administration of SP600125, a selective pJNK inhibitor, attenuated mechanical allodynia and heat hyperalgesia caused by tumor inoculation.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
26618262-10	2016	SP600125 (a JNK inhibitor) and SB203580 significantly abrogated the PM2.5-induced enhancement of ETA receptor-mediated contraction and receptor expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	12-15
26618262-10	2016	SP600125 (a JNK inhibitor) and SB203580 significantly abrogated the PM2.5-induced enhancement of ETA receptor-mediated contraction and receptor expression.	pyrazolanthrone	0-8	endothelin receptor type A	Rattus norvegicus	97-100
26373954-5	2016	A PE-10 catheter was placed intrathecally to deliver TNF-alpha neutralizing antibody, IL-1 receptor antagonist (IL-1ra) or the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	167-175	mitogen-activated protein kinase 8	Rattus norvegicus	152-155
26838746-9	2016	Intrathecal administration of SP600125 reduced CXCL1 increase in the spinal cord, whereas inhibition of CXCL1 in the spinal cord showed no influence on JNK activation.	pyrazolanthrone	30-38	C-X-C motif chemokine ligand 1	Rattus norvegicus	47-52
26363191-4	2016	This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation.	pyrazolanthrone	88-96	mitogen activated protein kinase 3	Rattus norvegicus	5-11
26648552-8	2016	JNK inhibitor SP600125 significantly reversed the oncogenic action of HBx and favored TGF-beta to regain the ability to inhibit the cell growth in HBx-expressing well-differentiated HCC cells.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
26648552-8	2016	JNK inhibitor SP600125 significantly reversed the oncogenic action of HBx and favored TGF-beta to regain the ability to inhibit the cell growth in HBx-expressing well-differentiated HCC cells.	pyrazolanthrone	14-22	X protein	Hepatitis B virus	70-73
26648552-8	2016	JNK inhibitor SP600125 significantly reversed the oncogenic action of HBx and favored TGF-beta to regain the ability to inhibit the cell growth in HBx-expressing well-differentiated HCC cells.	pyrazolanthrone	14-22	transforming growth factor beta 1	Homo sapiens	86-94
26648552-8	2016	JNK inhibitor SP600125 significantly reversed the oncogenic action of HBx and favored TGF-beta to regain the ability to inhibit the cell growth in HBx-expressing well-differentiated HCC cells.	pyrazolanthrone	14-22	X protein	Hepatitis B virus	147-150
26363191-4	2016	This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation.	pyrazolanthrone	88-96	mitogen activated protein kinase 3	Rattus norvegicus	61-67
26363191-4	2016	This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation.	pyrazolanthrone	88-96	mitogen activated protein kinase 3	Rattus norvegicus	61-67
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	pyrazolanthrone	217-225	FBJ osteosarcoma oncogene	Mus musculus	26-31
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	pyrazolanthrone	217-225	mitogen-activated protein kinase 1	Mus musculus	135-139
26862884-7	2016	NaF-induced expression of c-Fos protein was markedly suppressed with U0126, the inhibitor of both activated and non-activated forms of MAPK/ERK kinase 1/2 (MEK1/2) and BIX02189, the MEK5 inhibitor, but partially with SP600125, the JNK inhibitor and SB203580, the p38 inhibitor.	pyrazolanthrone	217-225	mitogen-activated protein kinase kinase 5	Mus musculus	182-186
26902409-9	2016	Decreased viability of cells was reversed by adding caspase inhibitors VAD and DEVD in SKOV-3 and A2780CP cells, and incubation of cells with JNK inhibitor SP600125 (SP) and JNKI, but not other MAPK and AKT inhibitors including PD98059, SB203580, significantly prevented the apoptosis elicited by EVO in human ovarian cancer cells.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	142-145
26780827-10	2016	Protein levels of COX-2 and mPGES-1 were reduced by SB203580, SP600125, and SC514 (p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and IkappaB kinase (IKK) inhibitors, respectively), as well as by PD98059 and PD0325901 (mitogen-activated protein kinase kinase (MEK) inhibitors).	pyrazolanthrone	62-70	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	18-23
26780827-10	2016	Protein levels of COX-2 and mPGES-1 were reduced by SB203580, SP600125, and SC514 (p38 mitogen-activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK), and IkappaB kinase (IKK) inhibitors, respectively), as well as by PD98059 and PD0325901 (mitogen-activated protein kinase kinase (MEK) inhibitors).	pyrazolanthrone	62-70	prostaglandin E synthase	Mus musculus	28-35
26808193-6	2016	C-Jun N-terminal kinase (JNK) was activated after treatment with PP7 and pretreatment with SP600125, a JNK inhibitor, reversed PP7-induced autophagy and cell death, suggesting that JNK plays a critical role in autophagy caused by PP7.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	0-23
26808193-6	2016	C-Jun N-terminal kinase (JNK) was activated after treatment with PP7 and pretreatment with SP600125, a JNK inhibitor, reversed PP7-induced autophagy and cell death, suggesting that JNK plays a critical role in autophagy caused by PP7.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	25-28
26808193-6	2016	C-Jun N-terminal kinase (JNK) was activated after treatment with PP7 and pretreatment with SP600125, a JNK inhibitor, reversed PP7-induced autophagy and cell death, suggesting that JNK plays a critical role in autophagy caused by PP7.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	103-106
26808193-6	2016	C-Jun N-terminal kinase (JNK) was activated after treatment with PP7 and pretreatment with SP600125, a JNK inhibitor, reversed PP7-induced autophagy and cell death, suggesting that JNK plays a critical role in autophagy caused by PP7.	pyrazolanthrone	91-99	protein phosphatase with EF-hand domain 1	Homo sapiens	127-130
26808193-6	2016	C-Jun N-terminal kinase (JNK) was activated after treatment with PP7 and pretreatment with SP600125, a JNK inhibitor, reversed PP7-induced autophagy and cell death, suggesting that JNK plays a critical role in autophagy caused by PP7.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	103-106
26808193-6	2016	C-Jun N-terminal kinase (JNK) was activated after treatment with PP7 and pretreatment with SP600125, a JNK inhibitor, reversed PP7-induced autophagy and cell death, suggesting that JNK plays a critical role in autophagy caused by PP7.	pyrazolanthrone	91-99	protein phosphatase with EF-hand domain 1	Homo sapiens	127-130
26902409-9	2016	Decreased viability of cells was reversed by adding caspase inhibitors VAD and DEVD in SKOV-3 and A2780CP cells, and incubation of cells with JNK inhibitor SP600125 (SP) and JNKI, but not other MAPK and AKT inhibitors including PD98059, SB203580, significantly prevented the apoptosis elicited by EVO in human ovarian cancer cells.	pyrazolanthrone	156-158	mitogen-activated protein kinase 8	Homo sapiens	142-145
26902409-10	2016	Furthermore, increased expression of phospho-eIF2alpha (peIF2alpha) and phospho-PERK (pPERK) proteins was detected in EVO-treated human ovarian cancer cells, and that was inhibited by adding JNK inhibitors SP600125 and JNKI.	pyrazolanthrone	206-214	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	80-84
26902409-10	2016	Furthermore, increased expression of phospho-eIF2alpha (peIF2alpha) and phospho-PERK (pPERK) proteins was detected in EVO-treated human ovarian cancer cells, and that was inhibited by adding JNK inhibitors SP600125 and JNKI.	pyrazolanthrone	206-214	mitogen-activated protein kinase 8	Homo sapiens	191-194
28097126-10	2016	Administration of JNK inhibitor SP600125 or ROS scavenger tocopherol with TMZ and NAMPT inhibitors substantially attenuated the sensitization of NAMPT inhibitor on TMZ antitumor action.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	18-21
27848251-9	2016	This subsequently increased Bax activation, leading to marked aRVS-induced apoptosis, whereas the JNK inhibitor SP600125 in aRVS extract treated SKOV-3 cells strongly inhibited Bax.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	98-101
27848251-9	2016	This subsequently increased Bax activation, leading to marked aRVS-induced apoptosis, whereas the JNK inhibitor SP600125 in aRVS extract treated SKOV-3 cells strongly inhibited Bax.	pyrazolanthrone	112-120	BCL2 associated X, apoptosis regulator	Homo sapiens	177-180
28097126-10	2016	Administration of JNK inhibitor SP600125 or ROS scavenger tocopherol with TMZ and NAMPT inhibitors substantially attenuated the sensitization of NAMPT inhibitor on TMZ antitumor action.	pyrazolanthrone	32-40	nicotinamide phosphoribosyltransferase	Homo sapiens	82-87
28097126-10	2016	Administration of JNK inhibitor SP600125 or ROS scavenger tocopherol with TMZ and NAMPT inhibitors substantially attenuated the sensitization of NAMPT inhibitor on TMZ antitumor action.	pyrazolanthrone	32-40	nicotinamide phosphoribosyltransferase	Homo sapiens	145-150
27478481-8	2016	The effects of berberine on LPS-treated HUVECs were prevented by SP600125, a JNK-specific inhibitor.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	77-80
27504140-4	2016	Intrathecal administration of MAPKs inhibitors, SB203580 (p38 inhibitor), SP600125 (JNK inhibitor), and U0126 (ERK inhibitor), resulted in a partial reduction in CCD-induced mechanical allodynia.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Rattus norvegicus	84-87
27096061-5	2016	The inhibitors SB203580, PD98059 and SP600125 were used for suppressing the expression of p38 mitogen-activated protein kinase (MAPK), p44/42 MAPK and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).	pyrazolanthrone	37-45	mitogen-activated protein kinase 14	Homo sapiens	90-126
26718129-11	2016	However, p-JNK, NF-kappaB and TRPC6 protein expression, the [Ca2+]i level and cell apoptosis decreased when the H9c2 cells were pre-treated with DSS or SP600125.	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Rattus norvegicus	11-14
26718129-11	2016	However, p-JNK, NF-kappaB and TRPC6 protein expression, the [Ca2+]i level and cell apoptosis decreased when the H9c2 cells were pre-treated with DSS or SP600125.	pyrazolanthrone	152-160	transient receptor potential cation channel, subfamily C, member 6	Rattus norvegicus	30-35
27096061-5	2016	The inhibitors SB203580, PD98059 and SP600125 were used for suppressing the expression of p38 mitogen-activated protein kinase (MAPK), p44/42 MAPK and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).	pyrazolanthrone	37-45	interferon induced protein 44	Homo sapiens	135-138
27096061-5	2016	The inhibitors SB203580, PD98059 and SP600125 were used for suppressing the expression of p38 mitogen-activated protein kinase (MAPK), p44/42 MAPK and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).	pyrazolanthrone	37-45	mitogen-activated protein kinase 9	Homo sapiens	208-212
27096061-5	2016	The inhibitors SB203580, PD98059 and SP600125 were used for suppressing the expression of p38 mitogen-activated protein kinase (MAPK), p44/42 MAPK and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK).	pyrazolanthrone	37-45	mitogen-activated protein kinase 9	Homo sapiens	213-216
28116315-7	2016	The effects of SP600125, an inhibitor of the JNK pathway, on the increase of p-JNK, IL-6, and IL-8 were also studied.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	79-82
26084532-6	2016	Treatment of VSMC with IGF-1 enhanced Egr-1 protein levels in a time and dose-dependent fashion and PD98059 and SP600125, two selective inhibitors of ERK1/2 and JNK, respectively, significantly decreased IGF-1-induced increase in Egr-1 expression in these cells.	pyrazolanthrone	112-120	insulin like growth factor 1	Homo sapiens	23-28
26084532-6	2016	Treatment of VSMC with IGF-1 enhanced Egr-1 protein levels in a time and dose-dependent fashion and PD98059 and SP600125, two selective inhibitors of ERK1/2 and JNK, respectively, significantly decreased IGF-1-induced increase in Egr-1 expression in these cells.	pyrazolanthrone	112-120	mitogen-activated protein kinase 3	Homo sapiens	150-156
26084532-6	2016	Treatment of VSMC with IGF-1 enhanced Egr-1 protein levels in a time and dose-dependent fashion and PD98059 and SP600125, two selective inhibitors of ERK1/2 and JNK, respectively, significantly decreased IGF-1-induced increase in Egr-1 expression in these cells.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	161-164
26084532-6	2016	Treatment of VSMC with IGF-1 enhanced Egr-1 protein levels in a time and dose-dependent fashion and PD98059 and SP600125, two selective inhibitors of ERK1/2 and JNK, respectively, significantly decreased IGF-1-induced increase in Egr-1 expression in these cells.	pyrazolanthrone	112-120	insulin like growth factor 1	Homo sapiens	204-209
26084532-6	2016	Treatment of VSMC with IGF-1 enhanced Egr-1 protein levels in a time and dose-dependent fashion and PD98059 and SP600125, two selective inhibitors of ERK1/2 and JNK, respectively, significantly decreased IGF-1-induced increase in Egr-1 expression in these cells.	pyrazolanthrone	112-120	early growth response 1	Homo sapiens	230-235
28116315-7	2016	The effects of SP600125, an inhibitor of the JNK pathway, on the increase of p-JNK, IL-6, and IL-8 were also studied.	pyrazolanthrone	15-23	interleukin 6	Homo sapiens	84-88
28116315-7	2016	The effects of SP600125, an inhibitor of the JNK pathway, on the increase of p-JNK, IL-6, and IL-8 were also studied.	pyrazolanthrone	15-23	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
28116315-11	2016	Furthermore, SP600125 significantly inhibited the activation of JNK signal, as well as reducing the productions of IL-6 and IL-8 in response to PLA+LPS stimulation.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	64-67
28116315-11	2016	Furthermore, SP600125 significantly inhibited the activation of JNK signal, as well as reducing the productions of IL-6 and IL-8 in response to PLA+LPS stimulation.	pyrazolanthrone	13-21	interleukin 6	Homo sapiens	115-119
28116315-11	2016	Furthermore, SP600125 significantly inhibited the activation of JNK signal, as well as reducing the productions of IL-6 and IL-8 in response to PLA+LPS stimulation.	pyrazolanthrone	13-21	C-X-C motif chemokine ligand 8	Homo sapiens	124-128
26431069-7	2016	SP600125 at 10 muM significantly suppressed the production of TNF alpha IL-6.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	62-71
26431069-7	2016	SP600125 at 10 muM significantly suppressed the production of TNF alpha IL-6.	pyrazolanthrone	0-8	interleukin 6	Homo sapiens	72-76
27057102-6	2016	LPS-induced apoptosis and release of inflammatory factors were alleviated by pretreatment of the Jun N-terminal kinase (JNK) inhibitor SP600125 or the p38 MAPK inhibitor SB203580, but not by the extracellular signal-regulated kinase (ERK) inhibitor PD98059 in UCP2-overexpressing mice.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Mus musculus	97-118
27057102-6	2016	LPS-induced apoptosis and release of inflammatory factors were alleviated by pretreatment of the Jun N-terminal kinase (JNK) inhibitor SP600125 or the p38 MAPK inhibitor SB203580, but not by the extracellular signal-regulated kinase (ERK) inhibitor PD98059 in UCP2-overexpressing mice.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Mus musculus	120-123
27057102-6	2016	LPS-induced apoptosis and release of inflammatory factors were alleviated by pretreatment of the Jun N-terminal kinase (JNK) inhibitor SP600125 or the p38 MAPK inhibitor SB203580, but not by the extracellular signal-regulated kinase (ERK) inhibitor PD98059 in UCP2-overexpressing mice.	pyrazolanthrone	135-143	mitogen-activated protein kinase 1	Mus musculus	234-237
27057102-6	2016	LPS-induced apoptosis and release of inflammatory factors were alleviated by pretreatment of the Jun N-terminal kinase (JNK) inhibitor SP600125 or the p38 MAPK inhibitor SB203580, but not by the extracellular signal-regulated kinase (ERK) inhibitor PD98059 in UCP2-overexpressing mice.	pyrazolanthrone	135-143	uncoupling protein 2 (mitochondrial, proton carrier)	Mus musculus	260-264
26641856-4	2016	LPS markedly induced the shedding activity of ADAM17 in alveolar epithelial cells, which was blocked by selective c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	154-162	ADAM metallopeptidase domain 17	Homo sapiens	46-52
26433471-7	2016	Fl-hIL-33-induced increases in EOC cell migration, invasive potential and proliferation were specifically abrogated by treatment with the ERK inhibitor U0126 while JNK inhibitor SP600125 only disrupted IL-33-induced enhancement of cell viability.	pyrazolanthrone	178-186	mitogen-activated protein kinase 8	Homo sapiens	164-167
26270131-13	2016	Furthermore, the expression level of HO-1 increased with taxol treatments, which could be inhibited by the specific inhibitor of JNK, SP600125.	pyrazolanthrone	134-142	heme oxygenase 1	Rattus norvegicus	37-41
26270131-13	2016	Furthermore, the expression level of HO-1 increased with taxol treatments, which could be inhibited by the specific inhibitor of JNK, SP600125.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Rattus norvegicus	129-132
27688602-3	2016	This study aimed to elucidate whether the JNK inhibitor SP600125 can attenuate nicotine plus angiotensin II- (AngII-) induced AAA formation and to assess the underlying molecular mechanisms.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Mus musculus	42-45
27688602-5	2016	The expression of matrix metalloproteinase- (MMP-) 2, MMP-9, monocyte chemoattractant protein- (MCP-) 1, and regulated-on-activation, normal T-cells expressed and secreted (RANTES) was significantly upregulated in aortic aneurysm lesions but inhibited by SP600125.	pyrazolanthrone	255-263	chemokine (C-C motif) ligand 5	Mus musculus	173-179
27688602-7	2016	SP600125 attenuated the upregulation of MCP-1 and RANTES expression and subsequent macrophage migration.	pyrazolanthrone	0-8	chemokine (C-C motif) ligand 2	Mus musculus	40-45
27688602-7	2016	SP600125 attenuated the upregulation of MCP-1 and RANTES expression and subsequent macrophage migration.	pyrazolanthrone	0-8	chemokine (C-C motif) ligand 5	Mus musculus	50-56
27688602-8	2016	In conclusion, SP600125 attenuates nicotine plus AngII-induced AAA formation likely by inhibiting MMP-2, MMP-9, MCP-1, and RANTES.	pyrazolanthrone	15-23	matrix metallopeptidase 2	Mus musculus	98-103
27688602-8	2016	In conclusion, SP600125 attenuates nicotine plus AngII-induced AAA formation likely by inhibiting MMP-2, MMP-9, MCP-1, and RANTES.	pyrazolanthrone	15-23	matrix metallopeptidase 9	Mus musculus	105-110
27688602-8	2016	In conclusion, SP600125 attenuates nicotine plus AngII-induced AAA formation likely by inhibiting MMP-2, MMP-9, MCP-1, and RANTES.	pyrazolanthrone	15-23	chemokine (C-C motif) ligand 2	Mus musculus	112-117
27688602-8	2016	In conclusion, SP600125 attenuates nicotine plus AngII-induced AAA formation likely by inhibiting MMP-2, MMP-9, MCP-1, and RANTES.	pyrazolanthrone	15-23	chemokine (C-C motif) ligand 5	Mus musculus	123-129
26641856-4	2016	LPS markedly induced the shedding activity of ADAM17 in alveolar epithelial cells, which was blocked by selective c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Homo sapiens	114-137
26641856-4	2016	LPS markedly induced the shedding activity of ADAM17 in alveolar epithelial cells, which was blocked by selective c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Homo sapiens	139-142
26549806-5	2015	The c-jun N-terminal kinase (JNK) pathway was activated after incubation with GA. Pretreatment with the JNK inhibitor SP600125 or silencing of the JNK pathway by siRNA of JNK or c-jun decreased GA-induced autophagy.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	4-27
26234766-10	2016	Both Snail and MT1-MMP expressions in fibroblasts and cellular invasive activities in 3D collagen induced by PDGF-D were inhibited by LY294002, SP600125, and U1026, the inhibitors of PI3K, JNK, and ERK1/2 signaling pathways, respectively.	pyrazolanthrone	144-152	snail family transcriptional repressor 1	Homo sapiens	5-10
26234766-10	2016	Both Snail and MT1-MMP expressions in fibroblasts and cellular invasive activities in 3D collagen induced by PDGF-D were inhibited by LY294002, SP600125, and U1026, the inhibitors of PI3K, JNK, and ERK1/2 signaling pathways, respectively.	pyrazolanthrone	144-152	matrix metallopeptidase 14	Homo sapiens	15-22
26234766-10	2016	Both Snail and MT1-MMP expressions in fibroblasts and cellular invasive activities in 3D collagen induced by PDGF-D were inhibited by LY294002, SP600125, and U1026, the inhibitors of PI3K, JNK, and ERK1/2 signaling pathways, respectively.	pyrazolanthrone	144-152	platelet derived growth factor D	Homo sapiens	109-115
26234766-10	2016	Both Snail and MT1-MMP expressions in fibroblasts and cellular invasive activities in 3D collagen induced by PDGF-D were inhibited by LY294002, SP600125, and U1026, the inhibitors of PI3K, JNK, and ERK1/2 signaling pathways, respectively.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	189-192
26234766-10	2016	Both Snail and MT1-MMP expressions in fibroblasts and cellular invasive activities in 3D collagen induced by PDGF-D were inhibited by LY294002, SP600125, and U1026, the inhibitors of PI3K, JNK, and ERK1/2 signaling pathways, respectively.	pyrazolanthrone	144-152	mitogen-activated protein kinase 3	Homo sapiens	198-204
26549806-5	2015	The c-jun N-terminal kinase (JNK) pathway was activated after incubation with GA. Pretreatment with the JNK inhibitor SP600125 or silencing of the JNK pathway by siRNA of JNK or c-jun decreased GA-induced autophagy.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	29-32
26549806-5	2015	The c-jun N-terminal kinase (JNK) pathway was activated after incubation with GA. Pretreatment with the JNK inhibitor SP600125 or silencing of the JNK pathway by siRNA of JNK or c-jun decreased GA-induced autophagy.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	104-107
26549806-5	2015	The c-jun N-terminal kinase (JNK) pathway was activated after incubation with GA. Pretreatment with the JNK inhibitor SP600125 or silencing of the JNK pathway by siRNA of JNK or c-jun decreased GA-induced autophagy.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	104-107
26549806-5	2015	The c-jun N-terminal kinase (JNK) pathway was activated after incubation with GA. Pretreatment with the JNK inhibitor SP600125 or silencing of the JNK pathway by siRNA of JNK or c-jun decreased GA-induced autophagy.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	104-107
26549806-5	2015	The c-jun N-terminal kinase (JNK) pathway was activated after incubation with GA. Pretreatment with the JNK inhibitor SP600125 or silencing of the JNK pathway by siRNA of JNK or c-jun decreased GA-induced autophagy.	pyrazolanthrone	118-126	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-9
26517353-4	2015	This is evidenced by the findings that inhibition of JNK with SP600125 or expression of dominant negative c-Jun partially prevented FC101-induced cell death.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	53-56
30090349-10	2016	Moreover, the NF-kappaB inhibitor (PDTC), the ERK inhibitor (PD98059), the JNK inhibitor (SP600125), and the p38 MAPK inhibitor (SB203580) markedly attenuated the growth of these cells.	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Homo sapiens	75-78
26500049-10	2015	SP600125 and SB203580, specific inhibitors of JNK kinase and p38 kinase, significantly retarded apoptosis induced by SL4.	pyrazolanthrone	0-8	mitogen-activated protein kinase 1	Homo sapiens	61-64
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	5-8
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	pyrazolanthrone	41-49	mitogen-activated protein kinase 3	Homo sapiens	13-19
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	pyrazolanthrone	41-49	tumor necrosis factor	Homo sapiens	104-107
26644796-12	2015	MAPK JNK and ERK1/2 specific inhibitors (SP600125 and UO126), but not p38, significantly down regulates TNF induced PTX3 promoter activity and protein release in HASMC.	pyrazolanthrone	41-49	pentraxin 3	Homo sapiens	116-120
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Mus musculus	49-52
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	pyrazolanthrone	63-71	bone morphogenetic protein 4	Mus musculus	82-86
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	pyrazolanthrone	63-71	bone morphogenetic protein 4	Mus musculus	95-99
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	pyrazolanthrone	63-71	bone morphogenetic protein 4	Mus musculus	95-99
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	pyrazolanthrone	63-71	bone morphogenetic protein 4	Mus musculus	95-99
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	pyrazolanthrone	63-71	bone morphogenetic protein 4	Mus musculus	95-99
25323043-9	2015	Treatment with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 inhibited BMP4-induced BMP4 expression in cardiomyocytes, but the ERK1/2 inhibitor U0126 increased BMP4-induced BMP4 expression, indicating that JNK, ERK1/2 and p38 MAPKs were all involved, although only JNK activation contributed to the inhibition of BMP4-induced BMP4 expression by oestrogen.	pyrazolanthrone	63-71	bone morphogenetic protein 4	Mus musculus	95-99
26592514-12	2015	Pretreatment with JNK inhibitor SP600125 (10 mumol/L) abrogated H2O2-induced accumulation of LC3-II, and attenuated H2O2-induced reduction of Bcl-2 levels in MSCs.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Mus musculus	18-21
26592514-12	2015	Pretreatment with JNK inhibitor SP600125 (10 mumol/L) abrogated H2O2-induced accumulation of LC3-II, and attenuated H2O2-induced reduction of Bcl-2 levels in MSCs.	pyrazolanthrone	32-40	B cell leukemia/lymphoma 2	Mus musculus	142-147
26335364-7	2015	FAm-induced lactic dehydrogenase (LDH) and caspase-3/7 activities were significantly decreased by LF and SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	105-113	caspase 3	Homo sapiens	43-52
26335364-7	2015	FAm-induced lactic dehydrogenase (LDH) and caspase-3/7 activities were significantly decreased by LF and SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	117-140
26335364-7	2015	FAm-induced lactic dehydrogenase (LDH) and caspase-3/7 activities were significantly decreased by LF and SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	142-145
26465378-8	2015	The JNK1/2 inhibitor SP 600125 attenuated PSP-induced caspase-3 and JNK1/2 activation, confirming the role of JNK1/2 in PSP-induced cytotoxicity.	pyrazolanthrone	21-30	caspase 3	Rattus norvegicus	54-63
26431905-9	2015	We evaluated the effects of the ROS inhibitor N-acetylcysteine (NAC) and the JNK inhibitor SP600125 on fluoride-induced SIRT1/autophagy activation.	pyrazolanthrone	91-99	sirtuin 1	Mus musculus	120-125
26431905-12	2015	SP600125 attenuated fluoride-induced SIRT1 phosphorylation, indicating that fluoride activates SIRT1/autophagy via the ROS-mediated JNK pathway.	pyrazolanthrone	0-8	sirtuin 1	Mus musculus	37-42
26431905-12	2015	SP600125 attenuated fluoride-induced SIRT1 phosphorylation, indicating that fluoride activates SIRT1/autophagy via the ROS-mediated JNK pathway.	pyrazolanthrone	0-8	sirtuin 1	Mus musculus	95-100
26431905-12	2015	SP600125 attenuated fluoride-induced SIRT1 phosphorylation, indicating that fluoride activates SIRT1/autophagy via the ROS-mediated JNK pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	132-135
26370512-4	2015	LMO7b phosphorylation was blocked by exposing the cells to the JNK inhibitor SP600125 and by infecting cells with dominant-negative JNK or AMPK adenovirus.	pyrazolanthrone	77-85	LIM and calponin homology domains 1	Homo sapiens	0-5
26370512-4	2015	LMO7b phosphorylation was blocked by exposing the cells to the JNK inhibitor SP600125 and by infecting cells with dominant-negative JNK or AMPK adenovirus.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	63-66
26593914-6	2015	Upregulated cPLA2-alpha protein was attenuated by pretreatment with an OB-R blocking antibody, U0126, SB202190, SP600125, Bay11-7086, garcinol, and p300 siRNA, suggesting roles of p42/p44 MAPK, p38 MAPK, JNK1/2, NF-kappaB, and p300 in leptin effects.	pyrazolanthrone	112-120	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	12-23
26176363-7	2015	Furthermore, inhibition of JNK and p38 mitogen-activated protein kinases (MAPKs) were observed after mGluR4 activation, and as paralleling control, JNK-specific inhibitor SP600125 and p38-specific inhibitor SB203580 significantly rescued the H2O2-mediated NSC apoptosis and cleavage of procaspase-3.	pyrazolanthrone	171-179	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
26272544-5	2015	Inhibition of the JNK signaling pathway using SP600125 blocked osteogenic differentiation in a dose-dependent manner, which was revealed by an ALP activity assay, extracellular calcium deposition detection, and expression of osteogenesis-relative genes (Runx2, ALP, and OCN) via RT-PCR and real-time PCR.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	18-21
26272544-5	2015	Inhibition of the JNK signaling pathway using SP600125 blocked osteogenic differentiation in a dose-dependent manner, which was revealed by an ALP activity assay, extracellular calcium deposition detection, and expression of osteogenesis-relative genes (Runx2, ALP, and OCN) via RT-PCR and real-time PCR.	pyrazolanthrone	46-54	ATHS	Homo sapiens	143-146
26272544-5	2015	Inhibition of the JNK signaling pathway using SP600125 blocked osteogenic differentiation in a dose-dependent manner, which was revealed by an ALP activity assay, extracellular calcium deposition detection, and expression of osteogenesis-relative genes (Runx2, ALP, and OCN) via RT-PCR and real-time PCR.	pyrazolanthrone	46-54	RUNX family transcription factor 2	Homo sapiens	254-259
26272544-5	2015	Inhibition of the JNK signaling pathway using SP600125 blocked osteogenic differentiation in a dose-dependent manner, which was revealed by an ALP activity assay, extracellular calcium deposition detection, and expression of osteogenesis-relative genes (Runx2, ALP, and OCN) via RT-PCR and real-time PCR.	pyrazolanthrone	46-54	ATHS	Homo sapiens	261-264
26272544-5	2015	Inhibition of the JNK signaling pathway using SP600125 blocked osteogenic differentiation in a dose-dependent manner, which was revealed by an ALP activity assay, extracellular calcium deposition detection, and expression of osteogenesis-relative genes (Runx2, ALP, and OCN) via RT-PCR and real-time PCR.	pyrazolanthrone	46-54	bone gamma-carboxyglutamate protein	Homo sapiens	270-273
26272544-7	2015	Significantly, the blockage of JNK activation in adipo-induced AMSCs by SP600125 stimulated adipogenic differentiation, which was confirmed by Oil Red O staining to detect intracellular lipid droplets, and RT-PCR and real-time PCR analysis for expression of adipogenesis-relative genes (PPARgamma2 and aP2).	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	31-34
26272544-7	2015	Significantly, the blockage of JNK activation in adipo-induced AMSCs by SP600125 stimulated adipogenic differentiation, which was confirmed by Oil Red O staining to detect intracellular lipid droplets, and RT-PCR and real-time PCR analysis for expression of adipogenesis-relative genes (PPARgamma2 and aP2).	pyrazolanthrone	72-80	transcription factor AP-2 alpha	Homo sapiens	302-305
26176363-7	2015	Furthermore, inhibition of JNK and p38 mitogen-activated protein kinases (MAPKs) were observed after mGluR4 activation, and as paralleling control, JNK-specific inhibitor SP600125 and p38-specific inhibitor SB203580 significantly rescued the H2O2-mediated NSC apoptosis and cleavage of procaspase-3.	pyrazolanthrone	171-179	mitogen activated protein kinase 14	Rattus norvegicus	35-38
26415230-0	2015	SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.	pyrazolanthrone	0-8	tumor protein p53	Homo sapiens	124-127
26415230-2	2015	However, undifferentiated thyroid cancers are one of the most lethal human malignancies because of their invasiveness, metastatization and refractoriness even to the most recently developed therapies.In this study we show for the first time a significant hyperactivation of ROCK/HDAC6 pathway in thyroid cancer tissues, and its negative correlation with p53 DNA binding ability.We demonstrate that a small compound, SP600125 (SP), is able to induce cell death selectively in undifferentiated thyroid cancer cell lines by specifically acting on the pathogenic pathways of cancer development.	pyrazolanthrone	416-424	tumor protein p53	Homo sapiens	354-357
26415230-2	2015	However, undifferentiated thyroid cancers are one of the most lethal human malignancies because of their invasiveness, metastatization and refractoriness even to the most recently developed therapies.In this study we show for the first time a significant hyperactivation of ROCK/HDAC6 pathway in thyroid cancer tissues, and its negative correlation with p53 DNA binding ability.We demonstrate that a small compound, SP600125 (SP), is able to induce cell death selectively in undifferentiated thyroid cancer cell lines by specifically acting on the pathogenic pathways of cancer development.	pyrazolanthrone	416-418	tumor protein p53	Homo sapiens	354-357
26415230-5	2015	Moreover, SP exerts a preferential action on the mutant p53 by increasing its DNA binding ability.	pyrazolanthrone	10-12	tumor protein p53	Homo sapiens	56-59
26416447-9	2015	Constitutive and HGF-induced Hic-5 expression in HCCs were suppressed by the reactive oxygen species (ROS) scavengers catalase and dithiotheritol and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	190-198	hepatocyte growth factor	Homo sapiens	17-20
26420479-8	2015	The expression of RANKL induced by IL-29 could be completely blocked by the inhibitors of mitogen-activated protein kinase (MAPK) signal pathway, including PD98059 (ERK inhibitor), SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	210-218	TNF superfamily member 11	Homo sapiens	18-23
26420479-8	2015	The expression of RANKL induced by IL-29 could be completely blocked by the inhibitors of mitogen-activated protein kinase (MAPK) signal pathway, including PD98059 (ERK inhibitor), SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	210-218	interferon lambda 1	Homo sapiens	35-40
26420479-8	2015	The expression of RANKL induced by IL-29 could be completely blocked by the inhibitors of mitogen-activated protein kinase (MAPK) signal pathway, including PD98059 (ERK inhibitor), SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	210-218	mitogen-activated protein kinase 1	Homo sapiens	124-128
26528819-9	2015	JNK inhibition by SP600125 upregulated IL-23 production, but IL-12 production was significantly downregulated dose-dependently.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	0-3
26528819-9	2015	JNK inhibition by SP600125 upregulated IL-23 production, but IL-12 production was significantly downregulated dose-dependently.	pyrazolanthrone	18-26	interleukin 23 subunit alpha	Homo sapiens	39-44
26455827-5	2015	In addition, pretreatment of cells with p38 inhibitor (SB203580) or JNK inhibitor (SP600125) can antagonize the elevation of BMP-2 expression, ALP activity, and cell viability induced by rbSWH.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Mus musculus	68-71
26455827-5	2015	In addition, pretreatment of cells with p38 inhibitor (SB203580) or JNK inhibitor (SP600125) can antagonize the elevation of BMP-2 expression, ALP activity, and cell viability induced by rbSWH.	pyrazolanthrone	83-91	bone morphogenetic protein 2	Mus musculus	125-130
26365345-6	2015	Selective inhibitors of TLR4 (CLI-095) and MAP kinase, including Erk1/2 (PD98059), JNK (SP600125) and p38 (SB203580), significantly reduced Areg expression in M1 macrophages, suggesting that M1 macrophages produce Areg mainly through the TLR4-MAPK pathway, which is involved in the mechanism of M1 activation.	pyrazolanthrone	88-96	toll-like receptor 4	Mus musculus	24-28
26365345-6	2015	Selective inhibitors of TLR4 (CLI-095) and MAP kinase, including Erk1/2 (PD98059), JNK (SP600125) and p38 (SB203580), significantly reduced Areg expression in M1 macrophages, suggesting that M1 macrophages produce Areg mainly through the TLR4-MAPK pathway, which is involved in the mechanism of M1 activation.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Mus musculus	83-86
26365345-6	2015	Selective inhibitors of TLR4 (CLI-095) and MAP kinase, including Erk1/2 (PD98059), JNK (SP600125) and p38 (SB203580), significantly reduced Areg expression in M1 macrophages, suggesting that M1 macrophages produce Areg mainly through the TLR4-MAPK pathway, which is involved in the mechanism of M1 activation.	pyrazolanthrone	88-96	amphiregulin	Mus musculus	140-144
26640410-10	2015	The JNK inhibitor SP600125 inhibited the TF-induced upregulation of TIMP-2 and -3.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
26640410-10	2015	The JNK inhibitor SP600125 inhibited the TF-induced upregulation of TIMP-2 and -3.	pyrazolanthrone	18-26	tissue inhibitor of metalloproteinase 2	Mus musculus	68-81
26416447-9	2015	Constitutive and HGF-induced Hic-5 expression in HCCs were suppressed by the reactive oxygen species (ROS) scavengers catalase and dithiotheritol and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	190-198	transforming growth factor beta 1 induced transcript 1	Homo sapiens	29-34
26416447-9	2015	Constitutive and HGF-induced Hic-5 expression in HCCs were suppressed by the reactive oxygen species (ROS) scavengers catalase and dithiotheritol and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	190-198	mitogen-activated protein kinase 8	Homo sapiens	150-173
26416447-9	2015	Constitutive and HGF-induced Hic-5 expression in HCCs were suppressed by the reactive oxygen species (ROS) scavengers catalase and dithiotheritol and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	190-198	mitogen-activated protein kinase 8	Homo sapiens	175-178
26291278-6	2015	Conversely, arsenite-induced H3S10 phosphorylation and HO-1 expression were blocked by N-acetylcysteine (NAC), the c-Jun N-terminal kinase (JNK) inhibitor SP600125, and JNK knockdown (siJNK).	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	140-143
26491301-9	2015	However, the selective inhibitor for JNK signaling pathway (SP600125) was effective in reducing tumor necrosis factor alpha release as well as monocyte chemotactic protein-1 and nitric oxide production.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	37-40
26491301-9	2015	However, the selective inhibitor for JNK signaling pathway (SP600125) was effective in reducing tumor necrosis factor alpha release as well as monocyte chemotactic protein-1 and nitric oxide production.	pyrazolanthrone	60-68	tumor necrosis factor	Homo sapiens	96-123
26491301-9	2015	However, the selective inhibitor for JNK signaling pathway (SP600125) was effective in reducing tumor necrosis factor alpha release as well as monocyte chemotactic protein-1 and nitric oxide production.	pyrazolanthrone	60-68	C-C motif chemokine ligand 2	Homo sapiens	143-173
26086160-7	2015	Moreover, the PFOS-induced iNOS expression and NO production were attenuated after the inhibition of ERK or JNK MAPK by their corresponding inhibitors, PD98059 and SP600125.	pyrazolanthrone	164-172	nitric oxide synthase 2	Homo sapiens	27-31
26086160-7	2015	Moreover, the PFOS-induced iNOS expression and NO production were attenuated after the inhibition of ERK or JNK MAPK by their corresponding inhibitors, PD98059 and SP600125.	pyrazolanthrone	164-172	mitogen-activated protein kinase 1	Homo sapiens	101-104
26086160-7	2015	Moreover, the PFOS-induced iNOS expression and NO production were attenuated after the inhibition of ERK or JNK MAPK by their corresponding inhibitors, PD98059 and SP600125.	pyrazolanthrone	164-172	mitogen-activated protein kinase 8	Homo sapiens	108-111
26086160-7	2015	Moreover, the PFOS-induced iNOS expression and NO production were attenuated after the inhibition of ERK or JNK MAPK by their corresponding inhibitors, PD98059 and SP600125.	pyrazolanthrone	164-172	mitogen-activated protein kinase 1	Homo sapiens	112-116
26126628-10	2015	Telmisartan, Y27632 and SP600125 effectively suppressed the expression of sFRP5.	pyrazolanthrone	24-32	secreted frizzled-related protein 5	Rattus norvegicus	74-79
25957028-7	2015	TRAF6 siRNA or JNK inhibitor SP600125 significantly reduced LPS-induced miR-146a-5p increase in astrocytes.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	15-18
25957028-7	2015	TRAF6 siRNA or JNK inhibitor SP600125 significantly reduced LPS-induced miR-146a-5p increase in astrocytes.	pyrazolanthrone	29-37	microRNA 146a	Homo sapiens	72-80
25916679-6	2015	Furthermore, DHQ enhanced phosphorylation of three members of the mitogen-activated protein kinase (MAPK) family, and cell treatment with MEK/ERK (PD98059), p38 (SB203580) and JNK (SP600125) inhibitors reduced DHQ-induced HO-1 expression.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Mus musculus	176-179
25921464-5	2015	We showed that CORM-2-induced HO-1 protein and mRNA levels were inhibited by the inhibitor of c-Src (PP1 or SU6656), EGFR (AG1478), PI3K (LY294002), Akt (SH-5), JNK1/2 (SP600125), or p38 MAPK (SB202190) and transfection with siRNA of c-Src, EGFR, Akt, p38, JNK2, or Nrf2 in HTSMCs.	pyrazolanthrone	169-177	heme oxygenase 1	Homo sapiens	30-34
25921464-5	2015	We showed that CORM-2-induced HO-1 protein and mRNA levels were inhibited by the inhibitor of c-Src (PP1 or SU6656), EGFR (AG1478), PI3K (LY294002), Akt (SH-5), JNK1/2 (SP600125), or p38 MAPK (SB202190) and transfection with siRNA of c-Src, EGFR, Akt, p38, JNK2, or Nrf2 in HTSMCs.	pyrazolanthrone	169-177	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	94-99
26122393-7	2015	Furthermore, inhibition of JNK signaling with SP600125 suppressed hyperoxia-induced Atg7 expression and SP-C accumulation.	pyrazolanthrone	46-54	autophagy related 7	Homo sapiens	84-88
26122393-7	2015	Furthermore, inhibition of JNK signaling with SP600125 suppressed hyperoxia-induced Atg7 expression and SP-C accumulation.	pyrazolanthrone	46-54	surfactant protein C	Homo sapiens	104-108
26126628-6	2015	PD98059, SB203580, and SP600125 were used to inhibit ERK1/2, p38 MAPK, and JNK signaling pathways, respectively, and anisomycin was used to activate JNK pathway.	pyrazolanthrone	23-31	mitogen activated protein kinase 3	Rattus norvegicus	53-59
26126628-6	2015	PD98059, SB203580, and SP600125 were used to inhibit ERK1/2, p38 MAPK, and JNK signaling pathways, respectively, and anisomycin was used to activate JNK pathway.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	75-78
25711139-8	2015	When JNK was specifically inhibited with SP600125, the upregulation of 14-3-3gamma induced by IPC was almost completely abolished; however, there was no effect on ATP or MDA levels.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	5-8
25711139-8	2015	When JNK was specifically inhibited with SP600125, the upregulation of 14-3-3gamma induced by IPC was almost completely abolished; however, there was no effect on ATP or MDA levels.	pyrazolanthrone	41-49	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	Homo sapiens	71-82
26139014-0	2015	SP600125 promotes resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model.	pyrazolanthrone	0-8	toll-like receptor 9	Mus musculus	65-69
26139014-2	2015	In the present study, we aimed to investigate the effect of the JNK inhibitor SP600125 on the resolution of airway inflammation, and the underlying mechanism using a murine acute asthma model.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	64-67
26139014-9	2015	Meanwhile, SP600125 inhibited OVA-induced, increased expression of p-JNK and TLR9 in the lung tissues.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Mus musculus	69-72
26139014-9	2015	Meanwhile, SP600125 inhibited OVA-induced, increased expression of p-JNK and TLR9 in the lung tissues.	pyrazolanthrone	11-19	toll-like receptor 9	Mus musculus	77-81
26139014-10	2015	CONCLUSIONS: Collectively, our data demonstrated that SP600125 promoted resolution of allergic airway inflammation via TLR9 in an OVA-induced murine acute asthma model.	pyrazolanthrone	54-62	toll-like receptor 9	Mus musculus	119-123
26238193-11	2015	When the phosphorylation of p38 and JNK were inhibited by SB203580 (p38 inhibitor) or SP600125 (JNK inhibitor), respectively, the NOV-induced proliferation inhibition and cell apoptosis were reversed.	pyrazolanthrone	86-94	mitogen-activated protein kinase 14	Homo sapiens	28-31
26247694-5	2015	A competitive assay of anhydroexfoliamycin (1) and the specific c-Jun N-terminal kinase (JNK) inhibitor, SP600125, showed that the reduction of the phosphorylated tau levels is mediated by the JNK pathway in SH-SY5Y-TMHT441 cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Mus musculus	64-87
26247694-5	2015	A competitive assay of anhydroexfoliamycin (1) and the specific c-Jun N-terminal kinase (JNK) inhibitor, SP600125, showed that the reduction of the phosphorylated tau levels is mediated by the JNK pathway in SH-SY5Y-TMHT441 cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Mus musculus	89-92
26247694-5	2015	A competitive assay of anhydroexfoliamycin (1) and the specific c-Jun N-terminal kinase (JNK) inhibitor, SP600125, showed that the reduction of the phosphorylated tau levels is mediated by the JNK pathway in SH-SY5Y-TMHT441 cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Mus musculus	193-196
26238193-11	2015	When the phosphorylation of p38 and JNK were inhibited by SB203580 (p38 inhibitor) or SP600125 (JNK inhibitor), respectively, the NOV-induced proliferation inhibition and cell apoptosis were reversed.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	36-39
26238193-11	2015	When the phosphorylation of p38 and JNK were inhibited by SB203580 (p38 inhibitor) or SP600125 (JNK inhibitor), respectively, the NOV-induced proliferation inhibition and cell apoptosis were reversed.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	96-99
26238193-11	2015	When the phosphorylation of p38 and JNK were inhibited by SB203580 (p38 inhibitor) or SP600125 (JNK inhibitor), respectively, the NOV-induced proliferation inhibition and cell apoptosis were reversed.	pyrazolanthrone	86-94	cellular communication network factor 3	Homo sapiens	130-133
26491285-8	2015	Moreover, both ROS scavenger (N-acetylcysteine) and JNK inhibitor (SP600125) partly blocked the induction of apoptosis in all AuNPs-treated cells.	pyrazolanthrone	67-75	mitogen-activated protein kinase 8	Homo sapiens	52-55
26696477-8	2015	Either a specific inhibitor (SB203580) of the p38MAPK pathway or a specific inhibitor (SP600125) of the JNK pathway increased the GRalpha/GRbeta ratio at the meantime of inhibiting their pathways.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	104-107
26022979-8	2015	Inhibiting ERK and JNK with U0126 and SP600125 respectively, we found that the autophagy level of the cells treated with AgNPs and radiation were attenuated.	pyrazolanthrone	38-46	mitogen-activated protein kinase 1	Homo sapiens	11-14
26254334-8	2015	Inhibitors of p38-MAPK (SB202190) and JNK-MAPK (SP600125) signaling pathways decreased the expression of Ets-1, MMP-1, and MMP-9 and increased collagen type I and III expression in EGF-treated VSMCs.	pyrazolanthrone	48-56	ETS proto-oncogene 1, transcription factor	Homo sapiens	105-110
26254334-8	2015	Inhibitors of p38-MAPK (SB202190) and JNK-MAPK (SP600125) signaling pathways decreased the expression of Ets-1, MMP-1, and MMP-9 and increased collagen type I and III expression in EGF-treated VSMCs.	pyrazolanthrone	48-56	matrix metallopeptidase 1	Homo sapiens	112-117
26254334-8	2015	Inhibitors of p38-MAPK (SB202190) and JNK-MAPK (SP600125) signaling pathways decreased the expression of Ets-1, MMP-1, and MMP-9 and increased collagen type I and III expression in EGF-treated VSMCs.	pyrazolanthrone	48-56	matrix metallopeptidase 9	Homo sapiens	123-128
26254334-8	2015	Inhibitors of p38-MAPK (SB202190) and JNK-MAPK (SP600125) signaling pathways decreased the expression of Ets-1, MMP-1, and MMP-9 and increased collagen type I and III expression in EGF-treated VSMCs.	pyrazolanthrone	48-56	epidermal growth factor	Homo sapiens	181-184
26362062-9	2015	The inhibitor of SAPK/JNK (SP600125) blocked the UA-reduced expression of DNMT1 and EZH2.	pyrazolanthrone	27-35	DNA methyltransferase 1	Homo sapiens	74-79
26362062-9	2015	The inhibitor of SAPK/JNK (SP600125) blocked the UA-reduced expression of DNMT1 and EZH2.	pyrazolanthrone	27-35	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	84-88
26400327-3	2015	We identified the effects of hypertension on the activation of JNK as well as its impact on SP600125, a JNK inhibitor, during endoplasmic reticulum stress (ERS) in the hippocampus using a rat model.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Rattus norvegicus	104-107
26400327-9	2015	SP600125 alleviated neurological dysfunction, improved neuron survival, decreased phosphorylation of JNK and levels of CHOP, but increased expression of GPR78 in rats with hypertension during cerebral ischemia by inhibition of ERS.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	101-104
26400327-9	2015	SP600125 alleviated neurological dysfunction, improved neuron survival, decreased phosphorylation of JNK and levels of CHOP, but increased expression of GPR78 in rats with hypertension during cerebral ischemia by inhibition of ERS.	pyrazolanthrone	0-8	DNA-damage inducible transcript 3	Rattus norvegicus	119-123
26212436-8	2015	In addition, TNF-alpha and IFN-gamma-induced activation of ubiquitin-proteasome systems was prevented by SP600125, a JNK inhibitor.	pyrazolanthrone	105-113	tumor necrosis factor	Rattus norvegicus	13-22
26212436-8	2015	In addition, TNF-alpha and IFN-gamma-induced activation of ubiquitin-proteasome systems was prevented by SP600125, a JNK inhibitor.	pyrazolanthrone	105-113	interferon gamma	Rattus norvegicus	27-36
26212436-8	2015	In addition, TNF-alpha and IFN-gamma-induced activation of ubiquitin-proteasome systems was prevented by SP600125, a JNK inhibitor.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Rattus norvegicus	117-120
26337463-8	2015	Similarly, inhibition of JNK and p38 with SP600125 and SB203580, respectively, also suppressed apoptosis, whereas siRNA-mediated HSP27 knockdown and treatment with the ERK 1/2 inhibitor PD98059 did otherwise.	pyrazolanthrone	42-50	mitogen-activated protein kinase 1	Homo sapiens	33-36
26235742-7	2015	RESULTS: We observed that suppressing JNK activity by its specific small molecule inhibitor SP600125 or by limiting JNK1/2 expression with JNK1/2 shRNA lentiviruses inhibited the expression of pluripotent stem cell markers such as Oct4, Sox2, and Nanog in KB/VCR cells and K562/A02 cells as well as sphere formation and self-renewal abilities of K562/A02 cells.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	38-41
26022979-8	2015	Inhibiting ERK and JNK with U0126 and SP600125 respectively, we found that the autophagy level of the cells treated with AgNPs and radiation were attenuated.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	19-22
26069075-8	2015	Furthermore, SP600125, an inhibitor of JNK, significantly blocked the upregulation of Angptl4 by IL-1beta.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	39-42
26069075-8	2015	Furthermore, SP600125, an inhibitor of JNK, significantly blocked the upregulation of Angptl4 by IL-1beta.	pyrazolanthrone	13-21	angiopoietin-like 4	Mus musculus	86-93
26069075-8	2015	Furthermore, SP600125, an inhibitor of JNK, significantly blocked the upregulation of Angptl4 by IL-1beta.	pyrazolanthrone	13-21	interleukin 1 beta	Mus musculus	97-105
26296767-3	2015	In this study, we showed that the HCV-induced activation and mitochondrial accumulation of Bax were significantly attenuated by treatment with a general antioxidant, N-acetyl cysteine (NAC), or a specific c-Jun N-terminal kinase (JNK) inhibitor, SP600125, with the result suggesting that the reactive oxygen species (ROS)/JNK signalling pathway is upstream of Bax activation in HCV-induced apoptosis.	pyrazolanthrone	246-254	BCL2 associated X, apoptosis regulator	Homo sapiens	91-94
26066304-7	2015	Pretreatment of C2C12 cells with the JNK inhibitor SP600125 induced a decrease in c-Jun and Nrf2 content and was able to counteract the NaAsO2-mediated increase in CRYAB expression.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Mus musculus	37-40
26066304-7	2015	Pretreatment of C2C12 cells with the JNK inhibitor SP600125 induced a decrease in c-Jun and Nrf2 content and was able to counteract the NaAsO2-mediated increase in CRYAB expression.	pyrazolanthrone	51-59	jun proto-oncogene	Mus musculus	82-87
26066304-7	2015	Pretreatment of C2C12 cells with the JNK inhibitor SP600125 induced a decrease in c-Jun and Nrf2 content and was able to counteract the NaAsO2-mediated increase in CRYAB expression.	pyrazolanthrone	51-59	nuclear factor, erythroid derived 2, like 2	Mus musculus	92-96
26066304-7	2015	Pretreatment of C2C12 cells with the JNK inhibitor SP600125 induced a decrease in c-Jun and Nrf2 content and was able to counteract the NaAsO2-mediated increase in CRYAB expression.	pyrazolanthrone	51-59	crystallin, alpha B	Mus musculus	164-169
26296767-3	2015	In this study, we showed that the HCV-induced activation and mitochondrial accumulation of Bax were significantly attenuated by treatment with a general antioxidant, N-acetyl cysteine (NAC), or a specific c-Jun N-terminal kinase (JNK) inhibitor, SP600125, with the result suggesting that the reactive oxygen species (ROS)/JNK signalling pathway is upstream of Bax activation in HCV-induced apoptosis.	pyrazolanthrone	246-254	mitogen-activated protein kinase 8	Homo sapiens	230-233
26296767-5	2015	The HCV-induced increase in the Bim mRNA and protein levels was significantly counteracted by treatment with NAC or SP600125, suggesting that the ROS/JNK signalling pathway is involved in Bim upregulation.	pyrazolanthrone	116-124	BCL2 like 11	Homo sapiens	32-35
26296767-5	2015	The HCV-induced increase in the Bim mRNA and protein levels was significantly counteracted by treatment with NAC or SP600125, suggesting that the ROS/JNK signalling pathway is involved in Bim upregulation.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	150-153
26296767-5	2015	The HCV-induced increase in the Bim mRNA and protein levels was significantly counteracted by treatment with NAC or SP600125, suggesting that the ROS/JNK signalling pathway is involved in Bim upregulation.	pyrazolanthrone	116-124	BCL2 like 11	Homo sapiens	188-191
26285901-6	2015	Furthermore, combining MLB with the JNK inhibitor SP600125 synergistically counteracts the Abeta (1-42)-induced reduction in cell viability and neurite growth, and the neuroprotective effects of MLB could be attenuated by the Akt inhibitor triciribine.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Mus musculus	36-39
26052658-8	2015	BAY also increased TNF-alpha-induced apoptosis of GH3 cells, an effect that was further increased by an inhibitor of the c-Jun N-terminal protein kinase pathway, SP600125 (10 mum).	pyrazolanthrone	162-170	tumor necrosis factor	Rattus norvegicus	19-28
25994505-7	2015	We found that apigenin treatment significantly increased the levels of p-JNK, p-p38 in hMSCs and addition of the inhibitors of JNK (SP600125) or p38 MAPK (SB203580) eliminated the stimulating effects of apigenin.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Homo sapiens	127-130
25994505-8	2015	In addition, addition of SP600125 or SB203580 also blocked apigenin-induced ALP activity, OPN, Runx2, and OSX expression and meanwhile inhibited bone nodule formation.	pyrazolanthrone	25-33	alkaline phosphatase, placental	Homo sapiens	76-79
25994505-8	2015	In addition, addition of SP600125 or SB203580 also blocked apigenin-induced ALP activity, OPN, Runx2, and OSX expression and meanwhile inhibited bone nodule formation.	pyrazolanthrone	25-33	secreted phosphoprotein 1	Homo sapiens	90-93
25994505-8	2015	In addition, addition of SP600125 or SB203580 also blocked apigenin-induced ALP activity, OPN, Runx2, and OSX expression and meanwhile inhibited bone nodule formation.	pyrazolanthrone	25-33	RUNX family transcription factor 2	Homo sapiens	95-100
25994505-8	2015	In addition, addition of SP600125 or SB203580 also blocked apigenin-induced ALP activity, OPN, Runx2, and OSX expression and meanwhile inhibited bone nodule formation.	pyrazolanthrone	25-33	Sp7 transcription factor	Homo sapiens	106-109
26285901-6	2015	Furthermore, combining MLB with the JNK inhibitor SP600125 synergistically counteracts the Abeta (1-42)-induced reduction in cell viability and neurite growth, and the neuroprotective effects of MLB could be attenuated by the Akt inhibitor triciribine.	pyrazolanthrone	50-58	thymoma viral proto-oncogene 1	Mus musculus	226-229
26054298-4	2015	Inhibition of c-Jun NH2-terminal kinase (JNK) in liver cells with SP600125 blocked migration of monocytes in a dose-dependent manner, indicating that JNK stimulates release of chemoattractants in lipoapoptosis.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	14-39
26054298-4	2015	Inhibition of c-Jun NH2-terminal kinase (JNK) in liver cells with SP600125 blocked migration of monocytes in a dose-dependent manner, indicating that JNK stimulates release of chemoattractants in lipoapoptosis.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	41-44
26054298-4	2015	Inhibition of c-Jun NH2-terminal kinase (JNK) in liver cells with SP600125 blocked migration of monocytes in a dose-dependent manner, indicating that JNK stimulates release of chemoattractants in lipoapoptosis.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	150-153
25795598-9	2015	Moreover, the selective JNK inhibitor SP600125 improved mitochondrial membrane dysfunction and blocked neuronal apoptosis induced by JNK-dependent Bcl-2 signaling.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
25795598-9	2015	Moreover, the selective JNK inhibitor SP600125 improved mitochondrial membrane dysfunction and blocked neuronal apoptosis induced by JNK-dependent Bcl-2 signaling.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Rattus norvegicus	133-136
25795598-9	2015	Moreover, the selective JNK inhibitor SP600125 improved mitochondrial membrane dysfunction and blocked neuronal apoptosis induced by JNK-dependent Bcl-2 signaling.	pyrazolanthrone	38-46	BCL2, apoptosis regulator	Rattus norvegicus	147-152
25795598-10	2015	WIN and URB enhanced the effects of SP600125, implying that they may exert anti-apoptotic effects in part by inhibiting a non-nuclear JNK pathway.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Rattus norvegicus	134-137
26116534-4	2015	The Netrin-1-induced RSC96 cells migration was significantly attenuated by inhibition of p38 and PI3K through pretreatment with SB203580 and LY294002 respectively, but not inhibition of MEK1/2 and JNK by U0126-EtOH and SP600125 individually.	pyrazolanthrone	219-227	netrin 1	Rattus norvegicus	4-12
26287126-6	2015	In addition, JNK inhibitors (SP600125) and/or p38 inhibitors (SB203580) could abolish the effect of aldosterone on MafA expression and activity.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	13-16
26287126-6	2015	In addition, JNK inhibitors (SP600125) and/or p38 inhibitors (SB203580) could abolish the effect of aldosterone on MafA expression and activity.	pyrazolanthrone	29-37	MAF bZIP transcription factor A	Homo sapiens	115-119
26003274-7	2015	The JNK inhibitor SP600125 (10muM) inhibited antigen-induced mRNA expression and protein production of IL-4.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
26003274-7	2015	The JNK inhibitor SP600125 (10muM) inhibited antigen-induced mRNA expression and protein production of IL-4.	pyrazolanthrone	18-26	interleukin 4	Rattus norvegicus	103-107
26287183-5	2015	The anti-Fas blocking antibody reversed the DHTS-induced cell death, and the JNK-specific inhibitor, SP600125, inhibited DHTS-induced caspase-3, -8, -9, and PARP cleavage.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Homo sapiens	77-80
26287183-5	2015	The anti-Fas blocking antibody reversed the DHTS-induced cell death, and the JNK-specific inhibitor, SP600125, inhibited DHTS-induced caspase-3, -8, -9, and PARP cleavage.	pyrazolanthrone	101-109	caspase 3	Homo sapiens	134-151
26287183-5	2015	The anti-Fas blocking antibody reversed the DHTS-induced cell death, and the JNK-specific inhibitor, SP600125, inhibited DHTS-induced caspase-3, -8, -9, and PARP cleavage.	pyrazolanthrone	101-109	poly(ADP-ribose) polymerase 1	Homo sapiens	157-161
26287184-7	2015	Treatment with the JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 prevented methyl sartortuoate-induced apoptosis in LoVo cells.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
26255263-8	2015	Moreover, metreleptin-activated all signaling pathways were blocked by pre-treatment of PD98095 (ERK inhibitor), SB203580 (p38 inhibitor) and/or SP600125 (JNK inhibitor), respectively.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	155-158
25204891-9	2015	Additionally, inhibition of JNK by SP600125 significantly reversed hesperetin-mediated apoptosis.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Homo sapiens	28-31
25033989-7	2015	Pre-treatment of the cells with PD184352, an inhibitor of the upstream kinase MEK1/2, or with wortmannin, an inhibitor of phosphoinositide 3-kinase, blocked triclosan-mediated phosphorylation of ERK1/2 and Akt, respectively, and substantially suppressed triclosan-stimulated cell proliferation, whereas the JNK inhibitor SP600125 or the p38 inhibitor SB203580 had little to no effect on triclosan-stimulated cell proliferation.	pyrazolanthrone	321-329	mitogen-activated protein kinase kinase 1	Mus musculus	78-84
25033989-7	2015	Pre-treatment of the cells with PD184352, an inhibitor of the upstream kinase MEK1/2, or with wortmannin, an inhibitor of phosphoinositide 3-kinase, blocked triclosan-mediated phosphorylation of ERK1/2 and Akt, respectively, and substantially suppressed triclosan-stimulated cell proliferation, whereas the JNK inhibitor SP600125 or the p38 inhibitor SB203580 had little to no effect on triclosan-stimulated cell proliferation.	pyrazolanthrone	321-329	mitogen-activated protein kinase 3	Mus musculus	195-201
25881548-10	2015	SP600125 and JNK siRNA decreased the increased p62 expression induced by quercetin.	pyrazolanthrone	0-8	nucleoporin 62	Homo sapiens	47-50
25881548-11	2015	In addition, SP600125 also decreased the increased mRNA and protein expression of GCLC, GCLM, and HO-1 induced by quercetin.	pyrazolanthrone	13-21	glutamate-cysteine ligase catalytic subunit	Homo sapiens	82-86
25881548-11	2015	In addition, SP600125 also decreased the increased mRNA and protein expression of GCLC, GCLM, and HO-1 induced by quercetin.	pyrazolanthrone	13-21	glutamate-cysteine ligase modifier subunit	Homo sapiens	88-92
25881548-11	2015	In addition, SP600125 also decreased the increased mRNA and protein expression of GCLC, GCLM, and HO-1 induced by quercetin.	pyrazolanthrone	13-21	heme oxygenase 1	Homo sapiens	98-102
25881548-9	2015	JNK inhibitor SP600125 and JNK siRNA both reduced quercetin-induced hepatoprotection.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
26101183-5	2015	Furthermore, the Akt inhibitor, LY294002, partly eliminated the protective effect of puerarin on DEX-induced apoptosis, and puerarin combined with the JNK inhibitor, SP600125, suppressed DEX-induced apoptosis to a lesser extent than in the cells treated with SP600125 alone.	pyrazolanthrone	166-174	mitogen-activated protein kinase 8	Homo sapiens	151-154
26622558-5	2015	In addition, SP600125, a general inhibitor of JNK, inhibited PPLGM-induced apoptosis in the HCT116 cells by inhibiting PPLGM-induced c-Jun phosphorylation.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	46-49
26323834-6	2015	TNF-alpha production was reduced in a dose-dependent manner by treatment with wortmannin and PD98059, whereas it was increased by SP600125.	pyrazolanthrone	130-138	tumor necrosis factor	Homo sapiens	0-9
25955000-8	2015	Furthermore, SP600125, a JNK inhibitor, decreased the high-glucose-induced gene expression of IL-18 in a dose-dependent manner.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	25-28
25955000-8	2015	Furthermore, SP600125, a JNK inhibitor, decreased the high-glucose-induced gene expression of IL-18 in a dose-dependent manner.	pyrazolanthrone	13-21	interleukin 18	Mus musculus	94-99
26622558-5	2015	In addition, SP600125, a general inhibitor of JNK, inhibited PPLGM-induced apoptosis in the HCT116 cells by inhibiting PPLGM-induced c-Jun phosphorylation.	pyrazolanthrone	13-21	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	133-138
26161982-9	2015	IL-13 induced mucin production in the presence of epinephrine was significantly reduced by treatment with selective inhibitors of ERK1/2 (FR180204), p38 (SB203580) and JNK (SP600125).	pyrazolanthrone	173-181	LOC100508689	Homo sapiens	14-19
25891417-9	2015	JNK inhibitor SP600125 blocked the inhibitory effect of chrysosplenol D on cytokine release.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	0-3
26161982-9	2015	IL-13 induced mucin production in the presence of epinephrine was significantly reduced by treatment with selective inhibitors of ERK1/2 (FR180204), p38 (SB203580) and JNK (SP600125).	pyrazolanthrone	173-181	mitogen-activated protein kinase 3	Homo sapiens	130-136
26161982-9	2015	IL-13 induced mucin production in the presence of epinephrine was significantly reduced by treatment with selective inhibitors of ERK1/2 (FR180204), p38 (SB203580) and JNK (SP600125).	pyrazolanthrone	173-181	interleukin 13	Homo sapiens	0-5
26161982-9	2015	IL-13 induced mucin production in the presence of epinephrine was significantly reduced by treatment with selective inhibitors of ERK1/2 (FR180204), p38 (SB203580) and JNK (SP600125).	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	168-171
25042557-8	2015	Moreover, olaquindox induced the activation of c-Jun N-terminal protein kinase (JNK), and JNK inhibitor SP600125 failed to block autophagy.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Homo sapiens	90-93
25857454-5	2015	These effects are independent of OX1R internalization but are blocked in the presence of the JNK inhibitor SP-600125.	pyrazolanthrone	107-116	hypocretin receptor 1	Homo sapiens	33-37
25857454-5	2015	These effects are independent of OX1R internalization but are blocked in the presence of the JNK inhibitor SP-600125.	pyrazolanthrone	107-116	mitogen-activated protein kinase 8	Homo sapiens	93-96
26047595-9	2015	Staurosporine, JNK inhibitor SP600125 and ERK inhibitor PD98059 significantly decreased DAX-1 expression in TNF-alpha-treated Leydig cells when compared to their respective controls.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Rattus norvegicus	15-18
26047595-9	2015	Staurosporine, JNK inhibitor SP600125 and ERK inhibitor PD98059 significantly decreased DAX-1 expression in TNF-alpha-treated Leydig cells when compared to their respective controls.	pyrazolanthrone	29-37	nuclear receptor subfamily 0, group B, member 1	Rattus norvegicus	88-93
26047595-9	2015	Staurosporine, JNK inhibitor SP600125 and ERK inhibitor PD98059 significantly decreased DAX-1 expression in TNF-alpha-treated Leydig cells when compared to their respective controls.	pyrazolanthrone	29-37	tumor necrosis factor	Rattus norvegicus	108-117
26098087-10	2015	The AM-induced increase in VEGF expression was significantly attenuated by SP600125, a specific JNK inhibitor.	pyrazolanthrone	75-83	adrenomedullin	Homo sapiens	4-6
26098087-10	2015	The AM-induced increase in VEGF expression was significantly attenuated by SP600125, a specific JNK inhibitor.	pyrazolanthrone	75-83	vascular endothelial growth factor A	Homo sapiens	27-31
26098087-10	2015	The AM-induced increase in VEGF expression was significantly attenuated by SP600125, a specific JNK inhibitor.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	96-99
25976678-6	2015	Pretreatment with ROS scavenger N-acetylcysteine (NAC), an antioxidant, or the JNK inhibitor SP600125 was able to restore cell viability in the presence of cambogin.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	79-82
25893737-6	2015	When MG-63 cells were treated with both baicalein and JNK inhibitor SP600125, the apoptosis and expression of c-MYC were not significantly decreased.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	54-57
25893737-6	2015	When MG-63 cells were treated with both baicalein and JNK inhibitor SP600125, the apoptosis and expression of c-MYC were not significantly decreased.	pyrazolanthrone	68-76	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	110-115
25998184-8	2015	However, DUSP9-induced resulted in the regulation of the levels of cycle-related molecules, whivh were inhibited when the JNK inhibitor SP600125 was added.	pyrazolanthrone	136-144	dual specificity phosphatase 9	Homo sapiens	9-14
25912158-9	2015	The additions of pharmacological agents LY294002, SP600125, and CAY10585 were found to inhibit arecoline-induced S100A4 expression in OE cells.	pyrazolanthrone	50-58	S100 calcium binding protein A4	Homo sapiens	113-119
25912158-10	2015	CONCLUSION: Arecoline-induced S100A4 expression was down-regulated by LY294002, SP600125, or CAY10585 treatment.	pyrazolanthrone	80-88	S100 calcium binding protein A4	Homo sapiens	30-36
25998184-8	2015	However, DUSP9-induced resulted in the regulation of the levels of cycle-related molecules, whivh were inhibited when the JNK inhibitor SP600125 was added.	pyrazolanthrone	136-144	mitogen-activated protein kinase 8	Homo sapiens	122-125
26136938-8	2015	Furthermore, the mRNA expression levels of TGF-beta1, BMP-2 and CBFalpha1 decreased in the quercetin + SP600125 (inhibitor of JNK) and quercetin + PD98059 (inhibitor of ERK1/2) groups.	pyrazolanthrone	103-111	transforming growth factor, beta 1	Rattus norvegicus	43-52
25958204-6	2015	SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	15-18
25958204-6	2015	SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria.	pyrazolanthrone	0-8	BCL2 like 1	Homo sapiens	94-100
25958204-6	2015	SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria.	pyrazolanthrone	0-8	BCL2 apoptosis regulator	Homo sapiens	101-106
25958204-6	2015	SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria.	pyrazolanthrone	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
25958204-6	2015	SP600125 (SAPK/JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated down-regulation of Bcl-xL/Bcl-2, mitochondrial translocation of Bax, and cytochrome c release from mitochondria.	pyrazolanthrone	0-8	cytochrome c, somatic	Homo sapiens	148-160
25882087-8	2015	Addition of SP600125, a JNK-specific inhibitor, blocked TEMPO-mediated JNK phosphorylation and also attenuated TEMPO-induced apoptosis.	pyrazolanthrone	12-20	mitogen-activated protein kinase 8	Mus musculus	24-27
25882087-8	2015	Addition of SP600125, a JNK-specific inhibitor, blocked TEMPO-mediated JNK phosphorylation and also attenuated TEMPO-induced apoptosis.	pyrazolanthrone	12-20	mitogen-activated protein kinase 8	Mus musculus	71-74
25867119-8	2015	Furthermore, icariin-stimulated osteogenic effects on BMSCs were dramatically attenuated by treatment with either specific ERK inhibitor of PD98059, p38 inhibitor of SB202190 or JNK inhibitor SP600125.	pyrazolanthrone	192-200	mitogen-activated protein kinase 8	Rattus norvegicus	178-181
25806604-6	2015	The astrocyte activation was selectively prevented by the opioid antagonist naloxone, the mu-opioid receptor (MOR) silencing and the JNK inhibitor SP600125.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	133-136
25840108-7	2015	We observed that the JNK-specific inhibitor SP600125 blocked either gp120- or Foxy5-induced allodynia.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	21-24
25840108-7	2015	We observed that the JNK-specific inhibitor SP600125 blocked either gp120- or Foxy5-induced allodynia.	pyrazolanthrone	44-52	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	68-73
25840108-11	2015	Both Box-5 and SP600125 negated gp120-induced potentiation of SDH neuron spiking evoked by mechanical stimulation of the hind paw.	pyrazolanthrone	15-23	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	32-37
25862966-8	2015	Co-treatment with MAPKs inhibitors U0126, SB202190 and SP600125 indicated JNK and p38 pathways were involved in the course.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	74-77
25862966-8	2015	Co-treatment with MAPKs inhibitors U0126, SB202190 and SP600125 indicated JNK and p38 pathways were involved in the course.	pyrazolanthrone	55-63	mitogen-activated protein kinase 14	Homo sapiens	82-85
26065412-6	2015	RESULTS: We found that JNK inhibition by SP600125 (3 mg/kg) produces a greater antinociceptive effect than morphine (6 mg/kg) alone in the formalin test.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	23-26
26065412-14	2015	Thus, inhibition of JNK signaling pathway, via SP600125, represents an efficacious pharmacological approach to delay tolerance to the antinociceptive effects of chronic morphine in diverse pain models.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	20-23
26049416-14	2015	We also demonstrated that cisplatin in combination with PP2 or SP600125 could be clinically beneficial, as inhibition of Src or JNK in an APC-mutant breast cancer patient may alleviate the resistance induced by mutant APC.	pyrazolanthrone	63-71	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	121-124
26049416-14	2015	We also demonstrated that cisplatin in combination with PP2 or SP600125 could be clinically beneficial, as inhibition of Src or JNK in an APC-mutant breast cancer patient may alleviate the resistance induced by mutant APC.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	128-131
26049416-14	2015	We also demonstrated that cisplatin in combination with PP2 or SP600125 could be clinically beneficial, as inhibition of Src or JNK in an APC-mutant breast cancer patient may alleviate the resistance induced by mutant APC.	pyrazolanthrone	63-71	APC regulator of WNT signaling pathway	Homo sapiens	138-141
26049416-14	2015	We also demonstrated that cisplatin in combination with PP2 or SP600125 could be clinically beneficial, as inhibition of Src or JNK in an APC-mutant breast cancer patient may alleviate the resistance induced by mutant APC.	pyrazolanthrone	63-71	APC regulator of WNT signaling pathway	Homo sapiens	218-221
26136938-8	2015	Furthermore, the mRNA expression levels of TGF-beta1, BMP-2 and CBFalpha1 decreased in the quercetin + SP600125 (inhibitor of JNK) and quercetin + PD98059 (inhibitor of ERK1/2) groups.	pyrazolanthrone	103-111	bone morphogenetic protein 2	Rattus norvegicus	54-59
26136938-8	2015	Furthermore, the mRNA expression levels of TGF-beta1, BMP-2 and CBFalpha1 decreased in the quercetin + SP600125 (inhibitor of JNK) and quercetin + PD98059 (inhibitor of ERK1/2) groups.	pyrazolanthrone	103-111	RUNX family transcription factor 2	Rattus norvegicus	64-73
26136938-8	2015	Furthermore, the mRNA expression levels of TGF-beta1, BMP-2 and CBFalpha1 decreased in the quercetin + SP600125 (inhibitor of JNK) and quercetin + PD98059 (inhibitor of ERK1/2) groups.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Rattus norvegicus	126-129
25749876-9	2015	Reducing Ror2 expression in the BMSC cell line by siRNA or blocking the downstream signalings with specific inhibitors also demonstrated a suppression of the capacity of the BMSC cell line to promote Wnt5a-dependent migration (including SP600125 and cyclosporine A) and differentiation (cyclosporine A only) of osteoclast precursors.	pyrazolanthrone	237-245	receptor tyrosine kinase-like orphan receptor 2	Rattus norvegicus	9-13
25847782-10	2015	Furthermore, both SB203580 (a specific inhibitor of p38) and SP600125 (JNK1, JNK2 and JNK3 inhibitor) diminished the Ang II-induced production of CTGF; however, the inhibition of FPPS reduced the Ang II-induced activation of p38 mitogen-activated protein kinase (MAPK) and JNK.	pyrazolanthrone	61-69	angiotensinogen	Rattus norvegicus	117-123
25847782-10	2015	Furthermore, both SB203580 (a specific inhibitor of p38) and SP600125 (JNK1, JNK2 and JNK3 inhibitor) diminished the Ang II-induced production of CTGF; however, the inhibition of FPPS reduced the Ang II-induced activation of p38 mitogen-activated protein kinase (MAPK) and JNK.	pyrazolanthrone	61-69	cellular communication network factor 2	Rattus norvegicus	146-150
25847782-10	2015	Furthermore, both SB203580 (a specific inhibitor of p38) and SP600125 (JNK1, JNK2 and JNK3 inhibitor) diminished the Ang II-induced production of CTGF; however, the inhibition of FPPS reduced the Ang II-induced activation of p38 mitogen-activated protein kinase (MAPK) and JNK.	pyrazolanthrone	61-69	farnesyl diphosphate synthase	Rattus norvegicus	179-183
25847782-10	2015	Furthermore, both SB203580 (a specific inhibitor of p38) and SP600125 (JNK1, JNK2 and JNK3 inhibitor) diminished the Ang II-induced production of CTGF; however, the inhibition of FPPS reduced the Ang II-induced activation of p38 mitogen-activated protein kinase (MAPK) and JNK.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
25817898-6	2015	SP600125, LY294002 and AG490 attenuated S100B-induced Steap4 protein expression or gene transcriptional activity.	pyrazolanthrone	0-8	S100 protein, beta polypeptide, neural	Mus musculus	40-45
25817898-6	2015	SP600125, LY294002 and AG490 attenuated S100B-induced Steap4 protein expression or gene transcriptional activity.	pyrazolanthrone	0-8	STEAP family member 4	Mus musculus	54-60
25839235-9	2015	Pharmacological inhibition of JNK (SP600125) or curcumin reduced transcriptional up-regulation of acid ceramidase.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Homo sapiens	30-33
26024533-5	2015	RESULTS: AGEs could enhance the expression of IL-1, TNF-alpha, and MMP-13, but the level of PPARgamma was decreased in a time- and dose-dependent manner, which was inhibited by anti-RAGE, SB203580 (P38 MAPK specific inhibitor) and SP600125 (a selective inhibitor of JNK).	pyrazolanthrone	231-239	peroxisome proliferator activated receptor gamma	Homo sapiens	92-101
26024533-5	2015	RESULTS: AGEs could enhance the expression of IL-1, TNF-alpha, and MMP-13, but the level of PPARgamma was decreased in a time- and dose-dependent manner, which was inhibited by anti-RAGE, SB203580 (P38 MAPK specific inhibitor) and SP600125 (a selective inhibitor of JNK).	pyrazolanthrone	231-239	long intergenic non-protein coding RNA 914	Homo sapiens	182-186
25784649-4	2015	Molecular docking of the IQ-1S syn isomer into the JNK1 binding site gave the best pose, which corresponded to the position of cocrystallized JNK inhibitor SP600125 (1,9-pyrazoloanthrone).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Mus musculus	51-55
25784649-4	2015	Molecular docking of the IQ-1S syn isomer into the JNK1 binding site gave the best pose, which corresponded to the position of cocrystallized JNK inhibitor SP600125 (1,9-pyrazoloanthrone).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Mus musculus	51-54
25784649-4	2015	Molecular docking of the IQ-1S syn isomer into the JNK1 binding site gave the best pose, which corresponded to the position of cocrystallized JNK inhibitor SP600125 (1,9-pyrazoloanthrone).	pyrazolanthrone	166-186	mitogen-activated protein kinase 8	Mus musculus	51-55
25784649-4	2015	Molecular docking of the IQ-1S syn isomer into the JNK1 binding site gave the best pose, which corresponded to the position of cocrystallized JNK inhibitor SP600125 (1,9-pyrazoloanthrone).	pyrazolanthrone	166-186	mitogen-activated protein kinase 8	Mus musculus	51-54
25846650-7	2015	Furthermore, SP600125, a selective inhibitor of the JNK pathway, significantly blocked the protective effects of IL-33 in gastric cancer cells.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	52-55
25846650-7	2015	Furthermore, SP600125, a selective inhibitor of the JNK pathway, significantly blocked the protective effects of IL-33 in gastric cancer cells.	pyrazolanthrone	13-21	interleukin 33	Homo sapiens	113-118
25843005-6	2015	The effect of the JNK inhibitor SP600125 on c-Jun phosphorylation was also tested.	pyrazolanthrone	32-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-49
25843005-10	2015	Nintedanib stimulated a rapid increase in phosphorylated JNK in A549 cells within 30 min of treatment and stimulated c-Jun phosphorylation, which was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Homo sapiens	57-60
25843005-10	2015	Nintedanib stimulated a rapid increase in phosphorylated JNK in A549 cells within 30 min of treatment and stimulated c-Jun phosphorylation, which was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	181-189	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	117-122
25843005-10	2015	Nintedanib stimulated a rapid increase in phosphorylated JNK in A549 cells within 30 min of treatment and stimulated c-Jun phosphorylation, which was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Homo sapiens	167-170
25839235-9	2015	Pharmacological inhibition of JNK (SP600125) or curcumin reduced transcriptional up-regulation of acid ceramidase.	pyrazolanthrone	35-43	N-acylsphingosine amidohydrolase 1	Homo sapiens	98-113
25996379-8	2015	In contrast, in the presence of JNK inhibitor (SP600125), p65 induced a marked increase of SOD1 promoter, suggesting that JNK pathway is up-stream of NF-kappaB signaling and controls negatively its activity.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	32-35
25993292-7	2015	Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Homo sapiens	44-47
25996379-8	2015	In contrast, in the presence of JNK inhibitor (SP600125), p65 induced a marked increase of SOD1 promoter, suggesting that JNK pathway is up-stream of NF-kappaB signaling and controls negatively its activity.	pyrazolanthrone	47-55	RELA proto-oncogene, NF-kB subunit	Homo sapiens	58-61
25996379-8	2015	In contrast, in the presence of JNK inhibitor (SP600125), p65 induced a marked increase of SOD1 promoter, suggesting that JNK pathway is up-stream of NF-kappaB signaling and controls negatively its activity.	pyrazolanthrone	47-55	superoxide dismutase 1	Homo sapiens	91-95
25996379-8	2015	In contrast, in the presence of JNK inhibitor (SP600125), p65 induced a marked increase of SOD1 promoter, suggesting that JNK pathway is up-stream of NF-kappaB signaling and controls negatively its activity.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	122-125
25996379-8	2015	In contrast, in the presence of JNK inhibitor (SP600125), p65 induced a marked increase of SOD1 promoter, suggesting that JNK pathway is up-stream of NF-kappaB signaling and controls negatively its activity.	pyrazolanthrone	47-55	nuclear factor kappa B subunit 1	Homo sapiens	150-159
25993292-7	2015	Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5.	pyrazolanthrone	58-66	matrix metallopeptidase 9	Homo sapiens	111-116
25993292-7	2015	Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5.	pyrazolanthrone	58-66	C-C motif chemokine ligand 8	Homo sapiens	118-123
25993292-7	2015	Moreover, the effect of simvastatin and the JNK inhibitor SP600125 was additive in inhibiting the secretion of MMP-9, MCP-2 and CXCL5.	pyrazolanthrone	58-66	C-X-C motif chemokine ligand 5	Homo sapiens	128-133
26221250-8	2015	Inhibition of ERK or p38 MAPK signaling by their specific inhibitors PD98059 or SP600125, respectively, not only prevents the activation of these kinases, but also attenuates cell proliferation induced by ICA.	pyrazolanthrone	80-88	mitogen activated protein kinase 14	Rattus norvegicus	21-24
25721793-6	2015	After JNK inhibitor SP600125 was administered to the endophilin-1 silenced hCMEC/D3 cells, the transendothelial electrical resistance (TEER) value was decreased and the permeability coefficient values to 4kDa and 40kDa FITC-dextran were increased.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	6-9
25721793-6	2015	After JNK inhibitor SP600125 was administered to the endophilin-1 silenced hCMEC/D3 cells, the transendothelial electrical resistance (TEER) value was decreased and the permeability coefficient values to 4kDa and 40kDa FITC-dextran were increased.	pyrazolanthrone	20-28	SH3 domain containing GRB2 like 2, endophilin A1	Homo sapiens	53-65
25839175-7	2015	A concentration of 25 muM EGCG significantly abolished thrombin-induced toxicity and prevented apoptosis by suppressing c-Jun-N-terminal kinase (JNK) phosphorylation, and the JNK inhibitor SP600125 reduced thrombin-induced caspase 3 activation and apoptosis.	pyrazolanthrone	189-197	coagulation factor II, thrombin	Homo sapiens	55-63
25204313-6	2015	Pretreatment with 50 nmol/L of c-Jun N-terminal kinases (JNK) inhibitor SP600125 abolished the upregulation of GADD34.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	31-55
25839175-7	2015	A concentration of 25 muM EGCG significantly abolished thrombin-induced toxicity and prevented apoptosis by suppressing c-Jun-N-terminal kinase (JNK) phosphorylation, and the JNK inhibitor SP600125 reduced thrombin-induced caspase 3 activation and apoptosis.	pyrazolanthrone	189-197	mitogen-activated protein kinase 8	Homo sapiens	145-148
25839175-7	2015	A concentration of 25 muM EGCG significantly abolished thrombin-induced toxicity and prevented apoptosis by suppressing c-Jun-N-terminal kinase (JNK) phosphorylation, and the JNK inhibitor SP600125 reduced thrombin-induced caspase 3 activation and apoptosis.	pyrazolanthrone	189-197	mitogen-activated protein kinase 8	Homo sapiens	175-178
25839175-7	2015	A concentration of 25 muM EGCG significantly abolished thrombin-induced toxicity and prevented apoptosis by suppressing c-Jun-N-terminal kinase (JNK) phosphorylation, and the JNK inhibitor SP600125 reduced thrombin-induced caspase 3 activation and apoptosis.	pyrazolanthrone	189-197	coagulation factor II, thrombin	Homo sapiens	206-214
25839175-7	2015	A concentration of 25 muM EGCG significantly abolished thrombin-induced toxicity and prevented apoptosis by suppressing c-Jun-N-terminal kinase (JNK) phosphorylation, and the JNK inhibitor SP600125 reduced thrombin-induced caspase 3 activation and apoptosis.	pyrazolanthrone	189-197	caspase 3	Homo sapiens	223-232
25204313-6	2015	Pretreatment with 50 nmol/L of c-Jun N-terminal kinases (JNK) inhibitor SP600125 abolished the upregulation of GADD34.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	57-60
25204313-6	2015	Pretreatment with 50 nmol/L of c-Jun N-terminal kinases (JNK) inhibitor SP600125 abolished the upregulation of GADD34.	pyrazolanthrone	72-80	protein phosphatase 1 regulatory subunit 15A	Homo sapiens	111-117
25713304-7	2015	In cardiomyocytes pretreatment with SP600125, a JNK inhibitor, suppressed the cardiomyocytes hypertrophy by inhibiting the ASK1/JNK pathway.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	48-51
25760015-0	2015	SP600125 reduces lipopolysaccharide-induced apoptosis and restores the early-stage differentiation of osteoblasts inhibited by LPS through the MAPK pathway in MC3T3-E1 cells.	pyrazolanthrone	0-8	mitogen-activated protein kinase 3	Mus musculus	143-147
25713304-7	2015	In cardiomyocytes pretreatment with SP600125, a JNK inhibitor, suppressed the cardiomyocytes hypertrophy by inhibiting the ASK1/JNK pathway.	pyrazolanthrone	36-44	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	123-127
25713304-7	2015	In cardiomyocytes pretreatment with SP600125, a JNK inhibitor, suppressed the cardiomyocytes hypertrophy by inhibiting the ASK1/JNK pathway.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	128-131
25511417-0	2015	c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	0-23
25511417-2	2015	The JNK inhibitor SP600125 enhances epithelial barrier function through modulation of tight junction molecules in normal human pancreatic epithelial cells.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
25511417-5	2015	In the present study, the JNK inhibitor SP600125 markedly enhanced the barrier function and cell elongation of well-differentiated human pancreatic cancer cell line HPAC in a Ca-switch model.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	26-29
25511417-6	2015	The epithelial barrier function induced by SP600125 was regulated by phosphorylated beta-catenin without changes in the tight junction molecules.	pyrazolanthrone	43-51	catenin beta 1	Homo sapiens	84-96
25964548-7	2015	SB203580, SP600125, and salubrinal effectively inhibited apoptosis and attenuated expression of phosphorylated protein kinase RNA-like endoplasmic reticulum kinase (PERK) and CCAAT-enhancer-binding protein homologous protein (CHOP).	pyrazolanthrone	10-18	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	111-163
25964548-7	2015	SB203580, SP600125, and salubrinal effectively inhibited apoptosis and attenuated expression of phosphorylated protein kinase RNA-like endoplasmic reticulum kinase (PERK) and CCAAT-enhancer-binding protein homologous protein (CHOP).	pyrazolanthrone	10-18	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	165-169
25964548-7	2015	SB203580, SP600125, and salubrinal effectively inhibited apoptosis and attenuated expression of phosphorylated protein kinase RNA-like endoplasmic reticulum kinase (PERK) and CCAAT-enhancer-binding protein homologous protein (CHOP).	pyrazolanthrone	10-18	DNA damage inducible transcript 3	Homo sapiens	175-224
25964548-7	2015	SB203580, SP600125, and salubrinal effectively inhibited apoptosis and attenuated expression of phosphorylated protein kinase RNA-like endoplasmic reticulum kinase (PERK) and CCAAT-enhancer-binding protein homologous protein (CHOP).	pyrazolanthrone	10-18	DNA damage inducible transcript 3	Homo sapiens	226-230
25572129-8	2015	Dominat-negative form of JNK1 and JNK inhibitor sp600125 partially inhibit the apoptosis upon IL-3 deprivation, suggesting that a sustained JNK1 activation was involved in the induction of apoptosis.	pyrazolanthrone	48-56	interleukin 3	Mus musculus	94-98
25572129-8	2015	Dominat-negative form of JNK1 and JNK inhibitor sp600125 partially inhibit the apoptosis upon IL-3 deprivation, suggesting that a sustained JNK1 activation was involved in the induction of apoptosis.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	140-144
25511417-9	2015	The JNK inhibitor SP600125 may have potential as a therapeutic drug for pancreatic cancer via induction of differentiation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
25760015-4	2015	This study aimed to investigate the effect of JNK inhibition by SP600125 on the apoptosis and differentiation of MC3T3-E1 osteoblasts suppressed by LPS.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Mus musculus	46-49
25760015-8	2015	The results showed that SP600125 significantly restored LPS-inhibited cell metabolism and ALP activity and reduced the upregulated caspase-3 activity of MC3T3-E1 cells induced by LPS.	pyrazolanthrone	24-32	caspase 3	Mus musculus	131-140
25760015-10	2015	SP600125 significantly downregulated expression of Bax and caspase-3 but upregulated Bcl-2 expression in MC3T3-E1 cells stimulated by LPS.	pyrazolanthrone	0-8	BCL2-associated X protein	Mus musculus	51-54
25760015-10	2015	SP600125 significantly downregulated expression of Bax and caspase-3 but upregulated Bcl-2 expression in MC3T3-E1 cells stimulated by LPS.	pyrazolanthrone	0-8	caspase 3	Mus musculus	59-68
25760015-10	2015	SP600125 significantly downregulated expression of Bax and caspase-3 but upregulated Bcl-2 expression in MC3T3-E1 cells stimulated by LPS.	pyrazolanthrone	0-8	B cell leukemia/lymphoma 2	Mus musculus	85-90
25760015-11	2015	Furthermore, SP600125 selectively triggered the MAPK pathway by reducing the expression of JNK1, while enhancing the expression of extracellular signal-regulated kinase 1 (ERK1).	pyrazolanthrone	13-21	mitogen-activated protein kinase 3	Mus musculus	48-52
25760015-11	2015	Furthermore, SP600125 selectively triggered the MAPK pathway by reducing the expression of JNK1, while enhancing the expression of extracellular signal-regulated kinase 1 (ERK1).	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	91-95
25760015-11	2015	Furthermore, SP600125 selectively triggered the MAPK pathway by reducing the expression of JNK1, while enhancing the expression of extracellular signal-regulated kinase 1 (ERK1).	pyrazolanthrone	13-21	mitogen-activated protein kinase 3	Mus musculus	131-170
25760015-11	2015	Furthermore, SP600125 selectively triggered the MAPK pathway by reducing the expression of JNK1, while enhancing the expression of extracellular signal-regulated kinase 1 (ERK1).	pyrazolanthrone	13-21	mitogen-activated protein kinase 3	Mus musculus	172-176
25760015-12	2015	Our results suggested that SP600125 reduced LPS-induced osteoblast apoptosis and restored early-stage differentiation of osteoblasts inhibited by LPS through MAPK signaling.	pyrazolanthrone	27-35	mitogen-activated protein kinase 3	Mus musculus	158-162
26018261-6	2015	Western blotting showed that beta-arrestin1 specifically enhanced the expression of p-JNK, and the JNK inhibitor SP600125 obviously suppressed p-JNK and cell proliferation of K562 cells.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	99-102
25530474-8	2015	Furthermore, the specific JNK inhibitor SP600125 blocked chrysotile asbestos-induced JNK activation and subsequent apoptosis, as assessed by both caspase-9 cleavage and PARP activation.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	26-29
25530474-8	2015	Furthermore, the specific JNK inhibitor SP600125 blocked chrysotile asbestos-induced JNK activation and subsequent apoptosis, as assessed by both caspase-9 cleavage and PARP activation.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	85-88
25530474-8	2015	Furthermore, the specific JNK inhibitor SP600125 blocked chrysotile asbestos-induced JNK activation and subsequent apoptosis, as assessed by both caspase-9 cleavage and PARP activation.	pyrazolanthrone	40-48	caspase 9	Homo sapiens	146-155
25530474-8	2015	Furthermore, the specific JNK inhibitor SP600125 blocked chrysotile asbestos-induced JNK activation and subsequent apoptosis, as assessed by both caspase-9 cleavage and PARP activation.	pyrazolanthrone	40-48	poly(ADP-ribose) polymerase 1	Homo sapiens	169-173
26018261-6	2015	Western blotting showed that beta-arrestin1 specifically enhanced the expression of p-JNK, and the JNK inhibitor SP600125 obviously suppressed p-JNK and cell proliferation of K562 cells.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	99-102
25560488-2	2015	After DEN-induced hepatocellular carcinoma (HCC) in rats showed increased phosphorylation of JNK1/2, p38, and ERK1/2, we next antagonized TGF-beta1-induced phosphorylation of JNK1/2, p38, ERK1/2, Smad2/3 signaling in HepG2 cells using SP600125, SB203580, and PD98059, respectively.	pyrazolanthrone	235-243	transforming growth factor, beta 1	Rattus norvegicus	138-147
25560488-9	2015	Both SP600125 and SB203580 inhibited HepG2 cells" proliferation and invasion by blocking oncogenic pSmad3L and Smad2/3/4 complex formation.	pyrazolanthrone	5-13	SMAD family member 3	Homo sapiens	111-118
25898323-9	2015	Addition of c-jun N-terminal kinase (JNK) inhibitor SP600125, TNF-alpha antibody and etanercept 30 min before stretch reversed the induction of TRB3 protein induced by stretch.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	12-35
25898323-9	2015	Addition of c-jun N-terminal kinase (JNK) inhibitor SP600125, TNF-alpha antibody and etanercept 30 min before stretch reversed the induction of TRB3 protein induced by stretch.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
25898323-9	2015	Addition of c-jun N-terminal kinase (JNK) inhibitor SP600125, TNF-alpha antibody and etanercept 30 min before stretch reversed the induction of TRB3 protein induced by stretch.	pyrazolanthrone	52-60	tribbles pseudokinase 3	Rattus norvegicus	144-148
25898323-12	2015	TRB3 promoter activity was enhanced by stretch and TRB3-mut plasmid, SP600125, TNF-alpha antibody and etanercept attenuated TRB3 promoter activity induced by stretch.	pyrazolanthrone	69-77	tribbles pseudokinase 3	Rattus norvegicus	0-4
25832431-12	2015	Physalin B treatment dose-dependently increased the phosphorylation of p38, ERK and JNK in the cells, whereas the p38 inhibitor SB202190, ERK inhibitor U0126 or JNK inhibitor SP600125 could partially reduce physalin B-induced PARP cleavage and p62 accumulation.	pyrazolanthrone	175-183	mitogen-activated protein kinase 8	Homo sapiens	161-164
25914463-5	2015	AQP3 protein expression was determined by Western blot in cells after treatment with SB203580, a selective p38 MAPK inhibitor, or SP600125, a selective JNK inhibitor.	pyrazolanthrone	130-138	aquaporin 3 (Gill blood group)	Homo sapiens	0-4
25914463-8	2015	Down-regulation of AQP3 expression was significantly inhibited by the p38 inhibitor (SB203580) and JNK inhibitor (SP600125).	pyrazolanthrone	114-122	aquaporin 3 (Gill blood group)	Homo sapiens	19-23
25914463-8	2015	Down-regulation of AQP3 expression was significantly inhibited by the p38 inhibitor (SB203580) and JNK inhibitor (SP600125).	pyrazolanthrone	114-122	mitogen-activated protein kinase 8	Homo sapiens	99-102
25848832-6	2015	CYTC and ATF3 were identified as candidate targets of the JNK/c-Jun pathway in this process because the specificity inhibitors SP600125 of JNK/C-jun pathways reduced the levels of C-jun, Cytc, and ATF3mRNA.	pyrazolanthrone	127-135	activating transcription factor 3	Rattus norvegicus	9-13
25848832-6	2015	CYTC and ATF3 were identified as candidate targets of the JNK/c-Jun pathway in this process because the specificity inhibitors SP600125 of JNK/C-jun pathways reduced the levels of C-jun, Cytc, and ATF3mRNA.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Rattus norvegicus	58-61
25848832-6	2015	CYTC and ATF3 were identified as candidate targets of the JNK/c-Jun pathway in this process because the specificity inhibitors SP600125 of JNK/C-jun pathways reduced the levels of C-jun, Cytc, and ATF3mRNA.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Rattus norvegicus	139-142
25848832-6	2015	CYTC and ATF3 were identified as candidate targets of the JNK/c-Jun pathway in this process because the specificity inhibitors SP600125 of JNK/C-jun pathways reduced the levels of C-jun, Cytc, and ATF3mRNA.	pyrazolanthrone	127-135	activating transcription factor 3	Rattus norvegicus	197-201
25848832-7	2015	The results suggested that SP600125 of JNK/C-jun can inhibit heroin-induced apoptosis of neurons.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Rattus norvegicus	39-42
25832424-8	2015	Pretreatment of the cells with the ROS scavenger N-acetyl-L-cysteine, ERK inhibitor PD98059 or NF-kappaB inhibitor PDTC blocked CRP-stimulated RAGE expression, but pretreatment with the NADPH oxidase inhibitor DPI, JNK inhibitor SP600125 or p38 MAPK inhibitor SB203580 did not significantly alter CRP-stimulated RAGE expression.	pyrazolanthrone	229-237	C-reactive protein	Homo sapiens	128-131
25611954-6	2015	In particular, we found that SP600125 treatment strongly promoted nonamyloidogenic amyloid precursor protein (APP) processing and inhibited amyloidogenic APP processing via regulating APP-cleavage secretase expression (ie, ADAM10, BACE1, and PS1) in APPswe/PS1dE9 mice.	pyrazolanthrone	29-37	a disintegrin and metallopeptidase domain 10	Mus musculus	223-229
25611954-3	2015	Here we first investigated the potential disease-modifying therapeutic effect of systemic administration of SP600125, a small-molecule JNK-specific inhibitor, in middle-aged APPswe/PS1dE9 mice.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Mus musculus	135-138
25611954-6	2015	In particular, we found that SP600125 treatment strongly promoted nonamyloidogenic amyloid precursor protein (APP) processing and inhibited amyloidogenic APP processing via regulating APP-cleavage secretase expression (ie, ADAM10, BACE1, and PS1) in APPswe/PS1dE9 mice.	pyrazolanthrone	29-37	beta-site APP cleaving enzyme 1	Mus musculus	231-236
25611954-5	2015	RESULTS: Compared with vehicle-treated APPswe/PS1dE9 mice, chronic treatment of SP600125 for 12 weeks potently inhibited JNK activation, which resulted in a marked improvement of behavioral measures of cognitive deficits and a dramatic reduction in amyloid plaque burden, beta-amyloid production, tau hyperphosphorylation, inflammatory responses, and synaptic loss in these transgenic animals.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Mus musculus	121-124
25611954-6	2015	In particular, we found that SP600125 treatment strongly promoted nonamyloidogenic amyloid precursor protein (APP) processing and inhibited amyloidogenic APP processing via regulating APP-cleavage secretase expression (ie, ADAM10, BACE1, and PS1) in APPswe/PS1dE9 mice.	pyrazolanthrone	29-37	presenilin 1	Mus musculus	242-245
25611954-6	2015	In particular, we found that SP600125 treatment strongly promoted nonamyloidogenic amyloid precursor protein (APP) processing and inhibited amyloidogenic APP processing via regulating APP-cleavage secretase expression (ie, ADAM10, BACE1, and PS1) in APPswe/PS1dE9 mice.	pyrazolanthrone	29-37	amyloid beta (A4) precursor protein	Mus musculus	83-108
25611954-8	2015	This study highlights the concept that active JNK actually contributes to the development of the disease, and provides critical preclinical evidence that specific inhibition of JNK activation by SP600125 treatment may be a novel promising disease-modifying therapeutic strategy for the treatment of AD.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Mus musculus	46-49
25611954-8	2015	This study highlights the concept that active JNK actually contributes to the development of the disease, and provides critical preclinical evidence that specific inhibition of JNK activation by SP600125 treatment may be a novel promising disease-modifying therapeutic strategy for the treatment of AD.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Mus musculus	177-180
25596551-17	2015	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed the decreased expression of cFos and VEGFD induced by Andro.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-49
25731856-7	2015	The TGF-alpha-induced migration was reduced by SB203580 (a p38 MAP kinase inhibitor), SP600125 (a SAPK/JNK inhibitor) and Y27632 (a Rho-kinase inhibitor).	pyrazolanthrone	86-94	transforming growth factor alpha	Homo sapiens	4-13
25596551-17	2015	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed the decreased expression of cFos and VEGFD induced by Andro.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	51-54
25596551-17	2015	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed the decreased expression of cFos and VEGFD induced by Andro.	pyrazolanthrone	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	94-98
25596551-17	2015	SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), reversed the decreased expression of cFos and VEGFD induced by Andro.	pyrazolanthrone	0-8	vascular endothelial growth factor D	Homo sapiens	103-108
25117566-8	2015	Furthermore, PD98059, a specific inhibitor for ERK, as well as SP600125, a specific inhibitor for JNK, inhibited LPS-induced mRNA upregulation of inflammatory mediators.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	98-101
25515776-8	2015	Accordingly, NFkappaB inhibitor Bay 11-7082 and JNK inhibitor SP600125 blocked the induction of the cytokine genes except IFN-beta.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	48-51
24436257-7	2015	Pretreatment with antioxidant N-acetyl-L-cysteine, c-Jun NH2-terminal kinase inhibitor SP600125, and extracellular signal-regulated kinase inhibitor PD98059 significantly reduced arecoline-induced Egr-1 synthesis.	pyrazolanthrone	87-95	early growth response 1	Homo sapiens	197-202
25047101-7	2015	In addition, the c-Jun N-terminal protein kinase (JNK) inhibitor (SP600125), rather than ERK1/2 blocker (PD98059), displayed anti-inflammatory properties on BPA-elicited cytokine responses.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Mus musculus	17-48
25047101-7	2015	In addition, the c-Jun N-terminal protein kinase (JNK) inhibitor (SP600125), rather than ERK1/2 blocker (PD98059), displayed anti-inflammatory properties on BPA-elicited cytokine responses.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Mus musculus	50-53
25734900-12	2015	S1P-induced c-Jun activation was reduced by PP1, AG1478, AG1296, U0126, SP600125, SB202190, or LY294002.	pyrazolanthrone	72-80	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	12-17
25647410-7	2015	We confirmed that autophagy was induced in response to JNK-dependent ER stress, as autophagy was suppressed by treatment with the ER stress inhibitor, 4-phenyl butyrate (4-PBA), and the JNK inhibitor, SP600125.	pyrazolanthrone	201-209	mitogen-activated protein kinase 8	Homo sapiens	55-58
25647410-7	2015	We confirmed that autophagy was induced in response to JNK-dependent ER stress, as autophagy was suppressed by treatment with the ER stress inhibitor, 4-phenyl butyrate (4-PBA), and the JNK inhibitor, SP600125.	pyrazolanthrone	201-209	mitogen-activated protein kinase 8	Homo sapiens	186-189
25889689-12	2015	After co-treatment with TIIAS and JNK inhibitor (SP600125), no significant increases in mechanical PWT and MCP-1 expression were observed compared with the TIIAS-treated group.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	34-37
25734900-10	2015	In addition, S1P-stimulated JNK1/2 phosphorylation was attenuated by SP600125 or PP1.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	28-32
25619392-8	2015	Pretreatment with the p38 inhibitor SB202190 or the JNK inhibitor SP600125 dose-dependently reduced resveratrol-induced phosphorylation of H2AX, which were also observed when the cells were transfected with p38- or JNK-specific siRNAs.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	52-55
25619392-8	2015	Pretreatment with the p38 inhibitor SB202190 or the JNK inhibitor SP600125 dose-dependently reduced resveratrol-induced phosphorylation of H2AX, which were also observed when the cells were transfected with p38- or JNK-specific siRNAs.	pyrazolanthrone	66-74	H2A.X variant histone	Homo sapiens	139-143
25619392-8	2015	Pretreatment with the p38 inhibitor SB202190 or the JNK inhibitor SP600125 dose-dependently reduced resveratrol-induced phosphorylation of H2AX, which were also observed when the cells were transfected with p38- or JNK-specific siRNAs.	pyrazolanthrone	66-74	mitogen-activated protein kinase 14	Homo sapiens	207-210
25619392-8	2015	Pretreatment with the p38 inhibitor SB202190 or the JNK inhibitor SP600125 dose-dependently reduced resveratrol-induced phosphorylation of H2AX, which were also observed when the cells were transfected with p38- or JNK-specific siRNAs.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	215-218
25573072-10	2015	Finally, pharmacological inhibitors OA, SB203580, SP600125 and PD98059 confirm the role of PP2A and its substrates ERK, p38 MAPK and Akt in mediating TP/HCPT-induced apoptosis.	pyrazolanthrone	50-58	protein phosphatase 2 phosphatase activator	Homo sapiens	91-95
25277399-5	2015	Pretreatment with the chemical chaperone 4-phenylbutyric acid, the JNK inhibitor SP600125, or the antioxidant N-acetylcysteine alleviated insulin resistance, demonstrating that ozone sequentially triggered oxidative stress, ER stress, and JNK activation to impair insulin signaling in muscle.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Rattus norvegicus	67-70
25573072-10	2015	Finally, pharmacological inhibitors OA, SB203580, SP600125 and PD98059 confirm the role of PP2A and its substrates ERK, p38 MAPK and Akt in mediating TP/HCPT-induced apoptosis.	pyrazolanthrone	50-58	mitogen-activated protein kinase 1	Homo sapiens	115-118
25573072-10	2015	Finally, pharmacological inhibitors OA, SB203580, SP600125 and PD98059 confirm the role of PP2A and its substrates ERK, p38 MAPK and Akt in mediating TP/HCPT-induced apoptosis.	pyrazolanthrone	50-58	mitogen-activated protein kinase 14	Homo sapiens	120-123
25542238-8	2015	SP600125, Ach, and etanercept significantly decreased the level of pJNK and TNF-alpha in the cerebral cortex and the hippocampus.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	76-85
25956603-9	2015	The JNK inhibitor SP600125, was found to eradicate almost all trace of Cx43 protein.	pyrazolanthrone	18-26	gap junction alpha-1 protein	Cavia porcellus	71-75
25542238-9	2015	In addition, SP600125 and etanercept reduced cellular apoptosis in the cerebral cortex and the hippocampus and significantly improved neurological scores at 2 days after SAH potentially via inhibition of the JNK-TNF-alpha pathway.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	208-211
25542238-9	2015	In addition, SP600125 and etanercept reduced cellular apoptosis in the cerebral cortex and the hippocampus and significantly improved neurological scores at 2 days after SAH potentially via inhibition of the JNK-TNF-alpha pathway.	pyrazolanthrone	13-21	tumor necrosis factor	Homo sapiens	212-221
25611974-8	2015	JNK and p38 inhibitors (SP600125 and SB203580, respectively) reversed TQ autophagic cell death.	pyrazolanthrone	24-32	mitogen-activated protein kinase 14	Homo sapiens	8-11
25607831-8	2015	Pretreatment with N-acetyl-cysteine (NAC), the inhibitor of ROS, or with SP600125, the inhibitor of JNK, prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	100-103
25607831-8	2015	Pretreatment with N-acetyl-cysteine (NAC), the inhibitor of ROS, or with SP600125, the inhibitor of JNK, prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	158-161
25607831-8	2015	Pretreatment with N-acetyl-cysteine (NAC), the inhibitor of ROS, or with SP600125, the inhibitor of JNK, prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells.	pyrazolanthrone	73-81	tumor protein p53	Homo sapiens	163-166
25607831-8	2015	Pretreatment with N-acetyl-cysteine (NAC), the inhibitor of ROS, or with SP600125, the inhibitor of JNK, prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells.	pyrazolanthrone	73-81	caspase 9	Homo sapiens	168-177
25607831-8	2015	Pretreatment with N-acetyl-cysteine (NAC), the inhibitor of ROS, or with SP600125, the inhibitor of JNK, prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells.	pyrazolanthrone	73-81	caspase 3	Homo sapiens	182-191
25607831-8	2015	Pretreatment with N-acetyl-cysteine (NAC), the inhibitor of ROS, or with SP600125, the inhibitor of JNK, prevented the apoptosis and the high expression of p-JNK, p53, caspase-9 and caspase-3 in CDK5RAP1-deficient MCF-7 cells.	pyrazolanthrone	73-81	CDK5 regulatory subunit associated protein 1	Homo sapiens	195-203
25600807-10	2015	Moreover, application with JNK inhibitor SP600125 reversed the effect of TRAM1 interference on Akt phosphorylation.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	27-30
25600807-10	2015	Moreover, application with JNK inhibitor SP600125 reversed the effect of TRAM1 interference on Akt phosphorylation.	pyrazolanthrone	41-49	translocation associated membrane protein 1	Homo sapiens	73-78
25600807-10	2015	Moreover, application with JNK inhibitor SP600125 reversed the effect of TRAM1 interference on Akt phosphorylation.	pyrazolanthrone	41-49	AKT serine/threonine kinase 1	Homo sapiens	95-98
25600807-12	2015	Glucose uptake assay indicated that knocking down TRAM1 augmented PA-induced down-regulation of glucose uptake, and inhibition of JNK using SP600125 could block the effect of TRAM1 on glucose uptake.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	130-133
25600807-12	2015	Glucose uptake assay indicated that knocking down TRAM1 augmented PA-induced down-regulation of glucose uptake, and inhibition of JNK using SP600125 could block the effect of TRAM1 on glucose uptake.	pyrazolanthrone	140-148	translocation associated membrane protein 1	Homo sapiens	175-180
25601926-7	2015	In iGB culture, JNK inhibitor SP600125 augmented the differentiation of C57BL/6 B1a cells into PBs.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	16-19
25449124-8	2015	Pretreatment with inhibitors of MAPKs PD98059 (a specific inhibitor of ERK), SP600125 (a specific inhibitor of JNK) abolished both EGB-induced Nrf2 nuclear translocation and HO-1 up-regulation.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Mus musculus	111-114
25449124-8	2015	Pretreatment with inhibitors of MAPKs PD98059 (a specific inhibitor of ERK), SP600125 (a specific inhibitor of JNK) abolished both EGB-induced Nrf2 nuclear translocation and HO-1 up-regulation.	pyrazolanthrone	77-85	nuclear factor, erythroid derived 2, like 2	Mus musculus	143-147
25449124-8	2015	Pretreatment with inhibitors of MAPKs PD98059 (a specific inhibitor of ERK), SP600125 (a specific inhibitor of JNK) abolished both EGB-induced Nrf2 nuclear translocation and HO-1 up-regulation.	pyrazolanthrone	77-85	heme oxygenase 1	Mus musculus	174-178
26165014-34	2015	Nar and SP600125 led to a largest decrease in levels of p-JNK and AP-1 when compared with group R2 (P &lt;0.	pyrazolanthrone	8-16	mitogen-activated protein kinase 8	Homo sapiens	58-61
26165014-34	2015	Nar and SP600125 led to a largest decrease in levels of p-JNK and AP-1 when compared with group R2 (P &lt;0.	pyrazolanthrone	8-16	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-70
26165014-46	2015	99) microg/L, Nar and SP600125 remarkably inhibited RSV-induced secretion of MUC5AC in supernatant of A549 cells (P &lt; 0.	pyrazolanthrone	22-30	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	77-83
25675437-5	2015	TNF-alpha-mediated responses were attenuated by pretreatment with the inhibitor of PKCs (Ro318220), PKCdelta (Rottlerin), MEK1/2 (U0126), JNK1/2 (SP600125), or AP-1 (Tanshinone IIA) and transfection with siRNA of TNFR1, TRAF2, JNK2, p42, or c-Jun.	pyrazolanthrone	146-154	tumor necrosis factor	Homo sapiens	0-9
25675437-7	2015	TNF-alpha-stimulated JNK1/2 was also reduced by Rottlerin or SP600125.	pyrazolanthrone	61-69	tumor necrosis factor	Homo sapiens	0-9
25675437-7	2015	TNF-alpha-stimulated JNK1/2 was also reduced by Rottlerin or SP600125.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	21-27
25675437-9	2015	We observed that TNF-alpha induced c-Jun phosphorylation which was inhibited by Rottlerin or SP600125.	pyrazolanthrone	93-101	tumor necrosis factor	Homo sapiens	17-26
25675437-9	2015	We observed that TNF-alpha induced c-Jun phosphorylation which was inhibited by Rottlerin or SP600125.	pyrazolanthrone	93-101	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	35-40
25916785-6	2015	The rats in groups V and VI received intracerebroventricular injection of JNK inhibitor SP600125 10 microl 30 min before ischemia, while group IV received intracerebroventricular injection of equal volume of DMSO.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Rattus norvegicus	74-77
23836369-7	2015	However, JNK inhibitor, SP600125, significantly attenuated the caspase-3 activity induced by 2-ABP.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	9-12
25496994-9	2015	Significantly, treatment with SP600125, a pharmacological inhibitor of JNKs, attenuates rotenone inhibition of VMAT2.	pyrazolanthrone	30-38	solute carrier family 18 member A2	Homo sapiens	111-116
25178491-7	2015	Specific JNK inhibitor SP600125 prevented the PYDDT-induced down-regulation of Bcl-2, mitochondrial translocation of Bax, activation of caspase 3, and apoptosis of SW620 cells.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	9-12
25178491-7	2015	Specific JNK inhibitor SP600125 prevented the PYDDT-induced down-regulation of Bcl-2, mitochondrial translocation of Bax, activation of caspase 3, and apoptosis of SW620 cells.	pyrazolanthrone	23-31	BCL2 apoptosis regulator	Homo sapiens	79-84
25178491-7	2015	Specific JNK inhibitor SP600125 prevented the PYDDT-induced down-regulation of Bcl-2, mitochondrial translocation of Bax, activation of caspase 3, and apoptosis of SW620 cells.	pyrazolanthrone	23-31	BCL2 associated X, apoptosis regulator	Homo sapiens	117-120
25178491-7	2015	Specific JNK inhibitor SP600125 prevented the PYDDT-induced down-regulation of Bcl-2, mitochondrial translocation of Bax, activation of caspase 3, and apoptosis of SW620 cells.	pyrazolanthrone	23-31	caspase 3	Homo sapiens	136-145
24859228-7	2015	Notably, selective inhibition of mitochondrial JNK activation using Tat-SabKIM1 produced a similar infarct size-reducing effect as inhibiting universal JNK activation with JNK inhibitor SP600125.	pyrazolanthrone	186-194	mitogen-activated protein kinase 8	Homo sapiens	152-155
24859228-7	2015	Notably, selective inhibition of mitochondrial JNK activation using Tat-SabKIM1 produced a similar infarct size-reducing effect as inhibiting universal JNK activation with JNK inhibitor SP600125.	pyrazolanthrone	186-194	mitogen-activated protein kinase 8	Homo sapiens	152-155
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	60-63
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	C-reactive protein	Homo sapiens	104-107
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	116-121
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	126-131
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	C-reactive protein	Homo sapiens	210-213
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	mitochondrially encoded cytochrome c oxidase I	Homo sapiens	284-289
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	294-299
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	mitogen-activated protein kinase 1	Homo sapiens	345-348
25399887-13	2015	Furthermore, the ERK inhibitor pd98059 (30 mumol/L) and the JNK inhibitor sp600125 (10 mumol/L) blocked CRP-induced COX-1 and COX-2 expression for 12 h. Together, the findings of the present study suggest that CRP can promote the development of the no-reflow phenomenon by increasing COX-1 and COX-2 expression, which is regulated, in part, via ERK and JNK activity.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	353-356
25312921-7	2015	The inhibition of the JNK pathway by SP600125 blocked the effects of Wnt11.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	22-25
25312921-7	2015	The inhibition of the JNK pathway by SP600125 blocked the effects of Wnt11.	pyrazolanthrone	37-45	Wnt family member 11	Homo sapiens	69-74
25168245-6	2015	The JNK inhibitor SP600125 blocked the phosphorylation and activation of nSMase1, which in turn blocked ceramide signaling and apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
25168245-6	2015	The JNK inhibitor SP600125 blocked the phosphorylation and activation of nSMase1, which in turn blocked ceramide signaling and apoptosis.	pyrazolanthrone	18-26	sphingomyelin phosphodiesterase 2	Homo sapiens	73-80
24942612-5	2015	The role of spinal TNF and JNK in inflammation-induced mechanical and thermal hypersensitivity was assessed by injecting the TNF inhibitor etanercept and the JNK inhibitors SP600125 and JIP-1 intrathecally (i.t.).	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	158-161
23836369-7	2015	However, JNK inhibitor, SP600125, significantly attenuated the caspase-3 activity induced by 2-ABP.	pyrazolanthrone	24-32	caspase 3	Homo sapiens	63-72
23836369-7	2015	However, JNK inhibitor, SP600125, significantly attenuated the caspase-3 activity induced by 2-ABP.	pyrazolanthrone	24-32	amine oxidase copper containing 1	Homo sapiens	95-98
25560393-11	2015	Pre-treatment of cells with SP600125 decreased cisplatin-induced activation of c-Jun and promoted apoptosis.	pyrazolanthrone	28-36	transcription factor Jun	Oryctolagus cuniculus	79-84
25435485-1	2015	To investigate the involvement of stress-activated protein kinases, JNK and p38 MAPK, in the assembly of tight junctions in keratinocytes, we treated HaCaT cells with various combinations of SP600125 (an inhibitor of JNK), SB202190 (an inhibitor of p38 MAPK) and anisomycin (an activator of both JNK and p38 MAPK) and examined the localization of ZO-1, an undercoat constitutive protein of the tight junction.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Homo sapiens	217-220
25501015-11	2015	Overexpression of miR-23a in both SCC-4 and Tca8113 cells markedly increased Twist expression, c-Jun N-terminal kinase (JNK) activity and the half maximal inhibitory concentration (IC50) of cisplain, and decreased cisplatin-induced apoptosis, all of which was abolished by knockdown of Twist or selective JNK inhibitor SP600125.	pyrazolanthrone	319-327	microRNA 23a	Homo sapiens	18-25
25435485-1	2015	To investigate the involvement of stress-activated protein kinases, JNK and p38 MAPK, in the assembly of tight junctions in keratinocytes, we treated HaCaT cells with various combinations of SP600125 (an inhibitor of JNK), SB202190 (an inhibitor of p38 MAPK) and anisomycin (an activator of both JNK and p38 MAPK) and examined the localization of ZO-1, an undercoat constitutive protein of the tight junction.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Homo sapiens	217-220
25435485-2	2015	Short-term (8h) incubation with SP600125, SB202190 or anisomycin induced the accumulation of ZO-1 in the cell-cell contacts, with reduced ZO-1 staining in the cytoplasm, while only long-term (24h) incubation with SP600125 induced the accumulation of ZO-1.	pyrazolanthrone	32-40	tight junction protein 1	Homo sapiens	93-97
25435485-2	2015	Short-term (8h) incubation with SP600125, SB202190 or anisomycin induced the accumulation of ZO-1 in the cell-cell contacts, with reduced ZO-1 staining in the cytoplasm, while only long-term (24h) incubation with SP600125 induced the accumulation of ZO-1.	pyrazolanthrone	32-40	tight junction protein 1	Homo sapiens	138-142
25435485-2	2015	Short-term (8h) incubation with SP600125, SB202190 or anisomycin induced the accumulation of ZO-1 in the cell-cell contacts, with reduced ZO-1 staining in the cytoplasm, while only long-term (24h) incubation with SP600125 induced the accumulation of ZO-1.	pyrazolanthrone	32-40	tight junction protein 1	Homo sapiens	138-142
25435485-2	2015	Short-term (8h) incubation with SP600125, SB202190 or anisomycin induced the accumulation of ZO-1 in the cell-cell contacts, with reduced ZO-1 staining in the cytoplasm, while only long-term (24h) incubation with SP600125 induced the accumulation of ZO-1.	pyrazolanthrone	213-221	tight junction protein 1	Homo sapiens	93-97
25435485-3	2015	SP600125, SB202190 or SP600125 plus SB202190 treatment induced thin linear staining for ZO-1 in the cell-cell contacts.	pyrazolanthrone	0-8	tight junction protein 1	Homo sapiens	88-92
25435485-3	2015	SP600125, SB202190 or SP600125 plus SB202190 treatment induced thin linear staining for ZO-1 in the cell-cell contacts.	pyrazolanthrone	22-30	tight junction protein 1	Homo sapiens	88-92
25435485-4	2015	Anisomycin treatment induced thick and irregular linear staining for ZO-1, while anisomycin plus SP600125 treatment induced zipper-like staining for ZO-1.	pyrazolanthrone	97-105	tight junction protein 1	Homo sapiens	149-153
25446857-7	2015	Immunoblots showed that the reduction of the Bcl-2/Bax ratio, the induction of caspase 3 cleavage, and the induction of poly(ADP-ribose) polymerase (PARP) cleavage by 6-OHDA was reversed in the presence of SB203580 (a p38 inhibitor) or SP600125 (a JNK inhibitor) in SH-SY5Y cells.	pyrazolanthrone	236-244	poly(ADP-ribose) polymerase 1	Homo sapiens	120-147
25473900-8	2015	Furthermore, JNK inhibitor SP600125 could attenuate the apoptotic effect achieved by AATBC knockdown, confirming the involvement of JNK signaling in the induced apoptosis.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	13-16
25473900-8	2015	Furthermore, JNK inhibitor SP600125 could attenuate the apoptotic effect achieved by AATBC knockdown, confirming the involvement of JNK signaling in the induced apoptosis.	pyrazolanthrone	27-35	apoptosis associated transcript in bladder cancer	Homo sapiens	85-90
25473900-8	2015	Furthermore, JNK inhibitor SP600125 could attenuate the apoptotic effect achieved by AATBC knockdown, confirming the involvement of JNK signaling in the induced apoptosis.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	132-135
25572360-10	2015	However, the effect of fucoidan on osteogenic differentiation was inhibited by specific inhibitors of ERK (PD98059) and JNK (SP600125) but not p38 (SB203580).	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Homo sapiens	120-123
25446857-7	2015	Immunoblots showed that the reduction of the Bcl-2/Bax ratio, the induction of caspase 3 cleavage, and the induction of poly(ADP-ribose) polymerase (PARP) cleavage by 6-OHDA was reversed in the presence of SB203580 (a p38 inhibitor) or SP600125 (a JNK inhibitor) in SH-SY5Y cells.	pyrazolanthrone	236-244	poly(ADP-ribose) polymerase 1	Homo sapiens	149-153
25446857-7	2015	Immunoblots showed that the reduction of the Bcl-2/Bax ratio, the induction of caspase 3 cleavage, and the induction of poly(ADP-ribose) polymerase (PARP) cleavage by 6-OHDA was reversed in the presence of SB203580 (a p38 inhibitor) or SP600125 (a JNK inhibitor) in SH-SY5Y cells.	pyrazolanthrone	236-244	mitogen-activated protein kinase 14	Homo sapiens	218-221
25446857-7	2015	Immunoblots showed that the reduction of the Bcl-2/Bax ratio, the induction of caspase 3 cleavage, and the induction of poly(ADP-ribose) polymerase (PARP) cleavage by 6-OHDA was reversed in the presence of SB203580 (a p38 inhibitor) or SP600125 (a JNK inhibitor) in SH-SY5Y cells.	pyrazolanthrone	236-244	mitogen-activated protein kinase 8	Homo sapiens	248-251
24984876-8	2015	Importantly, inhibition of the MAPK signaling pathway using SB203580 (p38 MAPK inhibitor), U0126 (extracellular signal-regulated kinase inhibitor), and SP600125 (c-Jun NH2-terminal kinase inhibitor) significantly potentiated the SUN-induced BNP and beta-MHC mRNA levels, but did alter the alpha-MHC level.	pyrazolanthrone	152-160	natriuretic peptide B	Rattus norvegicus	241-244
26090440-8	2015	Heteronemin also induced autophagy in A498 cells, and treatment with chloroquine (autophagy inhibitor) or SP600125 (JNK inhibitor) inhibited autophagy and increased heteronemin-induced cytotoxicity and apoptotic signaling.	pyrazolanthrone	106-114	mitogen-activated protein kinase 8	Homo sapiens	116-119
25242023-8	2015	To find the role of JNK in lesion formation, we evaluated the effects of JNK inhibitor, SP600125, on abdominal aortic lesions induced by CAWE.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Mus musculus	73-76
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	mitogen-activated protein kinase 14	Homo sapiens	29-32
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	37-40
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	mitogen-activated protein kinase 14	Homo sapiens	153-156
26584283-9	2015	Pretreatment of AEC or SAEC with SP600125, an inhibitor of JNK1 or SB200358, an inhibitor of P38, significantly reduced cell proliferation and migration.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	59-63
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	mitogen-activated protein kinase 1	Homo sapiens	157-161
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	166-169
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	RELA proto-oncogene, NF-kB subunit	Homo sapiens	252-255
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	mitogen-activated protein kinase 14	Homo sapiens	153-156
24820887-11	2015	The ERK1/2 antagonist U0126, p38 antagonist SB203580 and JNK antagonist SP600125 significantly reversed the facial mechanical allodynia in ION-CCI rats.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
26645893-7	2015	Our results demonstrate that p38 and JNK inhibitors (SB203580 and SP600125, respectively) prevented melatonin-induced apoptosis; thus, the propensity of p38 MAPK and JNK to promote apoptosis could be at least partly due to the inhibition of NF-x03BA;B p65 activation by p38 and JNK.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	166-169
25591955-4	2015	METHODS AND RESULTS: We showed that Ang II significantly up-regulated the expression of Egr-1 in RAW264.7 macrophages, and this effect was markedly attenuated by Eprosartan (an AT1R blocker), SP600125 (a JNK-specific inhibitor) and PD98059 (an ERK-specific inhibitor).	pyrazolanthrone	192-200	angiotensinogen	Homo sapiens	36-42
25591955-4	2015	METHODS AND RESULTS: We showed that Ang II significantly up-regulated the expression of Egr-1 in RAW264.7 macrophages, and this effect was markedly attenuated by Eprosartan (an AT1R blocker), SP600125 (a JNK-specific inhibitor) and PD98059 (an ERK-specific inhibitor).	pyrazolanthrone	192-200	early growth response 1	Homo sapiens	88-93
25591955-4	2015	METHODS AND RESULTS: We showed that Ang II significantly up-regulated the expression of Egr-1 in RAW264.7 macrophages, and this effect was markedly attenuated by Eprosartan (an AT1R blocker), SP600125 (a JNK-specific inhibitor) and PD98059 (an ERK-specific inhibitor).	pyrazolanthrone	192-200	angiotensin II receptor type 1	Homo sapiens	177-181
25966835-7	2015	The inhibition of JNK expression by SP600125 and JNK1-shRNA decreased UMT-induced Runx2 protein expression, and the activation of JNK expression by anisomycin and JNK1-cDNA increased UMT-induced Runx2 protein expression.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Rattus norvegicus	18-21
25337654-8	2015	Furthermore, like ghrelin treatment, the addition of the JNK inhibitor SP600125 or the glycogen synthase kinase-3beta inhibitor SB216763 rescued AMs from apoptosis.	pyrazolanthrone	71-79	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
25966835-7	2015	The inhibition of JNK expression by SP600125 and JNK1-shRNA decreased UMT-induced Runx2 protein expression, and the activation of JNK expression by anisomycin and JNK1-cDNA increased UMT-induced Runx2 protein expression.	pyrazolanthrone	36-44	RUNX family transcription factor 2	Rattus norvegicus	82-87
26783410-9	2015	Moreover, bufalin increased the phosphorylation of JNK and p38-MAPK in CAPAN-2 and CAL-27 cells, and blocking the JNK/p38-MAPK pathway using the JNK inhibitor SP600125 or the p38-MAPK inhibitor SB203580 reversed bufalin-induced hTERT downregulation.	pyrazolanthrone	159-167	mitogen-activated protein kinase 14	Homo sapiens	118-121
26229542-10	2015	Studies with JNK specific inhibitor, SP600125, showed that Huaier extract induced S phase arrest and decreased beta-catenin and cyclin D1 expression via JNK signaling pathway.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	13-16
26229542-10	2015	Studies with JNK specific inhibitor, SP600125, showed that Huaier extract induced S phase arrest and decreased beta-catenin and cyclin D1 expression via JNK signaling pathway.	pyrazolanthrone	37-45	catenin beta 1	Homo sapiens	111-123
26229542-10	2015	Studies with JNK specific inhibitor, SP600125, showed that Huaier extract induced S phase arrest and decreased beta-catenin and cyclin D1 expression via JNK signaling pathway.	pyrazolanthrone	37-45	cyclin D1	Homo sapiens	128-137
26229542-10	2015	Studies with JNK specific inhibitor, SP600125, showed that Huaier extract induced S phase arrest and decreased beta-catenin and cyclin D1 expression via JNK signaling pathway.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	153-156
26783410-9	2015	Moreover, bufalin increased the phosphorylation of JNK and p38-MAPK in CAPAN-2 and CAL-27 cells, and blocking the JNK/p38-MAPK pathway using the JNK inhibitor SP600125 or the p38-MAPK inhibitor SB203580 reversed bufalin-induced hTERT downregulation.	pyrazolanthrone	159-167	mitogen-activated protein kinase 14	Homo sapiens	118-121
25147119-8	2015	Auraptene also phosphorylated c-Jun N-terminal kinase (JNK), and pretreatment with the JNK inhibitor, SP600125, reduced auraptene-induced gamma-secretase activity.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	87-90
24958127-8	2015	On the other hand, JNK inhibitor SP600125 (10 mumol/L) clearly reduced the increased MCP-1, but not VEGF(120), release by 35% relative to the only ghrelin-stimulated cells (p &lt; 0.01).	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
24958127-8	2015	On the other hand, JNK inhibitor SP600125 (10 mumol/L) clearly reduced the increased MCP-1, but not VEGF(120), release by 35% relative to the only ghrelin-stimulated cells (p &lt; 0.01).	pyrazolanthrone	33-41	C-C motif chemokine ligand 2	Homo sapiens	85-90
25873765-2	2015	Aim of our study was to evaluate the effects of SP600125, a specific c-Jun NH2-terminal kinase (JNK) inhibitor, to modulate the early and late steps of the inflammatory cascade in a murine model of CLP-induced sepsis.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	69-94
25203596-8	2015	And the expression of arginase-1 and TGF-beta1 was partially blocked by the pretreated ERK biochemical inhibitor (U0126) instead of the JNK inhibitor (SP600125) and p38MAPK inhibitor (SB203580).	pyrazolanthrone	151-159	arginase, liver	Mus musculus	22-32
25203596-8	2015	And the expression of arginase-1 and TGF-beta1 was partially blocked by the pretreated ERK biochemical inhibitor (U0126) instead of the JNK inhibitor (SP600125) and p38MAPK inhibitor (SB203580).	pyrazolanthrone	151-159	transforming growth factor, beta 1	Mus musculus	37-46
25873765-2	2015	Aim of our study was to evaluate the effects of SP600125, a specific c-Jun NH2-terminal kinase (JNK) inhibitor, to modulate the early and late steps of the inflammatory cascade in a murine model of CLP-induced sepsis.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	96-99
25873765-8	2015	SP600125 protects against CLP induced sepsis by blocking JNK signalling; therefore, it can be considered a therapeutic approach in human sepsis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	57-60
25381636-4	2015	When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Mus musculus	49-52
25218495-14	2015	Finally, we demonstrated that knockdown of FAK by shRNA in combination with blockade of JNK signaling pathway with SP600125 completely inhibited GRP78-induced cancer cell invasion.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Homo sapiens	88-91
25218495-14	2015	Finally, we demonstrated that knockdown of FAK by shRNA in combination with blockade of JNK signaling pathway with SP600125 completely inhibited GRP78-induced cancer cell invasion.	pyrazolanthrone	115-123	heat shock protein family A (Hsp70) member 5	Homo sapiens	145-150
25351906-8	2015	The increase in the number of SP cells and the SAPK/JNK and c-Jun phosphorylation was reverted by SP600125 treatment in these cells.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Homo sapiens	52-55
25381636-4	2015	When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect.	pyrazolanthrone	39-47	vascular cell adhesion molecule 1	Mus musculus	166-172
25351906-8	2015	The increase in the number of SP cells and the SAPK/JNK and c-Jun phosphorylation was reverted by SP600125 treatment in these cells.	pyrazolanthrone	98-106	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	60-65
25381636-4	2015	When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect.	pyrazolanthrone	39-47	matrix metallopeptidase 2	Mus musculus	174-179
25381636-4	2015	When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect.	pyrazolanthrone	39-47	matrix metallopeptidase 9	Mus musculus	181-186
25381636-4	2015	When cells were pretreated with either SP600125 (JNK inhibitor) or PNU-282987 (alpha7-nAChR agonist) prior to nicotine exposure, the nicotine-induced upregulation of VCAM-1, MMP-2, MMP-9, and p-JNK was suppressed, with a joint treatment producing a more significant inhibitory effect.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Mus musculus	194-197
25866226-15	2015	JNK inhibitor SP 600125 reduced the HIF-2alpha expression and inhibited the adhesion and invasion of breast cancer cell.	pyrazolanthrone	14-23	mitogen-activated protein kinase 8	Homo sapiens	0-3
25866226-15	2015	JNK inhibitor SP 600125 reduced the HIF-2alpha expression and inhibited the adhesion and invasion of breast cancer cell.	pyrazolanthrone	14-23	endothelial PAS domain protein 1	Homo sapiens	36-46
26273426-6	2015	We found that JNK inhibitor SP600125 treatment decreased MRP1 mRNA expression in 16HBE14o- cells.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	14-17
26273426-6	2015	We found that JNK inhibitor SP600125 treatment decreased MRP1 mRNA expression in 16HBE14o- cells.	pyrazolanthrone	28-36	ATP binding cassette subfamily C member 1	Homo sapiens	57-61
26273426-8	2015	The AITC-induced increase of MRP1 mRNA expression was abolished by cotreatment of SP600125, while it was not obviously affected by U0126 or LY294002.	pyrazolanthrone	82-90	ATP binding cassette subfamily C member 1	Homo sapiens	29-33
26290681-3	2015	Human cerebral microvascular endothelial cells (hCMEC/D3) were exposed to LPS, SB203580 (p38MAPK inhibitor), or SP600125 (JNK inhibitor), and cell vitality was determined by MTT assay.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	122-125
25677506-8	2015	Both SB203580 and SP600125, a specific p38 MAP kinase inhibitor and a specific SAPK/JNK inhibitor, respectively, but not PD98059, a specific MEK inhibitor, reduced the PGE1-stimulated OPG release.	pyrazolanthrone	18-26	mitogen-activated protein kinase 14	Mus musculus	39-42
25677506-8	2015	Both SB203580 and SP600125, a specific p38 MAP kinase inhibitor and a specific SAPK/JNK inhibitor, respectively, but not PD98059, a specific MEK inhibitor, reduced the PGE1-stimulated OPG release.	pyrazolanthrone	18-26	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	184-187
25510849-15	2014	P-Jnk1/2 was activated in Wnt5a overexpressed dental follicle cells; conversely, exposure to SP600125, a c-Jun N-terminal kinase (JNK) inhibitor attenuated Runx2, collagen 1alpha1 and osteocalcin expression either in the presence or absence of Wnt5a.	pyrazolanthrone	93-101	RUNX family transcription factor 2	Rattus norvegicus	156-179
25510849-15	2014	P-Jnk1/2 was activated in Wnt5a overexpressed dental follicle cells; conversely, exposure to SP600125, a c-Jun N-terminal kinase (JNK) inhibitor attenuated Runx2, collagen 1alpha1 and osteocalcin expression either in the presence or absence of Wnt5a.	pyrazolanthrone	93-101	Wnt family member 5A	Rattus norvegicus	26-31
25510849-15	2014	P-Jnk1/2 was activated in Wnt5a overexpressed dental follicle cells; conversely, exposure to SP600125, a c-Jun N-terminal kinase (JNK) inhibitor attenuated Runx2, collagen 1alpha1 and osteocalcin expression either in the presence or absence of Wnt5a.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Rattus norvegicus	105-128
25510849-15	2014	P-Jnk1/2 was activated in Wnt5a overexpressed dental follicle cells; conversely, exposure to SP600125, a c-Jun N-terminal kinase (JNK) inhibitor attenuated Runx2, collagen 1alpha1 and osteocalcin expression either in the presence or absence of Wnt5a.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Rattus norvegicus	130-133
25316568-6	2014	Treatment with SP600125 (a JNK inhibitor) or knock-down of JNK1 reduced MMP-2 expression in simvastatin-treated cells.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	27-30
25316568-6	2014	Treatment with SP600125 (a JNK inhibitor) or knock-down of JNK1 reduced MMP-2 expression in simvastatin-treated cells.	pyrazolanthrone	15-23	matrix metallopeptidase 2	Homo sapiens	72-77
25510849-15	2014	P-Jnk1/2 was activated in Wnt5a overexpressed dental follicle cells; conversely, exposure to SP600125, a c-Jun N-terminal kinase (JNK) inhibitor attenuated Runx2, collagen 1alpha1 and osteocalcin expression either in the presence or absence of Wnt5a.	pyrazolanthrone	93-101	bone gamma-carboxyglutamate protein	Rattus norvegicus	184-195
25510849-15	2014	P-Jnk1/2 was activated in Wnt5a overexpressed dental follicle cells; conversely, exposure to SP600125, a c-Jun N-terminal kinase (JNK) inhibitor attenuated Runx2, collagen 1alpha1 and osteocalcin expression either in the presence or absence of Wnt5a.	pyrazolanthrone	93-101	Wnt family member 5A	Rattus norvegicus	244-249
25503060-5	2014	Microinjection of the JNK inhibitor SP600125 had no effect on morphine or fentanyl antinociception, but blocked the expression of tolerance to repeated morphine microinjections.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
25224579-9	2014	SP600125, rauwolscine, quinacrine dihydrochloride, nordihydroguaiaretic acid, AA-861, phenidone and GF 109203X attenuated dexmedetomidine-induced JNK phosphorylation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	146-149
25486532-3	2014	We found that SP600125 induced the polyploidization of Dami and CMK cells, concomitant with the phosphorylation of ribosomal protein S6 kinase 1 (S6K1) at Thr421/Ser424 and dephosphorylation at Thr389.	pyrazolanthrone	14-22	ribosomal protein S6 kinase B1	Homo sapiens	146-150
25486532-5	2014	Overexpression of a rapamycin-resistant mutant of S6K1 further enhanced the inhibitory effect of LY294002 on the SP600125-induced polyploidization of Dami and CMK cells.	pyrazolanthrone	113-121	ribosomal protein S6 kinase B1	Homo sapiens	50-54
25486532-6	2014	SP600125 also induced the polyploidization of Meg-01 cells, which are derived from a patient with chronic myelogenous leukemia, without causing a significant change in S6K1 phosphorylation.	pyrazolanthrone	0-8	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	46-49
25486532-7	2014	Additionally, SP600125 induced the polyploidization of HEL cells, which are derived from a patient with erythroleukemia, and phosphorylation at Thr389 of S6K1 was detected.	pyrazolanthrone	14-22	ribosomal protein S6 kinase B1	Homo sapiens	154-158
25486532-8	2014	However, the polyploidization of both Meg-01 cells and HEL cells as a result of SP600125 treatment was lower than that of SP600125-induced Dami and CMK cells, and it was not blocked by H-89 despite the increased phosphorylation of S6K1 at Thr389 in both cell lines in response to H-89.	pyrazolanthrone	80-88	protein tyrosine phosphatase non-receptor type 4	Homo sapiens	38-41
25245054-6	2014	Treatment with an ERK1/2 inhibitor (PD98059) or JNK1/2 inhibitor (SP600125) enhanced the inhibitory effects of metformin on the migration and invasion of HCC cells.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	48-54
25245054-7	2014	Moreover, metformin-induced inhibition of MMP-9 and uPA promoter activity also blocked the nuclear translocation of NF-kappaB and its binding to the MMP-9 and uPA promoters, and these suppressive effects were further enhanced by PD98059 or SP600125.	pyrazolanthrone	240-248	matrix metallopeptidase 9	Homo sapiens	42-47
25245054-7	2014	Moreover, metformin-induced inhibition of MMP-9 and uPA promoter activity also blocked the nuclear translocation of NF-kappaB and its binding to the MMP-9 and uPA promoters, and these suppressive effects were further enhanced by PD98059 or SP600125.	pyrazolanthrone	240-248	proline rich acidic protein 1	Homo sapiens	52-55
25245054-7	2014	Moreover, metformin-induced inhibition of MMP-9 and uPA promoter activity also blocked the nuclear translocation of NF-kappaB and its binding to the MMP-9 and uPA promoters, and these suppressive effects were further enhanced by PD98059 or SP600125.	pyrazolanthrone	240-248	matrix metallopeptidase 9	Homo sapiens	149-154
25245054-7	2014	Moreover, metformin-induced inhibition of MMP-9 and uPA promoter activity also blocked the nuclear translocation of NF-kappaB and its binding to the MMP-9 and uPA promoters, and these suppressive effects were further enhanced by PD98059 or SP600125.	pyrazolanthrone	240-248	proline rich acidic protein 1	Homo sapiens	159-162
25293876-9	2014	P39 cell treatment with a combination of quercetin and selective inhibitors of ERK1/2 and/or JNK (PD184352 or SP600125, respectively), significantly decreased cells in G1 phase, this treatment, however, did not change the apoptotic cell number.	pyrazolanthrone	110-118	cyclin dependent kinase 5 regulatory subunit 2	Homo sapiens	0-3
25293876-9	2014	P39 cell treatment with a combination of quercetin and selective inhibitors of ERK1/2 and/or JNK (PD184352 or SP600125, respectively), significantly decreased cells in G1 phase, this treatment, however, did not change the apoptotic cell number.	pyrazolanthrone	110-118	mitogen-activated protein kinase 3	Homo sapiens	79-85
25293876-9	2014	P39 cell treatment with a combination of quercetin and selective inhibitors of ERK1/2 and/or JNK (PD184352 or SP600125, respectively), significantly decreased cells in G1 phase, this treatment, however, did not change the apoptotic cell number.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	93-96
24963048-10	2014	Moreover, JNK inhibition by SP600125 or MKK7 siRNA knockdown antagonized the effects of p38 inhibition by SB202190.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	10-13
24963048-10	2014	Moreover, JNK inhibition by SP600125 or MKK7 siRNA knockdown antagonized the effects of p38 inhibition by SB202190.	pyrazolanthrone	28-36	mitogen-activated protein kinase 14	Homo sapiens	88-91
24963048-11	2014	In vivo, SP600125 significantly decreased growth rates of xenografts with high p38 activity compared with those without p38 expression.	pyrazolanthrone	9-17	mitogen-activated protein kinase 14	Homo sapiens	79-82
25469469-4	2014	The up-regulation of GADD45alpha was abolished by pretreatment with the c-Jun N-terminal kinases (JNK) inhibitor SP600125 but not the p38 specific inhibitor SB203580.	pyrazolanthrone	113-121	growth arrest and DNA damage inducible alpha	Homo sapiens	21-32
25218290-8	2014	However, female mice were still protected by the JNK inhibitor SP600125.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Mus musculus	49-52
25386685-10	2014	The increased phosphorylation levels of PI3-K, Akt and JNK in 4% HCM were blocked by LY294002 and SP600125.	pyrazolanthrone	98-106	AKT serine/threonine kinase 1	Rattus norvegicus	47-50
25386685-10	2014	The increased phosphorylation levels of PI3-K, Akt and JNK in 4% HCM were blocked by LY294002 and SP600125.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Rattus norvegicus	55-58
24101442-6	2014	Moreover, the JNK inhibitor SP600125 decreased production of IL-6 and TNF-alpha induced by LDH.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	14-17
24101442-6	2014	Moreover, the JNK inhibitor SP600125 decreased production of IL-6 and TNF-alpha induced by LDH.	pyrazolanthrone	28-36	interleukin 6	Mus musculus	61-65
24101442-6	2014	Moreover, the JNK inhibitor SP600125 decreased production of IL-6 and TNF-alpha induced by LDH.	pyrazolanthrone	28-36	tumor necrosis factor	Mus musculus	70-79
25173462-6	2014	Furthermore, the c-Jun-N-terminal kinase/Ste20-related protein proline/alanine-rich kinase (JNK/SPAK) pathway played a key role in the influence of NAG-1 on cell viability, whereas the addition of the JNK pathway inhibitor SP600125 resulted in an inhibitory effect on NAG-1 and recovery of Taiwanin-A-treated cells.	pyrazolanthrone	223-231	mitogen-activated protein kinase 8	Homo sapiens	92-95
25173462-6	2014	Furthermore, the c-Jun-N-terminal kinase/Ste20-related protein proline/alanine-rich kinase (JNK/SPAK) pathway played a key role in the influence of NAG-1 on cell viability, whereas the addition of the JNK pathway inhibitor SP600125 resulted in an inhibitory effect on NAG-1 and recovery of Taiwanin-A-treated cells.	pyrazolanthrone	223-231	serine/threonine kinase 39	Homo sapiens	96-100
25173462-6	2014	Furthermore, the c-Jun-N-terminal kinase/Ste20-related protein proline/alanine-rich kinase (JNK/SPAK) pathway played a key role in the influence of NAG-1 on cell viability, whereas the addition of the JNK pathway inhibitor SP600125 resulted in an inhibitory effect on NAG-1 and recovery of Taiwanin-A-treated cells.	pyrazolanthrone	223-231	growth differentiation factor 15	Homo sapiens	148-153
25173462-6	2014	Furthermore, the c-Jun-N-terminal kinase/Ste20-related protein proline/alanine-rich kinase (JNK/SPAK) pathway played a key role in the influence of NAG-1 on cell viability, whereas the addition of the JNK pathway inhibitor SP600125 resulted in an inhibitory effect on NAG-1 and recovery of Taiwanin-A-treated cells.	pyrazolanthrone	223-231	mitogen-activated protein kinase 8	Homo sapiens	201-204
25598661-7	2014	In addition, treatment with LY294002, SB202190, or SP600125 resulted in significantly attenuated secretion of IL-1alpha.	pyrazolanthrone	51-59	interleukin 1 alpha	Homo sapiens	110-119
25397676-8	2014	SP600125, a specific inhibitor of JNK, reduced RANKL-induced expression of phospho-c-Jun, c-Fos, and NFATc1 and inhibited osteoclast formation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	34-37
25397676-8	2014	SP600125, a specific inhibitor of JNK, reduced RANKL-induced expression of phospho-c-Jun, c-Fos, and NFATc1 and inhibited osteoclast formation.	pyrazolanthrone	0-8	TNF superfamily member 11	Homo sapiens	47-52
25397676-8	2014	SP600125, a specific inhibitor of JNK, reduced RANKL-induced expression of phospho-c-Jun, c-Fos, and NFATc1 and inhibited osteoclast formation.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	83-88
25397676-8	2014	SP600125, a specific inhibitor of JNK, reduced RANKL-induced expression of phospho-c-Jun, c-Fos, and NFATc1 and inhibited osteoclast formation.	pyrazolanthrone	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-95
25397676-8	2014	SP600125, a specific inhibitor of JNK, reduced RANKL-induced expression of phospho-c-Jun, c-Fos, and NFATc1 and inhibited osteoclast formation.	pyrazolanthrone	0-8	nuclear factor of activated T cells 1	Homo sapiens	101-107
25283505-10	2014	Addition of JNK inhibitor SP600125 (10 mumol/L) also significantly suppressed high glucose-induced apoptosis and JNK phosphorylation in bEND.3 cells.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Mus musculus	12-15
25283505-10	2014	Addition of JNK inhibitor SP600125 (10 mumol/L) also significantly suppressed high glucose-induced apoptosis and JNK phosphorylation in bEND.3 cells.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Mus musculus	113-116
25289048-6	2014	SP600125, a specific JNK inhibitor, attenuated Bim activation and apoptosis, but did not alter ASK1 phosphorylation levels.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	21-24
25289048-6	2014	SP600125, a specific JNK inhibitor, attenuated Bim activation and apoptosis, but did not alter ASK1 phosphorylation levels.	pyrazolanthrone	0-8	BCL2 like 11	Homo sapiens	47-50
25469469-4	2014	The up-regulation of GADD45alpha was abolished by pretreatment with the c-Jun N-terminal kinases (JNK) inhibitor SP600125 but not the p38 specific inhibitor SB203580.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	72-96
25469469-4	2014	The up-regulation of GADD45alpha was abolished by pretreatment with the c-Jun N-terminal kinases (JNK) inhibitor SP600125 but not the p38 specific inhibitor SB203580.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	98-101
25435694-7	2014	Furthermore, the decrease of PKB/Akt phosphorylation under serum-free starvation was partially restored by SP600125, an inhibitor of SAPK/JNK.	pyrazolanthrone	107-115	mitogen-activated protein kinase 9	Homo sapiens	133-137
24763745-2	2014	In this study, phosphorylation of JNK was examined in the urinary bladder with cyclophosphamide (CYP)-induced cystitis and the effects of SP600125, a selective inhibitor of phosphorylation of JNK, on urinary bladder function were assessed using conscious, open outlet, cystometry with continuous instillation of intravesical saline.	pyrazolanthrone	138-146	mitogen-activated protein kinase 8	Rattus norvegicus	192-195
25435694-7	2014	Furthermore, the decrease of PKB/Akt phosphorylation under serum-free starvation was partially restored by SP600125, an inhibitor of SAPK/JNK.	pyrazolanthrone	107-115	mitogen-activated protein kinase 9	Homo sapiens	138-141
25204501-3	2014	In this study, we determined that PD98059 and SP600125, the two mitogen-activated protein kinase (MAPK) family inhibitors, decreased the osteosarcoma cell U2OS-AEG-1 migration and invasion that was enhanced by astrocyte elevated gene-1 (AEG-1) in an in vitro wound-healing and Matrigel invasion assay independently of cell viability.	pyrazolanthrone	46-54	mitogen-activated protein kinase 3	Homo sapiens	98-102
24510064-9	2014	BMP4-induced upregulation of Cav3.1 mRNA was inhibited by NADPH oxidase inhibitor apocynin, the radical scavenger tempol, JNK inhibitor SP600125, and p38 inhibitor SB203580.	pyrazolanthrone	136-144	bone morphogenetic protein 4	Mus musculus	0-4
25294812-6	2014	However, only inhibition of JNK (with SP600125) or expression of dominant negative c-Jun partially prevented CPX-induced autophagy, indicating that ROS-mediated activation of JNK signaling pathway contributed to CPX-induced autophagy.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	28-31
25342459-5	2014	Furthermore, inhibition of p38 and JNK activity by pretreatment with SB03580 (a p38-specific inhibitor) and SP600125 (a JNK-specific inhibitor) led to rescue of the cell cytotoxicity of 13-AC-treated AGS cells, indicating that the p38 and the JNK pathways are also involved in the 13-AC-induced cell apoptosis.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	35-38
25342459-5	2014	Furthermore, inhibition of p38 and JNK activity by pretreatment with SB03580 (a p38-specific inhibitor) and SP600125 (a JNK-specific inhibitor) led to rescue of the cell cytotoxicity of 13-AC-treated AGS cells, indicating that the p38 and the JNK pathways are also involved in the 13-AC-induced cell apoptosis.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	120-123
25342459-5	2014	Furthermore, inhibition of p38 and JNK activity by pretreatment with SB03580 (a p38-specific inhibitor) and SP600125 (a JNK-specific inhibitor) led to rescue of the cell cytotoxicity of 13-AC-treated AGS cells, indicating that the p38 and the JNK pathways are also involved in the 13-AC-induced cell apoptosis.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	120-123
25290095-7	2014	On the other hand, SB203580, an inhibitor of p38 MAP kinase, SP600125, an inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and Akt inhibitor suppressed the OPG release induced by FGF-2.	pyrazolanthrone	61-69	TNF receptor superfamily member 11b	Homo sapiens	188-191
25204501-3	2014	In this study, we determined that PD98059 and SP600125, the two mitogen-activated protein kinase (MAPK) family inhibitors, decreased the osteosarcoma cell U2OS-AEG-1 migration and invasion that was enhanced by astrocyte elevated gene-1 (AEG-1) in an in vitro wound-healing and Matrigel invasion assay independently of cell viability.	pyrazolanthrone	46-54	metadherin	Homo sapiens	160-165
25204501-3	2014	In this study, we determined that PD98059 and SP600125, the two mitogen-activated protein kinase (MAPK) family inhibitors, decreased the osteosarcoma cell U2OS-AEG-1 migration and invasion that was enhanced by astrocyte elevated gene-1 (AEG-1) in an in vitro wound-healing and Matrigel invasion assay independently of cell viability.	pyrazolanthrone	46-54	metadherin	Homo sapiens	210-235
25204501-3	2014	In this study, we determined that PD98059 and SP600125, the two mitogen-activated protein kinase (MAPK) family inhibitors, decreased the osteosarcoma cell U2OS-AEG-1 migration and invasion that was enhanced by astrocyte elevated gene-1 (AEG-1) in an in vitro wound-healing and Matrigel invasion assay independently of cell viability.	pyrazolanthrone	46-54	metadherin	Homo sapiens	237-242
25204501-6	2014	SP600125 (a JNK inhibitor) decreased phosphor-c-Jun and MMP-2 in U2OS-AEG-1, while PD98059 (a ERK1/2 inhibitor) had no influence on the levels of phosphor-c-Jun or MMP-2 in U2OS-AEG-1.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
25204501-6	2014	SP600125 (a JNK inhibitor) decreased phosphor-c-Jun and MMP-2 in U2OS-AEG-1, while PD98059 (a ERK1/2 inhibitor) had no influence on the levels of phosphor-c-Jun or MMP-2 in U2OS-AEG-1.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	46-51
25204501-6	2014	SP600125 (a JNK inhibitor) decreased phosphor-c-Jun and MMP-2 in U2OS-AEG-1, while PD98059 (a ERK1/2 inhibitor) had no influence on the levels of phosphor-c-Jun or MMP-2 in U2OS-AEG-1.	pyrazolanthrone	0-8	matrix metallopeptidase 2	Homo sapiens	56-61
25204501-6	2014	SP600125 (a JNK inhibitor) decreased phosphor-c-Jun and MMP-2 in U2OS-AEG-1, while PD98059 (a ERK1/2 inhibitor) had no influence on the levels of phosphor-c-Jun or MMP-2 in U2OS-AEG-1.	pyrazolanthrone	0-8	metadherin	Homo sapiens	70-75
24969683-4	2014	As a result, SP600125 diminished the increased phosphorylation of JNK, whereas, expression of total JNK in the liver remained unchanged compared with the sham control and was not affected by SP600125.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Rattus norvegicus	66-69
24969683-5	2014	At the same time, SP600125 attenuated Bax translocation to mitochondria and the release of cytochrome c induced by brain death.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Rattus norvegicus	38-41
24969683-6	2014	Furthermore, the activation of caspase-3 and apoptosis induced by brain death was also significantly suppressed by the administration of SP600125.	pyrazolanthrone	137-145	caspase 3	Rattus norvegicus	31-40
24612223-4	2014	For example, SP 600125 was a potent inhibitor for CYP1A2, but enhanced the activity of CYP2C9 fourfolds.	pyrazolanthrone	13-22	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	50-56
24848068-5	2014	Furthermore, we showed that the inhibition of Jun NH2-terminal kinase (JNK) phosphorylation contributed to the protection of C66 from inflammation and cell apoptosis, which was validated by the use of SP600125 and dominant-negative JNK.	pyrazolanthrone	201-209	mitogen-activated protein kinase 8	Rattus norvegicus	46-69
24848068-5	2014	Furthermore, we showed that the inhibition of Jun NH2-terminal kinase (JNK) phosphorylation contributed to the protection of C66 from inflammation and cell apoptosis, which was validated by the use of SP600125 and dominant-negative JNK.	pyrazolanthrone	201-209	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
24848068-7	2014	In mice with type 1 diabetes, the administration of C66 or SP600125 at 5 mg/kg significantly decreased the levels of plasma and cardiac tumor necrosis factor-alpha, accompanied by decreasing cardiac apoptosis, and, finally, improved histological abnormalities, fibrosis, and cardiac dysfunction without affecting hyperglycemia.	pyrazolanthrone	59-67	tumor necrosis factor	Mus musculus	136-163
24976126-6	2014	Treatment of VS cells with proNGF activated NF-kappaB while inhibition of JNK with SP600125 or siRNA-mediated knockdown reduced NF-kappaB activity.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	74-77
24612223-4	2014	For example, SP 600125 was a potent inhibitor for CYP1A2, but enhanced the activity of CYP2C9 fourfolds.	pyrazolanthrone	13-22	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	87-93
25064633-10	2014	Additionally, the inhibition of JNK (SP600125) increased cholesterol efflux and increased the expression of ABCA1 and SR-BI, but had no effect on LXRalpha.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	32-35
25064633-10	2014	Additionally, the inhibition of JNK (SP600125) increased cholesterol efflux and increased the expression of ABCA1 and SR-BI, but had no effect on LXRalpha.	pyrazolanthrone	37-45	ATP binding cassette subfamily A member 1	Homo sapiens	108-113
25064633-7	2014	MCP-1 expression was restrained by the inhibition of c-Jun N-terminal kinase (JNK) pathway (SP600125) and NF-kappaB pathway (BAY11-7082).	pyrazolanthrone	92-100	C-C motif chemokine ligand 2	Homo sapiens	0-5
25064633-7	2014	MCP-1 expression was restrained by the inhibition of c-Jun N-terminal kinase (JNK) pathway (SP600125) and NF-kappaB pathway (BAY11-7082).	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	53-76
25064633-10	2014	Additionally, the inhibition of JNK (SP600125) increased cholesterol efflux and increased the expression of ABCA1 and SR-BI, but had no effect on LXRalpha.	pyrazolanthrone	37-45	scavenger receptor class B member 1	Homo sapiens	118-123
25064633-7	2014	MCP-1 expression was restrained by the inhibition of c-Jun N-terminal kinase (JNK) pathway (SP600125) and NF-kappaB pathway (BAY11-7082).	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	78-81
24706573-6	2014	Similarly, the inhibition of JNK signal pathway activation by pretreatment with SP600125 facilitated the protein phosphorylation of p38 MAPK caused by OA.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Homo sapiens	29-32
25066549-2	2014	Treatment of RAW264.7 cells with DL increased HO-1 expression in a time- and concentration-dependent manner, and this up-regulation of HO-1 by DL was significantly inhibited by silencing either Nrf2 and p38 or treating cells with SB203580 (a p38MAPK inhibitor), but it was not inhibited in the presence of SP600125 (an ERK inhibitor), PD98059 (a JNK inhibitor), or LY294002 (PI3K inhibitor).	pyrazolanthrone	306-314	nuclear factor, erythroid derived 2, like 2	Mus musculus	194-198
25066549-2	2014	Treatment of RAW264.7 cells with DL increased HO-1 expression in a time- and concentration-dependent manner, and this up-regulation of HO-1 by DL was significantly inhibited by silencing either Nrf2 and p38 or treating cells with SB203580 (a p38MAPK inhibitor), but it was not inhibited in the presence of SP600125 (an ERK inhibitor), PD98059 (a JNK inhibitor), or LY294002 (PI3K inhibitor).	pyrazolanthrone	306-314	mitogen-activated protein kinase 14	Mus musculus	203-206
25318890-13	2014	The upregulation of Beclin 1 expression, instead of HIF-1alpha, could be blocked by SP600125 (a specific inhibitor of c-Jun NH2-terminal kinase), followed by suppression of autophagy.	pyrazolanthrone	84-92	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	118-123
25318890-13	2014	The upregulation of Beclin 1 expression, instead of HIF-1alpha, could be blocked by SP600125 (a specific inhibitor of c-Jun NH2-terminal kinase), followed by suppression of autophagy.	pyrazolanthrone	84-92	beclin 1	Homo sapiens	20-28
24706573-6	2014	Similarly, the inhibition of JNK signal pathway activation by pretreatment with SP600125 facilitated the protein phosphorylation of p38 MAPK caused by OA.	pyrazolanthrone	80-88	mitogen-activated protein kinase 14	Homo sapiens	132-135
25226534-7	2014	IGF-IR knockdown blunts the induction of both Akt and Erk1/2 phosphorylation by SP600125.	pyrazolanthrone	80-88	AKT serine/threonine kinase 1	Homo sapiens	46-49
25256260-10	2014	Furthermore, the JNK (SP600125) inhibitor completely blocked Danggui inhibition of caspase-3 activation in Ang II-treated H9c2 cells.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
25256260-10	2014	Furthermore, the JNK (SP600125) inhibitor completely blocked Danggui inhibition of caspase-3 activation in Ang II-treated H9c2 cells.	pyrazolanthrone	22-30	caspase 3	Rattus norvegicus	83-92
25256260-10	2014	Furthermore, the JNK (SP600125) inhibitor completely blocked Danggui inhibition of caspase-3 activation in Ang II-treated H9c2 cells.	pyrazolanthrone	22-30	angiotensinogen	Rattus norvegicus	107-113
25332685-3	2014	SP600125 (a c-Jun NH2-terminal kinase [JNK] inhibitor) dose-response curves were generated in aortas that were pre-contracted with DMT or phorbol 12,13-dibutyrate (PDBu), a protein kinase C (PKC) activator.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	39-42
25226534-0	2014	SP600125 induces Src and type I IGF receptor phosphorylation independent of JNK.	pyrazolanthrone	0-8	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	17-20
25226534-7	2014	IGF-IR knockdown blunts the induction of both Akt and Erk1/2 phosphorylation by SP600125.	pyrazolanthrone	80-88	mitogen-activated protein kinase 3	Homo sapiens	54-60
25226534-2	2014	The small molecule SP600125 is widely used in biochemical studies as a JNK inhibitor.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	71-74
25226534-4	2014	Here, we report that SP600125 can induce Src, type I insulin-like growth factor receptor (IGF-IR), Akt and Erk1/2 phosphorylation.	pyrazolanthrone	21-29	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	41-44
25226534-9	2014	We conclude that SP600125 can activate Src-IGF-IR-Akt/Erk1/2 signaling pathways independent of JNK.	pyrazolanthrone	17-25	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	39-42
25226534-9	2014	We conclude that SP600125 can activate Src-IGF-IR-Akt/Erk1/2 signaling pathways independent of JNK.	pyrazolanthrone	17-25	insulin like growth factor 1 receptor	Homo sapiens	43-49
25226534-4	2014	Here, we report that SP600125 can induce Src, type I insulin-like growth factor receptor (IGF-IR), Akt and Erk1/2 phosphorylation.	pyrazolanthrone	21-29	insulin like growth factor 1 receptor	Homo sapiens	90-96
25226534-4	2014	Here, we report that SP600125 can induce Src, type I insulin-like growth factor receptor (IGF-IR), Akt and Erk1/2 phosphorylation.	pyrazolanthrone	21-29	AKT serine/threonine kinase 1	Homo sapiens	99-102
25226534-9	2014	We conclude that SP600125 can activate Src-IGF-IR-Akt/Erk1/2 signaling pathways independent of JNK.	pyrazolanthrone	17-25	AKT serine/threonine kinase 1	Homo sapiens	50-53
25226534-4	2014	Here, we report that SP600125 can induce Src, type I insulin-like growth factor receptor (IGF-IR), Akt and Erk1/2 phosphorylation.	pyrazolanthrone	21-29	mitogen-activated protein kinase 3	Homo sapiens	107-113
25226534-9	2014	We conclude that SP600125 can activate Src-IGF-IR-Akt/Erk1/2 signaling pathways independent of JNK.	pyrazolanthrone	17-25	mitogen-activated protein kinase 3	Homo sapiens	54-60
25226534-7	2014	IGF-IR knockdown blunts the induction of both Akt and Erk1/2 phosphorylation by SP600125.	pyrazolanthrone	80-88	insulin like growth factor 1 receptor	Homo sapiens	0-6
25198581-8	2014	ERK1/2 inhibitor U0126 and JNK2 inhibitor SP600125 attenuated the increase of proliferation induced by NAAG.	pyrazolanthrone	42-50	mitogen-activated protein kinase 9	Homo sapiens	27-31
24905542-9	2014	Both co-treatment and post-treatment (3h) with the JNK inhibitor SP600125 reduced JNK activation and significantly attenuated cell death at 24h and 48h after APAP.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	51-54
24905542-9	2014	Both co-treatment and post-treatment (3h) with the JNK inhibitor SP600125 reduced JNK activation and significantly attenuated cell death at 24h and 48h after APAP.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	82-85
25210730-10	2014	These effects could be inhibited by p38 MAPK inhibitor SB203580 and/or JNK inhibitor SP600125.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Homo sapiens	71-74
25010483-9	2014	Furthermore, EA and the JNK inhibitor SP600125 synergistically inhibited CFA-induced hyperalgesia and suppressed the COX-2 mRNA expression in the spinal dorsal horn.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
25179218-10	2014	Furthermore, the JNK inhibitor SP600125 inhibited invasion of P. gingivalis and also decreased the active form of Rab5 in Ca9-22 cells.	pyrazolanthrone	31-39	RAB5A, member RAS oncogene family	Homo sapiens	114-118
25152024-9	2014	Furthermore, pretreatment with JNK inhibitor SP600125 and p38 inhibitor SB203580, or with AKT inhibitor LY294002 abolished the effects of mig-2 on cisplaxtin-induced apoptosis.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
25152024-9	2014	Furthermore, pretreatment with JNK inhibitor SP600125 and p38 inhibitor SB203580, or with AKT inhibitor LY294002 abolished the effects of mig-2 on cisplaxtin-induced apoptosis.	pyrazolanthrone	45-53	FERM domain containing kindlin 2	Homo sapiens	138-143
25010483-9	2014	Furthermore, EA and the JNK inhibitor SP600125 synergistically inhibited CFA-induced hyperalgesia and suppressed the COX-2 mRNA expression in the spinal dorsal horn.	pyrazolanthrone	38-46	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	117-122
24961950-8	2014	Additionally, pretreatment with SB202190 and SP600125 also decreased the expression of CHOP.	pyrazolanthrone	45-53	DNA damage inducible transcript 3	Homo sapiens	87-91
24726898-9	2014	Inhibition of the down-stream DLK kinase c-Jun N-terminal kinase (JNK) by SP600125 attenuated DLK-induced MafA loss.	pyrazolanthrone	74-82	mitogen-activated protein kinase kinase kinase 12	Homo sapiens	94-97
24726898-9	2014	Inhibition of the down-stream DLK kinase c-Jun N-terminal kinase (JNK) by SP600125 attenuated DLK-induced MafA loss.	pyrazolanthrone	74-82	MAF bZIP transcription factor A	Homo sapiens	106-110
23172806-9	2014	Similarly, SP600125, an inhibitor of SAPK/JNK, moderately inhibited cytotoxicity and apoptosis induced by p-PD, thus implying that p38 MAPK and SAPK/JNK had a partial role in p-PD-induced apoptosis.	pyrazolanthrone	11-19	mitogen-activated protein kinase 9	Homo sapiens	37-41
23172806-9	2014	Similarly, SP600125, an inhibitor of SAPK/JNK, moderately inhibited cytotoxicity and apoptosis induced by p-PD, thus implying that p38 MAPK and SAPK/JNK had a partial role in p-PD-induced apoptosis.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Homo sapiens	42-45
23172806-9	2014	Similarly, SP600125, an inhibitor of SAPK/JNK, moderately inhibited cytotoxicity and apoptosis induced by p-PD, thus implying that p38 MAPK and SAPK/JNK had a partial role in p-PD-induced apoptosis.	pyrazolanthrone	11-19	mitogen-activated protein kinase 14	Homo sapiens	131-134
23172806-9	2014	Similarly, SP600125, an inhibitor of SAPK/JNK, moderately inhibited cytotoxicity and apoptosis induced by p-PD, thus implying that p38 MAPK and SAPK/JNK had a partial role in p-PD-induced apoptosis.	pyrazolanthrone	11-19	mitogen-activated protein kinase 9	Homo sapiens	144-148
23172806-9	2014	Similarly, SP600125, an inhibitor of SAPK/JNK, moderately inhibited cytotoxicity and apoptosis induced by p-PD, thus implying that p38 MAPK and SAPK/JNK had a partial role in p-PD-induced apoptosis.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Homo sapiens	149-152
24970310-6	2014	To explore the possible mechanisms, the HMGB1 receptor for advanced glycation endproducts (RAGE) in the NS/PCs was blocked with anti-RAGE antibody, and c-Jun N-terminal protein kinase (JNK) in the NS/PCs was inhibited using the potent JNK inhibitor, SP600125.	pyrazolanthrone	250-258	high mobility group box 1	Homo sapiens	40-45
24970310-6	2014	To explore the possible mechanisms, the HMGB1 receptor for advanced glycation endproducts (RAGE) in the NS/PCs was blocked with anti-RAGE antibody, and c-Jun N-terminal protein kinase (JNK) in the NS/PCs was inhibited using the potent JNK inhibitor, SP600125.	pyrazolanthrone	250-258	advanced glycosylation end-product specific receptor	Homo sapiens	91-95
24726898-9	2014	Inhibition of the down-stream DLK kinase c-Jun N-terminal kinase (JNK) by SP600125 attenuated DLK-induced MafA loss.	pyrazolanthrone	74-82	mitogen-activated protein kinase kinase kinase 12	Homo sapiens	30-33
24726898-9	2014	Inhibition of the down-stream DLK kinase c-Jun N-terminal kinase (JNK) by SP600125 attenuated DLK-induced MafA loss.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	41-64
24726898-9	2014	Inhibition of the down-stream DLK kinase c-Jun N-terminal kinase (JNK) by SP600125 attenuated DLK-induced MafA loss.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	66-69
24970310-6	2014	To explore the possible mechanisms, the HMGB1 receptor for advanced glycation endproducts (RAGE) in the NS/PCs was blocked with anti-RAGE antibody, and c-Jun N-terminal protein kinase (JNK) in the NS/PCs was inhibited using the potent JNK inhibitor, SP600125.	pyrazolanthrone	250-258	mitogen-activated protein kinase 8	Homo sapiens	152-183
24651933-7	2014	The increased phosphorylation of p38 and JNK induced by OGD was decreased under the treatment of curcumin, whereas the p38 inhibitor, SB203580, significantly inhibited OGD-induced IL-1beta production, but the JNK inhibitor, SP600125, failed to do so.	pyrazolanthrone	224-232	mitogen activated protein kinase 14	Rattus norvegicus	33-36
24651933-7	2014	The increased phosphorylation of p38 and JNK induced by OGD was decreased under the treatment of curcumin, whereas the p38 inhibitor, SB203580, significantly inhibited OGD-induced IL-1beta production, but the JNK inhibitor, SP600125, failed to do so.	pyrazolanthrone	224-232	mitogen activated protein kinase 14	Rattus norvegicus	119-122
24813642-6	2014	PD98059, a specific MEK inhibitor, SB203580, a specific p38 MAP kinase inhibitor, and SP600125, a specific SAPK/JNK inhibitor suppressed the PGD2-stimulated OPG release.	pyrazolanthrone	86-94	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	157-160
24838066-9	2014	Pre-treatment of HA with structurally distinct JNK inhibitors (25muM), either SP600125 or SU3327, reduced JNK phosphorylation (p&lt;0.05) and trauma-induced HA retraction (P&lt;0.05).	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	47-50
24534200-10	2014	JNK inhibition by SP600125 significantly increased apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
25564054-6	2014	After using the JNK inhibitor SP600125 to block JNK phosphorylation, the level of c-Jun phosphorylation was still dramatically reduced in the RIG-G-overexpressing U937T-RIG-G cells, compared with the control U937T-pTRE cells.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	16-19
25564054-6	2014	After using the JNK inhibitor SP600125 to block JNK phosphorylation, the level of c-Jun phosphorylation was still dramatically reduced in the RIG-G-overexpressing U937T-RIG-G cells, compared with the control U937T-pTRE cells.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	48-51
25564054-6	2014	After using the JNK inhibitor SP600125 to block JNK phosphorylation, the level of c-Jun phosphorylation was still dramatically reduced in the RIG-G-overexpressing U937T-RIG-G cells, compared with the control U937T-pTRE cells.	pyrazolanthrone	30-38	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	82-87
25564054-6	2014	After using the JNK inhibitor SP600125 to block JNK phosphorylation, the level of c-Jun phosphorylation was still dramatically reduced in the RIG-G-overexpressing U937T-RIG-G cells, compared with the control U937T-pTRE cells.	pyrazolanthrone	30-38	interferon induced protein with tetratricopeptide repeats 3	Homo sapiens	142-147
25564054-6	2014	After using the JNK inhibitor SP600125 to block JNK phosphorylation, the level of c-Jun phosphorylation was still dramatically reduced in the RIG-G-overexpressing U937T-RIG-G cells, compared with the control U937T-pTRE cells.	pyrazolanthrone	30-38	interferon induced protein with tetratricopeptide repeats 3	Homo sapiens	169-174
25165860-5	2014	We found that 3,6-DHF showed a similar IC50 (113 nM) value to that of the JNK inhibitor, SP600125 (IC50 = 118 nM) in a JNK1 kinase assay.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	74-77
25165860-5	2014	We found that 3,6-DHF showed a similar IC50 (113 nM) value to that of the JNK inhibitor, SP600125 (IC50 = 118 nM) in a JNK1 kinase assay.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	119-123
25131789-3	2014	HMGB1 at 10 ng/mL significantly increased the NSCs proliferation accompanied by the rising of phosphorylated JNK levels (P &lt; 0.01), and 10 mumol/L SP600125 prevented these effects in HMGB1-cultured NSCs (P &lt; 0.01).	pyrazolanthrone	150-158	high mobility group box 1	Rattus norvegicus	186-191
24838066-9	2014	Pre-treatment of HA with structurally distinct JNK inhibitors (25muM), either SP600125 or SU3327, reduced JNK phosphorylation (p&lt;0.05) and trauma-induced HA retraction (P&lt;0.05).	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	106-109
24913968-10	2014	Neuronal differentiation of ES cells was attenuated by treatment with SP600125, which inhibited the JNK activation and decreased the activation of STAT1 and STAT3, and consequently suppressed the expressions of GAP-43, neurofilament, betaIII-tubulin, and the secretion of VEGF.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Mus musculus	100-103
25003321-13	2014	Specific inhibitors of p38 (SB203580) and JNK (SP600125) inhibited tube formation and wound healing, while an ERK inhibitor (PD98059) did not.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	42-45
25095732-10	2014	alpha2AP-induced the TGF-beta production was significantly reduced by SP600125, c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	70-78	serine (or cysteine) peptidase inhibitor, clade F, member 2	Mus musculus	0-8
25095732-10	2014	alpha2AP-induced the TGF-beta production was significantly reduced by SP600125, c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	70-78	transforming growth factor, beta 1	Mus musculus	21-29
25121739-5	2014	CXCL12-induced CTGF expression was inhibited by a CXCR4 antagonist (AMD3100), small interfering RNA of CXCR4 (CXCR4 siRNA), a dominant negative mutant of Rac1 (RacN17), a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor (PD98059), a JNK inhibitor (SP600125), a p21-activated kinase inhibitor (PAK18), c-Jun siRNA, and an AP-1 inhibitor (curcumin).	pyrazolanthrone	262-270	C-X-C motif chemokine ligand 12	Homo sapiens	0-6
25121739-5	2014	CXCL12-induced CTGF expression was inhibited by a CXCR4 antagonist (AMD3100), small interfering RNA of CXCR4 (CXCR4 siRNA), a dominant negative mutant of Rac1 (RacN17), a mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor (PD98059), a JNK inhibitor (SP600125), a p21-activated kinase inhibitor (PAK18), c-Jun siRNA, and an AP-1 inhibitor (curcumin).	pyrazolanthrone	262-270	cellular communication network factor 2	Homo sapiens	15-19
25121739-8	2014	Treatment of cells with PD98059 and SP600125 both inhibited CXCL12-induced c-Jun phosphorylation.	pyrazolanthrone	36-44	C-X-C motif chemokine ligand 12	Homo sapiens	60-66
25121739-8	2014	Treatment of cells with PD98059 and SP600125 both inhibited CXCL12-induced c-Jun phosphorylation.	pyrazolanthrone	36-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	75-80
24913968-10	2014	Neuronal differentiation of ES cells was attenuated by treatment with SP600125, which inhibited the JNK activation and decreased the activation of STAT1 and STAT3, and consequently suppressed the expressions of GAP-43, neurofilament, betaIII-tubulin, and the secretion of VEGF.	pyrazolanthrone	70-78	signal transducer and activator of transcription 1	Mus musculus	147-152
24913968-10	2014	Neuronal differentiation of ES cells was attenuated by treatment with SP600125, which inhibited the JNK activation and decreased the activation of STAT1 and STAT3, and consequently suppressed the expressions of GAP-43, neurofilament, betaIII-tubulin, and the secretion of VEGF.	pyrazolanthrone	70-78	signal transducer and activator of transcription 3	Mus musculus	157-162
24913968-10	2014	Neuronal differentiation of ES cells was attenuated by treatment with SP600125, which inhibited the JNK activation and decreased the activation of STAT1 and STAT3, and consequently suppressed the expressions of GAP-43, neurofilament, betaIII-tubulin, and the secretion of VEGF.	pyrazolanthrone	70-78	growth associated protein 43	Mus musculus	211-217
24913968-10	2014	Neuronal differentiation of ES cells was attenuated by treatment with SP600125, which inhibited the JNK activation and decreased the activation of STAT1 and STAT3, and consequently suppressed the expressions of GAP-43, neurofilament, betaIII-tubulin, and the secretion of VEGF.	pyrazolanthrone	70-78	vascular endothelial growth factor A	Mus musculus	272-276
24913968-11	2014	Data from immunocytochemistry indicated that the nuclear translocation of STAT3 was reduced, and neurites of ES-derived neurons were shorter after treatment with SP600125 compared with control cells.	pyrazolanthrone	162-170	signal transducer and activator of transcription 3	Mus musculus	74-79
24928238-5	2014	We hypothesized that SP600125, a chemical inhibitor of JNK, may effectively ameliorate EBI by inhibiting Nur77 phosphorylation and its transcriptional activity.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Rattus norvegicus	55-58
23952046-10	2014	This was significantly decreased in a dose-dependent manner by NBD peptide or SP600125 [maximum inhibition ~30-40% (p &lt; 0.02)], and together, the two inhibitors decreased IL-6 by ~80%, similar to the inhibition caused by NDM (p &lt; 0.001).	pyrazolanthrone	78-86	interleukin 6	Homo sapiens	174-178
24830780-9	2014	JNK signaling pathway-specific inhibitor SP600125 and c-Jun shRNA both significantly increased the expression of steroidogenic enzymes and E2 production regardless of the presence or absence of DHA.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	0-3
24928238-8	2014	SP600125 markedly decreased expressions of p-JNK, p-Nur77, Bcl-2, cyto C, caspase-3 and inhibited apoptosis.	pyrazolanthrone	0-8	caspase 3	Rattus norvegicus	74-83
24820448-11	2014	Addition of JNK inhibitor SP600125 or p38 inhibitor SB203580 to myocytes plus H2O2 prevented H2O2 decrease in viability and increased hUCBC beneficial effects.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	12-15
24928238-5	2014	We hypothesized that SP600125, a chemical inhibitor of JNK, may effectively ameliorate EBI by inhibiting Nur77 phosphorylation and its transcriptional activity.	pyrazolanthrone	21-29	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	105-110
24928238-12	2014	These findings strongly support the hypothesis that SP600125 treatment can ameliorate EBI after experimentally induced SAH by inhibiting a Nur77-dependent apoptotic pathway.	pyrazolanthrone	52-60	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	139-144
24928238-8	2014	SP600125 markedly decreased expressions of p-JNK, p-Nur77, Bcl-2, cyto C, caspase-3 and inhibited apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	45-48
24928238-8	2014	SP600125 markedly decreased expressions of p-JNK, p-Nur77, Bcl-2, cyto C, caspase-3 and inhibited apoptosis.	pyrazolanthrone	0-8	nuclear receptor subfamily 4, group A, member 1	Rattus norvegicus	52-57
24928238-8	2014	SP600125 markedly decreased expressions of p-JNK, p-Nur77, Bcl-2, cyto C, caspase-3 and inhibited apoptosis.	pyrazolanthrone	0-8	BCL2, apoptosis regulator	Rattus norvegicus	59-64
24919794-8	2014	We investigated the upstream of the death receptor pathway and further observed that the levels of death receptor 5 (DR5) and phosphorylated c-Jun N-terminal kinase (JNK) signals were upregulated in HUVECs following HMJ-30 challenge, which was confirmed by a JNK-specific inhibitor (SP600125).	pyrazolanthrone	283-291	TNF receptor superfamily member 10b	Homo sapiens	99-115
25084093-12	2014	Importantly, an inhibitor of phospho-JNK, SP600125, protects against OGD-Rep induced apoptosis and inhibited NF-kappaB signaling pathway, similar to the roles of ginsenoside Rb3.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Mus musculus	37-40
24919794-8	2014	We investigated the upstream of the death receptor pathway and further observed that the levels of death receptor 5 (DR5) and phosphorylated c-Jun N-terminal kinase (JNK) signals were upregulated in HUVECs following HMJ-30 challenge, which was confirmed by a JNK-specific inhibitor (SP600125).	pyrazolanthrone	283-291	TNF receptor superfamily member 10b	Homo sapiens	117-120
24919794-8	2014	We investigated the upstream of the death receptor pathway and further observed that the levels of death receptor 5 (DR5) and phosphorylated c-Jun N-terminal kinase (JNK) signals were upregulated in HUVECs following HMJ-30 challenge, which was confirmed by a JNK-specific inhibitor (SP600125).	pyrazolanthrone	283-291	mitogen-activated protein kinase 8	Homo sapiens	141-164
24919794-8	2014	We investigated the upstream of the death receptor pathway and further observed that the levels of death receptor 5 (DR5) and phosphorylated c-Jun N-terminal kinase (JNK) signals were upregulated in HUVECs following HMJ-30 challenge, which was confirmed by a JNK-specific inhibitor (SP600125).	pyrazolanthrone	283-291	mitogen-activated protein kinase 8	Homo sapiens	166-169
25084093-12	2014	Importantly, an inhibitor of phospho-JNK, SP600125, protects against OGD-Rep induced apoptosis and inhibited NF-kappaB signaling pathway, similar to the roles of ginsenoside Rb3.	pyrazolanthrone	42-50	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	109-118
24953606-8	2014	Staurosporine, the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580 significantly increased Pax6 levels in high glucose-treated INS-1E cells compared to their respective controls.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	19-42
24812029-7	2014	Pretreatment with the JNK inhibitor, SP600125, suppressed DMAC-induced JNK phosphorylation, which was accompanied by a reversal of Bcl-XL expression.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	22-25
24812029-7	2014	Pretreatment with the JNK inhibitor, SP600125, suppressed DMAC-induced JNK phosphorylation, which was accompanied by a reversal of Bcl-XL expression.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	71-74
24812029-7	2014	Pretreatment with the JNK inhibitor, SP600125, suppressed DMAC-induced JNK phosphorylation, which was accompanied by a reversal of Bcl-XL expression.	pyrazolanthrone	37-45	BCL2 like 1	Homo sapiens	131-137
24953606-8	2014	Staurosporine, the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580 significantly increased Pax6 levels in high glucose-treated INS-1E cells compared to their respective controls.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	44-47
24953606-8	2014	Staurosporine, the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580 significantly increased Pax6 levels in high glucose-treated INS-1E cells compared to their respective controls.	pyrazolanthrone	59-67	paired box 6	Rattus norvegicus	167-171
25028967-8	2014	The activation of JNK signaling by RASSF6 and its subsequent sensitivity to apoptosis in NPC cells could be inhibited by applying the JNK inhibitor SP600125.	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Homo sapiens	18-21
25028967-8	2014	The activation of JNK signaling by RASSF6 and its subsequent sensitivity to apoptosis in NPC cells could be inhibited by applying the JNK inhibitor SP600125.	pyrazolanthrone	148-156	Ras association domain family member 6	Homo sapiens	35-41
25028967-8	2014	The activation of JNK signaling by RASSF6 and its subsequent sensitivity to apoptosis in NPC cells could be inhibited by applying the JNK inhibitor SP600125.	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Homo sapiens	134-137
24853961-0	2014	Alkyl chain substituted 1,9-pyrazoloanthrones exhibit prominent inhibitory effect on c-Jun N-terminal kinase (JNK).	pyrazolanthrone	24-45	mitogen-activated protein kinase 8	Homo sapiens	85-108
24853961-0	2014	Alkyl chain substituted 1,9-pyrazoloanthrones exhibit prominent inhibitory effect on c-Jun N-terminal kinase (JNK).	pyrazolanthrone	24-45	mitogen-activated protein kinase 8	Homo sapiens	110-113
24604564-5	2014	GRP78 protein levels were similar in the tunicamycin (Tm), salubrinal, and SP600125 groups, but were lower in cells treated with SN50.	pyrazolanthrone	75-83	heat shock protein family A (Hsp70) member 5	Homo sapiens	0-5
25062485-7	2014	Furthermore, treatment with HGF upregulated nexilin expression and the JNK inhibitor SP600125 partly inhibited HGF-induced nexilin upregulation.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Homo sapiens	71-74
25062485-7	2014	Furthermore, treatment with HGF upregulated nexilin expression and the JNK inhibitor SP600125 partly inhibited HGF-induced nexilin upregulation.	pyrazolanthrone	85-93	hepatocyte growth factor	Homo sapiens	111-114
25062485-7	2014	Furthermore, treatment with HGF upregulated nexilin expression and the JNK inhibitor SP600125 partly inhibited HGF-induced nexilin upregulation.	pyrazolanthrone	85-93	nexilin F-actin binding protein	Homo sapiens	123-130
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	77-98
24944614-0	2014	JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation of claudin-4.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
24944614-0	2014	JNK inhibitor SP600125 protects against lipopolysaccharide-induced acute lung injury via upregulation of claudin-4.	pyrazolanthrone	14-22	claudin 4	Homo sapiens	105-114
24944614-2	2014	The present study aimed to investigate the effect of the JNK selective inhibitor SP600125 on lipopolysaccharide (LPS)-induced ALI.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	57-60
24944614-6	2014	At the molecular level, SP600125 treatment dose-dependently inhibited JNK activation and upregulated claudin-4 expression in vivo and in vitro.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	70-73
24944614-6	2014	At the molecular level, SP600125 treatment dose-dependently inhibited JNK activation and upregulated claudin-4 expression in vivo and in vitro.	pyrazolanthrone	24-32	claudin 4	Homo sapiens	101-110
24944614-7	2014	In combination, the results from the present study indicated that the JNK inhibitor SP600125 protected against LPS-induced ALI in vivo and in vitro, possibly by upregulating the expression of claudin-4.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	70-73
24944614-7	2014	In combination, the results from the present study indicated that the JNK inhibitor SP600125 protected against LPS-induced ALI in vivo and in vitro, possibly by upregulating the expression of claudin-4.	pyrazolanthrone	84-92	claudin 4	Homo sapiens	192-201
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	pyrazolanthrone	100-108	bone gamma-carboxyglutamate protein	Homo sapiens	199-202
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	pyrazolanthrone	100-108	dentin sialophosphoprotein	Homo sapiens	204-208
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	pyrazolanthrone	100-108	dentin matrix acidic phosphoprotein 1	Homo sapiens	210-214
24935539-7	2014	The MAPK inhibitor for extracellular signal-regulated kinase 1/2 (U0126) and Jun N-terminal kinase (SP600125) significantly decreased the Biodentine-induced mineralized differentiation of hDPSCs and OCN, DSPP, DMP1, and BSP messenger RNA expression, whereas p38 MAPK inhibitors (SB203580) had no effect.	pyrazolanthrone	100-108	integrin binding sialoprotein	Homo sapiens	220-223
24911792-5	2014	Moreover, reactive oxygen species (ROS) generation and upregulation of both TAp73 and ER stress sensor proteins were detected after CD47 ligation, and p38 inhibitor SB203580 and JNK inhibitor SP600125 blocked upregulation of TAp73 and cell cycle arrest.	pyrazolanthrone	192-200	CD47 molecule	Homo sapiens	132-136
24911792-5	2014	Moreover, reactive oxygen species (ROS) generation and upregulation of both TAp73 and ER stress sensor proteins were detected after CD47 ligation, and p38 inhibitor SB203580 and JNK inhibitor SP600125 blocked upregulation of TAp73 and cell cycle arrest.	pyrazolanthrone	192-200	mitogen-activated protein kinase 8	Homo sapiens	178-181
24935540-5	2014	METHODS: The third passage of HDPCs were cultured in vitro and treated with WNT6 conditioned medium with or without the pretreatment of JNK inhibitor SP600125.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	136-139
24788963-5	2014	PODXL expression at both the mRNA and the protein level, as well as the PODXL gene promoter activity, were significantly increased and decreased in parallel with the overexpression and knockdown of SPAG9 in astrocytoma cells; these effects were blocked by the selective c-Jun N-terminal kinase (JNK) inhibitor SP600125 (5 microM) and restored by the JNK agonist anisomycin (25 ng/ml), respectively.	pyrazolanthrone	310-318	podocalyxin like	Homo sapiens	0-5
23359384-4	2014	Meanwhile, the mRNA and protein expression of JNK in Eca109 cells pretreated with SP600125 were examined by real-time quantitative reverse transcription PCR (qRT-PCR) and Western blotting, respectively.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	46-49
24841706-7	2014	Treatment with SP600125, a JNK inhibitor, attenuated the effects of resveratrol on MMP-2 and MMP-9, and accelerated resveratrol-induced effects on type II collagen, SOX-9 and sulfated proteoglycan production.	pyrazolanthrone	15-23	matrix metallopeptidase 2	Homo sapiens	83-88
24841706-7	2014	Treatment with SP600125, a JNK inhibitor, attenuated the effects of resveratrol on MMP-2 and MMP-9, and accelerated resveratrol-induced effects on type II collagen, SOX-9 and sulfated proteoglycan production.	pyrazolanthrone	15-23	matrix metallopeptidase 9	Homo sapiens	93-98
24841706-7	2014	Treatment with SP600125, a JNK inhibitor, attenuated the effects of resveratrol on MMP-2 and MMP-9, and accelerated resveratrol-induced effects on type II collagen, SOX-9 and sulfated proteoglycan production.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	27-30
24747804-4	2014	Our results also demonstrated that the expression patterns of the gsualpha:EGFP transgene were all identical to those expression patterns of the endogenous gsualpha expression in the pituitary tissue when our transgenic fish were treated with various endocrine chemicals, including forskolin (FSK), SP600125, trichostatin A (TSA), KClO4, dexamethasone (Dex), beta-estradiol and progesterone.	pyrazolanthrone	299-307	glycoprotein hormones, alpha polypeptide	Danio rerio	156-164
24788963-5	2014	PODXL expression at both the mRNA and the protein level, as well as the PODXL gene promoter activity, were significantly increased and decreased in parallel with the overexpression and knockdown of SPAG9 in astrocytoma cells; these effects were blocked by the selective c-Jun N-terminal kinase (JNK) inhibitor SP600125 (5 microM) and restored by the JNK agonist anisomycin (25 ng/ml), respectively.	pyrazolanthrone	310-318	sperm associated antigen 9	Homo sapiens	198-203
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	pyrazolanthrone	173-181	mitogen-activated protein kinase 1	Homo sapiens	13-50
24967732-6	2014	Moreover, combination treatment of BANCR knockdown and suppression ERK1/2 or JNK (induced by specific inhibitors U0126 or SP600125 respectively) produced synergistic inhibitory effects in vitro.	pyrazolanthrone	122-130	BRAF-activated non-protein coding RNA	Homo sapiens	35-40
24967732-6	2014	Moreover, combination treatment of BANCR knockdown and suppression ERK1/2 or JNK (induced by specific inhibitors U0126 or SP600125 respectively) produced synergistic inhibitory effects in vitro.	pyrazolanthrone	122-130	mitogen-activated protein kinase 3	Homo sapiens	67-73
24967732-6	2014	Moreover, combination treatment of BANCR knockdown and suppression ERK1/2 or JNK (induced by specific inhibitors U0126 or SP600125 respectively) produced synergistic inhibitory effects in vitro.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	77-80
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	pyrazolanthrone	173-181	mitogen-activated protein kinase 1	Homo sapiens	52-55
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	61-84
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	86-89
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	158-161
24959718-7	2014	Induction of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) protein phosphorylation was detected in EVO-treated cells, and the JNK inhibitor, SP600125, but not the ERK inhibitor, U0126, inhibited EVO-induced phosphorylated JNK protein expression, apoptosis, and G2/M arrest of colon carcinoma cells.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	158-161
24841907-5	2014	Also, the reactive oxygen species (ROS) inhibitor N-acetyl-L-cysteine (NAC), the JNK inhibitor SP600125, and the p38 inhibitor SB203580 efficiently downregulated the levels of these proteins.	pyrazolanthrone	95-103	mitogen-activated protein kinase 8	Homo sapiens	81-84
24801387-6	2014	JNK inhibition with SP600125 attenuated phosphorylation of the Thr421/Ser424 sites, and in combination with TORIN2 both the effect of IGF-I and the enhanced Thr421/Ser424 phosphorylation during serum deprivation were ablated.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	0-3
24801387-8	2014	The role of JNK in mediating p70S6K1 phosphorylation was confirmed in the animal model noted above, where rats treated with SP600125 exhibited attenuated Thr421/Ser424 phosphorylation.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Rattus norvegicus	12-15
24801387-8	2014	The role of JNK in mediating p70S6K1 phosphorylation was confirmed in the animal model noted above, where rats treated with SP600125 exhibited attenuated Thr421/Ser424 phosphorylation.	pyrazolanthrone	124-132	ribosomal protein S6 kinase B1	Rattus norvegicus	29-36
24740538-6	2014	The increase in LARG expression, Rho kinase and ZIP kinase activities, and sustained muscle contraction was abolished in cells pretreated with the Jun kinase inhibitor, SP600125.	pyrazolanthrone	169-177	Rho guanine nucleotide exchange factor (GEF) 12	Mus musculus	16-20
24740538-6	2014	The increase in LARG expression, Rho kinase and ZIP kinase activities, and sustained muscle contraction was abolished in cells pretreated with the Jun kinase inhibitor, SP600125.	pyrazolanthrone	169-177	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	33-43
24740538-6	2014	The increase in LARG expression, Rho kinase and ZIP kinase activities, and sustained muscle contraction was abolished in cells pretreated with the Jun kinase inhibitor, SP600125.	pyrazolanthrone	169-177	death-associated protein kinase 3	Mus musculus	48-58
24522860-6	2014	M3 mAChR-mediated IL-8 expression was almost completely inhibited by the NF-kappaB inhibitor BAY11-7082 and, to a lesser extent, by U0126, SB203580, and SP600125, which are inhibitors for ERK1/2, p38, and JNK, respectively.	pyrazolanthrone	153-161	C-X-C motif chemokine ligand 8	Homo sapiens	18-22
24727493-8	2014	SP-600125 and lactacystin, JNK and NF-kappaB inhibitors, respectively, reduced ANG II-induced ET-1, COX-2, and NOX-1 levels and NOX activity.	pyrazolanthrone	0-9	angiotensinogen	Rattus norvegicus	79-85
24727493-8	2014	SP-600125 and lactacystin, JNK and NF-kappaB inhibitors, respectively, reduced ANG II-induced ET-1, COX-2, and NOX-1 levels and NOX activity.	pyrazolanthrone	0-9	endothelin 1	Rattus norvegicus	94-98
24727493-8	2014	SP-600125 and lactacystin, JNK and NF-kappaB inhibitors, respectively, reduced ANG II-induced ET-1, COX-2, and NOX-1 levels and NOX activity.	pyrazolanthrone	0-9	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	100-105
24727493-8	2014	SP-600125 and lactacystin, JNK and NF-kappaB inhibitors, respectively, reduced ANG II-induced ET-1, COX-2, and NOX-1 levels and NOX activity.	pyrazolanthrone	0-9	NADPH oxidase 1	Rattus norvegicus	111-116
24429914-8	2014	Furthermore, JNK pathway might be involved in LPS-induced astrocyte activation because JNK phosphorylation was significantly increased, and the inhibition of this pathway mediated by DEX as well as SP600125 (JNK inhibitor) decreased TNF-alpha and IL-6 expressions.	pyrazolanthrone	198-206	mitogen-activated protein kinase 8	Homo sapiens	13-16
24429914-8	2014	Furthermore, JNK pathway might be involved in LPS-induced astrocyte activation because JNK phosphorylation was significantly increased, and the inhibition of this pathway mediated by DEX as well as SP600125 (JNK inhibitor) decreased TNF-alpha and IL-6 expressions.	pyrazolanthrone	198-206	tumor necrosis factor	Homo sapiens	233-242
24429914-8	2014	Furthermore, JNK pathway might be involved in LPS-induced astrocyte activation because JNK phosphorylation was significantly increased, and the inhibition of this pathway mediated by DEX as well as SP600125 (JNK inhibitor) decreased TNF-alpha and IL-6 expressions.	pyrazolanthrone	198-206	interleukin 6	Homo sapiens	247-251
24409810-4	2014	The levels of phosphorylated and unphosphorylated JNK MAPK were quantified by Western blot analysis following treatment with BMP-2 and the JNK inhibitor SP600125.	pyrazolanthrone	153-161	mitogen-activated protein kinase 8	Homo sapiens	139-142
24409810-9	2014	However, the JNK inhibitor, SP600125, significantly inhibited late-stage differentiation of odontoblasts, including the gene expression of osteocalcin, dentin sialophosphoprotein and bone sialoprotein, and also reduced the formation of mineralized nodules in BMP-2-treated DPCs.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	13-16
24409810-9	2014	However, the JNK inhibitor, SP600125, significantly inhibited late-stage differentiation of odontoblasts, including the gene expression of osteocalcin, dentin sialophosphoprotein and bone sialoprotein, and also reduced the formation of mineralized nodules in BMP-2-treated DPCs.	pyrazolanthrone	28-36	bone gamma-carboxyglutamate protein	Homo sapiens	139-150
24409810-9	2014	However, the JNK inhibitor, SP600125, significantly inhibited late-stage differentiation of odontoblasts, including the gene expression of osteocalcin, dentin sialophosphoprotein and bone sialoprotein, and also reduced the formation of mineralized nodules in BMP-2-treated DPCs.	pyrazolanthrone	28-36	bone morphogenetic protein 2	Homo sapiens	259-264
24522860-6	2014	M3 mAChR-mediated IL-8 expression was almost completely inhibited by the NF-kappaB inhibitor BAY11-7082 and, to a lesser extent, by U0126, SB203580, and SP600125, which are inhibitors for ERK1/2, p38, and JNK, respectively.	pyrazolanthrone	153-161	mitogen-activated protein kinase 3	Homo sapiens	188-194
24522860-6	2014	M3 mAChR-mediated IL-8 expression was almost completely inhibited by the NF-kappaB inhibitor BAY11-7082 and, to a lesser extent, by U0126, SB203580, and SP600125, which are inhibitors for ERK1/2, p38, and JNK, respectively.	pyrazolanthrone	153-161	mitogen-activated protein kinase 1	Homo sapiens	196-199
24522860-6	2014	M3 mAChR-mediated IL-8 expression was almost completely inhibited by the NF-kappaB inhibitor BAY11-7082 and, to a lesser extent, by U0126, SB203580, and SP600125, which are inhibitors for ERK1/2, p38, and JNK, respectively.	pyrazolanthrone	153-161	mitogen-activated protein kinase 8	Homo sapiens	205-208
24731555-7	2014	In addition, we found that various inhibitors, such as the PLCgamma2 inhibitor U73122, the PKC inhibitor Ro318220, the phospoinositide 3-kinase inhibitor LY294002, the p38 mitogen-activated protein kinase inhibitor SB203580, the ERK inhibitor PD98059, and the JNK inhibitor SP600125, had no effects on collagen-induced JAK2 activity.	pyrazolanthrone	274-282	mitogen-activated protein kinase 14	Homo sapiens	168-171
24668641-8	2014	The c-Jun N-terminal kinase (JNK) inhibitor, SP600125, suppressed the beta-carotene-induced GSH increase, whereas a p38 mitogen-activated protein kinase inhibitor or an extracellular signal-regulated kinase 1/2 inhibitor did not.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Mus musculus	29-32
24510324-6	2014	Furthermore, treating FAK small interfering RNA (FAK siRNA) and specific inhibitor for JNK (SP600125) to AGS cells could reduce the phosphorylation of JNK1/2 and the activity of MMP-2 and MMP-9.	pyrazolanthrone	92-100	protein tyrosine kinase 2	Homo sapiens	22-25
24510324-6	2014	Furthermore, treating FAK small interfering RNA (FAK siRNA) and specific inhibitor for JNK (SP600125) to AGS cells could reduce the phosphorylation of JNK1/2 and the activity of MMP-2 and MMP-9.	pyrazolanthrone	92-100	protein tyrosine kinase 2	Homo sapiens	49-58
24510324-6	2014	Furthermore, treating FAK small interfering RNA (FAK siRNA) and specific inhibitor for JNK (SP600125) to AGS cells could reduce the phosphorylation of JNK1/2 and the activity of MMP-2 and MMP-9.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	87-90
24510324-6	2014	Furthermore, treating FAK small interfering RNA (FAK siRNA) and specific inhibitor for JNK (SP600125) to AGS cells could reduce the phosphorylation of JNK1/2 and the activity of MMP-2 and MMP-9.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	151-157
24510324-6	2014	Furthermore, treating FAK small interfering RNA (FAK siRNA) and specific inhibitor for JNK (SP600125) to AGS cells could reduce the phosphorylation of JNK1/2 and the activity of MMP-2 and MMP-9.	pyrazolanthrone	92-100	matrix metallopeptidase 2	Homo sapiens	178-183
24510324-6	2014	Furthermore, treating FAK small interfering RNA (FAK siRNA) and specific inhibitor for JNK (SP600125) to AGS cells could reduce the phosphorylation of JNK1/2 and the activity of MMP-2 and MMP-9.	pyrazolanthrone	92-100	matrix metallopeptidase 9	Homo sapiens	188-193
24682498-8	2014	The JNK pathway participated in UA-induced mitochondrial apoptotic signaling transduction via increasing the phosphorylation and degradation of Bcl-2, which may be partly attenuated by the JNK inhibitor SP600125.	pyrazolanthrone	203-211	mitogen-activated protein kinase 8	Mus musculus	4-7
24682498-8	2014	The JNK pathway participated in UA-induced mitochondrial apoptotic signaling transduction via increasing the phosphorylation and degradation of Bcl-2, which may be partly attenuated by the JNK inhibitor SP600125.	pyrazolanthrone	203-211	B cell leukemia/lymphoma 2	Mus musculus	144-149
24682498-8	2014	The JNK pathway participated in UA-induced mitochondrial apoptotic signaling transduction via increasing the phosphorylation and degradation of Bcl-2, which may be partly attenuated by the JNK inhibitor SP600125.	pyrazolanthrone	203-211	mitogen-activated protein kinase 8	Mus musculus	189-192
24501244-13	2014	Furthermore, SP600125, a selective JNK inhibitor, blocked up-regulation of autophagy by NOS inhibitor.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	35-38
24731555-8	2014	However, U73122, Ro318220 and SP600125 significantly diminished collagen-induced STAT3 phosphorylation.	pyrazolanthrone	30-38	signal transducer and activator of transcription 3	Homo sapiens	81-86
24878898-10	2014	In particular, the JNK-specific inhibitor SP600125 blocked KIOM-C-induced ROS generation and CHOP expression almost completely, which consequently almost completely rescued cell death, indicating that JNK activation plays a critical role in KIOM-C-induced cell death.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	19-22
24878898-10	2014	In particular, the JNK-specific inhibitor SP600125 blocked KIOM-C-induced ROS generation and CHOP expression almost completely, which consequently almost completely rescued cell death, indicating that JNK activation plays a critical role in KIOM-C-induced cell death.	pyrazolanthrone	42-50	DNA damage inducible transcript 3	Homo sapiens	93-97
24878898-10	2014	In particular, the JNK-specific inhibitor SP600125 blocked KIOM-C-induced ROS generation and CHOP expression almost completely, which consequently almost completely rescued cell death, indicating that JNK activation plays a critical role in KIOM-C-induced cell death.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	201-204
24857920-6	2014	Furthermore, inhibition of c-Jun N-terminal kinase (JNK) by SP600125 led to a dramatic decrease of the GLP-induced apoptosis.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	27-50
24857920-6	2014	Furthermore, inhibition of c-Jun N-terminal kinase (JNK) by SP600125 led to a dramatic decrease of the GLP-induced apoptosis.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	52-55
24855454-4	2014	METHODS: BMDM from wild type (WT), MKK3-/-, and MKK6-/- mice were pre-treated with p38 inhibitor SB203580 (SB), JNK inhibitor SP600125 (SP), and/or ERK inhibitor PD98059 (PD) and stimulated with LPS.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Mus musculus	112-115
24857917-6	2014	Furthermore, cell treatment with a JNK inhibitor (SP600125) and ERK inhibitor (PD98059) reduced sulfuretin-induced HO-1 expression and decreased its protective effects.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	35-38
24855454-4	2014	METHODS: BMDM from wild type (WT), MKK3-/-, and MKK6-/- mice were pre-treated with p38 inhibitor SB203580 (SB), JNK inhibitor SP600125 (SP), and/or ERK inhibitor PD98059 (PD) and stimulated with LPS.	pyrazolanthrone	126-128	mitogen-activated protein kinase 8	Mus musculus	112-115
24607842-6	2014	Treatment of parental cells with SP600125, a c-JUN-NH2-kinase (JNK) inhibitor, recapitulated defects in EPHA2-deficient tumor cells, whereas constitutively activated JNK mutants were sufficient to rescue phenotypes.	pyrazolanthrone	33-41	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	45-50
24632094-10	2014	In addition, JNK phosphorylations were involved in activating the mitochondria-dependent apoptotic pathway following Ang II stimulation, as pre-treatment of JNK-specific inhibitor SP600125 could rescue osteoblast cells from apoptosis by enhancing the anti-apoptotic protein Bcl-2 expressions, suppressing the translocation of Bax from cytosol into mitochondria, blocking cytochrome C release and caspase-3 activation.	pyrazolanthrone	180-188	mitogen-activated protein kinase 8	Mus musculus	13-16
24632094-10	2014	In addition, JNK phosphorylations were involved in activating the mitochondria-dependent apoptotic pathway following Ang II stimulation, as pre-treatment of JNK-specific inhibitor SP600125 could rescue osteoblast cells from apoptosis by enhancing the anti-apoptotic protein Bcl-2 expressions, suppressing the translocation of Bax from cytosol into mitochondria, blocking cytochrome C release and caspase-3 activation.	pyrazolanthrone	180-188	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	117-123
24632094-10	2014	In addition, JNK phosphorylations were involved in activating the mitochondria-dependent apoptotic pathway following Ang II stimulation, as pre-treatment of JNK-specific inhibitor SP600125 could rescue osteoblast cells from apoptosis by enhancing the anti-apoptotic protein Bcl-2 expressions, suppressing the translocation of Bax from cytosol into mitochondria, blocking cytochrome C release and caspase-3 activation.	pyrazolanthrone	180-188	mitogen-activated protein kinase 8	Mus musculus	157-160
24632094-10	2014	In addition, JNK phosphorylations were involved in activating the mitochondria-dependent apoptotic pathway following Ang II stimulation, as pre-treatment of JNK-specific inhibitor SP600125 could rescue osteoblast cells from apoptosis by enhancing the anti-apoptotic protein Bcl-2 expressions, suppressing the translocation of Bax from cytosol into mitochondria, blocking cytochrome C release and caspase-3 activation.	pyrazolanthrone	180-188	B cell leukemia/lymphoma 2	Mus musculus	274-279
24632094-10	2014	In addition, JNK phosphorylations were involved in activating the mitochondria-dependent apoptotic pathway following Ang II stimulation, as pre-treatment of JNK-specific inhibitor SP600125 could rescue osteoblast cells from apoptosis by enhancing the anti-apoptotic protein Bcl-2 expressions, suppressing the translocation of Bax from cytosol into mitochondria, blocking cytochrome C release and caspase-3 activation.	pyrazolanthrone	180-188	BCL2-associated X protein	Mus musculus	326-329
24632094-10	2014	In addition, JNK phosphorylations were involved in activating the mitochondria-dependent apoptotic pathway following Ang II stimulation, as pre-treatment of JNK-specific inhibitor SP600125 could rescue osteoblast cells from apoptosis by enhancing the anti-apoptotic protein Bcl-2 expressions, suppressing the translocation of Bax from cytosol into mitochondria, blocking cytochrome C release and caspase-3 activation.	pyrazolanthrone	180-188	caspase 3	Mus musculus	396-405
24081812-6	2014	The MAPK inhibitors PD98059 and SP600125 increased the paracrine to promote tubular formation, while the SB203580 played an opposite role.	pyrazolanthrone	32-40	mitogen-activated protein kinase 3	Homo sapiens	4-8
24630927-9	2014	Early signalling events of ouabain exposure were ERK1/2 and JNK activation, however only JNK inhibition with SP600125 or JNK knockdown by shRNA were able to prevent Bcl-2 decrease, conversion of LC3-I to LC3-II and cell death.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Homo sapiens	89-92
24630927-9	2014	Early signalling events of ouabain exposure were ERK1/2 and JNK activation, however only JNK inhibition with SP600125 or JNK knockdown by shRNA were able to prevent Bcl-2 decrease, conversion of LC3-I to LC3-II and cell death.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Homo sapiens	89-92
24607842-6	2014	Treatment of parental cells with SP600125, a c-JUN-NH2-kinase (JNK) inhibitor, recapitulated defects in EPHA2-deficient tumor cells, whereas constitutively activated JNK mutants were sufficient to rescue phenotypes.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	63-66
24462521-11	2014	Our results collectively demonstrate that TP53-correlated kinase MPS1, is a potential therapeutic target in BC patients with TP53 mutated tumors, and that SP600125 warrant further development in future clinical trials.	pyrazolanthrone	155-163	tumor protein p53	Homo sapiens	42-46
24811302-7	2014	AOF-stimulated ERK1/2, JNK, and p38 phosphorylation attenuated by individual pretreatment with siRNAs or inhibitors (U0126, SP600125 and SB203580), resulting in migration and uPA-related signal pathway inhibition.	pyrazolanthrone	124-132	mitogen activated protein kinase 3	Rattus norvegicus	15-21
24811302-7	2014	AOF-stimulated ERK1/2, JNK, and p38 phosphorylation attenuated by individual pretreatment with siRNAs or inhibitors (U0126, SP600125 and SB203580), resulting in migration and uPA-related signal pathway inhibition.	pyrazolanthrone	124-132	mitogen activated protein kinase 14	Rattus norvegicus	32-35
24811302-7	2014	AOF-stimulated ERK1/2, JNK, and p38 phosphorylation attenuated by individual pretreatment with siRNAs or inhibitors (U0126, SP600125 and SB203580), resulting in migration and uPA-related signal pathway inhibition.	pyrazolanthrone	124-132	proline-rich acidic protein 1	Rattus norvegicus	175-178
24497579-6	2014	Inhibition of JNK by SP600125 (30 mg/kg) delayed PTL by 6 h (7.5 vs. 13.5 h P&lt;0.05).	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Mus musculus	14-17
24434636-8	2014	By using specific MAPK-Inhibitors (U0126, SB202190, SP600125) we demonstrated that ERK, p38 and JNK differently regulate each pathway of each cytokine.	pyrazolanthrone	52-60	mitogen-activated protein kinase 1	Mus musculus	83-86
24434636-8	2014	By using specific MAPK-Inhibitors (U0126, SB202190, SP600125) we demonstrated that ERK, p38 and JNK differently regulate each pathway of each cytokine.	pyrazolanthrone	52-60	mitogen-activated protein kinase 14	Mus musculus	88-91
24434636-8	2014	By using specific MAPK-Inhibitors (U0126, SB202190, SP600125) we demonstrated that ERK, p38 and JNK differently regulate each pathway of each cytokine.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Mus musculus	96-99
24777405-11	2014	In addition, c-Jun N-terminal kinase (JNK) inhibitor, SP600125 (20 mumol/L) significantly increased the surviving number of SGNs in C50 group.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Rattus norvegicus	13-52
24462521-9	2014	Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells.	pyrazolanthrone	90-98	TTK protein kinase	Homo sapiens	82-86
24462521-9	2014	Consistent with the gene expression profiling and siRNA assays, the inhibition of MPS1 by SP600125 led to a reduction in cell viability and a significant increase in cell death, selectively in TP53-mutated BC cells.	pyrazolanthrone	90-98	tumor protein p53	Homo sapiens	193-197
24847381-10	2014	UA in combination with the pan-JNK inhibitor SP600125 showed maximal reduction in viability across a panel of cancer cell lines, thereby corroborating our predictive simulation assays.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
24566851-8	2014	Upon pharmacological inhibition of the JNK/c-Jun pathway with CE11004 or SP600125, the expression of PUMA was notably suppressed with a concomitant decrease in apoptosis observed in IL-1beta-treated chondrocytes.	pyrazolanthrone	73-81	interleukin 1 beta	Mus musculus	182-190
24849420-8	2014	Inhibition of ERK with PD98059 deactivated eNOS-Thr495 and restored super oxide dismutase (SOD) activity, while inhibition of either p38 with SB202190 or c-Jun with SP600125 did no produce such effects.	pyrazolanthrone	165-173	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	154-159
24735601-8	2014	Spinal CXCL12 was predominately expressed in astrocytes, and an intrathecal injection of astrocyte metabolic inhibitor fluorocitrate or selective JNK inhibitor SP600125 abolished TCI-induced CXCL12 production.	pyrazolanthrone	160-168	C-X-C motif chemokine ligand 12	Rattus norvegicus	7-13
24735601-8	2014	Spinal CXCL12 was predominately expressed in astrocytes, and an intrathecal injection of astrocyte metabolic inhibitor fluorocitrate or selective JNK inhibitor SP600125 abolished TCI-induced CXCL12 production.	pyrazolanthrone	160-168	C-X-C motif chemokine ligand 12	Rattus norvegicus	191-197
24531809-10	2014	Inhibition of JNKs using SP600125 or ER stress using salubrinal or caspase-12 inhibitor significantly reduced OPN-stimulated apoptosis.	pyrazolanthrone	25-33	secreted phosphoprotein 1	Mus musculus	110-113
24733045-6	2014	Inhibition of JNK by the compound SP600125 or JNK siRNA suppressed autophagy and phosphorylation of c-Jun and Bcl-2 but increased 5-FU-induced apoptosis in both HCT116 p53(-/-) and HT29 cells.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	14-17
24739733-8	2014	Conversely, we found that treatment of specific JNK inhibitor SP600125 suppressed the cleavages of caspase 9/3 and PARP induced by hUCMSCs in PC-3 cells by Western blotting and immunofluorescence assay.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Mus musculus	48-51
24739733-8	2014	Conversely, we found that treatment of specific JNK inhibitor SP600125 suppressed the cleavages of caspase 9/3 and PARP induced by hUCMSCs in PC-3 cells by Western blotting and immunofluorescence assay.	pyrazolanthrone	62-70	caspase 9	Mus musculus	99-108
24739733-8	2014	Conversely, we found that treatment of specific JNK inhibitor SP600125 suppressed the cleavages of caspase 9/3 and PARP induced by hUCMSCs in PC-3 cells by Western blotting and immunofluorescence assay.	pyrazolanthrone	62-70	poly (ADP-ribose) polymerase family, member 1	Mus musculus	115-119
24733045-6	2014	Inhibition of JNK by the compound SP600125 or JNK siRNA suppressed autophagy and phosphorylation of c-Jun and Bcl-2 but increased 5-FU-induced apoptosis in both HCT116 p53(-/-) and HT29 cells.	pyrazolanthrone	34-42	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	100-105
24733045-6	2014	Inhibition of JNK by the compound SP600125 or JNK siRNA suppressed autophagy and phosphorylation of c-Jun and Bcl-2 but increased 5-FU-induced apoptosis in both HCT116 p53(-/-) and HT29 cells.	pyrazolanthrone	34-42	BCL2 apoptosis regulator	Homo sapiens	110-115
24406296-9	2014	In addition, inhibiting the JNK and p38 pathways by SP600125 and SB203580 respectively attenuated the LPS-induced apoptosis and regulated the expression of apoptosis-related proteins Bcl-2 and Bax.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	28-31
24486572-6	2014	Moreover, ET-1-induced CTGF expression was significantly reduced by JNK inhibitor (SP600125), the dominant-negative mutants of JNK1/2 (JNK1/2 DN), and AP-1 inhibitor (curcumin).	pyrazolanthrone	83-91	endothelin 1	Homo sapiens	10-14
24486572-6	2014	Moreover, ET-1-induced CTGF expression was significantly reduced by JNK inhibitor (SP600125), the dominant-negative mutants of JNK1/2 (JNK1/2 DN), and AP-1 inhibitor (curcumin).	pyrazolanthrone	83-91	cellular communication network factor 2	Homo sapiens	23-27
24486572-6	2014	Moreover, ET-1-induced CTGF expression was significantly reduced by JNK inhibitor (SP600125), the dominant-negative mutants of JNK1/2 (JNK1/2 DN), and AP-1 inhibitor (curcumin).	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	68-71
24486572-8	2014	AP-1 luciferase activity was concentration-dependently increased by ET-1, and this effect was attenuated by SP600125.	pyrazolanthrone	108-116	endothelin 1	Homo sapiens	68-72
24486572-12	2014	Moreover, we found that ET-1 induced alpha-smooth muscle actin (alpha-SMA) expression, which was inhibited by BQ123, SP600125, curcumin, and anti-CTGF antibody.	pyrazolanthrone	117-125	endothelin 1	Homo sapiens	24-28
24608675-10	2014	Moreover, pretreatment with SP600125, an inhibitor of JNK, effectively abrogated PA-mediated autophagy and apoptosis.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	54-57
24406296-9	2014	In addition, inhibiting the JNK and p38 pathways by SP600125 and SB203580 respectively attenuated the LPS-induced apoptosis and regulated the expression of apoptosis-related proteins Bcl-2 and Bax.	pyrazolanthrone	52-60	mitogen activated protein kinase 14	Rattus norvegicus	36-39
24406296-9	2014	In addition, inhibiting the JNK and p38 pathways by SP600125 and SB203580 respectively attenuated the LPS-induced apoptosis and regulated the expression of apoptosis-related proteins Bcl-2 and Bax.	pyrazolanthrone	52-60	BCL2, apoptosis regulator	Rattus norvegicus	183-188
24406296-9	2014	In addition, inhibiting the JNK and p38 pathways by SP600125 and SB203580 respectively attenuated the LPS-induced apoptosis and regulated the expression of apoptosis-related proteins Bcl-2 and Bax.	pyrazolanthrone	52-60	BCL2 associated X, apoptosis regulator	Rattus norvegicus	193-196
24364558-7	2014	Down-regulation of AQP1 by PGN was blocked only by SB203580, neither by SP600125 nor by PD98059.	pyrazolanthrone	72-80	aquaporin 1	Rattus norvegicus	19-23
24378536-6	2014	Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125.	pyrazolanthrone	246-254	nicotinamide phosphoribosyltransferase	Homo sapiens	0-8
24378536-6	2014	Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125.	pyrazolanthrone	246-254	interleukin 6	Homo sapiens	54-58
24378536-6	2014	Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125.	pyrazolanthrone	246-254	interleukin 1 beta	Homo sapiens	70-78
24378536-6	2014	Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125.	pyrazolanthrone	246-254	nuclear factor kappa B subunit 1	Homo sapiens	144-165
24378536-6	2014	Visfatin also significantly elevated the secretion of IL-6 as well as IL-1beta in a longer incubation period, which was partially suppressed by nuclear factor-kappaB (NF-kappaB) inhibitor, BAY11-7082, and c-Jun-N-terminal kinase (JNK) inhibitor, SP600125.	pyrazolanthrone	246-254	nuclear factor kappa B subunit 1	Homo sapiens	167-176
24294888-8	2014	VPA also inhibited cytochrome c release and caspase-9 activation, which was significantly inhibited by SP600125, a JNK inhibitor.	pyrazolanthrone	103-111	caspase 9	Rattus norvegicus	44-53
24674138-10	2014	Furthermore, JNK inhibition with SP600125 reduced TGFbeta-induced ATF2 (but not Smad2) phosphorylation and CRP2 protein expression while ROCK inhibition blocked JNK activation.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	13-16
24674138-10	2014	Furthermore, JNK inhibition with SP600125 reduced TGFbeta-induced ATF2 (but not Smad2) phosphorylation and CRP2 protein expression while ROCK inhibition blocked JNK activation.	pyrazolanthrone	33-41	transforming growth factor beta 1	Homo sapiens	50-57
24674138-10	2014	Furthermore, JNK inhibition with SP600125 reduced TGFbeta-induced ATF2 (but not Smad2) phosphorylation and CRP2 protein expression while ROCK inhibition blocked JNK activation.	pyrazolanthrone	33-41	activating transcription factor 2	Homo sapiens	66-70
24674138-10	2014	Furthermore, JNK inhibition with SP600125 reduced TGFbeta-induced ATF2 (but not Smad2) phosphorylation and CRP2 protein expression while ROCK inhibition blocked JNK activation.	pyrazolanthrone	33-41	cysteine rich protein 2	Homo sapiens	107-111
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	pyrazolanthrone	155-163	tumor necrosis factor	Homo sapiens	13-22
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	34-40
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	pyrazolanthrone	155-163	erythrocyte membrane protein band 4.2	Homo sapiens	45-48
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	pyrazolanthrone	155-163	interferon induced protein 44	Homo sapiens	49-52
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	pyrazolanthrone	155-163	mitogen-activated protein kinase 3	Homo sapiens	53-57
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	34-38
24414258-5	2014	In addition, TNF-alpha-stimulated JNK1/2 and p42/p44 MAPK phosphorylation, Nox activation, and ROS generation were inhibited by pretreatment with U0126 or SP600125 and transfection with siRNA of JNK1 or p42.	pyrazolanthrone	155-163	erythrocyte membrane protein band 4.2	Homo sapiens	203-206
24272171-9	2014	The MAPK signaling pathway was blocked by pretreatment with JNK inhibitor SP600125.	pyrazolanthrone	74-82	mitogen-activated protein kinase 1	Mus musculus	4-8
24272171-9	2014	The MAPK signaling pathway was blocked by pretreatment with JNK inhibitor SP600125.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Mus musculus	60-63
23805819-10	2014	Similarly, the addition of culture supernatant of PLFs induced the most prominent proliferation of mES cells, and this was significantly inhibited by treatment with antibody against fibroblast growth factor (FGF)4 or the c-Jun N-terminal kinase inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one).	pyrazolanthrone	265-296	fibroblast growth factor 4	Mus musculus	182-213
24651440-9	2014	Treatment with, the JNK inhibitor SP600125 prevented LK-A-induced apoptosis in SMMC-7721 cells.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	20-23
24294888-8	2014	VPA also inhibited cytochrome c release and caspase-9 activation, which was significantly inhibited by SP600125, a JNK inhibitor.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Rattus norvegicus	115-118
24294888-9	2014	The levels of phosphorylated Bim and Mcl-1, which are known as downstream targets of JNK, were significantly reduced by SP600125.	pyrazolanthrone	120-128	MCL1 apoptosis regulator, BCL2 family member	Rattus norvegicus	37-42
24294888-9	2014	The levels of phosphorylated Bim and Mcl-1, which are known as downstream targets of JNK, were significantly reduced by SP600125.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Rattus norvegicus	85-88
24496382-9	2014	The JNK1/2 inhibitor (SP600125) abolished CH-induced COL1A1 expression.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Homo sapiens	4-10
24624962-8	2014	Moreover, JNK inhibitor (SP600125) significantly reduced ZnO NP-induced cleaved PARP and cleaved caspase-3 expression, but not ERK inhibitor (U0126) or p38 MAPK inhibitor (SB203580), indicating that JNK signaling pathway is involved in ZnO NP-induced apoptosis in primary astrocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	10-13
24624962-8	2014	Moreover, JNK inhibitor (SP600125) significantly reduced ZnO NP-induced cleaved PARP and cleaved caspase-3 expression, but not ERK inhibitor (U0126) or p38 MAPK inhibitor (SB203580), indicating that JNK signaling pathway is involved in ZnO NP-induced apoptosis in primary astrocytes.	pyrazolanthrone	25-33	poly(ADP-ribose) polymerase 1	Homo sapiens	80-84
24624962-8	2014	Moreover, JNK inhibitor (SP600125) significantly reduced ZnO NP-induced cleaved PARP and cleaved caspase-3 expression, but not ERK inhibitor (U0126) or p38 MAPK inhibitor (SB203580), indicating that JNK signaling pathway is involved in ZnO NP-induced apoptosis in primary astrocytes.	pyrazolanthrone	25-33	caspase 3	Homo sapiens	97-106
24624962-8	2014	Moreover, JNK inhibitor (SP600125) significantly reduced ZnO NP-induced cleaved PARP and cleaved caspase-3 expression, but not ERK inhibitor (U0126) or p38 MAPK inhibitor (SB203580), indicating that JNK signaling pathway is involved in ZnO NP-induced apoptosis in primary astrocytes.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	199-202
24487964-12	2014	But only SP600125 significantly reduced TNF-alpha-induced CXCL1 mRNA expression in the cells.	pyrazolanthrone	9-17	tumor necrosis factor	Homo sapiens	40-49
24487964-12	2014	But only SP600125 significantly reduced TNF-alpha-induced CXCL1 mRNA expression in the cells.	pyrazolanthrone	9-17	C-X-C motif chemokine ligand 1	Homo sapiens	58-63
24270408-7	2014	Treatment of Prkg2(-/-) mice with the JNK inhibitor SP600125 reversed the defective homeostasis observed in these animals.	pyrazolanthrone	52-60	protein kinase, cGMP-dependent, type II	Mus musculus	13-18
24270408-7	2014	Treatment of Prkg2(-/-) mice with the JNK inhibitor SP600125 reversed the defective homeostasis observed in these animals.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Mus musculus	38-41
24520265-13	2014	The expression levels of p-JNK protein and alpha-SMA were significantly lower in groups SP, T and SP + T than those in group M on day 14 (P&lt;0.05).	pyrazolanthrone	88-90	actin gamma 2, smooth muscle	Rattus norvegicus	43-52
24520265-13	2014	The expression levels of p-JNK protein and alpha-SMA were significantly lower in groups SP, T and SP + T than those in group M on day 14 (P&lt;0.05).	pyrazolanthrone	98-100	actin gamma 2, smooth muscle	Rattus norvegicus	43-52
24520265-14	2014	The expression level of alpha-SMA was lower in group SP + T than those in groups SP and T on days 14 and 28 (P&lt;0.05).	pyrazolanthrone	53-55	actin gamma 2, smooth muscle	Rattus norvegicus	24-33
24520265-14	2014	The expression level of alpha-SMA was lower in group SP + T than those in groups SP and T on days 14 and 28 (P&lt;0.05).	pyrazolanthrone	81-83	actin gamma 2, smooth muscle	Rattus norvegicus	24-33
24496382-9	2014	The JNK1/2 inhibitor (SP600125) abolished CH-induced COL1A1 expression.	pyrazolanthrone	22-30	collagen type I alpha 1 chain	Homo sapiens	53-59
23640957-6	2014	Conversely, AMPK inhibitor compound C and JNK inhibitor SP600125 suppressed apoptosis induced by beta-sitosterol in U266 cells.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	42-45
24161965-8	2014	Similarly, ABCG2 gene expression increased above control levels in UL-1 and Ema cells treated with PMA and the JNK inhibitor SP600125.	pyrazolanthrone	125-133	ATP binding cassette subfamily G member 2	Canis lupus familiaris	11-16
24547878-7	2014	Moreover, 1 activated p38/c-Jun N-terminal kinase (JNK), and the extrinsic pathway-mediated apoptosis was attenuated by both SB202190 (a p38 inhibitor) and SP600125 (a JNK inhibitor).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	168-171
24587316-9	2014	TNF-alpha induced also an increase in AP-1 DNA-binding activity and the antiapoptotic effect of TNF-alpha was potentiated by inhibitors of AP-1, SR 11302 and tanshinone IIA and by an inhibitor of c-jun-N-terminal kinase, SP600125, which is an upstream kinase activating AP-1.	pyrazolanthrone	221-229	tumor necrosis factor	Homo sapiens	0-9
24587316-9	2014	TNF-alpha induced also an increase in AP-1 DNA-binding activity and the antiapoptotic effect of TNF-alpha was potentiated by inhibitors of AP-1, SR 11302 and tanshinone IIA and by an inhibitor of c-jun-N-terminal kinase, SP600125, which is an upstream kinase activating AP-1.	pyrazolanthrone	221-229	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	38-42
24587316-9	2014	TNF-alpha induced also an increase in AP-1 DNA-binding activity and the antiapoptotic effect of TNF-alpha was potentiated by inhibitors of AP-1, SR 11302 and tanshinone IIA and by an inhibitor of c-jun-N-terminal kinase, SP600125, which is an upstream kinase activating AP-1.	pyrazolanthrone	221-229	tumor necrosis factor	Homo sapiens	96-105
24556694-8	2014	This effect was reversible by blocking JNK activity with its selective inhibitor, SP600125.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	39-42
24461294-7	2014	Conversely, PKC promoter phorbol 12-myristate 13-acetate (PMA) and JNK inhibitor SP600125 reversed the cleavages of caspase 3 and PARP induced by GA in NCI-H460 cells.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	67-70
24374359-4	2014	The ROS elevation and ASK1 activation induced a sustained phosphorylation of c-Jun N-terminal kinase (JNK), while SP600125, as known as JNK inhibitor, almost reversed LW-214-induced apoptosis in MCF-7 cells.	pyrazolanthrone	114-122	mitogen-activated protein kinase 8	Homo sapiens	136-139
24461294-7	2014	Conversely, PKC promoter phorbol 12-myristate 13-acetate (PMA) and JNK inhibitor SP600125 reversed the cleavages of caspase 3 and PARP induced by GA in NCI-H460 cells.	pyrazolanthrone	81-89	caspase 3	Homo sapiens	116-125
24461294-7	2014	Conversely, PKC promoter phorbol 12-myristate 13-acetate (PMA) and JNK inhibitor SP600125 reversed the cleavages of caspase 3 and PARP induced by GA in NCI-H460 cells.	pyrazolanthrone	81-89	poly(ADP-ribose) polymerase 1	Homo sapiens	130-134
24695490-8	2014	Blocking the activation of JNK and p38 kinase increased cell viability and decreased apoptosis induced by H2O2 with their respective inhibitors, SP600125 and SB203580.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	27-30
24225419-3	2014	Therefore, by using the MAPK inhibitors SP600125 (a specific JNK inhibitor) and PD98059 (a specific ERK inhibitor), we have unmasked the particular MAPK that underlies the modulation of the expression levels of these PTPs.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Rattus norvegicus	61-64
24502696-4	2014	Here we demonstrated that TNF-alpha-induced MMP-9 expression was attenuated by Act.D, CHI, PP1, U0126, SB202190, SP600125, and Bay11-7082, and by the transfection with siRNAs for ERK2, p38 MAPK, and JNK2.	pyrazolanthrone	113-121	tumor necrosis factor	Mus musculus	26-35
24502696-4	2014	Here we demonstrated that TNF-alpha-induced MMP-9 expression was attenuated by Act.D, CHI, PP1, U0126, SB202190, SP600125, and Bay11-7082, and by the transfection with siRNAs for ERK2, p38 MAPK, and JNK2.	pyrazolanthrone	113-121	matrix metallopeptidase 9	Mus musculus	44-49
24502696-7	2014	TNF-alpha time-dependently induced MMP-9 promoter activity which was also inhibited by PP1, U0126, SB202190, SP600125, or Bay11-7082.	pyrazolanthrone	109-117	tumor necrosis factor	Mus musculus	0-9
24502696-7	2014	TNF-alpha time-dependently induced MMP-9 promoter activity which was also inhibited by PP1, U0126, SB202190, SP600125, or Bay11-7082.	pyrazolanthrone	109-117	matrix metallopeptidase 9	Mus musculus	35-40
24296130-5	2014	Phosphatidylinositol-3-kinase/Akt and MAPKs were also significantly activated by genipin, and Akt and MAPKs inhibitors (PD98059, SB20358, SP600125, and LY294002) inhibited genipin-induced COX-2 expression.	pyrazolanthrone	138-146	thymoma viral proto-oncogene 1	Mus musculus	30-33
24193738-8	2014	In ACE2-deficient VSMCs, inhibition of c-Jun N-terminal kinase (JNK) by pharmacological blockade with SP600125 or genetic knockdown with JNK-specific siRNA significantly attenuated their pro-inflammatory phenotype.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Mus musculus	39-62
24193738-8	2014	In ACE2-deficient VSMCs, inhibition of c-Jun N-terminal kinase (JNK) by pharmacological blockade with SP600125 or genetic knockdown with JNK-specific siRNA significantly attenuated their pro-inflammatory phenotype.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Mus musculus	64-67
24296130-5	2014	Phosphatidylinositol-3-kinase/Akt and MAPKs were also significantly activated by genipin, and Akt and MAPKs inhibitors (PD98059, SB20358, SP600125, and LY294002) inhibited genipin-induced COX-2 expression.	pyrazolanthrone	138-146	thymoma viral proto-oncogene 1	Mus musculus	94-97
24466137-9	2014	Furthermore, LicA significantly decreased uPA levels in SP600125-treated or si-MKK4-transfected cells alongside a marked reduction in cell migration and invasion, which supports the notion that an inhibition of MKK4/JNK results in anti-metastatic effects.	pyrazolanthrone	56-64	mitogen-activated protein kinase kinase 4	Homo sapiens	211-215
24103647-0	2014	The JNK inhibitor, SP600125, potentiates the glial response and cell death induced by methamphetamine in the mouse striatum.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Mus musculus	4-7
24103647-1	2014	This study investigates the effect of the selective Jun NH2-terminal kinase 1/2 (JNK1/2) inhibitor, (SP600125) on the striatal dopamine nerve terminal loss and on the increased interleukin-15 (IL-15) expression and glial response induced by methamphetamine (METH).	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Mus musculus	81-87
24103647-1	2014	This study investigates the effect of the selective Jun NH2-terminal kinase 1/2 (JNK1/2) inhibitor, (SP600125) on the striatal dopamine nerve terminal loss and on the increased interleukin-15 (IL-15) expression and glial response induced by methamphetamine (METH).	pyrazolanthrone	101-109	interleukin 15	Mus musculus	193-198
24103647-8	2014	In line with a deleterious effect of JNK1/2 inhibition, SP600125 increased the astroglial and microglial response induced by METH and interfered with drug-induced IL-15 expression.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Mus musculus	37-43
24103647-8	2014	In line with a deleterious effect of JNK1/2 inhibition, SP600125 increased the astroglial and microglial response induced by METH and interfered with drug-induced IL-15 expression.	pyrazolanthrone	56-64	interleukin 15	Mus musculus	163-168
24375967-0	2014	Proteomic analysis of SP600125-controlled TrkA-dependent targets in SK-N-MC neuroblastoma cells: inhibition of TrkA activity by SP600125.	pyrazolanthrone	22-30	neurotrophic receptor tyrosine kinase 1	Homo sapiens	42-46
24375967-0	2014	Proteomic analysis of SP600125-controlled TrkA-dependent targets in SK-N-MC neuroblastoma cells: inhibition of TrkA activity by SP600125.	pyrazolanthrone	22-30	neurotrophic receptor tyrosine kinase 1	Homo sapiens	111-115
24375967-0	2014	Proteomic analysis of SP600125-controlled TrkA-dependent targets in SK-N-MC neuroblastoma cells: inhibition of TrkA activity by SP600125.	pyrazolanthrone	128-136	neurotrophic receptor tyrosine kinase 1	Homo sapiens	42-46
24375967-0	2014	Proteomic analysis of SP600125-controlled TrkA-dependent targets in SK-N-MC neuroblastoma cells: inhibition of TrkA activity by SP600125.	pyrazolanthrone	128-136	neurotrophic receptor tyrosine kinase 1	Homo sapiens	111-115
24375967-3	2014	In this study, we investigated JNK inhibitor SP600125-controlled TrkA-dependent targets by proteomic analysis to better understand an involvement of JNK in TrkA-mediated signaling pathways.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
24375967-3	2014	In this study, we investigated JNK inhibitor SP600125-controlled TrkA-dependent targets by proteomic analysis to better understand an involvement of JNK in TrkA-mediated signaling pathways.	pyrazolanthrone	45-53	neurotrophic receptor tyrosine kinase 1	Homo sapiens	65-69
24375967-3	2014	In this study, we investigated JNK inhibitor SP600125-controlled TrkA-dependent targets by proteomic analysis to better understand an involvement of JNK in TrkA-mediated signaling pathways.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	149-152
24375967-3	2014	In this study, we investigated JNK inhibitor SP600125-controlled TrkA-dependent targets by proteomic analysis to better understand an involvement of JNK in TrkA-mediated signaling pathways.	pyrazolanthrone	45-53	neurotrophic receptor tyrosine kinase 1	Homo sapiens	156-160
24375967-5	2014	Notably, TrkA largely affected certain PTM(s) but not total protein amounts of the SP600125-controlled TrkA-dependent targets.	pyrazolanthrone	83-91	neurotrophic receptor tyrosine kinase 1	Homo sapiens	9-13
24375967-6	2014	Moreover, SP600125 strongly suppressed TrkA-mediated tyrosine phosphorylation signaling pathways as well as JNK signaling, indicating that SP600125 could function as a TrkA inhibitor.	pyrazolanthrone	10-18	neurotrophic receptor tyrosine kinase 1	Homo sapiens	39-43
24375967-6	2014	Moreover, SP600125 strongly suppressed TrkA-mediated tyrosine phosphorylation signaling pathways as well as JNK signaling, indicating that SP600125 could function as a TrkA inhibitor.	pyrazolanthrone	10-18	neurotrophic receptor tyrosine kinase 1	Homo sapiens	168-172
24466324-4	2014	Pretreatment of cells with specific inhibitors of p38 (PD169316) and JNK (SP600125) abrogated embelin-induced caspase-3 activation.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	69-72
24375967-6	2014	Moreover, SP600125 strongly suppressed TrkA-mediated tyrosine phosphorylation signaling pathways as well as JNK signaling, indicating that SP600125 could function as a TrkA inhibitor.	pyrazolanthrone	139-147	neurotrophic receptor tyrosine kinase 1	Homo sapiens	39-43
24375967-6	2014	Moreover, SP600125 strongly suppressed TrkA-mediated tyrosine phosphorylation signaling pathways as well as JNK signaling, indicating that SP600125 could function as a TrkA inhibitor.	pyrazolanthrone	139-147	mitogen-activated protein kinase 8	Homo sapiens	108-111
24375967-6	2014	Moreover, SP600125 strongly suppressed TrkA-mediated tyrosine phosphorylation signaling pathways as well as JNK signaling, indicating that SP600125 could function as a TrkA inhibitor.	pyrazolanthrone	139-147	neurotrophic receptor tyrosine kinase 1	Homo sapiens	168-172
24375967-7	2014	Taken together, our results suggest that TrkA could play an important role in the cytoskeleton, cell death, cellular processing, and glucose metabolism through activation or inactivation of the SP600125-controlled TrkA-dependent targets.	pyrazolanthrone	194-202	neurotrophic receptor tyrosine kinase 1	Homo sapiens	41-45
24375967-7	2014	Taken together, our results suggest that TrkA could play an important role in the cytoskeleton, cell death, cellular processing, and glucose metabolism through activation or inactivation of the SP600125-controlled TrkA-dependent targets.	pyrazolanthrone	194-202	neurotrophic receptor tyrosine kinase 1	Homo sapiens	214-218
24466137-9	2014	Furthermore, LicA significantly decreased uPA levels in SP600125-treated or si-MKK4-transfected cells alongside a marked reduction in cell migration and invasion, which supports the notion that an inhibition of MKK4/JNK results in anti-metastatic effects.	pyrazolanthrone	56-64	plasminogen activator, urokinase	Homo sapiens	42-45
24466137-9	2014	Furthermore, LicA significantly decreased uPA levels in SP600125-treated or si-MKK4-transfected cells alongside a marked reduction in cell migration and invasion, which supports the notion that an inhibition of MKK4/JNK results in anti-metastatic effects.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	216-219
24333214-0	2014	SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition.	pyrazolanthrone	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	108-112
24333214-2	2014	Using MTS assays, microscopic observation, assessment of cleaved PARP, FACS analysis, and Hoechst staining, we found that the c-Jun N-terminal kinase (Jnk) inhibitor SP600125 (SP) sensitized the antimitotic drug-resistant KBV20C cancer cell line.	pyrazolanthrone	166-174	poly(ADP-ribose) polymerase 1	Homo sapiens	65-69
24333214-2	2014	Using MTS assays, microscopic observation, assessment of cleaved PARP, FACS analysis, and Hoechst staining, we found that the c-Jun N-terminal kinase (Jnk) inhibitor SP600125 (SP) sensitized the antimitotic drug-resistant KBV20C cancer cell line.	pyrazolanthrone	166-174	mitogen-activated protein kinase 8	Homo sapiens	126-149
24333214-2	2014	Using MTS assays, microscopic observation, assessment of cleaved PARP, FACS analysis, and Hoechst staining, we found that the c-Jun N-terminal kinase (Jnk) inhibitor SP600125 (SP) sensitized the antimitotic drug-resistant KBV20C cancer cell line.	pyrazolanthrone	166-174	mitogen-activated protein kinase 8	Homo sapiens	151-154
24333214-2	2014	Using MTS assays, microscopic observation, assessment of cleaved PARP, FACS analysis, and Hoechst staining, we found that the c-Jun N-terminal kinase (Jnk) inhibitor SP600125 (SP) sensitized the antimitotic drug-resistant KBV20C cancer cell line.	pyrazolanthrone	166-168	poly(ADP-ribose) polymerase 1	Homo sapiens	65-69
24333214-2	2014	Using MTS assays, microscopic observation, assessment of cleaved PARP, FACS analysis, and Hoechst staining, we found that the c-Jun N-terminal kinase (Jnk) inhibitor SP600125 (SP) sensitized the antimitotic drug-resistant KBV20C cancer cell line.	pyrazolanthrone	166-168	mitogen-activated protein kinase 8	Homo sapiens	126-149
24333214-2	2014	Using MTS assays, microscopic observation, assessment of cleaved PARP, FACS analysis, and Hoechst staining, we found that the c-Jun N-terminal kinase (Jnk) inhibitor SP600125 (SP) sensitized the antimitotic drug-resistant KBV20C cancer cell line.	pyrazolanthrone	166-168	mitogen-activated protein kinase 8	Homo sapiens	151-154
24333215-10	2014	PD 98059 and SP600125 attenuated mepivacaine-induced ERK and JNK phosphorylation, respectively.	pyrazolanthrone	13-21	Eph receptor B1	Rattus norvegicus	53-56
24333215-10	2014	PD 98059 and SP600125 attenuated mepivacaine-induced ERK and JNK phosphorylation, respectively.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Rattus norvegicus	61-64
24239640-9	2014	The elevated COL1A1 and BGLAP expressions were inhibited by PD98059, SP600125 or SB203580.	pyrazolanthrone	69-77	collagen type I alpha 1 chain	Homo sapiens	13-19
24239640-9	2014	The elevated COL1A1 and BGLAP expressions were inhibited by PD98059, SP600125 or SB203580.	pyrazolanthrone	69-77	bone gamma-carboxyglutamate protein	Homo sapiens	24-29
24239640-11	2014	The elevated SPP1 expression was inhibited by SP600125 or SB203580.	pyrazolanthrone	46-54	secreted phosphoprotein 1	Homo sapiens	13-17
24157283-8	2014	NAC and the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059) abrogated iAs-induced cell cytotoxicity, caspase-3/-7 activity, and JNK and ERK1/2 activation.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	21-24
24157283-8	2014	NAC and the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059) abrogated iAs-induced cell cytotoxicity, caspase-3/-7 activity, and JNK and ERK1/2 activation.	pyrazolanthrone	36-44	caspase 3	Mus musculus	118-130
24157283-8	2014	NAC and the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059) abrogated iAs-induced cell cytotoxicity, caspase-3/-7 activity, and JNK and ERK1/2 activation.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	145-148
24157283-8	2014	NAC and the specific JNK inhibitor (SP600125) and ERK1/2 inhibitor (PD98059) abrogated iAs-induced cell cytotoxicity, caspase-3/-7 activity, and JNK and ERK1/2 activation.	pyrazolanthrone	36-44	mitogen-activated protein kinase 3	Mus musculus	153-159
25004880-6	2014	The JNK-specific inhibitor SP600125 decreased the proteins expression of phospho-JNK, iNOS, COX-2, and the mRNAs expression and levels of IL-6 and TNF-alpha.	pyrazolanthrone	27-35	cox2	Nelumbo nucifera	92-97
25004880-6	2014	The JNK-specific inhibitor SP600125 decreased the proteins expression of phospho-JNK, iNOS, COX-2, and the mRNAs expression and levels of IL-6 and TNF-alpha.	pyrazolanthrone	27-35	interleukin 6	Mus musculus	138-142
25004880-6	2014	The JNK-specific inhibitor SP600125 decreased the proteins expression of phospho-JNK, iNOS, COX-2, and the mRNAs expression and levels of IL-6 and TNF-alpha.	pyrazolanthrone	27-35	tumor necrosis factor	Mus musculus	147-156
24211866-5	2014	OLO-2-induced the externalization of phosphatidyl-serine (PS) and the loss of DeltaPsim are blocked by p38 inhibitor SB203580 or JNK inhibitor SP600125.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Homo sapiens	129-132
25386557-2	2014	RT-PCR and Western blot analysis were used to determine the effects of CH on the expression of MDR1 mRNA and P-glycoprotein in K562/ADR cells when CH was used alone and combined with SP600125, a JNK inhibitor, to explore the effects of CH on JNK pathway.	pyrazolanthrone	183-191	ATP binding cassette subfamily B member 1	Homo sapiens	95-99
24877090-7	2014	The JNK inhibitor SP600125 reduced Schwann cell proliferation, but did not affect the expression of ERK1/2 or injury-induced increases in c-Jun or ATF-3 levels.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
24556843-10	2014	The inhibitory effect of alpha7nAChR activation on VPO-1 was blocked by JNK inhibitor SP600125.	pyrazolanthrone	86-94	peroxidasin	Homo sapiens	51-56
24556843-10	2014	The inhibitory effect of alpha7nAChR activation on VPO-1 was blocked by JNK inhibitor SP600125.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	72-75
24125707-8	2014	PD98059, an inhibitor of ERK1/2 pathway, completely blocked PFHxS-induced apoptosis whereas SP600125, a JNK inhibitor, significantly increased the apoptosis, showing their opposite roles in the apoptosis of CGCs.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Rattus norvegicus	104-107
24088727-7	2014	The c-Jun inhibitor SP600125 and NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) suppressed the expression of MDR1 mRNA in Caco-2 vbl cells.	pyrazolanthrone	20-28	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-9
24088727-7	2014	The c-Jun inhibitor SP600125 and NF-kappaB inhibitor pyrrolidine dithiocarbamate (PDTC) suppressed the expression of MDR1 mRNA in Caco-2 vbl cells.	pyrazolanthrone	20-28	ATP binding cassette subfamily B member 1	Homo sapiens	117-121
24134657-16	2014	Furthermore, TNF-alpha-induced NF-kappaB activation was attenuated by SP600125 (JNK inhibitor), PD98059 (ERK1/2 inhibitor, SB203580 (p38 MAPK inhibitor) and MPA.	pyrazolanthrone	70-78	tumor necrosis factor	Homo sapiens	13-22
24134657-16	2014	Furthermore, TNF-alpha-induced NF-kappaB activation was attenuated by SP600125 (JNK inhibitor), PD98059 (ERK1/2 inhibitor, SB203580 (p38 MAPK inhibitor) and MPA.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	80-83
25572464-9	2014	Silencing VEGF-A decreased the level of c-fos and c-jun and bevacizumab and SP600125 treatment attenuated podocyte apoptosis.	pyrazolanthrone	76-84	vascular endothelial growth factor A	Rattus norvegicus	10-16
25572464-12	2014	With bevacizumab and SP600125 treatment, the level of VEGF-A and AP-1 decreased while bcl-2 increased.	pyrazolanthrone	21-29	vascular endothelial growth factor A	Rattus norvegicus	54-60
25572464-12	2014	With bevacizumab and SP600125 treatment, the level of VEGF-A and AP-1 decreased while bcl-2 increased.	pyrazolanthrone	21-29	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	65-69
25572464-12	2014	With bevacizumab and SP600125 treatment, the level of VEGF-A and AP-1 decreased while bcl-2 increased.	pyrazolanthrone	21-29	BCL2, apoptosis regulator	Rattus norvegicus	86-91
24105651-6	2014	Importantly, the in vivo inhibition of JNK signaling with SP600125 protected C57BL/6 CD4(+) CD8(+) thymocytes from depletion via multiple mechanisms as follows: lower intracellular ROS, inflammatory cytokines, Bax and caspase 3 activity, increase in Bcl-xL amounts, and prevention of the loss in mitochondrial membrane potential.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Mus musculus	39-42
24105651-6	2014	Importantly, the in vivo inhibition of JNK signaling with SP600125 protected C57BL/6 CD4(+) CD8(+) thymocytes from depletion via multiple mechanisms as follows: lower intracellular ROS, inflammatory cytokines, Bax and caspase 3 activity, increase in Bcl-xL amounts, and prevention of the loss in mitochondrial membrane potential.	pyrazolanthrone	58-66	CD4 antigen	Mus musculus	85-88
25097657-8	2014	Allicin induced SKOV3 cell apoptosis and JNK phosphorylation in a time- and dose-dependent manner, but these were significantly blocked by SP600125 (an inhibitor of JNK).	pyrazolanthrone	139-147	mitogen-activated protein kinase 8	Homo sapiens	41-44
25097657-8	2014	Allicin induced SKOV3 cell apoptosis and JNK phosphorylation in a time- and dose-dependent manner, but these were significantly blocked by SP600125 (an inhibitor of JNK).	pyrazolanthrone	139-147	mitogen-activated protein kinase 8	Homo sapiens	165-168
24111524-7	2014	Inhibition of JNK by SP600125 or over-expression of dominant negative c-Jun potentiated celastrol protection against Cd-induced cell death.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
24346217-5	2014	Concurrent treatment with Abeta1-42 and insulin or Abeta1-42 and JNK inhibitor SP600125 significantly improved cell viability.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	65-68
24346217-7	2014	ELISA confirmed the protective effect of insulin and SP600125 on Abeta-induced expression of interleukin (IL)-8 and Growth related oncogene-alpha (Gro-alpha).	pyrazolanthrone	53-61	C-X-C motif chemokine ligand 8	Homo sapiens	93-111
24346217-7	2014	ELISA confirmed the protective effect of insulin and SP600125 on Abeta-induced expression of interleukin (IL)-8 and Growth related oncogene-alpha (Gro-alpha).	pyrazolanthrone	53-61	C-X-C motif chemokine ligand 1	Homo sapiens	147-156
24114663-5	2014	The activation of mitogen-activated protein kinases (MAPKs) was blocked by ISO, and NF-kappaB nuclear translocation was decreased by ISO both alone and together with NF-kappaB inhibitor (PDTC) and MAPKs inhibitors (U0126, SP 600125, and SB 203580).	pyrazolanthrone	222-231	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	84-93
25048019-6	2014	SP600125 (20 muM), a JNK(1/2) inhibitor, markedly suppressed the formation of apoptotic bodies and JNK activation induced by oleuropein at 200 muM.	pyrazolanthrone	0-8	latexin	Homo sapiens	13-16
25048019-6	2014	SP600125 (20 muM), a JNK(1/2) inhibitor, markedly suppressed the formation of apoptotic bodies and JNK activation induced by oleuropein at 200 muM.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	21-28
25048019-6	2014	SP600125 (20 muM), a JNK(1/2) inhibitor, markedly suppressed the formation of apoptotic bodies and JNK activation induced by oleuropein at 200 muM.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	21-24
25048019-6	2014	SP600125 (20 muM), a JNK(1/2) inhibitor, markedly suppressed the formation of apoptotic bodies and JNK activation induced by oleuropein at 200 muM.	pyrazolanthrone	0-8	latexin	Homo sapiens	143-146
24114663-5	2014	The activation of mitogen-activated protein kinases (MAPKs) was blocked by ISO, and NF-kappaB nuclear translocation was decreased by ISO both alone and together with NF-kappaB inhibitor (PDTC) and MAPKs inhibitors (U0126, SP 600125, and SB 203580).	pyrazolanthrone	222-231	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	166-175
24308485-10	2013	Pretreatment with SP600125, U0126, or SB600125 abrogated HymnPro-induced activation of caspases-3 and caspase-7 and the cleavage of PARP, suggesting that MAPK signalings are involved in HymnPro-induced apoptosis.	pyrazolanthrone	18-26	caspase 7	Homo sapiens	102-111
24967005-7	2014	Pharmacological administration of specific p38 (SB203580) or JNK (SP600125) inhibitors significantly reduced the inhibitory effects of PL on LN229 cell migration and NF kappa B activity in scratch-wound and/or transwell models.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	61-64
24097668-9	2014	Prolonged activation of JNK occurred in TVX/TNF-induced cytotoxicity, and treatment with the JNK selective inhibitor SP600125 attenuated cytotoxicity.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Homo sapiens	93-96
24386130-7	2013	Our data showed that pretreatment with luteolin or SP600125 significantly improved the contraction of the isolated heart and cardiomyocytes, reduced infarct size and LDH activity, decreased the rate of apoptosis and increased the Bcl-2/Bax ratio.	pyrazolanthrone	51-59	BCL2, apoptosis regulator	Rattus norvegicus	230-235
24386130-7	2013	Our data showed that pretreatment with luteolin or SP600125 significantly improved the contraction of the isolated heart and cardiomyocytes, reduced infarct size and LDH activity, decreased the rate of apoptosis and increased the Bcl-2/Bax ratio.	pyrazolanthrone	51-59	BCL2 associated X, apoptosis regulator	Rattus norvegicus	236-239
24386130-10	2013	We also found that pretreatment with PD98059 caused a significant increase in JNK expression, and SP600125 could cause ERK1/2 activation during I/R.	pyrazolanthrone	98-106	mitogen activated protein kinase 3	Rattus norvegicus	119-125
24308485-10	2013	Pretreatment with SP600125, U0126, or SB600125 abrogated HymnPro-induced activation of caspases-3 and caspase-7 and the cleavage of PARP, suggesting that MAPK signalings are involved in HymnPro-induced apoptosis.	pyrazolanthrone	18-26	poly(ADP-ribose) polymerase 1	Homo sapiens	132-136
24127566-4	2013	In this study, we show that the suppression of Jun N-terminal kinase (JNK) by the JNK inhibitor SP600125 or short-hairpin RNA inhibited podosome rosette formation in SrcY527F-transformed NIH3T3 fibroblasts.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Mus musculus	47-68
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	pyrazolanthrone	48-56	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	105-110
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	pyrazolanthrone	48-56	mitogen-activated protein kinase 3	Mus musculus	112-118
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	pyrazolanthrone	48-56	mitogen-activated protein kinase 14	Mus musculus	120-123
24376609-9	2013	Pretreatment with AACOCF3, U0126, SB203580, and SP600125 significantly diminished the phosphorylation of cPLA2, ERK1/2, p38, and JNK stimulated by BisGMA, respectively (p&lt;0.05).	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	129-132
24376609-10	2013	BisGMA-induced cytotoxicity, cPLA2 phosphorylation, PGE2 generation, and caspases activation were reduced by AACOCF3, U0126, SB203580, and SP600125, respectively (p&lt;0.05).	pyrazolanthrone	139-147	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	29-34
24358263-10	2013	Pretreatment of 3T3L1 adipocytes with the JNK inhibitor SP600125, but not p38 MAPK inhibitor SB203580 blocked the inhibitory effects of TNFalpha on adipolin and KLF15 expression.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	42-45
24358263-10	2013	Pretreatment of 3T3L1 adipocytes with the JNK inhibitor SP600125, but not p38 MAPK inhibitor SB203580 blocked the inhibitory effects of TNFalpha on adipolin and KLF15 expression.	pyrazolanthrone	56-64	tumor necrosis factor	Homo sapiens	136-144
24358263-10	2013	Pretreatment of 3T3L1 adipocytes with the JNK inhibitor SP600125, but not p38 MAPK inhibitor SB203580 blocked the inhibitory effects of TNFalpha on adipolin and KLF15 expression.	pyrazolanthrone	56-64	C1q and TNF related 12	Homo sapiens	148-156
24358263-10	2013	Pretreatment of 3T3L1 adipocytes with the JNK inhibitor SP600125, but not p38 MAPK inhibitor SB203580 blocked the inhibitory effects of TNFalpha on adipolin and KLF15 expression.	pyrazolanthrone	56-64	Kruppel like factor 15	Homo sapiens	161-166
24127566-4	2013	In this study, we show that the suppression of Jun N-terminal kinase (JNK) by the JNK inhibitor SP600125 or short-hairpin RNA inhibited podosome rosette formation in SrcY527F-transformed NIH3T3 fibroblasts.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Mus musculus	70-73
24127566-4	2013	In this study, we show that the suppression of Jun N-terminal kinase (JNK) by the JNK inhibitor SP600125 or short-hairpin RNA inhibited podosome rosette formation in SrcY527F-transformed NIH3T3 fibroblasts.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Mus musculus	82-85
24330607-12	2013	Finally, chemical inhibition of c-Jun N-terminal kinases (JNK) using the SP600125 compound reduced the ability of cells to express EREG, demonstrating a link between the growth factor production and JNK activation under the dependence of IRE1alpha.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	32-56
24184660-10	2013	In addition, SB203580, a p38 MARK inhibitor, significantly attenuated the cytotoxic effect of Delta8-THC, whereas SP600125, a JNK inhibitor, significantly enhanced the cytotoxicity.	pyrazolanthrone	114-122	mitogen-activated protein kinase 8	Mus musculus	126-129
24285710-7	2013	In addition, osteoblasts could be protected from lipotoxicity by inhibiting autophagy with the phosphoinositide kinase inhibitor 3-methyladenine or by inhibiting apoptosis with the JNK inhibitor SP600125.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Homo sapiens	181-184
24330607-12	2013	Finally, chemical inhibition of c-Jun N-terminal kinases (JNK) using the SP600125 compound reduced the ability of cells to express EREG, demonstrating a link between the growth factor production and JNK activation under the dependence of IRE1alpha.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	199-202
24330607-12	2013	Finally, chemical inhibition of c-Jun N-terminal kinases (JNK) using the SP600125 compound reduced the ability of cells to express EREG, demonstrating a link between the growth factor production and JNK activation under the dependence of IRE1alpha.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	58-61
24330607-12	2013	Finally, chemical inhibition of c-Jun N-terminal kinases (JNK) using the SP600125 compound reduced the ability of cells to express EREG, demonstrating a link between the growth factor production and JNK activation under the dependence of IRE1alpha.	pyrazolanthrone	73-81	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	238-247
24330607-12	2013	Finally, chemical inhibition of c-Jun N-terminal kinases (JNK) using the SP600125 compound reduced the ability of cells to express EREG, demonstrating a link between the growth factor production and JNK activation under the dependence of IRE1alpha.	pyrazolanthrone	73-81	epiregulin	Homo sapiens	131-135
24349194-9	2013	Treatment of the cells with the JNK inhibitor SP600125 almost fully reverted BPA effect on insulin signaling and glucose utilization.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	32-35
24330599-7	2013	Inhibition of JNK using the SP600125 inhibitor reduced phosphorylation of 90 kDa ribosomal S6 kinase (P90RSK) in the NP and FP, but not EP, systems.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
24349481-9	2013	Inhibition of Jnk, a downstream target of Wnt/PCP signaling (via morpholino antisense knockdown and pharmacological inhibition with the kinase inhibitor SP600125) phenocopied pCAME-treated embryos.	pyrazolanthrone	153-161	mitogen-activated protein kinase 8b	Danio rerio	14-17
24340070-11	2013	Furthermore, the results also showed that SB203580, a p38 inhibitor, and SP600125, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduced cardiomyocyte apoptosis and ER stress, however, klotho suppressed isoproterenol-induced activation of p38 and JNK.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Mus musculus	112-115
24340070-11	2013	Furthermore, the results also showed that SB203580, a p38 inhibitor, and SP600125, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduced cardiomyocyte apoptosis and ER stress, however, klotho suppressed isoproterenol-induced activation of p38 and JNK.	pyrazolanthrone	73-81	klotho	Mus musculus	184-190
24349194-9	2013	Treatment of the cells with the JNK inhibitor SP600125 almost fully reverted BPA effect on insulin signaling and glucose utilization.	pyrazolanthrone	46-54	insulin	Homo sapiens	91-98
23982257-11	2013	SP600125 remarkably reduced the expression of cleaved caspase-8, -3, and PARP and the phosphorylation of FADD and c-Jun, as well as apoptotic cell death.	pyrazolanthrone	0-8	caspase 8	Homo sapiens	54-63
23982257-11	2013	SP600125 remarkably reduced the expression of cleaved caspase-8, -3, and PARP and the phosphorylation of FADD and c-Jun, as well as apoptotic cell death.	pyrazolanthrone	0-8	poly(ADP-ribose) polymerase 1	Homo sapiens	73-77
23982257-11	2013	SP600125 remarkably reduced the expression of cleaved caspase-8, -3, and PARP and the phosphorylation of FADD and c-Jun, as well as apoptotic cell death.	pyrazolanthrone	0-8	Fas associated via death domain	Homo sapiens	105-109
23982257-11	2013	SP600125 remarkably reduced the expression of cleaved caspase-8, -3, and PARP and the phosphorylation of FADD and c-Jun, as well as apoptotic cell death.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	114-119
23816505-4	2013	Both hyperosmolarity and H2O2 increased p-ERK1/2 and p-JNK, which were inhibited by U0126, a MEK inhibitor, and SP600125, a JNK inhibitor, respectively.	pyrazolanthrone	112-120	mitogen-activated protein kinase 1	Canis lupus familiaris	42-48
23816505-5	2013	Immunoprecipitation assay showed that hyperosmolarity increased the association of nuclear Sp1 with c-Jun, which was inhibited by U0126 and SP600125.	pyrazolanthrone	140-148	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	100-105
23906792-4	2013	CTGF-induced collagen I expression was inhibited by the dominant negative mutant (DN) of Rac1 (RacN17), MLK3DN, MLK3 inhibitor (K252a), JNK1DN, JNK2DN, a JNK inhibitor (SP600125), and an AP-1 inhibitor (curcumin).	pyrazolanthrone	169-177	cellular communication network factor 2	Homo sapiens	0-4
23816505-6	2013	In mouse inner medullary collecting duct cells and rat kidney slices, hyperosmolarity increased the expression level of claudin-4, which was inhibited by DPI, MnTBAP, U0126, and SP600125.	pyrazolanthrone	178-186	claudin 4	Rattus norvegicus	120-129
23816505-7	2013	Hyperosmolarity increased luciferase reporter activity of claudin-4, which was inhibited by U0126, SP600125, Sp1 siRNA, and c-Jun siRNA.	pyrazolanthrone	99-107	claudin 4	Canis lupus familiaris	58-67
23792773-9	2013	Preincubation with specific ERK (PD98059), p38 (SB203580), or JNK (SP600125) inhibitors prevented 15-F2t-IsoP-induced cell proliferation and collagen synthesis.	pyrazolanthrone	67-75	mitogen-activated protein kinase 8	Rattus norvegicus	62-65
24149112-3	2013	Because the AGE-elicited expression of LCN2 was diminished by an antibody against the AGE receptor (RAGE), diphenylene iodonium (DPI), N-acetyl cysteine, LY294002, and SP600125, we suggest that AGEs enhance the expression of LCN2 via a RAGE-NADPH oxidase-reactive oxygen species pathway, leading to the phosphorylation of PI3K-Akt and JNK in HASMCs.	pyrazolanthrone	168-176	lipocalin 2	Homo sapiens	39-43
24252081-4	2013	A JNK inhibitor, SP600125, inhibited cell proliferation of SK-MEL-3 but not SK-MEL-28 or WM164.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	2-5
24123203-5	2013	Using the calcium blocker BAPTA-AM and the JNK inhibitor SP600125, we demonstrated that the calcium wave triggered the activation of JNK, which then phosphorylated the transcription factor c-Jun to facilitate the binding of AP-1 to the GFAP gene promoter to switch on GFAP upregulation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	43-46
24123203-5	2013	Using the calcium blocker BAPTA-AM and the JNK inhibitor SP600125, we demonstrated that the calcium wave triggered the activation of JNK, which then phosphorylated the transcription factor c-Jun to facilitate the binding of AP-1 to the GFAP gene promoter to switch on GFAP upregulation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	133-136
24123203-5	2013	Using the calcium blocker BAPTA-AM and the JNK inhibitor SP600125, we demonstrated that the calcium wave triggered the activation of JNK, which then phosphorylated the transcription factor c-Jun to facilitate the binding of AP-1 to the GFAP gene promoter to switch on GFAP upregulation.	pyrazolanthrone	57-65	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	189-194
24123203-5	2013	Using the calcium blocker BAPTA-AM and the JNK inhibitor SP600125, we demonstrated that the calcium wave triggered the activation of JNK, which then phosphorylated the transcription factor c-Jun to facilitate the binding of AP-1 to the GFAP gene promoter to switch on GFAP upregulation.	pyrazolanthrone	57-65	glial fibrillary acidic protein	Homo sapiens	236-240
24123203-5	2013	Using the calcium blocker BAPTA-AM and the JNK inhibitor SP600125, we demonstrated that the calcium wave triggered the activation of JNK, which then phosphorylated the transcription factor c-Jun to facilitate the binding of AP-1 to the GFAP gene promoter to switch on GFAP upregulation.	pyrazolanthrone	57-65	glial fibrillary acidic protein	Homo sapiens	268-272
23584357-8	2013	Furthermore, PD98059 (ERK1/2 inhibitor), SP600125 (JNK inhibitor) and SB202190 (p38 inhibitor) notably blocked the effect of TCDD on cell apoptosis.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	51-54
24142192-6	2013	In addition, palmitate-induced autophagy was blocked by 500 microM of the ER stress inhibitor tauroursodeoxycholic acid (TUDCA) or 20 microM JNK inhibitor SP600125.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Mus musculus	141-144
23735482-8	2013	Quercetin attenuated p38(MAPK) and JNK1/2 but not ERK1/2 activations and this effect was further confirmed by SB203580 and SP600125-mediated suppressions of HO-1, iNOS, and COX-2 protein expressions.	pyrazolanthrone	123-131	mitogen-activated protein kinase 14	Mus musculus	21-24
23735482-8	2013	Quercetin attenuated p38(MAPK) and JNK1/2 but not ERK1/2 activations and this effect was further confirmed by SB203580 and SP600125-mediated suppressions of HO-1, iNOS, and COX-2 protein expressions.	pyrazolanthrone	123-131	nitric oxide synthase 2, inducible	Mus musculus	163-167
23735482-8	2013	Quercetin attenuated p38(MAPK) and JNK1/2 but not ERK1/2 activations and this effect was further confirmed by SB203580 and SP600125-mediated suppressions of HO-1, iNOS, and COX-2 protein expressions.	pyrazolanthrone	123-131	cytochrome c oxidase II, mitochondrial	Mus musculus	173-178
24142192-9	2013	Palmitate-induced phospho-Akt (Ser473) downregulation was also inhibited by TUDCA or SP600125.	pyrazolanthrone	85-93	thymoma viral proto-oncogene 1	Mus musculus	26-29
23884438-6	2013	SP600125, a JNK-specific inhibitor, gives rise to high mortality in zebrafish, similar to that caused by the jnk1 RNA interference.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8b	Danio rerio	12-15
23884438-8	2013	The results also indicate that the inhibition of JNK by SP600125 suppresses the ovarian differentiation during the embryo development in zebrafish.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8b	Danio rerio	49-52
24002703-7	2013	JSH-23 (30 muM), an NF-kB inhibitor, and SP600125 (10 muM), an AP-1/c-Jun inhibitor, attenuated the loss of Cx43.	pyrazolanthrone	41-49	latexin	Homo sapiens	54-57
23585120-9	2013	c-Fos mRNA levels induced by thrombin were reduced by PD98059, SP600125, and Go6976, but not SB202190.	pyrazolanthrone	63-71	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-5
23585120-9	2013	c-Fos mRNA levels induced by thrombin were reduced by PD98059, SP600125, and Go6976, but not SB202190.	pyrazolanthrone	63-71	coagulation factor II	Rattus norvegicus	29-37
23585120-10	2013	Thrombin stimulated in vivo binding of c-Fos to the MMP-9 promoter, which was reduced by pretreatment with SP600125 or PD98059, but not SB202190.	pyrazolanthrone	107-115	coagulation factor II	Rattus norvegicus	0-8
23585120-10	2013	Thrombin stimulated in vivo binding of c-Fos to the MMP-9 promoter, which was reduced by pretreatment with SP600125 or PD98059, but not SB202190.	pyrazolanthrone	107-115	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	39-44
23585120-10	2013	Thrombin stimulated in vivo binding of c-Fos to the MMP-9 promoter, which was reduced by pretreatment with SP600125 or PD98059, but not SB202190.	pyrazolanthrone	107-115	matrix metallopeptidase 9	Rattus norvegicus	52-57
24002703-7	2013	JSH-23 (30 muM), an NF-kB inhibitor, and SP600125 (10 muM), an AP-1/c-Jun inhibitor, attenuated the loss of Cx43.	pyrazolanthrone	41-49	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	63-67
24002703-7	2013	JSH-23 (30 muM), an NF-kB inhibitor, and SP600125 (10 muM), an AP-1/c-Jun inhibitor, attenuated the loss of Cx43.	pyrazolanthrone	41-49	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	68-73
23989929-4	2013	Inhibition of c-Jun N-terminal kinases (SP600125), Src kinases (AG1879), and clathrin-dependent endocytosis (monodansylcadaverine) to disrupt scavenger receptor-mediated uptake of lipids had no effect on serum-induced lipid accumulation by VSMC.	pyrazolanthrone	40-48	jun proto-oncogene	Mus musculus	14-19
24002703-7	2013	JSH-23 (30 muM), an NF-kB inhibitor, and SP600125 (10 muM), an AP-1/c-Jun inhibitor, attenuated the loss of Cx43.	pyrazolanthrone	41-49	gap junction protein alpha 1	Homo sapiens	108-112
24100678-0	2013	JNK inhibitor SP600125 enhances TGF-beta-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
24100678-0	2013	JNK inhibitor SP600125 enhances TGF-beta-induced apoptosis of RBE human cholangiocarcinoma cells in a Smad-dependent manner.	pyrazolanthrone	14-22	transforming growth factor beta 1	Homo sapiens	32-40
24100678-3	2013	In this study, the involvement of SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), in TGF-beta-induced apoptosis of the RBE human cholangiocarcinoma cell line was investigated.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	60-83
24100678-3	2013	In this study, the involvement of SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), in TGF-beta-induced apoptosis of the RBE human cholangiocarcinoma cell line was investigated.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	85-88
24100678-3	2013	In this study, the involvement of SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), in TGF-beta-induced apoptosis of the RBE human cholangiocarcinoma cell line was investigated.	pyrazolanthrone	34-42	transforming growth factor beta 1	Homo sapiens	94-102
24100678-5	2013	SP600125 increased the TGF-beta1-induced phosphorylation of Smad2 and Smad3, which enhanced the TGF-beta1-induced transcriptional response and apoptosis in RBE cells.	pyrazolanthrone	0-8	transforming growth factor beta 1	Homo sapiens	23-32
24100678-5	2013	SP600125 increased the TGF-beta1-induced phosphorylation of Smad2 and Smad3, which enhanced the TGF-beta1-induced transcriptional response and apoptosis in RBE cells.	pyrazolanthrone	0-8	SMAD family member 2	Homo sapiens	60-65
24100678-5	2013	SP600125 increased the TGF-beta1-induced phosphorylation of Smad2 and Smad3, which enhanced the TGF-beta1-induced transcriptional response and apoptosis in RBE cells.	pyrazolanthrone	0-8	SMAD family member 3	Homo sapiens	70-75
24100678-5	2013	SP600125 increased the TGF-beta1-induced phosphorylation of Smad2 and Smad3, which enhanced the TGF-beta1-induced transcriptional response and apoptosis in RBE cells.	pyrazolanthrone	0-8	transforming growth factor beta 1	Homo sapiens	96-105
24100678-6	2013	The effect of SP600125 on the transcriptional response and apoptosis was reduced by knockdown of Smad4 expression.	pyrazolanthrone	14-22	SMAD family member 4	Homo sapiens	97-102
24260158-8	2013	In vivo, administration of C66 or JNK special inhibitor SP600125 at 5 mg/kg markedly decreased diabetes-induced renal adhesion molecule expression, NF-kappaB activation, inflammatory cell infiltration, and pathological indexes in the kidneys of diabetic mice.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Mus musculus	34-37
24100678-8	2013	SP600125 promoted the TGF-beta1-induced caspase cleavage, while knockdown of Smad4 expression counteracted this effect.	pyrazolanthrone	0-8	transforming growth factor beta 1	Homo sapiens	22-31
24100678-9	2013	These results indicate that SP600125 enhances TGF-beta-induced apoptosis of RBE cells through a Smad-dependent pathway that involves Smad-dependent caspase activation.	pyrazolanthrone	28-36	transforming growth factor beta 1	Homo sapiens	46-54
23905689-5	2013	SP600125 abrogated the pressor action of EtOH, but not ACA, thus implicating JNK in EtOH action on BP.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	77-80
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	chemokine (C-C motif) ligand 2	Mus musculus	75-80
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	interleukin 6	Mus musculus	82-86
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	tumor necrosis factor	Mus musculus	91-100
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	mitogen-activated protein kinase 8	Mus musculus	114-117
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	122-131
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	nitrilase 1	Mus musculus	151-156
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	179-192
24188583-10	2013	BBR, TAK-242 or SP-600125 (1 muM) could significantly reduce the levels of MCP-1, IL-6 and TNF-alpha, insulin and JNK and NF-kappaB phosphorylation in NIT-1 cells, as well as the p65 NF-kappaB in INS-1 cells.	pyrazolanthrone	16-25	insulin 1	Rattus norvegicus	196-201
24236122-7	2013	Immunoprecipitation analyses revealed an increased association of Cx43 with both ubiquitin and E3 ubiquitin ligase Nedd4 in astrocytes after LPS stimulation for 6 h and this effect was prevented by SP600125.	pyrazolanthrone	198-206	gap junction protein, alpha 1	Rattus norvegicus	66-70
24236122-7	2013	Immunoprecipitation analyses revealed an increased association of Cx43 with both ubiquitin and E3 ubiquitin ligase Nedd4 in astrocytes after LPS stimulation for 6 h and this effect was prevented by SP600125.	pyrazolanthrone	198-206	NEDD4 E3 ubiquitin protein ligase	Rattus norvegicus	115-120
23872072-10	2013	Furthermore, inhibitors of NF-kappaB (PDTC), ERK (U0126 and PD98059) and JNK (SP600125) partially blocked the suppression by ox-LDL on the CSE mRNA levels.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	73-76
24103749-7	2013	JNK inhibition by its inhibitors (SP 600125 and JNK-IN-8), or by RNA interference (RNAi) alleviated AZD8055-induced cell death.	pyrazolanthrone	34-43	mitogen-activated protein kinase 8	Homo sapiens	0-3
23872072-10	2013	Furthermore, inhibitors of NF-kappaB (PDTC), ERK (U0126 and PD98059) and JNK (SP600125) partially blocked the suppression by ox-LDL on the CSE mRNA levels.	pyrazolanthrone	78-86	cystathionine gamma-lyase	Homo sapiens	139-142
24126115-10	2013	However, the pre-incubation with anti-TLR2 (OPN301, 1 mug/ml) or JNK inhibitor SP600125 (10 mug/ml) prior to Abeta1-42 administration, these upregulation events were all reduced.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Mus musculus	65-68
24070709-6	2013	The SP600125-treated group showed significantly decreased TNF-alpha expression, but no significant change in IL-8 expression.	pyrazolanthrone	4-12	tumor necrosis factor	Oryctolagus cuniculus	58-67
24036456-7	2013	When the cells were exposed to SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor), the deregulation of the expression of apoptotic proteins was attenuated.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	43-46
24036456-7	2013	When the cells were exposed to SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor), the deregulation of the expression of apoptotic proteins was attenuated.	pyrazolanthrone	31-39	mitogen-activated protein kinase 1	Homo sapiens	74-77
24008433-7	2013	However, inhibition of JNK using the specific inhibitor SP600125 completely prevented Phx-3-induced apoptosis and restored the phosphorylation states of ERK to the control levels.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	23-26
24008433-7	2013	However, inhibition of JNK using the specific inhibitor SP600125 completely prevented Phx-3-induced apoptosis and restored the phosphorylation states of ERK to the control levels.	pyrazolanthrone	56-64	mitogen-activated protein kinase 1	Homo sapiens	153-156
23876460-6	2013	Interestingly, Cd could activate both ERK and JNK signaling pathways in C6 cells; however, gamma-secretase-mediated N-cad/CTF2 production by Cd was completely blocked by MEK1/2 inhibitors PD184352 and U0126, but not by a JNK inhibitor SP600125, demonstrating that the ERK signaling pathway plays a major role in the cleavage.	pyrazolanthrone	235-243	cadherin 2	Homo sapiens	116-121
24120080-7	2013	Pre-treatment with losartan (10(-10)M) or MAPK pathway inhibitors (U0126 or SP600125) abolished aldosterone-induced MR upregulation and significantly inhibited the expression of the above fibrotic marker proteins, indicating the critical role of MR and the requirement for active AT1 in the development of aldosterone-induced atrial fibrosis.	pyrazolanthrone	76-84	angiotensin II receptor type 1	Homo sapiens	280-283
23876460-6	2013	Interestingly, Cd could activate both ERK and JNK signaling pathways in C6 cells; however, gamma-secretase-mediated N-cad/CTF2 production by Cd was completely blocked by MEK1/2 inhibitors PD184352 and U0126, but not by a JNK inhibitor SP600125, demonstrating that the ERK signaling pathway plays a major role in the cleavage.	pyrazolanthrone	235-243	mitogen-activated protein kinase kinase 1	Homo sapiens	170-176
23774252-7	2013	TNF-alpha-enhanced p42/p44 MAPK, p38 MAPK, JNK1/2, and NF-kappaB (p65) phosphorylation and in vivo binding of p65 to the MMP-9 promoter were inhibited by U0126, SB202190, SP600125, NAC, DPI, or APO.	pyrazolanthrone	171-179	tumor necrosis factor	Rattus norvegicus	0-9
24147081-9	2013	Coincidentally, we found that SP600125, a JNK pathway inhibitor, decreased the activity and expression of MMP-9 of CD9-silenced HaCaT cells.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	42-45
24147081-9	2013	Coincidentally, we found that SP600125, a JNK pathway inhibitor, decreased the activity and expression of MMP-9 of CD9-silenced HaCaT cells.	pyrazolanthrone	30-38	matrix metallopeptidase 9	Homo sapiens	106-111
24147081-9	2013	Coincidentally, we found that SP600125, a JNK pathway inhibitor, decreased the activity and expression of MMP-9 of CD9-silenced HaCaT cells.	pyrazolanthrone	30-38	CD9 molecule	Homo sapiens	115-118
23774252-7	2013	TNF-alpha-enhanced p42/p44 MAPK, p38 MAPK, JNK1/2, and NF-kappaB (p65) phosphorylation and in vivo binding of p65 to the MMP-9 promoter were inhibited by U0126, SB202190, SP600125, NAC, DPI, or APO.	pyrazolanthrone	171-179	synaptotagmin 1	Rattus norvegicus	110-113
23774252-7	2013	TNF-alpha-enhanced p42/p44 MAPK, p38 MAPK, JNK1/2, and NF-kappaB (p65) phosphorylation and in vivo binding of p65 to the MMP-9 promoter were inhibited by U0126, SB202190, SP600125, NAC, DPI, or APO.	pyrazolanthrone	171-179	matrix metallopeptidase 9	Rattus norvegicus	121-126
23994730-5	2013	Furthermore, HCA significantly increased the levels of p-JNK and p-c-Jun and its toxicity dramatically attenuated by SP600125, a specific JNK pathway inhibitor.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Mus musculus	57-60
23994730-5	2013	Furthermore, HCA significantly increased the levels of p-JNK and p-c-Jun and its toxicity dramatically attenuated by SP600125, a specific JNK pathway inhibitor.	pyrazolanthrone	117-125	jun proto-oncogene	Mus musculus	67-72
23994730-5	2013	Furthermore, HCA significantly increased the levels of p-JNK and p-c-Jun and its toxicity dramatically attenuated by SP600125, a specific JNK pathway inhibitor.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Mus musculus	138-141
23969120-5	2013	Blockage of p38 and JNK kinases with their specific inhibitors, SB202190 and SP600125, significantly reduced TCDD-induced iNOS expression and NO production.	pyrazolanthrone	77-85	mitogen activated protein kinase 14	Rattus norvegicus	12-15
23969120-5	2013	Blockage of p38 and JNK kinases with their specific inhibitors, SB202190 and SP600125, significantly reduced TCDD-induced iNOS expression and NO production.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Rattus norvegicus	20-23
23969120-5	2013	Blockage of p38 and JNK kinases with their specific inhibitors, SB202190 and SP600125, significantly reduced TCDD-induced iNOS expression and NO production.	pyrazolanthrone	77-85	nitric oxide synthase 2	Rattus norvegicus	122-126
23175174-9	2013	Wortmannin and LY294002 did not have any repressive effect on the OUMS-27 whereas SB203580 and SP600125 were found to decrease the expression of ADAMTS9 gene.	pyrazolanthrone	95-103	ADAM metallopeptidase with thrombospondin type 1 motif 9	Homo sapiens	145-152
24161765-8	2013	Pre-treatment with JNK inhibitor SP600125 did not prevent but reversed TNF-alpha-evoked mechanical allodynia during the subsequent detection time.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	19-22
24161765-9	2013	Post-treatment with PDTC, PD98059 or SP600125 (but not SB203580) at 4h after TNF-alpha microinjected into the RN significantly reversed TNF-alpha-evoked mechanical allodynia.	pyrazolanthrone	37-45	tumor necrosis factor	Rattus norvegicus	77-86
24161765-9	2013	Post-treatment with PDTC, PD98059 or SP600125 (but not SB203580) at 4h after TNF-alpha microinjected into the RN significantly reversed TNF-alpha-evoked mechanical allodynia.	pyrazolanthrone	37-45	tumor necrosis factor	Rattus norvegicus	136-145
23911608-8	2013	HMGB1-induced increases in ICAM-1 and P-selectin expression were also inhibited by a specific eIF2alpha inhibitor (salubrinal) and a specific JNK inhibitor (SP600125).	pyrazolanthrone	157-165	high mobility group box 1	Homo sapiens	0-5
23876806-8	2013	p38 MAPK (SB203580) and JNK (SP600125) inhibitors enhanced toxin-induced cell death.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	24-27
23857473-8	2013	In contrast, JNK-specific inhibition, by SP600125, triggered upregulation of DR4 and DR5, and sensitized SK-Hep1 cells to TRAIL, indicating that the CAPE-induced suppression of JNK may contribute to the sensitizing effect of CAPE through the upregulation of death receptors.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	13-16
23857473-8	2013	In contrast, JNK-specific inhibition, by SP600125, triggered upregulation of DR4 and DR5, and sensitized SK-Hep1 cells to TRAIL, indicating that the CAPE-induced suppression of JNK may contribute to the sensitizing effect of CAPE through the upregulation of death receptors.	pyrazolanthrone	41-49	TNF receptor superfamily member 10a	Homo sapiens	77-80
24144737-7	2013	The growth inhibitory effect of TSA was attenuated by the JNK inhibitor SP600125 in OS-RC-2 cells.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	58-61
24144737-8	2013	TSA-induced phosphorylation of c-Jun and Bax upregulation was partially counteracted by SP600125.	pyrazolanthrone	88-96	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	31-36
24069158-4	2013	These responses induced by TNF-alpha were inhibited by pretreatment with the inhibitor of MEK1/2 (PD98059), p38 MAPK (SB202190), JNK1/2 (SP600125), or AP-1 (Tanshinone IIA) and transfection with siRNA of TNFR1, p42, p38, JNK2, c-Jun, c-Fos, or ATF2.	pyrazolanthrone	137-145	tumor necrosis factor	Homo sapiens	27-36
24069158-6	2013	In addition, TNF-alpha also stimulated c-Jun and ATF2 phosphorylation which were inhibited by pretreatment with SP600125 and SB202190, respectively, but not PD98059.	pyrazolanthrone	112-120	tumor necrosis factor	Homo sapiens	13-22
24069158-6	2013	In addition, TNF-alpha also stimulated c-Jun and ATF2 phosphorylation which were inhibited by pretreatment with SP600125 and SB202190, respectively, but not PD98059.	pyrazolanthrone	112-120	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	39-44
24069158-6	2013	In addition, TNF-alpha also stimulated c-Jun and ATF2 phosphorylation which were inhibited by pretreatment with SP600125 and SB202190, respectively, but not PD98059.	pyrazolanthrone	112-120	activating transcription factor 2	Homo sapiens	49-53
22795399-9	2013	Furthermore, gp120 induced autophagic proteins and autophagosomes were significantly inhibited by the N-methyl-d-aspartic acid (NMDA) receptor inhibitor MK801, c-Jun N-terminal kinase (JNK) inhibitor SP600125, and the class III phosphoinositide 3-kinase (PI3K) inhibitor 3-methyladenine (3-MA), while there was no change in the cells pretreated with the CXCR4 antagonist AMD3100.	pyrazolanthrone	200-208	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	13-18
22795399-9	2013	Furthermore, gp120 induced autophagic proteins and autophagosomes were significantly inhibited by the N-methyl-d-aspartic acid (NMDA) receptor inhibitor MK801, c-Jun N-terminal kinase (JNK) inhibitor SP600125, and the class III phosphoinositide 3-kinase (PI3K) inhibitor 3-methyladenine (3-MA), while there was no change in the cells pretreated with the CXCR4 antagonist AMD3100.	pyrazolanthrone	200-208	mitogen-activated protein kinase 8	Homo sapiens	160-183
22795399-9	2013	Furthermore, gp120 induced autophagic proteins and autophagosomes were significantly inhibited by the N-methyl-d-aspartic acid (NMDA) receptor inhibitor MK801, c-Jun N-terminal kinase (JNK) inhibitor SP600125, and the class III phosphoinositide 3-kinase (PI3K) inhibitor 3-methyladenine (3-MA), while there was no change in the cells pretreated with the CXCR4 antagonist AMD3100.	pyrazolanthrone	200-208	mitogen-activated protein kinase 8	Homo sapiens	185-188
23612802-10	2013	Pretreatment of cells with SB203580 (inhibitor of p38) and SP600125 (inhibitor of JNK) attenuated LPS-induced IL-10 expression, whereas it markedly inhibited the STAT3 expression.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	82-85
23612802-10	2013	Pretreatment of cells with SB203580 (inhibitor of p38) and SP600125 (inhibitor of JNK) attenuated LPS-induced IL-10 expression, whereas it markedly inhibited the STAT3 expression.	pyrazolanthrone	59-67	interleukin 10	Homo sapiens	110-115
24417167-8	2013	The level of HMGB1 mRNA expression in Hep-2 cells increased after the cells were induced by hypoxia for 6h PD98059 and SP600125 with 20 micromol/ L and PDTC with 50 mg/L partly inhibited extracellular release of HMGB1 in hypoxia-cultured Hcp-2 cells.	pyrazolanthrone	119-127	high mobility group box 1	Homo sapiens	13-18
24417167-8	2013	The level of HMGB1 mRNA expression in Hep-2 cells increased after the cells were induced by hypoxia for 6h PD98059 and SP600125 with 20 micromol/ L and PDTC with 50 mg/L partly inhibited extracellular release of HMGB1 in hypoxia-cultured Hcp-2 cells.	pyrazolanthrone	119-127	high mobility group box 1	Homo sapiens	212-217
23912840-5	2013	Nevertheless, the same SP600125 treatment caused a marked reduction in the tumor-initiating population within the A549 tumors, suggesting that JNK may be specifically required in vivo for the maintenance of the tumor-initiating population of tumor cells rather than for proliferation and survival of the entire cell population.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	143-146
23681803-6	2013	We further demonstrated that the roles of ATDC on cell invasion, MMP-9 upregulation, and AP-1 activation were dependent on extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) pathway activation, and ERK inhibitor U0126 or JNK inhibitor SP600125 blocked these effects of ATDC.	pyrazolanthrone	270-278	ATM serine/threonine kinase	Homo sapiens	42-46
24040124-11	2013	When animals treated with SP600125, a specific JNK inhibitor, after SCI, both mechanical allodynia and thermal hyperalgesia were significantly attenuated by the inhibitor, suggesting that JNK activation is likely involved in SCI-induced NP.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	47-50
24040124-11	2013	When animals treated with SP600125, a specific JNK inhibitor, after SCI, both mechanical allodynia and thermal hyperalgesia were significantly attenuated by the inhibitor, suggesting that JNK activation is likely involved in SCI-induced NP.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	188-191
24040124-12	2013	Also, the expression of chemokines which is known to be mediated through JNK pathway was significantly decreased by AP and SP600125 treatment.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Homo sapiens	73-76
23911608-8	2013	HMGB1-induced increases in ICAM-1 and P-selectin expression were also inhibited by a specific eIF2alpha inhibitor (salubrinal) and a specific JNK inhibitor (SP600125).	pyrazolanthrone	157-165	intercellular adhesion molecule 1	Homo sapiens	27-33
23911608-8	2013	HMGB1-induced increases in ICAM-1 and P-selectin expression were also inhibited by a specific eIF2alpha inhibitor (salubrinal) and a specific JNK inhibitor (SP600125).	pyrazolanthrone	157-165	selectin P	Homo sapiens	38-48
23911608-8	2013	HMGB1-induced increases in ICAM-1 and P-selectin expression were also inhibited by a specific eIF2alpha inhibitor (salubrinal) and a specific JNK inhibitor (SP600125).	pyrazolanthrone	157-165	mitogen-activated protein kinase 8	Homo sapiens	142-145
23820674-7	2013	The inhibition of c-jun N-terminal kinase (JNK) by SP600125, a specific JNK inhibitor, decreased the expression of MVP and Sp1 under hyperosmotic conditions.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	18-41
24039775-9	2013	We also found that MBL-dependent inhibition of monocyte proliferation could be reversed by the TGF-beta receptor antagonist SB-431542, or by anti-TGF-beta1 antibody, or by the mitogen-activated protein kinase (MAPK) inhibitors specific for p38 (SB203580), but not ERK (U0126) or JNK (SP600125).	pyrazolanthrone	284-292	mannose binding lectin 2	Homo sapiens	19-22
24065227-9	2013	Furthermore, inhibition experiments with SP600125, the JNK inhibitor, were carried out in the passage 4 cells to assess the effects of the JNK pathway on natural degeneration of endplate chondrocytes.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	55-58
24279124-4	2013	In cultured vascular smooth muscle cells (SMCs), Tumor Necrosis Factor (TNF)-alpha significantly activated both Mmp9 and Timp1 expression, and they were blocked by Jun kinase inhibitor (SP600125) in a dose-dependent manner.	pyrazolanthrone	186-194	tumor necrosis factor	Mus musculus	49-82
24279124-4	2013	In cultured vascular smooth muscle cells (SMCs), Tumor Necrosis Factor (TNF)-alpha significantly activated both Mmp9 and Timp1 expression, and they were blocked by Jun kinase inhibitor (SP600125) in a dose-dependent manner.	pyrazolanthrone	186-194	matrix metallopeptidase 9	Mus musculus	112-116
24279124-4	2013	In cultured vascular smooth muscle cells (SMCs), Tumor Necrosis Factor (TNF)-alpha significantly activated both Mmp9 and Timp1 expression, and they were blocked by Jun kinase inhibitor (SP600125) in a dose-dependent manner.	pyrazolanthrone	186-194	tissue inhibitor of metalloproteinase 1	Mus musculus	121-126
23850994-5	2013	Furthermore, AS activated p38/c-Jun N-terminal kinase (JNK), which could be inhibited by BaF1, and caspase-3 activation was attenuated by both SB202190 and SP600125, indicating that AS-induced autophagy promotes mitogen-activated protein kinases (MAPKs)-mediated apoptosis.	pyrazolanthrone	156-164	caspase 3	Homo sapiens	99-108
23820674-7	2013	The inhibition of c-jun N-terminal kinase (JNK) by SP600125, a specific JNK inhibitor, decreased the expression of MVP and Sp1 under hyperosmotic conditions.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	43-46
23820674-7	2013	The inhibition of c-jun N-terminal kinase (JNK) by SP600125, a specific JNK inhibitor, decreased the expression of MVP and Sp1 under hyperosmotic conditions.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	72-75
23820674-7	2013	The inhibition of c-jun N-terminal kinase (JNK) by SP600125, a specific JNK inhibitor, decreased the expression of MVP and Sp1 under hyperosmotic conditions.	pyrazolanthrone	51-59	major vault protein	Homo sapiens	115-118
23828231-6	2013	Pretreatment with SP600125, a JNK inhibitor, resulted in a significantly increased sub-G1 population and caspase activity in cordycepin plus TRAIL-mediated apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	30-33
23554085-4	2013	The inhibition of stress kinases p38, JNK1,2, and MEK1,2 by SP600125, SB203580, and UO126, respectively, established the involvement of JNK1,2 and p38 as upstream, and ERK1,2 as downstream targets of Hsp70 induction.	pyrazolanthrone	60-68	dual specificity mitogen-activated protein kinase kinase 1	Oryctolagus cuniculus	50-56
23512893-8	2013	Treatment with the JNK1/2 inhibitor SP600125 reduced FFA-induced expression of TNFalpha.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	19-25
23512893-8	2013	Treatment with the JNK1/2 inhibitor SP600125 reduced FFA-induced expression of TNFalpha.	pyrazolanthrone	36-44	tumor necrosis factor	Homo sapiens	79-87
23828231-6	2013	Pretreatment with SP600125, a JNK inhibitor, resulted in a significantly increased sub-G1 population and caspase activity in cordycepin plus TRAIL-mediated apoptosis.	pyrazolanthrone	18-26	TNF superfamily member 10	Homo sapiens	141-146
23812630-4	2013	Olaquindox-induced apoptosis was significantly potentiated by the JNK inhibitor (SP600125) or the p38 MAPK inhibitor (SB203580).	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	66-69
23967228-6	2013	Blockage of JNK signaling by SP600125 or by transfection with its specific siRNA significantly inhibited FGF4-stimulated cell proliferation through the suppression of c-Jun induction and activator protein-1 (AP-1) activity.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Mus musculus	12-15
23967228-6	2013	Blockage of JNK signaling by SP600125 or by transfection with its specific siRNA significantly inhibited FGF4-stimulated cell proliferation through the suppression of c-Jun induction and activator protein-1 (AP-1) activity.	pyrazolanthrone	29-37	fibroblast growth factor 4	Mus musculus	105-109
23967228-6	2013	Blockage of JNK signaling by SP600125 or by transfection with its specific siRNA significantly inhibited FGF4-stimulated cell proliferation through the suppression of c-Jun induction and activator protein-1 (AP-1) activity.	pyrazolanthrone	29-37	jun proto-oncogene	Mus musculus	167-172
23950935-4	2013	MS-enhanced MMP-2 expression and activity were inhibited by molecular inhibition of Akt using Akt siRNA as well as by PI3K/Akt inhibitors, LY293002 and AI, but not by MAPK inhibitors such as PD98059, SP600125 and SB203580.	pyrazolanthrone	200-208	matrix metallopeptidase 2	Homo sapiens	12-17
23950935-4	2013	MS-enhanced MMP-2 expression and activity were inhibited by molecular inhibition of Akt using Akt siRNA as well as by PI3K/Akt inhibitors, LY293002 and AI, but not by MAPK inhibitors such as PD98059, SP600125 and SB203580.	pyrazolanthrone	200-208	AKT serine/threonine kinase 1	Homo sapiens	84-87
23829318-10	2013	Furthermore, blocking MEK/Erk signalling with specific Erk1/2 inhibitor PD98059, or JNK signalling with specific inhibitor SP600125, abolished effects of EREG on cell proliferation.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Homo sapiens	84-87
23829318-10	2013	Furthermore, blocking MEK/Erk signalling with specific Erk1/2 inhibitor PD98059, or JNK signalling with specific inhibitor SP600125, abolished effects of EREG on cell proliferation.	pyrazolanthrone	123-131	epiregulin	Homo sapiens	154-158
23836896-8	2013	Blockade of the JNK MAP kinase pathway with the JNK inhibitor SP600125 abrogated TNF-induced Gal-9, whereas p38 and MEK inhibitors had minimal effects.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Mus musculus	16-19
23836896-8	2013	Blockade of the JNK MAP kinase pathway with the JNK inhibitor SP600125 abrogated TNF-induced Gal-9, whereas p38 and MEK inhibitors had minimal effects.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Mus musculus	48-51
23836896-8	2013	Blockade of the JNK MAP kinase pathway with the JNK inhibitor SP600125 abrogated TNF-induced Gal-9, whereas p38 and MEK inhibitors had minimal effects.	pyrazolanthrone	62-70	tumor necrosis factor	Mus musculus	81-84
23836896-8	2013	Blockade of the JNK MAP kinase pathway with the JNK inhibitor SP600125 abrogated TNF-induced Gal-9, whereas p38 and MEK inhibitors had minimal effects.	pyrazolanthrone	62-70	lectin, galactose binding, soluble 9	Mus musculus	93-98
23764463-7	2013	Furthermore, Icariin-mediated effects on osteoblasts were dramatically attenuated by treatment with specific inhibitors of MAPKs, U0126 (ERK inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Mus musculus	166-169
23977991-4	2013	BMP9-induced osteogenic differentiation of MSCs was dramatically inhibited by JNKs inhibitor SP600125.	pyrazolanthrone	93-101	growth differentiation factor 2	Homo sapiens	0-4
23977991-5	2013	Moreover, BMP9-activated Smads signaling was decreased by SP600125 treatment in MSCs.	pyrazolanthrone	58-66	growth differentiation factor 2	Homo sapiens	10-14
23907464-8	2013	Moreover, compound K activated the c-Jun NH2-terminal kinase (JNK) signaling pathway, whereas downregulation of JNK by its specific inhibitor SP600125 or by small interfering RNA against JNK attenuated autophagy-mediated cell death in response to compound K. Compound K also provoked apoptosis, as evidenced by an increased number of apoptotic bodies and sub-G1 hypodiploid cells, enhanced activation of caspase-3 and caspase-9, and modulation of Bcl-2 and Bcl-2-associated X protein expression.	pyrazolanthrone	142-150	mitogen-activated protein kinase 8	Homo sapiens	112-115
23907464-8	2013	Moreover, compound K activated the c-Jun NH2-terminal kinase (JNK) signaling pathway, whereas downregulation of JNK by its specific inhibitor SP600125 or by small interfering RNA against JNK attenuated autophagy-mediated cell death in response to compound K. Compound K also provoked apoptosis, as evidenced by an increased number of apoptotic bodies and sub-G1 hypodiploid cells, enhanced activation of caspase-3 and caspase-9, and modulation of Bcl-2 and Bcl-2-associated X protein expression.	pyrazolanthrone	142-150	mitogen-activated protein kinase 8	Homo sapiens	112-115
23632970-1	2013	We hypothesized that targeting key points in the ischemic cascade with combined neuroglobin (Ngb) overexpression and c-jun N-terminal kinase (JNK) inhibition (SP600125) would offer greater neuroprotection than single treatment after in vitro hypoxia/reoxygenation and in a randomized, blinded in vivo experimental stroke study using a clinically relevant rat strain.	pyrazolanthrone	159-167	mitogen-activated protein kinase 8	Rattus norvegicus	117-140
23632970-1	2013	We hypothesized that targeting key points in the ischemic cascade with combined neuroglobin (Ngb) overexpression and c-jun N-terminal kinase (JNK) inhibition (SP600125) would offer greater neuroprotection than single treatment after in vitro hypoxia/reoxygenation and in a randomized, blinded in vivo experimental stroke study using a clinically relevant rat strain.	pyrazolanthrone	159-167	mitogen-activated protein kinase 8	Rattus norvegicus	142-145
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	advanced glycosylation end-product specific receptor	Homo sapiens	59-63
23657597-6	2013	Among the periosteal-derived cells pretreated with MAPK inhibitors, the ALP activity was markedly decreased in the cells pretreated with SP 600125, the specific inhibitor of C-Jun N-terminal kinase (JNK).	pyrazolanthrone	137-146	mitogen-activated protein kinase 1	Homo sapiens	51-55
23657597-6	2013	Among the periosteal-derived cells pretreated with MAPK inhibitors, the ALP activity was markedly decreased in the cells pretreated with SP 600125, the specific inhibitor of C-Jun N-terminal kinase (JNK).	pyrazolanthrone	137-146	alkaline phosphatase, placental	Homo sapiens	72-75
23657597-6	2013	Among the periosteal-derived cells pretreated with MAPK inhibitors, the ALP activity was markedly decreased in the cells pretreated with SP 600125, the specific inhibitor of C-Jun N-terminal kinase (JNK).	pyrazolanthrone	137-146	mitogen-activated protein kinase 8	Homo sapiens	174-197
23657597-6	2013	Among the periosteal-derived cells pretreated with MAPK inhibitors, the ALP activity was markedly decreased in the cells pretreated with SP 600125, the specific inhibitor of C-Jun N-terminal kinase (JNK).	pyrazolanthrone	137-146	mitogen-activated protein kinase 8	Homo sapiens	199-202
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Homo sapiens	102-126
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Homo sapiens	128-131
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	high mobility group box 1	Homo sapiens	166-171
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	tumor necrosis factor	Homo sapiens	228-237
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	C-X-C motif chemokine ligand 8	Homo sapiens	239-243
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	interleukin 10	Homo sapiens	245-250
23712703-4	2013	However, the receptor for advanced glycation end products (RAGE) blocker RAGE-Ab (5 mug/ml) or 10 muM c-Jun N-terminal kinases (JNK) inhibitor SP600125 could inhibit HMGB1-induced the release of inflammation cytokines including TNF-alpha, IL-8, IL-10, and MCP-1 in a dose-dependent manner.	pyrazolanthrone	143-151	C-C motif chemokine ligand 2	Homo sapiens	256-261
23712703-5	2013	Furthermore, HMGB1-induced RAGE protein expression, JNK and NF-kappaB activation were attenuated by the pretreatment with RAGE-Ab or JNK inhibitor SP600125 in Western blot analysis.	pyrazolanthrone	147-155	high mobility group box 1	Homo sapiens	13-18
23712703-5	2013	Furthermore, HMGB1-induced RAGE protein expression, JNK and NF-kappaB activation were attenuated by the pretreatment with RAGE-Ab or JNK inhibitor SP600125 in Western blot analysis.	pyrazolanthrone	147-155	advanced glycosylation end-product specific receptor	Homo sapiens	27-31
23712703-5	2013	Furthermore, HMGB1-induced RAGE protein expression, JNK and NF-kappaB activation were attenuated by the pretreatment with RAGE-Ab or JNK inhibitor SP600125 in Western blot analysis.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	52-55
23690070-8	2013	Pretreatment with 1,9-pyrazoloanthrone (SP600125), a potent JNK inhibitor, abrogates TNFalpha- and 9cRA-stimulated RXRalpha SUMOylation.	pyrazolanthrone	18-38	mitogen-activated protein kinase 8	Homo sapiens	60-63
23712703-5	2013	Furthermore, HMGB1-induced RAGE protein expression, JNK and NF-kappaB activation were attenuated by the pretreatment with RAGE-Ab or JNK inhibitor SP600125 in Western blot analysis.	pyrazolanthrone	147-155	nuclear factor kappa B subunit 1	Homo sapiens	60-69
23690070-8	2013	Pretreatment with 1,9-pyrazoloanthrone (SP600125), a potent JNK inhibitor, abrogates TNFalpha- and 9cRA-stimulated RXRalpha SUMOylation.	pyrazolanthrone	18-38	tumor necrosis factor	Homo sapiens	85-93
23690070-8	2013	Pretreatment with 1,9-pyrazoloanthrone (SP600125), a potent JNK inhibitor, abrogates TNFalpha- and 9cRA-stimulated RXRalpha SUMOylation.	pyrazolanthrone	18-38	retinoid X receptor alpha	Homo sapiens	115-123
23690070-8	2013	Pretreatment with 1,9-pyrazoloanthrone (SP600125), a potent JNK inhibitor, abrogates TNFalpha- and 9cRA-stimulated RXRalpha SUMOylation.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	60-63
23690070-8	2013	Pretreatment with 1,9-pyrazoloanthrone (SP600125), a potent JNK inhibitor, abrogates TNFalpha- and 9cRA-stimulated RXRalpha SUMOylation.	pyrazolanthrone	40-48	tumor necrosis factor	Homo sapiens	85-93
23690070-8	2013	Pretreatment with 1,9-pyrazoloanthrone (SP600125), a potent JNK inhibitor, abrogates TNFalpha- and 9cRA-stimulated RXRalpha SUMOylation.	pyrazolanthrone	40-48	retinoid X receptor alpha	Homo sapiens	115-123
23712703-5	2013	Furthermore, HMGB1-induced RAGE protein expression, JNK and NF-kappaB activation were attenuated by the pretreatment with RAGE-Ab or JNK inhibitor SP600125 in Western blot analysis.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	133-136
23670941-7	2013	In contrast, increased MCP-1 release was suppressed with JNK inhibitor SP600125 and p38 MAPK inhibitor SB203580 (P &lt; 0.01).	pyrazolanthrone	71-79	C-C motif chemokine ligand 2	Homo sapiens	23-28
23670941-7	2013	In contrast, increased MCP-1 release was suppressed with JNK inhibitor SP600125 and p38 MAPK inhibitor SB203580 (P &lt; 0.01).	pyrazolanthrone	71-79	mitogen-activated protein kinase 8	Homo sapiens	57-60
23796709-9	2013	JNK and p38 specific inhibitors, SB203580 and SP600125 respectively, significantly blocked the cytotoxic effects of PL in LN229 and U87 cells.	pyrazolanthrone	46-54	mitogen-activated protein kinase 14	Homo sapiens	8-11
23892595-7	2013	BDNF-mediated cell motility and MMP-1 up-regulation were attenuated by Trk inhibitor (K252a), ASK1 inhibitor (thioredoxin), JNK inhibitor (SP600125), and p38 inhibitor (SB203580).	pyrazolanthrone	139-147	brain derived neurotrophic factor	Homo sapiens	0-4
23624146-5	2013	SP600125, an inhibitor of SAPK/JNK, increased the release and the mRNA expression levels of IL-6 induced by IL-1.	pyrazolanthrone	0-8	mitogen-activated protein kinase 9	Homo sapiens	26-30
23894471-7	2013	Treatment with inhibitors of JNK (SP600125), p38 MAPK (SB203580), and ERK (PD98059) prior to mechanical stimulation reversed both the static load-induced chondrocyte apoptosis and the activation of JNK, p38 MAPK, and ERK.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Rattus norvegicus	29-32
23624146-5	2013	SP600125, an inhibitor of SAPK/JNK, increased the release and the mRNA expression levels of IL-6 induced by IL-1.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	31-34
23624146-5	2013	SP600125, an inhibitor of SAPK/JNK, increased the release and the mRNA expression levels of IL-6 induced by IL-1.	pyrazolanthrone	0-8	interleukin 6	Homo sapiens	92-96
23624146-5	2013	SP600125, an inhibitor of SAPK/JNK, increased the release and the mRNA expression levels of IL-6 induced by IL-1.	pyrazolanthrone	0-8	interleukin 1 alpha	Homo sapiens	108-112
23624146-7	2013	SP600125 remarkably suppressed the IL-1-induced phosphorylation of both IkappaB and NF-kappaB, whereas SP600125 failed to affect the IL-1-induced phosphorylation of AMPK, STAT3 or Src.	pyrazolanthrone	0-8	interleukin 1 alpha	Homo sapiens	35-39
23624146-9	2013	SP600125 enhanced IL-1-stimulated IL-6 release also in normal human osteoblasts.	pyrazolanthrone	0-8	interleukin 1 alpha	Homo sapiens	18-22
23624146-9	2013	SP600125 enhanced IL-1-stimulated IL-6 release also in normal human osteoblasts.	pyrazolanthrone	0-8	interleukin 6	Homo sapiens	34-38
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-60
23751346-5	2013	UFP-mediated reduction in NO production was restored in the presence of JNK inhibitor (SP600125), NADPH oxidase inhibitor (Apocynin), anti-oxidant (N-acetyl cysteine), and superoxide dismutase mimetics (Tempol and MnTMPyP).	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	72-75
23828575-8	2013	Substitution of insulin, inhibition of JNK using the SP600125 compound in vivo or genetic deletion of the mitogen-activated protein kinase (MAPK)9 (JNK2) in all tissues abolished the injurious effect.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Mus musculus	39-42
23645013-9	2013	The LPS-induced overexpression of MCP-1 and TNF-alpha, and NO production were attenuated by pretreatment with the ERK inhibitor PD98059, the p38 MAPK inhibitor SB203580, the NF-kappaB inhibitor PDTC or anti-TLR4 antibody, but not with the JNK inhibitor SP600125.	pyrazolanthrone	253-261	mast cell protease 1-like 1	Rattus norvegicus	34-39
23645013-9	2013	The LPS-induced overexpression of MCP-1 and TNF-alpha, and NO production were attenuated by pretreatment with the ERK inhibitor PD98059, the p38 MAPK inhibitor SB203580, the NF-kappaB inhibitor PDTC or anti-TLR4 antibody, but not with the JNK inhibitor SP600125.	pyrazolanthrone	253-261	tumor necrosis factor	Rattus norvegicus	44-53
23645013-9	2013	The LPS-induced overexpression of MCP-1 and TNF-alpha, and NO production were attenuated by pretreatment with the ERK inhibitor PD98059, the p38 MAPK inhibitor SB203580, the NF-kappaB inhibitor PDTC or anti-TLR4 antibody, but not with the JNK inhibitor SP600125.	pyrazolanthrone	253-261	Eph receptor B1	Rattus norvegicus	114-117
23395971-6	2013	Interestingly, the effects of this combination treatment were significantly enhanced in the cells pretreated with a JNK inhibitor, SP600125.	pyrazolanthrone	131-139	mitogen-activated protein kinase 8	Homo sapiens	116-119
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	pyrazolanthrone	0-8	mitogen-activated protein kinase kinase 1	Homo sapiens	65-71
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	83-86
23423712-9	2013	SP600125 and U0126, by blocking the phosphorylation of c-Jun and MEK1/2, inhibited JNK and ERK phosphorylation, respectively, and attenuated apoptosis significantly.	pyrazolanthrone	0-8	mitogen-activated protein kinase 1	Homo sapiens	91-94
23423712-12	2013	The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP.	pyrazolanthrone	4-12	nuclear factor kappa B subunit 1	Homo sapiens	58-67
23423712-12	2013	The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP.	pyrazolanthrone	4-12	BCL2 apoptosis regulator	Homo sapiens	105-110
23423712-12	2013	The SP600125 and U0126 neuroprotection appears related to NF-kappaB-regulated transcriptional control of Bcl-2 and XIAP.	pyrazolanthrone	4-12	X-linked inhibitor of apoptosis	Homo sapiens	115-119
23607503-5	2013	H2O2 treatment increased the phosphorylation of NF-kappaB, which was blocked by pretreatment with SB 203580, a p38 MAPK inhibitor, or SP 600125, a JNK inhibitor.	pyrazolanthrone	134-143	mitogen-activated protein kinase 8	Homo sapiens	147-150
23607596-6	2013	It also up-regulates the TGFbeta2 mRNA level, which can be abolished by the JNK-specific inhibitor SP600125, but not TGFbeta pathway-specific inhibitor SD-208, indicating that both JNK and TGFbeta signaling pathways are activated by BA-TPQ and that the JNK pathway activation precedes TGFbeta activation.	pyrazolanthrone	99-107	transforming growth factor beta 2	Homo sapiens	25-33
23607596-6	2013	It also up-regulates the TGFbeta2 mRNA level, which can be abolished by the JNK-specific inhibitor SP600125, but not TGFbeta pathway-specific inhibitor SD-208, indicating that both JNK and TGFbeta signaling pathways are activated by BA-TPQ and that the JNK pathway activation precedes TGFbeta activation.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	76-79
23607596-6	2013	It also up-regulates the TGFbeta2 mRNA level, which can be abolished by the JNK-specific inhibitor SP600125, but not TGFbeta pathway-specific inhibitor SD-208, indicating that both JNK and TGFbeta signaling pathways are activated by BA-TPQ and that the JNK pathway activation precedes TGFbeta activation.	pyrazolanthrone	99-107	transforming growth factor beta 2	Homo sapiens	25-32
23100504-5	2013	Upregulation of the enzyme in cells that were progressing to quiescence was completely inhibited by the transcription blocker actinomycin D or by SP600125, an inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	146-154	mitogen-activated protein kinase 8	Homo sapiens	172-195
23100504-5	2013	Upregulation of the enzyme in cells that were progressing to quiescence was completely inhibited by the transcription blocker actinomycin D or by SP600125, an inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	146-154	mitogen-activated protein kinase 8	Homo sapiens	197-200
23333289-9	2013	SP600125 and SB203580 abolished TNC-induced TLR4 upregulation and vasoconstrictive effects.	pyrazolanthrone	0-8	tenascin C	Rattus norvegicus	32-35
23333289-9	2013	SP600125 and SB203580 abolished TNC-induced TLR4 upregulation and vasoconstrictive effects.	pyrazolanthrone	0-8	toll-like receptor 4	Rattus norvegicus	44-48
23603260-6	2013	The JNK inhibitor SP600125 at 5 mug, 10 mug, 20 mug, 30 mug or the vehicle was intraventricularly administered before the exposure.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
23619396-5	2013	The effect of ET-1 was diminished by an ETB antagonist (1 muM BQ788) or inhibitors of Sp1 (500 nM mithramycin), ERK (50 muM PD98059), p38 (20 muM SB203580) and JNK (1 muM SP600125), but not inhibitors of NF-kappaB (10 muM SN50 and 100 muM pyrrolidine dithiocarbamate).	pyrazolanthrone	171-179	endothelin 1	Rattus norvegicus	14-18
23619396-8	2013	ET-1-induced phosphorylation of Sp1 was attenuated by PD98059 and SP600125.	pyrazolanthrone	66-74	endothelin 1	Rattus norvegicus	0-4
23619396-9	2013	Additionally, ET-1 increased the incorporation of bromodeoxyuridine (BrdU) in cultured astrocytes and the number of BrdU-positive cells decreased in the presence of PD98059, SP600125 and mithramycin.	pyrazolanthrone	174-182	endothelin 1	Rattus norvegicus	14-18
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	pyrazolanthrone	156-164	gonadotropin releasing hormone 2	Homo sapiens	4-11
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	pyrazolanthrone	156-164	mitogen-activated protein kinase 3	Homo sapiens	51-57
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	62-65
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	pyrazolanthrone	156-164	mitogen-activated protein kinase 3	Homo sapiens	108-114
23786715-11	2013	The GnRH-II agonist induced the phosphorylation of ERK1/2 and JNK, and the phosphorylation was abolished by ERK1/2 inhibitor (U0126) and the JNK inhibitor (SP600125).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	141-144
23786715-12	2013	Cell motility promoted by GnRH-II agonist was suppressed in cells that were pretreated with U0126 and SP600125.	pyrazolanthrone	102-110	gonadotropin releasing hormone 2	Homo sapiens	26-33
23786715-13	2013	Moreover, U0126 and SP600125 abolished the GnRH-II agonist-induced activation of MMP-2.	pyrazolanthrone	20-28	gonadotropin releasing hormone 2	Homo sapiens	43-50
23786715-13	2013	Moreover, U0126 and SP600125 abolished the GnRH-II agonist-induced activation of MMP-2.	pyrazolanthrone	20-28	matrix metallopeptidase 2	Homo sapiens	81-86
23603260-10	2013	The JNK inhibitor SP600125 dose-dependently inhibited isoflurane-induced neuronal apoptosis and increase of caspase-3 and phospho-JNK.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
23603260-10	2013	The JNK inhibitor SP600125 dose-dependently inhibited isoflurane-induced neuronal apoptosis and increase of caspase-3 and phospho-JNK.	pyrazolanthrone	18-26	caspase 3	Rattus norvegicus	108-117
23603260-10	2013	The JNK inhibitor SP600125 dose-dependently inhibited isoflurane-induced neuronal apoptosis and increase of caspase-3 and phospho-JNK.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	130-133
23603260-11	2013	SP600125 also attenuated isoflurane-induced down-regulation of Bcl-xL and maintained the activated Akt level to increase the phosphorylation of GSK-3beta at Ser9.	pyrazolanthrone	0-8	Bcl2-like 1	Rattus norvegicus	63-69
23603260-11	2013	SP600125 also attenuated isoflurane-induced down-regulation of Bcl-xL and maintained the activated Akt level to increase the phosphorylation of GSK-3beta at Ser9.	pyrazolanthrone	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	99-102
23603260-11	2013	SP600125 also attenuated isoflurane-induced down-regulation of Bcl-xL and maintained the activated Akt level to increase the phosphorylation of GSK-3beta at Ser9.	pyrazolanthrone	0-8	glycogen synthase kinase 3 beta	Rattus norvegicus	144-153
23603260-13	2013	Maintaining Bcl-xL and Akt activation may be involved in the neuroprotective effects of SP600125.	pyrazolanthrone	88-96	Bcl2-like 1	Rattus norvegicus	12-18
23603260-13	2013	Maintaining Bcl-xL and Akt activation may be involved in the neuroprotective effects of SP600125.	pyrazolanthrone	88-96	AKT serine/threonine kinase 1	Rattus norvegicus	23-26
23564506-5	2013	Neither agent caused additional inhibition of release when used in combination with the JNK inhibitor SP-600125.	pyrazolanthrone	102-111	mitogen-activated protein kinase 8	Homo sapiens	88-91
23634759-0	2013	Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).	pyrazolanthrone	122-130	TTK protein kinase	Homo sapiens	38-42
23634759-4	2013	To design novel Mps1 inhibitors, we utilized the pan-kinase inhibitor anthrapyrazolone (4, SP600125) and its crystal structure bound to JNK1.	pyrazolanthrone	91-99	TTK protein kinase	Homo sapiens	16-20
23634759-4	2013	To design novel Mps1 inhibitors, we utilized the pan-kinase inhibitor anthrapyrazolone (4, SP600125) and its crystal structure bound to JNK1.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	136-140
23744357-6	2013	Among the pathway inhibitors examined, only SP600125 (JNK inhibitor) markedly reversedWB-induced apoptosis, and only U0126 (ERK inhibitor) significantly blocked WB-triggered G2 phase arrest.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	54-57
23485395-4	2013	In this study, we show that inhibition of JNK by SP600125, its inhibitory peptide, or JNK-1 siRNA induced MOR at both mRNA and protein levels in neuronal cells.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	42-45
23485395-4	2013	In this study, we show that inhibition of JNK by SP600125, its inhibitory peptide, or JNK-1 siRNA induced MOR at both mRNA and protein levels in neuronal cells.	pyrazolanthrone	49-57	opioid receptor mu 1	Homo sapiens	106-109
23485395-7	2013	The p38 MAPK dependent phosphorylation of p65 NF-kappaB subunit in the nucleus was increased by SP600125 treatment.	pyrazolanthrone	96-104	nuclear factor kappa B subunit 1	Homo sapiens	46-55
23500539-6	2013	TGF-beta1 also induced phosphorylation of MAPKs (ERK1/2, p38, and JNK) and Smad2/3 and pretreatment with PD98059 (an ERK1/2 inhibitor), SB203580 (a p38 inhibitor), or SP600125 (a JNK inhibitor) inhibited TGF-beta1-induced fibronectin expression.	pyrazolanthrone	167-175	transforming growth factor beta 1	Homo sapiens	0-9
23545304-10	2013	Inhibition of c-Jun N-terminal kinase/stress-activated protein kinase (JNK) activity with the specific inhibitor SP600125 suppressed LPS-induced upregulation of Sca-1 expression by marrow lin(-) c-kit(+) Sca-1(-) cells.	pyrazolanthrone	113-121	lymphocyte antigen 6 complex, locus A	Mus musculus	161-166
23536693-4	2013	Specific inhibitors of mitogen-activated protein kinases (MAPKs), SB203580, PD98059, and SP600125, significantly abolished HO-1 expression.	pyrazolanthrone	89-97	heme oxygenase 1	Homo sapiens	123-127
23545304-10	2013	Inhibition of c-Jun N-terminal kinase/stress-activated protein kinase (JNK) activity with the specific inhibitor SP600125 suppressed LPS-induced upregulation of Sca-1 expression by marrow lin(-) c-kit(+) Sca-1(-) cells.	pyrazolanthrone	113-121	KIT proto-oncogene receptor tyrosine kinase	Mus musculus	195-203
23545304-10	2013	Inhibition of c-Jun N-terminal kinase/stress-activated protein kinase (JNK) activity with the specific inhibitor SP600125 suppressed LPS-induced upregulation of Sca-1 expression by marrow lin(-) c-kit(+) Sca-1(-) cells.	pyrazolanthrone	113-121	lymphocyte antigen 6 complex, locus A	Mus musculus	204-209
24059951-12	2013	Compared with those of group P, the protein levels of p-ERK1/2 (0.47 +- 0.05) in group PD98059, p-p38 (0.88 +- 0.07) in group SB203580, and p-JNK (0.91 +- 0.07) in group SP600125 were significantly reduced (P &lt; 0.05 or P &lt; 0.01).	pyrazolanthrone	170-178	mitogen activated protein kinase 14	Rattus norvegicus	98-101
23683282-9	2013	In addition, MTA-induced mineralization was blocked by inhibition of extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) by using U0126, SB203580, and SP600125, respectively.	pyrazolanthrone	181-189	mitogen-activated protein kinase 1	Homo sapiens	69-106
23683282-9	2013	In addition, MTA-induced mineralization was blocked by inhibition of extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) by using U0126, SB203580, and SP600125, respectively.	pyrazolanthrone	181-189	mitogen-activated protein kinase 1	Homo sapiens	108-111
23683282-9	2013	In addition, MTA-induced mineralization was blocked by inhibition of extracellular signal-regulated kinase (ERK), p38, and Jun N-terminal kinase (JNK) by using U0126, SB203580, and SP600125, respectively.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Homo sapiens	146-149
23515281-7	2013	The JNK inhibitor SP600125 blocked insulin-induced upregulation of SREBP-1c expression.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
23515281-7	2013	The JNK inhibitor SP600125 blocked insulin-induced upregulation of SREBP-1c expression.	pyrazolanthrone	18-26	insulin	Homo sapiens	35-42
23515281-7	2013	The JNK inhibitor SP600125 blocked insulin-induced upregulation of SREBP-1c expression.	pyrazolanthrone	18-26	sterol regulatory element binding transcription factor 1	Homo sapiens	67-75
23583400-6	2013	This effect was significantly depressed by the AT1R blocker losartan and different inhibitors (irestatin, IRE1 specific inhibitor; SP600125, JNK specific inhibitor; SB203580, p38 MAPK specific inhibitor) but not by the AT2R blocker PD123319.	pyrazolanthrone	131-139	angiotensin II receptor type 1	Homo sapiens	47-51
23691142-11	2013	An ERK1/2 and JNK antagonist (PD098059 and SP600125, respectively) protected against 2-ClHDA-induced barrier dysfunction in vitro.	pyrazolanthrone	43-51	mitogen-activated protein kinase 3	Mus musculus	3-9
23691142-11	2013	An ERK1/2 and JNK antagonist (PD098059 and SP600125, respectively) protected against 2-ClHDA-induced barrier dysfunction in vitro.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Mus musculus	14-17
24265868-6	2013	VPA increased the phosphorylation of Erk1/2 and JNK and pretreatment of a JNK inhibitor SP600125 prevented the VPA-induced increase in alpha-synuclein.	pyrazolanthrone	88-96	mitogen activated protein kinase 3	Rattus norvegicus	37-43
24265868-6	2013	VPA increased the phosphorylation of Erk1/2 and JNK and pretreatment of a JNK inhibitor SP600125 prevented the VPA-induced increase in alpha-synuclein.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Rattus norvegicus	74-77
24265868-6	2013	VPA increased the phosphorylation of Erk1/2 and JNK and pretreatment of a JNK inhibitor SP600125 prevented the VPA-induced increase in alpha-synuclein.	pyrazolanthrone	88-96	synuclein alpha	Rattus norvegicus	135-150
23583400-10	2013	The IRE1 specific inhibitor irestatin, the JNK specific inhibitor SP600125, and the p38 MAPK specific inhibitor SB203580 significantly inhibited Ang II-induced capillary formation from endothelial cells and VEGF expression but had no effect on GRP78.	pyrazolanthrone	66-74	vascular endothelial growth factor A	Homo sapiens	207-211
23301857-5	2013	injection of a pharmacological JNK-inhibitor (SP600125) improved impaired glucose homeostasis.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Mus musculus	31-34
23353793-11	2013	The JNK phosphorylation induced by CCh was significantly inhibited by SP600125 (n = 4).	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
23313051-4	2013	CCN4-induced VCAM-1 expression was attenuated by alphavbeta5 or alpha6beta1 integrin antibody, Syk inhibitor, PKCdelta inhibitor (rottlerin), JNK inhibitor (SP600125), and AP-1 inhibitors (curcumin and tanshinone).	pyrazolanthrone	157-165	cellular communication network factor 4	Homo sapiens	0-4
23313051-4	2013	CCN4-induced VCAM-1 expression was attenuated by alphavbeta5 or alpha6beta1 integrin antibody, Syk inhibitor, PKCdelta inhibitor (rottlerin), JNK inhibitor (SP600125), and AP-1 inhibitors (curcumin and tanshinone).	pyrazolanthrone	157-165	vascular cell adhesion molecule 1	Homo sapiens	13-19
23651874-8	2013	Furthermore, the changes in C33a and SiHa cell viability, migration and proliferation that were observed upon HPV 16 E2 transfection were abrogated by SB203580 (a p38 MAPK inhibitor) or SP600125 (a JNK inhibitor) treatment.	pyrazolanthrone	186-194	mitogen-activated protein kinase 8	Homo sapiens	198-201
23212307-6	2013	In addition, the DPQZ-induced cell death was attenuated by JNK inhibitor SP600125 (3 or 10 muM), not by the ERK or p38 inhibitors.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	59-62
23212307-6	2013	In addition, the DPQZ-induced cell death was attenuated by JNK inhibitor SP600125 (3 or 10 muM), not by the ERK or p38 inhibitors.	pyrazolanthrone	73-81	latexin	Homo sapiens	91-94
23290789-6	2013	Suppression of Tgase-2 or the c-Jun-N-terminal kinase (JNK) inhibitor, SP600125, significantly reduced and over-expression of Tgase-2 increased the expression of N-cadherin.	pyrazolanthrone	71-79	mitogen-activated protein kinase 8	Homo sapiens	30-53
23290789-6	2013	Suppression of Tgase-2 or the c-Jun-N-terminal kinase (JNK) inhibitor, SP600125, significantly reduced and over-expression of Tgase-2 increased the expression of N-cadherin.	pyrazolanthrone	71-79	mitogen-activated protein kinase 8	Homo sapiens	55-58
23290789-6	2013	Suppression of Tgase-2 or the c-Jun-N-terminal kinase (JNK) inhibitor, SP600125, significantly reduced and over-expression of Tgase-2 increased the expression of N-cadherin.	pyrazolanthrone	71-79	transglutaminase 2	Homo sapiens	126-133
23290789-6	2013	Suppression of Tgase-2 or the c-Jun-N-terminal kinase (JNK) inhibitor, SP600125, significantly reduced and over-expression of Tgase-2 increased the expression of N-cadherin.	pyrazolanthrone	71-79	cadherin 2	Homo sapiens	162-172
23301857-12	2013	In a hypothalamic cell line, and in the ARC and VMH of leptin-deficient mice, JNK inhibition by SP600125 consistently improved impaired insulin signalling.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Mus musculus	78-81
23201852-7	2013	It was further observed that the JNK MAPK inhibitor SP600125 attenuated the PGN+rHMGB1 induced iNOS/NO synergy whereas p38 MAPK inhibitor SB908912 inhibited iNOS/NO synergy induced by LPS+rHMGB1.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Mus musculus	33-36
23201852-7	2013	It was further observed that the JNK MAPK inhibitor SP600125 attenuated the PGN+rHMGB1 induced iNOS/NO synergy whereas p38 MAPK inhibitor SB908912 inhibited iNOS/NO synergy induced by LPS+rHMGB1.	pyrazolanthrone	52-60	high mobility group box 1	Rattus norvegicus	80-86
23201852-7	2013	It was further observed that the JNK MAPK inhibitor SP600125 attenuated the PGN+rHMGB1 induced iNOS/NO synergy whereas p38 MAPK inhibitor SB908912 inhibited iNOS/NO synergy induced by LPS+rHMGB1.	pyrazolanthrone	52-60	nitric oxide synthase 2, inducible	Mus musculus	95-99
23627909-13	2013	The increase in CCL2 and CXCL1 expression by ET-1 was inhibited by actinomycin D, pyrrolidine dithiocarbamate, SN50, mithramycin, SB203580 and SP600125.	pyrazolanthrone	143-151	C-C motif chemokine ligand 2	Rattus norvegicus	16-20
23627909-13	2013	The increase in CCL2 and CXCL1 expression by ET-1 was inhibited by actinomycin D, pyrrolidine dithiocarbamate, SN50, mithramycin, SB203580 and SP600125.	pyrazolanthrone	143-151	C-X-C motif chemokine ligand 1	Rattus norvegicus	25-30
23627909-13	2013	The increase in CCL2 and CXCL1 expression by ET-1 was inhibited by actinomycin D, pyrrolidine dithiocarbamate, SN50, mithramycin, SB203580 and SP600125.	pyrazolanthrone	143-151	endothelin 1	Rattus norvegicus	45-49
23353699-9	2013	Finally, we showed that, in H9c2 cells, TNF-alpha-stimulated AP-1 promoter activity, c-Jun mRNA expression, and c-Jun phosphorylation were attenuated by PP1, AG1478, AG1296, LY294002, SB202190, SP600125, or U0126.	pyrazolanthrone	194-202	tumor necrosis factor	Rattus norvegicus	40-49
23454527-5	2013	N-acetylcysteine (NAC, 33 mM) and the c-jun N-terminal kinase (JNK) inhibitor (SP600125, 33 muM) further decreased the viability in the presence of DEP (200 mug/ml) and 3.3% FCS.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	63-66
23630579-7	2013	Moreover, the knockdown of NDRG2 expression resulted in increased cell invasion, which was rescued by treating the HepG2 cells with the ERK1/2 inhibitor PD98059, but not with the p38MAPK inhibitor SB203580 or the JNK inhibitor SP600125.	pyrazolanthrone	227-235	NDRG family member 2	Homo sapiens	27-32
23353699-9	2013	Finally, we showed that, in H9c2 cells, TNF-alpha-stimulated AP-1 promoter activity, c-Jun mRNA expression, and c-Jun phosphorylation were attenuated by PP1, AG1478, AG1296, LY294002, SB202190, SP600125, or U0126.	pyrazolanthrone	194-202	neuropeptide Y receptor Y4	Rattus norvegicus	153-156
23546014-9	2013	Moreover, the effects of ET-1 on I(Ca,L) and alpha1C-subunit expression were abolished by the ERK1/2 inhibitor (PD98059) but not by the p38 MAPK inhibitor (SB203580) or the c-Jun N-terminal kinase inhibitor (SP600125).	pyrazolanthrone	208-216	endothelin 1	Rattus norvegicus	25-29
23277113-8	2013	MAPK kinase 1/2 inhibitor PD98059 and JNK inhibitor SP600125 suppressed Ang II-induced expression of MMP-3 and -13.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	38-41
23277113-8	2013	MAPK kinase 1/2 inhibitor PD98059 and JNK inhibitor SP600125 suppressed Ang II-induced expression of MMP-3 and -13.	pyrazolanthrone	52-60	angiotensinogen	Rattus norvegicus	72-78
23277113-8	2013	MAPK kinase 1/2 inhibitor PD98059 and JNK inhibitor SP600125 suppressed Ang II-induced expression of MMP-3 and -13.	pyrazolanthrone	52-60	matrix metallopeptidase 3	Rattus norvegicus	101-114
23457411-11	2013	The inhibitory effect of ET-1 on Ad was reverted by BQ-123/788 or PD-98059 but not SP-600125.	pyrazolanthrone	83-92	endothelin 1	Homo sapiens	25-29
23378009-6	2013	Concomitantly, LiCl strongly inhibited the activity of c-Jun N-terminal kinases (JNKs), and the inhibition of JNKs by SP600125 also induced G2/M arrest and augmented cell death caused by TRAIL or TRAIL plus LiCl.	pyrazolanthrone	118-126	TNF superfamily member 10	Homo sapiens	187-192
23378009-6	2013	Concomitantly, LiCl strongly inhibited the activity of c-Jun N-terminal kinases (JNKs), and the inhibition of JNKs by SP600125 also induced G2/M arrest and augmented cell death caused by TRAIL or TRAIL plus LiCl.	pyrazolanthrone	118-126	TNF superfamily member 10	Homo sapiens	196-201
23097189-8	2013	TNF-alpha also induced the phosphorylation of Jun N-terminal kinase (JNK) and c-Jun, and the morphogenesis was inhibited by SP600125, a specific JNK inhibitor.	pyrazolanthrone	124-132	tumor necrosis factor	Rattus norvegicus	0-9
23097189-8	2013	TNF-alpha also induced the phosphorylation of Jun N-terminal kinase (JNK) and c-Jun, and the morphogenesis was inhibited by SP600125, a specific JNK inhibitor.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Rattus norvegicus	46-67
23097189-8	2013	TNF-alpha also induced the phosphorylation of Jun N-terminal kinase (JNK) and c-Jun, and the morphogenesis was inhibited by SP600125, a specific JNK inhibitor.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Rattus norvegicus	69-72
23097189-8	2013	TNF-alpha also induced the phosphorylation of Jun N-terminal kinase (JNK) and c-Jun, and the morphogenesis was inhibited by SP600125, a specific JNK inhibitor.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Rattus norvegicus	145-148
23546014-9	2013	Moreover, the effects of ET-1 on I(Ca,L) and alpha1C-subunit expression were abolished by the ERK1/2 inhibitor (PD98059) but not by the p38 MAPK inhibitor (SB203580) or the c-Jun N-terminal kinase inhibitor (SP600125).	pyrazolanthrone	208-216	mitogen activated protein kinase 3	Rattus norvegicus	94-100
23404530-6	2013	In addition, the NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), and the AP-1 inhibitor, SP600125, decreased the protein levels of FN, collagen I and PAI-1, suggesting a role for the NF-kappaB and AP-1 pathways in the regulation of ECM accumulation induced by HG in RPMCs.	pyrazolanthrone	98-106	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	82-86
23626475-9	2013	SP600125, inhibitor of c-Jun N-terminal kinase (JNK), reduced LPS-mediated ICAM-1 but not VCAM-1 expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	23-46
23626475-9	2013	SP600125, inhibitor of c-Jun N-terminal kinase (JNK), reduced LPS-mediated ICAM-1 but not VCAM-1 expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	48-51
23626475-9	2013	SP600125, inhibitor of c-Jun N-terminal kinase (JNK), reduced LPS-mediated ICAM-1 but not VCAM-1 expression.	pyrazolanthrone	0-8	intercellular adhesion molecule 1	Homo sapiens	75-81
23626475-9	2013	SP600125, inhibitor of c-Jun N-terminal kinase (JNK), reduced LPS-mediated ICAM-1 but not VCAM-1 expression.	pyrazolanthrone	0-8	vascular cell adhesion molecule 1	Homo sapiens	90-96
23626476-11	2013	MEK inhibitor PD98059 and JNK inhibitor SP600125 blocked the contraction.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	26-29
23365451-8	2013	Screening of a panel of inhibitors targeting kinases that may be modulated by off-target effects of AS601245 and SP600125 led us to identify MKNK1 as a host factor involved in HCV entry.	pyrazolanthrone	113-121	MAPK interacting serine/threonine kinase 1	Homo sapiens	141-146
23404530-6	2013	In addition, the NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), and the AP-1 inhibitor, SP600125, decreased the protein levels of FN, collagen I and PAI-1, suggesting a role for the NF-kappaB and AP-1 pathways in the regulation of ECM accumulation induced by HG in RPMCs.	pyrazolanthrone	98-106	serpin family E member 1	Rattus norvegicus	159-164
23404530-6	2013	In addition, the NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC), and the AP-1 inhibitor, SP600125, decreased the protein levels of FN, collagen I and PAI-1, suggesting a role for the NF-kappaB and AP-1 pathways in the regulation of ECM accumulation induced by HG in RPMCs.	pyrazolanthrone	98-106	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	206-210
23467542-7	2013	SB203580/SP600125 or U0126/SP600125, but not SB203580/U0126, could reduce the phosphorylation of c-Jun/AP-1.	pyrazolanthrone	27-35	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
23490067-5	2013	Furthermore, activation of extracellular-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) by TPA+AA was identified in HL-60 cells, and the ERK inhibitor, PD98059, but not the JNK inhibitor, SP600125, inhibited TPA+AA-induced NBT-positive cells.	pyrazolanthrone	198-206	mitogen-activated protein kinase 1	Homo sapiens	59-62
23490067-5	2013	Furthermore, activation of extracellular-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) by TPA+AA was identified in HL-60 cells, and the ERK inhibitor, PD98059, but not the JNK inhibitor, SP600125, inhibited TPA+AA-induced NBT-positive cells.	pyrazolanthrone	198-206	mitogen-activated protein kinase 8	Homo sapiens	93-96
23376356-5	2013	The pharmacological inhibitors SB203580 (p38 inhibitor) and SP600125 (a JNK inhibitor) protected primary cultures of rat CGCs from LY294002-induced apoptosis.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Rattus norvegicus	72-75
23467542-7	2013	SB203580/SP600125 or U0126/SP600125, but not SB203580/U0126, could reduce the phosphorylation of c-Jun/AP-1.	pyrazolanthrone	27-35	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
23429506-6	2013	AG14361 was also applied to p53 and Bax knockout cultures and mice and combined with the JNK inhibitor SP600125.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Mus musculus	89-92
23519123-9	2013	In addition, inhibitors of JNK (SP600125) and SP1 (mithramycin A) completely abrogated induction of CYP2E1 by ethanol in SVGA astrocytes.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	27-30
23429506-12	2013	AG14361 and p53 knockout elicited additive effects with SP600125 on viability in vitro.	pyrazolanthrone	56-64	transformation related protein 53, pseudogene	Mus musculus	12-15
23467542-6	2013	Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB.	pyrazolanthrone	71-79	nuclear factor kappa B subunit 1	Homo sapiens	128-137
23467542-6	2013	Combination of any two inhibitors of MAPKs (SB203580/U0126 or SB203580/SP600125 or U0126/SP600125) could decrease activation of NF-kappaB.	pyrazolanthrone	89-97	nuclear factor kappa B subunit 1	Homo sapiens	128-137
23467542-7	2013	SB203580/SP600125 or U0126/SP600125, but not SB203580/U0126, could reduce the phosphorylation of c-Jun/AP-1.	pyrazolanthrone	9-17	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
23370001-8	2013	The p-ERK and p-JNK production were attenuated by their respective inhibitors (PD98059 and SP600125), as well as LXA4.	pyrazolanthrone	91-99	mitogen-activated protein kinase 1	Mus musculus	6-9
23370001-8	2013	The p-ERK and p-JNK production were attenuated by their respective inhibitors (PD98059 and SP600125), as well as LXA4.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Mus musculus	16-19
23467542-7	2013	SB203580/SP600125 or U0126/SP600125, but not SB203580/U0126, could reduce the phosphorylation of c-Jun/AP-1.	pyrazolanthrone	9-17	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	103-107
23595304-1	2013	OBJECTIVE: To study the role of c-jun N-terminal kinase (JNK) signaling pathway in chondrocyte apoptosis induced by nitric oxide (NO) using NO donor sodium nitroprusside (SNP) and JNK inhibitor SP600125.	pyrazolanthrone	194-202	mitogen-activated protein kinase 8	Homo sapiens	57-60
23595304-5	2013	JNK inhibitor SP600125 can reduce NO-induced apoptosis and expression of NF-kappaB p65 and p53 in articular chondrocytes of rabbits in a concentration-dependent manner.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
23485457-5	2013	The MAPK pathway inhibitor U0126, inhibitor of MEK1/2 had the same effect, however inhibition of c-Jun and JNK1,2,3 with SP600125 did not lead to down-regulation.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	107-111
23519123-9	2013	In addition, inhibitors of JNK (SP600125) and SP1 (mithramycin A) completely abrogated induction of CYP2E1 by ethanol in SVGA astrocytes.	pyrazolanthrone	32-40	cytochrome P450 family 2 subfamily E member 1	Homo sapiens	100-106
23422267-10	2013	Inhibition of JNK with SP600125 induced apoptosis and reduced level of basal and BCR-induced expression of EGR-1.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	14-17
23363008-7	2013	The employment of protein kinase inhibitors LY294002, SB203580, SP600125, and U0126 revealed that PI3K/Akt signaling pathway interplayed with MAPK signaling pathways.	pyrazolanthrone	64-72	AKT serine/threonine kinase 1	Homo sapiens	103-106
23220262-8	2013	Inhibition of c-Jun NH(2)-terminal kinase (JNK) with SP600125 partially rescued H(2)O(2)-induced apoptosis in WKY but not in SHR cells.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Rattus norvegicus	14-41
23220262-8	2013	Inhibition of c-Jun NH(2)-terminal kinase (JNK) with SP600125 partially rescued H(2)O(2)-induced apoptosis in WKY but not in SHR cells.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Rattus norvegicus	43-46
23220614-7	2013	While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.	pyrazolanthrone	6-14	mitogen-activated protein kinase 8	Homo sapiens	18-21
23363008-7	2013	The employment of protein kinase inhibitors LY294002, SB203580, SP600125, and U0126 revealed that PI3K/Akt signaling pathway interplayed with MAPK signaling pathways.	pyrazolanthrone	64-72	mitogen-activated protein kinase 3	Homo sapiens	142-146
23422267-10	2013	Inhibition of JNK with SP600125 induced apoptosis and reduced level of basal and BCR-induced expression of EGR-1.	pyrazolanthrone	23-31	early growth response 1	Homo sapiens	107-112
23348227-6	2013	The antioxidant effects of lancemaside A and SP600125 appear to be related with an increase of hemeoxygenase-1 expression by both agents.	pyrazolanthrone	45-53	heme oxygenase 1	Mus musculus	95-110
23394457-7	2013	The function of JNK was compromised by JNK siRNA or JNK inhibitor SP600125.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	16-19
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	pyrazolanthrone	202-210	mitogen-activated protein kinase kinase 1	Homo sapiens	56-60
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	pyrazolanthrone	202-210	mitogen-activated protein kinase 8	Homo sapiens	65-68
23237828-6	2013	While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.	pyrazolanthrone	202-210	mitogen-activated protein kinase 8	Homo sapiens	188-191
23394457-13	2013	Blockade of JNK signaling pathway by JNK specific inhibitor SP600125 enhanced apoptosis and hirsutanol A-induced ROS accumulation.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	12-15
23394457-13	2013	Blockade of JNK signaling pathway by JNK specific inhibitor SP600125 enhanced apoptosis and hirsutanol A-induced ROS accumulation.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	37-40
23428975-12	2013	Furthermore, Cav-1 increased proMMP-1 and VEGF secretion in HGFs, and the VEGF secretion was statistically suppressed by JNK inhibitor SP600125, but not ERK inhibitor PD98059.	pyrazolanthrone	135-143	caveolin 1	Homo sapiens	13-18
23376055-8	2013	TGF-beta1-induced EMT occurred through phosphorylation of p38 MAPK and JNK and was inhibited by inhibitor SB-203580 and SP-600125 and gene silencing.	pyrazolanthrone	120-129	transforming growth factor beta 1	Homo sapiens	0-9
23376055-8	2013	TGF-beta1-induced EMT occurred through phosphorylation of p38 MAPK and JNK and was inhibited by inhibitor SB-203580 and SP-600125 and gene silencing.	pyrazolanthrone	120-129	mitogen-activated protein kinase 14	Homo sapiens	58-61
23376055-8	2013	TGF-beta1-induced EMT occurred through phosphorylation of p38 MAPK and JNK and was inhibited by inhibitor SB-203580 and SP-600125 and gene silencing.	pyrazolanthrone	120-129	mitogen-activated protein kinase 8	Homo sapiens	71-74
23428975-12	2013	Furthermore, Cav-1 increased proMMP-1 and VEGF secretion in HGFs, and the VEGF secretion was statistically suppressed by JNK inhibitor SP600125, but not ERK inhibitor PD98059.	pyrazolanthrone	135-143	vascular endothelial growth factor A	Homo sapiens	74-78
23428975-12	2013	Furthermore, Cav-1 increased proMMP-1 and VEGF secretion in HGFs, and the VEGF secretion was statistically suppressed by JNK inhibitor SP600125, but not ERK inhibitor PD98059.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	121-124
22990021-6	2013	PFOS exposure selectively increased activation of ERK that remained above control over 6 h. The inhibitor of ERK pathway, PD98059, substantially blocked caspase-3 activation induced by PFOS, whereas inhibitors of JNK and p38 MAPK, SP600125 and SB203580, respectively, had no effect.	pyrazolanthrone	231-239	mitogen-activated protein kinase 1	Homo sapiens	50-53
22990021-6	2013	PFOS exposure selectively increased activation of ERK that remained above control over 6 h. The inhibitor of ERK pathway, PD98059, substantially blocked caspase-3 activation induced by PFOS, whereas inhibitors of JNK and p38 MAPK, SP600125 and SB203580, respectively, had no effect.	pyrazolanthrone	231-239	mitogen-activated protein kinase 1	Homo sapiens	109-112
22990021-6	2013	PFOS exposure selectively increased activation of ERK that remained above control over 6 h. The inhibitor of ERK pathway, PD98059, substantially blocked caspase-3 activation induced by PFOS, whereas inhibitors of JNK and p38 MAPK, SP600125 and SB203580, respectively, had no effect.	pyrazolanthrone	231-239	caspase 3	Homo sapiens	153-162
23370368-9	2013	The results indicated that the rErdr1 inhibited migration was primarily reversed by SP600125, a JNK inhibitor.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	96-99
23261760-5	2013	TGF-beta1 enhanced glioma-induced angiogenesis, which was inhibited by JNK inhibitor SP600125 but not p38 MAPK inhibitor SB202190, ERK inhibitor PD98059, or PI3K inhibitor LY294002, indicating the important role of TGF-beta1 and JNK pathways in this process.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8b	Danio rerio	71-74
22733377-5	2013	The addition of a JNK inhibitor, SP600125, partially reversed GUTK-induced caspase-3 activity, indicating the possible involvement of JNK in GUTK-induced apoptosis.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	18-21
22733377-5	2013	The addition of a JNK inhibitor, SP600125, partially reversed GUTK-induced caspase-3 activity, indicating the possible involvement of JNK in GUTK-induced apoptosis.	pyrazolanthrone	33-41	caspase 3	Homo sapiens	75-84
22733377-5	2013	The addition of a JNK inhibitor, SP600125, partially reversed GUTK-induced caspase-3 activity, indicating the possible involvement of JNK in GUTK-induced apoptosis.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	134-137
23261760-5	2013	TGF-beta1 enhanced glioma-induced angiogenesis, which was inhibited by JNK inhibitor SP600125 but not p38 MAPK inhibitor SB202190, ERK inhibitor PD98059, or PI3K inhibitor LY294002, indicating the important role of TGF-beta1 and JNK pathways in this process.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8b	Danio rerio	229-232
23142567-2	2013	We describe here the binding of quercetagetin (3,3",4",5,6,7-hydroxyflavone), related flavonoids, and SP600125 to JNK1 and PI3-K by ATP-competitive and immobilized metal ion affinity-based fluorescence polarization assays and measure the effect of quercetagetin on JNK1 and PI3-K activities.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Mus musculus	114-118
22706709-2	2013	Herein, we examine the effect of the JNK specific inhibitor, SP600125, on the level of functional proteins or transcription factors related to endoplasmic reticulum (ER) and oxidative stress induced by amyloid beta (Abeta).	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
22706709-2	2013	Herein, we examine the effect of the JNK specific inhibitor, SP600125, on the level of functional proteins or transcription factors related to endoplasmic reticulum (ER) and oxidative stress induced by amyloid beta (Abeta).	pyrazolanthrone	61-69	amyloid beta precursor protein	Rattus norvegicus	216-221
22706709-3	2013	Our results clearly showed the ability of SP600125 to decrease the levels of caspase 12 and calpain 2, two important enzymes involved in ER stress.	pyrazolanthrone	42-50	caspase 12	Rattus norvegicus	77-87
22706709-3	2013	Our results clearly showed the ability of SP600125 to decrease the levels of caspase 12 and calpain 2, two important enzymes involved in ER stress.	pyrazolanthrone	42-50	calpain 2	Rattus norvegicus	92-101
22706709-9	2013	Also, we observed that pretreatment with SP600125 leads to a greater increase of nuclear related factor-2 (Nrf2) level compared with the Abeta-injected group.	pyrazolanthrone	41-49	NFE2 like bZIP transcription factor 2	Rattus norvegicus	81-105
22706709-9	2013	Also, we observed that pretreatment with SP600125 leads to a greater increase of nuclear related factor-2 (Nrf2) level compared with the Abeta-injected group.	pyrazolanthrone	41-49	NFE2 like bZIP transcription factor 2	Rattus norvegicus	107-111
22706709-9	2013	Also, we observed that pretreatment with SP600125 leads to a greater increase of nuclear related factor-2 (Nrf2) level compared with the Abeta-injected group.	pyrazolanthrone	41-49	amyloid beta precursor protein	Rattus norvegicus	137-142
23069681-0	2013	A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Mus musculus	25-28
23069681-8	2013	SP600125 and BB-94 were used to inhibit JNK and MMPs respectively.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	40-43
23069681-8	2013	SP600125 and BB-94 were used to inhibit JNK and MMPs respectively.	pyrazolanthrone	0-8	matrix metallopeptidase 9	Mus musculus	48-52
23184810-7	2013	In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	17-20
23184810-7	2013	In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway.	pyrazolanthrone	32-40	tumor necrosis factor	Homo sapiens	87-90
23184810-7	2013	In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway.	pyrazolanthrone	32-40	ribosomal protein S6 kinase B1	Homo sapiens	113-122
23184810-7	2013	In addition, the JNK antagonist SP600125, but not the p38 inhibitor SB203580, prevents TNF-induced activation of S6 kinase, suggesting that pentoxifylline and propentofylline may regulate mTORC activity in spinal astrocytes partially through inhibition of the JNK pathway.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	260-263
23175437-4	2013	The expression change of c-Jun following treatment with brucine or brucine plus the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 was detected using RT-PCR.	pyrazolanthrone	133-141	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	25-30
23175437-4	2013	The expression change of c-Jun following treatment with brucine or brucine plus the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 was detected using RT-PCR.	pyrazolanthrone	133-141	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	84-89
23175437-4	2013	The expression change of c-Jun following treatment with brucine or brucine plus the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 was detected using RT-PCR.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Homo sapiens	109-112
23142567-2	2013	We describe here the binding of quercetagetin (3,3",4",5,6,7-hydroxyflavone), related flavonoids, and SP600125 to JNK1 and PI3-K by ATP-competitive and immobilized metal ion affinity-based fluorescence polarization assays and measure the effect of quercetagetin on JNK1 and PI3-K activities.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Mus musculus	265-269
23223444-5	2013	Inhibition of JNK signaling either by a JNK inhibitor, SP600125, or expression of a dominant negative form of MKK4, a JNK upstream activator, blocked Netrin-1-induced JNK1 activation in HEK293 cells.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	14-17
23223444-5	2013	Inhibition of JNK signaling either by a JNK inhibitor, SP600125, or expression of a dominant negative form of MKK4, a JNK upstream activator, blocked Netrin-1-induced JNK1 activation in HEK293 cells.	pyrazolanthrone	55-63	netrin 1	Homo sapiens	150-158
23983799-6	2013	Moreover, REM promoted phosphorylation of c-Jun NH2-terminal kinase 1/2 (JNK1/2) and JNK1/2 inhibitor, SP600125 and rescued REM inhibition of both MDR1 expression and viabilities in MCF-7/Dox cells.	pyrazolanthrone	103-111	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	42-47
23211822-7	2013	U0126, SB203580, and SP600125 were used to disrupt ERK-, p38-, and JNK-mediated signaling, respectively.	pyrazolanthrone	21-29	mitogen-activated protein kinase 1	Homo sapiens	51-54
23211822-7	2013	U0126, SB203580, and SP600125 were used to disrupt ERK-, p38-, and JNK-mediated signaling, respectively.	pyrazolanthrone	21-29	mitogen-activated protein kinase 14	Homo sapiens	57-60
23211822-7	2013	U0126, SB203580, and SP600125 were used to disrupt ERK-, p38-, and JNK-mediated signaling, respectively.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	67-70
22985747-8	2013	Also, the JNK inhibitor SP600125 and p38 inhibitor SB203580 reduced RANKL-induced expressions of phospho-c-Jun, c-fos and NFATc1 genes during osteoclast development.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Mus musculus	10-13
22985747-8	2013	Also, the JNK inhibitor SP600125 and p38 inhibitor SB203580 reduced RANKL-induced expressions of phospho-c-Jun, c-fos and NFATc1 genes during osteoclast development.	pyrazolanthrone	24-32	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	68-73
22985747-8	2013	Also, the JNK inhibitor SP600125 and p38 inhibitor SB203580 reduced RANKL-induced expressions of phospho-c-Jun, c-fos and NFATc1 genes during osteoclast development.	pyrazolanthrone	24-32	jun proto-oncogene	Mus musculus	105-110
22985747-8	2013	Also, the JNK inhibitor SP600125 and p38 inhibitor SB203580 reduced RANKL-induced expressions of phospho-c-Jun, c-fos and NFATc1 genes during osteoclast development.	pyrazolanthrone	24-32	FBJ osteosarcoma oncogene	Mus musculus	112-117
22985747-8	2013	Also, the JNK inhibitor SP600125 and p38 inhibitor SB203580 reduced RANKL-induced expressions of phospho-c-Jun, c-fos and NFATc1 genes during osteoclast development.	pyrazolanthrone	24-32	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	122-128
24217648-8	2013	The specific inhibitors for p38 (SB203580) and JNK (SP600125) may abolish doxorubicin-induced apoptosis of BMSCs but the specific ERK inhibitor (PD98059) not, indicating p38 and JNK activation contribute to BMSCs apoptosis.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	47-50
24217650-6	2013	Moreover, PGN markedly induced the expression and activity of CHIP in macrophages, whereas this effect was attenuated by SP600125, a selective inhibitor of JNK.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Mus musculus	156-159
23026374-8	2013	Inhibition of JNK by SP600125 significantly reduced tau hyperphosphorylation in neurons treated with morphine.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
23200840-4	2013	The expression of ABCA1 is up-regulated by treatment with oxLig-1in J774A.1 cells, and the increased expression of ABCA1 is dramatically down-regulated by pretreatment with pharmacological inhibitors of ERK (PD98059) and JNK (SP600125).	pyrazolanthrone	226-234	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	18-23
23200840-4	2013	The expression of ABCA1 is up-regulated by treatment with oxLig-1in J774A.1 cells, and the increased expression of ABCA1 is dramatically down-regulated by pretreatment with pharmacological inhibitors of ERK (PD98059) and JNK (SP600125).	pyrazolanthrone	226-234	ATP-binding cassette, sub-family A (ABC1), member 1	Mus musculus	115-120
23200840-4	2013	The expression of ABCA1 is up-regulated by treatment with oxLig-1in J774A.1 cells, and the increased expression of ABCA1 is dramatically down-regulated by pretreatment with pharmacological inhibitors of ERK (PD98059) and JNK (SP600125).	pyrazolanthrone	226-234	mitogen-activated protein kinase 1	Mus musculus	203-206
23054609-6	2013	We also found that Wnt5a-conditioned medium stimulated phosphorylation of c-jun N-terminal kinase (JNK) and c-Jun, and JNK inhibitor SP600125 blocked Wnt5a-induced CXCR4 expression and cell migration in SFRP5-negative cells.	pyrazolanthrone	133-141	Wnt family member 5A	Homo sapiens	19-24
23054609-6	2013	We also found that Wnt5a-conditioned medium stimulated phosphorylation of c-jun N-terminal kinase (JNK) and c-Jun, and JNK inhibitor SP600125 blocked Wnt5a-induced CXCR4 expression and cell migration in SFRP5-negative cells.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Homo sapiens	99-102
23054609-6	2013	We also found that Wnt5a-conditioned medium stimulated phosphorylation of c-jun N-terminal kinase (JNK) and c-Jun, and JNK inhibitor SP600125 blocked Wnt5a-induced CXCR4 expression and cell migration in SFRP5-negative cells.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Homo sapiens	119-122
23054609-6	2013	We also found that Wnt5a-conditioned medium stimulated phosphorylation of c-jun N-terminal kinase (JNK) and c-Jun, and JNK inhibitor SP600125 blocked Wnt5a-induced CXCR4 expression and cell migration in SFRP5-negative cells.	pyrazolanthrone	133-141	Wnt family member 5A	Homo sapiens	150-155
23054609-6	2013	We also found that Wnt5a-conditioned medium stimulated phosphorylation of c-jun N-terminal kinase (JNK) and c-Jun, and JNK inhibitor SP600125 blocked Wnt5a-induced CXCR4 expression and cell migration in SFRP5-negative cells.	pyrazolanthrone	133-141	C-X-C motif chemokine receptor 4	Homo sapiens	164-169
23054609-6	2013	We also found that Wnt5a-conditioned medium stimulated phosphorylation of c-jun N-terminal kinase (JNK) and c-Jun, and JNK inhibitor SP600125 blocked Wnt5a-induced CXCR4 expression and cell migration in SFRP5-negative cells.	pyrazolanthrone	133-141	secreted frizzled related protein 5	Homo sapiens	203-208
23983799-6	2013	Moreover, REM promoted phosphorylation of c-Jun NH2-terminal kinase 1/2 (JNK1/2) and JNK1/2 inhibitor, SP600125 and rescued REM inhibition of both MDR1 expression and viabilities in MCF-7/Dox cells.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	85-91
23983799-6	2013	Moreover, REM promoted phosphorylation of c-Jun NH2-terminal kinase 1/2 (JNK1/2) and JNK1/2 inhibitor, SP600125 and rescued REM inhibition of both MDR1 expression and viabilities in MCF-7/Dox cells.	pyrazolanthrone	103-111	ATP binding cassette subfamily B member 1	Homo sapiens	147-151
23258237-6	2013	Inhibitors of JNK (SP600125, 5 microM) or ERK1/2 (PD98059, 5 microM) significantly inhibited TNF-alpha-stimulated cell survival, contraction of collagen gels, and wound closure.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	14-17
21751222-0	2013	Exposure to the JNK inhibitor SP600125 (anthrapyrazolone) during early zebrafish development results in morphological defects.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8b	Danio rerio	16-19
21751222-1	2013	SP600125 (anthrapyrazolone) is a synthetic polyaromatic chemical that inhibits c-Jun N-terminal kinase (JNK) signaling by interfering with phosphorylation of c-Jun.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8b	Danio rerio	79-102
21751222-1	2013	SP600125 (anthrapyrazolone) is a synthetic polyaromatic chemical that inhibits c-Jun N-terminal kinase (JNK) signaling by interfering with phosphorylation of c-Jun.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8b	Danio rerio	104-107
21751222-1	2013	SP600125 (anthrapyrazolone) is a synthetic polyaromatic chemical that inhibits c-Jun N-terminal kinase (JNK) signaling by interfering with phosphorylation of c-Jun.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Danio rerio	79-84
23278900-5	2013	The treatment with LY294002, SP600125 or U0126 hindered the tension-induced TGFbeta2 upregulation, although the increase in NGF was regulated only by SP600125 or U0126, indicating the involvement of three signalling kinase pathways in the upregulation of TGFbeta2.	pyrazolanthrone	29-37	transforming growth factor beta 2	Homo sapiens	76-84
23278900-5	2013	The treatment with LY294002, SP600125 or U0126 hindered the tension-induced TGFbeta2 upregulation, although the increase in NGF was regulated only by SP600125 or U0126, indicating the involvement of three signalling kinase pathways in the upregulation of TGFbeta2.	pyrazolanthrone	150-158	nerve growth factor	Homo sapiens	124-127
23533505-6	2013	Inhibition of JNK using pharmacologic inhibitor (SP600125) and genetic knockdown (JNK specific siRNA) significantly inhibited p53 accumulation, reduced PUMA and Fas expression, and abolished apoptosis induced by gallic acid.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Mus musculus	14-17
23533505-6	2013	Inhibition of JNK using pharmacologic inhibitor (SP600125) and genetic knockdown (JNK specific siRNA) significantly inhibited p53 accumulation, reduced PUMA and Fas expression, and abolished apoptosis induced by gallic acid.	pyrazolanthrone	49-57	transformation related protein 53, pseudogene	Mus musculus	126-129
22833523-9	2013	Accordingly, EGFR, Src or Jnk inhibitors (AG1478, PP2, SP600125, respectively) abrogated Smk-induced MUC1-CT-TyrP, MUC1-CT/p120ctn interaction, AJ disruption, and loss of cellular polarity.	pyrazolanthrone	55-63	epidermal growth factor receptor	Homo sapiens	13-17
22833523-9	2013	Accordingly, EGFR, Src or Jnk inhibitors (AG1478, PP2, SP600125, respectively) abrogated Smk-induced MUC1-CT-TyrP, MUC1-CT/p120ctn interaction, AJ disruption, and loss of cellular polarity.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	26-29
22833523-9	2013	Accordingly, EGFR, Src or Jnk inhibitors (AG1478, PP2, SP600125, respectively) abrogated Smk-induced MUC1-CT-TyrP, MUC1-CT/p120ctn interaction, AJ disruption, and loss of cellular polarity.	pyrazolanthrone	55-63	mucin 1, cell surface associated	Homo sapiens	101-105
22833523-9	2013	Accordingly, EGFR, Src or Jnk inhibitors (AG1478, PP2, SP600125, respectively) abrogated Smk-induced MUC1-CT-TyrP, MUC1-CT/p120ctn interaction, AJ disruption, and loss of cellular polarity.	pyrazolanthrone	55-63	mucin 1, cell surface associated	Homo sapiens	115-119
22833523-9	2013	Accordingly, EGFR, Src or Jnk inhibitors (AG1478, PP2, SP600125, respectively) abrogated Smk-induced MUC1-CT-TyrP, MUC1-CT/p120ctn interaction, AJ disruption, and loss of cellular polarity.	pyrazolanthrone	55-63	catenin delta 1	Homo sapiens	123-130
22847537-8	2013	We show that locally administered MAPK/JNK inhibitor SP600125 and calcineurin/NFAT inhibitor cyclosporine-A effectively blocked PMMA-induced osteolysis in murine calvaria.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Mus musculus	39-42
23258237-6	2013	Inhibitors of JNK (SP600125, 5 microM) or ERK1/2 (PD98059, 5 microM) significantly inhibited TNF-alpha-stimulated cell survival, contraction of collagen gels, and wound closure.	pyrazolanthrone	19-27	tumor necrosis factor	Homo sapiens	93-102
22916958-3	2012	Importantly, insulin-stimulated glucose transport activity in the presence of H(2)O(2) was moderately improved with the selective JNK inhibitor SP600125.	pyrazolanthrone	144-152	insulin	Homo sapiens	13-20
24072958-5	2013	We found that fluoride increased JNK phosphorylation level of BV-2 cells and pretreatment with JNK inhibitor SP600125 markedly reduced the levels of intracellular O2( -) and NO.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Mus musculus	33-36
24072958-5	2013	We found that fluoride increased JNK phosphorylation level of BV-2 cells and pretreatment with JNK inhibitor SP600125 markedly reduced the levels of intracellular O2( -) and NO.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Mus musculus	95-98
23505448-5	2013	IL-1beta-induced pro-MMP-9 expression and MMP-9 mRNA levels were attenuated by pretreatment with the inhibitor of MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (Bay11-7082), or AP-1 (Tanshinone IIA) and transfection with siRNA of p42 or JNK2.	pyrazolanthrone	138-146	interleukin-1 beta	Oryctolagus cuniculus	0-8
23505448-5	2013	IL-1beta-induced pro-MMP-9 expression and MMP-9 mRNA levels were attenuated by pretreatment with the inhibitor of MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (Bay11-7082), or AP-1 (Tanshinone IIA) and transfection with siRNA of p42 or JNK2.	pyrazolanthrone	138-146	matrix metalloproteinase-9	Oryctolagus cuniculus	21-26
23505448-5	2013	IL-1beta-induced pro-MMP-9 expression and MMP-9 mRNA levels were attenuated by pretreatment with the inhibitor of MEK1/2 (U0126), JNK1/2 (SP600125), NF-kappaB (Bay11-7082), or AP-1 (Tanshinone IIA) and transfection with siRNA of p42 or JNK2.	pyrazolanthrone	138-146	matrix metalloproteinase-9	Oryctolagus cuniculus	42-47
23505448-10	2013	Pretreatment with U0126 or SP600125 inhibited IL-1beta-induced AP-1 and NF-kappaB promoter activity, but not NF-kappaB translocation from the cytosol into the nucleus.	pyrazolanthrone	27-35	interleukin-1 beta	Oryctolagus cuniculus	46-54
23405080-8	2013	Additionally, the specific JNK inhibitor SP600125 or JNK-specific small interference RNA (si-RNA) transfection suppressed Cd-induced beta-cell apoptosis and related signals, but not ERK1/2 and p38-MAPK inhibitors (PD98059 and SB203580) did not.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	27-30
23123629-8	2012	A combined treatment of SB203580 and SP600125 showed increased effects on the inhibition of Taiwanin A cytotoxicity, suggesting that both JNK and p38 play a role in Taiwanin A-induced apoptosis.	pyrazolanthrone	37-45	mitogen-activated protein kinase 1	Homo sapiens	146-149
23123629-11	2012	In addition, inhibition of JNK by SP600125 or silencing of the JNK scaffold protein JIP2 reduced phosphorylation of Bcl-2, which may help to promote anti-apoptotic pathways.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	27-30
23123629-11	2012	In addition, inhibition of JNK by SP600125 or silencing of the JNK scaffold protein JIP2 reduced phosphorylation of Bcl-2, which may help to promote anti-apoptotic pathways.	pyrazolanthrone	34-42	BCL2 apoptosis regulator	Homo sapiens	116-121
22982536-9	2012	Moreover, pharmacological inhibition of JNK by SP600125 or dominant-negative blockade of PERK-mediated eIF2alpha phosphorylation impaired prodigiosin-induced CHOP up-regulation and PARP cleavage.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	40-43
23064724-13	2012	Intravenous administration of SP600125, a selective phospho-JNK inhibitor (0.5 mg/kg), attenuated HMGB1-dependent Bax translocation and the subsequent apoptosis.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	60-63
23064724-13	2012	Intravenous administration of SP600125, a selective phospho-JNK inhibitor (0.5 mg/kg), attenuated HMGB1-dependent Bax translocation and the subsequent apoptosis.	pyrazolanthrone	30-38	high mobility group box 1	Rattus norvegicus	98-103
23064724-13	2012	Intravenous administration of SP600125, a selective phospho-JNK inhibitor (0.5 mg/kg), attenuated HMGB1-dependent Bax translocation and the subsequent apoptosis.	pyrazolanthrone	30-38	BCL2 associated X, apoptosis regulator	Rattus norvegicus	114-117
23007278-8	2012	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the SVT and TRAIL-induced upregulation of DR4 and DR5 expression, expression of the apoptosis related protein such as caspase-3 and-9, as well as cell growth inhibitory effects.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	22-45
23007278-8	2012	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the SVT and TRAIL-induced upregulation of DR4 and DR5 expression, expression of the apoptosis related protein such as caspase-3 and-9, as well as cell growth inhibitory effects.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	47-50
23007278-8	2012	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the SVT and TRAIL-induced upregulation of DR4 and DR5 expression, expression of the apoptosis related protein such as caspase-3 and-9, as well as cell growth inhibitory effects.	pyrazolanthrone	62-70	TNF superfamily member 10	Homo sapiens	156-161
23007278-8	2012	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the SVT and TRAIL-induced upregulation of DR4 and DR5 expression, expression of the apoptosis related protein such as caspase-3 and-9, as well as cell growth inhibitory effects.	pyrazolanthrone	62-70	TNF receptor superfamily member 10a	Homo sapiens	186-189
23007278-8	2012	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the SVT and TRAIL-induced upregulation of DR4 and DR5 expression, expression of the apoptosis related protein such as caspase-3 and-9, as well as cell growth inhibitory effects.	pyrazolanthrone	62-70	TNF receptor superfamily member 10b	Homo sapiens	194-197
23007278-8	2012	Pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the reactive oxygen species (ROS) scavenger N-acetylcysteine reduced the SVT and TRAIL-induced upregulation of DR4 and DR5 expression, expression of the apoptosis related protein such as caspase-3 and-9, as well as cell growth inhibitory effects.	pyrazolanthrone	62-70	caspase 3	Homo sapiens	262-277
23067223-8	2013	The activation of p38 and JNK could be blocked by respective inhibitors (SB203580 for p38 and SP600125 for JNK) accompanied with the inhibition of apoptosis and changes of apoptosis associated proteins in CEM-C1 cells.	pyrazolanthrone	94-102	mitogen-activated protein kinase 14	Homo sapiens	18-21
23067223-8	2013	The activation of p38 and JNK could be blocked by respective inhibitors (SB203580 for p38 and SP600125 for JNK) accompanied with the inhibition of apoptosis and changes of apoptosis associated proteins in CEM-C1 cells.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	26-29
23067223-8	2013	The activation of p38 and JNK could be blocked by respective inhibitors (SB203580 for p38 and SP600125 for JNK) accompanied with the inhibition of apoptosis and changes of apoptosis associated proteins in CEM-C1 cells.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	107-110
22452662-8	2013	In vitro, heat stress caused damage and apoptosis in IEC-6 cells; inhibition of ERK1/2 activation (by U0126) exacerbated these effects, which were attenuated by inhibition of JNK (by SP600125) and p38 (by SB203580) activation.	pyrazolanthrone	183-191	mitogen-activated protein kinase 8	Rattus norvegicus	175-178
23326144-13	2012	Furthermore, the JNK specific inhibitor, SP600125, suppressed p-JNK, Bax and caspase-3 at the protein level in SGC790l cells following thermotherapy, compared to mock-inhibitor treatment, which was in line with the decreased rate of apoptosis.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	17-20
23326144-13	2012	Furthermore, the JNK specific inhibitor, SP600125, suppressed p-JNK, Bax and caspase-3 at the protein level in SGC790l cells following thermotherapy, compared to mock-inhibitor treatment, which was in line with the decreased rate of apoptosis.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	64-67
23326144-13	2012	Furthermore, the JNK specific inhibitor, SP600125, suppressed p-JNK, Bax and caspase-3 at the protein level in SGC790l cells following thermotherapy, compared to mock-inhibitor treatment, which was in line with the decreased rate of apoptosis.	pyrazolanthrone	41-49	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
23326144-13	2012	Furthermore, the JNK specific inhibitor, SP600125, suppressed p-JNK, Bax and caspase-3 at the protein level in SGC790l cells following thermotherapy, compared to mock-inhibitor treatment, which was in line with the decreased rate of apoptosis.	pyrazolanthrone	41-49	caspase 3	Homo sapiens	77-86
23123629-7	2012	Cytotoxicity was blocked by the p38 MAPK inhibitor SB203580 and the JNK inhibitor SP600125 but not by the ERK inhibitor PD98059.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	68-71
23123629-8	2012	A combined treatment of SB203580 and SP600125 showed increased effects on the inhibition of Taiwanin A cytotoxicity, suggesting that both JNK and p38 play a role in Taiwanin A-induced apoptosis.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	138-141
22916958-3	2012	Importantly, insulin-stimulated glucose transport activity in the presence of H(2)O(2) was moderately improved with the selective JNK inhibitor SP600125.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Rattus norvegicus	130-133
22940540-8	2012	Be similar to the effects of GL, SP600125, U0126 and LY29400225, however not SB203580, also inhibited ConA-induced CD4(+)T cell proliferation, indicating the involvement of JNK, ERK and PI3K/AKT in this process.	pyrazolanthrone	33-41	CD4 antigen	Mus musculus	115-118
22925536-4	2012	Inhibition of ERK MAP kinase by PD98059 abolished the early and rapid induction of PPARgamma, while the inhibition of JNK MAP kinase by SP600125 nullifies the late inhibitory effect on the PPARgamma expression in a dose-dependent manner.	pyrazolanthrone	136-144	peroxisome proliferator activated receptor gamma	Mus musculus	189-198
22933112-5	2012	Inhibition of either p38 with SB203580 or JNK with SP600125 reduced superoxide production and improved shear stress-induced dilation (SSID) in 3M, but not in 9M, diabetic mice.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Mus musculus	42-45
23271287-13	2012	Finally, the pretreatment of SP600125, but not PD98059, alleviated the increase of Cu(2+)/Zn(2+)-SOD and GSH-Px mRNAs induced by MPP(+), suggesting that the activation of the JNK signal pathway, but not the ERK1/2 signal pathway, could, in some degree, antagonize the generation of ROS induced by oxidative stress.	pyrazolanthrone	29-37	glutathione peroxidase 1	Rattus norvegicus	105-111
23271287-13	2012	Finally, the pretreatment of SP600125, but not PD98059, alleviated the increase of Cu(2+)/Zn(2+)-SOD and GSH-Px mRNAs induced by MPP(+), suggesting that the activation of the JNK signal pathway, but not the ERK1/2 signal pathway, could, in some degree, antagonize the generation of ROS induced by oxidative stress.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Rattus norvegicus	175-178
23271287-10	2012	The pretreatment of SP600125 or PD98059 could effectively reduce the apoptosis rate by reducing the ratio of Bax/Bcl-2 mRNA levels.	pyrazolanthrone	20-28	BCL2 associated X, apoptosis regulator	Rattus norvegicus	109-112
23271287-10	2012	The pretreatment of SP600125 or PD98059 could effectively reduce the apoptosis rate by reducing the ratio of Bax/Bcl-2 mRNA levels.	pyrazolanthrone	20-28	BCL2, apoptosis regulator	Rattus norvegicus	113-118
23271287-13	2012	Finally, the pretreatment of SP600125, but not PD98059, alleviated the increase of Cu(2+)/Zn(2+)-SOD and GSH-Px mRNAs induced by MPP(+), suggesting that the activation of the JNK signal pathway, but not the ERK1/2 signal pathway, could, in some degree, antagonize the generation of ROS induced by oxidative stress.	pyrazolanthrone	29-37	mitogen activated protein kinase 3	Rattus norvegicus	207-213
22324466-9	2012	Pretreatment with antioxidant N-acetyl-l-cysteine, apoptosis signal-regulating kinase 1 (ASK1) inhibitor thioredoxin, and c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) significantly reduced thrombin-induced CCN2 expression in HGFs.	pyrazolanthrone	164-172	mitogen-activated protein kinase 8	Homo sapiens	149-152
22899172-9	2012	The TNFalpha-induced expression of MMP-9 was also affected by the JNK inhibitor SP600125.	pyrazolanthrone	80-88	tumor necrosis factor	Homo sapiens	4-12
22899172-9	2012	The TNFalpha-induced expression of MMP-9 was also affected by the JNK inhibitor SP600125.	pyrazolanthrone	80-88	matrix metallopeptidase 9	Homo sapiens	35-40
22899172-9	2012	The TNFalpha-induced expression of MMP-9 was also affected by the JNK inhibitor SP600125.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Homo sapiens	66-69
22981381-7	2012	DATS-induced apoptosis was blunted in MCF-7 cells treated with a specific JNK inhibitor SP600125 or transiently transfected with dominant negative JNK.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Homo sapiens	74-77
22750290-5	2012	Strikingly, the knockdown of ASK1 enhanced the sensitivity to pyrrolidinium fullerene derivative-induced apoptosis, and the treatment with a JNK inhibitor, SP600125, also induced apoptosis of the transformed cells by JAK2 V617F mutant.	pyrazolanthrone	156-164	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	29-33
23047827-6	2012	Upon using specific inhibitors of MEK1/2 (UO126, 10 muM), p38 (SB203580, 10 muM), or JNK (SP600125, 20 muM), we demonstrated that MEK, as well as JNK, but not p38, are involved in VLDL-induced macrophage PON2 upregulation.	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Homo sapiens	85-88
23047827-6	2012	Upon using specific inhibitors of MEK1/2 (UO126, 10 muM), p38 (SB203580, 10 muM), or JNK (SP600125, 20 muM), we demonstrated that MEK, as well as JNK, but not p38, are involved in VLDL-induced macrophage PON2 upregulation.	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Homo sapiens	146-149
23047827-6	2012	Upon using specific inhibitors of MEK1/2 (UO126, 10 muM), p38 (SB203580, 10 muM), or JNK (SP600125, 20 muM), we demonstrated that MEK, as well as JNK, but not p38, are involved in VLDL-induced macrophage PON2 upregulation.	pyrazolanthrone	90-98	mitogen-activated protein kinase 14	Homo sapiens	159-162
23047827-6	2012	Upon using specific inhibitors of MEK1/2 (UO126, 10 muM), p38 (SB203580, 10 muM), or JNK (SP600125, 20 muM), we demonstrated that MEK, as well as JNK, but not p38, are involved in VLDL-induced macrophage PON2 upregulation.	pyrazolanthrone	90-98	CD320 antigen	Mus musculus	180-184
23047827-6	2012	Upon using specific inhibitors of MEK1/2 (UO126, 10 muM), p38 (SB203580, 10 muM), or JNK (SP600125, 20 muM), we demonstrated that MEK, as well as JNK, but not p38, are involved in VLDL-induced macrophage PON2 upregulation.	pyrazolanthrone	90-98	paraoxonase 2	Homo sapiens	204-208
22972801-6	2012	Inhibition of c-Jun NH(2)-terminal kinase (JNK), a key mediator of lipoapoptosis, with SP600125 blocked pathophysiological ATP release in a dose-dependent manner.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	14-41
22972801-6	2012	Inhibition of c-Jun NH(2)-terminal kinase (JNK), a key mediator of lipoapoptosis, with SP600125 blocked pathophysiological ATP release in a dose-dependent manner.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	43-46
23203057-8	2012	A specific JNK inhibitor, SP600125, significantly blocked DADS-induced-apoptosis, whereas inhibitors of the ERK (PD98059) and p38 MAPK (SB203580) had no effect.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	11-14
22750290-5	2012	Strikingly, the knockdown of ASK1 enhanced the sensitivity to pyrrolidinium fullerene derivative-induced apoptosis, and the treatment with a JNK inhibitor, SP600125, also induced apoptosis of the transformed cells by JAK2 V617F mutant.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	141-144
22750290-5	2012	Strikingly, the knockdown of ASK1 enhanced the sensitivity to pyrrolidinium fullerene derivative-induced apoptosis, and the treatment with a JNK inhibitor, SP600125, also induced apoptosis of the transformed cells by JAK2 V617F mutant.	pyrazolanthrone	156-164	Janus kinase 2	Homo sapiens	217-221
22750290-6	2012	Furthermore, administration of both SP600125 and pyrrolidinium fullerene derivative markedly inhibited JAK2 V617F mutant-induced tumorigenesis in nude mice.	pyrazolanthrone	36-44	Janus kinase 2	Mus musculus	103-107
22881126-7	2012	Then after administration of ERK, JNK and P38 inhibitors, only JNK inhibitor SP600125 effectively augmented oridonin-induced apoptosis and ROS generation.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	63-66
23022184-5	2012	Furthermore, Bex2 down-regulation promotes cell apoptosis and activates the JNK pathway; these effects were abolished by administration of the JNK specific inhibitor, SP600125.	pyrazolanthrone	167-175	brain expressed X-linked 2	Homo sapiens	13-17
22791363-8	2012	NMDA-induced MIP-1alpha mRNA expression was partially but significantly inhibited by the c-Jun N-terminal kinase inhibitor SP600125; conversely, the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 enhanced it.	pyrazolanthrone	123-131	C-C motif chemokine ligand 3	Rattus norvegicus	13-23
23162652-6	2012	SP600125 (25 muM), a JNK blocker, inhibited the upregulation of AP-1 Luc and p21 Luc in the c-fos/c-jun transfected cells.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	21-24
23162652-6	2012	SP600125 (25 muM), a JNK blocker, inhibited the upregulation of AP-1 Luc and p21 Luc in the c-fos/c-jun transfected cells.	pyrazolanthrone	0-8	cyclin dependent kinase inhibitor 1A	Homo sapiens	77-80
23162652-6	2012	SP600125 (25 muM), a JNK blocker, inhibited the upregulation of AP-1 Luc and p21 Luc in the c-fos/c-jun transfected cells.	pyrazolanthrone	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	92-97
23162652-6	2012	SP600125 (25 muM), a JNK blocker, inhibited the upregulation of AP-1 Luc and p21 Luc in the c-fos/c-jun transfected cells.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	98-103
23210245-1	2012	SP600125 is a well studied inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	40-63
23210245-1	2012	SP600125 is a well studied inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	65-68
23210245-3	2012	In this study, we investigated the effects of SP600125 on JNK-inactive U251 human glioblastoma cells.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	58-61
22752116-4	2012	To inhibit activation of c-Jun-terminal kinase (JNK), we used a specific inhibitor, SP600125.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	25-46
22752116-4	2012	To inhibit activation of c-Jun-terminal kinase (JNK), we used a specific inhibitor, SP600125.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	48-51
22711527-8	2012	TNF-alpha-mediated AP-1-luciferase activity and c-Jun binding to the AP-1 element were inhibited by TNFR1 Ab, thioredoxin, SP600125, and SB203580.	pyrazolanthrone	123-131	tumor necrosis factor	Homo sapiens	0-9
22711527-8	2012	TNF-alpha-mediated AP-1-luciferase activity and c-Jun binding to the AP-1 element were inhibited by TNFR1 Ab, thioredoxin, SP600125, and SB203580.	pyrazolanthrone	123-131	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	48-53
22249269-5	2012	Importantly, blockade of JNK signaling with SP600125 or small interfering RNAs targeting JNK1 or JNK2 significantly reduced the CD133(+)/Nestin(+) population and suppressed sphere formation, colony formation in soft agar, and expression of stem cell markers in sphere-cultured glioma cells.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	25-28
22249269-5	2012	Importantly, blockade of JNK signaling with SP600125 or small interfering RNAs targeting JNK1 or JNK2 significantly reduced the CD133(+)/Nestin(+) population and suppressed sphere formation, colony formation in soft agar, and expression of stem cell markers in sphere-cultured glioma cells.	pyrazolanthrone	44-52	prominin 1	Homo sapiens	128-133
23210245-0	2012	SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
23210245-0	2012	SP600125, a JNK inhibitor, suppresses growth of JNK-inactive glioblastoma cells through cell-cycle G2/M phase arrest.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	48-51
23022184-5	2012	Furthermore, Bex2 down-regulation promotes cell apoptosis and activates the JNK pathway; these effects were abolished by administration of the JNK specific inhibitor, SP600125.	pyrazolanthrone	167-175	mitogen-activated protein kinase 8	Homo sapiens	76-79
23022184-5	2012	Furthermore, Bex2 down-regulation promotes cell apoptosis and activates the JNK pathway; these effects were abolished by administration of the JNK specific inhibitor, SP600125.	pyrazolanthrone	167-175	mitogen-activated protein kinase 8	Homo sapiens	143-146
22763043-8	2012	Interestingly, SP600125, a specific inhibitor of JNK, inhibited Wnt5a-induced activation of NF-kappaB, supporting JNK-dependent NF-kappaB activation.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	49-52
23034047-13	2012	In contrast, in neuronal cultures, LPS activated JNK but not ERK1/2 or p38, and the specific JNK inhibitor SP600125 significantly blocked LPS-induced KC expression and release.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Mus musculus	93-96
23034047-13	2012	In contrast, in neuronal cultures, LPS activated JNK but not ERK1/2 or p38, and the specific JNK inhibitor SP600125 significantly blocked LPS-induced KC expression and release.	pyrazolanthrone	107-115	toll-like receptor 4	Mus musculus	138-141
22729748-6	2012	Furthermore, FKB activated the mitogen-activated protein kinases and the JNK inhibitor SP600125 significantly decreased the growth-inhibitory and apoptotic effects of FKB.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	73-76
22749438-9	2012	The MAPK/ERK kinase inhibitor PD98059, the JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 all potently inhibited PMB-induced HGF production.	pyrazolanthrone	57-65	hepatocyte growth factor	Homo sapiens	137-140
22763043-8	2012	Interestingly, SP600125, a specific inhibitor of JNK, inhibited Wnt5a-induced activation of NF-kappaB, supporting JNK-dependent NF-kappaB activation.	pyrazolanthrone	15-23	Wnt family member 5A	Homo sapiens	64-69
22763043-8	2012	Interestingly, SP600125, a specific inhibitor of JNK, inhibited Wnt5a-induced activation of NF-kappaB, supporting JNK-dependent NF-kappaB activation.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	114-117
22020565-8	2012	Importantly, the phosphorylation was abolished by JNK inhibitor SP600125.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Homo sapiens	50-53
22020565-11	2012	Interestingly, SP600125 proved to prevent DATS-induced Akt inactivation.	pyrazolanthrone	15-23	AKT serine/threonine kinase 1	Homo sapiens	55-58
22824861-6	2012	Further, the downstream targets such as JNK and p38MAPK were also activated by this combination, and their pharmacological inhibition by SP600125 and SB201291 respectively resulted in suppression of 2-DG+6-AN mediated apoptosis in irradiated KB cells.	pyrazolanthrone	137-145	mitogen-activated protein kinase 8	Homo sapiens	40-43
22749815-6	2012	AngII (1 muM) also promoted TGFbeta1, TRAF6, CTGF expression and TAK1 phosphorylation, which were suppressed by angiotensin type I receptor antagonist (Losartan) as well as p38 MAPK inhibitor (SB202190), ERK1/2 inhibitor (PD98059) and JNK inhibitor (SP600125).	pyrazolanthrone	250-258	latexin	Homo sapiens	9-12
22797704-9	2012	Moreover, the specific JNK inhibitor SP600125 blocked rhNELL-1-induced mineralisation and intracellular phosphate accumulation, whereas ERK1/2 and P38 inhibitors showed no effect.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	23-26
22696236-4	2012	Disruption of the JNK signaling pathway by treatment with the JNK inhibitor SP600125, siRNA knockdown of JNK, or genetic deficiency of the JNK1 or JNK2 gene abrogated As(3+)-induced S727 phosphorylation of Stat3, Akt activation, and the consequent release of vascular endothelial growth factor (VEGF) and migration of the cells.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	18-21
23182046-8	2012	Inhibition of ERK1/2 with PD98059 exerted little effect on the derivative 6-induced apoptosis and p38 inhibition with SB203580 slightly lessened apoptosis, whereas inhibition of JNK with  SP600125 markedly suppressed derivative 6-induced apoptosis.	pyrazolanthrone	188-196	mitogen-activated protein kinase 8	Homo sapiens	178-181
23335521-4	2012	The expression of insulin receptor mRNA was detected by RT-PCR, with or without mitogen activated kinase (MAPK) signals blocked by their inhibitors: SP600125, the inhibitor of Jun N-terminal kinase (JNK), and PD98059, the inhibitor of extracellular signal-regulated (ERK1/2).	pyrazolanthrone	149-157	insulin receptor	Homo sapiens	18-34
23335521-4	2012	The expression of insulin receptor mRNA was detected by RT-PCR, with or without mitogen activated kinase (MAPK) signals blocked by their inhibitors: SP600125, the inhibitor of Jun N-terminal kinase (JNK), and PD98059, the inhibitor of extracellular signal-regulated (ERK1/2).	pyrazolanthrone	149-157	mitogen-activated protein kinase 3	Homo sapiens	106-110
23335521-10	2012	Western blot results showed that, while blocking the MAPK signaling pathway, 10 muM (ERK pathway inhibitor) could significantly inhibit phosphorylated activation of ERK1/2 with 200 nM insulin at 30 min, while no obvious inhibition with 20 muM SP600125 (JNK pathway inhibitor) of phosphorylated activation of ERK1/2 was noticed.	pyrazolanthrone	243-251	mitogen-activated protein kinase 3	Homo sapiens	53-57
23335521-10	2012	Western blot results showed that, while blocking the MAPK signaling pathway, 10 muM (ERK pathway inhibitor) could significantly inhibit phosphorylated activation of ERK1/2 with 200 nM insulin at 30 min, while no obvious inhibition with 20 muM SP600125 (JNK pathway inhibitor) of phosphorylated activation of ERK1/2 was noticed.	pyrazolanthrone	243-251	latexin	Homo sapiens	80-83
23335521-10	2012	Western blot results showed that, while blocking the MAPK signaling pathway, 10 muM (ERK pathway inhibitor) could significantly inhibit phosphorylated activation of ERK1/2 with 200 nM insulin at 30 min, while no obvious inhibition with 20 muM SP600125 (JNK pathway inhibitor) of phosphorylated activation of ERK1/2 was noticed.	pyrazolanthrone	243-251	mitogen-activated protein kinase 1	Homo sapiens	85-88
23335521-10	2012	Western blot results showed that, while blocking the MAPK signaling pathway, 10 muM (ERK pathway inhibitor) could significantly inhibit phosphorylated activation of ERK1/2 with 200 nM insulin at 30 min, while no obvious inhibition with 20 muM SP600125 (JNK pathway inhibitor) of phosphorylated activation of ERK1/2 was noticed.	pyrazolanthrone	243-251	mitogen-activated protein kinase 3	Homo sapiens	165-171
23335521-10	2012	Western blot results showed that, while blocking the MAPK signaling pathway, 10 muM (ERK pathway inhibitor) could significantly inhibit phosphorylated activation of ERK1/2 with 200 nM insulin at 30 min, while no obvious inhibition with 20 muM SP600125 (JNK pathway inhibitor) of phosphorylated activation of ERK1/2 was noticed.	pyrazolanthrone	243-251	insulin	Homo sapiens	184-191
22644775-5	2012	In contrast to the inhibitory effect of TAM67, pharmacological JNK inhibition by SP600125 sensitized the rat hepatocyte cell line RALA255-10G to death from menadione.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Rattus norvegicus	63-66
22644775-7	2012	Death from SP600125/menadione was c-Jun dependent as it was blocked by TAM67, but independent of c-Jun phosphorylation.	pyrazolanthrone	11-19	jun proto-oncogene	Mus musculus	34-39
22940059-4	2012	When the activity of MAPKs was blocked by their corresponding inhibitors (SB203580: p38; U0126: ERK; SP600125: JNK), the expression of TF was reduced significantly.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Homo sapiens	111-114
22940059-4	2012	When the activity of MAPKs was blocked by their corresponding inhibitors (SB203580: p38; U0126: ERK; SP600125: JNK), the expression of TF was reduced significantly.	pyrazolanthrone	101-109	coagulation factor III, tissue factor	Homo sapiens	135-137
22696236-4	2012	Disruption of the JNK signaling pathway by treatment with the JNK inhibitor SP600125, siRNA knockdown of JNK, or genetic deficiency of the JNK1 or JNK2 gene abrogated As(3+)-induced S727 phosphorylation of Stat3, Akt activation, and the consequent release of vascular endothelial growth factor (VEGF) and migration of the cells.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	62-65
22696236-4	2012	Disruption of the JNK signaling pathway by treatment with the JNK inhibitor SP600125, siRNA knockdown of JNK, or genetic deficiency of the JNK1 or JNK2 gene abrogated As(3+)-induced S727 phosphorylation of Stat3, Akt activation, and the consequent release of vascular endothelial growth factor (VEGF) and migration of the cells.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	62-65
22824464-7	2012	Treatment with SP600125 (an inhibitor of JNK) and SB203580 (an inhibitor of p38) prior to NG was found to reverse NG-induced apoptosis.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	41-44
22676888-7	2012	Treatment with SB203580, a selective p38 MAPK inhibitor, or SP600125, a selective c-Jun N-terminal kinase inhibitor, significantly attenuated the return of AQP4 to its normal level, and SB203580, but not SP600125, significantly decreased cell death.	pyrazolanthrone	60-68	aquaporin 4	Rattus norvegicus	156-160
22766066-5	2012	Moreover, any of three MAPKs inhibitors (PD98059, SB203580, and SP600125) significantly inhibited EGF-induced MUC5AC secretion.	pyrazolanthrone	64-72	epidermal growth factor	Homo sapiens	98-101
22766066-5	2012	Moreover, any of three MAPKs inhibitors (PD98059, SB203580, and SP600125) significantly inhibited EGF-induced MUC5AC secretion.	pyrazolanthrone	64-72	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	110-116
22766066-7	2012	Meanwhile, as compared to naringin, both SP600125 and azithromycin were less effective in suppressing EGF-induced secretion of MUC5AC because of the unchanged nucleus NF-kappaB p65.	pyrazolanthrone	41-49	epidermal growth factor	Homo sapiens	102-105
22766066-7	2012	Meanwhile, as compared to naringin, both SP600125 and azithromycin were less effective in suppressing EGF-induced secretion of MUC5AC because of the unchanged nucleus NF-kappaB p65.	pyrazolanthrone	41-49	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	127-133
22613808-8	2012	Furthermore, pretreatment of an inhibitor of JNK, SP600125, downregulated Fas and cleaved caspase-3 without change of ROS productions in tacrine-treated HepG2 cells.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	45-48
22824823-5	2012	Simultaneously, the apoptosis induced by MATP was reversed by SP600125 (a JNK inhibitor) whereas it was aggravated by LY294002 (an Akt inhibitor).	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	74-77
22592917-4	2012	Further results showed that VEGFA induced the activation of JNK/SAPK, p38 kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2), while JNK/SAPK inhibitor SP600125 and specific siRNA both blocked all those angiogenic effects induced by VEGFA.	pyrazolanthrone	167-175	vascular endothelial growth factor A	Homo sapiens	28-33
22592917-4	2012	Further results showed that VEGFA induced the activation of JNK/SAPK, p38 kinase and extracellular signal-regulated kinases 1 and 2 (ERK1/2), while JNK/SAPK inhibitor SP600125 and specific siRNA both blocked all those angiogenic effects induced by VEGFA.	pyrazolanthrone	167-175	mitogen-activated protein kinase 8	Homo sapiens	148-156
22592917-6	2012	In addition, in vivo matrigel plug assay further showed that SP600125 inhibited VEGFA-induced angiogenesis.	pyrazolanthrone	61-69	vascular endothelial growth factor A	Homo sapiens	80-85
22592917-7	2012	Further results showed that SP600125 and JNK/SAPK siRNA decreased VEGFA-induced VEGFR2 (Flk-1/KDR) sustained phosphorylation in HUVECs.	pyrazolanthrone	28-36	vascular endothelial growth factor A	Homo sapiens	66-71
22592917-7	2012	Further results showed that SP600125 and JNK/SAPK siRNA decreased VEGFA-induced VEGFR2 (Flk-1/KDR) sustained phosphorylation in HUVECs.	pyrazolanthrone	28-36	kinase insert domain receptor	Homo sapiens	80-86
22592917-7	2012	Further results showed that SP600125 and JNK/SAPK siRNA decreased VEGFA-induced VEGFR2 (Flk-1/KDR) sustained phosphorylation in HUVECs.	pyrazolanthrone	28-36	kinase insert domain receptor	Homo sapiens	88-93
22592917-7	2012	Further results showed that SP600125 and JNK/SAPK siRNA decreased VEGFA-induced VEGFR2 (Flk-1/KDR) sustained phosphorylation in HUVECs.	pyrazolanthrone	28-36	kinase insert domain receptor	Homo sapiens	94-97
22700825-7	2012	ERKs inhibitor PD98059, p38 inhibitor SB203580, and JNKs inhibitor SP600125 significantly blocked stretch-induced COX-2 expression.	pyrazolanthrone	67-75	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	114-119
22661329-2	2012	JNK inhibition using a chemical inhibitor SP600125 confers neuroprotection in an animal model of subarachnoid hemorrhage (SAH).	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
22528462-10	2012	However, they decreased markedly after rat TG pretreatment with PD98059 (ERK1/2 inhibitor), SB203580 (P38 inhibitor), or SP600125 (JNK inhibitor) compared with rat TG co-culture with TNF-alpha or IL-1beta.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Rattus norvegicus	131-134
22528462-10	2012	However, they decreased markedly after rat TG pretreatment with PD98059 (ERK1/2 inhibitor), SB203580 (P38 inhibitor), or SP600125 (JNK inhibitor) compared with rat TG co-culture with TNF-alpha or IL-1beta.	pyrazolanthrone	121-129	tumor necrosis factor	Rattus norvegicus	183-192
22528462-10	2012	However, they decreased markedly after rat TG pretreatment with PD98059 (ERK1/2 inhibitor), SB203580 (P38 inhibitor), or SP600125 (JNK inhibitor) compared with rat TG co-culture with TNF-alpha or IL-1beta.	pyrazolanthrone	121-129	interleukin 1 beta	Rattus norvegicus	196-204
22668848-5	2012	Moreover, BBP induced the activation of JNK, and JNK inhibitor SP600125 reversed autophagy, the increase of Atg4 levels, conversion of LC3 and growth inhibition induced by BBP.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	49-52
22668848-5	2012	Moreover, BBP induced the activation of JNK, and JNK inhibitor SP600125 reversed autophagy, the increase of Atg4 levels, conversion of LC3 and growth inhibition induced by BBP.	pyrazolanthrone	63-71	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	135-138
22661329-3	2012	The aim of this study is to investigate whether the protective effects of SP600125 were associated with modulation of tight junction proteins including claudin-5 and ZO-1 and to define which JNK isoforms were involved in the early brain injury after SAH.	pyrazolanthrone	74-82	claudin 5	Rattus norvegicus	152-161
22661329-3	2012	The aim of this study is to investigate whether the protective effects of SP600125 were associated with modulation of tight junction proteins including claudin-5 and ZO-1 and to define which JNK isoforms were involved in the early brain injury after SAH.	pyrazolanthrone	74-82	tight junction protein 1	Rattus norvegicus	166-170
22661329-8	2012	SP600125 exposure restored the reduced expression of both claudin-5 and ZO-1 following SAH and normalized the levels of JNK1 and JNK3.	pyrazolanthrone	0-8	claudin 5	Rattus norvegicus	58-67
22661329-8	2012	SP600125 exposure restored the reduced expression of both claudin-5 and ZO-1 following SAH and normalized the levels of JNK1 and JNK3.	pyrazolanthrone	0-8	tight junction protein 1	Rattus norvegicus	72-76
22661329-8	2012	SP600125 exposure restored the reduced expression of both claudin-5 and ZO-1 following SAH and normalized the levels of JNK1 and JNK3.	pyrazolanthrone	0-8	mitogen activated protein kinase 10	Rattus norvegicus	129-133
22610511-5	2012	While SP600125, a specific JNK pathway inhibitor, partly decreased cardiac cytoprotection assessed by incremental caspase-3 activation and subsequent TUNEL index, which led to no significantly different outcome between CM from ADSCs in normoxia culture and those in hypoxia culture.	pyrazolanthrone	6-14	mitogen-activated protein kinase 8	Homo sapiens	27-30
22410671-6	2012	Additionally, the c-jun N-terminal kinase (JNK) inhibitor (SP600125) dose-dependently inhibited LPS-induced CCL2 upregulation, whereas the MAPK kinase (MEK) inhibitor (PD98059) only had a mild effect and the p38 MAPK inhibitor (SB203580) had no effect.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	43-46
22410671-6	2012	Additionally, the c-jun N-terminal kinase (JNK) inhibitor (SP600125) dose-dependently inhibited LPS-induced CCL2 upregulation, whereas the MAPK kinase (MEK) inhibitor (PD98059) only had a mild effect and the p38 MAPK inhibitor (SB203580) had no effect.	pyrazolanthrone	59-67	C-C motif chemokine ligand 2	Rattus norvegicus	108-112
22610511-5	2012	While SP600125, a specific JNK pathway inhibitor, partly decreased cardiac cytoprotection assessed by incremental caspase-3 activation and subsequent TUNEL index, which led to no significantly different outcome between CM from ADSCs in normoxia culture and those in hypoxia culture.	pyrazolanthrone	6-14	caspase 3	Homo sapiens	114-123
22735370-8	2012	PDGF-BB-induced proliferation was dependent on reactive oxygen species generation and extracellular signal-regulated kinase1/2 activation in both cell populations; however, only Neo-PH cell division via PDGFbeta-R activation displayed a unique dependence on c-Jun N-terminal kinase1 (JNK1) stimulation as the blockade of JNK1 with SP600125, a pharmacological antagonist of the JNK pathway, and JNK1-targeted siRNA selectively blunted Neo-PH cell proliferation.	pyrazolanthrone	331-339	mitogen-activated protein kinase 8	Bos taurus	258-282
22607268-5	2012	Inhibition of basal c-jun-NH2-terminal kinase (JNK) activity by JNK inhibitor SP600125 repressed PS1 transcription and PS1 protein expression by augmenting p53 protein level in SK-N-SH cells (Lee and Das 2008).	pyrazolanthrone	78-86	tumor protein p53	Homo sapiens	156-159
21953860-6	2012	Pretreatment with antioxidant N-acetyl-L-cysteine, apoptosis signal-regulating kinase 1 inhibitor thioredoxin, and c-Jun NH(2) -terminal kinase inhibitor SP600125 significantly reduced thrombin-induced CCN2 synthesis.	pyrazolanthrone	154-162	coagulation factor II, thrombin	Homo sapiens	185-193
21953860-6	2012	Pretreatment with antioxidant N-acetyl-L-cysteine, apoptosis signal-regulating kinase 1 inhibitor thioredoxin, and c-Jun NH(2) -terminal kinase inhibitor SP600125 significantly reduced thrombin-induced CCN2 synthesis.	pyrazolanthrone	154-162	cellular communication network factor 2	Homo sapiens	202-206
22392728-7	2012	In contrast, the induction of Beclin 1 expression was blocked by SP600125 (a specific inhibitor of JNK) or by small interfering RNA directed against HDAC6.	pyrazolanthrone	65-73	beclin 1	Homo sapiens	30-38
22392728-7	2012	In contrast, the induction of Beclin 1 expression was blocked by SP600125 (a specific inhibitor of JNK) or by small interfering RNA directed against HDAC6.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	99-102
22607268-5	2012	Inhibition of basal c-jun-NH2-terminal kinase (JNK) activity by JNK inhibitor SP600125 repressed PS1 transcription and PS1 protein expression by augmenting p53 protein level in SK-N-SH cells (Lee and Das 2008).	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	20-45
22607268-6	2012	In this report we also showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited passive Ca2+ leak across ER membrane which could be rescued by expressing PS1 wild type and not by expressing FADPS1 (PS1-M146V) under a SP600125 non-responsive promoter.	pyrazolanthrone	84-92	presenilin 1	Homo sapiens	49-52
22607268-5	2012	Inhibition of basal c-jun-NH2-terminal kinase (JNK) activity by JNK inhibitor SP600125 repressed PS1 transcription and PS1 protein expression by augmenting p53 protein level in SK-N-SH cells (Lee and Das 2008).	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	47-50
22607268-6	2012	In this report we also showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited passive Ca2+ leak across ER membrane which could be rescued by expressing PS1 wild type and not by expressing FADPS1 (PS1-M146V) under a SP600125 non-responsive promoter.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	70-73
22607268-6	2012	In this report we also showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited passive Ca2+ leak across ER membrane which could be rescued by expressing PS1 wild type and not by expressing FADPS1 (PS1-M146V) under a SP600125 non-responsive promoter.	pyrazolanthrone	84-92	presenilin 1	Homo sapiens	177-180
22607268-5	2012	Inhibition of basal c-jun-NH2-terminal kinase (JNK) activity by JNK inhibitor SP600125 repressed PS1 transcription and PS1 protein expression by augmenting p53 protein level in SK-N-SH cells (Lee and Das 2008).	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	64-67
22607268-6	2012	In this report we also showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited passive Ca2+ leak across ER membrane which could be rescued by expressing PS1 wild type and not by expressing FADPS1 (PS1-M146V) under a SP600125 non-responsive promoter.	pyrazolanthrone	84-92	presenilin 1	Homo sapiens	177-180
22607268-5	2012	Inhibition of basal c-jun-NH2-terminal kinase (JNK) activity by JNK inhibitor SP600125 repressed PS1 transcription and PS1 protein expression by augmenting p53 protein level in SK-N-SH cells (Lee and Das 2008).	pyrazolanthrone	78-86	presenilin 1	Homo sapiens	97-100
22607268-6	2012	In this report we also showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited passive Ca2+ leak across ER membrane which could be rescued by expressing PS1 wild type and not by expressing FADPS1 (PS1-M146V) under a SP600125 non-responsive promoter.	pyrazolanthrone	240-248	presenilin 1	Homo sapiens	49-52
22607268-6	2012	In this report we also showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited passive Ca2+ leak across ER membrane which could be rescued by expressing PS1 wild type and not by expressing FADPS1 (PS1-M146V) under a SP600125 non-responsive promoter.	pyrazolanthrone	240-248	mitogen-activated protein kinase 8	Homo sapiens	70-73
22607268-5	2012	Inhibition of basal c-jun-NH2-terminal kinase (JNK) activity by JNK inhibitor SP600125 repressed PS1 transcription and PS1 protein expression by augmenting p53 protein level in SK-N-SH cells (Lee and Das 2008).	pyrazolanthrone	78-86	presenilin 1	Homo sapiens	119-122
22607268-7	2012	Treatment of SK-N-SH cells with SP600125 also triggered InsP3R-mediated Ca2+ release from the ER by addition of 500 nM bradykinin, an agonist of InsP3 receptor (InsP3R1) without changing the expression of InsP3R1.	pyrazolanthrone	32-40	kininogen 1	Homo sapiens	119-129
22607268-7	2012	Treatment of SK-N-SH cells with SP600125 also triggered InsP3R-mediated Ca2+ release from the ER by addition of 500 nM bradykinin, an agonist of InsP3 receptor (InsP3R1) without changing the expression of InsP3R1.	pyrazolanthrone	32-40	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	161-168
22607268-7	2012	Treatment of SK-N-SH cells with SP600125 also triggered InsP3R-mediated Ca2+ release from the ER by addition of 500 nM bradykinin, an agonist of InsP3 receptor (InsP3R1) without changing the expression of InsP3R1.	pyrazolanthrone	32-40	inositol 1,4,5-trisphosphate receptor type 1	Homo sapiens	205-212
22607268-8	2012	This data confirms that SP600125 increases the Ca2+ store in the ER by inhibiting PS1-mediated Ca2+ leak across ER membrane.	pyrazolanthrone	24-32	presenilin 1	Homo sapiens	82-85
22638761-9	2012	The synergistic PGE(2) production was abolished by the specific NF-kappaB inhibitor (BAY-117085), whereas specific inhibitors for the p38 (SB203580), JNK (SP600125), and ERK1/2 (PD98059) mitogen-activated protein kinases could prevent the prostanoid release.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	150-153
22231145-9	2012	RESULTS: IL-1beta-induced cPLA2 expression was mediated through NOX activation/ROS production, which was attenuated by N-acetylcysteine (NAC; a scavenger of ROS), the inhibitors of NOX (diphenyleneiodonium chloride and apocynin), MEK-1/2 (U0126), and JNK-1/2 (SP600125), transfection with the respective siRNAs, and the overexpression of HO-1 in RASFs.	pyrazolanthrone	260-268	interleukin 1 beta	Mus musculus	9-17
22641480-9	2012	The JNK inhibitor             SP600125 partly abrogated the caspase-9 activation caused by UA.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	4-7
22641480-9	2012	The JNK inhibitor             SP600125 partly abrogated the caspase-9 activation caused by UA.	pyrazolanthrone	30-38	caspase 9	Homo sapiens	60-69
22695114-1	2012	A JNK inhibitor SP600125 inhibited cAMP-dependent proteolysis of GATA-6 by proteasomes around its IC50.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Homo sapiens	2-5
22695114-1	2012	A JNK inhibitor SP600125 inhibited cAMP-dependent proteolysis of GATA-6 by proteasomes around its IC50.	pyrazolanthrone	16-24	GATA binding protein 6	Homo sapiens	65-71
22695114-2	2012	We further examined the effects of SP600125 on the degradation of GATA-6 in detail, since an activator of JNK (anisomycin) is available.	pyrazolanthrone	35-43	GATA binding protein 6	Homo sapiens	66-72
22695114-4	2012	Such an effect of anisomycin was inhibited by SP600125, indicating that the observed phenomenon might be linked to the JNK signaling pathway.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	119-122
22695114-5	2012	The inhibitory effect of SP600125 could not be ascribed to the inhibition of PKA, since phosphorylation of CREB occurred in the presence of dbcAMP and SP600125.	pyrazolanthrone	25-33	cAMP responsive element binding protein 1	Homo sapiens	107-111
22695114-5	2012	The inhibitory effect of SP600125 could not be ascribed to the inhibition of PKA, since phosphorylation of CREB occurred in the presence of dbcAMP and SP600125.	pyrazolanthrone	151-159	cAMP responsive element binding protein 1	Homo sapiens	107-111
22252525-7	2012	Inhibition of the JNK activity by chemical inhibitor (SP600125) significantly reduced the effects of PAK1 on CRC proliferation via accumulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN).	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	18-21
22252525-7	2012	Inhibition of the JNK activity by chemical inhibitor (SP600125) significantly reduced the effects of PAK1 on CRC proliferation via accumulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN).	pyrazolanthrone	54-62	p21 (RAC1) activated kinase 1	Homo sapiens	101-105
22252525-7	2012	Inhibition of the JNK activity by chemical inhibitor (SP600125) significantly reduced the effects of PAK1 on CRC proliferation via accumulation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN).	pyrazolanthrone	54-62	phosphatase and tensin homolog	Homo sapiens	204-208
22554771-7	2012	Both inhibitor of p38 (SB203580) and JNK (SP600125) significantly inhibited TNF-alpha-induced VCAM-1 expression.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
22554771-7	2012	Both inhibitor of p38 (SB203580) and JNK (SP600125) significantly inhibited TNF-alpha-induced VCAM-1 expression.	pyrazolanthrone	42-50	tumor necrosis factor	Rattus norvegicus	76-85
22554771-7	2012	Both inhibitor of p38 (SB203580) and JNK (SP600125) significantly inhibited TNF-alpha-induced VCAM-1 expression.	pyrazolanthrone	42-50	vascular cell adhesion molecule 1	Rattus norvegicus	94-100
22638597-5	2012	After interference by SP600125, the expression of p-JNk and caspase-12 obviously decreased, whereas the decrease of GADD153 occurred only after 24 h reperfusion.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Rattus norvegicus	52-55
22638597-5	2012	After interference by SP600125, the expression of p-JNk and caspase-12 obviously decreased, whereas the decrease of GADD153 occurred only after 24 h reperfusion.	pyrazolanthrone	22-30	caspase 12	Rattus norvegicus	60-70
22638597-5	2012	After interference by SP600125, the expression of p-JNk and caspase-12 obviously decreased, whereas the decrease of GADD153 occurred only after 24 h reperfusion.	pyrazolanthrone	22-30	DNA-damage inducible transcript 3	Rattus norvegicus	116-123
22231145-9	2012	RESULTS: IL-1beta-induced cPLA2 expression was mediated through NOX activation/ROS production, which was attenuated by N-acetylcysteine (NAC; a scavenger of ROS), the inhibitors of NOX (diphenyleneiodonium chloride and apocynin), MEK-1/2 (U0126), and JNK-1/2 (SP600125), transfection with the respective siRNAs, and the overexpression of HO-1 in RASFs.	pyrazolanthrone	260-268	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	26-31
21106355-7	2012	In addition, sp600125, the inhibitor of JNK, decreased the percentage of apoptosis induced by TAM in MCF-7 cells.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	40-43
22364229-8	2012	KEY RESULTS The JNK inhibitors SP600125 and BI-78D3 reduced phenylephrine- and noradrenaline-induced contractions of human prostate strips.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	16-19
22364229-11	2012	Incubation of prostate tissue with SP600125 or BI-78D3 reduced the phosphorylation state of c-Jun.	pyrazolanthrone	35-43	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	92-97
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	pyrazolanthrone	201-209	patchy fur	Mus musculus	76-79
21889331-5	2012	ERK, JNK, and p38 MAPKs were activated rapidly by PAF in the lungs, and the PAF-induced metastasis of B16F10 was inhibited in a dose-dependent manner by pretreatment with either U0126 (ERK inhibitor), SP600125 (JNK inhibitor), or SB202190 (p38 inhibitor).	pyrazolanthrone	201-209	mitogen-activated protein kinase 1	Mus musculus	185-188
21106355-9	2012	Furthermore, PKCalpha being the upstream of JNK in inhibiting apoptosis was suggested by using Go6976, the specific PKCalpha inhibitor, in the presence or absence of sp600125.	pyrazolanthrone	166-174	protein kinase C alpha	Homo sapiens	13-21
21106355-9	2012	Furthermore, PKCalpha being the upstream of JNK in inhibiting apoptosis was suggested by using Go6976, the specific PKCalpha inhibitor, in the presence or absence of sp600125.	pyrazolanthrone	166-174	mitogen-activated protein kinase 8	Homo sapiens	44-47
22409452-6	2012	Cultured cortical cells were pretreated with E2 and the specific JNK inhibitor SP600125 and then treated with glutamate-induced cytotoxicity in vitro.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Rattus norvegicus	65-68
22561121-6	2012	SP600125, PD98059, and LY294002 inhibited the induction of at least CCL2.	pyrazolanthrone	0-8	C-C motif chemokine ligand 2	Homo sapiens	68-72
22542939-5	2012	Treatment with the JNK-specific inhibitor SP600125 reduced the PA-induced PANDER expression.	pyrazolanthrone	42-50	FAM3 metabolism regulating signaling molecule B	Mus musculus	74-80
22459175-4	2012	Treatment with the inhibitors of PI3-K (LY294002), Akt (SH-5), MEK1/2 (U0126), and JNK1/2 (SP600125) attenuated the outgrowth area, indicating that PI3-K/Akt, p42/p44 MAPK, and JNK1/2 are involved in the outgrowth of intact AM-expanded limbal epithelial cells.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	83-89
22459175-5	2012	However, MMP-9 expression at both transcriptional and translational levels was attenuated by treatment with SP600125, LY294002, or SH-5, not by U0126 and SB202190, suggesting that JNK1/2 and PI3-K/Akt participate in MMP-9 expression.	pyrazolanthrone	108-116	matrix metallopeptidase 9	Homo sapiens	9-14
22459175-5	2012	However, MMP-9 expression at both transcriptional and translational levels was attenuated by treatment with SP600125, LY294002, or SH-5, not by U0126 and SB202190, suggesting that JNK1/2 and PI3-K/Akt participate in MMP-9 expression.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	180-186
22459175-6	2012	Moreover, NF-kappaB phosphorylation and nuclear translocation was especially noted at the leading edge, which was attenuated by treatment with SP600125 or LY294002.	pyrazolanthrone	143-151	nuclear factor kappa B subunit 1	Homo sapiens	10-19
22575563-9	2012	PD98059 (an inhibitor of MEK 1/2) or SP600125 (an inhibitor of SAPK/JNK), which suppressed FGF-2-induced phosphorylation of p44/p42 MAP kinase or SAPK/JNK respectively, did not affect FGF-2-induced Akt phosphorylation.	pyrazolanthrone	37-45	fibroblast growth factor 2	Rattus norvegicus	91-96
22575563-9	2012	PD98059 (an inhibitor of MEK 1/2) or SP600125 (an inhibitor of SAPK/JNK), which suppressed FGF-2-induced phosphorylation of p44/p42 MAP kinase or SAPK/JNK respectively, did not affect FGF-2-induced Akt phosphorylation.	pyrazolanthrone	37-45	mitogen activated protein kinase 3	Rattus norvegicus	124-127
22575563-9	2012	PD98059 (an inhibitor of MEK 1/2) or SP600125 (an inhibitor of SAPK/JNK), which suppressed FGF-2-induced phosphorylation of p44/p42 MAP kinase or SAPK/JNK respectively, did not affect FGF-2-induced Akt phosphorylation.	pyrazolanthrone	37-45	fibroblast growth factor 2	Rattus norvegicus	184-189
22575563-9	2012	PD98059 (an inhibitor of MEK 1/2) or SP600125 (an inhibitor of SAPK/JNK), which suppressed FGF-2-induced phosphorylation of p44/p42 MAP kinase or SAPK/JNK respectively, did not affect FGF-2-induced Akt phosphorylation.	pyrazolanthrone	37-45	AKT serine/threonine kinase 1	Rattus norvegicus	198-201
22634325-10	2012	LPS-activation of allele-2 EMSA complexes could be blocked by the specific c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Homo sapiens	75-98
22634325-10	2012	LPS-activation of allele-2 EMSA complexes could be blocked by the specific c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Homo sapiens	100-103
22488045-10	2012	Selective blocking of the MAPK pathways with p38 inhibitor SB203580 significantly decreased arsenic-induced HO-1 and VEGF expression, while JNKs inhibitor SP600125 increased IL-6 expression.	pyrazolanthrone	155-163	interleukin 6	Mus musculus	174-178
22438244-4	2012	Such a preferential cytotoxicity could be attributed to the failure of p53-deficient cells to undergo cell cycle arrest in response to SP600125.	pyrazolanthrone	135-143	tumor protein p53	Homo sapiens	71-74
22438244-5	2012	TP53(-/-)  (but not TP53(+/+) ) cells treated with SP600125 became polyploid upon mitotic abortion and progressively succumbed to mitochondrial apoptosis.	pyrazolanthrone	51-59	tumor protein p53	Homo sapiens	0-4
22438244-6	2012	The expression of an SP600125-resistant variant of the mitotic kinase MPS1 in TP53(-/-)  cells reduced SP600125-induced polyploidization.	pyrazolanthrone	21-29	TTK protein kinase	Homo sapiens	70-74
22438244-6	2012	The expression of an SP600125-resistant variant of the mitotic kinase MPS1 in TP53(-/-)  cells reduced SP600125-induced polyploidization.	pyrazolanthrone	21-29	tumor protein p53	Homo sapiens	78-82
22438244-6	2012	The expression of an SP600125-resistant variant of the mitotic kinase MPS1 in TP53(-/-)  cells reduced SP600125-induced polyploidization.	pyrazolanthrone	103-111	TTK protein kinase	Homo sapiens	70-74
22438244-6	2012	The expression of an SP600125-resistant variant of the mitotic kinase MPS1 in TP53(-/-)  cells reduced SP600125-induced polyploidization.	pyrazolanthrone	103-111	tumor protein p53	Homo sapiens	78-82
22438244-7	2012	Thus, by targeting MPS1, SP600125 triggers a polyploidization program that cannot be sustained by TP53(-/-)  cells, resulting in the activation of mitotic catastrophe, an oncosuppressive mechanism for the eradication of mitosis-incompetent cells.	pyrazolanthrone	25-33	TTK protein kinase	Homo sapiens	19-23
22504529-6	2012	Pretreatment with FAK inhibitor or JNK inhibitor (SP600125) also blocked the potentiating action of HGF.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	35-38
22504529-6	2012	Pretreatment with FAK inhibitor or JNK inhibitor (SP600125) also blocked the potentiating action of HGF.	pyrazolanthrone	50-58	hepatocyte growth factor	Homo sapiens	100-103
22504529-8	2012	HGF-mediated Runx2 binding to BMP-2 promoter was inhibited by c-Met inhibitor, FAK inhibitor, and SP600125.	pyrazolanthrone	98-106	hepatocyte growth factor	Homo sapiens	0-3
22504529-8	2012	HGF-mediated Runx2 binding to BMP-2 promoter was inhibited by c-Met inhibitor, FAK inhibitor, and SP600125.	pyrazolanthrone	98-106	RUNX family transcription factor 2	Homo sapiens	13-18
22493087-6	2012	All these effects were reversed after blocking JNK with Sp600125 (a JNK inhibitor) or JNK1/2 siRNA.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	47-50
22493087-6	2012	All these effects were reversed after blocking JNK with Sp600125 (a JNK inhibitor) or JNK1/2 siRNA.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	68-71
22544632-3	2012	Treatment with bFGF activated the RhoA/Rho-associated kinase (ROCK)/c-jun N-terminal kinase (JNK) pathway, and bFGF-induced NT-3 expression was blocked by a dominant-negative RhoA as well as by a specific Rho-kinase inhibitor (Y27632) and a SAPK/JNK inhibitor (SP600125).	pyrazolanthrone	261-269	fibroblast growth factor 2	Rattus norvegicus	15-19
22544632-3	2012	Treatment with bFGF activated the RhoA/Rho-associated kinase (ROCK)/c-jun N-terminal kinase (JNK) pathway, and bFGF-induced NT-3 expression was blocked by a dominant-negative RhoA as well as by a specific Rho-kinase inhibitor (Y27632) and a SAPK/JNK inhibitor (SP600125).	pyrazolanthrone	261-269	ras homolog family member A	Rattus norvegicus	34-38
22544632-3	2012	Treatment with bFGF activated the RhoA/Rho-associated kinase (ROCK)/c-jun N-terminal kinase (JNK) pathway, and bFGF-induced NT-3 expression was blocked by a dominant-negative RhoA as well as by a specific Rho-kinase inhibitor (Y27632) and a SAPK/JNK inhibitor (SP600125).	pyrazolanthrone	261-269	fibroblast growth factor 2	Rattus norvegicus	111-115
22544632-3	2012	Treatment with bFGF activated the RhoA/Rho-associated kinase (ROCK)/c-jun N-terminal kinase (JNK) pathway, and bFGF-induced NT-3 expression was blocked by a dominant-negative RhoA as well as by a specific Rho-kinase inhibitor (Y27632) and a SAPK/JNK inhibitor (SP600125).	pyrazolanthrone	261-269	neurotrophin 3	Rattus norvegicus	124-128
22544632-3	2012	Treatment with bFGF activated the RhoA/Rho-associated kinase (ROCK)/c-jun N-terminal kinase (JNK) pathway, and bFGF-induced NT-3 expression was blocked by a dominant-negative RhoA as well as by a specific Rho-kinase inhibitor (Y27632) and a SAPK/JNK inhibitor (SP600125).	pyrazolanthrone	261-269	ras homolog family member A	Rattus norvegicus	175-179
22472731-7	2012	We found that JNK inhibition by its inhibitor SP600125 led to the abolishment of PRRSV-mediated apoptosis, but did not suppress virus replication.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	14-17
22642771-9	2012	The JNK inhibitor SP600125 decreased IL-1beta-induced PGE2 release with a potency similar to that of telmisartan.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
22642771-9	2012	The JNK inhibitor SP600125 decreased IL-1beta-induced PGE2 release with a potency similar to that of telmisartan.	pyrazolanthrone	18-26	interleukin 1 beta	Rattus norvegicus	37-45
22542939-5	2012	Treatment with the JNK-specific inhibitor SP600125 reduced the PA-induced PANDER expression.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Mus musculus	19-22
22399333-6	2012	Pretreatment of brainstem astrocytes with the JNK inhibitor, SP600125, prevented Ang III phosphorylation of JNK, as well as Ang III-mediated astrocyte growth.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Rattus norvegicus	46-49
22399333-6	2012	Pretreatment of brainstem astrocytes with the JNK inhibitor, SP600125, prevented Ang III phosphorylation of JNK, as well as Ang III-mediated astrocyte growth.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Rattus norvegicus	108-111
22474074-9	2012	It was further demonstrated that FoxO1 was a downstream target of SAPK/JNK signaling by FoxO1 small interfering RNA and SP600125 (an inhibitor of SAPK/JNK pathway) treatment.	pyrazolanthrone	120-128	forkhead box O1	Mus musculus	33-38
22474074-10	2012	Additionally, SP600125 treatment or FoxO1 knockdown also blocked FasL/Fas signaling-dependent apoptosis and improved DA-induced cognitive deficits in the hippocampus of mice.	pyrazolanthrone	14-22	Fas ligand (TNF superfamily, member 6)	Mus musculus	65-69
22699892-6	2012	Acute treatment (10 min poststroke) with the JNK inhibitor SP600125 reduced infarction volumes.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Rattus norvegicus	45-48
22681856-7	2012	A single intrathecal injection with JNK inhibitor SP600125 by lumbar puncture attenuated mechanical allodynia on day 12, and repeated intrathecal injection of SP600126 from day 10 to day 14 had a cumulative analgesic effect on CIBP.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Rattus norvegicus	36-39
22884071-6	2012	JNK was treated with SP600125, a specific JNK inhibitor.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
22884071-6	2012	JNK was treated with SP600125, a specific JNK inhibitor.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Rattus norvegicus	42-45
22438244-2	2012	Using high-content videomicroscopy based on fluorescent TP53(+/+)  and TP53(-/-)  human colon carcinoma cells, we discovered that SP600125, a broad-spectrum serine/threonine kinase inhibitor, kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro.	pyrazolanthrone	130-138	tumor protein p53	Homo sapiens	56-60
22438244-2	2012	Using high-content videomicroscopy based on fluorescent TP53(+/+)  and TP53(-/-)  human colon carcinoma cells, we discovered that SP600125, a broad-spectrum serine/threonine kinase inhibitor, kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro.	pyrazolanthrone	130-138	tumor protein p53	Homo sapiens	71-75
22438244-2	2012	Using high-content videomicroscopy based on fluorescent TP53(+/+)  and TP53(-/-)  human colon carcinoma cells, we discovered that SP600125, a broad-spectrum serine/threonine kinase inhibitor, kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro.	pyrazolanthrone	130-138	tumor protein p53	Homo sapiens	198-201
22438244-2	2012	Using high-content videomicroscopy based on fluorescent TP53(+/+)  and TP53(-/-)  human colon carcinoma cells, we discovered that SP600125, a broad-spectrum serine/threonine kinase inhibitor, kills p53-deficient cells more efficiently than their p53-proficient counterparts, in vitro.	pyrazolanthrone	130-138	tumor protein p53	Homo sapiens	246-249
22440610-3	2012	PhB-induced apoptosis was significantly inhibited by N-acetyl-l-cysteine, but not by catalase, indicating that ROS generation occurred intracellularly, and by SP600125 and AG490, specific inhibitors of JNK and IFN-gamma signaling, respectively, confirming their roles in the apoptotic pathway.	pyrazolanthrone	159-167	prohibitin 1	Homo sapiens	0-3
22440610-4	2012	IFN-gamma up-regulation was also inhibited by SP600125, indicating that it was downstream of JNK activation.	pyrazolanthrone	46-54	interferon gamma	Homo sapiens	0-9
22440610-4	2012	IFN-gamma up-regulation was also inhibited by SP600125, indicating that it was downstream of JNK activation.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	93-96
22504529-8	2012	HGF-mediated Runx2 binding to BMP-2 promoter was inhibited by c-Met inhibitor, FAK inhibitor, and SP600125.	pyrazolanthrone	98-106	bone morphogenetic protein 2	Homo sapiens	30-35
22643045-11	2012	Further identifying the signaling pathway involved in the regulation, we found  Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-62 and c-Jun N-terminal kinase (JNK) inhibitor SP600125 reduced the expression of IP3R1 suggesting the role of CaMKII and JNK in the regulation of IP3R1 expression.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Rattus norvegicus	155-178
22643045-11	2012	Further identifying the signaling pathway involved in the regulation, we found  Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-62 and c-Jun N-terminal kinase (JNK) inhibitor SP600125 reduced the expression of IP3R1 suggesting the role of CaMKII and JNK in the regulation of IP3R1 expression.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Rattus norvegicus	180-183
22643045-11	2012	Further identifying the signaling pathway involved in the regulation, we found  Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-62 and c-Jun N-terminal kinase (JNK) inhibitor SP600125 reduced the expression of IP3R1 suggesting the role of CaMKII and JNK in the regulation of IP3R1 expression.	pyrazolanthrone	195-203	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	230-235
22643045-11	2012	Further identifying the signaling pathway involved in the regulation, we found  Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-62 and c-Jun N-terminal kinase (JNK) inhibitor SP600125 reduced the expression of IP3R1 suggesting the role of CaMKII and JNK in the regulation of IP3R1 expression.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Rattus norvegicus	270-273
22643045-11	2012	Further identifying the signaling pathway involved in the regulation, we found  Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-62 and c-Jun N-terminal kinase (JNK) inhibitor SP600125 reduced the expression of IP3R1 suggesting the role of CaMKII and JNK in the regulation of IP3R1 expression.	pyrazolanthrone	195-203	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	295-300
22461627-3	2012	SP600125, a known JNK inhibitor, prevented GITR-mediated phosphorylation of JNK.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	18-21
22461627-3	2012	SP600125, a known JNK inhibitor, prevented GITR-mediated phosphorylation of JNK.	pyrazolanthrone	0-8	tumor necrosis factor receptor superfamily, member 18	Mus musculus	43-47
22461627-3	2012	SP600125, a known JNK inhibitor, prevented GITR-mediated phosphorylation of JNK.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	76-79
22527657-9	2012	Genetic (JNK(-/-)) or pharmacological (SP600125) inhibition of JNK ameliorated the DOX-induced HMGB1 expression and diminished myocardial apoptosis and cardiac dysfunction.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Mus musculus	63-66
22387292-9	2012	However, in both, the JNK inhibitor SP600125 reduced JNK phosphorylation and CXCL10 mRNA levels but did not affect CXCL10 mRNA stability or Ikappa-Balpha degradation.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	22-25
22387292-9	2012	However, in both, the JNK inhibitor SP600125 reduced JNK phosphorylation and CXCL10 mRNA levels but did not affect CXCL10 mRNA stability or Ikappa-Balpha degradation.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	53-56
22387292-9	2012	However, in both, the JNK inhibitor SP600125 reduced JNK phosphorylation and CXCL10 mRNA levels but did not affect CXCL10 mRNA stability or Ikappa-Balpha degradation.	pyrazolanthrone	36-44	C-X-C motif chemokine ligand 10	Homo sapiens	77-83
22323130-8	2012	Cotreatment with SP600125, an inhibitor JNK, significantly reduced the phosphorylated Bcl-2 in death-prone cells and caused a significant reduction in cell death.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	40-43
22323130-8	2012	Cotreatment with SP600125, an inhibitor JNK, significantly reduced the phosphorylated Bcl-2 in death-prone cells and caused a significant reduction in cell death.	pyrazolanthrone	17-25	BCL2 apoptosis regulator	Homo sapiens	86-91
22644859-7	2012	Under serum withdrawal conditions, the JNK inhibitor SP600125 significantly decreased the viability of the parent MCF-7 cells but not of MCF-7/ADR cells.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	39-42
22628315-4	2012	The application of the JNK inhibitors SP600125 and AS601245 reduced IAV amplification by suppressing viral protein and RNA synthesis.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	23-26
22527657-9	2012	Genetic (JNK(-/-)) or pharmacological (SP600125) inhibition of JNK ameliorated the DOX-induced HMGB1 expression and diminished myocardial apoptosis and cardiac dysfunction.	pyrazolanthrone	39-47	high mobility group box 1	Mus musculus	95-100
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	pyrazolanthrone	141-149	caspase 9	Homo sapiens	18-34
22873067-7	2012	The inhibitor of extra cellular domains of TLR2 and TLR4 (OxPAPC) had almost the same anti-inflammatory effect, and an addition of the inhibitor of JNK cascade (SP600125) to cell culture practically neutralized effect of ammonium ions by decreasing cytokine production to control level.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Mus musculus	148-151
22537555-7	2012	Further studies suggested that hBD-2 mRNA and protein expression in responsive to andro were attenuated by pretreatment with SB203580 (an inhibitor of p38 mitogen-activated protein kinase (p38 MAPK)), MG-132 (an inhibitor of nuclear factor kappaB (NF-kappaB)), and an NF-kappaB activator inhibitor, but not by an inhibitor of ERK (PD98059) or by an inhibitor of JNK(SP600125).	pyrazolanthrone	366-374	defensin beta 4A	Homo sapiens	31-36
22490436-5	2012	Inhibition of p38 with SB202190 or JNK with SP600125 attenuated CPT-induced cell death.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	35-38
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	126-129
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	pyrazolanthrone	141-149	caspase 9	Homo sapiens	18-25
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	238-241
21074392-8	2012	The activities of caspase-9 and -3 were also increased upon treatment with taxol; however, pre-treatment of cells with NAC or JNK inhibitor (SP600125) impeded taxol-mediated caspase activation and apoptosis in K562 cells, suggesting that JNK acts upstream of the caspases.	pyrazolanthrone	141-149	caspase 9	Homo sapiens	263-271
22354990-4	2012	Use of an inactive JNK1 mutant or treatment with a JNK inhibitor (SP600125) significantly reduced JNK1-mediated phosphorylation and transcriptional activity of Nrl in cultured retinal explants.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Mus musculus	98-102
22105759-7	2012	These inductions were significantly reduced in the presence of the JNK inhibitor, SP600125.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	67-70
22105759-8	2012	TNFalpha treatment enhanced HepG2 cell nuclear extract-binding activity to the MRP3/ABCC3 promoter, but was abolished by SP600125, as demonstrated by electrophoretic mobility shift assay (EMSA).	pyrazolanthrone	121-129	tumor necrosis factor	Homo sapiens	0-8
22261313-8	2012	Treatment with nuclear factor kappaB inhibitor, PDTC, or JNK inhibitor, SP600125, attenuated BDNF-augmented MnSOD protein expression.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	57-60
22261313-8	2012	Treatment with nuclear factor kappaB inhibitor, PDTC, or JNK inhibitor, SP600125, attenuated BDNF-augmented MnSOD protein expression.	pyrazolanthrone	72-80	brain derived neurotrophic factor	Homo sapiens	93-97
22261313-8	2012	Treatment with nuclear factor kappaB inhibitor, PDTC, or JNK inhibitor, SP600125, attenuated BDNF-augmented MnSOD protein expression.	pyrazolanthrone	72-80	superoxide dismutase 2	Homo sapiens	108-113
22354990-4	2012	Use of an inactive JNK1 mutant or treatment with a JNK inhibitor (SP600125) significantly reduced JNK1-mediated phosphorylation and transcriptional activity of Nrl in cultured retinal explants.	pyrazolanthrone	66-74	neural retina leucine zipper gene	Mus musculus	160-163
22860429-1	2012	OBJECTIVE: To investigate the protective effects and mechanism of SP600125-specificity inhibitor of c-Jun N-terminal kinase (JNK)on lung ischemia /reperfusion injury in rats.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Rattus norvegicus	125-128
22322185-4	2012	SP600125, a specific inhibitor of p-JNK, could rescue SK-MES-1             cells from CrTX-induced apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	36-39
22860429-5	2012	RESULTS: Compared to I/R group, the expression of p-JNK, Bcl-2, Bax and caspase-3 protein were markedly decreased (all P &lt; 0.01), the expression of Bcl-2 protein and the ratio of Bcl-2/Bax were markedly increased in SP600125 group(all P &lt; 0.01).	pyrazolanthrone	219-227	BCL2, apoptosis regulator	Rattus norvegicus	151-156
22860429-5	2012	RESULTS: Compared to I/R group, the expression of p-JNK, Bcl-2, Bax and caspase-3 protein were markedly decreased (all P &lt; 0.01), the expression of Bcl-2 protein and the ratio of Bcl-2/Bax were markedly increased in SP600125 group(all P &lt; 0.01).	pyrazolanthrone	219-227	BCL2, apoptosis regulator	Rattus norvegicus	151-156
22860429-8	2012	CONCLUSION: SP600125 can suppress JNK signal pathway, up-regulate the ratio of Bcl-2/Bax to inhibit Caspase-3 dependent apoptosis, so that it protects lung tissue from ischemia/reperfusion injury.	pyrazolanthrone	12-20	mitogen-activated protein kinase 8	Rattus norvegicus	34-37
22860429-8	2012	CONCLUSION: SP600125 can suppress JNK signal pathway, up-regulate the ratio of Bcl-2/Bax to inhibit Caspase-3 dependent apoptosis, so that it protects lung tissue from ischemia/reperfusion injury.	pyrazolanthrone	12-20	BCL2, apoptosis regulator	Rattus norvegicus	79-84
22860429-8	2012	CONCLUSION: SP600125 can suppress JNK signal pathway, up-regulate the ratio of Bcl-2/Bax to inhibit Caspase-3 dependent apoptosis, so that it protects lung tissue from ischemia/reperfusion injury.	pyrazolanthrone	12-20	BCL2 associated X, apoptosis regulator	Rattus norvegicus	85-88
22860429-8	2012	CONCLUSION: SP600125 can suppress JNK signal pathway, up-regulate the ratio of Bcl-2/Bax to inhibit Caspase-3 dependent apoptosis, so that it protects lung tissue from ischemia/reperfusion injury.	pyrazolanthrone	12-20	caspase 3	Rattus norvegicus	100-109
22540380-7	2012	Moreover, the JNK -specific inhibitor SP600125 prevented Cas III-ia-induced cell death.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	14-17
22450316-7	2012	Inhibition of JNK with SP600125 (a JNK inhibitor) decreased the expression of TNFalpha and IL-1beta.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
22450316-7	2012	Inhibition of JNK with SP600125 (a JNK inhibitor) decreased the expression of TNFalpha and IL-1beta.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	35-38
22450316-7	2012	Inhibition of JNK with SP600125 (a JNK inhibitor) decreased the expression of TNFalpha and IL-1beta.	pyrazolanthrone	23-31	tumor necrosis factor	Rattus norvegicus	78-86
22450316-7	2012	Inhibition of JNK with SP600125 (a JNK inhibitor) decreased the expression of TNFalpha and IL-1beta.	pyrazolanthrone	23-31	interleukin 1 beta	Rattus norvegicus	91-99
22509080-7	2012	The activation of JNKs and expression of FasL protein were inhibited in the pcDNA3.1-X transfected group when treated with a known JNK inhibitor, SP600125.	pyrazolanthrone	146-154	Fas ligand	Homo sapiens	41-45
22353755-0	2012	Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and Notch signaling in mouse brain without induction of apoptosis.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Mus musculus	29-32
22353755-0	2012	Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and Notch signaling in mouse brain without induction of apoptosis.	pyrazolanthrone	52-60	presenilin 1	Mus musculus	88-100
22353755-0	2012	Intraperitoneal injection of JNK-specific inhibitor SP600125 inhibits the expression of presenilin-1 and Notch signaling in mouse brain without induction of apoptosis.	pyrazolanthrone	52-60	notch 1	Mus musculus	105-110
22353755-4	2012	We have previously shown that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses the expression of PS1 and gamma-secretase activity by increasing p53 level in SK-N-SH cell line in vitro (Lee and Das, 2008, 2010).	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	62-87
22353755-4	2012	We have previously shown that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses the expression of PS1 and gamma-secretase activity by increasing p53 level in SK-N-SH cell line in vitro (Lee and Das, 2008, 2010).	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	89-92
22353755-4	2012	We have previously shown that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses the expression of PS1 and gamma-secretase activity by increasing p53 level in SK-N-SH cell line in vitro (Lee and Das, 2008, 2010).	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	99-102
22353755-4	2012	We have previously shown that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses the expression of PS1 and gamma-secretase activity by increasing p53 level in SK-N-SH cell line in vitro (Lee and Das, 2008, 2010).	pyrazolanthrone	122-130	presenilin 1	Homo sapiens	159-162
22353755-4	2012	We have previously shown that inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) with JNK-specific inhibitor SP600125 represses the expression of PS1 and gamma-secretase activity by increasing p53 level in SK-N-SH cell line in vitro (Lee and Das, 2008, 2010).	pyrazolanthrone	122-130	tumor protein p53	Homo sapiens	206-209
22353755-6	2012	In this report we showed that intraperitoneal (i.p) injection of JNK-specific inhibitor SP600125 decreased p-JNK level, and reduced PS1 expression by increasing p53 level in adult mouse brains.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Mus musculus	65-68
22353755-6	2012	In this report we showed that intraperitoneal (i.p) injection of JNK-specific inhibitor SP600125 decreased p-JNK level, and reduced PS1 expression by increasing p53 level in adult mouse brains.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Mus musculus	109-112
22353755-6	2012	In this report we showed that intraperitoneal (i.p) injection of JNK-specific inhibitor SP600125 decreased p-JNK level, and reduced PS1 expression by increasing p53 level in adult mouse brains.	pyrazolanthrone	88-96	presenilin 1	Mus musculus	132-135
22353755-6	2012	In this report we showed that intraperitoneal (i.p) injection of JNK-specific inhibitor SP600125 decreased p-JNK level, and reduced PS1 expression by increasing p53 level in adult mouse brains.	pyrazolanthrone	88-96	transformation related protein 53, pseudogene	Mus musculus	161-164
22353755-7	2012	We also showed that suppression of PS1 expression by SP600125 reduced gamma-secretase activity which decreased Notch 1 processing to reduce NICD in mouse brains.	pyrazolanthrone	53-61	presenilin 1	Mus musculus	35-38
22353755-7	2012	We also showed that suppression of PS1 expression by SP600125 reduced gamma-secretase activity which decreased Notch 1 processing to reduce NICD in mouse brains.	pyrazolanthrone	53-61	notch 1	Mus musculus	111-118
22353755-8	2012	Furthermore, inhibition of Notch 1 processing by SP600125 decreased Notch 1 signaling by reducing the expression of the NICD target Hes1 gene in mouse brains without induction of apoptosis.	pyrazolanthrone	49-57	notch 1	Mus musculus	27-34
22353755-8	2012	Furthermore, inhibition of Notch 1 processing by SP600125 decreased Notch 1 signaling by reducing the expression of the NICD target Hes1 gene in mouse brains without induction of apoptosis.	pyrazolanthrone	49-57	notch 1	Mus musculus	68-75
22353755-8	2012	Furthermore, inhibition of Notch 1 processing by SP600125 decreased Notch 1 signaling by reducing the expression of the NICD target Hes1 gene in mouse brains without induction of apoptosis.	pyrazolanthrone	49-57	hes family bHLH transcription factor 1	Mus musculus	132-136
21612318-8	2012	After treatment with KN-62; (inhibitor of CaMKII) and SP600125 (inhibitor of JNK), there is a significant reduction in the expression of RyR2, indicating the role of these molecules in RyR2 regulation.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Rattus norvegicus	77-80
21612318-8	2012	After treatment with KN-62; (inhibitor of CaMKII) and SP600125 (inhibitor of JNK), there is a significant reduction in the expression of RyR2, indicating the role of these molecules in RyR2 regulation.	pyrazolanthrone	54-62	ryanodine receptor 2	Rattus norvegicus	137-141
21612318-8	2012	After treatment with KN-62; (inhibitor of CaMKII) and SP600125 (inhibitor of JNK), there is a significant reduction in the expression of RyR2, indicating the role of these molecules in RyR2 regulation.	pyrazolanthrone	54-62	ryanodine receptor 2	Rattus norvegicus	185-189
22509080-7	2012	The activation of JNKs and expression of FasL protein were inhibited in the pcDNA3.1-X transfected group when treated with a known JNK inhibitor, SP600125.	pyrazolanthrone	146-154	mitogen-activated protein kinase 8	Homo sapiens	18-21
22298641-5	2012	Inhibition of JNK (with SP600125) or Erk1/2 (with U0126) partially prevented curcumin-induced cell death in the cells.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	14-17
22285133-10	2012	Neuron apoptotic rate, examined by flow cytometry, is increased when CRH treatment and attenuated by salubrinal, thioredoxin (ASK1 inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	146-154	corticotropin releasing hormone	Homo sapiens	69-72
22182512-4	2012	Down-regulation of JNK by a specific inhibitor (SP600125) or dominant negative (DN) JNK1 plasmid enhanced TNF-alpha-induced VCAM-1 but not ICAM-1 expression.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	19-22
22182512-4	2012	Down-regulation of JNK by a specific inhibitor (SP600125) or dominant negative (DN) JNK1 plasmid enhanced TNF-alpha-induced VCAM-1 but not ICAM-1 expression.	pyrazolanthrone	48-56	tumor necrosis factor	Homo sapiens	106-115
22182512-4	2012	Down-regulation of JNK by a specific inhibitor (SP600125) or dominant negative (DN) JNK1 plasmid enhanced TNF-alpha-induced VCAM-1 but not ICAM-1 expression.	pyrazolanthrone	48-56	vascular cell adhesion molecule 1	Homo sapiens	124-130
22285133-10	2012	Neuron apoptotic rate, examined by flow cytometry, is increased when CRH treatment and attenuated by salubrinal, thioredoxin (ASK1 inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	146-154	mitogen-activated protein kinase 8	Homo sapiens	156-159
21590324-5	2012	Furthermore, JNK inhibitor SP600125, ERK inhibitor U0126, and p38 inhibitor SB203580 could all partially counteract NE"s effect on the phosphorylation of MAPKs, as well as TNF-alpha production by macrophages.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	13-16
21590324-5	2012	Furthermore, JNK inhibitor SP600125, ERK inhibitor U0126, and p38 inhibitor SB203580 could all partially counteract NE"s effect on the phosphorylation of MAPKs, as well as TNF-alpha production by macrophages.	pyrazolanthrone	27-35	tumor necrosis factor	Mus musculus	172-181
22200847-6	2012	In the presence of the JNK inhibitor SP600125, SDF-1alpha mRNA in PDL cells was not suppressed by the FGF-2 treatment.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	23-26
22015972-8	2012	The wet-to-dry weight ratio, MPO activity, IL-1beta, TNF-alpha, ICAM-1, p-JNK expressions, and lung pathologic injury scores in the SP600125 group decreased compared with those in the SAP group.	pyrazolanthrone	132-140	myeloperoxidase	Rattus norvegicus	29-32
22124574-9	2012	The combination of cyclosporin A or JNK inhibitor (SP600125) with acetaminophen blunted both acetaminophen-induced apoptotic and necrotic cell death in autophagy-deficient hepatocytes.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Mus musculus	36-39
22466127-9	2012	Pre-incubation with PD98059, SB203580, SP600125 or LY294002, but not BIM, inhibited the formaldehyde-induced increase of TRPV1 expression.	pyrazolanthrone	39-47	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	121-126
22015972-8	2012	The wet-to-dry weight ratio, MPO activity, IL-1beta, TNF-alpha, ICAM-1, p-JNK expressions, and lung pathologic injury scores in the SP600125 group decreased compared with those in the SAP group.	pyrazolanthrone	132-140	tumor necrosis factor	Rattus norvegicus	53-62
22015972-8	2012	The wet-to-dry weight ratio, MPO activity, IL-1beta, TNF-alpha, ICAM-1, p-JNK expressions, and lung pathologic injury scores in the SP600125 group decreased compared with those in the SAP group.	pyrazolanthrone	132-140	intercellular adhesion molecule 1	Rattus norvegicus	64-70
22015972-8	2012	The wet-to-dry weight ratio, MPO activity, IL-1beta, TNF-alpha, ICAM-1, p-JNK expressions, and lung pathologic injury scores in the SP600125 group decreased compared with those in the SAP group.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Rattus norvegicus	74-77
23577046-7	2012	In contrast, both pre- or post-injury thrombosis injection of RBC-tPA and JNK antagonist SP 600125 prevented impairment of Katp- and Kca-induced vasodilation.	pyrazolanthrone	89-98	mitogen-activated protein kinase 8	Sus scrofa	74-77
22285274-11	2012	A JNK specific inhibitor (SP600125) prevented the NaF-induced increase in growth arrest and the DNA damage-inducible protein 45alpha.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Mus musculus	2-5
22553064-8	2012	Role of JNK in NADPH oxidase-regulated H(2)O(2) productivity was pursued using specific inhibitors, including SP600125 and JNK inhibitory peptide (JIP).	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Mus musculus	8-11
22305016-9	2012	Suppression of phosphorylated JNK by the JNK inhibitor SP600125 greatly diminished TNF-alpha-induced expression of FAS and SREBP-1.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	30-33
22305016-9	2012	Suppression of phosphorylated JNK by the JNK inhibitor SP600125 greatly diminished TNF-alpha-induced expression of FAS and SREBP-1.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	41-44
22305016-9	2012	Suppression of phosphorylated JNK by the JNK inhibitor SP600125 greatly diminished TNF-alpha-induced expression of FAS and SREBP-1.	pyrazolanthrone	55-63	tumor necrosis factor	Homo sapiens	83-92
22305016-9	2012	Suppression of phosphorylated JNK by the JNK inhibitor SP600125 greatly diminished TNF-alpha-induced expression of FAS and SREBP-1.	pyrazolanthrone	55-63	sterol regulatory element binding transcription factor 1	Homo sapiens	123-130
22238304-6	2012	This effect of ORF12 protein was markedly inhibited by a MAPK/ERK kinase 1 and 2 (MEK1/2) inhibitor (U0126), partially blocked by a p38 inhibitor (SB202190), but not inhibited by a JNK inhibitor (SP600125).	pyrazolanthrone	196-204	tegument protein VP11/12	Human alphaherpesvirus 3	15-20
22238304-6	2012	This effect of ORF12 protein was markedly inhibited by a MAPK/ERK kinase 1 and 2 (MEK1/2) inhibitor (U0126), partially blocked by a p38 inhibitor (SB202190), but not inhibited by a JNK inhibitor (SP600125).	pyrazolanthrone	196-204	mitogen-activated protein kinase kinase 1	Homo sapiens	82-88
22198335-10	2012	SP600125 (C-jun terminal kinase inhibitor) and SB203580 (p38 inhibitor) attenuated both organ cultured-induced and mmLDL-induced upregulation of endothelin ET(B) receptors.	pyrazolanthrone	0-8	endothelin receptor type B	Rattus norvegicus	156-161
22166487-5	2012	Induction of ICAM-1 and phosphorylation of JNK and c-Jun could be inhibited by either JNK inhibitor SP600125 or Rac guanosine triphosphatase inhibitor NSC23766 pretreatment.	pyrazolanthrone	100-108	intercellular adhesion molecule 1	Homo sapiens	13-19
22166487-5	2012	Induction of ICAM-1 and phosphorylation of JNK and c-Jun could be inhibited by either JNK inhibitor SP600125 or Rac guanosine triphosphatase inhibitor NSC23766 pretreatment.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	43-46
22166487-5	2012	Induction of ICAM-1 and phosphorylation of JNK and c-Jun could be inhibited by either JNK inhibitor SP600125 or Rac guanosine triphosphatase inhibitor NSC23766 pretreatment.	pyrazolanthrone	100-108	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	51-56
22166487-5	2012	Induction of ICAM-1 and phosphorylation of JNK and c-Jun could be inhibited by either JNK inhibitor SP600125 or Rac guanosine triphosphatase inhibitor NSC23766 pretreatment.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	86-89
22314224-6	2012	By transient transfection analysis with the MMP-1 promoter (-2846 to -29 nt) and AP-1 promoter, MMP-1 and AP-1 promoter activities were induced by phorbol myristate acetate (PMA) but were significantly inhibited by PD98059 (ERK1/2 inhibitor) or SP600125 (JNK inhibitor).	pyrazolanthrone	245-253	matrix metallopeptidase 1	Homo sapiens	44-49
22314224-6	2012	By transient transfection analysis with the MMP-1 promoter (-2846 to -29 nt) and AP-1 promoter, MMP-1 and AP-1 promoter activities were induced by phorbol myristate acetate (PMA) but were significantly inhibited by PD98059 (ERK1/2 inhibitor) or SP600125 (JNK inhibitor).	pyrazolanthrone	245-253	matrix metallopeptidase 1	Homo sapiens	96-101
22314224-6	2012	By transient transfection analysis with the MMP-1 promoter (-2846 to -29 nt) and AP-1 promoter, MMP-1 and AP-1 promoter activities were induced by phorbol myristate acetate (PMA) but were significantly inhibited by PD98059 (ERK1/2 inhibitor) or SP600125 (JNK inhibitor).	pyrazolanthrone	245-253	mitogen-activated protein kinase 3	Homo sapiens	224-230
22314224-6	2012	By transient transfection analysis with the MMP-1 promoter (-2846 to -29 nt) and AP-1 promoter, MMP-1 and AP-1 promoter activities were induced by phorbol myristate acetate (PMA) but were significantly inhibited by PD98059 (ERK1/2 inhibitor) or SP600125 (JNK inhibitor).	pyrazolanthrone	245-253	mitogen-activated protein kinase 8	Homo sapiens	255-258
22283740-10	2012	Activation of p53 was suppressed by SP600125 and expression of p-JNK was inhibited by PFT-alpha, therefore silibinin might activate a ROS-JNK-p53 cycle to induce cell death.	pyrazolanthrone	36-44	tumor protein p53	Homo sapiens	14-17
22252084-13	2012	Cells pre-treated with U0126 and SP600125 were rescued from the GnRH antagonist-mediated inhibition of cell growth and did not exhibit GnRH antagonist-induced apoptosis and downstream GADD45alpha signaling.	pyrazolanthrone	33-41	gonadotropin releasing hormone 1	Homo sapiens	64-68
22083546-10	2012	In contrast, oxLDL had no stimulatory effect on the phosphorylation of JNK, and pretreatment with SP600125 (an inhibitor of JNK) produced no significant effect on oxLDL-induced MMP-2 production.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Rattus norvegicus	124-127
22261521-4	2012	Specific inhibitors of MEK-1 (PD98059) and JNK (SP600125) inhibited the nicotine-induced uPAR expression, while the p38 MAPK inhibitor SB203580 did not.	pyrazolanthrone	48-56	plasminogen activator, urokinase receptor	Homo sapiens	89-93
22222819-11	2012	Pretreatment with SP600125 or PD 98059 attenuated the levobupivacaine-induced phosphorylation of JNK and ERK, respectively.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	97-100
22222819-11	2012	Pretreatment with SP600125 or PD 98059 attenuated the levobupivacaine-induced phosphorylation of JNK and ERK, respectively.	pyrazolanthrone	18-26	Eph receptor B1	Rattus norvegicus	105-108
22049209-5	2012	Ischemic conditions have been shown to activate p38 and JNK MAP kinases (MAPKs) in brain, and the p38 and JNK inhibitors SB-239063 and SP-600125, respectively, have been found to reduce brain damage following middle cerebral artery occlusion and subarachnoid hemorrhage, respectively.	pyrazolanthrone	135-144	mitogen activated protein kinase 14	Rattus norvegicus	98-101
22173130-6	2012	This anti-neurotoxic action of L(3)Co was reduced by SP600125 and PD98059, selective inhibitors of c-Jun NH2-terminal kinase (JNK) and extracellular signal regulated kinase (ERK) kinase (MEK)1/2 respectively.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	99-124
22173130-6	2012	This anti-neurotoxic action of L(3)Co was reduced by SP600125 and PD98059, selective inhibitors of c-Jun NH2-terminal kinase (JNK) and extracellular signal regulated kinase (ERK) kinase (MEK)1/2 respectively.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	126-129
22173130-6	2012	This anti-neurotoxic action of L(3)Co was reduced by SP600125 and PD98059, selective inhibitors of c-Jun NH2-terminal kinase (JNK) and extracellular signal regulated kinase (ERK) kinase (MEK)1/2 respectively.	pyrazolanthrone	53-61	mitogen-activated protein kinase kinase 1	Homo sapiens	135-194
22085843-10	2012	Transfection with ERK2- and JNK-specific si-RNA and specific inhibitors SP600125 and PD98059 could inhibit ERK1/2 and JNK activation and attenuate MMP loss and caspase-3 activity induced by the Cu(2+)/PDTC complex.	pyrazolanthrone	72-80	mitogen activated protein kinase 1	Rattus norvegicus	18-22
22085843-10	2012	Transfection with ERK2- and JNK-specific si-RNA and specific inhibitors SP600125 and PD98059 could inhibit ERK1/2 and JNK activation and attenuate MMP loss and caspase-3 activity induced by the Cu(2+)/PDTC complex.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Rattus norvegicus	28-31
22085843-10	2012	Transfection with ERK2- and JNK-specific si-RNA and specific inhibitors SP600125 and PD98059 could inhibit ERK1/2 and JNK activation and attenuate MMP loss and caspase-3 activity induced by the Cu(2+)/PDTC complex.	pyrazolanthrone	72-80	mitogen activated protein kinase 3	Rattus norvegicus	107-113
22085843-10	2012	Transfection with ERK2- and JNK-specific si-RNA and specific inhibitors SP600125 and PD98059 could inhibit ERK1/2 and JNK activation and attenuate MMP loss and caspase-3 activity induced by the Cu(2+)/PDTC complex.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Rattus norvegicus	118-121
22085843-10	2012	Transfection with ERK2- and JNK-specific si-RNA and specific inhibitors SP600125 and PD98059 could inhibit ERK1/2 and JNK activation and attenuate MMP loss and caspase-3 activity induced by the Cu(2+)/PDTC complex.	pyrazolanthrone	72-80	caspase 3	Rattus norvegicus	160-169
22049209-5	2012	Ischemic conditions have been shown to activate p38 and JNK MAP kinases (MAPKs) in brain, and the p38 and JNK inhibitors SB-239063 and SP-600125, respectively, have been found to reduce brain damage following middle cerebral artery occlusion and subarachnoid hemorrhage, respectively.	pyrazolanthrone	135-144	mitogen-activated protein kinase 8	Rattus norvegicus	106-109
22293420-6	2012	To investigate the effect of JNK-specific inhibitor SP600125, chondrocytes were pretreated with SP600125 ahead of SNP treatment.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	29-32
22154513-8	2012	B type CpG-DNA decreased the poly(I:C)-induced phosphorylation of c-Jun N-terminal kinase (JNK), and pre-incubation with SP600125 (inhibitor of JNK) reduced the poly(I:C)-induced TSLP-production.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	66-89
22154513-8	2012	B type CpG-DNA decreased the poly(I:C)-induced phosphorylation of c-Jun N-terminal kinase (JNK), and pre-incubation with SP600125 (inhibitor of JNK) reduced the poly(I:C)-induced TSLP-production.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	91-94
22154513-8	2012	B type CpG-DNA decreased the poly(I:C)-induced phosphorylation of c-Jun N-terminal kinase (JNK), and pre-incubation with SP600125 (inhibitor of JNK) reduced the poly(I:C)-induced TSLP-production.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	144-147
22154513-8	2012	B type CpG-DNA decreased the poly(I:C)-induced phosphorylation of c-Jun N-terminal kinase (JNK), and pre-incubation with SP600125 (inhibitor of JNK) reduced the poly(I:C)-induced TSLP-production.	pyrazolanthrone	121-129	thymic stromal lymphopoietin	Homo sapiens	179-183
21792602-9	2012	While pretreatment with PD098059 had no marked inhibitory effect on MMP-9 expression induced by TNF-alpha or IL-1beta, SP600125 decreased significantly the MMP-9 expression induced by TNF-alpha or IL-1beta.	pyrazolanthrone	119-127	matrix metallopeptidase 9	Homo sapiens	156-161
21792602-9	2012	While pretreatment with PD098059 had no marked inhibitory effect on MMP-9 expression induced by TNF-alpha or IL-1beta, SP600125 decreased significantly the MMP-9 expression induced by TNF-alpha or IL-1beta.	pyrazolanthrone	119-127	tumor necrosis factor	Homo sapiens	184-193
21792602-9	2012	While pretreatment with PD098059 had no marked inhibitory effect on MMP-9 expression induced by TNF-alpha or IL-1beta, SP600125 decreased significantly the MMP-9 expression induced by TNF-alpha or IL-1beta.	pyrazolanthrone	119-127	interleukin 1 beta	Homo sapiens	197-205
22076560-6	2012	In a             series of NSCLC cell lines, inhibition of JNK using SP600125 resulted in inhibition             of 4E-BP1 phosphorylation and a decrease in formation of the cap-dependent translation             complex, eIF4F.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	59-62
22076560-6	2012	In a             series of NSCLC cell lines, inhibition of JNK using SP600125 resulted in inhibition             of 4E-BP1 phosphorylation and a decrease in formation of the cap-dependent translation             complex, eIF4F.	pyrazolanthrone	69-77	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	116-122
22076560-6	2012	In a             series of NSCLC cell lines, inhibition of JNK using SP600125 resulted in inhibition             of 4E-BP1 phosphorylation and a decrease in formation of the cap-dependent translation             complex, eIF4F.	pyrazolanthrone	69-77	eukaryotic translation initiation factor 4 gamma 1	Homo sapiens	221-226
22293420-8	2012	Moreover, we found that SP600125 significantly decreased NO-induced NF-kappaB, p53, caspase-3 protein expressions and caspase-3 mRNA expression, as well as intracellular caspase-3 activity (P &lt; 0.05).	pyrazolanthrone	24-32	caspase-3	Oryctolagus cuniculus	84-93
22293420-8	2012	Moreover, we found that SP600125 significantly decreased NO-induced NF-kappaB, p53, caspase-3 protein expressions and caspase-3 mRNA expression, as well as intracellular caspase-3 activity (P &lt; 0.05).	pyrazolanthrone	24-32	caspase-3	Oryctolagus cuniculus	118-127
22293420-8	2012	Moreover, we found that SP600125 significantly decreased NO-induced NF-kappaB, p53, caspase-3 protein expressions and caspase-3 mRNA expression, as well as intracellular caspase-3 activity (P &lt; 0.05).	pyrazolanthrone	24-32	caspase-3	Oryctolagus cuniculus	118-127
21993883-9	2012	Additionally, IL-17A induced MAPK (ERK1/2 but not p38 MAPK or JNK) activation, and pharmacological inhibitors of MEK1/2 (U0126) but not of p38 MAPK (SB203580) or JNK (SP600125), significantly blocked the IL-17A-mediated G-CSF release.	pyrazolanthrone	167-175	interleukin 17A	Homo sapiens	14-20
22490359-8	2012	CONCLUSIONS: The present results indicate that SP600125 can dramatically improve trauma brain injury from autophagy after DBI and the molecular mechanism is related to the modulation of JNK signal pathway following DBI, while it measures the neuron autophagy by means of intervening JNK signal pathway.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Rattus norvegicus	186-189
22490359-8	2012	CONCLUSIONS: The present results indicate that SP600125 can dramatically improve trauma brain injury from autophagy after DBI and the molecular mechanism is related to the modulation of JNK signal pathway following DBI, while it measures the neuron autophagy by means of intervening JNK signal pathway.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Rattus norvegicus	283-286
22142847-4	2012	In addition, the selective p38 inhibitor SB203580 suppressed PhSe-T/MeSe-T-induced apoptosis and activation of caspase-3, -9, -8, and -2, whereas the jun amino-terminal kinase (JNK) inhibitor SP600125 and the ERK inhibitor PD98059 had no effect.	pyrazolanthrone	192-200	mitogen-activated protein kinase 14	Homo sapiens	27-30
22080750-7	2012	PGE(2)-induced IL-8 production was accompanied by p38 phosphorylation and was significantly inhibited by a p38 inhibitor, SB-203580, but not by an ERK1/2 inhibitor, U-0126, or a JNK inhibitor, SP-600125.	pyrazolanthrone	193-202	C-X-C motif chemokine ligand 8	Homo sapiens	15-19
21946058-11	2012	The inhibitors of p38(MAPK) (sb202190) and JNK (sp600125) enhanced the inhibition induced by As2O3, which was counteracted by anisomycin, an activating agent of p38(MAPK) and JNK.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	43-46
22212430-9	2012	Pretreating with the JNK inhibitor SP600125 (3-30 mumol/L) or transfection with DNs of JNK1/2 significantly attenuated thrombin-induced CTGF expression.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Rattus norvegicus	21-24
22212430-9	2012	Pretreating with the JNK inhibitor SP600125 (3-30 mumol/L) or transfection with DNs of JNK1/2 significantly attenuated thrombin-induced CTGF expression.	pyrazolanthrone	35-43	coagulation factor II	Rattus norvegicus	119-127
22212430-9	2012	Pretreating with the JNK inhibitor SP600125 (3-30 mumol/L) or transfection with DNs of JNK1/2 significantly attenuated thrombin-induced CTGF expression.	pyrazolanthrone	35-43	cellular communication network factor 2	Rattus norvegicus	136-140
22212430-10	2012	Thrombin (0.3-3.0 U/mL) increased activator protein-1 (AP-1)-luciferase activity, which was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	123-131	coagulation factor II	Rattus norvegicus	0-8
22212430-10	2012	Thrombin (0.3-3.0 U/mL) increased activator protein-1 (AP-1)-luciferase activity, which was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	123-131	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	34-53
22212430-10	2012	Thrombin (0.3-3.0 U/mL) increased activator protein-1 (AP-1)-luciferase activity, which was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	123-131	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-59
22212430-10	2012	Thrombin (0.3-3.0 U/mL) increased activator protein-1 (AP-1)-luciferase activity, which was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Rattus norvegicus	109-112
22068148-0	2012	SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	51-57
21946058-11	2012	The inhibitors of p38(MAPK) (sb202190) and JNK (sp600125) enhanced the inhibition induced by As2O3, which was counteracted by anisomycin, an activating agent of p38(MAPK) and JNK.	pyrazolanthrone	48-56	mitogen-activated protein kinase 14	Homo sapiens	161-164
22068148-1	2012	The pharmacological inhibitor SP600125 [anthra(1,9-cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone] has been largely employed as a c-JUN N-terminal kinase (JNK1/2) inhibitor.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	150-154
22068148-1	2012	The pharmacological inhibitor SP600125 [anthra(1,9-cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone] has been largely employed as a c-JUN N-terminal kinase (JNK1/2) inhibitor.	pyrazolanthrone	40-71	mitogen-activated protein kinase 8	Homo sapiens	150-154
21946058-11	2012	The inhibitors of p38(MAPK) (sb202190) and JNK (sp600125) enhanced the inhibition induced by As2O3, which was counteracted by anisomycin, an activating agent of p38(MAPK) and JNK.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	175-178
22068148-1	2012	The pharmacological inhibitor SP600125 [anthra(1,9-cd)pyrazol-6(2H)-one 1,9-pyrazoloanthrone] has been largely employed as a c-JUN N-terminal kinase (JNK1/2) inhibitor.	pyrazolanthrone	72-92	mitogen-activated protein kinase 8	Homo sapiens	150-154
22068148-3	2012	We found that incubation with SP600125 not only blocked virus-stimulated JNK phosphorylation, but also, significantly reduced virus production.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	73-76
22938480-9	2012	Phosphorylation of JNK and Akt were abolished by the specific inhibitors SP600125 and LY294002, respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	19-22
22938480-9	2012	Phosphorylation of JNK and Akt were abolished by the specific inhibitors SP600125 and LY294002, respectively.	pyrazolanthrone	73-81	AKT serine/threonine kinase 1	Homo sapiens	27-30
22863969-7	2012	The fomitoside-K induced cell death by ROS was significantly inhibited by NAC, ERK (PD98059) and JNK inhibitor (SP600125).	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	97-100
22863922-3	2012	Importantly, treatment of SAS cells with a combination of the AHL analog and the Jun N-terminal kinase (JNK) inhibitor, SP600125, prevented mitosis and induced polyploidy.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	81-102
22863922-3	2012	Importantly, treatment of SAS cells with a combination of the AHL analog and the Jun N-terminal kinase (JNK) inhibitor, SP600125, prevented mitosis and induced polyploidy.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	104-107
22474427-12	2012	Furthermore, cytokine-stimulated JNK pathway downregulated the bcl-2 promoter activity which was reversed by preincubation with SP600125, a JNK inhibitor.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Mus musculus	33-36
21806545-9	2012	Atorvastatin, SP600125, JNK siRNA (small interfering RNA) and NAC (N-acetylcysteine) completely attenuated the leptin and phospho-JNK protein expression induced by Ang II.	pyrazolanthrone	14-22	leptin	Homo sapiens	111-117
21806545-9	2012	Atorvastatin, SP600125, JNK siRNA (small interfering RNA) and NAC (N-acetylcysteine) completely attenuated the leptin and phospho-JNK protein expression induced by Ang II.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	130-133
21806545-9	2012	Atorvastatin, SP600125, JNK siRNA (small interfering RNA) and NAC (N-acetylcysteine) completely attenuated the leptin and phospho-JNK protein expression induced by Ang II.	pyrazolanthrone	14-22	angiogenin	Homo sapiens	164-167
21806545-12	2012	Addition of atorvastatin and SP600125 inhibited the phosphorylation of Rac1 induced by Ang II.	pyrazolanthrone	29-37	Rac family small GTPase 1	Homo sapiens	71-75
21627650-7	2012	Hypoxia-induced increase in urotensin II protein and ROS was significantly attenuated after the addition of SP600125, JNK siRNA or N-acetylcysteine before hypoxia treatment.	pyrazolanthrone	108-116	urotensin 2	Rattus norvegicus	28-40
21627650-8	2012	The phosphorylated JNK protein was induced by hypoxia and was abolished by pretreatment with SP600125, losartan (an angiotensin II receptor antagonist) or N-acetylcysteine.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Rattus norvegicus	19-22
21627650-8	2012	The phosphorylated JNK protein was induced by hypoxia and was abolished by pretreatment with SP600125, losartan (an angiotensin II receptor antagonist) or N-acetylcysteine.	pyrazolanthrone	93-101	angiotensinogen	Rattus norvegicus	116-130
22832115-5	2012	C-Jun N-terminal kinase (JNK) inhibitor, SP600125 diminished IL-1-stimulated JNK phosphorylation, ADAMTS-4 mRNA expression and enzyme activity.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	0-39
22832115-5	2012	C-Jun N-terminal kinase (JNK) inhibitor, SP600125 diminished IL-1-stimulated JNK phosphorylation, ADAMTS-4 mRNA expression and enzyme activity.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	25-28
22832115-5	2012	C-Jun N-terminal kinase (JNK) inhibitor, SP600125 diminished IL-1-stimulated JNK phosphorylation, ADAMTS-4 mRNA expression and enzyme activity.	pyrazolanthrone	41-49	ADAM metallopeptidase with thrombospondin type 1 motif 4	Homo sapiens	98-106
21806545-12	2012	Addition of atorvastatin and SP600125 inhibited the phosphorylation of Rac1 induced by Ang II.	pyrazolanthrone	29-37	angiogenin	Homo sapiens	87-90
21806545-13	2012	The gel shift and promoter activity assay showed that Ang II increased AP-1 (activator protein-1)-binding activity and leptin promoter activity, while SP600125, NAC and atorvastatin inhibited the AP-1-binding activity and leptin promoter activity induced by Ang II.	pyrazolanthrone	151-159	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	196-200
21806545-13	2012	The gel shift and promoter activity assay showed that Ang II increased AP-1 (activator protein-1)-binding activity and leptin promoter activity, while SP600125, NAC and atorvastatin inhibited the AP-1-binding activity and leptin promoter activity induced by Ang II.	pyrazolanthrone	151-159	leptin	Homo sapiens	222-228
21806545-13	2012	The gel shift and promoter activity assay showed that Ang II increased AP-1 (activator protein-1)-binding activity and leptin promoter activity, while SP600125, NAC and atorvastatin inhibited the AP-1-binding activity and leptin promoter activity induced by Ang II.	pyrazolanthrone	151-159	angiogenin	Homo sapiens	258-261
21806545-15	2012	Ang II significantly increased secretion of leptin from human VSMCs, and addition of SP600125, atorvastatin and NAC before Ang II stimulation almost completely inhibited the leptin secretion induced by Ang II.	pyrazolanthrone	85-93	leptin	Homo sapiens	174-180
22474427-12	2012	Furthermore, cytokine-stimulated JNK pathway downregulated the bcl-2 promoter activity which was reversed by preincubation with SP600125, a JNK inhibitor.	pyrazolanthrone	128-136	B cell leukemia/lymphoma 2	Mus musculus	63-68
22474427-12	2012	Furthermore, cytokine-stimulated JNK pathway downregulated the bcl-2 promoter activity which was reversed by preincubation with SP600125, a JNK inhibitor.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Mus musculus	140-143
22005927-7	2012	Signal transduction studies indicated that the ox-LDL-induced MCP-1 expression in VSMCs could be partly reversed by the inhibitor of p38 MAPK (SB203580) and NF-kappaB (BAY11-7082), whereas the ERK inhibitor (PD98059) and the JNK inhibitor (SP600125) had no effect.	pyrazolanthrone	240-248	C-C motif chemokine ligand 2	Rattus norvegicus	62-67
22064360-8	2012	Addition of pharmacological kinase inhibitors, U0126, SP600125, and LY294002, caused cytotoxicity and the last significantly attenuated NOB- and DTF-mediated antiapoptotic actions, indicating the involvement of PI3K/Akt signaling in their cytoprotective effects.	pyrazolanthrone	54-62	AKT serine/threonine kinase 1	Rattus norvegicus	216-219
22110547-7	2012	In addition, EBNE-induced production of IL-6 and VEGF was inhibited by PD98059 (a p44/42 MAPK inhibitor), SB203580 (a p38 MAPK inhibitor), and PDTC (a NF-kappaB inhibitor), but not SP600125 (a JNK inhibitor).	pyrazolanthrone	181-189	interleukin 6	Homo sapiens	40-44
22110547-7	2012	In addition, EBNE-induced production of IL-6 and VEGF was inhibited by PD98059 (a p44/42 MAPK inhibitor), SB203580 (a p38 MAPK inhibitor), and PDTC (a NF-kappaB inhibitor), but not SP600125 (a JNK inhibitor).	pyrazolanthrone	181-189	vascular endothelial growth factor A	Homo sapiens	49-53
22005927-7	2012	Signal transduction studies indicated that the ox-LDL-induced MCP-1 expression in VSMCs could be partly reversed by the inhibitor of p38 MAPK (SB203580) and NF-kappaB (BAY11-7082), whereas the ERK inhibitor (PD98059) and the JNK inhibitor (SP600125) had no effect.	pyrazolanthrone	240-248	mitogen activated protein kinase 14	Rattus norvegicus	133-136
22870247-6	2012	Our findings indicate that blocking the JNK pathway by pathway inhibitor SP600125 reduces the expression level and transport function of ABCG2 in drug-resistant cells SW116/HCPT.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	40-43
22606012-5	2012	Pre-treatment with JNK inhibitor SP600125 could attenuate NF-kappaB inactivation and restored H929 cells" survival.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
22247602-7	2012	As for the phosphorylation pathway, PD98059 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor) decreased caspase-1 activity and interleukin-1beta production to approximately 50% of the controls.	pyrazolanthrone	95-103	mitogen-activated protein kinase 8	Homo sapiens	105-111
23240010-6	2012	MAPK"s role in IL-1beta-induced COX-2 expression was assessed by treating cells with ERK (PD98059), JNK (SP600125) and p38 MAPK (SB203580) inhibitors (0.1-10 microM) prior to IL-1beta exposure.	pyrazolanthrone	105-113	interleukin 1 beta	Homo sapiens	15-23
23240010-6	2012	MAPK"s role in IL-1beta-induced COX-2 expression was assessed by treating cells with ERK (PD98059), JNK (SP600125) and p38 MAPK (SB203580) inhibitors (0.1-10 microM) prior to IL-1beta exposure.	pyrazolanthrone	105-113	prostaglandin-endoperoxide synthase 2	Homo sapiens	32-37
23049844-10	2012	By using a very specific Mps1 inhibitor (SP600125) we show that compromised AtMps1 activity hampers the development of A. thaliana seedlings in a dose-dependent manner, especially in secondary roots.	pyrazolanthrone	41-49	multipolar spindle 1	Arabidopsis thaliana	25-29
23049844-10	2012	By using a very specific Mps1 inhibitor (SP600125) we show that compromised AtMps1 activity hampers the development of A. thaliana seedlings in a dose-dependent manner, especially in secondary roots.	pyrazolanthrone	41-49	multipolar spindle 1	Arabidopsis thaliana	76-82
22844495-9	2012	Both triterpenes at high doses produced an increase in annexing-V binding in the presence or absence of angiotensin II, which was reduced by either SP600125 or GW9662.	pyrazolanthrone	148-156	angiotensinogen	Rattus norvegicus	104-118
22082983-4	2012	S100B-induced MCP-1 expression was dose-dependently blocked by inhibitors of JNK (SP600125), p38 (SB203580), MEK-1 (U0126) as well as NF-kappaB (Bay117085).	pyrazolanthrone	82-90	S100 calcium binding protein B	Rattus norvegicus	0-5
22082983-4	2012	S100B-induced MCP-1 expression was dose-dependently blocked by inhibitors of JNK (SP600125), p38 (SB203580), MEK-1 (U0126) as well as NF-kappaB (Bay117085).	pyrazolanthrone	82-90	C-C motif chemokine ligand 2	Rattus norvegicus	14-19
22082983-6	2012	S100B-induced MCP-1 promoter activity via NF-kappaB binding sites and nuclear translocation of NF-kappaB p65 subunit were blocked by SP600125, U0126, and SB203580 in RAGE-A10.	pyrazolanthrone	133-141	S100 calcium binding protein B	Rattus norvegicus	0-5
22082983-6	2012	S100B-induced MCP-1 promoter activity via NF-kappaB binding sites and nuclear translocation of NF-kappaB p65 subunit were blocked by SP600125, U0126, and SB203580 in RAGE-A10.	pyrazolanthrone	133-141	C-C motif chemokine ligand 2	Rattus norvegicus	14-19
22082983-6	2012	S100B-induced MCP-1 promoter activity via NF-kappaB binding sites and nuclear translocation of NF-kappaB p65 subunit were blocked by SP600125, U0126, and SB203580 in RAGE-A10.	pyrazolanthrone	133-141	advanced glycosylation end product-specific receptor	Rattus norvegicus	166-174
22247602-7	2012	As for the phosphorylation pathway, PD98059 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor) decreased caspase-1 activity and interleukin-1beta production to approximately 50% of the controls.	pyrazolanthrone	95-103	caspase 1	Homo sapiens	133-142
22032908-10	2012	Interestingly, SRP induced a 3.21 fold increase in the JNK activity, whilst SP600125 (a JNK inhibitor) blocked the SRP-induced inter-nucleosomal DNA fragmentation.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	88-91
21964832-6	2012	In addition, TPA-induced down-regulation of             p53 mRNA and protein expression was increased by UO126, but not by SP600125 and             SB203580.	pyrazolanthrone	123-131	plasminogen activator, tissue type	Homo sapiens	13-16
23227240-8	2012	CTGF-mediated increase of NF-kappaB and AP-1 luciferase activity was inhibited by SB203580 and SP600125 or ASK1 shRNA or p38 and JNK mutant.	pyrazolanthrone	95-103	cellular communication network factor 2	Homo sapiens	0-4
22952879-6	2012	We presently found that the JNK antagonist, SP600125, (but not the p38 antagonist, SB203580) increased plasma corticosterone levels under resting conditions and in the context of an acute stressor (wet bedding + restraint).	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	28-31
22870247-6	2012	Our findings indicate that blocking the JNK pathway by pathway inhibitor SP600125 reduces the expression level and transport function of ABCG2 in drug-resistant cells SW116/HCPT.	pyrazolanthrone	73-81	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	137-142
22870247-7	2012	Notably, the experiments of small interfering RNA directed against JNK1 and JNK2 show that only silence of JNK1 gene has the equal effect as SP600125 on dephosphorylation of transcription factor c-Jun and the expression of ABCG2 protein, while the corresponding phenomena were not observed after silence of JNK2 gene.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	67-71
22870247-7	2012	Notably, the experiments of small interfering RNA directed against JNK1 and JNK2 show that only silence of JNK1 gene has the equal effect as SP600125 on dephosphorylation of transcription factor c-Jun and the expression of ABCG2 protein, while the corresponding phenomena were not observed after silence of JNK2 gene.	pyrazolanthrone	141-149	mitogen-activated protein kinase 9	Homo sapiens	76-80
22870247-7	2012	Notably, the experiments of small interfering RNA directed against JNK1 and JNK2 show that only silence of JNK1 gene has the equal effect as SP600125 on dephosphorylation of transcription factor c-Jun and the expression of ABCG2 protein, while the corresponding phenomena were not observed after silence of JNK2 gene.	pyrazolanthrone	141-149	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	195-200
22870247-7	2012	Notably, the experiments of small interfering RNA directed against JNK1 and JNK2 show that only silence of JNK1 gene has the equal effect as SP600125 on dephosphorylation of transcription factor c-Jun and the expression of ABCG2 protein, while the corresponding phenomena were not observed after silence of JNK2 gene.	pyrazolanthrone	141-149	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	223-228
22870247-8	2012	Meanwhile, SP600125 induces the apoptosis of SW116/HCPT cells by promoting the cleavage of PARP and suppressing the anti-apoptotic protein survivin and bcl-2, and increases the sensitivity of SW1116/HCPT to HCPT.	pyrazolanthrone	11-19	collagen type XI alpha 2 chain	Homo sapiens	91-95
22870247-8	2012	Meanwhile, SP600125 induces the apoptosis of SW116/HCPT cells by promoting the cleavage of PARP and suppressing the anti-apoptotic protein survivin and bcl-2, and increases the sensitivity of SW1116/HCPT to HCPT.	pyrazolanthrone	11-19	BCL2 apoptosis regulator	Homo sapiens	152-157
21900690-6	2011	The JNK inhibitor SP600125 reduced ANG II-induced IRS-1 Ser307 phosphorylation (by 80%), IRS-1 Ser302 phosphorylation (by 70%), and IRS-1 Ser632 phosphorylation (by 50%).	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
22655080-6	2012	In contrast, inhibition of JNK1/2 by the specific inhibitor SP600125 actually increased the level of expression and production of MMP-9 at both mRNA and protein levels, respectively by almost five fold.	pyrazolanthrone	60-68	matrix metallopeptidase 9	Mus musculus	130-135
22655080-9	2012	In contrast to and in parallel with the LOS-induced increased levels of MMP-9 in the presence of SP600125, we found a corresponding dose-dependent inhibition of TIMP-1 (tissue inhibitor of matrix metalloproteinase-1) secretion.	pyrazolanthrone	97-105	matrix metallopeptidase 9	Mus musculus	72-77
22276160-9	2012	Disruption of the JNK signal pathway by small interfering RNA (siRNA) against JNK or JNK specific inhibitor, SP-600125 inhibited the activation of p53 and attenuated apoptosis induced by RITA in myeloma cells carrying wild type p53.	pyrazolanthrone	109-118	mitogen-activated protein kinase 8	Homo sapiens	18-21
22276160-9	2012	Disruption of the JNK signal pathway by small interfering RNA (siRNA) against JNK or JNK specific inhibitor, SP-600125 inhibited the activation of p53 and attenuated apoptosis induced by RITA in myeloma cells carrying wild type p53.	pyrazolanthrone	109-118	tumor protein p53	Homo sapiens	147-150
22276160-9	2012	Disruption of the JNK signal pathway by small interfering RNA (siRNA) against JNK or JNK specific inhibitor, SP-600125 inhibited the activation of p53 and attenuated apoptosis induced by RITA in myeloma cells carrying wild type p53.	pyrazolanthrone	109-118	RBPJ interacting and tubulin associated 1	Homo sapiens	187-191
22276160-9	2012	Disruption of the JNK signal pathway by small interfering RNA (siRNA) against JNK or JNK specific inhibitor, SP-600125 inhibited the activation of p53 and attenuated apoptosis induced by RITA in myeloma cells carrying wild type p53.	pyrazolanthrone	109-118	tumor protein p53	Homo sapiens	228-231
21911303-5	2011	JNK inhibitor Sp600125 attenuated DS/Cu/Dox-induced apoptosis and suppressed DS/Cu/Dox-induced protein expression in JNK/c-jun pathway.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
21911303-5	2011	JNK inhibitor Sp600125 attenuated DS/Cu/Dox-induced apoptosis and suppressed DS/Cu/Dox-induced protein expression in JNK/c-jun pathway.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	117-120
21911303-5	2011	JNK inhibitor Sp600125 attenuated DS/Cu/Dox-induced apoptosis and suppressed DS/Cu/Dox-induced protein expression in JNK/c-jun pathway.	pyrazolanthrone	14-22	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	121-126
22545125-7	2012	SP600125 or JNK shRNA increased Rgs4 expression in the absence or presence of IL-1beta stimulation.	pyrazolanthrone	0-8	regulator of G-protein signaling 4	Oryctolagus cuniculus	32-36
22545125-9	2012	Both constitutive and inducible upregulation of Rgs4 expression by SP600125 was significantly inhibited by pretreatment with the transcription inhibitor, actinomycin D.	pyrazolanthrone	67-75	regulator of G-protein signaling 4	Oryctolagus cuniculus	48-52
22545125-10	2012	Dual reporter assay showed that pretreatment with SP600125 sensitized the promoter activity of Rgs4 in response to IL-1beta.	pyrazolanthrone	50-58	regulator of G-protein signaling 4	Oryctolagus cuniculus	95-99
22545125-10	2012	Dual reporter assay showed that pretreatment with SP600125 sensitized the promoter activity of Rgs4 in response to IL-1beta.	pyrazolanthrone	50-58	interleukin-1 beta	Oryctolagus cuniculus	115-123
21983652-8	2011	Increases in HSP27 phosphorylation were suppressed by pretreating cells with SB203580 or SP600125, which are inhibitors of p38 MAPK or JNK, respectively.	pyrazolanthrone	89-97	heat shock protein family B (small) member 1	Homo sapiens	13-18
21983652-8	2011	Increases in HSP27 phosphorylation were suppressed by pretreating cells with SB203580 or SP600125, which are inhibitors of p38 MAPK or JNK, respectively.	pyrazolanthrone	89-97	mitogen-activated protein kinase 1	Homo sapiens	123-126
21983652-8	2011	Increases in HSP27 phosphorylation were suppressed by pretreating cells with SB203580 or SP600125, which are inhibitors of p38 MAPK or JNK, respectively.	pyrazolanthrone	89-97	mitogen-activated protein kinase 3	Homo sapiens	127-131
21983652-8	2011	Increases in HSP27 phosphorylation were suppressed by pretreating cells with SB203580 or SP600125, which are inhibitors of p38 MAPK or JNK, respectively.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	135-138
21900690-6	2011	The JNK inhibitor SP600125 reduced ANG II-induced IRS-1 Ser307 phosphorylation (by 80%), IRS-1 Ser302 phosphorylation (by 70%), and IRS-1 Ser632 phosphorylation (by 50%).	pyrazolanthrone	18-26	angiotensinogen	Homo sapiens	35-41
21900690-6	2011	The JNK inhibitor SP600125 reduced ANG II-induced IRS-1 Ser307 phosphorylation (by 80%), IRS-1 Ser302 phosphorylation (by 70%), and IRS-1 Ser632 phosphorylation (by 50%).	pyrazolanthrone	18-26	insulin receptor substrate 1	Homo sapiens	50-55
21900690-6	2011	The JNK inhibitor SP600125 reduced ANG II-induced IRS-1 Ser307 phosphorylation (by 80%), IRS-1 Ser302 phosphorylation (by 70%), and IRS-1 Ser632 phosphorylation (by 50%).	pyrazolanthrone	18-26	insulin receptor substrate 1	Homo sapiens	89-94
21900690-6	2011	The JNK inhibitor SP600125 reduced ANG II-induced IRS-1 Ser307 phosphorylation (by 80%), IRS-1 Ser302 phosphorylation (by 70%), and IRS-1 Ser632 phosphorylation (by 50%).	pyrazolanthrone	18-26	insulin receptor substrate 1	Homo sapiens	89-94
21840417-5	2011	An inhibitor of c-Jun N-terminal kinase (JNK), SP600125, suppressed the SPC-induced phosphorylation of serine 431 in K8 and keratin reorganization.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	16-39
21840417-5	2011	An inhibitor of c-Jun N-terminal kinase (JNK), SP600125, suppressed the SPC-induced phosphorylation of serine 431 in K8 and keratin reorganization.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	41-44
21840417-5	2011	An inhibitor of c-Jun N-terminal kinase (JNK), SP600125, suppressed the SPC-induced phosphorylation of serine 431 in K8 and keratin reorganization.	pyrazolanthrone	47-55	keratin 8	Homo sapiens	117-119
21964323-5	2011	In this study we examine the effects of an anthrapyrazolone inhibitor of JNK (SP600125) on inducible osteoprogenitors as well as Nf1-deficient and Nf1-null primary osteoblasts.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	73-76
21889928-6	2011	Lonidamine/ATO stimulates JNK phosphorylation/activation, and apoptosis is attenuated by the JNK inhibitor SP600125.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	93-96
21964323-9	2011	Next, SP600125 was used to treat these cells and was found to facilitate osteogenesis in Nf1-deficient osteoprogenitors, and in Nf1-null osteoblasts when given in conjunction with rhBMP-2.	pyrazolanthrone	6-14	neurofibromin 1	Mus musculus	89-92
21826704-11	2011	Chemical inhibition of JNK1/2 (SP600125) in MPD cells increased IGF-I expression (non-significantly), however, did not enhance differentiation.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Mus musculus	23-29
21826704-11	2011	Chemical inhibition of JNK1/2 (SP600125) in MPD cells increased IGF-I expression (non-significantly), however, did not enhance differentiation.	pyrazolanthrone	31-39	insulin-like growth factor 1	Mus musculus	64-69
22099899-9	2011	SP600125 (c-Jun N-terminal kinase [JNK] inhibitor) prevented the up-regulation of RANKL expression in P. endodontalis LPS-infected osteoblasts (P &lt; .05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	35-38
21925842-8	2011	The specific pharmacological inhibitors UO126 and SP600125 were used to block Erk1/2 and JNK activity.	pyrazolanthrone	50-58	mitogen-activated protein kinase 3	Homo sapiens	78-84
22099899-9	2011	SP600125 (c-Jun N-terminal kinase [JNK] inhibitor) prevented the up-regulation of RANKL expression in P. endodontalis LPS-infected osteoblasts (P &lt; .05).	pyrazolanthrone	0-8	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	82-87
21925842-8	2011	The specific pharmacological inhibitors UO126 and SP600125 were used to block Erk1/2 and JNK activity.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	89-92
21771752-11	2011	Increased nuclear NF-kappaB activation was blocked by inhibitors of ERK (PD98059) or JNK (SP600125), but not affected by p38 MAPK inhibitor (SB203580).	pyrazolanthrone	90-98	nuclear factor kappa B subunit 1	Homo sapiens	18-27
20638679-14	2011	In contrast, inhibition of JNK (SP-600125) significantly enhanced the stimulatory effect of AGE on MMP-9.	pyrazolanthrone	32-41	mitogen-activated protein kinase 8	Homo sapiens	27-30
20638679-14	2011	In contrast, inhibition of JNK (SP-600125) significantly enhanced the stimulatory effect of AGE on MMP-9.	pyrazolanthrone	32-41	matrix metallopeptidase 9	Homo sapiens	99-104
21771752-11	2011	Increased nuclear NF-kappaB activation was blocked by inhibitors of ERK (PD98059) or JNK (SP600125), but not affected by p38 MAPK inhibitor (SB203580).	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Homo sapiens	85-88
21964475-5	2011	In addition, pretreatment of U937 cells with SP600125 (JNK inhibitor) or SB203589 (p38 MAPK inhibitor) dose-dependently inhibited the proteolytic cleavage of PARP.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	55-58
22056552-9	2011	Moreover, the phosphorylation states of Ser(217/221)-MEK and Thr(183)/Tyr(185)-p42MAPK were increased by Tianeptine and specific kinase blockers of the MAPK pathways (PD 98095, SB 203580 and SP600125) prevented the effects of Tianeptine.	pyrazolanthrone	191-199	mitogen-activated protein kinase 1	Mus musculus	79-86
22056552-9	2011	Moreover, the phosphorylation states of Ser(217/221)-MEK and Thr(183)/Tyr(185)-p42MAPK were increased by Tianeptine and specific kinase blockers of the MAPK pathways (PD 98095, SB 203580 and SP600125) prevented the effects of Tianeptine.	pyrazolanthrone	191-199	mitogen-activated protein kinase 1	Mus musculus	82-86
21963187-9	2011	The ERK inhibitor U0126, JNK inhibitor SP600125 and p38 MAPK inhibitor SB202190 all significantly decreased IL-beta-induced MMP-9 gene expression and pro MMP-9 in human primary amnion cells.	pyrazolanthrone	39-47	matrix metallopeptidase 9	Homo sapiens	124-129
21963187-9	2011	The ERK inhibitor U0126, JNK inhibitor SP600125 and p38 MAPK inhibitor SB202190 all significantly decreased IL-beta-induced MMP-9 gene expression and pro MMP-9 in human primary amnion cells.	pyrazolanthrone	39-47	matrix metallopeptidase 9	Homo sapiens	154-159
21958719-8	2011	Inhibition of JNK using SP600125 prevented the EFV- and 8-OHEFV-mediated cell death.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	14-17
21964475-5	2011	In addition, pretreatment of U937 cells with SP600125 (JNK inhibitor) or SB203589 (p38 MAPK inhibitor) dose-dependently inhibited the proteolytic cleavage of PARP.	pyrazolanthrone	45-53	collagen type XI alpha 2 chain	Homo sapiens	158-162
21843586-8	2011	These NiCl(2)-induced apoptosis-related signaling responses could be effectively reversed by specific JNK inhibitor SP600125.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Rattus norvegicus	102-105
22025571-3	2011	METHODS: Keratocytes, isolated from rabbit corneal stroma, and cultured in a serum-free medium, pretreated or not treated with JNK inhibitor (SP600125), were activated with FGF-2/heparin sulfate (HS) or TGF-beta1 in the presence or absence of SP600125.	pyrazolanthrone	142-150	fibroblast growth factor 2	Oryctolagus cuniculus	173-178
22025571-3	2011	METHODS: Keratocytes, isolated from rabbit corneal stroma, and cultured in a serum-free medium, pretreated or not treated with JNK inhibitor (SP600125), were activated with FGF-2/heparin sulfate (HS) or TGF-beta1 in the presence or absence of SP600125.	pyrazolanthrone	243-251	fibroblast growth factor 2	Oryctolagus cuniculus	173-178
21843499-3	2011	We found that pretreatment of SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), or an anti-oxidant, N-acetylcysteine (NAC), could not only prevent Daxx from trafficking but also increase the number of the surviving CA1 pyramidal cells of hippocampus at 5days of reperfusion.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	56-79
22033475-9	2011	Additionally, the treatment of inhibitors specific for PI3K (wortmannin), JNK (SP600125) or p38 MAPK (SB203580) to MDA-MB-231 cells could result in a reduced activation of MMP-9, concomitantly with a marked inhibition on cell migration and invasion.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	74-77
22033475-9	2011	Additionally, the treatment of inhibitors specific for PI3K (wortmannin), JNK (SP600125) or p38 MAPK (SB203580) to MDA-MB-231 cells could result in a reduced activation of MMP-9, concomitantly with a marked inhibition on cell migration and invasion.	pyrazolanthrone	79-87	matrix metallopeptidase 9	Homo sapiens	172-177
21843499-3	2011	We found that pretreatment of SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), or an anti-oxidant, N-acetylcysteine (NAC), could not only prevent Daxx from trafficking but also increase the number of the surviving CA1 pyramidal cells of hippocampus at 5days of reperfusion.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	81-84
21843499-3	2011	We found that pretreatment of SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), or an anti-oxidant, N-acetylcysteine (NAC), could not only prevent Daxx from trafficking but also increase the number of the surviving CA1 pyramidal cells of hippocampus at 5days of reperfusion.	pyrazolanthrone	30-38	death-domain associated protein	Rattus norvegicus	154-158
21843499-3	2011	We found that pretreatment of SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), or an anti-oxidant, N-acetylcysteine (NAC), could not only prevent Daxx from trafficking but also increase the number of the surviving CA1 pyramidal cells of hippocampus at 5days of reperfusion.	pyrazolanthrone	30-38	carbonic anhydrase 1	Rattus norvegicus	222-225
21843499-5	2011	We found the treatment of SP600125 or NAC could decrease the activation of Ask1 during ischemia/reperfusion and suppress the assembly of the Fas Daxx Ask1 signaling module, and in succession inhibit JNK activation and c-Jun phosphorylation.	pyrazolanthrone	26-34	mitogen-activated protein kinase kinase kinase 5	Rattus norvegicus	75-79
21843499-5	2011	We found the treatment of SP600125 or NAC could decrease the activation of Ask1 during ischemia/reperfusion and suppress the assembly of the Fas Daxx Ask1 signaling module, and in succession inhibit JNK activation and c-Jun phosphorylation.	pyrazolanthrone	26-34	death-domain associated protein	Rattus norvegicus	145-149
21843499-5	2011	We found the treatment of SP600125 or NAC could decrease the activation of Ask1 during ischemia/reperfusion and suppress the assembly of the Fas Daxx Ask1 signaling module, and in succession inhibit JNK activation and c-Jun phosphorylation.	pyrazolanthrone	26-34	mitogen-activated protein kinase kinase kinase 5	Rattus norvegicus	150-154
21843499-5	2011	We found the treatment of SP600125 or NAC could decrease the activation of Ask1 during ischemia/reperfusion and suppress the assembly of the Fas Daxx Ask1 signaling module, and in succession inhibit JNK activation and c-Jun phosphorylation.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Rattus norvegicus	199-202
21911753-6	2011	Chronic exposure of INS 832/13 cells to glucolipotoxic conditions resulted in increased JNK1/2 phosphorylation and caspase-3 activity; such effects were largely reversed by SP600125, a selective inhibitor of JNK.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	88-92
21911753-6	2011	Chronic exposure of INS 832/13 cells to glucolipotoxic conditions resulted in increased JNK1/2 phosphorylation and caspase-3 activity; such effects were largely reversed by SP600125, a selective inhibitor of JNK.	pyrazolanthrone	173-181	caspase 3	Rattus norvegicus	115-124
21911753-6	2011	Chronic exposure of INS 832/13 cells to glucolipotoxic conditions resulted in increased JNK1/2 phosphorylation and caspase-3 activity; such effects were largely reversed by SP600125, a selective inhibitor of JNK.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Rattus norvegicus	88-91
22126015-5	2011	Use of specific chemical inhibitors for JAK1 kinase (piceatannol), JAK2 kinase (AG-490), MEK1/2 (PD98059) and JNK1/2 (SP600125) revealed that IL-1beta-induced iNOS expression involved signaling pathways in addition to JAK-STAT and ERK1/2-JNK1/2 activation.	pyrazolanthrone	118-126	interleukin 1 beta	Homo sapiens	142-150
21799126-8	2011	To confirm JNK involvement in apoptosis, cells treated with a specific JNK inhibitor, SP600125, and subjected to preexposure to hyperoxia, followed by mechanical stretch, exhibited significantly reduced evidence of apoptosis.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Mus musculus	11-14
21799126-8	2011	To confirm JNK involvement in apoptosis, cells treated with a specific JNK inhibitor, SP600125, and subjected to preexposure to hyperoxia, followed by mechanical stretch, exhibited significantly reduced evidence of apoptosis.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Mus musculus	71-74
21718796-7	2011	Additionally, E-selectin expression in human CF was markedly potentiated by the JNK inhibitor SP600125, but this was not observed when a more selective inhibitor ((L)-JNKI-1) was used, or in human vascular endothelial cells.	pyrazolanthrone	94-102	selectin E	Homo sapiens	14-24
21824499-4	2011	Local administration of SP600125, a JNK inhibitor, prevented accumulation of amyloid-beta precursor protein and retraction of the severed CST axons as well as preserved the axonal arbors rostral to the injury site.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Mus musculus	36-39
21716329-7	2011	Treatment of a p38MAP kinase inhibitor, SB203580 (10 micromol/l), and a JNK inhibitor, SP600125 (20 micromol/l), abrogated the [(3)H]-leucine incorporation by insulin in the presence of Ang II.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Rattus norvegicus	72-75
21716329-7	2011	Treatment of a p38MAP kinase inhibitor, SB203580 (10 micromol/l), and a JNK inhibitor, SP600125 (20 micromol/l), abrogated the [(3)H]-leucine incorporation by insulin in the presence of Ang II.	pyrazolanthrone	87-95	angiotensinogen	Rattus norvegicus	186-192
21311948-0	2011	Role of p21 in SP600125-induced cell cycle arrest, endoreduplication, and apoptosis.	pyrazolanthrone	15-23	H3 histone pseudogene 16	Homo sapiens	8-11
21311948-1	2011	The anti-cancer effect of the c-Jun N-terminal kinase (JNK) inhibitor SP600125 has been well evaluated in human cancer cells.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	30-53
21311948-1	2011	The anti-cancer effect of the c-Jun N-terminal kinase (JNK) inhibitor SP600125 has been well evaluated in human cancer cells.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	55-58
21311948-2	2011	However the role of p21 in SP600125-mediated G(2)/M distribution is not fully understood.	pyrazolanthrone	27-35	H3 histone pseudogene 16	Homo sapiens	20-23
21311948-3	2011	Our results showed that the transcriptional activation of p21 by SP600125 is mediated through the proximal regions of multiple Sp1 sites in the p21 promoter following ERK-dependent phosphorylation of Sp1.	pyrazolanthrone	65-73	H3 histone pseudogene 16	Homo sapiens	58-61
21311948-3	2011	Our results showed that the transcriptional activation of p21 by SP600125 is mediated through the proximal regions of multiple Sp1 sites in the p21 promoter following ERK-dependent phosphorylation of Sp1.	pyrazolanthrone	65-73	H3 histone pseudogene 16	Homo sapiens	144-147
21311948-3	2011	Our results showed that the transcriptional activation of p21 by SP600125 is mediated through the proximal regions of multiple Sp1 sites in the p21 promoter following ERK-dependent phosphorylation of Sp1.	pyrazolanthrone	65-73	mitogen-activated protein kinase 1	Homo sapiens	167-170
21311948-5	2011	Furthermore, SP600125 induces the phosphorylation of p21 at Thr 145 through the PI3K/Akt pathway.	pyrazolanthrone	13-21	H3 histone pseudogene 16	Homo sapiens	53-56
21311948-5	2011	Furthermore, SP600125 induces the phosphorylation of p21 at Thr 145 through the PI3K/Akt pathway.	pyrazolanthrone	13-21	AKT serine/threonine kinase 1	Homo sapiens	85-88
21077940-11	2011	In addition, the NF-kappaB inhibitor PDTC and JNK inhibitor SP600125 pretreatment partly abolished ox-LDL-induced LOX-1 expression.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Rattus norvegicus	46-49
21077940-11	2011	In addition, the NF-kappaB inhibitor PDTC and JNK inhibitor SP600125 pretreatment partly abolished ox-LDL-induced LOX-1 expression.	pyrazolanthrone	60-68	oxidized low density lipoprotein receptor 1	Rattus norvegicus	114-119
21873422-8	2011	Treatment of C57BL/6 mice with a general JNK inhibitor (SP600125) increased fatty acid oxidation in mice and a cardiomyocyte-derived cell line.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Mus musculus	41-44
21768780-7	2011	Further, we found that both the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125, inhibited the atorvastatin-induced elevation of LC3-II, suggesting that the effect of atorvastatin on autophagy is mediated by the Erk and JNK pathways.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	63-66
21768780-7	2011	Further, we found that both the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125, inhibited the atorvastatin-induced elevation of LC3-II, suggesting that the effect of atorvastatin on autophagy is mediated by the Erk and JNK pathways.	pyrazolanthrone	77-85	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	135-138
21768780-7	2011	Further, we found that both the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125, inhibited the atorvastatin-induced elevation of LC3-II, suggesting that the effect of atorvastatin on autophagy is mediated by the Erk and JNK pathways.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	226-229
21763418-9	2011	ROS antioxidants (N-acetylcysteine and vitamin C), the JNK-specific inhibitor SP600125, and JNK2 siRNA attenuated bufalin-induced autophagy.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	55-58
21718796-7	2011	Additionally, E-selectin expression in human CF was markedly potentiated by the JNK inhibitor SP600125, but this was not observed when a more selective inhibitor ((L)-JNKI-1) was used, or in human vascular endothelial cells.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	80-83
21744278-0	2011	JNK inhibition by SP600125 attenuates trans-10, cis-12 conjugated linoleic acid-mediated regulation of inflammatory and lipogenic gene expression.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	0-3
21744278-5	2011	SP600125 attenuated t10,c12 CLA-mediated induction of inflammatory genes, including interleukin (IL)-6, IL-8, IL-1beta, ATF3, monocyte chemoattractant protein (MCP)-1, and cyclooxygenase-2.	pyrazolanthrone	0-8	interleukin 1 beta	Homo sapiens	110-118
21618589-12	2011	Co-treatment of cardiomyocytes with doxorubicin and JNK inhibitor SP600125 (10 microM; 24 h) reduced JNK phosphorylation and enhanced cell survival, suggesting that the baicalein protection against doxorubicin cardiotoxicity was mediated by JNK activation.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	52-55
21618589-12	2011	Co-treatment of cardiomyocytes with doxorubicin and JNK inhibitor SP600125 (10 microM; 24 h) reduced JNK phosphorylation and enhanced cell survival, suggesting that the baicalein protection against doxorubicin cardiotoxicity was mediated by JNK activation.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	101-104
21618589-12	2011	Co-treatment of cardiomyocytes with doxorubicin and JNK inhibitor SP600125 (10 microM; 24 h) reduced JNK phosphorylation and enhanced cell survival, suggesting that the baicalein protection against doxorubicin cardiotoxicity was mediated by JNK activation.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	101-104
21744278-3	2011	Thus, we examined the extent to which blocking c-Jun NH2-terminal kinase (JNK) signaling using the JNK inhibitor SP600125 attenuated markers of inflammation and insulin resistance in primary human adipocytes treated with t10,c12 CLA.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	74-77
21744278-5	2011	SP600125 attenuated t10,c12 CLA-mediated induction of inflammatory genes, including interleukin (IL)-6, IL-8, IL-1beta, ATF3, monocyte chemoattractant protein (MCP)-1, and cyclooxygenase-2.	pyrazolanthrone	0-8	activating transcription factor 3	Homo sapiens	120-124
21744278-5	2011	SP600125 attenuated t10,c12 CLA-mediated induction of inflammatory genes, including interleukin (IL)-6, IL-8, IL-1beta, ATF3, monocyte chemoattractant protein (MCP)-1, and cyclooxygenase-2.	pyrazolanthrone	0-8	C-C motif chemokine ligand 2	Homo sapiens	126-166
21744278-3	2011	Thus, we examined the extent to which blocking c-Jun NH2-terminal kinase (JNK) signaling using the JNK inhibitor SP600125 attenuated markers of inflammation and insulin resistance in primary human adipocytes treated with t10,c12 CLA.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	99-102
21744278-5	2011	SP600125 attenuated t10,c12 CLA-mediated induction of inflammatory genes, including interleukin (IL)-6, IL-8, IL-1beta, ATF3, monocyte chemoattractant protein (MCP)-1, and cyclooxygenase-2.	pyrazolanthrone	0-8	prostaglandin-endoperoxide synthase 2	Homo sapiens	172-188
21744278-4	2011	SP600125 attenuated t10,c12 CLA-mediated phosphorylation of cJun and increased protein levels of activating transcription factor (ATF) 3, two downstream targets of JNK.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	60-64
21744278-6	2011	Consistent with these data, SP600125 prevented t10,c12 CLA-mediated secretion of IL-8, IL-6, and MCP-1.	pyrazolanthrone	28-36	C-X-C motif chemokine ligand 8	Homo sapiens	81-85
21744278-6	2011	Consistent with these data, SP600125 prevented t10,c12 CLA-mediated secretion of IL-8, IL-6, and MCP-1.	pyrazolanthrone	28-36	interleukin 6	Homo sapiens	87-91
21744278-4	2011	SP600125 attenuated t10,c12 CLA-mediated phosphorylation of cJun and increased protein levels of activating transcription factor (ATF) 3, two downstream targets of JNK.	pyrazolanthrone	0-8	activating transcription factor 3	Homo sapiens	97-136
21744278-6	2011	Consistent with these data, SP600125 prevented t10,c12 CLA-mediated secretion of IL-8, IL-6, and MCP-1.	pyrazolanthrone	28-36	C-C motif chemokine ligand 2	Homo sapiens	97-102
21744278-4	2011	SP600125 attenuated t10,c12 CLA-mediated phosphorylation of cJun and increased protein levels of activating transcription factor (ATF) 3, two downstream targets of JNK.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	164-167
21744278-7	2011	SP600125 prevented t10,c12 CLA suppression of lipogenic genes including peroxisome proliferator activated receptor gamma, liver X receptor, sterol regulatory element binding protein, acetyl-CoA carboxylase, and stearoyl-CoA desaturase.	pyrazolanthrone	0-8	CCHC-type zinc finger nucleic acid binding protein	Homo sapiens	140-181
21744278-7	2011	SP600125 prevented t10,c12 CLA suppression of lipogenic genes including peroxisome proliferator activated receptor gamma, liver X receptor, sterol regulatory element binding protein, acetyl-CoA carboxylase, and stearoyl-CoA desaturase.	pyrazolanthrone	0-8	stearoyl-CoA desaturase	Homo sapiens	211-234
21744278-8	2011	Additionally, SP600125 blocked t10,c12 CLA-mediated induction of suppressor of cytokine synthesis-3 and suppression of adiponectin and insulin-dependent glucose transporter 4 mRNA levels.	pyrazolanthrone	14-22	adiponectin, C1Q and collagen domain containing	Homo sapiens	119-130
21744278-5	2011	SP600125 attenuated t10,c12 CLA-mediated induction of inflammatory genes, including interleukin (IL)-6, IL-8, IL-1beta, ATF3, monocyte chemoattractant protein (MCP)-1, and cyclooxygenase-2.	pyrazolanthrone	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	104-108
21943220-5	2011	The JNK activity specific inhibitor, SP600125, and siRNA directed against JNK were used to block JNK/c-Jun pathway.	pyrazolanthrone	37-45	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	101-106
21756552-8	2011	RESULTS: CSF JNK MAPK was increased by FPI, increased further by tPA, but blocked by JNK antagonists SP600125 and D-JNKI1.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Sus scrofa	13-16
21856377-3	2011	Inhibiting JNK with a specific inhibitor, SP600125, reduced the levels of c-Jun phosphorylation and caspase-3 activation.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	11-14
21856377-3	2011	Inhibiting JNK with a specific inhibitor, SP600125, reduced the levels of c-Jun phosphorylation and caspase-3 activation.	pyrazolanthrone	42-50	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-79
21856377-3	2011	Inhibiting JNK with a specific inhibitor, SP600125, reduced the levels of c-Jun phosphorylation and caspase-3 activation.	pyrazolanthrone	42-50	caspase 3	Homo sapiens	100-109
21856377-4	2011	We also showed that use the JNK inhibitor SP600125, caspase inhibitor z-VAD, or use SP600125 and z-VAD together significantly suppressed cell death induced by heroin.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	28-31
21889036-10	2011	Inhibition of c-jun N-terminal kinase (JNK) by SP600125, p38 by SB 203580, or tyrosine kinase by genistein reduced arecoline-induced HO-1 expression.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	14-37
21889036-10	2011	Inhibition of c-jun N-terminal kinase (JNK) by SP600125, p38 by SB 203580, or tyrosine kinase by genistein reduced arecoline-induced HO-1 expression.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	39-42
21629969-5	2011	We divided 84 male ApoE(-/-) mice into two groups for treatment with normal saline (NS) (n = 42) and JNK inhibitor SP600125 (JNK-I) (n = 42).	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Mus musculus	101-104
21629969-10	2011	In HUVECs under low shear stress, siRNA knockdown and SP600125 inhibition of JNK attenuated nuclear factor (NF)-kappaB activity and VCAM-1 expression.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Mus musculus	77-80
21629969-10	2011	In HUVECs under low shear stress, siRNA knockdown and SP600125 inhibition of JNK attenuated nuclear factor (NF)-kappaB activity and VCAM-1 expression.	pyrazolanthrone	54-62	vascular cell adhesion molecule 1	Mus musculus	132-138
21697181-5	2011	Inhibition of ERK or Akt signaling reduced VS cell proliferation but did not increase apoptosis, whereas inhibition of JNK with SP600125, I-JIP, or siRNA knock-down reduced VS cell proliferation and survival by inducing apoptosis.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	119-122
21756552-8	2011	RESULTS: CSF JNK MAPK was increased by FPI, increased further by tPA, but blocked by JNK antagonists SP600125 and D-JNKI1.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Sus scrofa	85-88
21737448-10	2011	Osmotic stress induced a robust increase in tyrosine phosphorylation of occludin, which was attenuated by BAPTA, SP600125 (JNK inhibitor), or PP2.	pyrazolanthrone	113-121	occludin	Homo sapiens	72-80
22129822-5	2011	Similarly, SP600125 at the concentration of 1 muM blocked the re-expression of Nav1.3 partially (P&lt;0.001), and at 10 and 100 muM blocked Nav1.3 completely (P&lt;0.001).	pyrazolanthrone	11-19	sodium voltage-gated channel alpha subunit 3	Rattus norvegicus	79-85
21737448-10	2011	Osmotic stress induced a robust increase in tyrosine phosphorylation of occludin, which was attenuated by BAPTA, SP600125 (JNK inhibitor), or PP2.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	123-126
22111069-9	2011	The inhibitory effect of theaflavin on MCP-1 expression was inhibited by SP600125 (JNK inhibitor).	pyrazolanthrone	73-81	chemokine (C-C motif) ligand 2	Mus musculus	39-44
21596101-5	2011	The JNK inhibitor SP600125, applied immediately post-injury, resulted in an upregulation of nNOS protein both in injured spinal cords and motoneurons and caused a slight alleviation of motoneuron death by inhibiting c-jun phosphorylation at 14 days post-injury.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
21596101-5	2011	The JNK inhibitor SP600125, applied immediately post-injury, resulted in an upregulation of nNOS protein both in injured spinal cords and motoneurons and caused a slight alleviation of motoneuron death by inhibiting c-jun phosphorylation at 14 days post-injury.	pyrazolanthrone	18-26	nitric oxide synthase 1	Homo sapiens	92-96
21596101-5	2011	The JNK inhibitor SP600125, applied immediately post-injury, resulted in an upregulation of nNOS protein both in injured spinal cords and motoneurons and caused a slight alleviation of motoneuron death by inhibiting c-jun phosphorylation at 14 days post-injury.	pyrazolanthrone	18-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	216-221
21050133-11	2011	In vivo treatment with the Jnk inhibitor SP600125 blocked the HGF-induced mobilization of EPCs.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	27-30
21050133-11	2011	In vivo treatment with the Jnk inhibitor SP600125 blocked the HGF-induced mobilization of EPCs.	pyrazolanthrone	41-49	hepatocyte growth factor	Homo sapiens	62-65
21050133-12	2011	Ex vivo, SP600125 blocked HGF-induced migration and tube formation.	pyrazolanthrone	9-17	hepatocyte growth factor	Homo sapiens	26-29
21669197-8	2011	Supplementation with MAPK inhibitor (MEK inhibitor PD98059, p38 MAPK inhibitor SB203580 and JNK inhibitor SP600125) or Cariporide all exhibited significant depression of MDA-MB-231 cells invasion and MT1-MMP expression.	pyrazolanthrone	106-114	mitogen-activated protein kinase 8	Homo sapiens	92-95
21669197-8	2011	Supplementation with MAPK inhibitor (MEK inhibitor PD98059, p38 MAPK inhibitor SB203580 and JNK inhibitor SP600125) or Cariporide all exhibited significant depression of MDA-MB-231 cells invasion and MT1-MMP expression.	pyrazolanthrone	106-114	matrix metallopeptidase 14	Homo sapiens	200-207
21572099-5	2011	Both JNK/SAPK inhibitor SP600125 and JNK/SAPK peptide inhibitor 420116 could inhibit bFGF-induced HUVECs proliferation, migration and tube formation, so did JNK/SAPK-specific siRNA.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	5-13
21572099-5	2011	Both JNK/SAPK inhibitor SP600125 and JNK/SAPK peptide inhibitor 420116 could inhibit bFGF-induced HUVECs proliferation, migration and tube formation, so did JNK/SAPK-specific siRNA.	pyrazolanthrone	24-32	fibroblast growth factor 2	Homo sapiens	85-89
20524115-4	2011	NO-induced MMP-13 expression was not suppressed by extracellular signal-regulated kinase (ERK) inhibitor (PD98059) or inhibitors of p38 kinase (SB203580), but was inhibited by a c-jun terminal kinase (JNK) inhibitor (SP600125) and inhibitors of NF-kappaB (SN-50).	pyrazolanthrone	217-225	matrix metallopeptidase 13	Homo sapiens	11-17
20524115-4	2011	NO-induced MMP-13 expression was not suppressed by extracellular signal-regulated kinase (ERK) inhibitor (PD98059) or inhibitors of p38 kinase (SB203580), but was inhibited by a c-jun terminal kinase (JNK) inhibitor (SP600125) and inhibitors of NF-kappaB (SN-50).	pyrazolanthrone	217-225	mitogen-activated protein kinase 8	Homo sapiens	201-204
21520062-8	2011	Association of p300 and histone H4 to cPLA(2) promoter was inhibited by U0126, SB202190, and SP600125.	pyrazolanthrone	93-101	E1A binding protein p300	Homo sapiens	15-19
22111069-9	2011	The inhibitory effect of theaflavin on MCP-1 expression was inhibited by SP600125 (JNK inhibitor).	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Mus musculus	83-86
21647617-7	2011	Furthermore, downregulation of AQP1 expression by LPS was blocked by SB203580, SP600125, and PD98059, which are inhibitors of p38, JNK, and ERK1/2, respectively.	pyrazolanthrone	79-87	aquaporin 1 (Colton blood group)	Homo sapiens	31-35
21636835-6	2011	The Akt inhibitor API-2 and the c-Jun N-terminal kinase (JNK) inhibitor SP600125 selectively inhibited insulin regulation of CIDEA and CIDEC expression, respectively, whereas the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 did not.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	32-55
21636835-6	2011	The Akt inhibitor API-2 and the c-Jun N-terminal kinase (JNK) inhibitor SP600125 selectively inhibited insulin regulation of CIDEA and CIDEC expression, respectively, whereas the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 did not.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	57-60
21636835-6	2011	The Akt inhibitor API-2 and the c-Jun N-terminal kinase (JNK) inhibitor SP600125 selectively inhibited insulin regulation of CIDEA and CIDEC expression, respectively, whereas the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 did not.	pyrazolanthrone	72-80	insulin	Homo sapiens	103-110
21636835-6	2011	The Akt inhibitor API-2 and the c-Jun N-terminal kinase (JNK) inhibitor SP600125 selectively inhibited insulin regulation of CIDEA and CIDEC expression, respectively, whereas the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 did not.	pyrazolanthrone	72-80	cell death inducing DFFA like effector a	Homo sapiens	125-130
21636835-6	2011	The Akt inhibitor API-2 and the c-Jun N-terminal kinase (JNK) inhibitor SP600125 selectively inhibited insulin regulation of CIDEA and CIDEC expression, respectively, whereas the MAPK/ERK kinase inhibitor U0126 and the p38 inhibitor SB203580 did not.	pyrazolanthrone	72-80	cell death inducing DFFA like effector c	Homo sapiens	135-140
21647617-7	2011	Furthermore, downregulation of AQP1 expression by LPS was blocked by SB203580, SP600125, and PD98059, which are inhibitors of p38, JNK, and ERK1/2, respectively.	pyrazolanthrone	79-87	mitogen-activated protein kinase 1	Homo sapiens	126-129
21647617-7	2011	Furthermore, downregulation of AQP1 expression by LPS was blocked by SB203580, SP600125, and PD98059, which are inhibitors of p38, JNK, and ERK1/2, respectively.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	131-134
21319226-7	2011	Further results showed that JNK inhibitor SP600125 and 420116 both reversed ANDRO-induced cytotoxicity, and SP600125 also decreased ANDRO-increased intracellular GSH and GCL activity.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	28-31
21647617-7	2011	Furthermore, downregulation of AQP1 expression by LPS was blocked by SB203580, SP600125, and PD98059, which are inhibitors of p38, JNK, and ERK1/2, respectively.	pyrazolanthrone	79-87	mitogen-activated protein kinase 3	Homo sapiens	140-146
21319226-7	2011	Further results showed that JNK inhibitor SP600125 and 420116 both reversed ANDRO-induced cytotoxicity, and SP600125 also decreased ANDRO-increased intracellular GSH and GCL activity.	pyrazolanthrone	108-116	germ cell-less 2, spermatogenesis associated	Homo sapiens	170-173
21610153-11	2011	The synergistic interaction of rapamycin and etoposide was lower when the c-Jun pathway was suppressed by a c-Jun N-terminal kinase inhibitor (SP600125).	pyrazolanthrone	143-151	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	74-79
21565259-9	2011	When SH-SY5Y cells were singly treated with SP600125, an inhibitor of phospho-JNK, the decreased expression of phospho-JNK, but no apoptosis, was detected.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	78-81
21565259-9	2011	When SH-SY5Y cells were singly treated with SP600125, an inhibitor of phospho-JNK, the decreased expression of phospho-JNK, but no apoptosis, was detected.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	119-122
21565259-10	2011	Interestingly, after JNK phosphorylation in the cultured cells was inhibited by SP600125, the treatment with high-fluoride did not induce the increase of apoptosis.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Rattus norvegicus	21-24
21610153-11	2011	The synergistic interaction of rapamycin and etoposide was lower when the c-Jun pathway was suppressed by a c-Jun N-terminal kinase inhibitor (SP600125).	pyrazolanthrone	143-151	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	108-113
21550972-8	2011	L-threonine-induced activation of mTOR, p70S6K, and 4E-BP1 as well as cyclins and Oct4 were blocked by PD 98059 (ERK inhibitor), SB 203580 (p38 inhibitor) or SP 600125 (JNK inhibitor).	pyrazolanthrone	158-167	mechanistic target of rapamycin kinase	Mus musculus	34-38
21550972-8	2011	L-threonine-induced activation of mTOR, p70S6K, and 4E-BP1 as well as cyclins and Oct4 were blocked by PD 98059 (ERK inhibitor), SB 203580 (p38 inhibitor) or SP 600125 (JNK inhibitor).	pyrazolanthrone	158-167	mitogen-activated protein kinase 14	Mus musculus	140-143
21558088-2	2011	SP600125 is a low-molecular weight compound that has been widely used to inhibit c-Jun-N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	81-104
21558088-2	2011	SP600125 is a low-molecular weight compound that has been widely used to inhibit c-Jun-N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	106-109
21558088-5	2011	145:345-354, 2009) indicated that SP600125 also inhibits phosphatidylinositol 3-kinase (PI3K) in an isoform-selective fashion: it efficiently inhibited the delta isoform of p110 catalytic subunit (p110delta), which is primarily expressed in leucocytes, but neither of the ubiquitously expressed isoforms, p110alpha and p110gamma.	pyrazolanthrone	34-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	57-86
21558088-5	2011	145:345-354, 2009) indicated that SP600125 also inhibits phosphatidylinositol 3-kinase (PI3K) in an isoform-selective fashion: it efficiently inhibited the delta isoform of p110 catalytic subunit (p110delta), which is primarily expressed in leucocytes, but neither of the ubiquitously expressed isoforms, p110alpha and p110gamma.	pyrazolanthrone	34-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	173-206
21558088-5	2011	145:345-354, 2009) indicated that SP600125 also inhibits phosphatidylinositol 3-kinase (PI3K) in an isoform-selective fashion: it efficiently inhibited the delta isoform of p110 catalytic subunit (p110delta), which is primarily expressed in leucocytes, but neither of the ubiquitously expressed isoforms, p110alpha and p110gamma.	pyrazolanthrone	34-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	305-314
21558088-5	2011	145:345-354, 2009) indicated that SP600125 also inhibits phosphatidylinositol 3-kinase (PI3K) in an isoform-selective fashion: it efficiently inhibited the delta isoform of p110 catalytic subunit (p110delta), which is primarily expressed in leucocytes, but neither of the ubiquitously expressed isoforms, p110alpha and p110gamma.	pyrazolanthrone	34-42	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Homo sapiens	319-328
21138480-7	2011	The caspases activation was inhibited by JNK inhibitor SP600125.	pyrazolanthrone	55-63	caspase 8	Homo sapiens	4-12
21138480-7	2011	The caspases activation was inhibited by JNK inhibitor SP600125.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	41-44
21682888-10	2011	The IL-1beta-stimulated levels of IL-6 were suppressed by wedelolactone (an inhibitor of IkappaB kinase), SP600125 (an inhibitor of SAPK/JNK), and JAK inhibitor I (an inhibitor of JAK 1, 2 and 3).	pyrazolanthrone	106-114	interleukin 1 beta	Rattus norvegicus	4-12
21710638-5	2011	Two MAPK8/9 inhibitors that work by different mechanisms, LJNKl1 and SP600125, block induction of Eomes protein by stress.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	4-9
21710638-5	2011	Two MAPK8/9 inhibitors that work by different mechanisms, LJNKl1 and SP600125, block induction of Eomes protein by stress.	pyrazolanthrone	69-77	eomesodermin	Homo sapiens	98-103
21621522-9	2011	Furthermore, treatment with SP600125 (a JNK inhibitor) and PD98059 (an ERK1/2 inhibitor) prior to ZL11n treatment was found to significantly reverse ZL11n-induced apoptosis.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	40-43
21682888-10	2011	The IL-1beta-stimulated levels of IL-6 were suppressed by wedelolactone (an inhibitor of IkappaB kinase), SP600125 (an inhibitor of SAPK/JNK), and JAK inhibitor I (an inhibitor of JAK 1, 2 and 3).	pyrazolanthrone	106-114	interleukin 6	Rattus norvegicus	34-38
21628505-6	2011	And CuB-induced autophagy was associated with c-Jun N-terminal kinase (JNK) activation, at least partly, since inhibition of JNK activity by SP600125 could alleviate the autophagy.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Mus musculus	71-74
21463260-6	2011	Serum-induced phosphorylation and degradation of JDP2 are specific to JNK activation since a JNK inhibitor (SP600125) abolishes these effects, whereas p38 and MEK inhibitors (SB203580 and UO126) have no effect.	pyrazolanthrone	108-116	Jun dimerization protein 2	Homo sapiens	49-53
21463260-6	2011	Serum-induced phosphorylation and degradation of JDP2 are specific to JNK activation since a JNK inhibitor (SP600125) abolishes these effects, whereas p38 and MEK inhibitors (SB203580 and UO126) have no effect.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	70-73
21463260-6	2011	Serum-induced phosphorylation and degradation of JDP2 are specific to JNK activation since a JNK inhibitor (SP600125) abolishes these effects, whereas p38 and MEK inhibitors (SB203580 and UO126) have no effect.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	93-96
21463260-8	2011	Pre-treatment of cells with SP600125 prior to cycloheximide treatment significantly prolongs the half-life of JDP2 that is found mainly in the unphosphorylated form.	pyrazolanthrone	28-36	Jun dimerization protein 2	Homo sapiens	110-114
21453755-8	2011	The results demonstrated that the protection of osthole was partly reversed by PD98059, a selective inhibitor of ERK1/2, but further enhanced by the JNK inhibitor SP600125.	pyrazolanthrone	163-171	mitogen-activated protein kinase 8	Rattus norvegicus	149-152
21453755-9	2011	In addition, osthole-induced reduction of neuronal apoptosis was abrogated by the ERK1/2 inhibitor PD98059, whereas the total neuronal death was further decreased by the JNK inhibitor SP600125.	pyrazolanthrone	184-192	mitogen-activated protein kinase 8	Rattus norvegicus	170-173
21628505-6	2011	And CuB-induced autophagy was associated with c-Jun N-terminal kinase (JNK) activation, at least partly, since inhibition of JNK activity by SP600125 could alleviate the autophagy.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Mus musculus	125-128
21435358-5	2011	Furthermore, SP600125 (a specific inhibitor of JNK) and 1400W (a specific inhibitor of iNOS) significantly attenuated cell apoptosis induced by high glucose.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	47-50
21250978-12	2011	Inhibition of JNK with SP600125 attenuated the mitochondrial translocation of JNK.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	14-17
21699754-4	2011	In addition, the transcriptional activity of hST3Gal V induced by VPA in ARPE-19 cells was inhibited by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	104-112	ST3 beta-galactoside alpha-2,3-sialyltransferase 5	Homo sapiens	45-54
21250978-12	2011	Inhibition of JNK with SP600125 attenuated the mitochondrial translocation of JNK.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	78-81
21699754-4	2011	In addition, the transcriptional activity of hST3Gal V induced by VPA in ARPE-19 cells was inhibited by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Homo sapiens	116-155
21250978-11	2011	RH1-induced generation and mitochondrial translocation of cleaved Bax were blocked by the JNK inhibitor, SP600125.	pyrazolanthrone	105-113	BCL2 associated X, apoptosis regulator	Homo sapiens	66-69
21250978-11	2011	RH1-induced generation and mitochondrial translocation of cleaved Bax were blocked by the JNK inhibitor, SP600125.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	90-93
21419123-8	2011	Interestingly, both L-NAME (NOS inhibitor) and SP600125 (JNK1/2 inhibitor) reversed the effects produced by UCB either alone, or in association with pro-inflammatory cytokines.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	57-63
20945380-7	2011	In contrast, PGN-induced IL-6 mRNA and protein up-regulation were attenuated by the SAPK/JNK (c-Jun N-terminal kinases) inhibitor SP600125.	pyrazolanthrone	130-138	interleukin 6	Homo sapiens	25-29
20945380-7	2011	In contrast, PGN-induced IL-6 mRNA and protein up-regulation were attenuated by the SAPK/JNK (c-Jun N-terminal kinases) inhibitor SP600125.	pyrazolanthrone	130-138	mitogen-activated protein kinase 8	Homo sapiens	89-92
20945380-7	2011	In contrast, PGN-induced IL-6 mRNA and protein up-regulation were attenuated by the SAPK/JNK (c-Jun N-terminal kinases) inhibitor SP600125.	pyrazolanthrone	130-138	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	94-99
20945380-13	2011	Co-transfection with dominant negative mutant of JNK (DN-JNK), or treatment with SP600125, curcumin, or Tanshinone IIA effectively antagonized PGN-increased IL-6 transcription activity.	pyrazolanthrone	81-89	interleukin 6	Homo sapiens	157-161
21478152-7	2011	Inhibition of JNK (with JNK inhibitor SP600125 or using dominant-negative JNK) reduced serine 307 phosphorylation of IRS1.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	14-17
21482077-8	2011	STI571-mediated a ROS-dependent apoptosis potentiated by JNK inhibitor SP600125 was first identified in melanoma B16F0 cells.	pyrazolanthrone	71-79	mitogen-activated protein kinase 8	Mus musculus	57-60
21354245-7	2011	Pretreatment of rat primary astrocytes with the MAPK kinase inhibitor U0126 or the JNK inhibitor SP600125 strongly inhibited imipramine-stimulated EGR-1 expression.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Rattus norvegicus	83-86
21354245-7	2011	Pretreatment of rat primary astrocytes with the MAPK kinase inhibitor U0126 or the JNK inhibitor SP600125 strongly inhibited imipramine-stimulated EGR-1 expression.	pyrazolanthrone	97-105	early growth response 1	Rattus norvegicus	147-152
21112663-10	2011	Pretreatment of A549 cells with SP600125, an inhibitor of JNK1, significantly lowered LPS-induced SP-A mRNA production.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	58-62
21112663-10	2011	Pretreatment of A549 cells with SP600125, an inhibitor of JNK1, significantly lowered LPS-induced SP-A mRNA production.	pyrazolanthrone	32-40	surfactant protein A1	Homo sapiens	98-102
21263381-3	2011	The JNK MAPK inhibitor, SP600125, on the contrary, influences neither stress-fiber formation nor EC tight-junction damage.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	4-7
21263381-5	2011	Western blotting, real-time reverse transcriptase-polymerase chain reaction, and confocal laser scanning microscopy proved that SP600125 significantly inhibits burn serum-induced intercellular adhesion molecule 1 expression, whereas SB203580 depresses the expression of P selectin.	pyrazolanthrone	128-136	intercellular adhesion molecule 1	Homo sapiens	179-212
21263381-5	2011	Western blotting, real-time reverse transcriptase-polymerase chain reaction, and confocal laser scanning microscopy proved that SP600125 significantly inhibits burn serum-induced intercellular adhesion molecule 1 expression, whereas SB203580 depresses the expression of P selectin.	pyrazolanthrone	128-136	selectin P	Homo sapiens	270-280
21478152-7	2011	Inhibition of JNK (with JNK inhibitor SP600125 or using dominant-negative JNK) reduced serine 307 phosphorylation of IRS1.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	24-27
21478152-7	2011	Inhibition of JNK (with JNK inhibitor SP600125 or using dominant-negative JNK) reduced serine 307 phosphorylation of IRS1.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	24-27
21478152-7	2011	Inhibition of JNK (with JNK inhibitor SP600125 or using dominant-negative JNK) reduced serine 307 phosphorylation of IRS1.	pyrazolanthrone	38-46	insulin receptor substrate 1	Homo sapiens	117-121
21324487-4	2011	Overexpression of a constitutively negative mutant of JNK in LS174T cells or treatment of LS174T cells with the JNK inhibitor SP600125 were used to determine the role of JNK in rapamycin-mediated tumor growth inhibition.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	112-115
21324487-4	2011	Overexpression of a constitutively negative mutant of JNK in LS174T cells or treatment of LS174T cells with the JNK inhibitor SP600125 were used to determine the role of JNK in rapamycin-mediated tumor growth inhibition.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	112-115
21542902-10	2011	Addition of SP600125 and TNF-alpha monoclonal antibody 30 min before HBO abolished the DNA-protein binding activity and visfatin promoter activity induced by HBO.	pyrazolanthrone	12-20	nicotinamide phosphoribosyltransferase	Homo sapiens	120-128
21569548-9	2011	JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor SP600125 (SP).	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	0-3
21569548-9	2011	JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor SP600125 (SP).	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	67-70
21569548-9	2011	JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor SP600125 (SP).	pyrazolanthrone	81-83	mitogen-activated protein kinase 8	Homo sapiens	0-3
21569548-9	2011	JNK phosphorylation induced by celastrol was suppressed by NAC and JNK inhibitor SP600125 (SP).	pyrazolanthrone	81-83	mitogen-activated protein kinase 8	Homo sapiens	67-70
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	pyrazolanthrone	10-12	collagen type XI alpha 2 chain	Homo sapiens	80-84
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	pyrazolanthrone	10-12	caspase 9	Homo sapiens	86-95
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	pyrazolanthrone	10-12	caspase 3	Homo sapiens	100-109
21569548-10	2011	Moreover, SP significantly inhibited celastrol-induced loss of MMP, cleavage of PARP, caspase 9 and caspase 3, mitochondrial translocation of Bad, cytoplasmic release of cytochrome c, and cell death.	pyrazolanthrone	10-12	cytochrome c, somatic	Homo sapiens	170-182
21589925-9	2011	Inhibitors for MEK1/2 (PD98059), JNK (SP600125) or AP1 (curcumin) significantly inhibited MCP-1-induced amylin mRNA expression.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Mus musculus	33-36
21589925-9	2011	Inhibitors for MEK1/2 (PD98059), JNK (SP600125) or AP1 (curcumin) significantly inhibited MCP-1-induced amylin mRNA expression.	pyrazolanthrone	38-46	chemokine (C-C motif) ligand 2	Mus musculus	90-95
21589925-9	2011	Inhibitors for MEK1/2 (PD98059), JNK (SP600125) or AP1 (curcumin) significantly inhibited MCP-1-induced amylin mRNA expression.	pyrazolanthrone	38-46	islet amyloid polypeptide	Mus musculus	104-110
21573233-8	2011	Specific inhibition of p38 with SB203580 did not show any effect whereas inhibition of JNK phosphorylation with SP600125 notably reversed pM-induced cleavage of PARP, caspase-8 and -3, demonstrating a significant role of JNK in pM-induced cell death.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	87-90
20868664-10	2011	U0126 inhibited only phosphorylation of ERK1/2, while SP600125 at higher concentrations not only inhibited phosphorylation of c-Jun but also ERK1/2 phosphorylation.	pyrazolanthrone	54-62	jun proto-oncogene	Mus musculus	126-131
21573233-8	2011	Specific inhibition of p38 with SB203580 did not show any effect whereas inhibition of JNK phosphorylation with SP600125 notably reversed pM-induced cleavage of PARP, caspase-8 and -3, demonstrating a significant role of JNK in pM-induced cell death.	pyrazolanthrone	112-120	collagen type XI alpha 2 chain	Homo sapiens	161-165
21573233-8	2011	Specific inhibition of p38 with SB203580 did not show any effect whereas inhibition of JNK phosphorylation with SP600125 notably reversed pM-induced cleavage of PARP, caspase-8 and -3, demonstrating a significant role of JNK in pM-induced cell death.	pyrazolanthrone	112-120	caspase 8	Homo sapiens	167-183
21573233-8	2011	Specific inhibition of p38 with SB203580 did not show any effect whereas inhibition of JNK phosphorylation with SP600125 notably reversed pM-induced cleavage of PARP, caspase-8 and -3, demonstrating a significant role of JNK in pM-induced cell death.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	221-224
21350193-9	2011	When administered with TNF + CPT, SP-600125, a specific inhibitor of MEKK4/7, completely inhibited JNK1/2 and decreased apoptosis.	pyrazolanthrone	34-43	tumor necrosis factor	Homo sapiens	23-26
21350193-9	2011	When administered with TNF + CPT, SP-600125, a specific inhibitor of MEKK4/7, completely inhibited JNK1/2 and decreased apoptosis.	pyrazolanthrone	34-43	mitogen-activated protein kinase kinase kinase 4	Homo sapiens	69-74
21350193-9	2011	When administered with TNF + CPT, SP-600125, a specific inhibitor of MEKK4/7, completely inhibited JNK1/2 and decreased apoptosis.	pyrazolanthrone	34-43	mitogen-activated protein kinase 8	Homo sapiens	99-105
21348853-10	2011	The specific inhibitor of JNK SP600125 largely abolished the changes caused by the shRNA- and etomoxir-mediated decrease in CPT1 activity.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	26-29
21348853-10	2011	The specific inhibitor of JNK SP600125 largely abolished the changes caused by the shRNA- and etomoxir-mediated decrease in CPT1 activity.	pyrazolanthrone	30-38	carnitine palmitoyltransferase 1a, liver	Mus musculus	124-128
21272161-8	2011	SP600125, an inhibitor of JNK, reversed the RARalpha protein level reduced by hydrogen peroxide.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
21272161-8	2011	SP600125, an inhibitor of JNK, reversed the RARalpha protein level reduced by hydrogen peroxide.	pyrazolanthrone	0-8	retinoic acid receptor alpha	Homo sapiens	44-52
21521634-5	2011	nsPEF-inducible events downstream of JNK were markedly suppressed by the JNK inhibitor SP600125, which confirmed JNK-dependency of these events in this pathway.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	37-40
21521634-5	2011	nsPEF-inducible events downstream of JNK were markedly suppressed by the JNK inhibitor SP600125, which confirmed JNK-dependency of these events in this pathway.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	73-76
21521634-5	2011	nsPEF-inducible events downstream of JNK were markedly suppressed by the JNK inhibitor SP600125, which confirmed JNK-dependency of these events in this pathway.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	73-76
21296766-3	2011	The results showed that SP600125, a JNK inhibitor, and NS-398, a COX-2 inhibitor, significantly reduced the degree of MDR in HCT8/V cells.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	36-39
20868664-10	2011	U0126 inhibited only phosphorylation of ERK1/2, while SP600125 at higher concentrations not only inhibited phosphorylation of c-Jun but also ERK1/2 phosphorylation.	pyrazolanthrone	54-62	mitogen-activated protein kinase 3	Mus musculus	141-147
21161310-6	2011	Meanwhile, ERK inhibitor PD98059 decreased MMP-1 secretion, but did not show a significant influence on TGF-beta1; JNK inhibitor SP600125 increased the secretion of MMP-1 and decreased the TGF-beta1 secretion; P38 inhibitor SB203580 had no significant influence on MMP-1 but increased the secretion of TGF-beta1.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	115-118
21320501-7	2011	RESULTS: JNK was activated in intestinal polyps of Apc((Delta716) mice); the JNK inhibitor SP600125 significantly suppressed tumor formation.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Mus musculus	77-80
21277902-7	2011	Incubation with the JNK inhibitor SP600125 also inhibited NKG2D expression in NK cells.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	20-23
21277902-7	2011	Incubation with the JNK inhibitor SP600125 also inhibited NKG2D expression in NK cells.	pyrazolanthrone	34-42	killer cell lectin like receptor K1	Homo sapiens	58-63
21161310-6	2011	Meanwhile, ERK inhibitor PD98059 decreased MMP-1 secretion, but did not show a significant influence on TGF-beta1; JNK inhibitor SP600125 increased the secretion of MMP-1 and decreased the TGF-beta1 secretion; P38 inhibitor SB203580 had no significant influence on MMP-1 but increased the secretion of TGF-beta1.	pyrazolanthrone	129-137	matrix metallopeptidase 1	Homo sapiens	165-170
21161310-6	2011	Meanwhile, ERK inhibitor PD98059 decreased MMP-1 secretion, but did not show a significant influence on TGF-beta1; JNK inhibitor SP600125 increased the secretion of MMP-1 and decreased the TGF-beta1 secretion; P38 inhibitor SB203580 had no significant influence on MMP-1 but increased the secretion of TGF-beta1.	pyrazolanthrone	129-137	transforming growth factor beta 1	Homo sapiens	189-198
21161310-6	2011	Meanwhile, ERK inhibitor PD98059 decreased MMP-1 secretion, but did not show a significant influence on TGF-beta1; JNK inhibitor SP600125 increased the secretion of MMP-1 and decreased the TGF-beta1 secretion; P38 inhibitor SB203580 had no significant influence on MMP-1 but increased the secretion of TGF-beta1.	pyrazolanthrone	129-137	matrix metallopeptidase 1	Homo sapiens	165-170
21161310-6	2011	Meanwhile, ERK inhibitor PD98059 decreased MMP-1 secretion, but did not show a significant influence on TGF-beta1; JNK inhibitor SP600125 increased the secretion of MMP-1 and decreased the TGF-beta1 secretion; P38 inhibitor SB203580 had no significant influence on MMP-1 but increased the secretion of TGF-beta1.	pyrazolanthrone	129-137	transforming growth factor beta 1	Homo sapiens	189-198
21789894-1	2011	The aim of the present study was to investigate the effect of SP600125 (1,9-pyrazoloanthrone), an inhibitor of JNK, on apoptosis of retinal ganglion cells (RGCs) induced by moderate elevation of intraocular pressure (IOP) in male rats.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Rattus norvegicus	111-114
21468599-6	2011	p38, ERK1/2 and JNK were respectively inhibited with the specific inhibitors SB203580, PD98059 and SP600125.	pyrazolanthrone	99-107	mitogen activated protein kinase 14	Rattus norvegicus	0-3
21468599-6	2011	p38, ERK1/2 and JNK were respectively inhibited with the specific inhibitors SB203580, PD98059 and SP600125.	pyrazolanthrone	99-107	mitogen activated protein kinase 3	Rattus norvegicus	5-11
21468599-6	2011	p38, ERK1/2 and JNK were respectively inhibited with the specific inhibitors SB203580, PD98059 and SP600125.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Rattus norvegicus	16-19
21172926-9	2011	However, SP600125 (JNK inhibitor) had no effect on AGE-BSA-induced IL-6 expression but inhibited the expression of IL-8.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Homo sapiens	19-22
21172926-9	2011	However, SP600125 (JNK inhibitor) had no effect on AGE-BSA-induced IL-6 expression but inhibited the expression of IL-8.	pyrazolanthrone	9-17	C-X-C motif chemokine ligand 8	Homo sapiens	115-119
21789894-1	2011	The aim of the present study was to investigate the effect of SP600125 (1,9-pyrazoloanthrone), an inhibitor of JNK, on apoptosis of retinal ganglion cells (RGCs) induced by moderate elevation of intraocular pressure (IOP) in male rats.	pyrazolanthrone	72-92	mitogen-activated protein kinase 8	Rattus norvegicus	111-114
21241688-8	2011	The DEDC-induced cell death was significantly inhibited by both NAC and JNK inhibitor SP600125, but promoted by p38 MAPK inhibitor, SB203580.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	72-75
21262218-6	2011	5-HT-induced COX-2 expression was markedly blunted by Ca(2+) depletion; GF 109203X, a protein kinase C (PKC) inhibitor; PP2, an inhibitor of Src-family tyrosine kinase (Src); PD 98059, an inhibitor of extracellular signal-regulated kinase (ERK) activation; SB 203580, an inhibitor of p38 mitogen-activated protein kinase (MAPK); and SP 600125, an inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	333-342	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	13-18
21527996-5	2011	A c-Jun N-terminal kinase (JNK) inhibitor, SP600125 (0, 1.5, 5, or 15 mg/kg), was administered by intraperitoneal injection immediately before and after induction of ocular hypertension, then once daily for seven days.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Rattus norvegicus	2-41
21325398-5	2011	Insulin induced HOX-1 expression in a time- and dose-dependent manner, an effect attenuated by selective inhibitors of ERK1/2 (PD98059), Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and c-Jun terminal kinases 1 and 2 (SP600125) pathways.	pyrazolanthrone	245-253	insulin	Homo sapiens	0-7
21325398-5	2011	Insulin induced HOX-1 expression in a time- and dose-dependent manner, an effect attenuated by selective inhibitors of ERK1/2 (PD98059), Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and c-Jun terminal kinases 1 and 2 (SP600125) pathways.	pyrazolanthrone	245-253	heme oxygenase 1	Homo sapiens	16-21
21325398-5	2011	Insulin induced HOX-1 expression in a time- and dose-dependent manner, an effect attenuated by selective inhibitors of ERK1/2 (PD98059), Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and c-Jun terminal kinases 1 and 2 (SP600125) pathways.	pyrazolanthrone	245-253	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	137-140
21246566-7	2011	The JNK inhibitor (SP600125) was used to block the JNK pathway.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
21246566-7	2011	The JNK inhibitor (SP600125) was used to block the JNK pathway.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	51-54
21246566-13	2011	The JNK inhibitor, SP600125, inhibited Nur77 mRNA expression and reduced PCH4-induced apoptosis.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
21246566-13	2011	The JNK inhibitor, SP600125, inhibited Nur77 mRNA expression and reduced PCH4-induced apoptosis.	pyrazolanthrone	19-27	nuclear receptor subfamily 4 group A member 1	Homo sapiens	39-44
21246566-13	2011	The JNK inhibitor, SP600125, inhibited Nur77 mRNA expression and reduced PCH4-induced apoptosis.	pyrazolanthrone	19-27	tRNA splicing endonuclease subunit 54	Homo sapiens	73-77
21281706-6	2011	p,p"-DDE-induced apoptosis was blocked by NAC (N-acetyl-L-cystein) preincubation and attenuated by pretreatment with p38 inhibitor (SB202190) or actinomycin D, but not with JNK inhibitor (SP600125).	pyrazolanthrone	188-196	mitogen activated protein kinase 14	Rattus norvegicus	117-120
21505995-1	2011	This study examined the effects of retinoic acid (RA), PD98059, SP600125 and SB203580 on the hyperoxia-induced expression and regulation of matrix metalloproteinase-2 (MMP-2) and metalloproteinase-2 (TIMP-2) in premature rat lung fibroblasts (LFs).	pyrazolanthrone	64-72	matrix metallopeptidase 2	Rattus norvegicus	140-166
21505995-6	2011	The results showed that: (1) PD98059, SP600125 and SB203580 significantly inhibited p-ERK1/2, p-JNK1/2 and p-p38 respectively in LFs; (2) The expression of MMP-2 mRNA in LFs exposed to hyperoxia was decreased after treatment with RA, SP600125 and SB203580 respectively (P&lt;0.01 or 0.05), but did not change after treatment with PD98059 (P&gt;0.05).	pyrazolanthrone	38-46	mitogen activated protein kinase 3	Rattus norvegicus	86-92
21505995-6	2011	The results showed that: (1) PD98059, SP600125 and SB203580 significantly inhibited p-ERK1/2, p-JNK1/2 and p-p38 respectively in LFs; (2) The expression of MMP-2 mRNA in LFs exposed to hyperoxia was decreased after treatment with RA, SP600125 and SB203580 respectively (P&lt;0.01 or 0.05), but did not change after treatment with PD98059 (P&gt;0.05).	pyrazolanthrone	38-46	mitogen activated protein kinase 14	Rattus norvegicus	109-112
21505995-6	2011	The results showed that: (1) PD98059, SP600125 and SB203580 significantly inhibited p-ERK1/2, p-JNK1/2 and p-p38 respectively in LFs; (2) The expression of MMP-2 mRNA in LFs exposed to hyperoxia was decreased after treatment with RA, SP600125 and SB203580 respectively (P&lt;0.01 or 0.05), but did not change after treatment with PD98059 (P&gt;0.05).	pyrazolanthrone	38-46	matrix metallopeptidase 2	Rattus norvegicus	156-161
21505995-6	2011	The results showed that: (1) PD98059, SP600125 and SB203580 significantly inhibited p-ERK1/2, p-JNK1/2 and p-p38 respectively in LFs; (2) The expression of MMP-2 mRNA in LFs exposed to hyperoxia was decreased after treatment with RA, SP600125 and SB203580 respectively (P&lt;0.01 or 0.05), but did not change after treatment with PD98059 (P&gt;0.05).	pyrazolanthrone	234-242	matrix metallopeptidase 2	Rattus norvegicus	156-161
21241747-5	2011	Nrf2 knockdown by siRNA and the inhibition of JNK (c-Jun N-terminal kinase) by SP600125 decreased both CA-induced NGF expression and Nrf2 nuclear accumulation and suppressed their synergistic effect on NGF expression.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	46-49
21241747-5	2011	Nrf2 knockdown by siRNA and the inhibition of JNK (c-Jun N-terminal kinase) by SP600125 decreased both CA-induced NGF expression and Nrf2 nuclear accumulation and suppressed their synergistic effect on NGF expression.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	51-74
21241747-5	2011	Nrf2 knockdown by siRNA and the inhibition of JNK (c-Jun N-terminal kinase) by SP600125 decreased both CA-induced NGF expression and Nrf2 nuclear accumulation and suppressed their synergistic effect on NGF expression.	pyrazolanthrone	79-87	nerve growth factor	Homo sapiens	114-117
21241747-5	2011	Nrf2 knockdown by siRNA and the inhibition of JNK (c-Jun N-terminal kinase) by SP600125 decreased both CA-induced NGF expression and Nrf2 nuclear accumulation and suppressed their synergistic effect on NGF expression.	pyrazolanthrone	79-87	NFE2 like bZIP transcription factor 2	Homo sapiens	133-137
21241747-5	2011	Nrf2 knockdown by siRNA and the inhibition of JNK (c-Jun N-terminal kinase) by SP600125 decreased both CA-induced NGF expression and Nrf2 nuclear accumulation and suppressed their synergistic effect on NGF expression.	pyrazolanthrone	79-87	nerve growth factor	Homo sapiens	202-205
21338578-2	2011	In this study we show that the JNK pathway plays an important role in the survival of resting microglia BV-2 cells, as evidenced by Annexin-V positive staining and caspase-3 activation in cells treated with the specific JNK inhibitor SP600125.	pyrazolanthrone	234-242	mitogen-activated protein kinase 8	Mus musculus	31-34
21338578-2	2011	In this study we show that the JNK pathway plays an important role in the survival of resting microglia BV-2 cells, as evidenced by Annexin-V positive staining and caspase-3 activation in cells treated with the specific JNK inhibitor SP600125.	pyrazolanthrone	234-242	annexin A5	Mus musculus	132-141
21338578-2	2011	In this study we show that the JNK pathway plays an important role in the survival of resting microglia BV-2 cells, as evidenced by Annexin-V positive staining and caspase-3 activation in cells treated with the specific JNK inhibitor SP600125.	pyrazolanthrone	234-242	caspase 3	Mus musculus	164-173
21338578-2	2011	In this study we show that the JNK pathway plays an important role in the survival of resting microglia BV-2 cells, as evidenced by Annexin-V positive staining and caspase-3 activation in cells treated with the specific JNK inhibitor SP600125.	pyrazolanthrone	234-242	mitogen-activated protein kinase 8	Mus musculus	220-223
21338578-3	2011	During LPS-induced activation of BV-2 cells inhibition of the p38 and JNK pathways with SB203580 and SP600125, respectively, results in apoptosis as detected by apoptotic markers.	pyrazolanthrone	101-109	mitogen-activated protein kinase 14	Mus musculus	62-65
21338578-3	2011	During LPS-induced activation of BV-2 cells inhibition of the p38 and JNK pathways with SB203580 and SP600125, respectively, results in apoptosis as detected by apoptotic markers.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Mus musculus	70-73
21338578-4	2011	In the presence SP600125 the phosphorylation of p38 was significantly increased both in control and LPS-activated BV-2 cells.	pyrazolanthrone	16-24	mitogen-activated protein kinase 14	Mus musculus	48-51
21070853-5	2011	The expression of ApoE and ABCA1 induced by synthetic or natural LXR ligands [TO901317, GW3965, and 22-(R)-hydroxycholesterol (22-(R)-HC), respectively] was attenuated by inhibitors of c-Jun N-terminal kinase (JNK) (curcumin and SP600125) and phosphoinositide 3-kinase (PI3K) (LY294002).	pyrazolanthrone	229-237	apolipoprotein E	Homo sapiens	18-22
20463293-7	2011	The stimulation of IL-8 cytokine release was completely attenuated by treatment with the JNK-specific inhibitor, SP600125.	pyrazolanthrone	113-121	C-X-C motif chemokine ligand 8	Homo sapiens	19-23
20463293-7	2011	The stimulation of IL-8 cytokine release was completely attenuated by treatment with the JNK-specific inhibitor, SP600125.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	89-92
21074575-9	2011	Our data indicated that intracerebroventricular administration of SP600125, a JNK inhibitor, could significantly decrease escape latency and increase time spent in target quadrant, in treatment group.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Rattus norvegicus	78-81
21186276-13	2011	Furthermore, inhibition of JNK (SP-600125) prevented the myocyte apoptosis induced by a TNF-alpha/HMGB1 cocktail.	pyrazolanthrone	32-41	mitogen-activated protein kinase 8	Homo sapiens	27-30
21186276-13	2011	Furthermore, inhibition of JNK (SP-600125) prevented the myocyte apoptosis induced by a TNF-alpha/HMGB1 cocktail.	pyrazolanthrone	32-41	tumor necrosis factor	Homo sapiens	88-97
21186276-13	2011	Furthermore, inhibition of JNK (SP-600125) prevented the myocyte apoptosis induced by a TNF-alpha/HMGB1 cocktail.	pyrazolanthrone	32-41	high mobility group box 1	Homo sapiens	98-103
21084431-4	2011	In the presence of NSC126188, c-Jun N-terminal kinase (JNK) signaling was activated, and the JNK inhibitor SP600125 reduced RhoB expression and suppressed the apoptosis of NUGC-3 cells.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	93-96
21084431-4	2011	In the presence of NSC126188, c-Jun N-terminal kinase (JNK) signaling was activated, and the JNK inhibitor SP600125 reduced RhoB expression and suppressed the apoptosis of NUGC-3 cells.	pyrazolanthrone	107-115	ras homolog family member B	Homo sapiens	124-128
21084431-6	2011	The JNK inhibitor SP600125 suppressed transcriptional activation of RhoB in the presence of NSC126188, as indicated by a reporter assay that used luciferase under the RhoB promoter.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
21084431-6	2011	The JNK inhibitor SP600125 suppressed transcriptional activation of RhoB in the presence of NSC126188, as indicated by a reporter assay that used luciferase under the RhoB promoter.	pyrazolanthrone	18-26	ras homolog family member B	Homo sapiens	68-72
21084431-6	2011	The JNK inhibitor SP600125 suppressed transcriptional activation of RhoB in the presence of NSC126188, as indicated by a reporter assay that used luciferase under the RhoB promoter.	pyrazolanthrone	18-26	ras homolog family member B	Homo sapiens	167-171
21070853-5	2011	The expression of ApoE and ABCA1 induced by synthetic or natural LXR ligands [TO901317, GW3965, and 22-(R)-hydroxycholesterol (22-(R)-HC), respectively] was attenuated by inhibitors of c-Jun N-terminal kinase (JNK) (curcumin and SP600125) and phosphoinositide 3-kinase (PI3K) (LY294002).	pyrazolanthrone	229-237	ATP binding cassette subfamily A member 1	Homo sapiens	27-32
21143557-12	2011	Pretreatment of DMV neurons with SP600125, a specific inhibitor for JNK, or SB203580, a specific inhibitor for P38, significantly inhibited apoptosis induced by thrombin.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	68-71
21143557-12	2011	Pretreatment of DMV neurons with SP600125, a specific inhibitor for JNK, or SB203580, a specific inhibitor for P38, significantly inhibited apoptosis induced by thrombin.	pyrazolanthrone	33-41	coagulation factor II	Rattus norvegicus	161-169
20934486-6	2011	Whereas, the neuroprotective effect of puerarin against MPP(+) insults can be blocked by SP600125 (inhibitor of JNK).	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Rattus norvegicus	112-115
21082355-11	2011	MAP kinase inhibitors SB203580, SP600125 and PD98059 confirm the role of p38 MAPK and JNK in OA induced caspase-3 activation and cell death.	pyrazolanthrone	32-40	mitogen-activated protein kinase 1	Homo sapiens	73-76
21082355-11	2011	MAP kinase inhibitors SB203580, SP600125 and PD98059 confirm the role of p38 MAPK and JNK in OA induced caspase-3 activation and cell death.	pyrazolanthrone	32-40	caspase 3	Homo sapiens	104-113
21030692-3	2011	Conversely, activation of JNK increased binding of alpha-catenin to beta-catenin, which was blocked by the JNK inhibitor SP600125 or JNK siRNA.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	26-29
21030692-3	2011	Conversely, activation of JNK increased binding of alpha-catenin to beta-catenin, which was blocked by the JNK inhibitor SP600125 or JNK siRNA.	pyrazolanthrone	121-129	catenin beta 1	Homo sapiens	68-80
21030692-3	2011	Conversely, activation of JNK increased binding of alpha-catenin to beta-catenin, which was blocked by the JNK inhibitor SP600125 or JNK siRNA.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	107-110
21030692-3	2011	Conversely, activation of JNK increased binding of alpha-catenin to beta-catenin, which was blocked by the JNK inhibitor SP600125 or JNK siRNA.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	107-110
21362231-6	2011	The suppressive effect of JNK inhibitor SP600125 on the proliferation of Daudi and Raji cells was assayed by ATPLite method.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	26-29
21362231-12	2011	Daudi and Raji cells treated with different concentrations of JNK selective inhibitor SP600125 showed dose-dependent reduction in the growth of Daudi and Raji cells.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	62-65
21182908-10	2011	The apoptotic effect of AgNPs was exerted via the activation of c-Jun NH(2)-terminal kinase (JNK) and was abrogated by the JNK-specific inhibitor, SP600125 and siRNA targeting JNK.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	64-91
21182908-10	2011	The apoptotic effect of AgNPs was exerted via the activation of c-Jun NH(2)-terminal kinase (JNK) and was abrogated by the JNK-specific inhibitor, SP600125 and siRNA targeting JNK.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	93-96
21108934-7	2011	Using both EMSA and chromatin immunoprecipitation (ChIP) analyses, we also showed that Ang II increases binding of GATA4 to DNA, and that this effect is attenuated in the presence of U0126 or SB203580, but not in the presence of SP600125.	pyrazolanthrone	229-237	angiotensinogen	Rattus norvegicus	87-93
21108934-7	2011	Using both EMSA and chromatin immunoprecipitation (ChIP) analyses, we also showed that Ang II increases binding of GATA4 to DNA, and that this effect is attenuated in the presence of U0126 or SB203580, but not in the presence of SP600125.	pyrazolanthrone	229-237	GATA binding protein 4	Rattus norvegicus	115-120
21268080-6	2011	CSE-induced c-Jun expression and phosphorylation were inhibited by pretreatment with the inhibitor of JNK1/2 (SP600125) or transfection with JNK2 siRNA.	pyrazolanthrone	110-118	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	12-17
21268080-6	2011	CSE-induced c-Jun expression and phosphorylation were inhibited by pretreatment with the inhibitor of JNK1/2 (SP600125) or transfection with JNK2 siRNA.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	102-108
21268080-8	2011	Furthermore, CSE-induced p300 and c-Jun complex formation was inhibited by pretreatment with diphenyleneiodonium chloride, apocynin, N-acetyl-L-cysteine or SP600125.	pyrazolanthrone	156-164	E1A binding protein p300	Homo sapiens	25-29
21268080-8	2011	Furthermore, CSE-induced p300 and c-Jun complex formation was inhibited by pretreatment with diphenyleneiodonium chloride, apocynin, N-acetyl-L-cysteine or SP600125.	pyrazolanthrone	156-164	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	34-39
21044622-9	2011	Moreover, pretreatment with SP600125 (JNK inhibitor) or curcumin (AP-1 inhibitor) markedly attenuated the berberine-induced PON1 promoter activity and protein expression.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	38-41
21044622-9	2011	Moreover, pretreatment with SP600125 (JNK inhibitor) or curcumin (AP-1 inhibitor) markedly attenuated the berberine-induced PON1 promoter activity and protein expression.	pyrazolanthrone	28-36	paraoxonase 1	Homo sapiens	124-128
21212517-9	2011	In the presence of JNK inhibitor SP600125, motility of FGD1-expressing cells is significantly impaired, indicating a critical role of JNK in cell migration.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
21468925-4	2011	The activities of matrix metalloproteinase (MMP)-9 and MMP-2 were increased under hypoxic conditions but treatment with PD98059, SP600125 and SB203580 inhibited their activation in cancer cells, as seen by zymography.	pyrazolanthrone	129-137	matrix metallopeptidase 9	Homo sapiens	18-50
21468925-4	2011	The activities of matrix metalloproteinase (MMP)-9 and MMP-2 were increased under hypoxic conditions but treatment with PD98059, SP600125 and SB203580 inhibited their activation in cancer cells, as seen by zymography.	pyrazolanthrone	129-137	matrix metallopeptidase 2	Homo sapiens	55-60
21212516-6	2011	Inhibition of JNK by SP600125 did not influence generation of ROS.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
21212517-9	2011	In the presence of JNK inhibitor SP600125, motility of FGD1-expressing cells is significantly impaired, indicating a critical role of JNK in cell migration.	pyrazolanthrone	33-41	FYVE, RhoGEF and PH domain containing 1	Homo sapiens	55-59
21212517-9	2011	In the presence of JNK inhibitor SP600125, motility of FGD1-expressing cells is significantly impaired, indicating a critical role of JNK in cell migration.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	134-137
21212516-8	2011	However, activation of p53 was suppressed by SP600125; therefore the function of p53 was possibly controlled by JNK as well.	pyrazolanthrone	45-53	tumor protein p53	Homo sapiens	23-26
21212516-8	2011	However, activation of p53 was suppressed by SP600125; therefore the function of p53 was possibly controlled by JNK as well.	pyrazolanthrone	45-53	tumor protein p53	Homo sapiens	81-84
21212516-8	2011	However, activation of p53 was suppressed by SP600125; therefore the function of p53 was possibly controlled by JNK as well.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	112-115
21865737-6	2011	Finally, SP600125, a Specific Inhibitor of JNK, suppressed stretch -induced CTGF Expression.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Homo sapiens	43-46
20955365-9	2011	Knock-down of MKK4 or JNK, or the presence of SP600125 (a JNK inhibitor), each inhibited glutamate-induced p53 activation and GADD45alpha expression.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Mus musculus	58-61
20955365-9	2011	Knock-down of MKK4 or JNK, or the presence of SP600125 (a JNK inhibitor), each inhibited glutamate-induced p53 activation and GADD45alpha expression.	pyrazolanthrone	46-54	transformation related protein 53, pseudogene	Mus musculus	107-110
20955365-9	2011	Knock-down of MKK4 or JNK, or the presence of SP600125 (a JNK inhibitor), each inhibited glutamate-induced p53 activation and GADD45alpha expression.	pyrazolanthrone	46-54	growth arrest and DNA-damage-inducible 45 alpha	Mus musculus	126-137
20846305-10	2011	The JNK inhibitor, SP600125, attenuated the gefitinib-induced cytotoxicity and apoptosis of HaCaT cells.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
21865737-6	2011	Finally, SP600125, a Specific Inhibitor of JNK, suppressed stretch -induced CTGF Expression.	pyrazolanthrone	9-17	cellular communication network factor 2	Homo sapiens	76-80
19752164-5	2011	In the presence of phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin and three individual MAPK inhibitors SB203580, PD98059 and SP600125, both Ang-II-induced cell proliferation and migration were significantly attenuated, although to differing extents, suggesting the PI3K and MAPK signal pathways all participated in regulating rVSMC proliferation and migration.	pyrazolanthrone	136-144	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma	Rattus norvegicus	19-48
21176401-5	2011	We performed porcine islet isolation with or without intraductal administration of SP600125, a JNK inhibitor.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	95-98
21263197-1	2011	We investigated the effects of SP600125 (formerly called c-Jun N-terminal kinase (JNK) inhibitor II) on translation using cultured mouse cells.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Mus musculus	57-80
21263197-1	2011	We investigated the effects of SP600125 (formerly called c-Jun N-terminal kinase (JNK) inhibitor II) on translation using cultured mouse cells.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Mus musculus	82-85
21263197-2	2011	SP600125 (50 microM) treatment rapidly repressed overall protein synthesis, accompanied by a reduction in the mRNAs for housekeeping genes such as glyceraldehyde-3-phosphate dehydrogenase in the polysomal fraction.	pyrazolanthrone	0-8	glyceraldehyde-3-phosphate dehydrogenase	Mus musculus	147-187
21263197-5	2011	SP600125 significantly attenuated phosphorylation of components in the mTOR pathway, which is responsible for cap-dependent translation.	pyrazolanthrone	0-8	mechanistic target of rapamycin kinase	Mus musculus	71-75
19752164-5	2011	In the presence of phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin and three individual MAPK inhibitors SB203580, PD98059 and SP600125, both Ang-II-induced cell proliferation and migration were significantly attenuated, although to differing extents, suggesting the PI3K and MAPK signal pathways all participated in regulating rVSMC proliferation and migration.	pyrazolanthrone	136-144	angiotensinogen	Rattus norvegicus	151-157
19752164-5	2011	In the presence of phosphatidylinositol 3-kinase (PI3K) inhibitor wortmannin and three individual MAPK inhibitors SB203580, PD98059 and SP600125, both Ang-II-induced cell proliferation and migration were significantly attenuated, although to differing extents, suggesting the PI3K and MAPK signal pathways all participated in regulating rVSMC proliferation and migration.	pyrazolanthrone	136-144	mitogen activated protein kinase 3	Rattus norvegicus	285-289
21269961-6	2011	The expression of MUC5AC was attenuated after treatment with SP600125.	pyrazolanthrone	61-69	mucin 5AC, oligomeric mucus/gel-forming	Rattus norvegicus	18-24
22161830-2	2011	Inhibition of JNK (using SP600125) or small interfering RNA-mediated knockdown of JNK1 blocked acinus formation, impaired cell polarisation and lumen clearance and allowed sustained extracellular signal-regulated kinase (ERK) phosphorylation, cell proliferation, adhesion-independent cell survival and expression of epithelial-mesenchymal transition markers.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	14-17
21046201-0	2011	Enteral arginine modulates inhibition of AP-1/c-Jun by SP600125 in the postischemic gut.	pyrazolanthrone	55-63	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	41-45
21046201-8	2011	In conclusion, SP600125 attenuated the activity of c-Jun/AP-1, iNOS expression, and neutrophil infiltration induced by arginine following mesenteric I/R.	pyrazolanthrone	15-23	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	57-61
21046201-8	2011	In conclusion, SP600125 attenuated the activity of c-Jun/AP-1, iNOS expression, and neutrophil infiltration induced by arginine following mesenteric I/R.	pyrazolanthrone	15-23	nitric oxide synthase 2	Rattus norvegicus	63-67
21053278-8	2011	SP600125, a JNK inhibitor, inhibited DATS-induced Bim phosphorylation and protected cells from DATS-induced cytotoxicity.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
21053278-8	2011	SP600125, a JNK inhibitor, inhibited DATS-induced Bim phosphorylation and protected cells from DATS-induced cytotoxicity.	pyrazolanthrone	0-8	BCL2 like 11	Homo sapiens	50-53
21112343-10	2011	Furthermore, JNK was involved in palmitate-induced expression of IL1A, IL8, CXCL3, SPP1 and CEBPB as determined with inhibitor SP600125 (all p&lt;0.05).	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Homo sapiens	13-16
21112343-10	2011	Furthermore, JNK was involved in palmitate-induced expression of IL1A, IL8, CXCL3, SPP1 and CEBPB as determined with inhibitor SP600125 (all p&lt;0.05).	pyrazolanthrone	127-135	interleukin 1 alpha	Homo sapiens	65-69
21112343-10	2011	Furthermore, JNK was involved in palmitate-induced expression of IL1A, IL8, CXCL3, SPP1 and CEBPB as determined with inhibitor SP600125 (all p&lt;0.05).	pyrazolanthrone	127-135	C-X-C motif chemokine ligand 3	Homo sapiens	76-81
21112343-10	2011	Furthermore, JNK was involved in palmitate-induced expression of IL1A, IL8, CXCL3, SPP1 and CEBPB as determined with inhibitor SP600125 (all p&lt;0.05).	pyrazolanthrone	127-135	CCAAT enhancer binding protein beta	Homo sapiens	92-97
21172010-7	2010	However, only DR5 upregulaiton induced by perifosine could be abrogated by both the JNK inhibitor SP600125 and JNK siRNA.	pyrazolanthrone	98-106	TNF receptor superfamily member 10b	Homo sapiens	14-17
22087283-10	2011	Using JNK inhibitor SP600125 to block JNK-dependent activity, the combination therapy-induced neuronal differentiation was partially attenuated.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	6-9
22087283-10	2011	Using JNK inhibitor SP600125 to block JNK-dependent activity, the combination therapy-induced neuronal differentiation was partially attenuated.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	38-41
21686277-6	2011	Moreover, inhibition of JNK by SP600125 rescued PC12 cells from Chp-triggered cell death and attenuated activation of caspases-9 and -3/7 suggesting that activation of JNK mediates pro-apoptotic effect of Chp.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
21686277-6	2011	Moreover, inhibition of JNK by SP600125 rescued PC12 cells from Chp-triggered cell death and attenuated activation of caspases-9 and -3/7 suggesting that activation of JNK mediates pro-apoptotic effect of Chp.	pyrazolanthrone	31-39	ras homolog family member V	Rattus norvegicus	64-67
21686277-6	2011	Moreover, inhibition of JNK by SP600125 rescued PC12 cells from Chp-triggered cell death and attenuated activation of caspases-9 and -3/7 suggesting that activation of JNK mediates pro-apoptotic effect of Chp.	pyrazolanthrone	31-39	caspase 9	Rattus norvegicus	118-135
21686277-6	2011	Moreover, inhibition of JNK by SP600125 rescued PC12 cells from Chp-triggered cell death and attenuated activation of caspases-9 and -3/7 suggesting that activation of JNK mediates pro-apoptotic effect of Chp.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Rattus norvegicus	168-171
21686277-6	2011	Moreover, inhibition of JNK by SP600125 rescued PC12 cells from Chp-triggered cell death and attenuated activation of caspases-9 and -3/7 suggesting that activation of JNK mediates pro-apoptotic effect of Chp.	pyrazolanthrone	31-39	ras homolog family member V	Rattus norvegicus	205-208
21434327-4	2011	The cells were pretreated with SP600125, an inhibitor of JNK pathway, and then the number of apoptotic cells were counted by using TUNEL stain, observing its influence on cell apoptosis seduced by MPP+.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
21434327-6	2011	The usage of JNK pathway inhibitor SP600125 can inhibit the PC12 cell apoptosis seduced by MPP+.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Rattus norvegicus	13-16
20959717-7	2010	Knock-down of CHOP expression by siRNA transfection and specific inhibitors of p38 (SB203580), JNK (SP600125), and ERK (PD98059) as well as anti-oxidant (N-acetylcysteine) reduced TG- or BFA-induced cell death.	pyrazolanthrone	100-108	DNA-damage inducible transcript 3	Mus musculus	14-18
21209911-0	2010	1, 9-Pyrazoloanthrones downregulate HIF-1alpha and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.	pyrazolanthrone	0-22	hypoxia inducible factor 1 subunit alpha	Homo sapiens	36-46
21209911-0	2010	1, 9-Pyrazoloanthrones downregulate HIF-1alpha and sensitize cancer cells to cetuximab-mediated anti-EGFR therapy.	pyrazolanthrone	0-22	epidermal growth factor receptor	Homo sapiens	101-105
21209911-3	2010	1, 9-pyrazoloanthrone (1, 9 PA) is an anthrapyrazolone compound best known as SP600125 that specifically inhibits c-jun N-terminal kinase (JNK).	pyrazolanthrone	0-21	mitogen-activated protein kinase 8	Homo sapiens	114-137
21209911-3	2010	1, 9-pyrazoloanthrone (1, 9 PA) is an anthrapyrazolone compound best known as SP600125 that specifically inhibits c-jun N-terminal kinase (JNK).	pyrazolanthrone	0-21	mitogen-activated protein kinase 8	Homo sapiens	139-142
21209911-3	2010	1, 9-pyrazoloanthrone (1, 9 PA) is an anthrapyrazolone compound best known as SP600125 that specifically inhibits c-jun N-terminal kinase (JNK).	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	114-137
21209911-3	2010	1, 9-pyrazoloanthrone (1, 9 PA) is an anthrapyrazolone compound best known as SP600125 that specifically inhibits c-jun N-terminal kinase (JNK).	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	139-142
22096483-7	2011	Both AG 1478 and PD 98059 enhanced expression of pSAPK/JNK, while selective JNK inhibitor SP 600125 enhanced expression of GSK-3beta (S9P).	pyrazolanthrone	90-99	mitogen-activated protein kinase 8	Homo sapiens	76-79
22096483-7	2011	Both AG 1478 and PD 98059 enhanced expression of pSAPK/JNK, while selective JNK inhibitor SP 600125 enhanced expression of GSK-3beta (S9P).	pyrazolanthrone	90-99	glycogen synthase kinase 3 beta	Homo sapiens	123-132
21901117-5	2011	The JNK inhibitor (SP600125, 18 h), in absence of SS, also decreased ACE promoter activity in wt-ACE.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
21901117-5	2011	The JNK inhibitor (SP600125, 18 h), in absence of SS, also decreased ACE promoter activity in wt-ACE.	pyrazolanthrone	19-27	angiotensin I converting enzyme	Homo sapiens	69-72
21901117-5	2011	The JNK inhibitor (SP600125, 18 h), in absence of SS, also decreased ACE promoter activity in wt-ACE.	pyrazolanthrone	19-27	angiotensin I converting enzyme	Homo sapiens	97-100
21901137-6	2011	When c-Jun N-terminal kinase activity was inhibited using SP600125, expression of miR-26b was induced following gamma-irradiation in H1299 cells.	pyrazolanthrone	58-66	microRNA 26b	Homo sapiens	82-89
21172010-7	2010	However, only DR5 upregulaiton induced by perifosine could be abrogated by both the JNK inhibitor SP600125 and JNK siRNA.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Homo sapiens	84-87
20920557-6	2010	ISA strongly induced apoptosis, which was partially suppressed by the JNK inhibitor SP600125, but not by the p38 inhibitor SB202190.	pyrazolanthrone	84-92	annexin A13	Homo sapiens	0-3
20937379-9	2010	Moreover, the JNK inhibitor SP600125 reversed paraquat-induced ER stress as evidenced by enhanced GADD153 and IRE1alpha phosphorylation.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	14-17
20937379-9	2010	Moreover, the JNK inhibitor SP600125 reversed paraquat-induced ER stress as evidenced by enhanced GADD153 and IRE1alpha phosphorylation.	pyrazolanthrone	28-36	DNA-damage inducible transcript 3	Mus musculus	98-105
20937379-9	2010	Moreover, the JNK inhibitor SP600125 reversed paraquat-induced ER stress as evidenced by enhanced GADD153 and IRE1alpha phosphorylation.	pyrazolanthrone	28-36	endoplasmic reticulum (ER) to nucleus signalling 1	Mus musculus	110-119
21078900-8	2010	JNK inhibitor SP600125 and p38 inhibitor SB203580 effectively blocked upregulation of ER stress-related genes and cleavage of caspases.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
20920557-6	2010	ISA strongly induced apoptosis, which was partially suppressed by the JNK inhibitor SP600125, but not by the p38 inhibitor SB202190.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	70-73
20920558-8	2010	PDTC/Cu complex was capable of activating the apoptosis-related caspases including caspase-9, caspase-7, and caspase-3, which could be reversed by the addition of JNK inhibitor SP600125 or transfection of MAPK8 short hairpin RNA.	pyrazolanthrone	177-185	mitogen-activated protein kinase 8	Homo sapiens	163-166
20920558-10	2010	The Bcl-2 mRNA and protein expressions were decreased in lung epithelial cells treated with PDTC/Cu complex, which could be reversed by SP600125.	pyrazolanthrone	136-144	BCL2 apoptosis regulator	Homo sapiens	4-9
20920558-11	2010	Furthermore, PDTC/Cu complex could trigger the expressions of ER stress-associated signaling molecules including Grp78, Grp94, caspase-12, ATF4, and CHOP, which could be reversed by SP600125.	pyrazolanthrone	182-190	heat shock protein family A (Hsp70) member 5	Homo sapiens	113-118
20920558-11	2010	Furthermore, PDTC/Cu complex could trigger the expressions of ER stress-associated signaling molecules including Grp78, Grp94, caspase-12, ATF4, and CHOP, which could be reversed by SP600125.	pyrazolanthrone	182-190	heat shock protein 90 beta family member 1	Homo sapiens	120-125
20920558-11	2010	Furthermore, PDTC/Cu complex could trigger the expressions of ER stress-associated signaling molecules including Grp78, Grp94, caspase-12, ATF4, and CHOP, which could be reversed by SP600125.	pyrazolanthrone	182-190	activating transcription factor 4	Homo sapiens	139-143
20920558-11	2010	Furthermore, PDTC/Cu complex could trigger the expressions of ER stress-associated signaling molecules including Grp78, Grp94, caspase-12, ATF4, and CHOP, which could be reversed by SP600125.	pyrazolanthrone	182-190	DNA damage inducible transcript 3	Homo sapiens	149-153
20683666-5	2010	Prior treatment of HCT-116 cells with the JNK inhibitor SP600125 and the RNA synthesis inhibitor DRB blocked apoptosis, implying that JNK activation and mRNA production are important for apoptosis by LB2A.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	42-45
20674153-3	2010	Moreover, icariin induced a sustained activation of the phosphorylation of c-Jun N-terminal kinase (JNK) but not p38 and ERK1/2, and SP600125 (an inhibitor of JNK) almost reversed icariin-induced apoptosis in SMMC-7721 cells.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Homo sapiens	159-162
21134294-7	2010	The JNK inhibitor (SP-600125) was injected into the mice 1 h after injury.	pyrazolanthrone	19-28	mitogen-activated protein kinase 8	Mus musculus	4-7
20683666-7	2010	LB2A decreased HDAC1 and increased acetyl-H3, both of which activate the RhoB promoter and were blocked by SP600125.	pyrazolanthrone	107-115	histone deacetylase 1	Homo sapiens	15-20
20971179-8	2010	Blockade of JNK activation with the pharmacologic inhibitor SP600125 attenuated cell death in utricles from both wild-type and Mlk3(-/-) mice.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Mus musculus	12-15
20876703-2	2010	Increased iNOS/NO induction and migration of macrophages by MDA-CM were significantly blocked by adding the c-Jun-N-terminal protein kinase (JNK) inhibitor, SP600125, the nuclear factor-kappa B (NF-kappaB) inhibitor, BAY117082 and pyrrolidine dithiocarbamic acid and a dominant-negative JNK.	pyrazolanthrone	157-165	nitric oxide synthase 2	Homo sapiens	10-14
20876703-3	2010	The addition of an NO donor, Diethylenetriamine-NONOate, significantly activated expressions of MMP-9 and VEGF-A genes in breast carcinoma MDA-MD-231 cells and invasion of MDA-MB-231 cells in coculture with RAW264.7 macrophages as determined using Transwell systems, but that was inhibited by adding SP600125, BAY117082 and the nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester.	pyrazolanthrone	300-308	matrix metallopeptidase 9	Homo sapiens	96-101
20876703-3	2010	The addition of an NO donor, Diethylenetriamine-NONOate, significantly activated expressions of MMP-9 and VEGF-A genes in breast carcinoma MDA-MD-231 cells and invasion of MDA-MB-231 cells in coculture with RAW264.7 macrophages as determined using Transwell systems, but that was inhibited by adding SP600125, BAY117082 and the nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester.	pyrazolanthrone	300-308	vascular endothelial growth factor A	Homo sapiens	106-112
20874679-7	2010	Furthermore, H2O2 also induced rapid and significant phosphorylation of the c-Jun-N-terminal kinase 1/2 (JNK1/2), which was inhibited SP600125 (a JNK1/2 inhibitor).	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Rattus norvegicus	76-103
20971179-8	2010	Blockade of JNK activation with the pharmacologic inhibitor SP600125 attenuated cell death in utricles from both wild-type and Mlk3(-/-) mice.	pyrazolanthrone	60-68	mitogen-activated protein kinase kinase kinase 11	Mus musculus	127-131
20688742-8	2010	The downregulation of MMP-2 expression in CFs by HCE cells was blocked by an inhibitor of signaling by the mitogen-activated protein kinase (MAPK) ERK (PD98059) but was not affected by those of signaling by the MAPKs p38 (SB203580) or JNK (SP600125).	pyrazolanthrone	240-248	matrix metallopeptidase 2	Homo sapiens	22-27
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	44-47
20931347-6	2010	We report that (1) organ culture of the TG is possible with preserved morphology, (2) organ culture is associated with enhanced expression of cytokines and mitogen-activated protein kinases (MAPKs) primarily in neurons, (3) CGRP can induce expression of some cytokines and (4) cytokine expression is still upregulated following MAPK pathway inhibition by MEK inhibitor U0126 and pp38 inhibitor SB202192, but the cytokine expression is abolished when co-incubating with the JNK inhibitor SP600125.	pyrazolanthrone	487-495	calcitonin-related polypeptide alpha	Rattus norvegicus	224-228
21311676-9	2010	These effects were opposite to the expression of p-p53, p21, and MDM2 observed with SP600125 and SB202190 treatments.	pyrazolanthrone	84-92	tumor protein p53	Homo sapiens	51-54
21311676-9	2010	These effects were opposite to the expression of p-p53, p21, and MDM2 observed with SP600125 and SB202190 treatments.	pyrazolanthrone	84-92	H3 histone pseudogene 16	Homo sapiens	56-59
21311676-9	2010	These effects were opposite to the expression of p-p53, p21, and MDM2 observed with SP600125 and SB202190 treatments.	pyrazolanthrone	84-92	MDM2 proto-oncogene	Homo sapiens	65-69
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	peroxisome proliferator activated receptor gamma	Homo sapiens	85-133
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	peroxisome proliferator activated receptor gamma	Homo sapiens	135-144
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	acetyl-CoA acetyltransferase 1	Homo sapiens	184-222
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	acetyl-CoA acetyltransferase 1	Homo sapiens	224-229
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	ATP binding cassette subfamily A member 1	Homo sapiens	232-274
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	ATP binding cassette subfamily A member 1	Homo sapiens	276-284
20870032-4	2010	We investigated whether SP600125, a special JNK inhibitor, affects the expression of peroxisome proliferator-activated receptor gamma (PPARgamma), and also its downstream target genes Acyl-CoA cholesterol acyltransferase-1 (ACAT1), ATP-binding cassette transporter A1 and G1 (ABCA1/G1) in human THP-1 macrophages infected with C. pneumoniae.	pyrazolanthrone	24-32	GLI family zinc finger 2	Homo sapiens	295-300
20729910-6	2010	Inhibition of FDH-induced apoptosis by the Jun N-terminal kinase inhibitor SP600125 or the pan-caspase inhibitor zVAD-fmk did not restore motility or levels of phosphor-cofilin, indicating that the observed effects are independent of FDH function in apoptosis.	pyrazolanthrone	75-83	aldehyde dehydrogenase 1 family member L1	Homo sapiens	14-17
20716444-10	2010	The increased upregulation of contractile ET(B) receptors by DSP was abrogated by U0126, SP600125, actinomycin D, and cycloheximide, suggesting that the underlying molecular mechanisms involved in this process include activation of MEK and JNK MAPK-mediated transcription and translation of new contractile ET(B) receptors.	pyrazolanthrone	89-97	endothelin receptor type B	Rattus norvegicus	42-47
20932751-6	2010	Moreover, CWJ-081-induced apoptosis was suppressed in the presence of SP600125, a specific JNK inhibitor.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	91-94
20560114-8	2010	Coincidently, icaritin-induced cell apoptosis was abolished by SP600125, a specific inhibitor for JNK.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	98-101
20952655-6	2010	Also, doxorubicin, cisplatin, and paclitaxel increased this enriched population which, conversely, was significantly inhibited by Mullerian inhibiting substance (MIS) or the MIS mimetic SP600125.	pyrazolanthrone	186-194	anti-Mullerian hormone	Homo sapiens	174-177
20510502-4	2010	Moreover, inhibition of JNK pathway by SP600125 blocks autophagy activation and p62 degradation induced by knockdown of DJ-1.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	24-27
20510502-4	2010	Moreover, inhibition of JNK pathway by SP600125 blocks autophagy activation and p62 degradation induced by knockdown of DJ-1.	pyrazolanthrone	39-47	nucleoporin 62	Homo sapiens	80-83
20510502-4	2010	Moreover, inhibition of JNK pathway by SP600125 blocks autophagy activation and p62 degradation induced by knockdown of DJ-1.	pyrazolanthrone	39-47	Parkinsonism associated deglycase	Homo sapiens	120-124
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	pyrazolanthrone	244-252	mitogen-activated protein kinase 1	Homo sapiens	14-51
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	pyrazolanthrone	244-252	mitogen-activated protein kinase 1	Homo sapiens	53-56
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	pyrazolanthrone	244-252	mitogen-activated protein kinase 8	Homo sapiens	87-90
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	pyrazolanthrone	244-252	matrix metallopeptidase 9	Homo sapiens	145-150
20458747-3	2010	Activation of extracellular signal-regulated kinase (ERK) and c-Jun-N-terminal kinase (JNK) by TPA was identified, and TPA-induced migration and MMP-9 activity was significantly blocked by ERK inhibitor PD98059 and U0126, but not JNK inhibitor SP600125.	pyrazolanthrone	244-252	mitogen-activated protein kinase 1	Homo sapiens	189-192
20728939-5	2010	Furthermore, we provide evidence that Poly I:C induced expression of IL-1beta, TNFalpha, IL-12p70 and IFN-beta was blocked by JNK inhibitor SP600125.	pyrazolanthrone	140-148	interleukin 1 beta	Homo sapiens	69-77
20728939-5	2010	Furthermore, we provide evidence that Poly I:C induced expression of IL-1beta, TNFalpha, IL-12p70 and IFN-beta was blocked by JNK inhibitor SP600125.	pyrazolanthrone	140-148	tumor necrosis factor	Homo sapiens	79-87
20728939-5	2010	Furthermore, we provide evidence that Poly I:C induced expression of IL-1beta, TNFalpha, IL-12p70 and IFN-beta was blocked by JNK inhibitor SP600125.	pyrazolanthrone	140-148	interferon beta 1	Homo sapiens	102-110
20728939-5	2010	Furthermore, we provide evidence that Poly I:C induced expression of IL-1beta, TNFalpha, IL-12p70 and IFN-beta was blocked by JNK inhibitor SP600125.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	126-129
20508600-7	2010	Pretreatment with the JNK inhibitor SP600125 successfully blocked beta-cell apoptosis and resulted in restoration of beta-cell mass and normalization of blood glucose level for up to 90 days.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
20533306-8	2010	SP600125, a JNK inhibitor, abrogated the response of ameloblasts to an experimental decrease in intracellular pH, while the inhibition of JNK also impaired ameloblast differentiation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
21131736-4	2010	SP600125 and PD98059 were used to block the activation of c-Jun terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) respectively.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	58-79
21131736-4	2010	SP600125 and PD98059 were used to block the activation of c-Jun terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) respectively.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	81-84
21131736-4	2010	SP600125 and PD98059 were used to block the activation of c-Jun terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) respectively.	pyrazolanthrone	0-8	mitogen-activated protein kinase 1	Homo sapiens	90-127
21131736-4	2010	SP600125 and PD98059 were used to block the activation of c-Jun terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) respectively.	pyrazolanthrone	0-8	mitogen-activated protein kinase 1	Homo sapiens	129-132
21131736-9	2010	The DNA binding activity of AP-1 and the expression levels of MUC5AC protein and mRNA were lower in the SP600125 group and in the PD98059 group than those in the CSE group (P&lt;0.05).	pyrazolanthrone	104-112	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-32
21034514-7	2010	The former effect of exogenous podoplanin was impaired by treatment with either JNK inhibitor sp600125 or podoplanin-siRNA, and the latter effect was impaired by treatment with podoplanin-siRNA, suggesting that podoplanin was able to activate JNK, thereby downregulating VEGF-C gene expression in LSCCs (podoplanin-JNK-VEGF-C axis).	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	80-83
21131736-9	2010	The DNA binding activity of AP-1 and the expression levels of MUC5AC protein and mRNA were lower in the SP600125 group and in the PD98059 group than those in the CSE group (P&lt;0.05).	pyrazolanthrone	104-112	mucin 5AC, oligomeric mucus/gel-forming	Homo sapiens	62-68
20692238-0	2010	The c-Jun N-terminal kinase inhibitor SP600125 is neuroprotective in amygdala kindled rats.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Rattus norvegicus	4-27
20692238-2	2010	JNK specific inhibitor SP600125 has been found to have a protective effect against transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 region.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
20692238-2	2010	JNK specific inhibitor SP600125 has been found to have a protective effect against transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 region.	pyrazolanthrone	23-31	carbonic anhydrase 1	Rattus norvegicus	162-165
20692238-7	2010	We found that the level of JNK phosphorylation (46KD) in the hippocampus increased in the amygdala kindled rats, whereas such JNK phosphorylation could be inhibited by SP600125.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
20692238-7	2010	We found that the level of JNK phosphorylation (46KD) in the hippocampus increased in the amygdala kindled rats, whereas such JNK phosphorylation could be inhibited by SP600125.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Rattus norvegicus	126-129
20692238-12	2010	The JNK inhibitor SP600125 can show a protective effect on hippocampal neurons in TLE by inhibiting JNK activation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
20692238-12	2010	The JNK inhibitor SP600125 can show a protective effect on hippocampal neurons in TLE by inhibiting JNK activation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	100-103
20818498-5	2010	Whereas, SP600125, a specific inhibitor of JNK, only down-regulated the phosphorylation of Smad2 at the C-terminal sites, but had little effect on the phosphorylation of Smad2 at linker sites.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Rattus norvegicus	43-46
20609399-7	2010	SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-alpha.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Mus musculus	23-26
20609399-7	2010	SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-alpha.	pyrazolanthrone	11-19	interleukin 6	Mus musculus	73-77
20609399-7	2010	SD-0006 or SP600125, a JNK inhibitor, partially blocked the elevation of IL-6 production in RASF following stimulation with TNF-alpha.	pyrazolanthrone	11-19	tumor necrosis factor	Mus musculus	124-133
20573157-10	2010	Pretreatment of cells with SP600125 and ISO-1 reduced glucose-induced apoptosis and caspase 3 activity.	pyrazolanthrone	27-35	caspase 3	Homo sapiens	84-93
20818498-5	2010	Whereas, SP600125, a specific inhibitor of JNK, only down-regulated the phosphorylation of Smad2 at the C-terminal sites, but had little effect on the phosphorylation of Smad2 at linker sites.	pyrazolanthrone	9-17	SMAD family member 2	Rattus norvegicus	91-96
20627382-7	2010	However, this increase was abrogated by pretreatment with an extracellular signal-regulated kinase (ERK) inhibitor PD98059 or p38MAPK inhibitor SB203580; pretreatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125 did not attenuate the effects of VIP on the expression of VEGF.	pyrazolanthrone	212-220	mitogen-activated protein kinase 1	Homo sapiens	61-98
20627382-7	2010	However, this increase was abrogated by pretreatment with an extracellular signal-regulated kinase (ERK) inhibitor PD98059 or p38MAPK inhibitor SB203580; pretreatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125 did not attenuate the effects of VIP on the expression of VEGF.	pyrazolanthrone	212-220	mitogen-activated protein kinase 1	Homo sapiens	100-103
20627382-7	2010	However, this increase was abrogated by pretreatment with an extracellular signal-regulated kinase (ERK) inhibitor PD98059 or p38MAPK inhibitor SB203580; pretreatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125 did not attenuate the effects of VIP on the expression of VEGF.	pyrazolanthrone	212-220	mitogen-activated protein kinase 8	Homo sapiens	172-195
20627382-7	2010	However, this increase was abrogated by pretreatment with an extracellular signal-regulated kinase (ERK) inhibitor PD98059 or p38MAPK inhibitor SB203580; pretreatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125 did not attenuate the effects of VIP on the expression of VEGF.	pyrazolanthrone	212-220	mitogen-activated protein kinase 8	Homo sapiens	197-200
20709060-0	2010	The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
20600246-0	2010	SP600125, a competitive inhibitor of JNK attenuates streptozotocin induced neurocognitive deficit and oxidative stress in rats.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
20600246-8	2010	Whereas, SP600125 treatment significantly restored acetylcholinesterase activity and reduced LDH levels indicating restorative capacity of SP600125 with respect to cholinergic functions and preventing the neuronal damage.	pyrazolanthrone	9-17	acetylcholinesterase	Rattus norvegicus	51-71
20709060-0	2010	The JNK inhibitor SP600125 enhances dihydroartemisinin-induced apoptosis by accelerating Bax translocation into mitochondria in human lung adenocarcinoma cells.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Homo sapiens	89-92
20709060-1	2010	The C-Jun N-terminal Kinase (JNK) inhibitor SP600125 is widely used to inhibit the JNK-mediated Bax activation and cell apoptosis.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	4-27
20709060-1	2010	The C-Jun N-terminal Kinase (JNK) inhibitor SP600125 is widely used to inhibit the JNK-mediated Bax activation and cell apoptosis.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	29-32
20709060-1	2010	The C-Jun N-terminal Kinase (JNK) inhibitor SP600125 is widely used to inhibit the JNK-mediated Bax activation and cell apoptosis.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	83-86
20709060-1	2010	The C-Jun N-terminal Kinase (JNK) inhibitor SP600125 is widely used to inhibit the JNK-mediated Bax activation and cell apoptosis.	pyrazolanthrone	44-52	BCL2 associated X, apoptosis regulator	Homo sapiens	96-99
20709060-2	2010	However, this report demonstrates that SP600125 synergistically enhances the dihydroartemisinin (DHA)-induced human lung adenocarcinoma cell apoptosis by accelerating Bax translocation and subsequent intrinsic apoptotic pathway involving mitochondrial membrane depolarization, cytochrome c release, caspase-9 and caspase-3 activation.	pyrazolanthrone	39-47	BCL2 associated X, apoptosis regulator	Homo sapiens	167-170
20709060-2	2010	However, this report demonstrates that SP600125 synergistically enhances the dihydroartemisinin (DHA)-induced human lung adenocarcinoma cell apoptosis by accelerating Bax translocation and subsequent intrinsic apoptotic pathway involving mitochondrial membrane depolarization, cytochrome c release, caspase-9 and caspase-3 activation.	pyrazolanthrone	39-47	cytochrome c, somatic	Homo sapiens	277-289
20709060-2	2010	However, this report demonstrates that SP600125 synergistically enhances the dihydroartemisinin (DHA)-induced human lung adenocarcinoma cell apoptosis by accelerating Bax translocation and subsequent intrinsic apoptotic pathway involving mitochondrial membrane depolarization, cytochrome c release, caspase-9 and caspase-3 activation.	pyrazolanthrone	39-47	caspase 9	Homo sapiens	299-308
20709060-2	2010	However, this report demonstrates that SP600125 synergistically enhances the dihydroartemisinin (DHA)-induced human lung adenocarcinoma cell apoptosis by accelerating Bax translocation and subsequent intrinsic apoptotic pathway involving mitochondrial membrane depolarization, cytochrome c release, caspase-9 and caspase-3 activation.	pyrazolanthrone	39-47	caspase 3	Homo sapiens	313-322
20709060-3	2010	The dynamical analysis of GFP-Bax mobility inside single living cells using fluorescence recovery after photobleaching revealed that SP600125 aggravated the DHA-induced decrease of Bax mobility and Bax translocation.	pyrazolanthrone	133-141	BCL2 associated X, apoptosis regulator	Homo sapiens	30-33
20709060-3	2010	The dynamical analysis of GFP-Bax mobility inside single living cells using fluorescence recovery after photobleaching revealed that SP600125 aggravated the DHA-induced decrease of Bax mobility and Bax translocation.	pyrazolanthrone	133-141	BCL2 associated X, apoptosis regulator	Homo sapiens	181-184
20709060-3	2010	The dynamical analysis of GFP-Bax mobility inside single living cells using fluorescence recovery after photobleaching revealed that SP600125 aggravated the DHA-induced decrease of Bax mobility and Bax translocation.	pyrazolanthrone	133-141	BCL2 associated X, apoptosis regulator	Homo sapiens	181-184
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	pyrazolanthrone	340-348	tumor necrosis factor	Homo sapiens	0-3
20493825-4	2010	The stimulatory effect of H2O2 on the exchanger activity was blocked by SP600125 (JNK inhibitor), but not by U0126 (MEK1/2 inhibitor) or SB203580 (p38 inhibitor) in both cell lines.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Rattus norvegicus	82-85
20553682-7	2010	The increased vascular O(2)(*-) production and p47(phox) up-regulation induced by ET-1 was only inhibited in aortic rings coincubated with the ERK1/2 inhibitor, PD98059; being without effects both the p38 MAPK inhibitor, SB203580, and JNK inhibitor, SP600125.	pyrazolanthrone	250-258	endothelin 1	Rattus norvegicus	82-86
20830294-9	2010	Pre-exposure of hepatocytes to a JNK inhibitor SP600125 prevented As-induced caspase-3 activation, ROS production and loss in cell viability.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Rattus norvegicus	33-36
20830294-9	2010	Pre-exposure of hepatocytes to a JNK inhibitor SP600125 prevented As-induced caspase-3 activation, ROS production and loss in cell viability.	pyrazolanthrone	47-55	caspase 3	Rattus norvegicus	77-86
20800791-11	2010	Furthermore, ERK1/2 (U0126) and JNK (SP600125) inhibitors inhibited CraA-induced IL-8 secretion by 100% and 45%, respectively.	pyrazolanthrone	37-45	C-X-C motif chemokine ligand 8	Homo sapiens	81-85
20538278-11	2010	The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs.	pyrazolanthrone	57-65	mitogen-activated protein kinase 3	Homo sapiens	90-96
20538278-11	2010	The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	101-104
20538278-11	2010	The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs.	pyrazolanthrone	57-65	angiotensinogen	Homo sapiens	173-178
20538278-11	2010	The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs.	pyrazolanthrone	57-65	C-reactive protein	Homo sapiens	187-190
20538278-11	2010	The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs.	pyrazolanthrone	135-143	synuclein alpha	Homo sapiens	43-46
20538278-11	2010	The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs.	pyrazolanthrone	135-143	angiotensinogen	Homo sapiens	173-178
20538278-11	2010	The further study indicated that losartan, NAC, PD98059, SP600125 significantly inhibited ERK1/2 and JNK phosphorylation, and PD98059, SP600125, PDTC completely antagonized AngII-induced CRP expression in HAECs.	pyrazolanthrone	135-143	C-reactive protein	Homo sapiens	187-190
20556404-4	2010	The role of the MAP kinases in TGF-beta1-dependent induction of the 37/67 LR was examined by addition of PD98059, SB202190 and SP600125.	pyrazolanthrone	127-135	transforming growth factor, beta 1	Mus musculus	31-40
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	pyrazolanthrone	340-348	tumor necrosis factor	Homo sapiens	98-101
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	pyrazolanthrone	340-348	TNF receptor superfamily member 1A	Homo sapiens	114-122
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	pyrazolanthrone	340-348	mitogen-activated protein kinase 13	Homo sapiens	174-181
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	pyrazolanthrone	181-189	mitogen-activated protein kinase 3	Homo sapiens	75-79
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	pyrazolanthrone	181-189	mitogen-activated protein kinase 3	Homo sapiens	218-224
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	pyrazolanthrone	181-189	mitogen-activated protein kinase 1	Homo sapiens	226-229
20562007-6	2010	Of physiological significance, in agreement with the mitogenic role of the MAPK cascade, ATP increased Caco-2 cell proliferation, and this effect was blocked by UO126, SB203580 and SP600125, the specific inhibitors of ERK1/2, p38 MAPK and JNK1/2, respectively.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Homo sapiens	239-245
20463356-4	2010	TNF-induced proMMP9 production, as measured by zymography, was significantly blocked/inhibited by TNF receptor 1 (TNFRSF1A) antibody, NFKB activation inhibitor (NFKBAI), and MAPK1/3 (ERK) inhibitor (U0126) (P &lt; 0.01), but not by TNF receptor 2 (TNFRSF1B) antibody, MAPK14 (p38 MAPK) inhibitor (SB203580), and MAPK8/9/10 (JNK) inhibitor (SP600125).	pyrazolanthrone	340-348	tumor necrosis factor	Homo sapiens	98-101
20607722-6	2010	MMP-2 promoter activity and cell invasion were inhibited by p38 mitogen-activated protein kinase (MAPK) siRNA, inhibitor 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole (SB203580), and AE, but not by JNK siRNA and inhibitor 1,9-pyrazoloanthrone.	pyrazolanthrone	251-271	matrix metallopeptidase 2	Homo sapiens	0-5
20607722-6	2010	MMP-2 promoter activity and cell invasion were inhibited by p38 mitogen-activated protein kinase (MAPK) siRNA, inhibitor 4-(4-Fluorophenyl)-2-[4-(methylsulfinyl)phenyl]-5-(4-pyridyl)-1H-imidazole (SB203580), and AE, but not by JNK siRNA and inhibitor 1,9-pyrazoloanthrone.	pyrazolanthrone	251-271	mitogen-activated protein kinase 14	Homo sapiens	60-96
20541731-5	2010	RESULTS: Hyperglycemia increased iNOS mRNA, and SP600125, a potent JNK1/2 inhibitor, abolished this effect.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	67-73
20561571-6	2010	The effects on the ET(A) receptor induced by DSP 0.4 microl/ml were inhibited by co-incubation with PD98059 (an ERK1/2 inhibitor) or SP600125 (a JNK inhibitor) and were further enhanced by SB203580.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Rattus norvegicus	145-148
20470842-3	2010	Treatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 or with pituitary adenylate activating polypeptide increased delta subunit expression by 70%.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Mus musculus	19-42
20470842-3	2010	Treatment with the c-Jun N-terminal kinase (JNK) inhibitor SP600125 or with pituitary adenylate activating polypeptide increased delta subunit expression by 70%.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Mus musculus	44-47
21038848-9	2010	In contrast, Sp600125, a specific inhibitor of JNK, blocked apoptosis of HL-60 cells exposed to DADS.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	47-50
20559021-9	2010	Finally, the JNK inhibitor SP 600125 abolished hypoxia-induced HIF-1alpha and HIF-2alpha expression, and inhibited the adhesive and invasive abilities of gastric cancer cells exposed to hypoxia in a dose-dependent manner.	pyrazolanthrone	27-36	mitogen-activated protein kinase 8	Homo sapiens	13-16
20559021-9	2010	Finally, the JNK inhibitor SP 600125 abolished hypoxia-induced HIF-1alpha and HIF-2alpha expression, and inhibited the adhesive and invasive abilities of gastric cancer cells exposed to hypoxia in a dose-dependent manner.	pyrazolanthrone	27-36	endothelial PAS domain protein 1	Homo sapiens	78-88
20629200-7	2010	Furthermore, the JNK-specific inhibitor SP600125, but not the p38-specific inhibitor SB203580, abolished mevastatin-induced cell growth inhibition and apoptosis in SACC cells.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	17-20
20522648-3	2010	In a tissue culture system, the LPS-induced decrease in the AQP5 mRNA level was blocked completely by pyrrolidine dithiocarbamate, MG132, tyrphostin AG126, SP600125, and partially by SB203580, which are inhibitors for IkappaB kinase, 26S proteasome, ERK1/2, JNK, and p38 MAPK, respectively.	pyrazolanthrone	156-164	aquaporin 5	Mus musculus	60-64
20522648-4	2010	In contrast, the expression of AQP1 mRNA was down-regulated by LPS and such down-regulation was blocked only by SP600125.	pyrazolanthrone	112-120	aquaporin 1	Mus musculus	31-35
20960100-8	2010	Importantly, we observed c-Jun NH(2)-terminal kinase (JNK) was activated in PAK3 transfected cells, and inhibition of JNK activity by SP600125, a JNK pathway inhibitor, abolished PAK3 mediated cell migration.	pyrazolanthrone	134-142	p21 (RAC1) activated kinase 3	Homo sapiens	179-183
20649571-11	2010	SP600125, a specific JNK inhibitor, significantly inhibited apoptotic signalling, indicating that JNK plays a key role in PPTMB action.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	21-24
20649571-11	2010	SP600125, a specific JNK inhibitor, significantly inhibited apoptotic signalling, indicating that JNK plays a key role in PPTMB action.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	98-101
20606042-7	2010	Treatments of PC-9 cells with c-Jun-NH(2)-kinase inhibitor SP600125, with p38 mitogen-activated protein kinase inhibitor SB202190 and with PD98059 (extracellular signal-regulated kinase 1/2 inhibitor) all increased the upregulation of GADD153 and GADD45 genes by the combination.	pyrazolanthrone	59-67	mitogen-activated protein kinase 3	Homo sapiens	148-189
20560104-7	2010	Ectopic expression of IRS1 or IRS2 strongly counteracted the inhibitory effect of ER stress on insulin signaling while pharmacological inhibition of JNK with SP600125 resulted only in a mild improvement.	pyrazolanthrone	158-166	mitogen-activated protein kinase 8	Rattus norvegicus	149-152
20960100-8	2010	Importantly, we observed c-Jun NH(2)-terminal kinase (JNK) was activated in PAK3 transfected cells, and inhibition of JNK activity by SP600125, a JNK pathway inhibitor, abolished PAK3 mediated cell migration.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	25-52
20960100-8	2010	Importantly, we observed c-Jun NH(2)-terminal kinase (JNK) was activated in PAK3 transfected cells, and inhibition of JNK activity by SP600125, a JNK pathway inhibitor, abolished PAK3 mediated cell migration.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	54-57
20960100-8	2010	Importantly, we observed c-Jun NH(2)-terminal kinase (JNK) was activated in PAK3 transfected cells, and inhibition of JNK activity by SP600125, a JNK pathway inhibitor, abolished PAK3 mediated cell migration.	pyrazolanthrone	134-142	p21 (RAC1) activated kinase 3	Homo sapiens	76-80
20960100-8	2010	Importantly, we observed c-Jun NH(2)-terminal kinase (JNK) was activated in PAK3 transfected cells, and inhibition of JNK activity by SP600125, a JNK pathway inhibitor, abolished PAK3 mediated cell migration.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	118-121
20960100-8	2010	Importantly, we observed c-Jun NH(2)-terminal kinase (JNK) was activated in PAK3 transfected cells, and inhibition of JNK activity by SP600125, a JNK pathway inhibitor, abolished PAK3 mediated cell migration.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	118-121
20653470-6	2010	SP600125, a specific inhibitor of JNK, can partially block H(2)O(2)-induced alveolar type II epithelial cells (ATII cells).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	34-37
20653470-7	2010	SP600125 also attenuated Bax protein content and p53 nuclear accumulation induced by H(2)O(2).	pyrazolanthrone	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	25-28
20653470-7	2010	SP600125 also attenuated Bax protein content and p53 nuclear accumulation induced by H(2)O(2).	pyrazolanthrone	0-8	tumor protein p53	Homo sapiens	49-52
20333651-9	2010	Pretreatment with the inhibitor of JNK1/2 (SP600125) but not the inhibitor of MEK1/2 (U0126), p38 MAPK (SB202190), or PI3K (LY294002), markedly inhibited TNF-alpha-induced c-Jun mRNA levels.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	35-41
20632440-14	2010	Peak JNK activation occurred at 12 h post-treatment and this activation persisted for up to 24 h. The expression of phosphorylated JNK and c-Jun protein after 12 h with BrMC-treated cells was inhibited by N-acetylcysteine and SP600125 pre-treatment, but GW9662 had no effect.	pyrazolanthrone	226-234	mitogen-activated protein kinase 8	Homo sapiens	5-8
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	pyrazolanthrone	60-68	interleukin 1 beta	Homo sapiens	0-8
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	pyrazolanthrone	60-68	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	20-24
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	pyrazolanthrone	60-68	mitogen-activated protein kinase 1	Homo sapiens	85-88
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	93-96
20432452-6	2010	IL-1beta-stimulated AP-1 activation was blocked by U0126 or SP600125, revealing that ERK and JNK linked to AP-1 on these responses.	pyrazolanthrone	60-68	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-111
20175209-7	2010	OX42 immunostaining revealed that apoptosis-like microglial cell death was induced only when thrombin treatment was combined with application of inhibitors of MAP kinase/extracellular signal-regulated kinase kinase (PD98059), p38 MAP kinase (SB203580), or c-Jun N-terminal kinase (SP600125).	pyrazolanthrone	281-289	coagulation factor II	Rattus norvegicus	93-101
20175209-9	2010	We also found that thrombin-induced production of tumor necrosis factor (TNF)-alpha was inhibited by PD98059, SB203580, and SP600125.	pyrazolanthrone	124-132	coagulation factor II	Rattus norvegicus	19-27
20175209-9	2010	We also found that thrombin-induced production of tumor necrosis factor (TNF)-alpha was inhibited by PD98059, SB203580, and SP600125.	pyrazolanthrone	124-132	tumor necrosis factor	Rattus norvegicus	50-83
20572161-10	2010	Depletion of MEKK1 and inhibition of MEK1 restored the intracellular glutathione content and abrogated NO production, whereas inhibition of JNK activation by SP600125 restored intracellular glutathione content but failed to inhibit NO production in fucoidan-treated HL-60 cells.	pyrazolanthrone	158-166	mitogen-activated protein kinase 8	Homo sapiens	140-143
20680486-6	2010	TrkA-induced cell death was synergistically increased by DNA damage, but it was blocked in the presence of the JNK inhibitor SP600125.	pyrazolanthrone	125-133	neurotrophic receptor tyrosine kinase 1	Homo sapiens	0-4
20680486-6	2010	TrkA-induced cell death was synergistically increased by DNA damage, but it was blocked in the presence of the JNK inhibitor SP600125.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Homo sapiens	111-114
20632440-14	2010	Peak JNK activation occurred at 12 h post-treatment and this activation persisted for up to 24 h. The expression of phosphorylated JNK and c-Jun protein after 12 h with BrMC-treated cells was inhibited by N-acetylcysteine and SP600125 pre-treatment, but GW9662 had no effect.	pyrazolanthrone	226-234	mitogen-activated protein kinase 8	Homo sapiens	131-134
20632440-14	2010	Peak JNK activation occurred at 12 h post-treatment and this activation persisted for up to 24 h. The expression of phosphorylated JNK and c-Jun protein after 12 h with BrMC-treated cells was inhibited by N-acetylcysteine and SP600125 pre-treatment, but GW9662 had no effect.	pyrazolanthrone	226-234	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	139-144
20632440-15	2010	SP600125 substantially reduced BrMC-induced cell death and caspase-3 activation of HepG2 cells.	pyrazolanthrone	0-8	caspase 3	Homo sapiens	59-68
20388542-4	2010	In the present study, we treated Lmna(H222P/H222P) mice with SP600125, an inhibitor of JNK signalling.	pyrazolanthrone	61-69	lamin A	Mus musculus	33-37
20411335-4	2010	IL-1beta also led to increased phosphorylation of eIF2alpha and all these events could be prevented by pretreatment with the JNK inhibitor, SP600125.	pyrazolanthrone	140-148	interleukin 1 beta	Homo sapiens	0-8
20411335-4	2010	IL-1beta also led to increased phosphorylation of eIF2alpha and all these events could be prevented by pretreatment with the JNK inhibitor, SP600125.	pyrazolanthrone	140-148	eukaryotic translation initiation factor 2A	Homo sapiens	50-59
20411335-4	2010	IL-1beta also led to increased phosphorylation of eIF2alpha and all these events could be prevented by pretreatment with the JNK inhibitor, SP600125.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Homo sapiens	125-128
20359507-5	2010	We found that JNK inhibition, by SP600125 treatment, increased (35)S-methionine incorporation.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	14-17
20138622-7	2010	N-acetylcysteine, SP600125 (JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated TNF-alpha-induced DNA-binding activities of both AP-1 and NF-kappaB.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	28-31
20138622-7	2010	N-acetylcysteine, SP600125 (JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated TNF-alpha-induced DNA-binding activities of both AP-1 and NF-kappaB.	pyrazolanthrone	18-26	tumor necrosis factor	Homo sapiens	88-97
20359850-5	2010	We demonstrated that transfection with PDCD4 or inhibition of JNK by SP600125 alters the expression and phosphorylation of eIF4E in the presence of H(2)O(2).	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	62-65
20359850-5	2010	We demonstrated that transfection with PDCD4 or inhibition of JNK by SP600125 alters the expression and phosphorylation of eIF4E in the presence of H(2)O(2).	pyrazolanthrone	69-77	eukaryotic translation initiation factor 4E	Homo sapiens	123-128
20359850-6	2010	PDCD4 results in a stronger inhibitory effect than SP600125.	pyrazolanthrone	51-59	programmed cell death 4	Homo sapiens	0-5
20388542-4	2010	In the present study, we treated Lmna(H222P/H222P) mice with SP600125, an inhibitor of JNK signalling.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Mus musculus	87-90
20388542-5	2010	Systemic treatment with SP600125 inhibited JNK phosphorylation, with no detectable effect on ERK.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Mus musculus	43-46
20589738-7	2010	Arsenite-induced 4E-BP1 mRNA and protein expressions were augmented by simultaneous treatment with a c-Jun N-terminal kinase (JNK) specific inhibitor, SP600125.	pyrazolanthrone	151-159	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	17-23
20442653-4	2010	ELISA and quantitative real-time reverse transcriptase-PCR were used to analyze TFPI expression after blocking ERK1/2 (with PD98059) or JNK (with SP600125) pathway in HUVECs.	pyrazolanthrone	146-154	tissue factor pathway inhibitor	Homo sapiens	80-84
20589738-7	2010	Arsenite-induced 4E-BP1 mRNA and protein expressions were augmented by simultaneous treatment with a c-Jun N-terminal kinase (JNK) specific inhibitor, SP600125.	pyrazolanthrone	151-159	mitogen-activated protein kinase 8	Mus musculus	101-124
20589738-7	2010	Arsenite-induced 4E-BP1 mRNA and protein expressions were augmented by simultaneous treatment with a c-Jun N-terminal kinase (JNK) specific inhibitor, SP600125.	pyrazolanthrone	151-159	mitogen-activated protein kinase 8	Mus musculus	126-129
20143420-6	2010	JNK-specific inhibitors, SP600125 and CEP11004, partially blocked the inhibitory effects of JNK on PGC-1alpha expression and its promoter activity.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	0-3
20463056-2	2010	VEGF-induced cell migration was blocked by specific kinase inhibitors of JNK1/2 (SP600125), c-Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and phosphatidylinositol 3-kinase/Akt (wortmannin) but not ERK2/1 (U0126) and p38MAPK (SB203580).	pyrazolanthrone	81-89	vascular endothelial growth factor A	Homo sapiens	0-4
20463056-2	2010	VEGF-induced cell migration was blocked by specific kinase inhibitors of JNK1/2 (SP600125), c-Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d] pyrimidine), and phosphatidylinositol 3-kinase/Akt (wortmannin) but not ERK2/1 (U0126) and p38MAPK (SB203580).	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	73-79
20444941-9	2010	SP600125 inhibited phosphorylation of NF-kappaB p65 (S536) and c-Jun (S63).	pyrazolanthrone	0-8	synaptotagmin 1	Rattus norvegicus	48-51
20446899-2	2010	This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125.	pyrazolanthrone	280-288	tumor protein p53	Homo sapiens	105-108
20446899-2	2010	This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125.	pyrazolanthrone	280-288	cell division cycle 25C	Homo sapiens	140-146
20446899-2	2010	This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125.	pyrazolanthrone	280-288	cyclin dependent kinase 1	Homo sapiens	140-144
20446899-2	2010	This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125.	pyrazolanthrone	280-288	cyclin B1	Homo sapiens	158-167
20446899-2	2010	This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125.	pyrazolanthrone	280-288	protein tyrosine kinase 2 beta	Homo sapiens	229-232
20446899-2	2010	This study suggested that G2/M cell cycle arrest was triggered by ROS/NO productions with regulations of p53, p21, cell division cycle 25C (Cdc25C), Cdc2 and cyclin B1, which were able to be prevented by protein tyrosine kinase (PTK) activity inhibitor genistein or JNK inhibitor SP600125.	pyrazolanthrone	280-288	mitogen-activated protein kinase 8	Homo sapiens	266-269
20143420-6	2010	JNK-specific inhibitors, SP600125 and CEP11004, partially blocked the inhibitory effects of JNK on PGC-1alpha expression and its promoter activity.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	92-95
20143420-6	2010	JNK-specific inhibitors, SP600125 and CEP11004, partially blocked the inhibitory effects of JNK on PGC-1alpha expression and its promoter activity.	pyrazolanthrone	25-33	PPARG coactivator 1 alpha	Homo sapiens	99-109
20338993-7	2010	Both the SP 600125 (JNK inhibitor) and LY 294002 (PI-3K/Akt inhibitor) can inhibit chloramphenicol-induced c-Jun phosphorylation, MMP-13 expression, and cell invasion.	pyrazolanthrone	9-18	mitogen-activated protein kinase 8	Homo sapiens	20-23
20124940-0	2010	Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats.	pyrazolanthrone	13-21	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	53-58
20124940-7	2010	Rolipram and SP600125 pretreatments mostly suppressed the increase in the expression of PTP1B during the early phase of AP.	pyrazolanthrone	13-21	protein tyrosine phosphatase, non-receptor type 1	Rattus norvegicus	88-93
20338993-7	2010	Both the SP 600125 (JNK inhibitor) and LY 294002 (PI-3K/Akt inhibitor) can inhibit chloramphenicol-induced c-Jun phosphorylation, MMP-13 expression, and cell invasion.	pyrazolanthrone	9-18	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-112
20338993-7	2010	Both the SP 600125 (JNK inhibitor) and LY 294002 (PI-3K/Akt inhibitor) can inhibit chloramphenicol-induced c-Jun phosphorylation, MMP-13 expression, and cell invasion.	pyrazolanthrone	9-18	matrix metallopeptidase 13	Homo sapiens	130-136
20431060-9	2010	SP600125 (specific JNK inhibitor) significantly induced mineralization of CVCs and alkaline phosphatase expression, suggesting that the anticalcific effect of INT-747 is attributable to JNK activation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	19-22
20423716-2	2010	Although it was shown that the JNK inhibitor SP600125 effectively reduced APAP hepatotoxicity, the mechanisms of protection remain unclear.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
20423716-5	2010	SP600125, but not the vehicle, reduced JNK activation, attenuated mitochondrial Bax translocation and prevented the mitochondrial release of apoptosis-inducing factor at 4-12h.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	39-42
20423716-5	2010	SP600125, but not the vehicle, reduced JNK activation, attenuated mitochondrial Bax translocation and prevented the mitochondrial release of apoptosis-inducing factor at 4-12h.	pyrazolanthrone	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	80-83
20423716-7	2010	Furthermore, SP600125 attenuated the increase of inducible nitric oxide synthase (iNOS) mRNA and protein.	pyrazolanthrone	13-21	nitric oxide synthase 2	Homo sapiens	49-80
20423716-7	2010	Furthermore, SP600125 attenuated the increase of inducible nitric oxide synthase (iNOS) mRNA and protein.	pyrazolanthrone	13-21	nitric oxide synthase 2	Homo sapiens	82-86
20423716-11	2010	Our data suggest that the JNK inhibitor SP600125 protects against APAP-induced liver injury in part by attenuation of mitochondrial Bax translocation but mainly by preventing mitochondrial oxidant stress and peroxynitrite formation and thereby preventing the mitochondrial permeability transition pore opening, a key event in APAP-induced cell necrosis.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	26-29
20423716-11	2010	Our data suggest that the JNK inhibitor SP600125 protects against APAP-induced liver injury in part by attenuation of mitochondrial Bax translocation but mainly by preventing mitochondrial oxidant stress and peroxynitrite formation and thereby preventing the mitochondrial permeability transition pore opening, a key event in APAP-induced cell necrosis.	pyrazolanthrone	40-48	BCL2 associated X, apoptosis regulator	Homo sapiens	132-135
20571742-11	2010	SP600125, a specific JNK inhibitor, significantly decreased periostin expression induced by high glucose.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	21-24
20431060-9	2010	SP600125 (specific JNK inhibitor) significantly induced mineralization of CVCs and alkaline phosphatase expression, suggesting that the anticalcific effect of INT-747 is attributable to JNK activation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	186-189
20144638-6	2010	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) suppressed CMS-9-induced dissipation of mitochondrial membrane potential, Bcl-2 down-regulation, Bax up-regulation and increased mitochondrial translocation of Bax.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	44-47
20571742-11	2010	SP600125, a specific JNK inhibitor, significantly decreased periostin expression induced by high glucose.	pyrazolanthrone	0-8	periostin	Rattus norvegicus	60-69
20363316-4	2010	NRK-52E cells were incubated with PA or hydrogen peroxide (H(2)O(2)) combined with SP600125 which blocks c-Jun N-terminal kinase (JNK) activation; salubrinal, which maintains eukaryotic initiation factor 2 alpha in its phosphorylated state and the antioxidant EUK-134 - a superoxide dismutase mimetic with catalase activity.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Rattus norvegicus	105-128
20363316-4	2010	NRK-52E cells were incubated with PA or hydrogen peroxide (H(2)O(2)) combined with SP600125 which blocks c-Jun N-terminal kinase (JNK) activation; salubrinal, which maintains eukaryotic initiation factor 2 alpha in its phosphorylated state and the antioxidant EUK-134 - a superoxide dismutase mimetic with catalase activity.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Rattus norvegicus	130-133
20144638-6	2010	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) suppressed CMS-9-induced dissipation of mitochondrial membrane potential, Bcl-2 down-regulation, Bax up-regulation and increased mitochondrial translocation of Bax.	pyrazolanthrone	34-42	muscle associated receptor tyrosine kinase	Homo sapiens	70-75
20144638-6	2010	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) suppressed CMS-9-induced dissipation of mitochondrial membrane potential, Bcl-2 down-regulation, Bax up-regulation and increased mitochondrial translocation of Bax.	pyrazolanthrone	34-42	BCL2 apoptosis regulator	Homo sapiens	133-138
20144638-6	2010	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) suppressed CMS-9-induced dissipation of mitochondrial membrane potential, Bcl-2 down-regulation, Bax up-regulation and increased mitochondrial translocation of Bax.	pyrazolanthrone	34-42	BCL2 associated X, apoptosis regulator	Homo sapiens	156-159
20144638-6	2010	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) suppressed CMS-9-induced dissipation of mitochondrial membrane potential, Bcl-2 down-regulation, Bax up-regulation and increased mitochondrial translocation of Bax.	pyrazolanthrone	34-42	BCL2 associated X, apoptosis regulator	Homo sapiens	219-222
20511679-8	2010	Furthermore, although TQ treatment resulted in the activation of Jun kinase (JNK), pretreatment with the JNK inhibitor, SP600125, did not protect cells from TQ.	pyrazolanthrone	120-128	mitogen-activated protein kinase 9	Homo sapiens	105-108
20228179-5	2010	Inhibition of JNK with its specific inhibitor, SP-600125, or its dominant-negative form, DN-JNK, significantly reduced 5-HT-stimulated [(3)H]thymidine incorporation and cyclin D1 expression.	pyrazolanthrone	47-56	cyclin D1	Bos taurus	169-178
20405237-7	2010	Likewise, SP600125, inhibitor of JNK, abrogated iNOS expression stimulated by LPS.	pyrazolanthrone	10-18	mitogen-activated protein kinase 8	Homo sapiens	33-36
20405237-7	2010	Likewise, SP600125, inhibitor of JNK, abrogated iNOS expression stimulated by LPS.	pyrazolanthrone	10-18	inositol-3-phosphate synthase 1	Homo sapiens	48-52
20380623-4	2010	To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively.	pyrazolanthrone	133-141	mitogen-activated protein kinase 1	Homo sapiens	88-91
20380623-4	2010	To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Homo sapiens	93-96
20380623-4	2010	To investigate the pathway of cell death, the mitogen-activated protein kinases (MAPKs) Erk, JNK, and p38 were inhibited with U0126, SP600125, and SB203580, respectively.	pyrazolanthrone	133-141	mitogen-activated protein kinase 14	Homo sapiens	102-105
20226460-7	2010	PA-induced EPCs apoptosis could be partly ameliorated by p38 inhibitor SB203580 and JNK inhibitor SP600125, but not by ERK1/2 inhibitor PD98059.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Homo sapiens	84-87
20200402-2	2010	The PGN-induced COX-2 expression was attenuated by the DNs of ASK1, JNK1, JNK2, a JNK inhibitor (SP600125), and an AP-1 inhibitor (curcumin).	pyrazolanthrone	97-105	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	4-7
20200402-2	2010	The PGN-induced COX-2 expression was attenuated by the DNs of ASK1, JNK1, JNK2, a JNK inhibitor (SP600125), and an AP-1 inhibitor (curcumin).	pyrazolanthrone	97-105	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	16-21
20346929-7	2010	Moreover, treatment of RKO cells with butyrate induced a sustained activation of the phosphorylation of c-jun N-terminal kinase (JNK) in a dose- and time-dependent manner, and the pharmacological inhibition of JNK MAPK by SP600125 significantly abolished the butyrate-induced apoptosis in RKO cells.	pyrazolanthrone	222-230	mitogen-activated protein kinase 8	Homo sapiens	104-127
20346929-7	2010	Moreover, treatment of RKO cells with butyrate induced a sustained activation of the phosphorylation of c-jun N-terminal kinase (JNK) in a dose- and time-dependent manner, and the pharmacological inhibition of JNK MAPK by SP600125 significantly abolished the butyrate-induced apoptosis in RKO cells.	pyrazolanthrone	222-230	mitogen-activated protein kinase 8	Homo sapiens	129-132
20346929-7	2010	Moreover, treatment of RKO cells with butyrate induced a sustained activation of the phosphorylation of c-jun N-terminal kinase (JNK) in a dose- and time-dependent manner, and the pharmacological inhibition of JNK MAPK by SP600125 significantly abolished the butyrate-induced apoptosis in RKO cells.	pyrazolanthrone	222-230	mitogen-activated protein kinase 8	Homo sapiens	210-213
20346929-9	2010	Butyrate triggered the caspase apoptotic pathway, indicated by an enhanced Bax-to-Bcl-2 expression ratio and caspase cascade reaction, which was blocked by SP600125.	pyrazolanthrone	156-164	BCL2 associated X, apoptosis regulator	Homo sapiens	75-78
20346929-9	2010	Butyrate triggered the caspase apoptotic pathway, indicated by an enhanced Bax-to-Bcl-2 expression ratio and caspase cascade reaction, which was blocked by SP600125.	pyrazolanthrone	156-164	BCL2 apoptosis regulator	Homo sapiens	82-87
19712679-9	2010	Similarly, the JNK 1/2 inhibitor SP600125 (1 microM) impaired TF promoter activity (n=4; p&lt;0.001) and protein expression (n=4; p&lt;0.001).	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	15-22
20152896-8	2010	Importantly, the manganese-mediated expression and activity of HIF-1alpha protein were largely blocked by treatment with the inhibitor of p38 MAPK (SB203580), JNK-1/2 (SP600125), or ERK-1/2 (PD98059), suggesting roles of these MAPKs in the manganese-induced HIF-1alpha protein expression and activity.	pyrazolanthrone	168-176	hypoxia inducible factor 1 subunit alpha	Homo sapiens	63-73
20152896-9	2010	Moreover, treatment with SP600125 or SB203580, but not PD98059, had partial inhibitory effects on the stability of HIF-1alpha protein induced by manganese, suggesting that p38 MAPK and JNK-1/2 also contribute to the Mn-mediated HIF-1alpha protein stability.	pyrazolanthrone	25-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	115-125
20152896-9	2010	Moreover, treatment with SP600125 or SB203580, but not PD98059, had partial inhibitory effects on the stability of HIF-1alpha protein induced by manganese, suggesting that p38 MAPK and JNK-1/2 also contribute to the Mn-mediated HIF-1alpha protein stability.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	185-192
20152896-9	2010	Moreover, treatment with SP600125 or SB203580, but not PD98059, had partial inhibitory effects on the stability of HIF-1alpha protein induced by manganese, suggesting that p38 MAPK and JNK-1/2 also contribute to the Mn-mediated HIF-1alpha protein stability.	pyrazolanthrone	25-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	228-238
20622336-7	2010	SP600125, the inhibitor of JNK, decreased the apoptosis rate induced by intermittent high glucose (P &lt; 0.05).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	27-30
20417179-4	2010	Treatment of VSMCs with PD98059 (ERK inhibitor), SP600125 (JNK inhibitor), or SB203580 (p38 MAPK inhibitor) significantly inhibited OPN-induced Egr-1 expression, and PD98059 treatment was associated with the most significant decrease in Egr-1 expression.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Rattus norvegicus	59-62
20417179-4	2010	Treatment of VSMCs with PD98059 (ERK inhibitor), SP600125 (JNK inhibitor), or SB203580 (p38 MAPK inhibitor) significantly inhibited OPN-induced Egr-1 expression, and PD98059 treatment was associated with the most significant decrease in Egr-1 expression.	pyrazolanthrone	49-57	secreted phosphoprotein 1	Rattus norvegicus	132-135
20417179-4	2010	Treatment of VSMCs with PD98059 (ERK inhibitor), SP600125 (JNK inhibitor), or SB203580 (p38 MAPK inhibitor) significantly inhibited OPN-induced Egr-1 expression, and PD98059 treatment was associated with the most significant decrease in Egr-1 expression.	pyrazolanthrone	49-57	early growth response 1	Rattus norvegicus	144-149
20417179-5	2010	OPN-stimulated VSMC cell migration was inhibited by SP600125 or SB203580, but not by PD98059.	pyrazolanthrone	52-60	secreted phosphoprotein 1	Rattus norvegicus	0-3
19941984-4	2010	Both SP600125, an inhibitor of JNK, and LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), dose-dependently decreased LPS-induced Prx I mRNA expression.	pyrazolanthrone	5-13	mitogen-activated protein kinase 8	Mus musculus	31-34
19942932-4	2010	The JNK inhibitor SP600125 abrogated MIA-induced mitotic arrest and downregulation of cFLIP and Mcl-1 and reduced the apoptosis caused by the combination of MIAs and TRAIL.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
19941984-4	2010	Both SP600125, an inhibitor of JNK, and LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), dose-dependently decreased LPS-induced Prx I mRNA expression.	pyrazolanthrone	5-13	toll-like receptor 4	Mus musculus	127-130
19941984-4	2010	Both SP600125, an inhibitor of JNK, and LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), dose-dependently decreased LPS-induced Prx I mRNA expression.	pyrazolanthrone	5-13	peroxiredoxin 1	Mus musculus	139-144
19763573-10	2010	PSC833 activated c-Jun NH2-terminal kinase (JNK)/c-Jun and enhanced AP-1 DNA-binding activity, but suppressed nuclear translocation of NF-kappaB, all of which were prevented by pretreatment with a JNK inhibitor SP600125.	pyrazolanthrone	211-219	mitogen-activated protein kinase 8	Homo sapiens	197-200
20130271-7	2010	Accumulation of HBEGF at reduced oxygen was blocked only by a combination of U0126, SB203580, and SP600125.	pyrazolanthrone	98-106	heparin binding EGF like growth factor	Homo sapiens	16-21
19942932-4	2010	The JNK inhibitor SP600125 abrogated MIA-induced mitotic arrest and downregulation of cFLIP and Mcl-1 and reduced the apoptosis caused by the combination of MIAs and TRAIL.	pyrazolanthrone	18-26	CASP8 and FADD like apoptosis regulator	Homo sapiens	86-91
19942932-4	2010	The JNK inhibitor SP600125 abrogated MIA-induced mitotic arrest and downregulation of cFLIP and Mcl-1 and reduced the apoptosis caused by the combination of MIAs and TRAIL.	pyrazolanthrone	18-26	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	96-101
19942932-4	2010	The JNK inhibitor SP600125 abrogated MIA-induced mitotic arrest and downregulation of cFLIP and Mcl-1 and reduced the apoptosis caused by the combination of MIAs and TRAIL.	pyrazolanthrone	18-26	TNF superfamily member 10	Homo sapiens	166-171
20177146-3	2010	Inhibition of p38 MAPK and JNK by their specific inhibitors (SB203580 and SP600125), or inhibition by a dominant negative mutant of p38 MAPK dramatically decreased SAA-induced CCL2 production.	pyrazolanthrone	74-82	mitogen-activated protein kinase 14	Homo sapiens	14-17
20376580-7	2010	z-DEVD-fmk (a caspase inhibitor) and SP600125 (a JNK inhibitor) significantly prevented the death of CHRF-288-11 cells induced by HCMV, respectively.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	49-52
20112290-9	2010	The JNK inhibitor SP600125 blocked high glucose-induced FN expression and inhibited cell cycle regulatory protein expression induced by high glucose or TGF-beta(1).	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
20112290-9	2010	The JNK inhibitor SP600125 blocked high glucose-induced FN expression and inhibited cell cycle regulatory protein expression induced by high glucose or TGF-beta(1).	pyrazolanthrone	18-26	transforming growth factor, beta 1	Mus musculus	152-163
20368270-4	2010	Treatment with a p38MAPK inhibitor (SB203580), an ERK inhibitor (PD98059), or an MEK inhibitor (U0126), suppressed the increase in MCP1 expression caused by hypertonic NaCl, whereas a JNK inhibitor (SP600125) and an AP1 inhibitor (curcumin) failed to attenuate MCP1 mRNA expression by NaCl.	pyrazolanthrone	199-207	C-C motif chemokine ligand 2	Rattus norvegicus	131-135
20082299-6	2010	Resveratrol-enhanced perforin expression and cytotoxic activity are effectively inhibited by pretreatment with the inhibitors of JNK (SP600125), ERK-1/2 (PD98059), or by siRNAs against JNK-1 and ERK-2.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	129-132
20490773-0	2010	SP600125, an inhibitor of c-Jun NH2-terminal kinase, blocks expression of angiotensin II-induced monocyte chemoattractant protein-1 in human mesangial cells.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-51
20490773-0	2010	SP600125, an inhibitor of c-Jun NH2-terminal kinase, blocks expression of angiotensin II-induced monocyte chemoattractant protein-1 in human mesangial cells.	pyrazolanthrone	0-8	angiotensinogen	Homo sapiens	74-88
20490773-0	2010	SP600125, an inhibitor of c-Jun NH2-terminal kinase, blocks expression of angiotensin II-induced monocyte chemoattractant protein-1 in human mesangial cells.	pyrazolanthrone	0-8	C-C motif chemokine ligand 2	Homo sapiens	97-131
20490773-9	2010	SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125.	pyrazolanthrone	0-8	C-C motif chemokine ligand 2	Homo sapiens	22-27
20490773-9	2010	SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125.	pyrazolanthrone	0-8	C-C motif chemokine ligand 2	Homo sapiens	60-65
20490773-9	2010	SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125.	pyrazolanthrone	0-8	angiotensinogen	Homo sapiens	119-125
20490773-9	2010	SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125.	pyrazolanthrone	0-8	angiotensinogen	Homo sapiens	194-200
20490773-9	2010	SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125.	pyrazolanthrone	205-213	C-C motif chemokine ligand 2	Homo sapiens	22-27
20490773-9	2010	SP600125 also reduced MCP-1 mRNA stability: the halflife of MCP-1 mRNA was approximately 5 hours in cells treated with Ang II only, but was reduced to 2 hours when treated with a combination of Ang II and SP600125.	pyrazolanthrone	205-213	C-C motif chemokine ligand 2	Homo sapiens	60-65
20177146-3	2010	Inhibition of p38 MAPK and JNK by their specific inhibitors (SB203580 and SP600125), or inhibition by a dominant negative mutant of p38 MAPK dramatically decreased SAA-induced CCL2 production.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	27-30
20177146-3	2010	Inhibition of p38 MAPK and JNK by their specific inhibitors (SB203580 and SP600125), or inhibition by a dominant negative mutant of p38 MAPK dramatically decreased SAA-induced CCL2 production.	pyrazolanthrone	74-82	serum amyloid A1 cluster	Homo sapiens	164-167
20177146-3	2010	Inhibition of p38 MAPK and JNK by their specific inhibitors (SB203580 and SP600125), or inhibition by a dominant negative mutant of p38 MAPK dramatically decreased SAA-induced CCL2 production.	pyrazolanthrone	74-82	C-C motif chemokine ligand 2	Homo sapiens	176-180
20442784-9	2010	Inhibition with U0126 and SP600125 prevented stretch-induced phosphorylation increases of ERK and JNK, respectively, however neither prevented increases in permeability following 10 minutes.	pyrazolanthrone	26-34	Eph receptor B1	Rattus norvegicus	90-93
20222869-5	2010	In an attempt to elucidate the signalling pathway involved, PDTC (pyrrolidinedithiocarbamate), SP600125 and FK009 respectively inhibitors of NF-kappaB, c-JNK and caspases, were added to the cells in the presence and absence of TNF, and changes in the activities of JNK and PDTC were determined.	pyrazolanthrone	95-103	mitogen-activated protein kinase 8	Sus scrofa	154-157
20442784-9	2010	Inhibition with U0126 and SP600125 prevented stretch-induced phosphorylation increases of ERK and JNK, respectively, however neither prevented increases in permeability following 10 minutes.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Rattus norvegicus	98-101
20398340-9	2010	Phosphorylation analysis of JNK (T183/Y185) and NF-kappaB p65 (S536) showed increased phosphorylation in response to TNFalpha treatment, which was decreased by specific inhibitors of JNK (SP600125) and NF-kappaB (Bay 11-7082, Ro 106-9920).	pyrazolanthrone	188-196	mitogen-activated protein kinase 8	Homo sapiens	28-31
20398340-9	2010	Phosphorylation analysis of JNK (T183/Y185) and NF-kappaB p65 (S536) showed increased phosphorylation in response to TNFalpha treatment, which was decreased by specific inhibitors of JNK (SP600125) and NF-kappaB (Bay 11-7082, Ro 106-9920).	pyrazolanthrone	188-196	nuclear factor kappa B subunit 1	Homo sapiens	48-57
20398340-9	2010	Phosphorylation analysis of JNK (T183/Y185) and NF-kappaB p65 (S536) showed increased phosphorylation in response to TNFalpha treatment, which was decreased by specific inhibitors of JNK (SP600125) and NF-kappaB (Bay 11-7082, Ro 106-9920).	pyrazolanthrone	188-196	tumor necrosis factor	Homo sapiens	117-125
20398340-9	2010	Phosphorylation analysis of JNK (T183/Y185) and NF-kappaB p65 (S536) showed increased phosphorylation in response to TNFalpha treatment, which was decreased by specific inhibitors of JNK (SP600125) and NF-kappaB (Bay 11-7082, Ro 106-9920).	pyrazolanthrone	188-196	mitogen-activated protein kinase 8	Homo sapiens	183-186
20398340-9	2010	Phosphorylation analysis of JNK (T183/Y185) and NF-kappaB p65 (S536) showed increased phosphorylation in response to TNFalpha treatment, which was decreased by specific inhibitors of JNK (SP600125) and NF-kappaB (Bay 11-7082, Ro 106-9920).	pyrazolanthrone	188-196	nuclear factor kappa B subunit 1	Homo sapiens	202-211
20079380-9	2010	Furthermore, LY294002, a PI3K inhibitor, abolished the anti-lipotoxic effect of ghrelin, as well as ghrelin-induced inhibition of JNK, while JNK inhibitor, SP600125 enhanced protective effect of ghrelin on MIN6 cells.	pyrazolanthrone	156-164	ghrelin	Mus musculus	80-87
20074581-9	2010	Finally, treatment with JNK inhibitor SP600125 could enhance ATO-induced apoptosis of HaCaT keratinocytes by using flow cytometry.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	24-27
20219632-6	2010	In addition, a JNK-specific inhibitor, SP600125, inhibited the CR-proBDNF-induced apoptosis but did not affect the antiapoptotic effect of matBDNF.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	15-18
20079380-9	2010	Furthermore, LY294002, a PI3K inhibitor, abolished the anti-lipotoxic effect of ghrelin, as well as ghrelin-induced inhibition of JNK, while JNK inhibitor, SP600125 enhanced protective effect of ghrelin on MIN6 cells.	pyrazolanthrone	156-164	ghrelin	Mus musculus	100-107
20079380-9	2010	Furthermore, LY294002, a PI3K inhibitor, abolished the anti-lipotoxic effect of ghrelin, as well as ghrelin-induced inhibition of JNK, while JNK inhibitor, SP600125 enhanced protective effect of ghrelin on MIN6 cells.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Mus musculus	141-144
20079380-9	2010	Furthermore, LY294002, a PI3K inhibitor, abolished the anti-lipotoxic effect of ghrelin, as well as ghrelin-induced inhibition of JNK, while JNK inhibitor, SP600125 enhanced protective effect of ghrelin on MIN6 cells.	pyrazolanthrone	156-164	ghrelin	Mus musculus	100-107
20371967-10	2010	The JNK inhibitor, SP600125 significantly diminished APAP and CPZ toxicity with or without TNF-alpha.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Mus musculus	4-7
19995368-9	2010	The bFGF-induced proliferation was suppressed by the MEK inhibitors PD98059 and U0126, and the JNK inhibitor SP600125.	pyrazolanthrone	109-117	fibroblast growth factor 2	Homo sapiens	4-8
19995368-9	2010	The bFGF-induced proliferation was suppressed by the MEK inhibitors PD98059 and U0126, and the JNK inhibitor SP600125.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Homo sapiens	95-98
20069553-3	2010	IL-1beta-induced cPLA(2) protein and mRNA expression, PGE(2) production, or phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK1/2, which was attenuated by pretreatment with the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK1/2 (SP600125) or transfection with siRNAs of MEK1, p42, p38, and JNK2.	pyrazolanthrone	240-248	interleukin 1 beta	Homo sapiens	0-8
20069553-3	2010	IL-1beta-induced cPLA(2) protein and mRNA expression, PGE(2) production, or phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK1/2, which was attenuated by pretreatment with the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK1/2 (SP600125) or transfection with siRNAs of MEK1, p42, p38, and JNK2.	pyrazolanthrone	240-248	phospholipase A2 group IVA	Homo sapiens	17-24
20069553-3	2010	IL-1beta-induced cPLA(2) protein and mRNA expression, PGE(2) production, or phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK1/2, which was attenuated by pretreatment with the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK1/2 (SP600125) or transfection with siRNAs of MEK1, p42, p38, and JNK2.	pyrazolanthrone	240-248	erythrocyte membrane protein band 4.2	Homo sapiens	95-98
20069553-3	2010	IL-1beta-induced cPLA(2) protein and mRNA expression, PGE(2) production, or phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK1/2, which was attenuated by pretreatment with the inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), and JNK1/2 (SP600125) or transfection with siRNAs of MEK1, p42, p38, and JNK2.	pyrazolanthrone	240-248	mitogen-activated protein kinase 8	Homo sapiens	123-129
20167866-6	2010	LTA-stimulated NF-kappaB translocation or cPLA(2) phosphorylation was attenuated by pretreatment with LY294002, SB202190, U0126, or SP600125.	pyrazolanthrone	132-140	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	15-24
20167866-6	2010	LTA-stimulated NF-kappaB translocation or cPLA(2) phosphorylation was attenuated by pretreatment with LY294002, SB202190, U0126, or SP600125.	pyrazolanthrone	132-140	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	42-49
20062077-0	2010	SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition.	pyrazolanthrone	0-8	cyclin dependent kinase 1	Homo sapiens	20-24
19898747-5	2010	Further, pretreatment of these cells with the highly specific MEK inhibitor (PD 098059), the JNK inhibitor (SP 600125), and the p38MAPK inhibitor (SB 203580) resulted in inhibition of the IL-8 secretion by EAEC (wild type as well as plasmid cured)-infected INT-407 cells.	pyrazolanthrone	108-117	mitogen-activated protein kinase kinase 7	Homo sapiens	62-65
19898747-5	2010	Further, pretreatment of these cells with the highly specific MEK inhibitor (PD 098059), the JNK inhibitor (SP 600125), and the p38MAPK inhibitor (SB 203580) resulted in inhibition of the IL-8 secretion by EAEC (wild type as well as plasmid cured)-infected INT-407 cells.	pyrazolanthrone	108-117	mitogen-activated protein kinase 8	Homo sapiens	93-96
19898747-5	2010	Further, pretreatment of these cells with the highly specific MEK inhibitor (PD 098059), the JNK inhibitor (SP 600125), and the p38MAPK inhibitor (SB 203580) resulted in inhibition of the IL-8 secretion by EAEC (wild type as well as plasmid cured)-infected INT-407 cells.	pyrazolanthrone	108-117	C-X-C motif chemokine ligand 8	Homo sapiens	188-192
20138367-5	2010	The gene upregulation caused by TLR was inhibited by Syk inhibitor (SykI) and JNK inhibitor (SP600125).	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Mus musculus	78-81
20071421-9	2010	Interestingly, the lead-induced upregulation of GRP78 and GRP94 was almost completely blocked by the JNK inhibitor SP600125 or activator protein-1 (AP-1) inhibitor curcumin.	pyrazolanthrone	115-123	heat shock protein family A (Hsp70) member 5	Bos taurus	48-53
20071421-9	2010	Interestingly, the lead-induced upregulation of GRP78 and GRP94 was almost completely blocked by the JNK inhibitor SP600125 or activator protein-1 (AP-1) inhibitor curcumin.	pyrazolanthrone	115-123	heat shock protein 90 beta family member 1	Bos taurus	58-63
20062077-5	2010	Using synchronized cells, we show that the c-Jun N-terminal kinase (JNK) inhibitor, SP600125, prevents the entry of cells into mitosis and leads to endoreplication of DNA from G2 phase.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	43-82
20062077-8	2010	Instead, the inhibitory effect of SP600125 on mitotic entry predominantly occurs upstream of Aurora A kinase and Polo-like kinase 1, resulting in a failure to remove the inhibitory phosphorylation of Cdk1.	pyrazolanthrone	34-42	polo like kinase 1	Homo sapiens	113-131
20062077-8	2010	Instead, the inhibitory effect of SP600125 on mitotic entry predominantly occurs upstream of Aurora A kinase and Polo-like kinase 1, resulting in a failure to remove the inhibitory phosphorylation of Cdk1.	pyrazolanthrone	34-42	cyclin dependent kinase 1	Homo sapiens	200-204
19883629-6	2010	Pre-treatment of 2ME2-treated HK-1 cells with JNK inhibitor (SP600125), ERK inhibitor (PD98059) and p38 MAPK inhibitor (SB203580) resulted in the reduction of endoreduplicating cells.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	46-49
20042461-8	2010	Additionally, we observed that IL-17A and IL-17F induced MAPK (p38 MAPK, ERK1/2, and JNK) activation and that pharmacological inhibitors of p38 MAPK (SB203580) and ERK1/2 (U0126), but not JNK (SP600125), blocked the IL-17A/IL-17F-mediated MCP-1 and MIP-2 release.	pyrazolanthrone	193-201	interleukin 17A	Mus musculus	31-37
20136087-12	2010	Furthermore, inhibitors specific for JNK (SP600125) reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	37-40
20136087-12	2010	Furthermore, inhibitors specific for JNK (SP600125) reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	42-50	matrix metallopeptidase 2	Homo sapiens	74-79
20136087-12	2010	Furthermore, inhibitors specific for JNK (SP600125) reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	42-50	matrix metallopeptidase 9	Homo sapiens	81-86
20136087-12	2010	Furthermore, inhibitors specific for JNK (SP600125) reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	42-50	plasminogen activator, urokinase	Homo sapiens	92-96
20099905-3	2010	We have previously determined the X-ray structure of the catalytic domain of human Mps1 in complex with the anthrapyrazolone kinase inhibitor SP600125.	pyrazolanthrone	142-150	TTK protein kinase	Homo sapiens	83-87
20099905-6	2010	A novel biophysical analysis demonstrated that the intrinsic fluorescence of SP600125 changed markedly upon Mps1 binding, allowing spectrophotometric displacement analysis and determination of dissociation constants for ATP-competitive Mps1 inhibitors.	pyrazolanthrone	77-85	TTK protein kinase	Homo sapiens	108-112
20099905-6	2010	A novel biophysical analysis demonstrated that the intrinsic fluorescence of SP600125 changed markedly upon Mps1 binding, allowing spectrophotometric displacement analysis and determination of dissociation constants for ATP-competitive Mps1 inhibitors.	pyrazolanthrone	77-85	TTK protein kinase	Homo sapiens	236-240
20074614-8	2010	The results of the immunoblotting analysis indicated that 20 microM SB203580 (the p38 inhibitor) or SP600125 (the JNK inhibitor) suppressed approximately 85% or 40% of PLGn-inducible PAI-1, respectively.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Rattus norvegicus	114-117
20074614-8	2010	The results of the immunoblotting analysis indicated that 20 microM SB203580 (the p38 inhibitor) or SP600125 (the JNK inhibitor) suppressed approximately 85% or 40% of PLGn-inducible PAI-1, respectively.	pyrazolanthrone	100-108	serpin family E member 1	Rattus norvegicus	183-188
20042461-8	2010	Additionally, we observed that IL-17A and IL-17F induced MAPK (p38 MAPK, ERK1/2, and JNK) activation and that pharmacological inhibitors of p38 MAPK (SB203580) and ERK1/2 (U0126), but not JNK (SP600125), blocked the IL-17A/IL-17F-mediated MCP-1 and MIP-2 release.	pyrazolanthrone	193-201	interleukin 17F	Mus musculus	42-48
20075153-5	2010	Preincubation with the JNK inhibitor SP600125 (20 micromol/L) slightly inhibited KCl-induced vasoconstriction (Emax: -19%) and markedly inhibited vasoconstriction to NE (-42%), Ang II (-54%), and ET-1 (-42%).	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	23-26
20335523-8	2010	CONCLUSION: These findings show that SP600125 exhibits cytostatic and cytolytic activities through MYC gene modulation.	pyrazolanthrone	37-45	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-102
20179211-6	2010	Pharmacologic inhibition of JNK or Akt by SP600125 or LY294002, respectively, resulted in diminished AP-1 DNA binding, reduced levels of c-Jun and c-Fos, and inhibition of COX-2 expression in TPA-treated mouse skin.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Mus musculus	28-31
20179211-6	2010	Pharmacologic inhibition of JNK or Akt by SP600125 or LY294002, respectively, resulted in diminished AP-1 DNA binding, reduced levels of c-Jun and c-Fos, and inhibition of COX-2 expression in TPA-treated mouse skin.	pyrazolanthrone	42-50	thymoma viral proto-oncogene 1	Mus musculus	35-38
20179211-6	2010	Pharmacologic inhibition of JNK or Akt by SP600125 or LY294002, respectively, resulted in diminished AP-1 DNA binding, reduced levels of c-Jun and c-Fos, and inhibition of COX-2 expression in TPA-treated mouse skin.	pyrazolanthrone	42-50	jun proto-oncogene	Mus musculus	101-105
20179211-6	2010	Pharmacologic inhibition of JNK or Akt by SP600125 or LY294002, respectively, resulted in diminished AP-1 DNA binding, reduced levels of c-Jun and c-Fos, and inhibition of COX-2 expression in TPA-treated mouse skin.	pyrazolanthrone	42-50	jun proto-oncogene	Mus musculus	137-142
20179211-6	2010	Pharmacologic inhibition of JNK or Akt by SP600125 or LY294002, respectively, resulted in diminished AP-1 DNA binding, reduced levels of c-Jun and c-Fos, and inhibition of COX-2 expression in TPA-treated mouse skin.	pyrazolanthrone	42-50	FBJ osteosarcoma oncogene	Mus musculus	147-152
20075153-5	2010	Preincubation with the JNK inhibitor SP600125 (20 micromol/L) slightly inhibited KCl-induced vasoconstriction (Emax: -19%) and markedly inhibited vasoconstriction to NE (-42%), Ang II (-54%), and ET-1 (-42%).	pyrazolanthrone	37-45	angiotensinogen	Rattus norvegicus	177-183
20075153-5	2010	Preincubation with the JNK inhibitor SP600125 (20 micromol/L) slightly inhibited KCl-induced vasoconstriction (Emax: -19%) and markedly inhibited vasoconstriction to NE (-42%), Ang II (-54%), and ET-1 (-42%).	pyrazolanthrone	37-45	endothelin 1	Rattus norvegicus	196-200
19643530-5	2010	The extent of butein-induced G(2)/M phase arrest significantly decreased following pretreatment with N-acetyl-l-cysteine or glutathione and following JNK phosphorylation reduction by SP600125.	pyrazolanthrone	183-191	mitogen-activated protein kinase 8	Homo sapiens	150-153
20150185-6	2010	G17-induced migration was preceded by activation of MAPK pathways and was antagonized after pretreatment with SP600125, a pharmacological inhibitor of c-Jun-NH(2)-terminal kinase (JNK) pathway.	pyrazolanthrone	110-118	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	151-156
20150185-6	2010	G17-induced migration was preceded by activation of MAPK pathways and was antagonized after pretreatment with SP600125, a pharmacological inhibitor of c-Jun-NH(2)-terminal kinase (JNK) pathway.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	180-183
20060865-8	2010	Co-incubation of C6 cells with diethylmaleate and the JNK-inhibitor, SP600125, abolished the increase in expression of cystathionine-gamma-lyase that had been observed in the presence of diethylmaleate alone.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	54-57
20060865-8	2010	Co-incubation of C6 cells with diethylmaleate and the JNK-inhibitor, SP600125, abolished the increase in expression of cystathionine-gamma-lyase that had been observed in the presence of diethylmaleate alone.	pyrazolanthrone	69-77	cystathionine gamma-lyase	Homo sapiens	119-144
19846041-8	2010	SU6656 suppressed Src, JNK, and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage; SP600125 reduced JNK and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Homo sapiens	114-117
19846041-8	2010	SU6656 suppressed Src, JNK, and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage; SP600125 reduced JNK and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage.	pyrazolanthrone	97-105	caspase 3	Homo sapiens	122-138
19846041-8	2010	SU6656 suppressed Src, JNK, and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage; SP600125 reduced JNK and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage.	pyrazolanthrone	97-105	poly(ADP-ribose) polymerase 1	Homo sapiens	162-166
19846041-8	2010	SU6656 suppressed Src, JNK, and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage; SP600125 reduced JNK and caspase-3 and -9 activation, as well as PARP and DFF45 cleavage.	pyrazolanthrone	97-105	DNA fragmentation factor subunit alpha	Homo sapiens	171-176
19909792-9	2010	JNK inhibitor SP600125 attenuated the increase of cyclin D1 induced by hypoxia.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
20025870-8	2010	The Ras inhibitor manumycin A, the MEK1/2 inhibitor U0126, and the JNK inhibitor SP600125, greatly reduce the increase in ANGPTL4 expression by PMA.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	67-70
20025870-8	2010	The Ras inhibitor manumycin A, the MEK1/2 inhibitor U0126, and the JNK inhibitor SP600125, greatly reduce the increase in ANGPTL4 expression by PMA.	pyrazolanthrone	81-89	angiopoietin like 4	Homo sapiens	122-129
19954742-6	2010	Moreover, surfactin-induced cell death was reversed by PD98059 (an inhibitor of ERK1/2) and SP600125 (an inhibitor of JNK), but not by SB203580 (an inhibitor of p38).	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	118-121
20149257-11	2010	Finally, intrathecal injections of the selective JNK inhibitor, SP600125, selectively reduced late phase licking behavior.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Mus musculus	49-52
19959466-6	2010	Furthermore, inhibition of JNK phosphorylation by a small molecule inhibitor, SP600125, resulted in inhibition of SCG10 phosphorylation and inhibition of neurite growth.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
19959466-6	2010	Furthermore, inhibition of JNK phosphorylation by a small molecule inhibitor, SP600125, resulted in inhibition of SCG10 phosphorylation and inhibition of neurite growth.	pyrazolanthrone	78-86	stathmin 2	Rattus norvegicus	114-119
19852986-6	2010	In addition, CRH treatment induced rapid phosphorylation of p38 MAPK and JNK1/2, and antalarmin, SB203580 and SP600125 inhibited CRH-induced phosphorylation of p38 MAPK and JNK1/2.	pyrazolanthrone	110-118	corticotropin releasing hormone	Homo sapiens	13-16
19852986-6	2010	In addition, CRH treatment induced rapid phosphorylation of p38 MAPK and JNK1/2, and antalarmin, SB203580 and SP600125 inhibited CRH-induced phosphorylation of p38 MAPK and JNK1/2.	pyrazolanthrone	110-118	corticotropin releasing hormone	Homo sapiens	129-132
19852986-6	2010	In addition, CRH treatment induced rapid phosphorylation of p38 MAPK and JNK1/2, and antalarmin, SB203580 and SP600125 inhibited CRH-induced phosphorylation of p38 MAPK and JNK1/2.	pyrazolanthrone	110-118	mitogen-activated protein kinase 14	Homo sapiens	160-163
19852986-6	2010	In addition, CRH treatment induced rapid phosphorylation of p38 MAPK and JNK1/2, and antalarmin, SB203580 and SP600125 inhibited CRH-induced phosphorylation of p38 MAPK and JNK1/2.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	173-179
19909792-9	2010	JNK inhibitor SP600125 attenuated the increase of cyclin D1 induced by hypoxia.	pyrazolanthrone	14-22	cyclin D1	Rattus norvegicus	50-59
19882352-7	2010	Using PD98059 and SP600125, specific ERK and JNK inhibitors, the two kinases were found to possess pro-survival activities in TQ-induced cell death.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	45-48
19577630-5	2010	To explore the mechanism of LPS-induced IDO expression, microglia were pretreated with the c-Jun-N-terminal kinase (JNK) inhibitor SP600125 for 30 min before LPS treatment.	pyrazolanthrone	131-139	indoleamine 2,3-dioxygenase 1	Mus musculus	40-43
19577630-5	2010	To explore the mechanism of LPS-induced IDO expression, microglia were pretreated with the c-Jun-N-terminal kinase (JNK) inhibitor SP600125 for 30 min before LPS treatment.	pyrazolanthrone	131-139	mitogen-activated protein kinase 8	Mus musculus	116-119
19577630-6	2010	We found that SP600125 blocked JNK phosphorylation and significantly decreased IDO expression induced by LPS, which was accompanied by a reduction of LPS-induced expression of TNFalpha and IL-6.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	31-34
19577630-6	2010	We found that SP600125 blocked JNK phosphorylation and significantly decreased IDO expression induced by LPS, which was accompanied by a reduction of LPS-induced expression of TNFalpha and IL-6.	pyrazolanthrone	14-22	indoleamine 2,3-dioxygenase 1	Mus musculus	79-82
19577630-6	2010	We found that SP600125 blocked JNK phosphorylation and significantly decreased IDO expression induced by LPS, which was accompanied by a reduction of LPS-induced expression of TNFalpha and IL-6.	pyrazolanthrone	14-22	tumor necrosis factor	Mus musculus	176-184
19577630-6	2010	We found that SP600125 blocked JNK phosphorylation and significantly decreased IDO expression induced by LPS, which was accompanied by a reduction of LPS-induced expression of TNFalpha and IL-6.	pyrazolanthrone	14-22	interleukin 6	Mus musculus	189-193
19747539-7	2010	Inhibitors of JNK (SP600125) and ERK (PD98059), but not p38 MAPK (SB203580) suppressed NFD-induced S-phase arrest and apoptosis in MDA-MB-231 cells.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	14-17
19800403-6	2010	In addition, EV71-induced AP-1 subunits (c-jun and c-fos mRNA) expression was also attenuated by pretreatment with a selective JNK inhibitor SP600125, suggesting that JNK cascade linking to AP-1 was involved in COX-2 expression induced by EV71.	pyrazolanthrone	141-149	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	26-30
19800403-6	2010	In addition, EV71-induced AP-1 subunits (c-jun and c-fos mRNA) expression was also attenuated by pretreatment with a selective JNK inhibitor SP600125, suggesting that JNK cascade linking to AP-1 was involved in COX-2 expression induced by EV71.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	127-130
19800403-6	2010	In addition, EV71-induced AP-1 subunits (c-jun and c-fos mRNA) expression was also attenuated by pretreatment with a selective JNK inhibitor SP600125, suggesting that JNK cascade linking to AP-1 was involved in COX-2 expression induced by EV71.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	167-170
19800403-6	2010	In addition, EV71-induced AP-1 subunits (c-jun and c-fos mRNA) expression was also attenuated by pretreatment with a selective JNK inhibitor SP600125, suggesting that JNK cascade linking to AP-1 was involved in COX-2 expression induced by EV71.	pyrazolanthrone	141-149	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	190-194
20070836-7	2010	SP600125 inhibited the UVA-induced increase in the expression of TNF-alpha mRNA and protein and in the expression of IL-1beta mRNA.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	65-74
20070836-7	2010	SP600125 inhibited the UVA-induced increase in the expression of TNF-alpha mRNA and protein and in the expression of IL-1beta mRNA.	pyrazolanthrone	0-8	interleukin 1 beta	Homo sapiens	117-125
19735724-6	2010	Co-treatment with SP600125 and ethanol decreased GSH levels, indicating that JNK phosphorylation is a critical factor during ethanol-induced injury and that the effect of Hf-PS-1 occurs via JNK down-regulation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	77-80
19735724-6	2010	Co-treatment with SP600125 and ethanol decreased GSH levels, indicating that JNK phosphorylation is a critical factor during ethanol-induced injury and that the effect of Hf-PS-1 occurs via JNK down-regulation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	190-193
19788921-7	2010	Studies with pharmacological inhibitors of JNK/c-Jun (SP600125) and NFkappaB (BAY11-7082) signaling pathways demonstrated that timp-2 expression is regulated by NFkappaB transcription factor.	pyrazolanthrone	54-62	TIMP metallopeptidase inhibitor 2	Homo sapiens	127-133
19747539-8	2010	Both SP600125 and PD98059 attenuated Bad up-regulation, and reversed down-regulation of Bcl-2, Bcl-X(L), survivin, cyclin A, cyclin B, and Cdk2 in NFD-treated cells.	pyrazolanthrone	5-13	BCL2 apoptosis regulator	Homo sapiens	88-93
19747539-8	2010	Both SP600125 and PD98059 attenuated Bad up-regulation, and reversed down-regulation of Bcl-2, Bcl-X(L), survivin, cyclin A, cyclin B, and Cdk2 in NFD-treated cells.	pyrazolanthrone	5-13	BCL2 like 1	Homo sapiens	95-103
19782127-4	2010	Cellular release of IL-1alpha, IL-1beta and IL-6 was significantly attenuated by curcumin and by inhibitors of the MAPKs ERK1/2 (PD98069), p38 (SB202190) and JNK (SP600125), whereas pyrrolidine dithiocarbamate (PDTC) attenuated the release of IL-6, but not of IL-1alpha and IL-1beta.	pyrazolanthrone	163-171	interleukin 1 alpha	Rattus norvegicus	20-29
19782127-4	2010	Cellular release of IL-1alpha, IL-1beta and IL-6 was significantly attenuated by curcumin and by inhibitors of the MAPKs ERK1/2 (PD98069), p38 (SB202190) and JNK (SP600125), whereas pyrrolidine dithiocarbamate (PDTC) attenuated the release of IL-6, but not of IL-1alpha and IL-1beta.	pyrazolanthrone	163-171	interleukin 1 beta	Rattus norvegicus	31-39
19782127-4	2010	Cellular release of IL-1alpha, IL-1beta and IL-6 was significantly attenuated by curcumin and by inhibitors of the MAPKs ERK1/2 (PD98069), p38 (SB202190) and JNK (SP600125), whereas pyrrolidine dithiocarbamate (PDTC) attenuated the release of IL-6, but not of IL-1alpha and IL-1beta.	pyrazolanthrone	163-171	interleukin 6	Rattus norvegicus	44-48
19782127-4	2010	Cellular release of IL-1alpha, IL-1beta and IL-6 was significantly attenuated by curcumin and by inhibitors of the MAPKs ERK1/2 (PD98069), p38 (SB202190) and JNK (SP600125), whereas pyrrolidine dithiocarbamate (PDTC) attenuated the release of IL-6, but not of IL-1alpha and IL-1beta.	pyrazolanthrone	163-171	mitogen activated protein kinase 3	Rattus norvegicus	121-127
19747539-8	2010	Both SP600125 and PD98059 attenuated Bad up-regulation, and reversed down-regulation of Bcl-2, Bcl-X(L), survivin, cyclin A, cyclin B, and Cdk2 in NFD-treated cells.	pyrazolanthrone	5-13	cyclin A2	Homo sapiens	115-123
19782127-4	2010	Cellular release of IL-1alpha, IL-1beta and IL-6 was significantly attenuated by curcumin and by inhibitors of the MAPKs ERK1/2 (PD98069), p38 (SB202190) and JNK (SP600125), whereas pyrrolidine dithiocarbamate (PDTC) attenuated the release of IL-6, but not of IL-1alpha and IL-1beta.	pyrazolanthrone	163-171	mitogen activated protein kinase 14	Rattus norvegicus	139-142
19747539-8	2010	Both SP600125 and PD98059 attenuated Bad up-regulation, and reversed down-regulation of Bcl-2, Bcl-X(L), survivin, cyclin A, cyclin B, and Cdk2 in NFD-treated cells.	pyrazolanthrone	5-13	cyclin dependent kinase 2	Homo sapiens	139-143
19887895-7	2010	Moreover, cholesterol depletion-induced TIMP-2 expression and MMP-2 activation was significantly decreased by MEK inhibitor U0126, and JNK inhibitor SP600125, respectively.	pyrazolanthrone	149-157	TIMP metallopeptidase inhibitor 2	Homo sapiens	40-46
19887895-7	2010	Moreover, cholesterol depletion-induced TIMP-2 expression and MMP-2 activation was significantly decreased by MEK inhibitor U0126, and JNK inhibitor SP600125, respectively.	pyrazolanthrone	149-157	matrix metallopeptidase 2	Homo sapiens	62-67
19887895-7	2010	Moreover, cholesterol depletion-induced TIMP-2 expression and MMP-2 activation was significantly decreased by MEK inhibitor U0126, and JNK inhibitor SP600125, respectively.	pyrazolanthrone	149-157	mitogen-activated protein kinase 8	Homo sapiens	135-138
20113502-13	2010	Inhibition of JNK with its specific inhibitor SP600125 abolished the nicotine-induced effects on kinin receptor-mediated contractions and reverted the enhanced receptor mRNA expression.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Mus musculus	14-17
19995557-6	2010	gamma-Radiation-induced RhoB expression was markedly attenuated by pretreatment with a JNK-specific inhibitor, SP600125, but not by a p38 MAPK inhibitor, SB203580.	pyrazolanthrone	111-119	ras homolog family member B	Homo sapiens	24-28
19855432-4	2010	Treatment of cells with the JNK-specific inhibitor SP600125 caused phenotypical changes of senescence and triggered a rapid increase in mitochondrial reactive oxygen species (ROS) production and DNA-damage response (DDR) in MCF7 breast carcinoma cells.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	28-31
20026063-4	2010	All specific NFkappaB and MAPKs pathway inhibitors (pyrrolidine dithiocarbamate, AG490, U0126, SB203580 and SP600125) remarkably attenuated NO production induced by the beta-glucan.	pyrazolanthrone	108-116	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	13-21
19944124-9	2010	In addition, treatment with ghrelin combined with SP600125 showed a synergistic antiapoptotic effect in palmitate-treated MIN6 cells.	pyrazolanthrone	50-58	ghrelin	Mus musculus	28-35
19995557-6	2010	gamma-Radiation-induced RhoB expression was markedly attenuated by pretreatment with a JNK-specific inhibitor, SP600125, but not by a p38 MAPK inhibitor, SB203580.	pyrazolanthrone	111-119	mitogen-activated protein kinase 8	Homo sapiens	87-90
21194467-14	2010	AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinase (JNK) inhibitors (compound C and SP600125) significantly suppressed adiponectin-induced production of total NO and MMP-1, -3, and -13.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Homo sapiens	40-63
19875701-8	2010	Pretreatment of voltage-clamped T(84) cells with SP600125 (2 microM), a specific JNK inhibitor, potentiated secretory responses to both CCh and TG but not to FSK.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	81-84
20039412-6	2010	RESULTS: TNFalpha-induced VCAM-1 expression, phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK, and translocation of NF-kappaB were attenuated by the inhibitors of MEK-1/2 (U0126), p38 (SB202190), JNK (SP600125), and NF-kappaB (helenalin) or by transfection with their respective shRNA.	pyrazolanthrone	203-211	tumor necrosis factor	Homo sapiens	9-17
20039412-6	2010	RESULTS: TNFalpha-induced VCAM-1 expression, phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK, and translocation of NF-kappaB were attenuated by the inhibitors of MEK-1/2 (U0126), p38 (SB202190), JNK (SP600125), and NF-kappaB (helenalin) or by transfection with their respective shRNA.	pyrazolanthrone	203-211	nuclear factor kappa B subunit 1	Homo sapiens	118-127
21194467-14	2010	AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinase (JNK) inhibitors (compound C and SP600125) significantly suppressed adiponectin-induced production of total NO and MMP-1, -3, and -13.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Homo sapiens	65-68
21194467-14	2010	AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinase (JNK) inhibitors (compound C and SP600125) significantly suppressed adiponectin-induced production of total NO and MMP-1, -3, and -13.	pyrazolanthrone	97-105	adiponectin, C1Q and collagen domain containing	Homo sapiens	132-143
20039412-9	2010	Moreover, up-regulation of VCAM-1 increased the adhesion of lymphocytes to the RASF monolayer, and this adhesion was attenuated by pretreatment with helenalin, U0126, SP600125, or SB202190 prior to exposure to TNFalpha or by anti-VCAM-1 antibody before the addition of lymphocytes.	pyrazolanthrone	167-175	vascular cell adhesion molecule 1	Homo sapiens	27-33
21194467-14	2010	AMP-activated protein kinase (AMPK) and c-Jun N-terminal kinase (JNK) inhibitors (compound C and SP600125) significantly suppressed adiponectin-induced production of total NO and MMP-1, -3, and -13.	pyrazolanthrone	97-105	matrix metallopeptidase 1	Homo sapiens	179-197
20039412-9	2010	Moreover, up-regulation of VCAM-1 increased the adhesion of lymphocytes to the RASF monolayer, and this adhesion was attenuated by pretreatment with helenalin, U0126, SP600125, or SB202190 prior to exposure to TNFalpha or by anti-VCAM-1 antibody before the addition of lymphocytes.	pyrazolanthrone	167-175	tumor necrosis factor	Homo sapiens	210-218
20039412-9	2010	Moreover, up-regulation of VCAM-1 increased the adhesion of lymphocytes to the RASF monolayer, and this adhesion was attenuated by pretreatment with helenalin, U0126, SP600125, or SB202190 prior to exposure to TNFalpha or by anti-VCAM-1 antibody before the addition of lymphocytes.	pyrazolanthrone	167-175	vascular cell adhesion molecule 1	Homo sapiens	230-236
21364631-5	2010	The pivotal role of the JNK/c-Jun/AP-1 pathway for gal-1-induced apoptosis was documented by reduction of DNA fragmentation after inhibition JNK by SP600125 (20 muM) or inhibition of AP-1 activation by curcumin (2 muM).	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Homo sapiens	24-27
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	pyrazolanthrone	46-54	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	4-9
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	31-34
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	pyrazolanthrone	46-54	coagulation factor II, thrombin	Homo sapiens	63-71
19944065-9	2010	The c-Jun terminal NH2 kinase (JNK) inhibitor SP600125 reduced thrombin/paclitaxel-induced TF expression.	pyrazolanthrone	46-54	coagulation factor III, tissue factor	Homo sapiens	91-93
20096139-7	2010	Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis.	pyrazolanthrone	174-182	mitogen-activated protein kinase 8	Homo sapiens	13-38
20096139-7	2010	Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis.	pyrazolanthrone	174-182	mitogen-activated protein kinase 8	Homo sapiens	40-43
20096139-7	2010	Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis.	pyrazolanthrone	174-182	mitogen-activated protein kinase 14	Homo sapiens	49-52
20096139-7	2010	Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis.	pyrazolanthrone	174-182	mitogen-activated protein kinase 14	Homo sapiens	93-96
20096139-7	2010	Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis.	pyrazolanthrone	174-182	mitogen-activated protein kinase 8	Homo sapiens	151-154
20096139-7	2010	Furthermore, c-Jun-NH2-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase (p38) were activated in the apoptosis induced by ABL-N and JNK-specific inhibitor SP600125 and JNK small interfering RNA (siRNA) antagonized ABL-N-mediated apoptosis.	pyrazolanthrone	174-182	mitogen-activated protein kinase 8	Homo sapiens	151-154
21364631-5	2010	The pivotal role of the JNK/c-Jun/AP-1 pathway for gal-1-induced apoptosis was documented by reduction of DNA fragmentation after inhibition JNK by SP600125 (20 muM) or inhibition of AP-1 activation by curcumin (2 muM).	pyrazolanthrone	148-156	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
21364631-5	2010	The pivotal role of the JNK/c-Jun/AP-1 pathway for gal-1-induced apoptosis was documented by reduction of DNA fragmentation after inhibition JNK by SP600125 (20 muM) or inhibition of AP-1 activation by curcumin (2 muM).	pyrazolanthrone	148-156	galectin 1	Homo sapiens	51-56
21364631-5	2010	The pivotal role of the JNK/c-Jun/AP-1 pathway for gal-1-induced apoptosis was documented by reduction of DNA fragmentation after inhibition JNK by SP600125 (20 muM) or inhibition of AP-1 activation by curcumin (2 muM).	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Homo sapiens	141-144
21063106-7	2010	In addition, PAF-induced migration of hBMSCs was abrogated by pretreating cells with mitogen-activated protein kinase (MAPK) inhibitors, including the MEK inhibitor U0126, the p38 MAPK inhibitor SB202190, and the JNK inhibitor SP600125.	pyrazolanthrone	227-235	PCNA clamp associated factor	Homo sapiens	13-16
19812349-5	2010	The c-Jun N-terminal kinase (JNK)-specific inhibitor 1,9-pyrazoloanthrone (SP600125) blocked the induction of CYP4F11 by both cytokines, indicating involvement of the JNK pathway.	pyrazolanthrone	53-73	mitogen-activated protein kinase 8	Homo sapiens	29-32
19812349-5	2010	The c-Jun N-terminal kinase (JNK)-specific inhibitor 1,9-pyrazoloanthrone (SP600125) blocked the induction of CYP4F11 by both cytokines, indicating involvement of the JNK pathway.	pyrazolanthrone	53-73	cytochrome P450 family 4 subfamily F member 11	Homo sapiens	110-117
19812349-5	2010	The c-Jun N-terminal kinase (JNK)-specific inhibitor 1,9-pyrazoloanthrone (SP600125) blocked the induction of CYP4F11 by both cytokines, indicating involvement of the JNK pathway.	pyrazolanthrone	53-73	mitogen-activated protein kinase 8	Homo sapiens	167-170
19812349-5	2010	The c-Jun N-terminal kinase (JNK)-specific inhibitor 1,9-pyrazoloanthrone (SP600125) blocked the induction of CYP4F11 by both cytokines, indicating involvement of the JNK pathway.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	29-32
19812349-5	2010	The c-Jun N-terminal kinase (JNK)-specific inhibitor 1,9-pyrazoloanthrone (SP600125) blocked the induction of CYP4F11 by both cytokines, indicating involvement of the JNK pathway.	pyrazolanthrone	75-83	cytochrome P450 family 4 subfamily F member 11	Homo sapiens	110-117
19812349-5	2010	The c-Jun N-terminal kinase (JNK)-specific inhibitor 1,9-pyrazoloanthrone (SP600125) blocked the induction of CYP4F11 by both cytokines, indicating involvement of the JNK pathway.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	167-170
20036849-1	2010	Inhibition of basal JNK activity by JNK inhibitor SP600125 or JNK1siRNA repressed presenilin-1 (PS1) expression in SK-N-SH cells by augmenting the level of p53, a repressor of the PS1 gene (1).	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	20-23
19833164-7	2010	Pretreatment with SP600125, a JNK-specific inhibitor, abrogated cordycepin-mediated p21WAF1 expression, cell growth inhibition, and reduced cell-cycle proteins.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	30-33
20036849-1	2010	Inhibition of basal JNK activity by JNK inhibitor SP600125 or JNK1siRNA repressed presenilin-1 (PS1) expression in SK-N-SH cells by augmenting the level of p53, a repressor of the PS1 gene (1).	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	36-39
20036849-1	2010	Inhibition of basal JNK activity by JNK inhibitor SP600125 or JNK1siRNA repressed presenilin-1 (PS1) expression in SK-N-SH cells by augmenting the level of p53, a repressor of the PS1 gene (1).	pyrazolanthrone	50-58	presenilin 1	Homo sapiens	82-94
20036849-2	2010	We now showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited gamma-secretase mediated processing of amyloid precursor protein (APP) resulting in the accumulation of C99 fragment and the reduction of secreted Abeta40 level without altering the expression of nicastrin (NCT).	pyrazolanthrone	68-76	presenilin 1	Homo sapiens	33-36
20036849-2	2010	We now showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited gamma-secretase mediated processing of amyloid precursor protein (APP) resulting in the accumulation of C99 fragment and the reduction of secreted Abeta40 level without altering the expression of nicastrin (NCT).	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	54-57
20036849-2	2010	We now showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited gamma-secretase mediated processing of amyloid precursor protein (APP) resulting in the accumulation of C99 fragment and the reduction of secreted Abeta40 level without altering the expression of nicastrin (NCT).	pyrazolanthrone	68-76	amyloid beta precursor protein	Homo sapiens	126-151
19782079-5	2010	Hepatic stellate cell (HSC) activation was determined in primary mouse HSCs incubated with pan-JNK inhibitors SP600125 and VIII.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Mus musculus	95-98
20036849-2	2010	We now showed that repression of PS1 transcription by JNK inhibitor SP600125 inhibited gamma-secretase mediated processing of amyloid precursor protein (APP) resulting in the accumulation of C99 fragment and the reduction of secreted Abeta40 level without altering the expression of nicastrin (NCT).	pyrazolanthrone	68-76	nicastrin	Homo sapiens	283-292
20036849-3	2010	Co-treatment of cells with SP600125 and p53 inhibitor, pifithrin-alpha, partially nullified the suppressive effects of SP610025 on PS1 expression and secreted Abeta40 level.	pyrazolanthrone	27-35	presenilin 1	Homo sapiens	131-134
21743791-5	2010	Inhibition of JNK by SP600125, but not of p38 MAPK by SB203580 attenuated LPS-induced apoptosis, indicating JNK dependency.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
19800021-6	2010	The IL-1-mediated induction of C/EBPdelta expression was attenuated in the presence of pharmacological inhibitors against c-Jun N-terminal kinase (JNK) (curcumin and SP600125), casein kinase 2 (CK2) (apigenin) and nuclear factor-kappaB (NF-kappaB) (NF-kappaB activation inhibitor).	pyrazolanthrone	166-174	interleukin 1 alpha	Homo sapiens	4-8
19800021-6	2010	The IL-1-mediated induction of C/EBPdelta expression was attenuated in the presence of pharmacological inhibitors against c-Jun N-terminal kinase (JNK) (curcumin and SP600125), casein kinase 2 (CK2) (apigenin) and nuclear factor-kappaB (NF-kappaB) (NF-kappaB activation inhibitor).	pyrazolanthrone	166-174	CCAAT enhancer binding protein delta	Homo sapiens	31-41
19780038-4	2010	Notexin-induced cell death, mitochondrial depolarization, and ROS generation were suppressed by SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	130-138	mitogen-activated protein kinase 8	Homo sapiens	140-143
20369072-4	2010	This response was strongly aggravated by the addition of cycloheximide and could partially be inhibited by the NF-kappaB inhibitor CAPE, but most effectively by the pan-caspase-inhibitor zVAD-fmk and not by the JNK inhibitor SP600125.	pyrazolanthrone	225-233	structural maintenance of chromosomes 2	Homo sapiens	131-135
20484865-6	2010	Furthermore, the effects of LPS on iNOS and NO production were inhibited by the c-Jun N-terminal kinase (JNK) inhibitor SP600125, and LPS-induced phosphorylation of JNK and c-Jun was inhibited by NOC18 and DBcGMP.	pyrazolanthrone	120-128	nitric oxide synthase 2, inducible	Mus musculus	35-39
19937732-7	2010	SP600125 (JNK inhibitor) abolished the cytotoxic effect of PLA(2) and PLA(2)-induced autocrine Fas death pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	10-13
19937732-7	2010	SP600125 (JNK inhibitor) abolished the cytotoxic effect of PLA(2) and PLA(2)-induced autocrine Fas death pathway.	pyrazolanthrone	0-8	phospholipase A2 group IB	Homo sapiens	59-65
19937732-7	2010	SP600125 (JNK inhibitor) abolished the cytotoxic effect of PLA(2) and PLA(2)-induced autocrine Fas death pathway.	pyrazolanthrone	0-8	phospholipase A2 group IB	Homo sapiens	70-76
20051654-4	2010	MMP-12 mRNA and protein expressions induced by TNF-alpha in the absence or presence of BMS-345541 (a selective IkappaB kinase inhibitor) or SP600125 [a selective c-Jun N-terminal kinase (JNK) inhibitor] were measured by quantitative real-time PCR and Western blotting, respectively.	pyrazolanthrone	140-148	matrix metallopeptidase 12	Homo sapiens	0-6
20051654-7	2010	Both BMS-345541 and SP600125 inhibited the upregulation of MMP-12 induced by TNF-alpha.	pyrazolanthrone	20-28	matrix metallopeptidase 12	Homo sapiens	59-65
20051654-7	2010	Both BMS-345541 and SP600125 inhibited the upregulation of MMP-12 induced by TNF-alpha.	pyrazolanthrone	20-28	tumor necrosis factor	Homo sapiens	77-86
20508392-7	2010	Olmesartan, U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and PP2 potently inhibited AII-induced RASMC migration.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	53-56
20492175-7	2010	Further, the treatment of specific inhibitor for JNK (SP600125) to A549 cells could inhibit TPA-induced MMP-2 and u-PA expressions along with an inhibition on cell invasion and migration.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	49-52
20492175-7	2010	Further, the treatment of specific inhibitor for JNK (SP600125) to A549 cells could inhibit TPA-induced MMP-2 and u-PA expressions along with an inhibition on cell invasion and migration.	pyrazolanthrone	54-62	matrix metallopeptidase 2	Homo sapiens	104-109
20492175-7	2010	Further, the treatment of specific inhibitor for JNK (SP600125) to A549 cells could inhibit TPA-induced MMP-2 and u-PA expressions along with an inhibition on cell invasion and migration.	pyrazolanthrone	54-62	plasminogen activator, urokinase	Homo sapiens	114-118
20484867-8	2010	A JNK inhibitor, SP600125, and a p38 inhibitor, SB203580, inhibited TNF-induced e-selectin expression.	pyrazolanthrone	17-25	tumor necrosis factor	Homo sapiens	68-71
20484867-8	2010	A JNK inhibitor, SP600125, and a p38 inhibitor, SB203580, inhibited TNF-induced e-selectin expression.	pyrazolanthrone	17-25	selectin E	Homo sapiens	80-90
20508392-7	2010	Olmesartan, U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and PP2 potently inhibited AII-induced RASMC migration.	pyrazolanthrone	41-49	angiotensinogen	Homo sapiens	96-99
20484865-6	2010	Furthermore, the effects of LPS on iNOS and NO production were inhibited by the c-Jun N-terminal kinase (JNK) inhibitor SP600125, and LPS-induced phosphorylation of JNK and c-Jun was inhibited by NOC18 and DBcGMP.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Mus musculus	80-103
20484865-6	2010	Furthermore, the effects of LPS on iNOS and NO production were inhibited by the c-Jun N-terminal kinase (JNK) inhibitor SP600125, and LPS-induced phosphorylation of JNK and c-Jun was inhibited by NOC18 and DBcGMP.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Mus musculus	105-108
20484865-6	2010	Furthermore, the effects of LPS on iNOS and NO production were inhibited by the c-Jun N-terminal kinase (JNK) inhibitor SP600125, and LPS-induced phosphorylation of JNK and c-Jun was inhibited by NOC18 and DBcGMP.	pyrazolanthrone	120-128	jun proto-oncogene	Mus musculus	80-85
21141738-9	2010	Treatment of the cells with the AP-1 inhibitor SP600125 attenuated miR-21 levels and increased topotecan sensitivity.	pyrazolanthrone	47-55	microRNA 21	Homo sapiens	67-73
19633975-7	2010	Further, treating specific inhibitors for PI3K (Wortmannin) or JNK (SP600125) to PC-3 cells could reduce the protein expressions of MMP-2 and MMP-9.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	63-66
19633975-7	2010	Further, treating specific inhibitors for PI3K (Wortmannin) or JNK (SP600125) to PC-3 cells could reduce the protein expressions of MMP-2 and MMP-9.	pyrazolanthrone	68-76	matrix metallopeptidase 2	Homo sapiens	132-137
19633975-7	2010	Further, treating specific inhibitors for PI3K (Wortmannin) or JNK (SP600125) to PC-3 cells could reduce the protein expressions of MMP-2 and MMP-9.	pyrazolanthrone	68-76	matrix metallopeptidase 9	Homo sapiens	142-147
19818835-6	2009	SP600125, a selective inhibitor of JNK, significantly attenuated morphine tolerance.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	35-38
19937471-3	2009	Inhibition of the MAPK pathway with SB203580, PD98059, or SP600125 significantly decreased IGF-I-induced AR phosphorylation and total AR protein expression.	pyrazolanthrone	58-66	mitogen-activated protein kinase 1	Mus musculus	18-22
19937471-3	2009	Inhibition of the MAPK pathway with SB203580, PD98059, or SP600125 significantly decreased IGF-I-induced AR phosphorylation and total AR protein expression.	pyrazolanthrone	58-66	insulin-like growth factor 1	Mus musculus	91-96
19937471-4	2009	IGF-I-induced nuclear fraction of total AR and phosphorylated AR were significantly inhibited by SB203580, PD98059, or SP600125.	pyrazolanthrone	119-127	insulin-like growth factor 1	Mus musculus	0-5
19937471-6	2009	Confocal images showed that IGF-I-induced AR nuclear translocation from cytosol was significantly blocked by SB203580, PD98059, or SP600125, suggesting that the MAPK pathway regulates IGF-I-induced AR nuclear localization in skeletal muscle cells.	pyrazolanthrone	131-139	insulin-like growth factor 1	Mus musculus	28-33
19937471-6	2009	Confocal images showed that IGF-I-induced AR nuclear translocation from cytosol was significantly blocked by SB203580, PD98059, or SP600125, suggesting that the MAPK pathway regulates IGF-I-induced AR nuclear localization in skeletal muscle cells.	pyrazolanthrone	131-139	mitogen-activated protein kinase 1	Mus musculus	161-165
19937471-6	2009	Confocal images showed that IGF-I-induced AR nuclear translocation from cytosol was significantly blocked by SB203580, PD98059, or SP600125, suggesting that the MAPK pathway regulates IGF-I-induced AR nuclear localization in skeletal muscle cells.	pyrazolanthrone	131-139	insulin-like growth factor 1	Mus musculus	184-189
20025777-8	2009	Furthermore, JNK inhibitor SP600125 inhibits the effectiveness of the TbetaRI inhibitor SB431542 to reverse EMT.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	13-16
20025777-8	2009	Furthermore, JNK inhibitor SP600125 inhibits the effectiveness of the TbetaRI inhibitor SB431542 to reverse EMT.	pyrazolanthrone	27-35	transforming growth factor, beta receptor I	Mus musculus	70-77
19712733-7	2009	Pretreatment of A549 cells with SP600125, an inhibitor of c-Jun N-terminal kinase, decreased c-Jun translocation, and significantly ameliorated LPS-induced SP-A mRNA production.	pyrazolanthrone	32-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-63
19712733-7	2009	Pretreatment of A549 cells with SP600125, an inhibitor of c-Jun N-terminal kinase, decreased c-Jun translocation, and significantly ameliorated LPS-induced SP-A mRNA production.	pyrazolanthrone	32-40	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	93-98
19712733-7	2009	Pretreatment of A549 cells with SP600125, an inhibitor of c-Jun N-terminal kinase, decreased c-Jun translocation, and significantly ameliorated LPS-induced SP-A mRNA production.	pyrazolanthrone	32-40	surfactant protein A1	Homo sapiens	156-160
19735704-10	2009	Finally, apoptotic DNA damage by paraquat was investigated and this damage was attenuated by salubrinal (ER stress inhibitor), thioredoxin (ASK1 inhibitor) and SP600125 (JNK inhibitor).	pyrazolanthrone	160-168	mitogen-activated protein kinase 8	Homo sapiens	170-173
19825968-9	2009	However, VEGF-C-induced COX-2 upregulation was effectively abolished by overexpression of dominant-negative c-Jun N-terminal kinase (JNK) or treatment with the JNK inhibitor, SP 600125.	pyrazolanthrone	175-184	vascular endothelial growth factor C	Homo sapiens	9-15
19818769-5	2009	Inhibition of JNK phosphorylation by SP600125 also resulted in increased resistance to 6-OHDA, suggesting that TrkA signaling underlies the susceptibility of these cells to oxidant stress.	pyrazolanthrone	37-45	neurotrophic receptor tyrosine kinase 1	Rattus norvegicus	111-115
19818769-5	2009	Inhibition of JNK phosphorylation by SP600125 also resulted in increased resistance to 6-OHDA, suggesting that TrkA signaling underlies the susceptibility of these cells to oxidant stress.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
19825968-9	2009	However, VEGF-C-induced COX-2 upregulation was effectively abolished by overexpression of dominant-negative c-Jun N-terminal kinase (JNK) or treatment with the JNK inhibitor, SP 600125.	pyrazolanthrone	175-184	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-29
19825968-9	2009	However, VEGF-C-induced COX-2 upregulation was effectively abolished by overexpression of dominant-negative c-Jun N-terminal kinase (JNK) or treatment with the JNK inhibitor, SP 600125.	pyrazolanthrone	175-184	mitogen-activated protein kinase 8	Homo sapiens	160-163
20121928-2	2009	Examination of a basaloid and a conventional oral squamous cell carcinoma cell line revealed that inhibition of c-Jun N-terminal kinase (JNK) with SP600125 increased EGF-induced (but not basal) COX-2 transcription 1.5-1.9-fold in extracellular signal-regulated kinase 1/2 and p38 pathway-dependent manners.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	112-135
19819946-11	2009	Finally, treatment with the c-JUN N-terminal kinase (JNK) antagonist SP600125 during infusion of LPS, but not Ucn1, decreased L(p).	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	28-51
19819946-11	2009	Finally, treatment with the c-JUN N-terminal kinase (JNK) antagonist SP600125 during infusion of LPS, but not Ucn1, decreased L(p).	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	53-56
19837872-5	2009	JNK inhibition by the JNK-specific inhibitor SP600125 reversed PGE(2)-inhibited glucose-stimulated insulin secretion (GSIS).	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Mus musculus	0-3
19837872-5	2009	JNK inhibition by the JNK-specific inhibitor SP600125 reversed PGE(2)-inhibited glucose-stimulated insulin secretion (GSIS).	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Mus musculus	22-25
20121928-2	2009	Examination of a basaloid and a conventional oral squamous cell carcinoma cell line revealed that inhibition of c-Jun N-terminal kinase (JNK) with SP600125 increased EGF-induced (but not basal) COX-2 transcription 1.5-1.9-fold in extracellular signal-regulated kinase 1/2 and p38 pathway-dependent manners.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	137-140
20121928-2	2009	Examination of a basaloid and a conventional oral squamous cell carcinoma cell line revealed that inhibition of c-Jun N-terminal kinase (JNK) with SP600125 increased EGF-induced (but not basal) COX-2 transcription 1.5-1.9-fold in extracellular signal-regulated kinase 1/2 and p38 pathway-dependent manners.	pyrazolanthrone	147-155	prostaglandin-endoperoxide synthase 2	Homo sapiens	194-199
19455716-5	2009	IL-1beta also stimulated phosphorylation of CaMKII and JNK1/2, and increase in intracellular Ca(2+) ([Ca(2+)](i)), which were inhibited by pretreatment with BAPTA, thapsigargin (TG), KN-62, or SP600125.	pyrazolanthrone	193-201	interleukin 1 beta	Rattus norvegicus	0-8
19455716-8	2009	The activation and recruitment of c-Jun to MMP-9 promoter were inhibited by pretreatment with BAPTA, TG, KN-62, or SP600125.	pyrazolanthrone	115-123	matrix metallopeptidase 9	Rattus norvegicus	43-48
19517066-4	2009	We found that JNK was phosphorylated 1-2 days after TMZ treatment and that pretreatment (for 24 h) and post-treatment (for 72 h) with a JNK inhibitor SP600125 at a concentration of 200 nM or higher remarkably reduced clonogenicity in the TMZ-treated cells.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	14-17
19517066-4	2009	We found that JNK was phosphorylated 1-2 days after TMZ treatment and that pretreatment (for 24 h) and post-treatment (for 72 h) with a JNK inhibitor SP600125 at a concentration of 200 nM or higher remarkably reduced clonogenicity in the TMZ-treated cells.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	136-139
19517066-5	2009	The phosphorylation of the JNK target protein c-Jun, but not of ATF-2, was inhibited by this concentration of SP600125.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	27-30
19517066-5	2009	The phosphorylation of the JNK target protein c-Jun, but not of ATF-2, was inhibited by this concentration of SP600125.	pyrazolanthrone	110-118	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	46-51
19517066-7	2009	SP600125 amplified the percentage of senescence-like cells and of mitotic catastrophe cells in TMZ-treated U87MG and U87MG-E6 cells, respectively, suggesting that the enhancement of TMZ-induced cytotoxicity by a JNK inhibitor in glioma cells is induced (at least in part) by the potentiation of cell death pathways induced by TMZ alone.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	212-215
19717791-5	2009	In NRK-52E cells, the JNK inhibitor anthra(1,9-cd)pyrazol-6(2H)-one-1,9-pyrazoloanthrone (SP600125) reduced interleukin-1beta-, transforming growth factor-beta-, or bovine serum albumin-induced MCP-1 expression in a potent manner (up to 150-fold).	pyrazolanthrone	36-67	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
19717791-5	2009	In NRK-52E cells, the JNK inhibitor anthra(1,9-cd)pyrazol-6(2H)-one-1,9-pyrazoloanthrone (SP600125) reduced interleukin-1beta-, transforming growth factor-beta-, or bovine serum albumin-induced MCP-1 expression in a potent manner (up to 150-fold).	pyrazolanthrone	36-67	C-C motif chemokine ligand 2	Rattus norvegicus	194-199
19717791-5	2009	In NRK-52E cells, the JNK inhibitor anthra(1,9-cd)pyrazol-6(2H)-one-1,9-pyrazoloanthrone (SP600125) reduced interleukin-1beta-, transforming growth factor-beta-, or bovine serum albumin-induced MCP-1 expression in a potent manner (up to 150-fold).	pyrazolanthrone	68-88	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
19717791-5	2009	In NRK-52E cells, the JNK inhibitor anthra(1,9-cd)pyrazol-6(2H)-one-1,9-pyrazoloanthrone (SP600125) reduced interleukin-1beta-, transforming growth factor-beta-, or bovine serum albumin-induced MCP-1 expression in a potent manner (up to 150-fold).	pyrazolanthrone	68-88	C-C motif chemokine ligand 2	Rattus norvegicus	194-199
19717791-5	2009	In NRK-52E cells, the JNK inhibitor anthra(1,9-cd)pyrazol-6(2H)-one-1,9-pyrazoloanthrone (SP600125) reduced interleukin-1beta-, transforming growth factor-beta-, or bovine serum albumin-induced MCP-1 expression in a potent manner (up to 150-fold).	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
19717791-5	2009	In NRK-52E cells, the JNK inhibitor anthra(1,9-cd)pyrazol-6(2H)-one-1,9-pyrazoloanthrone (SP600125) reduced interleukin-1beta-, transforming growth factor-beta-, or bovine serum albumin-induced MCP-1 expression in a potent manner (up to 150-fold).	pyrazolanthrone	90-98	C-C motif chemokine ligand 2	Rattus norvegicus	194-199
19927172-8	2009	The increase in FasL expression was detected at 8 h, 16 h and 24 h after Abeta(31-35) treatment, and SP600125 (100 nmol/L) significantly inhibited FasL expression.	pyrazolanthrone	101-109	Fas ligand	Homo sapiens	147-151
19486916-6	2009	In the present study we found that K5 activated the JNK pathway and that its inhibition with SP600125 markedly prevented caspase 3 activation, nuclear condensation and cell death induced by K5.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	52-55
19486916-6	2009	In the present study we found that K5 activated the JNK pathway and that its inhibition with SP600125 markedly prevented caspase 3 activation, nuclear condensation and cell death induced by K5.	pyrazolanthrone	93-101	caspase 3	Homo sapiens	121-130
19616091-6	2009	In addition, the IL-1 beta-induced c-Jun phosphorylation was reduced by pretreatment with U0126 or SP600125.	pyrazolanthrone	99-107	interleukin 1 beta	Homo sapiens	17-26
20501447-0	2009	Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Mus musculus	66-69
20501447-8	2009	The selective JNK inhibitor SP600125 (30 mg/kg ip), given both 1 h before and 1 h after DCF, blocked JNK kinase activity and afforded significant protection against DCF enteropathy.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	14-17
20501447-8	2009	The selective JNK inhibitor SP600125 (30 mg/kg ip), given both 1 h before and 1 h after DCF, blocked JNK kinase activity and afforded significant protection against DCF enteropathy.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	101-104
19681889-10	2009	In addition, SP600125 and dominant-negative JNK1 suppressed BAG3 promoter-driven reporter gene expression.	pyrazolanthrone	13-21	BAG cochaperone 3	Homo sapiens	60-64
19616091-6	2009	In addition, the IL-1 beta-induced c-Jun phosphorylation was reduced by pretreatment with U0126 or SP600125.	pyrazolanthrone	99-107	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	35-40
19616091-7	2009	IL-1 beta stimulated the transcriptional activity of wild-type MMP-9 promoter in A549 cells, which was inhibited by U0126, SB203580, SP600125, and helenalin.	pyrazolanthrone	133-141	interleukin 1 beta	Homo sapiens	0-9
19616091-7	2009	IL-1 beta stimulated the transcriptional activity of wild-type MMP-9 promoter in A549 cells, which was inhibited by U0126, SB203580, SP600125, and helenalin.	pyrazolanthrone	133-141	matrix metallopeptidase 9	Homo sapiens	63-68
19616091-9	2009	Finally, the IL-1 beta-induced MMP-9 expression led to cell migration which was attenuated by pretreatment with U0126, SB203580, SP600125, helenalin, or MMP-2/9 inhibitor.	pyrazolanthrone	129-137	interleukin 1 beta	Homo sapiens	13-22
19616091-9	2009	Finally, the IL-1 beta-induced MMP-9 expression led to cell migration which was attenuated by pretreatment with U0126, SB203580, SP600125, helenalin, or MMP-2/9 inhibitor.	pyrazolanthrone	129-137	matrix metallopeptidase 9	Homo sapiens	31-36
19860880-8	2009	Mutation of the NF-kappaB or AP-1 site within and downstream the iE kappa, inhibition of the NF-kappaB and AP-1 pathways by their respective chemical inhibitor Bay11-7082 and SP600125 as well as stable or transient expression of dominant-negative mutant of I kappaB alpha (DNMI kappaB alpha) or of c-Jun (TAM67) indicate that both sites are functional and LMP1-enhanced iE kappa activity is partly regulated by these two sites.	pyrazolanthrone	175-183	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-111
19614958-11	2009	Addition of c-jun N-terminal kinase (JNK) inhibitor SP600125, JNK small interfering RNA and tumour necrosis factor-alpha (TNF-alpha) antibody 30 min before stretch, reduced the induction of GADD153 protein.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	12-35
19614958-11	2009	Addition of c-jun N-terminal kinase (JNK) inhibitor SP600125, JNK small interfering RNA and tumour necrosis factor-alpha (TNF-alpha) antibody 30 min before stretch, reduced the induction of GADD153 protein.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
19614958-11	2009	Addition of c-jun N-terminal kinase (JNK) inhibitor SP600125, JNK small interfering RNA and tumour necrosis factor-alpha (TNF-alpha) antibody 30 min before stretch, reduced the induction of GADD153 protein.	pyrazolanthrone	52-60	DNA-damage inducible transcript 3	Rattus norvegicus	190-197
19614958-12	2009	Stretch increased, while GADD153-Mut plasmid, SP600125 and TNF-alpha antibody abolished the GADD153 promoter activity induced by stretch.	pyrazolanthrone	46-54	DNA-damage inducible transcript 3	Rattus norvegicus	92-99
19843937-7	2009	WKYMVm-induced chemotactic migration was partially inhibited by PD98059 (2"-amino-3"-methoxyflavone); however, the inhibition of JNK by its selective inhibitor (SP600125, anthra[1,9-cd]pyrazol-6(2H)-one) dramatically inhibited the WKYMVm-induced cytolytic activity.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	129-132
19427347-5	2009	The TNF-alpha-induced IL-6 release was suppressed by SB203580, a p38 MAPK inhibitor, or SP600125, a SAPK/JNK inhibitor, but not by PD98059, a MAP kinase/extracellular signal-regulated kinase kinase inhibitor.	pyrazolanthrone	88-96	tumor necrosis factor	Rattus norvegicus	4-13
19427347-5	2009	The TNF-alpha-induced IL-6 release was suppressed by SB203580, a p38 MAPK inhibitor, or SP600125, a SAPK/JNK inhibitor, but not by PD98059, a MAP kinase/extracellular signal-regulated kinase kinase inhibitor.	pyrazolanthrone	88-96	interleukin 6	Rattus norvegicus	22-26
19852810-10	2009	Like radiation, AT-101 activated SAPK/JNK which was blocked by the kinase inhibitor SP600125.	pyrazolanthrone	84-92	mitogen-activated protein kinase 9	Homo sapiens	33-37
19852810-10	2009	Like radiation, AT-101 activated SAPK/JNK which was blocked by the kinase inhibitor SP600125.	pyrazolanthrone	84-92	mitogen-activated protein kinase 9	Homo sapiens	38-41
19653997-6	2009	PDGF-induced Muller cell proliferation was significantly reduced by pre-treatment with SP600125 and LY294002, inhibitors of c-JNK and Akt phosphorylation, respectively.	pyrazolanthrone	87-95	AKT serine/threonine kinase 1	Homo sapiens	134-137
19604516-6	2009	We found that inhibiting JNK with SP600125, a special inhibitor of JNK, reduced the levels of c-Jun phosphorylation, blocked p-c-Jun translocation from the cytoplasm to the nucleus in dopaminergic neurons of substantia nigra, mitigated the loss of dopaminergic neurons, and improved motor function in MPTP-induced PD in C57BL/6N mice.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Mus musculus	25-28
19604516-6	2009	We found that inhibiting JNK with SP600125, a special inhibitor of JNK, reduced the levels of c-Jun phosphorylation, blocked p-c-Jun translocation from the cytoplasm to the nucleus in dopaminergic neurons of substantia nigra, mitigated the loss of dopaminergic neurons, and improved motor function in MPTP-induced PD in C57BL/6N mice.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Mus musculus	67-70
19604516-6	2009	We found that inhibiting JNK with SP600125, a special inhibitor of JNK, reduced the levels of c-Jun phosphorylation, blocked p-c-Jun translocation from the cytoplasm to the nucleus in dopaminergic neurons of substantia nigra, mitigated the loss of dopaminergic neurons, and improved motor function in MPTP-induced PD in C57BL/6N mice.	pyrazolanthrone	34-42	jun proto-oncogene	Mus musculus	94-99
19604516-6	2009	We found that inhibiting JNK with SP600125, a special inhibitor of JNK, reduced the levels of c-Jun phosphorylation, blocked p-c-Jun translocation from the cytoplasm to the nucleus in dopaminergic neurons of substantia nigra, mitigated the loss of dopaminergic neurons, and improved motor function in MPTP-induced PD in C57BL/6N mice.	pyrazolanthrone	34-42	jun proto-oncogene	Mus musculus	127-132
19616043-9	2009	The bFGF induced increase in AM expression was significantly attenuated by SP600125, a specific JNK inhibitor.	pyrazolanthrone	75-83	fibroblast growth factor 2	Homo sapiens	4-8
19616043-9	2009	The bFGF induced increase in AM expression was significantly attenuated by SP600125, a specific JNK inhibitor.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	96-99
19801842-3	2009	In this study, we clarified if mitogen-activated protein kinase (MAPK) signaling mediated MMP-9 expression by examining the effect of specific MAPK inhibitors, i.e. U0126, SB203580, and SP600125, on P. gingivalis supernatant-stimulated MMP-9 expression in KB cells.	pyrazolanthrone	186-194	matrix metallopeptidase 9	Homo sapiens	90-95
19729027-10	2009	SP600125, SB203580 and roscovitine but not U0126 inhibited the LPS-induced enhancement of both the phosphorylation and the downregulation of GR.	pyrazolanthrone	0-8	nuclear receptor subfamily 3 group C member 1	Homo sapiens	141-143
19669889-8	2009	Furthermore, both wortamannin (PI3K inhibitor) and U0126 (MEK1/2 inhibitor) markedly enhanced EGCG-induced apoptosis during I/R, whereas SP600125 (JNK inhibitor) attenuated the action of EGCG.	pyrazolanthrone	137-145	mitogen-activated protein kinase 8	Homo sapiens	147-150
19801848-6	2009	In addition, inhibition of the JNK pathway using a dominant-negative mutation of c-jun and JNK inhibitor SP600125, significantly prevented costunolide-induced apoptosis.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	31-34
19801842-6	2009	A JNK inhibitor (SP600125) significantly attenuated MMP-9 gene expression and AP-1 activity in KB cells in response to P. gingivalis supernatant.	pyrazolanthrone	17-25	matrix metallopeptidase 9	Homo sapiens	52-57
19801848-6	2009	In addition, inhibition of the JNK pathway using a dominant-negative mutation of c-jun and JNK inhibitor SP600125, significantly prevented costunolide-induced apoptosis.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	91-94
19711443-0	2009	A JNK inhibitor SP600125 induces defective cytokinesis and enlargement in P19 embryonal carcinoma cells.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Mus musculus	2-5
19801848-8	2009	Pretreatment with SP600125 recovered the costunolide-suppressed Bcl-2 expression.	pyrazolanthrone	18-26	BCL2 apoptosis regulator	Homo sapiens	64-69
19616639-5	2009	Both NaHS and SP600125 (specific JNK inhibitor) decreased the number of apoptotic cells, lowered cytochrome C release and enhanced Bcl-2 expression.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	33-36
19616639-5	2009	Both NaHS and SP600125 (specific JNK inhibitor) decreased the number of apoptotic cells, lowered cytochrome C release and enhanced Bcl-2 expression.	pyrazolanthrone	14-22	cytochrome c, somatic	Homo sapiens	97-109
19711443-1	2009	While analyzing the role of c-Jun NH(2)-terminal kinase (JNK) in neurogenesis in P19 embryonal carcinoma cells, we noticed that treatment with SP600125, a JNK inhibitor, increased the cell size markedly.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Mus musculus	28-55
19530246-7	2009	Furthermore, inhibition of JNK kinase activity by JNK inhibitor SP600125 abolished both HKH40A-induced H2A.X phosphorylation and apoptosis.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Homo sapiens	27-30
19711443-1	2009	While analyzing the role of c-Jun NH(2)-terminal kinase (JNK) in neurogenesis in P19 embryonal carcinoma cells, we noticed that treatment with SP600125, a JNK inhibitor, increased the cell size markedly.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Mus musculus	57-60
19711443-1	2009	While analyzing the role of c-Jun NH(2)-terminal kinase (JNK) in neurogenesis in P19 embryonal carcinoma cells, we noticed that treatment with SP600125, a JNK inhibitor, increased the cell size markedly.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Mus musculus	155-158
19711443-2	2009	SP600125-induced enlargement of P19 cells was time- and dose-dependent.	pyrazolanthrone	0-8	interleukin 23, alpha subunit p19	Mus musculus	32-35
19711443-5	2009	Concurrently, the gene expression of p21, a regulator of G2/M arrest as well as G1 arrest, was increased in cells treated with SP600125.	pyrazolanthrone	127-135	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	37-40
19711443-6	2009	The increased cell size in response to SP600125 was detected even in P19 cells treated with colcemide, an inhibitor of cell cycle progression at the metaphase.	pyrazolanthrone	39-47	interleukin 23, alpha subunit p19	Mus musculus	69-72
19711443-7	2009	The present study suggests that treatment with SP600125 progresses the cell cycle, skipping cytokinesis in P19 cells.	pyrazolanthrone	47-55	interleukin 23, alpha subunit p19	Mus musculus	107-110
19708869-7	2009	Extracellular signal-related kinase inhibitor PD98059 and c-Jun N-terminal kinase inhibitor SP600125 considerably decreased the upregulated level of MMP-1, whereas p38 inhibitor SB203580 markedly inhibited MMP-8 expression, suggesting that prostaglandin E(2) and mitogen-activated protein kinase signaling pathways are involved in P. intermedia-induced MMP-1 and MMP-8 upregulation.	pyrazolanthrone	92-100	matrix metallopeptidase 1	Homo sapiens	149-154
19708869-7	2009	Extracellular signal-related kinase inhibitor PD98059 and c-Jun N-terminal kinase inhibitor SP600125 considerably decreased the upregulated level of MMP-1, whereas p38 inhibitor SB203580 markedly inhibited MMP-8 expression, suggesting that prostaglandin E(2) and mitogen-activated protein kinase signaling pathways are involved in P. intermedia-induced MMP-1 and MMP-8 upregulation.	pyrazolanthrone	92-100	matrix metallopeptidase 1	Homo sapiens	353-358
19708869-7	2009	Extracellular signal-related kinase inhibitor PD98059 and c-Jun N-terminal kinase inhibitor SP600125 considerably decreased the upregulated level of MMP-1, whereas p38 inhibitor SB203580 markedly inhibited MMP-8 expression, suggesting that prostaglandin E(2) and mitogen-activated protein kinase signaling pathways are involved in P. intermedia-induced MMP-1 and MMP-8 upregulation.	pyrazolanthrone	92-100	matrix metallopeptidase 8	Homo sapiens	363-368
19907102-5	2009	In addition, preincubation of THP-1 with SP600125, a specific inhibitor of JNK, resulted in significant reduction of the PMA-induced adhesion of THP-1.	pyrazolanthrone	41-49	GLI family zinc finger 2	Homo sapiens	30-35
19907102-5	2009	In addition, preincubation of THP-1 with SP600125, a specific inhibitor of JNK, resulted in significant reduction of the PMA-induced adhesion of THP-1.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	75-78
19907102-5	2009	In addition, preincubation of THP-1 with SP600125, a specific inhibitor of JNK, resulted in significant reduction of the PMA-induced adhesion of THP-1.	pyrazolanthrone	41-49	GLI family zinc finger 2	Homo sapiens	145-150
19616639-5	2009	Both NaHS and SP600125 (specific JNK inhibitor) decreased the number of apoptotic cells, lowered cytochrome C release and enhanced Bcl-2 expression.	pyrazolanthrone	14-22	BCL2 apoptosis regulator	Homo sapiens	131-136
19607912-6	2009	Transfection of a JNK-specific siRNA as well as treatment with a JNK-specific inhibitor, SP600125, significantly reduced the EGCG-induced IL-13 mRNA expression, by 47.1 and 44.6%, respectively.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	65-68
19607912-6	2009	Transfection of a JNK-specific siRNA as well as treatment with a JNK-specific inhibitor, SP600125, significantly reduced the EGCG-induced IL-13 mRNA expression, by 47.1 and 44.6%, respectively.	pyrazolanthrone	89-97	interleukin 13	Homo sapiens	138-143
19530246-7	2009	Furthermore, inhibition of JNK kinase activity by JNK inhibitor SP600125 abolished both HKH40A-induced H2A.X phosphorylation and apoptosis.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Homo sapiens	50-53
19530246-7	2009	Furthermore, inhibition of JNK kinase activity by JNK inhibitor SP600125 abolished both HKH40A-induced H2A.X phosphorylation and apoptosis.	pyrazolanthrone	64-72	H2A.X variant histone	Homo sapiens	103-108
19560213-7	2009	The additive effect of combined agonists was partially inhibited by the Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) inhibitor SP600125 and almost completely abrogated by the extracellular signal-regulated kinase (ERK) MAPK inhibitor PD98059.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	72-93
19560213-7	2009	The additive effect of combined agonists was partially inhibited by the Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) inhibitor SP600125 and almost completely abrogated by the extracellular signal-regulated kinase (ERK) MAPK inhibitor PD98059.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	95-98
19607816-0	2009	SP600125, an inhibitor of Jnk pathway, reduces viability of relatively resistant cancer cells to doxorubicin.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
19631732-4	2009	Ketoconazole-induced cell death and apoptosis were partially reversed by the selective JNK inhibitor SP600125, but not by the selective ERK inhibitor PD98059, suggesting that ketoconazole"s cytotoxic action was via JNK, but not via ERK and p38 MAPKs.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Homo sapiens	87-90
19478553-0	2009	JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
19478553-1	2009	The JNK inhibitor SP600125 strongly inhibits cell proliferation in many human cancer cells by blocking cell-cycle progression and inducing apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
19478553-4	2009	Treatment of synchronized leukemia cells with varying concentrations of SP600125 results in significant G2/M cell cycle arrest with elevated p21 levels, phosphorylation of histone H3 within 24 h, and endoreduplication with elevated Cdk2 protein levels after 48 h. SP600125 also induces significant abnormal microtubule dynamics in vivo.	pyrazolanthrone	72-80	H3 histone pseudogene 16	Homo sapiens	141-144
19478553-4	2009	Treatment of synchronized leukemia cells with varying concentrations of SP600125 results in significant G2/M cell cycle arrest with elevated p21 levels, phosphorylation of histone H3 within 24 h, and endoreduplication with elevated Cdk2 protein levels after 48 h. SP600125 also induces significant abnormal microtubule dynamics in vivo.	pyrazolanthrone	72-80	cyclin dependent kinase 2	Homo sapiens	232-236
19478553-6	2009	Additionally, SP600125- induced delayed apoptosis and cell death was accompanied by significant poly ADP-ribose polymerase (PARP) cleavage and caspase-3 activity in the late phase (at 72 h).	pyrazolanthrone	14-22	poly(ADP-ribose) polymerase 1	Homo sapiens	96-122
19478553-6	2009	Additionally, SP600125- induced delayed apoptosis and cell death was accompanied by significant poly ADP-ribose polymerase (PARP) cleavage and caspase-3 activity in the late phase (at 72 h).	pyrazolanthrone	14-22	poly(ADP-ribose) polymerase 1	Homo sapiens	124-128
19478553-6	2009	Additionally, SP600125- induced delayed apoptosis and cell death was accompanied by significant poly ADP-ribose polymerase (PARP) cleavage and caspase-3 activity in the late phase (at 72 h).	pyrazolanthrone	14-22	caspase 3	Homo sapiens	143-152
19478553-8	2009	These results indicate that Bcl-2 suppresses apoptosis and SP600125-induced G2/M arrest and endoreduplication.	pyrazolanthrone	59-67	BCL2 apoptosis regulator	Homo sapiens	28-33
19695707-6	2009	CRTAM expression was reduced in activated CD8(+) T cells treated with the JNK inhibitor SP600125, indicating that CRTAM expression is driven by the JNK-AP-1 signaling pathway.	pyrazolanthrone	88-96	cytotoxic and regulatory T cell molecule	Homo sapiens	0-5
19695707-6	2009	CRTAM expression was reduced in activated CD8(+) T cells treated with the JNK inhibitor SP600125, indicating that CRTAM expression is driven by the JNK-AP-1 signaling pathway.	pyrazolanthrone	88-96	CD8a molecule	Homo sapiens	42-45
19695707-6	2009	CRTAM expression was reduced in activated CD8(+) T cells treated with the JNK inhibitor SP600125, indicating that CRTAM expression is driven by the JNK-AP-1 signaling pathway.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Homo sapiens	74-77
19695707-6	2009	CRTAM expression was reduced in activated CD8(+) T cells treated with the JNK inhibitor SP600125, indicating that CRTAM expression is driven by the JNK-AP-1 signaling pathway.	pyrazolanthrone	88-96	cytotoxic and regulatory T cell molecule	Homo sapiens	114-119
19695707-6	2009	CRTAM expression was reduced in activated CD8(+) T cells treated with the JNK inhibitor SP600125, indicating that CRTAM expression is driven by the JNK-AP-1 signaling pathway.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Homo sapiens	148-151
19616567-9	2009	Pre-treatment with SP600125 (JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated NF-kappaB and IKK phosphorylation indicating that p38 and JNK MAPKs are mainly involved in arsenic-induced NF-kappaB activation.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	29-32
19616567-9	2009	Pre-treatment with SP600125 (JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated NF-kappaB and IKK phosphorylation indicating that p38 and JNK MAPKs are mainly involved in arsenic-induced NF-kappaB activation.	pyrazolanthrone	19-27	mitogen-activated protein kinase 14	Homo sapiens	139-142
19616567-9	2009	Pre-treatment with SP600125 (JNK inhibitor) and SB203580 (p38 MAPK inhibitor) attenuated NF-kappaB and IKK phosphorylation indicating that p38 and JNK MAPKs are mainly involved in arsenic-induced NF-kappaB activation.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	147-150
19615976-5	2009	Similarly, pre-treatment with the JNK inhibitor SP600125 prevented the T-induced apoptosis, the phosphorylation of c-Jun and the upregulation of the Fas/FADD pathway.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	34-37
19615976-5	2009	Similarly, pre-treatment with the JNK inhibitor SP600125 prevented the T-induced apoptosis, the phosphorylation of c-Jun and the upregulation of the Fas/FADD pathway.	pyrazolanthrone	48-56	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	115-120
19615976-5	2009	Similarly, pre-treatment with the JNK inhibitor SP600125 prevented the T-induced apoptosis, the phosphorylation of c-Jun and the upregulation of the Fas/FADD pathway.	pyrazolanthrone	48-56	Fas associated via death domain	Homo sapiens	153-157
19607816-2	2009	SP600125, an inhibitor of the Jnk pathway, reduced the cellular viability of all five DOX-resistant cancer cell lines.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	30-33
19699753-6	2009	Unlike the ERK inhibitor (PD98059), inhibitors of JNK (SP600125) and p38 MAPK (SB203580) suppressed IQDMA-induced apoptosis and G(2)/M phase arrest in A549 cells.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	50-53
19699753-7	2009	Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells.	pyrazolanthrone	5-13	BCL2 associated X, apoptosis regulator	Homo sapiens	56-59
19699753-7	2009	Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells.	pyrazolanthrone	5-13	cytochrome c, somatic	Homo sapiens	64-76
19699753-7	2009	Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells.	pyrazolanthrone	5-13	BCL2 apoptosis regulator	Homo sapiens	118-123
19699753-7	2009	Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells.	pyrazolanthrone	5-13	X-linked inhibitor of apoptosis	Homo sapiens	125-129
19699753-7	2009	Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells.	pyrazolanthrone	5-13	cyclin A2	Homo sapiens	141-149
19699753-7	2009	Both SP600125 and SB203580 attenuated the activation of Bax and cytochrome c release, and reversed down-regulation of Bcl-2, XIAP, survivin, cyclin A, cyclin B, and Cdk1 in IQDMA-treated cells.	pyrazolanthrone	5-13	cyclin dependent kinase 1	Homo sapiens	165-169
19604147-4	2009	Suppression of JNK activity by the inhibitor SP600125 or by dominant-negative JNK2 re-sensitized cells to H2O2.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	15-18
19664626-4	2009	SP600125 and a dominant negative JNK1 significantly reduced the FGF2-enhanced proliferation of hMSCs.	pyrazolanthrone	0-8	fibroblast growth factor 2	Homo sapiens	64-68
19486889-4	2009	Inhibiting JNK by JNK inhibitor SP600125 or knockdown of JNK by JNK siRNA abrogated ATRA-induced HDAC2 phosphorylation and reversed ATRA-induced suppression of the interaction of HDAC2 with KLF4.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	11-14
19486889-4	2009	Inhibiting JNK by JNK inhibitor SP600125 or knockdown of JNK by JNK siRNA abrogated ATRA-induced HDAC2 phosphorylation and reversed ATRA-induced suppression of the interaction of HDAC2 with KLF4.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	18-21
19486889-4	2009	Inhibiting JNK by JNK inhibitor SP600125 or knockdown of JNK by JNK siRNA abrogated ATRA-induced HDAC2 phosphorylation and reversed ATRA-induced suppression of the interaction of HDAC2 with KLF4.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	18-21
19486889-4	2009	Inhibiting JNK by JNK inhibitor SP600125 or knockdown of JNK by JNK siRNA abrogated ATRA-induced HDAC2 phosphorylation and reversed ATRA-induced suppression of the interaction of HDAC2 with KLF4.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	18-21
19523467-6	2009	Furthermore, JNK activity, required for apoptosis in MCF-7, as indicated by the inhibition of both caspase-7 cleavage and cytochrome c release from the mitochondria in the presence of the JNK inhibitor SP600125, was also suppressed by PKCeta expression.	pyrazolanthrone	202-210	mitogen-activated protein kinase 8	Homo sapiens	13-16
19523467-6	2009	Furthermore, JNK activity, required for apoptosis in MCF-7, as indicated by the inhibition of both caspase-7 cleavage and cytochrome c release from the mitochondria in the presence of the JNK inhibitor SP600125, was also suppressed by PKCeta expression.	pyrazolanthrone	202-210	caspase 7	Homo sapiens	99-108
19523467-6	2009	Furthermore, JNK activity, required for apoptosis in MCF-7, as indicated by the inhibition of both caspase-7 cleavage and cytochrome c release from the mitochondria in the presence of the JNK inhibitor SP600125, was also suppressed by PKCeta expression.	pyrazolanthrone	202-210	cytochrome c, somatic	Homo sapiens	122-134
19523467-6	2009	Furthermore, JNK activity, required for apoptosis in MCF-7, as indicated by the inhibition of both caspase-7 cleavage and cytochrome c release from the mitochondria in the presence of the JNK inhibitor SP600125, was also suppressed by PKCeta expression.	pyrazolanthrone	202-210	mitogen-activated protein kinase 8	Homo sapiens	188-191
19555659-7	2009	In addition, the selective p38 inhibitor SB203580 and selective JNK inhibitor SP600125 suppressed nano-TiO(2)-induced apoptosis and caspase-8 activation to moderate and significant extents, respectively.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	64-67
19555659-7	2009	In addition, the selective p38 inhibitor SB203580 and selective JNK inhibitor SP600125 suppressed nano-TiO(2)-induced apoptosis and caspase-8 activation to moderate and significant extents, respectively.	pyrazolanthrone	78-86	caspase 8	Homo sapiens	132-141
19664626-5	2009	Treatment with SP600125 also diminished the activity of FGF2 in the maintenance of adipogenic and osteogenic differentiation potential.	pyrazolanthrone	15-23	fibroblast growth factor 2	Homo sapiens	56-60
19553502-7	2009	Furthermore, the neuronostatin-induced cardiomyocyte mechanical effects were ablated by the PKA inhibitor H89 (1 microM) and the Jun N-terminal kinase (JNK) inhibitor SP600125 (20 microM).	pyrazolanthrone	167-175	mitogen-activated protein kinase 8	Mus musculus	129-150
19553502-7	2009	Furthermore, the neuronostatin-induced cardiomyocyte mechanical effects were ablated by the PKA inhibitor H89 (1 microM) and the Jun N-terminal kinase (JNK) inhibitor SP600125 (20 microM).	pyrazolanthrone	167-175	mitogen-activated protein kinase 8	Mus musculus	152-155
21088717-7	2009	We found that a known JNK-specific inhibitor, SP600125, significantly down-regulates GITR expression on anti-CD3 antibody-mediated activated CD8(+) T cells by limiting JNK phosphorylation.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	22-25
19605737-4	2009	Addition of either PD169316 (a p38 inhibitor) or SP600125 (a JNK inhibitor) induced formation of domes (a phenomenon dependent on TJ barrier function) and enhanced transepithelial electrical resistance, whereas U0126 (an inhibitor of the ERK1/2 activators MEK1/MEK2) had no significant effect.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	61-64
19605737-4	2009	Addition of either PD169316 (a p38 inhibitor) or SP600125 (a JNK inhibitor) induced formation of domes (a phenomenon dependent on TJ barrier function) and enhanced transepithelial electrical resistance, whereas U0126 (an inhibitor of the ERK1/2 activators MEK1/MEK2) had no significant effect.	pyrazolanthrone	49-57	mitogen-activated protein kinase 3	Homo sapiens	238-244
19605737-4	2009	Addition of either PD169316 (a p38 inhibitor) or SP600125 (a JNK inhibitor) induced formation of domes (a phenomenon dependent on TJ barrier function) and enhanced transepithelial electrical resistance, whereas U0126 (an inhibitor of the ERK1/2 activators MEK1/MEK2) had no significant effect.	pyrazolanthrone	49-57	mitogen-activated protein kinase kinase 1	Homo sapiens	256-260
19605737-4	2009	Addition of either PD169316 (a p38 inhibitor) or SP600125 (a JNK inhibitor) induced formation of domes (a phenomenon dependent on TJ barrier function) and enhanced transepithelial electrical resistance, whereas U0126 (an inhibitor of the ERK1/2 activators MEK1/MEK2) had no significant effect.	pyrazolanthrone	49-57	mitogen-activated protein kinase kinase 2	Homo sapiens	261-265
19605737-6	2009	PD169316 increased the expression of claudin-4 and -8, whereas SP600125 increased claudin-4 and -9 and downregulated claudin-8.	pyrazolanthrone	63-71	claudin 4	Homo sapiens	82-98
19605737-6	2009	PD169316 increased the expression of claudin-4 and -8, whereas SP600125 increased claudin-4 and -9 and downregulated claudin-8.	pyrazolanthrone	63-71	claudin 8	Homo sapiens	117-126
19605759-8	2009	SP600125) could prevent caspase 8 activation and diaphragm weakness in endotoxin-treated mice.	pyrazolanthrone	0-8	caspase 8	Mus musculus	24-33
19605759-12	2009	Inhibition of JNK with SP600125 or by use of JNK-deficient animals prevented diaphragm caspase 8 activation (P &lt; 0.01) and prevented diaphragm weakness (P &lt; 0.05).	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Mus musculus	14-17
19605759-12	2009	Inhibition of JNK with SP600125 or by use of JNK-deficient animals prevented diaphragm caspase 8 activation (P &lt; 0.01) and prevented diaphragm weakness (P &lt; 0.05).	pyrazolanthrone	23-31	caspase 8	Mus musculus	87-96
21088717-7	2009	We found that a known JNK-specific inhibitor, SP600125, significantly down-regulates GITR expression on anti-CD3 antibody-mediated activated CD8(+) T cells by limiting JNK phosphorylation.	pyrazolanthrone	46-54	TNF receptor superfamily member 18	Homo sapiens	85-89
21088717-7	2009	We found that a known JNK-specific inhibitor, SP600125, significantly down-regulates GITR expression on anti-CD3 antibody-mediated activated CD8(+) T cells by limiting JNK phosphorylation.	pyrazolanthrone	46-54	CD8a molecule	Homo sapiens	141-144
21088717-7	2009	We found that a known JNK-specific inhibitor, SP600125, significantly down-regulates GITR expression on anti-CD3 antibody-mediated activated CD8(+) T cells by limiting JNK phosphorylation.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	168-171
21088717-10	2009	Therefore, GITR serves as an activation marker on activated CD8(+) cells and interference with JNK phosphorylation, partially or completely, by varying the doses of SP600125 might have implications in CD8(+) cytotoxic T cell response in translational research.	pyrazolanthrone	165-173	TNF receptor superfamily member 18	Homo sapiens	11-15
21088717-10	2009	Therefore, GITR serves as an activation marker on activated CD8(+) cells and interference with JNK phosphorylation, partially or completely, by varying the doses of SP600125 might have implications in CD8(+) cytotoxic T cell response in translational research.	pyrazolanthrone	165-173	mitogen-activated protein kinase 8	Homo sapiens	95-98
21088717-10	2009	Therefore, GITR serves as an activation marker on activated CD8(+) cells and interference with JNK phosphorylation, partially or completely, by varying the doses of SP600125 might have implications in CD8(+) cytotoxic T cell response in translational research.	pyrazolanthrone	165-173	CD8a molecule	Homo sapiens	201-204
18824345-9	2009	The JNK inhibitor SP600125 inhibited basal and EGF-induced secretion of uPA, VEGF, MMP-9 and TIMP-1, as well as AP-1 DNA binding activity and cell migration.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
19530228-10	2009	In addition, beta-1,4-GalT I production was drastically suppressed by U0126 (ERK inhibitor), SB203580 (p38 inhibitor), or SP600125 (SAPK/JNK inhibitor), which indicated that Schwann cells which regulated beta-1,4-GalT I expression after LPS stimulation were via ERK, SAPK/JNK, and P38 MAP kinase signal pathways.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Rattus norvegicus	137-140
18824345-9	2009	The JNK inhibitor SP600125 inhibited basal and EGF-induced secretion of uPA, VEGF, MMP-9 and TIMP-1, as well as AP-1 DNA binding activity and cell migration.	pyrazolanthrone	18-26	plasminogen activator, urokinase	Homo sapiens	72-75
18824345-9	2009	The JNK inhibitor SP600125 inhibited basal and EGF-induced secretion of uPA, VEGF, MMP-9 and TIMP-1, as well as AP-1 DNA binding activity and cell migration.	pyrazolanthrone	18-26	vascular endothelial growth factor A	Homo sapiens	77-81
18824345-9	2009	The JNK inhibitor SP600125 inhibited basal and EGF-induced secretion of uPA, VEGF, MMP-9 and TIMP-1, as well as AP-1 DNA binding activity and cell migration.	pyrazolanthrone	18-26	matrix metallopeptidase 9	Homo sapiens	83-88
18824345-9	2009	The JNK inhibitor SP600125 inhibited basal and EGF-induced secretion of uPA, VEGF, MMP-9 and TIMP-1, as well as AP-1 DNA binding activity and cell migration.	pyrazolanthrone	18-26	TIMP metallopeptidase inhibitor 1	Homo sapiens	93-99
19954621-8	2009	p38 MAPK JNK inhibitors SB203580 and SP600125 reduced allogeneic T lymphocytes-induced TF expression in HUVECs.	pyrazolanthrone	37-45	mitogen-activated protein kinase 14	Mus musculus	0-3
19723872-4	2009	Inhibition of c-Jun NH2-terminal kinase (JNK) by pretreatment with SP600125 or a dominant-negative form of JNK blocked cell death.	pyrazolanthrone	67-75	mitogen-activated protein kinase 8	Homo sapiens	14-39
19723872-4	2009	Inhibition of c-Jun NH2-terminal kinase (JNK) by pretreatment with SP600125 or a dominant-negative form of JNK blocked cell death.	pyrazolanthrone	67-75	mitogen-activated protein kinase 8	Homo sapiens	41-44
19954621-9	2009	(4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs.	pyrazolanthrone	17-25	interferon gamma	Mus musculus	93-102
19954621-9	2009	(4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs.	pyrazolanthrone	17-25	interleukin 6	Mus musculus	104-108
19573589-5	2009	Our data indicated that cell proliferation promoted by low concentrations of Cd was blocked obviously by ERK1/2 inhibitor PD98059 and partly by JNK inhibitor SP600125; while the decreases of cell proliferation induced by high concentrations of Cd were significantly restored by p38 inhibitor SB203580.	pyrazolanthrone	158-166	mitogen-activated protein kinase 8	Homo sapiens	144-147
19954621-8	2009	p38 MAPK JNK inhibitors SB203580 and SP600125 reduced allogeneic T lymphocytes-induced TF expression in HUVECs.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Mus musculus	9-12
19954621-9	2009	(4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs.	pyrazolanthrone	17-25	vascular cell adhesion molecule 1	Mus musculus	74-80
19954621-9	2009	(4) SB203580 and SP600125 down-regulated allogeneic T lymphocytes-induced VCAM-1, TNF-alpha, IFN-gamma, IL-6 expression in HUVECs.	pyrazolanthrone	17-25	tumor necrosis factor	Mus musculus	82-91
19345745-10	2009	These effects were reversed by blocking JNK or p38 MAPK using pharmacological inhibitors (SP 600125, and SB 203580).	pyrazolanthrone	90-99	mitogen-activated protein kinase 8	Rattus norvegicus	40-43
19540902-5	2009	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) attenuated mitochondrial depolarization, degradation of Bcl-2/Bcl-xL, and mitochondrial translocation of Bax.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	44-47
19540902-5	2009	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) attenuated mitochondrial depolarization, degradation of Bcl-2/Bcl-xL, and mitochondrial translocation of Bax.	pyrazolanthrone	34-42	BCL2 apoptosis regulator	Homo sapiens	115-120
19540902-5	2009	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) attenuated mitochondrial depolarization, degradation of Bcl-2/Bcl-xL, and mitochondrial translocation of Bax.	pyrazolanthrone	34-42	BCL2 like 1	Homo sapiens	121-127
19540902-5	2009	SB202190 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) attenuated mitochondrial depolarization, degradation of Bcl-2/Bcl-xL, and mitochondrial translocation of Bax.	pyrazolanthrone	34-42	BCL2 associated X, apoptosis regulator	Homo sapiens	164-167
19723096-5	2009	Treatment of ESC-B5 cells with a JNK-specific inhibitor (SP600125) reduced GKB-induced activation of both JNK and caspase-3, indicating that JNK activity is required for GKB-induced caspase activation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Mus musculus	33-36
19723096-5	2009	Treatment of ESC-B5 cells with a JNK-specific inhibitor (SP600125) reduced GKB-induced activation of both JNK and caspase-3, indicating that JNK activity is required for GKB-induced caspase activation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Mus musculus	106-109
19723096-5	2009	Treatment of ESC-B5 cells with a JNK-specific inhibitor (SP600125) reduced GKB-induced activation of both JNK and caspase-3, indicating that JNK activity is required for GKB-induced caspase activation.	pyrazolanthrone	57-65	caspase 3	Mus musculus	114-123
19723096-5	2009	Treatment of ESC-B5 cells with a JNK-specific inhibitor (SP600125) reduced GKB-induced activation of both JNK and caspase-3, indicating that JNK activity is required for GKB-induced caspase activation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Mus musculus	106-109
19427996-5	2009	The JNK inhibitor SP600125 inhibited vinblastine-induced JNK activation and in concert inhibited Bax mitochondrial translocation, Bax oligomerization, and Bax activation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
19427996-5	2009	The JNK inhibitor SP600125 inhibited vinblastine-induced JNK activation and in concert inhibited Bax mitochondrial translocation, Bax oligomerization, and Bax activation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	57-60
19427996-5	2009	The JNK inhibitor SP600125 inhibited vinblastine-induced JNK activation and in concert inhibited Bax mitochondrial translocation, Bax oligomerization, and Bax activation.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Homo sapiens	97-100
19723098-8	2009	The JNK inhibitor SP600125 protected against gallic acid-induced PC12 cell death.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
19638595-6	2009	We have previously shown that treatment with the c-Jun NH(2)-terminal kinase (JNK) inhibitor SP600125 protects human melanoma epitope Mart-1(27-35)-reactive CTL from apoptotic death upon their reencounter with cognate antigen.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	49-76
19427996-5	2009	The JNK inhibitor SP600125 inhibited vinblastine-induced JNK activation and in concert inhibited Bax mitochondrial translocation, Bax oligomerization, and Bax activation.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
19427996-5	2009	The JNK inhibitor SP600125 inhibited vinblastine-induced JNK activation and in concert inhibited Bax mitochondrial translocation, Bax oligomerization, and Bax activation.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
19427996-7	2009	The ability of vinblastine to induce Bax translocation and the inhibitory effect of SP600125 were confirmed in cells stably expressing GFP-Bax.	pyrazolanthrone	84-92	BCL2 associated X, apoptosis regulator	Homo sapiens	139-142
19558546-9	2009	The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38.	pyrazolanthrone	77-85	C-X-C motif chemokine ligand 8	Homo sapiens	17-21
19558546-9	2009	The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38.	pyrazolanthrone	77-85	tumor necrosis factor	Homo sapiens	36-39
19558546-9	2009	The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38.	pyrazolanthrone	77-85	interleukin 1 beta	Homo sapiens	44-52
19558546-9	2009	The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38.	pyrazolanthrone	77-85	mitogen-activated protein kinase 14	Homo sapiens	158-161
19558546-9	2009	The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38.	pyrazolanthrone	77-85	mitogen-activated protein kinase 1	Homo sapiens	191-194
19558546-9	2009	The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38.	pyrazolanthrone	77-85	C-X-C motif chemokine ligand 8	Homo sapiens	244-248
19558546-9	2009	The secretion of IL-8 and specially TNF and IL-1beta was blocked by PD98059, SP600125, SB203580 and Bay11-7082, suggesting the involvement of the MAP kinases p38, c-Jun N-terminal kinase and ERK and particularly the NF-kappaB pathway, although IL-8 secretion was independent of p38.	pyrazolanthrone	77-85	mitogen-activated protein kinase 14	Homo sapiens	278-281
19638595-6	2009	We have previously shown that treatment with the c-Jun NH(2)-terminal kinase (JNK) inhibitor SP600125 protects human melanoma epitope Mart-1(27-35)-reactive CTL from apoptotic death upon their reencounter with cognate antigen.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	78-81
19486902-8	2009	Anthra[1-9-cd]pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, decreased the [(3)H]thymidine incorporation induced by angiotensin II.	pyrazolanthrone	0-31	mitogen-activated protein kinase 8	Homo sapiens	60-63
19486902-8	2009	Anthra[1-9-cd]pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, decreased the [(3)H]thymidine incorporation induced by angiotensin II.	pyrazolanthrone	0-31	angiotensinogen	Homo sapiens	120-134
19486902-8	2009	Anthra[1-9-cd]pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, decreased the [(3)H]thymidine incorporation induced by angiotensin II.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	60-63
19486902-8	2009	Anthra[1-9-cd]pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, decreased the [(3)H]thymidine incorporation induced by angiotensin II.	pyrazolanthrone	33-41	angiotensinogen	Homo sapiens	120-134
19549188-7	2009	Moreover, pretreatment of cancer cells with the JNK inhibitor SP600125 abolished the repression of Akt and mTOR activity by E1, indicating that the inhibition of Akt and mTOR by E1 is mediated through JNK activation.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	48-51
19549188-7	2009	Moreover, pretreatment of cancer cells with the JNK inhibitor SP600125 abolished the repression of Akt and mTOR activity by E1, indicating that the inhibition of Akt and mTOR by E1 is mediated through JNK activation.	pyrazolanthrone	62-70	AKT serine/threonine kinase 1	Homo sapiens	99-102
19549188-7	2009	Moreover, pretreatment of cancer cells with the JNK inhibitor SP600125 abolished the repression of Akt and mTOR activity by E1, indicating that the inhibition of Akt and mTOR by E1 is mediated through JNK activation.	pyrazolanthrone	62-70	mechanistic target of rapamycin kinase	Homo sapiens	107-111
19549188-7	2009	Moreover, pretreatment of cancer cells with the JNK inhibitor SP600125 abolished the repression of Akt and mTOR activity by E1, indicating that the inhibition of Akt and mTOR by E1 is mediated through JNK activation.	pyrazolanthrone	62-70	AKT serine/threonine kinase 1	Homo sapiens	162-165
19549188-7	2009	Moreover, pretreatment of cancer cells with the JNK inhibitor SP600125 abolished the repression of Akt and mTOR activity by E1, indicating that the inhibition of Akt and mTOR by E1 is mediated through JNK activation.	pyrazolanthrone	62-70	mechanistic target of rapamycin kinase	Homo sapiens	170-174
19549188-7	2009	Moreover, pretreatment of cancer cells with the JNK inhibitor SP600125 abolished the repression of Akt and mTOR activity by E1, indicating that the inhibition of Akt and mTOR by E1 is mediated through JNK activation.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	201-204
19671676-9	2009	JNK inhibition by SP600125, a specific JNK inhibitor, resulted in restoration of EGFR levels in COX-2-overexpressing cells, whereas ERK inhibition by PD98059 did not.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	0-3
19406831-5	2009	It was of particular interest to observe that SP600125 and SB203580, specific inhibitors of JNK and p38, did not inhibit BAFF synthesis but inhibited the release of sBAFF in gangliosides-treated cells by regulating furin expression, suggesting that the JNK and p38 signaling pathways regulate the release but not the synthesis of BAFF.	pyrazolanthrone	46-54	mitogen activated protein kinase 14	Rattus norvegicus	100-103
19406831-5	2009	It was of particular interest to observe that SP600125 and SB203580, specific inhibitors of JNK and p38, did not inhibit BAFF synthesis but inhibited the release of sBAFF in gangliosides-treated cells by regulating furin expression, suggesting that the JNK and p38 signaling pathways regulate the release but not the synthesis of BAFF.	pyrazolanthrone	46-54	furin (paired basic amino acid cleaving enzyme)	Rattus norvegicus	215-220
19406831-5	2009	It was of particular interest to observe that SP600125 and SB203580, specific inhibitors of JNK and p38, did not inhibit BAFF synthesis but inhibited the release of sBAFF in gangliosides-treated cells by regulating furin expression, suggesting that the JNK and p38 signaling pathways regulate the release but not the synthesis of BAFF.	pyrazolanthrone	46-54	TNF superfamily member 13b	Rattus norvegicus	166-170
19528235-6	2009	Treatment with the JNK inhibitor SP600125 or cotransduction with GATA2 normalizes activating Shp2-generated CFU-M.	pyrazolanthrone	33-41	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	93-97
19671676-9	2009	JNK inhibition by SP600125, a specific JNK inhibitor, resulted in restoration of EGFR levels in COX-2-overexpressing cells, whereas ERK inhibition by PD98059 did not.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	39-42
19671676-9	2009	JNK inhibition by SP600125, a specific JNK inhibitor, resulted in restoration of EGFR levels in COX-2-overexpressing cells, whereas ERK inhibition by PD98059 did not.	pyrazolanthrone	18-26	epidermal growth factor receptor	Homo sapiens	81-85
19671676-9	2009	JNK inhibition by SP600125, a specific JNK inhibitor, resulted in restoration of EGFR levels in COX-2-overexpressing cells, whereas ERK inhibition by PD98059 did not.	pyrazolanthrone	18-26	prostaglandin-endoperoxide synthase 2	Homo sapiens	96-101
19553068-8	2009	TNF-alpha potently upregulated the mRNA and protein levels of VEGF, which were significantly reversed by JNK inhibitor SP600125.	pyrazolanthrone	119-127	tumor necrosis factor	Homo sapiens	0-9
19497418-6	2009	LPS- and LTA-induced NOS/NO productions were significantly suppressed by the JNK inhibitor, SP600125, but not by the ERK inhibitor, PD98059, through a reduction in JNK protein phosphorylation.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Mus musculus	77-80
19342094-2	2009	PCL-b-PEO micelles were loaded with c-Jun NH2-terminal kinases inhibitor SP600125 to rescue the isolated islets.	pyrazolanthrone	73-81	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	36-41
19342094-5	2009	To investigate the effectiveness of micelle-incorporated SP600125 in preventing the islet cell death, we challenged the islets with TNF-alpha, IL-1, and IFN gamma.	pyrazolanthrone	57-65	interferon gamma	Homo sapiens	153-162
19442700-7	2009	Pre-treatment with the JNK inhibitor SP600125, blocked 1S-cis-BF-induced cytotoxicity and apoptosis.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	23-26
19553068-8	2009	TNF-alpha potently upregulated the mRNA and protein levels of VEGF, which were significantly reversed by JNK inhibitor SP600125.	pyrazolanthrone	119-127	vascular endothelial growth factor A	Homo sapiens	62-66
19553068-8	2009	TNF-alpha potently upregulated the mRNA and protein levels of VEGF, which were significantly reversed by JNK inhibitor SP600125.	pyrazolanthrone	119-127	mitogen-activated protein kinase 8	Homo sapiens	105-108
19275968-8	2009	TNF-alpha-induced apoptosis was significantly decreased by SB203580, a p38 MAPK inhibitor or SP600125, a JNK inhibitor, but was enhanced by an ERK1/2 pathway inhibitor, PD98059 or a PI3-kinase/Akt pathway inhibitor, wortmannin.	pyrazolanthrone	93-101	tumor necrosis factor	Bos taurus	0-9
19508391-6	2009	Further, LPS + IFNgamma-induced expression of iNOS and Nox1 was attenuated by the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor SP600125, the Jak2 inhibitor AG490 and the NFkappaB inhibitor MG132, but not by the p38 mitogen-activated protein kinase inhibitor SB203580.	pyrazolanthrone	172-180	interferon gamma	Mus musculus	15-23
19508391-6	2009	Further, LPS + IFNgamma-induced expression of iNOS and Nox1 was attenuated by the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor SP600125, the Jak2 inhibitor AG490 and the NFkappaB inhibitor MG132, but not by the p38 mitogen-activated protein kinase inhibitor SB203580.	pyrazolanthrone	172-180	nitric oxide synthase 2, inducible	Mus musculus	46-50
19508391-6	2009	Further, LPS + IFNgamma-induced expression of iNOS and Nox1 was attenuated by the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor SP600125, the Jak2 inhibitor AG490 and the NFkappaB inhibitor MG132, but not by the p38 mitogen-activated protein kinase inhibitor SB203580.	pyrazolanthrone	172-180	NADPH oxidase 1	Mus musculus	55-59
19508391-6	2009	Further, LPS + IFNgamma-induced expression of iNOS and Nox1 was attenuated by the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor SP600125, the Jak2 inhibitor AG490 and the NFkappaB inhibitor MG132, but not by the p38 mitogen-activated protein kinase inhibitor SB203580.	pyrazolanthrone	172-180	mitogen-activated protein kinase 8	Mus musculus	158-161
19508391-6	2009	Further, LPS + IFNgamma-induced expression of iNOS and Nox1 was attenuated by the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor SP600125, the Jak2 inhibitor AG490 and the NFkappaB inhibitor MG132, but not by the p38 mitogen-activated protein kinase inhibitor SB203580.	pyrazolanthrone	172-180	Janus kinase 2	Mus musculus	186-190
19508391-6	2009	Further, LPS + IFNgamma-induced expression of iNOS and Nox1 was attenuated by the mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor PD98059, the JNK inhibitor SP600125, the Jak2 inhibitor AG490 and the NFkappaB inhibitor MG132, but not by the p38 mitogen-activated protein kinase inhibitor SB203580.	pyrazolanthrone	172-180	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	215-223
19277946-6	2009	The JNK inhibitor, SP600125, attenuated insulin resistance mediated by SFA and Tlr agonists, which corresponded with a diminished proinflammatory response and reduced ROS accumulation.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
19609071-3	2009	The Cd-induced VCAM-1 expression was significantly suppressed by either a specific p38 mitogen-activated protein kinase (MAPK) inhibitor (SB202190) or a JNK inhibitor (SP600125), but not by an ERK inhibitor (U0126).	pyrazolanthrone	168-176	vascular cell adhesion molecule 1	Mus musculus	15-21
19414586-5	2009	However, only the JNK-specific inhibitor SP600125 effectively blocked the apoptosis induced by NSC-741909.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	18-21
19428345-7	2009	Our study showed that esculetin, PD98059 (MEK/ERK inhibitor), and SP600125 (JNK inhibitor) similarly enhanced the As(2)O(3)-induced GSH depletion.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	76-79
19376148-4	2009	Activation of c-Jun N-terminal kinases (JNKs) and extracellular regulated kinases (ERKs) were detected in LPS-, LTA-, and PGN-treated RAW264.7 cells, and iNOS/NO production was blocked by adding the JNK inhibitor, SP600125, but not the ERK inhibitor, PD98059.	pyrazolanthrone	214-222	mitogen-activated protein kinase 1	Mus musculus	83-87
19494316-12	2009	Furthermore, thrombin-mediated AP-1 activation was inhibited by ASK1DN, JNK1/2DN, and SP600125.	pyrazolanthrone	86-94	coagulation factor II, thrombin	Homo sapiens	13-21
19376148-4	2009	Activation of c-Jun N-terminal kinases (JNKs) and extracellular regulated kinases (ERKs) were detected in LPS-, LTA-, and PGN-treated RAW264.7 cells, and iNOS/NO production was blocked by adding the JNK inhibitor, SP600125, but not the ERK inhibitor, PD98059.	pyrazolanthrone	214-222	mitogen-activated protein kinase 8	Mus musculus	40-43
19376148-4	2009	Activation of c-Jun N-terminal kinases (JNKs) and extracellular regulated kinases (ERKs) were detected in LPS-, LTA-, and PGN-treated RAW264.7 cells, and iNOS/NO production was blocked by adding the JNK inhibitor, SP600125, but not the ERK inhibitor, PD98059.	pyrazolanthrone	214-222	mitogen-activated protein kinase 1	Mus musculus	83-86
19393623-6	2009	In addition, inhibition of ET-1-induced c-Jun N-terminal kinase (JNK) activation by treatment with SP600125, a JNK inhibitor, also prevented the ET-1-mediated promotion of neurite elongation.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	40-63
19418558-10	2009	The specific inhibition of JNK activity by SP600125 suppressed pSmad3L/c-Myc in the damaged hepatocytes and enhanced pSmad3C/p21(WAF1), acting as a tumor suppressor in normal hepatocytes.	pyrazolanthrone	43-51	MYC proto-oncogene, bHLH transcription factor	Rattus norvegicus	71-76
19393623-6	2009	In addition, inhibition of ET-1-induced c-Jun N-terminal kinase (JNK) activation by treatment with SP600125, a JNK inhibitor, also prevented the ET-1-mediated promotion of neurite elongation.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	65-68
19393623-6	2009	In addition, inhibition of ET-1-induced c-Jun N-terminal kinase (JNK) activation by treatment with SP600125, a JNK inhibitor, also prevented the ET-1-mediated promotion of neurite elongation.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	111-114
19211687-11	2009	Moreover, SP600125 or SN50 effectively blocked SGLT expression and alpha-MG uptake in BSA- or PPARgamma agonists (troglitazone or PGJ2)-treated PTCs.	pyrazolanthrone	10-18	peroxisome proliferator activated receptor gamma	Homo sapiens	94-103
19363130-8	2009	The ratio of p-insulin receptor substrate (IRS)-1 at Ser307 to IRS-1 was elevated in Lepr(db) compared with mLepr(db) mice; both NaSal and the JNK inhibitor SP-600125 reduced the p-IRS-1-to-IRS-1 ratio in Lepr(db) mice.	pyrazolanthrone	157-166	insulin receptor substrate 1	Mus musculus	13-49
19363130-8	2009	The ratio of p-insulin receptor substrate (IRS)-1 at Ser307 to IRS-1 was elevated in Lepr(db) compared with mLepr(db) mice; both NaSal and the JNK inhibitor SP-600125 reduced the p-IRS-1-to-IRS-1 ratio in Lepr(db) mice.	pyrazolanthrone	157-166	mitogen-activated protein kinase 8	Mus musculus	143-146
19418558-4	2009	The aim of this study is to elucidate how SP600125, a JNK inhibitor, affected rat hepatocellular carcinoma (HCC) development, while focusing on the domain-specific phosphorylation of Smad3.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
19418558-10	2009	The specific inhibition of JNK activity by SP600125 suppressed pSmad3L/c-Myc in the damaged hepatocytes and enhanced pSmad3C/p21(WAF1), acting as a tumor suppressor in normal hepatocytes.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
18978303-7	2009	Among signaling inhibitors, a c-Jun NH(2)-terminal kinase (JNK) inhibitor (SP600125) markedly attenuated dynasore-stimulated PAI-1 protein production.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	30-57
18978303-7	2009	Among signaling inhibitors, a c-Jun NH(2)-terminal kinase (JNK) inhibitor (SP600125) markedly attenuated dynasore-stimulated PAI-1 protein production.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	59-62
18978303-7	2009	Among signaling inhibitors, a c-Jun NH(2)-terminal kinase (JNK) inhibitor (SP600125) markedly attenuated dynasore-stimulated PAI-1 protein production.	pyrazolanthrone	75-83	serpin family E member 1	Homo sapiens	125-130
19385049-7	2009	Using the chemical JNK inhibitor SP600125 as well as compartment-specific JNK-inhibiting constructs and dominant negative isoform mutants, we show that the nuclear subgroup of JNK2 is the dominant effector in colchicine and taxol-induced apoptosis, while cell cycle promotion is mediated by both cytoplasmic and nuclear JNK2.In contrast, cytochalasin D-triggered apoptosis is independent of JNK signaling.	pyrazolanthrone	33-41	mitogen-activated protein kinase 9	Homo sapiens	176-180
19418558-10	2009	The specific inhibition of JNK activity by SP600125 suppressed pSmad3L/c-Myc in the damaged hepatocytes and enhanced pSmad3C/p21(WAF1), acting as a tumor suppressor in normal hepatocytes.	pyrazolanthrone	43-51	KRAS proto-oncogene, GTPase	Rattus norvegicus	125-128
19418558-10	2009	The specific inhibition of JNK activity by SP600125 suppressed pSmad3L/c-Myc in the damaged hepatocytes and enhanced pSmad3C/p21(WAF1), acting as a tumor suppressor in normal hepatocytes.	pyrazolanthrone	43-51	cyclin-dependent kinase inhibitor 1A	Rattus norvegicus	129-133
19418558-11	2009	CONCLUSION: Administration of SP600125 to DEN-treated rats shifted hepatocytic Smad3-mediated signal from oncogenesis to tumor suppression, thus suggesting that JNK could be a therapeutic target of human HCC development and progression.	pyrazolanthrone	30-38	SMAD family member 3	Rattus norvegicus	79-84
19418558-11	2009	CONCLUSION: Administration of SP600125 to DEN-treated rats shifted hepatocytic Smad3-mediated signal from oncogenesis to tumor suppression, thus suggesting that JNK could be a therapeutic target of human HCC development and progression.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	161-164
19454725-5	2009	Herbimycin A, a tyrosine kinase inhibitor, and SP600125, a JNK inhibitor, suppressed the activation of caspases and lactate dehydrogenase release.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	59-62
19243022-5	2009	In addition, treatment with SP600125, an inhibitor for c-Jun NH(2)-terminal kinase (JNK), resulted in a significant inhibition of MT1-MMP production.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	55-82
19243022-5	2009	In addition, treatment with SP600125, an inhibitor for c-Jun NH(2)-terminal kinase (JNK), resulted in a significant inhibition of MT1-MMP production.	pyrazolanthrone	28-36	matrix metallopeptidase 14	Homo sapiens	130-137
19243022-5	2009	In addition, treatment with SP600125, an inhibitor for c-Jun NH(2)-terminal kinase (JNK), resulted in a significant inhibition of MT1-MMP production.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	84-87
19454725-5	2009	Herbimycin A, a tyrosine kinase inhibitor, and SP600125, a JNK inhibitor, suppressed the activation of caspases and lactate dehydrogenase release.	pyrazolanthrone	47-55	caspase 6	Homo sapiens	103-111
19454725-6	2009	Moreover, a PI3K inhibitor (LY294002) suppressed activation of caspases and combined treatment with both SP600125 and LY294002 completely inhibited the activation of caspases.	pyrazolanthrone	105-113	caspase 6	Homo sapiens	63-71
19454725-6	2009	Moreover, a PI3K inhibitor (LY294002) suppressed activation of caspases and combined treatment with both SP600125 and LY294002 completely inhibited the activation of caspases.	pyrazolanthrone	105-113	caspase 6	Homo sapiens	166-174
19454725-9	2009	The addition of SP600125 suppressed phosphorylation of JNK and the activation of caspase 3 in HMEC treated with LPS and CHX.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Homo sapiens	55-58
19454725-9	2009	The addition of SP600125 suppressed phosphorylation of JNK and the activation of caspase 3 in HMEC treated with LPS and CHX.	pyrazolanthrone	16-24	caspase 3	Homo sapiens	81-90
19286949-7	2009	ANG II-induced AT(1)R expression was blocked by ICV infusion of the p44/42 MAPK inhibitor PD-98059 (0.025 microg/h) and the JNK inhibitor SP-600125 (0.125 microg/h), but not by the p38 MAPK inhibitor SB-203580 (0.125 microg/h).	pyrazolanthrone	138-147	angiotensinogen	Rattus norvegicus	0-6
19509115-5	2009	MEK1/2 inhibitors, U0126 and PD98059, significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH(2)-terminal kinase inhibitor SP600125 abrogated only CXC chemokine production.	pyrazolanthrone	159-167	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
19509115-5	2009	MEK1/2 inhibitors, U0126 and PD98059, significantly inhibited the secretion of both CXC chemokines and VEGF, whereas the c-Jun NH(2)-terminal kinase inhibitor SP600125 abrogated only CXC chemokine production.	pyrazolanthrone	159-167	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	121-126
19473519-10	2009	The gel shift and promoter activity assay showed that TNF-alpha increased AP-1-binding activity and resistin promoter activity, while SP600125 and atorvastatin inhibited the AP-1-binding activity and resistin promoter activity induced by TNF-alpha.	pyrazolanthrone	134-142	tumor necrosis factor	Homo sapiens	238-247
19248828-9	2009	Data obtained with SP600125, a selective inhibitor of JNK, revealed that JNK is involved in HNE-induced apoptosis through the inhibition of PARP cleavage and caspase-3 activation in PC12 cells.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
19248828-9	2009	Data obtained with SP600125, a selective inhibitor of JNK, revealed that JNK is involved in HNE-induced apoptosis through the inhibition of PARP cleavage and caspase-3 activation in PC12 cells.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Rattus norvegicus	73-76
19248828-9	2009	Data obtained with SP600125, a selective inhibitor of JNK, revealed that JNK is involved in HNE-induced apoptosis through the inhibition of PARP cleavage and caspase-3 activation in PC12 cells.	pyrazolanthrone	19-27	caspase 3	Rattus norvegicus	158-167
19306295-7	2009	(2) SP600125, a JNK-specific inhibitor, which resulted in inhibition of AP-1 activity, enhanced the iNOS expression and promoter activity in clinorotation.	pyrazolanthrone	4-12	nitric oxide synthase 2	Homo sapiens	100-104
19125410-5	2009	The inhibition of an extracellular signal-regulated kinase (ERK) pathway by PD98059 and U0126 significantly suppressed ATPgammaS-induced MCP-1 mRNA expression and protein production, while inhibition of c-Jun N-terminal kinase by SP600125 resulted in the partial suppression.	pyrazolanthrone	230-238	Eph receptor B1	Rattus norvegicus	21-58
19125410-5	2009	The inhibition of an extracellular signal-regulated kinase (ERK) pathway by PD98059 and U0126 significantly suppressed ATPgammaS-induced MCP-1 mRNA expression and protein production, while inhibition of c-Jun N-terminal kinase by SP600125 resulted in the partial suppression.	pyrazolanthrone	230-238	Eph receptor B1	Rattus norvegicus	60-63
19286949-7	2009	ANG II-induced AT(1)R expression was blocked by ICV infusion of the p44/42 MAPK inhibitor PD-98059 (0.025 microg/h) and the JNK inhibitor SP-600125 (0.125 microg/h), but not by the p38 MAPK inhibitor SB-203580 (0.125 microg/h).	pyrazolanthrone	138-147	angiotensin II receptor, type 1a	Rattus norvegicus	15-21
19286949-7	2009	ANG II-induced AT(1)R expression was blocked by ICV infusion of the p44/42 MAPK inhibitor PD-98059 (0.025 microg/h) and the JNK inhibitor SP-600125 (0.125 microg/h), but not by the p38 MAPK inhibitor SB-203580 (0.125 microg/h).	pyrazolanthrone	138-147	mitogen-activated protein kinase 8	Rattus norvegicus	124-127
19325135-8	2009	The JNK inhibitor SP600125 reduced 4HPR-induced PLAB upregulation, by decreasing PLAB mRNA half-life, and protected the cells from apoptosis.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
19106147-6	2009	TRAIL-induced activation of JNK could be effectively interrupted by administration of the JNK inhibitor SP600125.	pyrazolanthrone	104-112	TNF superfamily member 10	Homo sapiens	0-5
19269342-5	2009	RESULTS: Real-time quantitative polymerase chain reaction and western blotting demonstrated that PD98059, SB203580 or SP600125 down-regulated the expression of ACAT1 in a dose-dependent manner.	pyrazolanthrone	118-126	acetyl-CoA acetyltransferase 1	Homo sapiens	160-165
19106147-6	2009	TRAIL-induced activation of JNK could be effectively interrupted by administration of the JNK inhibitor SP600125.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Homo sapiens	28-31
19106147-6	2009	TRAIL-induced activation of JNK could be effectively interrupted by administration of the JNK inhibitor SP600125.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Homo sapiens	90-93
19493891-6	2009	NaF-induced apoptosis was markedly suppressed by treatment with the JNK inhibitor, SP600125, and mildly suppressed by the MAPK/ERK kinase inhibitor, U0126.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Mus musculus	68-71
19405983-7	2009	The denbinobin-mediated increases in c-Jun phosphorylation and Bim expression were inhibited by NAC, GSH, SP600125, ASK1DN, JNK1DN, and JNK2DN.	pyrazolanthrone	106-114	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	37-42
19206150-0	2009	JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	0-3
19589256-3	2009	The effects of CTGF, TGF-beta(1) and a JNK inhibitor (SP600125) on the proliferation of THSF cells were studied using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	39-42
19589256-5	2009	Immunofluorescence analysis showed that TGF-beta(1) stimulated the activation of JNK1/2 and induced cell migration, effects that were inhibited by SP600125.	pyrazolanthrone	147-155	transforming growth factor beta 1	Homo sapiens	40-51
19589256-5	2009	Immunofluorescence analysis showed that TGF-beta(1) stimulated the activation of JNK1/2 and induced cell migration, effects that were inhibited by SP600125.	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	81-87
19589256-6	2009	Analysis by real-time reverse transcription-polymerase chain reaction showed that the mRNA levels of the genes for CTGF, fibronectin and collagen Ialpha(1) in wound and corneal scar formation were reduced by SP600125 pre-treatment.	pyrazolanthrone	208-216	cellular communication network factor 2	Homo sapiens	115-119
19589256-6	2009	Analysis by real-time reverse transcription-polymerase chain reaction showed that the mRNA levels of the genes for CTGF, fibronectin and collagen Ialpha(1) in wound and corneal scar formation were reduced by SP600125 pre-treatment.	pyrazolanthrone	208-216	fibronectin 1	Homo sapiens	121-132
19393026-7	2009	Only SP600125 could inhibit the ischemia-induced 14-3-3gamma up-regulation in astrocytes.	pyrazolanthrone	5-13	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	Homo sapiens	49-60
19206150-0	2009	JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	96-99
19206150-6	2009	Inhibition of p-JNK with SP600125 resulted in growth arrest in all four MCL cell lines (Jeko-1, HBL-2, UPN-1, Granta-519), which could be partly reversed by the addition of CD40L and IL-4.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	16-19
19206150-6	2009	Inhibition of p-JNK with SP600125 resulted in growth arrest in all four MCL cell lines (Jeko-1, HBL-2, UPN-1, Granta-519), which could be partly reversed by the addition of CD40L and IL-4.	pyrazolanthrone	25-33	CD40 ligand	Homo sapiens	173-178
19206150-6	2009	Inhibition of p-JNK with SP600125 resulted in growth arrest in all four MCL cell lines (Jeko-1, HBL-2, UPN-1, Granta-519), which could be partly reversed by the addition of CD40L and IL-4.	pyrazolanthrone	25-33	interleukin 4	Homo sapiens	183-187
19206150-9	2009	SP600125-induced polyploidy could be blocked by the BCL-2 inhibitor YC137.	pyrazolanthrone	0-8	BCL2 apoptosis regulator	Homo sapiens	52-57
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Mus musculus	14-17
19076312-6	2009	JNK kinase inactivation by the JNK inhibitor SP600125 significantly reduced light-induced cell death, suggesting that the cytoprotective properties of MKP-1 are mediated mainly by the JNK MAP kinase pathway.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	0-3
19076312-6	2009	JNK kinase inactivation by the JNK inhibitor SP600125 significantly reduced light-induced cell death, suggesting that the cytoprotective properties of MKP-1 are mediated mainly by the JNK MAP kinase pathway.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
19076312-6	2009	JNK kinase inactivation by the JNK inhibitor SP600125 significantly reduced light-induced cell death, suggesting that the cytoprotective properties of MKP-1 are mediated mainly by the JNK MAP kinase pathway.	pyrazolanthrone	45-53	dual specificity phosphatase 1	Homo sapiens	151-156
19076312-6	2009	JNK kinase inactivation by the JNK inhibitor SP600125 significantly reduced light-induced cell death, suggesting that the cytoprotective properties of MKP-1 are mediated mainly by the JNK MAP kinase pathway.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Mus musculus	25-28
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	matrix metallopeptidase 9	Mus musculus	56-61
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	tumor necrosis factor	Mus musculus	119-128
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	interleukin 6	Mus musculus	130-134
19299915-4	2009	Inhibition of JNK by the JNK inhibitor SP600125 induced MMP-9 in the absence of serum and suppressed the expression of TNF-alpha, IL-6 and cyclooxygenase-2 in LPS-treated Raw 264.7 cells.	pyrazolanthrone	39-47	prostaglandin-endoperoxide synthase 2	Mus musculus	139-155
19299915-6	2009	Interestingly, mouse serum suppressed SP600125- mediated MMP-9 induction, similar to IFN-gamma.	pyrazolanthrone	38-46	matrix metallopeptidase 9	Mus musculus	57-62
19299915-8	2009	In addition to mouse serum, conditioned media of Raw 264.7 cells contained the inhibitory factor(s) larger than 10 kDa, which suppressed SP600125- or LPS-induced MMP-9 expression.	pyrazolanthrone	137-145	matrix metallopeptidase 9	Mus musculus	162-167
19336889-7	2009	Eupatilin-induced HO-1 expression and Nrf2 were partly attenuated by MEK inhibitor PD98059 and almost completely by phosphatidyl-inactiol 3 kinase (PI3K) inhibitor LY294002, but not by c-Jun N-terminal kinase (JNK) inhibitor SP600125 or p38 mitogen activated protein kinase (MAPK) inhibitor SB202190.	pyrazolanthrone	225-233	heme oxygenase 1	Homo sapiens	18-22
19211917-8	2009	Inhibition of JNK activity using SP-600125 decreased SP-1 phosphorylation, increased p27 expression, and decreased cardiomyocyte proliferation.	pyrazolanthrone	33-42	mitogen-activated protein kinase 8	Mus musculus	14-17
19211917-8	2009	Inhibition of JNK activity using SP-600125 decreased SP-1 phosphorylation, increased p27 expression, and decreased cardiomyocyte proliferation.	pyrazolanthrone	33-42	cyclin-dependent kinase inhibitor 1B	Mus musculus	85-88
19190257-8	2009	A SAPK/JNK inhibitor, SP600125, suppressed aldosterone-induced TH mRNA expression; however, the aldosterone-induced TH expression was not affected by inhibition of ERK1/2, p38-MAPK, Rho-kinase, PI 3-kinase, and PKC.	pyrazolanthrone	22-30	mitogen-activated protein kinase 9	Rattus norvegicus	2-6
19190257-8	2009	A SAPK/JNK inhibitor, SP600125, suppressed aldosterone-induced TH mRNA expression; however, the aldosterone-induced TH expression was not affected by inhibition of ERK1/2, p38-MAPK, Rho-kinase, PI 3-kinase, and PKC.	pyrazolanthrone	22-30	mitogen-activated protein kinase 9	Rattus norvegicus	7-10
19190257-8	2009	A SAPK/JNK inhibitor, SP600125, suppressed aldosterone-induced TH mRNA expression; however, the aldosterone-induced TH expression was not affected by inhibition of ERK1/2, p38-MAPK, Rho-kinase, PI 3-kinase, and PKC.	pyrazolanthrone	22-30	tyrosine hydroxylase	Rattus norvegicus	63-65
19190257-9	2009	It was of note that cotreatment with eplerenone and SP600125 restored aldosterone-induced TH mRNA expression to basal levels.	pyrazolanthrone	52-60	tyrosine hydroxylase	Rattus norvegicus	90-92
19161988-7	2009	Inhibition of JNK-AP-1 with decoy oligonucleotides to AP-1 or JNK inhibitor SP600125 prevented the decreases in cell viability.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	14-17
19161988-7	2009	Inhibition of JNK-AP-1 with decoy oligonucleotides to AP-1 or JNK inhibitor SP600125 prevented the decreases in cell viability.	pyrazolanthrone	76-84	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-22
19161988-7	2009	Inhibition of JNK-AP-1 with decoy oligonucleotides to AP-1 or JNK inhibitor SP600125 prevented the decreases in cell viability.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	62-65
19407950-9	2009	Compared with the SP600125 group, the expressions of JNK, c-Jun, P-c-Jun and HO-1 mRNA and its protein in the TXLSP+SP600125 group were significantly increased at different time points (P&lt;0.05, P&lt;0.01).	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	53-56
19153595-4	2009	JNK specific inhibitor SP600125 inhibits the N-terminal phosphorylation without affecting the C-terminal phosphorylation.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	0-3
19153595-5	2009	In addition, IRF3-mediated gene expressions on lipopolysaccharide (LPS) or polyinosinic-cytidylic acid (polyI:C) treatment are severely impaired by SP600125, as well as for reporter gene assay of IRF3 activation.	pyrazolanthrone	148-156	interferon regulatory factor 3	Homo sapiens	13-17
19153595-7	2009	Interestingly, constitutive active IRF3(5D) can be inhibited by SP600125; JNK1 can synergize the action of IRF3(5D), but not the S173A-IRF3(5D) mutant.	pyrazolanthrone	64-72	interferon regulatory factor 3	Homo sapiens	35-39
19153595-8	2009	More importantly, polyI:C failed to induce the phosphorylation of mutant S173A and SP600125 dramatically abrogated IRF3 phosphorylation and dimerization that was stimulated by polyI:C.	pyrazolanthrone	83-91	interferon regulatory factor 3	Homo sapiens	115-119
19407950-9	2009	Compared with the SP600125 group, the expressions of JNK, c-Jun, P-c-Jun and HO-1 mRNA and its protein in the TXLSP+SP600125 group were significantly increased at different time points (P&lt;0.05, P&lt;0.01).	pyrazolanthrone	116-124	heme oxygenase 1	Homo sapiens	77-81
19407950-9	2009	Compared with the SP600125 group, the expressions of JNK, c-Jun, P-c-Jun and HO-1 mRNA and its protein in the TXLSP+SP600125 group were significantly increased at different time points (P&lt;0.05, P&lt;0.01).	pyrazolanthrone	116-124	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-63
19407950-9	2009	Compared with the SP600125 group, the expressions of JNK, c-Jun, P-c-Jun and HO-1 mRNA and its protein in the TXLSP+SP600125 group were significantly increased at different time points (P&lt;0.05, P&lt;0.01).	pyrazolanthrone	116-124	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	65-72
19127219-5	2009	Treatment with SP600125 stimulated Smad2 phosphorylation and enhanced TGF-beta1-induced Smad2 phosphorylation.	pyrazolanthrone	15-23	SMAD family member 2	Mus musculus	35-40
19197990-8	2009	Further investigation revealed that the specific JNK inhibitor SP600125 and the antioxidant NAC blocked DADS and DATS-induced apoptosis, whereas ERK inhibitors did not.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	49-52
19292871-7	2009	All of these effects of morphine could be suppressed by the JNK inhibitor SP600125 and N-acetylcysteine.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	60-63
19288033-7	2009	As expected, PD98059, an ERK inhibitor, SP600125, a JNK inhibitor and SB203580, a p38 MAPK inhibitor effectively inhibit UVB-induced phosphorylation of ERK, JNK and p38 MAPKs, respectively.	pyrazolanthrone	40-48	mitogen-activated protein kinase 1	Homo sapiens	152-155
19288033-7	2009	As expected, PD98059, an ERK inhibitor, SP600125, a JNK inhibitor and SB203580, a p38 MAPK inhibitor effectively inhibit UVB-induced phosphorylation of ERK, JNK and p38 MAPKs, respectively.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	157-160
19288033-7	2009	As expected, PD98059, an ERK inhibitor, SP600125, a JNK inhibitor and SB203580, a p38 MAPK inhibitor effectively inhibit UVB-induced phosphorylation of ERK, JNK and p38 MAPKs, respectively.	pyrazolanthrone	40-48	mitogen-activated protein kinase 14	Homo sapiens	165-168
19288033-9	2009	PD98059, SP600125 and SB203580 suppressed UVB-induced MMP-1 secretion, which is consistent with the above results.	pyrazolanthrone	9-17	matrix metallopeptidase 1	Homo sapiens	54-59
19339605-5	2009	MCP-1 upregulation by TNF-alpha was dose dependently inhibited by the JNK inhibitors SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) and D-JNKI-1.	pyrazolanthrone	85-93	C-C motif chemokine ligand 2	Homo sapiens	0-5
19339605-5	2009	MCP-1 upregulation by TNF-alpha was dose dependently inhibited by the JNK inhibitors SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) and D-JNKI-1.	pyrazolanthrone	85-93	tumor necrosis factor	Homo sapiens	22-31
19339605-5	2009	MCP-1 upregulation by TNF-alpha was dose dependently inhibited by the JNK inhibitors SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) and D-JNKI-1.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Homo sapiens	70-73
19339605-5	2009	MCP-1 upregulation by TNF-alpha was dose dependently inhibited by the JNK inhibitors SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) and D-JNKI-1.	pyrazolanthrone	95-126	C-C motif chemokine ligand 2	Homo sapiens	0-5
19339605-5	2009	MCP-1 upregulation by TNF-alpha was dose dependently inhibited by the JNK inhibitors SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) and D-JNKI-1.	pyrazolanthrone	95-126	tumor necrosis factor	Homo sapiens	22-31
19339605-5	2009	MCP-1 upregulation by TNF-alpha was dose dependently inhibited by the JNK inhibitors SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) and D-JNKI-1.	pyrazolanthrone	95-126	mitogen-activated protein kinase 8	Homo sapiens	70-73
19139269-12	2009	The JNK inhibitor SP600125 down-regulated the expression of IRE1, Chop, and LC3II induced by DHC, thapsigargin, and MG132 [N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal].	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
19139269-12	2009	The JNK inhibitor SP600125 down-regulated the expression of IRE1, Chop, and LC3II induced by DHC, thapsigargin, and MG132 [N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal].	pyrazolanthrone	18-26	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	60-64
19139269-12	2009	The JNK inhibitor SP600125 down-regulated the expression of IRE1, Chop, and LC3II induced by DHC, thapsigargin, and MG132 [N-benzoyloxycarbonyl (Z)-Leu-Leu-leucinal].	pyrazolanthrone	18-26	DNA damage inducible transcript 3	Homo sapiens	66-70
19109696-6	2009	Furthermore, reduced activation of JNK, utilizing JNK inhibitor SP600125, resulted in significant protection from IL-1beta- or thapsigargin-induced apoptosis via ER stress.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Rattus norvegicus	35-38
19109696-6	2009	Furthermore, reduced activation of JNK, utilizing JNK inhibitor SP600125, resulted in significant protection from IL-1beta- or thapsigargin-induced apoptosis via ER stress.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Rattus norvegicus	50-53
19109696-6	2009	Furthermore, reduced activation of JNK, utilizing JNK inhibitor SP600125, resulted in significant protection from IL-1beta- or thapsigargin-induced apoptosis via ER stress.	pyrazolanthrone	64-72	interleukin 1 beta	Rattus norvegicus	114-122
19162185-10	2009	A JNK inhibitor SP600125 strongly inhibited Abeta-induced c-Jun phosphorylation, AP-1 activation, AP-1 reporter gene activity and MCP-1 expression in cells stimulated with Abeta peptides.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Mus musculus	2-5
19162185-10	2009	A JNK inhibitor SP600125 strongly inhibited Abeta-induced c-Jun phosphorylation, AP-1 activation, AP-1 reporter gene activity and MCP-1 expression in cells stimulated with Abeta peptides.	pyrazolanthrone	16-24	amyloid beta precursor protein	Homo sapiens	44-49
19162185-10	2009	A JNK inhibitor SP600125 strongly inhibited Abeta-induced c-Jun phosphorylation, AP-1 activation, AP-1 reporter gene activity and MCP-1 expression in cells stimulated with Abeta peptides.	pyrazolanthrone	16-24	jun proto-oncogene	Mus musculus	58-63
19162185-10	2009	A JNK inhibitor SP600125 strongly inhibited Abeta-induced c-Jun phosphorylation, AP-1 activation, AP-1 reporter gene activity and MCP-1 expression in cells stimulated with Abeta peptides.	pyrazolanthrone	16-24	jun proto-oncogene	Mus musculus	81-85
19162185-10	2009	A JNK inhibitor SP600125 strongly inhibited Abeta-induced c-Jun phosphorylation, AP-1 activation, AP-1 reporter gene activity and MCP-1 expression in cells stimulated with Abeta peptides.	pyrazolanthrone	16-24	jun proto-oncogene	Mus musculus	98-102
19162185-10	2009	A JNK inhibitor SP600125 strongly inhibited Abeta-induced c-Jun phosphorylation, AP-1 activation, AP-1 reporter gene activity and MCP-1 expression in cells stimulated with Abeta peptides.	pyrazolanthrone	16-24	amyloid beta precursor protein	Homo sapiens	172-177
19201463-5	2009	TNF-mediated stimulation of CCL2 secretion was completely inhibited by incubating the trophoblast cells with the p38-MAPK inhibitor SB203580, whereas CCL5 secretion was inhibited by treating the trophoblast cells with inhibitors specific for JNK (SP600125) and ERK kinase (U0126).	pyrazolanthrone	247-255	tumor necrosis factor	Homo sapiens	0-3
19127219-5	2009	Treatment with SP600125 stimulated Smad2 phosphorylation and enhanced TGF-beta1-induced Smad2 phosphorylation.	pyrazolanthrone	15-23	transforming growth factor, beta 1	Mus musculus	70-79
19201463-5	2009	TNF-mediated stimulation of CCL2 secretion was completely inhibited by incubating the trophoblast cells with the p38-MAPK inhibitor SB203580, whereas CCL5 secretion was inhibited by treating the trophoblast cells with inhibitors specific for JNK (SP600125) and ERK kinase (U0126).	pyrazolanthrone	247-255	mitogen-activated protein kinase 14	Homo sapiens	113-116
19127219-5	2009	Treatment with SP600125 stimulated Smad2 phosphorylation and enhanced TGF-beta1-induced Smad2 phosphorylation.	pyrazolanthrone	15-23	SMAD family member 2	Mus musculus	88-93
19154785-10	2009	Treatment with the JNK inhibitor SP600125 and silencing of both JNK1 and JNK2 with siRNA inhibited UFP-stimulated O(2)(-) production and mRNA expression of HO-1 and TF.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
19428548-7	2009	Treatment with LY294002 (PI3K inhibitor) and SP600125 (JNK inhibitor) suppressed NF-kappaB inhibitor induced MIF mRNA expression and MIF secretion.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	55-58
19428548-7	2009	Treatment with LY294002 (PI3K inhibitor) and SP600125 (JNK inhibitor) suppressed NF-kappaB inhibitor induced MIF mRNA expression and MIF secretion.	pyrazolanthrone	45-53	nuclear factor kappa B subunit 1	Homo sapiens	81-90
19428548-7	2009	Treatment with LY294002 (PI3K inhibitor) and SP600125 (JNK inhibitor) suppressed NF-kappaB inhibitor induced MIF mRNA expression and MIF secretion.	pyrazolanthrone	45-53	macrophage migration inhibitory factor	Homo sapiens	109-112
19428548-7	2009	Treatment with LY294002 (PI3K inhibitor) and SP600125 (JNK inhibitor) suppressed NF-kappaB inhibitor induced MIF mRNA expression and MIF secretion.	pyrazolanthrone	45-53	macrophage migration inhibitory factor	Homo sapiens	133-136
19428548-8	2009	LY294002 and SP600125 inhibited the parthenolide-induced phosphorylation of c-Jun.	pyrazolanthrone	13-21	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	76-81
19356694-0	2009	Neuroprotection by c-Jun NH2-terminal kinase inhibitor SP600125 against potassium deprivation-induced apoptosis involves the Akt pathway and inhibition of cell cycle reentry.	pyrazolanthrone	55-63	AKT serine/threonine kinase 1	Rattus norvegicus	125-128
19356694-2	2009	In this study, we examined the neuroprotective effect of SP600125, a selective JNK inhibitor, in cerebellar granule cells (CGNs) deprived of serum and potassium (S/K withdrawal).	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Rattus norvegicus	79-82
19356694-4	2009	Here we demonstrate that SP600125 is able to inhibit all these pro-apoptotic pathways via the inhibition of JNK.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Rattus norvegicus	108-111
19356694-7	2009	In addition, the specific PI3K/Akt inhibitor LY294002 greatly diminished the antiapoptotic effects of SP600125 upon S/K withdrawal, confirming that Akt is involved in the neuroprotection achieved by SP600125.	pyrazolanthrone	102-110	AKT serine/threonine kinase 1	Rattus norvegicus	31-34
19356694-7	2009	In addition, the specific PI3K/Akt inhibitor LY294002 greatly diminished the antiapoptotic effects of SP600125 upon S/K withdrawal, confirming that Akt is involved in the neuroprotection achieved by SP600125.	pyrazolanthrone	102-110	AKT serine/threonine kinase 1	Rattus norvegicus	148-151
19356694-7	2009	In addition, the specific PI3K/Akt inhibitor LY294002 greatly diminished the antiapoptotic effects of SP600125 upon S/K withdrawal, confirming that Akt is involved in the neuroprotection achieved by SP600125.	pyrazolanthrone	199-207	AKT serine/threonine kinase 1	Rattus norvegicus	148-151
19338750-5	2009	Furthermore, Ang II-induced MMP 2 activation was markedly blocked by SP600125, a selective c-Jun N-terminal kinase (JNK) inhibitor, or pre-treatment of cells with antisense oligonucleotide to focal adhesion kinase (FAK), indicating that both molecules were important for the activation of MMP 2 by Ang II receptor stimulation.	pyrazolanthrone	69-77	angiotensinogen	Homo sapiens	13-19
19338750-5	2009	Furthermore, Ang II-induced MMP 2 activation was markedly blocked by SP600125, a selective c-Jun N-terminal kinase (JNK) inhibitor, or pre-treatment of cells with antisense oligonucleotide to focal adhesion kinase (FAK), indicating that both molecules were important for the activation of MMP 2 by Ang II receptor stimulation.	pyrazolanthrone	69-77	matrix metallopeptidase 2	Homo sapiens	28-33
19154785-10	2009	Treatment with the JNK inhibitor SP600125 and silencing of both JNK1 and JNK2 with siRNA inhibited UFP-stimulated O(2)(-) production and mRNA expression of HO-1 and TF.	pyrazolanthrone	33-41	heme oxygenase 1	Homo sapiens	156-167
19061880-7	2009	Additionally, administration of SP600125, an inhibitor of JNK, attenuated mitochondrial-nuclear translocation of AIF.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Rattus norvegicus	58-61
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	28-55
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	57-60
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	pyrazolanthrone	124-132	mitogen-activated protein kinase 1	Homo sapiens	66-103
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	pyrazolanthrone	124-132	mitogen-activated protein kinase 1	Homo sapiens	105-108
19223550-5	2009	Pharmacologic inhibition of c-Jun NH(2) terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation by SP600125 and PD98059, respectively, blocked LY30-induced increase in sensitization to TRAIL-mediated death.	pyrazolanthrone	124-132	TNF superfamily member 10	Homo sapiens	210-215
18986328-8	2009	Although pretreatment of cells with 20 mmol/L PD98059 (an ERK inhibitor) or 20 mmol/L SP600125 (an inhibitor of JNK) did not inhibit cell death, the addition of 20 mmol/L SB203580 (a p38 MAPK inhibitor) partially rescued cells from apoptosis.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	112-115
19302787-4	2009	Whereas treatment with U0126 (ERK inhibitor) enhanced CAR expression, SP600125 (stress-activated protein kinase inhibitor, SAPK) suppressed the phosphorylation of Elk-1 caused by serum-starvation stress and the elevation of CAR mRNA, suggesting that CAR expression may be mediated by phosphorylated Elk-1 via the SAPK signaling pathway.	pyrazolanthrone	70-78	mitogen-activated protein kinase 9	Homo sapiens	123-127
19302787-4	2009	Whereas treatment with U0126 (ERK inhibitor) enhanced CAR expression, SP600125 (stress-activated protein kinase inhibitor, SAPK) suppressed the phosphorylation of Elk-1 caused by serum-starvation stress and the elevation of CAR mRNA, suggesting that CAR expression may be mediated by phosphorylated Elk-1 via the SAPK signaling pathway.	pyrazolanthrone	70-78	ETS transcription factor ELK1	Homo sapiens	163-168
19302787-4	2009	Whereas treatment with U0126 (ERK inhibitor) enhanced CAR expression, SP600125 (stress-activated protein kinase inhibitor, SAPK) suppressed the phosphorylation of Elk-1 caused by serum-starvation stress and the elevation of CAR mRNA, suggesting that CAR expression may be mediated by phosphorylated Elk-1 via the SAPK signaling pathway.	pyrazolanthrone	70-78	nuclear receptor subfamily 1 group I member 3	Homo sapiens	224-227
19302787-4	2009	Whereas treatment with U0126 (ERK inhibitor) enhanced CAR expression, SP600125 (stress-activated protein kinase inhibitor, SAPK) suppressed the phosphorylation of Elk-1 caused by serum-starvation stress and the elevation of CAR mRNA, suggesting that CAR expression may be mediated by phosphorylated Elk-1 via the SAPK signaling pathway.	pyrazolanthrone	70-78	nuclear receptor subfamily 1 group I member 3	Homo sapiens	224-227
19302787-4	2009	Whereas treatment with U0126 (ERK inhibitor) enhanced CAR expression, SP600125 (stress-activated protein kinase inhibitor, SAPK) suppressed the phosphorylation of Elk-1 caused by serum-starvation stress and the elevation of CAR mRNA, suggesting that CAR expression may be mediated by phosphorylated Elk-1 via the SAPK signaling pathway.	pyrazolanthrone	70-78	ETS transcription factor ELK1	Homo sapiens	299-304
19302787-4	2009	Whereas treatment with U0126 (ERK inhibitor) enhanced CAR expression, SP600125 (stress-activated protein kinase inhibitor, SAPK) suppressed the phosphorylation of Elk-1 caused by serum-starvation stress and the elevation of CAR mRNA, suggesting that CAR expression may be mediated by phosphorylated Elk-1 via the SAPK signaling pathway.	pyrazolanthrone	70-78	mitogen-activated protein kinase 9	Homo sapiens	313-317
19136381-8	2009	Despite the activation of JNK after high doses of diquat, the JNK inhibitor SP-600125 did not protect against diquat-induced necrosis.	pyrazolanthrone	76-85	mitogen-activated protein kinase 8	Rattus norvegicus	62-65
19382420-1	2009	OBJECTIVE: To investigate the effect of SP600125, a specific c-jun N-terminal protein kinase (JNK) inhibitor, on Staphylococcus aureus (S. aureus)-induced U937 cell death and the underlying mechanism.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	94-97
19382420-7	2009	Inhibition of JNK with SP600125 significantly inhibited S. aureus-induced apoptosis in U937 cells.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	14-17
19382420-9	2009	SP600125 protects U937 cells from apoptosis induced by S. aureus via inhibiting the activity of JNK.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	96-99
19060920-11	2009	In addition, inhibition of JNK activity by SP600125 could inhibit autophagy induction by ceramide.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	27-30
18988195-7	2009	Furthermore, pretreatment with PD 98059 (a p44/42 inhibitor, 10(-5) M) or SP 600125 (a JNK inhibitor, 10(-6) M) inhibited ZnCl(2)-induced activation of mTOR, p70S6K, and 4E-BP1.	pyrazolanthrone	74-83	mitogen-activated protein kinase 8	Mus musculus	87-90
18988195-7	2009	Furthermore, pretreatment with PD 98059 (a p44/42 inhibitor, 10(-5) M) or SP 600125 (a JNK inhibitor, 10(-6) M) inhibited ZnCl(2)-induced activation of mTOR, p70S6K, and 4E-BP1.	pyrazolanthrone	74-83	mechanistic target of rapamycin kinase	Mus musculus	152-156
18988195-7	2009	Furthermore, pretreatment with PD 98059 (a p44/42 inhibitor, 10(-5) M) or SP 600125 (a JNK inhibitor, 10(-6) M) inhibited ZnCl(2)-induced activation of mTOR, p70S6K, and 4E-BP1.	pyrazolanthrone	74-83	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	158-164
18988195-7	2009	Furthermore, pretreatment with PD 98059 (a p44/42 inhibitor, 10(-5) M) or SP 600125 (a JNK inhibitor, 10(-6) M) inhibited ZnCl(2)-induced activation of mTOR, p70S6K, and 4E-BP1.	pyrazolanthrone	74-83	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	170-176
19117950-6	2009	Furthermore, JNK inhibitor SP600125 markedly blocked the effect of atrogin-1 on cell apoptosis and the expression of apoptotic-related proteins and caspases.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	13-16
19117950-6	2009	Furthermore, JNK inhibitor SP600125 markedly blocked the effect of atrogin-1 on cell apoptosis and the expression of apoptotic-related proteins and caspases.	pyrazolanthrone	27-35	F-box protein 32	Homo sapiens	67-76
19178296-7	2009	Furthermore, the treatment of inhibitors specific for JNK (SP600125) to PC-3 cells could result in a reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	54-57
19178296-7	2009	Furthermore, the treatment of inhibitors specific for JNK (SP600125) to PC-3 cells could result in a reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	59-67	matrix metallopeptidase 2	Homo sapiens	123-128
19178296-7	2009	Furthermore, the treatment of inhibitors specific for JNK (SP600125) to PC-3 cells could result in a reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	59-67	matrix metallopeptidase 9	Homo sapiens	130-135
19178296-7	2009	Furthermore, the treatment of inhibitors specific for JNK (SP600125) to PC-3 cells could result in a reduced expression of MMP-2, MMP-9, and u-PA.	pyrazolanthrone	59-67	plasminogen activator, urokinase	Homo sapiens	141-145
18803301-10	2009	Inhibition of JNK with SP600125 reduced LPS-induced NO production and apoE reduction in a dose-dependent manner.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Mus musculus	14-17
18803301-10	2009	Inhibition of JNK with SP600125 reduced LPS-induced NO production and apoE reduction in a dose-dependent manner.	pyrazolanthrone	23-31	apolipoprotein E	Mus musculus	70-74
19106158-1	2009	SP600125 is used as a specific inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	44-67
19106158-1	2009	SP600125 is used as a specific inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	69-72
19106158-3	2009	We found that Fc receptor for IgE (FcepsilonRI)-induced degranulation (serotonin release) and cytokine gene expression [interleukin (IL)-6, tumour necrosis factor-alpha and IL-13] in bone marrow-derived mast cells, were almost completely inhibited by SP600125.	pyrazolanthrone	251-259	Fc epsilon receptor Ia	Homo sapiens	35-46
19106158-7	2009	Instead, we found that SP600125 markedly inhibited the FcepsilonRI-induced activation of phosphatidylinositol 3-kinase (PI3K) and Akt, the same as a PI3K inhibitor, wortmannin.	pyrazolanthrone	23-31	Fc epsilon receptor Ia	Homo sapiens	55-66
19106158-8	2009	Finally, we found that SP600125 specifically inhibits delta form of p110 catalytic subunit (p110delta) of PI3K.	pyrazolanthrone	23-31	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	68-101
18668365-5	2009	Next RT-PCR and Western blot analysis were employed to study expression of iNOS after using inhibitors selective for ERK (PD98059), JNK/SAPK (SP600125) and p38 (SB202190).	pyrazolanthrone	142-150	nitric oxide synthase 2	Rattus norvegicus	75-79
19060920-9	2009	The upregulation of Beclin 1 expression could be blocked by SP600125 (a specific inhibitor of JNK) or a small interfering RNA (siRNA) directed against JNK1/2 or c-Jun.	pyrazolanthrone	60-68	beclin 1	Homo sapiens	20-28
19060920-9	2009	The upregulation of Beclin 1 expression could be blocked by SP600125 (a specific inhibitor of JNK) or a small interfering RNA (siRNA) directed against JNK1/2 or c-Jun.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	94-97
19074641-7	2009	The JNK inhibitor SP-600125 blocked expression/secretion of IL-6 but only partially attenuated IL-8 expression.	pyrazolanthrone	18-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
19074641-7	2009	The JNK inhibitor SP-600125 blocked expression/secretion of IL-6 but only partially attenuated IL-8 expression.	pyrazolanthrone	18-27	interleukin 6	Homo sapiens	60-64
19074641-7	2009	The JNK inhibitor SP-600125 blocked expression/secretion of IL-6 but only partially attenuated IL-8 expression.	pyrazolanthrone	18-27	C-X-C motif chemokine ligand 8	Homo sapiens	95-99
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	pyrazolanthrone	51-59	tumor necrosis factor	Homo sapiens	0-9
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	pyrazolanthrone	51-59	vascular endothelial growth factor A	Homo sapiens	18-22
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	95-98
19026990-8	2009	TNF-alpha-induced VEGF expression was inhibited by SP600125 and U0126, which are inhibitors of JNK and MEK, respectively.	pyrazolanthrone	51-59	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
18932216-5	2009	Activations of ERKs and JNKs were detected in PDGF- and FGF-2-treated NIH3T3 cells, and the telomerase activities induced by PDGF and FGF were respectively inhibited by the addition of the ERK inhibitor, PD98059, and the JNK inhibitor, SP600125.	pyrazolanthrone	236-244	mitogen-activated protein kinase 1	Mus musculus	15-19
19056926-8	2009	RESULT: Ectopic overexpression of JNK1-WT or treatment with IFN-alpha, TNF-alpha and PMA induced whereas SP600125 suppressed intrinsic and induced XAF1 expression.	pyrazolanthrone	105-113	XIAP associated factor 1	Homo sapiens	147-151
19056926-10	2009	Moreover, JNK1 stimulated whereas SP600125 suppressed XAF1 promoter activity.	pyrazolanthrone	34-42	XIAP associated factor 1	Homo sapiens	54-58
19148552-6	2009	SP600125, a specific inhibitor of SAPK/JNK, reduced the amplification by tacrolimus of the FGF-2-induced VEGF release.	pyrazolanthrone	0-8	fibroblast growth factor 2	Mus musculus	91-96
19148552-6	2009	SP600125, a specific inhibitor of SAPK/JNK, reduced the amplification by tacrolimus of the FGF-2-induced VEGF release.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Mus musculus	105-109
18932217-4	2009	SP600125, a potent JNK1 inhibitor, reduces the JNK1 activity associated with GLUT4 and the phosphorylation of two minor GLUT4 species in serum-starved 3T3-L1 adipocytes.	pyrazolanthrone	0-8	solute carrier family 2 member 4	Homo sapiens	77-82
19154444-7	2009	We found that mainly p38, p42 and p46 MAPKs were phosphorylated by SP and SB202190, PD98059 and SP600125, which are selective inhibitors of these kinases, blocked SP-induced COX-2 expression.	pyrazolanthrone	96-104	mitogen-activated protein kinase 14	Homo sapiens	21-24
19154444-7	2009	We found that mainly p38, p42 and p46 MAPKs were phosphorylated by SP and SB202190, PD98059 and SP600125, which are selective inhibitors of these kinases, blocked SP-induced COX-2 expression.	pyrazolanthrone	96-104	erythrocyte membrane protein band 4.2	Homo sapiens	26-29
19154444-7	2009	We found that mainly p38, p42 and p46 MAPKs were phosphorylated by SP and SB202190, PD98059 and SP600125, which are selective inhibitors of these kinases, blocked SP-induced COX-2 expression.	pyrazolanthrone	96-104	prostaglandin-endoperoxide synthase 2	Homo sapiens	174-179
19176398-10	2009	These changes were abrogated through c-Jun NH(2) kinase (JNK) chemical inhibitor (SP600125) or JNK2 siRNA.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	37-55
19176398-10	2009	These changes were abrogated through c-Jun NH(2) kinase (JNK) chemical inhibitor (SP600125) or JNK2 siRNA.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	57-60
18932217-4	2009	SP600125, a potent JNK1 inhibitor, reduces the JNK1 activity associated with GLUT4 and the phosphorylation of two minor GLUT4 species in serum-starved 3T3-L1 adipocytes.	pyrazolanthrone	0-8	solute carrier family 2 member 4	Homo sapiens	120-125
18932216-5	2009	Activations of ERKs and JNKs were detected in PDGF- and FGF-2-treated NIH3T3 cells, and the telomerase activities induced by PDGF and FGF were respectively inhibited by the addition of the ERK inhibitor, PD98059, and the JNK inhibitor, SP600125.	pyrazolanthrone	236-244	fibroblast growth factor 2	Mus musculus	56-61
18932216-5	2009	Activations of ERKs and JNKs were detected in PDGF- and FGF-2-treated NIH3T3 cells, and the telomerase activities induced by PDGF and FGF were respectively inhibited by the addition of the ERK inhibitor, PD98059, and the JNK inhibitor, SP600125.	pyrazolanthrone	236-244	mitogen-activated protein kinase 1	Mus musculus	15-18
18932216-5	2009	Activations of ERKs and JNKs were detected in PDGF- and FGF-2-treated NIH3T3 cells, and the telomerase activities induced by PDGF and FGF were respectively inhibited by the addition of the ERK inhibitor, PD98059, and the JNK inhibitor, SP600125.	pyrazolanthrone	236-244	mitogen-activated protein kinase 8	Mus musculus	24-27
18932217-4	2009	SP600125, a potent JNK1 inhibitor, reduces the JNK1 activity associated with GLUT4 and the phosphorylation of two minor GLUT4 species in serum-starved 3T3-L1 adipocytes.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	19-23
18932217-4	2009	SP600125, a potent JNK1 inhibitor, reduces the JNK1 activity associated with GLUT4 and the phosphorylation of two minor GLUT4 species in serum-starved 3T3-L1 adipocytes.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	47-51
18825399-9	2009	Cells treated with SP600125, an AP-1 inhibitor that inhibits JNK (c-Jun N-terminal kinase), also showed suppression of the 0.1 kbp TNF-alpha promoter/reporter construct.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	61-64
19033436-7	2009	Murine embryonic fibroblasts from ASK1 knock-out mice, alveolar epithelial cells transfected with dominant negative constructs against ASK1, and pharmacologic inhibition of JNK with SP600125 (25 microM) prevented the PM2.5-induced phosphorylation of p53 and cell death.	pyrazolanthrone	182-190	mitogen-activated protein kinase 8	Mus musculus	173-176
19214441-5	2009	In addition, the transcriptional activity of hST8Sia I induced by VPA in SK-N-BE(2)-C cells was strongly inhibited by SP600125, which is a c-Jun N-terminal kinase (JNK) inhibitor, and GO6976, which is a protein kinase C (PKC) inhibitor, as determined by RT-PCR (reverse transcription-polymerase chain reaction) and luciferase assays.	pyrazolanthrone	118-126	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1	Homo sapiens	45-54
19214441-5	2009	In addition, the transcriptional activity of hST8Sia I induced by VPA in SK-N-BE(2)-C cells was strongly inhibited by SP600125, which is a c-Jun N-terminal kinase (JNK) inhibitor, and GO6976, which is a protein kinase C (PKC) inhibitor, as determined by RT-PCR (reverse transcription-polymerase chain reaction) and luciferase assays.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	139-162
19214441-5	2009	In addition, the transcriptional activity of hST8Sia I induced by VPA in SK-N-BE(2)-C cells was strongly inhibited by SP600125, which is a c-Jun N-terminal kinase (JNK) inhibitor, and GO6976, which is a protein kinase C (PKC) inhibitor, as determined by RT-PCR (reverse transcription-polymerase chain reaction) and luciferase assays.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	164-167
19059405-0	2009	SP600125 negatively regulates the mammalian target of rapamycin via ATF4-induced Redd1 expression.	pyrazolanthrone	0-8	activating transcription factor 4	Homo sapiens	68-72
19059405-0	2009	SP600125 negatively regulates the mammalian target of rapamycin via ATF4-induced Redd1 expression.	pyrazolanthrone	0-8	DNA damage inducible transcript 4	Homo sapiens	81-86
19059405-1	2009	SP600125 (SAPK Inhibitor II) is reported to function as a reversible ATP competitive inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	98-121
19059405-1	2009	SP600125 (SAPK Inhibitor II) is reported to function as a reversible ATP competitive inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	123-126
19059405-2	2009	In the present study, we show that SP600125 induces a dose-dependent decrease in mTOR activity, as assessed by reduced phosphorylation of the downstream targets S6K1 and S6, and a significant increase in the expression of Redd1.	pyrazolanthrone	35-43	mechanistic target of rapamycin kinase	Homo sapiens	81-85
19059405-2	2009	In the present study, we show that SP600125 induces a dose-dependent decrease in mTOR activity, as assessed by reduced phosphorylation of the downstream targets S6K1 and S6, and a significant increase in the expression of Redd1.	pyrazolanthrone	35-43	ribosomal protein S6 kinase B1	Homo sapiens	161-165
19059405-2	2009	In the present study, we show that SP600125 induces a dose-dependent decrease in mTOR activity, as assessed by reduced phosphorylation of the downstream targets S6K1 and S6, and a significant increase in the expression of Redd1.	pyrazolanthrone	35-43	DNA damage inducible transcript 4	Homo sapiens	222-227
19059405-3	2009	Knockdown of Redd1 expression by siRNA resulted in a recovery of decreased S6 phosphorylation by SP600125.	pyrazolanthrone	97-105	DNA damage inducible transcript 4	Homo sapiens	13-18
19059405-4	2009	Overexpression of ATF4 upregulated the expression of Redd1, while suppression of ATF4 expression by siRNA enhanced the level of S6 phosphorylation by downregulating the SP600125-induced increase in Redd1 expression.	pyrazolanthrone	169-177	activating transcription factor 4	Homo sapiens	18-22
19059405-4	2009	Overexpression of ATF4 upregulated the expression of Redd1, while suppression of ATF4 expression by siRNA enhanced the level of S6 phosphorylation by downregulating the SP600125-induced increase in Redd1 expression.	pyrazolanthrone	169-177	DNA damage inducible transcript 4	Homo sapiens	53-58
19059405-4	2009	Overexpression of ATF4 upregulated the expression of Redd1, while suppression of ATF4 expression by siRNA enhanced the level of S6 phosphorylation by downregulating the SP600125-induced increase in Redd1 expression.	pyrazolanthrone	169-177	activating transcription factor 4	Homo sapiens	81-85
19059405-4	2009	Overexpression of ATF4 upregulated the expression of Redd1, while suppression of ATF4 expression by siRNA enhanced the level of S6 phosphorylation by downregulating the SP600125-induced increase in Redd1 expression.	pyrazolanthrone	169-177	DNA damage inducible transcript 4	Homo sapiens	198-203
19059405-5	2009	Together, these results indicate that SP600125 inhibits mTOR activity via an ATF4-induced increase in Redd1 expression.	pyrazolanthrone	38-46	mechanistic target of rapamycin kinase	Homo sapiens	56-60
19059405-5	2009	Together, these results indicate that SP600125 inhibits mTOR activity via an ATF4-induced increase in Redd1 expression.	pyrazolanthrone	38-46	activating transcription factor 4	Homo sapiens	77-81
19059405-5	2009	Together, these results indicate that SP600125 inhibits mTOR activity via an ATF4-induced increase in Redd1 expression.	pyrazolanthrone	38-46	DNA damage inducible transcript 4	Homo sapiens	102-107
18825399-9	2009	Cells treated with SP600125, an AP-1 inhibitor that inhibits JNK (c-Jun N-terminal kinase), also showed suppression of the 0.1 kbp TNF-alpha promoter/reporter construct.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	66-89
18825399-9	2009	Cells treated with SP600125, an AP-1 inhibitor that inhibits JNK (c-Jun N-terminal kinase), also showed suppression of the 0.1 kbp TNF-alpha promoter/reporter construct.	pyrazolanthrone	19-27	tumor necrosis factor	Homo sapiens	131-140
18534198-7	2009	The treatment of cells with the specific JNK inhibitor SP600125, but not the p38 MAPK inhibitor SB203580, revealed that the JNK-Bcl-2 signaling cascade is required for Lf-induced apoptosis.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	41-44
19052872-7	2009	Treatment with the JNK inhibitor SP600125 before irradiation resulted in increase in cell death whereas inhibition of p38 with SB203580 had no effect.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
19923808-3	2009	Other anti-apoptotic drugs that target the mitogen-activated protein kinase (MAPK)/c-Jun-N terminal kinase (JNK) signal cascade, such as D-JNKI-1 (AM-111) and SP600125, have produced promising results both in vitro and in laboratory animal studies, with AM-111 showing promise in preliminary clinical trials.	pyrazolanthrone	159-167	mitogen-activated protein kinase 8	Homo sapiens	108-111
18534198-7	2009	The treatment of cells with the specific JNK inhibitor SP600125, but not the p38 MAPK inhibitor SB203580, revealed that the JNK-Bcl-2 signaling cascade is required for Lf-induced apoptosis.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	124-127
18534198-7	2009	The treatment of cells with the specific JNK inhibitor SP600125, but not the p38 MAPK inhibitor SB203580, revealed that the JNK-Bcl-2 signaling cascade is required for Lf-induced apoptosis.	pyrazolanthrone	55-63	BCL2 apoptosis regulator	Homo sapiens	128-133
18534198-8	2009	When JNK activation was abolished by SP600125, no Bcl-2 phosphorylation was detected, and the Lf-treated Jurkat cells did not undergo cell death.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	5-8
21783934-4	2009	Treatment with the JNK inhibitor, SP600125, markedly suppressed TBT-induced GADD153 expression.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	19-22
19129699-6	2009	The Jun N-terminal kinase (JNK) inhibitor SP600125 suppressed MMP-2 protein (0.4-fold, p &lt; 0.05) and mRNA (0.7-fold, p &lt; 0.005) in AR CF; MMP-2 levels in NL CF were unaffected.	pyrazolanthrone	42-50	72 kDa type IV collagenase	Oryctolagus cuniculus	62-67
19129699-6	2009	The Jun N-terminal kinase (JNK) inhibitor SP600125 suppressed MMP-2 protein (0.4-fold, p &lt; 0.05) and mRNA (0.7-fold, p &lt; 0.005) in AR CF; MMP-2 levels in NL CF were unaffected.	pyrazolanthrone	42-50	72 kDa type IV collagenase	Oryctolagus cuniculus	144-149
19471112-7	2009	However, treatment of cells with SB202190 or SP600125, inhibitors of p38 MAPK and JNK respectively, did not affect HUVEC migration.	pyrazolanthrone	45-53	mitogen-activated protein kinase 14	Homo sapiens	69-72
19107874-6	2009	The inhibition of SAPK/JNK activation by SP600125 under oxidative stress almost completely blocked the translocation of Hsp60 in both young and aged cells.	pyrazolanthrone	41-49	mitogen-activated protein kinase 9	Homo sapiens	18-22
19107874-6	2009	The inhibition of SAPK/JNK activation by SP600125 under oxidative stress almost completely blocked the translocation of Hsp60 in both young and aged cells.	pyrazolanthrone	41-49	mitogen-activated protein kinase 9	Homo sapiens	23-26
19107874-6	2009	The inhibition of SAPK/JNK activation by SP600125 under oxidative stress almost completely blocked the translocation of Hsp60 in both young and aged cells.	pyrazolanthrone	41-49	heat shock protein family D (Hsp60) member 1	Homo sapiens	120-125
19118041-6	2009	Conversely, interruption of the JNK pathway by pharmacologic inhibitor (e.g., SP600125) or genetic (e.g., small interfering RNA) approaches displayed significant protection against GSE-mediated lethality in Jurkat cells.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	32-35
21783934-4	2009	Treatment with the JNK inhibitor, SP600125, markedly suppressed TBT-induced GADD153 expression.	pyrazolanthrone	34-42	DNA damage inducible transcript 3	Homo sapiens	76-83
19215802-10	2009	The c-Jun amino terminal kinase (JNK) inhibitor SP600125 was less effective in inhibiting the production of NO and proinflammatory cytokines.	pyrazolanthrone	48-56	jun proto-oncogene	Mus musculus	4-9
19218821-6	2009	Pretreatment with the ERK1/2 inhibitor PD98059 and JNK inhibitor SP600125 attenuated MCP-1 production by CysLTs.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	51-54
19127075-5	2009	Analysis of the signaling pathways responsible for RANTES production by Langerhans cells was performed by ELISA using N-acetyl-L-cysteine, SP600125, SB203580 and PD98059, which are specific inhibitors of NF-kappaB activation, JNK, p38 MAPK and ERK, respectively, and was finally confirmed by Western blot analysis.	pyrazolanthrone	139-147	chemokine (C-C motif) ligand 5	Mus musculus	51-57
19218821-6	2009	Pretreatment with the ERK1/2 inhibitor PD98059 and JNK inhibitor SP600125 attenuated MCP-1 production by CysLTs.	pyrazolanthrone	65-73	C-C motif chemokine ligand 2	Homo sapiens	85-90
19710936-6	2009	Additionally, TJ-41 stimulated phosphorylation of c-Jun NH2-terminal kinase (JNK) and pretreatment of breast cancer cells with JNK inhibitor SP600125 completely abolished TJ-41 induced apoptosis.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	50-75
19194552-9	2009	Pre-treatment of cells with ERK1/2 inhibitor, PD98059, or JNK inhibitor, SP600125 significantly inhibited aldosterone-induced ERK1/2 and JNK activity and subsequently TGF-beta(1) production, respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Rattus norvegicus	58-61
19194552-9	2009	Pre-treatment of cells with ERK1/2 inhibitor, PD98059, or JNK inhibitor, SP600125 significantly inhibited aldosterone-induced ERK1/2 and JNK activity and subsequently TGF-beta(1) production, respectively.	pyrazolanthrone	73-81	mitogen activated protein kinase 3	Rattus norvegicus	126-132
19194552-9	2009	Pre-treatment of cells with ERK1/2 inhibitor, PD98059, or JNK inhibitor, SP600125 significantly inhibited aldosterone-induced ERK1/2 and JNK activity and subsequently TGF-beta(1) production, respectively.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Rattus norvegicus	137-140
19194552-9	2009	Pre-treatment of cells with ERK1/2 inhibitor, PD98059, or JNK inhibitor, SP600125 significantly inhibited aldosterone-induced ERK1/2 and JNK activity and subsequently TGF-beta(1) production, respectively.	pyrazolanthrone	73-81	transforming growth factor, beta 1	Rattus norvegicus	167-178
19710936-6	2009	Additionally, TJ-41 stimulated phosphorylation of c-Jun NH2-terminal kinase (JNK) and pretreatment of breast cancer cells with JNK inhibitor SP600125 completely abolished TJ-41 induced apoptosis.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	77-80
19710936-6	2009	Additionally, TJ-41 stimulated phosphorylation of c-Jun NH2-terminal kinase (JNK) and pretreatment of breast cancer cells with JNK inhibitor SP600125 completely abolished TJ-41 induced apoptosis.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	127-130
19505051-4	2009	The action of inhibitors of MAP-kinases JNK (SP600125) and p38 (ML3403) in vitro under condition of oxidative stress prevents increase in the quantity of annexin-positive mononuclear leucocytes that testifies to involving JNK and p38 MAP-kinases in apoptosis deregulation oxidative mechanisms.	pyrazolanthrone	45-53	mitogen-activated protein kinase 14	Homo sapiens	230-233
18718660-5	2009	JNK inhibitors (SP600125 or JNK inhibitor VIII) significantly suppressed the apoptosis as well as caspase cleavage and cytochrome c release.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Homo sapiens	0-3
18718660-5	2009	JNK inhibitors (SP600125 or JNK inhibitor VIII) significantly suppressed the apoptosis as well as caspase cleavage and cytochrome c release.	pyrazolanthrone	16-24	cytochrome c, somatic	Homo sapiens	119-131
19147541-3	2009	The JNK1/2 inhibitor SP600125 or ERK1/2 inhibitor PD98059 prevented phosphorylation of c-Jun and Elk-1, correspondingly and partially protected PC-3 cells from FDH-induced cytotoxicity.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	4-10
19147541-3	2009	The JNK1/2 inhibitor SP600125 or ERK1/2 inhibitor PD98059 prevented phosphorylation of c-Jun and Elk-1, correspondingly and partially protected PC-3 cells from FDH-induced cytotoxicity.	pyrazolanthrone	21-29	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	87-92
19147541-3	2009	The JNK1/2 inhibitor SP600125 or ERK1/2 inhibitor PD98059 prevented phosphorylation of c-Jun and Elk-1, correspondingly and partially protected PC-3 cells from FDH-induced cytotoxicity.	pyrazolanthrone	21-29	ETS transcription factor ELK1	Homo sapiens	97-102
19147541-3	2009	The JNK1/2 inhibitor SP600125 or ERK1/2 inhibitor PD98059 prevented phosphorylation of c-Jun and Elk-1, correspondingly and partially protected PC-3 cells from FDH-induced cytotoxicity.	pyrazolanthrone	21-29	aldehyde dehydrogenase 1 family member L1	Homo sapiens	160-163
19122368-8	2009	The JNK inhibitor SP600125 was effective in significantly but only partially attenuating the TMT-induced nuclear condensation and accumulation of lactate dehydrogenase in the culture medium.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
19116455-4	2008	Luciferase reporter assays showed that DXR-induced activation of the PKCdelta promoter was enhanced by ectopic expression of JNK1, c-Jun, or ATF2, whereas it was strongly reduced by expression of dominant negative JNK1 or by treatment with the JNK inhibitor SP600125.	pyrazolanthrone	258-266	protein kinase C, delta	Mus musculus	69-77
18996088-4	2008	In addition, the CH11-induced autophagy was blocked by JNK inhibitor (SP600125), but it was not affected by caspase 8 inhibitor (Z-IETD); whereas the CH11-induced apoptosis was increased by SP600125, and it was suppressed by Z-IETD.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	55-58
19002171-5	2008	Meanwhile, gamma-tocotrienol treatment also resulted in the induction of JNK-signalling pathway and inhibition of JNK activity by a specific inhibitor (SP600125) was able to partially block the effect of gamma-tocotrienol.	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Homo sapiens	73-76
19074905-9	2008	SP600125 inhibition of JNK activity in Nf1+/- microglia results in amelioration of the increased proliferation and motility phenotypes and reduces the levels of expression of activated microglia-associated transcripts.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	23-26
19074905-9	2008	SP600125 inhibition of JNK activity in Nf1+/- microglia results in amelioration of the increased proliferation and motility phenotypes and reduces the levels of expression of activated microglia-associated transcripts.	pyrazolanthrone	0-8	neurofibromin 1	Mus musculus	39-42
19074905-10	2008	Moreover, SP600125 treatment of Nf1 optic glioma-bearing GEM results in reduced optic glioma proliferation in vivo.	pyrazolanthrone	10-18	neurofibromin 1	Mus musculus	32-35
19052522-4	2008	To investigate regulatory mechanism of TNF-alpha-induced MMP-9 expression, we pretreated cells with UO126 (MEK inhibitor), SB203580 (p38 inhibitor) and SP600125 (JNK inhibitor), respectively.	pyrazolanthrone	152-160	tumor necrosis factor	Homo sapiens	39-48
19002171-5	2008	Meanwhile, gamma-tocotrienol treatment also resulted in the induction of JNK-signalling pathway and inhibition of JNK activity by a specific inhibitor (SP600125) was able to partially block the effect of gamma-tocotrienol.	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Homo sapiens	114-117
18822271-5	2008	However, increases in phospho-c-Jun and c-Jun activity were significantly blocked by a JNK inhibitor, SP600125.	pyrazolanthrone	102-110	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-35
18842828-8	2008	Both the JNK inhibitor SP600125 and the p38 inhibitor SB203580 prevented the MGO induction of COX-2.	pyrazolanthrone	23-31	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	94-99
19002586-7	2008	Capsaicin-treatment resulted in the activation of JNK and JNK inhibitor SP600125 afforded protection against capsaicin-induced apoptosis.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	58-61
18552392-11	2008	Pretreatment of cells with SB203580, an inhibitor for p38MAP kinase, reduced the H(2)O(2)- and TGF-beta2-stimulated Hsp27 expression, whereas pretreatment with PD98059 and U0126, specific inhibitors of ERK1/2, and SP600125, a specific c-Jun N-terminal kinase inhibitor, had no effects.	pyrazolanthrone	214-222	mitogen-activated protein kinase 14	Homo sapiens	54-67
18552392-11	2008	Pretreatment of cells with SB203580, an inhibitor for p38MAP kinase, reduced the H(2)O(2)- and TGF-beta2-stimulated Hsp27 expression, whereas pretreatment with PD98059 and U0126, specific inhibitors of ERK1/2, and SP600125, a specific c-Jun N-terminal kinase inhibitor, had no effects.	pyrazolanthrone	214-222	transforming growth factor beta 2	Homo sapiens	95-104
19079986-10	2008	Early apoptosis of MCF-7 cells was induced by SP600125 after knocking down PTEN, with an early apoptosis rate of (32.4+/-2.4)%; MCF-7 cells were arrested at G1 phase.	pyrazolanthrone	46-54	phosphatase and tensin homolog	Homo sapiens	75-79
19111119-1	2008	OBJECTIVE: To investigate the effect and mechanism of JNK mitogen-activated protein kinases (JNK MAPKs) inhibitor SP 600125 on hemodynamics after ischemia/reperfusion (I/R) injury to heart in anesthetized rats.	pyrazolanthrone	114-123	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
19111119-1	2008	OBJECTIVE: To investigate the effect and mechanism of JNK mitogen-activated protein kinases (JNK MAPKs) inhibitor SP 600125 on hemodynamics after ischemia/reperfusion (I/R) injury to heart in anesthetized rats.	pyrazolanthrone	114-123	mitogen-activated protein kinase 8	Rattus norvegicus	93-96
18822271-5	2008	However, increases in phospho-c-Jun and c-Jun activity were significantly blocked by a JNK inhibitor, SP600125.	pyrazolanthrone	102-110	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	40-45
18822271-5	2008	However, increases in phospho-c-Jun and c-Jun activity were significantly blocked by a JNK inhibitor, SP600125.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	87-90
18801734-9	2008	ERK inhibitor PD098059 or ERK shRNA abolished the nuclear c-Ets-2 DNA binding activity and hFGL2 induction in response to HBc, whereas JNK inhibitor SP600125 or JNK shRNA abolished the nuclear c-Ets-2 DNA binding activity and hFGL2 induction in response to HBx.	pyrazolanthrone	149-157	mitogen-activated protein kinase 8	Homo sapiens	135-138
18657106-7	2008	Mitogen-activated protein kinase inhibitors, especially the JNK inhibitor SP600125, reduced secretion of SP-D, but not production, in the presence of P. aeruginosa.	pyrazolanthrone	74-82	surfactant protein D	Homo sapiens	105-109
18600231-8	2008	Moreover, treatment of MVP knocked-down senescent HDFs with SP600125, a specific c-Jun NH(2)-terminal kinase (JNK) inhibitor, restored the level of Bcl-2 protein.	pyrazolanthrone	60-68	major vault protein	Homo sapiens	23-26
18600231-8	2008	Moreover, treatment of MVP knocked-down senescent HDFs with SP600125, a specific c-Jun NH(2)-terminal kinase (JNK) inhibitor, restored the level of Bcl-2 protein.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	81-108
18713649-8	2008	Importantly, inhibition of JNK by SP600125 or overexpression of paxillin-S178A mutant prevented the association of FAK with paxillin.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	27-30
18981152-6	2008	Examination of the specificity of TAT-JIP revealed that although the peptide was more selective than the pharmacological inhibitor, SP600125, it also inhibited cyclin-dependent kinase 2, p70 ribosomal protein S6 kinase, and serum and glucocorticoid-regulated kinase activity.	pyrazolanthrone	132-140	SMAD family member 4	Homo sapiens	38-41
18600231-8	2008	Moreover, treatment of MVP knocked-down senescent HDFs with SP600125, a specific c-Jun NH(2)-terminal kinase (JNK) inhibitor, restored the level of Bcl-2 protein.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	110-113
18600231-8	2008	Moreover, treatment of MVP knocked-down senescent HDFs with SP600125, a specific c-Jun NH(2)-terminal kinase (JNK) inhibitor, restored the level of Bcl-2 protein.	pyrazolanthrone	60-68	BCL2 apoptosis regulator	Homo sapiens	148-153
18713649-5	2008	Specific inhibition of JNK activation by inhibitor SP600125 or overexpression of a dominant-negative JNK mutant not only blocked EGF-induced cell migration, but also eliminated tyrosine phosphorylation of paxillin on Tyr 31 and Tyr 118.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	23-26
18596194-9	2008	Similarly COX-2 expression in HIMECs was significantly inhibited by Jun N-terminal kinase (JNK; SP600125) and p38 mitogen-activated protein kinase (MAPK; SB203580) inhibitors and was reduced by p44/42 MAPK inhibitor (PD098059).	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	68-89
18786529-9	2008	Furthermore, overexpression of mutant claudin-4 protein S195A, which was not phosphorylated by aPKC, perturbed the TJ formation mediated by SP600125.	pyrazolanthrone	140-148	claudin 4	Homo sapiens	38-47
18786529-3	2008	In HaCaT, a human epidermal keratinocyte cell line, TJ were newly formed when cells were cultured in the presence of SP600125, a JNK inhibitor.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Homo sapiens	129-132
18718527-7	2008	The response of these cells to Bz-423 is critically dependent on both superoxide and JNK activation as antioxidants and the JNK inhibitor SP600125 prevents Bax translocation, cytochrome c release, and cell death.	pyrazolanthrone	138-146	mitogen-activated protein kinase 8	Mus musculus	124-127
18718527-7	2008	The response of these cells to Bz-423 is critically dependent on both superoxide and JNK activation as antioxidants and the JNK inhibitor SP600125 prevents Bax translocation, cytochrome c release, and cell death.	pyrazolanthrone	138-146	BCL2-associated X protein	Mus musculus	156-159
18596194-9	2008	Similarly COX-2 expression in HIMECs was significantly inhibited by Jun N-terminal kinase (JNK; SP600125) and p38 mitogen-activated protein kinase (MAPK; SB203580) inhibitors and was reduced by p44/42 MAPK inhibitor (PD098059).	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	91-94
18718914-5	2008	JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) pretreatment attenuated 15d-PGJ(2)-mediated apoptosis and suppressed the p21(Waf1) and Bax expressions without affecting p53 protein accumulation.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	0-3
18941206-10	2008	SP600125 blocked fasL induction and apoptosis but did not affect ROS generation after B7-H1 stimulation.	pyrazolanthrone	0-8	Fas ligand (TNF superfamily, member 6)	Mus musculus	17-21
18521936-7	2008	Pretreatment with JNK inhibitor (SP600125) of SH-SY5Y cells inhibited JNK phosphorylation and interaction between p-JNK and 14-3-3 resulting from ethanol.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	18-21
18521936-7	2008	Pretreatment with JNK inhibitor (SP600125) of SH-SY5Y cells inhibited JNK phosphorylation and interaction between p-JNK and 14-3-3 resulting from ethanol.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	70-73
18521936-7	2008	Pretreatment with JNK inhibitor (SP600125) of SH-SY5Y cells inhibited JNK phosphorylation and interaction between p-JNK and 14-3-3 resulting from ethanol.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	70-73
18718914-6	2008	Pretreatment with SP600125 partially prevented the phosphorylation of p53 at serines 33 and 392 induced by 15d-PGJ(2).	pyrazolanthrone	18-26	tumor protein p53	Homo sapiens	70-73
18706445-5	2008	In addition, PD98059 (an ERK1/2 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated IL-18-induced ULBP2 expression in a dose-dependent manner.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	64-67
18718914-5	2008	JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) pretreatment attenuated 15d-PGJ(2)-mediated apoptosis and suppressed the p21(Waf1) and Bax expressions without affecting p53 protein accumulation.	pyrazolanthrone	15-23	cyclin dependent kinase inhibitor 1A	Homo sapiens	131-134
18706445-5	2008	In addition, PD98059 (an ERK1/2 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated IL-18-induced ULBP2 expression in a dose-dependent manner.	pyrazolanthrone	52-60	interleukin 18	Homo sapiens	90-95
18718914-5	2008	JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) pretreatment attenuated 15d-PGJ(2)-mediated apoptosis and suppressed the p21(Waf1) and Bax expressions without affecting p53 protein accumulation.	pyrazolanthrone	15-23	cyclin dependent kinase inhibitor 1A	Homo sapiens	135-139
18706445-5	2008	In addition, PD98059 (an ERK1/2 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated IL-18-induced ULBP2 expression in a dose-dependent manner.	pyrazolanthrone	52-60	UL16 binding protein 2	Homo sapiens	104-109
18718914-5	2008	JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) pretreatment attenuated 15d-PGJ(2)-mediated apoptosis and suppressed the p21(Waf1) and Bax expressions without affecting p53 protein accumulation.	pyrazolanthrone	15-23	BCL2 associated X, apoptosis regulator	Homo sapiens	145-148
18847500-11	2008	SAPK/JNKs inhibitor SP600125 inhibited gelatinase production and expression.	pyrazolanthrone	20-28	mitogen-activated protein kinase 9	Homo sapiens	0-4
18768402-7	2008	A 4-week ICV infusion of the p44/42 MAPK inhibitor PD98059 or the c-Jun N-terminal kinase inhibitor SP600125 significantly decreased AT(1)-R protein and AT(1)-R immunoreactivity in the paraventricular nucleus and subfornical organ, but the p38 MAPK inhibitor SB203580 did not.	pyrazolanthrone	100-108	angiotensin II receptor, type 1a	Rattus norvegicus	133-140
18701631-6	2008	The increase of V2R promoter activity by hypertonicity was significantly inhibited by a JNK inhibitor (SP600125) and PKA inhibitor (H89).	pyrazolanthrone	103-111	arginine vasopressin receptor 2	Rattus norvegicus	16-19
18701631-6	2008	The increase of V2R promoter activity by hypertonicity was significantly inhibited by a JNK inhibitor (SP600125) and PKA inhibitor (H89).	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Rattus norvegicus	88-91
18703151-10	2008	A chemical inhibitor of JNK, SP600125, prevented the decreased expression of both cyclin D1 and CDK4, whereas SB203580, a chemical inhibitor of p38, did not.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	24-27
18703151-10	2008	A chemical inhibitor of JNK, SP600125, prevented the decreased expression of both cyclin D1 and CDK4, whereas SB203580, a chemical inhibitor of p38, did not.	pyrazolanthrone	29-37	cyclin D1	Homo sapiens	82-91
18703151-10	2008	A chemical inhibitor of JNK, SP600125, prevented the decreased expression of both cyclin D1 and CDK4, whereas SB203580, a chemical inhibitor of p38, did not.	pyrazolanthrone	29-37	cyclin dependent kinase 4	Homo sapiens	96-100
18515471-9	2008	Pre-incubation of cells with 1 micromol l(-1) SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), restored the response of Luc activity to 5 micromol l(-1) DBcAMP under hypotonic conditions.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Mus musculus	72-95
18515471-9	2008	Pre-incubation of cells with 1 micromol l(-1) SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), restored the response of Luc activity to 5 micromol l(-1) DBcAMP under hypotonic conditions.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Mus musculus	97-100
18689604-13	2008	Reduction of c-Fos and c-Jun nuclear translocation by SP-600125 attenuated the CSE-induced expression of HO-1.	pyrazolanthrone	54-63	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	13-18
18689604-13	2008	Reduction of c-Fos and c-Jun nuclear translocation by SP-600125 attenuated the CSE-induced expression of HO-1.	pyrazolanthrone	54-63	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	23-28
18689604-13	2008	Reduction of c-Fos and c-Jun nuclear translocation by SP-600125 attenuated the CSE-induced expression of HO-1.	pyrazolanthrone	54-63	heme oxygenase 1	Homo sapiens	105-109
18641674-10	2008	Furthermore, YC-1 markedly induced phosphorylation of JNK and a JNK inhibitor, SP600125, and siRNA JNK1/2 significantly reversed YC-1-induced cytotoxicity and protein expression.	pyrazolanthrone	79-87	RNA binding motif single stranded interacting protein 1	Homo sapiens	13-17
18641674-10	2008	Furthermore, YC-1 markedly induced phosphorylation of JNK and a JNK inhibitor, SP600125, and siRNA JNK1/2 significantly reversed YC-1-induced cytotoxicity and protein expression.	pyrazolanthrone	79-87	RNA binding motif single stranded interacting protein 1	Homo sapiens	129-133
18703135-9	2008	Pretreatment with inhibitors of JNK (SP600125) and Erk1/2 (U0126) partially blocked Cd-induced cleavage of caspase-3 and prevented cell death.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	32-35
18703135-9	2008	Pretreatment with inhibitors of JNK (SP600125) and Erk1/2 (U0126) partially blocked Cd-induced cleavage of caspase-3 and prevented cell death.	pyrazolanthrone	37-45	caspase 3	Homo sapiens	107-116
18506470-8	2008	Upon treatment with JNK inhibitor SP600125, we observed a significantly decreased interleukin (IL)-8 level (P &lt; 0.05) in the presence and absence of E(2).	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	20-23
18506470-10	2008	Inhibition of IL-8 expression by SP600125 suggests that JNK is involved in regulation of proinflammatory mediators of endometrium.	pyrazolanthrone	33-41	C-X-C motif chemokine ligand 8	Homo sapiens	14-18
18506470-10	2008	Inhibition of IL-8 expression by SP600125 suggests that JNK is involved in regulation of proinflammatory mediators of endometrium.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	56-59
18768402-7	2008	A 4-week ICV infusion of the p44/42 MAPK inhibitor PD98059 or the c-Jun N-terminal kinase inhibitor SP600125 significantly decreased AT(1)-R protein and AT(1)-R immunoreactivity in the paraventricular nucleus and subfornical organ, but the p38 MAPK inhibitor SB203580 did not.	pyrazolanthrone	100-108	angiotensin II receptor, type 1a	Rattus norvegicus	153-160
18768402-7	2008	A 4-week ICV infusion of the p44/42 MAPK inhibitor PD98059 or the c-Jun N-terminal kinase inhibitor SP600125 significantly decreased AT(1)-R protein and AT(1)-R immunoreactivity in the paraventricular nucleus and subfornical organ, but the p38 MAPK inhibitor SB203580 did not.	pyrazolanthrone	100-108	mitogen activated protein kinase 14	Rattus norvegicus	240-243
18813780-11	2008	Incubation with either the irreversible pan-caspase inhibitors Z-VAD-FMK, or SP600125, a selective inhibitor of JNK, or pifithrin alpha, a potent p53 inhibitor, significantly inhibited the effects induced by PTX.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	112-115
18768402-9	2008	In untreated HF rats 4 weeks after coronary ligation, a 3-hour ICV infusion of PD98059, SP600125, or losartan reduced AT(1)-R mRNA in paraventricular nucleus and subfornical organ.	pyrazolanthrone	88-96	angiotensin II receptor, type 1a	Rattus norvegicus	118-125
18813780-11	2008	Incubation with either the irreversible pan-caspase inhibitors Z-VAD-FMK, or SP600125, a selective inhibitor of JNK, or pifithrin alpha, a potent p53 inhibitor, significantly inhibited the effects induced by PTX.	pyrazolanthrone	77-85	tumor protein p53	Homo sapiens	146-149
18800014-4	2008	Most of these effects can be attenuated by the JNK inhibitor SP600125.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	47-50
18412143-8	2008	The As2O3-induced Bcl-2 phosphorylation was attenuated largely by JNK inhibition using SP600125 or si-JNK and to some extent by p38 MAPK inhibition with PD169316 or si-p38 MAPK.	pyrazolanthrone	87-95	BCL2 apoptosis regulator	Homo sapiens	18-23
18412143-8	2008	The As2O3-induced Bcl-2 phosphorylation was attenuated largely by JNK inhibition using SP600125 or si-JNK and to some extent by p38 MAPK inhibition with PD169316 or si-p38 MAPK.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	66-69
18974961-12	2008	Pretreatment with PD98059 (ERK inhibitor), SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) decreased the IL-8 production induced by H(2)O(2).	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	82-85
18974961-12	2008	Pretreatment with PD98059 (ERK inhibitor), SB203580 (p38 inhibitor), or SP600125 (JNK inhibitor) decreased the IL-8 production induced by H(2)O(2).	pyrazolanthrone	72-80	C-X-C motif chemokine ligand 8	Homo sapiens	111-115
18800014-5	2008	Furthermore, infusion of lactacystin in rats in vivo also leads to phosphorylation of JNK before nigral neuron loss; chronic administration of SP600125 also blocks this loss.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Rattus norvegicus	86-89
18922980-6	2008	Induction of CTGF by S1P was sensitive to ROCK inhibitor Y-27632 and c-Jun NH2-terminal kinase inhibitor SP600125, suggesting the requirement of RhoA/ROCK and c-Jun NH2-terminal kinase pathways for S1P-induced CTGF expression.	pyrazolanthrone	105-113	cellular communication network factor 2	Homo sapiens	13-17
18667537-4	2008	Blocking of JNK activity with a potent JNK inhibitor (SP600125) reduces TNF-alpha-triggered phosphorylation of PS1 and NCT.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	12-15
18667537-4	2008	Blocking of JNK activity with a potent JNK inhibitor (SP600125) reduces TNF-alpha-triggered phosphorylation of PS1 and NCT.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	39-42
18667537-4	2008	Blocking of JNK activity with a potent JNK inhibitor (SP600125) reduces TNF-alpha-triggered phosphorylation of PS1 and NCT.	pyrazolanthrone	54-62	tumor necrosis factor	Homo sapiens	72-81
18667537-4	2008	Blocking of JNK activity with a potent JNK inhibitor (SP600125) reduces TNF-alpha-triggered phosphorylation of PS1 and NCT.	pyrazolanthrone	54-62	presenilin 1	Homo sapiens	111-114
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	14-17
18813807-10	2008	SP600125, a JNK inhibitor, also blocked PMA-induced phosphorylation of paxillin and aggregation of phosphorylated paxillin (Ser178) in focal complexes.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	pyrazolanthrone	28-36	DNA damage inducible transcript 3	Homo sapiens	47-51
18561312-8	2008	Interestingly, alterations in cell morphology caused by Cucurbitacin B (10(-7) M) were blocked by the JNK inhibitor SP600125.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	102-105
18794131-8	2008	Curcumin was able to induce c-Jun NH(2)-kinase (JNK) phosphorylation, whereas the JNK inhibitor (SP-600125) could attenuate curcumin-induced JunD and HLJ1 expression.	pyrazolanthrone	97-106	mitogen-activated protein kinase 8	Homo sapiens	82-85
18794131-8	2008	Curcumin was able to induce c-Jun NH(2)-kinase (JNK) phosphorylation, whereas the JNK inhibitor (SP-600125) could attenuate curcumin-induced JunD and HLJ1 expression.	pyrazolanthrone	97-106	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	141-145
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	87-90
18794136-8	2008	Moreover, the JNK inhibitor SP600125 abrogated CHOP induction by CDDO-Me, suggesting a JNK-dependent CHOP up-regulation by CDDO-Me as well.	pyrazolanthrone	28-36	DNA damage inducible transcript 3	Homo sapiens	101-105
18794131-8	2008	Curcumin was able to induce c-Jun NH(2)-kinase (JNK) phosphorylation, whereas the JNK inhibitor (SP-600125) could attenuate curcumin-induced JunD and HLJ1 expression.	pyrazolanthrone	97-106	DnaJ heat shock protein family (Hsp40) member B4	Homo sapiens	150-154
18778461-9	2008	This increase was antagonized by; (1) PKC inhibitors (10 microM bisindolylmaleimide I and 10 microM Ro-32-0432), and (2) inhibitors of the p38, extracellular signal related kinases 1 and 2 (ERK1/2) and C-jun terminal kinase (JNK) MAPK pathways (10 microM SB203580, 10 microM PD98059 and 10 microM SP600125, respectively).	pyrazolanthrone	297-305	mitogen-activated protein kinase 1	Homo sapiens	139-142
18778461-9	2008	This increase was antagonized by; (1) PKC inhibitors (10 microM bisindolylmaleimide I and 10 microM Ro-32-0432), and (2) inhibitors of the p38, extracellular signal related kinases 1 and 2 (ERK1/2) and C-jun terminal kinase (JNK) MAPK pathways (10 microM SB203580, 10 microM PD98059 and 10 microM SP600125, respectively).	pyrazolanthrone	297-305	mitogen-activated protein kinase 3	Homo sapiens	144-188
18281123-5	2008	Blockage of JNK by pretreatment with SP600125, a pharmacological inhibitor, or transfection with dominant-negative (DN) JNK1 vectors abrogated sulindac/ATO-induced apoptosis, as evident from the disruption of caspase activation.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	12-15
18758067-6	2008	The enhancement of NGF gene expression by H. erinaceus extracts was inhibited by the c-jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	125-133	nerve growth factor	Homo sapiens	19-22
18497756-2	2008	Our experiments with the selective JNK inhibitor SP600125 reveal that calphostin C is capable of causing JNK activation and JNK-dependent apoptosis in both cell lines.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	35-38
18177422-7	2008	Ectopic wnt7b overexpression was sufficient to rescue neurite outgrowth in NGF-treated p53-silenced PC12 cells, which could be blocked by c-Jun N-terminal kinase (JNK) inhibition with SP600125 and did not involve beta-catenin nuclear translocation.	pyrazolanthrone	184-192	Wnt family member 7B	Rattus norvegicus	8-13
18177422-7	2008	Ectopic wnt7b overexpression was sufficient to rescue neurite outgrowth in NGF-treated p53-silenced PC12 cells, which could be blocked by c-Jun N-terminal kinase (JNK) inhibition with SP600125 and did not involve beta-catenin nuclear translocation.	pyrazolanthrone	184-192	tumor protein p53	Rattus norvegicus	87-90
18177422-7	2008	Ectopic wnt7b overexpression was sufficient to rescue neurite outgrowth in NGF-treated p53-silenced PC12 cells, which could be blocked by c-Jun N-terminal kinase (JNK) inhibition with SP600125 and did not involve beta-catenin nuclear translocation.	pyrazolanthrone	184-192	mitogen-activated protein kinase 8	Rattus norvegicus	138-161
18177422-7	2008	Ectopic wnt7b overexpression was sufficient to rescue neurite outgrowth in NGF-treated p53-silenced PC12 cells, which could be blocked by c-Jun N-terminal kinase (JNK) inhibition with SP600125 and did not involve beta-catenin nuclear translocation.	pyrazolanthrone	184-192	mitogen-activated protein kinase 8	Rattus norvegicus	163-166
18713996-12	2008	These results were mimicked by the JNK inhibitor SP600125, indicating that JNK can directly phosphorylate IRF3.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	35-38
18713996-12	2008	These results were mimicked by the JNK inhibitor SP600125, indicating that JNK can directly phosphorylate IRF3.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	75-78
18713996-12	2008	These results were mimicked by the JNK inhibitor SP600125, indicating that JNK can directly phosphorylate IRF3.	pyrazolanthrone	49-57	interferon regulatory factor 3	Homo sapiens	106-110
18281123-9	2008	Treatment with SP600125 and transfection with DN-JNK blocked Bcl-xL phosphorylation, suggesting that JNK plays an important role in sulindac/ATO-induced Bcl-xL phosphorylation.	pyrazolanthrone	15-23	BCL2 like 1	Homo sapiens	61-67
18281123-9	2008	Treatment with SP600125 and transfection with DN-JNK blocked Bcl-xL phosphorylation, suggesting that JNK plays an important role in sulindac/ATO-induced Bcl-xL phosphorylation.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	101-104
18281123-9	2008	Treatment with SP600125 and transfection with DN-JNK blocked Bcl-xL phosphorylation, suggesting that JNK plays an important role in sulindac/ATO-induced Bcl-xL phosphorylation.	pyrazolanthrone	15-23	BCL2 like 1	Homo sapiens	153-159
18606486-7	2008	SP600125 (a selective JNK inhibitor) partially prevented cells from apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	22-25
18567920-9	2008	CypA-induced nuclear factor kappaB (NF-kappaB) activity for MMP-9 transcription were strongly blocked by extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) inhibitors (U0126 and SP600125, respectively), but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203580).	pyrazolanthrone	206-214	peptidylprolyl isomerase A	Homo sapiens	0-4
18567920-9	2008	CypA-induced nuclear factor kappaB (NF-kappaB) activity for MMP-9 transcription were strongly blocked by extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) inhibitors (U0126 and SP600125, respectively), but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203580).	pyrazolanthrone	206-214	matrix metallopeptidase 9	Homo sapiens	60-65
18567920-9	2008	CypA-induced nuclear factor kappaB (NF-kappaB) activity for MMP-9 transcription were strongly blocked by extracellular signal-regulated kinase (ERK), c-Jun amino terminal kinase (JNK) inhibitors (U0126 and SP600125, respectively), but not by p38 mitogen-activated protein kinase (MAPK) inhibitors (SB203580).	pyrazolanthrone	206-214	mitogen-activated protein kinase 1	Homo sapiens	144-147
18695917-7	2008	Moreover, pretreatment of SP600125, JNK specific inhibitor, clearly attenuated Bcl-2 phosphorylation, but did not affect Bax translocation to the mitochondria.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	36-39
18695917-7	2008	Moreover, pretreatment of SP600125, JNK specific inhibitor, clearly attenuated Bcl-2 phosphorylation, but did not affect Bax translocation to the mitochondria.	pyrazolanthrone	26-34	BCL2 apoptosis regulator	Homo sapiens	79-84
18579129-7	2008	On the other hand, LPS-induced c-Jun phosphorylation was attenuated in the presence of SP600125.	pyrazolanthrone	87-95	jun proto-oncogene	Mus musculus	31-36
18636161-4	2008	Bcl-xL deamidation and caspase-3 activation were also suppressed by co-treatment with SP600125, a specific inhibitor of JNK activity.	pyrazolanthrone	86-94	BCL2 like 1	Homo sapiens	0-6
18550701-7	2008	Treatment of cells with mitogen-activated protein/ERK kinase (MEK) inhibitor PD98059 or JNK inhibitor SP600125 significantly inhibited EPO-enhanced proliferation and also increased the fraction of cells in G0/G1 phase.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Rattus norvegicus	88-91
18550701-7	2008	Treatment of cells with mitogen-activated protein/ERK kinase (MEK) inhibitor PD98059 or JNK inhibitor SP600125 significantly inhibited EPO-enhanced proliferation and also increased the fraction of cells in G0/G1 phase.	pyrazolanthrone	102-110	erythropoietin	Rattus norvegicus	135-138
18458532-6	2008	Suppression of JNK activation with the specific inhibitor, SP600125 also prevented FNQ-mediated cell death.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	15-18
18445604-8	2008	Inhibition of JNK by SP600125 blocked the siRNA-induced increased expression of PAI-1 and partially recovered the impaired angiogenic potential.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
18445604-8	2008	Inhibition of JNK by SP600125 blocked the siRNA-induced increased expression of PAI-1 and partially recovered the impaired angiogenic potential.	pyrazolanthrone	21-29	serpin family E member 1	Homo sapiens	80-85
18636161-4	2008	Bcl-xL deamidation and caspase-3 activation were also suppressed by co-treatment with SP600125, a specific inhibitor of JNK activity.	pyrazolanthrone	86-94	caspase 3	Homo sapiens	23-32
18636161-4	2008	Bcl-xL deamidation and caspase-3 activation were also suppressed by co-treatment with SP600125, a specific inhibitor of JNK activity.	pyrazolanthrone	86-94	mitogen-activated protein kinase 8	Homo sapiens	120-123
18782186-8	2008	Additionally, administration of SP600125, an inhibitor of JNK, attenuated mitochondrial-nuclear translocation of AIF.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	58-61
18404675-10	2008	It appears that apoptotic cell death was protected by the JNK inhibitor SP600125.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	58-61
18480048-0	2008	Crystal structure of the catalytic domain of the mitotic checkpoint kinase Mps1 in complex with SP600125.	pyrazolanthrone	96-104	TTK protein kinase	Homo sapiens	75-79
18480048-3	2008	To gain insights into the molecular mechanism of Mps1 inhibition by small molecules, we determined the x-ray structure of Mps1, both alone and in complex with the ATP-competitive inhibitor SP600125.	pyrazolanthrone	189-197	TTK protein kinase	Homo sapiens	49-53
18480048-3	2008	To gain insights into the molecular mechanism of Mps1 inhibition by small molecules, we determined the x-ray structure of Mps1, both alone and in complex with the ATP-competitive inhibitor SP600125.	pyrazolanthrone	189-197	TTK protein kinase	Homo sapiens	122-126
19967054-5	2008	In addition, JNK inhibitor SP-600125 significantly blocked the Adr-induced cell death, but it did not affect the cell death induced by MNNG.	pyrazolanthrone	27-36	mitogen-activated protein kinase 8	Homo sapiens	13-16
18330891-6	2008	The JNK pathway is most likely involved in prothrombin-induced hepatocyte apoptosis, because pre-treatment of hepatocytes with JNK kinase inhibitor II (SP600125) antagonized these prothrombin actions.	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
18330891-6	2008	The JNK pathway is most likely involved in prothrombin-induced hepatocyte apoptosis, because pre-treatment of hepatocytes with JNK kinase inhibitor II (SP600125) antagonized these prothrombin actions.	pyrazolanthrone	152-160	coagulation factor II	Rattus norvegicus	43-54
18330891-6	2008	The JNK pathway is most likely involved in prothrombin-induced hepatocyte apoptosis, because pre-treatment of hepatocytes with JNK kinase inhibitor II (SP600125) antagonized these prothrombin actions.	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Rattus norvegicus	127-130
18330891-6	2008	The JNK pathway is most likely involved in prothrombin-induced hepatocyte apoptosis, because pre-treatment of hepatocytes with JNK kinase inhibitor II (SP600125) antagonized these prothrombin actions.	pyrazolanthrone	152-160	coagulation factor II	Rattus norvegicus	180-191
18373739-5	2008	For the evaluation of the role of MAPKs, PD98059, SP600125 and SB203580 were used as MAPKs inhibitors for ERK1/2, JNK1/2 and p38 MAPK, respectively.	pyrazolanthrone	50-58	mitogen-activated protein kinase 1	Homo sapiens	125-128
18550202-7	2008	SP-600125, a JNK inhibitor, prevented LM and PL potentiation of bile acid apoptosis.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	13-16
18487435-5	2008	This was associated with the increased phosphorylation of c-Jun and activation of an activator protein (AP)-1 reporter construct, which were inhibited by the JNK inhibitor SP600125 (3 microM).	pyrazolanthrone	172-180	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-63
18538428-6	2008	Moreover, Drosophila fed with (1-200 microM) SP600125, a specific inhibitor of the stress responsive Jun-N-terminal kinase (JNK) signaling, and 20 mM PQ increased survival percentage and movement function (i.e., climbing capability) when compared to flies only treated with PQ.	pyrazolanthrone	45-53	basket	Drosophila melanogaster	101-122
18538428-6	2008	Moreover, Drosophila fed with (1-200 microM) SP600125, a specific inhibitor of the stress responsive Jun-N-terminal kinase (JNK) signaling, and 20 mM PQ increased survival percentage and movement function (i.e., climbing capability) when compared to flies only treated with PQ.	pyrazolanthrone	45-53	basket	Drosophila melanogaster	124-127
18541008-3	2008	In this report, we provide evidence that, in human melanoma cells, JNK inhibition with the small molecule inhibitor SP600125 induces either predominantly a G2/M arrest or apoptosis depending on the cell line.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	67-70
18541008-5	2008	JNK inhibition with the small molecule inhibitor SP600125 slowed growth of all cell lines, although the effect was markedly greater in cells exhibiting high phospho- (P-)JNK1 levels.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	0-3
18541008-5	2008	JNK inhibition with the small molecule inhibitor SP600125 slowed growth of all cell lines, although the effect was markedly greater in cells exhibiting high phospho- (P-)JNK1 levels.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	170-174
18588889-5	2008	PSC833 induced the phosphorylation of c-Jun NH2-terminal kinase (JNK) and c-Jun, while the JNK inhibitor SP600125 inhibited this effect.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	91-94
18710638-9	2008	Human monocytes COX-2 mRNA, by RT-PCR, and protein expression, by Western blot analysis, were inhibited when incubated with PD98059, SP600125 and SB203580 (P &lt; 0.05).	pyrazolanthrone	133-141	prostaglandin-endoperoxide synthase 2	Homo sapiens	16-21
18541274-4	2008	Moreover, partial inhibition of AP-1 activity by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, resulted in marked reduction of IFN-gamma transcription.	pyrazolanthrone	49-57	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	32-36
18541274-4	2008	Moreover, partial inhibition of AP-1 activity by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, resulted in marked reduction of IFN-gamma transcription.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	61-100
18541274-4	2008	Moreover, partial inhibition of AP-1 activity by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, resulted in marked reduction of IFN-gamma transcription.	pyrazolanthrone	49-57	interferon gamma	Homo sapiens	134-143
18571718-10	2008	Inhibitors of MEK-ERK2/1 (PD98059), JNK1/2 (SP600125) and PI3K (wortmannin), but not p38MAPK (SB203580) and SRC (PP2), decreased the FGF2-increased eNOS protein expression.	pyrazolanthrone	44-52	midkine	Mus musculus	14-17
18571718-10	2008	Inhibitors of MEK-ERK2/1 (PD98059), JNK1/2 (SP600125) and PI3K (wortmannin), but not p38MAPK (SB203580) and SRC (PP2), decreased the FGF2-increased eNOS protein expression.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Mus musculus	36-42
18487435-5	2008	This was associated with the increased phosphorylation of c-Jun and activation of an activator protein (AP)-1 reporter construct, which were inhibited by the JNK inhibitor SP600125 (3 microM).	pyrazolanthrone	172-180	mitogen-activated protein kinase 8	Homo sapiens	158-161
18487435-6	2008	Rap1CA increased the activity of an alpha(2C)-AR promoter-reporter construct, which was inhibited by SP600125 (3 microM) or by the mutation of an AP-1 binding site in the alpha(2C)-AR promoter.	pyrazolanthrone	101-109	RAP1A, member of RAS oncogene family	Homo sapiens	0-6
18500555-6	2008	Furthermore, SP600125 (specific inhibitor of JNK) could inhibit the Cyt c release from mitochondria.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	45-48
18500555-6	2008	Furthermore, SP600125 (specific inhibitor of JNK) could inhibit the Cyt c release from mitochondria.	pyrazolanthrone	13-21	cytochrome c, somatic	Homo sapiens	68-73
18403484-6	2008	By applying the kinase inhibitors PD98059 (MAPK kinase-1) and SP600125 (JNK), ERK and JNK were shown to be crucial for the induction of MKP-1.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	72-75
18455449-5	2008	Using SP600125, inhibition of JNK attenuated sprout growth in 3D capillary sprout cultures.	pyrazolanthrone	6-14	mitogen-activated protein kinase 8	Homo sapiens	30-33
18455449-8	2008	Matrix metalloproteinase-2 (MMP-2) production, and activity also, was reduced in sprout cultures treated with SP600125.	pyrazolanthrone	110-118	matrix metallopeptidase 2	Homo sapiens	0-26
18455449-8	2008	Matrix metalloproteinase-2 (MMP-2) production, and activity also, was reduced in sprout cultures treated with SP600125.	pyrazolanthrone	110-118	matrix metallopeptidase 2	Homo sapiens	28-33
18594007-5	2008	Specific JNK inhibitor SP600125 was cotreated to reverse moscatilin-induced apoptosis.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	9-12
18594007-10	2008	SP600125 significantly inhibited the activation of caspase-9 and caspase-3 and the subsequent moscatilin-induced apoptosis.	pyrazolanthrone	0-8	caspase 9	Homo sapiens	51-60
18594007-10	2008	SP600125 significantly inhibited the activation of caspase-9 and caspase-3 and the subsequent moscatilin-induced apoptosis.	pyrazolanthrone	0-8	caspase 3	Homo sapiens	65-74
18403484-6	2008	By applying the kinase inhibitors PD98059 (MAPK kinase-1) and SP600125 (JNK), ERK and JNK were shown to be crucial for the induction of MKP-1.	pyrazolanthrone	62-70	dual specificity phosphatase 1	Homo sapiens	136-141
18491380-8	2008	The ERK kinase inhibitor PD98059 and the JNK inhibitor SP600125 potently inhibited maleic acid-induced HGF production, while the p38 inhibitor SB203580 did not significantly inhibit the production.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	41-44
18545934-6	2008	The inhibition of [3H]-thymidine incorporation by IL-1beta was partially reversed with SB203580, SP600125 or curcumin, but not PDTC.	pyrazolanthrone	97-105	interleukin 1 beta	Bos taurus	50-58
18202854-9	2008	Treatment of PA-1 cells with small interfering RNA (siRNA) directed against TR3, and with cycloheximide or SP600125 (an inhibitor of c-jun N-terminal kinase; JNK), separately, inhibited the VK(2)-induced synthesis of TR3 and apoptosis.	pyrazolanthrone	107-115	nuclear receptor subfamily 4 group A member 1	Homo sapiens	217-220
18491380-8	2008	The ERK kinase inhibitor PD98059 and the JNK inhibitor SP600125 potently inhibited maleic acid-induced HGF production, while the p38 inhibitor SB203580 did not significantly inhibit the production.	pyrazolanthrone	55-63	hepatocyte growth factor	Homo sapiens	103-106
18645026-7	2008	Pretreatment with an antioxidant (N-acetylcysteine) or a c-Jun NH(2)-terminal kinase inhibitor (SP600125) effectively prevented Andro-induced p53 activation and DR4 up-regulation and eventually blocked the Andro-induced sensitization on TRAIL-induced apoptosis.	pyrazolanthrone	96-104	tumor protein p53	Homo sapiens	142-145
18752316-6	2008	Inhibition of AP-1 upstream signaling pathway such as JNK by SP600125 significantly suppressed heavy metal-mediated induction of Nqo1 mRNA and activity levels.	pyrazolanthrone	61-69	jun proto-oncogene	Mus musculus	14-18
18752316-6	2008	Inhibition of AP-1 upstream signaling pathway such as JNK by SP600125 significantly suppressed heavy metal-mediated induction of Nqo1 mRNA and activity levels.	pyrazolanthrone	61-69	NAD(P)H dehydrogenase, quinone 1	Mus musculus	129-133
17869087-8	2008	Moreover, SP600125 (a JNK inhibitor) significantly inhibited hydrogen-peroxide- and peroxynitrite-induced PC12 cell death, revealing inactivation of the JNK pathway as a possible molecular mechanism for the protective effects of piceatannol against hydrogen-peroxide- and peroxynitrite-induced apoptosis of PC12 cells.	pyrazolanthrone	10-18	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
17869087-8	2008	Moreover, SP600125 (a JNK inhibitor) significantly inhibited hydrogen-peroxide- and peroxynitrite-induced PC12 cell death, revealing inactivation of the JNK pathway as a possible molecular mechanism for the protective effects of piceatannol against hydrogen-peroxide- and peroxynitrite-induced apoptosis of PC12 cells.	pyrazolanthrone	10-18	mitogen-activated protein kinase 8	Rattus norvegicus	153-156
18645026-7	2008	Pretreatment with an antioxidant (N-acetylcysteine) or a c-Jun NH(2)-terminal kinase inhibitor (SP600125) effectively prevented Andro-induced p53 activation and DR4 up-regulation and eventually blocked the Andro-induced sensitization on TRAIL-induced apoptosis.	pyrazolanthrone	96-104	TNF receptor superfamily member 10a	Homo sapiens	161-164
18645026-7	2008	Pretreatment with an antioxidant (N-acetylcysteine) or a c-Jun NH(2)-terminal kinase inhibitor (SP600125) effectively prevented Andro-induced p53 activation and DR4 up-regulation and eventually blocked the Andro-induced sensitization on TRAIL-induced apoptosis.	pyrazolanthrone	96-104	TNF superfamily member 10	Homo sapiens	237-242
18587265-6	2008	In this study, we also reveal that gammaH2AX production by TrkA is blocked by TrkA kinase inhibitors K-252a and GW441756, and it is also significantly inhibited by JNK inhibitor SP600125.	pyrazolanthrone	178-186	mitogen-activated protein kinase 8	Homo sapiens	164-167
19080374-6	2008	The chemical inhibitor of c-Jun NH2-terminal amino kinase (JNK), SP600125, could prevent both cyclin D1 and CDK4 protein expression level decrease.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	26-57
19080374-6	2008	The chemical inhibitor of c-Jun NH2-terminal amino kinase (JNK), SP600125, could prevent both cyclin D1 and CDK4 protein expression level decrease.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	59-62
19080374-6	2008	The chemical inhibitor of c-Jun NH2-terminal amino kinase (JNK), SP600125, could prevent both cyclin D1 and CDK4 protein expression level decrease.	pyrazolanthrone	65-73	cyclin D1	Homo sapiens	94-103
19080374-6	2008	The chemical inhibitor of c-Jun NH2-terminal amino kinase (JNK), SP600125, could prevent both cyclin D1 and CDK4 protein expression level decrease.	pyrazolanthrone	65-73	cyclin dependent kinase 4	Homo sapiens	108-112
18587265-6	2008	In this study, we also reveal that gammaH2AX production by TrkA is blocked by TrkA kinase inhibitors K-252a and GW441756, and it is also significantly inhibited by JNK inhibitor SP600125.	pyrazolanthrone	178-186	neurotrophic receptor tyrosine kinase 1	Homo sapiens	59-63
18587265-7	2008	Moreover, reduction of cell viability by TrkA was strongly suppressed by SP600125 treatment, suggesting a critical role of JNK in TrkA-induced cell death.	pyrazolanthrone	73-81	neurotrophic receptor tyrosine kinase 1	Homo sapiens	41-45
18587265-7	2008	Moreover, reduction of cell viability by TrkA was strongly suppressed by SP600125 treatment, suggesting a critical role of JNK in TrkA-induced cell death.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	123-126
18587265-7	2008	Moreover, reduction of cell viability by TrkA was strongly suppressed by SP600125 treatment, suggesting a critical role of JNK in TrkA-induced cell death.	pyrazolanthrone	73-81	neurotrophic receptor tyrosine kinase 1	Homo sapiens	130-134
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	pyrazolanthrone	123-131	tumor necrosis factor	Homo sapiens	0-9
18436531-6	2008	Silencing of the stress-activated JNK by small interfering RNA or the specific JNK inhibitor SP600125 reduced H(2)O(2)-induced gamma-secretase-mediated cleavage of APP.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	34-37
18436531-6	2008	Silencing of the stress-activated JNK by small interfering RNA or the specific JNK inhibitor SP600125 reduced H(2)O(2)-induced gamma-secretase-mediated cleavage of APP.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	79-82
18343029-0	2008	Bcl-2 overexpression attenuates SP600125-induced apoptosis in human leukemia U937 cells.	pyrazolanthrone	32-40	BCL2 apoptosis regulator	Homo sapiens	0-5
18343029-1	2008	SP600125 is a specific inhibitor of c-Jun N-terminal kinase (JNK) that is known to strongly induce apoptosis and block cell cycle progression in G2/M phase.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	36-59
18343029-1	2008	SP600125 is a specific inhibitor of c-Jun N-terminal kinase (JNK) that is known to strongly induce apoptosis and block cell cycle progression in G2/M phase.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	61-64
18343029-2	2008	In this study, we demonstrated that treatment of U937 cells with SP600125 resulted in significant G2/M cell cycle arrest that was due to decreased cyclin B1 and cdc25c protein levels.	pyrazolanthrone	65-73	cyclin B1	Homo sapiens	147-156
18343029-2	2008	In this study, we demonstrated that treatment of U937 cells with SP600125 resulted in significant G2/M cell cycle arrest that was due to decreased cyclin B1 and cdc25c protein levels.	pyrazolanthrone	65-73	cell division cycle 25C	Homo sapiens	161-167
18343029-3	2008	Moreover, SP600125 promoted LDH release and DNA fragmentation that was associated with caspase-3 activation and degradation of its substrates.	pyrazolanthrone	10-18	caspase 3	Homo sapiens	87-96
18343029-4	2008	In contrast, overexpression of the antiapoptotic protein Bcl-2 rendered leukemia cells resistant to SP600125-induced apoptosis, but more sensitive to G2/M phase arrest and endoreduplication (&gt;4N DNA).	pyrazolanthrone	100-108	BCL2 apoptosis regulator	Homo sapiens	57-62
18343029-5	2008	Overexpression of Bcl-2 significantly inhibited SP600125-induced caspase-3 activation and degradation of its substrates, and sustained expression levels of the IAP-2 proteins following SP600125 treatment.	pyrazolanthrone	48-56	BCL2 apoptosis regulator	Homo sapiens	18-23
18343029-5	2008	Overexpression of Bcl-2 significantly inhibited SP600125-induced caspase-3 activation and degradation of its substrates, and sustained expression levels of the IAP-2 proteins following SP600125 treatment.	pyrazolanthrone	48-56	caspase 3	Homo sapiens	65-74
18343029-5	2008	Overexpression of Bcl-2 significantly inhibited SP600125-induced caspase-3 activation and degradation of its substrates, and sustained expression levels of the IAP-2 proteins following SP600125 treatment.	pyrazolanthrone	185-193	BCL2 apoptosis regulator	Homo sapiens	18-23
18343029-5	2008	Overexpression of Bcl-2 significantly inhibited SP600125-induced caspase-3 activation and degradation of its substrates, and sustained expression levels of the IAP-2 proteins following SP600125 treatment.	pyrazolanthrone	185-193	baculoviral IAP repeat containing 2	Homo sapiens	160-165
18343029-7	2008	These data provide important mechanistic insights related to Bcl-2-mediated resistance to SP600125-induced apoptosis, and induction of G2/M phase arrest and endoreduplication.	pyrazolanthrone	90-98	BCL2 apoptosis regulator	Homo sapiens	61-66
18374989-6	2008	Significantly, up-regulation of Ifi202 expression in stimulated T cells was inhibited by treatment of cells with SP600125, a specific inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	113-121	interferon activated gene 202B	Mus musculus	32-38
18374989-6	2008	Significantly, up-regulation of Ifi202 expression in stimulated T cells was inhibited by treatment of cells with SP600125, a specific inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Mus musculus	147-170
18374989-6	2008	Significantly, up-regulation of Ifi202 expression in stimulated T cells was inhibited by treatment of cells with SP600125, a specific inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Mus musculus	172-175
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	pyrazolanthrone	123-131	erythrocyte membrane protein band 4.2	Homo sapiens	40-43
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	pyrazolanthrone	123-131	interferon induced protein 44	Homo sapiens	44-47
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	pyrazolanthrone	123-131	mitogen-activated protein kinase 1	Homo sapiens	48-52
18336852-4	2008	TNF-alpha-stimulated phosphorylation of p42/p44 MAPK and JNK were attenuated by pretreatment with the inhibitors U0126 and SP600125 or transfection with dominant negative mutants of DeltaERK and DeltaJNK.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Homo sapiens	57-60
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	pyrazolanthrone	257-265	nuclear factor kappa B subunit 1	Homo sapiens	32-41
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	pyrazolanthrone	257-265	tumor necrosis factor	Homo sapiens	45-54
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	pyrazolanthrone	257-265	matrix metallopeptidase 9	Homo sapiens	63-68
18336852-5	2008	Furthermore, the involvement of NF-kappaB in TNF-alpha-induced MMP-9 production was consistent with that TNF-alpha-stimulated degradation of IkappaB-alpha and translocation of NF-kappaB into the nucleus which were blocked by helenalin, but not by U0126 and SP600125, revealed by immunofluorescence staining.	pyrazolanthrone	257-265	tumor necrosis factor	Homo sapiens	105-114
18336852-7	2008	MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125.	pyrazolanthrone	146-154	matrix metallopeptidase 9	Homo sapiens	0-5
18336852-7	2008	MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125.	pyrazolanthrone	146-154	tumor necrosis factor	Homo sapiens	40-49
18336852-7	2008	MMP-9 promoter activity was enhanced by TNF-alpha in A549 cells transfected with wild-type MMP-9-Luc, which was inhibited by helenalin, U0126, or SP600125.	pyrazolanthrone	146-154	matrix metallopeptidase 9	Homo sapiens	91-96
18181766-5	2008	Treatment with an MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] inhibitor (PD98059) and a JNK (c-Jun N-terminal kinase) inhibitor (SP600125) suppresses PMA-induced MD-2 gene expression, whereas impairment of p38 function by treatment with the inhibitor SB203580 has no effect on MD-2 mRNA.	pyrazolanthrone	182-190	mitogen-activated protein kinase 8	Homo sapiens	141-144
18383341-9	2008	The LPS-induced increase of mPGES-1 was inhibited by different signaling pathway inhibitors, such as SP600125, LY294002, GF109203X, and SC-514, suggesting the involvement of c-Jun N-terminal kinase (JNK), phosphatidylinositol 3-kinase (PI-3K)/Akt, protein kinase C (PKC) pathways, and the nuclear factor (NF)-kappaB, respectively.	pyrazolanthrone	101-109	prostaglandin E synthase	Mus musculus	28-35
18308848-6	2008	Inhibition of JNK by treatment with SP600125 partially protected against DETA/NO- or STZ-induced cell death.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	14-17
18645229-0	2008	Pharmacological inhibitors of JNK and ERK kinases SP600125 and U0126 are not appropriate tools for studies of drug metabolism because they activate aryl hydrocarbon receptor.	pyrazolanthrone	50-58	aryl hydrocarbon receptor	Homo sapiens	148-173
18645229-3	2008	Unfortunately, the inhibitors of JNK and ERK MAPKs, i.e. SP600125 and U0126, respectively, affect AhR-CYP1A signaling pathway because they are partial agonists of AhR and induce CYP1A genes.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	33-36
18645229-3	2008	Unfortunately, the inhibitors of JNK and ERK MAPKs, i.e. SP600125 and U0126, respectively, affect AhR-CYP1A signaling pathway because they are partial agonists of AhR and induce CYP1A genes.	pyrazolanthrone	57-65	aryl hydrocarbon receptor	Homo sapiens	98-101
18645229-3	2008	Unfortunately, the inhibitors of JNK and ERK MAPKs, i.e. SP600125 and U0126, respectively, affect AhR-CYP1A signaling pathway because they are partial agonists of AhR and induce CYP1A genes.	pyrazolanthrone	57-65	aryl hydrocarbon receptor	Homo sapiens	163-166
18569012-5	2008	The JNK inhibitor SP600125 attenuated the activation of caspase-9 and -3 and reduced 25-OH-chol-induced cell death.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
18569012-5	2008	The JNK inhibitor SP600125 attenuated the activation of caspase-9 and -3 and reduced 25-OH-chol-induced cell death.	pyrazolanthrone	18-26	caspase 9	Rattus norvegicus	56-72
18383341-9	2008	The LPS-induced increase of mPGES-1 was inhibited by different signaling pathway inhibitors, such as SP600125, LY294002, GF109203X, and SC-514, suggesting the involvement of c-Jun N-terminal kinase (JNK), phosphatidylinositol 3-kinase (PI-3K)/Akt, protein kinase C (PKC) pathways, and the nuclear factor (NF)-kappaB, respectively.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Rattus norvegicus	174-197
18330685-7	2008	Additionally, preincubation of cardiomyocytes with the extracellular signal-regulated kinase-1 and -2 (ERK1/2) inhibitor PD98059 attenuated the protective effect of SOCS-1, but the p38-MAPK inhibitor SB203580 and the c-Jun amino-terminal kinase (JNK) inhibitor SP600125 had no effect.	pyrazolanthrone	261-269	mitogen activated protein kinase 3	Rattus norvegicus	55-101
18330685-7	2008	Additionally, preincubation of cardiomyocytes with the extracellular signal-regulated kinase-1 and -2 (ERK1/2) inhibitor PD98059 attenuated the protective effect of SOCS-1, but the p38-MAPK inhibitor SB203580 and the c-Jun amino-terminal kinase (JNK) inhibitor SP600125 had no effect.	pyrazolanthrone	261-269	mitogen activated protein kinase 3	Rattus norvegicus	103-109
18330685-7	2008	Additionally, preincubation of cardiomyocytes with the extracellular signal-regulated kinase-1 and -2 (ERK1/2) inhibitor PD98059 attenuated the protective effect of SOCS-1, but the p38-MAPK inhibitor SB203580 and the c-Jun amino-terminal kinase (JNK) inhibitor SP600125 had no effect.	pyrazolanthrone	261-269	suppressor of cytokine signaling 1	Rattus norvegicus	165-171
18251700-9	2008	An anti-apoptotic effect of RANKL/RANK/TRAF6 signaling on osteoclast was inhibited by JNK-specific inhibitor SP600125 and by overexpression of dominant-negative JNK1, c-jun, and c-fos.	pyrazolanthrone	109-117	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	28-33
18251700-9	2008	An anti-apoptotic effect of RANKL/RANK/TRAF6 signaling on osteoclast was inhibited by JNK-specific inhibitor SP600125 and by overexpression of dominant-negative JNK1, c-jun, and c-fos.	pyrazolanthrone	109-117	TNF receptor-associated factor 6	Mus musculus	39-44
18251700-9	2008	An anti-apoptotic effect of RANKL/RANK/TRAF6 signaling on osteoclast was inhibited by JNK-specific inhibitor SP600125 and by overexpression of dominant-negative JNK1, c-jun, and c-fos.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Mus musculus	86-89
18600064-10	2008	In the case of stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK), the SAPK/JNK inhibitor SP600125 did not inhibit IL-10 mRNA synthesis but inhibited the production of IL-10 protein remarkably.	pyrazolanthrone	108-116	interleukin 10	Mus musculus	186-191
18385943-1	2008	We show that H2O2 increases acetylcholinesterase (AChE) expression via transcriptional activation through c-Jun N-terminal kinase (JNK), since the JNK inhibitor SP600125, but not the extracellular signal-regulated kinase (ERK) pathway inhibitor PD98059 or p38 kinase inhibitor SB203580, attenuated H2O2-induced AChE expression and its promoter activity.	pyrazolanthrone	161-169	acetylcholinesterase (Cartwright blood group)	Homo sapiens	50-54
18058803-7	2008	SP600125, a specific inhibitor for JNK and SB203580, a p38 MAPK-specific inhibitor suppressed AMR-Me induced apoptosis indicating that activation of JNK and p38 MAPKs involved in the mitochondrial activation-mediated cell death pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 14	Homo sapiens	55-58
18058803-7	2008	SP600125, a specific inhibitor for JNK and SB203580, a p38 MAPK-specific inhibitor suppressed AMR-Me induced apoptosis indicating that activation of JNK and p38 MAPKs involved in the mitochondrial activation-mediated cell death pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	149-152
18058803-7	2008	SP600125, a specific inhibitor for JNK and SB203580, a p38 MAPK-specific inhibitor suppressed AMR-Me induced apoptosis indicating that activation of JNK and p38 MAPKs involved in the mitochondrial activation-mediated cell death pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 14	Homo sapiens	157-160
32038782-4	2008	SP-600125, an anthrapyrazole small molecule inhibitor for JNK with high potency and selectivity has been widely used for dissecting JNK signaling pathway.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Mus musculus	132-135
18337250-3	2008	JNK inhibitor (SP600125) was observed to significantly protect against APAP-induced liver injury.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	0-3
18303122-6	2008	MCP-1 secretion from hypertrophied cells was significantly decreased by treatment with antioxidant N-acetyl-cysteine, JNK inhibitors SP600125 and JIP-1 peptide, and IkappaB phosphorylation inhibitors BAY 11-7085 and BMS-345541 (P &lt; 0.01).	pyrazolanthrone	133-141	chemokine (C-C motif) ligand 2	Mus musculus	0-5
18303122-6	2008	MCP-1 secretion from hypertrophied cells was significantly decreased by treatment with antioxidant N-acetyl-cysteine, JNK inhibitors SP600125 and JIP-1 peptide, and IkappaB phosphorylation inhibitors BAY 11-7085 and BMS-345541 (P &lt; 0.01).	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Mus musculus	118-121
18552272-8	2008	The cells were pretreated with SP600125, a specific inhibitor of JNK, for 4 hours before incubation with TGFbeta1.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Rattus norvegicus	65-68
18552272-8	2008	The cells were pretreated with SP600125, a specific inhibitor of JNK, for 4 hours before incubation with TGFbeta1.	pyrazolanthrone	31-39	transforming growth factor, beta 1	Rattus norvegicus	105-113
18552272-13	2008	The addition of SP600125, which blocked activation of JNK, effectively inhibited TGFbeta1-induced phosphorylation of Smad3, but not Smad2.	pyrazolanthrone	16-24	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
18552272-13	2008	The addition of SP600125, which blocked activation of JNK, effectively inhibited TGFbeta1-induced phosphorylation of Smad3, but not Smad2.	pyrazolanthrone	16-24	transforming growth factor, beta 1	Rattus norvegicus	81-89
18552272-13	2008	The addition of SP600125, which blocked activation of JNK, effectively inhibited TGFbeta1-induced phosphorylation of Smad3, but not Smad2.	pyrazolanthrone	16-24	SMAD family member 3	Rattus norvegicus	117-122
18552272-14	2008	Also, our results showed that SP600125 effectively suppressed TGFbeta1-induced high expression of alpha-SMA and collagen I, and prevented TGFbeta1-induced downregulation of E-cadherin expression in RPMCs.	pyrazolanthrone	30-38	transforming growth factor, beta 1	Rattus norvegicus	62-70
18552272-14	2008	Also, our results showed that SP600125 effectively suppressed TGFbeta1-induced high expression of alpha-SMA and collagen I, and prevented TGFbeta1-induced downregulation of E-cadherin expression in RPMCs.	pyrazolanthrone	30-38	actin gamma 2, smooth muscle	Rattus norvegicus	98-107
18552272-14	2008	Also, our results showed that SP600125 effectively suppressed TGFbeta1-induced high expression of alpha-SMA and collagen I, and prevented TGFbeta1-induced downregulation of E-cadherin expression in RPMCs.	pyrazolanthrone	30-38	transforming growth factor, beta 1	Rattus norvegicus	138-146
18552272-14	2008	Also, our results showed that SP600125 effectively suppressed TGFbeta1-induced high expression of alpha-SMA and collagen I, and prevented TGFbeta1-induced downregulation of E-cadherin expression in RPMCs.	pyrazolanthrone	30-38	cadherin 1	Rattus norvegicus	173-183
18727380-4	2008	The treatment of selective inhibitors JNK SP600125 and p38 ML3403 in vitro prevents peroxide-induced appearance of P53 and NF-kB in blood mononuclear cells, associated with increasing of their apoptotic activity.	pyrazolanthrone	42-50	tumor protein p53	Homo sapiens	115-118
32038782-4	2008	SP-600125, an anthrapyrazole small molecule inhibitor for JNK with high potency and selectivity has been widely used for dissecting JNK signaling pathway.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Mus musculus	58-61
18407296-6	2008	SP600125, a specific inhibitor of stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK), markedly reduced the HSP27 expression induced by TGF-beta.	pyrazolanthrone	0-8	heat shock protein 1	Mus musculus	125-130
18407296-6	2008	SP600125, a specific inhibitor of stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK), markedly reduced the HSP27 expression induced by TGF-beta.	pyrazolanthrone	0-8	transforming growth factor, beta 1	Mus musculus	153-161
18374905-4	2008	SP600125 efficiently suppressed basal JNK activity in SK-N-SH cell line as shown by inhibition of phosphor-JNK and phosphor-c-jun, and also decreased PS1 expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	38-41
18374905-4	2008	SP600125 efficiently suppressed basal JNK activity in SK-N-SH cell line as shown by inhibition of phosphor-JNK and phosphor-c-jun, and also decreased PS1 expression.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	107-110
18374905-4	2008	SP600125 efficiently suppressed basal JNK activity in SK-N-SH cell line as shown by inhibition of phosphor-JNK and phosphor-c-jun, and also decreased PS1 expression.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	124-129
18374905-4	2008	SP600125 efficiently suppressed basal JNK activity in SK-N-SH cell line as shown by inhibition of phosphor-JNK and phosphor-c-jun, and also decreased PS1 expression.	pyrazolanthrone	0-8	presenilin 1	Homo sapiens	150-153
18374905-11	2008	In this report we showed that p53 level was upregulated by SP600125 in SK-N-SH cell line.	pyrazolanthrone	59-67	tumor protein p53	Homo sapiens	30-33
18374905-15	2008	Furthermore, p53 inhibitor pifithrin-alpha partially nullified the suppressive effects of SP600125 on PS1 expression.	pyrazolanthrone	90-98	tumor protein p53	Homo sapiens	13-16
18374905-15	2008	Furthermore, p53 inhibitor pifithrin-alpha partially nullified the suppressive effects of SP600125 on PS1 expression.	pyrazolanthrone	90-98	presenilin 1	Homo sapiens	102-105
18374905-16	2008	We also showed that transfection of p53 was required for SP600125-mediated suppression of PS1 expression in p53-deficient PC3 cell line suggesting that inhibition of basal JNK activity suppresses PS1 expression through a p53-dependent mechanism.	pyrazolanthrone	57-65	tumor protein p53	Homo sapiens	36-39
18374905-16	2008	We also showed that transfection of p53 was required for SP600125-mediated suppression of PS1 expression in p53-deficient PC3 cell line suggesting that inhibition of basal JNK activity suppresses PS1 expression through a p53-dependent mechanism.	pyrazolanthrone	57-65	presenilin 1	Homo sapiens	90-93
18374905-16	2008	We also showed that transfection of p53 was required for SP600125-mediated suppression of PS1 expression in p53-deficient PC3 cell line suggesting that inhibition of basal JNK activity suppresses PS1 expression through a p53-dependent mechanism.	pyrazolanthrone	57-65	tumor protein p53	Homo sapiens	108-111
18374905-16	2008	We also showed that transfection of p53 was required for SP600125-mediated suppression of PS1 expression in p53-deficient PC3 cell line suggesting that inhibition of basal JNK activity suppresses PS1 expression through a p53-dependent mechanism.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	172-175
18374905-16	2008	We also showed that transfection of p53 was required for SP600125-mediated suppression of PS1 expression in p53-deficient PC3 cell line suggesting that inhibition of basal JNK activity suppresses PS1 expression through a p53-dependent mechanism.	pyrazolanthrone	57-65	presenilin 1	Homo sapiens	196-199
18374905-16	2008	We also showed that transfection of p53 was required for SP600125-mediated suppression of PS1 expression in p53-deficient PC3 cell line suggesting that inhibition of basal JNK activity suppresses PS1 expression through a p53-dependent mechanism.	pyrazolanthrone	57-65	tumor protein p53	Homo sapiens	108-111
18728404-6	2008	The kinase activity of JNK was induced by selenite in a dose-dependent manner and HepG2 cells exposed to selenite (10 microM) for 4 h showed increased levels of phosphorylated JNK, which decreased when exposed for additional 4 h. In contrast, Sp600125, a specific inhibitor of JNK, remarkably blocked the apoptosis of HepG2 exposed to selenite.	pyrazolanthrone	243-251	mitogen-activated protein kinase 8	Homo sapiens	23-26
18728404-6	2008	The kinase activity of JNK was induced by selenite in a dose-dependent manner and HepG2 cells exposed to selenite (10 microM) for 4 h showed increased levels of phosphorylated JNK, which decreased when exposed for additional 4 h. In contrast, Sp600125, a specific inhibitor of JNK, remarkably blocked the apoptosis of HepG2 exposed to selenite.	pyrazolanthrone	243-251	mitogen-activated protein kinase 8	Homo sapiens	176-179
18728404-6	2008	The kinase activity of JNK was induced by selenite in a dose-dependent manner and HepG2 cells exposed to selenite (10 microM) for 4 h showed increased levels of phosphorylated JNK, which decreased when exposed for additional 4 h. In contrast, Sp600125, a specific inhibitor of JNK, remarkably blocked the apoptosis of HepG2 exposed to selenite.	pyrazolanthrone	243-251	mitogen-activated protein kinase 8	Homo sapiens	176-179
18385943-1	2008	We show that H2O2 increases acetylcholinesterase (AChE) expression via transcriptional activation through c-Jun N-terminal kinase (JNK), since the JNK inhibitor SP600125, but not the extracellular signal-regulated kinase (ERK) pathway inhibitor PD98059 or p38 kinase inhibitor SB203580, attenuated H2O2-induced AChE expression and its promoter activity.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	106-129
18385943-1	2008	We show that H2O2 increases acetylcholinesterase (AChE) expression via transcriptional activation through c-Jun N-terminal kinase (JNK), since the JNK inhibitor SP600125, but not the extracellular signal-regulated kinase (ERK) pathway inhibitor PD98059 or p38 kinase inhibitor SB203580, attenuated H2O2-induced AChE expression and its promoter activity.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	131-134
18385943-1	2008	We show that H2O2 increases acetylcholinesterase (AChE) expression via transcriptional activation through c-Jun N-terminal kinase (JNK), since the JNK inhibitor SP600125, but not the extracellular signal-regulated kinase (ERK) pathway inhibitor PD98059 or p38 kinase inhibitor SB203580, attenuated H2O2-induced AChE expression and its promoter activity.	pyrazolanthrone	161-169	mitogen-activated protein kinase 8	Homo sapiens	147-150
18325654-6	2008	Moreover, a JNK-specific inhibitor, SP600125, partially but significantly rescued METH-induced cell death, while PD98059 (an ERK kinase inhibitor) and SB203580 (a p38 inhibitor) had no protective effect.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	12-15
17941091-6	2008	p38 inhibitor, SB203580 or JNK inhibitor, SP600125 but not ERK inhibitor, PD98059 attenuated the US-induced MMP-13, c-Fos, and c-Jun expression; these results were further substantiated by transfecting with the dominant negative mutants of p38 or JNK.	pyrazolanthrone	42-50	matrix metallopeptidase 13	Rattus norvegicus	108-114
18164102-8	2008	Inhibitors of p38 (SB203580) and of JNK (SP600125) antagonize DomA-induced apoptosis.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Mus musculus	36-39
18427129-8	2008	Wnt11-induced cardiac-specific expression was completely abolished by the protein kinase C inhibitor bisindolylmaleimide I, partially abolished by the c-Jun-N-terminal kinase inhibitor SP600125, and attenuated by the Wnt inhibitor Dickkopf-1.	pyrazolanthrone	185-193	wingless-type MMTV integration site family, member 11	Mus musculus	0-5
18427129-8	2008	Wnt11-induced cardiac-specific expression was completely abolished by the protein kinase C inhibitor bisindolylmaleimide I, partially abolished by the c-Jun-N-terminal kinase inhibitor SP600125, and attenuated by the Wnt inhibitor Dickkopf-1.	pyrazolanthrone	185-193	wingless-type MMTV integration site family, member 3A	Mus musculus	0-3
17990290-8	2008	We observed that PD98059 and SP600125 (MEK-ERK and JNK inhibitors, respectively) added 1 h prior to the MIX-Dexa induction produced a decrease in erbB2 expression after 6 h, which is even greater than the one produced by the inducers, MIX-Dexa.	pyrazolanthrone	29-37	midkine	Mus musculus	39-42
17990290-8	2008	We observed that PD98059 and SP600125 (MEK-ERK and JNK inhibitors, respectively) added 1 h prior to the MIX-Dexa induction produced a decrease in erbB2 expression after 6 h, which is even greater than the one produced by the inducers, MIX-Dexa.	pyrazolanthrone	29-37	mitogen-activated protein kinase 1	Mus musculus	43-46
17990290-8	2008	We observed that PD98059 and SP600125 (MEK-ERK and JNK inhibitors, respectively) added 1 h prior to the MIX-Dexa induction produced a decrease in erbB2 expression after 6 h, which is even greater than the one produced by the inducers, MIX-Dexa.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Mus musculus	51-54
17990290-8	2008	We observed that PD98059 and SP600125 (MEK-ERK and JNK inhibitors, respectively) added 1 h prior to the MIX-Dexa induction produced a decrease in erbB2 expression after 6 h, which is even greater than the one produced by the inducers, MIX-Dexa.	pyrazolanthrone	29-37	erb-b2 receptor tyrosine kinase 2	Mus musculus	146-151
18325654-7	2008	We also found that vitamin E (Vit E) prevented METH-induced JNK phosporylation and SP600125 inhibited METH-induced c-Jun phosphorylation.	pyrazolanthrone	83-91	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	115-120
18325654-8	2008	Furthermore, METH-activated caspase-3 activity was significantly repressed by Vit E and in SP600125 treated cells.	pyrazolanthrone	91-99	caspase 3	Homo sapiens	28-37
18404528-4	2008	The tyrosine kinase inhibitor genistein and JNK inhibitor SP600125 significantly attenuated arsenite induced increases in ho-1 mRNA levels in Nrf2 deficient cells but had negligible effects on Nrf2 activation, suggesting tyrosine kinase/JNK/c-Jun plays a key role in the HO-1 upregulation via AP-1.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Mus musculus	44-47
18263671-6	2008	Inhibition of the JNK pathway using SP-600125 or l-stereoisomer (l-JNKI-1) blocked network formation, whereas the p38 MAPK blocker SB-203580 slightly enhanced it.	pyrazolanthrone	36-45	mitogen-activated protein kinase 8	Homo sapiens	18-21
18341587-7	2008	Transient knockdown of the transcription factor GADD153/C/EBP homologous protein and application of the synthetic c-Jun N-terminal kinase inhibitor SP600125 indicated that enhanced DR5 expression occurred independently of GADD153/C/EBP homologous protein, but required activation of the c-Jun N-terminal kinase/c-Jun signaling pathway.	pyrazolanthrone	148-156	TNF receptor superfamily member 10b	Homo sapiens	181-184
18294464-8	2008	Inhibition of JNK and ERK1/2 with SP600125 pre-treatment further increased the expression of both SHP-1 and SHP-2 proteins in the early phase of Cer-induced AP, while the inhibition of type IV phosphodiesterase with rolipram only suppressed the increase in SHP-2 protein expression during the same phase.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
18294464-8	2008	Inhibition of JNK and ERK1/2 with SP600125 pre-treatment further increased the expression of both SHP-1 and SHP-2 proteins in the early phase of Cer-induced AP, while the inhibition of type IV phosphodiesterase with rolipram only suppressed the increase in SHP-2 protein expression during the same phase.	pyrazolanthrone	34-42	mitogen activated protein kinase 3	Rattus norvegicus	22-28
18294464-8	2008	Inhibition of JNK and ERK1/2 with SP600125 pre-treatment further increased the expression of both SHP-1 and SHP-2 proteins in the early phase of Cer-induced AP, while the inhibition of type IV phosphodiesterase with rolipram only suppressed the increase in SHP-2 protein expression during the same phase.	pyrazolanthrone	34-42	protein tyrosine phosphatase, non-receptor type 6	Rattus norvegicus	98-103
18294464-8	2008	Inhibition of JNK and ERK1/2 with SP600125 pre-treatment further increased the expression of both SHP-1 and SHP-2 proteins in the early phase of Cer-induced AP, while the inhibition of type IV phosphodiesterase with rolipram only suppressed the increase in SHP-2 protein expression during the same phase.	pyrazolanthrone	34-42	protein tyrosine phosphatase, non-receptor type 11	Rattus norvegicus	108-113
18294464-8	2008	Inhibition of JNK and ERK1/2 with SP600125 pre-treatment further increased the expression of both SHP-1 and SHP-2 proteins in the early phase of Cer-induced AP, while the inhibition of type IV phosphodiesterase with rolipram only suppressed the increase in SHP-2 protein expression during the same phase.	pyrazolanthrone	34-42	protein tyrosine phosphatase, non-receptor type 11	Rattus norvegicus	257-262
18404528-4	2008	The tyrosine kinase inhibitor genistein and JNK inhibitor SP600125 significantly attenuated arsenite induced increases in ho-1 mRNA levels in Nrf2 deficient cells but had negligible effects on Nrf2 activation, suggesting tyrosine kinase/JNK/c-Jun plays a key role in the HO-1 upregulation via AP-1.	pyrazolanthrone	58-66	heme oxygenase 1	Mus musculus	122-126
18404528-4	2008	The tyrosine kinase inhibitor genistein and JNK inhibitor SP600125 significantly attenuated arsenite induced increases in ho-1 mRNA levels in Nrf2 deficient cells but had negligible effects on Nrf2 activation, suggesting tyrosine kinase/JNK/c-Jun plays a key role in the HO-1 upregulation via AP-1.	pyrazolanthrone	58-66	nuclear factor, erythroid derived 2, like 2	Mus musculus	142-146
18404528-4	2008	The tyrosine kinase inhibitor genistein and JNK inhibitor SP600125 significantly attenuated arsenite induced increases in ho-1 mRNA levels in Nrf2 deficient cells but had negligible effects on Nrf2 activation, suggesting tyrosine kinase/JNK/c-Jun plays a key role in the HO-1 upregulation via AP-1.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Mus musculus	237-240
18404528-4	2008	The tyrosine kinase inhibitor genistein and JNK inhibitor SP600125 significantly attenuated arsenite induced increases in ho-1 mRNA levels in Nrf2 deficient cells but had negligible effects on Nrf2 activation, suggesting tyrosine kinase/JNK/c-Jun plays a key role in the HO-1 upregulation via AP-1.	pyrazolanthrone	58-66	jun proto-oncogene	Mus musculus	241-246
18404528-4	2008	The tyrosine kinase inhibitor genistein and JNK inhibitor SP600125 significantly attenuated arsenite induced increases in ho-1 mRNA levels in Nrf2 deficient cells but had negligible effects on Nrf2 activation, suggesting tyrosine kinase/JNK/c-Jun plays a key role in the HO-1 upregulation via AP-1.	pyrazolanthrone	58-66	heme oxygenase 1	Mus musculus	271-275
18404528-4	2008	The tyrosine kinase inhibitor genistein and JNK inhibitor SP600125 significantly attenuated arsenite induced increases in ho-1 mRNA levels in Nrf2 deficient cells but had negligible effects on Nrf2 activation, suggesting tyrosine kinase/JNK/c-Jun plays a key role in the HO-1 upregulation via AP-1.	pyrazolanthrone	58-66	jun proto-oncogene	Mus musculus	293-297
18664199-8	2008	The Western blotting analysis presented the inhibitory effect on apoptosis induced by STS of SP600125 which is a specific JNK inhibitor.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	122-125
18439101-7	2008	The JNK inhibitors (SP600125 and TAT-TI-JIP(153163)) suppressed neutrophil apoptosis induced by TNF-alpha plus cycloheximide, whereas they attenuated the GM-CSF-mediated antiapoptotic effect on neutrophils.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	4-7
18439101-7	2008	The JNK inhibitors (SP600125 and TAT-TI-JIP(153163)) suppressed neutrophil apoptosis induced by TNF-alpha plus cycloheximide, whereas they attenuated the GM-CSF-mediated antiapoptotic effect on neutrophils.	pyrazolanthrone	20-28	tumor necrosis factor	Homo sapiens	96-105
18439101-7	2008	The JNK inhibitors (SP600125 and TAT-TI-JIP(153163)) suppressed neutrophil apoptosis induced by TNF-alpha plus cycloheximide, whereas they attenuated the GM-CSF-mediated antiapoptotic effect on neutrophils.	pyrazolanthrone	20-28	colony stimulating factor 2	Homo sapiens	154-160
18342935-8	2008	Furthermore, the anti-Fas activating antibody-enhanced EEC apoptosis and spheroid expansion on EEC were significantly inhibited by the p38 MAPK inhibitor SB203580 and JNK inhibitor SP600125.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Homo sapiens	167-170
18285354-7	2008	Pre-treatment with the MAPK inhibitors SP600125 (JNK inhibitor), SB202190 (p38 inhibitor) or PD98059 (ERK inhibitor) significantly inhibited AGE-BSA induction of COX-2 expression and production of PGE(2).	pyrazolanthrone	39-47	mitogen-activated protein kinase 1	Homo sapiens	23-27
18285354-7	2008	Pre-treatment with the MAPK inhibitors SP600125 (JNK inhibitor), SB202190 (p38 inhibitor) or PD98059 (ERK inhibitor) significantly inhibited AGE-BSA induction of COX-2 expression and production of PGE(2).	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	49-52
18285354-7	2008	Pre-treatment with the MAPK inhibitors SP600125 (JNK inhibitor), SB202190 (p38 inhibitor) or PD98059 (ERK inhibitor) significantly inhibited AGE-BSA induction of COX-2 expression and production of PGE(2).	pyrazolanthrone	39-47	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	162-167
18358890-4	2008	LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein.	pyrazolanthrone	273-281	nuclear factor kappa B subunit 1	Homo sapiens	32-54
18358890-4	2008	LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein.	pyrazolanthrone	273-281	nuclear factor kappa B subunit 1	Homo sapiens	56-65
18358890-4	2008	LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein.	pyrazolanthrone	273-281	mitogen-activated protein kinase 1	Homo sapiens	159-200
18358890-4	2008	LPS-stimulated translocation of nuclear factor kappa B (NF-kappaB) into the nucleus, which was blocked by inhibitors of amino kinase terminal (AKT, LY294002), extracellular signal regulated kinase 1/2 (ERK 1/2, PD98059), p38 (SB203580), and c-jun NH2-terminal kinase (JNK, SP600125) or terrein.	pyrazolanthrone	273-281	mitogen-activated protein kinase 3	Homo sapiens	202-209
18084318-8	2008	Pretreatment with SB202190 or SP600125, specific inhibitors of p38 and JNK MAPKs, respectively, reduced ICAM-1 and VCAM-1 expression in HT29 cells dose-dependently.	pyrazolanthrone	30-38	mitogen-activated protein kinase 14	Homo sapiens	63-66
18078968-9	2008	Inhibition of JNK by SP600125 also reduced flavonoid-stimulated nuclear induction of JunD which was known to have protective role in apoptosis, whereas JNK inhibition alone had little effect on apoptosis.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
18078968-9	2008	Inhibition of JNK by SP600125 also reduced flavonoid-stimulated nuclear induction of JunD which was known to have protective role in apoptosis, whereas JNK inhibition alone had little effect on apoptosis.	pyrazolanthrone	21-29	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	85-89
18047469-7	2008	Blockage of the JNK (c-Jun N-terminal kinase) signalling pathway by SP600125 significantly abolished the TNFalpha-mediated destabilization of CLMP mRNA.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Mus musculus	16-19
18047469-7	2008	Blockage of the JNK (c-Jun N-terminal kinase) signalling pathway by SP600125 significantly abolished the TNFalpha-mediated destabilization of CLMP mRNA.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Mus musculus	21-44
18047469-7	2008	Blockage of the JNK (c-Jun N-terminal kinase) signalling pathway by SP600125 significantly abolished the TNFalpha-mediated destabilization of CLMP mRNA.	pyrazolanthrone	68-76	tumor necrosis factor	Mus musculus	105-113
18047469-7	2008	Blockage of the JNK (c-Jun N-terminal kinase) signalling pathway by SP600125 significantly abolished the TNFalpha-mediated destabilization of CLMP mRNA.	pyrazolanthrone	68-76	CXADR-like membrane protein	Mus musculus	142-146
18084318-8	2008	Pretreatment with SB202190 or SP600125, specific inhibitors of p38 and JNK MAPKs, respectively, reduced ICAM-1 and VCAM-1 expression in HT29 cells dose-dependently.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	71-74
18084318-8	2008	Pretreatment with SB202190 or SP600125, specific inhibitors of p38 and JNK MAPKs, respectively, reduced ICAM-1 and VCAM-1 expression in HT29 cells dose-dependently.	pyrazolanthrone	30-38	intercellular adhesion molecule 1	Homo sapiens	104-110
18084318-8	2008	Pretreatment with SB202190 or SP600125, specific inhibitors of p38 and JNK MAPKs, respectively, reduced ICAM-1 and VCAM-1 expression in HT29 cells dose-dependently.	pyrazolanthrone	30-38	vascular cell adhesion molecule 1	Homo sapiens	115-121
18045762-7	2008	In addition, the ERK1/2 inhibitor, PD98059, could partially rescue alpha-LA-induced cell death, while the JNK inhibitor, SP600125, could weakly protect cells from death.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Mus musculus	106-109
18174237-6	2008	Pretreatment of Sup-T1 cells with a specific JNK inhibitor, SP600125, also increased the Bim(EL) level and resensitized the cells to etoposide-induced apoptosis.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	45-48
18206384-5	2008	Treatment of cells with SB203580 and SP600125 (inhibitors of p38 and JNK, respectively) significantly affected porin-stimulated iNOS and NO production.	pyrazolanthrone	37-45	nitric oxide synthase 2, inducible	Mus musculus	128-132
18078826-6	2008	Inhibition of AP-1 upstream signaling pathway activators such as JNK by SP600125 suppressed Cyp1a1 mRNA induction by heavy metals, whereas it potentiated their inhibitory effects at the activity level.	pyrazolanthrone	72-80	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	14-18
18078826-6	2008	Inhibition of AP-1 upstream signaling pathway activators such as JNK by SP600125 suppressed Cyp1a1 mRNA induction by heavy metals, whereas it potentiated their inhibitory effects at the activity level.	pyrazolanthrone	72-80	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	92-98
17786963-5	2008	The HNP-induced IL-8 production was blocked by the Src tyrosine kinase inhibitor PP2, MEK1/2 inhibitor U0126, and the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002, but not by the JNK inhibitor SP600125 in both cell types.	pyrazolanthrone	204-212	kallikrein related peptidase 8	Homo sapiens	4-7
18177344-5	2008	SAPK/JNK-specific inhibitor SP600125 slightly suppressed IL-6 production although no evident effects were obtained for TNF-alpha and IL-1beta; ERK1/2 inhibitor PD98059 blocked both TNF-alpha and IL-1beta, but not IL-6 production.	pyrazolanthrone	28-36	interleukin 6	Homo sapiens	57-61
18177344-5	2008	SAPK/JNK-specific inhibitor SP600125 slightly suppressed IL-6 production although no evident effects were obtained for TNF-alpha and IL-1beta; ERK1/2 inhibitor PD98059 blocked both TNF-alpha and IL-1beta, but not IL-6 production.	pyrazolanthrone	28-36	tumor necrosis factor	Homo sapiens	181-190
18177344-5	2008	SAPK/JNK-specific inhibitor SP600125 slightly suppressed IL-6 production although no evident effects were obtained for TNF-alpha and IL-1beta; ERK1/2 inhibitor PD98059 blocked both TNF-alpha and IL-1beta, but not IL-6 production.	pyrazolanthrone	28-36	interleukin 1 beta	Homo sapiens	195-203
18177344-5	2008	SAPK/JNK-specific inhibitor SP600125 slightly suppressed IL-6 production although no evident effects were obtained for TNF-alpha and IL-1beta; ERK1/2 inhibitor PD98059 blocked both TNF-alpha and IL-1beta, but not IL-6 production.	pyrazolanthrone	28-36	interleukin 6	Homo sapiens	213-217
18095305-3	2008	The c-Jun N-terminal kinase (JNK) inhibitor SP600125 or p38 MAPK inhibitor SB203580 prevented this liver injury.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Mus musculus	4-27
18095305-3	2008	The c-Jun N-terminal kinase (JNK) inhibitor SP600125 or p38 MAPK inhibitor SB203580 prevented this liver injury.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Mus musculus	29-32
18095305-7	2008	PY plus LPS treatment elevated TNF-alpha production, and this was blocked by SP600125 or SB203580.	pyrazolanthrone	77-85	tumor necrosis factor	Mus musculus	31-40
18095305-13	2008	Liver mitochondria from PY plus LPS or PY plus TNF-alpha treated mice underwent calcium-dependent, cyclosporine A-sensitive swelling, which was prevented by SB203580 or SP600125.	pyrazolanthrone	169-177	tumor necrosis factor	Mus musculus	47-56
18187558-8	2008	It is observed that pre-treatment of macrophages with JNK inhibitor, SP600125; tyrosine kinase inhibitor, genistein; PI3K inhibitor, Wortmannin and JAK2 inhibitor, AG490 inhibited the phosphorylation of JNK MAPK.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Mus musculus	203-206
18187558-9	2008	Further, pre-treatment of macrophages with SP600125 inhibited the PRL-induced production of IFN-gamma and TNF-alpha.	pyrazolanthrone	43-51	prolactin	Mus musculus	66-69
18187558-9	2008	Further, pre-treatment of macrophages with SP600125 inhibited the PRL-induced production of IFN-gamma and TNF-alpha.	pyrazolanthrone	43-51	interferon gamma	Mus musculus	92-101
18187558-9	2008	Further, pre-treatment of macrophages with SP600125 inhibited the PRL-induced production of IFN-gamma and TNF-alpha.	pyrazolanthrone	43-51	tumor necrosis factor	Mus musculus	106-115
17786963-5	2008	The HNP-induced IL-8 production was blocked by the Src tyrosine kinase inhibitor PP2, MEK1/2 inhibitor U0126, and the phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002, but not by the JNK inhibitor SP600125 in both cell types.	pyrazolanthrone	204-212	C-X-C motif chemokine ligand 8	Homo sapiens	16-20
18031783-8	2008	In addition, an ERK-specific inhibitor, PD98059, and a JNK-specific inhibitor, SP600125, showed inhibited sub-G1 phase DNA content, DNA fragmentation, caspase activation, and mitochondrial dysfunction induced by esculetin treatment.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	55-58
18441395-3	2008	Further study revealed that the inhibitor of c-Jun N-terminal kinase - mitogen-activated protein kinase (JNK-MAPK), SP600125 (0.1 microM), reversed the imipramine-induced suppression of GR function, whereas the inhibitor of extracellular signal-regulated kinase (ERK)-MAPK, PD 98059 (15 microM), potentiated the antidepressant action.	pyrazolanthrone	116-124	mitogen-activated protein kinase 1	Homo sapiens	224-261
18441395-3	2008	Further study revealed that the inhibitor of c-Jun N-terminal kinase - mitogen-activated protein kinase (JNK-MAPK), SP600125 (0.1 microM), reversed the imipramine-induced suppression of GR function, whereas the inhibitor of extracellular signal-regulated kinase (ERK)-MAPK, PD 98059 (15 microM), potentiated the antidepressant action.	pyrazolanthrone	116-124	mitogen-activated protein kinase 1	Homo sapiens	263-266
18292576-5	2008	SP600125 reduced the expression of the CRP gene induced by IL-1 plus IL-6.	pyrazolanthrone	0-8	C-reactive protein	Homo sapiens	39-42
18292576-5	2008	SP600125 reduced the expression of the CRP gene induced by IL-1 plus IL-6.	pyrazolanthrone	0-8	interleukin 1 alpha	Homo sapiens	59-63
18292576-5	2008	SP600125 reduced the expression of the CRP gene induced by IL-1 plus IL-6.	pyrazolanthrone	0-8	interleukin 6	Homo sapiens	69-73
18174464-8	2008	Furthermore, blockade of the ERK or JNK pathways by U0126 and SP600125, respectively, abolished ADP- and 2-MeSADP-stimulated HUVEC migration.	pyrazolanthrone	62-70	mitogen-activated protein kinase 3	Homo sapiens	29-32
18164262-7	2008	However, a JNK-specific inhibitor, SP600125, strongly suppressed etoposide-induced eIF-4E phosphorylation.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Homo sapiens	11-14
18164262-7	2008	However, a JNK-specific inhibitor, SP600125, strongly suppressed etoposide-induced eIF-4E phosphorylation.	pyrazolanthrone	35-43	eukaryotic translation initiation factor 4E	Homo sapiens	83-89
18174464-8	2008	Furthermore, blockade of the ERK or JNK pathways by U0126 and SP600125, respectively, abolished ADP- and 2-MeSADP-stimulated HUVEC migration.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	36-39
17996917-4	2008	The ERK1/2-inhibitor PD98059, the p38-inhibitor SB202190 and the JNK1/2-inhibitor SP600125 partially inhibited the fluoride-induced IL-8 response.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	65-69
18086564-5	2008	The proliferation of EoL-1 cells and expression of c-Myc were also inhibited by the MEK inhibitor U0126 and JNK inhibitor SP600125.	pyrazolanthrone	122-130	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	51-56
18086564-5	2008	The proliferation of EoL-1 cells and expression of c-Myc were also inhibited by the MEK inhibitor U0126 and JNK inhibitor SP600125.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	108-111
17967471-4	2008	The JNK-specific inhibitor SP600125 reproduced this effect in Rat1-LMP1 cells and efficiently interfered with proliferation of EBV-transformed lymphoblastoid cells (LCLs).	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	4-7
17967471-4	2008	The JNK-specific inhibitor SP600125 reproduced this effect in Rat1-LMP1 cells and efficiently interfered with proliferation of EBV-transformed lymphoblastoid cells (LCLs).	pyrazolanthrone	27-35	PDZ and LIM domain 7	Homo sapiens	67-71
18057004-8	2008	Consistent with this finding, the JNK inhibitor SP600125, but not p38 inhibitor SB203580, ablated this response.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Mus musculus	34-37
18344085-2	2008	METHODS: The p-JNK expression was blocked by the JNK inhibitor SP600125.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	15-18
18344085-2	2008	METHODS: The p-JNK expression was blocked by the JNK inhibitor SP600125.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	49-52
18082627-0	2008	SP600125 inhibits Kv channels through a JNK-independent pathway in cancer cells.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	40-43
18082627-3	2008	We have found that the commonly used JNK inhibitor SP600125 strongly inhibits Kv channels through a JNK-independent pathway, likely interacting directly with the channels at the external side of the membrane.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	37-40
18082627-3	2008	We have found that the commonly used JNK inhibitor SP600125 strongly inhibits Kv channels through a JNK-independent pathway, likely interacting directly with the channels at the external side of the membrane.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	100-103
17654528-3	2008	Treatment with either SP600125, a specific chemical inhibitor of JNK, or the expression of a dominant-negative JNK form inhibited autocrine production of uPA and HB-EGF, which block EGFR phosphorylation and mitigates invasive capacity.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Homo sapiens	65-68
17654528-3	2008	Treatment with either SP600125, a specific chemical inhibitor of JNK, or the expression of a dominant-negative JNK form inhibited autocrine production of uPA and HB-EGF, which block EGFR phosphorylation and mitigates invasive capacity.	pyrazolanthrone	22-30	proline rich acidic protein 1	Homo sapiens	154-157
17654528-3	2008	Treatment with either SP600125, a specific chemical inhibitor of JNK, or the expression of a dominant-negative JNK form inhibited autocrine production of uPA and HB-EGF, which block EGFR phosphorylation and mitigates invasive capacity.	pyrazolanthrone	22-30	heparin binding EGF like growth factor	Homo sapiens	162-168
17654528-3	2008	Treatment with either SP600125, a specific chemical inhibitor of JNK, or the expression of a dominant-negative JNK form inhibited autocrine production of uPA and HB-EGF, which block EGFR phosphorylation and mitigates invasive capacity.	pyrazolanthrone	22-30	epidermal growth factor receptor	Homo sapiens	182-186
17996917-4	2008	The ERK1/2-inhibitor PD98059, the p38-inhibitor SB202190 and the JNK1/2-inhibitor SP600125 partially inhibited the fluoride-induced IL-8 response.	pyrazolanthrone	82-90	C-X-C motif chemokine ligand 8	Homo sapiens	132-136
18049903-7	2008	Moreover, hypoxic exposure (90 min) increased the level of nuclear factor-kappa B (NF-kappa B) phosphorylation, which was blocked by a pretreatment with SB 203580 (p38 MAPK inhibitor) or SP 600125 (JNK inhibitor).	pyrazolanthrone	187-196	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	59-81
18065414-8	2008	Transfection of c-Jun and two activators of c-Jun (LiCl and sodium valproate) increased MTHFR expression, whereas a reported inhibitor of c-Jun (SP600125) and a dominant-negative derivative of c-Jun N-terminal kinase-1 reduced MTHFR activation.	pyrazolanthrone	145-153	jun proto-oncogene	Mus musculus	16-21
18049903-7	2008	Moreover, hypoxic exposure (90 min) increased the level of nuclear factor-kappa B (NF-kappa B) phosphorylation, which was blocked by a pretreatment with SB 203580 (p38 MAPK inhibitor) or SP 600125 (JNK inhibitor).	pyrazolanthrone	187-196	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	83-93
18049903-7	2008	Moreover, hypoxic exposure (90 min) increased the level of nuclear factor-kappa B (NF-kappa B) phosphorylation, which was blocked by a pretreatment with SB 203580 (p38 MAPK inhibitor) or SP 600125 (JNK inhibitor).	pyrazolanthrone	187-196	mitogen-activated protein kinase 8	Mus musculus	198-201
18068334-8	2008	Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	40-43
18068334-8	2008	Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect.	pyrazolanthrone	55-63	uncoupling protein 2	Homo sapiens	119-123
18068334-8	2008	Pretreatment of melanoma cells with the JNK inhibitor (SP600125) or the p38 inhibitor (SB203580) blocked taxol-induced UCP2 downregulation, ROS generation and apoptosis, whereas the ERK inhibitor (PD98059) had no such effect.	pyrazolanthrone	55-63	mitogen-activated protein kinase 1	Homo sapiens	182-185
17920124-8	2008	Moreover, the rIL-1beta-induced IL-1beta and COX-2 expression were reduced by p38 MAPK inhibitor (SB203580) and JNK inhibitor (SP600125), respectively.	pyrazolanthrone	127-135	interleukin 1 beta	Rattus norvegicus	14-23
18164704-6	2008	The bFGF-mediated surface cadherin downregulation was significantly reversed only when the HUVECs were treated with JNK inhibitor (SP600125), but not ERK (PD98059) or p38 inhibitor (SB203580).	pyrazolanthrone	131-139	fibroblast growth factor 2	Homo sapiens	4-8
18164704-6	2008	The bFGF-mediated surface cadherin downregulation was significantly reversed only when the HUVECs were treated with JNK inhibitor (SP600125), but not ERK (PD98059) or p38 inhibitor (SB203580).	pyrazolanthrone	131-139	cadherin 5	Homo sapiens	26-34
18164704-6	2008	The bFGF-mediated surface cadherin downregulation was significantly reversed only when the HUVECs were treated with JNK inhibitor (SP600125), but not ERK (PD98059) or p38 inhibitor (SB203580).	pyrazolanthrone	131-139	mitogen-activated protein kinase 8	Homo sapiens	116-119
17973977-8	2008	Despite these similarities, JNK inhibition by SP600125 only affected neurite outgrowth in hippocampal cells.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Mus musculus	28-31
17920124-8	2008	Moreover, the rIL-1beta-induced IL-1beta and COX-2 expression were reduced by p38 MAPK inhibitor (SB203580) and JNK inhibitor (SP600125), respectively.	pyrazolanthrone	127-135	interleukin 1 beta	Homo sapiens	15-23
17920124-8	2008	Moreover, the rIL-1beta-induced IL-1beta and COX-2 expression were reduced by p38 MAPK inhibitor (SB203580) and JNK inhibitor (SP600125), respectively.	pyrazolanthrone	127-135	COX2	Epinephelus coioides	45-50
18256527-4	2008	The JNK-specific inhibitor SP600125 blocked mitotic entry, as shown by its ability to prevent CDK1 dephosphorylation and cyclin A degradation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	4-7
18201371-6	2008	Finally, TNF-alpha treatment of BEC after the addition of both SP and SB, induced a significant increase in S. aureus internalization above the control value.	pyrazolanthrone	63-65	tumor necrosis factor	Bos taurus	9-18
18158102-6	2008	The JNK inhibitor, SP600125 (10 microM), markedly inhibited Ang II-induced JNK phosphorylation (by 84%) and astrocyte proliferation (by over 90%).	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
18158102-6	2008	The JNK inhibitor, SP600125 (10 microM), markedly inhibited Ang II-induced JNK phosphorylation (by 84%) and astrocyte proliferation (by over 90%).	pyrazolanthrone	19-27	angiotensinogen	Rattus norvegicus	60-66
18158102-6	2008	The JNK inhibitor, SP600125 (10 microM), markedly inhibited Ang II-induced JNK phosphorylation (by 84%) and astrocyte proliferation (by over 90%).	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Rattus norvegicus	75-78
17942133-8	2008	Since the MAP kinase pathway induces or inhibits apoptosis depending on the context, we used JNK inhibitor SP600125 and demonstrated drastic suppression of CVPE-induced apoptosis.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	93-96
17959153-0	2008	JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	0-3
17959153-0	2008	JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes.	pyrazolanthrone	14-22	aryl hydrocarbon receptor	Homo sapiens	53-78
17959153-0	2008	JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes.	pyrazolanthrone	14-22	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	91-97
17959153-0	2008	JNK inhibitor SP600125 is a partial agonist of human aryl hydrocarbon receptor and induces CYP1A1 and CYP1A2 genes in primary human hepatocytes.	pyrazolanthrone	14-22	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	102-108
17959153-1	2008	SP600125, a specific inhibitor of c-Jun-N-Terminal kinase (JNK), was reported as a ligand and antagonist of aryl hydrocarbon receptor (AhR) [Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA, Reiners Jr JJ.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	34-57
17959153-1	2008	SP600125, a specific inhibitor of c-Jun-N-Terminal kinase (JNK), was reported as a ligand and antagonist of aryl hydrocarbon receptor (AhR) [Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA, Reiners Jr JJ.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	59-62
17959153-1	2008	SP600125, a specific inhibitor of c-Jun-N-Terminal kinase (JNK), was reported as a ligand and antagonist of aryl hydrocarbon receptor (AhR) [Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA, Reiners Jr JJ.	pyrazolanthrone	0-8	aryl hydrocarbon receptor	Homo sapiens	108-133
17959153-1	2008	SP600125, a specific inhibitor of c-Jun-N-Terminal kinase (JNK), was reported as a ligand and antagonist of aryl hydrocarbon receptor (AhR) [Joiakim A, Mathieu PA, Palermo C, Gasiewicz TA, Reiners Jr JJ.	pyrazolanthrone	0-8	aryl hydrocarbon receptor	Homo sapiens	135-138
17959153-2	2008	The Jun N terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	4-25
17959153-2	2008	The Jun N terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor.	pyrazolanthrone	36-44	aryl hydrocarbon receptor	Homo sapiens	79-104
17959153-4	2008	Here we show that SP600125 is not an antagonist but a partial agonist of human AhR.	pyrazolanthrone	18-26	aryl hydrocarbon receptor	Homo sapiens	79-82
17959153-5	2008	SP600125 significantly induced CYP1A1 and CYP1A2 mRNAs in primary human hepatocytes and CYP1A1 mRNA in human hepatoma cells HepG2.	pyrazolanthrone	0-8	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	31-37
17959153-5	2008	SP600125 significantly induced CYP1A1 and CYP1A2 mRNAs in primary human hepatocytes and CYP1A1 mRNA in human hepatoma cells HepG2.	pyrazolanthrone	0-8	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	42-48
17959153-5	2008	SP600125 significantly induced CYP1A1 and CYP1A2 mRNAs in primary human hepatocytes and CYP1A1 mRNA in human hepatoma cells HepG2.	pyrazolanthrone	0-8	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	88-94
17959153-7	2008	Consistent with the recent report, SP600125 dose-dependently inhibited CYP1A1 and CYP1A2 genes induction by a prototype AhR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in human hepatocytes.	pyrazolanthrone	35-43	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	71-77
17959153-7	2008	Consistent with the recent report, SP600125 dose-dependently inhibited CYP1A1 and CYP1A2 genes induction by a prototype AhR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in human hepatocytes.	pyrazolanthrone	35-43	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	82-88
17959153-7	2008	Consistent with the recent report, SP600125 dose-dependently inhibited CYP1A1 and CYP1A2 genes induction by a prototype AhR ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in human hepatocytes.	pyrazolanthrone	35-43	aryl hydrocarbon receptor	Homo sapiens	120-123
18256527-4	2008	The JNK-specific inhibitor SP600125 blocked mitotic entry, as shown by its ability to prevent CDK1 dephosphorylation and cyclin A degradation.	pyrazolanthrone	27-35	cyclin dependent kinase 1	Homo sapiens	94-98
17959153-14	2008	In conclusion, we demonstrate that SP600125 is a partial agonist of human AhR, which induces CYP1A genes.	pyrazolanthrone	35-43	aryl hydrocarbon receptor	Homo sapiens	74-77
18256527-4	2008	The JNK-specific inhibitor SP600125 blocked mitotic entry, as shown by its ability to prevent CDK1 dephosphorylation and cyclin A degradation.	pyrazolanthrone	27-35	cyclin A2	Homo sapiens	121-129
18187455-7	2008	Chemical inhibitors of JNK (SP600125), but not p38 (SB203580), block WNT3a activation of JNK, whereas both the inhibitors attenuate the WNT3a-beta-catenin pathway.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	23-26
18187455-7	2008	Chemical inhibitors of JNK (SP600125), but not p38 (SB203580), block WNT3a activation of JNK, whereas both the inhibitors attenuate the WNT3a-beta-catenin pathway.	pyrazolanthrone	28-36	Wnt family member 3A	Homo sapiens	69-74
17949889-7	2008	SP600125, an inhibitor of N-terminal c-jun kinases, arrested cells in G(2) and induced an endoreplicative process.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	37-42
18187455-7	2008	Chemical inhibitors of JNK (SP600125), but not p38 (SB203580), block WNT3a activation of JNK, whereas both the inhibitors attenuate the WNT3a-beta-catenin pathway.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	89-92
18456994-1	2008	BACKGROUND: Recent studies have demonstrated that apoptosis in cerebral arteries could play an essential role in cerebral vasospasm after subarachnoid hemorrhage (SAH) and that SP600125, an inhibitor of c-Jun N-terminal kinase (JNK) could suppress apoptosis.	pyrazolanthrone	177-185	Jun proto-oncogene, AP-1 transcription factor subunit	Canis lupus familiaris	203-208
18456994-9	2008	SP600125 reduced angiographic and morphological vasospasm and reduced the expression of cleaved caspase-3, thereby suppressing apoptosis.	pyrazolanthrone	0-8	caspase 3	Canis lupus familiaris	96-105
18043130-7	2008	JNK inhibitor (SP600125) in the culture effectively blocked NCTD-induced cytotoxicity and detachment of cells.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	0-3
18032781-4	2008	The enhancement of VCAM-1 expression caused by U46619 occurred at the transcriptional level and was inhibited either by SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, or by overexpression of a dominant-negative JNK1, but not by SB203580, a p38 mitogen-activated protein kinase inhibitor.	pyrazolanthrone	120-128	vascular cell adhesion molecule 1	Homo sapiens	19-25
17900936-7	2008	In order to know the signaling events involved in the above biological phenomena, caspase-3-like activities of the transfected cells were measured in the absence or presence of JNK inhibitor SP600125, in which caspase-3 and JNK (C-jun-N-terminal kinase) are both known to be critical components of the neuronal apoptosis.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Homo sapiens	177-180
17900936-7	2008	In order to know the signaling events involved in the above biological phenomena, caspase-3-like activities of the transfected cells were measured in the absence or presence of JNK inhibitor SP600125, in which caspase-3 and JNK (C-jun-N-terminal kinase) are both known to be critical components of the neuronal apoptosis.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Homo sapiens	224-227
17900936-8	2008	The results showed that the apoptotic cells exhibited elevated caspase-3-like activity, which could be reduced by SP600125 to some extent.	pyrazolanthrone	114-122	caspase 3	Homo sapiens	63-72
18639962-11	2008	Inhibition of ERK1/2, JNK1/2 and p38 MAPK with PD98059, SP600125 and SB203580, respectively, led to the suppression of the shear stress-induced IL-8 gene expression (P&lt;0.01), which was also blocked by JNK1/2 siRNA (small interfering RNA) (P&lt;0.01).	pyrazolanthrone	56-64	mitogen-activated protein kinase 3	Homo sapiens	14-20
18639962-11	2008	Inhibition of ERK1/2, JNK1/2 and p38 MAPK with PD98059, SP600125 and SB203580, respectively, led to the suppression of the shear stress-induced IL-8 gene expression (P&lt;0.01), which was also blocked by JNK1/2 siRNA (small interfering RNA) (P&lt;0.01).	pyrazolanthrone	56-64	mitogen-activated protein kinase 1	Homo sapiens	33-36
18639962-11	2008	Inhibition of ERK1/2, JNK1/2 and p38 MAPK with PD98059, SP600125 and SB203580, respectively, led to the suppression of the shear stress-induced IL-8 gene expression (P&lt;0.01), which was also blocked by JNK1/2 siRNA (small interfering RNA) (P&lt;0.01).	pyrazolanthrone	56-64	mitogen-activated protein kinase 3	Homo sapiens	37-41
18639962-11	2008	Inhibition of ERK1/2, JNK1/2 and p38 MAPK with PD98059, SP600125 and SB203580, respectively, led to the suppression of the shear stress-induced IL-8 gene expression (P&lt;0.01), which was also blocked by JNK1/2 siRNA (small interfering RNA) (P&lt;0.01).	pyrazolanthrone	56-64	C-X-C motif chemokine ligand 8	Homo sapiens	144-148
17932215-5	2008	Rat pituitary cells were given 60-min pulses of GnRH or media plus the JNK inhibitor SP600125 (SP, 20 microM), p38 inhibitor SB203580 (20 microM), or vehicle.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
17932215-5	2008	Rat pituitary cells were given 60-min pulses of GnRH or media plus the JNK inhibitor SP600125 (SP, 20 microM), p38 inhibitor SB203580 (20 microM), or vehicle.	pyrazolanthrone	85-87	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
17932215-7	2008	SP suppressed both basal and GnRH-induced increases in FSHbeta PT by half, but the magnitude of responses to GnRH was unchanged.	pyrazolanthrone	0-2	follicle stimulating hormone subunit beta	Rattus norvegicus	55-62
18497083-8	2008	Inhibition of JNK activity by a specific inhibitor, SP600125, blocked the siId-1-induced sensitivity to Tx.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	14-17
18497084-6	2008	Furthermore, treatment with 1,25D decreased LNCaP cell invasiveness by approximately 20% after 48 h. Using an inhibitor (SP600125) for the JNK/SAPK MAPK signaling pathway in combination with 1,25D on LNCaP cells, the inhibitory action of 1,25D on invasiveness was eliminated.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	139-142
18457359-5	2008	A selective inhibitor of c-jun N-terminal or stress-activated protein kinases (JNK/SAPK)-SP600125 significantly reversed paeonol-induced down-regulation of melanogenesis.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Mus musculus	79-87
18032781-7	2008	Furthermore, U46619 enhanced IL-1beta-induced THP-1 monocyte binding to VSMCs, which was inhibited by SQ29548 or SP600125.	pyrazolanthrone	113-121	interleukin 1 beta	Homo sapiens	29-37
18032781-7	2008	Furthermore, U46619 enhanced IL-1beta-induced THP-1 monocyte binding to VSMCs, which was inhibited by SQ29548 or SP600125.	pyrazolanthrone	113-121	GLI family zinc finger 2	Homo sapiens	46-51
17514639-6	2008	Consistently, the SP600125 compound, an anthrapyrazolone inhibitor of JNK, suppressed apoptosis induced by CTX III.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	70-73
17947357-0	2008	c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.	pyrazolanthrone	38-46	anti-Mullerian hormone	Mus musculus	58-88
17947357-3	2008	Using an MISRII-dependent activity assay in a small-molecule screen for MIS-mimetic compounds, we have identified the c-Jun N-terminal kinase inhibitor SP600125 as an activator of the MIS signal transduction pathway.	pyrazolanthrone	152-160	anti-Mullerian hormone type 2 receptor	Mus musculus	9-15
17947357-3	2008	Using an MISRII-dependent activity assay in a small-molecule screen for MIS-mimetic compounds, we have identified the c-Jun N-terminal kinase inhibitor SP600125 as an activator of the MIS signal transduction pathway.	pyrazolanthrone	152-160	anti-Mullerian hormone	Mus musculus	9-12
17947357-3	2008	Using an MISRII-dependent activity assay in a small-molecule screen for MIS-mimetic compounds, we have identified the c-Jun N-terminal kinase inhibitor SP600125 as an activator of the MIS signal transduction pathway.	pyrazolanthrone	152-160	anti-Mullerian hormone	Mus musculus	72-75
17947357-4	2008	SP600125 increased the activity of a bone morphogenetic protein-responsive reporter gene in a dose-dependent manner and exerted a synergistic effect when used in combination with MIS.	pyrazolanthrone	0-8	anti-Mullerian hormone	Mus musculus	179-182
17949889-8	2008	SP600125 increased p21 at both the mRNA and protein levels.	pyrazolanthrone	0-8	cyclin dependent kinase inhibitor 1A	Homo sapiens	19-22
17949889-12	2008	CONCLUSION: Our results suggest that KIs modulate proliferation of leukemia cells and that the MEK/ERK inhibitor, PD098059, in combination with either SP600125 or LY294002, could have clinical value.	pyrazolanthrone	151-159	mitogen-activated protein kinase kinase 7	Homo sapiens	95-98
17996851-9	2007	Inhibition of JNK with SP600125 did not affect caspase-3 activation in hippocampal slices.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
18324519-5	2008	Pre-treatment with ROS scavenger NAC, ASMase inhibitor desipramine or JNK inhibitor SP600125 was found to effectively prohibit UVA-induced apoptosis and desipramine markedly blocked phosphorylation of JNK.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	70-73
18324519-5	2008	Pre-treatment with ROS scavenger NAC, ASMase inhibitor desipramine or JNK inhibitor SP600125 was found to effectively prohibit UVA-induced apoptosis and desipramine markedly blocked phosphorylation of JNK.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	201-204
18172084-7	2008	Immunoblot analysis showed that wounding increased the phosphorylation of JNK and of paxillin on serine (Ser) 178 in a manner sensitive to SP600125.	pyrazolanthrone	139-147	mitogen-activated protein kinase 8	Homo sapiens	74-77
18172084-7	2008	Immunoblot analysis showed that wounding increased the phosphorylation of JNK and of paxillin on serine (Ser) 178 in a manner sensitive to SP600125.	pyrazolanthrone	139-147	paxillin	Homo sapiens	85-93
18172084-8	2008	Immunofluorescence staining revealed that phosphorylated JNK colocalized with paxillin at focal adhesions formed by HCE cells at the wound margin and that SP600125 inhibited the formation of such adhesions.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Homo sapiens	57-60
18656701-7	2008	Selective inhibitors of p38 MAPK (SB203580), JNK (SP600125) and ERK (PD98059) could suppress TNF-alpha-induced CCL2 and ICAM-1 expression, while only p38 MAPK and ERK inhibitors could suppress TNF-alpha-induced VCAM-1 expression.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	45-48
18656701-7	2008	Selective inhibitors of p38 MAPK (SB203580), JNK (SP600125) and ERK (PD98059) could suppress TNF-alpha-induced CCL2 and ICAM-1 expression, while only p38 MAPK and ERK inhibitors could suppress TNF-alpha-induced VCAM-1 expression.	pyrazolanthrone	50-58	tumor necrosis factor	Homo sapiens	93-102
18656701-7	2008	Selective inhibitors of p38 MAPK (SB203580), JNK (SP600125) and ERK (PD98059) could suppress TNF-alpha-induced CCL2 and ICAM-1 expression, while only p38 MAPK and ERK inhibitors could suppress TNF-alpha-induced VCAM-1 expression.	pyrazolanthrone	50-58	C-C motif chemokine ligand 2	Homo sapiens	111-115
18656701-7	2008	Selective inhibitors of p38 MAPK (SB203580), JNK (SP600125) and ERK (PD98059) could suppress TNF-alpha-induced CCL2 and ICAM-1 expression, while only p38 MAPK and ERK inhibitors could suppress TNF-alpha-induced VCAM-1 expression.	pyrazolanthrone	50-58	intercellular adhesion molecule 1	Homo sapiens	120-126
18600399-7	2008	The amplification by PDGF-BB of FGF-2-stimulated VEGF release was reduced by PD98059, a specific inhibitor of MEK, or SP600125, a specific inhibitor of SAPK/JNK.	pyrazolanthrone	118-126	fibroblast growth factor 2	Mus musculus	32-37
18600399-7	2008	The amplification by PDGF-BB of FGF-2-stimulated VEGF release was reduced by PD98059, a specific inhibitor of MEK, or SP600125, a specific inhibitor of SAPK/JNK.	pyrazolanthrone	118-126	vascular endothelial growth factor A	Mus musculus	49-53
17904874-0	2007	Induction of endoreduplication by a JNK inhibitor SP600125 in human lung carcinoma A 549 cells.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	36-39
18053155-9	2007	Inhibitors of c-Jun N-terminal kinase (JNK) and p38, other members of MAPK family, SP600125 and SB203850, suppressed the induction of cingulate LTP generated by the pairing protocol.	pyrazolanthrone	83-91	mitogen-activated protein kinase 14	Mus musculus	48-51
17904874-1	2007	The effect of the pan c-Jun N-terminal kinase (JNK) inhibitor SP600125 on the proliferation of human lung carcinoma A549 cells has been evaluated.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	47-50
17904874-4	2007	Moreover, the effect of SP600125 on the expression of cell cycle related proteins was an upregulation of p53 protein accompanied by an increase in its molecular mass.	pyrazolanthrone	24-32	tumor protein p53	Homo sapiens	105-108
17904874-5	2007	Prolonged SP600125 treatment downregulated p21, Bax and Mdm2 expression, but increased the level of the cellular p53-Mdm2 complex.	pyrazolanthrone	10-18	H3 histone pseudogene 16	Homo sapiens	43-46
17904874-5	2007	Prolonged SP600125 treatment downregulated p21, Bax and Mdm2 expression, but increased the level of the cellular p53-Mdm2 complex.	pyrazolanthrone	10-18	BCL2 associated X, apoptosis regulator	Homo sapiens	48-51
17904874-5	2007	Prolonged SP600125 treatment downregulated p21, Bax and Mdm2 expression, but increased the level of the cellular p53-Mdm2 complex.	pyrazolanthrone	10-18	MDM2 proto-oncogene	Homo sapiens	56-60
17904874-5	2007	Prolonged SP600125 treatment downregulated p21, Bax and Mdm2 expression, but increased the level of the cellular p53-Mdm2 complex.	pyrazolanthrone	10-18	tumor protein p53	Homo sapiens	113-116
17904874-5	2007	Prolonged SP600125 treatment downregulated p21, Bax and Mdm2 expression, but increased the level of the cellular p53-Mdm2 complex.	pyrazolanthrone	10-18	MDM2 proto-oncogene	Homo sapiens	117-121
17904874-6	2007	Taken together, we show that SP600125 could induce G2/M cell cycle arrest and endoreduplication in a p21 independent manner, and that SP600125 could also post-translationally modify p53 to modify its function.	pyrazolanthrone	29-37	H3 histone pseudogene 16	Homo sapiens	101-104
17904874-6	2007	Taken together, we show that SP600125 could induce G2/M cell cycle arrest and endoreduplication in a p21 independent manner, and that SP600125 could also post-translationally modify p53 to modify its function.	pyrazolanthrone	134-142	tumor protein p53	Homo sapiens	182-185
17673346-2	2007	The aim of this study was to investigate the effect of pifithrin-alpha (PFTalpha; a specific p53 inhibitor) and mitogen-activated protein kinases (MAPKs) inhibitors [namely SP600125 (a specific JNK inhibitor), SB203580 (a specific p38 inhibitor) and PD98059 (a specific ERK inhibitor)] on apoptotic signaling transduction mechanism induced by Cin in human hepatoma PLC/PRF/5 (CD95-negative) cells.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	194-197
17627770-9	2007	Selective inhibitors of p38 MAPK (SB203580), ERK (PD98059), and JNK (SP600125) could differentially inhibit the production of EGF, VEGF and CCL2, thereby suggesting a role for MAPKs in IL-31 functions.	pyrazolanthrone	69-77	mitogen-activated protein kinase 1	Homo sapiens	24-27
17627770-9	2007	Selective inhibitors of p38 MAPK (SB203580), ERK (PD98059), and JNK (SP600125) could differentially inhibit the production of EGF, VEGF and CCL2, thereby suggesting a role for MAPKs in IL-31 functions.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	64-67
17627770-9	2007	Selective inhibitors of p38 MAPK (SB203580), ERK (PD98059), and JNK (SP600125) could differentially inhibit the production of EGF, VEGF and CCL2, thereby suggesting a role for MAPKs in IL-31 functions.	pyrazolanthrone	69-77	epidermal growth factor	Homo sapiens	126-129
17627770-9	2007	Selective inhibitors of p38 MAPK (SB203580), ERK (PD98059), and JNK (SP600125) could differentially inhibit the production of EGF, VEGF and CCL2, thereby suggesting a role for MAPKs in IL-31 functions.	pyrazolanthrone	69-77	vascular endothelial growth factor A	Homo sapiens	131-135
17627770-9	2007	Selective inhibitors of p38 MAPK (SB203580), ERK (PD98059), and JNK (SP600125) could differentially inhibit the production of EGF, VEGF and CCL2, thereby suggesting a role for MAPKs in IL-31 functions.	pyrazolanthrone	69-77	C-C motif chemokine ligand 2	Homo sapiens	140-144
17961518-4	2007	Both of these effects were prevented by a pharmacological inhibitor (SP600125) of c-jun terminal kinase and by expression of a dominant-negative form of this kinase.	pyrazolanthrone	69-77	jun proto-oncogene	Mus musculus	82-87
17967469-3	2007	We found that inhibition of JNK with SP600125 or JNK inhibitor V, but not an inactive analogue, attenuated the depression of fEPSPs induced by adenosine, hypoxia, and the A1 receptor agonist N(6)-cyclopentyladenosine (CPA).	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	28-31
17967469-4	2007	In contrast, the JNK inhibitor SP600125 did not inhibit GABA(B)-mediated synaptic depression.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
17767919-4	2007	As evidenced by RT-PCR, berberine-induced LDLR mRNA expression was inhibited by JNK inhibitor SP600125 pretreatment.	pyrazolanthrone	94-102	low density lipoprotein receptor	Homo sapiens	42-46
17525747-4	2007	We have demonstrated that FDH induces phosphorylation of JNK1 and JNK2, while treatment of FDH-expressing cells with JNK inhibitor SP600125, as well as knockdown of JNK1 or JNK2 by siRNA, prevents phosphorylation of p53 at Ser6 and protects cells from apoptosis.	pyrazolanthrone	131-139	aldehyde dehydrogenase 1 family member L1	Homo sapiens	91-94
17767919-4	2007	As evidenced by RT-PCR, berberine-induced LDLR mRNA expression was inhibited by JNK inhibitor SP600125 pretreatment.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	80-83
17767919-6	2007	The result of EMSA also shows that berberine induces c-jun binding to LDLR promoter and this is decreased by SP600125 pretreatment.	pyrazolanthrone	109-117	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	53-58
17767919-6	2007	The result of EMSA also shows that berberine induces c-jun binding to LDLR promoter and this is decreased by SP600125 pretreatment.	pyrazolanthrone	109-117	low density lipoprotein receptor	Homo sapiens	70-74
17785464-2	2007	Using two JNK inhibitors (SP600125 and 6o), we have demonstrated that JNK1 is involved in collagen-induced platelet aggregation dependent on ADP.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	70-74
17786558-5	2007	Concomitant administration of SP600125, a selective JNK inhibitor, or aminoguanidine (AG), a selected inducible nitric oxide synthase (iNOS) inhibitor, effectively diminished BCL-2 phosphorylation, suppressed cytochrome c release from mitochondria and caspase activation, and significantly prevented ctx-induced muscle cell apoptosis.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	52-55
17786558-5	2007	Concomitant administration of SP600125, a selective JNK inhibitor, or aminoguanidine (AG), a selected inducible nitric oxide synthase (iNOS) inhibitor, effectively diminished BCL-2 phosphorylation, suppressed cytochrome c release from mitochondria and caspase activation, and significantly prevented ctx-induced muscle cell apoptosis.	pyrazolanthrone	30-38	nitric oxide synthase 2, inducible	Mus musculus	102-133
17786558-5	2007	Concomitant administration of SP600125, a selective JNK inhibitor, or aminoguanidine (AG), a selected inducible nitric oxide synthase (iNOS) inhibitor, effectively diminished BCL-2 phosphorylation, suppressed cytochrome c release from mitochondria and caspase activation, and significantly prevented ctx-induced muscle cell apoptosis.	pyrazolanthrone	30-38	B cell leukemia/lymphoma 2	Mus musculus	175-180
18025271-10	2007	Anti-HER2 antibody in combination with LY294002, rapamycin, or SP600125 induced greater cyclin G2 expression than either agent alone.	pyrazolanthrone	63-71	erb-b2 receptor tyrosine kinase 2	Homo sapiens	5-9
17187235-5	2007	Interestingly, when the c-jun NH2-terminal kinase (JNK) signalling pathway was disrupted by the JNK inhibitor SP600125, the ability of estradiol to inhibit the growth of MCF-7 cells and to induce apoptosis was completely blocked.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	24-49
17187235-5	2007	Interestingly, when the c-jun NH2-terminal kinase (JNK) signalling pathway was disrupted by the JNK inhibitor SP600125, the ability of estradiol to inhibit the growth of MCF-7 cells and to induce apoptosis was completely blocked.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	51-54
17187235-5	2007	Interestingly, when the c-jun NH2-terminal kinase (JNK) signalling pathway was disrupted by the JNK inhibitor SP600125, the ability of estradiol to inhibit the growth of MCF-7 cells and to induce apoptosis was completely blocked.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Homo sapiens	96-99
17689926-6	2007	We also found that blocking JNK signaling pathway by pretreatment with JNK specific inhibitor SP600125, attenuated myostatin-induced upregulation of p21 and downregulation of the differentiation marker gene expression.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Mus musculus	28-31
17689926-6	2007	We also found that blocking JNK signaling pathway by pretreatment with JNK specific inhibitor SP600125, attenuated myostatin-induced upregulation of p21 and downregulation of the differentiation marker gene expression.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Mus musculus	71-74
17689926-6	2007	We also found that blocking JNK signaling pathway by pretreatment with JNK specific inhibitor SP600125, attenuated myostatin-induced upregulation of p21 and downregulation of the differentiation marker gene expression.	pyrazolanthrone	94-102	myostatin	Mus musculus	115-124
17689926-6	2007	We also found that blocking JNK signaling pathway by pretreatment with JNK specific inhibitor SP600125, attenuated myostatin-induced upregulation of p21 and downregulation of the differentiation marker gene expression.	pyrazolanthrone	94-102	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	149-152
17689926-7	2007	Furthermore, it was also observed that the presence of SP600125 almost annulled the growth inhibitory role of myostatin.	pyrazolanthrone	55-63	myostatin	Mus musculus	110-119
17902045-9	2007	LPS-elicited SCs TNF-alpha production was also drastically suppressed by PD98059 (ERK inhibitor), SB202190 (P38 inhibitor), or SP600125 (SAPK/JNK inhibitor).	pyrazolanthrone	127-135	tumor necrosis factor	Homo sapiens	17-26
17702888-7	2007	Inhibition of c-Jun NH(2)-terminal kinase, the molecule downstream of IRE1, by 1,9-pyrazoloanthrone (SP600125) did not improve cell survival.	pyrazolanthrone	79-99	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	70-74
17702888-7	2007	Inhibition of c-Jun NH(2)-terminal kinase, the molecule downstream of IRE1, by 1,9-pyrazoloanthrone (SP600125) did not improve cell survival.	pyrazolanthrone	101-109	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	70-74
18025271-10	2007	Anti-HER2 antibody in combination with LY294002, rapamycin, or SP600125 induced greater cyclin G2 expression than either agent alone.	pyrazolanthrone	63-71	cyclin G2	Homo sapiens	88-97
17923327-3	2007	pre-administration of a p38 inhibitor SB239063 and a JNK inhibitor SP600125 in the conscious rat.	pyrazolanthrone	67-75	mitogen-activated protein kinase 8	Rattus norvegicus	53-56
17940558-7	2007	(3) The upregulation effect of ProMMP-7 was partially blocked after incubation of ERK1/2 inhibitors PD98059 and P38 inhibitors SB203580 prior to FVIIa, The expression of ProMMP-7 decreased by 32%+/-5% and 61%+/-10% respectively (P&lt;0.05).whereas JNK inhibitors SP600125 did not have the effect.	pyrazolanthrone	263-271	mitogen-activated protein kinase 3	Homo sapiens	82-88
17940706-10	2007	Inhibition of Akt activation with LY294002 abolished, and inhibition of JNK activation with SP600125 enhanced the cardioprotection by insulin, respectively.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Rattus norvegicus	72-75
17940706-12	2007	In addition, SP600125 also decreased the Akt phosphorylation (n=6, P&lt;0.05).	pyrazolanthrone	13-21	AKT serine/threonine kinase 1	Rattus norvegicus	41-44
17940558-7	2007	(3) The upregulation effect of ProMMP-7 was partially blocked after incubation of ERK1/2 inhibitors PD98059 and P38 inhibitors SB203580 prior to FVIIa, The expression of ProMMP-7 decreased by 32%+/-5% and 61%+/-10% respectively (P&lt;0.05).whereas JNK inhibitors SP600125 did not have the effect.	pyrazolanthrone	263-271	mitogen-activated protein kinase 1	Homo sapiens	112-115
17940558-7	2007	(3) The upregulation effect of ProMMP-7 was partially blocked after incubation of ERK1/2 inhibitors PD98059 and P38 inhibitors SB203580 prior to FVIIa, The expression of ProMMP-7 decreased by 32%+/-5% and 61%+/-10% respectively (P&lt;0.05).whereas JNK inhibitors SP600125 did not have the effect.	pyrazolanthrone	263-271	mitogen-activated protein kinase 8	Homo sapiens	248-251
17908987-11	2007	Reduced amounts and phosphorylation of epidermal growth factor receptor were found in tumor cells after treatment with SP600125.	pyrazolanthrone	119-127	epidermal growth factor receptor	Homo sapiens	39-71
17698840-4	2007	In contrast, TRAIL caused increased binding between Mcl-1 and Bak that was diminished by treatment with the caspase 8 inhibitor N-(N(alpha)-acetylisoleucylglutamylthreonyl) aspartic acid (O-methyl ester)-fluoromethyl ketone (IETD(OMe)-fmk) or the c-Jun N-terminal kinase inhibitor SP600125.	pyrazolanthrone	281-289	TNF superfamily member 10	Homo sapiens	13-18
17698840-4	2007	In contrast, TRAIL caused increased binding between Mcl-1 and Bak that was diminished by treatment with the caspase 8 inhibitor N-(N(alpha)-acetylisoleucylglutamylthreonyl) aspartic acid (O-methyl ester)-fluoromethyl ketone (IETD(OMe)-fmk) or the c-Jun N-terminal kinase inhibitor SP600125.	pyrazolanthrone	281-289	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	52-57
17698840-4	2007	In contrast, TRAIL caused increased binding between Mcl-1 and Bak that was diminished by treatment with the caspase 8 inhibitor N-(N(alpha)-acetylisoleucylglutamylthreonyl) aspartic acid (O-methyl ester)-fluoromethyl ketone (IETD(OMe)-fmk) or the c-Jun N-terminal kinase inhibitor SP600125.	pyrazolanthrone	281-289	BCL2 antagonist/killer 1	Homo sapiens	62-65
17698840-4	2007	In contrast, TRAIL caused increased binding between Mcl-1 and Bak that was diminished by treatment with the caspase 8 inhibitor N-(N(alpha)-acetylisoleucylglutamylthreonyl) aspartic acid (O-methyl ester)-fluoromethyl ketone (IETD(OMe)-fmk) or the c-Jun N-terminal kinase inhibitor SP600125.	pyrazolanthrone	281-289	caspase 8	Homo sapiens	108-117
17698840-5	2007	In addition, TRAIL caused increased binding of Bim and Puma to Mcl-1 that was inhibited by IETD(OMe)-fmk but not SP600125.	pyrazolanthrone	113-121	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	63-68
17669626-7	2007	In contrast, JNK inhibitor SP600125 inhibited EV71-induced VCAM-1 expression.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Rattus norvegicus	13-16
17669626-7	2007	In contrast, JNK inhibitor SP600125 inhibited EV71-induced VCAM-1 expression.	pyrazolanthrone	27-35	vascular cell adhesion molecule 1	Rattus norvegicus	59-65
17702750-8	2007	Pretreatment of mice with the JNK inhibitor SP600125 before norBNI attenuated the long acting antagonism.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Mus musculus	30-33
17916230-6	2007	Selective inhibitors of MAPKinases (respectively PD98059, SB203580 and SP600125) and of Sp-1 signaling (mithramycin) decreased IL-10 expression in HAM.	pyrazolanthrone	71-79	interleukin 10	Homo sapiens	127-132
17626263-5	2007	SNP-induced cytotoxicity was blocked by the c-jun N-terminal protein kinase (JNK) inhibitor SP600125 (20 microM), the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (20 microM), and the extracellular signal-regulating kinase (ERK) inhibitor U0126 (10 microM), and the nitric oxide donor stimulated the phosphorylation of p38 MAP kinase, JNK, and ERK.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	44-75
17965521-3	2007	A protein kinase (PK) inhibitor (staurosporine), c-jun N-terminal kinase (JNK) pathway inhibitor (curcumin), and JNK inhibitor (SP600125) attenuated 1alpha,25(OH)(2)D(3)-induced CYP3A4 mRNA expression, suggesting that the PK-JNK pathway contributed to the rapid and drastic induction of CYP3A4 expression via VDR in LS180 cells.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	113-116
17965521-3	2007	A protein kinase (PK) inhibitor (staurosporine), c-jun N-terminal kinase (JNK) pathway inhibitor (curcumin), and JNK inhibitor (SP600125) attenuated 1alpha,25(OH)(2)D(3)-induced CYP3A4 mRNA expression, suggesting that the PK-JNK pathway contributed to the rapid and drastic induction of CYP3A4 expression via VDR in LS180 cells.	pyrazolanthrone	128-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	178-184
17965521-3	2007	A protein kinase (PK) inhibitor (staurosporine), c-jun N-terminal kinase (JNK) pathway inhibitor (curcumin), and JNK inhibitor (SP600125) attenuated 1alpha,25(OH)(2)D(3)-induced CYP3A4 mRNA expression, suggesting that the PK-JNK pathway contributed to the rapid and drastic induction of CYP3A4 expression via VDR in LS180 cells.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	113-116
17965521-3	2007	A protein kinase (PK) inhibitor (staurosporine), c-jun N-terminal kinase (JNK) pathway inhibitor (curcumin), and JNK inhibitor (SP600125) attenuated 1alpha,25(OH)(2)D(3)-induced CYP3A4 mRNA expression, suggesting that the PK-JNK pathway contributed to the rapid and drastic induction of CYP3A4 expression via VDR in LS180 cells.	pyrazolanthrone	128-136	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	287-293
17965521-3	2007	A protein kinase (PK) inhibitor (staurosporine), c-jun N-terminal kinase (JNK) pathway inhibitor (curcumin), and JNK inhibitor (SP600125) attenuated 1alpha,25(OH)(2)D(3)-induced CYP3A4 mRNA expression, suggesting that the PK-JNK pathway contributed to the rapid and drastic induction of CYP3A4 expression via VDR in LS180 cells.	pyrazolanthrone	128-136	vitamin D receptor	Homo sapiens	309-312
17596899-8	2007	Both a p38 inhibitor (SB203580) and a JNK inhibitor (SP600125) reverse the effects of Abeta as an increase in the mEPSCs frequency and amplitude was observed.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	38-41
17596899-8	2007	Both a p38 inhibitor (SB203580) and a JNK inhibitor (SP600125) reverse the effects of Abeta as an increase in the mEPSCs frequency and amplitude was observed.	pyrazolanthrone	53-61	amyloid beta precursor protein	Homo sapiens	86-91
17626263-5	2007	SNP-induced cytotoxicity was blocked by the c-jun N-terminal protein kinase (JNK) inhibitor SP600125 (20 microM), the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (20 microM), and the extracellular signal-regulating kinase (ERK) inhibitor U0126 (10 microM), and the nitric oxide donor stimulated the phosphorylation of p38 MAP kinase, JNK, and ERK.	pyrazolanthrone	92-100	mitogen-activated protein kinase 8	Homo sapiens	77-80
17631902-17	2007	Local application of MAPK inhibitors (PD98059, SB230580, and SP600125) within a pluronic gel reduced respective MAPK activity, decreased cell proliferation and enhanced cell apoptosis, increased PAI-1, and decreased uPA expression and activity; at 14 days there was a decrease in intimal hyperplasia.	pyrazolanthrone	61-69	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	195-200
17982228-5	2007	In addition, pretreatment of cells with NF-kappaB inhibitor (MG-132) or JNK inhibitor (SP600125) significantly inhibited ICAM-1 expression promoted by HDM extract.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	72-75
17982228-5	2007	In addition, pretreatment of cells with NF-kappaB inhibitor (MG-132) or JNK inhibitor (SP600125) significantly inhibited ICAM-1 expression promoted by HDM extract.	pyrazolanthrone	87-95	intercellular adhesion molecule 1	Homo sapiens	121-127
17891746-8	2007	The specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 abolished c-Jun phosphorylation at all time points and blunted TGF-beta- or BSA-induced procollagen-1alpha 1 and MCP-1 gene expression in HK-2 cells.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Mus musculus	13-36
17891746-8	2007	The specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 abolished c-Jun phosphorylation at all time points and blunted TGF-beta- or BSA-induced procollagen-1alpha 1 and MCP-1 gene expression in HK-2 cells.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Mus musculus	38-41
17891746-8	2007	The specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 abolished c-Jun phosphorylation at all time points and blunted TGF-beta- or BSA-induced procollagen-1alpha 1 and MCP-1 gene expression in HK-2 cells.	pyrazolanthrone	53-61	jun proto-oncogene	Mus musculus	13-18
17891746-8	2007	The specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 abolished c-Jun phosphorylation at all time points and blunted TGF-beta- or BSA-induced procollagen-1alpha 1 and MCP-1 gene expression in HK-2 cells.	pyrazolanthrone	53-61	transforming growth factor beta 1	Homo sapiens	125-133
17891746-8	2007	The specific c-Jun N-terminal kinase (JNK) inhibitor SP600125 abolished c-Jun phosphorylation at all time points and blunted TGF-beta- or BSA-induced procollagen-1alpha 1 and MCP-1 gene expression in HK-2 cells.	pyrazolanthrone	53-61	mast cell protease 1	Mus musculus	175-180
17397922-4	2007	Moreover, IQDMA-mediated G2/M phase arrest and apoptosis were reversed after treatment with the JNK-specific inhibitors, SP600125 and JNK inhibitor 1.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	96-99
17631902-17	2007	Local application of MAPK inhibitors (PD98059, SB230580, and SP600125) within a pluronic gel reduced respective MAPK activity, decreased cell proliferation and enhanced cell apoptosis, increased PAI-1, and decreased uPA expression and activity; at 14 days there was a decrease in intimal hyperplasia.	pyrazolanthrone	61-69	proline-rich acidic protein 1	Mus musculus	216-219
17875713-6	2007	Double mutations at Ser(213) and Ser(217) suppressed NFAT3 transactivation activity; and SP600125, a JNK inhibitor, suppressed NFAT3-induced 3xNFAT-luciferase activity.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Mus musculus	101-104
17397922-5	2007	Further investigation showed that SP600125 reduced the activation of FasL, caspase-3, caspase-8, and led to a marked decline of p21.	pyrazolanthrone	34-42	Fas ligand	Homo sapiens	69-73
17397922-5	2007	Further investigation showed that SP600125 reduced the activation of FasL, caspase-3, caspase-8, and led to a marked decline of p21.	pyrazolanthrone	34-42	caspase 3	Homo sapiens	75-84
17397922-5	2007	Further investigation showed that SP600125 reduced the activation of FasL, caspase-3, caspase-8, and led to a marked decline of p21.	pyrazolanthrone	34-42	caspase 8	Homo sapiens	86-95
17397922-5	2007	Further investigation showed that SP600125 reduced the activation of FasL, caspase-3, caspase-8, and led to a marked decline of p21.	pyrazolanthrone	34-42	H3 histone pseudogene 16	Homo sapiens	128-131
17686764-5	2007	In contrast, treatment of the cells with Bim siRNA or the JNK inhibitor SP600125 attenuated lysosomal permeabilization and cell death.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Homo sapiens	58-61
17645865-3	2007	Employment of c-Jun N-terminal kinase (JNK) inhibitor SP600125 resulted in 3-fold reduction of IGFBP-1 mRNA and protein levels, indicating that IL-1beta-induced IGFBP-1 production is mediated through JNK activation.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Rattus norvegicus	14-37
17645865-3	2007	Employment of c-Jun N-terminal kinase (JNK) inhibitor SP600125 resulted in 3-fold reduction of IGFBP-1 mRNA and protein levels, indicating that IL-1beta-induced IGFBP-1 production is mediated through JNK activation.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Rattus norvegicus	39-42
17645865-3	2007	Employment of c-Jun N-terminal kinase (JNK) inhibitor SP600125 resulted in 3-fold reduction of IGFBP-1 mRNA and protein levels, indicating that IL-1beta-induced IGFBP-1 production is mediated through JNK activation.	pyrazolanthrone	54-62	insulin-like growth factor binding protein 1	Rattus norvegicus	95-102
17645865-3	2007	Employment of c-Jun N-terminal kinase (JNK) inhibitor SP600125 resulted in 3-fold reduction of IGFBP-1 mRNA and protein levels, indicating that IL-1beta-induced IGFBP-1 production is mediated through JNK activation.	pyrazolanthrone	54-62	interleukin 1 beta	Rattus norvegicus	144-152
17645865-3	2007	Employment of c-Jun N-terminal kinase (JNK) inhibitor SP600125 resulted in 3-fold reduction of IGFBP-1 mRNA and protein levels, indicating that IL-1beta-induced IGFBP-1 production is mediated through JNK activation.	pyrazolanthrone	54-62	insulin-like growth factor binding protein 1	Rattus norvegicus	161-168
17645865-3	2007	Employment of c-Jun N-terminal kinase (JNK) inhibitor SP600125 resulted in 3-fold reduction of IGFBP-1 mRNA and protein levels, indicating that IL-1beta-induced IGFBP-1 production is mediated through JNK activation.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Rattus norvegicus	200-203
17645865-5	2007	IL-1beta-induced phosphorylation of JNK was also significantly higher in aged hepatocytes, and SP600125 treatment eliminated age-related differences in IGFBP-1 mRNA production.	pyrazolanthrone	95-103	insulin-like growth factor binding protein 1	Rattus norvegicus	152-159
17875713-6	2007	Double mutations at Ser(213) and Ser(217) suppressed NFAT3 transactivation activity; and SP600125, a JNK inhibitor, suppressed NFAT3-induced 3xNFAT-luciferase activity.	pyrazolanthrone	89-97	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 4	Mus musculus	127-132
17458902-4	2007	E2/IGF-I-induced proliferation was blocked by chemical inhibitors of ERKs (PD98059) and JNKs (SP600125).	pyrazolanthrone	94-102	cystatin 12, pseudogene	Homo sapiens	0-8
17615156-5	2007	Prolongation of events associated with NF-kappaB activation was also observed in cells pretreated and/or cotransfected with the JNK inhibitor SP600125 or deletion mutants of MEKK1 (MEKK1-KD) or Jun (Jun-DN).	pyrazolanthrone	142-150	mitogen-activated protein kinase 8	Rattus norvegicus	128-131
17615156-5	2007	Prolongation of events associated with NF-kappaB activation was also observed in cells pretreated and/or cotransfected with the JNK inhibitor SP600125 or deletion mutants of MEKK1 (MEKK1-KD) or Jun (Jun-DN).	pyrazolanthrone	142-150	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	199-205
17690186-2	2007	In vitro and in vivo invasion assays using Matrigel and chick embryo chorioallantoic membrane approaches showed constitutive activation of JNK to significantly increase two processes, invasion and angiogenesis, in the human urothelial carcinoma cell line kU-7, this being suppressed by a JNK inhibitor, SP600125, or cell-permeable peptides.	pyrazolanthrone	303-311	mitogen-activated protein kinase 8	Homo sapiens	139-142
17416736-6	2007	Inhibition of JNK activity using SP600125 decreased cJun phosphorylation and AP-1 transcriptional activity and this was associated with decreased cell proliferation and G2/M cell-cycle arrest in a dose-dependent manner.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	14-17
17416736-6	2007	Inhibition of JNK activity using SP600125 decreased cJun phosphorylation and AP-1 transcriptional activity and this was associated with decreased cell proliferation and G2/M cell-cycle arrest in a dose-dependent manner.	pyrazolanthrone	33-41	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	52-56
17651887-4	2007	Treatment of PD98059 (ERK-specific inhibitor), SB203580 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) decreases the elevation of NGF and p75 mRNA induced by (Ac)(5)GP, indicating possible transcription regulation via MAPKs.	pyrazolanthrone	81-89	mitogen-activated protein kinase 8	Homo sapiens	91-94
17651887-4	2007	Treatment of PD98059 (ERK-specific inhibitor), SB203580 (p38 MAPK inhibitor) and SP600125 (JNK inhibitor) decreases the elevation of NGF and p75 mRNA induced by (Ac)(5)GP, indicating possible transcription regulation via MAPKs.	pyrazolanthrone	81-89	PC4 and SFRS1 interacting protein 1	Homo sapiens	141-144
17458902-5	2007	An increase in the expression of c-Jun protein was detected in E2/IGF-I-treated MCF-7 cells, and this was inhibited by PD98059 and SP600125.	pyrazolanthrone	131-139	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	33-38
17458902-5	2007	An increase in the expression of c-Jun protein was detected in E2/IGF-I-treated MCF-7 cells, and this was inhibited by PD98059 and SP600125.	pyrazolanthrone	131-139	cystatin 12, pseudogene	Homo sapiens	63-71
17533154-7	2007	A Galpha(12/13)-inhibitory polypeptide derived from the regulator of the G-protein signaling domain of p115-Rho guanine nucleotide exchange factor and a JNK inhibitor, SP600125, suppressed the ET-1-induced increase in expression of marker proteins of myofibroblast formation through a Galpha(12/13)-reactive oxygen species-JNK pathway.	pyrazolanthrone	168-176	G protein subunit alpha 13	Rattus norvegicus	2-14
17805054-9	2007	SP600125-mediated c-Jun N-terminal kinase inhibition, but not extracellular-regulated kinase 1/2 inhibition, resulted in a decrease in phosphorylation of 4E-BP1, consequently decreasing cap-dependent activation.	pyrazolanthrone	0-8	eukaryotic translation initiation factor 4E binding protein 1	Homo sapiens	154-160
17586463-3	2007	CTAR2 is known to engage the c-Jun N-terminal kinase (JNK) and NF-kappaB pathways, and we show here that SP600125, a selective JNK inhibitor, suppresses LMP1 potentiation of cisplatin-induced mitochondrial damage and caspase activation in HeLa cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	29-52
17586463-3	2007	CTAR2 is known to engage the c-Jun N-terminal kinase (JNK) and NF-kappaB pathways, and we show here that SP600125, a selective JNK inhibitor, suppresses LMP1 potentiation of cisplatin-induced mitochondrial damage and caspase activation in HeLa cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	54-57
17586463-3	2007	CTAR2 is known to engage the c-Jun N-terminal kinase (JNK) and NF-kappaB pathways, and we show here that SP600125, a selective JNK inhibitor, suppresses LMP1 potentiation of cisplatin-induced mitochondrial damage and caspase activation in HeLa cells.	pyrazolanthrone	105-113	nuclear factor kappa B subunit 1	Homo sapiens	63-72
17586463-3	2007	CTAR2 is known to engage the c-Jun N-terminal kinase (JNK) and NF-kappaB pathways, and we show here that SP600125, a selective JNK inhibitor, suppresses LMP1 potentiation of cisplatin-induced mitochondrial damage and caspase activation in HeLa cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	127-130
17586463-3	2007	CTAR2 is known to engage the c-Jun N-terminal kinase (JNK) and NF-kappaB pathways, and we show here that SP600125, a selective JNK inhibitor, suppresses LMP1 potentiation of cisplatin-induced mitochondrial damage and caspase activation in HeLa cells.	pyrazolanthrone	105-113	PDZ and LIM domain 7	Homo sapiens	153-157
17533154-7	2007	A Galpha(12/13)-inhibitory polypeptide derived from the regulator of the G-protein signaling domain of p115-Rho guanine nucleotide exchange factor and a JNK inhibitor, SP600125, suppressed the ET-1-induced increase in expression of marker proteins of myofibroblast formation through a Galpha(12/13)-reactive oxygen species-JNK pathway.	pyrazolanthrone	168-176	G protein subunit alpha 12	Rattus norvegicus	285-297
17533154-7	2007	A Galpha(12/13)-inhibitory polypeptide derived from the regulator of the G-protein signaling domain of p115-Rho guanine nucleotide exchange factor and a JNK inhibitor, SP600125, suppressed the ET-1-induced increase in expression of marker proteins of myofibroblast formation through a Galpha(12/13)-reactive oxygen species-JNK pathway.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Rattus norvegicus	323-326
17557802-6	2007	Importantly, the decrease in TEpR was attenuated by using p38 MAPK inhibitors (SB-203580) but was partially affected by JNK inhibitor SP-600125.	pyrazolanthrone	134-143	mitogen-activated protein kinase 8	Homo sapiens	120-123
17671214-4	2007	The guggulsterone-induced apoptosis in PC-3/LNCaP cells was partially but statistically significantly attenuated by pharmacologic inhibition (SP600125) as well as genetic suppression of JNK activation.	pyrazolanthrone	142-150	proprotein convertase subtilisin/kexin type 1	Homo sapiens	39-43
17603935-7	2007	Moreover, we observed that the JNK inhibitor SP600125 abolished TNF-induced changes in LIP, which suggests that JNK kinases are involved in this process.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
17470478-7	2007	c-jun N-terminal kinase (JNK) inhibition was attained with SP600125.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	0-23
17570321-7	2007	A specific ERK inhibitor PD98059 significantly blocks SITO-induced-apoptosis, whereas a JNK inhibitor SP600125 has no affect.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Mus musculus	88-91
17641275-8	2007	Using the NFkappaB inhibitor sulfasalazine and the AP-1 inhibitor SP600125, it became clear that the IL-1beta-induced decrease in TRalpha mRNA expression in HepG2 cells can only be abolished by simultaneous inhibition of NFkappaB and AP-1.	pyrazolanthrone	66-74	interleukin 1 beta	Homo sapiens	101-109
17641275-8	2007	Using the NFkappaB inhibitor sulfasalazine and the AP-1 inhibitor SP600125, it became clear that the IL-1beta-induced decrease in TRalpha mRNA expression in HepG2 cells can only be abolished by simultaneous inhibition of NFkappaB and AP-1.	pyrazolanthrone	66-74	T cell receptor alpha locus	Homo sapiens	130-137
17433832-11	2007	SP600125 significantly repressed LPS-stimulated release of IL-1beta and TNF-alpha at all concentrations, whereas LPS-stimulated IL-6, PGE(2) and PGF(2alpha) release were inhibited at 25 and 50 microM.	pyrazolanthrone	0-8	interleukin 1 beta	Homo sapiens	59-67
17433832-11	2007	SP600125 significantly repressed LPS-stimulated release of IL-1beta and TNF-alpha at all concentrations, whereas LPS-stimulated IL-6, PGE(2) and PGF(2alpha) release were inhibited at 25 and 50 microM.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	72-81
17485074-12	2007	The JNK inhibitor SP600125 seemed to slightly diminish AZA-1 effects, however due to the effects of the drug by itself the involvement of JNK in AZA-1 toxicity needs further investigation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
17470478-7	2007	c-jun N-terminal kinase (JNK) inhibition was attained with SP600125.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	25-28
17438009-4	2007	In this study, we evaluated the effect that SP600125, a selective inhibitor of phosphorylated JNK (p-JNK), has on the renal damage caused by cisplatin use.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Rattus norvegicus	94-97
17438009-4	2007	In this study, we evaluated the effect that SP600125, a selective inhibitor of phosphorylated JNK (p-JNK), has on the renal damage caused by cisplatin use.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Rattus norvegicus	101-104
17408985-10	2007	MS-induced JNK phosphorylation was inhibited by SB203580 at concentrations &gt; or =5 microM and activation of JNK1 following MS was blocked by SP600125 and partially inhibited by anti-CD29.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	11-14
17408985-10	2007	MS-induced JNK phosphorylation was inhibited by SB203580 at concentrations &gt; or =5 microM and activation of JNK1 following MS was blocked by SP600125 and partially inhibited by anti-CD29.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	111-115
17433832-8	2007	Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively.	pyrazolanthrone	26-34	mitogen-activated protein kinase 3	Homo sapiens	102-109
17433832-8	2007	Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	111-114
17433832-8	2007	Co-incubation with U0126, SP600125 and SB202190 significantly suppressed LPS-stimulated activation of ERK 1/2, JNK, and p38 MAPK, respectively.	pyrazolanthrone	26-34	mitogen-activated protein kinase 1	Homo sapiens	120-123
17499220-4	2007	The HO-1 inducting effect of LCY-2-CHO was inhibited by SB203580, N(G)-nitro-l-arginine methylester (l-NAME), and wortmannin, but was not affected by U0126 or SP600125.	pyrazolanthrone	159-167	heme oxygenase 1	Rattus norvegicus	4-8
17603935-7	2007	Moreover, we observed that the JNK inhibitor SP600125 abolished TNF-induced changes in LIP, which suggests that JNK kinases are involved in this process.	pyrazolanthrone	45-53	tumor necrosis factor	Homo sapiens	64-67
17603935-7	2007	Moreover, we observed that the JNK inhibitor SP600125 abolished TNF-induced changes in LIP, which suggests that JNK kinases are involved in this process.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	112-115
17471173-8	2007	C5a-evoked migration in RAW264.7 cells was significantly suppressed by wortmannin (phosphatidylinositol 3-kinase (PI3K) inhibitor), PD98059 (MEK1/2 inhibitor) and SB203580 (p38 mitogen-activated protein kinase (MAPK) inhibitor), but not by SP600125 (c-Jun N-terminal kinase (JNK) inhibitor), suggesting that activation of PI3K, ERK1/2 and p38 MAPK signal pathways was involved in responses to C5a.	pyrazolanthrone	240-248	hemolytic complement	Mus musculus	0-3
17600621-11	2007	Furthermore, the p38 MAPK-specific inhibitor SB203580 and the JNK-specific inhibitor SP600125 prevented glutamate-induced neuronal death in these primary cultures.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Homo sapiens	62-65
17468136-5	2007	The mitogenic activity of TGF-beta1 on ASM cells was inhibited by selective inhibitors of TGF-beta receptor I kinase (SD-208), phosphatidylinositol 3-kinase (PI3K, LY-294002), ERK (PD-98059), JNK (SP-600125), and NF-kappaB (AS-602868).	pyrazolanthrone	197-206	transforming growth factor beta 1	Homo sapiens	26-35
17463335-7	2007	Furthermore, pretreatment with the respective specific mitogen-activated protein kinase (MAPK) inhibitors (SB203580, PD98059, and SP600125) and NFkappaB inhibitor (Bay-11 to 7082) could block SAA-dependent TF induction.	pyrazolanthrone	130-138	serum amyloid A1 cluster	Homo sapiens	192-195
17463335-7	2007	Furthermore, pretreatment with the respective specific mitogen-activated protein kinase (MAPK) inhibitors (SB203580, PD98059, and SP600125) and NFkappaB inhibitor (Bay-11 to 7082) could block SAA-dependent TF induction.	pyrazolanthrone	130-138	coagulation factor III, tissue factor	Homo sapiens	206-208
17431009-10	2007	Insulin or SP600125, a chemical inhibitor of c-Jun NH2 terminal kinase, blocked palmitate-mediated activation of c-Jun NH2 terminal kinase and reduced apoptosis.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Rattus norvegicus	45-70
17372274-11	2007	The present study revealed that topical application of SP600125, a pharmacological inhibitor of c-Jun-N-terminal kinase (JNK), abrogated the activation of AP-1 and the expression of COX-2 in TPA-treated mouse skin.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Mus musculus	96-119
17372274-11	2007	The present study revealed that topical application of SP600125, a pharmacological inhibitor of c-Jun-N-terminal kinase (JNK), abrogated the activation of AP-1 and the expression of COX-2 in TPA-treated mouse skin.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Mus musculus	121-124
17372274-11	2007	The present study revealed that topical application of SP600125, a pharmacological inhibitor of c-Jun-N-terminal kinase (JNK), abrogated the activation of AP-1 and the expression of COX-2 in TPA-treated mouse skin.	pyrazolanthrone	55-63	jun proto-oncogene	Mus musculus	155-159
17372274-11	2007	The present study revealed that topical application of SP600125, a pharmacological inhibitor of c-Jun-N-terminal kinase (JNK), abrogated the activation of AP-1 and the expression of COX-2 in TPA-treated mouse skin.	pyrazolanthrone	55-63	prostaglandin-endoperoxide synthase 2	Mus musculus	182-187
17431009-10	2007	Insulin or SP600125, a chemical inhibitor of c-Jun NH2 terminal kinase, blocked palmitate-mediated activation of c-Jun NH2 terminal kinase and reduced apoptosis.	pyrazolanthrone	11-19	mitogen-activated protein kinase 8	Rattus norvegicus	113-138
17460151-0	2007	Attenuation of ozone-induced airway inflammation and hyper-responsiveness by c-Jun NH2 terminal kinase inhibitor SP600125.	pyrazolanthrone	113-121	jun proto-oncogene	Mus musculus	77-82
17460151-3	2007	SP600125 [anthra[1,9-cd] pyrazol-6 (2H)-one], a specific JNK inhibitor (30 mg/kg) or vehicle, was administered by intraperitoneal injection before and after ozone exposure (3 ppm for 3 h).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	57-60
17460151-5	2007	Ozone exposure induced activation of JNK in the lung as measured by the expression of phosphorylated-c-Jun, an effect abolished by SP600125.	pyrazolanthrone	131-139	mitogen-activated protein kinase 8	Mus musculus	37-40
17460151-5	2007	Ozone exposure induced activation of JNK in the lung as measured by the expression of phosphorylated-c-Jun, an effect abolished by SP600125.	pyrazolanthrone	131-139	jun proto-oncogene	Mus musculus	101-106
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	0-8	interleukin 6	Mus musculus	73-77
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	0-8	chemokine (C-C motif) ligand 2	Mus musculus	82-86
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	0-8	metallothionein 1	Mus musculus	148-165
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	0-8	hemopexin	Mus musculus	167-176
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	228-236	metallothionein 1	Mus musculus	148-165
17460151-7	2007	SP600125 modulated the expression of a subset of 29 ozone-induced genes; IL-6 and CCL2 expression were further increased, whereas the expression of metallothionein 1, hemopexin, and mitogen-activated 3 kinase 6 was decreased in SP600125-treated ozone-exposed mice.	pyrazolanthrone	228-236	hemopexin	Mus musculus	167-176
17494073-8	2007	Moreover, the pharmacological inhibition of JNK by SP600125 inhibits Bax activation and cytochrome c release.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	44-47
17125918-6	2007	On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells.	pyrazolanthrone	156-164	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	70-75
17494073-8	2007	Moreover, the pharmacological inhibition of JNK by SP600125 inhibits Bax activation and cytochrome c release.	pyrazolanthrone	51-59	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
17494073-8	2007	Moreover, the pharmacological inhibition of JNK by SP600125 inhibits Bax activation and cytochrome c release.	pyrazolanthrone	51-59	cytochrome c, somatic	Homo sapiens	88-100
17592815-8	2007	Addition of SP600125, a specific JNK inhibitor, protected hepatocytes against GCDC-induced apoptosis.	pyrazolanthrone	12-20	mitogen-activated protein kinase 8	Rattus norvegicus	33-36
17959047-7	2007	Three chemical inhibitors of MAPK (AG126, SP600125 and SB203580) could significantly inhibit the cell cycle alteration because of BaP treatment.	pyrazolanthrone	42-50	mitogen-activated protein kinase 3	Homo sapiens	29-33
17568197-8	2007	While in differentiated PC12 cells, the process of apoptosis could only be inhibited effectively by Z-IETD-fmk and SP600125 cotreatment, and SP600125 inhibited the Bax translocation to mitochondria implying that JNK mediated activation of Bax.	pyrazolanthrone	141-149	BCL2 associated X, apoptosis regulator	Rattus norvegicus	164-167
17568197-8	2007	While in differentiated PC12 cells, the process of apoptosis could only be inhibited effectively by Z-IETD-fmk and SP600125 cotreatment, and SP600125 inhibited the Bax translocation to mitochondria implying that JNK mediated activation of Bax.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Rattus norvegicus	212-215
17568197-8	2007	While in differentiated PC12 cells, the process of apoptosis could only be inhibited effectively by Z-IETD-fmk and SP600125 cotreatment, and SP600125 inhibited the Bax translocation to mitochondria implying that JNK mediated activation of Bax.	pyrazolanthrone	141-149	BCL2 associated X, apoptosis regulator	Rattus norvegicus	239-242
17125918-6	2007	On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	114-139
17125918-6	2007	On the other hand, simvastatin strongly stimulated phosphorylation of c-jun which was completely abolished by the c-jun NH2-terminal kinase (JNK) inhibitor SP600125, which also significantly reduced the antiproliferative and apoptotic effects of simvastatin in these cells.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	141-144
17303384-3	2007	LPS-induced expression of VCAM-1 protein and mRNA in a time-dependent manner, was significantly inhibited by inhibitors of MEK1/2 (U0126), p38 (SB202190), and c-Jun-N-terminal kinase (JNK; SP600125).	pyrazolanthrone	189-197	vascular cell adhesion molecule 1	Homo sapiens	26-32
17506939-9	2007	In addition, the extracellularly responsive kinase (ERK) inhibitor, PD98059, suppressed silibinin-protected apoptosis, whereas the p38 MAPK inhibitor, SB203580, protected cardiac myocytes from isoproterenol-induced injury, and the c-Jun N-terminal kinase (JNK) inhibitor, SP600125 had no protective effects.	pyrazolanthrone	272-280	Eph receptor B1	Rattus norvegicus	52-55
17449011-4	2007	In a dose-dependent manner, JNK inhibitor (SP600125) significantly reduced hyperglycemia-induced embryopathy.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Mus musculus	28-31
17255557-6	2007	Transcriptional inhibitor actinomycin D, c-Jun N-terminal kinase (JNK) inhibitors SP600125 and TAT-TI-JIP(153-163), but not extracellular signal-regulated kinase 1 and 2 (ERK 1/2) inhibitor PD98059, significantly attenuated this up-regulation, indicating that a transcriptional mechanism and intracellular JNK signal transduction pathway were involved.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Mus musculus	41-64
17255557-6	2007	Transcriptional inhibitor actinomycin D, c-Jun N-terminal kinase (JNK) inhibitors SP600125 and TAT-TI-JIP(153-163), but not extracellular signal-regulated kinase 1 and 2 (ERK 1/2) inhibitor PD98059, significantly attenuated this up-regulation, indicating that a transcriptional mechanism and intracellular JNK signal transduction pathway were involved.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Mus musculus	66-69
17303384-7	2007	LPS-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha was blocked by helenalin, U0126, SB202190, or SP600125.	pyrazolanthrone	138-146	nuclear factor kappa B subunit 1	Homo sapiens	32-41
17303384-3	2007	LPS-induced expression of VCAM-1 protein and mRNA in a time-dependent manner, was significantly inhibited by inhibitors of MEK1/2 (U0126), p38 (SB202190), and c-Jun-N-terminal kinase (JNK; SP600125).	pyrazolanthrone	189-197	mitogen-activated protein kinase kinase 1	Homo sapiens	123-129
17303384-7	2007	LPS-stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha was blocked by helenalin, U0126, SB202190, or SP600125.	pyrazolanthrone	138-146	NFKB inhibitor alpha	Homo sapiens	78-91
17303384-8	2007	Moreover, the resultant enhancement of VCAM-1 expression increased the adhesion of polymorphonuclear cells to monolayer of HTSMCs which was blocked by pretreatment with helenalin, U0126, or SP600125 prior to LPS exposure.	pyrazolanthrone	190-198	vascular cell adhesion molecule 1	Homo sapiens	39-45
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	25-28
17311279-5	2007	IL-1beta induced production of MMP-9 protein and mRNA in a time- and concentration-dependent manner determined by zymographic, Western blotting, and RT-PCR analyses, which was attenuated by inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), JNK (SP600125), and NF-kappaB (helenalin), and transfection with dominant negative mutants of MEK1/2, p38 and JNK, respectively.	pyrazolanthrone	246-254	interleukin 1 beta	Homo sapiens	0-8
17311279-5	2007	IL-1beta induced production of MMP-9 protein and mRNA in a time- and concentration-dependent manner determined by zymographic, Western blotting, and RT-PCR analyses, which was attenuated by inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), JNK (SP600125), and NF-kappaB (helenalin), and transfection with dominant negative mutants of MEK1/2, p38 and JNK, respectively.	pyrazolanthrone	246-254	matrix metallopeptidase 9	Homo sapiens	31-36
17311279-5	2007	IL-1beta induced production of MMP-9 protein and mRNA in a time- and concentration-dependent manner determined by zymographic, Western blotting, and RT-PCR analyses, which was attenuated by inhibitors of MEK1/2 (U0126), p38 MAPK (SB202190), JNK (SP600125), and NF-kappaB (helenalin), and transfection with dominant negative mutants of MEK1/2, p38 and JNK, respectively.	pyrazolanthrone	246-254	mitogen-activated protein kinase kinase 1	Homo sapiens	204-210
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	pyrazolanthrone	124-132	interleukin 1 beta	Homo sapiens	0-8
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	pyrazolanthrone	124-132	erythrocyte membrane protein band 4.2	Homo sapiens	39-42
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	pyrazolanthrone	124-132	mitogen-activated protein kinase 14	Homo sapiens	53-56
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	pyrazolanthrone	124-132	mitogen-activated protein kinase 3	Homo sapiens	47-51
17311279-6	2007	IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38 MAPK, and JNK was attenuated by pretreatment with U0126, SB202190, SP600125, or transfection with these dominant negative mutants of MEK, ERK, p38 and JNK, respectively.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Homo sapiens	67-70
17311279-9	2007	MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	pyrazolanthrone	142-150	matrix metallopeptidase 9	Homo sapiens	0-5
17311279-9	2007	MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	pyrazolanthrone	142-150	interleukin 1 beta	Homo sapiens	40-48
17311279-9	2007	MMP-9 promoter activity was enhanced by IL-1beta in HTSMCs transfected with MMP-9-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	pyrazolanthrone	142-150	matrix metallopeptidase 9	Homo sapiens	76-81
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	interleukin 1 beta	Homo sapiens	45-53
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	calcitonin related polypeptide alpha	Homo sapiens	62-66
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	82-85
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	interleukin 1 beta	Homo sapiens	149-157
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	calcitonin related polypeptide alpha	Homo sapiens	166-170
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	185-190
17481780-4	2007	In investigating whether JNK was involved in IL-1beta-induced CGRP secretion, the JNK II inhibitor SP600125 was used and it significantly attenuated IL-1beta-induced CGRP secretion and c-Jun activity, which was elevated after IL-1beta stimulation from mRNA to protein level.	pyrazolanthrone	99-107	interleukin 1 beta	Homo sapiens	149-157
17368702-4	2007	CTX III-mediated G2/M phase arrest and apoptosis were reduced by treatment with the JNK-specific inhibitor SP600125, but not by ERK and p38MAPK inhibitors.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	84-87
17368702-5	2007	Further investigation showed that the specific JNK inhibitor, SP600125, reduced the activation of caspase-3, caspase-9, and reversed the decline in the expression of cyclin B1.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	47-50
17369605-14	2007	In addition, the cytotoxicity of microcystin-LR was attenuated by the inhibitors of MAPK pathways, including U0126, SP600125, and SB203580.	pyrazolanthrone	116-124	mitogen-activated protein kinase 1	Mus musculus	84-88
17368702-5	2007	Further investigation showed that the specific JNK inhibitor, SP600125, reduced the activation of caspase-3, caspase-9, and reversed the decline in the expression of cyclin B1.	pyrazolanthrone	62-70	caspase 3	Homo sapiens	98-107
17368702-5	2007	Further investigation showed that the specific JNK inhibitor, SP600125, reduced the activation of caspase-3, caspase-9, and reversed the decline in the expression of cyclin B1.	pyrazolanthrone	62-70	caspase 9	Homo sapiens	109-118
17368702-5	2007	Further investigation showed that the specific JNK inhibitor, SP600125, reduced the activation of caspase-3, caspase-9, and reversed the decline in the expression of cyclin B1.	pyrazolanthrone	62-70	cyclin B1	Homo sapiens	166-175
17459422-0	2007	SP600125, a selective JNK inhibitor, protects ischemic renal injury via suppressing the extrinsic pathways of apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	22-25
18019060-10	2007	hy926 cells were pretreated with different concentrations of JNK specific inhibitor SP 600125 (0, 10, 100 nmol/L and 1,10 micromol/L) 1h before hypoxic treatment of various duration, and the cell lysates were extracted to detect CASK expression with Western blot.	pyrazolanthrone	84-93	mitogen-activated protein kinase 8	Homo sapiens	61-64
17519787-0	2007	Suppression of alloreactivity and allograft rejection by SP600125, a small molecule inhibitor of c-Jun N-terminal kinase.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Rattus norvegicus	97-120
17519787-1	2007	BACKGROUND: c-Jun N-terminal kinase (JNK) is reported to play crucial roles in T-cell activation and differentiation, and SP600125 is a small molecule that inhibits JNK.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Rattus norvegicus	12-35
17519787-1	2007	BACKGROUND: c-Jun N-terminal kinase (JNK) is reported to play crucial roles in T-cell activation and differentiation, and SP600125 is a small molecule that inhibits JNK.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Rattus norvegicus	37-40
17519787-1	2007	BACKGROUND: c-Jun N-terminal kinase (JNK) is reported to play crucial roles in T-cell activation and differentiation, and SP600125 is a small molecule that inhibits JNK.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Rattus norvegicus	165-168
17410600-5	2007	The JNK inhibitor SP600125 was administered intraperitoneally at 1 hr before and 6 hr after SAH.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
17362885-3	2007	L-JNKI1, a highly specific c-jun N-terminal kinase (JNK) inhibitor, and a second specific JNK inhibitor, SP600125, prevented thrombin preconditioning (TPC).	pyrazolanthrone	105-113	coagulation factor II	Mus musculus	125-133
18019060-14	2007	CASK protein expression was suppressed by JNK specific inhibitor SP600125 in a dose dependent manner, and it decreased to the lowest level with 10 micromol/L SP600125 pretreatment.	pyrazolanthrone	65-73	calcium/calmodulin dependent serine protein kinase	Homo sapiens	0-4
18019060-14	2007	CASK protein expression was suppressed by JNK specific inhibitor SP600125 in a dose dependent manner, and it decreased to the lowest level with 10 micromol/L SP600125 pretreatment.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	42-45
18019060-14	2007	CASK protein expression was suppressed by JNK specific inhibitor SP600125 in a dose dependent manner, and it decreased to the lowest level with 10 micromol/L SP600125 pretreatment.	pyrazolanthrone	158-166	calcium/calmodulin dependent serine protein kinase	Homo sapiens	0-4
17434686-10	2007	Moreover, growth of neurites induced by octanoic acid was potently inhibited by treatment of cells with the p38 MAPK inhibitor SB203580 and the ERK kinase inhibitor PD98059 but not inhibited and only slightly inhibited by the JNK inhibitor SP600125 and the PI3K inhibitor wortmannin, respectively.	pyrazolanthrone	240-248	Eph receptor B1	Rattus norvegicus	144-147
17371872-9	2007	Pretreatment of MCF7/ADR cells with SP600125, a specific inhibitor of JNK, or with rottlerin, a specific inhibitor of protein kinase Cdelta (PKCdelta), significantly reduced the sangivamycin-induced apoptosis and almost completely abolished sangivamycin-induced phosphorylation of c-Jun and cleavage of lamin A and PARP.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	70-73
17371872-9	2007	Pretreatment of MCF7/ADR cells with SP600125, a specific inhibitor of JNK, or with rottlerin, a specific inhibitor of protein kinase Cdelta (PKCdelta), significantly reduced the sangivamycin-induced apoptosis and almost completely abolished sangivamycin-induced phosphorylation of c-Jun and cleavage of lamin A and PARP.	pyrazolanthrone	36-44	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	281-286
17371872-9	2007	Pretreatment of MCF7/ADR cells with SP600125, a specific inhibitor of JNK, or with rottlerin, a specific inhibitor of protein kinase Cdelta (PKCdelta), significantly reduced the sangivamycin-induced apoptosis and almost completely abolished sangivamycin-induced phosphorylation of c-Jun and cleavage of lamin A and PARP.	pyrazolanthrone	36-44	poly(ADP-ribose) polymerase 1	Homo sapiens	315-319
17428471-3	2007	VPA induces the phosphorylation of c-Jun N-terminal kinase (JNK) and the substrate paxillin, while VPA induction of neurite outgrowth is inhibited by JNK inhibitors (SP600125 and the small JNK-binding peptide) or a paxillin construct harboring a Ser 178-to-Ala mutation at the JNK phosphorylation.	pyrazolanthrone	166-174	mitogen-activated protein kinase 8	Mus musculus	150-153
17428471-3	2007	VPA induces the phosphorylation of c-Jun N-terminal kinase (JNK) and the substrate paxillin, while VPA induction of neurite outgrowth is inhibited by JNK inhibitors (SP600125 and the small JNK-binding peptide) or a paxillin construct harboring a Ser 178-to-Ala mutation at the JNK phosphorylation.	pyrazolanthrone	166-174	mitogen-activated protein kinase 8	Mus musculus	150-153
17428471-3	2007	VPA induces the phosphorylation of c-Jun N-terminal kinase (JNK) and the substrate paxillin, while VPA induction of neurite outgrowth is inhibited by JNK inhibitors (SP600125 and the small JNK-binding peptide) or a paxillin construct harboring a Ser 178-to-Ala mutation at the JNK phosphorylation.	pyrazolanthrone	166-174	mitogen-activated protein kinase 8	Mus musculus	150-153
17367753-6	2007	In agreement, AML1-ETO overexpression in leukemic U937 cells activated c-Jun N-terminal kinase (JNK), while its specific inhibitor SP600125 effectively abrogated AML1-ETO-induced Cx43 expression, indicating that JNK signaling pathway contributes to AML1-ETO induced Cx43 expression.	pyrazolanthrone	131-139	RUNX family transcription factor 1	Homo sapiens	162-166
17367753-6	2007	In agreement, AML1-ETO overexpression in leukemic U937 cells activated c-Jun N-terminal kinase (JNK), while its specific inhibitor SP600125 effectively abrogated AML1-ETO-induced Cx43 expression, indicating that JNK signaling pathway contributes to AML1-ETO induced Cx43 expression.	pyrazolanthrone	131-139	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	167-170
17367753-6	2007	In agreement, AML1-ETO overexpression in leukemic U937 cells activated c-Jun N-terminal kinase (JNK), while its specific inhibitor SP600125 effectively abrogated AML1-ETO-induced Cx43 expression, indicating that JNK signaling pathway contributes to AML1-ETO induced Cx43 expression.	pyrazolanthrone	131-139	gap junction protein alpha 1	Homo sapiens	179-183
17367753-6	2007	In agreement, AML1-ETO overexpression in leukemic U937 cells activated c-Jun N-terminal kinase (JNK), while its specific inhibitor SP600125 effectively abrogated AML1-ETO-induced Cx43 expression, indicating that JNK signaling pathway contributes to AML1-ETO induced Cx43 expression.	pyrazolanthrone	131-139	mitogen-activated protein kinase 8	Homo sapiens	212-215
17367753-6	2007	In agreement, AML1-ETO overexpression in leukemic U937 cells activated c-Jun N-terminal kinase (JNK), while its specific inhibitor SP600125 effectively abrogated AML1-ETO-induced Cx43 expression, indicating that JNK signaling pathway contributes to AML1-ETO induced Cx43 expression.	pyrazolanthrone	131-139	RUNX family transcription factor 1	Homo sapiens	162-166
17367753-6	2007	In agreement, AML1-ETO overexpression in leukemic U937 cells activated c-Jun N-terminal kinase (JNK), while its specific inhibitor SP600125 effectively abrogated AML1-ETO-induced Cx43 expression, indicating that JNK signaling pathway contributes to AML1-ETO induced Cx43 expression.	pyrazolanthrone	131-139	RUNX1 partner transcriptional co-repressor 1	Homo sapiens	167-170
17367753-6	2007	In agreement, AML1-ETO overexpression in leukemic U937 cells activated c-Jun N-terminal kinase (JNK), while its specific inhibitor SP600125 effectively abrogated AML1-ETO-induced Cx43 expression, indicating that JNK signaling pathway contributes to AML1-ETO induced Cx43 expression.	pyrazolanthrone	131-139	gap junction protein alpha 1	Homo sapiens	266-270
17459422-3	2007	We report that SP600125, a potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK), potently decreased renal epithelial tubular cell apoptosis induced by renal ischemia/reperfusion via suppression of the extrinsic pathway.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	90-113
17459422-3	2007	We report that SP600125, a potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK), potently decreased renal epithelial tubular cell apoptosis induced by renal ischemia/reperfusion via suppression of the extrinsic pathway.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	115-118
17459422-5	2007	Additionally, SP600125 attenuated the increased expression of FasL induced by ischemia/reperfusion at 3 h. The administration of SP600125 prior to ischemia was also protective.	pyrazolanthrone	14-22	Fas ligand	Homo sapiens	62-66
17459422-5	2007	Additionally, SP600125 attenuated the increased expression of FasL induced by ischemia/reperfusion at 3 h. The administration of SP600125 prior to ischemia was also protective.	pyrazolanthrone	129-137	Fas ligand	Homo sapiens	62-66
17459422-6	2007	Thus, our findings imply that SP600125 can inhibit the activation of the JNK-c-Jun-FasL pathway and protect renal tubular epithelial cells against ischemia/reperfusion-induced apoptosis.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	73-76
17459422-6	2007	Thus, our findings imply that SP600125 can inhibit the activation of the JNK-c-Jun-FasL pathway and protect renal tubular epithelial cells against ischemia/reperfusion-induced apoptosis.	pyrazolanthrone	30-38	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	77-82
17459422-6	2007	Thus, our findings imply that SP600125 can inhibit the activation of the JNK-c-Jun-FasL pathway and protect renal tubular epithelial cells against ischemia/reperfusion-induced apoptosis.	pyrazolanthrone	30-38	Fas ligand	Homo sapiens	83-87
17244894-5	2007	MAPK inhibitors including U-0126 and SP-600125, but not SB-203580, suppressed aldosterone-induced cellular DNA synthesis, implying that ERK1/2 and SAPK/JNK pathways play crucial roles in mesangial cell proliferation.	pyrazolanthrone	37-46	mitogen-activated protein kinase 3	Mus musculus	136-142
17244894-5	2007	MAPK inhibitors including U-0126 and SP-600125, but not SB-203580, suppressed aldosterone-induced cellular DNA synthesis, implying that ERK1/2 and SAPK/JNK pathways play crucial roles in mesangial cell proliferation.	pyrazolanthrone	37-46	mitogen-activated protein kinase 8	Mus musculus	152-155
17615687-6	2007	Although p38 inhibitor (SB203580) and ERK inhibitor (PD98059) failed to block cell death, JNK inhibitor (SP600125) had marked inhibitory effects on NRP -induced apoptosis.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	90-93
17483345-8	2007	Attenuation of cell migration and invasion was revealed in the SK-Hep-1 cells treated with the SB203580 or DN-p38, but not with ERK-1/2 inhibitor PD98059 or JNK-1/2 inhibitor SP600125.	pyrazolanthrone	175-183	mitogen-activated protein kinase 1	Homo sapiens	110-113
17447005-4	2007	Metformin-triggered apoptosis was completely prevented by agents that block mitochondrial permeability transition (cyclosporin A) and oxygen radical production (N-acetylcisteine), while the inhibitors of JNK activation (SP600125) or glycolysis (sodium fluoride, iodoacetate) provided partial protection.	pyrazolanthrone	220-228	mitogen-activated protein kinase 8	Rattus norvegicus	204-207
17460254-10	2007	A JNK inhibitor (SP600125) reduced the expression of MMC-induced MCP-1 but not of IL-8.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	2-5
17414734-7	2007	JNK inhibitor (SP600125) or p38 inhibitor (SB203580) was given to mice immediately after burn injury.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	0-3
17414734-10	2007	SP600125 decreased intestinal permeability and increased phosphorylated p38 and tumor necrosis factor receptor-associated factor 2 expression of intestinal mucosa in Vil-Cre/Ikkbeta(F/Delta) mice.	pyrazolanthrone	0-8	mitogen-activated protein kinase 14	Mus musculus	72-130
17414734-10	2007	SP600125 decreased intestinal permeability and increased phosphorylated p38 and tumor necrosis factor receptor-associated factor 2 expression of intestinal mucosa in Vil-Cre/Ikkbeta(F/Delta) mice.	pyrazolanthrone	0-8	villin 1	Mus musculus	166-169
17414734-10	2007	SP600125 decreased intestinal permeability and increased phosphorylated p38 and tumor necrosis factor receptor-associated factor 2 expression of intestinal mucosa in Vil-Cre/Ikkbeta(F/Delta) mice.	pyrazolanthrone	0-8	inhibitor of kappaB kinase beta	Mus musculus	174-181
17331500-9	2007	Moreover, TGF-beta2-induced RPE VEGF secretion was significantly reduced by inhibitors of mitogen-activated protein (MAP) kinase (MEK) (U0126), p38 (SB202190), c-Jun NH2-terminal kinase (JNK), Sp600125, protein tyrosine kinase (PTK) (Genistein), and phosphatidylinositol 3-kinase (PI3K) (Ly294002).	pyrazolanthrone	193-201	transforming growth factor beta 2	Homo sapiens	10-19
17331500-9	2007	Moreover, TGF-beta2-induced RPE VEGF secretion was significantly reduced by inhibitors of mitogen-activated protein (MAP) kinase (MEK) (U0126), p38 (SB202190), c-Jun NH2-terminal kinase (JNK), Sp600125, protein tyrosine kinase (PTK) (Genistein), and phosphatidylinositol 3-kinase (PI3K) (Ly294002).	pyrazolanthrone	193-201	vascular endothelial growth factor A	Homo sapiens	32-36
17325051-7	2007	Finally, the JNK inhibitor SP600125 significantly inhibited mucosal hyperplasia during in vivo bacterial otitis media in guinea pigs.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Rattus norvegicus	13-16
17460254-10	2007	A JNK inhibitor (SP600125) reduced the expression of MMC-induced MCP-1 but not of IL-8.	pyrazolanthrone	17-25	C-C motif chemokine ligand 2	Homo sapiens	65-70
17322004-3	2007	In A549/8 human alveolar epithelial cells, both the inhibition of JNK by a pharmacological inhibitor anthra[1,9-cd]pyrazol-6(2H)-one1,9-pyrazoloanthrone (SP600125) and small interfering RNA (siRNA)-mediated down-regulation of JNK led to a reduction of iNOS mRNA and protein expression.	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Homo sapiens	66-69
17171644-7	2007	The specific chemical inhibitors LY294002 (PI3K), PP2 (Src), U0126 (MAPK-ERK kinase (MEK)/ERK), and SP600125 (JNK) effectively suppressed cell fusion, although SB203580 (p38) did not.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Mus musculus	110-113
17171644-7	2007	The specific chemical inhibitors LY294002 (PI3K), PP2 (Src), U0126 (MAPK-ERK kinase (MEK)/ERK), and SP600125 (JNK) effectively suppressed cell fusion, although SB203580 (p38) did not.	pyrazolanthrone	100-108	mitogen-activated protein kinase 14	Mus musculus	170-173
17322004-7	2007	Therefore, the effect of JNK inhibition by SP600125 or down-regulation by siRNA on TTP expression was investigated.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	25-28
17322004-8	2007	Both SP600125 and siRNA targeted at JNK resulted in a reduction of TTP protein expression without affecting the amount of TTP mRNA.	pyrazolanthrone	5-13	ZFP36 ring finger protein	Homo sapiens	67-70
17322004-10	2007	Moreover, the modulation of JNK signaling by SP600125 or siRNA did not change p38 phosphorylation.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	28-31
17622308-8	2007	In addition, we observed that inhibiting Rac proteins prevents JNK activation and that the JNK inhibitor SP600125 strongly inhibits RA-FLS invasion, suggesting that Rac-mediated JNK activation contributes to the role of Rac proteins in the invasive behavior of RA-FLS.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	91-94
17622308-8	2007	In addition, we observed that inhibiting Rac proteins prevents JNK activation and that the JNK inhibitor SP600125 strongly inhibits RA-FLS invasion, suggesting that Rac-mediated JNK activation contributes to the role of Rac proteins in the invasive behavior of RA-FLS.	pyrazolanthrone	105-113	Rac family small GTPase 1	Homo sapiens	165-168
17622308-8	2007	In addition, we observed that inhibiting Rac proteins prevents JNK activation and that the JNK inhibitor SP600125 strongly inhibits RA-FLS invasion, suggesting that Rac-mediated JNK activation contributes to the role of Rac proteins in the invasive behavior of RA-FLS.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	91-94
17622308-8	2007	In addition, we observed that inhibiting Rac proteins prevents JNK activation and that the JNK inhibitor SP600125 strongly inhibits RA-FLS invasion, suggesting that Rac-mediated JNK activation contributes to the role of Rac proteins in the invasive behavior of RA-FLS.	pyrazolanthrone	105-113	Rac family small GTPase 1	Homo sapiens	165-168
17390063-9	2007	SP600125, a JNK-specific inhibitor, suppressed the IR-induced accumulation of ROS.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
17697615-13	2007	Inhibitors specific for the JNK (SP600125), MEK (PD98059), and p38 MAPK (SB203580), abrogated HMGB1-induced TNF-alpha secretion.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	28-31
17697615-13	2007	Inhibitors specific for the JNK (SP600125), MEK (PD98059), and p38 MAPK (SB203580), abrogated HMGB1-induced TNF-alpha secretion.	pyrazolanthrone	33-41	high mobility group box 1	Homo sapiens	94-99
17057737-6	2007	The proliferation of NSCLC cell lines HCC827 and H2009, in which JNK and its substrate c-Jun are constitutively phosphorylated, was inhibited by SP600125, a JNK kinase inhibitor.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	65-68
17397142-7	2007	In contrast, the anthrapyrazolone compound, SP600125, exhibited competitive inhibition for ATP and noncompetitive inhibition against ATF2.	pyrazolanthrone	44-52	activating transcription factor 2	Homo sapiens	133-137
17057737-6	2007	The proliferation of NSCLC cell lines HCC827 and H2009, in which JNK and its substrate c-Jun are constitutively phosphorylated, was inhibited by SP600125, a JNK kinase inhibitor.	pyrazolanthrone	145-153	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	87-92
17057737-6	2007	The proliferation of NSCLC cell lines HCC827 and H2009, in which JNK and its substrate c-Jun are constitutively phosphorylated, was inhibited by SP600125, a JNK kinase inhibitor.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	157-160
17209141-3	2007	Male Sprague-Dawley rats were exposed to smoke from burning cotton for 15 min, and 1 h after injury a JNK inhibitor (SP-600125) or vehicle was injected.	pyrazolanthrone	117-126	mitogen-activated protein kinase 8	Rattus norvegicus	102-105
17367785-6	2007	However, LPS-induced expression of IDO was inhibited by LY294002 and SP600125 but not by JAK inhibitor I, SB203580, or U0126.	pyrazolanthrone	69-77	toll-like receptor 4	Mus musculus	9-12
17367785-6	2007	However, LPS-induced expression of IDO was inhibited by LY294002 and SP600125 but not by JAK inhibitor I, SB203580, or U0126.	pyrazolanthrone	69-77	indoleamine 2,3-dioxygenase 1	Mus musculus	35-38
17149706-8	2007	Pretreatment of WT monolayers with ERK1/2 inhibitor U0126 (20 microM, 1 h) prevented the LPS-induced decrease in coupling, while inhibition of JNK1/2 with SP600125 (20 microM, 1 h) and p38 with a p38 inhibitor (10 nM, 1 h) had no effect.	pyrazolanthrone	155-163	mitogen-activated protein kinase 8	Mus musculus	143-147
16912864-9	2007	The proliferative and anti-apoptotic effects of leptin were abolished by inhibition of JAK2 with AG490, phosphatidylinositol 3"-kinase (PI3 kinase) with LY294002 and c-Jun NH(2)-terminal kinase (JNK) with SP600125.	pyrazolanthrone	205-213	leptin	Homo sapiens	48-54
17031857-7	2007	SB203580, a specific inhibitor of p38 MAP kinase, and SP600125, a specific inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), reduced the PGF(2alpha)-induced VEGF synthesis.	pyrazolanthrone	54-62	jun proto-oncogene	Mus musculus	120-125
17031857-7	2007	SB203580, a specific inhibitor of p38 MAP kinase, and SP600125, a specific inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), reduced the PGF(2alpha)-induced VEGF synthesis.	pyrazolanthrone	54-62	vascular endothelial growth factor A	Mus musculus	188-192
17120084-4	2007	PTH-induced JNK 1/2 phosphorylation was suppressed by its selective inhibitor SP600125.	pyrazolanthrone	78-86	parathyroid hormone	Rattus norvegicus	0-3
17120084-4	2007	PTH-induced JNK 1/2 phosphorylation was suppressed by its selective inhibitor SP600125.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Rattus norvegicus	12-15
17334237-7	2007	The JNK inhibitor, SP600125, was given to mice to study the involvement of the JNK pathway in thermal injury-induced lung damage.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Mus musculus	4-7
17334237-12	2007	SP600125 significantly reduced thermal injury-induced blood dihydrorhodamine (DHR) 123 oxidation, iNOS expression, and lung permeability in WT mice but not in IL-1R1 mice.	pyrazolanthrone	0-8	nitric oxide synthase 2, inducible	Mus musculus	98-102
17270352-5	2007	The JNK-inhibitor SP600125 dose-dependently extended the period of Period1-luciferase rhythms in rat-1 fibroblasts from 24.23+/-0.17-31.48+/-0.07 h. This treatment also dose-dependently delayed the onset of the bioluminescence rhythms.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
17457842-5	2007	Additionally, MAPK pathway activities were studied using the PD98059 (an ERK inhibitor), SB203580 (a p38 kinase inhibitor), and SP600125 (a JNK inhibitor), to determine the role in keloid following PDL treatment.	pyrazolanthrone	128-136	mitogen-activated protein kinase 3	Homo sapiens	14-18
17289100-7	2007	Phospho-ERK1/2 levels were increased with different concentrations (0.1-10 microM) of arsenite at 6, 12, and 24 h. Blocking of JNK pathway with 20 microM SP600125 or ERK1/2 by 100 microM PD98059 significantly inhibited biphasic effect of arsenite in cells.	pyrazolanthrone	154-162	mitogen-activated protein kinase 3	Homo sapiens	8-14
17289100-7	2007	Phospho-ERK1/2 levels were increased with different concentrations (0.1-10 microM) of arsenite at 6, 12, and 24 h. Blocking of JNK pathway with 20 microM SP600125 or ERK1/2 by 100 microM PD98059 significantly inhibited biphasic effect of arsenite in cells.	pyrazolanthrone	154-162	mitogen-activated protein kinase 8	Homo sapiens	127-130
17394769-4	2007	It is also known that p38 MAPK inhibitor SB203580 and JNK inhibitor SP600125 had slight effects on apoptosis.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	54-57
17270352-5	2007	The JNK-inhibitor SP600125 dose-dependently extended the period of Period1-luciferase rhythms in rat-1 fibroblasts from 24.23+/-0.17-31.48+/-0.07 h. This treatment also dose-dependently delayed the onset of the bioluminescence rhythms.	pyrazolanthrone	18-26	period circadian regulator 1	Rattus norvegicus	67-74
17270352-6	2007	The effects of SP600125 on explant cultures from Period1-luciferase transgenic mice and Period2(Luciferase) knockin mice appeared tissue-specific.	pyrazolanthrone	15-23	period circadian regulator 1	Rattus norvegicus	49-56
17270352-7	2007	SP600125 lengthened the period in SCN, pineal gland, and lung explants in Period1-luciferase and Period2(Luciferase) mice.	pyrazolanthrone	0-8	period circadian regulator 1	Rattus norvegicus	74-81
17270352-7	2007	SP600125 lengthened the period in SCN, pineal gland, and lung explants in Period1-luciferase and Period2(Luciferase) mice.	pyrazolanthrone	0-8	period circadian clock 2	Mus musculus	97-116
17270352-10	2007	In conclusion, our results showed that SP600125 treatment, as well as valproic acid, alters JNK phosphorylation levels, and modulates the period length in various tissues.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Mus musculus	92-95
17292878-6	2007	Pretreatment with SP600125 attenuated the bakuchiol-induced translocation of Bax into mitochondria, cytochrome c release into the cytosol, caspase-3 activation, and PARP cleavage.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Rattus norvegicus	77-80
17292878-6	2007	Pretreatment with SP600125 attenuated the bakuchiol-induced translocation of Bax into mitochondria, cytochrome c release into the cytosol, caspase-3 activation, and PARP cleavage.	pyrazolanthrone	18-26	caspase 3	Rattus norvegicus	139-148
17292878-6	2007	Pretreatment with SP600125 attenuated the bakuchiol-induced translocation of Bax into mitochondria, cytochrome c release into the cytosol, caspase-3 activation, and PARP cleavage.	pyrazolanthrone	18-26	poly (ADP-ribose) polymerase 1	Rattus norvegicus	165-169
17300814-6	2007	Administration of SP600125 diminished JNK activity, suppressed lethality and the elevation of both serum alanine aminotransferase and aspartate aminotransferase, but had no effect on serum tumor necrosis factor-alpha, and reduced hepatocyte apoptosis after GalN/LPS administration.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	38-41
17300814-7	2007	In support of the role of JNK in promoting the mitochondria-mediated apoptosis pathway, SP600125 prevented cytochrome c release, caspase-9 and caspase-3 activity.	pyrazolanthrone	88-96	caspase 9	Mus musculus	129-138
17300814-7	2007	In support of the role of JNK in promoting the mitochondria-mediated apoptosis pathway, SP600125 prevented cytochrome c release, caspase-9 and caspase-3 activity.	pyrazolanthrone	88-96	caspase 3	Mus musculus	143-152
17300814-8	2007	Moreover, SP600125 downregulated the mRNA and protein expression of Bad in the early periods following GalN/LPS injection and prevented Bid cleavage in the late periods.	pyrazolanthrone	10-18	BH3 interacting domain death agonist	Mus musculus	136-139
17300814-10	2007	SP600125 has the potential to protect FHF by downregulating Bad and inhibiting Bid cleavage.	pyrazolanthrone	0-8	BH3 interacting domain death agonist	Mus musculus	79-82
17108331-7	2007	MAPK8/9 was activated by heat, and the MAPK8/9 inhibitor SP600125, but not JUN N-terminal kinase I, blocked heat-induced maturation.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Mus musculus	39-44
17411352-8	2007	An inhibitor of JNK1/2, SP600125, had a negligible negative effect on REH cell viability after DON treatment, demonstrating that JNK does not contribute to DON-induced apoptosis.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	16-22
17411352-8	2007	An inhibitor of JNK1/2, SP600125, had a negligible negative effect on REH cell viability after DON treatment, demonstrating that JNK does not contribute to DON-induced apoptosis.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	16-19
17131386-5	2007	Treatment of osteoblasts with SP600125, a JNK-specific inhibitor, led to a reduction in MG-induced apoptosis and decreased activation of caspase-3 and PAK2, indicating that JNK activity is upstream of these events.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	42-45
16820799-5	2007	Administration of LY294002, a PI3-K-specific inhibitor, exacerbated DNA fragmentation, whereas administration of SP600125, a JNK-specific inhibitor, attenuated it.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Rattus norvegicus	125-128
17131386-5	2007	Treatment of osteoblasts with SP600125, a JNK-specific inhibitor, led to a reduction in MG-induced apoptosis and decreased activation of caspase-3 and PAK2, indicating that JNK activity is upstream of these events.	pyrazolanthrone	30-38	caspase 3	Homo sapiens	137-146
16820799-8	2007	Decreases in phospho-Bad (Ser136) and Bad/14-3-3 dimerization and increases in Bcl-X(L)/Bad or Bcl-2/Bad dimerization observed 7 to 24 h after tFCI, were prevented by SP600125 administration, with inhibition of JNK activity.	pyrazolanthrone	167-175	Bcl2-like 1	Rattus norvegicus	79-87
17133355-6	2007	In contrast, extracellular signal-regulated kinase, p38 MAP kinase, and c-Jun N-terminal kinase were activated after stimulation with TNF-alpha, and inhibition of each kinase by PD098059, SB203580, curcumin, or SP600125 substantially attenuated the TNF-alpha-induced c-IAP1 and c-IAP2 expression.	pyrazolanthrone	211-219	tumor necrosis factor	Homo sapiens	134-143
17131386-5	2007	Treatment of osteoblasts with SP600125, a JNK-specific inhibitor, led to a reduction in MG-induced apoptosis and decreased activation of caspase-3 and PAK2, indicating that JNK activity is upstream of these events.	pyrazolanthrone	30-38	p21 (RAC1) activated kinase 2	Homo sapiens	151-155
17131386-5	2007	Treatment of osteoblasts with SP600125, a JNK-specific inhibitor, led to a reduction in MG-induced apoptosis and decreased activation of caspase-3 and PAK2, indicating that JNK activity is upstream of these events.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	173-176
17084420-5	2007	Spinal application of JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) did not affect the spinal LTP induced by tetanic stimulation in intact rats, but completely blocked LTP induced by TNF-alpha in L5 VRT rats.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Rattus norvegicus	22-25
17301078-6	2007	Pretreatment with a JNK inhibitor, SP600125, suppressed the brefeldin A-induced caspase-2 activation and cell death significantly.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Rattus norvegicus	20-23
17301078-6	2007	Pretreatment with a JNK inhibitor, SP600125, suppressed the brefeldin A-induced caspase-2 activation and cell death significantly.	pyrazolanthrone	35-43	caspase 2	Rattus norvegicus	80-89
17181399-13	2007	SP600125, a specific inhibitor of SAPK/JNK, suppressed the amplification by rapamycin of the FGF-2-stimulated VEGF release similar to the levels of FGF-2 with SP600125.	pyrazolanthrone	0-8	fibroblast growth factor 2	Mus musculus	93-98
17181399-13	2007	SP600125, a specific inhibitor of SAPK/JNK, suppressed the amplification by rapamycin of the FGF-2-stimulated VEGF release similar to the levels of FGF-2 with SP600125.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Mus musculus	110-114
17135572-5	2007	Inhibitors specific for the JNK (SP600125) and MEK (PD98059), but not p38 MAPK (SB203580), abrogated H(2)O(2)-induced, active HMGB1 release.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	28-31
17135572-5	2007	Inhibitors specific for the JNK (SP600125) and MEK (PD98059), but not p38 MAPK (SB203580), abrogated H(2)O(2)-induced, active HMGB1 release.	pyrazolanthrone	33-41	high mobility group box 1	Homo sapiens	126-131
17084420-5	2007	Spinal application of JNK inhibitor (SP600125) or p38 MAPK inhibitor (SB203580) did not affect the spinal LTP induced by tetanic stimulation in intact rats, but completely blocked LTP induced by TNF-alpha in L5 VRT rats.	pyrazolanthrone	37-45	tumor necrosis factor	Rattus norvegicus	195-204
17032922-5	2007	The latter was inhibited by cotreatment with the JNK inhibitor SP600125, which similarly abrogated PKC412-induced apoptosis, suggesting that PKC412-induced apoptosis is a JNK-dependent event.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	49-52
17300148-10	2007	The effects of PI3K and MAPK kinase inhibitors, LY294002, PD98059, SP600125, and SB202190, have been investigated on the sulforaphane-induced expression of thioredoxin reductase and thioredoxin.	pyrazolanthrone	67-75	peroxiredoxin 5	Homo sapiens	156-177
17300148-10	2007	The effects of PI3K and MAPK kinase inhibitors, LY294002, PD98059, SP600125, and SB202190, have been investigated on the sulforaphane-induced expression of thioredoxin reductase and thioredoxin.	pyrazolanthrone	67-75	thioredoxin	Homo sapiens	156-167
17032922-5	2007	The latter was inhibited by cotreatment with the JNK inhibitor SP600125, which similarly abrogated PKC412-induced apoptosis, suggesting that PKC412-induced apoptosis is a JNK-dependent event.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	171-174
17287517-5	2007	These neuroprotective effects of E2 against Abeta-induced apoptosis are mimicked by the JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one).	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	88-91
17287517-5	2007	These neuroprotective effects of E2 against Abeta-induced apoptosis are mimicked by the JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one).	pyrazolanthrone	112-143	mitogen-activated protein kinase 8	Homo sapiens	88-91
16979873-4	2007	Here, Western blot and flow cytometric analysis of intracellular kappa staining indicated that upregulation of the expression of kappa was inhibited by using LMP1-targeted DNAzyme and that Bay11-7082 and SP600125, inhibitors of JNK and NF-kappaB, respectively, inhibited LMP1-augmented kappa light chain expression in NPC cells.	pyrazolanthrone	204-212	mitogen-activated protein kinase 8	Homo sapiens	228-231
17191113-7	2007	For the evaluation of the role of MAPKs, PD98059, SB203580 and SP600125 were used as MAPKs inhibitors for ERK1/2, p38 MAPK and JNK.	pyrazolanthrone	63-71	mitogen-activated protein kinase 1	Homo sapiens	114-117
17191113-8	2007	Inhibition of ERK1/2 with PD98059 caused further enhancement in apoptosis and caspase-3 and 9 activity, while a selective p38 MAPK inhibitor, SB203580 and JNK inhibitor, SP600125 significantly inhibited E. coli-induced apoptosis and caspase-3 and 9 activity in U937 cells.	pyrazolanthrone	170-178	mitogen-activated protein kinase 1	Homo sapiens	122-125
16979873-4	2007	Here, Western blot and flow cytometric analysis of intracellular kappa staining indicated that upregulation of the expression of kappa was inhibited by using LMP1-targeted DNAzyme and that Bay11-7082 and SP600125, inhibitors of JNK and NF-kappaB, respectively, inhibited LMP1-augmented kappa light chain expression in NPC cells.	pyrazolanthrone	204-212	nuclear factor kappa B subunit 1	Homo sapiens	236-245
16979873-4	2007	Here, Western blot and flow cytometric analysis of intracellular kappa staining indicated that upregulation of the expression of kappa was inhibited by using LMP1-targeted DNAzyme and that Bay11-7082 and SP600125, inhibitors of JNK and NF-kappaB, respectively, inhibited LMP1-augmented kappa light chain expression in NPC cells.	pyrazolanthrone	204-212	PDZ and LIM domain 7	Homo sapiens	271-275
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	32-35
17305717-4	2007	Blockade of the p38 MAPK and JNK pathways with the respective upstream inhibitors (SB203580 and SP600125) abolished the TGF-beta1-mediated induction of NGF.	pyrazolanthrone	96-104	mitogen-activated protein kinase 14	Homo sapiens	16-19
17305717-4	2007	Blockade of the p38 MAPK and JNK pathways with the respective upstream inhibitors (SB203580 and SP600125) abolished the TGF-beta1-mediated induction of NGF.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	29-32
17305717-4	2007	Blockade of the p38 MAPK and JNK pathways with the respective upstream inhibitors (SB203580 and SP600125) abolished the TGF-beta1-mediated induction of NGF.	pyrazolanthrone	96-104	transforming growth factor beta 1	Homo sapiens	120-129
17305717-4	2007	Blockade of the p38 MAPK and JNK pathways with the respective upstream inhibitors (SB203580 and SP600125) abolished the TGF-beta1-mediated induction of NGF.	pyrazolanthrone	96-104	nerve growth factor	Homo sapiens	152-155
17283157-9	2007	SP600125, an inhibitor of JNK, or antioxidant N-acetyl-L-cysteine inhibited the enhancement of chemosensitivity against CDDP by galectin-7 transfection.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
17283157-9	2007	SP600125, an inhibitor of JNK, or antioxidant N-acetyl-L-cysteine inhibited the enhancement of chemosensitivity against CDDP by galectin-7 transfection.	pyrazolanthrone	0-8	galectin 7	Homo sapiens	128-138
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	pyrazolanthrone	46-54	matrix metallopeptidase 9	Homo sapiens	87-92
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	143-146
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	pyrazolanthrone	46-54	nuclear factor kappa B subunit 1	Homo sapiens	187-196
17202418-10	2007	It is interesting that only the JNK inhibitor SP600125 impaired the cytokine-triggered MMP-9 level, suggesting that CsA, via inhibition of the JNK pathway, negatively interferes with the NF-kappaB-dependent transcriptional control of MMP-9.	pyrazolanthrone	46-54	matrix metallopeptidase 9	Homo sapiens	234-239
17062604-8	2007	However, the MP(58-66)-specific CTL can be rescued from AICD by the c-jun-N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	68-91
17251521-6	2007	PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion.	pyrazolanthrone	21-30	mitogen-activated protein kinase 3	Homo sapiens	65-71
17251521-6	2007	PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion.	pyrazolanthrone	21-30	mitogen-activated protein kinase 1	Homo sapiens	73-76
17251521-6	2007	PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion.	pyrazolanthrone	21-30	mitogen-activated protein kinase 8	Homo sapiens	78-81
17251521-6	2007	PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion.	pyrazolanthrone	21-30	nuclear factor kappa B subunit 1	Homo sapiens	87-108
17251521-6	2007	PD-98059, SB-203580, SP-600125, and PDTC-which are inhibitors of ERK1/2, p38, JNK, and nuclear factor-kappaB (NF-kappaB), respectively-attenuated the IL-1alpha-induced COX-2 mRNA expression and activated protein kinase C PGE(2) secretion.	pyrazolanthrone	21-30	nuclear factor kappa B subunit 1	Homo sapiens	110-119
17062604-8	2007	However, the MP(58-66)-specific CTL can be rescued from AICD by the c-jun-N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	108-116	mitogen-activated protein kinase 8	Homo sapiens	93-96
17316137-4	2007	This was confirmed by the findings that addition of an ERK MAP kinase inhibitor (PD98059) but not a p38 inhibitor (SB203589) abolished MIF-induced MMP-9 expression and activation, whereas addition of a JNK inhibitor (SP600125) produced a partially inhibitory effect.	pyrazolanthrone	217-225	macrophage migration inhibitory factor (glycosylation-inhibiting factor)	Mus musculus	135-138
17108235-9	2007	Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Mus musculus	17-20
17108235-9	2007	Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction.	pyrazolanthrone	32-40	signal transducer and activator of transcription 1	Mus musculus	116-122
17108235-9	2007	Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Mus musculus	174-177
17108235-9	2007	Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction.	pyrazolanthrone	32-40	tyrosine kinase 2	Mus musculus	228-232
17108235-9	2007	Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction.	pyrazolanthrone	32-40	signal transducer and activator of transcription 1	Mus musculus	250-256
17108235-9	2007	Interestingly, a JNK inhibitor (SP600125) and another tyrosine kinase inhibitor (genistein) significantly inhibited STAT-1 phosphorylation, suggesting that the LPS-activated JNK pathway and a tyrosine kinase pathway (especially Tyk2) may link to the STAT-1 pathway, which is involved in iNOS induction.	pyrazolanthrone	32-40	nitric oxide synthase 2, inducible	Mus musculus	287-291
17113036-10	2007	Cell incubation with either PRIMA-1 or SP600125 (c-Jun NH2-terminal kinase inhibitor) resulted in the abrogation of adriamycin-induced c-Jun NH2-terminal kinase (JNK) activation, whereas Bax activation was not inhibited.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	49-74
17095576-4	2007	These events were blocked by treatment with an inhibitor of RhoA-dependent kinase Y27632, or an inhibitor of JNK SP600125, or the transfection of dominant negative RhoA cDNA.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	109-112
16909121-6	2007	Exposure to either 200 microg/ml of the antioxidant alpha-tocopherol or 10 microM JNK inhibitor SP600125 before the combined treatment resulted in decreased activation of JNK and caspase-3 as well as decreased DNA fragmentation.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	82-85
16909121-6	2007	Exposure to either 200 microg/ml of the antioxidant alpha-tocopherol or 10 microM JNK inhibitor SP600125 before the combined treatment resulted in decreased activation of JNK and caspase-3 as well as decreased DNA fragmentation.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	171-174
16909121-6	2007	Exposure to either 200 microg/ml of the antioxidant alpha-tocopherol or 10 microM JNK inhibitor SP600125 before the combined treatment resulted in decreased activation of JNK and caspase-3 as well as decreased DNA fragmentation.	pyrazolanthrone	96-104	caspase 3	Homo sapiens	179-188
17277740-12	2007	Inhibitors of the mitogen-activated protein kinase (p38MAPK; SB203580) and Jun N-terminal kinase (JNK; SP600125) pathways inhibited vitreous-induction of HO-1.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	75-96
17277740-12	2007	Inhibitors of the mitogen-activated protein kinase (p38MAPK; SB203580) and Jun N-terminal kinase (JNK; SP600125) pathways inhibited vitreous-induction of HO-1.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	98-101
17277740-12	2007	Inhibitors of the mitogen-activated protein kinase (p38MAPK; SB203580) and Jun N-terminal kinase (JNK; SP600125) pathways inhibited vitreous-induction of HO-1.	pyrazolanthrone	103-111	heme oxygenase 1	Homo sapiens	154-158
17067555-9	2007	COX-2 expression in response to IL-1beta was attenuated by pretreatment with SB203580, SP600125, and LY294002, but not with PD98059, suggesting the involvement of p38 MAPK, JNK, and PI3K in this response.	pyrazolanthrone	87-95	interleukin 1 beta	Homo sapiens	32-40
17067555-9	2007	COX-2 expression in response to IL-1beta was attenuated by pretreatment with SB203580, SP600125, and LY294002, but not with PD98059, suggesting the involvement of p38 MAPK, JNK, and PI3K in this response.	pyrazolanthrone	87-95	mitogen-activated protein kinase 14	Homo sapiens	163-166
17067555-9	2007	COX-2 expression in response to IL-1beta was attenuated by pretreatment with SB203580, SP600125, and LY294002, but not with PD98059, suggesting the involvement of p38 MAPK, JNK, and PI3K in this response.	pyrazolanthrone	87-95	mitogen-activated protein kinase 1	Homo sapiens	167-171
17067555-9	2007	COX-2 expression in response to IL-1beta was attenuated by pretreatment with SB203580, SP600125, and LY294002, but not with PD98059, suggesting the involvement of p38 MAPK, JNK, and PI3K in this response.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	173-176
17078024-8	2007	The LPS-induced increase in microglial C/EBPbeta is prevented by coadministration of the MAP kinase inhibitors SB203580 (p38 inhibitor) + SP600125 (JNK inhibitor) or SB203580 + U0126 (ERK inhibitor).	pyrazolanthrone	138-146	CCAAT/enhancer binding protein (C/EBP), beta	Mus musculus	39-48
17113036-10	2007	Cell incubation with either PRIMA-1 or SP600125 (c-Jun NH2-terminal kinase inhibitor) resulted in the abrogation of adriamycin-induced c-Jun NH2-terminal kinase (JNK) activation, whereas Bax activation was not inhibited.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	135-160
17113036-10	2007	Cell incubation with either PRIMA-1 or SP600125 (c-Jun NH2-terminal kinase inhibitor) resulted in the abrogation of adriamycin-induced c-Jun NH2-terminal kinase (JNK) activation, whereas Bax activation was not inhibited.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	162-165
17113036-10	2007	Cell incubation with either PRIMA-1 or SP600125 (c-Jun NH2-terminal kinase inhibitor) resulted in the abrogation of adriamycin-induced c-Jun NH2-terminal kinase (JNK) activation, whereas Bax activation was not inhibited.	pyrazolanthrone	39-47	BCL2 associated X, apoptosis regulator	Homo sapiens	187-190
17055484-5	2007	Inhibition of JNK by SP600125 or expression of a dominant negative JNK1 construct abrogated the migratory response of HBMECs to HGF.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
17404068-10	2007	The JNK inhibitor SP600125 attenuated COX-2 expression in TPA-treated MCF-10A cells.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
17404068-10	2007	The JNK inhibitor SP600125 attenuated COX-2 expression in TPA-treated MCF-10A cells.	pyrazolanthrone	18-26	prostaglandin-endoperoxide synthase 2	Homo sapiens	38-43
16829684-6	2007	Inhibition of early JNK activation by the JNK inhibitor SP600125 attenuated CPD repair and increased UV-C induced apoptosis whereas inhibition of late JNK activation attenuated the apoptotic response of c-Fos-deficient cells.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	20-23
16829684-6	2007	Inhibition of early JNK activation by the JNK inhibitor SP600125 attenuated CPD repair and increased UV-C induced apoptosis whereas inhibition of late JNK activation attenuated the apoptotic response of c-Fos-deficient cells.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	42-45
16829684-6	2007	Inhibition of early JNK activation by the JNK inhibitor SP600125 attenuated CPD repair and increased UV-C induced apoptosis whereas inhibition of late JNK activation attenuated the apoptotic response of c-Fos-deficient cells.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Homo sapiens	42-45
17204142-15	2007	Pre-incubation of SH-SY5Y human neuroblastoma cells with either RAR-pan-antagonist LE540 or MAP kinase kinase 1 (MEK-1) inhibitor PD98059 resulted in the abolition of ATRA-induced COX-2 promoter activity, COX-2 protein expression and PGE2 production whereas the retinoid X receptor pan-antagonist HX531, the p38 MAPK inhibitor SB203580 or the c-Jun kinase inhibitor SP600125 did not have any effect.	pyrazolanthrone	366-374	retinoic acid receptor alpha	Homo sapiens	64-67
17204142-15	2007	Pre-incubation of SH-SY5Y human neuroblastoma cells with either RAR-pan-antagonist LE540 or MAP kinase kinase 1 (MEK-1) inhibitor PD98059 resulted in the abolition of ATRA-induced COX-2 promoter activity, COX-2 protein expression and PGE2 production whereas the retinoid X receptor pan-antagonist HX531, the p38 MAPK inhibitor SB203580 or the c-Jun kinase inhibitor SP600125 did not have any effect.	pyrazolanthrone	366-374	mitogen-activated protein kinase kinase 1	Homo sapiens	92-111
17204142-15	2007	Pre-incubation of SH-SY5Y human neuroblastoma cells with either RAR-pan-antagonist LE540 or MAP kinase kinase 1 (MEK-1) inhibitor PD98059 resulted in the abolition of ATRA-induced COX-2 promoter activity, COX-2 protein expression and PGE2 production whereas the retinoid X receptor pan-antagonist HX531, the p38 MAPK inhibitor SB203580 or the c-Jun kinase inhibitor SP600125 did not have any effect.	pyrazolanthrone	366-374	mitogen-activated protein kinase kinase 1	Homo sapiens	113-118
17982278-6	2007	Interestingly, the specific c-Jun-N-terminal protein kinase (JNK) inhibitor SP 600125 protected cultured neurons against AZA-induced cytotoxicity.	pyrazolanthrone	76-85	mitogen-activated protein kinase 8	Homo sapiens	28-59
17982278-6	2007	Interestingly, the specific c-Jun-N-terminal protein kinase (JNK) inhibitor SP 600125 protected cultured neurons against AZA-induced cytotoxicity.	pyrazolanthrone	76-85	mitogen-activated protein kinase 8	Homo sapiens	61-64
17284179-5	2007	Induction of mGluR-dependent LTD resulted in an increase in phosphorylation of JNK1 substrates, including p-c-Jun and p-ATF2 in wild-type (WT) mice, and these increases failed to occur in the JNK1-/- or SP600125-pretreated mice.	pyrazolanthrone	203-211	mitogen-activated protein kinase 8	Mus musculus	79-83
17055484-5	2007	Inhibition of JNK by SP600125 or expression of a dominant negative JNK1 construct abrogated the migratory response of HBMECs to HGF.	pyrazolanthrone	21-29	hepatocyte growth factor	Homo sapiens	128-131
17143555-9	2007	SB203580 and SP600125 (p38 and JNK inhibitors) reduced diosgenin-induced DNA fragmentation whereas U0126 and LY294002 (MEK and PI3 kinase/Akt inhibitors) caused an amplification of proapoptotic effect of diosgenin.	pyrazolanthrone	13-21	mitogen-activated protein kinase 14	Homo sapiens	23-26
17097910-8	2007	The presence of ERK inhibitor PD98059, JNK inhibitor SP600125 and p38 inhibitor SB203580 decreased cell death in 4Gy-irradiated thymocytes.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	39-42
17143555-9	2007	SB203580 and SP600125 (p38 and JNK inhibitors) reduced diosgenin-induced DNA fragmentation whereas U0126 and LY294002 (MEK and PI3 kinase/Akt inhibitors) caused an amplification of proapoptotic effect of diosgenin.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	31-34
17956941-10	2007	SP600125, a selective inhibitor of JNK, dose-dependently suppressed the production of these cytokine.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	35-38
17202844-8	2006	Furthermore, pretreatment with specific MAPK pathway inhibitors, including the MEK inhibitor U0126, the JNK inhibitor SP600125, and the p38 kinase inhibitor SB202190, completely inhibited ANX-inducible expression of Egr-1.	pyrazolanthrone	118-126	mitogen-activated protein kinase 3	Homo sapiens	40-44
17237278-6	2007	A specific JNK inhibitor, SP600125, inhibited EPA-induced apoptosis, confirming the involvement of the JNK pathway in EPA-induced apoptotic cell death.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	11-14
17237278-6	2007	A specific JNK inhibitor, SP600125, inhibited EPA-induced apoptosis, confirming the involvement of the JNK pathway in EPA-induced apoptotic cell death.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	103-106
17079291-7	2007	The competitive inhibitor of JNK, SP600125, caused a dose-dependent reduction in VZV yield (50% effective concentration, congruent with 8 microM).	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	29-32
17374178-10	2007	Inhibition of ERKs activation by AG126, AP-1 by curcumin, and JNKs by SP600125 could reduced the induction of cyclin D1 and CDK4, whereas inhibition of p38K by SB203580 did not show any inhibitory effects on S-HELF.	pyrazolanthrone	70-78	mitogen-activated protein kinase 3	Homo sapiens	14-18
17202844-8	2006	Furthermore, pretreatment with specific MAPK pathway inhibitors, including the MEK inhibitor U0126, the JNK inhibitor SP600125, and the p38 kinase inhibitor SB202190, completely inhibited ANX-inducible expression of Egr-1.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	104-107
17374178-10	2007	Inhibition of ERKs activation by AG126, AP-1 by curcumin, and JNKs by SP600125 could reduced the induction of cyclin D1 and CDK4, whereas inhibition of p38K by SB203580 did not show any inhibitory effects on S-HELF.	pyrazolanthrone	70-78	cyclin D1	Homo sapiens	110-119
17202844-8	2006	Furthermore, pretreatment with specific MAPK pathway inhibitors, including the MEK inhibitor U0126, the JNK inhibitor SP600125, and the p38 kinase inhibitor SB202190, completely inhibited ANX-inducible expression of Egr-1.	pyrazolanthrone	118-126	early growth response 1	Homo sapiens	216-221
17374178-10	2007	Inhibition of ERKs activation by AG126, AP-1 by curcumin, and JNKs by SP600125 could reduced the induction of cyclin D1 and CDK4, whereas inhibition of p38K by SB203580 did not show any inhibitory effects on S-HELF.	pyrazolanthrone	70-78	cyclin dependent kinase 4	Homo sapiens	124-128
17178861-8	2006	Treatment with JNK inhibitor, SP600125, prevents the formation of this repression complex.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	15-18
17097611-6	2006	The inhibitors for each kinase, PD98059, SB203580, and SP600125, attenuated the Ca(2+)-induced expression of COX-2 mRNA.	pyrazolanthrone	55-63	prostaglandin-endoperoxide synthase 2	Homo sapiens	109-114
16823772-6	2006	In addition, PD 98059 (a MEK inhibitor), SB 203580 (a p38 MAPK inhibitor), and SP 600125 (a JNK inhibitor) blocked the EGF-induced stimulation of [3H]-thymidine incorporation and CDK-2/4 expression.	pyrazolanthrone	79-88	epidermal growth factor	Gallus gallus	119-122
16823772-6	2006	In addition, PD 98059 (a MEK inhibitor), SB 203580 (a p38 MAPK inhibitor), and SP 600125 (a JNK inhibitor) blocked the EGF-induced stimulation of [3H]-thymidine incorporation and CDK-2/4 expression.	pyrazolanthrone	79-88	cyclin dependent kinase 2	Gallus gallus	179-184
17178877-7	2006	Furthermore, TG-ODN-induced apoptosis was inhibited by the c-Jun NH(2)-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Mus musculus	59-86
17178877-7	2006	Furthermore, TG-ODN-induced apoptosis was inhibited by the c-Jun NH(2)-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Mus musculus	88-91
16978663-6	2006	The JNK inhibitor SP600125 (3-30 microM) suppressed the LPS-induced phosphorylation of c-Jun, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa protein in a concentration-dependent manner.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
16455194-9	2006	Interestingly, treatment of HaCaT/GFP cells with SP600125 (a specific inhibitor of JNK) could reverse UVB mediated suppression of ARE activation by tBHQ.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	83-86
17078934-4	2006	Steady-state levels of perikaryal phospho-NF immunoreactivity are reduced and the increase resulting from expression of caMEKK-1 is prevented, by the JNK inhibitor SP600125, suggesting that JNK is a major downstream effector of MEKK-1 on NF phosphorylation.	pyrazolanthrone	164-172	mitogen-activated protein kinase 8	Mus musculus	150-153
17078934-4	2006	Steady-state levels of perikaryal phospho-NF immunoreactivity are reduced and the increase resulting from expression of caMEKK-1 is prevented, by the JNK inhibitor SP600125, suggesting that JNK is a major downstream effector of MEKK-1 on NF phosphorylation.	pyrazolanthrone	164-172	mitogen-activated protein kinase 8	Mus musculus	190-193
17078934-4	2006	Steady-state levels of perikaryal phospho-NF immunoreactivity are reduced and the increase resulting from expression of caMEKK-1 is prevented, by the JNK inhibitor SP600125, suggesting that JNK is a major downstream effector of MEKK-1 on NF phosphorylation.	pyrazolanthrone	164-172	mitogen-activated protein kinase kinase kinase 1	Mus musculus	122-128
17078934-6	2006	The JNK inhibitor SP600125 also inhibited NF transport in a dose-dependent manner.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
16978663-6	2006	The JNK inhibitor SP600125 (3-30 microM) suppressed the LPS-induced phosphorylation of c-Jun, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa protein in a concentration-dependent manner.	pyrazolanthrone	18-26	toll-like receptor 4	Mus musculus	56-59
16978663-6	2006	The JNK inhibitor SP600125 (3-30 microM) suppressed the LPS-induced phosphorylation of c-Jun, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa protein in a concentration-dependent manner.	pyrazolanthrone	18-26	jun proto-oncogene	Mus musculus	87-92
16978663-6	2006	The JNK inhibitor SP600125 (3-30 microM) suppressed the LPS-induced phosphorylation of c-Jun, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa protein in a concentration-dependent manner.	pyrazolanthrone	18-26	toll-like receptor 4	Mus musculus	112-115
16978663-6	2006	The JNK inhibitor SP600125 (3-30 microM) suppressed the LPS-induced phosphorylation of c-Jun, and inhibited the LPS-induced production of histamine and expression of the HDC mRNA and 74-kDa protein in a concentration-dependent manner.	pyrazolanthrone	18-26	histidine decarboxylase	Mus musculus	170-173
16978663-7	2006	Combined treatment with U0126 (0.3 microM) and SP600125 (10 microM) inhibited the LPS-induced production of histamine additively.	pyrazolanthrone	47-55	toll-like receptor 4	Mus musculus	82-85
17109472-5	2006	The c-jun-N terminal kinase (JNK) inhibitor, SP600125, blocks the mitochondrio-nuclear translocation of AIF and prevents AICD in these CTL.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	4-27
17054427-0	2006	The c-Jun-N-terminal-Kinase inhibitor SP600125 enhances the butyrate derivative D1-induced apoptosis via caspase 8 activation in Kasumi 1 t(8;21) acute myeloid leukaemia cells.	pyrazolanthrone	38-46	caspase 8	Homo sapiens	105-114
17054427-4	2006	These experiments showed that SP600125 activated caspase 8 and confirmed that D1 activated the intrinsic pathway of apoptosis, as caspase 8 was not affected while Bcl-2 was down-regulated following D1 administration.	pyrazolanthrone	30-38	caspase 8	Homo sapiens	49-58
17054427-4	2006	These experiments showed that SP600125 activated caspase 8 and confirmed that D1 activated the intrinsic pathway of apoptosis, as caspase 8 was not affected while Bcl-2 was down-regulated following D1 administration.	pyrazolanthrone	30-38	BCL2 apoptosis regulator	Homo sapiens	163-168
17145888-7	2006	The JNK inhibitor SP600125 inhibited the increase in DR5 protein and attenuated apoptosis induced by treatment with As(2)O(3) plus BSO.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
17145888-7	2006	The JNK inhibitor SP600125 inhibited the increase in DR5 protein and attenuated apoptosis induced by treatment with As(2)O(3) plus BSO.	pyrazolanthrone	18-26	TNF receptor superfamily member 10b	Homo sapiens	53-56
17113937-5	2006	A jun N-terminal kinase (JNK) pathway is activated by EtOH and their pharmacological inhibition (by SP600125) neutralized ethanol-induced apoptosis, suggesting a role for JNK in EtOH neurotoxicity.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	2-23
17113937-5	2006	A jun N-terminal kinase (JNK) pathway is activated by EtOH and their pharmacological inhibition (by SP600125) neutralized ethanol-induced apoptosis, suggesting a role for JNK in EtOH neurotoxicity.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	25-28
17113937-5	2006	A jun N-terminal kinase (JNK) pathway is activated by EtOH and their pharmacological inhibition (by SP600125) neutralized ethanol-induced apoptosis, suggesting a role for JNK in EtOH neurotoxicity.	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Homo sapiens	171-174
17109472-5	2006	The c-jun-N terminal kinase (JNK) inhibitor, SP600125, blocks the mitochondrio-nuclear translocation of AIF and prevents AICD in these CTL.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	29-32
17109472-5	2006	The c-jun-N terminal kinase (JNK) inhibitor, SP600125, blocks the mitochondrio-nuclear translocation of AIF and prevents AICD in these CTL.	pyrazolanthrone	45-53	apoptosis inducing factor mitochondria associated 1	Homo sapiens	104-107
16972261-2	2006	This effect was potentiated by co-treatment with MEK/ERK (PD98059, U0126) and JNK (SP600125, AS601245) inhibitors, but not with p38 (SB203580, SB220025) inhibitors.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	78-81
16972261-6	2006	Thus, while it was prevented by N-acetyl-L-cysteine (NAC) in the case of U0126, it behaved as a NAC-insensitive process, regulated at the level of DL-buthionine-(S,R)-sulfoximine (BSO)-sensitive enzyme activity, in the case of SP600125.	pyrazolanthrone	227-235	X-linked Kx blood group	Homo sapiens	53-56
16845490-13	2006	On the other hand, SP600125 caused 85% inhibition of c-Fos induction by ACTH(39) and, in addition, ACTH(39) promotes JNK1/2 phosphorylation, suggesting that JNK is a major signaling pathway mediating c-Fos induction by ACTH(39) in these cells.	pyrazolanthrone	19-27	FBJ osteosarcoma oncogene	Mus musculus	53-58
16845490-13	2006	On the other hand, SP600125 caused 85% inhibition of c-Fos induction by ACTH(39) and, in addition, ACTH(39) promotes JNK1/2 phosphorylation, suggesting that JNK is a major signaling pathway mediating c-Fos induction by ACTH(39) in these cells.	pyrazolanthrone	19-27	pro-opiomelanocortin-alpha	Mus musculus	72-76
16845490-13	2006	On the other hand, SP600125 caused 85% inhibition of c-Fos induction by ACTH(39) and, in addition, ACTH(39) promotes JNK1/2 phosphorylation, suggesting that JNK is a major signaling pathway mediating c-Fos induction by ACTH(39) in these cells.	pyrazolanthrone	19-27	FBJ osteosarcoma oncogene	Mus musculus	200-205
16914544-7	2006	Conversely, the JNK inhibitor SP600125 inhibited rapamycin-induced MMP-1 gene transactivation and AP-1/DNA interactions.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	16-19
17438698-1	2006	OBJECTIVE: To investigate the role and mechanism of c-Jun N-terminal kinase (JNk) inhibitor (SP600125) in amelioration of insulin resistance after scald.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Rattus norvegicus	52-75
17438698-1	2006	OBJECTIVE: To investigate the role and mechanism of c-Jun N-terminal kinase (JNk) inhibitor (SP600125) in amelioration of insulin resistance after scald.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Rattus norvegicus	77-80
17438698-15	2006	Compared with scald group, the level of IRS-1 Serine307 phosphorylation and JNK activity in scald and SP600125 group were decreased but tyrosine phosphorylation was elevated.	pyrazolanthrone	102-110	insulin receptor substrate 1	Rattus norvegicus	40-45
17438698-15	2006	Compared with scald group, the level of IRS-1 Serine307 phosphorylation and JNK activity in scald and SP600125 group were decreased but tyrosine phosphorylation was elevated.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Rattus norvegicus	76-79
17313766-6	2006	The production of TGF-beta1 in the groups which were incubated with SP600125 and SB203580 did not appear significant decrease compared with that in 10(-7) mol/L ALDO incubated group (P &gt; 0.05), the production of TGF-beta1 in these groups was also significant higher than that in the control group (P &lt; 0.05).	pyrazolanthrone	68-76	transforming growth factor beta 1	Homo sapiens	18-27
16979204-10	2006	The specific JNK2 inhibitor SP600125 similarly protected from APAP-induced cell death.	pyrazolanthrone	28-36	mitogen-activated protein kinase 9	Homo sapiens	13-17
16715131-7	2006	The induced AChE mRNA and protein expression could be blocked by SP600125, a specific inhibitor of SAPK/JNK, and small interfering RNA directed against JNK1/2.	pyrazolanthrone	65-73	acetylcholinesterase (Cartwright blood group)	Homo sapiens	12-16
16715131-7	2006	The induced AChE mRNA and protein expression could be blocked by SP600125, a specific inhibitor of SAPK/JNK, and small interfering RNA directed against JNK1/2.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Homo sapiens	104-107
17438698-16	2006	CONCLUSION: SP600125 can partially ameliorate insulin resistance after scald by inhibition of JNK activation, and decrease the level of IRS-1 phospho-serine307.	pyrazolanthrone	12-20	mitogen-activated protein kinase 8	Rattus norvegicus	94-97
17438698-16	2006	CONCLUSION: SP600125 can partially ameliorate insulin resistance after scald by inhibition of JNK activation, and decrease the level of IRS-1 phospho-serine307.	pyrazolanthrone	12-20	insulin receptor substrate 1	Rattus norvegicus	136-141
16914544-7	2006	Conversely, the JNK inhibitor SP600125 inhibited rapamycin-induced MMP-1 gene transactivation and AP-1/DNA interactions.	pyrazolanthrone	30-38	matrix metallopeptidase 1	Homo sapiens	67-72
17182924-8	2006	Treatment of mice with SP600125, a specific JNK inhibitor, completely abrogated the formation of CaCl(2)-induced AAA.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Mus musculus	44-47
16715133-8	2006	Induction of TMS1/ASC by TNFalpha was blocked by co-expression of a dominant negative IkappaBalpha, small interfering RNA-mediated knockdown of RelA/p65, or concurrent treatment with SP600125, indicating a requirement for the nuclear factor-kappaB (NF-kappaB) and jun kinase signaling pathways.	pyrazolanthrone	183-191	PYD and CARD domain containing	Homo sapiens	13-17
16715133-8	2006	Induction of TMS1/ASC by TNFalpha was blocked by co-expression of a dominant negative IkappaBalpha, small interfering RNA-mediated knockdown of RelA/p65, or concurrent treatment with SP600125, indicating a requirement for the nuclear factor-kappaB (NF-kappaB) and jun kinase signaling pathways.	pyrazolanthrone	183-191	PYD and CARD domain containing	Homo sapiens	18-21
16715133-8	2006	Induction of TMS1/ASC by TNFalpha was blocked by co-expression of a dominant negative IkappaBalpha, small interfering RNA-mediated knockdown of RelA/p65, or concurrent treatment with SP600125, indicating a requirement for the nuclear factor-kappaB (NF-kappaB) and jun kinase signaling pathways.	pyrazolanthrone	183-191	tumor necrosis factor	Homo sapiens	25-33
17182924-8	2006	Treatment of mice with SP600125, a specific JNK inhibitor, completely abrogated the formation of CaCl(2)-induced AAA.	pyrazolanthrone	23-31	AAA1	Homo sapiens	113-116
17182924-9	2006	Furthermore, SP600125 treatment after the establishment of AAA caused a reduction in the aortic diameters with normalized tissue architecture.	pyrazolanthrone	13-21	AAA1	Homo sapiens	59-62
17041759-10	2006	The NE-induced apoptosis was abrogated by SP600125 (a specific inhibitor of JNK).	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Rattus norvegicus	76-79
17013757-9	2006	GF-109203X and SP600125 suppression of TPA against cytochrome c release induced by BE was identified.	pyrazolanthrone	15-23	cytochrome c, somatic	Homo sapiens	51-63
17182924-10	2006	SP600125 treatment also caused significant regression of angiotensin II-induced AAA in ApoE-null mice after its establishment, as demonstrated by serial ultrasonographic studies in live animals.	pyrazolanthrone	0-8	AAA1	Homo sapiens	80-83
17182924-10	2006	SP600125 treatment also caused significant regression of angiotensin II-induced AAA in ApoE-null mice after its establishment, as demonstrated by serial ultrasonographic studies in live animals.	pyrazolanthrone	0-8	apolipoprotein E	Mus musculus	87-91
16895977-3	2006	NO production induced by these V-ATPase inhibitors was suppressed by the NF-kappaB inhibitor Bay 11-7082 [(E)3-[(4-methylphenyl)sulfonyl])-2-propenenitrile] and the JNK inhibitor SP600125 [anthra[1,9-cd]pyrazol-6(2H)-one] in parallel with the partial alleviation of the V-ATPase inhibitor-induced decrease in MTT response.	pyrazolanthrone	189-220	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	31-39
17085668-5	2006	The c-Jun NH2-terminal kinase (JNK) activation was evaluated by anti-phosphorylated JNK antibody and inhibited by the JNK-specific inhibitor SP600125 or dominant-negative SEK1 expression.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	4-29
17085668-5	2006	The c-Jun NH2-terminal kinase (JNK) activation was evaluated by anti-phosphorylated JNK antibody and inhibited by the JNK-specific inhibitor SP600125 or dominant-negative SEK1 expression.	pyrazolanthrone	141-149	mitogen-activated protein kinase 8	Homo sapiens	31-34
17085668-9	2006	Augmentation of both radiosensitivity and H2AX phosphorylation was substantially reduced by SP600125 or overexpression of a dominant-negative mutant SEK1.	pyrazolanthrone	92-100	H2A.X variant histone	Homo sapiens	42-46
17050626-8	2006	The JNK inhibitor SP600125 and the PKA inhibitor KT5720 suppressed migration of the ENCCs in cultured guts from wild-type mice to comparable degrees.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
16895977-3	2006	NO production induced by these V-ATPase inhibitors was suppressed by the NF-kappaB inhibitor Bay 11-7082 [(E)3-[(4-methylphenyl)sulfonyl])-2-propenenitrile] and the JNK inhibitor SP600125 [anthra[1,9-cd]pyrazol-6(2H)-one] in parallel with the partial alleviation of the V-ATPase inhibitor-induced decrease in MTT response.	pyrazolanthrone	179-187	ATPase, H+ transporting, lysosomal V0 subunit D2	Mus musculus	31-39
17056565-5	2006	A JNK inhibitor (1,9-pyrazoloanthrone) inhibited pfGPI-induced phosphorylation of JNK, c-Jun, and activating transcription factor-2 and significantly decreased pfGPI-induced TNF-alpha secretion.	pyrazolanthrone	17-37	tumor necrosis factor	Mus musculus	174-183
16882877-6	2006	However, inhibition of p53 with alpha-PFT or p53 siRNA or JNK with SP600125 (1,9-pyrazoloanthrone) failed to protect WI38 cells from BU-induced senescence.	pyrazolanthrone	67-75	mitogen-activated protein kinase 8	Homo sapiens	58-61
16938121-11	2006	Selective inhibition of this second JNK activation by SP600125 reduced TF induction to histamine plus TNF-alpha by 67%, but to histamine plus thrombin by only 32%.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	36-39
16938121-11	2006	Selective inhibition of this second JNK activation by SP600125 reduced TF induction to histamine plus TNF-alpha by 67%, but to histamine plus thrombin by only 32%.	pyrazolanthrone	54-62	tumor necrosis factor	Homo sapiens	102-111
16751226-11	2006	The combined response to M. fermentans and TNF-beta, however, was uniquely sensitive to delayed application of SP-600125, suggesting that JNK/stress-activated protein kinase contributes to the amplification of IL-6 release.	pyrazolanthrone	111-120	lymphotoxin alpha	Homo sapiens	43-51
17079869-7	2006	U0126, a MEK inhibitor, SP600125, a JNK inhibitor, or SB203580, a p38 inhibitor, attenuates the Ang II-induced [3H]thymidine incorporation into the VSMC.	pyrazolanthrone	24-32	angiotensinogen	Rattus norvegicus	96-102
17015748-8	2006	The JNK inhibitor SP600125 prevented the RANTES increases by all three stimuli.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
17015748-8	2006	The JNK inhibitor SP600125 prevented the RANTES increases by all three stimuli.	pyrazolanthrone	18-26	C-C motif chemokine ligand 5	Homo sapiens	41-47
16782691-7	2006	In addition, the EGF-induced decrease in GLUT2 protein expression was inhibited by staurosporine, H-7, or bisindolylmaleimide I (PKC inhibitors), PD-98059 (a MEK inhibitor), SB-203580 (a p38 MAPK inhibitor), and SP-600125 (a JNK inhibitor), suggesting a role of both PKC and MAPKs (p44/42 MAPK, p38 MAPK, and JNK).	pyrazolanthrone	212-221	solute carrier family 2 member 2	Gallus gallus	41-46
16672691-3	2006	The pharmacological actin depolymerization agent cytochalasin D increased expression of MMP-2 and membrane type 1-matrix metalloproteinase (MT1-MMP) mRNA, and this was reduced significantly in the presence of the JNK inhibitor SP600125.	pyrazolanthrone	227-235	matrix metallopeptidase 2	Homo sapiens	88-93
16672691-3	2006	The pharmacological actin depolymerization agent cytochalasin D increased expression of MMP-2 and membrane type 1-matrix metalloproteinase (MT1-MMP) mRNA, and this was reduced significantly in the presence of the JNK inhibitor SP600125.	pyrazolanthrone	227-235	matrix metallopeptidase 14	Homo sapiens	98-138
16672691-3	2006	The pharmacological actin depolymerization agent cytochalasin D increased expression of MMP-2 and membrane type 1-matrix metalloproteinase (MT1-MMP) mRNA, and this was reduced significantly in the presence of the JNK inhibitor SP600125.	pyrazolanthrone	227-235	matrix metallopeptidase 14	Homo sapiens	140-147
16672691-3	2006	The pharmacological actin depolymerization agent cytochalasin D increased expression of MMP-2 and membrane type 1-matrix metalloproteinase (MT1-MMP) mRNA, and this was reduced significantly in the presence of the JNK inhibitor SP600125.	pyrazolanthrone	227-235	mitogen-activated protein kinase 8	Homo sapiens	213-216
17069899-6	2006	In addition, the transcriptional activity of hST8Sia III induced by RA in U-87MG cells was strongly inhibited by SP600125, c-Jun N-terminal Kinase (JNK) inhibitor, as determined by RT-PCR and luciferase assay of hST8Sia III promoter containing the -1194 to -816 regions.	pyrazolanthrone	113-121	ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3	Homo sapiens	45-56
17069899-6	2006	In addition, the transcriptional activity of hST8Sia III induced by RA in U-87MG cells was strongly inhibited by SP600125, c-Jun N-terminal Kinase (JNK) inhibitor, as determined by RT-PCR and luciferase assay of hST8Sia III promoter containing the -1194 to -816 regions.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	148-151
17069899-6	2006	In addition, the transcriptional activity of hST8Sia III induced by RA in U-87MG cells was strongly inhibited by SP600125, c-Jun N-terminal Kinase (JNK) inhibitor, as determined by RT-PCR and luciferase assay of hST8Sia III promoter containing the -1194 to -816 regions.	pyrazolanthrone	113-121	Oncogene OVC (ovarian adenocarcinoma oncogene)	Homo sapiens	45-49
17283870-8	2006	Mox-LDL at 5 microg/ml showed the maximal mitogenic effect (211%), which was inhibited by free radical scavenger (catalase), intracellular and extracellular antioxidants (N-acetylcysteine and probucol), nicotinamide adenine dinucleotide phosphate oxidase inhibitor (diphenylene iodonium), or c-Jun N-terminal kinase (JNK) inhibitor (SP600125).	pyrazolanthrone	333-341	monooxygenase DBH like 1	Homo sapiens	0-3
16531007-7	2006	In an effort to define possible substrates of MSK1, we found that ATF2 as well as cJun phosphorylation were equally induced after 30 min and 60 min, respectively, a response inhibited by SP600125 (JNKs inhibitor) and H89 (MSK1 inhibitor), indicating the involvement of these kinases in the observed response.	pyrazolanthrone	187-195	ribosomal protein S6 kinase A5	Rattus norvegicus	46-50
16531007-7	2006	In an effort to define possible substrates of MSK1, we found that ATF2 as well as cJun phosphorylation were equally induced after 30 min and 60 min, respectively, a response inhibited by SP600125 (JNKs inhibitor) and H89 (MSK1 inhibitor), indicating the involvement of these kinases in the observed response.	pyrazolanthrone	187-195	activating transcription factor 2	Rattus norvegicus	66-70
16531007-11	2006	Electrophoretic mobility shift assays performed showed a maximal upregulation of AP1 binding activity after 60 min of H2O2 treatment, which was significantly inhibited by SP600125 and H89.	pyrazolanthrone	171-179	Jun proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	81-84
16896943-7	2006	Salicylic acid and SP600125 partially inhibited IKKbeta and JNK, respectively, which indicated distinct roles for these two kinases in the phosphorylation of IRS1 at the two serine sites.	pyrazolanthrone	19-27	inhibitor of nuclear factor kappa B kinase subunit beta	Rattus norvegicus	48-55
16896943-7	2006	Salicylic acid and SP600125 partially inhibited IKKbeta and JNK, respectively, which indicated distinct roles for these two kinases in the phosphorylation of IRS1 at the two serine sites.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Rattus norvegicus	60-63
16896943-7	2006	Salicylic acid and SP600125 partially inhibited IKKbeta and JNK, respectively, which indicated distinct roles for these two kinases in the phosphorylation of IRS1 at the two serine sites.	pyrazolanthrone	19-27	insulin receptor substrate 1	Rattus norvegicus	158-162
16896943-8	2006	Protection against oxidation-mediated impairment in insulin-induced phosphorylation of protein kinase B/Akt and in glycogen synthesis was achieved only by combining salicylic acid and SP600125.	pyrazolanthrone	184-192	AKT serine/threonine kinase 1	Rattus norvegicus	104-107
16953819-15	2006	Finally, induction of the myofibroblast marker alpha-smooth muscle actin by TGF-beta1 was abolished by the c-Jun N-terminal protein kinase inhibitor SP600125, suggesting a role for this signaling pathway during the induction of this phenotype.	pyrazolanthrone	149-157	transforming growth factor beta 1	Homo sapiens	76-85
16953819-15	2006	Finally, induction of the myofibroblast marker alpha-smooth muscle actin by TGF-beta1 was abolished by the c-Jun N-terminal protein kinase inhibitor SP600125, suggesting a role for this signaling pathway during the induction of this phenotype.	pyrazolanthrone	149-157	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	107-112
16337741-0	2006	Induction of apoptosis and cell cycle arrest by a specific c-Jun NH2-terminal kinase (JNK) inhibitor, SP-600125, in gastrointestinal cancers.	pyrazolanthrone	102-111	mitogen-activated protein kinase 8	Homo sapiens	86-89
16905119-5	2006	And JNK-specific inhibitor SP600125 could reduce cell apoptosis induced by Nogo-C.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	4-7
16905119-5	2006	And JNK-specific inhibitor SP600125 could reduce cell apoptosis induced by Nogo-C.	pyrazolanthrone	27-35	reticulon 4	Homo sapiens	75-81
16932349-6	2006	Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
16932349-6	2006	Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	43-62
16932349-6	2006	Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-68
16932349-6	2006	Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Homo sapiens	85-89
16932349-6	2006	Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Homo sapiens	118-122
16932349-6	2006	Sp600125, an inhibitor of JNK activity and activator protein-1 (AP-1) binding to the VEGF promoter, downregulates the VEGF production without affecting Jak3 activity.	pyrazolanthrone	0-8	Janus kinase 3	Homo sapiens	152-156
16337741-2	2006	The aim of this study was to determine the effects of SP-600125, a specific JNK inhibitor, on the viability, apoptosis, cell cycle distribution of gastrointestinal cancer cells, and the potential anti-tumor mechanisms.	pyrazolanthrone	54-63	mitogen-activated protein kinase 8	Homo sapiens	76-79
16337741-7	2006	SP-600125 caused G2/M cell cycle arrest and elevation of cyclin B1 and p27(kip).	pyrazolanthrone	0-9	cyclin B1	Homo sapiens	57-66
16337741-7	2006	SP-600125 caused G2/M cell cycle arrest and elevation of cyclin B1 and p27(kip).	pyrazolanthrone	0-9	dynactin subunit 6	Homo sapiens	71-74
16337741-8	2006	The differential response in cells to SP-600125 was associated with the basal level of phosphorylated JNK2.	pyrazolanthrone	38-47	mitogen-activated protein kinase 9	Homo sapiens	102-106
16337741-9	2006	It is concluded that SP-600125 inhibits proliferation, induces apoptosis and causes cell cycle arrest in gastrointestinal cancer cells, indicating that JNK inhibitors have an anti-tumor effect and are potential therapeutic agents for cancers.	pyrazolanthrone	21-30	mitogen-activated protein kinase 8	Homo sapiens	152-155
16814769-4	2006	The extension is inhibited by JNK inhibitors (SP600125 and the small JNK-binding peptide) and Clostridium difficile Toxin B, the inhibitor for Rho GTPases.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Mus musculus	30-33
16971530-6	2006	Treatment with SP600125, a specific inhibitor of JNK, reversibly inhibits axonogenesis but does not prevent the formation of minor processes or their differentiation into dendrites (based on their immunostaining with marker proteins).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	49-52
16985072-6	2006	Alternatively, the JNK inhibitor SP600125 could also protect cells from apoptosis induced by the combination, indicating that both inhibition of Akt and activation of JNK were required for the synergism.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	19-22
16923120-0	2006	Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125.	pyrazolanthrone	105-113	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	72-77
16923120-0	2006	Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	91-94
16923120-4	2006	In the present study, we demonstrate that an anthrapyrazole SP600125, a reversible ATP-competitive inhibitor of JNK inhibits proliferation of human HMC-1 showed constitutive activation of JNK/c-Jun, and the inhibitory effect of SP600125 on cell proliferation was associated with cell cycle arrest at the G1 phase and apoptosis accompanied by the cleavage of caspase-3 and PARP.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	112-115
16923120-4	2006	In the present study, we demonstrate that an anthrapyrazole SP600125, a reversible ATP-competitive inhibitor of JNK inhibits proliferation of human HMC-1 showed constitutive activation of JNK/c-Jun, and the inhibitory effect of SP600125 on cell proliferation was associated with cell cycle arrest at the G1 phase and apoptosis accompanied by the cleavage of caspase-3 and PARP.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	188-191
16923120-4	2006	In the present study, we demonstrate that an anthrapyrazole SP600125, a reversible ATP-competitive inhibitor of JNK inhibits proliferation of human HMC-1 showed constitutive activation of JNK/c-Jun, and the inhibitory effect of SP600125 on cell proliferation was associated with cell cycle arrest at the G1 phase and apoptosis accompanied by the cleavage of caspase-3 and PARP.	pyrazolanthrone	60-68	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	192-197
16923120-4	2006	In the present study, we demonstrate that an anthrapyrazole SP600125, a reversible ATP-competitive inhibitor of JNK inhibits proliferation of human HMC-1 showed constitutive activation of JNK/c-Jun, and the inhibitory effect of SP600125 on cell proliferation was associated with cell cycle arrest at the G1 phase and apoptosis accompanied by the cleavage of caspase-3 and PARP.	pyrazolanthrone	60-68	caspase 3	Homo sapiens	358-367
16923120-4	2006	In the present study, we demonstrate that an anthrapyrazole SP600125, a reversible ATP-competitive inhibitor of JNK inhibits proliferation of human HMC-1 showed constitutive activation of JNK/c-Jun, and the inhibitory effect of SP600125 on cell proliferation was associated with cell cycle arrest at the G1 phase and apoptosis accompanied by the cleavage of caspase-3 and PARP.	pyrazolanthrone	60-68	poly(ADP-ribose) polymerase 1	Homo sapiens	372-376
16923120-4	2006	In the present study, we demonstrate that an anthrapyrazole SP600125, a reversible ATP-competitive inhibitor of JNK inhibits proliferation of human HMC-1 showed constitutive activation of JNK/c-Jun, and the inhibitory effect of SP600125 on cell proliferation was associated with cell cycle arrest at the G1 phase and apoptosis accompanied by the cleavage of caspase-3 and PARP.	pyrazolanthrone	228-236	mitogen-activated protein kinase 8	Homo sapiens	112-115
16923120-5	2006	Caspase-3 inhibitor Z-DEVD-FMK almost completely inhibited SP600125-induced apoptosis of HMC-1 cells.	pyrazolanthrone	59-67	caspase 3	Homo sapiens	0-9
16923120-7	2006	Following Sp600125 treatment, down-regulation of cyclin D3 protein expression, but not p53 was also observed.	pyrazolanthrone	10-18	cyclin D3	Homo sapiens	49-58
16564547-6	2006	Inhibition of ERK1/2, p38 kinase, and JNK pathways was performed with PD98059, SB203580, and SP600125, respectively.	pyrazolanthrone	93-101	mitogen-activated protein kinase 3	Homo sapiens	14-20
16564547-6	2006	Inhibition of ERK1/2, p38 kinase, and JNK pathways was performed with PD98059, SB203580, and SP600125, respectively.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Homo sapiens	38-41
16985072-6	2006	Alternatively, the JNK inhibitor SP600125 could also protect cells from apoptosis induced by the combination, indicating that both inhibition of Akt and activation of JNK were required for the synergism.	pyrazolanthrone	33-41	AKT serine/threonine kinase 1	Homo sapiens	145-148
16985072-6	2006	Alternatively, the JNK inhibitor SP600125 could also protect cells from apoptosis induced by the combination, indicating that both inhibition of Akt and activation of JNK were required for the synergism.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	167-170
16953120-0	2006	SP600125, a selective JNK inhibitor, aggravates hepatic ischemia-reperfusion injury.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	22-25
16953120-2	2006	We attempted to determine the effect of SP600125, a JNK inhibitor, on hepatic I/R injury using a partial ischemia model in mice.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Mus musculus	52-55
16953120-3	2006	Compared to a vehicle-treated group, the SP600125- treated group showed a greater increase in serum ALT levels 24 h after reperfusion with more severe parenchymal destruction and leukocyte infiltration.	pyrazolanthrone	41-49	glutamic pyruvic transaminase, soluble	Mus musculus	100-103
16953120-5	2006	These data, which are contradictory to previous results, indicate that JNK inhibition by SP600125 may be harmful in hepatic I/R injury.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Mus musculus	71-74
16516943-7	2006	Treatment of cells with high levels of cadmium resulted in decreased phosphorylation of c-Jun N-terminal kinase (JNK1/2) in adapted cells than in sensitive cells and this cadmium-induced JNK activity was blocked by JNK inhibitor II, SP600125.	pyrazolanthrone	233-241	mitogen-activated protein kinase 8	Rattus norvegicus	187-190
16712891-8	2006	Importantly, atRA-induced DNA fragmentation and capase-3 activation were prevented by pretreatment with the JNK inhibitor (SP600125) and the p38 MAPK inhibitor (SB202190), but not by pretreatment with MEK inhibitor (U0126).	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Mus musculus	108-111
16861427-7	2006	JNK was phosphorylated in hypoxic neurons in the presence of isoflurane, as was the transcription factor c-Jun; JNK inhibition with SP600125 prevented both phosphorylation of c-Jun and neuroprotection.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Mus musculus	0-3
16547493-3	2006	In an attempt to explore what genes are transcriptionally regulated by the activated JNK signaling pathway upon paclitaxel treatment, we used cDNA microarrays to analyse the changes of gene expression in human ovarian cancer cells that were treated with paclitaxel and/or the JNK inhibitor SP600125.	pyrazolanthrone	290-298	mitogen-activated protein kinase 8	Homo sapiens	85-88
16825605-7	2006	The increased gene expressions of IGF-II and -IIR induced by ANG II were reversed by U-0126 and Sp600125, respectively.	pyrazolanthrone	96-104	insulin-like growth factor 2	Rattus norvegicus	34-67
16825605-8	2006	Caspase 8 activities induced by ANG II were attenuated by U-0126, SP-600125, and CsA.	pyrazolanthrone	66-75	caspase 8	Rattus norvegicus	0-9
16825605-8	2006	Caspase 8 activities induced by ANG II were attenuated by U-0126, SP-600125, and CsA.	pyrazolanthrone	66-75	angiotensinogen	Rattus norvegicus	32-38
16516943-7	2006	Treatment of cells with high levels of cadmium resulted in decreased phosphorylation of c-Jun N-terminal kinase (JNK1/2) in adapted cells than in sensitive cells and this cadmium-induced JNK activity was blocked by JNK inhibitor II, SP600125.	pyrazolanthrone	233-241	mitogen-activated protein kinase 8	Rattus norvegicus	113-116
16825605-9	2006	DNA fragmentation induced by ANG II was totally blocked by SP-600125, and CsA and was attenuated by U-0126.	pyrazolanthrone	59-68	angiotensinogen	Rattus norvegicus	29-35
16861427-7	2006	JNK was phosphorylated in hypoxic neurons in the presence of isoflurane, as was the transcription factor c-Jun; JNK inhibition with SP600125 prevented both phosphorylation of c-Jun and neuroprotection.	pyrazolanthrone	132-140	jun proto-oncogene	Mus musculus	105-110
16861427-7	2006	JNK was phosphorylated in hypoxic neurons in the presence of isoflurane, as was the transcription factor c-Jun; JNK inhibition with SP600125 prevented both phosphorylation of c-Jun and neuroprotection.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Mus musculus	112-115
16699950-6	2006	In addition, an inhibitor of the JNK MAP kinase pathway, SP600125, reduced esculetin-induced cytochrome c release.	pyrazolanthrone	57-65	mitogen-activated protein kinase 8	Homo sapiens	33-36
16861427-7	2006	JNK was phosphorylated in hypoxic neurons in the presence of isoflurane, as was the transcription factor c-Jun; JNK inhibition with SP600125 prevented both phosphorylation of c-Jun and neuroprotection.	pyrazolanthrone	132-140	jun proto-oncogene	Mus musculus	175-180
16699950-6	2006	In addition, an inhibitor of the JNK MAP kinase pathway, SP600125, reduced esculetin-induced cytochrome c release.	pyrazolanthrone	57-65	cytochrome c, somatic	Homo sapiens	93-105
16480751-15	2006	In addition, only the JNK inhibitor SP600125 and tyrosine kinase inhibitor genistein had any significant inhibitory impact upon the upregulation of HO-1 by acrolein.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	22-25
16697003-9	2006	NAC, PD 098059 and SP600125, but not SB202190, also abolished the cardioprotective effect of Ang II preconditioning.	pyrazolanthrone	19-27	angiotensinogen	Rattus norvegicus	93-99
16601071-7	2006	Use of the JNK inhibitor SP600125 or expression of dominant-negative JNK-activator SAPK kinase (SEK1) prevented the induction of ATF2-Thr69+71, but not ATF2-Thr71 phosphorylation by insulin.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Homo sapiens	11-14
16601071-7	2006	Use of the JNK inhibitor SP600125 or expression of dominant-negative JNK-activator SAPK kinase (SEK1) prevented the induction of ATF2-Thr69+71, but not ATF2-Thr71 phosphorylation by insulin.	pyrazolanthrone	25-33	activating transcription factor 2	Homo sapiens	129-133
16843825-7	2006	Cell preincubation with the JNK inhibitor SP600125 significantly prevented JNK and Smad4 enhancement and, subsequently, the cooperative proapoptotic effect was abolished.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	28-31
16843825-7	2006	Cell preincubation with the JNK inhibitor SP600125 significantly prevented JNK and Smad4 enhancement and, subsequently, the cooperative proapoptotic effect was abolished.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Homo sapiens	75-78
16843825-7	2006	Cell preincubation with the JNK inhibitor SP600125 significantly prevented JNK and Smad4 enhancement and, subsequently, the cooperative proapoptotic effect was abolished.	pyrazolanthrone	42-50	SMAD family member 4	Homo sapiens	83-88
16632641-9	2006	SP600125 (anthra [1,9-cd]pyrazol-6(2H)-one-1,9-pyrazoloanthrone), a specific inhibitor of JNK, significantly decreased apoptosis by inhibiting the phosphorylation of p53 (serine 15) and subsequently increased the interaction of p53 and MDM2.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	90-93
16632641-9	2006	SP600125 (anthra [1,9-cd]pyrazol-6(2H)-one-1,9-pyrazoloanthrone), a specific inhibitor of JNK, significantly decreased apoptosis by inhibiting the phosphorylation of p53 (serine 15) and subsequently increased the interaction of p53 and MDM2.	pyrazolanthrone	0-8	tumor protein p53	Homo sapiens	166-169
16632641-9	2006	SP600125 (anthra [1,9-cd]pyrazol-6(2H)-one-1,9-pyrazoloanthrone), a specific inhibitor of JNK, significantly decreased apoptosis by inhibiting the phosphorylation of p53 (serine 15) and subsequently increased the interaction of p53 and MDM2.	pyrazolanthrone	0-8	tumor protein p53	Homo sapiens	228-231
16632641-9	2006	SP600125 (anthra [1,9-cd]pyrazol-6(2H)-one-1,9-pyrazoloanthrone), a specific inhibitor of JNK, significantly decreased apoptosis by inhibiting the phosphorylation of p53 (serine 15) and subsequently increased the interaction of p53 and MDM2.	pyrazolanthrone	0-8	MDM2 proto-oncogene	Homo sapiens	236-240
16697175-8	2006	Mechanical stimulation in the presence of the JNK inhibitor, SP600125, blocked AP-1 binding preventing the increased gene expression of MMP-3 and -13 at 2 h and type II collagen and aggrecan at 12 h as well as the increased matrix synthesis and accumulation.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	46-49
16480751-15	2006	In addition, only the JNK inhibitor SP600125 and tyrosine kinase inhibitor genistein had any significant inhibitory impact upon the upregulation of HO-1 by acrolein.	pyrazolanthrone	36-44	heme oxygenase 1	Homo sapiens	148-152
16679312-5	2006	Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	39-42
16687388-6	2006	Furthermore, early paraquat-mediated increases in ERK1/2 activation were sensitive to the mitogen-activated protein kinase kinase 1 (MEK1) inhibitor PD 98059 (2"-amino-3"-methoxyflavone), whereas JNK1/2 responses were blocked by the JNK1/2 inhibitor SP 600125 (anthra[1-9-cd]pyrazol-6(2H)-one).	pyrazolanthrone	250-259	mitogen-activated protein kinase 3	Homo sapiens	50-56
16687388-6	2006	Furthermore, early paraquat-mediated increases in ERK1/2 activation were sensitive to the mitogen-activated protein kinase kinase 1 (MEK1) inhibitor PD 98059 (2"-amino-3"-methoxyflavone), whereas JNK1/2 responses were blocked by the JNK1/2 inhibitor SP 600125 (anthra[1-9-cd]pyrazol-6(2H)-one).	pyrazolanthrone	261-292	mitogen-activated protein kinase 3	Homo sapiens	50-56
16794185-10	2006	The JNK inhibitor SP600125 reduced thrombin-induced TF expression by 35%.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
16794185-10	2006	The JNK inhibitor SP600125 reduced thrombin-induced TF expression by 35%.	pyrazolanthrone	18-26	coagulation factor II, thrombin	Homo sapiens	35-43
16794185-10	2006	The JNK inhibitor SP600125 reduced thrombin-induced TF expression by 35%.	pyrazolanthrone	18-26	coagulation factor III, tissue factor	Homo sapiens	52-54
16794185-11	2006	Moreover, SP600125 blunted the effect of paclitaxel and docetaxel on thrombin-induced TF expression.	pyrazolanthrone	10-18	coagulation factor II, thrombin	Homo sapiens	69-77
16794185-11	2006	Moreover, SP600125 blunted the effect of paclitaxel and docetaxel on thrombin-induced TF expression.	pyrazolanthrone	10-18	coagulation factor III, tissue factor	Homo sapiens	86-88
16818793-9	2006	In addition, IL-13 potentiated LPS-induced activation of JNK, and the JNK inhibitor SP600125 suppressed the enhancement of COX-2 expression and attenuated microglial death.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Rattus norvegicus	70-73
16818793-9	2006	In addition, IL-13 potentiated LPS-induced activation of JNK, and the JNK inhibitor SP600125 suppressed the enhancement of COX-2 expression and attenuated microglial death.	pyrazolanthrone	84-92	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	123-128
16679312-5	2006	Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	165-168
16679312-5	2006	Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.	pyrazolanthrone	62-70	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	169-174
16679312-5	2006	Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.	pyrazolanthrone	62-70	estrogen receptor 1	Homo sapiens	217-224
16679312-5	2006	Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.	pyrazolanthrone	62-70	estrogen receptor 1	Homo sapiens	285-292
16679312-5	2006	Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	165-168
16679312-5	2006	Treatment of MDA-MB-231 cells with the JNK-specific inhibitor SP600125 or expression of the c-Jun dominant negative inhibitor TAM67 blocked the oligoamine-activated JNK/c-Jun pathway and enhanced oligoamine-inhibited ERalpha expression, suggesting that AP-1 is a positive regulator of ERalpha expression and that oligoamine-activated JNK/AP-1 activity may antagonize the down-regulation of ERalpha induced by oligoamines.	pyrazolanthrone	62-70	estrogen receptor 1	Homo sapiens	285-292
16785500-3	2006	In DC, the inhibitory effect of LPS on CIITA expression was prevented by MyD88 deficiency or pharmacological MAPK inhibitors specific for MEK (U0126) and p38 (SB203580), but not JNK (SP600125).	pyrazolanthrone	183-191	toll-like receptor 4	Mus musculus	32-35
16787641-7	2006	In contrast, the increase in caspase-3 protein was suppressed by both U0126 and SP600125.	pyrazolanthrone	80-88	caspase 3	Rattus norvegicus	29-38
16834785-4	2006	JNK was modulated by the small molecule inhibitor SP600125 and AP1 by transfection of a dominant negative mutant.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	0-3
16834785-7	2006	Inhibition of JNK by small molecule inhibitor SP600125 reduced pneumococci-induced IL-8 mRNA expression and release of IL-8 and IL-6.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	14-17
16834785-7	2006	Inhibition of JNK by small molecule inhibitor SP600125 reduced pneumococci-induced IL-8 mRNA expression and release of IL-8 and IL-6.	pyrazolanthrone	46-54	C-X-C motif chemokine ligand 8	Homo sapiens	83-87
16834785-7	2006	Inhibition of JNK by small molecule inhibitor SP600125 reduced pneumococci-induced IL-8 mRNA expression and release of IL-8 and IL-6.	pyrazolanthrone	46-54	C-X-C motif chemokine ligand 8	Homo sapiens	119-123
16834785-7	2006	Inhibition of JNK by small molecule inhibitor SP600125 reduced pneumococci-induced IL-8 mRNA expression and release of IL-8 and IL-6.	pyrazolanthrone	46-54	interleukin 6	Homo sapiens	128-132
16617094-8	2006	AS-602868, an inhibitor of IKK-2, and PD-98059, an inhibitor of ERK, inhibited GRO-alpha release and mRNA expression, whereas SP-600125, an inhibitor of JNK, reduced GRO-alpha release without effect on mRNA expression.	pyrazolanthrone	126-135	mitogen-activated protein kinase 8	Homo sapiens	153-156
16617094-8	2006	AS-602868, an inhibitor of IKK-2, and PD-98059, an inhibitor of ERK, inhibited GRO-alpha release and mRNA expression, whereas SP-600125, an inhibitor of JNK, reduced GRO-alpha release without effect on mRNA expression.	pyrazolanthrone	126-135	C-X-C motif chemokine ligand 1	Homo sapiens	166-175
17070508-4	2006	Incubation with the JNK inhibitor SP600125 inhibited the NKG2D expression induced by IL-2/IL-18 in the TGF-beta treated human NK cell line.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	20-23
17070508-4	2006	Incubation with the JNK inhibitor SP600125 inhibited the NKG2D expression induced by IL-2/IL-18 in the TGF-beta treated human NK cell line.	pyrazolanthrone	34-42	killer cell lectin like receptor K1	Homo sapiens	57-62
17070508-4	2006	Incubation with the JNK inhibitor SP600125 inhibited the NKG2D expression induced by IL-2/IL-18 in the TGF-beta treated human NK cell line.	pyrazolanthrone	34-42	interleukin 2	Homo sapiens	85-89
17070508-4	2006	Incubation with the JNK inhibitor SP600125 inhibited the NKG2D expression induced by IL-2/IL-18 in the TGF-beta treated human NK cell line.	pyrazolanthrone	34-42	interleukin 18	Homo sapiens	90-95
17070508-4	2006	Incubation with the JNK inhibitor SP600125 inhibited the NKG2D expression induced by IL-2/IL-18 in the TGF-beta treated human NK cell line.	pyrazolanthrone	34-42	transforming growth factor beta 1	Homo sapiens	103-111
16831600-2	2006	METHODS: Mouse hepatocytes and C57BL/6 mice were administered a toxic dose of APAP with or without SP600125, a chemical c-jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	99-107	jun proto-oncogene	Mus musculus	120-125
16831600-2	2006	METHODS: Mouse hepatocytes and C57BL/6 mice were administered a toxic dose of APAP with or without SP600125, a chemical c-jun N-terminal kinase (JNK) inhibitor.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Mus musculus	145-148
16827853-6	2006	However, the inhibition of JNK pathway, with the specific SP600125 inhibitor, in the presence of PEG 35,000 Da did not affect cell survival.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Sus scrofa	27-30
16785500-3	2006	In DC, the inhibitory effect of LPS on CIITA expression was prevented by MyD88 deficiency or pharmacological MAPK inhibitors specific for MEK (U0126) and p38 (SB203580), but not JNK (SP600125).	pyrazolanthrone	183-191	class II transactivator	Mus musculus	39-44
16624973-9	2006	c-Jun NH2-terminal kinase (JNK) was found to be activated by salicylate, and we could causally link this activation to the induction of HO-1 by using the JNK inhibitor 1,9-pyrazoloanthrone.	pyrazolanthrone	168-188	mitogen-activated protein kinase 8	Homo sapiens	0-25
16732613-8	2006	This activation was selectively blocked in a dose-dependent fashion by the JNK inhibitor SP600125.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	75-78
16624973-9	2006	c-Jun NH2-terminal kinase (JNK) was found to be activated by salicylate, and we could causally link this activation to the induction of HO-1 by using the JNK inhibitor 1,9-pyrazoloanthrone.	pyrazolanthrone	168-188	mitogen-activated protein kinase 8	Homo sapiens	27-30
16624973-9	2006	c-Jun NH2-terminal kinase (JNK) was found to be activated by salicylate, and we could causally link this activation to the induction of HO-1 by using the JNK inhibitor 1,9-pyrazoloanthrone.	pyrazolanthrone	168-188	heme oxygenase 1	Homo sapiens	136-140
16624973-9	2006	c-Jun NH2-terminal kinase (JNK) was found to be activated by salicylate, and we could causally link this activation to the induction of HO-1 by using the JNK inhibitor 1,9-pyrazoloanthrone.	pyrazolanthrone	168-188	mitogen-activated protein kinase 8	Homo sapiens	154-157
16817155-9	2006	Furthermore, inhibition of the p38 MAPK with SB202190 abolished, while inhibition of the JNK with SP600125 enhanced the CRT up-regulation in cardiomyocytes induced by HPC.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Homo sapiens	89-92
16680485-7	2006	The NaCl-induced increase in alphaB-crystallin expression was concentration-dependently blunted by SP600125, a specific JNK inhibitor.	pyrazolanthrone	99-107	crystallin, alpha B	Rattus norvegicus	29-46
16680485-7	2006	The NaCl-induced increase in alphaB-crystallin expression was concentration-dependently blunted by SP600125, a specific JNK inhibitor.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	120-123
16817155-9	2006	Furthermore, inhibition of the p38 MAPK with SB202190 abolished, while inhibition of the JNK with SP600125 enhanced the CRT up-regulation in cardiomyocytes induced by HPC.	pyrazolanthrone	98-106	calreticulin	Homo sapiens	120-123
16650813-8	2006	IL-18-enhanced TSP-1 expression was blocked by SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	47-55	interleukin 18	Homo sapiens	0-5
16624850-7	2006	Cells pretreated with SP600125 showed decreases in activation of caspases 9 and 3, decreases in degradation of poly(ADP-ribose) polymerase (PARP), and decreased levels of proapoptotic Bim, in comparison to cells treated with thimerosal alone.	pyrazolanthrone	22-30	caspase 9	Homo sapiens	65-81
16624850-7	2006	Cells pretreated with SP600125 showed decreases in activation of caspases 9 and 3, decreases in degradation of poly(ADP-ribose) polymerase (PARP), and decreased levels of proapoptotic Bim, in comparison to cells treated with thimerosal alone.	pyrazolanthrone	22-30	poly(ADP-ribose) polymerase 1	Homo sapiens	111-138
16624850-7	2006	Cells pretreated with SP600125 showed decreases in activation of caspases 9 and 3, decreases in degradation of poly(ADP-ribose) polymerase (PARP), and decreased levels of proapoptotic Bim, in comparison to cells treated with thimerosal alone.	pyrazolanthrone	22-30	poly(ADP-ribose) polymerase 1	Homo sapiens	140-144
16491125-7	2006	Interestingly, JNK inhibition by the specific inhibitor SP600125 rescued NSCs from apoptosis and improved neuronal differentiation.	pyrazolanthrone	56-64	mitogen-activated protein kinase 8	Rattus norvegicus	15-18
16627484-4	2006	Treatment with the JNK1/2 inhibitor, SP600125, abrogated the increases in mPGES-1 mRNA stability, mPGES-1 protein synthesis, and PGE(2) release induced by interleukin-1beta or LPS.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Mus musculus	19-25
16627484-4	2006	Treatment with the JNK1/2 inhibitor, SP600125, abrogated the increases in mPGES-1 mRNA stability, mPGES-1 protein synthesis, and PGE(2) release induced by interleukin-1beta or LPS.	pyrazolanthrone	37-45	prostaglandin E synthase	Mus musculus	74-81
16627484-4	2006	Treatment with the JNK1/2 inhibitor, SP600125, abrogated the increases in mPGES-1 mRNA stability, mPGES-1 protein synthesis, and PGE(2) release induced by interleukin-1beta or LPS.	pyrazolanthrone	37-45	prostaglandin E synthase	Mus musculus	98-105
16627484-4	2006	Treatment with the JNK1/2 inhibitor, SP600125, abrogated the increases in mPGES-1 mRNA stability, mPGES-1 protein synthesis, and PGE(2) release induced by interleukin-1beta or LPS.	pyrazolanthrone	37-45	interleukin 1 beta	Mus musculus	155-172
16650813-8	2006	IL-18-enhanced TSP-1 expression was blocked by SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	47-55	thrombospondin 1	Homo sapiens	15-20
16650813-8	2006	IL-18-enhanced TSP-1 expression was blocked by SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	59-82
16650813-8	2006	IL-18-enhanced TSP-1 expression was blocked by SP600125, a c-Jun N-terminal kinase (JNK) specific inhibitor.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	84-87
16551633-5	2006	The nuclear residence of RXRalpha is maintained by inhibiting c-jun N-terminal kinase (JNK, curcumin or SP600125) or CRM-1-mediated nuclear export (Leptomycin B).	pyrazolanthrone	104-112	retinoid X receptor alpha	Homo sapiens	25-33
16684952-12	2006	OSM-induced HGF secretion was inhibited by PD-98059 (a specific pharmacological inhibitor of ERK1/2), SB-203580 (a p38 MAPK inhibitor), and SP-600125 (a JNK inhibitor) by 70, 82, and 100%, respectively, whereas basal HGF secretion was only inhibited by SP-600125 by 30%.	pyrazolanthrone	140-149	hepatocyte growth factor	Homo sapiens	12-15
16684952-12	2006	OSM-induced HGF secretion was inhibited by PD-98059 (a specific pharmacological inhibitor of ERK1/2), SB-203580 (a p38 MAPK inhibitor), and SP-600125 (a JNK inhibitor) by 70, 82, and 100%, respectively, whereas basal HGF secretion was only inhibited by SP-600125 by 30%.	pyrazolanthrone	253-262	hepatocyte growth factor	Homo sapiens	12-15
16636108-8	2006	Cardiomyogenesis was inhibited by the p38 inhibitor SB203580, the ERK1,2 inhibitor UO126, and the JNK inhibitor SP600125.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Mus musculus	98-101
16787171-6	2006	Recently, the anti-inflammatory effects of MAPK kinase inhibitor (U0126), p38 MAPK inhibitors (SB239063 and respirable p38alpha MAPK antisense oligonucleotide) and JNK inhibitor (SP600125) have been demonstrated in in vivo animal models of asthma.	pyrazolanthrone	179-187	mitogen-activated protein kinase 8	Homo sapiens	164-167
16734619-11	2006	Interestingly, VCAM-1 expression was enhanced by MEK inhibitor (PD98059) and c-Jun NH2-terminal kinase (JNK) inhibitor (SP600125).	pyrazolanthrone	120-128	vascular cell adhesion molecule 1	Homo sapiens	15-21
16635481-4	2006	This induction was suppressed by pharmacological inhibitors of p38 MAPK (i.e., SB203580) and c-Jun N-terminal kinase (JNK, SP600125), suggesting the involvement of the two kinases in IP10 expression.	pyrazolanthrone	123-131	chemokine (C-X-C motif) ligand 10	Mus musculus	183-187
16385569-3	2006	Treatment with a specific inhibitor, SP600125 or SB203580, in vitro suppressed TNF-alpha-induced migration and pulmonary metastasis.	pyrazolanthrone	37-45	tumor necrosis factor	Mus musculus	79-88
16864444-5	2006	The cell death was accompanied with phosphorylation of ERK, JNK and p38 MAPK and partially reduced by MEK inhibitor (PD98059), JNK MAPK inhibitor (SP600125) and p38 MAPK inhibitor (SB 203580).	pyrazolanthrone	147-155	mitogen-activated protein kinase 8	Homo sapiens	127-130
16407847-5	2006	SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
16407847-5	2006	SP600125, a JNK inhibitor, suppressed 4HPR-induced c-Jun phosphorylation, cytochrome c release from mitochondria and apoptosis.	pyrazolanthrone	0-8	cytochrome c, somatic	Homo sapiens	74-86
16309985-12	2006	In addition, SP600125, a specific JNK inhibitor, markedly reduced OCL formation in BMM cultures that were treated with RANKL or the combination of RANKL and IL-1.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	34-37
16309985-12	2006	In addition, SP600125, a specific JNK inhibitor, markedly reduced OCL formation in BMM cultures that were treated with RANKL or the combination of RANKL and IL-1.	pyrazolanthrone	13-21	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	119-124
16309985-12	2006	In addition, SP600125, a specific JNK inhibitor, markedly reduced OCL formation in BMM cultures that were treated with RANKL or the combination of RANKL and IL-1.	pyrazolanthrone	13-21	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	147-152
16309985-12	2006	In addition, SP600125, a specific JNK inhibitor, markedly reduced OCL formation in BMM cultures that were treated with RANKL or the combination of RANKL and IL-1.	pyrazolanthrone	13-21	interleukin 1 complex	Mus musculus	157-161
16644485-0	2006	JNK inhibitor SP600125 reduces COX-2 expression by attenuating mRNA in activated murine J774 macrophages.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Mus musculus	0-3
16644485-0	2006	JNK inhibitor SP600125 reduces COX-2 expression by attenuating mRNA in activated murine J774 macrophages.	pyrazolanthrone	14-22	cytochrome c oxidase II, mitochondrial	Mus musculus	31-36
16644485-5	2006	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5-10 microM.	pyrazolanthrone	0-31	mitogen-activated protein kinase 8	Mus musculus	60-63
16644485-5	2006	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5-10 microM.	pyrazolanthrone	0-31	jun proto-oncogene	Mus musculus	94-99
16644485-5	2006	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5-10 microM.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Mus musculus	60-63
16644485-5	2006	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), an inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5-10 microM.	pyrazolanthrone	33-41	jun proto-oncogene	Mus musculus	94-99
16644485-6	2006	At the same concentrations SP600125 suppressed also LPS-induced COX-2 protein levels and PGE2 production.	pyrazolanthrone	27-35	cytochrome c oxidase II, mitochondrial	Mus musculus	64-69
16644485-8	2006	LPS-induced COX-2 mRNA levels reduced faster in cells treated with SP600125 than in control cells.	pyrazolanthrone	67-75	cytochrome c oxidase II, mitochondrial	Mus musculus	12-17
16644485-9	2006	Cycloheximide (that is known to activate JNK) enhanced COX-2 expression and its effect was inhibited by SP600125.	pyrazolanthrone	104-112	mitogen-activated protein kinase 8	Mus musculus	41-44
16644485-9	2006	Cycloheximide (that is known to activate JNK) enhanced COX-2 expression and its effect was inhibited by SP600125.	pyrazolanthrone	104-112	cytochrome c oxidase II, mitochondrial	Mus musculus	55-60
16440309-6	2006	The JNK inhibitor (SP600125) abolished c-jun phosphorylation and COL1 expression.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
16440309-6	2006	The JNK inhibitor (SP600125) abolished c-jun phosphorylation and COL1 expression.	pyrazolanthrone	19-27	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	39-44
16674927-2	2006	Here, we reported that SP600125, a potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK), potently decrease neuronal apoptosis induced by global ischemia/reperfusion in the vulnerable hippocampal CA1 subregion.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	98-121
16674927-2	2006	Here, we reported that SP600125, a potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK), potently decrease neuronal apoptosis induced by global ischemia/reperfusion in the vulnerable hippocampal CA1 subregion.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Rattus norvegicus	123-126
16674927-2	2006	Here, we reported that SP600125, a potent, cell-permeable, selective, and reversible inhibitor of c-Jun N-terminal kinase (JNK), potently decrease neuronal apoptosis induced by global ischemia/reperfusion in the vulnerable hippocampal CA1 subregion.	pyrazolanthrone	23-31	carbonic anhydrase 1	Rattus norvegicus	235-238
16674927-3	2006	As a result, SP600125 diminished the increased phosphorylation of c-Jun and the increased expression of FasL induced by ischemia/reperfusion in the vulnerable hippocampal CA1 subregion.	pyrazolanthrone	13-21	Fas ligand	Rattus norvegicus	104-108
16674927-3	2006	As a result, SP600125 diminished the increased phosphorylation of c-Jun and the increased expression of FasL induced by ischemia/reperfusion in the vulnerable hippocampal CA1 subregion.	pyrazolanthrone	13-21	carbonic anhydrase 1	Rattus norvegicus	171-174
16674927-4	2006	At the same time, through inhibiting phosphorylation of Bcl-2 and the release of Bax from Bcl-2/Bax dimers, SP600125 attenuated Bax translocation to mitochondria and the release of cytochrome c induced by ischemia/reperfusion (I/R).	pyrazolanthrone	108-116	BCL2, apoptosis regulator	Rattus norvegicus	56-61
16674927-4	2006	At the same time, through inhibiting phosphorylation of Bcl-2 and the release of Bax from Bcl-2/Bax dimers, SP600125 attenuated Bax translocation to mitochondria and the release of cytochrome c induced by ischemia/reperfusion (I/R).	pyrazolanthrone	108-116	BCL2 associated X, apoptosis regulator	Rattus norvegicus	81-84
16674927-4	2006	At the same time, through inhibiting phosphorylation of Bcl-2 and the release of Bax from Bcl-2/Bax dimers, SP600125 attenuated Bax translocation to mitochondria and the release of cytochrome c induced by ischemia/reperfusion (I/R).	pyrazolanthrone	108-116	BCL2, apoptosis regulator	Rattus norvegicus	90-95
16674927-4	2006	At the same time, through inhibiting phosphorylation of Bcl-2 and the release of Bax from Bcl-2/Bax dimers, SP600125 attenuated Bax translocation to mitochondria and the release of cytochrome c induced by ischemia/reperfusion (I/R).	pyrazolanthrone	108-116	BCL2 associated X, apoptosis regulator	Rattus norvegicus	96-99
16674927-4	2006	At the same time, through inhibiting phosphorylation of Bcl-2 and the release of Bax from Bcl-2/Bax dimers, SP600125 attenuated Bax translocation to mitochondria and the release of cytochrome c induced by ischemia/reperfusion (I/R).	pyrazolanthrone	108-116	BCL2 associated X, apoptosis regulator	Rattus norvegicus	96-99
16674927-5	2006	Furthermore, the activation of caspase-3 induced by ischemia/reperfusion was also significantly suppressed by preinfusion of SP600125.	pyrazolanthrone	125-133	caspase 3	Rattus norvegicus	31-40
16674927-7	2006	Thus, our findings imply that SP600125 can inhibit the activation of JNK signaling pathway and induce neuroprotection against ischemia/reperfusion in rat hippocampal CA1 region via suppressing the extrinsic and intrinsic pathways of apoptosis.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	69-72
16674927-7	2006	Thus, our findings imply that SP600125 can inhibit the activation of JNK signaling pathway and induce neuroprotection against ischemia/reperfusion in rat hippocampal CA1 region via suppressing the extrinsic and intrinsic pathways of apoptosis.	pyrazolanthrone	30-38	carbonic anhydrase 1	Rattus norvegicus	166-169
16443326-6	2006	The JNK inhibitor SP600125 had a weak but statistically significant effect, while the p38 inhibitor SB239063 was ineffective.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
16651615-10	2006	Like HSP72, both p38 and JNK appeared not to be crucial in preconditioning, and inhibitors of p38 (SB203580) and JNK (SP600125) were less effective against hepatic injury than HO-1 activators.	pyrazolanthrone	118-126	mitogen-activated protein kinase 8	Homo sapiens	113-116
16771680-5	2006	While an inhibitor of the JNK pathway (SP600125) inhibited iNOS expression, ectopic expression of a constitutively active form of MEKK1 (MAPK/ERK kinase kinase- 1), an upstream activator of JNK, led to an induction of co-transfected iNOS promoter activity and, in the presence of LPS, to an enhanced expression of iNOS.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	26-29
16771680-5	2006	While an inhibitor of the JNK pathway (SP600125) inhibited iNOS expression, ectopic expression of a constitutively active form of MEKK1 (MAPK/ERK kinase kinase- 1), an upstream activator of JNK, led to an induction of co-transfected iNOS promoter activity and, in the presence of LPS, to an enhanced expression of iNOS.	pyrazolanthrone	39-47	nitric oxide synthase 2	Homo sapiens	59-63
16771680-5	2006	While an inhibitor of the JNK pathway (SP600125) inhibited iNOS expression, ectopic expression of a constitutively active form of MEKK1 (MAPK/ERK kinase kinase- 1), an upstream activator of JNK, led to an induction of co-transfected iNOS promoter activity and, in the presence of LPS, to an enhanced expression of iNOS.	pyrazolanthrone	39-47	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	130-135
16635481-4	2006	This induction was suppressed by pharmacological inhibitors of p38 MAPK (i.e., SB203580) and c-Jun N-terminal kinase (JNK, SP600125), suggesting the involvement of the two kinases in IP10 expression.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Mus musculus	93-116
16455066-7	2006	Glc-HSA-induced E-selectin expression was suppressed by the phosphatidylinositol 3 kinase (PI3K) inhibitors wortmannin and LY294002, the protein kinase B (PKB) inhibitor ML-9, the IkappaB kinase (IKK) inhibitor BAY117082, and the Jun N-terminal kinase (JNK) inhibitor SP600125, On the other hand, the protein kinase C inhibitors calphostin C and H-7 did not suppress Glc-HSA-induced E-selectin expression.	pyrazolanthrone	268-276	selectin E	Homo sapiens	16-26
16651444-8	2006	Using specific kinase inhibitors (SB203580 and SP600125), we showed the central role of p38 and c-Jun NH(2)-terminal kinase (JNK) pathways in 3,3"-diindolylmethane-induced p21 mRNA transcription.	pyrazolanthrone	47-55	mitogen-activated protein kinase 14	Homo sapiens	88-91
16651444-8	2006	Using specific kinase inhibitors (SB203580 and SP600125), we showed the central role of p38 and c-Jun NH(2)-terminal kinase (JNK) pathways in 3,3"-diindolylmethane-induced p21 mRNA transcription.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	96-123
16651444-8	2006	Using specific kinase inhibitors (SB203580 and SP600125), we showed the central role of p38 and c-Jun NH(2)-terminal kinase (JNK) pathways in 3,3"-diindolylmethane-induced p21 mRNA transcription.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	125-128
16651444-8	2006	Using specific kinase inhibitors (SB203580 and SP600125), we showed the central role of p38 and c-Jun NH(2)-terminal kinase (JNK) pathways in 3,3"-diindolylmethane-induced p21 mRNA transcription.	pyrazolanthrone	47-55	cyclin dependent kinase inhibitor 1A	Homo sapiens	172-175
16619289-3	2006	Here we report that pharmacological inhibitors of phosphoinositide 3-kinases (wortmannin, WMN), Bruton"s tyrosine kinase (LFM-A13), and Jun kinases (SP600125) all significantly impair CXCL12-induced mouse B cell chemotaxis and that of a human B lymphoma cell line.	pyrazolanthrone	149-157	chemokine (C-X-C motif) ligand 12	Mus musculus	184-190
16506055-6	2006	The insulin-induced increase of HIF-1alpha is blunted by the translation inhibitor cycloheximide, LY294002, PD98059, SP600125 and rapamycin, but not by SB203580.	pyrazolanthrone	117-125	insulin	Homo sapiens	4-11
16506055-6	2006	The insulin-induced increase of HIF-1alpha is blunted by the translation inhibitor cycloheximide, LY294002, PD98059, SP600125 and rapamycin, but not by SB203580.	pyrazolanthrone	117-125	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	32-42
16619289-4	2006	Examination of two CXCR4-induced signaling pathways revealed that LFM-A13 and WMN blocked Akt activation, while SP600125 and WMN blocked JNK activation.	pyrazolanthrone	112-120	chemokine (C-X-C motif) receptor 4	Mus musculus	19-24
16619289-4	2006	Examination of two CXCR4-induced signaling pathways revealed that LFM-A13 and WMN blocked Akt activation, while SP600125 and WMN blocked JNK activation.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Mus musculus	137-140
16630028-0	2006	The specific JNK inhibitor SP600125 targets tumour necrosis factor-alpha production and epithelial cell apoptosis in acute murine colitis.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	13-16
16630028-5	2006	Our studies in mice with DSS-induced colitis treated with the JNK inhibitor SP600125, indicate that there is a significant reduction in wasting as well as a significant reduction in histological damage scores.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Mus musculus	62-65
16417967-6	2006	Both protein and mRNA levels of iNOS expression were abrogated by specific inhibitors, SP600125 (JNK inhibitor, 20 microM), PD98059 (ERKs inhibitor, 50 microM), or LY294002 (PI 3-kinase inhibitor, 20 microM), but not by SB203580 (20 microM), a p38 specific inhibitor.	pyrazolanthrone	87-95	nitric oxide synthase 2, inducible	Mus musculus	32-36
16417967-6	2006	Both protein and mRNA levels of iNOS expression were abrogated by specific inhibitors, SP600125 (JNK inhibitor, 20 microM), PD98059 (ERKs inhibitor, 50 microM), or LY294002 (PI 3-kinase inhibitor, 20 microM), but not by SB203580 (20 microM), a p38 specific inhibitor.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Mus musculus	97-100
16516846-6	2006	The p38 MAPK inhibitor (SB 203580) prevented MG132-induced COX-2 expression, whereas c-Jun N-terminal kinase (JNK) inhibitor (SP 600125) and MAPK kinase 4 (MKK4)-DN (dominant negative mutant) and MKK7-DN significantly enhanced COX-2 expression.	pyrazolanthrone	126-135	mitogen-activated protein kinase 8	Mus musculus	85-108
16516846-6	2006	The p38 MAPK inhibitor (SB 203580) prevented MG132-induced COX-2 expression, whereas c-Jun N-terminal kinase (JNK) inhibitor (SP 600125) and MAPK kinase 4 (MKK4)-DN (dominant negative mutant) and MKK7-DN significantly enhanced COX-2 expression.	pyrazolanthrone	126-135	mitogen-activated protein kinase 8	Mus musculus	110-113
16287069-8	2006	Blocking JNK activity with JNK inhibitor SP600125 inhibited migration, suggesting that the JNK pathway may regulate radiation-induced, as well as inherent, migration of C6-RacN17 cells.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	9-12
16518417-6	2006	Furthermore, inhibition of JNK, using SP600125, completely suppressed activity of caspases and poly-(ADP-ribose) polymerase cleavage, leading to suppression of enhancement of CDDP-mediated apoptosis by dicoumarol.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	27-30
16287069-8	2006	Blocking JNK activity with JNK inhibitor SP600125 inhibited migration, suggesting that the JNK pathway may regulate radiation-induced, as well as inherent, migration of C6-RacN17 cells.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
16287069-8	2006	Blocking JNK activity with JNK inhibitor SP600125 inhibited migration, suggesting that the JNK pathway may regulate radiation-induced, as well as inherent, migration of C6-RacN17 cells.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
16287090-8	2006	Inhibition of JNK activity by a specific inhibitor, SP600125, blocked the si-Id-1-induced sensitivity to taxol.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	14-17
16287090-8	2006	Inhibition of JNK activity by a specific inhibitor, SP600125, blocked the si-Id-1-induced sensitivity to taxol.	pyrazolanthrone	52-60	inhibitor of DNA binding 1, HLH protein	Homo sapiens	77-81
16478768-5	2006	This was confirmed by PHF-1 hyperphosphorylation of R406W tau in mitotic cells, its association with cytoplasmic JNK activation, and its inhibition by a JNK inhibitor, SP600125.	pyrazolanthrone	168-176	PHD finger protein 1	Homo sapiens	22-27
16331261-7	2006	Radiosensitization to mda-7/IL-24 is dependent on JNK signaling, as treatment with the JNK 1/2/3 inhibitor SP600125 abolishes this effect.	pyrazolanthrone	107-115	interleukin 24	Homo sapiens	22-27
16331261-7	2006	Radiosensitization to mda-7/IL-24 is dependent on JNK signaling, as treatment with the JNK 1/2/3 inhibitor SP600125 abolishes this effect.	pyrazolanthrone	107-115	interleukin 24	Homo sapiens	28-33
16331261-7	2006	Radiosensitization to mda-7/IL-24 is dependent on JNK signaling, as treatment with the JNK 1/2/3 inhibitor SP600125 abolishes this effect.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	50-53
16331261-7	2006	Radiosensitization to mda-7/IL-24 is dependent on JNK signaling, as treatment with the JNK 1/2/3 inhibitor SP600125 abolishes this effect.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	87-96
16272194-12	2006	On the other hand, SP-600125, a specific inhibitor of c-Jun NH(2)-terminal kinase, suppressed LDL-induced TGF-beta, CTGF, and collagen IV expression, and PD-98059, a selective inhibitor of p44/42(mapk), suppressed LDL-induced TGF-beta and CTGF expression.	pyrazolanthrone	19-28	transforming growth factor beta 1	Homo sapiens	106-114
16272194-12	2006	On the other hand, SP-600125, a specific inhibitor of c-Jun NH(2)-terminal kinase, suppressed LDL-induced TGF-beta, CTGF, and collagen IV expression, and PD-98059, a selective inhibitor of p44/42(mapk), suppressed LDL-induced TGF-beta and CTGF expression.	pyrazolanthrone	19-28	cellular communication network factor 2	Homo sapiens	116-120
16272194-12	2006	On the other hand, SP-600125, a specific inhibitor of c-Jun NH(2)-terminal kinase, suppressed LDL-induced TGF-beta, CTGF, and collagen IV expression, and PD-98059, a selective inhibitor of p44/42(mapk), suppressed LDL-induced TGF-beta and CTGF expression.	pyrazolanthrone	19-28	interferon induced protein 44	Homo sapiens	189-192
16272194-12	2006	On the other hand, SP-600125, a specific inhibitor of c-Jun NH(2)-terminal kinase, suppressed LDL-induced TGF-beta, CTGF, and collagen IV expression, and PD-98059, a selective inhibitor of p44/42(mapk), suppressed LDL-induced TGF-beta and CTGF expression.	pyrazolanthrone	19-28	transforming growth factor beta 1	Homo sapiens	226-234
16272194-12	2006	On the other hand, SP-600125, a specific inhibitor of c-Jun NH(2)-terminal kinase, suppressed LDL-induced TGF-beta, CTGF, and collagen IV expression, and PD-98059, a selective inhibitor of p44/42(mapk), suppressed LDL-induced TGF-beta and CTGF expression.	pyrazolanthrone	19-28	cellular communication network factor 2	Homo sapiens	239-243
16478768-5	2006	This was confirmed by PHF-1 hyperphosphorylation of R406W tau in mitotic cells, its association with cytoplasmic JNK activation, and its inhibition by a JNK inhibitor, SP600125.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Homo sapiens	113-116
16478768-5	2006	This was confirmed by PHF-1 hyperphosphorylation of R406W tau in mitotic cells, its association with cytoplasmic JNK activation, and its inhibition by a JNK inhibitor, SP600125.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Homo sapiens	153-156
16525641-8	2006	Both ZD1839 and LY294002 significantly suppressed colony formation by clonogenic assay; however, U0126 (a MEK1/2 inhibitor), SB203580 (a p38 inhibitor), and SP600125 (a JNK inhibitor) had no effect on colony formation.	pyrazolanthrone	157-165	mitogen-activated protein kinase 8	Homo sapiens	169-172
16288471-7	2006	VCAM-1 promoter activity was enhanced by TNF-alpha in HTSMCs transfected with VCAM-1-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	pyrazolanthrone	145-153	vascular cell adhesion molecule 1	Homo sapiens	0-6
16288471-7	2006	VCAM-1 promoter activity was enhanced by TNF-alpha in HTSMCs transfected with VCAM-1-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	pyrazolanthrone	145-153	tumor necrosis factor	Homo sapiens	41-50
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	pyrazolanthrone	202-210	tumor necrosis factor	Homo sapiens	0-9
16288471-7	2006	VCAM-1 promoter activity was enhanced by TNF-alpha in HTSMCs transfected with VCAM-1-Luc, which was inhibited by helenalin, U0126, SB202190, and SP600125.	pyrazolanthrone	145-153	vascular cell adhesion molecule 1	Homo sapiens	78-84
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	pyrazolanthrone	202-210	vascular cell adhesion molecule 1	Homo sapiens	33-39
16288471-10	2006	Moreover, the resultant enhancement of VCAM-1 expression increased the adhesion of polymorphonuclear cells (PMNs) to monolayer of HTSMCs, which was blocked by helenalin, U0126, SB202190, or SP600125.	pyrazolanthrone	190-198	vascular cell adhesion molecule 1	Homo sapiens	39-45
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	pyrazolanthrone	202-210	erythrocyte membrane protein band 4.2	Homo sapiens	87-90
16288471-3	2006	TNF-alpha-enhanced expression of VCAM-1 protein and mRNA as well as phosphorylation of p42/p44 MAPK, p38, and JNK were significantly attenuated by inhibitors of MEK1/2 (U0126), p38 (SB202190), and JNK (SP600125).	pyrazolanthrone	202-210	mitogen-activated protein kinase kinase 1	Homo sapiens	161-167
16648577-7	2006	Pretreatment of the cells with the specific AMPK inhibitor compound C and JNK inhibitor SP600125 blocked activation of AMPK and JNK, respectively, and subsequently sensitized the cells to 425.3PE-induced cell death.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Homo sapiens	74-77
16614379-5	2006	Sulfasalazine was used to inhibit the nuclear factor-kappaB (NFkappaB) pathway and SP600125, a chemical inhibitor of the c-Jun N-terminal kinase, was used as an inhibitor of the activator protein-1 (AP-1) pathway.	pyrazolanthrone	83-91	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	178-197
16614379-5	2006	Sulfasalazine was used to inhibit the nuclear factor-kappaB (NFkappaB) pathway and SP600125, a chemical inhibitor of the c-Jun N-terminal kinase, was used as an inhibitor of the activator protein-1 (AP-1) pathway.	pyrazolanthrone	83-91	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	199-203
16648577-7	2006	Pretreatment of the cells with the specific AMPK inhibitor compound C and JNK inhibitor SP600125 blocked activation of AMPK and JNK, respectively, and subsequently sensitized the cells to 425.3PE-induced cell death.	pyrazolanthrone	88-96	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	119-123
16648577-7	2006	Pretreatment of the cells with the specific AMPK inhibitor compound C and JNK inhibitor SP600125 blocked activation of AMPK and JNK, respectively, and subsequently sensitized the cells to 425.3PE-induced cell death.	pyrazolanthrone	88-96	mitogen-activated protein kinase 8	Homo sapiens	128-131
16507596-6	2006	The proxidant- and CoCl2-mediated upregulation of CT-1 was significantly inhibited in the presence of the ERK1,2 antagonist UO126, the JNK antagonist SP600125, the p38 antagonist SKF86002, the PI3-kinase antagonist LY294002, the Jak-2 antagonist AG490 as well as in the presence of free radical scavengers.	pyrazolanthrone	150-158	cardiotrophin 1	Mus musculus	50-54
16442178-3	2006	The increase of TRAIL mRNA expression by LPS was preceded by phosphorylation of the c-Jun N-terminal kinase (JNK) and consequently abrogated in the presence of the specific JNK inhibitor SP600125.	pyrazolanthrone	187-195	TNF superfamily member 10	Homo sapiens	16-21
16442178-3	2006	The increase of TRAIL mRNA expression by LPS was preceded by phosphorylation of the c-Jun N-terminal kinase (JNK) and consequently abrogated in the presence of the specific JNK inhibitor SP600125.	pyrazolanthrone	187-195	mitogen-activated protein kinase 8	Homo sapiens	84-107
16442178-3	2006	The increase of TRAIL mRNA expression by LPS was preceded by phosphorylation of the c-Jun N-terminal kinase (JNK) and consequently abrogated in the presence of the specific JNK inhibitor SP600125.	pyrazolanthrone	187-195	mitogen-activated protein kinase 8	Homo sapiens	109-112
16442178-3	2006	The increase of TRAIL mRNA expression by LPS was preceded by phosphorylation of the c-Jun N-terminal kinase (JNK) and consequently abrogated in the presence of the specific JNK inhibitor SP600125.	pyrazolanthrone	187-195	mitogen-activated protein kinase 8	Homo sapiens	173-176
16533053-5	2006	Because phosphorylation of cdc2 and upregulation of wee1 by 2-ME(2) can be abolished by both extracellular receptor kinase (ERK) inhibitor (U0126) and c-Jun N-terminal kinase (JNK) inhibitor (SP600125), our studies indicate that the 2-ME(2)-induced upregulation of wee1 and subsequent cdc2 phosphorylation are mediated through mitogen-activated protein kinase (MAPK)-ERK-JNK signaling pathways.	pyrazolanthrone	192-200	cyclin dependent kinase 1	Homo sapiens	27-31
16533053-5	2006	Because phosphorylation of cdc2 and upregulation of wee1 by 2-ME(2) can be abolished by both extracellular receptor kinase (ERK) inhibitor (U0126) and c-Jun N-terminal kinase (JNK) inhibitor (SP600125), our studies indicate that the 2-ME(2)-induced upregulation of wee1 and subsequent cdc2 phosphorylation are mediated through mitogen-activated protein kinase (MAPK)-ERK-JNK signaling pathways.	pyrazolanthrone	192-200	WEE1 G2 checkpoint kinase	Homo sapiens	52-56
16480952-5	2006	Inhibitors of JNK (SP600125) and PKC (GF109203X) mainly blocked expression and phosphorylation of c-Jun, while inhibition of MEK-ERK activity with PD98059 (an inhibitor of MEK) had little effect.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	14-17
16480952-5	2006	Inhibitors of JNK (SP600125) and PKC (GF109203X) mainly blocked expression and phosphorylation of c-Jun, while inhibition of MEK-ERK activity with PD98059 (an inhibitor of MEK) had little effect.	pyrazolanthrone	19-27	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	98-103
16480952-6	2006	Expression of involucrin and keratin 4 in response to TPA was attenuated by pretreatments with GF109203X and SP600125, but not PD98059, suggesting involvement of PKC and JNK in this response.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Homo sapiens	170-173
16609996-4	2006	JNK activity and its inhibition by SP600125 and AdoMet were determined by Western blot analysis of c-jun phosphorylation and Bid fragmentation.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Homo sapiens	0-3
16609996-4	2006	JNK activity and its inhibition by SP600125 and AdoMet were determined by Western blot analysis of c-jun phosphorylation and Bid fragmentation.	pyrazolanthrone	35-43	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	99-104
16609996-5	2006	SP600125 and AdoMet effects on the apoptotic signaling pathway were determined by Western blot analysis of cytochrome c release and pro-caspase 3 fragmentation.	pyrazolanthrone	0-8	cytochrome c, somatic	Homo sapiens	107-119
16609996-5	2006	SP600125 and AdoMet effects on the apoptotic signaling pathway were determined by Western blot analysis of cytochrome c release and pro-caspase 3 fragmentation.	pyrazolanthrone	0-8	caspase 3	Homo sapiens	132-145
16609996-7	2006	RESULTS: The exposure of hepatocytes to ethanol induced JNK activation, c-jun phosphorylation, Bid fragmentation, cytochrome c release and pro-caspase 3 cleavage; these effects were diminished by SP600125, and caused a significant decrease in ethanol-induced apoptosis (P&lt; 0.05).	pyrazolanthrone	196-204	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	72-77
16609996-7	2006	RESULTS: The exposure of hepatocytes to ethanol induced JNK activation, c-jun phosphorylation, Bid fragmentation, cytochrome c release and pro-caspase 3 cleavage; these effects were diminished by SP600125, and caused a significant decrease in ethanol-induced apoptosis (P&lt; 0.05).	pyrazolanthrone	196-204	cytochrome c, somatic	Homo sapiens	114-126
16609996-7	2006	RESULTS: The exposure of hepatocytes to ethanol induced JNK activation, c-jun phosphorylation, Bid fragmentation, cytochrome c release and pro-caspase 3 cleavage; these effects were diminished by SP600125, and caused a significant decrease in ethanol-induced apoptosis (P&lt; 0.05).	pyrazolanthrone	196-204	caspase 3	Homo sapiens	139-152
16442704-4	2006	Inhibition of signalling via c-Jun NH2-terminal kinase (JNK) with SP600125 or PI3-kinase/Akt with LY294002 abolished the effects of G-Gly.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	29-54
16442704-4	2006	Inhibition of signalling via c-Jun NH2-terminal kinase (JNK) with SP600125 or PI3-kinase/Akt with LY294002 abolished the effects of G-Gly.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	56-59
16552807-9	2006	There was a significant difference in p38 activity at 5 min (P&lt;0.05),15 min (P&lt;0.01), 30 min (P&lt;0.01) and 60 min (P&lt;0.01) compared to that at 0 min.TIMMP-1 mRNA expression trended to decrease in 3 groups pretreated with different concentrations of SP600125 (10 micromol/L, 1.022+/-0.113; 20 micromol/L, 0.869+/-0.070; 40 micromol/L, 0.666+/-0.123).	pyrazolanthrone	260-268	mitogen activated protein kinase 14	Rattus norvegicus	38-41
16300886-12	2006	The JNK inhibitor SP600125 was shown to inhibit c-Jun phosphorylation without affecting MKK4 phosphorylation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
16300886-12	2006	The JNK inhibitor SP600125 was shown to inhibit c-Jun phosphorylation without affecting MKK4 phosphorylation.	pyrazolanthrone	18-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	48-53
16428083-6	2006	Treating the macrophages with a JNK inhibitor (SP600125) partially blocked the tumoricidal activation and NO production induced by MSE, whereas inhibitors of the other kinases did not have an inhibitory effect.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Mus musculus	32-35
16272172-7	2006	Pretreatment with MEK1-ERK inhibitor U0126 and JNK inhibitor SP600125 substantially attenuated the decrease in cell viability induced by SFN, PEITC and AITC.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	47-50
16410344-10	2006	The specific N-terminal Jun-kinase inhibitor SP-600125 selectively abrogated c-Jun phosphorylation and, in a dose-dependent fashion, the up-regulated synthesis of MMP-1 induced by PI.	pyrazolanthrone	45-54	mitogen-activated protein kinase 9	Homo sapiens	24-34
16410344-10	2006	The specific N-terminal Jun-kinase inhibitor SP-600125 selectively abrogated c-Jun phosphorylation and, in a dose-dependent fashion, the up-regulated synthesis of MMP-1 induced by PI.	pyrazolanthrone	45-54	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	77-82
16410344-10	2006	The specific N-terminal Jun-kinase inhibitor SP-600125 selectively abrogated c-Jun phosphorylation and, in a dose-dependent fashion, the up-regulated synthesis of MMP-1 induced by PI.	pyrazolanthrone	45-54	matrix metallopeptidase 1	Homo sapiens	163-168
16475830-6	2006	ApoAI promoter activity increased in cells treated with the specific JNK inhibitor SP600125, but unlike SB202190 treatment, the level of TNF alpha-related apoAI promoter inhibition was reduced by 50%.	pyrazolanthrone	83-91	apolipoprotein A1	Homo sapiens	0-5
16339111-4	2006	In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126.	pyrazolanthrone	236-244	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	58-63
16339111-4	2006	In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126.	pyrazolanthrone	236-244	mitogen-activated protein kinase 8	Homo sapiens	187-210
16339111-4	2006	In addition, SPC treatment induced the phosphorylation of c-Jun and extracellular signal-regulated kinase, and SPC-induced proliferation was completely prevented by pretreatment with the c-Jun N-terminal kinase (JNK)-specific inhibitor SP600125 but not with the MEK-specific inhibitor U0126.	pyrazolanthrone	236-244	mitogen-activated protein kinase 8	Homo sapiens	212-215
16613495-1	2006	Inhibition of c-Jun N-terminal kinase (JNK) with the pharmacologic inhibitor SP600125 in UVA-irradiated HaCaT cells and human primary keratinocytes resulted in dramatic phenotypic changes indicative of cell death.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	14-37
16613495-1	2006	Inhibition of c-Jun N-terminal kinase (JNK) with the pharmacologic inhibitor SP600125 in UVA-irradiated HaCaT cells and human primary keratinocytes resulted in dramatic phenotypic changes indicative of cell death.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	39-42
16613495-8	2006	In conclusion, we have observed that inhibition of UVA-induced JNK activity with the pharmacologic inhibitor SP600125 resulted in caspase-dependent apoptotic cell death in both the immortalized keratinocyte cell line HaCaT and primary keratinocytes.	pyrazolanthrone	109-117	mitogen-activated protein kinase 8	Homo sapiens	63-66
16504051-8	2006	Interestingly, JNK inhibitor SP600125 reversed the effect of SB220025 on LPS-induced iNOS mRNA expression and NO production.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Mus musculus	15-18
16475830-6	2006	ApoAI promoter activity increased in cells treated with the specific JNK inhibitor SP600125, but unlike SB202190 treatment, the level of TNF alpha-related apoAI promoter inhibition was reduced by 50%.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	69-72
16504051-8	2006	Interestingly, JNK inhibitor SP600125 reversed the effect of SB220025 on LPS-induced iNOS mRNA expression and NO production.	pyrazolanthrone	29-37	nitric oxide synthase 2, inducible	Mus musculus	85-89
16475830-6	2006	ApoAI promoter activity increased in cells treated with the specific JNK inhibitor SP600125, but unlike SB202190 treatment, the level of TNF alpha-related apoAI promoter inhibition was reduced by 50%.	pyrazolanthrone	83-91	tumor necrosis factor	Homo sapiens	137-146
16475830-6	2006	ApoAI promoter activity increased in cells treated with the specific JNK inhibitor SP600125, but unlike SB202190 treatment, the level of TNF alpha-related apoAI promoter inhibition was reduced by 50%.	pyrazolanthrone	83-91	apolipoprotein A1	Homo sapiens	155-160
16452190-6	2006	Promoter activity was induced by the JNK inhibitor SP600125 and was repressed by activated MEKK1.	pyrazolanthrone	51-59	mitogen-activated protein kinase 8	Homo sapiens	37-40
16455978-2	2006	Inhibition of JNK with two distinct classes of inhibitors, the pharmacological agent SP600125, or the peptide D-JNKI1 resulted in cell cycle inhibition with an arrest at the G(2)/M transition and subsequent apoptosis.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Homo sapiens	14-17
16452190-6	2006	Promoter activity was induced by the JNK inhibitor SP600125 and was repressed by activated MEKK1.	pyrazolanthrone	51-59	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	91-96
16452190-7	2006	Repression by MEKK1 was blocked by SP600125 or enhanced by coexpression of wild-type but not phosphoacceptor mutated JNK.	pyrazolanthrone	35-43	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	14-19
16452190-8	2006	SP600125 treatment also increased levels of endogenous hTR.	pyrazolanthrone	0-8	telomerase RNA component	Homo sapiens	55-58
16452190-9	2006	Mutations in the hTR promoter Sp1/Sp3 binding sites attenuated SP600125-mediated promoter induction, whereas coexpression of MEKK1 with Sp3 enhanced hTR promoter repression.	pyrazolanthrone	63-71	telomerase RNA component	Homo sapiens	17-20
16452190-9	2006	Mutations in the hTR promoter Sp1/Sp3 binding sites attenuated SP600125-mediated promoter induction, whereas coexpression of MEKK1 with Sp3 enhanced hTR promoter repression.	pyrazolanthrone	63-71	Sp3 transcription factor	Homo sapiens	34-37
16474208-4	2006	NE evoked contraction in a dose-dependent manner, and this effect was inhibited by the JNK inhibitor SP600125.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Rattus norvegicus	87-90
16269458-8	2006	However, SP600125 effectively inhibited IL-1beta-induced PAPP-A protein expression.	pyrazolanthrone	9-17	interleukin 1 beta	Homo sapiens	40-48
16269458-8	2006	However, SP600125 effectively inhibited IL-1beta-induced PAPP-A protein expression.	pyrazolanthrone	9-17	pappalysin 1	Homo sapiens	57-63
16474208-6	2006	NE-induced JNK phosphorylation was significantly inhibited by SP600125 and the conventional-type PKC (cPKC) inhibitor Go6976, but not by the Rho kinase inhibitor Y27632 or the phosphatidylinositol 3-kinase inhibitor LY294002.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Rattus norvegicus	11-14
16412424-4	2006	Antioxidants and SP600125, an inhibitor of JNK1/2, but not inhibitors of p38 MAPK and MEK1/2, significantly prevented cell death, thus implying that reactive oxygen species and JNK1/2 play crucial roles in the CEP-induced apoptosis of HuH-7 cells.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	43-49
16449644-0	2006	Selective repression of low-density lipoprotein receptor expression by SP600125: coupling of histone H3-Ser10 phosphorylation and Sp1 occupancy.	pyrazolanthrone	71-79	low density lipoprotein receptor	Homo sapiens	24-56
16449644-3	2006	Moreover, SP600125 repressed the basal expression of the endogenous LDL receptor in a gene-specific manner, whereas the expression of squalene synthase, sterol response element-binding protein-1, and beta-actin was not altered by SP600125.	pyrazolanthrone	10-18	low density lipoprotein receptor	Homo sapiens	68-80
16243436-6	2006	Systemic administration of SP600125, a small molecule JNK-specific inhibitor, diminished the induction of DP5 and its interaction with Bcl-2 after 2 days of ischemia.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
16243436-6	2006	Systemic administration of SP600125, a small molecule JNK-specific inhibitor, diminished the induction of DP5 and its interaction with Bcl-2 after 2 days of ischemia.	pyrazolanthrone	27-35	harakiri, BCL2 interacting protein	Rattus norvegicus	106-109
16243436-6	2006	Systemic administration of SP600125, a small molecule JNK-specific inhibitor, diminished the induction of DP5 and its interaction with Bcl-2 after 2 days of ischemia.	pyrazolanthrone	27-35	BCL2, apoptosis regulator	Rattus norvegicus	135-140
16243436-7	2006	At the same time, SP600125 increased the interaction of Bax with Bcl-2 after 2 days of reperfusion.	pyrazolanthrone	18-26	BCL2 associated X, apoptosis regulator	Rattus norvegicus	56-59
16243436-7	2006	At the same time, SP600125 increased the interaction of Bax with Bcl-2 after 2 days of reperfusion.	pyrazolanthrone	18-26	BCL2, apoptosis regulator	Rattus norvegicus	65-70
16125882-8	2006	Inhibition of ERKs activation by AG126, JNK by SP600125, and AP-1 by curcumin could reduced the induction of cyclin D1 and CDK4.	pyrazolanthrone	47-55	cyclin D1	Homo sapiens	109-118
16125882-8	2006	Inhibition of ERKs activation by AG126, JNK by SP600125, and AP-1 by curcumin could reduced the induction of cyclin D1 and CDK4.	pyrazolanthrone	47-55	cyclin dependent kinase 4	Homo sapiens	123-127
16412424-4	2006	Antioxidants and SP600125, an inhibitor of JNK1/2, but not inhibitors of p38 MAPK and MEK1/2, significantly prevented cell death, thus implying that reactive oxygen species and JNK1/2 play crucial roles in the CEP-induced apoptosis of HuH-7 cells.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	177-183
16412424-4	2006	Antioxidants and SP600125, an inhibitor of JNK1/2, but not inhibitors of p38 MAPK and MEK1/2, significantly prevented cell death, thus implying that reactive oxygen species and JNK1/2 play crucial roles in the CEP-induced apoptosis of HuH-7 cells.	pyrazolanthrone	17-25	MIR7-3 host gene	Homo sapiens	235-240
16352304-5	2006	In contrast, administration of SP 600125 (10(-6) and 10(-5) M) (JNK MAPK inhibitor) only attenuated brain injury induced U 46619 potentiation and such responses were significantly different than that in the presence of either U 0126 or SB 203580 after FPI.	pyrazolanthrone	31-40	mitogen-activated protein kinase 8	Sus scrofa	64-67
16298339-7	2006	Inhibiting p38MAPK with SB202190 or JNK with SP600125 also reduced angiotensin II-induced alpha-SMA expression.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Rattus norvegicus	36-39
16298339-7	2006	Inhibiting p38MAPK with SB202190 or JNK with SP600125 also reduced angiotensin II-induced alpha-SMA expression.	pyrazolanthrone	45-53	angiotensinogen	Rattus norvegicus	67-81
16298339-7	2006	Inhibiting p38MAPK with SB202190 or JNK with SP600125 also reduced angiotensin II-induced alpha-SMA expression.	pyrazolanthrone	45-53	actin gamma 2, smooth muscle	Rattus norvegicus	90-99
16216413-8	2006	Using the specific JNK inhibitor SP600125, we show that the biphasic activation is necessary for neurite outgrowth and branching, and that inhibition of either phase suppresses neuritogenesis in the N1 cells.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	19-22
16433890-10	2006	Inhibition of c-Jun NH2-terminal kinase (JNK) by SP600125 appreciably protected cells from trimidox-induced apoptosis, but no effect inhibition of p38 mitogen-activated protein kinase (MAPK) by SB203580.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	14-39
16874071-8	2006	In addition, the c-Jun N-terminal kinase (JNK) inhibitors, SCP25041 and SP600125, blocked LTR uptake by 47% and 61%, respectively, but ERK1, p38 and caspase inhibitors had no effect.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Rattus norvegicus	17-40
16874071-8	2006	In addition, the c-Jun N-terminal kinase (JNK) inhibitors, SCP25041 and SP600125, blocked LTR uptake by 47% and 61%, respectively, but ERK1, p38 and caspase inhibitors had no effect.	pyrazolanthrone	72-80	mitogen-activated protein kinase 8	Rattus norvegicus	42-45
16874071-8	2006	In addition, the c-Jun N-terminal kinase (JNK) inhibitors, SCP25041 and SP600125, blocked LTR uptake by 47% and 61%, respectively, but ERK1, p38 and caspase inhibitors had no effect.	pyrazolanthrone	72-80	mitogen activated protein kinase 3	Rattus norvegicus	135-139
16433890-10	2006	Inhibition of c-Jun NH2-terminal kinase (JNK) by SP600125 appreciably protected cells from trimidox-induced apoptosis, but no effect inhibition of p38 mitogen-activated protein kinase (MAPK) by SB203580.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	41-44
16428834-7	2006	PAI-1 gene expression by 13-deoxytedanolide and anisomycin was blocked by SB202190, a specific inhibitor of p38, and SP600125, an inhibitor of both p38 and JNK.	pyrazolanthrone	117-125	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	0-5
16428834-7	2006	PAI-1 gene expression by 13-deoxytedanolide and anisomycin was blocked by SB202190, a specific inhibitor of p38, and SP600125, an inhibitor of both p38 and JNK.	pyrazolanthrone	117-125	mitogen-activated protein kinase 14	Mus musculus	148-151
16428834-7	2006	PAI-1 gene expression by 13-deoxytedanolide and anisomycin was blocked by SB202190, a specific inhibitor of p38, and SP600125, an inhibitor of both p38 and JNK.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Mus musculus	156-159
16253565-6	2006	The JNK inhibitor SP600125 and the PI3-kinase inhibitor LY294002 significantly blocked the poly(I:C)-induced release of RANTES and IL-8, whereas the p38 MAP kinase inhibitor SB203580 suppressed poly(I:C)-induced secretion of IL-8, but not RANTES.	pyrazolanthrone	18-26	C-C motif chemokine ligand 5	Homo sapiens	120-126
16397234-5	2006	SP600125 reversed Akt inhibition and abolished FOXO3a nuclear accumulation in response to paclitaxel.	pyrazolanthrone	0-8	AKT serine/threonine kinase 1	Homo sapiens	18-21
16397234-5	2006	SP600125 reversed Akt inhibition and abolished FOXO3a nuclear accumulation in response to paclitaxel.	pyrazolanthrone	0-8	forkhead box O3	Homo sapiens	47-53
16253565-6	2006	The JNK inhibitor SP600125 and the PI3-kinase inhibitor LY294002 significantly blocked the poly(I:C)-induced release of RANTES and IL-8, whereas the p38 MAP kinase inhibitor SB203580 suppressed poly(I:C)-induced secretion of IL-8, but not RANTES.	pyrazolanthrone	18-26	C-X-C motif chemokine ligand 8	Homo sapiens	131-135
16253565-6	2006	The JNK inhibitor SP600125 and the PI3-kinase inhibitor LY294002 significantly blocked the poly(I:C)-induced release of RANTES and IL-8, whereas the p38 MAP kinase inhibitor SB203580 suppressed poly(I:C)-induced secretion of IL-8, but not RANTES.	pyrazolanthrone	18-26	C-X-C motif chemokine ligand 8	Homo sapiens	225-229
16253565-6	2006	The JNK inhibitor SP600125 and the PI3-kinase inhibitor LY294002 significantly blocked the poly(I:C)-induced release of RANTES and IL-8, whereas the p38 MAP kinase inhibitor SB203580 suppressed poly(I:C)-induced secretion of IL-8, but not RANTES.	pyrazolanthrone	18-26	C-C motif chemokine ligand 5	Homo sapiens	239-245
16367930-6	2006	Animals received subcutaneous injections of a specific JNK inhibitor SP600125 or vehicle and the extent of mucosal damage in the stomach was determined.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Rattus norvegicus	55-58
16081763-9	2005	Inhibitors of MEK (U0126) and JNK (SP600125), but not p38 MAPK inhibitor (SB203580), suppressed ethanol-induced H3 acetylation.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Rattus norvegicus	30-33
16374168-7	2006	In experiment 2, a specific JNK inhibitor, SP600125, was given (30 mg/kg intraperitoneally) to mice immediately postburn to suppress the JNK activity.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Mus musculus	28-31
16374168-7	2006	In experiment 2, a specific JNK inhibitor, SP600125, was given (30 mg/kg intraperitoneally) to mice immediately postburn to suppress the JNK activity.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Mus musculus	137-140
16374168-14	2006	SP600125 administration obliterated the thermal injury-induced JNK activity, AP-1 DNA-binding activity, and iNOS expression in lung tissue.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	63-66
16374168-14	2006	SP600125 administration obliterated the thermal injury-induced JNK activity, AP-1 DNA-binding activity, and iNOS expression in lung tissue.	pyrazolanthrone	0-8	nitric oxide synthase 2, inducible	Mus musculus	108-112
16374168-15	2006	SP600125 treatment also significantly decreased MPO activity, blood DHR 123 oxidation, and lung permeability by 54%, 8%, and 47%, respectively, and markedly decreased the thermal injury-induced perivascular and interstitial inflammatory cell infiltration and septum edema.	pyrazolanthrone	0-8	myeloperoxidase	Mus musculus	48-51
16374168-16	2006	Furthermore, SP600125 abolished thermal injury-induced ICAM-1, VCAM-1, CXCR2, MIP-2, and KC but not interleukin-1beta and interleukin-6 messenger RNA levels of lung tissues.	pyrazolanthrone	13-21	intercellular adhesion molecule 1	Mus musculus	55-61
16374168-16	2006	Furthermore, SP600125 abolished thermal injury-induced ICAM-1, VCAM-1, CXCR2, MIP-2, and KC but not interleukin-1beta and interleukin-6 messenger RNA levels of lung tissues.	pyrazolanthrone	13-21	vascular cell adhesion molecule 1	Mus musculus	63-69
16374168-16	2006	Furthermore, SP600125 abolished thermal injury-induced ICAM-1, VCAM-1, CXCR2, MIP-2, and KC but not interleukin-1beta and interleukin-6 messenger RNA levels of lung tissues.	pyrazolanthrone	13-21	chemokine (C-X-C motif) receptor 2	Mus musculus	71-76
16374168-16	2006	Furthermore, SP600125 abolished thermal injury-induced ICAM-1, VCAM-1, CXCR2, MIP-2, and KC but not interleukin-1beta and interleukin-6 messenger RNA levels of lung tissues.	pyrazolanthrone	13-21	chemokine (C-X-C motif) ligand 2	Mus musculus	78-83
16328781-6	2006	The VEGF mRNA induced by HBO was blocked by both PD98059 and SP600125, the ERK and JNK inhibitors respectively.	pyrazolanthrone	61-69	vascular endothelial growth factor A	Homo sapiens	4-8
17024969-10	2006	While JNK inhibitor SP600125 and p38 inhibitor SB203580, abolished the cytotoxic effect of BITC, MEK inhibitor, PD98059 and PI3 kinase inhibitor, LY294002 failed to show such reversal indicating a critical role played by JNK1/2 and p38 signaling in apoptosis induced by BITC.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	6-9
17024969-10	2006	While JNK inhibitor SP600125 and p38 inhibitor SB203580, abolished the cytotoxic effect of BITC, MEK inhibitor, PD98059 and PI3 kinase inhibitor, LY294002 failed to show such reversal indicating a critical role played by JNK1/2 and p38 signaling in apoptosis induced by BITC.	pyrazolanthrone	20-28	mitogen-activated protein kinase kinase 7	Homo sapiens	97-100
16365456-4	2006	IL-1beta-induced TGF-beta1 protein secretion and mRNA expression were prevented by actinomycin D and were attenuated by the inhibitor of kappaB kinase 2 inhibitor AS602868 and the JNK inhibitor SP600125, suggesting a degree of transcriptional regulation mediated by the NF-kappaB and AP-1 pathways.	pyrazolanthrone	194-202	interleukin 1 beta	Homo sapiens	0-8
16365456-4	2006	IL-1beta-induced TGF-beta1 protein secretion and mRNA expression were prevented by actinomycin D and were attenuated by the inhibitor of kappaB kinase 2 inhibitor AS602868 and the JNK inhibitor SP600125, suggesting a degree of transcriptional regulation mediated by the NF-kappaB and AP-1 pathways.	pyrazolanthrone	194-202	transforming growth factor beta 1	Homo sapiens	17-26
16420771-0	2006	[Effects of sp600125 on proliferation and protein expression of bcl-2 and c-myc in hepatic stellate cells].	pyrazolanthrone	12-20	BCL2 apoptosis regulator	Homo sapiens	64-69
16420771-0	2006	[Effects of sp600125 on proliferation and protein expression of bcl-2 and c-myc in hepatic stellate cells].	pyrazolanthrone	12-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	74-79
16167336-7	2005	Radiation-induced apoptosis in Saos2-mIkappaB cells was inhibited by the JNK specific inhibitor SP600125 as well as by Bcl-2 over-expression.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	73-76
16339571-10	2005	The TNF-alpha-induced PTX3 expression was blocked by SP600125, a JNK-specific inhibitor, but not by the inhibitors against NF-kappaB, ERKs, or p38 MAPK.	pyrazolanthrone	53-61	tumor necrosis factor	Homo sapiens	4-13
16339571-10	2005	The TNF-alpha-induced PTX3 expression was blocked by SP600125, a JNK-specific inhibitor, but not by the inhibitors against NF-kappaB, ERKs, or p38 MAPK.	pyrazolanthrone	53-61	pentraxin 3	Homo sapiens	22-26
16339571-10	2005	The TNF-alpha-induced PTX3 expression was blocked by SP600125, a JNK-specific inhibitor, but not by the inhibitors against NF-kappaB, ERKs, or p38 MAPK.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	65-68
16300639-5	2006	SP600125, a JNK inhibitor, inhibited, in a concentration-dependent manner, IL-1beta-induced activation of JNK with a maximum of 87% at 10(-4) m. In vivo, IL-1beta stimulated JNK and the expression of the inducible isoform of nitric oxide synthase (iNOS).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	12-15
16300639-5	2006	SP600125, a JNK inhibitor, inhibited, in a concentration-dependent manner, IL-1beta-induced activation of JNK with a maximum of 87% at 10(-4) m. In vivo, IL-1beta stimulated JNK and the expression of the inducible isoform of nitric oxide synthase (iNOS).	pyrazolanthrone	0-8	interleukin 1 beta	Mus musculus	75-83
16300639-5	2006	SP600125, a JNK inhibitor, inhibited, in a concentration-dependent manner, IL-1beta-induced activation of JNK with a maximum of 87% at 10(-4) m. In vivo, IL-1beta stimulated JNK and the expression of the inducible isoform of nitric oxide synthase (iNOS).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	106-109
16300639-5	2006	SP600125, a JNK inhibitor, inhibited, in a concentration-dependent manner, IL-1beta-induced activation of JNK with a maximum of 87% at 10(-4) m. In vivo, IL-1beta stimulated JNK and the expression of the inducible isoform of nitric oxide synthase (iNOS).	pyrazolanthrone	0-8	interleukin 1 beta	Mus musculus	154-162
16300639-5	2006	SP600125, a JNK inhibitor, inhibited, in a concentration-dependent manner, IL-1beta-induced activation of JNK with a maximum of 87% at 10(-4) m. In vivo, IL-1beta stimulated JNK and the expression of the inducible isoform of nitric oxide synthase (iNOS).	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	106-109
16300639-5	2006	SP600125, a JNK inhibitor, inhibited, in a concentration-dependent manner, IL-1beta-induced activation of JNK with a maximum of 87% at 10(-4) m. In vivo, IL-1beta stimulated JNK and the expression of the inducible isoform of nitric oxide synthase (iNOS).	pyrazolanthrone	0-8	nitric oxide synthase 2, inducible	Mus musculus	248-252
16300639-7	2006	SP600125 alleviated the inhibitory effect of IL-1beta on KCl- and agonist-induced protein secretion by 79% and 47%, respectively, and completely blocked the expression of iNOS.	pyrazolanthrone	0-8	interleukin 1 beta	Mus musculus	45-53
16300639-7	2006	SP600125 alleviated the inhibitory effect of IL-1beta on KCl- and agonist-induced protein secretion by 79% and 47%, respectively, and completely blocked the expression of iNOS.	pyrazolanthrone	0-8	nitric oxide synthase 2, inducible	Mus musculus	171-175
16302268-5	2006	Furthermore, PD98059, a mitogen-activated protein (MAP) kinase/ERK kinase (MEK) inhibitor, or SP600125, c-Jun N-terminal kinase (JNK) inhibitor, decreased cell growth, EGF-induced DNA synthesis and transformation.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	129-132
16302268-5	2006	Furthermore, PD98059, a mitogen-activated protein (MAP) kinase/ERK kinase (MEK) inhibitor, or SP600125, c-Jun N-terminal kinase (JNK) inhibitor, decreased cell growth, EGF-induced DNA synthesis and transformation.	pyrazolanthrone	94-102	epidermal growth factor	Homo sapiens	168-171
16984740-6	2006	The JNK inhibitor SP600125 abolished the positive effects of catalase on drug transporter activity in a dose-dependent manner.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
16289960-7	2005	MEK1/2 and nuclear factor kappa B (NF-kappaB) inhibitors (U0126 and TLCK, respectively) blocked the ability of b-FGF to induce NRP-1 mRNA expression, but inhibition of JNK (SP600125) or PI3-kinase activity (wortmannin) did not.	pyrazolanthrone	173-181	mitogen-activated protein kinase kinase 1	Homo sapiens	0-6
16307741-5	2005	Gemcitabine induced activation of c-Jun NH2-terminal kinase (JNK) in parental H1299 cells but not in H1299/GR cells after 48 h. Blocking JNK activation by pretreatment with SP600125, a specific JNK inhibitor, or by transfection with dominant-negative JNK vectors abrogated gemcitabine-induced apoptosis in parental H1299 cells as evidenced by interruption of caspase activation.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	34-59
16307741-5	2005	Gemcitabine induced activation of c-Jun NH2-terminal kinase (JNK) in parental H1299 cells but not in H1299/GR cells after 48 h. Blocking JNK activation by pretreatment with SP600125, a specific JNK inhibitor, or by transfection with dominant-negative JNK vectors abrogated gemcitabine-induced apoptosis in parental H1299 cells as evidenced by interruption of caspase activation.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	61-64
16307741-5	2005	Gemcitabine induced activation of c-Jun NH2-terminal kinase (JNK) in parental H1299 cells but not in H1299/GR cells after 48 h. Blocking JNK activation by pretreatment with SP600125, a specific JNK inhibitor, or by transfection with dominant-negative JNK vectors abrogated gemcitabine-induced apoptosis in parental H1299 cells as evidenced by interruption of caspase activation.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	137-140
16307741-5	2005	Gemcitabine induced activation of c-Jun NH2-terminal kinase (JNK) in parental H1299 cells but not in H1299/GR cells after 48 h. Blocking JNK activation by pretreatment with SP600125, a specific JNK inhibitor, or by transfection with dominant-negative JNK vectors abrogated gemcitabine-induced apoptosis in parental H1299 cells as evidenced by interruption of caspase activation.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	137-140
16307741-5	2005	Gemcitabine induced activation of c-Jun NH2-terminal kinase (JNK) in parental H1299 cells but not in H1299/GR cells after 48 h. Blocking JNK activation by pretreatment with SP600125, a specific JNK inhibitor, or by transfection with dominant-negative JNK vectors abrogated gemcitabine-induced apoptosis in parental H1299 cells as evidenced by interruption of caspase activation.	pyrazolanthrone	173-181	mitogen-activated protein kinase 8	Homo sapiens	137-140
16162944-5	2005	Induction of SREBP-1, SCD-1, and FAS by KGF was inhibited by the JNK inhibitor SP600125 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 but not by the ERK inhibitor PD98059.	pyrazolanthrone	79-87	sterol regulatory element binding transcription factor 1	Homo sapiens	13-20
15908180-3	2005	Additionally, cells transfected with wild-type JNK1 became more susceptible to apoptosis induced by TNF-alpha/IFN-gamma through ROS production and loss of delta psi m, while cascading apoptotic events were prevented in dominant-negative JNK1-transfected or JNK inhibitor SP600125-treated cells.	pyrazolanthrone	271-279	mitogen-activated protein kinase 8	Homo sapiens	47-51
15908180-3	2005	Additionally, cells transfected with wild-type JNK1 became more susceptible to apoptosis induced by TNF-alpha/IFN-gamma through ROS production and loss of delta psi m, while cascading apoptotic events were prevented in dominant-negative JNK1-transfected or JNK inhibitor SP600125-treated cells.	pyrazolanthrone	271-279	tumor necrosis factor	Homo sapiens	100-109
15908180-3	2005	Additionally, cells transfected with wild-type JNK1 became more susceptible to apoptosis induced by TNF-alpha/IFN-gamma through ROS production and loss of delta psi m, while cascading apoptotic events were prevented in dominant-negative JNK1-transfected or JNK inhibitor SP600125-treated cells.	pyrazolanthrone	271-279	mitogen-activated protein kinase 8	Homo sapiens	47-50
15908180-7	2005	This synergistic activation of JNK/SAPK by TNF-alpha/IFN-gamma was also induced in insulin-expressing pancreatic islet cells, and increased ROS production and p53 level, which was significantly inhibited by SP600125.	pyrazolanthrone	207-215	mitogen-activated protein kinase 8	Homo sapiens	31-34
15908180-7	2005	This synergistic activation of JNK/SAPK by TNF-alpha/IFN-gamma was also induced in insulin-expressing pancreatic islet cells, and increased ROS production and p53 level, which was significantly inhibited by SP600125.	pyrazolanthrone	207-215	mitogen-activated protein kinase 9	Homo sapiens	35-39
15908180-7	2005	This synergistic activation of JNK/SAPK by TNF-alpha/IFN-gamma was also induced in insulin-expressing pancreatic islet cells, and increased ROS production and p53 level, which was significantly inhibited by SP600125.	pyrazolanthrone	207-215	tumor necrosis factor	Homo sapiens	43-52
15908180-7	2005	This synergistic activation of JNK/SAPK by TNF-alpha/IFN-gamma was also induced in insulin-expressing pancreatic islet cells, and increased ROS production and p53 level, which was significantly inhibited by SP600125.	pyrazolanthrone	207-215	interferon gamma	Homo sapiens	53-62
15908180-7	2005	This synergistic activation of JNK/SAPK by TNF-alpha/IFN-gamma was also induced in insulin-expressing pancreatic islet cells, and increased ROS production and p53 level, which was significantly inhibited by SP600125.	pyrazolanthrone	207-215	tumor protein p53	Homo sapiens	159-162
16162944-5	2005	Induction of SREBP-1, SCD-1, and FAS by KGF was inhibited by the JNK inhibitor SP600125 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 but not by the ERK inhibitor PD98059.	pyrazolanthrone	79-87	stearoyl-CoA desaturase	Homo sapiens	22-27
16162944-5	2005	Induction of SREBP-1, SCD-1, and FAS by KGF was inhibited by the JNK inhibitor SP600125 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 but not by the ERK inhibitor PD98059.	pyrazolanthrone	79-87	fibroblast growth factor 7	Homo sapiens	40-43
16162944-5	2005	Induction of SREBP-1, SCD-1, and FAS by KGF was inhibited by the JNK inhibitor SP600125 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 but not by the ERK inhibitor PD98059.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Homo sapiens	65-68
16162944-5	2005	Induction of SREBP-1, SCD-1, and FAS by KGF was inhibited by the JNK inhibitor SP600125 and the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 but not by the ERK inhibitor PD98059.	pyrazolanthrone	79-87	mitogen-activated protein kinase 1	Homo sapiens	167-170
15886223-11	2005	This phosphorylation may be partly mediated by p38 and JNK kinases, since specific inhibitors (SB-203580 and SP-600125) partly reverted the inhibitory effect of OEA on insulin-stimulated glucose uptake.	pyrazolanthrone	109-118	mitogen activated protein kinase 14	Rattus norvegicus	47-50
16005241-8	2005	Furthermore, inhibition of JNK activity with in vivo delivery of SP600125 or a jnk1 antisense oligodeoxynucleotide (ODN) attenuated DP5 induction and caspase-3 activation.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
16005241-8	2005	Furthermore, inhibition of JNK activity with in vivo delivery of SP600125 or a jnk1 antisense oligodeoxynucleotide (ODN) attenuated DP5 induction and caspase-3 activation.	pyrazolanthrone	65-73	harakiri, BCL2 interacting protein	Rattus norvegicus	132-135
16005241-8	2005	Furthermore, inhibition of JNK activity with in vivo delivery of SP600125 or a jnk1 antisense oligodeoxynucleotide (ODN) attenuated DP5 induction and caspase-3 activation.	pyrazolanthrone	65-73	caspase 3	Rattus norvegicus	150-159
16172114-7	2005	Hsp70 inhibited stress-induced JNK activation and inhibition of JNK with SP600125 or by expression of a dominant negative mutant of JNK-blocked Bax translocation as effectively as Hsp70 overexpression.	pyrazolanthrone	73-81	heat shock protein family A (Hsp70) member 4	Homo sapiens	0-5
16172114-7	2005	Hsp70 inhibited stress-induced JNK activation and inhibition of JNK with SP600125 or by expression of a dominant negative mutant of JNK-blocked Bax translocation as effectively as Hsp70 overexpression.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	64-67
16172114-7	2005	Hsp70 inhibited stress-induced JNK activation and inhibition of JNK with SP600125 or by expression of a dominant negative mutant of JNK-blocked Bax translocation as effectively as Hsp70 overexpression.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	64-67
16044154-6	2005	Inhibition of JNK by the specific inhibitor SP600125 or by transfection of a dominant-negative mutant of JNK1 reduced the percentage of apoptotic cells, thus showing that JNK activation constitutes a death signal.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	14-17
16151469-6	2005	The phospho-JNK inhibitor SP600125 partially protected Sup-M2 cells from LY293111-induced apoptosis, PARP cleavage and ROS generation, suggesting a role for JNK in LY293111-induced cell death.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	12-15
15979056-6	2005	RESULTS: Treatment of endothelial cells with the JNK-specific inhibitors, SP600125 or JNK inhibitory peptide 1 (JNKI1), resulted in a significant decrease in thrombin-induced ICAM-1 expression as demonstrated by Western blot analysis (67 +/- 3% and 72 +/- 7%, respectively).	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	49-52
15979056-6	2005	RESULTS: Treatment of endothelial cells with the JNK-specific inhibitors, SP600125 or JNK inhibitory peptide 1 (JNKI1), resulted in a significant decrease in thrombin-induced ICAM-1 expression as demonstrated by Western blot analysis (67 +/- 3% and 72 +/- 7%, respectively).	pyrazolanthrone	74-82	coagulation factor II, thrombin	Homo sapiens	158-166
15979056-6	2005	RESULTS: Treatment of endothelial cells with the JNK-specific inhibitors, SP600125 or JNK inhibitory peptide 1 (JNKI1), resulted in a significant decrease in thrombin-induced ICAM-1 expression as demonstrated by Western blot analysis (67 +/- 3% and 72 +/- 7%, respectively).	pyrazolanthrone	74-82	intercellular adhesion molecule 1	Homo sapiens	175-181
15979056-8	2005	The combination of SP600125 and the NF-kappaB inhibitor, BAY11-7082, resulted in complete inhibition of thrombin-induced ICAM-1 expression.	pyrazolanthrone	19-27	coagulation factor II, thrombin	Homo sapiens	104-112
15979056-8	2005	The combination of SP600125 and the NF-kappaB inhibitor, BAY11-7082, resulted in complete inhibition of thrombin-induced ICAM-1 expression.	pyrazolanthrone	19-27	intercellular adhesion molecule 1	Homo sapiens	121-127
16126201-4	2005	In organ-cultured ganglia, we found that c-Jun was activated within 24 h of explantation in both types of neurons, and that the JNK inhibitor SP600125 could mitigate this response.	pyrazolanthrone	142-150	mitogen-activated protein kinase 8	Rattus norvegicus	128-131
16149076-6	2005	Docetaxel-induced bcl-2 phosphorylation was completely blocked by expression of dominant negative JNK or the JNK/SAPK inhibitor SP600125.	pyrazolanthrone	128-136	BCL2 apoptosis regulator	Homo sapiens	18-23
16149076-6	2005	Docetaxel-induced bcl-2 phosphorylation was completely blocked by expression of dominant negative JNK or the JNK/SAPK inhibitor SP600125.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	109-117
16143311-5	2005	SP600125, an SAPK/JNK1/2 inhibitor, markedly suppressed apoptotic cell death in the genipin-treated cells.	pyrazolanthrone	0-8	mitogen-activated protein kinase 9	Rattus norvegicus	13-17
16237059-7	2005	Furthermore, SP600125 and dexamethasone inhibited LPS-induced IRF-7 activity.	pyrazolanthrone	13-21	interferon regulatory factor 7	Homo sapiens	62-67
16151469-6	2005	The phospho-JNK inhibitor SP600125 partially protected Sup-M2 cells from LY293111-induced apoptosis, PARP cleavage and ROS generation, suggesting a role for JNK in LY293111-induced cell death.	pyrazolanthrone	26-34	poly(ADP-ribose) polymerase 1	Homo sapiens	101-105
16151469-6	2005	The phospho-JNK inhibitor SP600125 partially protected Sup-M2 cells from LY293111-induced apoptosis, PARP cleavage and ROS generation, suggesting a role for JNK in LY293111-induced cell death.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Homo sapiens	157-160
15880572-7	2005	Treatment with a JNK inhibitor, SP600125, significantly inhibited MRP1 induction.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Homo sapiens	17-20
15880572-7	2005	Treatment with a JNK inhibitor, SP600125, significantly inhibited MRP1 induction.	pyrazolanthrone	32-40	ATP binding cassette subfamily C member 1	Homo sapiens	66-70
15880572-11	2005	Pretreatment with SP600125 before DOX stimulation blocked the appearance of the MDR phenotype as well as MRP1 induction in GLC4 cells.	pyrazolanthrone	18-26	ATP binding cassette subfamily C member 1	Homo sapiens	105-109
15880572-9	2005	Chromatin immunoprecipitation assays revealed an enhanced recruitment of phosphorylated c-jun to the MRP1 promoter containing the AP-1 site upon DOX stimulation, which was inhibited by pretreatment with SP600125.	pyrazolanthrone	203-211	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	88-93
15880572-9	2005	Chromatin immunoprecipitation assays revealed an enhanced recruitment of phosphorylated c-jun to the MRP1 promoter containing the AP-1 site upon DOX stimulation, which was inhibited by pretreatment with SP600125.	pyrazolanthrone	203-211	ATP binding cassette subfamily C member 1	Homo sapiens	101-105
15978632-4	2005	SP600125 and dominant-negative SEK suppressed Hsp70 promoter-driven reporter gene expression, suggesting that JNK would be preferentially associated with the protective heat shock response against arsenic trioxide stress.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	110-113
16139249-7	2005	Cellular signaling analysis using MAPK-(U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) and Jak2-specific (AG490) inhibitors demonstrated that LPS stimulated iNOS expression via activating Jak2-mediated JNK, but not ERK and p38, pathway.	pyrazolanthrone	86-94	toll-like receptor 4	Mus musculus	159-162
15978632-5	2005	In addition, SP600125, a specific JNK inhibitor, significantly reduced the amount of phosphorylated HSF1 upon administration of arsenic trioxide.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	34-37
15961069-8	2005	Finally, treatment of NRVMs with the specific JNK/c-Jun inhibitor SP600125 significantly reduced the stretch-induced increase of atrial natriuretic factor promoter activity.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Rattus norvegicus	46-49
15978632-5	2005	In addition, SP600125, a specific JNK inhibitor, significantly reduced the amount of phosphorylated HSF1 upon administration of arsenic trioxide.	pyrazolanthrone	13-21	heat shock transcription factor 1	Homo sapiens	100-104
15888553-0	2005	Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.	pyrazolanthrone	29-60	mitogen-activated protein kinase 8	Rattus norvegicus	15-18
15888553-0	2005	Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.	pyrazolanthrone	29-60	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	76-100
15888553-0	2005	Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.	pyrazolanthrone	62-71	mitogen-activated protein kinase 8	Rattus norvegicus	15-18
15888553-0	2005	Effects of the JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) on soluble guanylyl cyclase alpha1 gene regulation and cGMP synthesis.	pyrazolanthrone	62-71	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	76-100
15888553-3	2005	We demonstrate herein that the c-Jun NH2-terminal kinase JNK II inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) completely blocked the decreased expression of sGCalpha1-subunit mRNA by nerve growth factor (NGF) in PC12 cells.	pyrazolanthrone	74-105	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
15888553-3	2005	We demonstrate herein that the c-Jun NH2-terminal kinase JNK II inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125) completely blocked the decreased expression of sGCalpha1-subunit mRNA by nerve growth factor (NGF) in PC12 cells.	pyrazolanthrone	107-116	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
15888553-5	2005	SP-600125 also inhibited the NGF-mediated decrease in the expression of sGCalpha1 protein as well as sGC activity in PC12 cells.	pyrazolanthrone	0-9	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	72-75
15888553-7	2005	We also demonstrate that TNF-alpha/IL-1beta stimulation of rat fetal lung (RFL-6) fibroblast cells resulted in sGCalpha1 mRNA inhibition, which was blocked by SP-600125.	pyrazolanthrone	159-168	tumor necrosis factor	Rattus norvegicus	25-34
15888553-7	2005	We also demonstrate that TNF-alpha/IL-1beta stimulation of rat fetal lung (RFL-6) fibroblast cells resulted in sGCalpha1 mRNA inhibition, which was blocked by SP-600125.	pyrazolanthrone	159-168	interleukin 1 beta	Rattus norvegicus	35-43
16024134-5	2005	A specific JNK inhibitor SP600125 (Anthra[1,9-cd]pyrazol-6(2H)-one1,9-pyrazoloanthrone), but not its negative control (N1-Methyl-1,9-pyrazoloanthrone), significantly reduced cAMP-stimulated Aa-Nat, Period1, and MKP-1 mRNA levels.	pyrazolanthrone	25-33	mitogen-activated protein kinase 8	Rattus norvegicus	11-14
16038800-6	2005	Furthermore, whilst pre-treatment of cells with either the JNK inhibitor SP600125, or the MEK-1 inhibitor PD98059, also reverses UV-C and cisplatin-induced apoptosis, the anti-apoptotic effect of MKP-2 overexpression is not additive with SP600125 but is with PD098059, suggesting that MKP-2 is involved in specifically terminating JNK activity and not ERK.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	59-62
16038800-6	2005	Furthermore, whilst pre-treatment of cells with either the JNK inhibitor SP600125, or the MEK-1 inhibitor PD98059, also reverses UV-C and cisplatin-induced apoptosis, the anti-apoptotic effect of MKP-2 overexpression is not additive with SP600125 but is with PD098059, suggesting that MKP-2 is involved in specifically terminating JNK activity and not ERK.	pyrazolanthrone	73-81	dual specificity phosphatase 4	Homo sapiens	196-201
16038800-6	2005	Furthermore, whilst pre-treatment of cells with either the JNK inhibitor SP600125, or the MEK-1 inhibitor PD98059, also reverses UV-C and cisplatin-induced apoptosis, the anti-apoptotic effect of MKP-2 overexpression is not additive with SP600125 but is with PD098059, suggesting that MKP-2 is involved in specifically terminating JNK activity and not ERK.	pyrazolanthrone	73-81	dual specificity phosphatase 4	Homo sapiens	285-290
16038800-6	2005	Furthermore, whilst pre-treatment of cells with either the JNK inhibitor SP600125, or the MEK-1 inhibitor PD98059, also reverses UV-C and cisplatin-induced apoptosis, the anti-apoptotic effect of MKP-2 overexpression is not additive with SP600125 but is with PD098059, suggesting that MKP-2 is involved in specifically terminating JNK activity and not ERK.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	331-334
16179969-5	2005	DBPT-mediated G2/M phase arrest and phosphorylation of cdc25C and histone H3 were abrogated when JNK activation was blocked either with SP600125, a specific JNK inhibitor, or a dominant-negative JNK1 gene.	pyrazolanthrone	136-144	cell division cycle 25C	Homo sapiens	55-61
16179969-5	2005	DBPT-mediated G2/M phase arrest and phosphorylation of cdc25C and histone H3 were abrogated when JNK activation was blocked either with SP600125, a specific JNK inhibitor, or a dominant-negative JNK1 gene.	pyrazolanthrone	136-144	mitogen-activated protein kinase 8	Homo sapiens	97-100
16038800-6	2005	Furthermore, whilst pre-treatment of cells with either the JNK inhibitor SP600125, or the MEK-1 inhibitor PD98059, also reverses UV-C and cisplatin-induced apoptosis, the anti-apoptotic effect of MKP-2 overexpression is not additive with SP600125 but is with PD098059, suggesting that MKP-2 is involved in specifically terminating JNK activity and not ERK.	pyrazolanthrone	73-81	mitogen-activated protein kinase 1	Homo sapiens	352-355
16038800-6	2005	Furthermore, whilst pre-treatment of cells with either the JNK inhibitor SP600125, or the MEK-1 inhibitor PD98059, also reverses UV-C and cisplatin-induced apoptosis, the anti-apoptotic effect of MKP-2 overexpression is not additive with SP600125 but is with PD098059, suggesting that MKP-2 is involved in specifically terminating JNK activity and not ERK.	pyrazolanthrone	238-246	mitogen-activated protein kinase 8	Homo sapiens	59-62
16038800-6	2005	Furthermore, whilst pre-treatment of cells with either the JNK inhibitor SP600125, or the MEK-1 inhibitor PD98059, also reverses UV-C and cisplatin-induced apoptosis, the anti-apoptotic effect of MKP-2 overexpression is not additive with SP600125 but is with PD098059, suggesting that MKP-2 is involved in specifically terminating JNK activity and not ERK.	pyrazolanthrone	238-246	mitogen-activated protein kinase kinase 1	Homo sapiens	90-95
15961069-8	2005	Finally, treatment of NRVMs with the specific JNK/c-Jun inhibitor SP600125 significantly reduced the stretch-induced increase of atrial natriuretic factor promoter activity.	pyrazolanthrone	66-74	natriuretic peptide A	Rattus norvegicus	129-154
16088958-7	2005	Both inhibitors of MEK (PD098059) and JNK (SP600125) inhibited serum induction of COX-2.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Mus musculus	38-41
16186362-7	2005	SP600125, a specific pharmacologic inhibitor of JNK, blocked MCP-1 but not IL-8 mRNA and protein expression.	pyrazolanthrone	0-8	C-C motif chemokine ligand 2	Homo sapiens	61-66
16088958-7	2005	Both inhibitors of MEK (PD098059) and JNK (SP600125) inhibited serum induction of COX-2.	pyrazolanthrone	43-51	prostaglandin-endoperoxide synthase 2	Mus musculus	82-87
16088958-8	2005	PD98059 only inhibited constitutively active Ras-induced COX-2 expression, while SP600125 significantly inhibited both constitutively active Ras- and RhoA-induced COX-2 expression.	pyrazolanthrone	81-89	ras homolog family member A	Mus musculus	150-154
16088958-8	2005	PD98059 only inhibited constitutively active Ras-induced COX-2 expression, while SP600125 significantly inhibited both constitutively active Ras- and RhoA-induced COX-2 expression.	pyrazolanthrone	81-89	prostaglandin-endoperoxide synthase 2	Mus musculus	163-168
16099428-1	2005	In 3T3-L1 adipocytes, insulin or anisomycin stimulated phosphorylation of IRS-1 at Ser(307) and Ser(636/639), both of which were partially reduced by the mTOR inhibitor, rapamycin, or the JNK inhibitor, SP600125, and were further inhibited by a combination of them.	pyrazolanthrone	203-211	insulin	Homo sapiens	22-29
16099428-1	2005	In 3T3-L1 adipocytes, insulin or anisomycin stimulated phosphorylation of IRS-1 at Ser(307) and Ser(636/639), both of which were partially reduced by the mTOR inhibitor, rapamycin, or the JNK inhibitor, SP600125, and were further inhibited by a combination of them.	pyrazolanthrone	203-211	insulin receptor substrate 1	Homo sapiens	74-79
16099428-1	2005	In 3T3-L1 adipocytes, insulin or anisomycin stimulated phosphorylation of IRS-1 at Ser(307) and Ser(636/639), both of which were partially reduced by the mTOR inhibitor, rapamycin, or the JNK inhibitor, SP600125, and were further inhibited by a combination of them.	pyrazolanthrone	203-211	mechanistic target of rapamycin kinase	Homo sapiens	154-158
16099428-2	2005	Interestingly, anisomycin-induced p70(S6K) phosphorylation was reduced by SP600125, while insulin-induced p70(S6K) phosphorylation was not.	pyrazolanthrone	74-82	annexin A6	Homo sapiens	34-37
16099428-2	2005	Interestingly, anisomycin-induced p70(S6K) phosphorylation was reduced by SP600125, while insulin-induced p70(S6K) phosphorylation was not.	pyrazolanthrone	74-82	ribosomal protein S6 kinase B1	Homo sapiens	38-41
16055088-6	2005	Pre-treatment as well as post-treatment of rats with a JNK inhibitor, SP600125, significantly attenuated thermal hyperalgesia, as assessed by paw-withdrawal latency, and the upregulation of c-fos immunoreactivity in dorsal horn neurons.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Rattus norvegicus	55-58
16055440-8	2005	Furthermore, Shp2-dependent phorbol ester effects on Ser-307 were blocked by wortmannin, rapamycin, and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	150-158	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	13-17
16055440-8	2005	Furthermore, Shp2-dependent phorbol ester effects on Ser-307 were blocked by wortmannin, rapamycin, and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	108-133
16055440-8	2005	Furthermore, Shp2-dependent phorbol ester effects on Ser-307 were blocked by wortmannin, rapamycin, and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	135-138
16055088-6	2005	Pre-treatment as well as post-treatment of rats with a JNK inhibitor, SP600125, significantly attenuated thermal hyperalgesia, as assessed by paw-withdrawal latency, and the upregulation of c-fos immunoreactivity in dorsal horn neurons.	pyrazolanthrone	70-78	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	190-195
16055088-8	2005	injection of nerve growth factor (NGF) also induced the phosphorylation of JNK as well as thermal hyperalgesia, and SP600125 improved hyperalgesia.	pyrazolanthrone	116-124	nerve growth factor	Rattus norvegicus	13-32
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	pyrazolanthrone	178-186	mitogen-activated protein kinase 1	Homo sapiens	60-63
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	pyrazolanthrone	178-186	mitogen-activated protein kinase 8	Homo sapiens	65-68
16113653-2	2005	Here, we show that the previously reported c-Jun amino-terminal kinase (JNK) inhibitor SP600125 effectively disrupts spindle checkpoint function in a JNK-independent fashion.	pyrazolanthrone	87-95	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	43-48
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	pyrazolanthrone	178-186	AKT serine/threonine kinase 1	Homo sapiens	74-77
16100051-7	2005	In addition, adenosine- and CCPA-induced phosphorylation of ERK, JNK, and AKT is inhibited, respectively, by U0126, PD98059 (mitogen-activated protein kinase kinase inhibitors), SP600125 (JNK kinase inhibitor), and wortmannin (phosphatidylinositol 3-kinase inhibitor).	pyrazolanthrone	178-186	mitogen-activated protein kinase 8	Homo sapiens	188-191
16148154-4	2005	We show in this study that exposure of mice to aerosolized LPS increased PAI-1 expression in the lung and alveolar compartment, which was decreased by pretreatment with the JNK inhibitor SP600125.	pyrazolanthrone	187-195	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	73-78
16148154-4	2005	We show in this study that exposure of mice to aerosolized LPS increased PAI-1 expression in the lung and alveolar compartment, which was decreased by pretreatment with the JNK inhibitor SP600125.	pyrazolanthrone	187-195	mitogen-activated protein kinase 8	Mus musculus	173-176
16148154-7	2005	An increase in the intravascular level of KC is a likely mechanism for the inhibition of pulmonary neutrophil recruitment after LPS exposure in the setting of decreased PAI-1 expression, as systemic KC levels after exposure to LPS were increased in PAI-1-deficient mice and in mice pretreated with SP600125, with augmentation of intravascular KC levels inhibiting neutrophil recruitment to the lung after exposure to LPS.	pyrazolanthrone	298-306	serine (or cysteine) peptidase inhibitor, clade E, member 1	Mus musculus	249-254
15963981-7	2005	Furthermore, pretreatment of osteoblasts with the JNK inhibitor SP600125 abolished the adiponectin-induced cell proliferation.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Homo sapiens	50-53
15963981-7	2005	Furthermore, pretreatment of osteoblasts with the JNK inhibitor SP600125 abolished the adiponectin-induced cell proliferation.	pyrazolanthrone	64-72	adiponectin, C1Q and collagen domain containing	Homo sapiens	87-98
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Rattus norvegicus	13-16
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	pyrazolanthrone	78-86	Eph receptor B1	Rattus norvegicus	21-24
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Rattus norvegicus	92-95
16179908-11	2005	Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest.	pyrazolanthrone	78-86	cyclin dependent kinase inhibitor 1A	Homo sapiens	130-137
16082226-5	2005	Serine 15-phosphorylation is due to GADD45alpha-dependent induction of JNK kinase, which can be blocked by SP600125, a JNK kinase inhibitor.	pyrazolanthrone	107-115	growth arrest and DNA damage inducible alpha	Homo sapiens	36-47
16082226-5	2005	Serine 15-phosphorylation is due to GADD45alpha-dependent induction of JNK kinase, which can be blocked by SP600125, a JNK kinase inhibitor.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	71-74
16082226-5	2005	Serine 15-phosphorylation is due to GADD45alpha-dependent induction of JNK kinase, which can be blocked by SP600125, a JNK kinase inhibitor.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	119-122
16113653-2	2005	Here, we show that the previously reported c-Jun amino-terminal kinase (JNK) inhibitor SP600125 effectively disrupts spindle checkpoint function in a JNK-independent fashion.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	72-75
16113653-2	2005	Here, we show that the previously reported c-Jun amino-terminal kinase (JNK) inhibitor SP600125 effectively disrupts spindle checkpoint function in a JNK-independent fashion.	pyrazolanthrone	87-95	mitogen-activated protein kinase 8	Homo sapiens	150-153
16113653-3	2005	SP600125 potently inhibits activity of the mitotic checkpoint kinase monopolar spindle 1 (Mps1) in vitro and triggers efficient progression through a mitotic arrest imposed by spindle poisons.	pyrazolanthrone	0-8	TTK protein kinase	Homo sapiens	90-94
16113653-4	2005	Importantly, expression of an Mps1 mutant protein refractory to SP600125-mediated inhibition restores spindle checkpoint function in the presence of SP600125, showing that its mitotic phenotype is induced by Mps1 inhibition in vivo.	pyrazolanthrone	64-72	TTK protein kinase	Homo sapiens	30-34
16113653-4	2005	Importantly, expression of an Mps1 mutant protein refractory to SP600125-mediated inhibition restores spindle checkpoint function in the presence of SP600125, showing that its mitotic phenotype is induced by Mps1 inhibition in vivo.	pyrazolanthrone	149-157	TTK protein kinase	Homo sapiens	30-34
16113653-5	2005	Remarkably, primary human cells are largely resistant to the checkpoint-inactivating action of SP600125, suggesting the existence of Mps1-independent checkpoint pathways that are compromised in tumour cells.	pyrazolanthrone	95-103	TTK protein kinase	Homo sapiens	133-137
16116085-10	2005	Moreover, the inhibitory effect of ET-1 was suppressed by the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the expression of the JNK-binding domain of JNK-interacting protein-1, a specific inhibitor of the JNK pathway.	pyrazolanthrone	102-110	endothelin 1	Mus musculus	35-39
15799027-8	2005	The potentiation of differentiation by antioxidants was inhibited by JNK inhibitor SP600125 and a dominant negative JNK 1/2 construct, and Egr-1 and c-fos expression was proportionally decreased, suggesting that JNK pathway regulates these transcription factors.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	69-72
16116085-10	2005	Moreover, the inhibitory effect of ET-1 was suppressed by the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the expression of the JNK-binding domain of JNK-interacting protein-1, a specific inhibitor of the JNK pathway.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Mus musculus	62-85
16116085-10	2005	Moreover, the inhibitory effect of ET-1 was suppressed by the c-Jun N-terminal kinase (JNK) inhibitor SP600125 and the expression of the JNK-binding domain of JNK-interacting protein-1, a specific inhibitor of the JNK pathway.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Mus musculus	87-90
16155405-5	2005	This type of cell death was accompanied by JNK activation, and was reversed by the use of a JNK-specific inhibitor SP600125.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Homo sapiens	43-46
16155405-5	2005	This type of cell death was accompanied by JNK activation, and was reversed by the use of a JNK-specific inhibitor SP600125.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Homo sapiens	92-95
15896775-6	2005	Only SP600125 significantly attenuates the AP-1 responsive gene activation by ICP0.	pyrazolanthrone	5-13	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	43-47
16099438-3	2005	FPI blunted PGE2 pial artery dilation, but U 0126 and SP 600125 (10(-6) M) (ERK and JNK MAPK inhibitors, respectively) partially prevented such impairment (7 +/- 1, 12 +/- 1, and 17 +/- 1 vs. 2 +/- 1, 3 +/- 1, and 5 +/- 1 vs. 4 +/- 1, 7 +/- 1, and 12 +/- 1% for 1, 10, and 100 ng/ml PGE2 in control, FPI, and FPI + U 0126 pretreated animals, respectively).	pyrazolanthrone	54-63	mitogen-activated protein kinase 8	Sus scrofa	84-87
15944157-6	2005	In contrast, inhibition of JNK with SP600125 maintained cell adhesion as well as protection against apoptosis.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Sus scrofa	27-30
15962287-3	2005	The PDGF-induced proliferation was prevented by a pretreatment with the c-Jun N-terminal kinase (JNK) inhibitor, SP600125.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	72-111
15962287-5	2005	Treatment with PDGF induced the activation of JNK and ERK in hATSCs, and pretreatment with SP600125 specifically inhibited the PDGF-induced activation of JNK.	pyrazolanthrone	91-99	mitogen-activated protein kinase 8	Homo sapiens	154-157
15962287-6	2005	Treatment with PDGF induced the cell cycle transition from the G0/G1 phase to the S phase, the elevated expression of cyclin D1, and the phosphorylation of Rb, which were prevented by a pretreatment with SP600125.	pyrazolanthrone	204-212	cyclin D1	Homo sapiens	118-127
15860795-6	2005	IL-25 could also activate the JNK, p38 MAPK, and NF-kappaB activities of eosinophils, while inhibitor of IkappaB-alpha phosphorylation (BAY11-7082), JNK (SP600125), and p38 MAPK (SB203580) could suppress the release of IL-8, MIP-1alpha, MCP-1, and IL-6.	pyrazolanthrone	154-162	interleukin 25	Homo sapiens	0-5
16061660-4	2005	Here we show that CD95-induced apoptosis is augmented by the JNK inhibitor SP600125 and small interfering RNA directed against JNK1/2.	pyrazolanthrone	75-83	Fas cell surface death receptor	Homo sapiens	18-22
16061660-4	2005	Here we show that CD95-induced apoptosis is augmented by the JNK inhibitor SP600125 and small interfering RNA directed against JNK1/2.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	61-64
16061660-5	2005	SP600125 potently inhibited methyl methane sulfonate-induced phosphorylation of c-Jun, but had minimal effect on apoptosis alone.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	80-85
16061660-7	2005	SP600125 enhanced cleavage of caspase 3 and caspase 8, the most upstream caspase in the CD95 pathway.	pyrazolanthrone	0-8	caspase 3	Homo sapiens	30-39
16061660-7	2005	SP600125 enhanced cleavage of caspase 3 and caspase 8, the most upstream caspase in the CD95 pathway.	pyrazolanthrone	0-8	caspase 8	Homo sapiens	44-53
16061660-7	2005	SP600125 enhanced cleavage of caspase 3 and caspase 8, the most upstream caspase in the CD95 pathway.	pyrazolanthrone	0-8	Fas cell surface death receptor	Homo sapiens	88-92
16103364-7	2005	DA-dependent potentiation of c-Jun activation was reversed by ascorbate, a reactive oxygen species (ROS) scavenger, and SP-600125, a selective inhibitor of the c-Jun N-terminal kinase (JNK) pathway.	pyrazolanthrone	120-129	jun proto-oncogene	Mus musculus	29-34
16103364-7	2005	DA-dependent potentiation of c-Jun activation was reversed by ascorbate, a reactive oxygen species (ROS) scavenger, and SP-600125, a selective inhibitor of the c-Jun N-terminal kinase (JNK) pathway.	pyrazolanthrone	120-129	mitogen-activated protein kinase 8	Mus musculus	160-183
16103364-7	2005	DA-dependent potentiation of c-Jun activation was reversed by ascorbate, a reactive oxygen species (ROS) scavenger, and SP-600125, a selective inhibitor of the c-Jun N-terminal kinase (JNK) pathway.	pyrazolanthrone	120-129	mitogen-activated protein kinase 8	Mus musculus	185-188
15921682-7	2005	Ang II-induced Ser307 and Ser616 phophorylation of IRS-1 was inhibited by a MEK inhibitor, PD98059, and a JNK inhibitor, SP600125.	pyrazolanthrone	121-129	angiotensinogen	Rattus norvegicus	0-6
15921682-7	2005	Ang II-induced Ser307 and Ser616 phophorylation of IRS-1 was inhibited by a MEK inhibitor, PD98059, and a JNK inhibitor, SP600125.	pyrazolanthrone	121-129	insulin receptor substrate 1	Rattus norvegicus	51-56
15921682-7	2005	Ang II-induced Ser307 and Ser616 phophorylation of IRS-1 was inhibited by a MEK inhibitor, PD98059, and a JNK inhibitor, SP600125.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Rattus norvegicus	106-109
15963474-7	2005	MAPK inhibitors (U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) specifically blocked LPS-induced COX-2 expression.	pyrazolanthrone	63-71	mitogen-activated protein kinase 1	Mus musculus	0-4
15963474-7	2005	MAPK inhibitors (U0126 for MEK1/2, SB203580 for p38 kinase and SP600125 for JNK) specifically blocked LPS-induced COX-2 expression.	pyrazolanthrone	63-71	prostaglandin-endoperoxide synthase 2	Mus musculus	114-119
15936998-12	2005	Moreover, SP600125, a specific inhibitor of JNK, suppressed Bax expression induced by syndecan-2 overexpression, indicating that JNK activation mediates syndecan-2-induced apoptosis.	pyrazolanthrone	10-18	mitogen-activated protein kinase 8	Homo sapiens	44-47
15936998-12	2005	Moreover, SP600125, a specific inhibitor of JNK, suppressed Bax expression induced by syndecan-2 overexpression, indicating that JNK activation mediates syndecan-2-induced apoptosis.	pyrazolanthrone	10-18	BCL2 associated X, apoptosis regulator	Homo sapiens	60-63
15936998-12	2005	Moreover, SP600125, a specific inhibitor of JNK, suppressed Bax expression induced by syndecan-2 overexpression, indicating that JNK activation mediates syndecan-2-induced apoptosis.	pyrazolanthrone	10-18	syndecan 2	Homo sapiens	86-96
15936998-12	2005	Moreover, SP600125, a specific inhibitor of JNK, suppressed Bax expression induced by syndecan-2 overexpression, indicating that JNK activation mediates syndecan-2-induced apoptosis.	pyrazolanthrone	10-18	mitogen-activated protein kinase 8	Homo sapiens	129-132
15936998-12	2005	Moreover, SP600125, a specific inhibitor of JNK, suppressed Bax expression induced by syndecan-2 overexpression, indicating that JNK activation mediates syndecan-2-induced apoptosis.	pyrazolanthrone	10-18	syndecan 2	Homo sapiens	153-163
15917298-7	2005	Jnk-deficient mouse embryo fibroblasts (MEFs) were highly resistant to doxorubicin compared with wild type (WT), as were WT Jurkat cells treated with SP600125, further supporting the importance of JNK in doxorubicin-induced apoptosis.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Mus musculus	0-3
15734884-8	2005	Moreover, inhibition of JNK with SP-600125 or dominant negative MKK7 inhibited only p21Cip1/Waf1 induction, whereas the p38 MAPK inhibitor SB-203580 or dominant negative MKK4 inhibited both p21Cip1/Waf1 and p53 induction.	pyrazolanthrone	33-42	mitogen-activated protein kinase 8	Homo sapiens	24-27
16132679-5	2005	The addition of curcumin, nicotinamide and Jun N-terminal kinase (JNK) inhibitor, SP 600125, reduced the levels of NO, iNOS expression and nitration of proteins in macrophages.	pyrazolanthrone	82-91	mitogen-activated protein kinase 8	Mus musculus	66-69
16132679-5	2005	The addition of curcumin, nicotinamide and Jun N-terminal kinase (JNK) inhibitor, SP 600125, reduced the levels of NO, iNOS expression and nitration of proteins in macrophages.	pyrazolanthrone	82-91	nitric oxide synthase 2, inducible	Mus musculus	119-123
15993704-4	2005	However, inhibition of JNK phosphorylation with the specific inhibitor SP600125 increases apoptosis in a manner refractory to the addition of EGF but inhibition of p38 phosphorylation with its specific inhibitor SB 203580 does not increase apoptosis.	pyrazolanthrone	71-79	mitogen-activated protein kinase 8	Homo sapiens	23-26
15979399-7	2005	PD98059, an ERK inhibitor, SB203580, a p38 inhibitor, and SP600125, an JNK inhibitor, abolished the stimulation of all three members of the MAPK family by oxLDL.	pyrazolanthrone	58-66	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
15979399-7	2005	PD98059, an ERK inhibitor, SB203580, a p38 inhibitor, and SP600125, an JNK inhibitor, abolished the stimulation of all three members of the MAPK family by oxLDL.	pyrazolanthrone	58-66	mitogen activated protein kinase 3	Rattus norvegicus	140-144
15964311-10	2005	Both SP600125 and SB203580 significantly prevented the phosphorylation of JNK and p38 proteins, but not ERK.	pyrazolanthrone	5-13	mitogen-activated protein kinase 8	Homo sapiens	74-77
15964311-10	2005	Both SP600125 and SB203580 significantly prevented the phosphorylation of JNK and p38 proteins, but not ERK.	pyrazolanthrone	5-13	mitogen-activated protein kinase 14	Homo sapiens	82-85
16009787-9	2005	Blocking of p38, ERK, or JNK with SB203580 (P&lt;0.0001), PD98059 (P&lt;0.0001), or SP600125 (P&lt;0.0001), respectively, impaired histamine-induced TF expression in a concentration-dependent manner.	pyrazolanthrone	84-92	mitogen-activated protein kinase 8	Homo sapiens	25-28
16000878-4	2005	Among several signal pathway inhibitors tested, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, completely blocked the CD9-stimulated MMP-2 expression.	pyrazolanthrone	61-69	mitogen-activated protein kinase 14	Homo sapiens	85-88
15922728-11	2005	In addition, using SP600125, JNK inhibitor, we demonstrated that CD437 activates the JNK-MAP kinase signaling pathway upstream to mitochondrial and caspase-8 pathways.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	85-88
15922728-11	2005	In addition, using SP600125, JNK inhibitor, we demonstrated that CD437 activates the JNK-MAP kinase signaling pathway upstream to mitochondrial and caspase-8 pathways.	pyrazolanthrone	19-27	caspase 8	Homo sapiens	148-157
15831436-7	2005	MMPT-induced apoptosis was abrogated when c-Jun N-terminal kinase (JNK) activation was blocked with a specific JNK inhibitor, SP600125.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	42-65
15831436-7	2005	MMPT-induced apoptosis was abrogated when c-Jun N-terminal kinase (JNK) activation was blocked with a specific JNK inhibitor, SP600125.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	67-70
15831436-7	2005	MMPT-induced apoptosis was abrogated when c-Jun N-terminal kinase (JNK) activation was blocked with a specific JNK inhibitor, SP600125.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	111-114
15947258-10	2005	The JNK signaling pathway was activated in the basilar artery after SAH and SP600125 reduced angiographic and morphological vasospasm and improved behavior scores with a concomitant reduction of infiltrated leukocytes and IL-6 production.	pyrazolanthrone	76-84	interleukin 6	Canis lupus familiaris	222-226
16082182-7	2005	Blocking JNK activation with the JNK inhibitor SP600125 attenuated DR5 increase, but enhancement of apoptosis induction and increase of Bik protein were not affected.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	9-12
16082182-7	2005	Blocking JNK activation with the JNK inhibitor SP600125 attenuated DR5 increase, but enhancement of apoptosis induction and increase of Bik protein were not affected.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	33-36
16082182-7	2005	Blocking JNK activation with the JNK inhibitor SP600125 attenuated DR5 increase, but enhancement of apoptosis induction and increase of Bik protein were not affected.	pyrazolanthrone	47-55	TNF receptor superfamily member 10b	Homo sapiens	67-70
15838870-4	2005	Co-administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c-Jun, but did not affect neuroprotection by the CDK5 inhibitor.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	81-84
15838870-4	2005	Co-administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c-Jun, but did not affect neuroprotection by the CDK5 inhibitor.	pyrazolanthrone	55-63	mitogen-activated protein kinase 3	Homo sapiens	113-119
15838870-4	2005	Co-administration of U0126, an inhibitor of ERK1/2, or SP600125, an inhibitor of JNK, blocked phosphorylation of ERK1/2 or c-Jun, but did not affect neuroprotection by the CDK5 inhibitor.	pyrazolanthrone	55-63	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	123-128
15936351-6	2005	On the other hand, the JNKs and p38 inhibitor SP600125 and SB203580 additively enhanced the cytoprotective effect of PCF.	pyrazolanthrone	46-54	mitogen-activated protein kinase 14	Mus musculus	32-35
16000878-4	2005	Among several signal pathway inhibitors tested, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, completely blocked the CD9-stimulated MMP-2 expression.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	98-101
16000878-4	2005	Among several signal pathway inhibitors tested, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, completely blocked the CD9-stimulated MMP-2 expression.	pyrazolanthrone	61-69	CD9 molecule	Homo sapiens	139-142
16000878-4	2005	Among several signal pathway inhibitors tested, SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, completely blocked the CD9-stimulated MMP-2 expression.	pyrazolanthrone	61-69	matrix metallopeptidase 2	Homo sapiens	154-159
15917192-8	2005	An upstream JNK inhibitor (CEP11004) and a competitive JNK inhibitor (SP600125) both partially protected the DC from the proapoptotic effects of hydrogen peroxide.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Homo sapiens	55-58
15958059-5	2005	Furthermore, PAI-1 expression by onnamide A, theopederin B, and anisomycin was inhibited by SB202190 and SP600125, specific inhibitors of stress-activated protein kinases.	pyrazolanthrone	105-113	serpin family E member 1	Homo sapiens	13-18
15884019-5	2005	The upregulation of PrP(C) and Hsp70 under hypoglycemic conditions was disrupted by the specific JNK inhibitor SP600125.	pyrazolanthrone	111-119	prion protein	Mus musculus	20-26
15884019-5	2005	The upregulation of PrP(C) and Hsp70 under hypoglycemic conditions was disrupted by the specific JNK inhibitor SP600125.	pyrazolanthrone	111-119	heat shock protein 1B	Mus musculus	31-36
15884019-5	2005	The upregulation of PrP(C) and Hsp70 under hypoglycemic conditions was disrupted by the specific JNK inhibitor SP600125.	pyrazolanthrone	111-119	mitogen-activated protein kinase 8	Mus musculus	97-100
15701817-2	2005	Therefore, the present study was carried out to examine whether JNK is involved in ANG II-induced cell proliferation in cultured human mesangial cells (HMCs) with the use of a newly developed JNK-selective blocker, SP-600125.	pyrazolanthrone	215-224	mitogen-activated protein kinase 8	Homo sapiens	64-67
15701817-2	2005	Therefore, the present study was carried out to examine whether JNK is involved in ANG II-induced cell proliferation in cultured human mesangial cells (HMCs) with the use of a newly developed JNK-selective blocker, SP-600125.	pyrazolanthrone	215-224	angiotensinogen	Homo sapiens	83-89
15701817-2	2005	Therefore, the present study was carried out to examine whether JNK is involved in ANG II-induced cell proliferation in cultured human mesangial cells (HMCs) with the use of a newly developed JNK-selective blocker, SP-600125.	pyrazolanthrone	215-224	mitogen-activated protein kinase 8	Homo sapiens	192-195
15701817-5	2005	SP-600125 ranging from 5 to 10 microM almost completely abolished the activation of JNK by ANG II without affecting the activities of Erk1/2 and p38.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Homo sapiens	84-87
15701817-5	2005	SP-600125 ranging from 5 to 10 microM almost completely abolished the activation of JNK by ANG II without affecting the activities of Erk1/2 and p38.	pyrazolanthrone	0-9	angiotensinogen	Homo sapiens	91-97
15701817-7	2005	Similarly, SP-600125 dose dependently reduced the ANG II-induced increase in cell number.	pyrazolanthrone	11-20	angiotensinogen	Homo sapiens	50-56
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	18-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	137-142
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	18-26	mitogen-activated protein kinase 14	Homo sapiens	194-197
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	18-26	nuclear factor kappa B subunit 1	Homo sapiens	202-210
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	18-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	211-214
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	18-26	RELA proto-oncogene, NF-kB subunit	Homo sapiens	215-219
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	269-277	mitogen-activated protein kinase 8	Homo sapiens	4-7
15971988-6	2005	The JNK inhibitor SP600125 was used as a demonstration compound because in addition to inhibiting nuclear accumulation of phosphorylated c-Jun it reduced nuclear translocation of phosphorylated p38 and NFkappaB p65/RelA in a dose-dependent manner, indicating a lack of SP600125 selectivity.	pyrazolanthrone	269-277	RELA proto-oncogene, NF-kB subunit	Homo sapiens	215-219
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	interleukin 6	Homo sapiens	0-4
15701058-9	2005	Furthermore, specific MAPK inhibitors (PD98059, SB203580 and SP600125) inhibited the expression of IL-8 mRNA induced by CRP (50 microg/ml).	pyrazolanthrone	61-69	C-X-C motif chemokine ligand 8	Homo sapiens	99-103
15701058-9	2005	Furthermore, specific MAPK inhibitors (PD98059, SB203580 and SP600125) inhibited the expression of IL-8 mRNA induced by CRP (50 microg/ml).	pyrazolanthrone	61-69	C-reactive protein	Homo sapiens	120-123
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	interleukin 1 alpha	Homo sapiens	27-31
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	tumor necrosis factor	Homo sapiens	33-42
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	interleukin 17A	Homo sapiens	48-53
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Homo sapiens	88-115
15716857-4	2005	Systemic administration of SP600125, a small molecule JNK-specific inhibitor, diminished JNK activity after ischemia and dose-dependently reduced infarct volume.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	54-57
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Homo sapiens	117-120
15716857-4	2005	Systemic administration of SP600125, a small molecule JNK-specific inhibitor, diminished JNK activity after ischemia and dose-dependently reduced infarct volume.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	89-92
15843470-3	2005	IL-6 production induced by IL-1, TNF-alpha, and IL-17 was specifically inhibited by the c-jun NH(2)-terminal kinase (JNK) inhibitor SP600125, but not by a selective inhibitor of p38 MAPK, and was moderately increased when the ERK1/2 pathway was inhibited.	pyrazolanthrone	132-140	mitogen-activated protein kinase 3	Homo sapiens	226-232
15843470-6	2005	Furthermore, IL-1-induced transcriptional activation of the IL-6 promotor was repressed by SP600125 or by co-transfection of a dominant-negative expression plasmid of c-jun even in the absence of a functional AP-1 binding site.	pyrazolanthrone	91-99	interleukin 1 alpha	Homo sapiens	13-17
15843470-6	2005	Furthermore, IL-1-induced transcriptional activation of the IL-6 promotor was repressed by SP600125 or by co-transfection of a dominant-negative expression plasmid of c-jun even in the absence of a functional AP-1 binding site.	pyrazolanthrone	91-99	interleukin 6	Homo sapiens	60-64
15930183-15	2005	The specific c-Jun phosphorylation inhibitor SP600125 dose dependently inhibited c-Jun phosphorylation and VDR expression.	pyrazolanthrone	45-53	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	13-18
15930183-15	2005	The specific c-Jun phosphorylation inhibitor SP600125 dose dependently inhibited c-Jun phosphorylation and VDR expression.	pyrazolanthrone	45-53	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	81-86
15930183-15	2005	The specific c-Jun phosphorylation inhibitor SP600125 dose dependently inhibited c-Jun phosphorylation and VDR expression.	pyrazolanthrone	45-53	vitamin D receptor	Homo sapiens	107-110
15677771-6	2005	SP600125, a specific c-Jun N-terminal kinase (JNK) inhibitor, inhibited the effect of IL-1beta.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	21-60
15735060-4	2005	Systemic inhibition of c-Jun N-terminal kinase, with the specific c-Jun N-terminal kinase inhibitor SP600125, decreased the LPS-induced accumulation of neutrophils into the lung parenchyma and alveolar space.	pyrazolanthrone	100-108	interferon regulatory factor 6	Homo sapiens	124-127
15735060-7	2005	Neutrophil actin assembly was decreased after LPS and TNF-alpha stimulation with SP600125 pretreatment, as well as LPS-induced neutrophil retention.	pyrazolanthrone	81-89	interferon regulatory factor 6	Homo sapiens	46-49
15880353-5	2005	Moreover, to determine whether an intracellular signaling pathway mediates the IL-1beta-induced increase in sAPP(alpha) secretion, we used various specific signaling inhibitors and found that sAPP(alpha) release is significantly blocked by the mitogen-activated protein kinase (MEK1/2) inhibitor PD98059 and the c-Jun N-terminal kinase inhibitor SP600125.	pyrazolanthrone	346-354	interleukin 1 beta	Homo sapiens	79-87
15956247-9	2005	The c-Jun-NH(2)-kinase (JNK) inhibitor SP 600125, but not p38 mitogen-activated protein kinase inhibitor SB 203580 or extracellular signal-regulated kinase inhibitor PD 98059, blocked PRIMA-1-induced apoptosis.	pyrazolanthrone	39-48	mitogen-activated protein kinase 8	Homo sapiens	4-22
15956247-9	2005	The c-Jun-NH(2)-kinase (JNK) inhibitor SP 600125, but not p38 mitogen-activated protein kinase inhibitor SB 203580 or extracellular signal-regulated kinase inhibitor PD 98059, blocked PRIMA-1-induced apoptosis.	pyrazolanthrone	39-48	mitogen-activated protein kinase 8	Homo sapiens	24-27
15885221-5	2005	Moreover, co-injection of inhibitors for JNK (0.2 nmol SP600125) and/or p38 (2.0 nmol SB203580) with NMDA was effective in ameliorating NMDA-induced apoptotic cell loss in the RGCL 12 h after injection, as shown by TUNEL-positive cell counts.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Rattus norvegicus	41-44
15753078-5	2005	Accordingly, SP600125, the inhibitor of JNK, and wortmannin, the inhibitor of phosphatidylinositol 3-kinase, which is the upstream activator of PKB, inhibited the increase in the cellular content of p21.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Homo sapiens	40-43
15753078-5	2005	Accordingly, SP600125, the inhibitor of JNK, and wortmannin, the inhibitor of phosphatidylinositol 3-kinase, which is the upstream activator of PKB, inhibited the increase in the cellular content of p21.	pyrazolanthrone	13-21	H3 histone pseudogene 16	Homo sapiens	199-202
15735060-7	2005	Neutrophil actin assembly was decreased after LPS and TNF-alpha stimulation with SP600125 pretreatment, as well as LPS-induced neutrophil retention.	pyrazolanthrone	81-89	tumor necrosis factor	Homo sapiens	54-63
15677771-6	2005	SP600125, a specific c-Jun N-terminal kinase (JNK) inhibitor, inhibited the effect of IL-1beta.	pyrazolanthrone	0-8	interleukin 1 beta	Homo sapiens	86-94
15718494-7	2005	SP600125, a c-Jun N-terminal kinase inhibitor, decreased the c-Jun phosphorylation, DNA binding of AP-1, and l-PGDS expression induced by shear stress.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	12-17
15965068-8	2005	Celecoxib-induced HO-1 expression was attenuated by pretreatment of the cells with SP 600125 (a specific JNK inhibitor), but not SB 203580 (a specific p38 MAPK inhibitor), or PD 98059 (a specific MEK inhibitor).	pyrazolanthrone	83-92	heme oxygenase 1	Homo sapiens	18-22
15965068-8	2005	Celecoxib-induced HO-1 expression was attenuated by pretreatment of the cells with SP 600125 (a specific JNK inhibitor), but not SB 203580 (a specific p38 MAPK inhibitor), or PD 98059 (a specific MEK inhibitor).	pyrazolanthrone	83-92	mitogen-activated protein kinase 8	Homo sapiens	105-108
15718494-7	2005	SP600125, a c-Jun N-terminal kinase inhibitor, decreased the c-Jun phosphorylation, DNA binding of AP-1, and l-PGDS expression induced by shear stress.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	61-66
15718494-7	2005	SP600125, a c-Jun N-terminal kinase inhibitor, decreased the c-Jun phosphorylation, DNA binding of AP-1, and l-PGDS expression induced by shear stress.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	99-103
15718494-7	2005	SP600125, a c-Jun N-terminal kinase inhibitor, decreased the c-Jun phosphorylation, DNA binding of AP-1, and l-PGDS expression induced by shear stress.	pyrazolanthrone	0-8	prostaglandin D2 synthase	Homo sapiens	109-115
15981086-4	2005	SP600125, a specific inhibitor of JNK, inhibited JNK MAPK phosphorylation, indicating the specificity of the above response.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	34-37
15981086-4	2005	SP600125, a specific inhibitor of JNK, inhibited JNK MAPK phosphorylation, indicating the specificity of the above response.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	49-52
15981086-7	2005	The rF1-induced JNK MAPK activity was correlated to the functional activation of macrophages by demonstrating the inhibition of NO, TNF-alpha production and microtubule polymerization caused by SP600125.	pyrazolanthrone	194-202	Renal disease susceptibility QTL 1	Rattus norvegicus	4-7
15981086-7	2005	The rF1-induced JNK MAPK activity was correlated to the functional activation of macrophages by demonstrating the inhibition of NO, TNF-alpha production and microtubule polymerization caused by SP600125.	pyrazolanthrone	194-202	mitogen-activated protein kinase 8	Mus musculus	16-19
15981086-7	2005	The rF1-induced JNK MAPK activity was correlated to the functional activation of macrophages by demonstrating the inhibition of NO, TNF-alpha production and microtubule polymerization caused by SP600125.	pyrazolanthrone	194-202	tumor necrosis factor	Mus musculus	132-141
15769552-3	2005	By using various inhibitors of signal transduction, we found that p38 mitogen-activated protein kinases (MAPK) activation (inhibitor SB202190), but not extracellular signal-regulated kinase (ERK) (PD98059) and c-jun N-terminal kinase (JNK)(SP600125), is essential in the NECA-induced signalling cascade that leads to the increase in IL-6 synthesis in U373 MG cells.	pyrazolanthrone	240-248	mitogen-activated protein kinase 1	Homo sapiens	66-69
15879678-7	2005	Pretreatment of SAS cells with SP600125, a JNK/SAPK inhibitor, diminished Lfn-induced apoptosis, as assessed by determining released lactate dehydrogenase activity.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	43-51
15703383-5	2005	Reduction of Bcl-2 phosphorylation by the specific JNK inhibitor (anthra(1,3-cd)pyrazol-6(2H)-one) SP600125 suggested a crucial role for JNK in this process.	pyrazolanthrone	99-107	BCL2 apoptosis regulator	Homo sapiens	13-18
15703383-5	2005	Reduction of Bcl-2 phosphorylation by the specific JNK inhibitor (anthra(1,3-cd)pyrazol-6(2H)-one) SP600125 suggested a crucial role for JNK in this process.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	51-54
15769552-3	2005	By using various inhibitors of signal transduction, we found that p38 mitogen-activated protein kinases (MAPK) activation (inhibitor SB202190), but not extracellular signal-regulated kinase (ERK) (PD98059) and c-jun N-terminal kinase (JNK)(SP600125), is essential in the NECA-induced signalling cascade that leads to the increase in IL-6 synthesis in U373 MG cells.	pyrazolanthrone	240-248	mitogen-activated protein kinase 1	Homo sapiens	105-109
15626722-3	2005	We hypothesize that inhibiting JNK will lead to the inhibition of tumor growth; therefore, we evaluated the efficacy of the recently described JNK inhibitor SP600125 [anthra[1,9-cd] pyrazol-6 (2H)-one].	pyrazolanthrone	157-165	mitogen-activated protein kinase 8	Homo sapiens	143-146
15793284-9	2005	The JNK pathway may be involved in migration of resident HSCs within the space of Disse to the sites of tissue damage because the JNK inhibitor SP600125 inhibited HSC migration induced by TGF-beta and PDGF signals.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Rattus norvegicus	4-7
15793284-9	2005	The JNK pathway may be involved in migration of resident HSCs within the space of Disse to the sites of tissue damage because the JNK inhibitor SP600125 inhibited HSC migration induced by TGF-beta and PDGF signals.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Rattus norvegicus	130-133
15793284-9	2005	The JNK pathway may be involved in migration of resident HSCs within the space of Disse to the sites of tissue damage because the JNK inhibitor SP600125 inhibited HSC migration induced by TGF-beta and PDGF signals.	pyrazolanthrone	144-152	transforming growth factor, beta 1	Rattus norvegicus	188-196
15748885-6	2005	Pretreatment with the JNK inhibitor SP600125 resulted in a significant decrease in capillary areas under control conditions as well as under conditions of electrical field treatment, whereas the p38 inhibitor SB203580 was without effects.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	22-25
15833106-14	2005	Using a murine asthma model of late phase eosinophilia, we demonstrated that the ERK inhibitor U0126 and the JNK inhibitor SP600125 inhibited lung inflammation in vivo.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Mus musculus	109-112
15795326-6	2005	TF expression was reduced in a concentration-dependent manner by pretreatment with SP600125 (10(-7) to 10(-6) mol/L), a specific inhibitor of JNK, which confirms that JNK regulates tumor necrosis factor-alpha-induced TF expression.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	142-145
15795326-6	2005	TF expression was reduced in a concentration-dependent manner by pretreatment with SP600125 (10(-7) to 10(-6) mol/L), a specific inhibitor of JNK, which confirms that JNK regulates tumor necrosis factor-alpha-induced TF expression.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Homo sapiens	167-170
15795326-6	2005	TF expression was reduced in a concentration-dependent manner by pretreatment with SP600125 (10(-7) to 10(-6) mol/L), a specific inhibitor of JNK, which confirms that JNK regulates tumor necrosis factor-alpha-induced TF expression.	pyrazolanthrone	83-91	tumor necrosis factor	Homo sapiens	181-208
15668325-8	2005	The downstream effector of p38, heat shock protein 27, also was phosphorylated rapidly after injury; phosphorylation could be blocked by prior treatment with SB203580 but not SP600125.	pyrazolanthrone	175-183	mitogen-activated protein kinase 1	Homo sapiens	27-30
15721273-5	2005	CSE activated c-Jun N-terminal kinase (JNK), and treatment of HUVECs with SP600125, a specific inhibitor of the JNK pathway, significantly suppressed endothelial cell damage by CSE.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	14-37
15721273-5	2005	CSE activated c-Jun N-terminal kinase (JNK), and treatment of HUVECs with SP600125, a specific inhibitor of the JNK pathway, significantly suppressed endothelial cell damage by CSE.	pyrazolanthrone	74-82	mitogen-activated protein kinase 8	Homo sapiens	112-115
15806010-7	2005	RESULTS: SP600125 at 10 microM drastically inhibited JNK phosphorylation but had little effect on CD40-mediated p38 phosphorylation and expression of the NF-kappaB dependent genes c-Myc and bcl-xL.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Mus musculus	53-56
15806010-7	2005	RESULTS: SP600125 at 10 microM drastically inhibited JNK phosphorylation but had little effect on CD40-mediated p38 phosphorylation and expression of the NF-kappaB dependent genes c-Myc and bcl-xL.	pyrazolanthrone	9-17	BCL2-like 1	Mus musculus	190-196
15626722-4	2005	SP600125 is an anthrapyrazole that is a reversible, ATP-competitive inhibitor of JNK1/2.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	81-87
15788689-7	2005	The JNK inhibitor SP600125 substantially decreased the activation of caspases and apoptosis induced by MSeA combination with SN38 or etoposide and completely blocked these events induced by MSeA/paclitaxel.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
15781658-7	2005	However, inhibition of JNK activation (e.g., by the JNK inhibitor SP600125) did not attenuate sodium butyrate/perifosine-induced apoptosis.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	23-26
15788689-7	2005	The JNK inhibitor SP600125 substantially decreased the activation of caspases and apoptosis induced by MSeA combination with SN38 or etoposide and completely blocked these events induced by MSeA/paclitaxel.	pyrazolanthrone	18-26	caspase 8	Homo sapiens	69-77
15781658-7	2005	However, inhibition of JNK activation (e.g., by the JNK inhibitor SP600125) did not attenuate sodium butyrate/perifosine-induced apoptosis.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	52-55
15728454-5	2005	However, the IL-4 induction of SOCS3 is blocked by inhibitors of either the JNK or p38 MAPK pathways (SP600125 and SB203580, respectively).	pyrazolanthrone	102-110	interleukin 4	Mus musculus	13-17
15670752-5	2005	TLR2 expression in response to TPA was attenuated by pretreatments with GF109203X and Go6976 (inhibitors of protein kinase C (PKC)) and PD98059 (an inhibitor of extracellular signal-regulated kinases (ERKs)), but not SB203580 (an inhibitor of p38s) and SP600125 (an inhibitor of c-Jun N-terminal kinases), suggesting involvement of PKC and ERKs in this response.	pyrazolanthrone	253-261	toll like receptor 2	Homo sapiens	0-4
15824967-4	2005	SP600125, a specific inhibitor of SAPK/JNK, markedly reduced TGF-beta-induced VEGF synthesis.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Mus musculus	78-82
15824967-5	2005	SP600125 suppressed TGF-beta-induced SAPK/JNK phosphorylation.	pyrazolanthrone	0-8	transforming growth factor, beta 1	Mus musculus	20-28
15824967-7	2005	A combination of SP600125 and PD98059 or SP600125 and SB203580 suppressed TGF-beta-stimulated VEGF synthesis in an additive manner.	pyrazolanthrone	17-25	transforming growth factor, beta 1	Mus musculus	74-82
15824967-7	2005	A combination of SP600125 and PD98059 or SP600125 and SB203580 suppressed TGF-beta-stimulated VEGF synthesis in an additive manner.	pyrazolanthrone	17-25	vascular endothelial growth factor A	Mus musculus	94-98
15824967-7	2005	A combination of SP600125 and PD98059 or SP600125 and SB203580 suppressed TGF-beta-stimulated VEGF synthesis in an additive manner.	pyrazolanthrone	41-49	transforming growth factor, beta 1	Mus musculus	74-82
15824967-7	2005	A combination of SP600125 and PD98059 or SP600125 and SB203580 suppressed TGF-beta-stimulated VEGF synthesis in an additive manner.	pyrazolanthrone	41-49	vascular endothelial growth factor A	Mus musculus	94-98
15721365-5	2005	Pre-treatment of NS3 protein-expressing cells with JNK inhibitor, SP600125, abolished activation of AP-1 and ATF-2 and inhibited c-jun expression and induced cell growth, suggesting that JNK activation is essential for the stimulation of NS3-mediated cell growth.	pyrazolanthrone	66-74	KRAS proto-oncogene, GTPase	Homo sapiens	17-20
15721365-5	2005	Pre-treatment of NS3 protein-expressing cells with JNK inhibitor, SP600125, abolished activation of AP-1 and ATF-2 and inhibited c-jun expression and induced cell growth, suggesting that JNK activation is essential for the stimulation of NS3-mediated cell growth.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	51-54
15721365-5	2005	Pre-treatment of NS3 protein-expressing cells with JNK inhibitor, SP600125, abolished activation of AP-1 and ATF-2 and inhibited c-jun expression and induced cell growth, suggesting that JNK activation is essential for the stimulation of NS3-mediated cell growth.	pyrazolanthrone	66-74	activating transcription factor 2	Homo sapiens	109-114
15721365-5	2005	Pre-treatment of NS3 protein-expressing cells with JNK inhibitor, SP600125, abolished activation of AP-1 and ATF-2 and inhibited c-jun expression and induced cell growth, suggesting that JNK activation is essential for the stimulation of NS3-mediated cell growth.	pyrazolanthrone	66-74	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	129-134
15721365-5	2005	Pre-treatment of NS3 protein-expressing cells with JNK inhibitor, SP600125, abolished activation of AP-1 and ATF-2 and inhibited c-jun expression and induced cell growth, suggesting that JNK activation is essential for the stimulation of NS3-mediated cell growth.	pyrazolanthrone	66-74	mitogen-activated protein kinase 8	Homo sapiens	187-190
15721365-5	2005	Pre-treatment of NS3 protein-expressing cells with JNK inhibitor, SP600125, abolished activation of AP-1 and ATF-2 and inhibited c-jun expression and induced cell growth, suggesting that JNK activation is essential for the stimulation of NS3-mediated cell growth.	pyrazolanthrone	66-74	KRAS proto-oncogene, GTPase	Homo sapiens	238-241
15824967-4	2005	SP600125, a specific inhibitor of SAPK/JNK, markedly reduced TGF-beta-induced VEGF synthesis.	pyrazolanthrone	0-8	transforming growth factor, beta 1	Mus musculus	61-69
15728454-5	2005	However, the IL-4 induction of SOCS3 is blocked by inhibitors of either the JNK or p38 MAPK pathways (SP600125 and SB203580, respectively).	pyrazolanthrone	102-110	suppressor of cytokine signaling 3	Mus musculus	31-36
15728454-5	2005	However, the IL-4 induction of SOCS3 is blocked by inhibitors of either the JNK or p38 MAPK pathways (SP600125 and SB203580, respectively).	pyrazolanthrone	102-110	mitogen-activated protein kinase 14	Mus musculus	83-91
15767555-7	2005	Finally, inhibition of the stress-related JNK by SP600125 or by the expression of a dominant-negative mutant of c-Jun significantly attenuated apoptosis induced by rapamycin/UCN-01.	pyrazolanthrone	49-57	mitogen-activated protein kinase 8	Homo sapiens	42-45
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	pyrazolanthrone	137-146	interleukin 1 beta	Homo sapiens	14-22
15710173-5	2005	We found that Bax and Bak translocated to mitochondria apparently, whereas Fas ligand (FasL) was unchanged after a treatment with luteolin for 3 h. In addition, it showed that c-Jun NH2-terminal kinase (JNK) was activated after the treatment of luteolin for 3-12 h. Further investigation showed that a specific JNK inhibitor, SP600125, reduced the activation of CPP 32, the mitochondrial translocation of Bax, as well as the cytosolic release of cytochrome c that induced by luteolin.	pyrazolanthrone	326-334	mitogen-activated protein kinase 8	Homo sapiens	176-201
15710173-5	2005	We found that Bax and Bak translocated to mitochondria apparently, whereas Fas ligand (FasL) was unchanged after a treatment with luteolin for 3 h. In addition, it showed that c-Jun NH2-terminal kinase (JNK) was activated after the treatment of luteolin for 3-12 h. Further investigation showed that a specific JNK inhibitor, SP600125, reduced the activation of CPP 32, the mitochondrial translocation of Bax, as well as the cytosolic release of cytochrome c that induced by luteolin.	pyrazolanthrone	326-334	mitogen-activated protein kinase 8	Homo sapiens	203-206
15710173-6	2005	Finally, the apoptosis induced by luteolin was suppressed by a pretreatment with SP600125 via evaluating annexin V-FITC binding assay.	pyrazolanthrone	81-89	annexin A5	Homo sapiens	105-114
15713276-0	2005	The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Rattus norvegicus	59-62
15713276-0	2005	The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways.	pyrazolanthrone	30-38	carbonic anhydrase 1	Rattus norvegicus	146-149
15713276-3	2005	Our results demonstrated that SP600125 significantly increased the number of surviving cells in hippocampal CA1 subfield and decreased the activation of p-JNK1/2 and p-JNK3 at 30 min and 3 days after brain ischemia.	pyrazolanthrone	30-38	carbonic anhydrase 1	Rattus norvegicus	108-111
15713276-3	2005	Our results demonstrated that SP600125 significantly increased the number of surviving cells in hippocampal CA1 subfield and decreased the activation of p-JNK1/2 and p-JNK3 at 30 min and 3 days after brain ischemia.	pyrazolanthrone	30-38	mitogen activated protein kinase 10	Rattus norvegicus	168-172
15713276-4	2005	Moreover, SP600125 significantly diminished the increased levels of phosphorylated-c-Jun (Ser63/73) and phosphorylated-Bcl-2 (Ser87) at 3 h after brain ischemia.	pyrazolanthrone	10-18	BCL2, apoptosis regulator	Rattus norvegicus	119-124
15713276-5	2005	These results indicate that SP600125, a new inhibitor of JNK, protected transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 region at least via suppressing the activation of nuclear substrate (c-Jun) and inactivating non-nuclear substrate (Bcl-2) induced by ischemic insult.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Rattus norvegicus	57-60
15713276-5	2005	These results indicate that SP600125, a new inhibitor of JNK, protected transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 region at least via suppressing the activation of nuclear substrate (c-Jun) and inactivating non-nuclear substrate (Bcl-2) induced by ischemic insult.	pyrazolanthrone	28-36	carbonic anhydrase 1	Rattus norvegicus	151-154
15713276-5	2005	These results indicate that SP600125, a new inhibitor of JNK, protected transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 region at least via suppressing the activation of nuclear substrate (c-Jun) and inactivating non-nuclear substrate (Bcl-2) induced by ischemic insult.	pyrazolanthrone	28-36	BCL2, apoptosis regulator	Rattus norvegicus	271-276
15713276-6	2005	Thus, inhibiting JNK activity by SP600125 may represent a new and effective strategy to treat ischemic stoke.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
15680548-8	2005	Inhibition of JNK by SP600125 reduced increases in C/EBP beta and alpha-synuclein expression, whereas inhibition of both JNK and p38MAPK (with SB203580) blocked the increase in GADD153 expression.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
15680548-8	2005	Inhibition of JNK by SP600125 reduced increases in C/EBP beta and alpha-synuclein expression, whereas inhibition of both JNK and p38MAPK (with SB203580) blocked the increase in GADD153 expression.	pyrazolanthrone	21-29	CCAAT enhancer binding protein beta	Homo sapiens	51-61
15629451-10	2005	IL-1beta plus IFN-gamma-induced synergistic production of HGF was potently inhibited by treatment of cells with the extracellular signal-regulated kinase (ERK) kinase inhibitor PD98059 and the p38 inhibitor SB203580 but not by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	271-279	interleukin 1 beta	Homo sapiens	0-8
15629451-10	2005	IL-1beta plus IFN-gamma-induced synergistic production of HGF was potently inhibited by treatment of cells with the extracellular signal-regulated kinase (ERK) kinase inhibitor PD98059 and the p38 inhibitor SB203580 but not by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	271-279	interferon gamma	Homo sapiens	14-23
15629451-10	2005	IL-1beta plus IFN-gamma-induced synergistic production of HGF was potently inhibited by treatment of cells with the extracellular signal-regulated kinase (ERK) kinase inhibitor PD98059 and the p38 inhibitor SB203580 but not by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	271-279	hepatocyte growth factor	Homo sapiens	58-61
15629451-10	2005	IL-1beta plus IFN-gamma-induced synergistic production of HGF was potently inhibited by treatment of cells with the extracellular signal-regulated kinase (ERK) kinase inhibitor PD98059 and the p38 inhibitor SB203580 but not by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	271-279	mitogen-activated protein kinase 1	Homo sapiens	155-158
15489374-3	2005	IL-1beta induced expression of VCAM-1 protein and mRNA in a time-dependent manner, which was significantly inhibited by inhibitors of MEK1/2 (U0126 and PD-98059), p38 (SB-202190), and c-Jun NH(2)-terminal kinase (JNK; SP-600125).	pyrazolanthrone	218-227	interleukin 1 beta	Homo sapiens	0-8
15489374-3	2005	IL-1beta induced expression of VCAM-1 protein and mRNA in a time-dependent manner, which was significantly inhibited by inhibitors of MEK1/2 (U0126 and PD-98059), p38 (SB-202190), and c-Jun NH(2)-terminal kinase (JNK; SP-600125).	pyrazolanthrone	218-227	vascular cell adhesion molecule 1	Homo sapiens	31-37
15489374-3	2005	IL-1beta induced expression of VCAM-1 protein and mRNA in a time-dependent manner, which was significantly inhibited by inhibitors of MEK1/2 (U0126 and PD-98059), p38 (SB-202190), and c-Jun NH(2)-terminal kinase (JNK; SP-600125).	pyrazolanthrone	218-227	mitogen-activated protein kinase kinase 1	Homo sapiens	134-140
15603921-3	2005	Compared with rubratoxin B-treatment alone, treatment with both rubratoxin B and the JNK inhibitor SP600125 decreased cell morphology changes and the activity of the apoptosis-related enzymes caspase-3 and caspase-7, indicating that JNKs are involved in rubratoxin B-induced apoptosis.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	85-88
15603921-3	2005	Compared with rubratoxin B-treatment alone, treatment with both rubratoxin B and the JNK inhibitor SP600125 decreased cell morphology changes and the activity of the apoptosis-related enzymes caspase-3 and caspase-7, indicating that JNKs are involved in rubratoxin B-induced apoptosis.	pyrazolanthrone	99-107	caspase 3	Homo sapiens	192-201
15603921-3	2005	Compared with rubratoxin B-treatment alone, treatment with both rubratoxin B and the JNK inhibitor SP600125 decreased cell morphology changes and the activity of the apoptosis-related enzymes caspase-3 and caspase-7, indicating that JNKs are involved in rubratoxin B-induced apoptosis.	pyrazolanthrone	99-107	caspase 7	Homo sapiens	206-215
15740647-5	2005	The expression of phosphorylated JNK and p38 also increased after the treatment with NCTD, and inhibitors of c-Jun NH2-terminal kinase (JNK) and p38 (SP600125 and SB203580, respectively) had significant inhibitory effects on the upregulation of phosphorylated JNK and p38 expression.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	33-36
15740647-5	2005	The expression of phosphorylated JNK and p38 also increased after the treatment with NCTD, and inhibitors of c-Jun NH2-terminal kinase (JNK) and p38 (SP600125 and SB203580, respectively) had significant inhibitory effects on the upregulation of phosphorylated JNK and p38 expression.	pyrazolanthrone	150-158	mitogen-activated protein kinase 1	Homo sapiens	41-44
15740647-5	2005	The expression of phosphorylated JNK and p38 also increased after the treatment with NCTD, and inhibitors of c-Jun NH2-terminal kinase (JNK) and p38 (SP600125 and SB203580, respectively) had significant inhibitory effects on the upregulation of phosphorylated JNK and p38 expression.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	109-134
15740647-5	2005	The expression of phosphorylated JNK and p38 also increased after the treatment with NCTD, and inhibitors of c-Jun NH2-terminal kinase (JNK) and p38 (SP600125 and SB203580, respectively) had significant inhibitory effects on the upregulation of phosphorylated JNK and p38 expression.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	136-139
15740647-5	2005	The expression of phosphorylated JNK and p38 also increased after the treatment with NCTD, and inhibitors of c-Jun NH2-terminal kinase (JNK) and p38 (SP600125 and SB203580, respectively) had significant inhibitory effects on the upregulation of phosphorylated JNK and p38 expression.	pyrazolanthrone	150-158	mitogen-activated protein kinase 1	Homo sapiens	145-148
15740647-5	2005	The expression of phosphorylated JNK and p38 also increased after the treatment with NCTD, and inhibitors of c-Jun NH2-terminal kinase (JNK) and p38 (SP600125 and SB203580, respectively) had significant inhibitory effects on the upregulation of phosphorylated JNK and p38 expression.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	136-139
15740647-5	2005	The expression of phosphorylated JNK and p38 also increased after the treatment with NCTD, and inhibitors of c-Jun NH2-terminal kinase (JNK) and p38 (SP600125 and SB203580, respectively) had significant inhibitory effects on the upregulation of phosphorylated JNK and p38 expression.	pyrazolanthrone	150-158	mitogen-activated protein kinase 1	Homo sapiens	145-148
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	pyrazolanthrone	137-146	cyclin dependent kinase 20	Homo sapiens	53-56
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	pyrazolanthrone	137-146	mitogen-activated protein kinase 3	Homo sapiens	57-65
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	pyrazolanthrone	137-146	mitogen-activated protein kinase 14	Homo sapiens	67-70
15489374-4	2005	Consistently, IL-1beta-stimulated phosphorylation of p42/p44 MAPK, p38, and JNK was attenuated by pretreatment with U0126, SB-202190, or SP-600125, respectively.	pyrazolanthrone	137-146	mitogen-activated protein kinase 8	Homo sapiens	76-79
15489374-7	2005	Moreover, the resultant enhancement of VCAM-1 expression increased the adhesion of polymorphonuclear cells to a monolayer of HTSMC, which was blocked by pretreatment with helenalin, U0126, SB-202190, or SP-600125 before IL-1beta exposure or by anti-VCAM-1 antibody.	pyrazolanthrone	203-212	vascular cell adhesion molecule 1	Homo sapiens	39-45
15684474-5	2005	The cell death was partially reduced by the mitogen-activated protein kinase c-JUN NH2-terminal protein kinase (JNK MAPK) inhibitor (SP600125) and p38 MAPK inhibitor (SB 203580), while the MEK inhibitor (PD98059) augmented cell death; the drug induced sustained phosphorylation of JNK and p38 MAPK.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Homo sapiens	112-115
15684474-5	2005	The cell death was partially reduced by the mitogen-activated protein kinase c-JUN NH2-terminal protein kinase (JNK MAPK) inhibitor (SP600125) and p38 MAPK inhibitor (SB 203580), while the MEK inhibitor (PD98059) augmented cell death; the drug induced sustained phosphorylation of JNK and p38 MAPK.	pyrazolanthrone	133-141	mitogen-activated protein kinase kinase 7	Homo sapiens	189-192
15474987-6	2005	Pharmacological studies using PD098059 (a MEK inhibitor), SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor) suggested that the MEK pathway was important for VD3 and ATRA-induced differentiation and also its enhancement by MG or HK, the p38 MAPK pathway had a inhibitory effect and the JNK pathway had little influence.	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	106-109
15711095-5	2005	METHODS: C1.MC/C57.1 mouse mast cells were exposed in vitro to increasing concentrations of Hg(2+) in the absence or presence of the specific c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	182-190	mitogen-activated protein kinase 8	Mus musculus	167-170
15711095-9	2005	The specific JNK inhibitor SP600125 abolished both mercuric-induced c-Jun phosphorylation and IL-4 secretion in mast cells.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Mus musculus	13-16
15711095-9	2005	The specific JNK inhibitor SP600125 abolished both mercuric-induced c-Jun phosphorylation and IL-4 secretion in mast cells.	pyrazolanthrone	27-35	jun proto-oncogene	Mus musculus	68-73
15711095-9	2005	The specific JNK inhibitor SP600125 abolished both mercuric-induced c-Jun phosphorylation and IL-4 secretion in mast cells.	pyrazolanthrone	27-35	interleukin 4	Mus musculus	94-98
15474987-6	2005	Pharmacological studies using PD098059 (a MEK inhibitor), SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor) suggested that the MEK pathway was important for VD3 and ATRA-induced differentiation and also its enhancement by MG or HK, the p38 MAPK pathway had a inhibitory effect and the JNK pathway had little influence.	pyrazolanthrone	94-102	mitogen-activated protein kinase kinase 7	Homo sapiens	140-143
15588914-6	2005	The MEK1 inhibitor PD98059 which blocks ERK activation had only a small inhibitory effect on DON-induced apoptosis while the JNK inhibitor SP600125 was without effect.	pyrazolanthrone	139-147	mitogen-activated protein kinase 8	Homo sapiens	125-128
15680252-3	2005	Ethanol-induced apoptosis was blocked by JNK inhibitor 1,9-pyrazoloanthrone (SP600125), indicating that JNK activation is pro-apoptotic.	pyrazolanthrone	55-75	mitogen-activated protein kinase 8	Rattus norvegicus	41-44
15680252-3	2005	Ethanol-induced apoptosis was blocked by JNK inhibitor 1,9-pyrazoloanthrone (SP600125), indicating that JNK activation is pro-apoptotic.	pyrazolanthrone	55-75	mitogen-activated protein kinase 8	Rattus norvegicus	104-107
15680252-3	2005	Ethanol-induced apoptosis was blocked by JNK inhibitor 1,9-pyrazoloanthrone (SP600125), indicating that JNK activation is pro-apoptotic.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Rattus norvegicus	41-44
15680252-3	2005	Ethanol-induced apoptosis was blocked by JNK inhibitor 1,9-pyrazoloanthrone (SP600125), indicating that JNK activation is pro-apoptotic.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Rattus norvegicus	104-107
15680252-5	2005	In fact, SP600125 potentiated acetaldehyde-induced apoptosis, suggesting that JNK activation is anti-apoptotic.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Rattus norvegicus	78-81
15629192-6	2005	Using SP600125 to block JNK activation shows that (AC)(5)GP-mediated apoptosis and related proteins expression are attenuated.	pyrazolanthrone	6-14	mitogen-activated protein kinase 8	Homo sapiens	24-27
15389584-5	2005	The IL-1beta induction of ICAM-1 mRNA and protein were partially inhibited by U0126 and PD98059 (specific inhibitors of MEK1/2) and SP600125 [a specific inhibitor of c-Jun-N-terminal kinase (JNK)].	pyrazolanthrone	132-140	interleukin 1 beta	Homo sapiens	4-12
15389584-5	2005	The IL-1beta induction of ICAM-1 mRNA and protein were partially inhibited by U0126 and PD98059 (specific inhibitors of MEK1/2) and SP600125 [a specific inhibitor of c-Jun-N-terminal kinase (JNK)].	pyrazolanthrone	132-140	intercellular adhesion molecule 1	Homo sapiens	26-32
15389584-5	2005	The IL-1beta induction of ICAM-1 mRNA and protein were partially inhibited by U0126 and PD98059 (specific inhibitors of MEK1/2) and SP600125 [a specific inhibitor of c-Jun-N-terminal kinase (JNK)].	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Homo sapiens	166-189
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	pyrazolanthrone	125-133	interleukin 1 beta	Homo sapiens	14-22
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	pyrazolanthrone	125-133	cyclin dependent kinase 20	Homo sapiens	53-56
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	pyrazolanthrone	125-133	interferon induced protein 44	Homo sapiens	57-60
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	pyrazolanthrone	125-133	mitogen-activated protein kinase 1	Homo sapiens	61-65
15389584-7	2005	Consistently, IL-1beta stimulated phosphorylation of p42/p44 MAPK and JNK which was attenuated by pretreatment with U0126 or SP600125, respectively.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Homo sapiens	70-73
15389584-9	2005	The combination of PD98059 and SP600125 displayed an additive effect on IL-1beta-induced ICAM-1 gene expression.	pyrazolanthrone	31-39	interleukin 1 beta	Homo sapiens	72-80
15389584-9	2005	The combination of PD98059 and SP600125 displayed an additive effect on IL-1beta-induced ICAM-1 gene expression.	pyrazolanthrone	31-39	intercellular adhesion molecule 1	Homo sapiens	89-95
15389584-11	2005	Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125.	pyrazolanthrone	153-161	interleukin 1 beta	Homo sapiens	14-22
15389584-11	2005	Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125.	pyrazolanthrone	153-161	nuclear factor kappa B subunit 1	Homo sapiens	51-60
15389584-11	2005	Consistently, IL-1beta stimulated translocation of NF-kappaB into the nucleus and degradation of IkappaB-alpha which was blocked by helenalin, U0126, or SP600125.	pyrazolanthrone	153-161	NFKB inhibitor alpha	Homo sapiens	97-110
15536494-4	2005	Treatment of mouse hippocampal (HT22) cells with the selective JNK inhibitor, SP-600125 (0.1-10 microM), resulted in dose-dependent induction of GR-mediated MMTV-luciferase activity.	pyrazolanthrone	78-87	mitogen-activated protein kinase 8	Mus musculus	63-66
15536494-4	2005	Treatment of mouse hippocampal (HT22) cells with the selective JNK inhibitor, SP-600125 (0.1-10 microM), resulted in dose-dependent induction of GR-mediated MMTV-luciferase activity.	pyrazolanthrone	78-87	nuclear receptor subfamily 3, group C, member 1	Mus musculus	145-147
15536494-7	2005	The induction of GR-mediated function by SP-600125 was not due to altered cytosolic GR binding or GR protein expression or enhancement of GR nuclear translocation as determined by Western blot.	pyrazolanthrone	41-50	nuclear receptor subfamily 3, group C, member 1	Mus musculus	17-19
15582605-2	2005	We found that SP600125, an inhibitor of Jun N-terminal kinase (JNK), promoted adipogenesis whereas it repressed osteogenesis from hMSCs.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	40-61
15582605-2	2005	We found that SP600125, an inhibitor of Jun N-terminal kinase (JNK), promoted adipogenesis whereas it repressed osteogenesis from hMSCs.	pyrazolanthrone	14-22	mitogen-activated protein kinase 8	Homo sapiens	63-66
15582605-3	2005	SP600125 increased the expression of adipogenic transcription factors, CCAAT/enhancer-binding proteins alpha and beta as well as peroxisome proliferator-activated receptor gamma2, which suggested that the chemical acted on the early steps of transcriptional regulatory cascade in adipogenesis.	pyrazolanthrone	0-8	peroxisome proliferator activated receptor gamma	Homo sapiens	129-178
16277680-10	2005	In addition, inhibition of Cyp7b mRNA expression and activity was observed with SN50, PSI and SP600125, suggesting that NF-kappaB and AP-1 induce Cyp7b transcription.	pyrazolanthrone	94-102	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	134-138
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	283-286
15531918-9	2005	PS-341 activated JNK/c-Jun signaling in GBM cells, and the JNK inhibitor SP600125 blocked the JNK signaling to reverse partially the PS-341 growth inhibition.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	59-62
15531918-9	2005	PS-341 activated JNK/c-Jun signaling in GBM cells, and the JNK inhibitor SP600125 blocked the JNK signaling to reverse partially the PS-341 growth inhibition.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	59-62
15627438-7	2005	SP600125 inhibited JNK activity in the challenged lungs.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	19-22
15627438-8	2005	Although SP 600125 may also have other effects, we conclude that c-Jun NH2-terminal kinase may play a role in allergen-induced inflammation and remodelling associated with bronchial hyperresponsiveness.	pyrazolanthrone	9-18	mitogen-activated protein kinase 8	Mus musculus	65-90
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Homo sapiens	16-19
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	pyrazolanthrone	30-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	94-104
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	pyrazolanthrone	30-38	ATP binding cassette subfamily B member 1	Homo sapiens	109-123
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	pyrazolanthrone	30-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	228-238
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	pyrazolanthrone	30-38	ATP binding cassette subfamily B member 1	Homo sapiens	243-257
15389514-10	2005	In contrast the JNK inhibitor SP600125 and the ERK1,2 inhibitor UO126 resulted in increase of HIF-1alpha and P-glycoprotein in the control as well as the hyperthermia-treated samples, indicating negative regulation of intrinsic HIF-1alpha and P-glycoprotein expression by ERK1,2 and JNK signaling cascades.	pyrazolanthrone	30-38	mitogen-activated protein kinase 3	Homo sapiens	272-278
15659314-6	2005	Pre-incubation with SB203580, a p38 MAPK inhibitor, or SP600125, a JNK inhibitor, but not PD98059, an ERK inhibitor, reduced satratoxin-induced cytotoxicity.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Rattus norvegicus	67-70
15383396-3	2005	Inhibition of JNK with SP-600125 (20 muM), a concentration that causes an approximately 95% inhibition of hypertonicity-stimulated JNK activation, markedly decreased the amount of the gamma-subunit in response to 550 mosmol/kgH(2)O for 48 h. This was accompanied by a parallel decrease in the gamma-subunit mRNA.	pyrazolanthrone	23-32	mitogen-activated protein kinase 8	Mus musculus	14-17
15383396-3	2005	Inhibition of JNK with SP-600125 (20 muM), a concentration that causes an approximately 95% inhibition of hypertonicity-stimulated JNK activation, markedly decreased the amount of the gamma-subunit in response to 550 mosmol/kgH(2)O for 48 h. This was accompanied by a parallel decrease in the gamma-subunit mRNA.	pyrazolanthrone	23-32	mitogen-activated protein kinase 8	Mus musculus	131-134
15665513-6	2005	TNF-alpha activated JNK, but JNK inhibitor SP600125 and dominant negative cJun consistently activated transcription, revealing a negative role for this signaling pathway.	pyrazolanthrone	43-51	mitogen-activated protein kinase 8	Homo sapiens	29-32
15664007-11	2005	U0126, a specific inhibitor of the ERK pathway, completely blocked both TGF(beta)- and PGE2-induced cell proliferation whereas SB203580 and SP600125, which are selective inhibitors of, respectively, p38 and JNK pathways, had no effect.	pyrazolanthrone	140-148	mitogen-activated protein kinase 14	Mus musculus	199-202
15664007-11	2005	U0126, a specific inhibitor of the ERK pathway, completely blocked both TGF(beta)- and PGE2-induced cell proliferation whereas SB203580 and SP600125, which are selective inhibitors of, respectively, p38 and JNK pathways, had no effect.	pyrazolanthrone	140-148	mitogen-activated protein kinase 8	Mus musculus	207-210
15596805-9	2005	IE1 induced c-Jun phosphorylation, and treatment with SP600125, a selective JNK inhibitor, as well as overexpression of JNK-binding domain of JIP1, blocked IE1-mediated induction of AP-1 and relB promoter activity in NIH 3T3 cells and SMCs.	pyrazolanthrone	54-62	jun proto-oncogene	Mus musculus	12-17
15665553-5	2005	Both SP600125, a specific inhibitor of JNK, and SB203580, a specific inhibitor of p38 MAPK, suppressed the IL-1beta-induced expression of alpha-SMA and cell migration, but these effects were not observed with PD98059, a specific inhibitor of ERK.	pyrazolanthrone	5-13	mitogen-activated protein kinase 8	Homo sapiens	39-42
15665553-5	2005	Both SP600125, a specific inhibitor of JNK, and SB203580, a specific inhibitor of p38 MAPK, suppressed the IL-1beta-induced expression of alpha-SMA and cell migration, but these effects were not observed with PD98059, a specific inhibitor of ERK.	pyrazolanthrone	5-13	interleukin 1 beta	Homo sapiens	107-115
16111829-3	2005	Tat-induced increases in caspase-3 activity were significantly attenuated by an inhibitor of c-jun-N-terminal kinase (anthra[1,9-cd]pyrazol-6(2H)-one), but not by an inhibitor of p38 ([4-(4-fluorophenyl)-2-(4-methylsul-finylphenyl)-5-(4-pyridyl)1 H-imidazole]), mitogen-activated protein kinase.	pyrazolanthrone	118-149	caspase 3	Homo sapiens	25-34
16421893-9	2005	JNK inhibitor (SP600125) and anti-TNFalpha reduced the apoptosis induced by fumonisin B(1).	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	0-3
15585341-5	2005	The JNK inhibitor SP600125 and the p38 inhibitor SB203580 independently reduced both nitrite accumulation and induction of inflammatory nitric oxide synthase (iNOS).	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
15585341-5	2005	The JNK inhibitor SP600125 and the p38 inhibitor SB203580 independently reduced both nitrite accumulation and induction of inflammatory nitric oxide synthase (iNOS).	pyrazolanthrone	18-26	nitric oxide synthase 2	Homo sapiens	159-163
15596805-9	2005	IE1 induced c-Jun phosphorylation, and treatment with SP600125, a selective JNK inhibitor, as well as overexpression of JNK-binding domain of JIP1, blocked IE1-mediated induction of AP-1 and relB promoter activity in NIH 3T3 cells and SMCs.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Mus musculus	76-79
15504737-6	2004	JNK inhibition by SP600125 or transfection of dnJNK2 reduced the pool of active JNKs in the nucleus, the release of cytochrome c, as well as the cleavage of caspase-3 and its substrate poly(ADP-ribose) polymerase-1.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
16201852-8	2005	Inhibiting the JNK activity with a pharmacologic inhibitor SP600125 abolished the induction of G2/M arrest and apoptosis by SFN, whereas chemical inhibitors for p38MAPK and MEK1/2 did not have any modulating effect on SFN-induced apoptosis.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Homo sapiens	15-18
15504737-6	2004	JNK inhibition by SP600125 or transfection of dnJNK2 reduced the pool of active JNKs in the nucleus, the release of cytochrome c, as well as the cleavage of caspase-3 and its substrate poly(ADP-ribose) polymerase-1.	pyrazolanthrone	18-26	caspase 3	Rattus norvegicus	157-166
15544923-9	2004	PON2 expression was found to be regulated, at least in part, by the transcription factor AP-1, as suggested by decreased JDP2 (AP-1 repressor) protein expression in the nucleus and by decreased PON2 expression in the presence of a Jun N-terminal kinase inhibitor (SP600125).	pyrazolanthrone	264-272	paraoxonase 2	Mus musculus	0-4
15665588-4	2004	JNK inhibitor, SP600125,markedly inhibited pseudolaric acid B-induced celldeath.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	0-3
15454113-5	2004	However, the up-regulation of CD83 by PA/TNF-alpha on KG1 was significantly abrogated by PD98059, a specific inhibitor of ERK kinase, but was enhanced by SP600125, a JNK inhibitor.	pyrazolanthrone	154-162	CD83 molecule	Homo sapiens	30-34
15454113-5	2004	However, the up-regulation of CD83 by PA/TNF-alpha on KG1 was significantly abrogated by PD98059, a specific inhibitor of ERK kinase, but was enhanced by SP600125, a JNK inhibitor.	pyrazolanthrone	154-162	tumor necrosis factor	Homo sapiens	41-50
15544923-9	2004	PON2 expression was found to be regulated, at least in part, by the transcription factor AP-1, as suggested by decreased JDP2 (AP-1 repressor) protein expression in the nucleus and by decreased PON2 expression in the presence of a Jun N-terminal kinase inhibitor (SP600125).	pyrazolanthrone	264-272	jun proto-oncogene	Mus musculus	89-93
15386367-10	2004	Ethanol activated conventional PKCs and JNKs in fibroblasts; inhibitors of PKC (Go6850 and Go6976) and JNKs (SP600125) significantly inhibited ethanol-mediated MMP-2 activation as well as cell invasion, indicating that PKCs and JNKs play a role in ethanol-induced MMP-2 activation and cell invasion in vitro.	pyrazolanthrone	109-117	matrix metallopeptidase 2	Homo sapiens	160-165
15572410-1	2004	Pharmacological inhibitors of JNK (SP600125) and p38 (PD169316) sensitize tumor cells to Fas-mediated apoptosis.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Homo sapiens	30-33
15604272-6	2004	Furthermore, the JNK inhibitor SP600125 selectively and specifically inhibits hypoxia- and MEKK-1-induced MDR1 promoter activity in a dose-dependent manner.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	17-20
15604272-6	2004	Furthermore, the JNK inhibitor SP600125 selectively and specifically inhibits hypoxia- and MEKK-1-induced MDR1 promoter activity in a dose-dependent manner.	pyrazolanthrone	31-39	mitogen-activated protein kinase kinase kinase 1	Homo sapiens	91-97
15604272-6	2004	Furthermore, the JNK inhibitor SP600125 selectively and specifically inhibits hypoxia- and MEKK-1-induced MDR1 promoter activity in a dose-dependent manner.	pyrazolanthrone	31-39	ATP binding cassette subfamily B member 1	Homo sapiens	106-110
15386367-10	2004	Ethanol activated conventional PKCs and JNKs in fibroblasts; inhibitors of PKC (Go6850 and Go6976) and JNKs (SP600125) significantly inhibited ethanol-mediated MMP-2 activation as well as cell invasion, indicating that PKCs and JNKs play a role in ethanol-induced MMP-2 activation and cell invasion in vitro.	pyrazolanthrone	109-117	matrix metallopeptidase 2	Homo sapiens	264-269
15282190-12	2004	SP-600125 [a c-Jun NH(2)-terminal kinase (JNK) inhibitor] also prevented LPS stimulation of NOS2 expression.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Mus musculus	13-40
15282190-12	2004	SP-600125 [a c-Jun NH(2)-terminal kinase (JNK) inhibitor] also prevented LPS stimulation of NOS2 expression.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Mus musculus	42-45
15282190-12	2004	SP-600125 [a c-Jun NH(2)-terminal kinase (JNK) inhibitor] also prevented LPS stimulation of NOS2 expression.	pyrazolanthrone	0-9	toll-like receptor 4	Mus musculus	73-76
15282190-12	2004	SP-600125 [a c-Jun NH(2)-terminal kinase (JNK) inhibitor] also prevented LPS stimulation of NOS2 expression.	pyrazolanthrone	0-9	nitric oxide synthase 2, inducible	Mus musculus	92-96
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	pyrazolanthrone	20-28	interleukin 1 beta	Rattus norvegicus	56-64
15744361-5	2004	On the other hand, we demonstrate that JNK mediates hGR transcriptional inhibition by microtubules disarray, because a specific inhibitor of JNK, 1,9-pyrazoloanthrone (SP600125), partially blocked tyrosine aminotransferase mRNA suppression due to colchicine treatment.	pyrazolanthrone	146-166	mitogen-activated protein kinase 8	Homo sapiens	39-42
15744361-5	2004	On the other hand, we demonstrate that JNK mediates hGR transcriptional inhibition by microtubules disarray, because a specific inhibitor of JNK, 1,9-pyrazoloanthrone (SP600125), partially blocked tyrosine aminotransferase mRNA suppression due to colchicine treatment.	pyrazolanthrone	146-166	mitogen-activated protein kinase 8	Homo sapiens	141-144
15744361-5	2004	On the other hand, we demonstrate that JNK mediates hGR transcriptional inhibition by microtubules disarray, because a specific inhibitor of JNK, 1,9-pyrazoloanthrone (SP600125), partially blocked tyrosine aminotransferase mRNA suppression due to colchicine treatment.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Homo sapiens	39-42
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	pyrazolanthrone	20-28	mitogen activated protein kinase 14	Rattus norvegicus	129-132
15744361-5	2004	On the other hand, we demonstrate that JNK mediates hGR transcriptional inhibition by microtubules disarray, because a specific inhibitor of JNK, 1,9-pyrazoloanthrone (SP600125), partially blocked tyrosine aminotransferase mRNA suppression due to colchicine treatment.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Homo sapiens	141-144
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	pyrazolanthrone	20-28	Eph receptor B1	Rattus norvegicus	134-137
15477222-9	2004	SB239063, U0126 and SP600125 dose-dependently inhibited IL-1beta-dependent proliferation at doses that inhibit the activities of p38, ERK and JNK MAPKs, respectively.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Rattus norvegicus	142-145
15389548-6	2004	From the set of NGF-specific genes, the induction by NGF of ten genes with diverse predicted cellular functions was tested for ERK and JNK pathway requirements using the protein kinase inhibitors, PD98059 and SP600125, respectively.	pyrazolanthrone	209-217	nerve growth factor	Rattus norvegicus	53-56
15477228-5	2004	SP600125, a specific inhibitor of JNK, inhibited the LPS-induced up-regulation of CD80, CD83, CD86 and CD54, but augmented the up-regulation of HLA-DR. SP600125 slightly inhibited the down-regulation of FITC-dextran uptake during DC maturation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	34-37
15477228-5	2004	SP600125, a specific inhibitor of JNK, inhibited the LPS-induced up-regulation of CD80, CD83, CD86 and CD54, but augmented the up-regulation of HLA-DR. SP600125 slightly inhibited the down-regulation of FITC-dextran uptake during DC maturation.	pyrazolanthrone	0-8	CD80 molecule	Homo sapiens	82-86
15477228-5	2004	SP600125, a specific inhibitor of JNK, inhibited the LPS-induced up-regulation of CD80, CD83, CD86 and CD54, but augmented the up-regulation of HLA-DR. SP600125 slightly inhibited the down-regulation of FITC-dextran uptake during DC maturation.	pyrazolanthrone	0-8	CD83 molecule	Homo sapiens	88-92
15477228-5	2004	SP600125, a specific inhibitor of JNK, inhibited the LPS-induced up-regulation of CD80, CD83, CD86 and CD54, but augmented the up-regulation of HLA-DR. SP600125 slightly inhibited the down-regulation of FITC-dextran uptake during DC maturation.	pyrazolanthrone	0-8	CD86 molecule	Homo sapiens	94-98
15477228-5	2004	SP600125, a specific inhibitor of JNK, inhibited the LPS-induced up-regulation of CD80, CD83, CD86 and CD54, but augmented the up-regulation of HLA-DR. SP600125 slightly inhibited the down-regulation of FITC-dextran uptake during DC maturation.	pyrazolanthrone	0-8	intercellular adhesion molecule 1	Homo sapiens	103-107
15477228-5	2004	SP600125, a specific inhibitor of JNK, inhibited the LPS-induced up-regulation of CD80, CD83, CD86 and CD54, but augmented the up-regulation of HLA-DR. SP600125 slightly inhibited the down-regulation of FITC-dextran uptake during DC maturation.	pyrazolanthrone	152-160	mitogen-activated protein kinase 8	Homo sapiens	34-37
15477228-7	2004	SP600125 inhibited the release of IL-12 p70 and TNF-alpha from mature DCs.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	48-57
15477228-8	2004	Although autologous T cells primed by the ovalbumin (OVA)-pulsed mature DCs produced IFN-gamma, but not IL-4, OVA-pulsed SP600125-treated mature DCs could initiate IL-4 production from autologous T cells.	pyrazolanthrone	121-129	interferon gamma	Homo sapiens	85-94
15477228-8	2004	Although autologous T cells primed by the ovalbumin (OVA)-pulsed mature DCs produced IFN-gamma, but not IL-4, OVA-pulsed SP600125-treated mature DCs could initiate IL-4 production from autologous T cells.	pyrazolanthrone	121-129	interleukin 4	Homo sapiens	164-168
15696229-7	2004	Studies including our own showed that the inhibition of JNK with SP-600125, a specific inhibitor of JNK, protects dopaminergic neurons both from MPP(+)-induced neuronal apoptosis in vitro and in MPTP Parkinson"s disease model.	pyrazolanthrone	65-74	mitogen-activated protein kinase 8	Homo sapiens	56-59
15696229-7	2004	Studies including our own showed that the inhibition of JNK with SP-600125, a specific inhibitor of JNK, protects dopaminergic neurons both from MPP(+)-induced neuronal apoptosis in vitro and in MPTP Parkinson"s disease model.	pyrazolanthrone	65-74	mitogen-activated protein kinase 8	Homo sapiens	100-103
15389548-8	2004	NGF-induction of the bradykinin B2 receptor and c-Ret mRNAs was partially inhibited by SP600125, but not PD98059.	pyrazolanthrone	87-95	nerve growth factor	Rattus norvegicus	0-3
15634454-9	2004	Significant down-regulation of AP-1 activation and MCP-1 expression were observed in angiotensin II-induced human mesangial cells pretreated with JNK specific inhibitor SP600125.	pyrazolanthrone	169-177	angiotensinogen	Homo sapiens	85-99
15491342-10	2004	Using more specific inhibitors, we found that the mitogen-activated extracellular kinase and c-Jun N-terminal kinase (JNK) inhibitors PD98059 and SP600125 also blocked the EGF-dependent stimulatory effect.	pyrazolanthrone	146-154	mitogen-activated protein kinase 8	Homo sapiens	93-116
15491342-10	2004	Using more specific inhibitors, we found that the mitogen-activated extracellular kinase and c-Jun N-terminal kinase (JNK) inhibitors PD98059 and SP600125 also blocked the EGF-dependent stimulatory effect.	pyrazolanthrone	146-154	mitogen-activated protein kinase 8	Homo sapiens	118-121
15491342-10	2004	Using more specific inhibitors, we found that the mitogen-activated extracellular kinase and c-Jun N-terminal kinase (JNK) inhibitors PD98059 and SP600125 also blocked the EGF-dependent stimulatory effect.	pyrazolanthrone	146-154	epidermal growth factor	Homo sapiens	172-175
15634454-9	2004	Significant down-regulation of AP-1 activation and MCP-1 expression were observed in angiotensin II-induced human mesangial cells pretreated with JNK specific inhibitor SP600125.	pyrazolanthrone	169-177	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	31-35
15634454-9	2004	Significant down-regulation of AP-1 activation and MCP-1 expression were observed in angiotensin II-induced human mesangial cells pretreated with JNK specific inhibitor SP600125.	pyrazolanthrone	169-177	C-C motif chemokine ligand 2	Homo sapiens	51-56
15634454-9	2004	Significant down-regulation of AP-1 activation and MCP-1 expression were observed in angiotensin II-induced human mesangial cells pretreated with JNK specific inhibitor SP600125.	pyrazolanthrone	169-177	mitogen-activated protein kinase 8	Homo sapiens	146-149
15566575-4	2004	RESULTS: SP600125 or PD98059 inhibited LPS-induced phosphorylation of JNK and ERK, total protein and LDH activity in BAL fluid, and neutrophil influx into the lungs.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Rattus norvegicus	70-73
15566575-4	2004	RESULTS: SP600125 or PD98059 inhibited LPS-induced phosphorylation of JNK and ERK, total protein and LDH activity in BAL fluid, and neutrophil influx into the lungs.	pyrazolanthrone	9-17	Eph receptor B1	Rattus norvegicus	78-81
15389828-4	2004	We also demonstrate that phosphorylation of c-Jun at Ser63 is an early event coinciding with JNK activation, and that the phosphorylation of c-Jun is partially prevented by the JNK inhibitor SP600125.	pyrazolanthrone	191-199	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	44-49
15389828-4	2004	We also demonstrate that phosphorylation of c-Jun at Ser63 is an early event coinciding with JNK activation, and that the phosphorylation of c-Jun is partially prevented by the JNK inhibitor SP600125.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Homo sapiens	93-96
15389828-4	2004	We also demonstrate that phosphorylation of c-Jun at Ser63 is an early event coinciding with JNK activation, and that the phosphorylation of c-Jun is partially prevented by the JNK inhibitor SP600125.	pyrazolanthrone	191-199	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	141-146
15389828-4	2004	We also demonstrate that phosphorylation of c-Jun at Ser63 is an early event coinciding with JNK activation, and that the phosphorylation of c-Jun is partially prevented by the JNK inhibitor SP600125.	pyrazolanthrone	191-199	mitogen-activated protein kinase 8	Homo sapiens	177-180
15525474-12	2004	Although p38 MAPK inhibitor (SB203580) failed to block cell death, ERK MAPK inhibitor (PD98059) and JNK MAPK inhibitor (SP600125) had marked inhibitory effects on norcantharidin-induced apoptosis.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	100-103
15528336-0	2004	Rescuing melanoma epitope-specific cytolytic T lymphocytes from activation-induced cell death, by SP600125, an inhibitor of JNK: implications in cancer immunotherapy.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Homo sapiens	124-127
15528336-7	2004	These CTLs, interestingly, could be rescued from AICD by the JNK inhibitor, SP600125.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	61-64
15528336-8	2004	We also found that SP600125 interferes with their IFN-gamma response but does not block their cytolytic function.	pyrazolanthrone	19-27	interferon gamma	Homo sapiens	50-59
15464728-6	2004	Furthermore, the level of mMCP-6 mRNA in mast cells was attenuated by the introduction of dominant negative c-jun (TAM-67) and the treatment of Jun N-terminal kinase inhibitor, SP600125.	pyrazolanthrone	177-185	tryptase beta 2	Mus musculus	26-32
15550066-5	2004	Effects of PD98059, SB202190 and SP600125 (inhibitors of ERK, p38 and JNK, respectively) on IL-1beta-induced secretion of IL-6 and IL-8, and on IL-1beta-induced expression of cyclo-oxygenase-2 (COX-2) in endometriotic cells were studied.	pyrazolanthrone	33-41	mitogen-activated protein kinase 1	Homo sapiens	57-60
15550066-5	2004	Effects of PD98059, SB202190 and SP600125 (inhibitors of ERK, p38 and JNK, respectively) on IL-1beta-induced secretion of IL-6 and IL-8, and on IL-1beta-induced expression of cyclo-oxygenase-2 (COX-2) in endometriotic cells were studied.	pyrazolanthrone	33-41	mitogen-activated protein kinase 1	Homo sapiens	62-65
15550066-5	2004	Effects of PD98059, SB202190 and SP600125 (inhibitors of ERK, p38 and JNK, respectively) on IL-1beta-induced secretion of IL-6 and IL-8, and on IL-1beta-induced expression of cyclo-oxygenase-2 (COX-2) in endometriotic cells were studied.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Homo sapiens	70-73
15550066-5	2004	Effects of PD98059, SB202190 and SP600125 (inhibitors of ERK, p38 and JNK, respectively) on IL-1beta-induced secretion of IL-6 and IL-8, and on IL-1beta-induced expression of cyclo-oxygenase-2 (COX-2) in endometriotic cells were studied.	pyrazolanthrone	33-41	interleukin 1 beta	Homo sapiens	92-100
15550066-5	2004	Effects of PD98059, SB202190 and SP600125 (inhibitors of ERK, p38 and JNK, respectively) on IL-1beta-induced secretion of IL-6 and IL-8, and on IL-1beta-induced expression of cyclo-oxygenase-2 (COX-2) in endometriotic cells were studied.	pyrazolanthrone	33-41	interleukin 6	Homo sapiens	122-126
15550066-5	2004	Effects of PD98059, SB202190 and SP600125 (inhibitors of ERK, p38 and JNK, respectively) on IL-1beta-induced secretion of IL-6 and IL-8, and on IL-1beta-induced expression of cyclo-oxygenase-2 (COX-2) in endometriotic cells were studied.	pyrazolanthrone	33-41	C-X-C motif chemokine ligand 8	Homo sapiens	131-135
15550066-8	2004	Both SB202190 and SP600125 suppressed IL-1beta-induced secretion of IL-6 and IL-8, and PD98059 suppressed IL-1beta-induced secretion of IL-8.	pyrazolanthrone	18-26	interleukin 1 beta	Homo sapiens	38-46
15520191-5	2004	The JNK inhibitor SP600125 proved effective at protecting cells from the lethal effects of ceramide.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
15550066-8	2004	Both SB202190 and SP600125 suppressed IL-1beta-induced secretion of IL-6 and IL-8, and PD98059 suppressed IL-1beta-induced secretion of IL-8.	pyrazolanthrone	18-26	interleukin 6	Homo sapiens	68-72
15550066-8	2004	Both SB202190 and SP600125 suppressed IL-1beta-induced secretion of IL-6 and IL-8, and PD98059 suppressed IL-1beta-induced secretion of IL-8.	pyrazolanthrone	18-26	C-X-C motif chemokine ligand 8	Homo sapiens	77-81
15256484-7	2004	Curcumin-mediated c-jun phosphorylation and apoptosis were reduced by treatment with the JNK-specific inhibitor SP600125.	pyrazolanthrone	112-120	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	18-23
15256484-7	2004	Curcumin-mediated c-jun phosphorylation and apoptosis were reduced by treatment with the JNK-specific inhibitor SP600125.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	89-92
15256485-8	2004	A specific JNK inhibitor (SP600125), as well as over-expression of dominant-negative forms of JNK1 and JNK2 abolished the sensitization effect of PN on TNF-alpha-induced apoptosis.	pyrazolanthrone	26-34	tumor necrosis factor	Homo sapiens	152-161
15217830-7	2004	Blocking JNK, by either dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor SP600125, abrogates both PK + bortezomib-induced release of cyto-c/Smac and induction of apoptosis.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	9-12
15660418-10	2004	Inhibition of JNK activity by SP600125 inhibited both migration and proliferation.	pyrazolanthrone	30-38	mitogen-activated protein kinase 8	Mus musculus	14-17
15454338-0	2004	Protective effects of SP600125 a new inhibitor of c-jun N-terminal kinase (JNK) and extracellular-regulated kinase (ERK1/2) in an experimental model of cerulein-induced pancreatitis.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Homo sapiens	75-78
15454338-0	2004	Protective effects of SP600125 a new inhibitor of c-jun N-terminal kinase (JNK) and extracellular-regulated kinase (ERK1/2) in an experimental model of cerulein-induced pancreatitis.	pyrazolanthrone	22-30	mitogen-activated protein kinase 3	Homo sapiens	116-122
15454338-8	2004	SP600125 inhibited almost totally JNK activation (90%) and partially ERK1/2 activation (45%), reduced the serum lipase and amylase levels and the degree of oedema, blunted the increased pancreatic content of TNF-alpha and ICAM-1 and protected against the histological damage.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	34-37
15454338-8	2004	SP600125 inhibited almost totally JNK activation (90%) and partially ERK1/2 activation (45%), reduced the serum lipase and amylase levels and the degree of oedema, blunted the increased pancreatic content of TNF-alpha and ICAM-1 and protected against the histological damage.	pyrazolanthrone	0-8	mitogen-activated protein kinase 3	Homo sapiens	69-75
15454338-8	2004	SP600125 inhibited almost totally JNK activation (90%) and partially ERK1/2 activation (45%), reduced the serum lipase and amylase levels and the degree of oedema, blunted the increased pancreatic content of TNF-alpha and ICAM-1 and protected against the histological damage.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	208-217
15454338-8	2004	SP600125 inhibited almost totally JNK activation (90%) and partially ERK1/2 activation (45%), reduced the serum lipase and amylase levels and the degree of oedema, blunted the increased pancreatic content of TNF-alpha and ICAM-1 and protected against the histological damage.	pyrazolanthrone	0-8	intercellular adhesion molecule 1	Homo sapiens	222-228
15546505-8	2004	Mitogen-activated protein (MAP) kinase inhibitors, PD98059, SB203580, and SP600125, abolished this protective effect of beta 1-integrin, but herbimycin A and wortmannin were ineffective.	pyrazolanthrone	74-82	integrin subunit beta 1	Homo sapiens	120-135
15519242-4	2004	JNK inhibition by the selective JNK inhibitors SP600125 and (D)-JNKI1 did not affect neuronal survival in explanted or dissociated ganglia, but dramatically reduced axonal outgrowth, c-Jun activation, and ATF3 induction.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Rattus norvegicus	0-3
15519242-4	2004	JNK inhibition by the selective JNK inhibitors SP600125 and (D)-JNKI1 did not affect neuronal survival in explanted or dissociated ganglia, but dramatically reduced axonal outgrowth, c-Jun activation, and ATF3 induction.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Rattus norvegicus	32-35
15217830-7	2004	Blocking JNK, by either dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor SP600125, abrogates both PK + bortezomib-induced release of cyto-c/Smac and induction of apoptosis.	pyrazolanthrone	103-111	diablo IAP-binding mitochondrial protein	Homo sapiens	170-174
15254339-6	2004	Use of the selective JNK inhibitor SP600125 suggested that activation of JNK is pro-apoptotic and pro-necrotic.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Mus musculus	21-24
15334063-7	2004	Suppression of JNK activation, either by a synthetic JNK inhibitor (SP600125) or by overexpression of the dominant negative forms of JNK kinase 1 (JNKK1) and JNK kinase 2 (JNKK2), conferred significant protection against apoptotic cell death induced by luteolin and TNFalpha, suggesting that NF-kappaB and JNK are closely associated with the sensitization effect of luteolin.	pyrazolanthrone	68-76	mitogen-activated protein kinase 8	Homo sapiens	15-18
15201140-9	2004	In contrast, the DNA intercalator WP631 and TNF-alpha counteracted the TGF-beta1-induced morphogenetic effect while the JNK inhibitor SP600125 effectively inhibited capillary tube formation.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	120-123
15242986-6	2004	PI3K inhibition led to increased JNK phosphorylation and islet cell death, which could be reversed by the specific JNK inhibitor SP600125.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	33-36
15242986-6	2004	PI3K inhibition led to increased JNK phosphorylation and islet cell death, which could be reversed by the specific JNK inhibitor SP600125.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	115-118
15242986-10	2004	When administered immediately after isolation, SP600125 improved islet survival and function, even 48 h after removal of SP600125, suggesting that JNK inhibition by SP600125 may be a viable strategy for improving isolated islet survival.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	147-150
15528845-5	2004	SP600125, an inhibitor of JNK suppressed the induction of cell death in both heated LEC and WKAH rat cells, but SB203580, an inhibitor of p38 mapk, did not.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	26-29
15492284-8	2004	Moreover, application of the JNK-specific inhibitor SP600125 blocked CDDO-Me-induced increases in JNK activation, DR up-regulation, caspase-8 activation, and DNA fragmentation.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	29-32
15492284-8	2004	Moreover, application of the JNK-specific inhibitor SP600125 blocked CDDO-Me-induced increases in JNK activation, DR up-regulation, caspase-8 activation, and DNA fragmentation.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	98-101
15492284-8	2004	Moreover, application of the JNK-specific inhibitor SP600125 blocked CDDO-Me-induced increases in JNK activation, DR up-regulation, caspase-8 activation, and DNA fragmentation.	pyrazolanthrone	52-60	caspase 8	Homo sapiens	132-141
15467189-8	2004	In addition, an MEK/ERK inhibitor (PD98059) markedly blocked oridonin-induced cell death, whereas a p38 inhibitor (SB203580) and JNK inhibitor (SP600125) weakly protected the cells against death.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Mus musculus	129-132
15333603-8	2004	To understand the role of c-jun, endometrial stromal cells were treated with SP600125 which is a specific inhibitor of c-jun.	pyrazolanthrone	77-85	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	119-124
15385474-6	2004	Treatment with the NF-kappaB inhibitor Helenalin, as well as with SP600125, a selective inhibitor of c-Jun N-terminal kinase, blocked hBD-2 induction by E. coli Nissle 1917 in Caco-2 cells.	pyrazolanthrone	66-74	defensin beta 4A	Homo sapiens	134-139
15121739-5	2004	FGF-1-induced PN expression was blocked by the FGF-1 receptor antagonist PD-166866 and by inhibitors of phosphatidylinositol 3-kinase (PI3K) (LY-294002, wortmannin), p70S6K (rapamycin), MEK1/2 (U-0126, PD-98059), and p38MAPK (SB-203580) but not of JNK (SP-600125).	pyrazolanthrone	253-262	fibroblast growth factor 1	Rattus norvegicus	0-5
15121739-5	2004	FGF-1-induced PN expression was blocked by the FGF-1 receptor antagonist PD-166866 and by inhibitors of phosphatidylinositol 3-kinase (PI3K) (LY-294002, wortmannin), p70S6K (rapamycin), MEK1/2 (U-0126, PD-98059), and p38MAPK (SB-203580) but not of JNK (SP-600125).	pyrazolanthrone	253-262	periostin	Rattus norvegicus	14-16
15254339-6	2004	Use of the selective JNK inhibitor SP600125 suggested that activation of JNK is pro-apoptotic and pro-necrotic.	pyrazolanthrone	35-43	mitogen-activated protein kinase 8	Mus musculus	73-76
15286701-5	2004	JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis.	pyrazolanthrone	131-139	mitogen-activated protein kinase 8	Homo sapiens	0-3
15286701-5	2004	JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis.	pyrazolanthrone	131-139	TNF superfamily member 10	Homo sapiens	72-77
15326485-7	2004	JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals.	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Homo sapiens	0-3
15326485-7	2004	JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals.	pyrazolanthrone	90-98	hepatocyte growth factor	Homo sapiens	21-24
15326485-7	2004	JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals.	pyrazolanthrone	90-98	transforming growth factor beta 1	Homo sapiens	29-37
15326485-7	2004	JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals.	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Homo sapiens	76-79
15326485-7	2004	JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals.	pyrazolanthrone	90-98	hepatocyte growth factor	Homo sapiens	152-155
15286701-5	2004	JNK activity is necessary for the parthenolide-induced sensitization to TRAIL because a dominant-negative JNK or the JNK inhibitor SP600125 reduced TRAIL plus parthenolide-induced apoptosis.	pyrazolanthrone	131-139	TNF superfamily member 10	Homo sapiens	148-153
15326485-7	2004	JNK pathway involved HGF and TGF-beta-mediated infiltration potency since a JNK inhibitor SP600125 caused the reduction of invasive capacity induced by HGF and TGF-beta signals.	pyrazolanthrone	90-98	transforming growth factor beta 1	Homo sapiens	160-168
15365619-10	2004	However, in the presence of SP600125, an inhibitor of JNK, TNF-alpha still produced insulin resistance.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Rattus norvegicus	54-57
15356200-5	2004	Inhibition of JNK activity by anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), a selective JNK inhibitor, protected neurons from ischemia-induced apoptosis detected by TUNEL staining and an apoptotic-related DNA fragmentation assay.	pyrazolanthrone	30-61	mitogen-activated protein kinase 8	Homo sapiens	14-17
15356200-5	2004	Inhibition of JNK activity by anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), a selective JNK inhibitor, protected neurons from ischemia-induced apoptosis detected by TUNEL staining and an apoptotic-related DNA fragmentation assay.	pyrazolanthrone	30-61	mitogen-activated protein kinase 8	Homo sapiens	86-89
15356200-5	2004	Inhibition of JNK activity by anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), a selective JNK inhibitor, protected neurons from ischemia-induced apoptosis detected by TUNEL staining and an apoptotic-related DNA fragmentation assay.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	14-17
15356200-5	2004	Inhibition of JNK activity by anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), a selective JNK inhibitor, protected neurons from ischemia-induced apoptosis detected by TUNEL staining and an apoptotic-related DNA fragmentation assay.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Homo sapiens	86-89
15356200-6	2004	SP600125 blocked translocation of the cell death effector Bax from the cytosol to the mitochondria after tFCI.	pyrazolanthrone	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	58-61
15356200-9	2004	SP600125 blocked these interactions at a dose that significantly inhibited JNK-induced neuronal apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	75-78
15342404-5	2004	The inhibition of erk, p38, jnk, and akt with U0126, SB203580, SP600125, and Akt inhibitor, respectively, document that normal cells require simultaneous erk and jnk signaling for survival, plus akt signaling for proliferation.	pyrazolanthrone	63-71	mitogen-activated protein kinase 1	Homo sapiens	18-21
15342404-5	2004	The inhibition of erk, p38, jnk, and akt with U0126, SB203580, SP600125, and Akt inhibitor, respectively, document that normal cells require simultaneous erk and jnk signaling for survival, plus akt signaling for proliferation.	pyrazolanthrone	63-71	AKT serine/threonine kinase 1	Homo sapiens	37-40
15347384-13	2004	Individually, SP600125 and PD98059, but not SB203580, could partly reverse the reduction induced by IL-1beta.	pyrazolanthrone	14-22	interleukin 1 beta	Mus musculus	100-108
15365619-10	2004	However, in the presence of SP600125, an inhibitor of JNK, TNF-alpha still produced insulin resistance.	pyrazolanthrone	28-36	tumor necrosis factor	Rattus norvegicus	59-68
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	pyrazolanthrone	172-180	interleukin 1 beta	Rattus norvegicus	35-43
15341531-6	2004	Consistently, IL-1beta-stimulated translocation of NF-kappaB into the nucleus and degradation of inhibitory kappa B-alpha (IkappaB-alpha) was revealed by western blotting and immunofluorescence staining, which was blocked by helenalin, but not by U0126, SB202190, or SP600125.	pyrazolanthrone	267-275	interleukin 1 beta	Rattus norvegicus	14-22
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	pyrazolanthrone	172-180	mitogen activated protein kinase 3	Rattus norvegicus	78-86
15341531-6	2004	Consistently, IL-1beta-stimulated translocation of NF-kappaB into the nucleus and degradation of inhibitory kappa B-alpha (IkappaB-alpha) was revealed by western blotting and immunofluorescence staining, which was blocked by helenalin, but not by U0126, SB202190, or SP600125.	pyrazolanthrone	267-275	NFKB inhibitor alpha	Rattus norvegicus	123-136
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	pyrazolanthrone	172-180	mitogen-activated protein kinase 8	Rattus norvegicus	97-120
15341531-4	2004	In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively.	pyrazolanthrone	172-180	mitogen-activated protein kinase 8	Rattus norvegicus	122-125
15358141-5	2004	Moreover, EA could activate c-Jun NH(2)-terminal kinase (JNK) and p38 kinase, and JNK-specific inhibitor SP600125 and p38 kinase-specific inhibitor SB200235 could block serial molecular events of EA-induced apoptosis such as Bid truncation, Bcl-2 reduction, cytochrome c release, caspase activation, and DNA fragmentation in HepG2 cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	82-85
15184882-7	2004	Phosphorylation of Bcl-2 in DATS-treated PC-3 cells was fully blocked in the presence of JNK-specific inhibitor SP600125.	pyrazolanthrone	112-120	BCL2 apoptosis regulator	Homo sapiens	19-24
15358225-4	2004	A specific inhibitor of JNK, SP600125, abolished paclitaxel-induced HO-1 mRNA expression, whereas PD98059, a specific inhibitor of ERK, and SB203580, a specific inhibitor of p38, had no significant effect.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Rattus norvegicus	24-27
15358225-4	2004	A specific inhibitor of JNK, SP600125, abolished paclitaxel-induced HO-1 mRNA expression, whereas PD98059, a specific inhibitor of ERK, and SB203580, a specific inhibitor of p38, had no significant effect.	pyrazolanthrone	29-37	heme oxygenase 1	Rattus norvegicus	68-72
15388230-5	2004	Inhibition of c-jun-NH2-terminal kinase (JNK) by using both dicoumarol and SP600125 totally inhibited the stimulatory effect of hypoosmolarity.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	14-39
15388230-5	2004	Inhibition of c-jun-NH2-terminal kinase (JNK) by using both dicoumarol and SP600125 totally inhibited the stimulatory effect of hypoosmolarity.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	41-44
15197348-5	2004	The reduction in cell growth and enhancement in cell killing by the combination of GST-MDA-7 and radiation were blocked by an ROS scavenger, N-acetyl cysteine (NAC), a JNK1/2/3 inhibitor SP600125, a pan-caspase inhibitor (zVAD) and by an inhibitor of caspase 9 (LEHD), but not by an inhibitor of caspase 8 (IETD).	pyrazolanthrone	187-195	interleukin 24	Homo sapiens	87-92
15197348-5	2004	The reduction in cell growth and enhancement in cell killing by the combination of GST-MDA-7 and radiation were blocked by an ROS scavenger, N-acetyl cysteine (NAC), a JNK1/2/3 inhibitor SP600125, a pan-caspase inhibitor (zVAD) and by an inhibitor of caspase 9 (LEHD), but not by an inhibitor of caspase 8 (IETD).	pyrazolanthrone	187-195	mitogen-activated protein kinase 8	Homo sapiens	168-176
15056726-3	2004	We here evaluated the effects of SP600125 (anthra[1,9-cd]pyrazole-6 (2H)-one), an inhibitor of c-Jun NH(2)-terminal kinase (JNK), on the activation of PSCs.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	95-122
15056726-3	2004	We here evaluated the effects of SP600125 (anthra[1,9-cd]pyrazole-6 (2H)-one), an inhibitor of c-Jun NH(2)-terminal kinase (JNK), on the activation of PSCs.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Rattus norvegicus	124-127
15056726-10	2004	SP600125 inhibited interleukin-1beta-induced JNK activity and activator protein-1 activation, but it did not affect the activation of extracellular-regulated kinase, p38 mitogen-activated protein kinase, and nuclear factor-kappaB.	pyrazolanthrone	0-8	interleukin 1 beta	Rattus norvegicus	19-36
15056726-10	2004	SP600125 inhibited interleukin-1beta-induced JNK activity and activator protein-1 activation, but it did not affect the activation of extracellular-regulated kinase, p38 mitogen-activated protein kinase, and nuclear factor-kappaB.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	45-48
15056726-11	2004	SP600125 inhibited platelet-derived growth factor-induced proliferation, inducible monocyte chemoattractant protein-1 production, and serum-induced type I collagen production.	pyrazolanthrone	0-8	C-C motif chemokine ligand 2	Rattus norvegicus	83-117
15155744-4	2004	These effects are diminished by the specific JNK inhibitor SP600125 and the antioxidant manganese(III) tetrakis (4-benzoic acid) porphyrin in vitro.	pyrazolanthrone	59-67	mitogen-activated protein kinase 8	Mus musculus	45-48
15249198-4	2004	Conversely, the JNK inhibitor (SP600125) enhanced the synthesis of glycosaminoglycan and expression of chondrogenic differentiation markers.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Mus musculus	16-19
15249198-10	2004	Inhibitory effects of U0126 or stimulatory effects of SP600125 on insulin-induced chondrogenic differentiation were observed when these inhibitors exist in the early phase of differentiation, suggesting that MEK/ERK and JNK act on early phase differentiation.	pyrazolanthrone	54-62	midkine	Mus musculus	208-211
15249198-10	2004	Inhibitory effects of U0126 or stimulatory effects of SP600125 on insulin-induced chondrogenic differentiation were observed when these inhibitors exist in the early phase of differentiation, suggesting that MEK/ERK and JNK act on early phase differentiation.	pyrazolanthrone	54-62	mitogen-activated protein kinase 1	Mus musculus	212-215
15249198-10	2004	Inhibitory effects of U0126 or stimulatory effects of SP600125 on insulin-induced chondrogenic differentiation were observed when these inhibitors exist in the early phase of differentiation, suggesting that MEK/ERK and JNK act on early phase differentiation.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Mus musculus	220-223
15059850-4	2004	Treatment with the JNK inhibitor SP600125 inhibited JNK activity and EPO-dependent proliferation of HCD57 cells and the human EPO-dependent cell lines TF-1 and UT7-EPO.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Mus musculus	19-22
15059850-4	2004	Treatment with the JNK inhibitor SP600125 inhibited JNK activity and EPO-dependent proliferation of HCD57 cells and the human EPO-dependent cell lines TF-1 and UT7-EPO.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Mus musculus	52-55
15059850-4	2004	Treatment with the JNK inhibitor SP600125 inhibited JNK activity and EPO-dependent proliferation of HCD57 cells and the human EPO-dependent cell lines TF-1 and UT7-EPO.	pyrazolanthrone	33-41	erythropoietin	Mus musculus	69-72
15059850-4	2004	Treatment with the JNK inhibitor SP600125 inhibited JNK activity and EPO-dependent proliferation of HCD57 cells and the human EPO-dependent cell lines TF-1 and UT7-EPO.	pyrazolanthrone	33-41	erythropoietin	Homo sapiens	126-129
15059850-4	2004	Treatment with the JNK inhibitor SP600125 inhibited JNK activity and EPO-dependent proliferation of HCD57 cells and the human EPO-dependent cell lines TF-1 and UT7-EPO.	pyrazolanthrone	33-41	erythropoietin	Mus musculus	126-129
15145928-7	2004	Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants.	pyrazolanthrone	42-50	major intrinsic protein of lens fiber	Rattus norvegicus	70-73
15145928-7	2004	Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants.	pyrazolanthrone	42-50	fibroblast growth factor 2	Rattus norvegicus	100-105
15184882-7	2004	Phosphorylation of Bcl-2 in DATS-treated PC-3 cells was fully blocked in the presence of JNK-specific inhibitor SP600125.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	89-92
15212943-8	2004	In addition, treatment of TNX-/- fibroblasts with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, and genistein, a tyrosine kinase inhibitor, suppressed the increased level of proMMP-2 and increased MMP-2 promoter activity in TNX-/- fibroblasts.	pyrazolanthrone	50-58	tenascin XB	Mus musculus	26-29
15126504-7	2004	Activation of JNK1 by anisomycin further increased Tau phosphorylation, and SP600125 (a JNK inhibitor) and PD-98059 (an MEK1/2 inhibitor) blocked Tau phosphorylation and NFT formation in these WOX1 knock-down cells.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Homo sapiens	14-17
15126504-7	2004	Activation of JNK1 by anisomycin further increased Tau phosphorylation, and SP600125 (a JNK inhibitor) and PD-98059 (an MEK1/2 inhibitor) blocked Tau phosphorylation and NFT formation in these WOX1 knock-down cells.	pyrazolanthrone	76-84	microtubule associated protein tau	Homo sapiens	146-149
15207722-3	2004	RT-PCR analysis and gene reporter assays using the human tPA promoter indicated that upregulation of the tPA gene transcription by both Neovastat and TNFalpha was correlated with the phosphorylation of JNK1/2 and of IkappaB and that SP600125 and BAY11-7082, inhibitors of JNK and IkappaK, respectively, inhibit the increase of tPA gene transcription induced by Neovastat and TNFalpha.	pyrazolanthrone	233-241	plasminogen activator, tissue type	Homo sapiens	57-60
15207722-3	2004	RT-PCR analysis and gene reporter assays using the human tPA promoter indicated that upregulation of the tPA gene transcription by both Neovastat and TNFalpha was correlated with the phosphorylation of JNK1/2 and of IkappaB and that SP600125 and BAY11-7082, inhibitors of JNK and IkappaK, respectively, inhibit the increase of tPA gene transcription induced by Neovastat and TNFalpha.	pyrazolanthrone	233-241	plasminogen activator, tissue type	Homo sapiens	105-108
15207722-3	2004	RT-PCR analysis and gene reporter assays using the human tPA promoter indicated that upregulation of the tPA gene transcription by both Neovastat and TNFalpha was correlated with the phosphorylation of JNK1/2 and of IkappaB and that SP600125 and BAY11-7082, inhibitors of JNK and IkappaK, respectively, inhibit the increase of tPA gene transcription induced by Neovastat and TNFalpha.	pyrazolanthrone	233-241	tumor necrosis factor	Homo sapiens	150-158
15207722-3	2004	RT-PCR analysis and gene reporter assays using the human tPA promoter indicated that upregulation of the tPA gene transcription by both Neovastat and TNFalpha was correlated with the phosphorylation of JNK1/2 and of IkappaB and that SP600125 and BAY11-7082, inhibitors of JNK and IkappaK, respectively, inhibit the increase of tPA gene transcription induced by Neovastat and TNFalpha.	pyrazolanthrone	233-241	plasminogen activator, tissue type	Homo sapiens	105-108
15212943-8	2004	In addition, treatment of TNX-/- fibroblasts with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, and genistein, a tyrosine kinase inhibitor, suppressed the increased level of proMMP-2 and increased MMP-2 promoter activity in TNX-/- fibroblasts.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Mus musculus	62-85
15212943-8	2004	In addition, treatment of TNX-/- fibroblasts with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, and genistein, a tyrosine kinase inhibitor, suppressed the increased level of proMMP-2 and increased MMP-2 promoter activity in TNX-/- fibroblasts.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Mus musculus	87-90
15212943-8	2004	In addition, treatment of TNX-/- fibroblasts with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, and genistein, a tyrosine kinase inhibitor, suppressed the increased level of proMMP-2 and increased MMP-2 promoter activity in TNX-/- fibroblasts.	pyrazolanthrone	50-58	matrix metallopeptidase 2	Mus musculus	184-189
15212943-8	2004	In addition, treatment of TNX-/- fibroblasts with SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, and genistein, a tyrosine kinase inhibitor, suppressed the increased level of proMMP-2 and increased MMP-2 promoter activity in TNX-/- fibroblasts.	pyrazolanthrone	50-58	tenascin XB	Mus musculus	231-234
15212945-12	2004	Moreover, pretreatment of specific inhibitor of JNK SP600125 blocked the 15-deoxy-PGJ(2)-induced JNK activation.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	48-51
15212945-12	2004	Moreover, pretreatment of specific inhibitor of JNK SP600125 blocked the 15-deoxy-PGJ(2)-induced JNK activation.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Rattus norvegicus	97-100
15016614-6	2004	SB203580 and SP600125 dose-dependently inhibited CCL2 secretion and gene expression induced by IL-1 or TNF.	pyrazolanthrone	13-21	C-C motif chemokine ligand 2	Homo sapiens	49-53
15226308-3	2004	Treatment with the JNK inhibitor, SP600125, caused similar effects, whereas normal organization of the mammary epithelial cells as acini caused JNK activation in a glucocorticoid-dependent manner.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	19-22
15016614-6	2004	SB203580 and SP600125 dose-dependently inhibited CCL2 secretion and gene expression induced by IL-1 or TNF.	pyrazolanthrone	13-21	tumor necrosis factor	Homo sapiens	103-106
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	33-58
15001534-4	2004	Inhibition of paclitaxel-induced c-jun NH2-terminal kinase (JNK) activation by treatment with a specific inhibitor, SP600125, or overexpression of a dominant-negative mutant form of upstream kinases, MEK kinase 1 (MEKK1) and mitogen-activated protein kinase kinase (MKK) 7, significantly reduced the increase in phosphorylated FADD.	pyrazolanthrone	116-124	mitogen-activated protein kinase 8	Homo sapiens	60-63
15194466-9	2004	The Cx43 mRNA increased maximally to 4.2-fold at 6 h after addition of amphetamine and returned to the baseline level at 48 h. These increases of Cx43 protein at 24 h were completely attenuated (P&lt;0.001) by SP600125 (20 microM) and JNK1 dsRNAi.	pyrazolanthrone	210-218	gap junction protein, alpha 1	Rattus norvegicus	4-8
15115662-3	2004	The JNK inhibitor, SP 600125, effectively reversed the inhibitory effects of cAMP on iNOS expression and significantly increased iNOS promoter activity.	pyrazolanthrone	19-28	mitogen-activated protein kinase 8	Homo sapiens	4-7
15194466-10	2004	Amphetamine increased and SP600125 decreased the immunohistochemical labeling of Cx43.	pyrazolanthrone	26-34	gap junction protein, alpha 1	Rattus norvegicus	81-85
15115662-3	2004	The JNK inhibitor, SP 600125, effectively reversed the inhibitory effects of cAMP on iNOS expression and significantly increased iNOS promoter activity.	pyrazolanthrone	19-28	nitric oxide synthase 2	Homo sapiens	85-89
15194466-11	2004	Amphetamine increased and SP600125 decreased the phosphorylated JNK and c-Jun proteins.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Rattus norvegicus	64-67
15115662-3	2004	The JNK inhibitor, SP 600125, effectively reversed the inhibitory effects of cAMP on iNOS expression and significantly increased iNOS promoter activity.	pyrazolanthrone	19-28	nitric oxide synthase 2	Homo sapiens	129-133
15115662-5	2004	The JNK activator, anisomycin, inhibited iNOS expression and transcription in hepatocytes as well as AP-1 binding activity; and SP600125 reversed this effect of anisomycin.	pyrazolanthrone	128-136	mitogen-activated protein kinase 8	Homo sapiens	4-7
15018608-7	2004	Furthermore, treatment of mIMCD3 cells with MAPK (mitogen-activated protein kinase) inhibitors (SB203580, PD98059, U0126 and SP600125) and a proteasome inhibitor (MG132) suppressed the increase in Osp94 gene expression caused by hypertonic NaCl.	pyrazolanthrone	125-133	heat shock protein 4 like	Mus musculus	197-202
15194466-9	2004	The Cx43 mRNA increased maximally to 4.2-fold at 6 h after addition of amphetamine and returned to the baseline level at 48 h. These increases of Cx43 protein at 24 h were completely attenuated (P&lt;0.001) by SP600125 (20 microM) and JNK1 dsRNAi.	pyrazolanthrone	210-218	gap junction protein, alpha 1	Rattus norvegicus	146-150
15084499-7	2004	Stimulation of proliferation by the CaR involves the Jun-terminal kinase (JNK) pathway, as high Ca(2+)(o) stimulated the phosphorylation of JNK in a CaR-mediated manner, and the JNK inhibitor SP600125 abolished CaR-induced proliferation.	pyrazolanthrone	192-200	calcium-sensing receptor	Rattus norvegicus	36-39
15084499-7	2004	Stimulation of proliferation by the CaR involves the Jun-terminal kinase (JNK) pathway, as high Ca(2+)(o) stimulated the phosphorylation of JNK in a CaR-mediated manner, and the JNK inhibitor SP600125 abolished CaR-induced proliferation.	pyrazolanthrone	192-200	mitogen-activated protein kinase 8	Rattus norvegicus	53-72
15084499-7	2004	Stimulation of proliferation by the CaR involves the Jun-terminal kinase (JNK) pathway, as high Ca(2+)(o) stimulated the phosphorylation of JNK in a CaR-mediated manner, and the JNK inhibitor SP600125 abolished CaR-induced proliferation.	pyrazolanthrone	192-200	mitogen-activated protein kinase 8	Rattus norvegicus	74-77
15196213-2	2004	We examined the effect of SP600125 (anthra [1,9-cd] pyrazol-6 (2H)-one), a novel inhibitor of JNK in a model of asthma.	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Rattus norvegicus	94-97
15252145-9	2004	Furthermore, nobiletin enhancement of TIMP-1 production in TPA-stimulated HT-1080 cells was found to be diminished by adding a JNK inhibitor, SP600125.	pyrazolanthrone	142-150	TIMP metallopeptidase inhibitor 1	Homo sapiens	38-44
15252145-9	2004	Furthermore, nobiletin enhancement of TIMP-1 production in TPA-stimulated HT-1080 cells was found to be diminished by adding a JNK inhibitor, SP600125.	pyrazolanthrone	142-150	mitogen-activated protein kinase 8	Homo sapiens	127-130
15205382-6	2004	In addition, we demonstrated that SP600125 dose-dependently inhibited the CYP3A4 promoter activity induced by 1,25(OH)(2)D(3) using the reporter plasmid of the CYP3A4 promoter.	pyrazolanthrone	34-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	74-80
15205382-6	2004	In addition, we demonstrated that SP600125 dose-dependently inhibited the CYP3A4 promoter activity induced by 1,25(OH)(2)D(3) using the reporter plasmid of the CYP3A4 promoter.	pyrazolanthrone	34-42	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	160-166
15141161-0	2004	Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125.	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Homo sapiens	49-53
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	23-26
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	tumor necrosis factor	Homo sapiens	73-76
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	85-88
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	BH3 interacting domain death agonist	Homo sapiens	101-104
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	BCL2 associated X, apoptosis regulator	Homo sapiens	119-122
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	cytochrome c, somatic	Homo sapiens	180-192
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	tumor necrosis factor	Homo sapiens	231-234
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	85-88
15117824-6	2004	We further show that a JNK-specific inhibitor SP600125 completely blocks TNF induced JNK activation, Bid cleavage, and Bax mitochondrial translocation, but only partially inhibits cytochrome c release and EC death, suggesting that TNF induces both JNK-dependent and JNK-independent apoptotic pathways in EC.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	85-88
15064713-8	2004	Inhibition of the c-jun N-terminal kinase MAPK pathway by SP600125 partially abolished TRO-induced GADD45 mRNA, and protein expression and apoptosis.	pyrazolanthrone	58-66	growth arrest and DNA damage inducible alpha	Homo sapiens	99-105
15141161-6	2004	In addition, we also determined the ternary complex structure of pepJIP1-bound JNK1 complexed with SP600125, an ATP-competitive inhibitor of JNK, providing the basis for the JNK specificity of the compound.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	79-83
15141161-6	2004	In addition, we also determined the ternary complex structure of pepJIP1-bound JNK1 complexed with SP600125, an ATP-competitive inhibitor of JNK, providing the basis for the JNK specificity of the compound.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	79-82
15141161-6	2004	In addition, we also determined the ternary complex structure of pepJIP1-bound JNK1 complexed with SP600125, an ATP-competitive inhibitor of JNK, providing the basis for the JNK specificity of the compound.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Homo sapiens	141-144
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	pyrazolanthrone	41-49	mitogen-activated protein kinase 14	Homo sapiens	84-87
14764449-9	2004	The JNK inhibitor SP-600125 (0.1 mM) significantly increased TER and resulted in COX-2 upregulation.	pyrazolanthrone	18-27	mitogen-activated protein kinase 8	Homo sapiens	4-7
14764449-9	2004	The JNK inhibitor SP-600125 (0.1 mM) significantly increased TER and resulted in COX-2 upregulation.	pyrazolanthrone	18-27	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	81-86
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	93-96
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	pyrazolanthrone	41-49	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	139-144
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	pyrazolanthrone	41-49	mitogen-activated protein kinase 14	Homo sapiens	208-211
15044466-7	2004	To investigate which of the mitogen-activated protein kinase (MAPK) pathways involves in the expression of MMP-13, inhibitors such as PD98059, SB203580, and SP600125 were used.	pyrazolanthrone	157-165	matrix metallopeptidase 13	Mus musculus	107-113
15161854-9	2004	Ly294002 as well as U0126, SB202190, and SP600125, the selective inhibitors of MEK, p38, and JNK, respectively, strongly inhibited induced c-fos expression, whereas Ly294002 did not inhibit induction of MEK, p38, or JNK.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	216-219
14978197-7	2004	When SP600125 was added simultaneously, MG132 completely inhibited TNF-alpha-induced CCL2/MCP-1 production.	pyrazolanthrone	5-13	C-C motif chemokine ligand 2	Rattus norvegicus	85-89
14978197-7	2004	When SP600125 was added simultaneously, MG132 completely inhibited TNF-alpha-induced CCL2/MCP-1 production.	pyrazolanthrone	5-13	C-C motif chemokine ligand 2	Rattus norvegicus	90-95
15196703-4	2004	SP600125, a specific inhibitor of SAPK/JNK, markedly reduced the PGE(1)-induced VEGF synthesis.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Mus musculus	80-84
15196703-7	2004	The phosphorylation of c-Jun induced by PGE(1) was also inhibited by SP600125.	pyrazolanthrone	69-77	jun proto-oncogene	Mus musculus	23-28
15196703-9	2004	A combination of SP600125 and SB203580 suppressed the PGE(1)-stimulated VEGF synthesis in an additive manner.	pyrazolanthrone	17-25	vascular endothelial growth factor A	Mus musculus	72-76
15110769-6	2004	Both these effects were inhibited in a concentration-dependent manner in the presence of MAPK inhibitors specific for p44/42 (PD98059) and JNK (SP600125).	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	139-142
14978197-5	2004	PD98059 abolished TNF-alpha-activated p42/44 MAPK phosphorylation and c-Fos up-regulation, whereas SP600125 inhibited TNF-alpha-activated JNK and c-Jun phosphorylation.	pyrazolanthrone	99-107	tumor necrosis factor	Rattus norvegicus	118-127
14978197-5	2004	PD98059 abolished TNF-alpha-activated p42/44 MAPK phosphorylation and c-Fos up-regulation, whereas SP600125 inhibited TNF-alpha-activated JNK and c-Jun phosphorylation.	pyrazolanthrone	99-107	mitogen-activated protein kinase 8	Rattus norvegicus	138-141
14978197-7	2004	When SP600125 was added simultaneously, MG132 completely inhibited TNF-alpha-induced CCL2/MCP-1 production.	pyrazolanthrone	5-13	tumor necrosis factor	Rattus norvegicus	67-76
15130758-7	2004	For the evaluation of the role of MAPKs, PD98059, SB202190 and SP600125 were used as MAPK inhibitors for ERK-1/2, p38 and JNK.	pyrazolanthrone	63-71	mitogen-activated protein kinase 3	Homo sapiens	105-112
15130758-7	2004	For the evaluation of the role of MAPKs, PD98059, SB202190 and SP600125 were used as MAPK inhibitors for ERK-1/2, p38 and JNK.	pyrazolanthrone	63-71	mitogen-activated protein kinase 1	Homo sapiens	114-117
15130758-10	2004	Similarly, SB202190 and SP600125 significantly disturbed the caspase-3 activity after a co-treatment with cantharidin by colorimetric assay.	pyrazolanthrone	24-32	caspase 3	Homo sapiens	61-70
15130759-8	2004	However, inhibition of the JNK activity with SP600125 did not block tetrandrine-induced apoptosis.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	27-30
15027120-7	2004	Promoter activity of the 0.6 kb construct was suppressed with SP600125, a potent inhibitor of JNK, but not with PD98059 and SB203580, potent inhibitors of MEK1/2 and p38, respectively.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	94-97
15027120-8	2004	The inhibitory effect of SP600125 was also observed at protein expression level and in enzymatic activity of MMP-1.	pyrazolanthrone	25-33	matrix metallopeptidase 1	Homo sapiens	109-114
15093752-3	2004	Bortezomib-mediated cytochrome c release and caspase activation were blocked by the pharmacologic JNK inhibitor SP600125, but lethality was not diminished by the p38 MAPK inhibitor SB203580.	pyrazolanthrone	112-120	cytochrome c, somatic	Homo sapiens	20-32
14722032-9	2004	SP-600125 (a JNK inhibitor) and SB-202190 (a p38 MAP kinase inhibitor) completely blocked epinephrine-induced IL-6 synthesis.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	110-114
15093752-3	2004	Bortezomib-mediated cytochrome c release and caspase activation were blocked by the pharmacologic JNK inhibitor SP600125, but lethality was not diminished by the p38 MAPK inhibitor SB203580.	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	98-101
15040011-4	2004	TGF-beta induction of both JNK1 activity and JunD phosphorylation was blocked by expression of a dominant-negative mutant of the type II TGF-beta receptor (DN TbetaRII), a dominant-negative mutant of MKK4 (DN MKK4), or a dominant-negative mutant of Ras (RasN17), or by the addition of the JNK inhibitor SP600125.	pyrazolanthrone	303-311	transforming growth factor beta 1	Homo sapiens	0-8
15040011-4	2004	TGF-beta induction of both JNK1 activity and JunD phosphorylation was blocked by expression of a dominant-negative mutant of the type II TGF-beta receptor (DN TbetaRII), a dominant-negative mutant of MKK4 (DN MKK4), or a dominant-negative mutant of Ras (RasN17), or by the addition of the JNK inhibitor SP600125.	pyrazolanthrone	303-311	mitogen-activated protein kinase 8	Homo sapiens	27-31
15040011-4	2004	TGF-beta induction of both JNK1 activity and JunD phosphorylation was blocked by expression of a dominant-negative mutant of the type II TGF-beta receptor (DN TbetaRII), a dominant-negative mutant of MKK4 (DN MKK4), or a dominant-negative mutant of Ras (RasN17), or by the addition of the JNK inhibitor SP600125.	pyrazolanthrone	303-311	mitogen-activated protein kinase 8	Homo sapiens	27-30
15040011-7	2004	Moreover, addition of SP600125, or expression of DN MKK4 or DN TbetaRII, blocked TGF-beta up-regulation of uPAR in IECs.	pyrazolanthrone	22-30	transforming growth factor beta 1	Homo sapiens	81-89
15095415-8	2004	In addition, we found that SP600125, a JNK-specific inhibitor, reduced PDT-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for PDT-induced caspase activation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	39-42
15040011-7	2004	Moreover, addition of SP600125, or expression of DN MKK4 or DN TbetaRII, blocked TGF-beta up-regulation of uPAR in IECs.	pyrazolanthrone	22-30	plasminogen activator, urokinase receptor	Homo sapiens	107-111
15095415-8	2004	In addition, we found that SP600125, a JNK-specific inhibitor, reduced PDT-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for PDT-induced caspase activation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	83-86
15095415-8	2004	In addition, we found that SP600125, a JNK-specific inhibitor, reduced PDT-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for PDT-induced caspase activation.	pyrazolanthrone	27-35	caspase 3	Homo sapiens	109-118
15135155-8	2004	The inhibition of activation of JNK as a possible mechanism whereby DMAP affects insulin-induced antilipolysis, lipogenesis, and glucose uptake, was investigated using the JNK inhibitor SP600125.	pyrazolanthrone	186-194	mitogen-activated protein kinase 8	Homo sapiens	32-35
15095415-8	2004	In addition, we found that SP600125, a JNK-specific inhibitor, reduced PDT-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for PDT-induced caspase activation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	83-86
15135155-9	2004	At 100 micromol/L, SP600125 completely reversed the antilipolytic effect of insulin, as well as partially inhibited insulin-induced lipogenesis and glucose-uptake, indicating that JNK may be involved in mediating these actions of insulin.	pyrazolanthrone	19-27	insulin	Homo sapiens	76-83
15135155-9	2004	At 100 micromol/L, SP600125 completely reversed the antilipolytic effect of insulin, as well as partially inhibited insulin-induced lipogenesis and glucose-uptake, indicating that JNK may be involved in mediating these actions of insulin.	pyrazolanthrone	19-27	insulin	Homo sapiens	116-123
15135155-9	2004	At 100 micromol/L, SP600125 completely reversed the antilipolytic effect of insulin, as well as partially inhibited insulin-induced lipogenesis and glucose-uptake, indicating that JNK may be involved in mediating these actions of insulin.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	180-183
15135155-9	2004	At 100 micromol/L, SP600125 completely reversed the antilipolytic effect of insulin, as well as partially inhibited insulin-induced lipogenesis and glucose-uptake, indicating that JNK may be involved in mediating these actions of insulin.	pyrazolanthrone	19-27	insulin	Homo sapiens	116-123
14963047-8	2004	A role for JNK in the survival of FL5.12 cells was supported by the observation that the JNK inhibitor SP600125 suppressed IGF-I-mediated protection from apoptosis.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Mus musculus	11-14
15062846-4	2004	SP600125, a specific inhibitor of SAPK/JNK, markedly reduced the PGF2(alpha)-stimulated HSP27 accumulation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	39-42
15062846-4	2004	SP600125, a specific inhibitor of SAPK/JNK, markedly reduced the PGF2(alpha)-stimulated HSP27 accumulation.	pyrazolanthrone	0-8	heat shock protein 1	Mus musculus	88-93
15062846-6	2004	SP600125 reduced the PGF2(alpha)-increased level of HSP27 mRNA.	pyrazolanthrone	0-8	heat shock protein 1	Mus musculus	52-57
15062846-7	2004	SP600125 suppressed the phosphorylation of SAPK/JNK induced by PGF2(alpha), but did not affect the PGF2(alpha)-induced phosphorylation of p44/p42 MAP kinase.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	48-51
14963047-8	2004	A role for JNK in the survival of FL5.12 cells was supported by the observation that the JNK inhibitor SP600125 suppressed IGF-I-mediated protection from apoptosis.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Mus musculus	89-92
14963047-8	2004	A role for JNK in the survival of FL5.12 cells was supported by the observation that the JNK inhibitor SP600125 suppressed IGF-I-mediated protection from apoptosis.	pyrazolanthrone	103-111	insulin-like growth factor 1	Mus musculus	123-128
14766760-4	2004	Consequently, we have used the recently described specific JNK inhibitor SP600125 and RNA interference to inhibit endogenous JNK activity in the prostate carcinoma cell line DU 145.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	59-62
15150444-6	2004	The selenite-induced cell death was attenuated by SP600125, a specific inhibitor of JNK, and by dominant negative JNK1 (DN-JNK1).	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Homo sapiens	84-87
14764603-5	2004	However, in the presence of PD98059 or SP600125, inhibitors of p42/p44 MAPK or JNK, respectively, insulin resistance by TNF-alpha was still produced.	pyrazolanthrone	39-47	mitogen activated protein kinase 3	Rattus norvegicus	67-70
14764603-5	2004	However, in the presence of PD98059 or SP600125, inhibitors of p42/p44 MAPK or JNK, respectively, insulin resistance by TNF-alpha was still produced.	pyrazolanthrone	39-47	mitogen activated protein kinase 3	Rattus norvegicus	71-75
14766760-4	2004	Consequently, we have used the recently described specific JNK inhibitor SP600125 and RNA interference to inhibit endogenous JNK activity in the prostate carcinoma cell line DU 145.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Homo sapiens	125-128
14764603-5	2004	However, in the presence of PD98059 or SP600125, inhibitors of p42/p44 MAPK or JNK, respectively, insulin resistance by TNF-alpha was still produced.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Rattus norvegicus	79-82
14764603-5	2004	However, in the presence of PD98059 or SP600125, inhibitors of p42/p44 MAPK or JNK, respectively, insulin resistance by TNF-alpha was still produced.	pyrazolanthrone	39-47	tumor necrosis factor	Rattus norvegicus	120-129
15048731-8	2004	The LPS and poly-I-C enhancement of bradykinin-induced contraction was inhibited by the transcriptional inhibitor actinomycin-D, dexamethasone, the proteasome inhibitor MG-132 and the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	224-232	mitogen-activated protein kinase 8	Mus musculus	184-207
15020231-6	2004	Catalase-induced COX-2 expression was abrogated by treatment of MG-132 (a NF-kappaB inhibitor) or LY294002 (a PI3K inhibitor), but not by treatment of PD98059 (an ERK inhibitor), SB203580 (a p38 inhibitor), or SP600125 (a JNK inhibitor).	pyrazolanthrone	210-218	catalase	Homo sapiens	0-8
15020231-6	2004	Catalase-induced COX-2 expression was abrogated by treatment of MG-132 (a NF-kappaB inhibitor) or LY294002 (a PI3K inhibitor), but not by treatment of PD98059 (an ERK inhibitor), SB203580 (a p38 inhibitor), or SP600125 (a JNK inhibitor).	pyrazolanthrone	210-218	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	17-22
14645003-7	2004	Inhibiting JNK activation with SP600125 or D-JNKI1 peptide markedly reduced Bay/UCN-01-mediated mitochondrial dysfunction and apoptosis and the down-regulation of Mcl-1, XIAP, and Bcl-xL but not of cdc2/cdk1 activation.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	11-14
14645003-7	2004	Inhibiting JNK activation with SP600125 or D-JNKI1 peptide markedly reduced Bay/UCN-01-mediated mitochondrial dysfunction and apoptosis and the down-regulation of Mcl-1, XIAP, and Bcl-xL but not of cdc2/cdk1 activation.	pyrazolanthrone	31-39	urocortin	Homo sapiens	80-83
14645003-7	2004	Inhibiting JNK activation with SP600125 or D-JNKI1 peptide markedly reduced Bay/UCN-01-mediated mitochondrial dysfunction and apoptosis and the down-regulation of Mcl-1, XIAP, and Bcl-xL but not of cdc2/cdk1 activation.	pyrazolanthrone	31-39	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	163-168
14645003-7	2004	Inhibiting JNK activation with SP600125 or D-JNKI1 peptide markedly reduced Bay/UCN-01-mediated mitochondrial dysfunction and apoptosis and the down-regulation of Mcl-1, XIAP, and Bcl-xL but not of cdc2/cdk1 activation.	pyrazolanthrone	31-39	X-linked inhibitor of apoptosis	Homo sapiens	170-174
14645003-7	2004	Inhibiting JNK activation with SP600125 or D-JNKI1 peptide markedly reduced Bay/UCN-01-mediated mitochondrial dysfunction and apoptosis and the down-regulation of Mcl-1, XIAP, and Bcl-xL but not of cdc2/cdk1 activation.	pyrazolanthrone	31-39	BCL2 like 1	Homo sapiens	180-186
14645003-7	2004	Inhibiting JNK activation with SP600125 or D-JNKI1 peptide markedly reduced Bay/UCN-01-mediated mitochondrial dysfunction and apoptosis and the down-regulation of Mcl-1, XIAP, and Bcl-xL but not of cdc2/cdk1 activation.	pyrazolanthrone	31-39	cyclin dependent kinase 1	Homo sapiens	198-202
14645003-7	2004	Inhibiting JNK activation with SP600125 or D-JNKI1 peptide markedly reduced Bay/UCN-01-mediated mitochondrial dysfunction and apoptosis and the down-regulation of Mcl-1, XIAP, and Bcl-xL but not of cdc2/cdk1 activation.	pyrazolanthrone	31-39	cyclin dependent kinase 1	Homo sapiens	203-207
14996543-3	2004	The anthra[1,9-cd]pyrazol-6(2H)-one, SP600125, was used to inhibit c-Jun N-terminal kinase (JNK) activity, which is believed to mediate cell death.	pyrazolanthrone	4-35	mitogen-activated protein kinase 8	Homo sapiens	67-90
15034932-8	2004	SP600125 decreased not only the phosphorylation level of jun protein but also AP-1/DNA binding activity.	pyrazolanthrone	0-8	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	78-82
15034932-9	2004	Also, apoptosis was observed to be induced by SP600125, concomitant with the increase in c-myc, p53, and bax protein level.	pyrazolanthrone	46-54	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	89-94
15034932-9	2004	Also, apoptosis was observed to be induced by SP600125, concomitant with the increase in c-myc, p53, and bax protein level.	pyrazolanthrone	46-54	tumor protein p53	Homo sapiens	96-99
15034932-9	2004	Also, apoptosis was observed to be induced by SP600125, concomitant with the increase in c-myc, p53, and bax protein level.	pyrazolanthrone	46-54	BCL2 associated X, apoptosis regulator	Homo sapiens	105-108
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	pyrazolanthrone	41-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	79-84
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	pyrazolanthrone	41-49	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	149-154
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	pyrazolanthrone	41-49	tumor protein p53	Homo sapiens	156-159
15034932-11	2004	When the cells were treated with NDGA or SP600125 in the presence of antisense c-myc oligonucleotides, apoptosis was not observed and an increase of c-myc, p53, and bax proteins was not manifested.	pyrazolanthrone	41-49	BCL2 associated X, apoptosis regulator	Homo sapiens	165-168
14766793-2	2004	In primary rat hepatocytes expressing an IkappaB superrepressor, the JNK inhibitor SP600125 strongly decreased TNF-alpha-induced cell death, caspase 3 activation, and DNA laddering.	pyrazolanthrone	83-91	mitogen-activated protein kinase 8	Rattus norvegicus	69-72
14766793-2	2004	In primary rat hepatocytes expressing an IkappaB superrepressor, the JNK inhibitor SP600125 strongly decreased TNF-alpha-induced cell death, caspase 3 activation, and DNA laddering.	pyrazolanthrone	83-91	tumor necrosis factor	Rattus norvegicus	111-120
14766793-2	2004	In primary rat hepatocytes expressing an IkappaB superrepressor, the JNK inhibitor SP600125 strongly decreased TNF-alpha-induced cell death, caspase 3 activation, and DNA laddering.	pyrazolanthrone	83-91	caspase 3	Rattus norvegicus	141-150
14766793-4	2004	Apoptosis in mouse hepatocytes, induced by human TNF-alpha, was blocked by SP600125, indicating that TNF-receptor (TNF-R) 1-mediated JNK activation is important for TNF-alpha-induced death.	pyrazolanthrone	75-83	tumor necrosis factor	Homo sapiens	49-58
14766793-4	2004	Apoptosis in mouse hepatocytes, induced by human TNF-alpha, was blocked by SP600125, indicating that TNF-receptor (TNF-R) 1-mediated JNK activation is important for TNF-alpha-induced death.	pyrazolanthrone	75-83	TNF receptor superfamily member 1A	Homo sapiens	115-123
14766793-4	2004	Apoptosis in mouse hepatocytes, induced by human TNF-alpha, was blocked by SP600125, indicating that TNF-receptor (TNF-R) 1-mediated JNK activation is important for TNF-alpha-induced death.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Homo sapiens	133-136
14766793-4	2004	Apoptosis in mouse hepatocytes, induced by human TNF-alpha, was blocked by SP600125, indicating that TNF-receptor (TNF-R) 1-mediated JNK activation is important for TNF-alpha-induced death.	pyrazolanthrone	75-83	tumor necrosis factor	Homo sapiens	165-174
14766793-6	2004	SP600125 rescued actinomycin D-pretreated hepatocytes and hepatocytes expressing a dominant negative c-Jun from TNF-alpha, indicating that JNK exerts its proapoptotic effect independently of transcription and c-Jun.	pyrazolanthrone	0-8	jun proto-oncogene	Mus musculus	101-106
14766793-6	2004	SP600125 rescued actinomycin D-pretreated hepatocytes and hepatocytes expressing a dominant negative c-Jun from TNF-alpha, indicating that JNK exerts its proapoptotic effect independently of transcription and c-Jun.	pyrazolanthrone	0-8	tumor necrosis factor	Mus musculus	112-121
14766793-6	2004	SP600125 rescued actinomycin D-pretreated hepatocytes and hepatocytes expressing a dominant negative c-Jun from TNF-alpha, indicating that JNK exerts its proapoptotic effect independently of transcription and c-Jun.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	139-142
14766793-7	2004	SP600125 delayed the mitochondrial permeability transition, inhibited cytochrome c release and prevented bid degradation after TNF-alpha, suggesting that JNK-regulated proapoptotic factors act upstream of the mitochondria.	pyrazolanthrone	0-8	BH3 interacting domain death agonist	Mus musculus	105-108
14766793-7	2004	SP600125 delayed the mitochondrial permeability transition, inhibited cytochrome c release and prevented bid degradation after TNF-alpha, suggesting that JNK-regulated proapoptotic factors act upstream of the mitochondria.	pyrazolanthrone	0-8	tumor necrosis factor	Mus musculus	127-136
14766793-7	2004	SP600125 delayed the mitochondrial permeability transition, inhibited cytochrome c release and prevented bid degradation after TNF-alpha, suggesting that JNK-regulated proapoptotic factors act upstream of the mitochondria.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	154-157
15044612-10	2004	In addition, HA, PP2, ERK1/2 inhibitor, 2"-amino-3"-methoxyflavone (PD98059) and JNK inhibitor, and anthra[1,9-cd]pyrazol-6(2H)-one (SP600125) significantly inhibited Ang II-stimulated migration of RASMC.	pyrazolanthrone	100-131	angiogenin	Rattus norvegicus	167-170
14996543-3	2004	The anthra[1,9-cd]pyrazol-6(2H)-one, SP600125, was used to inhibit c-Jun N-terminal kinase (JNK) activity, which is believed to mediate cell death.	pyrazolanthrone	4-35	mitogen-activated protein kinase 8	Homo sapiens	92-95
14996543-3	2004	The anthra[1,9-cd]pyrazol-6(2H)-one, SP600125, was used to inhibit c-Jun N-terminal kinase (JNK) activity, which is believed to mediate cell death.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	67-90
14996543-3	2004	The anthra[1,9-cd]pyrazol-6(2H)-one, SP600125, was used to inhibit c-Jun N-terminal kinase (JNK) activity, which is believed to mediate cell death.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Homo sapiens	92-95
14996543-4	2004	Prior application of SP600125 attenuated the Abeta([25-35])-mediated impairment of PTP and LTP, when measured from the pre-drug baseline.	pyrazolanthrone	21-29	amyloid beta precursor protein	Homo sapiens	45-50
14704147-3	2004	SP600125 was selective for JNK in vitro and in vivo versus other kinases tested including ERK, p38, cyclin-dependent protein kinase 1 (CDK1), and CDK2.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	27-30
14704147-3	2004	SP600125 was selective for JNK in vitro and in vivo versus other kinases tested including ERK, p38, cyclin-dependent protein kinase 1 (CDK1), and CDK2.	pyrazolanthrone	0-8	cyclin-dependent kinase 1	Mus musculus	100-133
14704147-3	2004	SP600125 was selective for JNK in vitro and in vivo versus other kinases tested including ERK, p38, cyclin-dependent protein kinase 1 (CDK1), and CDK2.	pyrazolanthrone	0-8	cyclin-dependent kinase 1	Mus musculus	135-139
14704147-4	2004	SP600125 inhibited JNK activity and KB-3 cell proliferation with the same dose dependence, suggesting that inhibition of proliferation was a direct consequence of JNK inhibition.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	19-22
14704147-4	2004	SP600125 inhibited JNK activity and KB-3 cell proliferation with the same dose dependence, suggesting that inhibition of proliferation was a direct consequence of JNK inhibition.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	163-166
14704147-11	2004	In the presence of SP600125, mitotic progression was prolonged, and c-Jun phosphorylation was inhibited, but neither H1 nor Bcl-2 phosphorylation was inhibited.	pyrazolanthrone	19-27	jun proto-oncogene	Mus musculus	68-73
14684749-7	2004	The JNK inhibitor SP600125 which caused little inhibition of cytokine-induced myeloproliferation in wild type mice, decreased the number of colonies in GSTpi(-/-) animals.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
15026354-8	2004	This was abrogated by a JNK specific inhibitor SP600125 at the concentration required for specific inhibition of the c-Jun phosphorylation.	pyrazolanthrone	47-55	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	117-122
15023353-8	2004	Considerable effort is being directed to the development of chemical inhibitors of the activators of JNKs (e.g. CEP-1347, an inhibitor of the MLK family of JNK pathway activators) or of the JNKs themselves (e.g. SP600125, a direct inhibitor of JNK activity).	pyrazolanthrone	212-220	mitogen-activated protein kinase 8	Homo sapiens	101-104
15026354-5	2004	An experiment using a JNK-specific inhibitor SP600125 or a p38 MAPK inhibitor SB202190 indicated that BITC-induced apoptosis might be regulated by the activation of these two kinases.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	22-25
15026354-8	2004	This was abrogated by a JNK specific inhibitor SP600125 at the concentration required for specific inhibition of the c-Jun phosphorylation.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	24-27
15113050-6	2004	Pretreatment with the JNK/SAPK inhibitor SP600125 significantly abolished these inhibitory responses, and especially restored the erianin-induced decreases in ATP and the erianin-induced phosphorylation of JNK/SAPK with dose- and time- dependence.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	22-30
14996741-7	2004	Ceruloplasmin promoter activity was significantly activated by 1-O-tetradecanoyl phorbol-13-acetate, a c-jun activator, and conversely suppressed by SP600125, a c-jun inhibitor.	pyrazolanthrone	149-157	ceruloplasmin	Homo sapiens	0-13
14996741-7	2004	Ceruloplasmin promoter activity was significantly activated by 1-O-tetradecanoyl phorbol-13-acetate, a c-jun activator, and conversely suppressed by SP600125, a c-jun inhibitor.	pyrazolanthrone	149-157	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	161-166
15113050-6	2004	Pretreatment with the JNK/SAPK inhibitor SP600125 significantly abolished these inhibitory responses, and especially restored the erianin-induced decreases in ATP and the erianin-induced phosphorylation of JNK/SAPK with dose- and time- dependence.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	22-25
15113050-6	2004	Pretreatment with the JNK/SAPK inhibitor SP600125 significantly abolished these inhibitory responses, and especially restored the erianin-induced decreases in ATP and the erianin-induced phosphorylation of JNK/SAPK with dose- and time- dependence.	pyrazolanthrone	41-49	mitogen-activated protein kinase 9	Homo sapiens	26-30
14991847-7	2004	The JNK inhibitor SP600125 protects cells against BH4 toxicity and inhibits cytochrome c release and apoptotic nuclear condensation induced by BH4.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Mus musculus	4-7
14755545-13	2004	PD98059, ERK1/2 pathway inhibitor, and SP600125, JNKs inhibitor, partially inhibited Ang II + IL-1beta-stimulated increases in OPN mRNA.	pyrazolanthrone	39-47	angiotensinogen	Rattus norvegicus	85-91
14755545-13	2004	PD98059, ERK1/2 pathway inhibitor, and SP600125, JNKs inhibitor, partially inhibited Ang II + IL-1beta-stimulated increases in OPN mRNA.	pyrazolanthrone	39-47	interleukin 1 beta	Rattus norvegicus	94-102
14755545-13	2004	PD98059, ERK1/2 pathway inhibitor, and SP600125, JNKs inhibitor, partially inhibited Ang II + IL-1beta-stimulated increases in OPN mRNA.	pyrazolanthrone	39-47	secreted phosphoprotein 1	Rattus norvegicus	127-130
14755545-14	2004	A combination of PD98059 and SP600125 almost completely inhibited Ang II + IL-1beta-stimulated increases in OPN mRNA.	pyrazolanthrone	29-37	angiotensinogen	Rattus norvegicus	66-72
14755545-14	2004	A combination of PD98059 and SP600125 almost completely inhibited Ang II + IL-1beta-stimulated increases in OPN mRNA.	pyrazolanthrone	29-37	interleukin 1 beta	Rattus norvegicus	75-83
14755545-14	2004	A combination of PD98059 and SP600125 almost completely inhibited Ang II + IL-1beta-stimulated increases in OPN mRNA.	pyrazolanthrone	29-37	secreted phosphoprotein 1	Rattus norvegicus	108-111
15028947-9	2004	This effect was potentiated by SP600125, an inhibitor of JNK, although SP600125 alone had no significant effect on 15d-PGJ2-induced apoptosis.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	57-60
14716300-11	2004	The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASC-mediated apoptosis.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	13-16
14716300-11	2004	The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASC-mediated apoptosis.	pyrazolanthrone	27-35	caspase 2	Homo sapiens	56-72
14716300-11	2004	The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASC-mediated apoptosis.	pyrazolanthrone	27-35	cytochrome c, somatic	Homo sapiens	95-107
14716300-11	2004	The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASC-mediated apoptosis.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	154-157
14644930-6	2004	Large VT ventilation of JNK knockout mice and pharmacologic JNK inhibition with SP600125 attenuated neutrophil sequestration and blocked MIP-2 messenger RNA expression and MIP-2 production.	pyrazolanthrone	80-88	mitogen-activated protein kinase 8	Mus musculus	60-63
14676217-10	2004	In addition, the VEGF165 secretion was completely inhibited by the combination of PD98059 and SP600125 (JNK inhibitor).	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Homo sapiens	104-107
14644930-6	2004	Large VT ventilation of JNK knockout mice and pharmacologic JNK inhibition with SP600125 attenuated neutrophil sequestration and blocked MIP-2 messenger RNA expression and MIP-2 production.	pyrazolanthrone	80-88	chemokine (C-X-C motif) ligand 2	Mus musculus	137-142
14644930-6	2004	Large VT ventilation of JNK knockout mice and pharmacologic JNK inhibition with SP600125 attenuated neutrophil sequestration and blocked MIP-2 messenger RNA expression and MIP-2 production.	pyrazolanthrone	80-88	chemokine (C-X-C motif) ligand 2	Mus musculus	172-177
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	34-38
14741745-6	2004	Treatment with specific inhibitors of p38 MAP kinase (SB203580) and JNK (SP600125) activities markedly impaired the adaptation of Dunaliella to osmotic stress.	pyrazolanthrone	73-81	mitogen-activated protein kinase 14	Homo sapiens	38-41
14512277-6	2004	Moreover, experiments performed with the specific JNK inhibitor SP-600125 abolished c-Jun phosphorylation and markedly attenuated its expression as well as the expression of the fetal gene beta-myosin heavy chain.	pyrazolanthrone	64-73	mitogen-activated protein kinase 8	Rattus norvegicus	50-53
14512277-6	2004	Moreover, experiments performed with the specific JNK inhibitor SP-600125 abolished c-Jun phosphorylation and markedly attenuated its expression as well as the expression of the fetal gene beta-myosin heavy chain.	pyrazolanthrone	64-73	myosin heavy chain 7	Rattus norvegicus	189-212
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	24-27
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
14733915-4	2004	Consequently, neurite extension in MN9D/Bcl-2 but not in MN9D/Bcl-X(L) cells was suppressed by treatment with SP600125, a specific inhibitor of JNK.	pyrazolanthrone	110-118	B cell leukemia/lymphoma 2	Mus musculus	40-45
14733915-4	2004	Consequently, neurite extension in MN9D/Bcl-2 but not in MN9D/Bcl-X(L) cells was suppressed by treatment with SP600125, a specific inhibitor of JNK.	pyrazolanthrone	110-118	mitogen-activated protein kinase 8	Mus musculus	144-147
14872485-10	2004	NF-kappaB inhibitors N-acetyl-L-cysteine and Bay 11-7085 and PI 3-kinase inhibitor LY294002 inhibited the enhancing effects of IL-18, but MAPK p38 inhibitor SB203580, ERK inhibitor PD98059, and JNK inhibitor SP600125 did not.	pyrazolanthrone	208-216	interleukin 18	Homo sapiens	127-132
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	75-78
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	cyclin dependent kinase inhibitor 1A	Homo sapiens	191-194
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	tumor protein p53	Homo sapiens	251-254
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	mitogen-activated protein kinase 8	Homo sapiens	75-78
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	310-315
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	316-320
14965369-5	2004	Interestingly, when the JNK/c-Jun/AP-1 signal pathway was disrupted by the JNK inhibitor SP600125, the ability of PS-341 to inhibit the growth of NSCLC cells and to up-regulate the levels of p21(waf1) in these cells was blunted, but the expression of p53 was sustained at a high level, suggesting that the JNK/c-Jun/AP-1 signal pathway might mediate the anti-lung cancer effects of PS-341, with p21(waf1) playing the central role.	pyrazolanthrone	89-97	cyclin dependent kinase inhibitor 1A	Homo sapiens	395-398
14610070-5	2004	The addition of N-acetyl-L-cysteine, the PKC inhibitor GF109203X, and the MEK/ERK inhibitors PD98059 and U0126 attenuated both apoptosis induction and GSH decrease, whereas the p38 inhibitor SB203580 and the JNK inhibitor SP600125 were ineffective.	pyrazolanthrone	222-230	mitogen-activated protein kinase kinase 7	Homo sapiens	74-77
14716206-10	2004	In addition, a specific JNK inhibitor, SP600125, dose-dependently suppressed Ang II-stimulated VSMC hypertrophy.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	24-27
14716206-10	2004	In addition, a specific JNK inhibitor, SP600125, dose-dependently suppressed Ang II-stimulated VSMC hypertrophy.	pyrazolanthrone	39-47	angiogenin	Homo sapiens	77-80
14741394-0	2004	SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson"s disease.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	16-19
14741394-2	2004	In order to study roles of JNK activity in neuronal apoptosis in this model, we blocked JNK activity in vivo using a specific inhibitor of JNK, SP600125.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	88-91
14741394-2	2004	In order to study roles of JNK activity in neuronal apoptosis in this model, we blocked JNK activity in vivo using a specific inhibitor of JNK, SP600125.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	88-91
14741394-4	2004	We found that inhibiting JNK with SP600125 reduced the levels of c-Jun phosphorylation, protected dopaminergic neurons from apoptosis, and partly restored the level of dopamine in MPTP-induced PD in C57BL/6N mice.	pyrazolanthrone	34-42	mitogen-activated protein kinase 8	Homo sapiens	25-28
14741394-4	2004	We found that inhibiting JNK with SP600125 reduced the levels of c-Jun phosphorylation, protected dopaminergic neurons from apoptosis, and partly restored the level of dopamine in MPTP-induced PD in C57BL/6N mice.	pyrazolanthrone	34-42	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	65-70
14734742-9	2004	Furthermore, MEKK2 immunoprecipitates activated c-Jun in an IL-1 dependent manner and this activity was inhibited by the selective JNK inhibitor SP600125.	pyrazolanthrone	145-153	mitogen-activated protein kinase kinase kinase 2	Homo sapiens	13-18
14734742-9	2004	Furthermore, MEKK2 immunoprecipitates activated c-Jun in an IL-1 dependent manner and this activity was inhibited by the selective JNK inhibitor SP600125.	pyrazolanthrone	145-153	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	48-53
14734742-9	2004	Furthermore, MEKK2 immunoprecipitates activated c-Jun in an IL-1 dependent manner and this activity was inhibited by the selective JNK inhibitor SP600125.	pyrazolanthrone	145-153	interleukin 1 beta	Homo sapiens	60-64
14734742-9	2004	Furthermore, MEKK2 immunoprecipitates activated c-Jun in an IL-1 dependent manner and this activity was inhibited by the selective JNK inhibitor SP600125.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	131-134
14985464-5	2004	However, the use of a novel c-Jun NH(2)-terminal kinase (JNK) inhibitor, SP600125, suggests that inhibition of c-Jun activity sensitized tumor cells to oligoamine-induced cell death.	pyrazolanthrone	73-81	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	28-33
14985464-5	2004	However, the use of a novel c-Jun NH(2)-terminal kinase (JNK) inhibitor, SP600125, suggests that inhibition of c-Jun activity sensitized tumor cells to oligoamine-induced cell death.	pyrazolanthrone	73-81	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	111-116
14581488-9	2004	The up-regulation of MMP-1 mRNA by MIF stimulation was found to be inhibited by a PKC inhibitor (GF109203X), a Src-family tyrosine kinase inhibitor (herbimycin A), a tyrosine kinase inhibitor (genistein), a PKA inhibitor (H89), a MEK inhibitor (PD98089), and a JNK inhibitor (SP600125).	pyrazolanthrone	276-284	matrix metallopeptidase 1	Homo sapiens	21-26
14581488-9	2004	The up-regulation of MMP-1 mRNA by MIF stimulation was found to be inhibited by a PKC inhibitor (GF109203X), a Src-family tyrosine kinase inhibitor (herbimycin A), a tyrosine kinase inhibitor (genistein), a PKA inhibitor (H89), a MEK inhibitor (PD98089), and a JNK inhibitor (SP600125).	pyrazolanthrone	276-284	macrophage migration inhibitory factor	Homo sapiens	35-38
14724571-8	2004	JNK activation and PARP cleavage induced by 30 nM Taxotere at 48 h were reversed by curcumin, PD169316 and SP600125, JNK inhibitors in order of progressive specificity.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	0-3
14724571-8	2004	JNK activation and PARP cleavage induced by 30 nM Taxotere at 48 h were reversed by curcumin, PD169316 and SP600125, JNK inhibitors in order of progressive specificity.	pyrazolanthrone	107-115	collagen type XI alpha 2 chain	Homo sapiens	19-23
14724588-4	2004	Here, we show that the majority of both paclitaxel- and UV-induced apoptosis can be inhibited by the pharmacological JNK inhibitor, SP600125, in MCF-7 cells.	pyrazolanthrone	132-140	mitogen-activated protein kinase 8	Homo sapiens	117-120
14724571-8	2004	JNK activation and PARP cleavage induced by 30 nM Taxotere at 48 h were reversed by curcumin, PD169316 and SP600125, JNK inhibitors in order of progressive specificity.	pyrazolanthrone	107-115	mitogen-activated protein kinase 8	Homo sapiens	117-120
14672714-6	2004	Additionally, specific inhibitors of SAPK/JNK and p38 MAP kinase, SP600125 and SB203580, also suppressed LPS-induced increase in IL-1beta gene expression and AP-1 DNA binding.	pyrazolanthrone	66-74	mitogen-activated protein kinase 14	Mus musculus	50-53
14615289-7	2004	Prolonged ramiprilat treatment increased ACE expression in primary cultures of human endothelial cells and in vivo (mouse lung), a response that was prevented by pretreatment with the JNK inhibitor SP600125.	pyrazolanthrone	198-206	angiotensin I converting enzyme	Homo sapiens	41-44
14615289-7	2004	Prolonged ramiprilat treatment increased ACE expression in primary cultures of human endothelial cells and in vivo (mouse lung), a response that was prevented by pretreatment with the JNK inhibitor SP600125.	pyrazolanthrone	198-206	mitogen-activated protein kinase 8	Mus musculus	184-187
14570908-7	2004	Furthermore, suppression of JNK activity with the chemical inhibitor, SP600125, prevented apoptosis induced by 2-5A.	pyrazolanthrone	70-78	mitogen-activated protein kinase 8	Mus musculus	28-31
14729104-8	2004	Furthermore, H(2)O(2)-mediated increases in ERK1/2 activation were sensitive to the MAPK kinase 1 (MEK1) inhibitor PD 98059 (2"-amino-3"-methoxyflavone), whereas JNK responses were blocked by the JNK inhibitor SP 600125 (anthra[1-9-cd]pyrazol-6(2H)-one).	pyrazolanthrone	210-219	mitogen-activated protein kinase 3	Homo sapiens	44-50
14729104-8	2004	Furthermore, H(2)O(2)-mediated increases in ERK1/2 activation were sensitive to the MAPK kinase 1 (MEK1) inhibitor PD 98059 (2"-amino-3"-methoxyflavone), whereas JNK responses were blocked by the JNK inhibitor SP 600125 (anthra[1-9-cd]pyrazol-6(2H)-one).	pyrazolanthrone	221-252	mitogen-activated protein kinase 3	Homo sapiens	44-50
14561739-4	2004	DCA stimulated JNK activation and the JNK inhibitor SP600125 blocked DCA-induced DR5/TRAIL-R2 mRNA and protein expression.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	38-41
14561739-4	2004	DCA stimulated JNK activation and the JNK inhibitor SP600125 blocked DCA-induced DR5/TRAIL-R2 mRNA and protein expression.	pyrazolanthrone	52-60	TNF receptor superfamily member 10b	Homo sapiens	81-84
14561739-4	2004	DCA stimulated JNK activation and the JNK inhibitor SP600125 blocked DCA-induced DR5/TRAIL-R2 mRNA and protein expression.	pyrazolanthrone	52-60	TNF receptor superfamily member 10b	Homo sapiens	85-93
14561739-7	2004	JNK inhibition with SP600125 also blocked binding of Sp1 to the DR5/TRAIL-R2 promoter.	pyrazolanthrone	20-28	mitogen-activated protein kinase 8	Homo sapiens	0-3
14561739-7	2004	JNK inhibition with SP600125 also blocked binding of Sp1 to the DR5/TRAIL-R2 promoter.	pyrazolanthrone	20-28	TNF receptor superfamily member 10b	Homo sapiens	64-67
14561739-7	2004	JNK inhibition with SP600125 also blocked binding of Sp1 to the DR5/TRAIL-R2 promoter.	pyrazolanthrone	20-28	TNF receptor superfamily member 10b	Homo sapiens	68-76
14672714-6	2004	Additionally, specific inhibitors of SAPK/JNK and p38 MAP kinase, SP600125 and SB203580, also suppressed LPS-induced increase in IL-1beta gene expression and AP-1 DNA binding.	pyrazolanthrone	66-74	interleukin 1 beta	Mus musculus	129-137
14514659-6	2004	In contrast, a high level (40 micro M) of arsenite stimulated the c-Jun N-terminal kinase (JNK) signaling pathway and induced cell apoptosis, and this arsenite-induced JNK activity was blocked by JNK inhibitor II, SP600125.	pyrazolanthrone	214-222	mitogen-activated protein kinase 8	Homo sapiens	66-89
14754743-5	2004	CONCLUSION: Addition of IGF-1 and JNK inhibitor Sp600125 enabled the cartilage to maintain significantly higher levels of proteoglycan synthesis immediately after thermal stress.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	34-37
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	pyrazolanthrone	78-86	mitogen-activated protein kinase 1	Homo sapiens	51-55
14514659-6	2004	In contrast, a high level (40 micro M) of arsenite stimulated the c-Jun N-terminal kinase (JNK) signaling pathway and induced cell apoptosis, and this arsenite-induced JNK activity was blocked by JNK inhibitor II, SP600125.	pyrazolanthrone	214-222	mitogen-activated protein kinase 8	Homo sapiens	91-94
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	91-94
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	pyrazolanthrone	78-86	mitogen-activated protein kinase 1	Homo sapiens	109-112
14514659-6	2004	In contrast, a high level (40 micro M) of arsenite stimulated the c-Jun N-terminal kinase (JNK) signaling pathway and induced cell apoptosis, and this arsenite-induced JNK activity was blocked by JNK inhibitor II, SP600125.	pyrazolanthrone	214-222	mitogen-activated protein kinase 8	Homo sapiens	168-171
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Homo sapiens	157-160
14514659-6	2004	In contrast, a high level (40 micro M) of arsenite stimulated the c-Jun N-terminal kinase (JNK) signaling pathway and induced cell apoptosis, and this arsenite-induced JNK activity was blocked by JNK inhibitor II, SP600125.	pyrazolanthrone	214-222	mitogen-activated protein kinase 8	Homo sapiens	168-171
14514663-7	2004	Furthermore, two mitogen-activated protein kinase (MAPK) specific inhibitors (SP600125 for JNK and UO126 for ERK) could specifically block the activation of JNK and ERK and cell transformation.	pyrazolanthrone	78-86	mitogen-activated protein kinase 1	Homo sapiens	165-168
14688340-8	2004	Studies conducted to understand the regulation of AP-1 and NF-kappaB activation by JNK MAPK revealed that both DXM and SP600125 inhibited IL-12p40 gene transcription by inhibiting the activation of AP-1 and NF-kappaB transcription factors as revealed by luciferase reporter and gel mobility shift assays.	pyrazolanthrone	119-127	nuclear factor kappa B subunit 1	Homo sapiens	59-68
15252869-7	2004	Blocking JNK activity and c-jun mRNA by SP600125 (20 microM), a JNK inhibitor, supports the role of JNK in transmission of signals induced by Cd.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Rattus norvegicus	9-12
15252869-7	2004	Blocking JNK activity and c-jun mRNA by SP600125 (20 microM), a JNK inhibitor, supports the role of JNK in transmission of signals induced by Cd.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Rattus norvegicus	64-67
15252869-7	2004	Blocking JNK activity and c-jun mRNA by SP600125 (20 microM), a JNK inhibitor, supports the role of JNK in transmission of signals induced by Cd.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Rattus norvegicus	64-67
14738765-5	2004	Combined biochemical and pharmacological inhibitor (PD98059, U0126, SB203580, SP600125) approaches positioned MEK1/ERK1-2, but not p38 MAPK or JNK, in the IL-6/sIL-6Ralpha signaling pathway upstream of activation of L-selectin/cytoskeletal interactions and L-selectin avidity/affinity.	pyrazolanthrone	78-86	mitogen-activated protein kinase kinase 1	Mus musculus	110-114
14738765-5	2004	Combined biochemical and pharmacological inhibitor (PD98059, U0126, SB203580, SP600125) approaches positioned MEK1/ERK1-2, but not p38 MAPK or JNK, in the IL-6/sIL-6Ralpha signaling pathway upstream of activation of L-selectin/cytoskeletal interactions and L-selectin avidity/affinity.	pyrazolanthrone	78-86	mitogen-activated protein kinase 3	Mus musculus	115-121
14688340-8	2004	Studies conducted to understand the regulation of AP-1 and NF-kappaB activation by JNK MAPK revealed that both DXM and SP600125 inhibited IL-12p40 gene transcription by inhibiting the activation of AP-1 and NF-kappaB transcription factors as revealed by luciferase reporter and gel mobility shift assays.	pyrazolanthrone	119-127	mitogen-activated protein kinase 8	Homo sapiens	83-86
14688340-8	2004	Studies conducted to understand the regulation of AP-1 and NF-kappaB activation by JNK MAPK revealed that both DXM and SP600125 inhibited IL-12p40 gene transcription by inhibiting the activation of AP-1 and NF-kappaB transcription factors as revealed by luciferase reporter and gel mobility shift assays.	pyrazolanthrone	119-127	nuclear factor kappa B subunit 1	Homo sapiens	207-216
14722256-7	2004	To test this hypothesis, we used the specific JNK inhibitor SP600125; when JNK was inhibited pharmacologically in HCT 116 and DLD1 cells, they demonstrated increased survival in clonogenic assays.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	46-49
14722256-7	2004	To test this hypothesis, we used the specific JNK inhibitor SP600125; when JNK was inhibited pharmacologically in HCT 116 and DLD1 cells, they demonstrated increased survival in clonogenic assays.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Homo sapiens	75-78
14597601-11	2003	Pretreatment of monocytes with SP600125 inhibited both GM-CSF and TNF-alpha production; however, significant effects upon p38 MAP kinase and ERK activation were observed.	pyrazolanthrone	31-39	colony stimulating factor 2	Homo sapiens	55-61
15316244-8	2004	The pyridinylimidazole inhibitor of p38, SB-203580, completely blocked stimulation of IL-6 release by IL-1 beta or LPC; conversely, the anthrapyrazolone JNK inhibitor, SP-600125, was ineffective in modifying stimulated IL-6 release.	pyrazolanthrone	168-177	mitogen activated protein kinase 14	Rattus norvegicus	36-39
15316244-8	2004	The pyridinylimidazole inhibitor of p38, SB-203580, completely blocked stimulation of IL-6 release by IL-1 beta or LPC; conversely, the anthrapyrazolone JNK inhibitor, SP-600125, was ineffective in modifying stimulated IL-6 release.	pyrazolanthrone	168-177	mitogen-activated protein kinase 8	Rattus norvegicus	153-156
14623764-3	2003	We examined the effects of an inhibitor of JNK, SP600125 (anthra [1,9-cd] pyrazole-6 (2 H)-one), in a model of chronic allergic inflammation in the rat.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Rattus norvegicus	43-46
20021133-3	2004	Pretreatment of macrophages with a p38 mitogen activated protein kinase (MAPK) inhibitor SB202190, and c-Jun N-terminal kinase (JNK) inhibitor SP600125, inhibited UVB irradiation induced Fas expression and apoptosis.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Mus musculus	103-126
20021133-3	2004	Pretreatment of macrophages with a p38 mitogen activated protein kinase (MAPK) inhibitor SB202190, and c-Jun N-terminal kinase (JNK) inhibitor SP600125, inhibited UVB irradiation induced Fas expression and apoptosis.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Mus musculus	128-131
14597601-11	2003	Pretreatment of monocytes with SP600125 inhibited both GM-CSF and TNF-alpha production; however, significant effects upon p38 MAP kinase and ERK activation were observed.	pyrazolanthrone	31-39	tumor necrosis factor	Homo sapiens	66-75
14597601-11	2003	Pretreatment of monocytes with SP600125 inhibited both GM-CSF and TNF-alpha production; however, significant effects upon p38 MAP kinase and ERK activation were observed.	pyrazolanthrone	31-39	mitogen-activated protein kinase 1	Homo sapiens	141-144
14575864-3	2003	Stimulation of IL-8 expression was completely attenuated by two inhibitors of mitogen-activated protein kinase (MAPK) kinase (MEK), which phosphorylates the MAPKs extracellular-regulated kinase (ERK)1 and ERK2, and by the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	264-272	C-X-C motif chemokine ligand 8	Homo sapiens	15-19
14575864-3	2003	Stimulation of IL-8 expression was completely attenuated by two inhibitors of mitogen-activated protein kinase (MAPK) kinase (MEK), which phosphorylates the MAPKs extracellular-regulated kinase (ERK)1 and ERK2, and by the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	264-272	mitogen-activated protein kinase 3	Homo sapiens	112-116
14575864-3	2003	Stimulation of IL-8 expression was completely attenuated by two inhibitors of mitogen-activated protein kinase (MAPK) kinase (MEK), which phosphorylates the MAPKs extracellular-regulated kinase (ERK)1 and ERK2, and by the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	264-272	mitogen-activated protein kinase kinase 7	Homo sapiens	126-129
14575864-3	2003	Stimulation of IL-8 expression was completely attenuated by two inhibitors of mitogen-activated protein kinase (MAPK) kinase (MEK), which phosphorylates the MAPKs extracellular-regulated kinase (ERK)1 and ERK2, and by the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	264-272	mitogen-activated protein kinase 1	Homo sapiens	205-209
14647474-3	2003	JNK-specific inhibitor SP600125 induces growth inhibition via induction of G1 or G2/M arrest in U266 and MM.1S multiple myeloma cell lines, respectively.	pyrazolanthrone	23-31	mitogen-activated protein kinase 8	Homo sapiens	0-3
14647474-4	2003	Neither exogenous IL-6 nor insulin-like growth factor-1 (IGF-1) overcome SP600125-induced growth inhibition, and IL-6 enhances SP600125-induced G2/M phase in MM.1S cells.	pyrazolanthrone	127-135	interleukin 6	Homo sapiens	113-117
14647474-7	2003	SP600125 induces NF-kappaB activation in a dose-dependent fashion, associated with phosphorylation of IkappaB kinase alpha (IKKalpha) and degradation of IkappaBalpha.	pyrazolanthrone	0-8	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	102-122
14647474-7	2003	SP600125 induces NF-kappaB activation in a dose-dependent fashion, associated with phosphorylation of IkappaB kinase alpha (IKKalpha) and degradation of IkappaBalpha.	pyrazolanthrone	0-8	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	124-132
14647474-7	2003	SP600125 induces NF-kappaB activation in a dose-dependent fashion, associated with phosphorylation of IkappaB kinase alpha (IKKalpha) and degradation of IkappaBalpha.	pyrazolanthrone	0-8	NFKB inhibitor alpha	Homo sapiens	153-165
12842862-9	2003	The response to all three stimuli was completely blocked by the JNK inhibitor SP-600125 but not as effectively by other MAP kinase inhibitors.	pyrazolanthrone	78-87	mitogen-activated protein kinase 8	Mus musculus	64-67
14623117-1	2003	The antigen stimulation of RBL-2H3 cells induced interleukin 13 (IL-13) production, which was inhibited by the steroidal anti-inflammatory drug dexamethasone and by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	209-217	RB transcriptional corepressor like 2	Rattus norvegicus	27-32
14623117-1	2003	The antigen stimulation of RBL-2H3 cells induced interleukin 13 (IL-13) production, which was inhibited by the steroidal anti-inflammatory drug dexamethasone and by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	209-217	interleukin 13	Rattus norvegicus	49-63
14623117-1	2003	The antigen stimulation of RBL-2H3 cells induced interleukin 13 (IL-13) production, which was inhibited by the steroidal anti-inflammatory drug dexamethasone and by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	209-217	interleukin 13	Rattus norvegicus	65-70
14623117-1	2003	The antigen stimulation of RBL-2H3 cells induced interleukin 13 (IL-13) production, which was inhibited by the steroidal anti-inflammatory drug dexamethasone and by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	209-217	mitogen-activated protein kinase 8	Rattus norvegicus	169-192
14623117-1	2003	The antigen stimulation of RBL-2H3 cells induced interleukin 13 (IL-13) production, which was inhibited by the steroidal anti-inflammatory drug dexamethasone and by the c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	209-217	mitogen-activated protein kinase 8	Rattus norvegicus	194-197
12829440-6	2003	The JNK/activator protein-1 pathway also contributed to RANTES expression as demonstrated by the blocking effects of the JNK inhibitor SP600125.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	4-7
12829440-6	2003	The JNK/activator protein-1 pathway also contributed to RANTES expression as demonstrated by the blocking effects of the JNK inhibitor SP600125.	pyrazolanthrone	135-143	C-C motif chemokine ligand 5	Homo sapiens	56-62
12829440-6	2003	The JNK/activator protein-1 pathway also contributed to RANTES expression as demonstrated by the blocking effects of the JNK inhibitor SP600125.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	121-124
14520687-2	2003	JNK activity was inhibited by stable transfection with a dominant negative mutant of the upstream kinase JNKK/MKK4 or with the novel, potent and selective JNK1, -2 and -3 inhibitor SP600125.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Homo sapiens	0-3
14520687-2	2003	JNK activity was inhibited by stable transfection with a dominant negative mutant of the upstream kinase JNKK/MKK4 or with the novel, potent and selective JNK1, -2 and -3 inhibitor SP600125.	pyrazolanthrone	181-189	mitogen-activated protein kinase 8	Homo sapiens	155-170
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	0-23
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	pyrazolanthrone	41-49	mitogen-activated protein kinase 8	Homo sapiens	25-28
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	pyrazolanthrone	41-49	interleukin 6	Homo sapiens	58-76
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	pyrazolanthrone	41-49	vascular endothelial growth factor A	Homo sapiens	85-119
14627919-0	2003	C-jun N-terminal kinase (JNK) inhibitor, SP600125, blocks interleukin (IL)-6-induced vascular endothelial growth factor (VEGF) production: cyclosporine A partially mimics this inhibitory effect.	pyrazolanthrone	41-49	vascular endothelial growth factor A	Homo sapiens	121-125
14627919-5	2003	Thus, we tested the effect of a novel JNK inhibitor, SP600125, on VEGF production in fibroblasts.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	38-41
14627919-5	2003	Thus, we tested the effect of a novel JNK inhibitor, SP600125, on VEGF production in fibroblasts.	pyrazolanthrone	53-61	vascular endothelial growth factor A	Homo sapiens	66-70
14627919-6	2003	SP600125 significantly suppressed interleukin (IL)-6-induced production of VEGF in cultured fibroblasts.	pyrazolanthrone	0-8	interleukin 6	Homo sapiens	34-52
14627919-6	2003	SP600125 significantly suppressed interleukin (IL)-6-induced production of VEGF in cultured fibroblasts.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Homo sapiens	75-79
14627919-9	2003	The results indicate that although both SP600125 and CsA are anti-angiogenic by inhibiting VEGF production by way of a JNK-dependent pathway, the inhibitory effect was much stronger with the novel inhibitor of JNK than with CsA.	pyrazolanthrone	40-48	vascular endothelial growth factor A	Homo sapiens	91-95
14627919-9	2003	The results indicate that although both SP600125 and CsA are anti-angiogenic by inhibiting VEGF production by way of a JNK-dependent pathway, the inhibitory effect was much stronger with the novel inhibitor of JNK than with CsA.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	119-122
14627919-9	2003	The results indicate that although both SP600125 and CsA are anti-angiogenic by inhibiting VEGF production by way of a JNK-dependent pathway, the inhibitory effect was much stronger with the novel inhibitor of JNK than with CsA.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Homo sapiens	210-213
14613582-8	2003	In addition, the MEK1/2 inhibitor U0126 and the JNK inhibitor SP600125 up-regulates expression of p8.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Homo sapiens	48-51
12842862-10	2003	SP-600125 blocked LPS-stimulated IL-6 synthesis dose dependently at both the RNA and protein level.	pyrazolanthrone	0-9	toll-like receptor 4	Mus musculus	18-21
12842862-10	2003	SP-600125 blocked LPS-stimulated IL-6 synthesis dose dependently at both the RNA and protein level.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	33-37
12869386-10	2003	SP-600125, a specific inhibitor of JNK activation, prevented cytochrome c release from mitochondria, JNK activation, DNA fragmentation, and caspase-9 activation in response to TNF-alpha/CHX.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	35-38
12842862-11	2003	SP-600125 was as effective as the synthetic glucocorticoid dexamethasone at inhibiting IL-6 expression.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	87-91
12869386-10	2003	SP-600125, a specific inhibitor of JNK activation, prevented cytochrome c release from mitochondria, JNK activation, DNA fragmentation, and caspase-9 activation in response to TNF-alpha/CHX.	pyrazolanthrone	0-9	mitogen-activated protein kinase 8	Rattus norvegicus	101-104
12869386-10	2003	SP-600125, a specific inhibitor of JNK activation, prevented cytochrome c release from mitochondria, JNK activation, DNA fragmentation, and caspase-9 activation in response to TNF-alpha/CHX.	pyrazolanthrone	0-9	caspase 9	Rattus norvegicus	140-149
12869386-10	2003	SP-600125, a specific inhibitor of JNK activation, prevented cytochrome c release from mitochondria, JNK activation, DNA fragmentation, and caspase-9 activation in response to TNF-alpha/CHX.	pyrazolanthrone	0-9	tumor necrosis factor	Rattus norvegicus	176-185
12842862-12	2003	SP-600125 inhibited IL-6 synthesis when added to cells up to 60 min after LPS stimulation, but its inhibitory effect waned with time.	pyrazolanthrone	0-9	interleukin 6	Mus musculus	20-24
12842862-12	2003	SP-600125 inhibited IL-6 synthesis when added to cells up to 60 min after LPS stimulation, but its inhibitory effect waned with time.	pyrazolanthrone	0-9	toll-like receptor 4	Mus musculus	74-77
12842862-14	2003	SP-600125 and the proteasomal inhibitor MG-132 blocked LPS-induced degradation of IkappaB-alpha/epsilon and LPS-stimulated expression of IkappaB-alpha mRNA.	pyrazolanthrone	0-9	toll-like receptor 4	Mus musculus	55-58
12842862-14	2003	SP-600125 and the proteasomal inhibitor MG-132 blocked LPS-induced degradation of IkappaB-alpha/epsilon and LPS-stimulated expression of IkappaB-alpha mRNA.	pyrazolanthrone	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	82-95
12842862-14	2003	SP-600125 and the proteasomal inhibitor MG-132 blocked LPS-induced degradation of IkappaB-alpha/epsilon and LPS-stimulated expression of IkappaB-alpha mRNA.	pyrazolanthrone	0-9	toll-like receptor 4	Mus musculus	108-111
12842862-14	2003	SP-600125 and the proteasomal inhibitor MG-132 blocked LPS-induced degradation of IkappaB-alpha/epsilon and LPS-stimulated expression of IkappaB-alpha mRNA.	pyrazolanthrone	0-9	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	137-150
12842862-15	2003	Yet, only SP-600125 and not MG-132 blocked LPS-induced IL-6 mRNA expression.	pyrazolanthrone	10-19	toll-like receptor 4	Mus musculus	43-46
12842862-15	2003	Yet, only SP-600125 and not MG-132 blocked LPS-induced IL-6 mRNA expression.	pyrazolanthrone	10-19	interleukin 6	Mus musculus	55-59
14606520-8	2003	The role of p38 and JNK in mediating BMP-2-induced stimulation of osteoblastic cell differentiation was evaluated using the respective specific inhibitors SB203580 and SP600125.	pyrazolanthrone	168-176	bone morphogenetic protein 2	Mus musculus	37-42
14570754-0	2003	The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Rattus norvegicus	4-25
14570754-0	2003	The Jun N-terminal kinase inhibitor SP600125 is a ligand and antagonist of the aryl hydrocarbon receptor.	pyrazolanthrone	36-44	aryl hydrocarbon receptor	Rattus norvegicus	79-104
14570754-1	2003	Exposure of the immortalized human breast epithelial cell line MCF10A to the Jun N-terminal kinase (JNK) inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP600125) suppressed, in a concentration-dependent manner (IC50 is approximately 2 microM), the induction of CYP1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	pyrazolanthrone	115-146	mitogen-activated protein kinase 8	Homo sapiens	77-98
14570754-1	2003	Exposure of the immortalized human breast epithelial cell line MCF10A to the Jun N-terminal kinase (JNK) inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP600125) suppressed, in a concentration-dependent manner (IC50 is approximately 2 microM), the induction of CYP1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	pyrazolanthrone	115-146	mitogen-activated protein kinase 8	Homo sapiens	100-103
14570754-1	2003	Exposure of the immortalized human breast epithelial cell line MCF10A to the Jun N-terminal kinase (JNK) inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP600125) suppressed, in a concentration-dependent manner (IC50 is approximately 2 microM), the induction of CYP1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	pyrazolanthrone	115-146	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	257-263
14570754-1	2003	Exposure of the immortalized human breast epithelial cell line MCF10A to the Jun N-terminal kinase (JNK) inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP600125) suppressed, in a concentration-dependent manner (IC50 is approximately 2 microM), the induction of CYP1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Homo sapiens	77-98
14570754-1	2003	Exposure of the immortalized human breast epithelial cell line MCF10A to the Jun N-terminal kinase (JNK) inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP600125) suppressed, in a concentration-dependent manner (IC50 is approximately 2 microM), the induction of CYP1A1 by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Homo sapiens	100-103
14570754-2	2003	Cotreatment with SP600125 also suppressed the accumulation of TCDD-induced nuclear aryl hydrocarbon receptor (AhR)-DNA complexes, as assessed by electrophoretic mobility shift assays.	pyrazolanthrone	17-25	aryl hydrocarbon receptor	Rattus norvegicus	83-108
14570754-2	2003	Cotreatment with SP600125 also suppressed the accumulation of TCDD-induced nuclear aryl hydrocarbon receptor (AhR)-DNA complexes, as assessed by electrophoretic mobility shift assays.	pyrazolanthrone	17-25	aryl hydrocarbon receptor	Rattus norvegicus	110-113
14570754-4	2003	However, addition of SP600125 to cytosol just before TCDD addition completely suppressed AhR transformation and DNA binding (IC50 approximately 7 microM).	pyrazolanthrone	21-29	aryl hydrocarbon receptor	Rattus norvegicus	89-92
14570754-5	2003	Sucrose gradient analyses using rat liver and murine hepatoma 1c1c7 extracts demonstrated that SP600125 competed with TCDD for binding to the AhR.	pyrazolanthrone	95-103	aryl-hydrocarbon receptor	Mus musculus	142-145
14570754-6	2003	These results suggest that SP600125 is an AhR ligand and functions as an AhR antagonist at concentrations used to pharmacologically inhibit JNK.	pyrazolanthrone	27-35	aryl hydrocarbon receptor	Rattus norvegicus	42-45
14570754-6	2003	These results suggest that SP600125 is an AhR ligand and functions as an AhR antagonist at concentrations used to pharmacologically inhibit JNK.	pyrazolanthrone	27-35	aryl hydrocarbon receptor	Rattus norvegicus	73-76
14570754-6	2003	These results suggest that SP600125 is an AhR ligand and functions as an AhR antagonist at concentrations used to pharmacologically inhibit JNK.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Rattus norvegicus	140-143
14602779-7	2003	The IGF-I-induced up-regulation of VEGF production was associated with activation of AP-1 and HIF-1 alpha and was abrogated by phosphatidylinositol 3-kinase inhibitors (wortmannin and LY294002); Jun kinase inhibitor (SP600125); HIF-1 alpha antisense oligonucleotide; or geldanamycin, an inhibitor of the heat shock protein 90 molecular chaperone, which regulates the three-dimensional conformation and function of IGF-I-receptor and Akt.	pyrazolanthrone	217-225	insulin like growth factor 1	Homo sapiens	4-9
14602779-7	2003	The IGF-I-induced up-regulation of VEGF production was associated with activation of AP-1 and HIF-1 alpha and was abrogated by phosphatidylinositol 3-kinase inhibitors (wortmannin and LY294002); Jun kinase inhibitor (SP600125); HIF-1 alpha antisense oligonucleotide; or geldanamycin, an inhibitor of the heat shock protein 90 molecular chaperone, which regulates the three-dimensional conformation and function of IGF-I-receptor and Akt.	pyrazolanthrone	217-225	vascular endothelial growth factor A	Homo sapiens	35-39
14606520-9	2003	Inhibition of p38 by SB203580 was mainly associated with decreased alkaline phosphatase (ALP) activity, whereas inhibition of JNK by SP600125 was associated with a marked reduction in osteocalcin (OC) production induced by BMP-2.	pyrazolanthrone	133-141	mitogen-activated protein kinase 8	Mus musculus	126-129
14606520-9	2003	Inhibition of p38 by SB203580 was mainly associated with decreased alkaline phosphatase (ALP) activity, whereas inhibition of JNK by SP600125 was associated with a marked reduction in osteocalcin (OC) production induced by BMP-2.	pyrazolanthrone	133-141	bone gamma-carboxyglutamate protein 2	Mus musculus	184-195
14606520-9	2003	Inhibition of p38 by SB203580 was mainly associated with decreased alkaline phosphatase (ALP) activity, whereas inhibition of JNK by SP600125 was associated with a marked reduction in osteocalcin (OC) production induced by BMP-2.	pyrazolanthrone	133-141	bone gamma-carboxyglutamate protein 2	Mus musculus	197-199
14622133-4	2003	Blockade of ERK activation with U0126, of PKC with Go6976 and of SAPK with SP600125 decreased basal P-gp but did not abolish the H2O2-induced increase.	pyrazolanthrone	75-83	mitogen-activated protein kinase 9	Rattus norvegicus	65-69
14622133-4	2003	Blockade of ERK activation with U0126, of PKC with Go6976 and of SAPK with SP600125 decreased basal P-gp but did not abolish the H2O2-induced increase.	pyrazolanthrone	75-83	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	100-104
14551401-8	2003	U0126, SB203580, and SP600125 were used to interrupt the ERK, p38, and JNK pathways, respectively.	pyrazolanthrone	21-29	mitogen-activated protein kinase 1	Homo sapiens	57-60
14551401-8	2003	U0126, SB203580, and SP600125 were used to interrupt the ERK, p38, and JNK pathways, respectively.	pyrazolanthrone	21-29	mitogen-activated protein kinase 14	Homo sapiens	62-65
14551401-8	2003	U0126, SB203580, and SP600125 were used to interrupt the ERK, p38, and JNK pathways, respectively.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	71-74
12832416-8	2003	Only a small group of genes, namely pent(r)axin-3, CXCL10, ICAM-1, and IL-1 beta, was inhibited by both the c-JUN peptide and the JNK inhibitor SP600125.	pyrazolanthrone	144-152	C-X-C motif chemokine ligand 10	Homo sapiens	51-57
14583480-8	2003	The selective JNK inhibitor SP600125 inhibited the early phase (24 h) but not the late phase (48 h and later) of apoptosis induced by SAMC.	pyrazolanthrone	28-36	solute carrier family 25 member 26	Homo sapiens	134-138
14646597-4	2003	Blockage of these two mediators activities by specific inhibitors, SP600125 and Ad-IkappaBalpha-SR restored adipogenesis differentiation suggesting their involvement in the inhibited differentiation of 3T3-L1 cells by TNF-alpha.	pyrazolanthrone	67-75	tumor necrosis factor	Mus musculus	218-227
14646597-6	2003	Compared with adipogenesis, however, SP600125, a chemical JNK inhibitor hardly relieved TNF-alpha effect on PPARgamma expression whereas S32A/S36A mutant of IkappaBalpha considerably recovered PPARgamma expression, indicating that two signal mediators exploit separable main routes to achieve reduced adipogenesis.	pyrazolanthrone	37-45	mitogen-activated protein kinase 8	Mus musculus	58-61
12832416-8	2003	Only a small group of genes, namely pent(r)axin-3, CXCL10, ICAM-1, and IL-1 beta, was inhibited by both the c-JUN peptide and the JNK inhibitor SP600125.	pyrazolanthrone	144-152	intercellular adhesion molecule 1	Homo sapiens	59-65
12832416-8	2003	Only a small group of genes, namely pent(r)axin-3, CXCL10, ICAM-1, and IL-1 beta, was inhibited by both the c-JUN peptide and the JNK inhibitor SP600125.	pyrazolanthrone	144-152	interleukin 1 beta	Homo sapiens	71-80
12832416-8	2003	Only a small group of genes, namely pent(r)axin-3, CXCL10, ICAM-1, and IL-1 beta, was inhibited by both the c-JUN peptide and the JNK inhibitor SP600125.	pyrazolanthrone	144-152	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	108-113
12832416-8	2003	Only a small group of genes, namely pent(r)axin-3, CXCL10, ICAM-1, and IL-1 beta, was inhibited by both the c-JUN peptide and the JNK inhibitor SP600125.	pyrazolanthrone	144-152	mitogen-activated protein kinase 8	Homo sapiens	130-133
12970086-9	2003	The inhibitor of ERK pathway (U0126 or PD98059) or JNK pathway (SP600125) markedly prevented kinase activation, and also greatly reduced NCTD-induced apoptotic cell death.	pyrazolanthrone	64-72	mitogen-activated protein kinase 8	Homo sapiens	51-54
14500654-9	2003	Pretreatment of cells with the JNK inhibitor SP600125 attenuated the effect of butyric acid on apoptosis, whereas no effect was seen with the p38 inhibitor SB202190 or the ERK inhibitor PD98059.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Homo sapiens	31-34
14505349-5	2003	In addition, we found that SP600125, a JNK-specific inhibitor, reduced UV irradiation-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for UV irradiation-induced caspase activation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	94-97
14505349-5	2003	In addition, we found that SP600125, a JNK-specific inhibitor, reduced UV irradiation-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for UV irradiation-induced caspase activation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	39-42
14505349-5	2003	In addition, we found that SP600125, a JNK-specific inhibitor, reduced UV irradiation-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for UV irradiation-induced caspase activation.	pyrazolanthrone	27-35	mitogen-activated protein kinase 8	Homo sapiens	94-97
14505349-5	2003	In addition, we found that SP600125, a JNK-specific inhibitor, reduced UV irradiation-induced JNK activation as well as caspase-3 activation, indicating that JNK activity is required for UV irradiation-induced caspase activation.	pyrazolanthrone	27-35	caspase 3	Homo sapiens	120-129
12943527-5	2003	RESULTS: SP600125, a specific inhibitor of SAPK/JNK, markedly reduced ET-1-stimulated HSP27 accumulation.	pyrazolanthrone	9-17	mitogen-activated protein kinase 8	Mus musculus	48-51
12943527-5	2003	RESULTS: SP600125, a specific inhibitor of SAPK/JNK, markedly reduced ET-1-stimulated HSP27 accumulation.	pyrazolanthrone	9-17	endothelin 1	Mus musculus	70-74
12943527-5	2003	RESULTS: SP600125, a specific inhibitor of SAPK/JNK, markedly reduced ET-1-stimulated HSP27 accumulation.	pyrazolanthrone	9-17	heat shock protein 1	Mus musculus	86-91
12943527-7	2003	SP600125 reduced the ET-1-increased level of HSP27 mRNA.	pyrazolanthrone	0-8	endothelin 1	Mus musculus	21-25
12943527-7	2003	SP600125 reduced the ET-1-increased level of HSP27 mRNA.	pyrazolanthrone	0-8	heat shock protein 1	Mus musculus	45-50
12943527-9	2003	12-O-Tetradecanoylphorbol-13-acetate, a direct activator of protein kinase C, induced SAPK/JNK phosphorylation, which was suppressed by SP600125.	pyrazolanthrone	136-144	mitogen-activated protein kinase 8	Mus musculus	91-94
12943527-10	2003	A combination of SP600125 and p38 MAP kinase inhibitor such as SB203580 and PD169316 additively reduced the ET-1-stimulated accumulation of HSP27.	pyrazolanthrone	17-25	endothelin 1	Mus musculus	108-112
12943527-10	2003	A combination of SP600125 and p38 MAP kinase inhibitor such as SB203580 and PD169316 additively reduced the ET-1-stimulated accumulation of HSP27.	pyrazolanthrone	17-25	heat shock protein 1	Mus musculus	140-145
12888452-3	2003	LPS-mediated TLR2 mRNA up-regulation was attenuated by inhibition of p38 kinase (with SB203580) or nuclear factor (NF)-kappaB (with sulfasalazine or SN-50), but not by inhibition of extracellular signal-regulated kinase (with PD98059) or c-Jun N-terminal kinase (with SP600125), suggesting that LPS may induce TLR2 mRNA expression through p38 kinase and NF-kappaB activation.	pyrazolanthrone	268-276	toll-like receptor 2	Mus musculus	13-17
12941464-9	2003	NELL2-enhanced survival of hippocampal neurons was completely blocked by SP600125, an anthrapyrazolone inhibitor of JNK, while treatment of MEK (MAPK/ERK kinase) inhibitors per se enhanced survival of neurons similar to NELL2 treatment.	pyrazolanthrone	73-81	neural EGFL like 2	Rattus norvegicus	0-5
12829723-8	2003	EGFR/AbetaPP hybrid-induced and caASK1-induced neuronal cell deaths were specifically blocked by SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one), a specific JNK inhibitor.	pyrazolanthrone	97-105	epidermal growth factor receptor	Homo sapiens	0-4
12829723-8	2003	EGFR/AbetaPP hybrid-induced and caASK1-induced neuronal cell deaths were specifically blocked by SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one), a specific JNK inhibitor.	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Homo sapiens	152-155
12898704-8	2003	But in this case, all three MAP kinase inhibitors (U0126, SB203580, and SP600125) reduced TNFalpha-induced MMP-9 upregulation.	pyrazolanthrone	72-80	tumor necrosis factor	Rattus norvegicus	90-98
12898704-8	2003	But in this case, all three MAP kinase inhibitors (U0126, SB203580, and SP600125) reduced TNFalpha-induced MMP-9 upregulation.	pyrazolanthrone	72-80	matrix metallopeptidase 9	Rattus norvegicus	107-112
12941464-9	2003	NELL2-enhanced survival of hippocampal neurons was completely blocked by SP600125, an anthrapyrazolone inhibitor of JNK, while treatment of MEK (MAPK/ERK kinase) inhibitors per se enhanced survival of neurons similar to NELL2 treatment.	pyrazolanthrone	73-81	mitogen-activated protein kinase 8	Rattus norvegicus	116-119
12898508-5	2003	Similarly, inhibition of JNK1 and JNK2 activities by the selective inhibitor SP600125 led to both dose-dependent reduction of c-jun and ATF-2 phosphorylation, and of the differentiation of HL60 cells.	pyrazolanthrone	77-85	mitogen-activated protein kinase 8	Homo sapiens	25-29
12898508-5	2003	Similarly, inhibition of JNK1 and JNK2 activities by the selective inhibitor SP600125 led to both dose-dependent reduction of c-jun and ATF-2 phosphorylation, and of the differentiation of HL60 cells.	pyrazolanthrone	77-85	mitogen-activated protein kinase 9	Homo sapiens	34-38
12898508-5	2003	Similarly, inhibition of JNK1 and JNK2 activities by the selective inhibitor SP600125 led to both dose-dependent reduction of c-jun and ATF-2 phosphorylation, and of the differentiation of HL60 cells.	pyrazolanthrone	77-85	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	126-131
12898508-5	2003	Similarly, inhibition of JNK1 and JNK2 activities by the selective inhibitor SP600125 led to both dose-dependent reduction of c-jun and ATF-2 phosphorylation, and of the differentiation of HL60 cells.	pyrazolanthrone	77-85	activating transcription factor 2	Homo sapiens	136-141
12716652-5	2003	Inhibition of stretch-induced JNK activation by adenovirus-mediated gene transfer of stress-activated protein kinase (SEK-1), a dominant-negative mutant of SEK-1, the immediate upstream activator of the JNKs, and pharmacological JNK inhibitor II SP-600125 blocked IL-8 mRNA expression and attenuated IL-8 production.	pyrazolanthrone	246-255	mitogen-activated protein kinase 8	Homo sapiens	30-33
12878189-0	2003	SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	26-49
12878189-0	2003	SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway.	pyrazolanthrone	0-8	cAMP responsive element binding protein 1	Mus musculus	61-65
12878189-0	2003	SP600125, an inhibitor of c-jun N-terminal kinase, activates CREB by a p38 MAPK-mediated pathway.	pyrazolanthrone	0-8	mitogen-activated protein kinase 14	Mus musculus	71-79
12878189-1	2003	SP600125, an anthrapyrazolone inhibitor of c-jun N-terminal kinase (JNK), has been used to characterize the role of JNK in apoptotic pathways.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	43-66
12878189-1	2003	SP600125, an anthrapyrazolone inhibitor of c-jun N-terminal kinase (JNK), has been used to characterize the role of JNK in apoptotic pathways.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	68-71
12878189-1	2003	SP600125, an anthrapyrazolone inhibitor of c-jun N-terminal kinase (JNK), has been used to characterize the role of JNK in apoptotic pathways.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	116-119
12878189-3	2003	SP600125 induced CREB-dependent promoter activation by 2.8-fold at 20 microM, the concentration at which it inhibited c-jun-dependent promoter activation by 51%.	pyrazolanthrone	0-8	cAMP responsive element binding protein 1	Mus musculus	17-21
12878189-3	2003	SP600125 induced CREB-dependent promoter activation by 2.8-fold at 20 microM, the concentration at which it inhibited c-jun-dependent promoter activation by 51%.	pyrazolanthrone	0-8	jun proto-oncogene	Mus musculus	118-123
12878189-7	2003	SB203580, an inhibitor of p38 MAPK, partially blocked SP600125-mediated activation of CREB.	pyrazolanthrone	54-62	mitogen-activated protein kinase 14	Mus musculus	26-34
12878189-7	2003	SB203580, an inhibitor of p38 MAPK, partially blocked SP600125-mediated activation of CREB.	pyrazolanthrone	54-62	cAMP responsive element binding protein 1	Mus musculus	86-90
12878189-8	2003	These observations suggest that SP600125 could be used as a small molecular weight activator of CREB.	pyrazolanthrone	32-40	cAMP responsive element binding protein 1	Mus musculus	96-100
12909329-5	2003	RESULTS: Cyclical mechanical stretch significantly increased protein synthesis and mRNA expression for MMP-14 and -2 from 2 to 24 h. The increased MMP-14 and-2 proteins after stretch were completely blocked after the addition of TNF-alpha monoclonal antibody (5 microg/ml) or SP600125 (20 microM) 30 min before stretch.	pyrazolanthrone	276-284	matrix metallopeptidase 14	Homo sapiens	103-116
12907245-6	2003	Inhibition of JNK by SP600125 protected cells from drug-induced cytotoxicity.	pyrazolanthrone	21-29	mitogen-activated protein kinase 8	Homo sapiens	14-17
12819185-9	2003	Importantly, the SP600125 compound, an anthrapyrazolone inhibitor of JNK, but not the ERK and p38 inhibitor, suppressed apoptosis induced by PEITC.	pyrazolanthrone	17-25	mitogen-activated protein kinase 8	Homo sapiens	69-72
12909329-5	2003	RESULTS: Cyclical mechanical stretch significantly increased protein synthesis and mRNA expression for MMP-14 and -2 from 2 to 24 h. The increased MMP-14 and-2 proteins after stretch were completely blocked after the addition of TNF-alpha monoclonal antibody (5 microg/ml) or SP600125 (20 microM) 30 min before stretch.	pyrazolanthrone	276-284	matrix metallopeptidase 14	Homo sapiens	147-159
12909329-5	2003	RESULTS: Cyclical mechanical stretch significantly increased protein synthesis and mRNA expression for MMP-14 and -2 from 2 to 24 h. The increased MMP-14 and-2 proteins after stretch were completely blocked after the addition of TNF-alpha monoclonal antibody (5 microg/ml) or SP600125 (20 microM) 30 min before stretch.	pyrazolanthrone	276-284	tumor necrosis factor	Homo sapiens	229-238
12909329-6	2003	By zymography, MMP-2 expression was induced by cyclical stretch and was attenuated by TNF-alpha monoclonal antibody and SP600125.	pyrazolanthrone	120-128	matrix metallopeptidase 2	Homo sapiens	15-20
12868068-8	2003	Both cell viability and the increase in alpha-synuclein expression are prevented by antioxidants; by the specific inhibitors of p38 and SAPK/JNK, SB203580 and SP600125, respectively; and by the inhibitor of autophagy 3-methyladenine.	pyrazolanthrone	159-167	synuclein alpha	Homo sapiens	40-55
15012721-9	2003	Pretreatment with SP600125 (JNK inhibitor) verified its pro-apoptotic activity only in epithelial cells.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	28-31
12869635-0	2003	c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages.	pyrazolanthrone	36-67	mitogen-activated protein kinase 8	Mus musculus	0-25
12869635-0	2003	c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages.	pyrazolanthrone	36-67	nitric oxide synthase 2, inducible	Mus musculus	76-107
12869635-2	2003	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), a pharmacological inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5 to 10 microM.	pyrazolanthrone	0-31	mitogen-activated protein kinase 8	Mus musculus	75-78
12869635-2	2003	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), a pharmacological inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5 to 10 microM.	pyrazolanthrone	0-31	jun proto-oncogene	Mus musculus	109-114
12869635-2	2003	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), a pharmacological inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5 to 10 microM.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Mus musculus	75-78
12869635-2	2003	Anthra(1,9-cd)pyrazol-6(2H)-one (SP600125), a pharmacological inhibitor of JNK, inhibited phosphorylation of c-Jun with an IC50 of 5 to 10 microM.	pyrazolanthrone	33-41	jun proto-oncogene	Mus musculus	109-114
12869635-3	2003	At the same concentrations, SP600125 inhibited LPS-induced iNOS protein expression and NO production.	pyrazolanthrone	28-36	nitric oxide synthase 2, inducible	Mus musculus	59-63
12869635-6	2003	In contrast, SP600125 reduced iNOS mRNA levels &gt;90% when measured 8 h after LPS.	pyrazolanthrone	13-21	nitric oxide synthase 2, inducible	Mus musculus	30-34
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	24-32	nitric oxide synthase 2, inducible	Mus musculus	41-45
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	24-32	nitric oxide synthase 2, inducible	Mus musculus	166-170
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Mus musculus	229-232
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	24-32	nitric oxide synthase 2, inducible	Mus musculus	166-170
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	24-32	nitric oxide synthase 2, inducible	Mus musculus	166-170
12859962-11	2003	Apoptosis is also blocked by SP600125, a specific inhibitor of JNK activity, indicating that JNK activity is required for the induction of apoptosis in these cells.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	63-66
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	145-153	nitric oxide synthase 2, inducible	Mus musculus	41-45
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	145-153	nitric oxide synthase 2, inducible	Mus musculus	166-170
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Mus musculus	229-232
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	145-153	nitric oxide synthase 2, inducible	Mus musculus	166-170
12869635-7	2003	These data suggest that SP600125 reduced iNOS mRNA stability, and this was confirmed in the mRNA degradation assay using actinomycin D, in which SP600125 reduced the iNOS mRNA half-life from 5 to 2 h. These results show that the JNK pathway is involved in the up-regulation of LPS-induced iNOS expression and NO production by a mechanism related to the stabilization of iNOS mRNA.	pyrazolanthrone	145-153	nitric oxide synthase 2, inducible	Mus musculus	166-170
12947330-4	2003	METHODS: Rat hepatocytes were harvested from Sprague-Dawley rats and pretreated with SP600125, a JNK inhibitor.	pyrazolanthrone	85-93	mitogen-activated protein kinase 8	Rattus norvegicus	97-100
12947330-6	2003	RESULTS: Western blotting demonstrated specific inhibition of JNK by SP600125.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Rattus norvegicus	62-65
12730216-6	2003	Furthermore, we observed an enhanced activation of JNK pathway and an attenuation of apoptosis by SP600125, a JNK inhibitor, through protection of mitochondrial dysfunction and reduction of caspase 9 activity.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Homo sapiens	51-54
12730216-6	2003	Furthermore, we observed an enhanced activation of JNK pathway and an attenuation of apoptosis by SP600125, a JNK inhibitor, through protection of mitochondrial dysfunction and reduction of caspase 9 activity.	pyrazolanthrone	98-106	mitogen-activated protein kinase 8	Homo sapiens	110-113
12730216-6	2003	Furthermore, we observed an enhanced activation of JNK pathway and an attenuation of apoptosis by SP600125, a JNK inhibitor, through protection of mitochondrial dysfunction and reduction of caspase 9 activity.	pyrazolanthrone	98-106	caspase 9	Homo sapiens	190-199
12859962-11	2003	Apoptosis is also blocked by SP600125, a specific inhibitor of JNK activity, indicating that JNK activity is required for the induction of apoptosis in these cells.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	93-96
12871843-5	2003	We examined the role of the mitogen-activated protein kinase (MAPK) c-jun N-terminal kinase (JNK) in TNFalpha- and IL-1beta-induced GM-CSF, RANTES and IL-8 production in HASMC by using a novel specific inhibitor for JNK (SP600125).	pyrazolanthrone	221-229	mitogen-activated protein kinase 1	Homo sapiens	62-66
12847227-5	2003	Conversely, inhibition of JNK activation using SP600125 dose dependently enhanced both LPS-induced IL-12 p40 production from THP-1 cells and p70 production from human monocytes.	pyrazolanthrone	47-55	mitogen-activated protein kinase 8	Homo sapiens	26-29
12847227-5	2003	Conversely, inhibition of JNK activation using SP600125 dose dependently enhanced both LPS-induced IL-12 p40 production from THP-1 cells and p70 production from human monocytes.	pyrazolanthrone	47-55	interleukin 9	Homo sapiens	105-108
12847227-5	2003	Conversely, inhibition of JNK activation using SP600125 dose dependently enhanced both LPS-induced IL-12 p40 production from THP-1 cells and p70 production from human monocytes.	pyrazolanthrone	47-55	GLI family zinc finger 2	Homo sapiens	125-130
12847227-5	2003	Conversely, inhibition of JNK activation using SP600125 dose dependently enhanced both LPS-induced IL-12 p40 production from THP-1 cells and p70 production from human monocytes.	pyrazolanthrone	47-55	ubiquitin associated and SH3 domain containing B	Homo sapiens	141-144
12709432-8	2003	Consistent with these observations, activation of JNK and the resulting morphological changes mediated by ephrin-B1 could be abolished by the JNK inhibitor SP600125 but not the Src inhibitor PP2.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	50-53
12709432-8	2003	Consistent with these observations, activation of JNK and the resulting morphological changes mediated by ephrin-B1 could be abolished by the JNK inhibitor SP600125 but not the Src inhibitor PP2.	pyrazolanthrone	156-164	ephrin B1	Homo sapiens	106-115
12709432-8	2003	Consistent with these observations, activation of JNK and the resulting morphological changes mediated by ephrin-B1 could be abolished by the JNK inhibitor SP600125 but not the Src inhibitor PP2.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Homo sapiens	142-145
12871843-13	2003	Furthermore, GM-CSF, RANTES and to a lesser extent IL-8 release from HASMC treated with TNFalpha and IL-1beta was inhibited dosedependently by SP600125.	pyrazolanthrone	143-151	interleukin 1 beta	Homo sapiens	101-109
12730213-3	2003	We demonstrate that basal JNK activity is critical for fibroblast motility because (a) mouse embryo jnk-/- fibroblasts exhibit significantly lower ability to close mechanically induced cell layer wounds than their wild-type (wt) counterparts, and (b) wound closure by human dermal fibroblasts is dramatically impaired by the specific JNK inhibitor SP600125.	pyrazolanthrone	348-356	mitogen-activated protein kinase 8	Mus musculus	26-29
12871843-5	2003	We examined the role of the mitogen-activated protein kinase (MAPK) c-jun N-terminal kinase (JNK) in TNFalpha- and IL-1beta-induced GM-CSF, RANTES and IL-8 production in HASMC by using a novel specific inhibitor for JNK (SP600125).	pyrazolanthrone	221-229	mitogen-activated protein kinase 8	Homo sapiens	93-96
12871843-5	2003	We examined the role of the mitogen-activated protein kinase (MAPK) c-jun N-terminal kinase (JNK) in TNFalpha- and IL-1beta-induced GM-CSF, RANTES and IL-8 production in HASMC by using a novel specific inhibitor for JNK (SP600125).	pyrazolanthrone	221-229	interleukin 1 beta	Homo sapiens	115-123
12871843-12	2003	Maximum TNFalpha- or IL-1beta-induced phosphorylation of JNK in HASMC occurred after 15 min and returned to baseline levels after 4 h. SP600125 inhibited TNFalpha- and IL-1beta-induced JNK activity in HASMC as shown by the reduced phosphorylation of its substrate c-jun.	pyrazolanthrone	135-143	tumor necrosis factor	Homo sapiens	8-16
12871843-12	2003	Maximum TNFalpha- or IL-1beta-induced phosphorylation of JNK in HASMC occurred after 15 min and returned to baseline levels after 4 h. SP600125 inhibited TNFalpha- and IL-1beta-induced JNK activity in HASMC as shown by the reduced phosphorylation of its substrate c-jun.	pyrazolanthrone	135-143	interleukin 1 beta	Homo sapiens	21-29
12871843-12	2003	Maximum TNFalpha- or IL-1beta-induced phosphorylation of JNK in HASMC occurred after 15 min and returned to baseline levels after 4 h. SP600125 inhibited TNFalpha- and IL-1beta-induced JNK activity in HASMC as shown by the reduced phosphorylation of its substrate c-jun.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	57-60
12871843-12	2003	Maximum TNFalpha- or IL-1beta-induced phosphorylation of JNK in HASMC occurred after 15 min and returned to baseline levels after 4 h. SP600125 inhibited TNFalpha- and IL-1beta-induced JNK activity in HASMC as shown by the reduced phosphorylation of its substrate c-jun.	pyrazolanthrone	135-143	tumor necrosis factor	Homo sapiens	154-162
12871843-12	2003	Maximum TNFalpha- or IL-1beta-induced phosphorylation of JNK in HASMC occurred after 15 min and returned to baseline levels after 4 h. SP600125 inhibited TNFalpha- and IL-1beta-induced JNK activity in HASMC as shown by the reduced phosphorylation of its substrate c-jun.	pyrazolanthrone	135-143	interleukin 1 beta	Homo sapiens	168-176
12871843-12	2003	Maximum TNFalpha- or IL-1beta-induced phosphorylation of JNK in HASMC occurred after 15 min and returned to baseline levels after 4 h. SP600125 inhibited TNFalpha- and IL-1beta-induced JNK activity in HASMC as shown by the reduced phosphorylation of its substrate c-jun.	pyrazolanthrone	135-143	mitogen-activated protein kinase 8	Homo sapiens	185-188
12871843-12	2003	Maximum TNFalpha- or IL-1beta-induced phosphorylation of JNK in HASMC occurred after 15 min and returned to baseline levels after 4 h. SP600125 inhibited TNFalpha- and IL-1beta-induced JNK activity in HASMC as shown by the reduced phosphorylation of its substrate c-jun.	pyrazolanthrone	135-143	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	264-269
12871843-13	2003	Furthermore, GM-CSF, RANTES and to a lesser extent IL-8 release from HASMC treated with TNFalpha and IL-1beta was inhibited dosedependently by SP600125.	pyrazolanthrone	143-151	colony stimulating factor 2	Homo sapiens	13-19
12871843-13	2003	Furthermore, GM-CSF, RANTES and to a lesser extent IL-8 release from HASMC treated with TNFalpha and IL-1beta was inhibited dosedependently by SP600125.	pyrazolanthrone	143-151	C-C motif chemokine ligand 5	Homo sapiens	21-27
12871843-13	2003	Furthermore, GM-CSF, RANTES and to a lesser extent IL-8 release from HASMC treated with TNFalpha and IL-1beta was inhibited dosedependently by SP600125.	pyrazolanthrone	143-151	C-X-C motif chemokine ligand 8	Homo sapiens	51-55
12871843-13	2003	Furthermore, GM-CSF, RANTES and to a lesser extent IL-8 release from HASMC treated with TNFalpha and IL-1beta was inhibited dosedependently by SP600125.	pyrazolanthrone	143-151	tumor necrosis factor	Homo sapiens	88-96
12759338-9	2003	The JNK inhibitor SP600125 antagonized R- and S-flurbiprofen-induced AP-1 DNA binding, suppression of cyclin D1 expression, and the G1-cell cycle block.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	4-7
12759338-9	2003	The JNK inhibitor SP600125 antagonized R- and S-flurbiprofen-induced AP-1 DNA binding, suppression of cyclin D1 expression, and the G1-cell cycle block.	pyrazolanthrone	18-26	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	69-73
12759338-9	2003	The JNK inhibitor SP600125 antagonized R- and S-flurbiprofen-induced AP-1 DNA binding, suppression of cyclin D1 expression, and the G1-cell cycle block.	pyrazolanthrone	18-26	cyclin D1	Homo sapiens	102-111
12663670-4	2003	Selective inhibition studies with PD98059, SB202190, SP600125, and the dominant negative JNK indicate that activation of JNK but not p38 kinase or ERK kinase is required for the phosphorylation and transcriptional activation of ATF2.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	121-124
14511403-5	2003	Both SB202190 and SP600125 dose-dependently inhibited UVA-induced AP-1 and c-fos transactivations.	pyrazolanthrone	18-26	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	66-70
14511403-5	2003	Both SB202190 and SP600125 dose-dependently inhibited UVA-induced AP-1 and c-fos transactivations.	pyrazolanthrone	18-26	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	75-80
14511403-6	2003	SB202190 (0.25-0.5 microM) and SP600125 (62-125 nM) treatments also primarily inhibited UVA-induced c-Fos expression.	pyrazolanthrone	31-39	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	100-105
12858017-5	2003	Inhibition of ERK1/2 with PD98059 exerted little effect on the heat-induced apoptosis and p38 inhibition with SB203580 slightly lessened apoptosis whereas, inhibition of JNK with SP600125 markedly suppressed the heat-induced apoptosis.	pyrazolanthrone	179-187	mitogen-activated protein kinase 8	Homo sapiens	170-173
12663670-7	2003	Similarly, application of SB202190 at 50 micro m or SP600125 inhibited JNK activity, blocked transactivation, and sensitized parental cells to the four DNA-damaging drugs.	pyrazolanthrone	52-60	mitogen-activated protein kinase 8	Homo sapiens	71-74
12637567-3	2003	The Jun N-terminal kinase (JNK) inhibitor SP600125 decreased sodium arsenite-mediated induction of HO-1 mRNA expression.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Rattus norvegicus	4-25
12842758-7	2003	JNK inhibitor (SP600125), but not Src inhibitor (PP2), suppressed both L243 stimulated RANTES mRNA expression and protein secretion.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	0-3
12842758-7	2003	JNK inhibitor (SP600125), but not Src inhibitor (PP2), suppressed both L243 stimulated RANTES mRNA expression and protein secretion.	pyrazolanthrone	15-23	chemokine (C-C motif) ligand 5	Mus musculus	87-93
12842758-8	2003	The maximum inhibition for RANTES production by SP600125 was more than 80%.	pyrazolanthrone	48-56	chemokine (C-C motif) ligand 5	Mus musculus	27-33
12665525-4	2003	Blocking JNK either by dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor, SP600125, abrogates both stress-induced release of Smac and induction of apoptosis.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	9-12
12665525-4	2003	Blocking JNK either by dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor, SP600125, abrogates both stress-induced release of Smac and induction of apoptosis.	pyrazolanthrone	103-111	diablo IAP-binding mitochondrial protein	Homo sapiens	154-158
12637567-3	2003	The Jun N-terminal kinase (JNK) inhibitor SP600125 decreased sodium arsenite-mediated induction of HO-1 mRNA expression.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
12637567-3	2003	The Jun N-terminal kinase (JNK) inhibitor SP600125 decreased sodium arsenite-mediated induction of HO-1 mRNA expression.	pyrazolanthrone	42-50	heme oxygenase 1	Rattus norvegicus	99-103
12600999-7	2003	The treatments with MEK inhibitor U0126, p38 kinase inhibitor SB203580, and JNK inhibitor SP600125 significantly attenuated hypertonicity-induced AQP1 expression in mIMCD-3 cells.	pyrazolanthrone	90-98	mitogen-activated protein kinase 8	Mus musculus	76-79
12704792-5	2003	Proliferation of both SMC subtypes was attenuated by PD98059, SP600125 and SB202190, inhibitors of ERK, JNK, and p38, respectively.	pyrazolanthrone	62-70	Eph receptor B1	Rattus norvegicus	99-102
12704792-5	2003	Proliferation of both SMC subtypes was attenuated by PD98059, SP600125 and SB202190, inhibitors of ERK, JNK, and p38, respectively.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Rattus norvegicus	104-107
12704792-5	2003	Proliferation of both SMC subtypes was attenuated by PD98059, SP600125 and SB202190, inhibitors of ERK, JNK, and p38, respectively.	pyrazolanthrone	62-70	mitogen activated protein kinase 14	Rattus norvegicus	113-116
12600999-7	2003	The treatments with MEK inhibitor U0126, p38 kinase inhibitor SB203580, and JNK inhibitor SP600125 significantly attenuated hypertonicity-induced AQP1 expression in mIMCD-3 cells.	pyrazolanthrone	90-98	aquaporin 1	Mus musculus	146-150
12600999-9	2003	NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2.	pyrazolanthrone	146-154	aquaporin 1	Mus musculus	27-31
12600999-9	2003	NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2.	pyrazolanthrone	146-154	mitogen-activated protein kinase 8	Mus musculus	253-257
12600999-9	2003	NaCl-inducible activity of AQP1 promoter, which contains a hypertonicity response element, was attenuated in the presence of U0126, SB203580, and SP600125 in a dose-dependent manner and was also significantly reduced by the dominant-negative mutants of JNK1 and JNK2.	pyrazolanthrone	146-154	mitogen-activated protein kinase 9	Mus musculus	262-266
12717136-12	2003	SP600125, a specific inhibitor of SAPK/JNK, significantly reduced midazolam-stimulated VEGF release.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Rattus norvegicus	87-91
12717136-13	2003	Applied together, PD98059 and SP600125 produced an additive reduction in midazolam-stimulated VEGF release.	pyrazolanthrone	30-38	vascular endothelial growth factor A	Rattus norvegicus	94-98
14574080-6	2003	In a number of experiments activation of JNK by anisomycin was blocked by SP 600125 (10 muM).	pyrazolanthrone	74-83	mitogen-activated protein kinase 8	Rattus norvegicus	41-44
12654505-5	2003	The increases in p38 and JNK phosphorylation were implicated in the death of the cells, since the p38 inhibitor PD169316 and the JNK inhibitor SP600125 were protective.	pyrazolanthrone	143-151	mitogen activated protein kinase 14	Rattus norvegicus	17-20
12717385-11	2003	LPS-induced IL-8 secretion is completely inhibited by the IkappaB super repressor (Ad5IkappaB) and partially inhibited by a specific JNK inhibitor, SP600125.	pyrazolanthrone	148-156	C-X-C motif chemokine ligand 8	Homo sapiens	12-16
12717385-11	2003	LPS-induced IL-8 secretion is completely inhibited by the IkappaB super repressor (Ad5IkappaB) and partially inhibited by a specific JNK inhibitor, SP600125.	pyrazolanthrone	148-156	mitogen-activated protein kinase 8	Homo sapiens	133-136
12714616-15	2003	The p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (5 microM) and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 (25 microM) partially blocked (by 47% and 59%, respectively) the effect of IL-1beta.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Homo sapiens	85-110
12714616-15	2003	The p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (5 microM) and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 (25 microM) partially blocked (by 47% and 59%, respectively) the effect of IL-1beta.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Homo sapiens	112-115
12714616-15	2003	The p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 (5 microM) and the c-Jun NH2-terminal kinase (JNK) inhibitor SP600125 (25 microM) partially blocked (by 47% and 59%, respectively) the effect of IL-1beta.	pyrazolanthrone	127-135	interleukin 1 beta	Homo sapiens	211-219
12681294-8	2003	Transient HA-JNK1 expression also reduced H(2)O(2) generation, and this effect was reversed by the JNK inhibitor SP600125.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	13-17
12681294-8	2003	Transient HA-JNK1 expression also reduced H(2)O(2) generation, and this effect was reversed by the JNK inhibitor SP600125.	pyrazolanthrone	113-121	mitogen-activated protein kinase 8	Homo sapiens	13-16
12668975-2	2003	In this study, JNK activity was blocked with the small molecule inhibitor JNK SP600125 in vivo and in vitro as shown by a reduction of c-Jun phosphorylation, AP-1 DNA binding activity, and c-jun messenger RNA (mRNA) expression.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Rattus norvegicus	15-18
12668975-2	2003	In this study, JNK activity was blocked with the small molecule inhibitor JNK SP600125 in vivo and in vitro as shown by a reduction of c-Jun phosphorylation, AP-1 DNA binding activity, and c-jun messenger RNA (mRNA) expression.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Rattus norvegicus	74-77
12668975-3	2003	SP600125 inhibited proliferating cell nuclear antigen (PCNA) expression, cyclin D1 mRNA and protein expression and reduced mitotic figures after PH.	pyrazolanthrone	0-8	proliferating cell nuclear antigen	Rattus norvegicus	19-53
12668975-3	2003	SP600125 inhibited proliferating cell nuclear antigen (PCNA) expression, cyclin D1 mRNA and protein expression and reduced mitotic figures after PH.	pyrazolanthrone	0-8	proliferating cell nuclear antigen	Rattus norvegicus	55-59
12668975-3	2003	SP600125 inhibited proliferating cell nuclear antigen (PCNA) expression, cyclin D1 mRNA and protein expression and reduced mitotic figures after PH.	pyrazolanthrone	0-8	cyclin D1	Rattus norvegicus	73-82
12668975-5	2003	In epidermal growth factor (EGF)-treated primary cultures of rat hepatocytes, SP600125 decreased (3)H-thymidine uptake, cyclin D1 mRNA and protein expression, and inhibited the EGF-induced transcription of a cyclin D1 promoter-driven reporter gene.	pyrazolanthrone	78-86	epidermal growth factor like 1	Rattus norvegicus	3-26
12668975-5	2003	In epidermal growth factor (EGF)-treated primary cultures of rat hepatocytes, SP600125 decreased (3)H-thymidine uptake, cyclin D1 mRNA and protein expression, and inhibited the EGF-induced transcription of a cyclin D1 promoter-driven reporter gene.	pyrazolanthrone	78-86	epidermal growth factor like 1	Rattus norvegicus	28-31
12668975-5	2003	In epidermal growth factor (EGF)-treated primary cultures of rat hepatocytes, SP600125 decreased (3)H-thymidine uptake, cyclin D1 mRNA and protein expression, and inhibited the EGF-induced transcription of a cyclin D1 promoter-driven reporter gene.	pyrazolanthrone	78-86	cyclin D1	Rattus norvegicus	120-129
12668975-5	2003	In epidermal growth factor (EGF)-treated primary cultures of rat hepatocytes, SP600125 decreased (3)H-thymidine uptake, cyclin D1 mRNA and protein expression, and inhibited the EGF-induced transcription of a cyclin D1 promoter-driven reporter gene.	pyrazolanthrone	78-86	epidermal growth factor like 1	Rattus norvegicus	177-180
12668975-5	2003	In epidermal growth factor (EGF)-treated primary cultures of rat hepatocytes, SP600125 decreased (3)H-thymidine uptake, cyclin D1 mRNA and protein expression, and inhibited the EGF-induced transcription of a cyclin D1 promoter-driven reporter gene.	pyrazolanthrone	78-86	cyclin D1	Rattus norvegicus	208-217
12668975-6	2003	The defective regeneration and the decreased survival in SP600125-treated rats did not result from a major increase in apoptosis as shown by normal levels of caspase 3 activity and only slight increases in apoptotic figures.	pyrazolanthrone	57-65	caspase 3	Rattus norvegicus	158-167
12697041-4	2003	SP600125, an inhibitor of SAPK/JNK, markedly reduced the FGF-2-induced VEGF release.	pyrazolanthrone	0-8	fibroblast growth factor 2	Mus musculus	57-62
12697041-4	2003	SP600125, an inhibitor of SAPK/JNK, markedly reduced the FGF-2-induced VEGF release.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Mus musculus	71-75
12697041-5	2003	SP600125 suppressed the FGF-2-induced phosphorylation of SAPK/JNK without affecting the phosphorylation of p44/p42 MAP kinase or p38 MAP kinase induced by FGF-2.	pyrazolanthrone	0-8	fibroblast growth factor 2	Mus musculus	24-29
12697041-7	2003	A combination of SP600125 and SB203580 suppressed the FGF-2-stimulated VEGF release in an additive manner.	pyrazolanthrone	17-25	fibroblast growth factor 2	Mus musculus	54-59
12697041-7	2003	A combination of SP600125 and SB203580 suppressed the FGF-2-stimulated VEGF release in an additive manner.	pyrazolanthrone	17-25	vascular endothelial growth factor A	Mus musculus	71-75
12654505-5	2003	The increases in p38 and JNK phosphorylation were implicated in the death of the cells, since the p38 inhibitor PD169316 and the JNK inhibitor SP600125 were protective.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Rattus norvegicus	25-28
12654505-5	2003	The increases in p38 and JNK phosphorylation were implicated in the death of the cells, since the p38 inhibitor PD169316 and the JNK inhibitor SP600125 were protective.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Rattus norvegicus	129-132
12644304-6	2003	SB203580, a specific inhibitor of p38 mitogen-activated protein (MAP) kinase, and SP600125, a specific inhibitor of c-Jun N-terminal kinase (JNK), also reduced the induction by both PDGF-BB and bFGF.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	116-139
12510059-12	2003	Finally, an inhibitor of c-Jun N-terminal kinase, SP600125, at 10 microm did not block IRS-1 degradation and IRS-1 Ser(312) phosphorylation yet completely blocked insulin-stimulated c-Jun phosphorylation.	pyrazolanthrone	50-58	insulin	Homo sapiens	163-170
12618755-14	2003	An inhibition of GSE-induced JNK activation by a novel JNK inhibitor SP600125 resulted in a significant reversal of GSE-induced apoptotic death suggesting the involvement of JNK activation by GSE in its apoptosis response.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	29-32
12618755-14	2003	An inhibition of GSE-induced JNK activation by a novel JNK inhibitor SP600125 resulted in a significant reversal of GSE-induced apoptotic death suggesting the involvement of JNK activation by GSE in its apoptosis response.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	55-58
12618755-14	2003	An inhibition of GSE-induced JNK activation by a novel JNK inhibitor SP600125 resulted in a significant reversal of GSE-induced apoptotic death suggesting the involvement of JNK activation by GSE in its apoptosis response.	pyrazolanthrone	69-77	mitogen-activated protein kinase 8	Homo sapiens	55-58
12644304-6	2003	SB203580, a specific inhibitor of p38 mitogen-activated protein (MAP) kinase, and SP600125, a specific inhibitor of c-Jun N-terminal kinase (JNK), also reduced the induction by both PDGF-BB and bFGF.	pyrazolanthrone	82-90	mitogen-activated protein kinase 8	Homo sapiens	141-144
12644304-6	2003	SB203580, a specific inhibitor of p38 mitogen-activated protein (MAP) kinase, and SP600125, a specific inhibitor of c-Jun N-terminal kinase (JNK), also reduced the induction by both PDGF-BB and bFGF.	pyrazolanthrone	82-90	fibroblast growth factor 2	Homo sapiens	194-198
12589827-6	2003	By statistical analysis, the amphiregulin-induced growth effect was significantly decreased by the MAP kinase/ extracellular regulated kinase kinase-1 (MEK-1) inhibitor PD98059, p38-MAPK inhibitor SB203580, and phosphatidylinositol 3-kinase (PI-3 kinase) inhibitor wortmannin, respectively, but was not decreased by JNK inhibitor SP600125.	pyrazolanthrone	330-338	amphiregulin	Homo sapiens	29-41
12562529-4	2003	Here we examined whether JNK is involved in APP-mediated neuronal cell death and found that: (i) neuronal cell death by antibody-bound APP was inhibited by dominant-negative JNK, JIP-1b and SP600125, the specific inhibitor of JNK, but not by SB203580 or PD98059; (ii) constitutively active (ca) JNK caused neuronal cell death and (iii) the pharmacological profile of caJNK-mediated cell death closely coincided with that of APP-mediated cell death.	pyrazolanthrone	190-198	mitogen-activated protein kinase 8	Homo sapiens	25-28
12603281-4	2003	The intra-CA1 infusion of SP600125, at a dose that in naive animals significantly reduced the phosphorylation levels of c-Jun without affecting the activity of ERK1/2 or p38 MAPK, enhanced short-term memory (STM) but blocked long-term memory (LTM) formation and retrieval of an inhibitory avoidance learning task.	pyrazolanthrone	26-34	carbonic anhydrase 1	Rattus norvegicus	10-13
12603281-4	2003	The intra-CA1 infusion of SP600125, at a dose that in naive animals significantly reduced the phosphorylation levels of c-Jun without affecting the activity of ERK1/2 or p38 MAPK, enhanced short-term memory (STM) but blocked long-term memory (LTM) formation and retrieval of an inhibitory avoidance learning task.	pyrazolanthrone	26-34	mitogen activated protein kinase 3	Rattus norvegicus	160-166
12574140-9	2003	Transfection with an adenovirus expressing dominant-negative JNK inhibited betaAR-stimulated apoptosis by 81+/-12%, and the JNK inhibitor SP600125 inhibited both betaAR-stimulated apoptosis and cytochrome c release.	pyrazolanthrone	138-146	mitogen-activated protein kinase 8	Rattus norvegicus	124-127
12699771-3	2003	Here, the effects of the novel JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-1 (SP600125) were investigated on the inhibition of LTP by cytokines interleukin-1beta, interleukin-18 and tumour necrosis factor-alpha in the dentate gyrus.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Rattus norvegicus	31-34
12527812-10	2003	Pretreatment of hepatoma cells with a selective JNK inhibitor, anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), significantly reduced the rate of TRO-induced cell death, whereas 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), an inhibitor of p38 kinase, had little effect on apoptosis.	pyrazolanthrone	63-94	mitogen-activated protein kinase 8	Homo sapiens	48-51
12527812-10	2003	Pretreatment of hepatoma cells with a selective JNK inhibitor, anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), significantly reduced the rate of TRO-induced cell death, whereas 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), an inhibitor of p38 kinase, had little effect on apoptosis.	pyrazolanthrone	63-94	mitogen-activated protein kinase 14	Homo sapiens	274-277
12527812-10	2003	Pretreatment of hepatoma cells with a selective JNK inhibitor, anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), significantly reduced the rate of TRO-induced cell death, whereas 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), an inhibitor of p38 kinase, had little effect on apoptosis.	pyrazolanthrone	96-104	mitogen-activated protein kinase 8	Homo sapiens	48-51
12527812-10	2003	Pretreatment of hepatoma cells with a selective JNK inhibitor, anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), significantly reduced the rate of TRO-induced cell death, whereas 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB203580), an inhibitor of p38 kinase, had little effect on apoptosis.	pyrazolanthrone	96-104	mitogen-activated protein kinase 14	Homo sapiens	274-277
12527812-11	2003	Pretreatment with SP600125 also prevented JNK activation and c-Jun phosphorylation.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	42-45
12409308-9	2003	SP600125, a JNK inhibitor, prevented PMA and TNFalpha-induced IRS1 Ser-307 phosphorylation.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
12409308-9	2003	SP600125, a JNK inhibitor, prevented PMA and TNFalpha-induced IRS1 Ser-307 phosphorylation.	pyrazolanthrone	0-8	tumor necrosis factor	Homo sapiens	45-53
12409308-9	2003	SP600125, a JNK inhibitor, prevented PMA and TNFalpha-induced IRS1 Ser-307 phosphorylation.	pyrazolanthrone	0-8	insulin receptor substrate 1	Homo sapiens	62-66
12409308-12	2003	The role of JNK in salicylic acid-mediated insulin sensitization, however, requires further validation because the JNK inhibitor SP600125 appears to have other nonspecific activity in addition to inhibiting JNK activity.	pyrazolanthrone	129-137	insulin	Homo sapiens	43-50
12409308-12	2003	The role of JNK in salicylic acid-mediated insulin sensitization, however, requires further validation because the JNK inhibitor SP600125 appears to have other nonspecific activity in addition to inhibiting JNK activity.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	115-118
12409308-12	2003	The role of JNK in salicylic acid-mediated insulin sensitization, however, requires further validation because the JNK inhibitor SP600125 appears to have other nonspecific activity in addition to inhibiting JNK activity.	pyrazolanthrone	129-137	mitogen-activated protein kinase 8	Homo sapiens	115-118
12587073-3	2003	JNK activation was involved in HSV-1-induced apoptosis as evidenced by apoptosis inhibition with the JNK inhibitor SP600125.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Homo sapiens	0-3
12587073-3	2003	JNK activation was involved in HSV-1-induced apoptosis as evidenced by apoptosis inhibition with the JNK inhibitor SP600125.	pyrazolanthrone	115-123	mitogen-activated protein kinase 8	Homo sapiens	101-104
12527812-11	2003	Pretreatment with SP600125 also prevented JNK activation and c-Jun phosphorylation.	pyrazolanthrone	18-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	61-66
12527812-14	2003	Furthermore, SP600125 pretreatment effectively prevented the TRO-mediated changes in Bad, Bax, Bid cleavage, and cytochrome c release.	pyrazolanthrone	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	90-93
12527812-14	2003	Furthermore, SP600125 pretreatment effectively prevented the TRO-mediated changes in Bad, Bax, Bid cleavage, and cytochrome c release.	pyrazolanthrone	13-21	BH3 interacting domain death agonist	Homo sapiens	95-98
12527812-14	2003	Furthermore, SP600125 pretreatment effectively prevented the TRO-mediated changes in Bad, Bax, Bid cleavage, and cytochrome c release.	pyrazolanthrone	13-21	cytochrome c, somatic	Homo sapiens	113-125
12502846-8	2003	c-Jun activation and apoptosis are inhibited in hippocampal cultures infected with HSV-1 in the presence of the JNK inhibitor SP600125, suggesting that JNK/c-Jun activation is required for HSV-1-induced apoptosis.	pyrazolanthrone	126-134	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	0-5
12502846-8	2003	c-Jun activation and apoptosis are inhibited in hippocampal cultures infected with HSV-1 in the presence of the JNK inhibitor SP600125, suggesting that JNK/c-Jun activation is required for HSV-1-induced apoptosis.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	112-115
12502846-8	2003	c-Jun activation and apoptosis are inhibited in hippocampal cultures infected with HSV-1 in the presence of the JNK inhibitor SP600125, suggesting that JNK/c-Jun activation is required for HSV-1-induced apoptosis.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Homo sapiens	152-155
12502846-8	2003	c-Jun activation and apoptosis are inhibited in hippocampal cultures infected with HSV-1 in the presence of the JNK inhibitor SP600125, suggesting that JNK/c-Jun activation is required for HSV-1-induced apoptosis.	pyrazolanthrone	126-134	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	156-161
12699771-3	2003	Here, the effects of the novel JNK inhibitor anthra[1,9-cd]pyrazol-6(2H)-1 (SP600125) were investigated on the inhibition of LTP by cytokines interleukin-1beta, interleukin-18 and tumour necrosis factor-alpha in the dentate gyrus.	pyrazolanthrone	76-84	interleukin 1 beta	Rattus norvegicus	142-159
12699771-8	2003	Whilst not affecting baseline amplitude when perfused alone, prior perfusion of SP600125 alleviated the depressive effect of interleukin-18 on NMDA-EPSPs.	pyrazolanthrone	80-88	interleukin 18	Rattus norvegicus	125-139
12699771-10	2003	Perfusion of SP600125 prior to low-frequency stimulation of the perforant path resulted in a significant attenuation of induced LTD, which suggests that JNK activation is a critical mediator of LTD in the dentate gyrus.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Rattus norvegicus	153-156
12221076-8	2002	Surprisingly, cotransfection of p53+/+ cells with dominant negative mutants of JNK isoforms and treatment of p53+/+ cells with the JNK inhibitor SP600125 actually further enhanced apoptosis in p53+/+ cells by up to 2-fold in response to nocodazole.	pyrazolanthrone	145-153	tumor protein p53	Homo sapiens	32-35
12368275-11	2002	Importantly, this effect is blocked by prior treatment with the JNK inhibitor SP600125 confirming that JNK as a key effector in T1/ST2 signaling.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	64-67
12368275-11	2002	Importantly, this effect is blocked by prior treatment with the JNK inhibitor SP600125 confirming that JNK as a key effector in T1/ST2 signaling.	pyrazolanthrone	78-86	mitogen-activated protein kinase 8	Mus musculus	103-106
12368275-11	2002	Importantly, this effect is blocked by prior treatment with the JNK inhibitor SP600125 confirming that JNK as a key effector in T1/ST2 signaling.	pyrazolanthrone	78-86	interleukin 1 receptor-like 1	Mus musculus	131-134
12169099-5	2002	Up-regulation of c- jun mRNA by endothelin-1 was attenuated by inhibitors of protein kinase C (GF109203X) and the extracellular signal-regulated kinase (ERK) cascade (PD98059 or U0126), but not by inhibitors of the JNK (SP600125) or p38-MAPK (SB203580) cascades.	pyrazolanthrone	220-228	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	17-23
12169099-5	2002	Up-regulation of c- jun mRNA by endothelin-1 was attenuated by inhibitors of protein kinase C (GF109203X) and the extracellular signal-regulated kinase (ERK) cascade (PD98059 or U0126), but not by inhibitors of the JNK (SP600125) or p38-MAPK (SB203580) cascades.	pyrazolanthrone	220-228	endothelin 1	Homo sapiens	32-44
12169099-5	2002	Up-regulation of c- jun mRNA by endothelin-1 was attenuated by inhibitors of protein kinase C (GF109203X) and the extracellular signal-regulated kinase (ERK) cascade (PD98059 or U0126), but not by inhibitors of the JNK (SP600125) or p38-MAPK (SB203580) cascades.	pyrazolanthrone	220-228	mitogen-activated protein kinase 1	Homo sapiens	153-156
12169099-10	2002	In addition, SP600125 inhibited the phosphorylation of c-Jun(Ser-63/73), attenuated the increase in c-Jun protein induced by endothelin-1 and increased the rate of c-Jun degradation.	pyrazolanthrone	13-21	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	55-60
12169099-10	2002	In addition, SP600125 inhibited the phosphorylation of c-Jun(Ser-63/73), attenuated the increase in c-Jun protein induced by endothelin-1 and increased the rate of c-Jun degradation.	pyrazolanthrone	13-21	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	100-105
12169099-10	2002	In addition, SP600125 inhibited the phosphorylation of c-Jun(Ser-63/73), attenuated the increase in c-Jun protein induced by endothelin-1 and increased the rate of c-Jun degradation.	pyrazolanthrone	13-21	endothelin 1	Homo sapiens	125-137
12169099-10	2002	In addition, SP600125 inhibited the phosphorylation of c-Jun(Ser-63/73), attenuated the increase in c-Jun protein induced by endothelin-1 and increased the rate of c-Jun degradation.	pyrazolanthrone	13-21	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	100-105
12221076-8	2002	Surprisingly, cotransfection of p53+/+ cells with dominant negative mutants of JNK isoforms and treatment of p53+/+ cells with the JNK inhibitor SP600125 actually further enhanced apoptosis in p53+/+ cells by up to 2-fold in response to nocodazole.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	79-82
12421945-9	2002	This conclusion was based on results derived by transfection of THP-1 cells with a dominant-negative mutant of stress-activated protein/extracellular signal-regulated kinase kinase 1, and by exposure of cells to JNK inhibitors dexamethasone and SP600125.	pyrazolanthrone	245-253	mitogen-activated protein kinase 8	Homo sapiens	212-215
12221076-8	2002	Surprisingly, cotransfection of p53+/+ cells with dominant negative mutants of JNK isoforms and treatment of p53+/+ cells with the JNK inhibitor SP600125 actually further enhanced apoptosis in p53+/+ cells by up to 2-fold in response to nocodazole.	pyrazolanthrone	145-153	tumor protein p53	Homo sapiens	109-112
12221076-8	2002	Surprisingly, cotransfection of p53+/+ cells with dominant negative mutants of JNK isoforms and treatment of p53+/+ cells with the JNK inhibitor SP600125 actually further enhanced apoptosis in p53+/+ cells by up to 2-fold in response to nocodazole.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	131-134
12221076-8	2002	Surprisingly, cotransfection of p53+/+ cells with dominant negative mutants of JNK isoforms and treatment of p53+/+ cells with the JNK inhibitor SP600125 actually further enhanced apoptosis in p53+/+ cells by up to 2-fold in response to nocodazole.	pyrazolanthrone	145-153	tumor protein p53	Homo sapiens	109-112
12509925-5	2002	RT-PCR was used to detect the influence of the MEK/REK inhibitor PD98059, JNK inhibitor SP600125, and p38 inhibitor SB203580 on the expression of TNF-alpha gene induced by LPS.	pyrazolanthrone	88-96	tumor necrosis factor	Mus musculus	146-155
12642693-6	2002	Coadministration of the JNK inhibitor SP600125 attenuated UCN-01/MEK inhibitor- associated lethality, suggesting a functional role for JNK activation in enhanced lethality.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	24-27
12642693-6	2002	Coadministration of the JNK inhibitor SP600125 attenuated UCN-01/MEK inhibitor- associated lethality, suggesting a functional role for JNK activation in enhanced lethality.	pyrazolanthrone	38-46	urocortin	Homo sapiens	58-61
12642693-6	2002	Coadministration of the JNK inhibitor SP600125 attenuated UCN-01/MEK inhibitor- associated lethality, suggesting a functional role for JNK activation in enhanced lethality.	pyrazolanthrone	38-46	mitogen-activated protein kinase kinase 7	Homo sapiens	65-68
12642693-6	2002	Coadministration of the JNK inhibitor SP600125 attenuated UCN-01/MEK inhibitor- associated lethality, suggesting a functional role for JNK activation in enhanced lethality.	pyrazolanthrone	38-46	mitogen-activated protein kinase 8	Homo sapiens	135-138
12509925-5	2002	RT-PCR was used to detect the influence of the MEK/REK inhibitor PD98059, JNK inhibitor SP600125, and p38 inhibitor SB203580 on the expression of TNF-alpha gene induced by LPS.	pyrazolanthrone	88-96	toll-like receptor 4	Mus musculus	172-175
12176045-4	2002	In addition, the JNK MAPK inhibitor SP600125 inhibited IL-18 mRNA transcription in a dose-dependent manner.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	17-20
12220537-5	2002	Although, the JNK inhibitor, SP600125, inhibited JNK-dependent anisomycin-induced c-Jun phosphorylation, it was ineffective in preventing anisomycin-induced caspase activation and cell death.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	14-17
12220537-5	2002	Although, the JNK inhibitor, SP600125, inhibited JNK-dependent anisomycin-induced c-Jun phosphorylation, it was ineffective in preventing anisomycin-induced caspase activation and cell death.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Homo sapiens	49-52
12220537-5	2002	Although, the JNK inhibitor, SP600125, inhibited JNK-dependent anisomycin-induced c-Jun phosphorylation, it was ineffective in preventing anisomycin-induced caspase activation and cell death.	pyrazolanthrone	29-37	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	82-87
12176045-4	2002	In addition, the JNK MAPK inhibitor SP600125 inhibited IL-18 mRNA transcription in a dose-dependent manner.	pyrazolanthrone	36-44	interleukin 18	Mus musculus	55-60
12031798-0	2002	An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression.	pyrazolanthrone	44-52	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	16-21
12031798-0	2002	An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression.	pyrazolanthrone	44-52	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	64-69
12031798-4	2002	Therefore, we undertook a study to determine the efficacy of a novel compound (SP600125), which binds to the ATP binding site of all known JNKs, in repressing MMP-9 expression.	pyrazolanthrone	79-87	matrix metallopeptidase 9	Homo sapiens	159-164
12031798-5	2002	In OVCAR-3 cells, SP600125 inhibited the PMA-dependent secretion of MMP-9 in a time-dependent manner and over a dose range that blocked c-Jun phosphorylation and AP-1 binding.	pyrazolanthrone	18-26	matrix metallopeptidase 9	Homo sapiens	68-73
12031798-5	2002	In OVCAR-3 cells, SP600125 inhibited the PMA-dependent secretion of MMP-9 in a time-dependent manner and over a dose range that blocked c-Jun phosphorylation and AP-1 binding.	pyrazolanthrone	18-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	136-141
12031798-6	2002	SP600125 repressed the activity of a PMA-stimulated MMP-9 promoter-driven luciferase reporter, suggesting that diminished secretion of this collagenase reflected reduced transcription.	pyrazolanthrone	0-8	matrix metallopeptidase 9	Homo sapiens	52-57
12031798-7	2002	Further, the activity of a GAL4-driven reporter in PMA-treated cells, co-transfected with an expression construct encoding the trans-activation domain of c-Jun fused to the DNA binding domain of GAL4, was repressed by SP600125.	pyrazolanthrone	218-226	galectin 4	Homo sapiens	27-31
12031798-7	2002	Further, the activity of a GAL4-driven reporter in PMA-treated cells, co-transfected with an expression construct encoding the trans-activation domain of c-Jun fused to the DNA binding domain of GAL4, was repressed by SP600125.	pyrazolanthrone	218-226	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	154-159
12031798-7	2002	Further, the activity of a GAL4-driven reporter in PMA-treated cells, co-transfected with an expression construct encoding the trans-activation domain of c-Jun fused to the DNA binding domain of GAL4, was repressed by SP600125.	pyrazolanthrone	218-226	galectin 4	Homo sapiens	195-199
12031798-8	2002	These findings indicate the efficacy of SP600125 in inhibiting c-Jun activation, DNA-binding and the PMA-dependent induction of MMP-9 expression.	pyrazolanthrone	40-48	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	63-68
12031798-8	2002	These findings indicate the efficacy of SP600125 in inhibiting c-Jun activation, DNA-binding and the PMA-dependent induction of MMP-9 expression.	pyrazolanthrone	40-48	matrix metallopeptidase 9	Homo sapiens	128-133
11717429-0	2001	SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	43-64
12397601-4	2002	SP600125, an inhibitor of JNK, markedly reduced the ET-1-induced VEGF synthesis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	26-29
12397601-4	2002	SP600125, an inhibitor of JNK, markedly reduced the ET-1-induced VEGF synthesis.	pyrazolanthrone	0-8	endothelin 1	Mus musculus	52-56
12397601-4	2002	SP600125, an inhibitor of JNK, markedly reduced the ET-1-induced VEGF synthesis.	pyrazolanthrone	0-8	vascular endothelial growth factor A	Mus musculus	65-69
12397601-5	2002	A combination of SP600125 and SB203580 additively reduced the ET-1-stimulated VEGF synthesis.	pyrazolanthrone	17-25	endothelin 1	Mus musculus	62-66
12397601-5	2002	A combination of SP600125 and SB203580 additively reduced the ET-1-stimulated VEGF synthesis.	pyrazolanthrone	17-25	vascular endothelial growth factor A	Mus musculus	78-82
12397601-6	2002	SP600125 suppressed the ET-1-induced phosphorylation of JNK, while having no effect on the phosphorylation of p38 MAP kinase elicited by ET-1.	pyrazolanthrone	0-8	endothelin 1	Mus musculus	24-28
12397601-6	2002	SP600125 suppressed the ET-1-induced phosphorylation of JNK, while having no effect on the phosphorylation of p38 MAP kinase elicited by ET-1.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	56-59
11717429-4	2001	In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures.	pyrazolanthrone	10-18	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	113-118
11717429-4	2001	In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures.	pyrazolanthrone	10-18	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	69-74
11717429-4	2001	In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures.	pyrazolanthrone	10-18	interleukin 2	Homo sapiens	120-124
11717429-4	2001	In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures.	pyrazolanthrone	10-18	interferon gamma	Homo sapiens	126-135
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Mus musculus	10-13
11717429-4	2001	In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures.	pyrazolanthrone	10-18	tumor necrosis factor	Homo sapiens	137-146
11717429-4	2001	In cells, SP600125 dose dependently inhibited the phosphorylation of c-Jun, the expression of inflammatory genes COX-2, IL-2, IFN-gamma, TNF-alpha, and prevented the activation and differentiation of primary human CD4 cell cultures.	pyrazolanthrone	10-18	CD4 molecule	Homo sapiens	214-217
11717429-5	2001	In animal studies, SP600125 blocked (bacterial) lipopolysaccharide-induced expression of tumor necrosis factor-alpha and inhibited anti-CD3-induced apoptosis of CD4(+) CD8(+) thymocytes.	pyrazolanthrone	19-27	tumor necrosis factor	Homo sapiens	89-116
11717429-5	2001	In animal studies, SP600125 blocked (bacterial) lipopolysaccharide-induced expression of tumor necrosis factor-alpha and inhibited anti-CD3-induced apoptosis of CD4(+) CD8(+) thymocytes.	pyrazolanthrone	19-27	CD4 molecule	Homo sapiens	161-164
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	24-32	interleukin 1 complex	Mus musculus	86-90
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	24-32	jun proto-oncogene	Mus musculus	145-150
33781347-6	2021	Mechanistically, we established that LPS activated sigma-1R-JNK/p38 pathway, and sigma-1R antagonist BD1047, JNK inhibitor SP600125, or p38 inhibitor SB203580 reversed LPS-induced expression of HECTD1, thus restored LPS-induced astrocyte activation.	pyrazolanthrone	123-131	sigma non-opioid intracellular receptor 1	Mus musculus	51-59
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	34-65	mitogen-activated protein kinase 8	Mus musculus	10-13
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	34-65	interleukin 1 complex	Mus musculus	86-90
11435459-5	2001	The novel JNK inhibitor SP600125 (anthra[1,9-cd]pyrazol-6(2H)-one) completely blocked IL-1--induced accumulation of phospho-Jun and induction of c-Jun transcription in synoviocytes.	pyrazolanthrone	34-65	jun proto-oncogene	Mus musculus	145-150
33781347-6	2021	Mechanistically, we established that LPS activated sigma-1R-JNK/p38 pathway, and sigma-1R antagonist BD1047, JNK inhibitor SP600125, or p38 inhibitor SB203580 reversed LPS-induced expression of HECTD1, thus restored LPS-induced astrocyte activation.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Mus musculus	60-63
33781347-6	2021	Mechanistically, we established that LPS activated sigma-1R-JNK/p38 pathway, and sigma-1R antagonist BD1047, JNK inhibitor SP600125, or p38 inhibitor SB203580 reversed LPS-induced expression of HECTD1, thus restored LPS-induced astrocyte activation.	pyrazolanthrone	123-131	sigma non-opioid intracellular receptor 1	Mus musculus	81-89
33781347-6	2021	Mechanistically, we established that LPS activated sigma-1R-JNK/p38 pathway, and sigma-1R antagonist BD1047, JNK inhibitor SP600125, or p38 inhibitor SB203580 reversed LPS-induced expression of HECTD1, thus restored LPS-induced astrocyte activation.	pyrazolanthrone	123-131	mitogen-activated protein kinase 8	Mus musculus	109-112
33781347-7	2021	In addition, FOXJ2 functioned as a transcription factor of HECTD1, and pretreatment of primary mouse astrocytes with BD1047, SB203580, and SP600125 significantly inhibited LPS-mediated translocation of FOXJ2 into the nucleus.	pyrazolanthrone	139-147	forkhead box J2	Mus musculus	13-18
33781347-7	2021	In addition, FOXJ2 functioned as a transcription factor of HECTD1, and pretreatment of primary mouse astrocytes with BD1047, SB203580, and SP600125 significantly inhibited LPS-mediated translocation of FOXJ2 into the nucleus.	pyrazolanthrone	139-147	HECT domain E3 ubiquitin protein ligase 1	Mus musculus	59-65
33781347-7	2021	In addition, FOXJ2 functioned as a transcription factor of HECTD1, and pretreatment of primary mouse astrocytes with BD1047, SB203580, and SP600125 significantly inhibited LPS-mediated translocation of FOXJ2 into the nucleus.	pyrazolanthrone	139-147	forkhead box J2	Mus musculus	202-207
33770099-5	2021	After performing an in vitro tooth germ organ culture and cell culture, we found that JNK inhibitor SP600125 postponed tooth germ development and reduced the polarization, migration and differentiation of mouse dental papilla cells (mDPCs).	pyrazolanthrone	100-108	mitogen-activated protein kinase 8	Mus musculus	86-89
33770099-8	2021	Further, constitutively active RhoA mutant (RhoA Q63L) partly rescued the inhibition of SP600125 on cell differentiation and polarity formation of mDPCs.	pyrazolanthrone	88-96	ras homolog family member A	Mus musculus	31-35
33770099-8	2021	Further, constitutively active RhoA mutant (RhoA Q63L) partly rescued the inhibition of SP600125 on cell differentiation and polarity formation of mDPCs.	pyrazolanthrone	88-96	ras homolog family member A	Mus musculus	44-48
33816301-7	2021	The ERK 1/2 inhibitor SCH772984 and the JNK inhibitor SP600125 significantly increased the apoptosis of both PMN-MDSCs and M-MDSCs in vitro.	pyrazolanthrone	54-62	mitogen-activated protein kinase 8	Homo sapiens	40-43
33775574-6	2021	JNK/pSmad3L specific inhibitor SP600125 or Smad3 mutant plasmid was used to suppress JNK/pSmad3L pathway, and QPCR assay was performed to investigate the effect of pSmad3L on miR-140-5p level.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	0-3
33775574-6	2021	JNK/pSmad3L specific inhibitor SP600125 or Smad3 mutant plasmid was used to suppress JNK/pSmad3L pathway, and QPCR assay was performed to investigate the effect of pSmad3L on miR-140-5p level.	pyrazolanthrone	31-39	SMAD family member 3	Homo sapiens	5-10
33775574-6	2021	JNK/pSmad3L specific inhibitor SP600125 or Smad3 mutant plasmid was used to suppress JNK/pSmad3L pathway, and QPCR assay was performed to investigate the effect of pSmad3L on miR-140-5p level.	pyrazolanthrone	31-39	mitogen-activated protein kinase 8	Homo sapiens	85-88
33806765-5	2021	The inhibition of hypoxia-activated phosphorylation of JNK signal components (JNK, MKK4, nuclear c-Jun and ATF-2) by pre-treatment with SP600125 could suppress hypoxia-stimulated HIF-1alpha upregulation and fibrotic marker proteins expression.	pyrazolanthrone	136-144	mitogen-activated protein kinase kinase 4	Homo sapiens	83-87
33806765-5	2021	The inhibition of hypoxia-activated phosphorylation of JNK signal components (JNK, MKK4, nuclear c-Jun and ATF-2) by pre-treatment with SP600125 could suppress hypoxia-stimulated HIF-1alpha upregulation and fibrotic marker proteins expression.	pyrazolanthrone	136-144	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	97-102
33806765-5	2021	The inhibition of hypoxia-activated phosphorylation of JNK signal components (JNK, MKK4, nuclear c-Jun and ATF-2) by pre-treatment with SP600125 could suppress hypoxia-stimulated HIF-1alpha upregulation and fibrotic marker proteins expression.	pyrazolanthrone	136-144	activating transcription factor 2	Homo sapiens	107-112
33806765-5	2021	The inhibition of hypoxia-activated phosphorylation of JNK signal components (JNK, MKK4, nuclear c-Jun and ATF-2) by pre-treatment with SP600125 could suppress hypoxia-stimulated HIF-1alpha upregulation and fibrotic marker proteins expression.	pyrazolanthrone	136-144	hypoxia inducible factor 1 subunit alpha	Homo sapiens	179-189
33806765-4	2021	Western blot or immunohistochemistry analysis showed that hypoxia-induced increase in COL1A and COL3A was significantly attenuated by the addition of SP600125 (a specific c-Jun N-terminal kinase [JNK] inhibitor) or expression of dominant-negative JNK before hypoxia treatment.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	171-194
33806765-4	2021	Western blot or immunohistochemistry analysis showed that hypoxia-induced increase in COL1A and COL3A was significantly attenuated by the addition of SP600125 (a specific c-Jun N-terminal kinase [JNK] inhibitor) or expression of dominant-negative JNK before hypoxia treatment.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	196-199
33806765-4	2021	Western blot or immunohistochemistry analysis showed that hypoxia-induced increase in COL1A and COL3A was significantly attenuated by the addition of SP600125 (a specific c-Jun N-terminal kinase [JNK] inhibitor) or expression of dominant-negative JNK before hypoxia treatment.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Homo sapiens	247-250
33806765-5	2021	The inhibition of hypoxia-activated phosphorylation of JNK signal components (JNK, MKK4, nuclear c-Jun and ATF-2) by pre-treatment with SP600125 could suppress hypoxia-stimulated HIF-1alpha upregulation and fibrotic marker proteins expression.	pyrazolanthrone	136-144	mitogen-activated protein kinase 8	Homo sapiens	55-58
33806765-5	2021	The inhibition of hypoxia-activated phosphorylation of JNK signal components (JNK, MKK4, nuclear c-Jun and ATF-2) by pre-treatment with SP600125 could suppress hypoxia-stimulated HIF-1alpha upregulation and fibrotic marker proteins expression.	pyrazolanthrone	136-144	mitogen-activated protein kinase 8	Homo sapiens	78-81
33236148-10	2021	Subsequently, it was shown that the ERK inhibitor, PD98059, and JNK inhibitor, SP600125, were able to reverse TGF-beta1-induced autophagy and fibrosis.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Mus musculus	64-67
33816478-0	2021	SP600125, a JNK-Specific Inhibitor, Regulates in vitro Auricular Cartilage Regeneration by Promoting Cell Proliferation and Inhibiting Extracellular Matrix Metabolism.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	12-15
33804101-11	2021	The inhibition of signal transduction by SP600125 reversed leptin-mediated cell migration properties in RCC cell lines.	pyrazolanthrone	41-49	leptin	Homo sapiens	59-65
33236148-10	2021	Subsequently, it was shown that the ERK inhibitor, PD98059, and JNK inhibitor, SP600125, were able to reverse TGF-beta1-induced autophagy and fibrosis.	pyrazolanthrone	79-87	transforming growth factor, beta 1	Mus musculus	110-119
33426091-15	2020	Proliferation and invasion of RA-FLS incubated with TNF-alpha and nrf2 siRNA were inhibited by pretreatment with JNK inhibitor SP600125.	pyrazolanthrone	127-135	tumor necrosis factor	Homo sapiens	52-61
33426091-15	2020	Proliferation and invasion of RA-FLS incubated with TNF-alpha and nrf2 siRNA were inhibited by pretreatment with JNK inhibitor SP600125.	pyrazolanthrone	127-135	NFE2 like bZIP transcription factor 2	Homo sapiens	66-70
33426091-15	2020	Proliferation and invasion of RA-FLS incubated with TNF-alpha and nrf2 siRNA were inhibited by pretreatment with JNK inhibitor SP600125.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Homo sapiens	113-116
34952043-13	2022	CC90003 (ERK inhibitor) or SB203580 (p38 inhibitor) did not significantly affect the expression of FoxO3a in TECs treated with 3-DZNeP and oxalate; only SP600125 (JNK inhibitor) significantly decreased FoxO3a expression.	pyrazolanthrone	153-161	mitogen-activated protein kinase 8	Rattus norvegicus	163-166
15826947-10	2005	Furthermore, activation of c-Jun NH(2)-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor.	pyrazolanthrone	179-187	mitogen-activated protein kinase 8	Rattus norvegicus	27-54
15826947-10	2005	Furthermore, activation of c-Jun NH(2)-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor.	pyrazolanthrone	179-187	mitogen-activated protein kinase 8	Rattus norvegicus	56-59
15826947-10	2005	Furthermore, activation of c-Jun NH(2)-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor.	pyrazolanthrone	179-187	angiotensinogen	Rattus norvegicus	72-78
18803253-8	2009	Both SP600125 (a JNK inhibitor) and SB203580 (a p38 MAPK inhibitor) inhibited CYP 2B1 protein and mRNA expression induced by phenobarbital.	pyrazolanthrone	5-13	mitogen-activated protein kinase 8	Rattus norvegicus	17-20
18803253-8	2009	Both SP600125 (a JNK inhibitor) and SB203580 (a p38 MAPK inhibitor) inhibited CYP 2B1 protein and mRNA expression induced by phenobarbital.	pyrazolanthrone	5-13	cytochrome P450 2B1	Rattus norvegicus	78-85
15826947-10	2005	Furthermore, activation of c-Jun NH(2)-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor.	pyrazolanthrone	179-187	nuclear factor of activated T-cells 5	Rattus norvegicus	107-111
15826947-10	2005	Furthermore, activation of c-Jun NH(2)-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor.	pyrazolanthrone	179-187	angiotensinogen	Rattus norvegicus	131-137
15826947-10	2005	Furthermore, activation of c-Jun NH(2)-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor.	pyrazolanthrone	179-187	nuclear factor of activated T-cells 5	Rattus norvegicus	146-150
15826947-10	2005	Furthermore, activation of c-Jun NH(2)-terminal kinase (JNK) induced by Ang II stimulation is required for NFAT activation because Ang II-induced NFAT activation was inhibited by SP600125, a selective JNK inhibitor.	pyrazolanthrone	179-187	mitogen-activated protein kinase 8	Rattus norvegicus	201-204
34952043-13	2022	CC90003 (ERK inhibitor) or SB203580 (p38 inhibitor) did not significantly affect the expression of FoxO3a in TECs treated with 3-DZNeP and oxalate; only SP600125 (JNK inhibitor) significantly decreased FoxO3a expression.	pyrazolanthrone	153-161	forkhead box O3	Rattus norvegicus	202-208
34896468-10	2022	Sp600125, an inhibitor of JNK signaling pathway, can prevent subsequent apoptosis and autophagy events, suggesting that JNK pathway was at least one of the pathways of Curcin C action.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	26-29
34730869-7	2022	Of note, the AP-1 activation induced by TiO2 NPs could be blocked by specific inhibitors (SB203580, PD98059, and SP 600125, respectively) that inhibit ERKs and p38 kinase but not JNKs.	pyrazolanthrone	113-122	jun proto-oncogene	Mus musculus	13-17
34730869-7	2022	Of note, the AP-1 activation induced by TiO2 NPs could be blocked by specific inhibitors (SB203580, PD98059, and SP 600125, respectively) that inhibit ERKs and p38 kinase but not JNKs.	pyrazolanthrone	113-122	mitogen-activated protein kinase 1	Homo sapiens	151-155
34896864-3	2022	The purpose of this study was to investigate the effects of a c-Jun N-terminal kinase (JNK) inhibitor, SP600125, on the osteoblastic differentiation of periodontal ligament stem cells (PDLSCs) in vitro, and the function of SP600125 on the regeneration of alveolar bone in vivo.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	62-85
34896864-3	2022	The purpose of this study was to investigate the effects of a c-Jun N-terminal kinase (JNK) inhibitor, SP600125, on the osteoblastic differentiation of periodontal ligament stem cells (PDLSCs) in vitro, and the function of SP600125 on the regeneration of alveolar bone in vivo.	pyrazolanthrone	103-111	mitogen-activated protein kinase 8	Homo sapiens	87-90
34896468-10	2022	Sp600125, an inhibitor of JNK signaling pathway, can prevent subsequent apoptosis and autophagy events, suggesting that JNK pathway was at least one of the pathways of Curcin C action.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	120-123
34601054-8	2022	In addition, V. alginolyticus stimulation activated the phosphorylation of p38, JNK and ERK were TLR2 heterodimers-dependent, whereas inhibitors of SB203580 (p38), SCH772984 (ERK) and SP600125 (JNK) significantly reduced IL-1beta, IL-6, IL-12 and TNF-alpha production.	pyrazolanthrone	184-192	mitogen-activated protein kinase 8	Mus musculus	194-197
34959222-7	2021	FFAs significantly promoted ROS production and increased the expression of ERK, p38 and JNK, and treatment of the inhibitors of NAPDH oxidase (DPI), p38 (SB202190), ERK1/2 (U0126) and JNK (SP600125) inhibited FAAs-induced NETs production.	pyrazolanthrone	189-197	mitogen-activated protein kinase 8	Homo sapiens	184-187
34763314-11	2022	Moreover, these elevated levels of the proteins were inhibited by the antioxidant N-acetylcysteine and the JNK inhibitor SP600125, suggesting the involvement of ROS/JNK-dependent mechanisms in AGS-30-induced apoptosis.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	107-110
34763314-11	2022	Moreover, these elevated levels of the proteins were inhibited by the antioxidant N-acetylcysteine and the JNK inhibitor SP600125, suggesting the involvement of ROS/JNK-dependent mechanisms in AGS-30-induced apoptosis.	pyrazolanthrone	121-129	mitogen-activated protein kinase 8	Homo sapiens	165-168
34984018-12	2021	In contrast, pharmacological inhibition of JNK phosphorylation activity by SP600125 muted the detrimental effects of mCRP in MI mice.	pyrazolanthrone	75-83	mitogen-activated protein kinase 8	Mus musculus	43-46
34976299-9	2021	Meanwhile, neuronal death and neuron apoptosis were observed in PC12 and primary cultured hippocampal neurons after exposure to KN93, which was reversed by SP600125, an inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Rattus norvegicus	182-205
34976299-9	2021	Meanwhile, neuronal death and neuron apoptosis were observed in PC12 and primary cultured hippocampal neurons after exposure to KN93, which was reversed by SP600125, an inhibitor of c-Jun N-terminal kinase (JNK).	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Rattus norvegicus	207-210
34984018-13	2021	Furthermore, in vitro and in vivo co-culture experiments showed that mCRP shifted macrophage polarization towards pro-inflammatory phenotypes, and this polarization could be abolished by sp600125.	pyrazolanthrone	187-195	C-reactive protein, pentraxin-related	Mus musculus	69-73
34895315-6	2021	In addition, T. vaginalis induced the phosphorylation of apoptosis signal regulating kinase 1 (ASK1) and c-Jun N-terminal kinases (JNK) in SiHa cells, whereas 4-PBA or SP600125 (JNK inhibitor) pretreatment significantly attenuated ASK1/JNK phosphorylation, mitochondrial dysfunction, apoptosis and ER stress response in SiHa cells, in a dose-dependent manner.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Homo sapiens	178-181
34914791-8	2021	In addition, both the JNK inhibitor SP600125 and the HAT inhibitor AA attenuated p-JNK overexpression and H3K9ac hyperacetylation by inhibiting P300 and PCAF during PE-induced cardiomyocyte hypertrophy.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	22-25
34914791-8	2021	In addition, both the JNK inhibitor SP600125 and the HAT inhibitor AA attenuated p-JNK overexpression and H3K9ac hyperacetylation by inhibiting P300 and PCAF during PE-induced cardiomyocyte hypertrophy.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Mus musculus	83-86
34914791-8	2021	In addition, both the JNK inhibitor SP600125 and the HAT inhibitor AA attenuated p-JNK overexpression and H3K9ac hyperacetylation by inhibiting P300 and PCAF during PE-induced cardiomyocyte hypertrophy.	pyrazolanthrone	36-44	K(lysine) acetyltransferase 2B	Mus musculus	153-157
34914791-9	2021	Moreover, we demonstrated that both SP600125 and AA attenuate the overexpression of cardiac hypertrophy-related genes (MEF2A, ANP, BNP, and beta-MHC), preventing cardiomyocyte hypertrophy and dysfunction.	pyrazolanthrone	36-44	myocyte enhancer factor 2A	Mus musculus	119-124
34914791-9	2021	Moreover, we demonstrated that both SP600125 and AA attenuate the overexpression of cardiac hypertrophy-related genes (MEF2A, ANP, BNP, and beta-MHC), preventing cardiomyocyte hypertrophy and dysfunction.	pyrazolanthrone	36-44	natriuretic peptide type A	Mus musculus	126-129
34914791-9	2021	Moreover, we demonstrated that both SP600125 and AA attenuate the overexpression of cardiac hypertrophy-related genes (MEF2A, ANP, BNP, and beta-MHC), preventing cardiomyocyte hypertrophy and dysfunction.	pyrazolanthrone	36-44	natriuretic peptide type B	Mus musculus	131-134
34914791-9	2021	Moreover, we demonstrated that both SP600125 and AA attenuate the overexpression of cardiac hypertrophy-related genes (MEF2A, ANP, BNP, and beta-MHC), preventing cardiomyocyte hypertrophy and dysfunction.	pyrazolanthrone	36-44	myosin, heavy polypeptide 7, cardiac muscle, beta	Mus musculus	140-148
34895315-6	2021	In addition, T. vaginalis induced the phosphorylation of apoptosis signal regulating kinase 1 (ASK1) and c-Jun N-terminal kinases (JNK) in SiHa cells, whereas 4-PBA or SP600125 (JNK inhibitor) pretreatment significantly attenuated ASK1/JNK phosphorylation, mitochondrial dysfunction, apoptosis and ER stress response in SiHa cells, in a dose-dependent manner.	pyrazolanthrone	168-176	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	231-235
34895315-6	2021	In addition, T. vaginalis induced the phosphorylation of apoptosis signal regulating kinase 1 (ASK1) and c-Jun N-terminal kinases (JNK) in SiHa cells, whereas 4-PBA or SP600125 (JNK inhibitor) pretreatment significantly attenuated ASK1/JNK phosphorylation, mitochondrial dysfunction, apoptosis and ER stress response in SiHa cells, in a dose-dependent manner.	pyrazolanthrone	168-176	mitogen-activated protein kinase 8	Homo sapiens	236-239
34895315-6	2021	In addition, T. vaginalis induced the phosphorylation of apoptosis signal regulating kinase 1 (ASK1) and c-Jun N-terminal kinases (JNK) in SiHa cells, whereas 4-PBA or SP600125 (JNK inhibitor) pretreatment significantly attenuated ASK1/JNK phosphorylation, mitochondrial dysfunction, apoptosis and ER stress response in SiHa cells, in a dose-dependent manner.	pyrazolanthrone	168-176	epiregulin	Homo sapiens	298-300
34747196-7	2021	JNK inhibitor, SP600125, partially reversed SEMA3A and TGF-beta1-induced cell transformation, indicating that JNK signaling is involved in SEMA3A-induced renal fibrosis.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	0-3
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	peroxisome proliferator-activated receptor gamma	Gallus gallus	181-229
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	peroxisome proliferator-activated receptor gamma	Gallus gallus	231-240
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	CCAAT/enhancer binding protein alpha	Gallus gallus	243-279
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	CCAAT/enhancer binding protein alpha	Gallus gallus	281-291
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	adipocyte fatty acid binding protein	Gallus gallus	294-330
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	adipocyte fatty acid binding protein	Gallus gallus	332-338
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	lipoprotein lipase	Gallus gallus	345-363
34946919-5	2021	After treating ICP cells with a JNK inhibitor SP600125, the differentiation of ICP was inhibited, as evidenced by decreased accumulation of lipid droplets and reduced expression of peroxisome proliferator-activated receptor gamma (PPARgamma), CCAAT/enhancer binding protein alpha (C/EBPalpha), adipocyte fatty acid binding protein (A-FABP), and lipoprotein lipase (LPL).	pyrazolanthrone	46-54	lipoprotein lipase	Gallus gallus	365-368
34946919-6	2021	Moreover, we found that the inhibition of JNK by SP600125 remarkably impaired the ability of TCF21 to drive adipogenesis.	pyrazolanthrone	49-57	transcription factor 21	Gallus gallus	93-98
34747196-7	2021	JNK inhibitor, SP600125, partially reversed SEMA3A and TGF-beta1-induced cell transformation, indicating that JNK signaling is involved in SEMA3A-induced renal fibrosis.	pyrazolanthrone	15-23	semaphorin 3A	Homo sapiens	44-50
34747196-7	2021	JNK inhibitor, SP600125, partially reversed SEMA3A and TGF-beta1-induced cell transformation, indicating that JNK signaling is involved in SEMA3A-induced renal fibrosis.	pyrazolanthrone	15-23	transforming growth factor beta 1	Homo sapiens	55-64
34747196-7	2021	JNK inhibitor, SP600125, partially reversed SEMA3A and TGF-beta1-induced cell transformation, indicating that JNK signaling is involved in SEMA3A-induced renal fibrosis.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Homo sapiens	110-113
34750753-5	2021	Comparison of cell sensitivities using SP600125 (JNK inhibitor), SB206580 (p38 kinase inhibitor), or MK-2206 (AKT inhibitor) revealed that cell proliferation inhibition was strongly observed in HT29 cells compared to that in HCT116 cells in both OxS and OxR cells.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	49-52
34786818-10	2021	JNK inhibitor (SP600125) mimicked the protective effects of NGR1while JNK agonist (Anisomycin) abolished it.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	0-3
34659502-8	2021	Interestingly, only treatment with SP600125 blocked the FGF2-mediated suppression of CCL11.	pyrazolanthrone	35-43	fibroblast growth factor 2	Homo sapiens	56-60
34659502-8	2021	Interestingly, only treatment with SP600125 blocked the FGF2-mediated suppression of CCL11.	pyrazolanthrone	35-43	C-C motif chemokine ligand 11	Homo sapiens	85-90
33896366-7	2021	JNK inhibition by SP600125 inhibited LPS-induced autophagy, and BBR could not alter the LPS-induced autophagy in HUVECs and HPMECs that were pretreated with SP600125.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Homo sapiens	0-3
34628110-7	2021	More importantly, JNK inhibition (with SP600125) or CaMKII inhibition (with KN93 or in transgenic AC3-I mice) could prevent GSK101-induced myocardial injury during IR.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Mus musculus	18-21
34721682-4	2021	In order to explore the relationship between the proliferation-enhancing effect of low-dose aspirin and mitogen-activated protein kinase (MAPK) signaling activation, PC-9 cells were pretreated with 10 microM PD98059 (a specific inhibitor of ERK), SB203580 (a specific inhibitor of p38) and SP600125 (a specific inhibitor of JNK) for 30 min respectively.	pyrazolanthrone	290-298	mitogen-activated protein kinase 8	Homo sapiens	324-327
34786818-10	2021	JNK inhibitor (SP600125) mimicked the protective effects of NGR1while JNK agonist (Anisomycin) abolished it.	pyrazolanthrone	15-23	reticulon 4 receptor	Mus musculus	60-64
34786818-10	2021	JNK inhibitor (SP600125) mimicked the protective effects of NGR1while JNK agonist (Anisomycin) abolished it.	pyrazolanthrone	15-23	mitogen-activated protein kinase 8	Mus musculus	70-73
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Homo sapiens	14-17
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	pyrazolanthrone	28-36	dicer 1, ribonuclease III	Homo sapiens	83-89
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	pyrazolanthrone	28-36	dicer 1, ribonuclease III	Homo sapiens	174-180
34695450-8	2021	Addition of a JNK inhibitor,SP600125, or an ERK inhibitor,U0126, further increased Dicer1 protein compared to Abetao treatment alone, with simultaneaous reduction of phospho-Dicer1, but with different effects on phospho-TRBP.	pyrazolanthrone	28-36	TARBP2 pseudogene 1	Homo sapiens	220-224
34837962-15	2021	An ERK inhibitor (10 muM SCH772984) or JNK inhibitor (25 muM SP600125) repressed the upregulated LAGE3-induced proliferation, migration, and invasion of HCC cells.	pyrazolanthrone	61-69	mitogen-activated protein kinase 8	Homo sapiens	39-42
34837962-15	2021	An ERK inhibitor (10 muM SCH772984) or JNK inhibitor (25 muM SP600125) repressed the upregulated LAGE3-induced proliferation, migration, and invasion of HCC cells.	pyrazolanthrone	61-69	L antigen family member 3	Homo sapiens	97-102
34848975-13	2021	Remarkably, single treatment of SP600125, an antagonist of JNK, functioned similarly as CpG-ODN in mitigating allergic airway inflammation and suppressing OVA-induced activation of ER stress; however, no significant synergistic effect was evidenced by combined treatment of SP600125 and CpG-ODN.	pyrazolanthrone	32-40	mitogen-activated protein kinase 8	Mus musculus	59-62
34837126-10	2022	Interestingly, LPS-mediated ubiquitin-dependent degradation of FTL is significantly inhibited by the JNK-specific inhibitor SP600125.	pyrazolanthrone	124-132	ferritin light polypeptide 1	Mus musculus	63-66
34837126-10	2022	Interestingly, LPS-mediated ubiquitin-dependent degradation of FTL is significantly inhibited by the JNK-specific inhibitor SP600125.	pyrazolanthrone	124-132	mitogen-activated protein kinase 8	Mus musculus	101-104
34837126-13	2022	SP600125 decreased LPS-induced Itch upregulation.	pyrazolanthrone	0-8	itchy, E3 ubiquitin protein ligase	Mus musculus	31-35
34431619-4	2021	In this study, we investigated the antidepressant effect and possible mechanism of EA in regulating the expression of c-Fos/AP-1 under the condition of JNK inhibition by SP600125 in rats exposed to chronic unpredictable mild stress (CUMS).	pyrazolanthrone	170-178	mitogen-activated protein kinase 8	Rattus norvegicus	152-155
34431619-8	2021	Of note, the data demonstrated that SP600125, the inhibitor of JNK signaling pathway, can exert synergistic effect with EA in regulating CUMS-induced abnormal activation of the JNK signaling pathway.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Rattus norvegicus	63-66
34431619-8	2021	Of note, the data demonstrated that SP600125, the inhibitor of JNK signaling pathway, can exert synergistic effect with EA in regulating CUMS-induced abnormal activation of the JNK signaling pathway.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Rattus norvegicus	177-180
34803671-8	2021	In vitro, AZM also effectively inhibited type I collagen, LOX, LOXL-2 and JNK-c-Jun signaling pathways in TGF-beta1-stimulated primary mouse fibroblasts, and this effect was similar to that of a JNK-specific inhibitor (SP600125).	pyrazolanthrone	219-227	mitogen-activated protein kinase 8	Mus musculus	195-198
34486378-11	2021	Our results indicated that SP600125 rescued the chondrogenesis of BMSCs by inhibiting inflammation induced by TNF-alpha, which provides a theoretical basis for solving the problem of cartilage repair under inflammatory conditions.	pyrazolanthrone	27-35	tumor necrosis factor	Mus musculus	110-119
34380759-4	2021	Recombinant H+-induced ASIC currents in HEK293 cells are potently inhibited within minutes by the JNK inhibitor SP600125 in a subunit dependent manner, targeting both rodent and human ASIC1b and ASIC3 subunits (except mouse ASIC3).	pyrazolanthrone	112-120	acid sensing ion channel subunit 1	Homo sapiens	23-27
34380759-4	2021	Recombinant H+-induced ASIC currents in HEK293 cells are potently inhibited within minutes by the JNK inhibitor SP600125 in a subunit dependent manner, targeting both rodent and human ASIC1b and ASIC3 subunits (except mouse ASIC3).	pyrazolanthrone	112-120	mitogen-activated protein kinase 8	Homo sapiens	98-101
34380759-4	2021	Recombinant H+-induced ASIC currents in HEK293 cells are potently inhibited within minutes by the JNK inhibitor SP600125 in a subunit dependent manner, targeting both rodent and human ASIC1b and ASIC3 subunits (except mouse ASIC3).	pyrazolanthrone	112-120	acid sensing ion channel subunit 3	Homo sapiens	195-200
34486378-0	2021	SP600125 restored tumor necrosis factor-alpha-induced impaired chondrogenesis in bone mesenchymal stem cells and its anti-osteoarthritis effect in mice.	pyrazolanthrone	0-8	tumor necrosis factor	Mus musculus	18-45
34486378-2	2021	This article aimed to investigate whether SP600125, a competitive ATP-specific inhibitor of the JNK pathway, could promote the chondrogenesis of BMSCs by enhancing their anti-inflammatory capacity.	pyrazolanthrone	42-50	mitogen-activated protein kinase 8	Mus musculus	96-99
34486378-7	2021	We showed that SP600125 could inhibit inflammation induced by tumor necrosis factor-alpha (TNF-alpha) and promote the chondrogenesis of BMSCs.	pyrazolanthrone	15-23	tumor necrosis factor	Mus musculus	62-89
34719794-11	2021	Inhibition of JNK activity conferred by SP promoted autophagy and prevented LPS-induced ALI.	pyrazolanthrone	40-42	mitogen-activated protein kinase 8	Rattus norvegicus	14-17
34776955-5	2021	This was confirmed by which the JNK inhibitor SP600125 partially rescued CRC cells from chaetocin induced apoptosis and the ROS scavenger N-acetyl-L-cysteine (NAC) reversed both the chaetocin induced apoptosis and the JNK/c-Jun pathway activation.	pyrazolanthrone	46-54	mitogen-activated protein kinase 8	Homo sapiens	32-35
34703220-11	2021	Moreover, the JNK inhibitor SP600125 also reduced the level of NF-kappaB phosphorylation induced by PM2.5.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Mus musculus	14-17
34486378-7	2021	We showed that SP600125 could inhibit inflammation induced by tumor necrosis factor-alpha (TNF-alpha) and promote the chondrogenesis of BMSCs.	pyrazolanthrone	15-23	tumor necrosis factor	Mus musculus	91-100
34486378-8	2021	In the presence of TNF-alpha, the expression of aggrecan (Agc) and collagen type II alpha 1 (Col2) was significantly decreased compared with that in the control group and increased with the addition of SP600125.	pyrazolanthrone	202-210	tumor necrosis factor	Mus musculus	19-28
34486378-8	2021	In the presence of TNF-alpha, the expression of aggrecan (Agc) and collagen type II alpha 1 (Col2) was significantly decreased compared with that in the control group and increased with the addition of SP600125.	pyrazolanthrone	202-210	collagen, type II, alpha 1	Mus musculus	67-91
34486378-8	2021	In the presence of TNF-alpha, the expression of aggrecan (Agc) and collagen type II alpha 1 (Col2) was significantly decreased compared with that in the control group and increased with the addition of SP600125.	pyrazolanthrone	202-210	collagen, type II, alpha 1	Mus musculus	93-97
34486378-9	2021	Moreover, the expression of Mmp-1, Mmp-3, and Mmp-13 was increased in BMSCs treated only with TNF-alpha and downregulated in SP600125-treated BMSCs.	pyrazolanthrone	125-133	matrix metallopeptidase 13	Mus musculus	28-33
34486378-9	2021	Moreover, the expression of Mmp-1, Mmp-3, and Mmp-13 was increased in BMSCs treated only with TNF-alpha and downregulated in SP600125-treated BMSCs.	pyrazolanthrone	125-133	matrix metallopeptidase 3	Mus musculus	35-40
34486378-9	2021	Moreover, the expression of Mmp-1, Mmp-3, and Mmp-13 was increased in BMSCs treated only with TNF-alpha and downregulated in SP600125-treated BMSCs.	pyrazolanthrone	125-133	matrix metallopeptidase 13	Mus musculus	46-52
34703220-11	2021	Moreover, the JNK inhibitor SP600125 also reduced the level of NF-kappaB phosphorylation induced by PM2.5.	pyrazolanthrone	28-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	63-72
34333051-6	2021	Intrathecally infusion of the JNK inhibitor SP600125 significantly inhibited SNL-induced upregulation of HDAC2.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Rattus norvegicus	30-33
34411914-10	2021	Moreover, TG and 22-HTG induced DNA double-strand break and phosphorylation of JNK2 (T183/Y185) and p38alpha (T180/Y182), and co-incubation with SP 600125 (JNK/SAPK inhibitor) and PD 169316 (p38 MAPK inhibitor) partially prevented apoptosis induced by TG and 22-HTG.	pyrazolanthrone	145-154	mitogen-activated protein kinase 9	Homo sapiens	79-83
34411914-10	2021	Moreover, TG and 22-HTG induced DNA double-strand break and phosphorylation of JNK2 (T183/Y185) and p38alpha (T180/Y182), and co-incubation with SP 600125 (JNK/SAPK inhibitor) and PD 169316 (p38 MAPK inhibitor) partially prevented apoptosis induced by TG and 22-HTG.	pyrazolanthrone	145-154	mitogen-activated protein kinase 14	Homo sapiens	100-108
34411914-10	2021	Moreover, TG and 22-HTG induced DNA double-strand break and phosphorylation of JNK2 (T183/Y185) and p38alpha (T180/Y182), and co-incubation with SP 600125 (JNK/SAPK inhibitor) and PD 169316 (p38 MAPK inhibitor) partially prevented apoptosis induced by TG and 22-HTG.	pyrazolanthrone	145-154	mitogen-activated protein kinase 8	Homo sapiens	156-164
34333051-8	2021	In cultured astrocytes, TNF-alpha induced enhanced phosphorylation of JNK and a significant increase of HDAC2, as well as a remarkable decrease of GLT-1, which could be prevented by SP600125 or the HDAC2 specific inhibitor CAY10683.	pyrazolanthrone	182-190	mitogen-activated protein kinase 8	Rattus norvegicus	70-73
34488936-11	2021	Interestingly, Avn-C added with SB203580 and SP600125 as specific inhibitors of p38 kinase and JNK, respectively, enhanced its inhibitory effect on the expression of MMPs in IL-1beta treated chondrocytes.	pyrazolanthrone	45-53	mitogen-activated protein kinase 8	Mus musculus	95-98
34488936-11	2021	Interestingly, Avn-C added with SB203580 and SP600125 as specific inhibitors of p38 kinase and JNK, respectively, enhanced its inhibitory effect on the expression of MMPs in IL-1beta treated chondrocytes.	pyrazolanthrone	45-53	interleukin 1 alpha	Mus musculus	174-182
34333051-8	2021	In cultured astrocytes, TNF-alpha induced enhanced phosphorylation of JNK and a significant increase of HDAC2, as well as a remarkable decrease of GLT-1, which could be prevented by SP600125 or the HDAC2 specific inhibitor CAY10683.	pyrazolanthrone	182-190	histone deacetylase 2	Rattus norvegicus	104-109
34333051-6	2021	Intrathecally infusion of the JNK inhibitor SP600125 significantly inhibited SNL-induced upregulation of HDAC2.	pyrazolanthrone	44-52	histone deacetylase 2	Rattus norvegicus	105-110
34333051-8	2021	In cultured astrocytes, TNF-alpha induced enhanced phosphorylation of JNK and a significant increase of HDAC2, as well as a remarkable decrease of GLT-1, which could be prevented by SP600125 or the HDAC2 specific inhibitor CAY10683.	pyrazolanthrone	182-190	solute carrier family 1 member 2	Rattus norvegicus	147-152
34333051-8	2021	In cultured astrocytes, TNF-alpha induced enhanced phosphorylation of JNK and a significant increase of HDAC2, as well as a remarkable decrease of GLT-1, which could be prevented by SP600125 or the HDAC2 specific inhibitor CAY10683.	pyrazolanthrone	182-190	tumor necrosis factor	Rattus norvegicus	24-33
34685593-6	2021	Inhibition of either mTOR (rapamycin) or SAP/JNK-MAPK signaling (SP600125) resulted in dose-dependent metabolic suppression.	pyrazolanthrone	65-73	SH2 domain containing 1A	Mus musculus	41-44
34685593-6	2021	Inhibition of either mTOR (rapamycin) or SAP/JNK-MAPK signaling (SP600125) resulted in dose-dependent metabolic suppression.	pyrazolanthrone	65-73	mitogen-activated protein kinase 8	Mus musculus	45-48
34472704-5	2021	Treatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125, JNK small interfering RNA (siRNA) and tumour necrosis factor-alpha (TNF-alpha) antibodies reversed the BTXA-induced GADD153 expression.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	15-38
34298396-7	2021	Interestingly, JNK inhibitor SP600125 significantly attenuated surgery-induced cognitive impairments through inhibiting pyroptosis, inflammatory responses, and reducing immunoreactivity of NLRP3 and gasdermin D N terminus (GSDMD-N) in hippocampal microglia.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Mus musculus	15-18
34298396-7	2021	Interestingly, JNK inhibitor SP600125 significantly attenuated surgery-induced cognitive impairments through inhibiting pyroptosis, inflammatory responses, and reducing immunoreactivity of NLRP3 and gasdermin D N terminus (GSDMD-N) in hippocampal microglia.	pyrazolanthrone	29-37	NLR family, pyrin domain containing 3	Mus musculus	189-194
34353852-5	2021	ET-1-induced vasoconstriction was abolished in the absence of extracellular Ca2+ and sensitive to c-Jun N-terminal kinase (JNK) inhibitor SP600125 but unaffected by extracellular signal-regulated kinase (ERK) inhibitor PD98059, p38 kinase inhibitor SB203580, or a broad-spectrum PKC inhibitor Go 6983.	pyrazolanthrone	138-146	endothelin-1	Sus scrofa	0-4
34353852-5	2021	ET-1-induced vasoconstriction was abolished in the absence of extracellular Ca2+ and sensitive to c-Jun N-terminal kinase (JNK) inhibitor SP600125 but unaffected by extracellular signal-regulated kinase (ERK) inhibitor PD98059, p38 kinase inhibitor SB203580, or a broad-spectrum PKC inhibitor Go 6983.	pyrazolanthrone	138-146	mitogen-activated protein kinase 8	Sus scrofa	98-121
34353852-5	2021	ET-1-induced vasoconstriction was abolished in the absence of extracellular Ca2+ and sensitive to c-Jun N-terminal kinase (JNK) inhibitor SP600125 but unaffected by extracellular signal-regulated kinase (ERK) inhibitor PD98059, p38 kinase inhibitor SB203580, or a broad-spectrum PKC inhibitor Go 6983.	pyrazolanthrone	138-146	mitogen-activated protein kinase 8	Sus scrofa	123-126
34353852-6	2021	Diabetes (2 weeks) enhanced venular constriction to ET-1, which was insensitive to PD98059 and Go 6983 but was prevented by NHE1 inhibitor cariporide, SB203580, and SP600125.	pyrazolanthrone	165-173	endothelin-1	Sus scrofa	52-56
34472704-5	2021	Treatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125, JNK small interfering RNA (siRNA) and tumour necrosis factor-alpha (TNF-alpha) antibodies reversed the BTXA-induced GADD153 expression.	pyrazolanthrone	55-63	mitogen-activated protein kinase 8	Homo sapiens	40-43
34472704-5	2021	Treatment with c-Jun N-terminal kinase (JNK) inhibitor SP600125, JNK small interfering RNA (siRNA) and tumour necrosis factor-alpha (TNF-alpha) antibodies reversed the BTXA-induced GADD153 expression.	pyrazolanthrone	55-63	DNA damage inducible transcript 3	Homo sapiens	181-188
34472704-8	2021	The addition of GADD153 siRNA, SP600125 and anti-TNF-alpha antibodies reversed cell death and caspase 3 and 9 activity induced by BTXA.	pyrazolanthrone	31-39	caspase 3	Homo sapiens	94-103
33642401-7	2021	Application of the JNK inhibitor SP600125 exerted a similar protective effect to luteolin, suggesting that luteolin delays photoreceptor degeneration and functional deterioration in rd10 mice through regulation of retinal oxidation and inflammation by inhibiting the JNK pathway.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Mus musculus	19-22
33642401-7	2021	Application of the JNK inhibitor SP600125 exerted a similar protective effect to luteolin, suggesting that luteolin delays photoreceptor degeneration and functional deterioration in rd10 mice through regulation of retinal oxidation and inflammation by inhibiting the JNK pathway.	pyrazolanthrone	33-41	mitogen-activated protein kinase 8	Mus musculus	267-270
34572567-6	2021	Inhibition of JNK (SP600125) significantly suppressed the TNF-alpha-induced IP-10 in MCF-7 cells, while the inhibition of p38 MAPK (SB203580), MEK1/2 (U0126), and ERK1/2 (PD98059) had no significant effect.	pyrazolanthrone	19-27	mitogen-activated protein kinase 8	Homo sapiens	14-17
34572149-7	2021	The synergistic catabolic effects of palmitate and IL-26 were attenuated by inhibitors of TLR4 (TAK242), ERK1/2 (U0126), or c-Jun (SP600125) in HACs and cartilage matrix.	pyrazolanthrone	131-139	interleukin 26	Homo sapiens	51-56
34572149-7	2021	The synergistic catabolic effects of palmitate and IL-26 were attenuated by inhibitors of TLR4 (TAK242), ERK1/2 (U0126), or c-Jun (SP600125) in HACs and cartilage matrix.	pyrazolanthrone	131-139	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	124-129
34572567-6	2021	Inhibition of JNK (SP600125) significantly suppressed the TNF-alpha-induced IP-10 in MCF-7 cells, while the inhibition of p38 MAPK (SB203580), MEK1/2 (U0126), and ERK1/2 (PD98059) had no significant effect.	pyrazolanthrone	19-27	tumor necrosis factor	Homo sapiens	58-67
34572567-6	2021	Inhibition of JNK (SP600125) significantly suppressed the TNF-alpha-induced IP-10 in MCF-7 cells, while the inhibition of p38 MAPK (SB203580), MEK1/2 (U0126), and ERK1/2 (PD98059) had no significant effect.	pyrazolanthrone	19-27	C-X-C motif chemokine ligand 10	Homo sapiens	76-81
34572567-10	2021	The kinase activity of JNK induced by TNF-alpha stimulation of MCF-7 cells was significantly inhibited by SP600125.	pyrazolanthrone	106-114	mitogen-activated protein kinase 8	Homo sapiens	23-26
34572567-10	2021	The kinase activity of JNK induced by TNF-alpha stimulation of MCF-7 cells was significantly inhibited by SP600125.	pyrazolanthrone	106-114	tumor necrosis factor	Homo sapiens	38-47
34511433-5	2021	Furthermore, DMC-induced autophagy could remarkably attenuate after the treatment of reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC) and c-Jun N-terminal kinase (JNK) inhibitor SP600125 (SP).	pyrazolanthrone	193-201	mitogen-activated protein kinase 8	Homo sapiens	153-176
34448459-8	2021	In a similar way, SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), also attenuated renal apoptosis and enhanced renal function in IRI rats.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	44-67
34511433-5	2021	Furthermore, DMC-induced autophagy could remarkably attenuate after the treatment of reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC) and c-Jun N-terminal kinase (JNK) inhibitor SP600125 (SP).	pyrazolanthrone	193-201	mitogen-activated protein kinase 8	Homo sapiens	178-181
34511433-5	2021	Furthermore, DMC-induced autophagy could remarkably attenuate after the treatment of reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC) and c-Jun N-terminal kinase (JNK) inhibitor SP600125 (SP).	pyrazolanthrone	203-205	mitogen-activated protein kinase 8	Homo sapiens	153-176
34511433-5	2021	Furthermore, DMC-induced autophagy could remarkably attenuate after the treatment of reactive oxygen species (ROS) scavenger N-acetyl cysteine (NAC) and c-Jun N-terminal kinase (JNK) inhibitor SP600125 (SP).	pyrazolanthrone	203-205	mitogen-activated protein kinase 8	Homo sapiens	178-181
34448459-8	2021	In a similar way, SP600125, an inhibitor of c-Jun N-terminal kinase (JNK), also attenuated renal apoptosis and enhanced renal function in IRI rats.	pyrazolanthrone	18-26	mitogen-activated protein kinase 8	Rattus norvegicus	69-72
34448459-9	2021	In addition, SP600125 suppressed the binding level of p300/CBP and H3K9 acetylation near the promoter region of caspase-3/-9, and curcumin could inhibit JNK phosphorylation like SP600125.	pyrazolanthrone	13-21	CREB binding protein	Rattus norvegicus	59-62
34448459-9	2021	In addition, SP600125 suppressed the binding level of p300/CBP and H3K9 acetylation near the promoter region of caspase-3/-9, and curcumin could inhibit JNK phosphorylation like SP600125.	pyrazolanthrone	13-21	caspase 3	Rattus norvegicus	112-124
34448459-9	2021	In addition, SP600125 suppressed the binding level of p300/CBP and H3K9 acetylation near the promoter region of caspase-3/-9, and curcumin could inhibit JNK phosphorylation like SP600125.	pyrazolanthrone	178-186	caspase 3	Rattus norvegicus	112-124
34448459-9	2021	In addition, SP600125 suppressed the binding level of p300/CBP and H3K9 acetylation near the promoter region of caspase-3/-9, and curcumin could inhibit JNK phosphorylation like SP600125.	pyrazolanthrone	178-186	mitogen-activated protein kinase 8	Rattus norvegicus	153-156
34278468-10	2021	The addition of an AP-1 inhibitor (SP600125) further inhibited pathway activity, and IL-13-induced inflammation and mucus formation was restored.	pyrazolanthrone	35-43	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	19-23
34278468-10	2021	The addition of an AP-1 inhibitor (SP600125) further inhibited pathway activity, and IL-13-induced inflammation and mucus formation was restored.	pyrazolanthrone	35-43	interleukin 13	Homo sapiens	85-90
34237977-7	2021	RESULTS: Compared with the Sham group, the rats in I/R, I/R + Dex, I/R + Yoh + Dex, and I/R + SP600125 groups developed hemiparesis of the left forelimb at different levels with a higher neurological deficit score, brain water content, infarct volume, and markedly upregulated expression of cleaved caspase-3, p-JNK (P<0.05).	pyrazolanthrone	94-102	caspase 3	Rattus norvegicus	299-308
34392133-9	2021	Both SB203580 and SP600125 suppressed the tramadol effect to enhance the PGD2-stimulated osteoprotegerin release.	pyrazolanthrone	18-26	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	89-104
34350461-10	2021	SP600125, a selective inhibitor targeting JNK mitogen-activated protein kinase (MAPK) signaling, weakened the effects of PTH.	pyrazolanthrone	0-8	parathyroid hormone	Homo sapiens	121-124
34165177-9	2021	Notably, DC induced apoptosis by affecting the phosphorylation of JNK and ERK, and DC and inhibitors (SP600125 and U0126) in combination restored the overexpression of p-JNK and p-ERK.	pyrazolanthrone	102-110	mitogen-activated protein kinase 8	Homo sapiens	170-173
34165177-9	2021	Notably, DC induced apoptosis by affecting the phosphorylation of JNK and ERK, and DC and inhibitors (SP600125 and U0126) in combination restored the overexpression of p-JNK and p-ERK.	pyrazolanthrone	102-110	mitogen-activated protein kinase 1	Homo sapiens	180-183
34281218-9	2021	Then, hVCAM1 expression and B cell adhesion to FLSs were reduced by the treatment with JNK inhibitor SP600125.	pyrazolanthrone	101-109	vascular cell adhesion molecule 1	Homo sapiens	6-12
34281218-9	2021	Then, hVCAM1 expression and B cell adhesion to FLSs were reduced by the treatment with JNK inhibitor SP600125.	pyrazolanthrone	101-109	mitogen-activated protein kinase 8	Homo sapiens	87-90
34234507-11	2021	Moreover, TNF-alpha-triggered FoxO1 phosphorylation was abolished by AS1842856, TNFR1 nAb, and its upstream inhibitors MitoTEMPO, Go6976, p38i VIII, and SP600125.	pyrazolanthrone	153-161	tumor necrosis factor	Homo sapiens	10-19
34234507-11	2021	Moreover, TNF-alpha-triggered FoxO1 phosphorylation was abolished by AS1842856, TNFR1 nAb, and its upstream inhibitors MitoTEMPO, Go6976, p38i VIII, and SP600125.	pyrazolanthrone	153-161	forkhead box O1	Homo sapiens	30-35
34249726-7	2021	In molecular level, CASK knockout activated the c-Jun N-terminal kinase (JNK) pathway, and treatment with JNK inhibitor SP600125 or transiently transfected with siRNA targeting JNK significantly attenuated CASK knockout-mediated autophagic cell death.	pyrazolanthrone	120-128	calcium/calmodulin dependent serine protein kinase	Homo sapiens	20-24
34249726-7	2021	In molecular level, CASK knockout activated the c-Jun N-terminal kinase (JNK) pathway, and treatment with JNK inhibitor SP600125 or transiently transfected with siRNA targeting JNK significantly attenuated CASK knockout-mediated autophagic cell death.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	48-71
34249726-7	2021	In molecular level, CASK knockout activated the c-Jun N-terminal kinase (JNK) pathway, and treatment with JNK inhibitor SP600125 or transiently transfected with siRNA targeting JNK significantly attenuated CASK knockout-mediated autophagic cell death.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	73-76
34249726-7	2021	In molecular level, CASK knockout activated the c-Jun N-terminal kinase (JNK) pathway, and treatment with JNK inhibitor SP600125 or transiently transfected with siRNA targeting JNK significantly attenuated CASK knockout-mediated autophagic cell death.	pyrazolanthrone	120-128	mitogen-activated protein kinase 8	Homo sapiens	106-109
34249726-7	2021	In molecular level, CASK knockout activated the c-Jun N-terminal kinase (JNK) pathway, and treatment with JNK inhibitor SP600125 or transiently transfected with siRNA targeting JNK significantly attenuated CASK knockout-mediated autophagic cell death.	pyrazolanthrone	120-128	calcium/calmodulin dependent serine protein kinase	Homo sapiens	206-210
34326698-9	2021	RHOV-induced malignant biological behaviors are inhibited by pyrazolanthrone, a JNK inhibitor.	pyrazolanthrone	61-76	ras homolog family member V	Mus musculus	0-4
34326698-9	2021	RHOV-induced malignant biological behaviors are inhibited by pyrazolanthrone, a JNK inhibitor.	pyrazolanthrone	61-76	mitogen-activated protein kinase 8	Homo sapiens	80-83
34199278-5	2021	Specific pharmacological antagonists U0126, SP600125 and SB203580, were used to inhibit the activities of ERK, JNK and p38 in the MAPK signaling pathway, respectively.	pyrazolanthrone	44-52	mitogen-activated protein kinase 1	Homo sapiens	106-109
34199278-5	2021	Specific pharmacological antagonists U0126, SP600125 and SB203580, were used to inhibit the activities of ERK, JNK and p38 in the MAPK signaling pathway, respectively.	pyrazolanthrone	44-52	mitogen-activated protein kinase 8	Homo sapiens	111-114
34199278-5	2021	Specific pharmacological antagonists U0126, SP600125 and SB203580, were used to inhibit the activities of ERK, JNK and p38 in the MAPK signaling pathway, respectively.	pyrazolanthrone	44-52	mitogen-activated protein kinase 14	Homo sapiens	119-122
34177589-8	2021	Moreover, the CGGD-containing serum also decreased LC3B or collagen I expression after rapamycin (mTOR inhibitor) or SP600125 (JNK inhibitor) treatment in PSCs.	pyrazolanthrone	117-125	mitogen-activated protein kinase 8	Rattus norvegicus	127-130
33151174-7	2021	Moreover, SCH772984 and SP600125, ERK and JNK inhibitors, respectively, could partially abolish NCTD-induced apoptosis and G2/M phase cell cycle arrest.	pyrazolanthrone	24-32	mitogen-activated protein kinase 1	Homo sapiens	34-37
33151174-7	2021	Moreover, SCH772984 and SP600125, ERK and JNK inhibitors, respectively, could partially abolish NCTD-induced apoptosis and G2/M phase cell cycle arrest.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	42-45
34419138-6	2021	SP600125 (SP), a selective JNK inhibitor, had the same effects.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
34419138-6	2021	SP600125 (SP), a selective JNK inhibitor, had the same effects.	pyrazolanthrone	10-12	mitogen-activated protein kinase 8	Rattus norvegicus	27-30
34437475-3	2021	SP600125, a JNK inhibitor, was used to examine whether it would decrease tumor growth and bone tumor phenotype in canine PCa cells in vitro and in vivo.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Mus musculus	12-15
34437475-11	2021	Finally, SP600125 has the potential to serve as an alternative adjuvant therapy in some early-stage PCa patients, especially those with high Dkk-1 expression.	pyrazolanthrone	9-17	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	141-146
34234507-10	2021	TNF-alpha stimulated phosphorylation of p38 MAPK and JNK1/2 was attenuated by TNFR1 nAb, MitoTEMPO, Go6976, and their inhibitors p38i VIII and SP600125.	pyrazolanthrone	143-151	tumor necrosis factor	Homo sapiens	0-9
34234507-10	2021	TNF-alpha stimulated phosphorylation of p38 MAPK and JNK1/2 was attenuated by TNFR1 nAb, MitoTEMPO, Go6976, and their inhibitors p38i VIII and SP600125.	pyrazolanthrone	143-151	mitogen-activated protein kinase 8	Homo sapiens	53-59
34237977-7	2021	RESULTS: Compared with the Sham group, the rats in I/R, I/R + Dex, I/R + Yoh + Dex, and I/R + SP600125 groups developed hemiparesis of the left forelimb at different levels with a higher neurological deficit score, brain water content, infarct volume, and markedly upregulated expression of cleaved caspase-3, p-JNK (P<0.05).	pyrazolanthrone	94-102	mitogen-activated protein kinase 8	Rattus norvegicus	312-315
34311140-11	2021	This caused mitochondrial p-Src inactivation and more reactive oxygen species production, which directly amplifies hepatocytes necrotic cell death, while administration of JNK specific inhibitor SP600125 could abrogate the differences.	pyrazolanthrone	195-203	Rous sarcoma oncogene	Mus musculus	28-31
34027642-5	2021	In addition, the JNK activator Anisomycin and JNK inhibitor SP600125 were used on VILI mice and CS-treated cells.	pyrazolanthrone	60-68	mitogen-activated protein kinase 8	Mus musculus	46-49
34027642-9	2021	Contrary results were found in experiments with JNK inhibitor SP600125.	pyrazolanthrone	62-70	mitogen-activated protein kinase 8	Mus musculus	48-51
34079254-11	2021	HAp-induced osteogenic transformation of VSMCs was blocked by JNK inhibitor SP600125, resulted in decreased ALP activity, less Runx2 and OPN expressions.	pyrazolanthrone	76-84	mitogen-activated protein kinase 8	Mus musculus	62-65
34079254-11	2021	HAp-induced osteogenic transformation of VSMCs was blocked by JNK inhibitor SP600125, resulted in decreased ALP activity, less Runx2 and OPN expressions.	pyrazolanthrone	76-84	runt related transcription factor 2	Mus musculus	127-132
34079254-11	2021	HAp-induced osteogenic transformation of VSMCs was blocked by JNK inhibitor SP600125, resulted in decreased ALP activity, less Runx2 and OPN expressions.	pyrazolanthrone	76-84	secreted phosphoprotein 1	Mus musculus	137-140
34476441-7	2021	Runx2, OCN were tested by Western blot before and after application of JNK pathway inhibitor SP600125.	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Rattus norvegicus	71-74
34107857-12	2021	Moreover, neohesperidin induced activation of the c-Jun N-terminal kinase (JNK) signaling pathway and inhibition of JNK with SP600125 attenuated neohesperidin-induced apoptosis and autophagy simultaneously.	pyrazolanthrone	125-133	mitogen-activated protein kinase 8	Homo sapiens	116-119
34311140-11	2021	This caused mitochondrial p-Src inactivation and more reactive oxygen species production, which directly amplifies hepatocytes necrotic cell death, while administration of JNK specific inhibitor SP600125 could abrogate the differences.	pyrazolanthrone	195-203	mitogen-activated protein kinase 8	Mus musculus	172-175
35514314-9	2022	However, the inhibition of this kinase revealed its unexpected role in oxidative stress management: Treatment with the JNK inhibitor, SP600125, increased the viability of pseudo-starved cells following erastin treatment.	pyrazolanthrone	134-142	mitogen-activated protein kinase 8	Homo sapiens	119-122
35624854-9	2022	SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated the tomentosin-induced phosphorylation of Nrf2, suggesting that JNK and p38 MAPK signaling pathways can contribute to the tomentosin-induced Nrf2 activation through phosphorylation of Nrf2.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	48-51
35619094-11	2022	Furthermore, SP600125, a specific inhibitor for SAPK/JNK, significantly suppressed onalespib or geldanamycin"s enhancing effect of the TGF-beta-induced HSP27 expression levels.	pyrazolanthrone	13-21	mitogen-activated protein kinase 8	Mus musculus	53-56
35619094-11	2022	Furthermore, SP600125, a specific inhibitor for SAPK/JNK, significantly suppressed onalespib or geldanamycin"s enhancing effect of the TGF-beta-induced HSP27 expression levels.	pyrazolanthrone	13-21	transforming growth factor alpha	Mus musculus	135-143
34982483-15	2022	In addition, the treatment of JNK pathway inhibitor, SP600125, could inhibit the expression and secretion level of anti-inflammatory factor such as IL-10 in M2 polarization induced by PDLSCs-CM.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Homo sapiens	30-33
34982483-15	2022	In addition, the treatment of JNK pathway inhibitor, SP600125, could inhibit the expression and secretion level of anti-inflammatory factor such as IL-10 in M2 polarization induced by PDLSCs-CM.	pyrazolanthrone	53-61	interleukin 10	Homo sapiens	148-153
35619094-11	2022	Furthermore, SP600125, a specific inhibitor for SAPK/JNK, significantly suppressed onalespib or geldanamycin"s enhancing effect of the TGF-beta-induced HSP27 expression levels.	pyrazolanthrone	13-21	heat shock protein 2	Mus musculus	152-157
35624854-9	2022	SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated the tomentosin-induced phosphorylation of Nrf2, suggesting that JNK and p38 MAPK signaling pathways can contribute to the tomentosin-induced Nrf2 activation through phosphorylation of Nrf2.	pyrazolanthrone	36-44	NFE2 like bZIP transcription factor 2	Homo sapiens	116-120
35624854-9	2022	SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated the tomentosin-induced phosphorylation of Nrf2, suggesting that JNK and p38 MAPK signaling pathways can contribute to the tomentosin-induced Nrf2 activation through phosphorylation of Nrf2.	pyrazolanthrone	36-44	mitogen-activated protein kinase 8	Homo sapiens	138-141
35624854-9	2022	SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated the tomentosin-induced phosphorylation of Nrf2, suggesting that JNK and p38 MAPK signaling pathways can contribute to the tomentosin-induced Nrf2 activation through phosphorylation of Nrf2.	pyrazolanthrone	36-44	NFE2 like bZIP transcription factor 2	Homo sapiens	215-219
35624854-9	2022	SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor) attenuated the tomentosin-induced phosphorylation of Nrf2, suggesting that JNK and p38 MAPK signaling pathways can contribute to the tomentosin-induced Nrf2 activation through phosphorylation of Nrf2.	pyrazolanthrone	36-44	NFE2 like bZIP transcription factor 2	Homo sapiens	258-262
35497094-10	2022	Thrombin promoted phosphorylation of NF-kappaB p65, leading to nuclear translocation and binding to the COX-2 promoter element to enhance promoter activity, which was reduced by Go6976, SP600125, SB202190, or U0126.	pyrazolanthrone	186-194	RELA proto-oncogene, NF-kB subunit	Homo sapiens	37-50
35499276-12	2022	MAPK pathway inhibitors (10 muM SB203580 and 10 muM SP600125) could attenuate the NiSO4 -induced increase in apoptosis and inflammation in HUVECs.	pyrazolanthrone	52-60	mitogen-activated protein kinase 3	Homo sapiens	0-4
35506262-11	2022	Howerver, The JNK inhibitor (SP600125) enhanced the down-regulation of Wnt5a/JNK pathway proteins by SFRP5.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Mus musculus	14-17
35506262-11	2022	Howerver, The JNK inhibitor (SP600125) enhanced the down-regulation of Wnt5a/JNK pathway proteins by SFRP5.	pyrazolanthrone	29-37	wingless-type MMTV integration site family, member 5A	Mus musculus	71-76
35506262-11	2022	Howerver, The JNK inhibitor (SP600125) enhanced the down-regulation of Wnt5a/JNK pathway proteins by SFRP5.	pyrazolanthrone	29-37	mitogen-activated protein kinase 8	Mus musculus	77-80
35506262-11	2022	Howerver, The JNK inhibitor (SP600125) enhanced the down-regulation of Wnt5a/JNK pathway proteins by SFRP5.	pyrazolanthrone	29-37	secreted frizzled-related sequence protein 5	Mus musculus	101-106
35504258-9	2022	SP600125 suppressed the JNK signal pathway, reduced the proliferation, and increased BLCA cell apoptosis, with the reductions in the invasion and migration and the upregulation of phospho-histone H3 Ser-10 (pHH3), which was abolished by the overexpression of ANLN.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Homo sapiens	24-27
35504258-9	2022	SP600125 suppressed the JNK signal pathway, reduced the proliferation, and increased BLCA cell apoptosis, with the reductions in the invasion and migration and the upregulation of phospho-histone H3 Ser-10 (pHH3), which was abolished by the overexpression of ANLN.	pyrazolanthrone	0-8	anillin, actin binding protein	Homo sapiens	259-263
35497094-10	2022	Thrombin promoted phosphorylation of NF-kappaB p65, leading to nuclear translocation and binding to the COX-2 promoter element to enhance promoter activity, which was reduced by Go6976, SP600125, SB202190, or U0126.	pyrazolanthrone	186-194	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	104-109
35119079-8	2022	Moreover, Cyt-c, Caspase-3, JNK and JUN expression levels were detected following treatment with a specific inhibitor of JNK (SP600125).	pyrazolanthrone	126-134	caspase 3	Rattus norvegicus	17-26
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	130-133
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	pyrazolanthrone	145-153	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	277-313
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	pyrazolanthrone	145-153	mitogen-activated protein kinase kinase kinase 5	Homo sapiens	315-319
35571453-11	2022	BBR-induced, dose-dependent induction of apoptosis was accompanied by sustained phosphorylation of c-jun-NH2-kinase (JNK) and the JNK inhibitor (SP600125) significantly suppressed BBR-induced apoptosis, N-acetyl cysteine (NAC), a ROS scavenger, was sufficient to both suppress apoptosis signal-regulating kinase 1 (ASK1) and JNK activation and disrupt apoptotic induction.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	325-328
35119079-9	2022	The results revealed that SP600125 had similar inhibitory effects on the JNK pathway and ERS-related protein expression (Cyt-t, Caspase-3, p-JNK and p-c-JUN).	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Rattus norvegicus	141-144
35453404-9	2022	We further demonstrated that phosphorylation of c-Jun N-terminal kinase (JNK)1/2 participated in 15d-PGJ2-upregulated HO-1 expression, which was blocked by SP600125 or Rottlerin.	pyrazolanthrone	156-164	mitogen-activated protein kinase 8	Mus musculus	73-80
35453404-9	2022	We further demonstrated that phosphorylation of c-Jun N-terminal kinase (JNK)1/2 participated in 15d-PGJ2-upregulated HO-1 expression, which was blocked by SP600125 or Rottlerin.	pyrazolanthrone	156-164	heme oxygenase 1	Mus musculus	118-122
35453404-10	2022	Moreover, 15d-PGJ2-induced HO-1 expression was mediated through the activation of c-Jun (a subunit of activator protein 1 (AP-1)) and specificity protein 1 (Sp1), leading to their interaction with the HO-1 promoter, revealed by chromatin immunoprecipitation assay, which was attenuated by SP600125, Mithramycin A, or Tanshinone II A.	pyrazolanthrone	289-297	heme oxygenase 1	Mus musculus	27-31
35453404-10	2022	Moreover, 15d-PGJ2-induced HO-1 expression was mediated through the activation of c-Jun (a subunit of activator protein 1 (AP-1)) and specificity protein 1 (Sp1), leading to their interaction with the HO-1 promoter, revealed by chromatin immunoprecipitation assay, which was attenuated by SP600125, Mithramycin A, or Tanshinone II A.	pyrazolanthrone	289-297	jun proto-oncogene	Mus musculus	82-87
35453404-10	2022	Moreover, 15d-PGJ2-induced HO-1 expression was mediated through the activation of c-Jun (a subunit of activator protein 1 (AP-1)) and specificity protein 1 (Sp1), leading to their interaction with the HO-1 promoter, revealed by chromatin immunoprecipitation assay, which was attenuated by SP600125, Mithramycin A, or Tanshinone II A.	pyrazolanthrone	289-297	jun proto-oncogene	Mus musculus	123-127
35453404-10	2022	Moreover, 15d-PGJ2-induced HO-1 expression was mediated through the activation of c-Jun (a subunit of activator protein 1 (AP-1)) and specificity protein 1 (Sp1), leading to their interaction with the HO-1 promoter, revealed by chromatin immunoprecipitation assay, which was attenuated by SP600125, Mithramycin A, or Tanshinone II A.	pyrazolanthrone	289-297	trans-acting transcription factor 1	Mus musculus	134-155
35453404-10	2022	Moreover, 15d-PGJ2-induced HO-1 expression was mediated through the activation of c-Jun (a subunit of activator protein 1 (AP-1)) and specificity protein 1 (Sp1), leading to their interaction with the HO-1 promoter, revealed by chromatin immunoprecipitation assay, which was attenuated by SP600125, Mithramycin A, or Tanshinone II A.	pyrazolanthrone	289-297	heme oxygenase 1	Mus musculus	201-205
35406794-6	2022	Blocking these TFs using specific inhibitors for ALK-5-induced SMAD signaling (5 microM SB-505124), JAK-STAT signaling (1 microM Tofacitinib) and JNK signaling (10 microM SP-600125) led to the striking observation that only SB-505124 repressed the expression of hypertrophy factors in TGF-beta-stimulated chondrocytes.	pyrazolanthrone	171-180	transforming growth factor beta receptor 1	Homo sapiens	49-54
35383226-6	2022	Besides, AKT activator (SC79) or JNK inhibitor (SP600125) effectively reversed the anticancer effects of rhoifolin in pancreatic cancer.	pyrazolanthrone	48-56	mitogen-activated protein kinase 8	Homo sapiens	33-36
35444554-15	2022	Specific inhibitors of JNK (SP600125), ERK (PD98059) or p38 (SB203580) inhibited DOX-induced apoptosis of NRCMs.	pyrazolanthrone	28-36	mitogen-activated protein kinase 8	Rattus norvegicus	23-26
35230626-11	2022	Similar protective effects were observed upon JNK/p53 pathway inhibition using SP600125.	pyrazolanthrone	79-87	mitogen-activated protein kinase 8	Mus musculus	46-49
35230626-11	2022	Similar protective effects were observed upon JNK/p53 pathway inhibition using SP600125.	pyrazolanthrone	79-87	transformation related protein 53	Mus musculus	50-53
35119079-8	2022	Moreover, Cyt-c, Caspase-3, JNK and JUN expression levels were detected following treatment with a specific inhibitor of JNK (SP600125).	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Rattus norvegicus	28-31
35119079-8	2022	Moreover, Cyt-c, Caspase-3, JNK and JUN expression levels were detected following treatment with a specific inhibitor of JNK (SP600125).	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Rattus norvegicus	121-124
35119079-9	2022	The results revealed that SP600125 had similar inhibitory effects on the JNK pathway and ERS-related protein expression (Cyt-t, Caspase-3, p-JNK and p-c-JUN).	pyrazolanthrone	26-34	mitogen-activated protein kinase 8	Rattus norvegicus	73-76
35119079-9	2022	The results revealed that SP600125 had similar inhibitory effects on the JNK pathway and ERS-related protein expression (Cyt-t, Caspase-3, p-JNK and p-c-JUN).	pyrazolanthrone	26-34	caspase 3	Rattus norvegicus	128-137
35408955-8	2022	Moreover, melatonin activated JNK signaling and upregulated hepcidin expression, both of which were significantly decreased by SP600125, a specific JNK inhibitor.	pyrazolanthrone	127-135	hepcidin antimicrobial peptide	Mus musculus	60-68
35408955-8	2022	Moreover, melatonin activated JNK signaling and upregulated hepcidin expression, both of which were significantly decreased by SP600125, a specific JNK inhibitor.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Mus musculus	148-151
35408955-8	2022	Moreover, melatonin activated JNK signaling and upregulated hepcidin expression, both of which were significantly decreased by SP600125, a specific JNK inhibitor.	pyrazolanthrone	127-135	mitogen-activated protein kinase 8	Mus musculus	30-33
35187930-9	2022	TW-7 also downregulated C-Jun N-terminal kinase (JNK) phosphorylation and activated PTEN-induced putative kinase 1 (PINK1)-mediated mitophagy in H2O2-induced HT-22 cells treated with JNK activator (anisomycin) and inhibitor (SP600125).	pyrazolanthrone	225-233	PTEN induced putative kinase 1	Mus musculus	84-114
35172196-8	2022	In addition, IL-1 receptor antagonist (IL-1Ra) or SP600125 (JNK pathway inhibitor) diminished the IL-1beta-induced activation of JNK pathway-mediated neuron apoptosis.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Rattus norvegicus	60-63
35172196-8	2022	In addition, IL-1 receptor antagonist (IL-1Ra) or SP600125 (JNK pathway inhibitor) diminished the IL-1beta-induced activation of JNK pathway-mediated neuron apoptosis.	pyrazolanthrone	50-58	interleukin 1 alpha	Rattus norvegicus	98-106
35172196-8	2022	In addition, IL-1 receptor antagonist (IL-1Ra) or SP600125 (JNK pathway inhibitor) diminished the IL-1beta-induced activation of JNK pathway-mediated neuron apoptosis.	pyrazolanthrone	50-58	mitogen-activated protein kinase 8	Rattus norvegicus	129-132
35270009-10	2022	Furthermore, pretreatment of cells with SP600125 (JNK inhibitor; 10 muM) or NAC (1 mM) or transfection with JNK-specific siRNA obviously attenuated the MeHg-induced JNK phosphorylation, CHOP and XBP-1 protein expression, apoptotic events, and insulin secretion dysfunction.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Rattus norvegicus	50-53
35270009-10	2022	Furthermore, pretreatment of cells with SP600125 (JNK inhibitor; 10 muM) or NAC (1 mM) or transfection with JNK-specific siRNA obviously attenuated the MeHg-induced JNK phosphorylation, CHOP and XBP-1 protein expression, apoptotic events, and insulin secretion dysfunction.	pyrazolanthrone	40-48	mitogen-activated protein kinase 8	Rattus norvegicus	165-168
35270009-10	2022	Furthermore, pretreatment of cells with SP600125 (JNK inhibitor; 10 muM) or NAC (1 mM) or transfection with JNK-specific siRNA obviously attenuated the MeHg-induced JNK phosphorylation, CHOP and XBP-1 protein expression, apoptotic events, and insulin secretion dysfunction.	pyrazolanthrone	40-48	DNA-damage inducible transcript 3	Rattus norvegicus	186-190
35270009-10	2022	Furthermore, pretreatment of cells with SP600125 (JNK inhibitor; 10 muM) or NAC (1 mM) or transfection with JNK-specific siRNA obviously attenuated the MeHg-induced JNK phosphorylation, CHOP and XBP-1 protein expression, apoptotic events, and insulin secretion dysfunction.	pyrazolanthrone	40-48	X-box binding protein 1	Rattus norvegicus	195-200
35187930-9	2022	TW-7 also downregulated C-Jun N-terminal kinase (JNK) phosphorylation and activated PTEN-induced putative kinase 1 (PINK1)-mediated mitophagy in H2O2-induced HT-22 cells treated with JNK activator (anisomycin) and inhibitor (SP600125).	pyrazolanthrone	225-233	PTEN induced putative kinase 1	Mus musculus	116-121
35059734-17	2022	Inhibiting p-JNK with SP600125 reversed the increased prosurvival effects caused by XBP1s overexpression.	pyrazolanthrone	22-30	mitogen-activated protein kinase 8	Homo sapiens	13-16
35093571-8	2022	In addition, phenotypes similar to WDR62 depletion were observed during the function-loss analysis of p-JNK using a specific inhibitor (SP600125), which signifies that WDR62 is important for spindle organization and meiotic progression, and this function might be via its regulation of p-JNK.	pyrazolanthrone	136-144	WD repeat domain 62	Mus musculus	35-40
35093571-8	2022	In addition, phenotypes similar to WDR62 depletion were observed during the function-loss analysis of p-JNK using a specific inhibitor (SP600125), which signifies that WDR62 is important for spindle organization and meiotic progression, and this function might be via its regulation of p-JNK.	pyrazolanthrone	136-144	mitogen-activated protein kinase 8	Mus musculus	104-107
35093571-8	2022	In addition, phenotypes similar to WDR62 depletion were observed during the function-loss analysis of p-JNK using a specific inhibitor (SP600125), which signifies that WDR62 is important for spindle organization and meiotic progression, and this function might be via its regulation of p-JNK.	pyrazolanthrone	136-144	WD repeat domain 62	Mus musculus	168-173
35093571-8	2022	In addition, phenotypes similar to WDR62 depletion were observed during the function-loss analysis of p-JNK using a specific inhibitor (SP600125), which signifies that WDR62 is important for spindle organization and meiotic progression, and this function might be via its regulation of p-JNK.	pyrazolanthrone	136-144	mitogen-activated protein kinase 8	Mus musculus	288-291
35215410-7	2022	Meanwhile, CD44 siRNA transfection and JNK inhibitor SP600125 reduced the hypoxia-induced expression of phospho-JNK and cytokines.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Rattus norvegicus	39-42
35250857-18	2022	IL-15 promoted p38 MAPK and JNK phosphorylation in KGN cells, treating KGN cells with p38 MAPK inhibitor SP600125 and JNK inhibitor SB203580 could reverse the effect of IL-15 on the proliferation and function of KGN cells.	pyrazolanthrone	105-113	interleukin 15	Homo sapiens	0-5
35250857-18	2022	IL-15 promoted p38 MAPK and JNK phosphorylation in KGN cells, treating KGN cells with p38 MAPK inhibitor SP600125 and JNK inhibitor SB203580 could reverse the effect of IL-15 on the proliferation and function of KGN cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 14	Mus musculus	15-23
35250857-18	2022	IL-15 promoted p38 MAPK and JNK phosphorylation in KGN cells, treating KGN cells with p38 MAPK inhibitor SP600125 and JNK inhibitor SB203580 could reverse the effect of IL-15 on the proliferation and function of KGN cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 8	Homo sapiens	28-31
35250857-18	2022	IL-15 promoted p38 MAPK and JNK phosphorylation in KGN cells, treating KGN cells with p38 MAPK inhibitor SP600125 and JNK inhibitor SB203580 could reverse the effect of IL-15 on the proliferation and function of KGN cells.	pyrazolanthrone	105-113	mitogen-activated protein kinase 14	Mus musculus	86-94
35250857-18	2022	IL-15 promoted p38 MAPK and JNK phosphorylation in KGN cells, treating KGN cells with p38 MAPK inhibitor SP600125 and JNK inhibitor SB203580 could reverse the effect of IL-15 on the proliferation and function of KGN cells.	pyrazolanthrone	105-113	interleukin 15	Homo sapiens	169-174
35215410-7	2022	Meanwhile, CD44 siRNA transfection and JNK inhibitor SP600125 reduced the hypoxia-induced expression of phospho-JNK and cytokines.	pyrazolanthrone	53-61	mitogen-activated protein kinase 8	Rattus norvegicus	112-115
35114641-11	2022	SP600125 (JNK inhibitor) could restore the effects of CTRP3 or LAMP1 overexpression on the expression of JIP2 and phosphorylated-JNK (p-JNK), proliferation and apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	10-13
35163786-9	2022	Silencing DUSP9 was found to facilitate the expression of proinflammatory cytokines and COX2 as well as PGE2 secretion in WISH cells, which could be attenuated by p38 inhibitor SB203580 or JNK inhibitor SP600125.	pyrazolanthrone	203-211	dual specificity phosphatase 9	Mus musculus	10-15
35163786-9	2022	Silencing DUSP9 was found to facilitate the expression of proinflammatory cytokines and COX2 as well as PGE2 secretion in WISH cells, which could be attenuated by p38 inhibitor SB203580 or JNK inhibitor SP600125.	pyrazolanthrone	203-211	prostaglandin-endoperoxide synthase 2	Homo sapiens	88-92
35163786-9	2022	Silencing DUSP9 was found to facilitate the expression of proinflammatory cytokines and COX2 as well as PGE2 secretion in WISH cells, which could be attenuated by p38 inhibitor SB203580 or JNK inhibitor SP600125.	pyrazolanthrone	203-211	NCK interacting protein with SH3 domain	Mus musculus	122-126
35163786-9	2022	Silencing DUSP9 was found to facilitate the expression of proinflammatory cytokines and COX2 as well as PGE2 secretion in WISH cells, which could be attenuated by p38 inhibitor SB203580 or JNK inhibitor SP600125.	pyrazolanthrone	203-211	mitogen-activated protein kinase 14	Mus musculus	163-166
35163786-9	2022	Silencing DUSP9 was found to facilitate the expression of proinflammatory cytokines and COX2 as well as PGE2 secretion in WISH cells, which could be attenuated by p38 inhibitor SB203580 or JNK inhibitor SP600125.	pyrazolanthrone	203-211	mitogen-activated protein kinase 8	Mus musculus	189-192
35114641-11	2022	SP600125 (JNK inhibitor) could restore the effects of CTRP3 or LAMP1 overexpression on the expression of JIP2 and phosphorylated-JNK (p-JNK), proliferation and apoptosis.	pyrazolanthrone	0-8	lysosomal-associated membrane protein 1	Rattus norvegicus	63-68
35114641-11	2022	SP600125 (JNK inhibitor) could restore the effects of CTRP3 or LAMP1 overexpression on the expression of JIP2 and phosphorylated-JNK (p-JNK), proliferation and apoptosis.	pyrazolanthrone	0-8	mitogen-activated protein kinase 8	Rattus norvegicus	136-139
35049439-17	2022	The apoptosis and G2/M cell cycle arrest were inhibited in cells co-treated with the p38 inhibitor SB203580 and JNK inhibitor SP600125.	pyrazolanthrone	126-134	mitogen-activated protein kinase 8	Mus musculus	112-115
35155684-9	2022	The AGE-induced upregulation of osteoblast proteins (RUNX2 and OPG) was suppressed by treatment with a p38MAPK inhibitor (SB203580) or JNK inhibitor (SP600125), but not by treatment with an ERK inhibitor (PD98059), which indicated that AGE-induced osteoblast differentiation from EPCs may be mediated by p38MAPK and JNK signaling, but not by ERK signaling.	pyrazolanthrone	150-158	renin binding protein	Rattus norvegicus	4-7
35155684-9	2022	The AGE-induced upregulation of osteoblast proteins (RUNX2 and OPG) was suppressed by treatment with a p38MAPK inhibitor (SB203580) or JNK inhibitor (SP600125), but not by treatment with an ERK inhibitor (PD98059), which indicated that AGE-induced osteoblast differentiation from EPCs may be mediated by p38MAPK and JNK signaling, but not by ERK signaling.	pyrazolanthrone	150-158	RUNX family transcription factor 2	Rattus norvegicus	53-58
35155684-9	2022	The AGE-induced upregulation of osteoblast proteins (RUNX2 and OPG) was suppressed by treatment with a p38MAPK inhibitor (SB203580) or JNK inhibitor (SP600125), but not by treatment with an ERK inhibitor (PD98059), which indicated that AGE-induced osteoblast differentiation from EPCs may be mediated by p38MAPK and JNK signaling, but not by ERK signaling.	pyrazolanthrone	150-158	TNF receptor superfamily member 11B	Rattus norvegicus	63-66
35155684-9	2022	The AGE-induced upregulation of osteoblast proteins (RUNX2 and OPG) was suppressed by treatment with a p38MAPK inhibitor (SB203580) or JNK inhibitor (SP600125), but not by treatment with an ERK inhibitor (PD98059), which indicated that AGE-induced osteoblast differentiation from EPCs may be mediated by p38MAPK and JNK signaling, but not by ERK signaling.	pyrazolanthrone	150-158	mitogen-activated protein kinase 8	Rattus norvegicus	135-138
34710487-7	2022	Whereas PON2 overexpression similar to SP600125 (a specific JNK inhibitor) was able to decrease Fis1 (p = 0.036) and reverse the Bcl-2 and Bax ratio, and inhibit the JNK1/2 signaling pathway.	pyrazolanthrone	39-47	mitogen-activated protein kinase 8	Homo sapiens	60-63
35017529-4	2022	We observed marked induction of EE cell differentiation and gut-derived expression and secretion of SST, 5HT, GIP, CCK, GLP-1 and PYY upon treatment with various combinations of three small molecules: rimonabant, SP600125 and AS1842856.	pyrazolanthrone	213-221	somatostatin	Homo sapiens	100-103
35017529-4	2022	We observed marked induction of EE cell differentiation and gut-derived expression and secretion of SST, 5HT, GIP, CCK, GLP-1 and PYY upon treatment with various combinations of three small molecules: rimonabant, SP600125 and AS1842856.	pyrazolanthrone	213-221	gastric inhibitory polypeptide	Homo sapiens	110-113
35017529-4	2022	We observed marked induction of EE cell differentiation and gut-derived expression and secretion of SST, 5HT, GIP, CCK, GLP-1 and PYY upon treatment with various combinations of three small molecules: rimonabant, SP600125 and AS1842856.	pyrazolanthrone	213-221	cholecystokinin	Homo sapiens	115-118
35017529-4	2022	We observed marked induction of EE cell differentiation and gut-derived expression and secretion of SST, 5HT, GIP, CCK, GLP-1 and PYY upon treatment with various combinations of three small molecules: rimonabant, SP600125 and AS1842856.	pyrazolanthrone	213-221	glucagon like peptide 1 receptor	Homo sapiens	120-125
35017529-4	2022	We observed marked induction of EE cell differentiation and gut-derived expression and secretion of SST, 5HT, GIP, CCK, GLP-1 and PYY upon treatment with various combinations of three small molecules: rimonabant, SP600125 and AS1842856.	pyrazolanthrone	213-221	peptide YY	Homo sapiens	130-133
34710487-7	2022	Whereas PON2 overexpression similar to SP600125 (a specific JNK inhibitor) was able to decrease Fis1 (p = 0.036) and reverse the Bcl-2 and Bax ratio, and inhibit the JNK1/2 signaling pathway.	pyrazolanthrone	39-47	fission, mitochondrial 1	Homo sapiens	96-100
35100937-7	2022	Both the JNK inhibitor (SP600125) and p38 inhibitor (SB203580) reversed the phosphorylation of STAT3, and the ERK inhibitor (FR180204) and AKT inhibitor (LY294002) reduced the expression of STAT3.	pyrazolanthrone	24-32	mitogen-activated protein kinase 8	Homo sapiens	9-12
35431291-6	2022	SMAD3 inhibitor SIS3, p38 MAP kinase inhibitor SB203580, MEK1/2 inhibitor PD98059, and SAPK/JNK inhibitor SP600125 significantly suppressed the M-CSF release.	pyrazolanthrone	106-114	mitogen-activated protein kinase 8	Mus musculus	92-95
35431291-6	2022	SMAD3 inhibitor SIS3, p38 MAP kinase inhibitor SB203580, MEK1/2 inhibitor PD98059, and SAPK/JNK inhibitor SP600125 significantly suppressed the M-CSF release.	pyrazolanthrone	106-114	colony stimulating factor 1 (macrophage)	Mus musculus	144-149
35228396-9	2022	The inhibitory effect of 3",4",7-trihydroxyflavone on NO generation was mimicked by pharmacological inhibition of the JNK signaling pathway with SP600125.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Mus musculus	118-121
35228396-10	2022	Furthermore, SP600125 significantly inhibited LPS- or IFN-gamma-mediated phosphorylation of STAT1 in MG6 cells.	pyrazolanthrone	13-21	interferon gamma	Mus musculus	54-63
35228396-10	2022	Furthermore, SP600125 significantly inhibited LPS- or IFN-gamma-mediated phosphorylation of STAT1 in MG6 cells.	pyrazolanthrone	13-21	signal transducer and activator of transcription 1	Mus musculus	92-97
35100937-7	2022	Both the JNK inhibitor (SP600125) and p38 inhibitor (SB203580) reversed the phosphorylation of STAT3, and the ERK inhibitor (FR180204) and AKT inhibitor (LY294002) reduced the expression of STAT3.	pyrazolanthrone	24-32	signal transducer and activator of transcription 3	Homo sapiens	95-100
35100937-7	2022	Both the JNK inhibitor (SP600125) and p38 inhibitor (SB203580) reversed the phosphorylation of STAT3, and the ERK inhibitor (FR180204) and AKT inhibitor (LY294002) reduced the expression of STAT3.	pyrazolanthrone	24-32	signal transducer and activator of transcription 3	Homo sapiens	190-195
35130734-14	2022	Further experiments indicated apoptosis and autophagy could be attenuated by the N-acetyl-L-cysteine and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	105-128
35130734-14	2022	Further experiments indicated apoptosis and autophagy could be attenuated by the N-acetyl-L-cysteine and c-Jun N-terminal kinase (JNK) inhibitor SP600125.	pyrazolanthrone	145-153	mitogen-activated protein kinase 8	Homo sapiens	130-133
35173528-11	2022	The expression levels of RhoJ was upregulated with the stimulation of VEGF, and reduced by the treatment of JNK inhibitor SP600125.	pyrazolanthrone	122-130	ras homolog family member J	Homo sapiens	25-29
35173528-11	2022	The expression levels of RhoJ was upregulated with the stimulation of VEGF, and reduced by the treatment of JNK inhibitor SP600125.	pyrazolanthrone	122-130	mitogen-activated protein kinase 8	Homo sapiens	108-111
35002432-4	2022	On the other hand, treatment with scutellarin alone and in combination with a JNK inhibitor, SP600125, both significantly attenuated pulmonary edema as shown via reduced wet/dry lung mass ratios (1.7 +- 0.09 and 1.8 +- 0.23; P < 0.05, respectively).	pyrazolanthrone	93-101	mitogen-activated protein kinase 8	Rattus norvegicus	78-81
35002432-10	2022	Moreover, the combined effect of scutellarin and JNK inhibitor SP600125 on the levels of ROS and the SOD activity followed a similar trend to that of scutellarin alone albeit with a lower magnitude of change.	pyrazolanthrone	63-71	mitogen-activated protein kinase 8	Rattus norvegicus	49-52
35002432-13	2022	The rise was, however, attenuated via pre-treatment with scutellarin only or in conjunction with SP600125, a JNK inhibitor (all P < 0.05).	pyrazolanthrone	97-105	mitogen-activated protein kinase 8	Rattus norvegicus	109-112